<SEC-DOCUMENT>0001641172-25-002362.txt : 20250402
<SEC-HEADER>0001641172-25-002362.hdr.sgml : 20250402
<ACCEPTANCE-DATETIME>20250402160540
ACCESSION NUMBER:		0001641172-25-002362
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		91
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250402
DATE AS OF CHANGE:		20250402

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Galmed Pharmaceuticals Ltd.
		CENTRAL INDEX KEY:			0001595353
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				981147233
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36345
		FILM NUMBER:		25804340

	BUSINESS ADDRESS:	
		STREET 1:		C/O MEITAR LAW OFFICES
		STREET 2:		16 ABBA HILLEL SILVER RD.
		CITY:			RAMAT GAN
		STATE:			L3
		ZIP:			5250608
		BUSINESS PHONE:		97236938448

	MAIL ADDRESS:	
		STREET 1:		C/O MEITAR LAW OFFICES
		STREET 2:		16 ABBA HILLEL SILVER RD.
		CITY:			RAMAT GAN
		STATE:			L3
		ZIP:			5250608
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>form20-f.htm
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:GLMD="http://galmedpharma.com/20241231">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_029_US%2DGAAP%2D2024%2D(with%2DECD%2Dand%2DCYD) -->
<!-- Field: Set; Name: xdx; ID: xdx_033_GLMD_galmedpharma.com_20241231 -->
<!-- Field: Set; Name: xdx; ID: xdx_04C_20240101_20241231 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_05E_edei%2D%2DEntityCentralIndexKey_0001595353 -->
<!-- Field: Set; Name: xdx; ID: xdx_07A_XDX_form20%2Df.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06A_Sqft_8_utr%2D%2Dsqft -->
<!-- Field: Set; Name: xdx; ID: xdx_061_Integer_0_Integer -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_06F_ILSPShares_0_iso4217%2D%2DILS_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_ILS_0_iso4217%2D%2DILS -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000004" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000005" name="dei:EntityCentralIndexKey">0001595353</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2024-12-31" id="xdx2ixbrl0089" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-12-31" id="xdx2ixbrl0092" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2023-12-31" id="xdx2ixbrl0099" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2024-12-31" id="xdx2ixbrl0122" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2023-12-31" id="xdx2ixbrl0123" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GLMD:FinancialExpenses" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0182" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GLMD:FinancialExpenses" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0183" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GLMD:ImpairmentOnAssociate" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0186" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GLMD:ImpairmentOnAssociate" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0187" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0244" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0246" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0247" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0250" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0252" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0253" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0260" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0261" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0263" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0266" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0267" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0268" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GLMD:StockIssuedDuringPeriodValueOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0282" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GLMD:StockIssuedDuringPeriodValueOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0283" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GLMD:ExerciseOfPrefundedWarrants" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0292" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GLMD:ExerciseOfPrefundedWarrants" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0293" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GLMD:ExerciseOfPrefundedWarrants" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0294" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0298" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0300" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0301" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0304" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0305" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0307" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0310" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0311" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0312" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0334" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0335" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GLMD:ExerciseOfPrefundedWarrants" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0352" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0360" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0372" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0374" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0375" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0378" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0379" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0381" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0384" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0385" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0386" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GLMD:FinancialExpenses" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0437" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GLMD:FinancialExpenses" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0438" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GLMD:DecreaseInShorttermDeposits" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0446" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0449" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0450" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherAssetImpairmentCharges" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0457" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherAssetImpairmentCharges" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0458" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GLMD:ChangeInFairValueConvertibleNote" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0462" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0488" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0489" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GLMD:PaymentsForProceedsFromInvestmentInConvertibleNote" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0496" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GLMD:PaymentsForProceedsFromInvestmentInConvertibleNote" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0497" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsToAcquireBusinessesGross" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0501" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsToAcquireBusinessesGross" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0502" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GLMD:PaymentsForProceedsFromInvestmentInAssociate" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0504" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GLMD:PaymentsForProceedsFromInvestmentInAssociate" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0506" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsForProceedsFromOtherDeposits" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0514" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0524" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0525" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0529" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0530" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GLMD:ConversionOfConvertibleNoteIntoInvestmentInAssociate" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0564" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GLMD:ConversionOfConvertibleNoteIntoInvestmentInAssociate" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0566" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember" id="xdx2ixbrl0628" name="us-gaap:PropertyPlantAndEquipmentDepreciationMethodExtensibleEnumeration">http://fasb.org/us-gaap/2024#UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member_us-gaap_CorporateDebtSecuritiesMember" id="xdx2ixbrl0644" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member_us-gaap_CorporateDebtSecuritiesMember" id="xdx2ixbrl0646" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member_us-gaap_USTreasurySecuritiesMember" id="xdx2ixbrl0649" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member_us-gaap_USTreasurySecuritiesMember" id="xdx2ixbrl0651" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member_us-gaap_MutualFundMember" id="xdx2ixbrl0655" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member_us-gaap_MutualFundMember" id="xdx2ixbrl0656" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member_custom_InvestmentInAssociateMember" id="xdx2ixbrl0659" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member_custom_InvestmentInAssociateMember" id="xdx2ixbrl0660" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member_us-gaap_CorporateDebtSecuritiesMember" id="xdx2ixbrl0669" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member_us-gaap_CorporateDebtSecuritiesMember" id="xdx2ixbrl0671" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member_us-gaap_USTreasurySecuritiesMember" id="xdx2ixbrl0674" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member_us-gaap_USTreasurySecuritiesMember" id="xdx2ixbrl0676" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member_us-gaap_MutualFundMember" id="xdx2ixbrl0680" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member_us-gaap_MutualFundMember" id="xdx2ixbrl0681" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member_custom_InvestmentInAssociateMember" id="xdx2ixbrl0684" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member_custom_InvestmentInAssociateMember" id="xdx2ixbrl0685" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" contextRef="From2024-01-012024-12-31_us-gaap_USTreasurySecuritiesMember" id="xdx2ixbrl0728" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" contextRef="From2023-01-012023-12-31_us-gaap_USTreasurySecuritiesMember" id="xdx2ixbrl0760" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2024-12-31" id="xdx2ixbrl0808" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="AsOf2023-12-31" id="xdx2ixbrl0811" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">http://fasb.org/us-gaap/2024#OperatingLeaseRightOfUseAsset</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2023-12-31" id="xdx2ixbrl0812" name="us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList">http://fasb.org/us-gaap/2024#OperatingLeaseLiability</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-12-31" id="xdx2ixbrl0836" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GLMD:ShorttermLeaseObligation" contextRef="AsOf2024-12-31" id="xdx2ixbrl0902" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherNotesPayable" contextRef="AsOf2023-12-31" id="xdx2ixbrl0906" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember94762828" id="xdx2ixbrl1060" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember94762828" id="xdx2ixbrl1062" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GLMD:ChangeInFairValueOfConvertibleNote" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl1290" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GLMD:ChangeInFairValueOfConvertibleNote" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1292" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl1346" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1347" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1348" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="glmd-20241231.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2024-01-01to2024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_dei_BusinessContactMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_srt_MinimumMember_custom_OfficeFurnitureAndEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">GLMD:OfficeFurnitureAndEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_srt_MaximumMember_custom_OfficeFurnitureAndEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">GLMD:OfficeFurnitureAndEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_srt_MinimumMember_custom_ComputerSoftwareElectronicEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">GLMD:ComputerSoftwareElectronicEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_srt_MaximumMember_custom_ComputerSoftwareElectronicEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">GLMD:ComputerSoftwareElectronicEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member_us-gaap_CorporateDebtSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member_us-gaap_CorporateDebtSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member_us-gaap_CorporateDebtSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_CorporateDebtSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member_us-gaap_USTreasurySecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member_us-gaap_USTreasurySecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member_us-gaap_USTreasurySecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USTreasurySecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member_us-gaap_MutualFundMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member_us-gaap_MutualFundMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member_us-gaap_MutualFundMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_MutualFundMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member_custom_InvestmentInAssociateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">GLMD:InvestmentInAssociateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member_custom_InvestmentInAssociateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">GLMD:InvestmentInAssociateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member_custom_InvestmentInAssociateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">GLMD:InvestmentInAssociateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_custom_InvestmentInAssociateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">GLMD:InvestmentInAssociateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member_us-gaap_CorporateDebtSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member_us-gaap_CorporateDebtSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member_us-gaap_CorporateDebtSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_CorporateDebtSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member_us-gaap_USTreasurySecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member_us-gaap_USTreasurySecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member_us-gaap_USTreasurySecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USTreasurySecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member_us-gaap_MutualFundMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member_us-gaap_MutualFundMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member_us-gaap_MutualFundMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_MutualFundMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member_custom_InvestmentInAssociateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">GLMD:InvestmentInAssociateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member_custom_InvestmentInAssociateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">GLMD:InvestmentInAssociateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member_custom_InvestmentInAssociateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">GLMD:InvestmentInAssociateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_custom_InvestmentInAssociateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">GLMD:InvestmentInAssociateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_CorporateDebtSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_CorporateDebtSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_USTreasurySecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_USTreasurySecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_MutualFundMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_MutualFundMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CorporateDebtSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_CorporateDebtSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_USTreasurySecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_USTreasurySecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MutualFundMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_MutualFundMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-05-042023-05-04_custom_OnkaiIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GLMD:OnkaiIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-05-04</xbrli:startDate>
        <xbrli:endDate>2023-05-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-11-302022-11-30_custom_OnkaiIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GLMD:OnkaiIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-11-30</xbrli:startDate>
        <xbrli:endDate>2022-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_OnkaiIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GLMD:OnkaiIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_OnkaiIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GLMD:OnkaiIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-19_custom_OnkaiIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GLMD:OnkaiIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_AdministrativeServiceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:AdministrativeServiceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_AdministrativeServiceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:AdministrativeServiceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-15_custom_BridgeLoanAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GLMD:BridgeLoanAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-152024-10-15_custom_ServicesAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GLMD:ServicesAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-15</xbrli:startDate>
        <xbrli:endDate>2024-10-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_OnkaiIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GLMD:OnkaiIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_OfficersAndDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GLMD:OfficersAndDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_OfficersAndDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GLMD:OfficersAndDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_ServiceAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GLMD:ServiceAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ServiceAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GLMD:ServiceAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-06-272021-06-28">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-06-27</xbrli:startDate>
        <xbrli:endDate>2021-06-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-06-272021-06-28_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-06-27</xbrli:startDate>
        <xbrli:endDate>2021-06-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-26_custom_NewSalesAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GLMD:NewSalesAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_NewSalesAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GLMD:NewSalesAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-05-152023-05-15_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-05-15</xbrli:startDate>
        <xbrli:endDate>2023-05-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-05-15_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-05-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-08-292024-08-29_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-08-29</xbrli:startDate>
        <xbrli:endDate>2024-08-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-08-29">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-08-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-08-29_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-08-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-182023-07-18">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-18</xbrli:startDate>
        <xbrli:endDate>2023-07-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-07-18_custom_PrefundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">GLMD:PrefundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-07-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-182023-07-18_custom_PrefundedWarrantsMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">GLMD:PrefundedWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-18</xbrli:startDate>
        <xbrli:endDate>2023-07-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-07-18_custom_InvestorWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">GLMD:InvestorWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-07-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-182023-07-18_custom_InvestorWarrantsMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">GLMD:InvestorWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-18</xbrli:startDate>
        <xbrli:endDate>2023-07-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-07-18_custom_InvestorWarrantsMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">GLMD:InvestorWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-07-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-182023-07-18_custom_InvestorWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">GLMD:InvestorWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-18</xbrli:startDate>
        <xbrli:endDate>2023-07-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_PrefundedWarrantsMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">GLMD:PrefundedWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-07-18_custom_PrefundedWarrantsMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">GLMD:PrefundedWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-07-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-07-18_custom_PrefundedWarrantsMember_us-gaap_CommonStockMember_us-gaap_InvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">GLMD:PrefundedWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-07-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-08-30_custom_StandbyEquityPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GLMD:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-08-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-21_custom_StandbyEquityPurchaseAgreementMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GLMD:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-08-302024-08-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-08-30</xbrli:startDate>
        <xbrli:endDate>2024-08-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-08-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-08-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_StandbyEquityPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GLMD:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_StandbyEquityPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GLMD:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_CommonStockMember_custom_CaymanIslandsExemptLimitedPartnershipMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GLMD:CaymanIslandsExemptLimitedPartnershipMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_CaymanIslandsExemptLimitedPartnershipMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GLMD:CaymanIslandsExemptLimitedPartnershipMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-14_custom_DemandSalesAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GLMD:DemandSalesAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-03-202025-03-21_custom_TwoThousandAndTwentySalesAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GLMD:TwoThousandAndTwentySalesAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-03-20</xbrli:startDate>
        <xbrli:endDate>2025-03-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_IncentiveShareOptionPlan2013Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">GLMD:IncentiveShareOptionPlan2013Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-012022-02-28">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-01</xbrli:startDate>
        <xbrli:endDate>2022-02-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-02-28">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-02-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-08-012023-08-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-08-01</xbrli:startDate>
        <xbrli:endDate>2023-08-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-08-012023-08-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-08-01</xbrli:startDate>
        <xbrli:endDate>2023-08-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-08-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-08-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-09-012023-09-30_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-09-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-122024-11-12_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-12</xbrli:startDate>
        <xbrli:endDate>2024-11-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-122024-11-12">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-12</xbrli:startDate>
        <xbrli:endDate>2024-11-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-122024-11-12_us-gaap_OptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-12</xbrli:startDate>
        <xbrli:endDate>2024-11-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_srt_MinimumMember_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_srt_MinimumMember_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_srt_MinimumMember_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_srt_MaximumMember_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_srt_MaximumMember_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_srt_MaximumMember_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-08-072023-08-07_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-08-07</xbrli:startDate>
        <xbrli:endDate>2023-08-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-12_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember94762828">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_EmployeeStockOptionMember94762828">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember94762828">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember94762843">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember94762843">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_ChemistryAndFormulationStudiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">GLMD:ChemistryAndFormulationStudiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_ChemistryAndFormulationStudiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">GLMD:ChemistryAndFormulationStudiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_ChemistryAndFormulationStudiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">GLMD:ChemistryAndFormulationStudiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_SalariesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">GLMD:SalariesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_SalariesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">GLMD:SalariesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_SalariesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">GLMD:SalariesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_StockBasedCompensationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">GLMD:StockBasedCompensationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_StockBasedCompensationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">GLMD:StockBasedCompensationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_StockBasedCompensationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">GLMD:StockBasedCompensationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_ResearchAndPreclinicalStudiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">GLMD:ResearchAndPreclinicalStudiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_ResearchAndPreclinicalStudiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">GLMD:ResearchAndPreclinicalStudiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_ResearchAndPreclinicalStudiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">GLMD:ResearchAndPreclinicalStudiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_ClinicalStudiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">GLMD:ClinicalStudiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_ClinicalStudiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">GLMD:ClinicalStudiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_ClinicalStudiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">GLMD:ClinicalStudiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_RegulatoryAndOtherExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">GLMD:RegulatoryAndOtherExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_RegulatoryAndOtherExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">GLMD:RegulatoryAndOtherExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_RegulatoryAndOtherExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">GLMD:RegulatoryAndOtherExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_ProfessionalFeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">GLMD:ProfessionalFeeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_ProfessionalFeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">GLMD:ProfessionalFeeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_ProfessionalFeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">GLMD:ProfessionalFeeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_SalariesAndBenefitsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">GLMD:SalariesAndBenefitsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_SalariesAndBenefitsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">GLMD:SalariesAndBenefitsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_SalariesAndBenefitsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">GLMD:SalariesAndBenefitsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_RentAndOfficeMaintenanceFeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">GLMD:RentAndOfficeMaintenanceFeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_RentAndOfficeMaintenanceFeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">GLMD:RentAndOfficeMaintenanceFeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_RentAndOfficeMaintenanceFeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">GLMD:RentAndOfficeMaintenanceFeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_InsuranceAndOtherExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">GLMD:InsuranceAndOtherExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_InsuranceAndOtherExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">GLMD:InsuranceAndOtherExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_InsuranceAndOtherExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">GLMD:InsuranceAndOtherExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_IsraelTaxAuthorityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_IsraelTaxAuthorityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_IsraelTaxAuthorityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_MalteseSubsidiaryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">GLMD:MalteseSubsidiaryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_MalteseSubsidiaryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">GLMD:MalteseSubsidiaryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_MalteseSubsidiaryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">GLMD:MalteseSubsidiaryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_MalteseSubsidiaryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GLMD:MalteseSubsidiaryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_IsraeliSubsidiaryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GLMD:IsraeliSubsidiaryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_DeferredIncomeTaxChargesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RegulatoryAssetAxis">us-gaap:DeferredIncomeTaxChargesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-03-202025-03-21_custom_TwoThousandAndTwentySalesAgreementMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GLMD:TwoThousandAndTwentySalesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-03-20</xbrli:startDate>
        <xbrli:endDate>2025-03-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-03-202025-03-21_us-gaap_SubsequentEventMember_custom_CaymanIslandsExemptLimitedPartnershipMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GLMD:CaymanIslandsExemptLimitedPartnershipMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-03-20</xbrli:startDate>
        <xbrli:endDate>2025-03-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-03-202025-03-21_custom_TwoThousandAndTwentySalesAgreementMember_us-gaap_SubsequentEventMember_custom_CaymanIslandsExemptLimitedPartnershipMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GLMD:TwoThousandAndTwentySalesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">GLMD:CaymanIslandsExemptLimitedPartnershipMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-03-20</xbrli:startDate>
        <xbrli:endDate>2025-03-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-03-212025-03-21_custom_TwoThousandAndTwentySalesAgreementMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595353</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GLMD:TwoThousandAndTwentySalesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-03-21</xbrli:startDate>
        <xbrli:endDate>2025-03-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Sqft">
      <xbrli:measure>utr:sqft</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Integer">
      <xbrli:measure>GLMD:Integer</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="ILSPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:ILS</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="ILS">
      <xbrli:measure>iso4217:ILS</xbrli:measure>
    </xbrli:unit>
  <ix:relationship fromRefs="Fact000128" toRefs="Footnote000161"/>
  <ix:relationship fromRefs="Fact000129" toRefs="Footnote000161"/>
  <ix:relationship fromRefs="Fact000193" toRefs="Footnote000216"/>
  <ix:relationship fromRefs="Fact000195" toRefs="Footnote000216"/>
  <ix:relationship fromRefs="Fact000197" toRefs="Footnote000216"/>
  <ix:relationship fromRefs="Fact000199" toRefs="Footnote000216"/>
  <ix:relationship fromRefs="Fact000201" toRefs="Footnote000216"/>
  <ix:relationship fromRefs="Fact000203" toRefs="Footnote000216"/>
  <ix:relationship fromRefs="Fact000205" toRefs="Footnote000216"/>
  <ix:relationship fromRefs="Fact000207" toRefs="Footnote000216"/>
  <ix:relationship fromRefs="Fact000209" toRefs="Footnote000216"/>
  <ix:relationship fromRefs="Fact000211" toRefs="Footnote000216"/>
  <ix:relationship fromRefs="Fact000213" toRefs="Footnote000216"/>
  <ix:relationship fromRefs="Fact000215" toRefs="Footnote000216"/>
  <ix:relationship fromRefs="xdx2ixbrl0250" toRefs="Footnote000405"/>
  <ix:relationship fromRefs="Fact000242" toRefs="Footnote000406"/>
  <ix:relationship fromRefs="Fact000258" toRefs="Footnote000406"/>
  <ix:relationship fromRefs="Fact000278" toRefs="Footnote000406"/>
  <ix:relationship fromRefs="Fact000288" toRefs="Footnote000406 Footnote000409"/>
  <ix:relationship fromRefs="Fact000296" toRefs="Footnote000406 Footnote000409"/>
  <ix:relationship fromRefs="Fact000322" toRefs="Footnote000406"/>
  <ix:relationship fromRefs="Fact000330" toRefs="Footnote000406"/>
  <ix:relationship fromRefs="Fact000338" toRefs="Footnote000406 Footnote000410"/>
  <ix:relationship fromRefs="Fact000346" toRefs="Footnote000406 Footnote000410"/>
  <ix:relationship fromRefs="Fact000354" toRefs="Footnote000406 Footnote000409"/>
  <ix:relationship fromRefs="Fact000362" toRefs="Footnote000406"/>
  <ix:relationship fromRefs="Fact000370" toRefs="Footnote000406 Footnote000409"/>
  <ix:relationship fromRefs="Fact000396" toRefs="Footnote000406"/>
  <ix:relationship fromRefs="Fact000404" toRefs="Footnote000406"/>
  <ix:relationship fromRefs="Fact000280" toRefs="Footnote000409"/>
  <ix:relationship fromRefs="Fact000281" toRefs="Footnote000409"/>
  <ix:relationship fromRefs="xdx2ixbrl0282" toRefs="Footnote000409"/>
  <ix:relationship fromRefs="xdx2ixbrl0283" toRefs="Footnote000409"/>
  <ix:relationship fromRefs="Fact000284" toRefs="Footnote000409"/>
  <ix:relationship fromRefs="Fact000290" toRefs="Footnote000409"/>
  <ix:relationship fromRefs="Fact000291" toRefs="Footnote000409"/>
  <ix:relationship fromRefs="xdx2ixbrl0292" toRefs="Footnote000409"/>
  <ix:relationship fromRefs="xdx2ixbrl0293" toRefs="Footnote000409"/>
  <ix:relationship fromRefs="xdx2ixbrl0294" toRefs="Footnote000409"/>
  <ix:relationship fromRefs="Fact000348" toRefs="Footnote000409"/>
  <ix:relationship fromRefs="Fact000349" toRefs="Footnote000409"/>
  <ix:relationship fromRefs="xdx2ixbrl0352" toRefs="Footnote000409"/>
  <ix:relationship fromRefs="Fact000364" toRefs="Footnote000409"/>
  <ix:relationship fromRefs="Fact000365" toRefs="Footnote000409"/>
  <ix:relationship fromRefs="Fact000368" toRefs="Footnote000409"/>
  <ix:relationship fromRefs="Fact000332" toRefs="Footnote000410"/>
  <ix:relationship fromRefs="Fact000333" toRefs="Footnote000410"/>
  <ix:relationship fromRefs="xdx2ixbrl0334" toRefs="Footnote000410"/>
  <ix:relationship fromRefs="xdx2ixbrl0335" toRefs="Footnote000410"/>
  <ix:relationship fromRefs="Fact000336" toRefs="Footnote000410"/>
  <ix:relationship fromRefs="Fact000340" toRefs="Footnote000410"/>
  <ix:relationship fromRefs="Fact000341" toRefs="Footnote000410"/>
  <ix:relationship fromRefs="Fact000344" toRefs="Footnote000410"/>
  <ix:relationship fromRefs="Fact000448" toRefs="Footnote000567"/>
  <ix:relationship fromRefs="xdx2ixbrl0449" toRefs="Footnote000567"/>
  <ix:relationship fromRefs="xdx2ixbrl0450" toRefs="Footnote000567"/>
  <ix:relationship fromRefs="Fact000456" toRefs="Footnote000567"/>
  <ix:relationship fromRefs="xdx2ixbrl0457" toRefs="Footnote000567"/>
  <ix:relationship fromRefs="xdx2ixbrl0458" toRefs="Footnote000567"/>
  <ix:relationship fromRefs="xdx2ixbrl0496" toRefs="Footnote000567"/>
  <ix:relationship fromRefs="xdx2ixbrl0497" toRefs="Footnote000567"/>
  <ix:relationship fromRefs="Fact000498" toRefs="Footnote000567"/>
  <ix:relationship fromRefs="Fact000500" toRefs="Footnote000567"/>
  <ix:relationship fromRefs="xdx2ixbrl0501" toRefs="Footnote000567"/>
  <ix:relationship fromRefs="xdx2ixbrl0502" toRefs="Footnote000567"/>
  <ix:relationship fromRefs="xdx2ixbrl0504" toRefs="Footnote000567"/>
  <ix:relationship fromRefs="Fact000505" toRefs="Footnote000567"/>
  <ix:relationship fromRefs="xdx2ixbrl0506" toRefs="Footnote000567"/>
  <ix:relationship fromRefs="Fact000436" toRefs="Footnote000568"/>
  <ix:relationship fromRefs="xdx2ixbrl0437" toRefs="Footnote000568"/>
  <ix:relationship fromRefs="xdx2ixbrl0438" toRefs="Footnote000568"/>
  <ix:relationship fromRefs="Fact000528" toRefs="Footnote000568"/>
  <ix:relationship fromRefs="xdx2ixbrl0529" toRefs="Footnote000568"/>
  <ix:relationship fromRefs="xdx2ixbrl0530" toRefs="Footnote000568"/>
  <ix:relationship fromRefs="Fact000532" toRefs="Footnote000569"/>
  <ix:relationship fromRefs="Fact000533" toRefs="Footnote000569"/>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 4pt solid; border-bottom: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>Form
<span id="xdx_90E_edei--DocumentType_c20240101__20241231_zmQv5BB9ZzBj"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000015" name="dei:DocumentType">20-F</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--DocumentRegistrationStatement_c20240101__20241231_z3RVrYBSsiel"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000016" name="dei:DocumentRegistrationStatement">&#9744;</ix:nonNumeric></span>
<b>REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OR</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--DocumentAnnualReport_c20240101__20241231_zXuypOY4Wa04"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000017" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric></span>
<b>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the fiscal year ended <span id="xdx_90B_edei--DocumentPeriodEndDate_c20240101__20241231_zhKGqndtYHYh"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:datemonthdayyearen" id="Fact000018" name="dei:DocumentPeriodEndDate"><span id="xdx_905_edei--CurrentFiscalYearEndDate_c20240101__20241231_zbxC2k68AxGh"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:datemonthdayen" id="Fact000019" name="dei:CurrentFiscalYearEndDate">December 31</ix:nonNumeric></span>, <span id="xdx_901_edei--DocumentFiscalYearFocus_c20240101__20241231_z0AfsPqqGmJi"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000020" name="dei:DocumentFiscalYearFocus">2024</ix:nonNumeric></span></ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_edei--DocumentTransitionReport_c20240101__20241231_zMgsg4MmTJD7"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000021" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span>
<b>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OR</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_edei--DocumentShellCompanyReport_c20240101__20241231_zTySjMHMEIGg"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000022" name="dei:DocumentShellCompanyReport">&#9744;</ix:nonNumeric></span>
<b>SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date
of event requiring this shell company report ________________</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the transition period from _______________________________ </b>to <b>_______________________________</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Commission
File No. <span id="xdx_907_edei--EntityFileNumber_c20240101__20241231_zTznvLxx6pA7"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000023" name="dei:EntityFileNumber">001-36345</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_90B_edei--EntityRegistrantName_c20240101__20241231_zEdKaSdXRQof"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000024" name="dei:EntityRegistrantName">GALMED
PHARMACEUTICALS LTD.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(Exact
name of Registrant as specified in its charter)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>N/A</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(Translation
of the Registrant&#8217;s name into English)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>State
of <span id="xdx_902_edei--EntityIncorporationStateCountryCode_c20240101__20241231_z2tO25yi2dIg"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:edgarprovcountryen" id="Fact000025" name="dei:EntityIncorporationStateCountryCode">Israel</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(Jurisdiction
of incorporation or organization)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90D_edei--EntityAddressAddressLine1_c20240101__20241231_zu6GwnygjW59"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000026" name="dei:EntityAddressAddressLine1">16
Abba Hillel Road</ix:nonNumeric></span>, <span id="xdx_906_edei--EntityAddressCityOrTown_c20240101__20241231_zVTHkR7EoUpf"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000027" name="dei:EntityAddressCityOrTown">Ramat Gan</ix:nonNumeric></span>, <span id="xdx_901_edei--EntityAddressCountry_c20240101__20241231_zF4pUGcS9sse"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:countrynameen" id="Fact000028" name="dei:EntityAddressCountry">Israel</ix:nonNumeric></span> <span id="xdx_901_edei--EntityAddressPostalZipCode_c20240101__20241231_zgM6QWk8Ju5c"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000029" name="dei:EntityAddressPostalZipCode">5250608</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(Address
of principal executive offices)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90D_edei--ContactPersonnelName_c20240101__20241231__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zb10VaqxEP63"><ix:nonNumeric contextRef="From2024-01-012024-12-31_dei_BusinessContactMember" id="Fact000030" name="dei:ContactPersonnelName">Allen
Baharaff</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>President
and Chief Executive Officer</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_906_edei--EntityAddressAddressLine1_c20240101__20241231__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_z11STqGOo0uk"><ix:nonNumeric contextRef="From2024-01-012024-12-31_dei_BusinessContactMember" id="Fact000031" name="dei:EntityAddressAddressLine1">16
Abba Hillel Road</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_905_edei--EntityAddressCityOrTown_c20240101__20241231__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zPNjHTjvARg6"><ix:nonNumeric contextRef="From2024-01-012024-12-31_dei_BusinessContactMember" id="Fact000032" name="dei:EntityAddressCityOrTown">Ramat
Gan</ix:nonNumeric></span>, <span id="xdx_905_edei--EntityAddressCountry_c20240101__20241231__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zCpkdQ1AC4y5"><ix:nonNumeric contextRef="From2024-01-012024-12-31_dei_BusinessContactMember" format="ixt-sec:countrynameen" id="Fact000033" name="dei:EntityAddressCountry">Israel</ix:nonNumeric></span> <span id="xdx_90E_edei--EntityAddressPostalZipCode_c20240101__20241231__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zrGCQwAQx1x1"><ix:nonNumeric contextRef="From2024-01-012024-12-31_dei_BusinessContactMember" id="Fact000034" name="dei:EntityAddressPostalZipCode">5250608</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E-mail:
<span id="xdx_905_edei--ContactPersonnelEmailAddress_c20240101__20241231__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zCH8JOv4fCJc"><ix:nonNumeric contextRef="From2024-01-012024-12-31_dei_BusinessContactMember" id="Fact000035" name="dei:ContactPersonnelEmailAddress">ab@galmedpharma.com</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Tel:
<span id="xdx_904_edei--CityAreaCode_c20240101__20241231__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zhItUwZwXULh"><ix:nonNumeric contextRef="From2024-01-012024-12-31_dei_BusinessContactMember" id="Fact000036" name="dei:CityAreaCode">+972.3</ix:nonNumeric></span>.<span id="xdx_906_edei--LocalPhoneNumber_c20240101__20241231__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zMWXgJmbCCNh"><ix:nonNumeric contextRef="From2024-01-012024-12-31_dei_BusinessContactMember" id="Fact000037" name="dei:LocalPhoneNumber">693.8448</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fax:
+972.3.693.8447</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(Name,
Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities
registered or to be registered pursuant to Section 12(b) of the Act.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 36%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Title
    of each class</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 22%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Trading
    Symbol(s)</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 38%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Name
    of each exchange on which registered</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_903_edei--Security12bTitle_c20240101__20241231_zNkRjO6MVteb"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000038" name="dei:Security12bTitle">Ordinary shares, par
    value NIS 0.15 per share</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90A_edei--TradingSymbol_c20240101__20241231_zk8O7d59ay6b"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000039" name="dei:TradingSymbol">GLMD</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_908_edei--SecurityExchangeName_c20240101__20241231_zDSbbvoiBGQ1"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:exchnameen" id="Fact000040" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Capital Market</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities
registered or to be registered pursuant to Section 12(g) of the Act.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>N/A</b></span></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(Title
of each class)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities
registered or to be registered pursuant to Section 15(d) of the Act.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>N/A</b></span></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(Title
of each class)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Indicate
the number of outstanding shares of each of the issuer&#8217;s classes of capital or common stock as of the close of the period covered
by the annual report (December 31, 2024): <span id="xdx_90F_edei--EntityCommonStockSharesOutstanding_iI_c20241231_zSBwDVPFAWG1"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2024-12-31" id="Fact000041" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,654,428</ix:nonFraction></span> ordinary shares are outstanding</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes </b>&#9744; <b><span id="xdx_908_edei--EntityWellKnownSeasonedIssuer_c20240101__20241231_zL0TNseaxljd"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000042" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric></span>
</b>&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>If
this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section
13 or 15(d) of the Securities Exchange Act of 1934. Yes </b>&#9744; <b><span id="xdx_909_edei--EntityVoluntaryFilers_c20240101__20241231_zGecGBHJOxN5"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000043" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric></span> </b>&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 16.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
&#8211; Checking the box above will not relieve any registrant required to file reports pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934 from their obligations under those Sections.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. <span id="xdx_905_edei--EntityCurrentReportingStatus_c20240101__20241231_z15UOOVFUZ4l"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000044" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span> </b>&#9746; <b>No </b>&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit and post such files). <span id="xdx_90B_edei--EntityInteractiveDataCurrent_c20240101__20241231_zOxdPYAnSqRk"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000045" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span> </b>&#9746; <b>No </b>&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or an emerging growth
company. See definition of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; and &#8220;emerging growth company&#8221;
in Rule 12b-2 of the Exchange Act.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Large accelerated filer </b>&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 35%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accelerated filer </b>&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 35%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_904_edei--EntityFilerCategory_c20240101__20241231_zRdiD0obZFU7"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:entityfilercategoryen" id="Fact000046" name="dei:EntityFilerCategory">Non-accelerated filer</ix:nonNumeric></span> </b>&#9746;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Emerging growth company </b><span id="xdx_902_edei--EntityEmergingGrowthCompany_c20240101__20241231_z4NRccrMqwP1"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000047" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>If
an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards &#8224; provided
pursuant to Section 13(a) of the Securities Act. &#9744;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8224;
<b>The term &#8220;new or revised financial accounting standard&#8221; refers to any update issued by the Financial Accounting Standards
Board to its Accounting Standards Codification after April 5, 2012.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Indicate
by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness
of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered
public accounting firm that prepared or issued its audit report. </b><span id="xdx_902_edei--IcfrAuditorAttestationFlag_c20240101__20241231_z4anQXAvFYLl"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000048" name="dei:IcfrAuditorAttestationFlag">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 16.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>If
securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant
included in the filing reflect the correction of an error to previously issued financial statements. <span id="xdx_90C_edei--DocumentFinStmtErrorCorrectionFlag_c20240101__20241231_zxjEK0dEa109"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000049" name="dei:DocumentFinStmtErrorCorrectionFlag">&#9744;</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 16.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Indicate
by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation
received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Indicate
by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_907_edei--DocumentAccountingStandard_c20240101__20241231_zrvVSCEfGo94"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000050" name="dei:DocumentAccountingStandard">U.S. GAAP</ix:nonNumeric></span> </b>&#9746;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>International
                           Financial Reporting Standards</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>as
    issued by the International Accounting Standards Board </b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>If
&#8220;Other&#8221; has been checked in response to the previous question indicate by check mark which financial statement item the Registrant
has elected to follow: Item 17 &#9744; Item 18 </b>&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>If
this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange
Act). Yes </b>&#9744; <b>No </b><span id="xdx_90B_edei--EntityShellCompany_dbF_c20240101__20241231_z90wraeTotL4"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000051" name="dei:EntityShellCompany">&#9746;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 16.2pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 16.2pt"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; border-bottom: Black 4pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 16.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: right">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TABLE
OF CONTENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#aj_001">PART I</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#aj_002">ITEM 1. Identity of Directors, Senior Management and Advisers.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#aj_003">ITEM 2. Offer Statistics and Expected Timetable.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#aj_004">ITEM 3. Key Information.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_001">ITEM 4. Information on the Company.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_002">ITEM 4A. Unresolved Staff Comments.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">89</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_003">ITEM 5. Operating and Financial Review and Prospects.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">90</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><a href="#aa_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 6. Directors, Senior Management and Employees.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">97</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><a href="#aa_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 7. Major Shareholders and Related Party Transactions.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">120<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><a href="#aa_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 8. Financial Information.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">121<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><a href="#aa_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 9. The Offer and Listing.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">124<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><a href="#aa_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 10. Additional Information.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">122</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><a href="#aa_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 11. Quantitative and Qualitative Disclosures About Market Risk.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">135</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><a href="#aa_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 12. Description of Securities Other Than Equity Securities.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">136<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#aa_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART II</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">136</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><a href="#aa_009"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 13. Defaults, Dividend Arrearages and Delinquencies.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">136</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><a href="#aa_010"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 14. Material Modifications to the Rights of Security Holders and Use of Proceeds.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">136</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><a href="#aa_011"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 15. Controls and Procedures.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">136</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><a href="#aa_012"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16. [RESERVED]</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">137</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><a href="#aa_013"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16A. Audit Committee Financial Expert.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">137</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><a href="#aa_014"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16B. Code of Ethics.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">137</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><a href="#aa_015"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16C. Principal Accountant Fees and Services.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">138</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><a href="#aa_016"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16D. Exemptions from the Listing Standards for Audit Committees.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">138</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><a href="#aa_017"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16E. Purchases of Equity Securities by the Issuer and Affiliated Purchasers.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">139</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><a href="#aa_018"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16F. Change in Registrant&#8217;s Certifying Accountant.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">139</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><a href="#aa_019"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16G. Corporate Governance.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">139</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><a href="#aa_020"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16H. Mine Safety Disclosure.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">140</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><a href="#aa_021"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16I. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">141</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><a href="#aa_022"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16J. Insider Trading Policies.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">141</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><a href="#aa_023"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16K. Cybersecurity.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">141</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#aa_024"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART III</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">141</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><a href="#aa_025"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 17. Financial Statements.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">143</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><a href="#aa_026"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 18. Financial Statements.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">142<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><a href="#aa_027"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 19. Exhibits</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">143</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ABOUT
THIS ANNUAL REPORT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
references to &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;the Company&#8221; and &#8220;our Company&#8221;, in this
Annual Report on Form 20-F, or our annual report, are to Galmed Pharmaceuticals Ltd. and its subsidiaries, unless the context otherwise
requires. All references to Aramchol mean Aramchol acid or Aramchol meglumine (salt), unless the context otherwise requires. All references
to &#8220;shares&#8221; or &#8220;ordinary shares&#8221; are to our ordinary shares, NIS 0.15 nominal par value per share. All references
to &#8220;Israel&#8221; are to the State of Israel. &#8220;U.S. GAAP&#8221; means the generally accepted accounting principles of the
United States. Unless otherwise stated, all of our financial information presented in this annual report has been prepared in accordance
with U.S. GAAP. Any discrepancies in any table between totals and sums of the amounts listed are due to rounding. Unless otherwise indicated,
or the context otherwise requires, references in this annual report to financial and operational data for a particular year refer to
the fiscal year of our company ended December 31 of that year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
reporting currency and financial currency is the U.S. dollar. In this annual report, &#8220;NIS&#8221; means New Israeli Shekel, and
&#8220;$,&#8221; &#8220;US$&#8221; and &#8220;U.S. dollars&#8221; mean United States dollars.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
information in this Annual Report on Form 20-F relating to shares or price per share reflects the 1-for-15 reverse share split effected
by us on May 15, 2023 and the 1-for-12 reverse share split effected by us on August 29, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
annual report contains forward-looking statements about our expectations, beliefs or intentions regarding, among other things, our product
development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time to time, we
or our representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified
by the use of forward-looking words such as &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;may,&#8221;
&#8220;should,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;might,&#8221; &#8220;seek,&#8221; &#8220;target,&#8221; &#8220;will,&#8221;
&#8220;project,&#8221; &#8220;forecast,&#8221; &#8220;continue&#8221; or their negatives or variations of these words or other comparable
words or by the fact that these statements do not relate strictly to historical matters. These forward-looking statements may be included
in, among other things, various filings made by us with the U.S. Securities and Exchange Commission, or the SEC, press releases or oral
statements made by or with the approval of one of our authorized executive officers. Forward-looking statements relate to anticipated
or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters
that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to
differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause our actual
activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but
not limited to, the factors summarized below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">the development and approval of the use of Aramchol or any other product candidate for indications outside of non-alcoholic steatohepatitis,
or NASH, also known as metabolic dysfunction-associated steatohepatitis, or MASH, and fibrosis or in combination therapy;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing and cost  of any pre-clinical or clinical trials of Aramchol or any other product candidate we develop;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">completion and receiving
    favorable results of any pre-clinical
    or clinical trial;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory action with
    respect to Aramchol or any other product candidate by the U.S. Food and Drug Administration, or the FDA, or the European Medicines
    Authority, or EMA, including but not limited to acceptance of an application for marketing authorization, review and approval of
    such application, and, if approved, the scope of the approved indication and labeling;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the commercial launch and
    future sales of Aramchol and any future product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to comply with
    all applicable post-market regulatory requirements for Aramchol, or any other product candidate in the countries in which
    we seek to market the product;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to achieve
    favorable pricing for Aramchol, or any other product candidate;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">third-party payor reimbursement
    for Aramchol, or any other product candidate;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our estimates regarding
    anticipated capital requirements and our needs for additional financing;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">market adoption of Aramchol
    or any other product candidate by physicians and patients;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the timing, cost or other
    aspects of the commercial launch of Aramchol or any other product candidate;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to obtain and
    maintain adequate protection of our intellectual property;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the possibility that we
    may face third-party claims of intellectual property infringement;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to manufacture
    our product candidates in commercial quantities, at an adequate quality or at an acceptable cost;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to establish
    adequate sales, marketing and distribution channels;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">intense competition in
    our industry, with competitors having substantially greater financial, technological, research and development, regulatory and clinical,
    manufacturing, marketing and sales, distribution and personnel resources than we do;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our expectations
    regarding licensing, acquisitions and strategic operations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">current or
    future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated
    liquidity risk;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability
    to maintain the listing of our ordinary shares on The Nasdaq Capital Market;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">security, political
    and economic instability in the Middle East that could harm our business, including due to the current security situation in Israel;
    and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">those factors
    referred to in &#8220;Item 3.D. Risk Factors,&#8221; &#8220;Item 4. Information on the Company,&#8221; and &#8220;Item 5. Operating
    and Financial Review and Prospects&#8221;, as well as in this annual report on Form 20-F generally.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe these forward-looking statements are reasonable; however, these statements are only current predictions and are subject to known
and unknown risks, uncertainties and other factors that may cause our or our industry&#8217;s actual results, levels of activity, performance
or achievements to be materially different from those anticipated by the forward-looking statements. We discuss many of these risks in
this annual report in greater detail under the heading &#8220;Risk Factors&#8221; and elsewhere in this annual report. Given these uncertainties,
you should not rely upon forward-looking statements as predictions of future events.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
forward-looking statements attributable to us or persons acting on our behalf speak only as of the date hereof and are expressly qualified
in their entirety by the cautionary statements included in this annual report. We undertake no obligations to update or revise forward-looking
statements to reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated events. In
evaluating forward-looking statements, you should consider these risks and uncertainties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXPLANATORY
NOTE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market
data and certain industry data and forecasts used throughout this annual report were obtained from internal company surveys, market research,
consultant surveys commissioned by the Company, publicly available information, reports of governmental agencies and industry publications
and surveys. Industry surveys, publications, consultant surveys commissioned by the Company and forecasts generally state that the information
contained therein has been obtained from sources believed to be reliable. However, this information may prove to be inaccurate because
of the method by which some of the data for the estimates is obtained or because this information cannot always be verified with complete
certainty due to the limits on the availability and reliability of raw data, the voluntary nature of the data gathering process and other
limitations and uncertainties. As a result, the market and industry data and forecasts included or incorporated by reference in this
annual report, and estimates and beliefs based on that data, may not be reliable. We have relied on certain data from third-party sources,
including internal surveys, industry forecasts and market research, which we believe to be reliable based on our management&#8217;s knowledge
of the industry. However, we have not ascertained the underlying economic assumptions relied upon therein. Forecasts are particularly
likely to be inaccurate, especially over long periods of time. In addition, we do not necessarily know what assumptions regarding general
economic growth were used in preparing the forecasts we cite. Statements as to our market position are based to the best of our knowledge
on the most currently available data. While we are not aware of any misstatements regarding the industry data presented in this annual
report, our estimates involve risks and uncertainties and are subject to change based on various factors, including those discussed under
the heading &#8220;Risk Factors&#8221; in this annual report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aj_001"></span>PART
I</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aj_002"></span>ITEM
1. Identity of Directors, Senior Management and Advisers.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aj_003"></span>ITEM
2. Offer Statistics and Expected Timetable.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aj_004"></span>ITEM
3. Key Information.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.
[Reserved.]</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.
Capitalization and Indebtedness.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.
Reasons for the Offer and Use of Proceeds.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.
Risk Factors.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
of Risk Factors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
investment in our ordinary shares is subject to a number of risks. The following summarizes some, but not all, of these risks. Please
carefully consider all of the information discussed in &#8220;Item 3. Key Information&#8212;D. Risk Factors&#8221; in this annual report
for a more thorough description of these and other risks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
Related to Our Financial Position and Capital Requirements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are a biopharmaceutical
    company with a history of operating losses. We expect to incur significant additional losses in the future and may never be profitable.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have not yet commercialized
    any products and we may never be able to do so, and even if we do, the products may not gain market acceptance.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We will need substantial,
    additional capital in the future. If additional capital is not available, we will have to delay, reduce or cease operations.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are unable to estimate
    our long-term capital requirements due to uncertainties associated with the development and commercialization of Aramchol or any other product candidate. If we fail to obtain necessary funds for our operations, we will be unable to develop and commercialize
    Aramchol or any other product candidate.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
Related to Our Business, Industry and Regulatory Requirements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    depend largely on the success of our lead product candidate, Aramchol, and we may not obtain regulatory approval of Aramchol.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    activities to identify and, evaluate new indications and product candidates and expand our product portfolio may not be successful.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span>&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    clinical trial process is complex and expensive, and commencement and completion of clinical trials can be delayed or prevented for
    a number of reasons.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are advancing the development of Aramchol in combination with other therapies, which exposes us to additional risks.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may be forced to abandon development of Aramchol or any other product candidate which would have a material adverse effect on our
    business and may force us to cease operations.</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have historically developed Aramchol for the treatment of NASH, and there is significant uncertainty regarding the regulatory approval process. In addition, during 2022,
    we discontinued our open label part of the ARMOR Study and we do not currently expect to initiate the second part of the ARMOR Study.
    </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We manage our business
    through a small number of senior executive officers. We depend on them even more than similarly- situated companies.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
Related to Our Reliance on Third Parties</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have no manufacturing
    capacity and anticipate reliance on third-party manufacturers for Aramchol or any other product candidate.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any collaboration arrangements
    that we may enter into in the future may not be successful, which could adversely affect our ability to develop and commercialize
    our current and potential future product candidates.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We depend on third parties
    to conduct our clinical trials.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
Related to Our Intellectual Property</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The failure to obtain or
    maintain patents, licensing agreements and other intellectual property rights that are sufficiently broad and protective could impact
    our ability to compete effectively.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">We may infringe the intellectual property rights of others, which may prevent or delay our product development efforts and stop us from
commercializing, or increase the costs of commercializing, Aramchol or or any other product candidate.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
Related to Ownership of Our Ordinary Shares</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our business, operating
    results and growth rates may be adversely affected by current or future unfavorable economic and market conditions and adverse developments
    with respect to financial institutions and associated liquidity risk.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The market price of our
    ordinary shares is volatile and you may sustain a complete loss of your investment.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we fail to comply with
    the continued listing requirements of the Nasdaq Capital Market, our ordinary shares may be delisted and the price of our ordinary
    shares and our ability to access the capital markets could be negatively impacted.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our U.S. shareholders may
    suffer adverse tax consequences due to our classification as a passive foreign investment company.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
Related to Israeli Law and Our Operations in Israel</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our headquarters and other
    significant operations are located in Israel and, therefore, our results may be adversely affected by political, economic and military
    instability in Israel, such as the current war and security situation therein </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provisions of Israeli law
    and our articles of association, or Articles, may delay, prevent or otherwise impede a merger with, or an acquisition of, our company,
    which could prevent a change of control, even when the terms of such a transaction are favorable to us and our shareholders.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Your rights, liabilities
    and responsibilities as a shareholder will be governed by Israeli law and differ in some material respects from those under U.S.
    law.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RISK
FACTORS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
investment in our ordinary shares involves a high degree of risk. Prior to making a decision about investing in our ordinary shares,
you should carefully consider the risks, uncertainties and assumptions set forth below. Additional risks and uncertainties not presently
known to us, or that we currently see as immaterial, may also harm our business. If any of these risks occur, our business, financial
condition and operating results could be harmed, the trading price of our ordinary shares could decline and you could lose part or all
of your investment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Financial Position and Capital Requirements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are a biopharmaceutical company with a history of operating losses. We expect to incur significant additional losses in the future and
may never be profitable.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a biopharmaceutical company with an operating history limited to pre-clinical and clinical drug development and no approved
products. We are currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis. <span style="background-color: white">In
addition, as part of our growth strategy, we are actively pursuing opportunities to expand and diversify our product pipeline
specifically targeting cardiometabolic indications and other innovative product candidates that align with our core expertise in
drug development.</span> During 2022, we discontinued the open-label part of the ARMOR Study having reached its objectives and at
various times since have conducted a strategic review process. Following the discontinuation of our open label part of the ARMOR
Study, we do not currently expect to initiate the second part of the ARMOR Study. In addition, we have limited operating experience
and have not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by
companies in new and rapidly evolving fields, particularly in the pharmaceutical industry. We have funded our research and
development programs and operations to date primarily through proceeds from private placements and public offerings. We currently
have no products approved for marketing in the United States or any other jurisdiction and have not generated any revenue from
product sales to date, although we have historically generated revenue from our licensing agreement with Samil Pharm. Co., Ltd., or
Samil. We have incurred operating losses in each year since the inception of our predecessor in 2000. Our loss attributable to
holders of our ordinary shares for the years ended December 31, 2023, and 2024 was approximately $6.9 &#160;&#160;million and $7.5
&#160;&#160;million, respectively. As of December 31, 2024, we had an accumulated deficit of $200.5 million. Substantially all of
our operating losses resulted from costs incurred in connection with our development program and from general and administrative
costs associated with our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to become profitable depends upon our ability to generate revenue in excess of our expenses. To date, we have not generated
any significant revenue, excluding the licensing revenue we recorded in connection with that certain Samil Agreement (as defined
below), as our lead product candidate, Aramchol and has not been approved by the FDA, nor has any other product candidate. We do not
know when, or if, we will generate any revenue from sales of Aramchol and/or any other product candidate. We do not expect to
generate revenue other than subsequent royalties and/or milestones that can be earned in connection with the Samil Agreement or
other potential license agreements, unless and until we, or an ultimate third-party licensor or acquirer, obtain regulatory and
marketing approval of, and commercialize, Aramchol or any other product candidate. We expect to continue to incur significant research
and development and general and administrative expenses related to our operations. We expect to continue to incur losses, which may
be significant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on our current operating plan, we expect to continue to incur significant
expenses and operating losses for the foreseeable future. We anticipate that our expenses will increase substantially if and as we:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> commence any clinical trials for Aramchol and or any other product candidate and initiate additional
    research and development programs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek regulatory approvals
    for Aramchol or any other product candidate;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek to in-license additional
    products or technologies to develop;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expand our operational,
    financial and management systems and personnel, including personnel to support our clinical development, manufacturing and commercialization
    efforts and our operations as a public company;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">hire additional management
    and other personnel; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">move towards commercialization
    of Aramchol or any other product candidate.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may out-license Aramchol or any other product candidate including through a territorial license, a worldwide license, or
a license for a particular indication, before it is approved by any applicable regulatory agency, commercialized and/or generates revenue,
depending on a number of factors, including, but not limited to, our ability to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">demonstrate a compelling
    and/or novel, pre-clinical, unique mechanism of action of Aramchol or any other product candidate;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain adequate clinical
    results from and progress from the clinical development of Aramchol or any other product candidate;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">develop and obtain regulatory
    approvals in the countries and for the uses we intend to pursue for Aramchol or any other product candidate;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">contract for the manufacture
    of commercial quantities of Aramchol or any other product candidate by a current good manufacturing practice, or cGMP,
    compliant manufacturing facility at acceptable cost levels if marketing approval is received; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish external, and
    potentially in the future, internal, sales and marketing capabilities to effectively market and sell Aramchol or any
    other product candidate in the United States and other countries.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if Aramchol or any other product candidate is approved for commercial sale, it may not gain market acceptance or achieve
commercial success. In addition, we anticipate incurring significant costs associated with seeking regulatory approval and commercialization.
We may not achieve profitability soon after generating product revenue, if ever. If we are unable to generate product revenue, we will
not become profitable and would be unable to continue operations without additional funding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect our research and development expenses to significantly increase if we were to re-initiate our ARMOR Study or initiate any
other pre-clinical or clinical trials. In addition, if we obtain marketing approval for Aramchol or any other product
candidate and opt to commercialize it ourselves, we will likely initially incur significant expenses associated with outsourcing
sales, marketing and manufacturing functions to third parties, as well as continued research and development expenses. Furthermore,
we expect to incur additional costs associated with operating as a public company. As a result, we expect to continue to incur significant and increasing operating losses for the foreseeable future. Because of the numerous risks
and uncertainties associated with developing pharmaceutical products, we are unable to predict the extent of any future losses or
when we will become profitable, if at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
limited operating history makes it difficult to evaluate our business and prospects.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operating history is limited to pre-clinical and clinical development and our operations to date have been limited primarily
to research and development, raising capital and recruiting scientific and management personnel and third-party partners. Therefore,
it may be difficult to evaluate our business and prospects. We have not yet demonstrated an ability to commercialize or obtain regulatory
approval for any product candidate. Consequently, any predictions about our future performance may not be accurate, and you may not be
able to fully assess our ability to complete development and/or commercialize our product candidates, obtain regulatory approvals or
achieve market acceptance or favorable pricing for our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have not yet commercialized any products and we may never be able to do so, and even if we do, the products may not gain market acceptance.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not yet commercialized any products and we may never be able to do so. During 2022, we discontinued the open-label part of the
ARMOR Study having reached its objectives and at various times since have conducted a strategic review process. Following the
discontinuation of our open label part of the ARMOR Study, we do not currently expect to initiate the second part of the ARMOR
Study. We are currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis. In
addition, as part of our growth strategy, we are actively pursuing opportunities to expand and diversify our product pipeline
specifically targeting cardiometabolic indications and other innovative product candidates that align with our core expertise in
drug development. We do not know when or if we will complete development of Aramchol or any other product candidate,
obtain regulatory approval, or successfully commercialize any approved products. Even if we are successful in developing products
that are approved for marketing, we will not be successful unless these products gain market acceptance for appropriate indications
at favorable reimbursement rates. The degree of market acceptance for these products will depend on a number of factors,
including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the timing and scope of
    regulatory approvals in the countries we intend to pursue with respect to the commercialization of Aramchol or any other
    product candidate, including the indications for which they are approved;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the competitive environment;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the ability for Aramchol or any other product candidate to be manufactured, whether by us or third parties, in compliance with applicable regulatory
    requirements, including cGMP;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to effectively
    promote Aramchol or any other product candidate, whether directly or using third parties, consistent with the approved indications
    and labeling in the countries in which we intend to pursue approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the acceptance by the medical
    community of the safety and clinical efficacy of Aramchol or any other product candidate and their potential advantages
    over other therapeutic products;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the development of a non-invasive
    method for diagnosing NASH as an alternative to the current gold standard of liver biopsy, which we view as a rate-limiting factor
    to complete market uptake because of its expense and its risks and discomfort to patients;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the adequacy and success
    of distribution, sales and marketing efforts, including through strategic agreements with pharmaceutical and biotechnology companies;
    and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the pricing and reimbursement
    policies of government and third-party payors, such as insurance companies, health maintenance organizations and other plan administrators.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Physicians,
patients, third-party payors or the medical community in general may be unwilling to accept, utilize or recommend, and in the case of
third-party payors, reimburse any of our planned future products. As a result, we are unable to predict the extent of future losses or
the time required to achieve profitability, if at all. Even if we successfully develop one or more products, we may not become profitable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
will need substantial, additional capital in the future. If additional capital is not available, we will have to delay, reduce or cease
operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, we had a net working capital of $14.0 million, cash and cash equivalents of $4.7 million, restricted cash of $0.1
million, short term deposits of $3.5 million and marketable debt securities of $7.2 million. Based on our current operating plan, we currently estimate that our cash position will support our current operations
as currently conducted for more than 12 months from the date of issuance of this annual report. We will need to raise substantial, additional
capital to fund our operations and develop Aramchol for, and beyond its current development
stage, and ultimately commercialize it, if we opt to do so ourselves. In addition, we may expand our current research and development
focus and clinical operations beyond our current focus, which we expect will also require additional capital. Our future capital requirements will depend on many factors including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the progress and costs
    of our pre-clinical studies, clinical trials and other research and development activities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the regulatory pathway
    of Aramchol or any other product candidate;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the scope, prioritization
    and number of our clinical trials and other collaboration, research and development programs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the amount of revenues
    and contributions we receive under future licensing, development and commercialization arrangements with respect to Aramchol or any other product candidate;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs of the development
    and expansion of our operational infrastructure;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs and timing of
    obtaining regulatory approval for Aramchol or any other product candidate;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the ability of us, or our
    collaborators, to achieve development milestones, marketing approval and other events or developments under our potential future
    licensing agreements;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs of filing, prosecuting,
    enforcing and defending patent claims and other intellectual property rights;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs and timing of
    securing manufacturing arrangements for clinical or commercial production;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs of contracting
    with third parties to provide sales and marketing capabilities for us;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs of acquiring
    or undertaking development and commercialization efforts for any future products, product candidates or platforms;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the magnitude of our general
    and administrative expenses;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any cost that we may incur
    under future in- and out-licensing arrangements relating to Aramchol or any other product candidate;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">market conditions; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to maintain
    the listing of our ordinary shares on The Nasdaq Capital Market; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the security situation in Israel, which may exacerbate the magnitude of the factors discussed above.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
General Instruction I.B.5 to Form F-3, or the Baby Shelf Rule, the amount of funds we can raise through primary public offerings of securities
in any 12-month period using our registration statement on Form F-3 is limited to one-third of the aggregate market value of the ordinary
shares held by non-affiliates of the Company. As of March 21, 2025, our public float was approximately $5.0 million, based on 2,192,597
ordinary shares held by non-affiliates and a price of $2.26 per share, which was the last reported sale price of our ordinary shares
on the Nasdaq Capital Market on 21, 2025. We therefore are limited by the Baby Shelf Rule as of the filing of this annual report, until
such time as our public float exceeds $75 million. If we are required to file a new registration statement on another form, we may incur
additional costs and be subject to delays due to review by the SEC Staff.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changing
circumstances may cause us to consume capital significantly faster than we currently anticipate, such as losing our Small and Medium
Enterprise status at the EMA, which entitles us to significant fee reductions. Because there are numerous risks and uncertainties associated
with the development and commercialization of Aramchol or any other product candidate, we are unable to estimate the amount
of increased capital outlays and operating expenditures associated with our anticipated clinical trials. We have no committed external
sources of funds. Additional financing may not be available when we need it or may not be available on terms that are favorable to us
and additional financing may cause significant dilution to our existing shareholders. If adequate funds are not available to us on a
timely basis, or at all, we may be required to terminate or delay planned clinical trials or other development activities
for Aramchol or any other product candidate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Raising
additional capital may be costly or difficult to obtain and will dilute current shareholders&#8217; ownership interests, potentially
substantially.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
debt, equity or structured financing that we may need or desire may not be available on terms favorable to us, or at all. If we obtain
funding through a strategic collaboration or licensing arrangement, we may be required to relinquish our rights to certain of our technologies,
products or marketing territories. If we are unable to obtain required additional capital, we may have to curtail our growth plans or
cut back on existing business, and we may not be able to continue operating if we do not generate sufficient revenues from operations
needed to stay in business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may incur substantial costs in pursuing future capital financing, including investment banking fees, legal fees, accounting fees, securities
law compliance fees, printing and distribution expenses and other costs. We may also be required to recognize non-cash expenses in connection
with certain securities we issue, such as convertible notes and warrants, which may adversely impact our capital structure, financial
condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, our authorized share capital consists of 50,000,000 ordinary shares, par value NIS 0.15 &#160;per share. As of March 21, 2025,
we had 2,258,034 &#160;&#160;ordinary shares issued and outstanding. As of the date of this Annual Report, we also had outstanding warrants
to purchase 173,333 ordinary shares with an exercise price of $15.00 per share. To the extent that warrants are exercised, holders of
our ordinary shares will experience dilution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
additional capital raised through the sale of equity or equity-linked securities, will dilute our current shareholders&#8217; ownership
in us, potentially substantially, and could also result in a decrease in the market price of our ordinary shares. The terms and conditions
of those securities issued by us in future capital transactions may be more favorable to new investors and may include the issuance of
warrants or other derivative securities, which may have a further dilutive effect.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are unable to estimate our long-term capital requirements due to uncertainties associated with the development
and commercialization of Aramchol or any other product candidate. If we fail to obtain necessary funds for our operations,
we will be unable to develop and commercialize Aramchol or any other product candidate.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
long-term capital requirements are expected to depend on many potential factors, including, among others:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the number
    of product candidates in development;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the size, duration and
    scope of existing and future clinical trials and pre-clinical studies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the regulatory pathway
    for the approval of Aramchol or any other product candidate;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the results of our clinical
    trials, which are unpredictable in product candidate development;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to successfully
    commercialize Aramchol or any other product candidate, including securing commercialization and out-licensing agreements
    with third parties and favorable pricing and market share;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the progress, success and
    cost of our clinical trials and research and development programs, including those associated with milestones and royalties;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs, timing and outcome
    of regulatory review and obtaining regulatory approval of Aramchol or any other product candidate and addressing regulatory
    and other issues that may arise post-approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the breadth of the labeling,
    assuming that Aramchol or any other product candidate are approved for commercialization by a relevant regulatory authority,
    which may not occur;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our need, or decision,
    to acquire or in-license complementary technologies or new platform technologies or product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs of enforcing
    our issued patents and defending intellectual property-related claims;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs of investigating
    patents that might block us from developing potential product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs of recruiting
    and retaining qualified personnel;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs associated with
    contracting with third parties to manufacture the product and to perform other necessary services;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our revenue, if any; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our consumption of available
    resources more rapidly than currently anticipated, resulting in the need for additional funding sooner than anticipated.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unable to obtain the funds necessary for our operations, we will be unable to develop and commercialize Aramchol or
any other product candidate which would materially and adversely affect our business, liquidity and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Business, Industry and Regulatory Requirements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
depend largely on the success of our lead product candidate, Aramchol, and we may not obtain regulatory approval of Aramchol.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have invested almost all of our efforts and financial resources in the research and development (clinical and pre-clinical) of our lead
product candidate, Aramchol. As a result, our business is largely dependent on our ability to complete the development of, obtain regulatory
approval for and successfully commercialize Aramchol in a timely manner. The process to develop, obtain regulatory approval for and commercialize
Aramchol is long, complex, costly and uncertain as to its outcome and we do not currently expect to initiate the second part of the ARMOR
Study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
research, development, testing, clinical trials, manufacturing, labeling, approval, sale, marketing and distribution of drugs are subject
to extensive regulation by the FDA and other regulatory agencies in other countries. These regulations differ from jurisdiction to jurisdiction.
We have not received marketing approval for Aramchol in any jurisdiction. We are not permitted to market Aramchol, or any other product
candidate, in the United States until we receive approval of a New Drug Application, or NDA, from the FDA, or in any foreign countries
until we receive the requisite approval from the respective regulatory agencies in such countries. The results of clinical trials may
be unsatisfactory, and even if we believe those clinical trials to be successful, the FDA, or other regulatory authorities, may not grant
marketing authorization should we be in a position to request it.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
activities to identify and evaluate new indications and product candidates and expand our product portfolio may not be successful.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis. In addition, as part
of our growth strategy, we are actively pursuing opportunities to expand and diversify our product pipeline specifically targeting cardiometabolic
indications and other innovative product candidates that align with our core expertise in drug development. <span style="background-color: white">However,
there can be no assurance that our research efforts or our screening system will accurately or consistently select among various indications
and product candidates those that have the highest likelihood to achieve, and that ultimately achieve, commercial success. </span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
product candidate or technologies we in-license or acquire will likely require additional development efforts prior to commercial sale,
including extensive pre-clinical or clinical testing, or both, and approval by the FDA and applicable foreign regulatory authorities,
if any. All product candidates are prone to risks of failure inherent in pharmaceutical product development, including the possibility
that the product candidate, or product developed based on in-licensed technology, will not be shown to be sufficiently safe and effective
for approval by regulatory authorities. In addition, we cannot assure that any product candidate that we develop based on acquired or
in-licensed technology that is granted regulatory approval will be manufactured or produced economically, successfully commercialized
or widely accepted or competitive in the marketplace. Moreover, integrating any newly acquired or in-licensed product candidates could
be expensive and time-consuming. If we cannot effectively manage these aspects of our business strategy, our business may not succeed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, at various times in the past we have conducted a strategic review process. If we conduct any further strategic review process,
any strategic transaction may require us to incur non-recurring or other charges, may increase our near- and long-term expenditures and
may pose significant integration challenges or disrupt our management or business, which could adversely affect our operations and financial
results. For example, these transactions may entail numerous operational and financial risks, including:</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exposure to unknown liabilities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">incurrence of substantial
    debt or dilutive issuances of equity securities to pay for acquisitions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">higher than anticipated
    acquisition and/or integration costs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">write downs of assets or
    goodwill or impairment charges;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increased amortization
    expenses;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulty and cost in
    combining the operations and personnel of any acquired businesses with our operations and personnel;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">impairment of relationships
    with key suppliers or customers of any acquired businesses due to changes in management and ownership; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the inability to retain
    our key employees or our other service providers or those of any acquired businesses.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">For example, in June 2023, we announced
the closing of a strategic investment in OnKai, Inc., or OnKai, (see &#8220;Item 4. Information on the Company&#8212; Strategic Collaborations,
Research Arrangements and other Agreements&#8212;Onkai.&#8221;) and determined that an impairment in the amount of approximately $1.1
million should be recognized as of December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accordingly,
there can be no assurance that we will undertake or successfully complete any strategic transactions of the nature described above and
any transactions that we do complete may be subject to the foregoing or other risks and could have a material adverse effect on our business,
financial condition and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
clinical trial process is complex and expensive, and commencement and completion of clinical trials can be delayed or prevented for a
number of reasons.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not be able to complete or commence the clinical trials that would support our submission of an NDA to the FDA, a Marketing Authorization
Application or MAA, to the EMA or MHRA or any similar submission to regulatory authorities in other countries. Drug development is a
long, expensive and uncertain process, and delay or failure can occur at any stage of any of our clinical trials. The fact that the FDA,
EMA, MHRA or other regulatory authorities generally require a company to conduct human clinical trials is no assurance or guarantee that
the trials will be successful. On the contrary, most candidate drugs that begin clinical trials do not prove to be successful and do
not result in the filing of an NDA, MAA or similar filing. Drug candidates that successfully complete one phase of clinical trials may
prove unsuccessful at a subsequent phase. Human clinical trials are very expensive and difficult to design and implement, in part because
they are subject to rigorous regulatory requirements and in part because the results of clinical trials are inherently uncertain and
unpredictable. In addition, the design of a clinical trial can determine whether its results will support approval of a product, and
flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced. Regulatory authorities, such
as the FDA, may decline to permit a clinical trial to proceed or may suspend a clinical trial that it has previously permitted to proceed.
Additionally, the clinical trial process is time-consuming, and failure can occur at any stage of the trials. We may encounter problems
that cause us to abandon, delay or repeat clinical trials. The commencement and completion of clinical trials may be delayed by several
factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties obtaining
    regulatory authorization to commence a clinical trial or complying with regulatory requirements for clinical trials or with the conditions
    imposed by a regulatory authority regarding the scope, duration or conduct of a clinical trial;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in reaching or failing
    to reach agreement on acceptable terms with prospective contract research organizations, or CROs, and trial sites, the terms of which
    can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">insufficient or inadequate
    supply or quality of a product candidate or other materials necessary to conduct our clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties in obtaining
    institutional review board, or IRB, approval to conduct a clinical trial at a prospective site;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">challenges in recruiting
    and enrolling patients to participate in clinical trials for a variety of reasons, including size and nature of patient population,
    proximity of patients to clinical sites, eligibility and exclusion criteria for the trial, nature of trial protocol, the availability
    of approved effective treatments for the relevant disease and competition from other clinical trial programs for similar indications;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">challenges in identifying
    or recruiting sufficient study sites or investigators for clinical trials; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limitations on employee
    resources that would otherwise be focused on the conduct of our business including because of military reserve duty call-ups in the
    future that impact our employees and the affect the current war between Israel and Hamas on the productivity of our employees and
    external partners;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in necessary interactions
    with vendors, local regulators, and other important agencies and contractors due to limitations in employee resources;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">impacts from prolonged
    remote work arrangements, such as increased cybersecurity risks and strains on our business continuity plans; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">lack of adequate funding
    to initiate or continue our clinical trials.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we re-initiate the Phase 3 ARMOR Study, the ARMOR Study may still be terminated as a result of, but not limited to, safety signals,
lack of efficacy, uncertainties with regard to the regulatory pathway for the approval of NASH drugs, or commercial considerations based
on the cost-benefit of continuing to run the study. In addition, any clinical trial that we conduct may be suspended or terminated
by us, the FDA or other regulatory authorities, the principal investigator at a site, the IRBs at the sites where such boards are overseeing
a trial or the data safety monitoring board, or the DSMB, that is overseeing the clinical trial at issue, or other regulatory authorities
due to a number of factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">irregularities in conducting
    a clinical trial, including by way of example, failure to conduct the clinical trial in accordance with regulatory requirements,
    in particular good clinical practice requirements, or GCP, or the FDA-authorized clinical protocols;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">negative findings upon
    inspection of the clinical trial operations or trial sites by the FDA or other regulatory authorities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">safety issues or lack of
    clinical drug activity or effectiveness; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">lack of adequate funding
    to continue the clinical trials.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Historically,
we experienced material delays in both the ARMOR Study largely related to significantly slower than expected recruitment and the
ARREST Study largely related to significantly slower than expected recruitment and the length of time required to obtain regulatory
authorizations to proceed with clinical trials. We may experience delays in any or all of our clinical trials that we conduct and
there can be no assurance that we will not experience such risks in the future as we progress with our planned clinical
trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
positive results in previous clinical studies of our product candidates may not be predictive of similar results in future clinical trials.
Also, interim results, if at all, during a clinical trial do not necessarily predict final results. A number of companies in the pharmaceutical
and biotechnology industries have suffered significant setbacks in late-stage clinical trials even after achieving promising results
in early- and mid-stage development. Accordingly, the results from the completed pre-clinical studies and clinical trials for our product
candidates may not be predictive of the results we may obtain in later stage trials. Our clinical trials may produce negative or inconclusive
results, and we may decide, or regulators may require us, to conduct additional clinical and/or pre-clinical trials, or to even terminate
the development program entirely. Many companies that believed their product candidates performed satisfactorily in pre-clinical and
clinical studies have nonetheless failed to obtain FDA or EMA, or other regulatory agency, approval for their products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we or regulatory authorities may suspend our clinical trials at any time if it appears that we are exposing participants to
unacceptable health risks or if the regulatory authorities find deficiencies in our regulatory submissions or the conduct of such trials.
Any suspension of clinical trials will delay possible regulatory approval, if any, and adversely impact our ability to develop products
and generate revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We are advancing the development of Aramchol
in combination with other therapies, which exposes us to additional risks.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">We are advancing the development
of Aramchol in combination with investigational therapies. We will not be able to market and sell Aramchol or any product candidate we
develop in combination with an unapproved therapy for a combination indication if that unapproved therapy does not ultimately obtain marketing
approval either alone or in combination with our product candidate. In addition, unapproved therapies face the same risks described with
respect to Aramchol or any other product candidate currently in development and clinical trials, including the potential for serious adverse
effects, delay in their clinical trials and lack of FDA, EMA or MHRA approval. If the FDA, EMA, MHRA or comparable foreign regulatory
authorities do not approve these other drugs or revoke their approval of, or if safety, efficacy, quality, manufacturing or supply issues
arise with the product candidates we choose to evaluate in combination with our product candidate we develop, we may be unable to obtain
approval of or market such combination therapy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><b><i>We may be forced to abandon development of Aramchol
or any other product candidate which would have a material adverse effect on our business and may force us to cease operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Upon the completion of any clinical
or pre-clinical trial and/or tests, the results might not support the desired indications for use. Further, success in earlier clinical
trials does not ensure that later clinical trials will be successful, and the results of later clinical trials may not replicate the results
of prior clinical trials or pre-clinical testing. In addition, the design of a clinical trial can determine whether its results will support
approval of a product, and flaws in the design of a clinical trial or variability in interpretation of results may not become apparent
until the clinical trial is well advanced. The clinical trial process may fail to demonstrate that Aramchol or any other product candidate
is sufficiently safe and/or effective for the indications we seek to receive FDA or other regulatory approval. Any such failure may cause
us to abandon Aramchol or any other product candidate and may delay development of other potential product candidates. Any delay in, or
termination or suspension of, our clinical trials may delay the requisite filings with the FDA or other regulatory agencies and, ultimately,
our ability to commercialize Aramchol or any other product candidate and generate product revenues. If the results of any study, including
in any interim readout, are not sufficiently compelling, then the completion of development of our product candidates may be significantly
delayed or abandoned which would have material adverse effect on our business, liquidity, operating results and financial condition and
may force us to cease operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have historically developed Aramchol for the treatment of NASH and there is significant uncertainty regarding the regulatory approval
process. In addition, during 2022, we discontinued our open label part of the ARMOR Study and we do not currently expect to initiate
the second part of the ARMOR Study.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pharmaceutical
products generally are subject to rigorous nonclinical testing and clinical studies and other approval procedures mandated by the FDA
and foreign regulatory authorities. We have historically developed Aramchol for the treatment of NASH.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2019, we initiated the ARMOR Study and during 2022 we discontinued the open-label part of the ARMOR Study having reached its
objectives. Following the discontinuation of our open label part of the ARMOR Study, we do not currently expect to initiate the second
part of the ARMOR Study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
there are guidelines issued by the FDA for the development of drugs for the treatment of NASH, it is our current assessment that despite
considerable efforts from the scientific community and regulatory agencies, there are significant uncertainties that remain unresolved
with regards to the conduct of NASH Phase 3 registrational studies. These risks include dependence on biopsies as the primary surrogate
endpoint which are subjective in nature and prone to sampling errors and inadequacy; high screen failure rates which pose a burden to
patients, investigators, and study budget; lack of validated biomarkers and the heterogenous population included under the NASH diagnosis.
Moreover, pathology plays a role in NASH clinical trials with histology being the current reference method to determine inclusion in
trials and change in disease activity and fibrosis stage. Manual histological review is complex, subjective, and prone to inter- and
intra-reader variability and error. Existing pathology scoring systems and practices show only moderate to fair reproducibility, limiting
their utility for clinical research and practice.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the FDA has indicated that the results of the ARMOR Study must demonstrate study findings that demonstrate findings of a high level of efficacy for a single Phase
3 study to support approval of an NDA. Therefore, even if the ARMOR Study meets all of its statistical goals and protocol endpoints,
the FDA may not view the results as sufficient to support an NDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that the path for regulatory approval for NASH drugs to continue to evolve in the near term as we and other companies in late-stage
development of NASH drugs refine our regulatory approval strategies and interact with the FDA and other regulatory authorities. In particular,
FDA expectations about interpretation of liver biopsy data may evolve especially as more information is published about the inherent
variability in interpretation of liver biopsy data. Certain of our competitors have experienced regulatory setbacks for NASH therapies
following communications from the FDA. See also &#8220;Item 4. Information on the Company&#8212;Competition.&#8221; Even after we receive
and incorporate guidance from the FDA or other regulatory authorities, they could disagree that we have satisfied their requirements,
which may require us to complete additional preclinical studies or clinical trials or impose stricter approval conditions than we currently
expect. Furthermore, as the path for regulatory approval for NASH drugs evolves, it may impact our ARMOR Study in ways that could significantly
increase the development costs and call into question the future viability of continuing to conduct the ARMOR Study. Additionally, we
are considering more robust changes to our development program for NASH. Changes may include focusing on higher risk patients (F3), evaluating
patients with compensated cirrhosis (F4) as well as changes to study design such as two smaller studies instead of one pivotal study
and the addition of a combination arm.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
additional delays in the completion of the ARMOR Study or any additional preclinical studies or clinical trials would require us to expend
substantial additional resources and could significantly extend the timeline for clinical development prior to market approval. As a
result of the foregoing, the research and development, preclinical studies and clinical testing of Aramchol and any other product candidate
is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the development
process. If we experience delays in the completion of, or if we terminate, any of our clinical trials, this would have a material adverse
effect on our business, liquidity, operating results and financial condition and may force us to cease operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
lack of a reliable non-invasive method for the diagnosis of NASH and fibrosis is likely to present a major challenge to Aramchol&#8217;s
market penetration in the NASH market, if ever commercialized for this indication.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liver
biopsy is the standard approach for the diagnosis of inflammation and fibrosis associated with NASH. However, the procedure-related morbidity
and, in rare cases, mortality, sample errors, costs, patient discomfort and thus lack of patient interest in undergoing the procedure
limit its use. As such, only patients with a high risk of NASH, which includes patients with metabolic syndrome and an indication of
Non-Alcoholic Fatty Liver Disease, or NAFLD, are generally sent for liver biopsy. Because NASH tends to be asymptomatic until the disease
progresses, many individuals with NASH remain undiagnosed until the disease has reached its late stages, if at all. The lack of a reliable
non-invasive method for the diagnosis of NASH and fibrosis is likely to present a major challenge to Aramchol&#8217;s market penetration,
as many practitioners and patients may not be aware that a patient suffers from NASH and requires treatment. As such, use of Aramchol
might not be as wide-spread as our actual target market and this may limit the commercial potential of Aramchol.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
further challenge to Aramchol&#8217;s market penetration is that currently a liver biopsy is the standard approach for measuring improvement
in NASH patients. Because it would be impractical to subject all patients that take Aramchol, when and if it is approved, to regular
and repeated liver biopsies, it will be difficult to demonstrate Aramchol&#8217;s effectiveness to practitioners and patients unless
and until a reliable non-invasive method for the diagnosis and monitoring of NASH becomes available, as to which there can be no assurance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">While other companies in the industry
are currently working on advancing non-invasive diagnostic approaches, none of these has been clinically validated, and the timetable
for commercial validation, if at all, is uncertain. Moreover, such diagnostics may also be subject to regulation by FDA or other regulatory
authorities as medical devices and may require premarket clearance or approval. See also &#8220;Item 3. Key Information&#8212;Risk Factors
&#8212;Risk Factors&#8212;Risks Related to Our Business, Industry and Regulatory Requirements &#8212;- We have historically developed
Aramchol for the treatment of NASH, an indication for which there are no approved products, and there is significant uncertainty regarding
the regulatory approval process. In addition, during 2022, we discontinued our open label part of the ARMOR Study and we do not currently
expect to initiate the second part of the ARMOR Study.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Obtaining
approval of an NDA, or other regulatory approval, even after clinical trials that are believed to be successful, is an uncertain process.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we complete clinical trials and believe that the clinical data confirms that Aramchol or any other product candidate is
sufficiently safe and effective for its intended use or uses, obtaining approval of an NDA, or other regulatory approval, is an extensive,
lengthy, expensive and uncertain process, and the FDA and other regulatory agencies may delay, limit or deny approval of such product
candidate for many reasons, including, without limitation, the fact that:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may not be able to demonstrate
    to the satisfaction of the applicable regulatory agencies that the product candidate is safe and effective for treatment of the targeted
    indication in patients;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the results of clinical
    trials may not meet the level of statistical significance or clinical significance required by the applicable regulatory agencies
    for approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the applicable regulatory
    agencies may disagree with the number, design, size, conduct or implementation of our clinical trials;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the applicable regulatory
    agencies may not find the data from pre-clinical studies and clinical trials sufficient to demonstrate the clinical and other benefits
    outweigh its safety risks;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the applicable regulatory
    agencies may disagree with our interpretation of data from pre-clinical studies or clinical trials;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the applicable regulatory
    agencies may not accept data generated at our clinical trial sites;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the data collected from
    pre-clinical studies and clinical trials may not be sufficient to support the submission of an NDA or similar regulatory application;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the applicable regulatory
    agencies may not schedule an advisory committee meeting in a timely manner or the advisory committee may recommend against approval
    of our application or may recommend that the applicable regulatory agencies require, as a condition of approval, additional pre-clinical
    studies or clinical trials, limitations on approved labeling or distribution and use restrictions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the applicable regulatory
    agencies may require development of a risk evaluation and mitigation strategy, or REMS, as a condition of approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the applicable regulatory
    agencies may require simultaneous approval for both adults and children, which would delay required approvals, or we may have successful
    clinical trial results for adults, but not children, or vice versa;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the applicable regulatory
    agencies may change their approval policies or adopt new regulations that may impede consideration or approval of our NDA, or similar
    regulatory application;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the applicable regulatory
    agencies may identify deficiencies in the manufacturing processes or facilities of third-party manufacturers, or suppliers of active
    pharmaceutical ingredients, or APIs, with which we enter into agreements for clinical and commercial supplies; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the applicable regulatory
    agencies may require post-marketing approval studies, such as Phase 4 clinical trials, in connection with Aramchol or any other product
    candidate.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
we can submit an NDA to the FDA or a similar approval application to other regulatory authorities, as applicable, we (or our commercialization
partner, as the case may be) must conduct one or more clinical trials that will be substantially broader than our prior completed trials.
We will also need to agree on a protocol with the FDA or any other regulatory authorities for any clinical trial(s) before commencing
any such trial. Clinical trials frequently produce unsatisfactory results even though prior clinical trials were successful. Therefore,
the results of any prior trial or any future clinical trials that we may conduct may or may not be successful. The applicable regulatory
agencies may suspend all clinical trials or require that we conduct additional clinical, pre-clinical, manufacturing, validation or drug
product quality studies and submit data from these additional studies before considering or reconsidering the NDA or similar regulatory
application. Depending on the extent of these, or any other studies, approval of any applications that we submit may be delayed by several
years, or may require us to expend more resources than we have available. It is also possible that additional studies, if performed and
completed, may not be considered sufficient by the applicable regulatory agencies to provide regulatory approval. If any of these outcomes
occur, we would not receive approval for Aramchol or any other product candidate and may be forced to cease operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we obtain regulatory approval for Aramchol or any other product candidate, the approval might contain significant limitations
related to the indications for use for which the drug is approved, use restrictions including, without limitation, for certain labeled
populations, age groups, warnings, precautions or contraindications, or may be subject to significant post-marketing studies or risk
mitigation requirements. If we are unable to successfully commercialize Aramchol or any other product candidate, we may be
forced to cease operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
product candidates may produce undesirable side effects or have other properties that could delay or prevent its regulatory approval
or result in significant negative consequences following marketing approval, if any, which could substantially increase commercialization
costs or even force us to cease operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Undesirable
side effects caused by Aramchol or any other product candidate could cause us or regulatory authorities to interrupt, delay or halt clinical
trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or applicable foreign regulatory
authorities. To date, we have completed seven clinical trials of Aramchol, and additionally one proof of concept study in patient with
gallstones, and a Phase 2a, investigator initiated clinical trial were completed. Although we have not seen any evidence of reactions
causing a safety concern in our completed clinical trials, it is possible that the FDA may ask for additional data regarding any adverse
events seen in our trials. Results of our future trials could reveal a high and unacceptable severity and prevalence of these or other
side effects. In such an event, our trials could be suspended or terminated and the FDA or applicable foreign regulatory authorities
could order us to cease further development of or deny approval for Aramchol or any other product candidate for any or all
targeted indications. The drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete
future trials or result in potential product liability claims. Any of these occurrences may harm our business, financial condition and
prospects significantly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if Aramchol or any other product candidate receives marketing approval, we or others may later identify undesirable side effects caused
by the product. In such an event, regulatory authorities may:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspend or withdraw their
    approval of the product;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">require the addition of
    labeling statements, such as warnings, so-called &#8220;black box warnings,&#8221; contraindications or restrictions on the product&#8217;s
    intended use;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">require us to issue specific
    communications to healthcare professionals, such as &#8220;Dear Doctor&#8221; letters;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">issue negative publicity
    regarding the affected product, including safety communications;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">impose a risk evaluation
    and mitigation strategy (REMS), in the case of FDA, or similar risk management strategies in the case of foreign regulators;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to these potentially significant negative consequences, we could be required to change the way the product is administered,
conduct additional pre-clinical studies or clinical trials or restrict or cease the distribution or use of the product, and/or be sued
and held liable for harm caused to patients. The foregoing or other events could prevent us from achieving or maintaining market acceptance
of the affected product candidate and could substantially increase commercialization costs or even force us to cease operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise
adversely affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patient
enrollment, a significant factor in the timing of clinical trials, is affected by many factors including the size and nature of the
patient population, the proximity of patients to clinical sites, the eligibility criteria for the trial, the design of the clinical
trial, patient willingness to undergo a liver biopsy (in the case of NASH), competing clinical trials and clinicians&#8217;
and patients&#8217; perceptions as to the potential advantages and disadvantages of the product candidate being studied in relation
to other available therapies, including any new drugs that may be approved for the indications we are investigating, and actual or
threatened public health emergencies and outbreaks of disease.
Potential patients for Aramchol or any other product candidate may not be adequately diagnosed or identified with the
diseases which we are targeting or may not meet the entry criteria for our studies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> We may not be able to initiate or continue clinical trials if we are unable to locate a sufficient number
of eligible patients to participate in the clinical trials required by the FDA or other foreign regulatory agencies. In addition, the
process of finding and diagnosing patients may prove costly. To date, we have already experienced significant delays in our clinical
trials largely related to significantly slower than expected recruitment and the length of time required to obtain regulatory authorizations
to proceed with clinical trials. Our inability to enroll a sufficient number of patients for any of our clinical trials could result
in further significant delays, additional expenses, or may require us to abandon one or more clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Even
if Aramchol or any other product candidate that we develop, receives marketing approval, we will continue to face extensive
regulatory oversight and requirements, and any such product may still face future regulatory risks or new requirements.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we receive regulatory approval to market a particular product candidate, any such product will remain subject to extensive regulatory
requirements, including requirements relating to manufacturing, labeling, packaging, adverse event reporting, storage, advertising, promotion,
distribution and recordkeeping. Even if regulatory approval of a product is granted, the approval may be subject to limitations on the
uses for which the product may be marketed or the conditions of approval, or may contain requirements for costly post-marketing testing
and surveillance to monitor the safety or efficacy of the product, which could negatively affect us by reducing revenues or increasing
expenses, and cause the approved product candidate not to be commercially viable. In addition, as clinical experience with a drug expands
after approval, typically because it is used by a greater number and more diverse group of patients after approval than during clinical
trials, side effects and other problems may be observed over time after approval that were not seen or anticipated during pre-approval
studies. Any adverse effects observed after the approval and marketing of a product candidate could result in limitations on the use
of the approved product, withdrawal of FDA approval of the previously approved product, or voluntary withdrawal from the marketplace
of the approved product. Absence of long-term safety data may also limit the approved uses of Aramchol or any other product candidate,
if any. If we fail to comply with the regulatory requirements of the FDA, and other applicable U.S. and foreign regulatory authorities,
or previously unknown problems with any approved commercial products, manufacturers or manufacturing processes are discovered, we could
be subject to administrative or judicially imposed sanctions or other setbacks, including the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspension or imposition
    of restrictions on operations, including costly new manufacturing requirements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal to approve pending
    applications or supplements to applications;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspension of any clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspension or withdrawal
    of marketing approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an injunction or imposition
    of civil or criminal penalties or monetary fines;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seizure or detainment of
    products;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">banning or restriction
    of imports and exports;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">issuance of warning letters
    or untitled letters;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspension or imposition
    of restrictions on operations, including costly new manufacturing requirements; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal to approve pending
    applications or supplements to applications.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, various aspects of our operations are subject to federal, state or local laws, rules and regulations, any of which may change
from time to time. Costs arising out of any regulatory developments could be time-consuming and expensive and could divert management
resources and attention and, consequently, could adversely affect our business operations and financial performance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delays
in regulatory approval, limitations in regulatory approval and withdrawals of regulatory approval may have a material adverse effect
on us. If we experience significant delays in testing or receiving approvals or sign-offs to conduct clinical trials, Aramchol or any
other product candidate development costs will increase and our ability to out-license our product candidates may be impeded.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we obtain approval to commercialize any product candidate outside of the United States or out-license a product candidate to additional
territories outside the United States, a variety of risks associated with international operations could materially adversely affect
our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any product candidate is approved for commercialization outside the United States or we out-license a product candidate to additional
territories outside the United States, we will likely enter into agreements with third parties to commercialize a product candidate outside
the United States. We expect that we will be subject to additional risks related to entering into or maintaining international business
relationships, including, without limitation:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">different regulatory requirements
    for drug approvals in foreign countries;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">differing U.S. and foreign
    drug import and export rules;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced protection for
    intellectual property rights in foreign countries;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unexpected changes in tariffs,
    trade barriers and regulatory requirements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">different reimbursement
    systems;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">economic weakness, including
    inflation, or political instability in particular foreign economies and markets;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">compliance with tax, employment,
    immigration and labor laws for employees living or traveling abroad;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">foreign currency fluctuations,
    which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another
    country;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">workforce uncertainty in
    countries where labor unrest is more common than in the United States;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">production shortages resulting
    from any events affecting raw material supply or manufacturing capabilities abroad;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential liability resulting
    from development work conducted by these distributors;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">business interruptions
    resulting from geopolitical actions, including war and terrorism, or natural disasters, emergence of a pandemic, or other widespread
    health emergencies (or concerns over the possibility of such an emergency); and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">risks associated with clinical
    co-development agreements in other jurisdictions prior to or post-regulatory approval.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
failure to timely and effectively address the additional risks related to entering into or maintaining international business relationships
could have a material adverse effect on our business, liquidity, operating results and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we receive marketing approval for a product candidate, sales will be limited unless the product achieves broad market acceptance.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
commercial success of a product candidate for which we obtain marketing approval from the FDA, or other regulatory authorities, will
depend on the breadth of its approved labeling and upon the acceptance of the product by the medical community, including physicians,
patients and healthcare payors. The degree of market acceptance of any approved product will depend on a number of factors, including,
without limitation:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">demonstration of clinical
    safety and efficacy compared to other products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ability of physicians to
    accurately make a diagnosis in its early stages;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the relative convenience
    and ease of administration;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the prevalence and severity
    of any adverse side effects;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limitations, warnings or
    contraindications contained in the product&#8217;s approved labeling;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">distribution and use restrictions
    imposed by the FDA, or other regulatory agencies, or agreed to by us as part of a mandatory or voluntary REMS;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">availability of alternative
    treatments, including, any competitive products already approved or expected to be commercially launched in the near future;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pricing and cost effectiveness;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the effectiveness of our,
    or any future collaborators&#8217;, sales and marketing strategies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to obtain sufficient
    third-party coverage or reimbursement; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the willingness of patients
    to pay for drugs out of pocket in the absence of third-party coverage.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a product candidate is approved, but does not achieve an adequate level of acceptance by physicians, healthcare payors and patients,
we may not generate sufficient revenue from the product, and we may not become profitable. In addition, our efforts to educate the medical
community and third-party payors on the benefits of the product may require significant resources and may never be successful.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
FDA and other regulatory agencies may actively enforce the laws and regulations prohibiting the promotion of off-label uses. If we are
found to have improperly promoted off-label uses, we may become subject to significant liability.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA and other regulatory agencies strictly regulate the promotional claims that may be made about prescription products. In particular,
a product may not be promoted for uses that are inconsistent with the FDA-approved indications and other conditions or restrictions contained
in the approved labeling, including the prescribing information, for the product. In particular, any labeling approved by FDA or other
foreign regulatory agencies for a product candidate necessarily limits its use for certain conditions in certain patient populations.
Also, regulatory agencies may impose further requirements or restrictions on the distribution or use of Aramchol or any other
product candidate as part of a mandatory plan, such as limiting prescribing to certain physicians or medical centers that have undergone
specialized training, limiting treatment to patients who meet certain safe-use criteria and requiring treated patients to enroll in a
registry. If we receive marketing approval for a product candidate, physicians may nevertheless prescribe the product candidate to their
patients in a manner that is inconsistent with the approved labeling, which is commonly known as &#8220;off label&#8221; use. If we are
found to have promoted any product candidate for such &#8220;off label&#8221; uses, we may become subject to significant liability under
a variety of statutory theories typically alleged by U.S. regulatory authorities. In particular, the U.S. federal government has levied
large civil and criminal fines against companies for alleged improper promotion, has enjoined several companies from engaging in off-label
promotion, and has requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct
is changed or curtailed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
business and operations may be materially adversely affected in the event of computer system failures or security or breaches due to
cyber-attacks or cyber intrusions, including ransomware, phishing attacks and other malicious intrusions.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
recent years, cybersecurity threats have become a greater risk and focus for companies. In particular, ransomware attacks, where a hacker
locks and threatens to delete or disclose the victim&#8217;s data unless a ransom is paid, has become a major risk. We and those of our
CROs and other third parties on which we rely are at risk of cyber-attacks or cyber intrusions via the Internet, computer viruses, break-ins,
malware, ransomware, phishing attacks, hacking, denial-of-service attacks or other attacks and similar disruptions from the unauthorized
use of, or access to, computer systems (including from internal and external sources). These types of incidents continue to be prevalent
and pervasive across industries, including in our industry. In addition, we expect information security risks to continue to increase
due to the proliferation of new technologies and the increased sophistication and activities of organized crime, hackers, terrorists
and other external parties, including foreign state actors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Despite
the implementation of security measures, our internal computer systems, and those of our CROs and other third parties on which we rely,
are vulnerable to damage from computer viruses, unauthorized access, cyber-attacks, cyber intrusions, natural disasters, fire, terrorism,
war, and telecommunication and electrical failures. If such an event were to occur and interrupt our operations, it could result in a
material disruption of our drug development programs and inflict reputational harm upon us that may result in decreased market value
and erode public trust. For example, the loss of clinical trial data from planned clinical trials could result in delays in
our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption
or security breach results in a loss of or damage to our data or applications, loss of trade secrets or inappropriate disclosure of confidential
or proprietary information, including protected health information or personal data of employees or former employees, access to our clinical
data, or disruption of the manufacturing process, we could incur liability and the further development of our drug candidates could be
delayed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be subject to extensive environmental, health and safety, and other laws and regulations in multiple jurisdictions.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business involves the controlled use, through our service providers, of hazardous materials, various biological compounds and chemicals,
and as such, we, our agents and our service providers may be subject to various environmental, health and safety laws and regulations,
including those governing air emissions, water and wastewater discharges, noise emissions, the use, management and disposal of hazardous,
radioactive and biological materials and wastes and the cleanup of contaminated sites. The risk of accidental contamination or injury
from these materials cannot be eliminated. If an accident, spill or release of any regulated chemicals or substances occurs, we could
be held liable for resulting damages, including for investigation, remediation and monitoring of the contamination, including natural
resource damages, the costs of which could be substantial. We may incur substantial capital costs and operating expenses and may be required
to obtain consents to comply with any environmental and health laws or regulations and the terms and conditions of any permits required
pursuant to such laws and regulations, including costs incurred by us to install new or updated pollution control equipment for our service
providers, modify our operations or perform other corrective actions at our facilities or the facilities of our service providers. In
addition, fines and penalties may be imposed on us, our agents and/or our service providers for noncompliance with environmental, health
and safety and other laws and regulations or for the failure to have, or comply with the terms and conditions of, required environmental
or other permits or consents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
expect the healthcare industry to face increased limitations on coverage of and reimbursement, rebates and other payments as a result
of healthcare reform, which could adversely affect third-party coverage of Aramchol or any other product candidate and how
much or under what circumstances healthcare providers will prescribe or administer Aramchol or any other product candidate.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States and other countries, sales of Aramchol or any other product candidate will depend in part upon coverage
of the product and the availability of reimbursement from third party payors, including governmental authorities, managed care organizations
and other private health insurers. Third-party payors are increasingly challenging the price and examining the coverage of products based
on cost effectiveness of the medical products and services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increasing
expenditures for healthcare have been the subject of considerable public attention in the United States. Both private and government
entities are seeking ways to reduce or contain healthcare costs. Numerous proposals that would effect changes in the U.S. healthcare
system have been introduced or proposed in the U.S. Congress, or Congress, and in some state legislatures, including reducing reimbursement
for prescription products and reducing the levels at which consumers and healthcare providers are reimbursed for purchases of pharmaceutical
products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, or the Modernization Act, changed the
way Medicare covers and pays for most pharmaceutical products in a number of ways. Medicare is the single largest third-party payment
program and is administered by the Centers for Medicare &amp; Medicaid Services, or the CMS. Medicare traditionally covered prescription
drugs administered by physicians. The Modernization Act introduced a new reimbursement methodology based on average sales prices for
many of these drugs. The Modernization Act also established a new competitive acquisition program for the purchase of Part B drugs. This
program, when fully implemented, will likely reduce the prices of these drugs. While the Medicare provisions of the Modernization Act
apply only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations
in setting their own reimbursement rates. Therefore, any reduction in reimbursement that results from federal legislation or regulation
may result in a similar reduction in payments from private payors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Most
notably, the Modernization Act also expanded coverage through a new Part D to include ordinary self-administered outpatient drugs. Medicare
part D though operates through private insurers, and these insurers negotiate prices with pharmacies and with manufacturers. Intense
negotiations can result in reduced revenues to manufacturers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increasing
expenditures for healthcare have been the subject of considerable public attention in the United States. Both private and government
entities are seeking ways to reduce or contain healthcare costs. Numerous proposals that would effect changes in the U.S. healthcare
system have been introduced or proposed in U.S. Congress, and in some state legislatures, including reducing reimbursement for prescription
products and reducing the levels at which consumers and healthcare providers are reimbursed for purchases of pharmaceutical products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2010, President Barack Obama signed into law the Patient Protection and Affordable Care Act and the Health Care and Education Affordability
Reconciliation Act of 2010, or the Affordable Care Act, a sweeping law intended to broaden access to health insurance, reduce or constrain
the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for healthcare and health
insurance industries, impose new taxes and fees on pharmaceutical and medical device manufacturers and impose additional health policy
reforms. The Affordable Care Act expanded manufacturers&#8217; Medicaid rebate liability to include covered drugs dispensed to individuals
who are enrolled in Medicaid managed care organizations, increased the minimum rebate due for innovator drugs from 15.1% of average manufacturer
price, or the AMP, to 23.1% of AMP. The rebate on innovator drugs is the greater of 23.1% of the AMP per unit or the difference between
the AMP and the best price per unit and adjusted by the Consumer Price Index-Urban (CPI-U) based on a launch date and current quarter
AMP. The total rebate amount for innovator drugs is capped at 100.0% of AMP. The Affordable Care Act and subsequent legislation also
narrowed the definition of AMP. Furthermore, the Affordable Care Act imposes a significant annual, nondeductible fee on companies that
manufacture or import certain branded prescription drug products. The Affordable Care Act appears likely to continue to put pressure
on pharmaceutical pricing, especially under the Medicare and Medicaid programs, and may also increase our regulatory burdens and operating
costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
have been judicial and congressional challenges to the Affordable Care Act. If successful in the challenges, many if not all of the provisions
of the PPACA may no longer apply to prescription drugs. While we are unable to predict what changes may ultimately be enacted, to the
extent that future changes affect how any future products are paid for and reimbursed by government and private payers our business could
be adversely impacted. On December 14, 2018, a federal district court in Texas ruled that the PPACA is unconstitutional as a result of
the Tax Cuts and Jobs Act, the federal income tax reform legislation previously passed by Congress and signed by President Trump on December
22, 2017, that eliminated the individual mandate portion of the PPACA. The case, Texas, et al, v. United States of America, et al., (N.D.
Texas), is an outlier, and the ruling has been stayed by the ruling judge, but in 2019, the Fifth Circuit Court of Appeals subsequently
upheld the lower court decision which was then appealed to the United States Supreme Court. The U.S. Supreme Court declined to hear the
appeal on an expedited basis and so no decision is expected until sometime in 2021 before the end of the next Supreme Court&#8217;s current
term in early 2021. We are not able to state with any certainty what will be the impact of this court decision on our business pending
further court action and possible appeals. In November 2020, Joseph Biden was elected President and, in January 2021, the Democratic
Party obtained control of the Senate. As a result of these electoral developments, it is unlikely that continued legislative efforts
will be pursued to repeal PPACA. Instead, it is possible that executive and regulatory initiatives, as well as legislation will be pursued
to enhance or reform PPACA. We are not able to state with certainty what the impact of potential legislation will be on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. In August 2011, President
Obama signed into law the Budget Control Act of 2011, which, among other things, created the Joint Select Committee on Deficit Reduction
to recommend to Congress proposals in spending reductions. The Joint Select Committee did not achieve a targeted deficit reduction of
an amount greater than $1.2 trillion for the years 2013 through 2021, triggering the legislation&#8217;s automatic reduction to several
government programs. This includes aggregate reductions to Medicare payments to healthcare providers of up to 2.0% per fiscal year, starting
in 2013. These reductions will stay in effect through 2030 unless additional congressional action is taken. However, COVID-19 relief
legislation suspended the 2% Medicare sequester from May 1, 2020 through March 31, 2021. In January 2013, President Obama signed into
law the American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several categories of healthcare
providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five
years. If we ever obtain regulatory approval and commercialization of Aramchol or any other product candidate, these laws may result
in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on our customers and accordingly,
our financial operations. Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales
and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or
whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals
of Aramchol or any other product candidate may be. Further, the Deficit Reduction Act of 2010, directed CMS to contract a vendor to determine
&#8220;retail survey prices for covered outpatient drugs that represent a nationwide average of consumer purchase prices for such drugs,
net of all discounts and rebates (to the extent any information with respect to such discounts and rebates is available).&#8221; This
survey information can be used to determine the National Average Drug Acquisition Cost, NADAC. Some states have indicated that they will
reimburse based on the NADAC and this can result in further reductions in the prices paid for various outpatient drugs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Various
states, such as California and Florida, have also taken steps to consider and enact laws or regulations that are intended to increase
the visibility of the pricing of pharmaceutical products with the goal of reducing the prices at which pharmaceutical products are sold.
On August 16, 2022, President Biden signed into law the Inflation Reduction Act of 2022 that contains significant reforms affecting the
pricing of drugs and biologics paid by Medicare. The new requirements establish a timeline for certain drugs to negotiate with the federal
government a &#8220;maximum fair price&#8221; for certain selected drugs beginning in 2026. The numbers of drugs, as well as the selection
criteria, is established for each year. Because these various actual and proposed legislative changes are intended to operate on a state-by-state
level and the new national law, we cannot predict what the full effect of state legislative activities, and the IRA may be on our business
in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we cannot predict the full effect on our business of the implementation of existing legislation or the enactment of additional legislation
pursuant to healthcare and other legislative reform, we believe that legislation or regulations that would reduce reimbursement for,
or restrict coverage of, Aramchol or any other product candidate, could adversely affect how much or under what circumstances healthcare
providers will prescribe or administer our products. This could materially and adversely affect our business by reducing our ability
to generate revenue, raise capital, obtain additional collaborators and market Aramchol or any other product candidate. In addition,
we believe the increasing emphasis on managed care in the United States has and will continue to put pressure on the price and usage
of pharmaceutical products, which may adversely impact any other product sales.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>It
will be difficult for us to profitably sell any product candidate if reimbursement for the product is limited by government authorities
and third-party payor policies.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to any healthcare reform measures that may affect reimbursement, the market acceptance and sales of any product candidate will
depend on the reimbursement policies of government authorities and third-party payors. It will be difficult for us to profitably sell
a product candidate if reimbursement for the product is limited by government authorities or third-party payors. Government authorities
and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay
for and establish reimbursement levels. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government
authorities and these third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular
medications. We cannot be sure that coverage or reimbursement will be available for any product candidate and, if coverage and reimbursement
are available, of the extent of coverage and the level of reimbursement. Reimbursement may affect the demand for, or the price of, any
product for which we obtain marketing approval. In addition, third-party payors are likely to impose strict requirements for reimbursement
in order to limit off-label use of a higher priced drug. Reimbursement by a third-party payor may depend upon a number of factors including
the third-party payor&#8217;s determination that use of a product is:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a covered benefit under its health plan;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">safe, effective and medically necessary;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">appropriate for the specific patient;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">cost-effective; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">neither experimental nor investigational.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtaining
coverage and reimbursement approval for a product from a government or other third-party payor is a time-consuming and costly process
that could require us to provide supporting scientific, clinical and cost effectiveness data for the use of a product candidate to the
payor. We may not be able to provide data sufficient to gain acceptance with respect to coverage and reimbursement. We cannot be sure
that coverage or adequate reimbursement will be available for any product candidates. Also, we cannot be sure that reimbursement amounts
will not reduce the demand for, or the price of, any product candidates. If reimbursement is not available, or is available only to limited
levels, we may not be able to commercialize any product candidates, profitably, or at all, even if approved. In addition, if physicians,
government agencies and other third-party payors do not accept the use or efficacy of any product candidates, we will not be able to
generate significant revenue, if any.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Governments
outside the United States tend to impose strict price controls, which may adversely affect our revenues, if any.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
some countries, particularly the countries of the EU, the pricing of prescription pharmaceuticals is subject to governmental control.
In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval
for a product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares
the cost-effectiveness of Aramchol or any other product candidate to other available therapies. If reimbursement of our products is unavailable
or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be harmed, possibly materially.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we or any of our independent contractors, consultants, collaborators, manufacturers, or service providers fail to comply with healthcare
and data privacy laws and regulations, we or they could be subject to enforcement actions, which could result in penalties and affect
our ability to develop, market and sell Aramchol or any other product candidate and may harm our reputation.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are or may in the future be subject to federal, state, and foreign healthcare and data privacy laws and regulations pertaining to, among
other things, fraud and abuse of patients&#8217; rights. These laws and regulations include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The federal Anti-Kickback
    Statute prohibits, among other things, knowingly and willfully soliciting, offering, receiving, or paying any remuneration, directly
    or indirectly, in cash or in kind, to induce or reward purchasing, ordering or arranging for or recommending the purchase or order
    of any item or service for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare and
    Medicaid. Liability may be established without a person or entity having actual knowledge of the federal Anti-Kickback Statute or
    specific intent to violate it. This statute has been interpreted to apply broadly to arrangements between pharmaceutical manufacturers
    on the one hand and prescribers, patients, purchasers and formulary managers on the other. In addition, the Affordable Care Act amended
    the Social Security Act to provide that the U.S. government may assert that a claim including items or services resulting from a
    violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims
    Act. A conviction for violation of the Anti-kickback Statute requires mandatory exclusion from participation in federal health care
    programs. Although there are a number of statutory exemptions and regulatory safe harbors protecting certain common activities from
    prosecution, the exemptions and safe harbors are drawn narrowly, and those activities may be subject to scrutiny or penalty if they
    do not qualify for an exemption or safe harbor.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The federal civil False
    Claims Act, or FCA, prohibits, among other things, knowingly presenting, or causing to be presented claims for payment of government
    funds that are false or fraudulent, or knowingly making, using or causing to be made or used a false record or statement material
    to such a false or fraudulent claim, or knowingly concealing or knowingly and improperly avoiding, decreasing, or concealing an obligation
    to pay money to the federal government. This statute also permits a private individual acting as a &#8220;whistleblower&#8221; to
    bring actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery. The FCA prohibits
    anyone from knowingly presenting, conspiring to present, making a false statement in order to present, or causing to be presented,
    for payment to federal programs (including Medicare and Medicaid) claims for items or services, including drugs, that are false or
    fraudulent, claims for items or services not provided as claimed, or claims for medically unnecessary items or services. This law
    also prohibits anyone from knowingly underpaying an obligation owed to a federal program. Increasingly, U.S. federal agencies are
    requiring nonmonetary remedial measures, such as corporate integrity agreements in FCA settlements. The U.S. Department of Justice
    announced in 2016 its intent to follow the &#8220;Yates Memo,&#8221; taking a far more aggressive approach in pursuing individuals
    as FCA defendants in addition to the corporations. FCA liability is potentially significant in the healthcare industry because the
    statute provides for treble damages and mandatory penalties assessed on a per false claim or statement basis. Government enforcement
    agencies and private whistleblowers have investigated pharmaceutical companies for or asserted liability under the FCA for a variety
    of alleged promotional and marketing activities, such as providing free product to customers with the expectation that the customers
    would bill federal programs for the product; providing consulting fees and other benefits to physicians to induce them to prescribe
    products; engaging in promotion for &#8220;off-label&#8221; uses; and submitting inflated best price information to the Medicaid
    Rebate Program.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The federal False Statements
    Statute prohibits knowingly and willfully falsifying, concealing, or covering up a material fact or making any materially false,
    fictitious or fraudulent statement or representation, or making or using any false writing or document knowing the same to contain
    any materially false, fictitious or fraudulent statement or entry, in connection with the delivery of or payment for healthcare benefits,
    items, or services.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The federal Civil Monetary
    Penalties Law authorizes the imposition of substantial civil monetary penalties against an entity, such as a pharmaceutical manufacturer,
    that engages in activities including, among others (1) knowingly presenting, or causing to be presented, a claim for services not
    provided as claimed or that is otherwise false or fraudulent in any way; (2) arranging for or contracting with an individual or entity
    that is excluded from participation in federal healthcare programs to provide items or services reimbursable by a federal healthcare
    program; (3) violations of the federal Anti-Kickback Statute; or (4) failing to report and return a known overpayment.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The federal Health Insurance
    Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for knowingly and willfully executing,
    or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or
    covering up a material fact or making any materially false statement in connection with the delivery of, or payment for, healthcare
    benefits, items or services; similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge
    of the statute or specific intent to violate it in order to have committed a violation.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA, as amended by the
    Health Information Technology for Economic and Clinical Health Act (HITECH), which imposes requirements on certain types of people
    and entities relating to the privacy, security, and transmission of individually identifiable health information, requires notification
    to affected individuals and regulatory authorities of certain breaches of security of individually identifiable health information.
    Additionally, Washington State has enacted the My Health My Data Act, which enhances the privacy and security of consumer health
    data not covered by HIPAA. The law&#8217;s provisions began to take effect on March 31, 2024, for larger entities, with additional
    requirements for smaller entities taking effect on June 30, 2024. This legislation aims to enhance the privacy and security of consumer
    health data not covered by HIPAA. This law grants consumers rights over their health data, requires explicit consent for data collection
    and sharing, and mandates reasonable security measures. It applies to entities doing business in Washington or targeting Washington
    residents.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The federal Physician Payment
    Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available
    under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program, to report annually to the Centers for Medicare &amp;
    Medicaid Services (CMS) information related to payments and other transfers of value to physicians (defined to include doctors, dentists,
    optometrists, podiatrists and chiropractors) and teaching hospitals, and ownership and investment interests held by physicians and
    other healthcare providers and their immediate family members, which is published in a searchable form on an annual basis. Effective
    January 1, 2022, covered manufacturers will also be required to report on payments and other transfers of value to physician assistants,
    nurse practitioners or clinical nurse specialists, anesthesiologist assistants, certified registered nurse anesthetists, and certified
    nurse-midwives during the previous year.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State laws comparable to
    each of the above federal laws, such as, for example, anti-kickback and false claims laws that may be broader in scope and also apply
    to commercial insurers and other non-federal.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payors requirements for
    mandatory corporate regulatory compliance programs, and laws relating to patient data privacy and security. Other state laws require
    pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance
    guidance promulgated by the federal government; require drug manufacturers to report information related to payments and other transfers
    of value to physicians and other healthcare providers or marketing expenditures; and state and foreign laws govern the privacy and
    security of health information in some circumstances, many of which differ from each other in significant ways and often are not
    preempted by HIPAA, thus complicating compliance efforts.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the European Union,
    the General Data Protection Regulation, or GDPR,&#8212;Regulation EU 2016/679&#8212;was adopted in May 2016 and became applicable
    on May 25, 2018, or GDPR. The GDPR, as amended on May 4, 2016, further harmonizes data protection requirements across the European
    Union member states and Norway, Iceland and Liechtenstein by establishing new and expanded operational requirements for entities
    that collect, process or use personal data generated in the European Economic Area (the 27 member states of the EU and Norway, Iceland
    and Liechtenstein), including consent requirements for disclosing the way personal information will be used, information retention
    requirements, and notification requirements in the event of a data breach.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the United Kingdom,
    following the UK&#8217;s exit from the European Union on 31 December 2020, the GDPR continues to form part of the law in the UK with
    some amendments (UK GDPR). There is a risk of divergence in the future, which may increase our overall data protection compliance
    costs.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
        California Consumer Privacy Act of 2018, or CCPA, effective as of January 1, 2020, as amended by the California Privacy Rights
        Act, or the CPRA, which entered into substantial effect on January 1, 2023 (referred to as CCPA), gives California residents
        expanded rights to access and require deletion of their personal information, opt out of certain personal information sharing,
        and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations,
        as well as a private right of action for data breaches, that is expected to increase data breach litigation. The CCPA imposes
        new operational requirements for companies, including new data privacy rights for consumers, increasing regulation on online
        advertising, creating a new California Privacy Protection Agency (CPPA) to enforce the law, regulating the sale or sharing of
        personal information, and adding greater transparency standards for privacy policies. Lack of compliance with the CCPA and its
        requirements could result in enforcement actions, litigation, fines and penalties (up to $7,500 per intentional violation and
        $2,500 per other violation). California consumers also have a private right of action under the CCPA for certain data breaches
        and can recover civil damages of up to $750 per incident, per consumer or actual damages, whichever is greater. In addition,
        over a dozen other states have passed or are considering similar legislation, which has created and will continue to create additional
        compliance obligations and risks. More generally, some observers have noted the CCPA, and other state laws could mark the beginning
        of a trend toward more stringent United States federal privacy legislation, which could increase our potential liability and
        adversely affect our business. In California, certain practices related to tracking technologies, chatbots, cookies or session
        recording have triggered CIPA-based claims (i.e. based on California&#8217;s Invasion of Privacy Act).</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
    U.S. states have implemented, or are in the process of implementing, similar new laws or regulations (for example, the Virginia Consumer
    Data Protection Act (VCDPA) effective as of January 1, 2023, the Colorado Privacy Act (CPA) effective as of July 1, 2023, Connecticut
    Data Privacy Act (CDPA) effective as of July 1, 2023, Utah Consumer Privacy Act (UCPA) effective as of December 31, 2023, the Texas
    Data Privacy and Security Act (TDPSA) effective as of July 1, 2024, the Oregon Consumer Privacy Law (OCPA) effective as of July 1,
    2024, the Florida Digital Bill of Rights (FDBR) effective as of July 1, 2024 and the Montana Consumer Data Privacy Act (MTCDPA) effective
    as of October 1, 2024) that impose new privacy rights and obligations. More generally, some observers have noted that the CCPA, together
    with the VCDPA, the CPA, the CDPA, the UCPA, the TDPSA, the OCPA, the FDBR and MTCDPA could mark the represent a trend toward more
    stringent United States federal privacy legislation, which could increase our potential liability and adversely affect our business.</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
        addition, we are subject to the Israeli Privacy Protection Law, 1981 (&#8220;PPL&#8221;), and its regulations, including but
        not limited to the Israeli Privacy Protection Regulations (Data Security) 2017 (&#8220;Security Regulations&#8221;), as well
        as the guidelines of the Israeli Privacy Protection Authority (&#8220;PPA&#8221;). These impose obligations regarding how certain
        personal data is processed, maintained, transferred, disclosed, accessed, and secured. Therefore, significant changes to the
        PPL or Security Regulations may necessitate adjustments to our data protection and security practices.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    this context, material amendments to the PPL were approved by the Israeli Parliament in August 2024 and will take effect on August
    14, 2025 (&#8220;Amendment 13&#8221;). Among other things, Amendment 13 expands the PPA&#8217;s authority to investigate incidents
    where there is concern of privacy violation and to impose monetary sanctions that are considerably higher than those currently available
    under the PPL and its regulations. Additionally, Amendment 13 introduces new obligations for parties processing personal data, which
    may require us to modify our data practices and policies, appoint mandatory positions, and consequently, to incur substantial costs
    to align our privacy and data protection practices in Israel.</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
        in January 2025, the Privacy Protection Regulations (Provisions Regarding Information Transferred to Israel from the European
        Economic Area), 2023 (&#8220;EU Regulations&#8221;) came into effect also with respect to personal data related to Israeli individuals.
        As a result, we may need to adjust our practices, particularly those concerning data subjects&#8217; rights.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure
    to comply with the PPL, its regulations, and PPA guidelines may expose us to administrative fines, civil claims (including class
    actions), and, in certain cases, criminal liability. Upon Amendment 13 taking effect in August 2025, the sanctions for non-compliance
    with the PPL and its regulations (including the Security Regulations and the EU Regulations) will be significantly increased and,
    in certain cases, may reach substantial amounts in the millions of NIS.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    rapid advancements in artificial intelligence (&#8220;AI&#8221;) present both opportunities and challenges for our industry. There
    is a risk that the evolving AI landscape could reduce the demand for some of our simple service offerings within the writing, translation,
    and graphic and design verticals. At the same time, our recent initiatives to provide services that support AI technology could create
    additional demand for new services that were not previously on our marketplace. As we continue to invest in and expand our AI related
    services, we are fully aware of the complexities and the competitive nature of this area. We are also attentive to the evolving regulatory
    environment surrounding AI. Our ability to successfully adapt and incorporate AI technologies and related services into our product
    offerings in a timely, effective, and compliant manner is critical. Failure to do so may result in a competitive disadvantage, potentially
    reducing the demand for our services and adversely affecting our business performance.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    May 17, 2024, Colorado enacted the Colorado AI Act. The Colorado AI Act creates duties for developers and for those that deploy AI.
    There is a specific focus on bias and discrimination. The Act will go into effect on February 1, 2026. More than 40 state AI bills
    were introduced in the U.S.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    European Union&#8217;s Artificial Intelligence Act (the &#8220;EU AI Act&#8221;) was published in the EU Official Journal on July
    12, 2024, and is the first comprehensive horizontal legal framework for the regulation of AI across the EU. The EU AI Act entered
    into force on August 1, 2024, and the provisions on Prohibited Activities and article 4 on AI Literacy will take effect on 2 February
    2025, and most of the other obligations are expected to take gradual effect by 2026, including requirements around transparency,
    conformity assessments and monitoring, risk assessments, human oversight, security, accuracy, general purpose artificial intelligence
    and foundation models. The EU AI ACT will apply to six categories of entities: providers, deployers, importers, distributors, product
    manufacturers and authorized representatives. Examples of fines for noncompliance include administrative fines ranging from the higher
    of &#8364;35,000,000 or up to 7 percent of a company&#8217;s total worldwide annual turnover for non-compliance with prohibited AI
    practices, or the higher of &#8364;7,500,000 or up to 1 percent of a company&#8217;s total worldwide annual turnover for the supply
    of incorrect, incomplete, or misleading information to notified bodies and national competent authorities. Once gradually applicable,
    the EU AI Act will have a material impact on the way artificial intelligence is regulated in the EU, including requirements around
    transparency, conformity assessments and monitoring, risk assessments, human oversight, security, accuracy and general purpose artificial
    intelligence. Further, the cost to comply with such laws or regulations could be significant and would increase our operating expenses,
    require technical changes, development and implementations, which could adversely affect our business, financial condition and results
    of operations.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    EU Data Act, adopted on November 27, 2023, establishes rules for data sharing and reuse in the European Union, with most obligations
    effective from September 2025. It aims to enhance the EU&#8217;s data economy by improving data accessibility and usability, fostering
    innovation, and ensuring equitable value distribution among data economy participants. The EU Data Act empowers users of connected
    products&#8212;whether owned, leased, or rented&#8212;with greater control over the data they generate, while maintaining incentives
    for investments in data technologies. It also sets general conditions for data sharing between businesses and imposes measures to
    boost fairness and competition in the European cloud market. Additionally, the EU Data Act safeguards companies from unfair contractual
    terms related to data sharing imposed by dominant market players. Compliance may require us to implement new data management protocols,
    technological development and changes and review contractual practices, potentially increasing operational costs.</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our operations are found to be in violation of any such health care laws and regulations, we may be subject to penalties, including significant
administrative, civil and criminal penalties, monetary damages, disgorgement, imprisonment, the curtailment or restructuring of our operations,
loss of eligibility to obtain approvals from the FDA or foreign regulatory authorities, or exclusion from participation in government
contracting, healthcare reimbursement or other government programs, including Medicare and Medicaid, any of which could adversely our
financial results. Any action against us for an alleged or suspected violation could cause us to incur significant legal expenses and
could divert our management&#8217;s attention from the operation of our business, even if our defense is successful. In addition, achieving
and sustaining compliance with applicable laws and regulations may be costly to us in terms of money, time and resources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
employees, principal investigators, consultants, commercial partners or vendors may engage in misconduct or other improper activities,
including non-compliance with regulatory standards.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also exposed to the risk of employees, independent contractors, principal investigators, consultants, commercial partners or vendors
engaging in fraud or other misconduct. Misconduct by employees, independent contractors, principal investigators, consultants, commercial
partners and vendors could include intentional failures to comply with EU or UK regulations, to provide accurate information to the EMA,
MHRA or EU Member States authorities or to comply with manufacturing or quality standards we have or will have established. In particular,
sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent
fraud, misconduct, kickbacks, self-dealing and other abusive practices such as promotion of products by medical practitioners. The EU
Member States in which we operate have different statutory provisions regulating the cooperation of pharmaceutical companies with healthcare
professionals. In addition to these statutory provisions, codes of conduct issued by business associations or other non-statutory standards
may be applicable to our activities. Both statutory provisions and non-statutory codes or standards restrict payments or other benefits
provided to healthcare professionals, and in case of non-compliance, may result in severe sanctions such as bans, administrative fines,
criminal fines or even imprisonment. The advertising of medicinal products for human use in the EU is regulated by Title VIII of European
Directive 2001/83/EC, as amended. These provisions have been implemented into the law of the EU member States. Such laws inter alia restrict
or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business
arrangements. Misconduct could also involve the improper use of information obtained in the course of clinical studies, which could result
in regulatory sanctions and serious and irreparable harm to our reputation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
could also apply with respect to data privacy. In the EU (at that time including the United Kingdom), the EU Directive 95/46/EEC was
replaced by the GDPR on May 25, 2018. The GDPR, as amended on May 4, 2016, as an EU regulation does not have to be implemented into Member
States&#8217; national law, but applies directly in all Member States since May 25, 2018. It applies to companies with an establishment
in the European Economic Area (EEA) and to certain other companies not in the EEA that offer or provide goods or services to individuals
located in the EEA or monitor individuals located in the EEA. The GDPR implements more stringent operational requirements for controllers
of personal data, including, for example, expanded disclosures about how personal information is to be used, limitations on retention
of information, increased requirements pertaining to health data and pseudonymized (i.e., key-coded) data, increased cyber security requirements,
mandatory data breach notification requirements and higher standards for controllers to demonstrate that they have obtained a valid legal
basis for certain data processing activities. The GDPR provides that EU Member States may continue to make their own further laws and
regulations in relation to the processing of genetic, biometric or health data, which could result in continued or new differences between
Member States, limit our ability to use and share personal data or could cause our costs to increase, and harm our business and financial
condition. The GDPR continues to form part of law in the United Kingdom with some amendments following the United Kingdom&#8217;s exit
from the European Union on 31 December 2020 (UK GDPR) although there is a risk of divergence in the future which may increase our overall
data protection compliance cost. We are also subject to evolving and strict rules on the transfer of personal data out of the European
Union and United Kingdom to the United States. Further prospective revision of the Directive on privacy and electronic communications
(Directive 2002/58/EC, as amended), or ePrivacy Directive, and equivalent United Kingdom Legislation may affect our marketing communications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have implemented procedures to ensure compliance with the GDPR and UK GDPR and its requirements. Our actual or alleged failure to comply
with this regulation, or to protect personal data, could result in enforcement actions and significant penalties against us, which could
result in negative publicity, increase our operating costs, subject us to claims or other remedies and have a material adverse effect
on our business, financial condition, and results of operations. It is not always possible to identify and deter misconduct by employees
or other parties. The precautions we take to detect and prevent such activity may not protect us from legal or regulatory action resulting
from a failure to comply with applicable laws or regulations. Misconduct by our employees, principal investigators, consultants, commercial
partners or vendors could result in significant financial penalties, criminal sanctions, civil law claims and/or negative media coverage,
and thus have a material adverse effect on our business, including through the imposition of significant fines or other sanctions, and
our reputation. In particular, failure to comply with EU laws, including failure under the GDPR, UK GDPR and other laws relating to the
security of personal data may result in fines up to &#8364;20,000,000 or up to 4% of the total worldwide annual turnover of the preceding
financial year, if greater, and other administrative penalties including criminal liability, which may be onerous and adversely affect
our business, financial condition, results of operations and prospects. Failure to comply with the GDPR, UK GDPR and related laws may
also give risk to increase risk of private actions, including a new form of class action that is available under the GDPR and UK GDPR.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we or our manufacturers fail to comply with manufacturing regulations, our financial results and financial condition could be adversely
affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
an NDA is approved, and before we begin the commercial manufacture of any product candidate, contract manufacturers must register with
FDA or foreign regulators undergo regulatory inspection of their manufacturing facilities, processes and quality systems. In addition,
pharmaceutical manufacturing facilities are subject to periodic inspection by the FDA and foreign regulatory authorities after product
approval. Due to the complexity of the processes used to manufacture pharmaceutical products and product candidates, any potential third-party
manufacturer may be unable to meet local, federal, or international regulatory requirements either at the outset or on an ongoing basis,
in a cost-effective manner, if at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not intend to engage in the manufacture of Aramchol or any other product candidate other than for pre-clinical and clinical studies,
but we or our materials suppliers may face manufacturing or quality control problems causing product production and shipment delays or
a situation where we or the supplier may not be able to maintain compliance with the FDA&#8217;s or foreign regulators&#8217; requirements
necessary to continue manufacturing Aramchol or any other product candidate. Drug manufacturers are subject to ongoing periodic unannounced
inspections by the FDA and corresponding foreign regulators to ensure continuing compliance with applicable requirements. Any failure
to comply with FDA or foreign regulatory requirements could adversely affect our clinical research activities and our ability to develop
and market Aramchol or any other product candidate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a third-party manufacturer with whom we contract is unable to comply with manufacturing requirements, we may be subject to fines, unanticipated
compliance expenses, recall or seizure of Aramchol or any other product candidate, total or partial suspension of production and/or enforcement
actions, including injunctions, and criminal or civil prosecution. These possible sanctions could adversely affect our financial results
and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
market is subject to intense competition. If we are unable to compete effectively, Aramchol or any other product candidate
that we develop may be rendered suboptimal, noncompetitive or obsolete.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are a number of products in development for our target indications, many of which are being developed by pharmaceutical companies that
are far larger than us, with significantly greater resources and more experience than us in all aspects of drug development and commercialization.
Further, our industry is highly competitive and subject to rapid and significant technological change. Our potential competitors include
large, fully-integrated pharmaceutical and biotechnology companies, specialty pharmaceutical and generic drug companies, academic institutions,
government agencies and research institutions. All of these competitors currently engage in, have engaged in or may engage in the future
in the development, manufacturing, marketing and commercialization of new pharmaceuticals, some of which may compete with Aramchol or other product candidates. Smaller or early stage companies may also prove to be significant competitors, particularly through collaborative
arrangements with large, established companies. These companies may have products in development that are superior to any Aramchol or
any other product candidate. Key competitive factors affecting the commercial success of Aramchol or any other product candidate that
we develop are likely to be efficacy, time of onset, safety and tolerability profile, reliability, convenience of dosing, price and reimbursement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of our potential competitors have substantially greater financial, technical and human resources than we do and significantly greater
experience in the discovery and development of drug candidates, obtaining FDA and other regulatory approvals of products and the commercialization
of those products. Accordingly, our competitors may be more successful than us in obtaining FDA and other marketing approvals for drugs
and achieving widespread market acceptance. Our competitors&#8217; drugs may be more effective, or more effectively marketed and sold,
than any drug we may commercialize and may render the product candidates that we develop suboptimal, obsolete or non-competitive before
we can recover the expenses of developing and commercializing the product. We anticipate that we will face intense and increasing competition
as new drugs enter the market and advanced technologies become available. Finally, the development of new treatment methods for the diseases
we are targeting could render Aramchol or any other product candidate that we develop, non-competitive or obsolete. If we cannot successfully
compete with new or existing products, our marketing and sales will suffer and we may never be profitable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
competitors in the NASH field currently include companies with marketed products and/or advanced clinical programs. Our main competitors
of Aramchol include, but are not limited to Novo Nordisk, Akero Therapeutics, Inc., Inc., Madrigal Pharmaceuticals Inc., and Viking Therapeutics
among others. <span style="background-color: white">In March 2024, Madrigal Pharmaceuticals announced FDA approval of Rezdiffra (resmetirom)
for the treatment of NASH with moderate to advanced liver fibrosis. </span>See also &#8220;Item 4. Information on the Company&#8212;Competition.&#8221;
Moreover, several additional companies have reported the commencement of research projects and proof-of-concept trials related to our
target indications, including those mentioned in the preceding sentence.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
operate in a competitive sector. Several companies are working on technologies, therapeutic targets or drug or biomarker candidates that
aim to treat or diagnose the same diseases or identify the same patient population as our product candidates. While we believe that our
drug candidates and diagnostic solutions, combined with our expertise and know-how, provide us with competitive advantages, we face potential
competition from various sources, including pharmaceutical and biotechnology companies, as well as from academic institutions, governmental
agencies and public and private research institutions. We anticipate that we will face intense and increasing competition as new drugs
and therapies enter the market and advanced technologies become available. In some indications, off-label use of non-approved drugs can
also be considered as competition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
face potential product and other liability exposure, and, if claims are brought against us, we may incur substantial liability.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
product candidates could cause adverse events. These adverse events may not be observed in clinical trials, but may nonetheless occur
in the future. If any of these adverse events occur, they may render Aramchol or any other product candidate ineffective or harmful in
some patients, and our sales would suffer, materially adversely affecting our business, financial conditions and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, potential adverse events caused by Aramchol or any other product candidate, could lead to product liability claims. Product
liability claims might be brought against us by consumers, healthcare providers or others coming into contact with Aramchol or any other
product candidate. If we cannot successfully defend ourselves against product liability claims, we could incur substantial liabilities.
In addition, regardless of merit or eventual outcome, product liability claims may result in, among other things:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">decreased demand for our product candidate for which
    we obtain marketing approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">impairment of our business reputation and exposure
    to adverse publicity;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increased warnings on product labels or other regulatory
    actions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawal of clinical trial participants;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs of related litigation;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 33; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">distraction of management&#8217;s attention from our
    primary business;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">substantial monetary awards to patients or other claimants;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">loss of revenue; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the inability to successfully commercialize any product
    candidates, for which we obtain marketing approval. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unable to obtain adequate insurance with respect to our clinical trials against and from any losses or claims from third parties,
our financial condition could be adversely affected in the event of uninsured or inadequately insured loss or damage. We may not be able
to obtain insurance policies on terms affordable to us that would adequately cover loss or claims by third parties. To the extent our
business suffers any losses or claims by third parties, which are not covered, or adequately covered, by insurance, our financial condition
may be materially adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
product liability lawsuits are successfully brought against us, our insurance may be inadequate.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have obtained insurance coverage for our clinical trials in accordance with market standards and in compliance with applicable Israeli
law. However, our insurance coverage may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance
coverage is becoming increasingly expensive, and, in the future, we may not be able to maintain insurance coverage at a reasonable cost
or in sufficient amounts to protect us against losses due to liability. If and when we obtain marketing approval for any product candidate,
we intend to expand our insurance coverage to include the sale of commercial products; however, we may be unable to obtain this product
liability insurance on commercially reasonable terms. On occasion, large judgments have been awarded in class action lawsuits based on
drugs that had unanticipated side effects. The cost of any product liability litigation or other proceedings, even if resolved in our
favor, could be substantial. A successful product liability claim, or series of claims, brought against us could cause our share price
to decline and, if judgments exceed our insurance coverage, could decrease our cash and adversely affect our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
product liability insurance we will need to obtain in connection with the commercial sales of any product candidate, if and when they
receive regulatory approval, may be unavailable in meaningful amounts or at a reasonable cost. If we are the subject of a successful
product liability claim that exceeds the limits of any insurance coverage we obtain, we would incur substantial charges that would adversely
affect our earnings and require the commitment of capital resources that might otherwise be available for the development and commercial
launch of any product candidate&#8217;s programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
manage our business through a small number of senior executive officers. We depend on them even more than similarly- situated companies.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of the specialized scientific and managerial nature of our business, we rely heavily on our ability to recruit, attract, retain, manage
and motivate qualified senior executive officers with adequate operational, scientific and technical experience. The loss of the services
of our senior executive officers, including our President, Chief Executive Officer, or the inability to hire or retain experienced management
personnel, could adversely affect our ability to execute our business plan and harm our operating results. In particular, the loss of
one or more of our senior executive officers could be detrimental to us if we cannot recruit suitable replacements in a timely manner.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not currently carry &#8220;key person&#8221; insurance on the lives of members of senior management. The competition for qualified
personnel in the pharmaceutical field is intense. Due to this intense competition, we may be unable to attract and retain qualified personnel
necessary for the development of our business or to recruit suitable replacement personnel. Additionally, our ability to effectively
recruit and retain qualified officers and directors could also be adversely affected if we experience difficulty in obtaining adequate
directors&#8217; and officers&#8217; liability insurance. We may be unable to maintain sufficient insurance as a public company to cover
liability claims made against our officers and directors. If we are unable to adequately insure our officers and directors, we may not
be able to retain or recruit qualified officers and directors to manage the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 34; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Failure
to build our finance infrastructure and improve our accounting systems and controls could impair our ability to comply with the financial
reporting and internal control requirements for publicly traded companies.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a public company, we operate in an increasingly challenging regulatory environment which requires us to comply with the Sarbanes-Oxley
Act of 2002, or the Sarbanes-Oxley Act, and the related rules and regulations of the SEC and securities exchanges, expanded disclosures,
accelerated reporting requirements and more complex accounting rules. Company responsibilities required by the Sarbanes-Oxley Act include
establishing corporate oversight and adequate internal control over financial reporting and disclosure controls and procedures. Effective
internal controls are necessary for us to produce reliable financial reports and are important to help prevent financial fraud.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to the requirements of the Sarbanes-Oxley Act. Section 404 of the Sarbanes-Oxley Act requires companies subject to the reporting
requirements of the U.S. securities laws to do a comprehensive evaluation of its and its subsidiaries&#8217; internal control over financial
reporting. To comply with this statute, we must document and test our internal control procedures and our management and issue a report
concerning our internal control over financial reporting. In addition, as long as we do not become an accelerated or large accelerated
filer, we are exempt from the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act. Under this exemption, our
auditor will not be required to attest to and report on our management&#8217;s assessment of our internal control over financial reporting
until the date we are no longer a non-accelerated filer. We have an ongoing program to perform the system and process evaluation and
testing necessary to continue to comply with these requirements. During the course of our review and testing, we may identify deficiencies
and be unable to remediate them before we must provide the required reports. Furthermore, if we have a material weakness in our internal
controls over financial reporting, we may not detect errors on a timely basis and our financial statements may be materially misstated.
We may not be able to conclude on an ongoing basis that we have effective internal control over financial reporting, which could harm
our operating results, cause investors to lose confidence in our reported financial information and cause the trading price of our stock
to fall.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
build our finance infrastructure, we may need to improve our accounting systems, disclosure policies, procedures and controls. If we
are unsuccessful in building an appropriate accounting infrastructure, we may not be able to prepare and disclose, in a timely manner,
our financial statements and other required disclosures, or comply with existing or new reporting requirements. Any failure to report
our financial results on an accurate and timely basis could result in sanctions, lawsuits, delisting of our shares from the Nasdaq Capital
Market or other adverse consequences that would materially harm our business. If we cannot provide reliable financial reports or prevent
fraud, our business and results of operations could be harmed and investors could lose confidence in our reported financial information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may need to significantly increase the size of our organization, and we may experience difficulties in managing growth.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> We may experience rapid and substantial growth in order to achieve our operating plans, which will place a strain
on our human and capital resources. Successful implementation of our business plan will require management of growth, which will result
in an increase in the level of responsibility for management personnel. Any future growth will impose significant added responsibilities
on members of management, including the need to identify, recruit, maintain and integrate additional employees. To that end, we must
be able to, among other things:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">manage our clinical trials
    and the regulatory process effectively;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">develop our administrative,
    accounting and management information systems and controls;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">hire and train additional
    qualified personnel; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">integrate current and additional
    management, administrative, financial and sales and marketing personnel.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 35; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unable to establish, scale-up and implement improvements to our control systems in an efficient or timely manner, or if we encounter
deficiencies in existing systems and controls, investors may choose not to invest in us, which could cause our share price to decline
and negatively impact our ability to successfully commercialize Aramchol or any other product candidate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure
to attract and retain sufficient numbers of talented employees will further strain our human resources and could impede our growth or
result in ineffective growth. If we are unable to manage our growth effectively, our losses could materially increase and it will have
a material adverse effect on our business, results of operations and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Scrutiny
of sustainability and environmental, social, and governance, or ESG, initiatives could increase our costs or otherwise adversely impact
our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Public
companies have recently faced scrutiny related to ESG practices and disclosures from certain investors, capital providers, shareholder
advocacy groups, other market participants and other stakeholder groups. Such scrutiny may result in increased costs, enhanced compliance
or disclosure obligations, or other adverse impacts on our business, financial condition or results of operations. If our ESG practices
and reporting do not meet investor or other stakeholder expectations, we may be subject to investor or regulator engagement regarding
such matters. Our failure to comply with any applicable ESG rules or regulations could lead to penalties and adversely impact our reputation,
access to capital and employee retention. Such ESG matters may also impact our third-party contract manufacturers and other third parties
on which we rely, which may augment or cause additional impacts on our business, financial condition, or results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Reliance on Third Parties</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have no manufacturing capacity and anticipate reliance on third-party manufacturers for Aramchol any other product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not currently operate manufacturing facilities for the production of Aramchol or its API. We still have not, and may
never, develop facilities for the manufacture of product candidates or products for clinical trials or commercial purposes. We rely on
third-party manufacturers to produce bulk drug products required for our clinical trials. Our contract manufacturers have not completed
commercial development and validation processes of the Aramchol API and we have experienced delays in the development
of the Aramchol meglumine formulation. Drug product manufacturing processes may experience further difficulties and delays in production.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
if our contract manufacturers and their facilities, as applicable, are not approved by the FDA, or other applicable regulatory authorities,
our commercial supply of the drug substance will be significantly delayed and may result in significant additional costs. We purchase
finished Aramchol from a third-party under a clinical supply agreement. If we will be required to change the finished product manufacturer,
we may encounter significant delay and likely significant additional cost.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 36; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
failure by our contract manufacturer to achieve and maintain high manufacturing standards, in accordance with applicable good manufacturing
practices and other applicable regulatory requirements could result in patient injury or death, product shortages, product recalls or
withdrawals, delays or failures in product testing or delivery, cost overruns or other problems that could seriously harm our business.
Contract manufacturers often encounter difficulties involving production yields, quality control and quality assurance, as well as shortages
of qualified personnel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
existing manufacturers and any future contract manufacturers may not perform as agreed or may not remain in the contract manufacturing
business. In the event of a natural disaster, business failure, strike or other difficulty, we may be unable to replace a third-party
manufacturer in a timely manner and the production of our product candidates would be interrupted, resulting in delays and additional
costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
intend to rely primarily on third parties to market and sell Aramchol or any other product candidate.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have no sales or distribution capabilities. To the extent we rely on third parties to commercialize Aramchol or any other
product candidate, if marketing approval is obtained, we may receive less revenue than if we commercialize them ourselves. In addition,
we would have less control over the sales efforts of any third parties involved in our commercialization efforts. In the event we are
unable to collaborate with a third-party marketing and sales organization to commercialize Aramchol or any other product
candidate, particularly for broader patient populations, our ability to generate revenue will be limited.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we may ultimately develop a marketing and sales force with technical expertise and supporting distribution capabilities in the longer
term, we do not currently intend to do so and, as such, we will be unable to market our product candidates directly in the near future.
To promote any of our potential products through third parties, we will have to locate acceptable third parties for these functions and
enter into agreements with them on acceptable terms, and we may not be able to do so. Any third-party arrangements we are able to enter
into may result in lower revenues than we could achieve by directly marketing and selling our potential products. In addition, to the
extent that we depend on third parties for marketing and distribution, any revenues we receive will depend upon the efforts of such third
parties, as well as the terms of our agreements with such third parties, which cannot be predicted in most cases at this time. As a result,
we might not be able to market and sell our product candidates in the United States or overseas, which would have a material adverse
effect on us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Any
collaboration arrangements that we may enter into in the future may not be successful, which could adversely affect our ability to develop
and commercialize our current and potential other product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to seek collaboration arrangements with pharmaceutical or biotechnology companies for the continued development and commercialization
of our current and potential other product candidates. We will face, to the extent that we decide to enter into collaboration agreements,
significant competition in seeking appropriate collaborators. Moreover, collaboration arrangements are complex and time consuming to
negotiate, document and implement. We may not be successful in our efforts to establish and implement collaborations or other alternative
arrangements. The terms of any collaborations or other arrangements that we may establish may not be favorable to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
future collaborations that we enter into may not be successful. The success of our collaboration arrangements will depend heavily on
the efforts and activities of our collaborators. Collaborators generally have significant discretion in determining the efforts and resources
that they will apply to these collaborations. Disagreements between parties to a collaboration arrangement regarding clinical development
and commercialization matters can lead to delays in the development process or commercializing the applicable product candidate and,
in some cases, termination of the collaboration arrangement. These disagreements can be difficult to resolve if neither of the parties
has final decision making authority. Moreover, collaborations with pharmaceutical or biotechnology companies and other third parties
are often terminated or allowed to expire by the other party. Any lack of effort or ability by our collaborators or any such disagreement,
termination or expiration could adversely affect us financially and could harm our business reputation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 37; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
depend on third parties to conduct our clinical trials.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on third parties, such as contract research organizations, medical institutions, clinical investigators and contract laboratories
to oversee most of the operations of our clinical trials and to perform data collection and analysis. As a result, we may face additional
delays outside of our control if these parties do not perform their obligations in a timely fashion or in accordance with regulatory
requirements. If these third parties do not successfully carry out their contractual duties or obligations and meet expected deadlines,
if they need to be replaced, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere
to our clinical protocols or for other reasons, our financial results and the commercial prospects for Aramchol or any other
product candidate could be harmed, our costs could increase and our ability to obtain regulatory approval and commence product sales
could be delayed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Intellectual Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
failure to obtain or maintain patents, licensing agreements and other intellectual property rights that are sufficiently broad and protective
could impact our ability to compete effectively.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
compete effectively, we must develop and maintain a proprietary position with regard to our own technologies, intellectual property,
licensing agreements, product candidates and business. Legal standards relating to the validity and scope of claims in the biotechnology
and biopharmaceutical fields are still evolving. We cannot predict the scope and extent of patent protection for Aramchol or any other product candidate because the patent positions of pharmaceutical products are complex and uncertain. Therefore, the degree
of future protection for our proprietary rights in our core technologies and any product candidates or products that might be developed
using these technologies is also uncertain. The risks and uncertainties that we face with respect to our patents and other proprietary
rights include, but are not limited to, the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">while the patents we own
    have been issued, pending patent applications we have filed may not result in issued patents or may take longer than we expect to
    result in issued patents;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may be subject to interference,
    reexamination, inter pares review, or post-grant review proceedings in the U.S.;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may be subject to opposition
    proceedings in certain foreign countries;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any patents that are issued
    may not provide meaningful protection for any significant period of time, if at all;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any issued patents may
    not be broad or strong enough to prevent competition from other products including identical or similar products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may not be able to develop
    additional proprietary technologies that are patentable;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">there may be prior art
    of which we are not aware that may affect the validity or enforceability of a patent claim;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">there may be other patents
    or pending patent applications existing in the patent landscape that will affect our freedom to operate for our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other companies may challenge
    and invalidate patents licensed or issued to us or our customers;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a court could determine
    that a competitor&#8217;s technology or product does not infringe our patents;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other companies may independently
    develop similar or alternative technologies, or duplicate our technologies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other companies may design
    around technologies we have licensed or developed;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 38; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if we are not awarded patents
    or if issued patents expire or are declared invalid or not infringed, there may be no protections against competitors making generic
    equivalents;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">enforcement of patents
    is complex, uncertain and expensive, and our patents may be found invalid or enforceable;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our patents could irretrievably
    lapse due to failure to pay fees or otherwise comply with regulations, or could be subject to compulsory licensing; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if we encounter delays
    in our development or clinical trials, the period of time during which we could market our product candidates under patent protection
    would be reduced.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot be certain that patents will be issued as a result of any of our pending applications, and we cannot be certain that any of our
issued patents, whether issued pursuant to our pending applications or licensed from third parties, will give us adequate protection
from competing products. For example, issued patents may be circumvented or challenged, declared invalid or unenforceable, or narrowed
in scope. In addition, because publication of discoveries in the scientific or patent literature often lags behind actual discoveries,
we cannot be certain that we were the first to make our inventions or to file patent applications covering those inventions. If any of
our composition of matter patents, or pending applications, was subject to a successful challenge or failed to issue, our business and
competitive advantage could be significantly affected. Our current patents will expire or they may otherwise cease to provide meaningful
competitive advantage, and we may be unable to adequately develop new technologies and obtain future patent protection to preserve our
competitive advantage or avoid adverse effects on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We transitioned from Aramchol free acid to Aramchol meglumine (salt) in our double-blind, placebo-controlled
histology-based registrational part of the ARMOR Study and are continuing this transition in other clinical trials of Aramchol. As part of our research and development
studies, we have confirmed that several Aramchol salts have improved solubility as compared to the existing form of Aramchol free acid.
We have pending patent applications and have been granted patents directed to composition of matter of Aramchol meglumine as well as
a wide range of other salts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
can be no assurance that the U.S. Patent and Trademark Office, or the USPTO, or any other foreign equivalent will issue any additional
patents based on the patent applications that we submitted to protect our Aramchol salts or nor, should the USPTO or foreign
equivalent issue any patents to us with respect to the Aramchol salts or that we will be provided with adequate protection
against potentially competitive products. Furthermore, if foreign equivalent issues us one or more patents for the Aramchol salts or with respect to already issued patents for the Aramchol salts or there can be no assurance that the issued
patents will be of any commercial value, or that private parties or competitors will not successfully challenge these patents or circumvent
these patents in the United States or their counterparts abroad. In the absence of adequate patent protection, our business may be adversely
affected by competitors who develop comparable technology or products and our commercial prospects may be materially adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Others
may obtain issued patents that could prevent us from commercializing our product candidates or require us to obtain licenses requiring
the payment of significant fees or royalties in order to enable us to conduct our business. As to those patents that we have licensed,
our rights depend on maintaining our obligations to the licensor under the applicable license agreement, and we may be unable to do so.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to patents and patent applications, we depend upon trade secrets and proprietary know-how to protect our proprietary technology.
We require our employees, consultants, advisors and collaborators to enter into confidentiality agreements that prohibit the disclosure
of confidential information to any other parties. We also require our employees and consultants to disclose and assign to us their ideas,
developments, discoveries and inventions. These agreements may not, however, provide adequate protection for our trade secrets, know-how
or other proprietary information in the event of any unauthorized use or disclosure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 39; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Patent
terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patents
have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally
20 years from the PCT application. Various extensions may be available, but the life of a patent, and the protection it affords, is limited.
Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive
products, including generics or biosimilars. Given the amount of time required for the development, testing and regulatory review of
new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As
a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products
similar or identical to ours.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be able to enforce our intellectual property rights throughout the world. This risk is exacerbated for us because we expect Aramchol
or Aramchol meglumine will be manufactured and used in a number of foreign countries.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the United States. Many
companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions.
This risk is exacerbated for us because we expect Aramchol will be manufactured and used in a number of foreign countries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
legal systems of some countries, particularly developing countries, do not favor the enforcement of patents and other intellectual property
protection, especially those relating to life sciences. This could make it difficult for us to stop the infringement of our other intellectual
property rights. For example, several foreign countries have compulsory licensing laws under which a patent owner must grant licenses
to third parties. In addition, some countries limit the enforceability of patents against third parties, including government agencies
or government contractors. In these countries, patents may provide limited or no benefit.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
most jurisdictions in which the Company has applied for, intends to apply for, or has been issued patents have patent protection laws
similar to those of the United States, some of them do not. For example, the Company expects to do business in South America, Eurasia,
China and Indochina in the future and the countries in these regions may not provide the same or similar protection as that provided
in the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceedings
to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other
aspects of our business. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate. In
addition, changes in the law and legal decisions by courts in the United States and foreign countries may affect our ability to obtain
adequate protection for our technology and the enforcement of intellectual property.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may rely on third party patents</i></b><i>.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not have rights under some patents or patent applications related to products we may commercialize in the future. Third parties may
own or control these patents and patent applications in the United States and abroad. Therefore, in some cases, to manufacture, sell
or import some of our future products, we or our collaborators may choose to seek, or be required to seek, licenses under third party
patents issued in the United States and abroad or under patents that might be issued from United States and foreign patent applications.
In instances in which we must obtain a license for third party patents, we may be required to pay license fees or royalties or both to
the licensor. If licenses are not available to us on acceptable terms, we or our collaborators may not be able to develop, manufacture,
sell or import these products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be unable to protect the intellectual property rights of third parties from whom we may license certain of our intellectual property
or with whom we have entered into other strategic relationships, which could have a material adverse effect on our business, results
of operations and financial condition.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
of our intellectual property rights may be licensed from third parties, including universities and strategic partners. Such third parties
may determine not to or fail to protect the intellectual property rights that we license from them and we may be unable to defend such
intellectual property rights on our own or we may have to undertake costly litigation to defend the intellectual property rights of such
third parties. There can be no assurances that we will continue to have proprietary rights to any of the intellectual property that we
license from such third parties or otherwise have the right to use through similar strategic relationships. Any loss or limitations on
use with respect to such intellectual property licensed from third parties or otherwise obtained from third parties with whom we have
entered into strategic relationships could have a material adverse effect on our business, results of operations and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 40; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise
experience disruptions to our business relationships with our licensors, we could lose intellectual property rights that are important
to our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may be party to license agreements with third parties and may need to obtain additional licenses from others to advance our research
and development activities or allow the commercialization product candidates we may identify and pursue. License agreements may impose
various development, diligence, commercialization, and other obligations on us. For example, we may be required to use commercially reasonable
efforts to engage in various development and commercialization activities with respect to licensed products, and satisfy specified milestone
and royalty payment obligations. In spite of our efforts, our licensors might conclude that we have materially breached our obligations
under such license agreements and might therefore terminate the license agreements, thereby removing or limiting our ability to develop
and commercialize products and technology covered by these license agreements. If these in-licenses are terminated, or if the underlying
patents fail to provide the intended exclusivity, competitors or other third parties would have the freedom to seek regulatory approval
of, and to market, products identical to ours and we may be required to cease our development and commercialization of product candidates
that we may identify. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions,
results of operations, and prospects. Moreover, disputes may arise regarding intellectual property subject to a licensing agreement,
including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the scope of rights granted
    under the license agreement and other interpretation-related issues;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the extent to which our
    product candidates, technology and processes infringe on intellectual property of the licensor that is not subject to the licensing
    agreement;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the sublicensing of patent
    and other rights under our collaborative development relationships;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our diligence obligations
    under the license agreement and what activities satisfy those diligence obligations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the inventorship and ownership
    of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners;
    and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the priority of invention
    of patented technology. In addition, the agreements under which we currently or in the future license intellectual property or technology
    from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution
    of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant
    intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement,
    either of which could have a material adverse effect on our business, financial condition, results of operations, and prospects.
    Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing
    arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates,
    which could have a material adverse effect on our business, financial conditions, results of operations, and prospects.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 41; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may infringe the intellectual property rights of others, which may prevent or delay our product development efforts and stop us from
commercializing, or increase the costs of commercializing, Aramchol or or any other product candidate.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial success depends significantly on our ability to operate without infringing the patents and other intellectual property rights
of third parties. For example, there could be issued patents of which we are not aware that our product candidate infringes. There also
could be patents that we believe we do not infringe, but that we may ultimately be found to infringe. Moreover, patent applications are
in some cases maintained in secrecy until patents are issued. The publication of discoveries in the scientific or patent literature frequently
occurs substantially later than the date on which the underlying discoveries were made and patent applications were filed. Because patents
can take many years to issue, there may be currently pending applications of which we are unaware that may later result in issued patents
that our product candidates infringe. For example, pending applications may exist that provide support or can be amended to provide support
for a claim that results in an issued patent that our product candidates infringes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third
parties may assert that we are employing their proprietary technology without authorization. If a court held that any third-party patents
are valid, enforceable and cover any of our product candidates or their use, the holders of any of these patents may be able to block
our ability to commercialize any such product candidate unless we obtained a license under the applicable patents, or until the patents
expire. In addition to litigation proceedings which may be filed against us, we may not be able to enter into licensing arrangements
or make other arrangements at a reasonable cost or on reasonable terms. Any inability to secure licenses or alternative technology could
result in delays in the introduction of our product candidates or lead to prohibition of the manufacture or sale of products by us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time consuming
and unsuccessful.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Competitors
may infringe our patents or other intellectual property. Although we are not currently involved in any litigation, if we were to initiate
legal proceedings against a third party to enforce a patent covering our product candidates, the defendant could counterclaim that the
patent covering our product candidate is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims
alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any
of several statutory requirements, including lack of novelty, obviousness, written description or non-enablement. Grounds for an unenforceability
assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO,
or made a misleading statement, during prosecution. The outcome following legal assertions of invalidity and unenforceability is unpredictable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interference
or derivation proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority
of inventions with respect to our patents or patent applications. An unfavorable outcome could require us to cease using the related
technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does
not offer us a license on commercially reasonable terms or at all, or if a non-exclusive license is offered and our competitors gain
access to the same technology. Our defense of litigation or interference or derivation proceedings may fail and, even if successful,
may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with litigation
could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research
programs, license necessary technology from third parties, or enter into development partnerships that would help us bring our product
candidates to market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some
of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements
of the results of hearings, motions, or other interim proceedings or developments. If securities analysts or investors perceive these
results to be negative, it could have a material adverse effect on the price of our ordinary shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be unable to adequately prevent disclosure and unauthorized use of trade secrets and other proprietary information by third parties.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to obtain and maintain patent protection and trade secret protection for our intellectual property and proprietary technologies,
our product candidates and their uses is important to our commercial success. We rely on a combination of patent, copyright, trademark
and trade secret laws, non-disclosure and confidentiality agreements, licenses, assignment of inventions agreements and other restrictions
on disclosure and use to protect our intellectual property rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 42; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also rely on trade secrets to protect our proprietary know-how and technological advances, especially where we do not believe patent
protection is appropriate or obtainable. However, trade secrets are difficult to protect. We rely in part on confidentiality agreements
with our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to protect our trade secrets
and other proprietary information. These agreements may not effectively prevent disclosure of confidential information and may not provide
an adequate remedy in the event of unauthorized disclosure of confidential information. In addition, others may independently discover
our trade secrets and proprietary information. Costly and time-consuming litigation could be necessary to enforce and determine the scope
of our proprietary rights. Failure to obtain or maintain trade secret protection could enable competitors to use our proprietary information
to develop products that compete with our product candidates or cause additional material adverse effects upon our competitive business
position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot be certain that the steps that we have taken will prevent the misappropriation or other violation of our confidential information
and other intellectual property, particularly in foreign countries in which laws may not protect our proprietary rights as fully as in
the United States and other developed economies. Moreover, if we lose any key personnel, we may not be able to prevent the unauthorized
disclosure or use of our technical knowledge or other trade secrets by those former employees. If we are unable to maintain the security
of our proprietary technology, this could materially adversely affect our competitive advantage, business and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Under
applicable U.S. and Israeli law, we may not be able to enforce covenants not to compete and therefore may be unable to prevent our competitors
from benefiting from the expertise of some of our former employees. In addition, employees may be entitled to seek compensation for their
inventions irrespective of their agreements with us, which in turn could impact our future profitability.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
generally enter into non-competition agreements with our employees and certain key consultants, or our employment and consulting agreements
contain non-competition provisions. These agreements, to the extent they are in place and in effect, prohibit our employees and certain
key consultants, if they cease working for us, from competing directly with us or working for our competitors or clients for a limited
period of time. We may be unable to enforce these agreements under the laws of the jurisdictions in which our employees work and it may
be difficult for us to restrict our competitors from benefitting from the expertise our former employees or consultants developed while
working for us. For example, Israeli courts have required employers seeking to enforce non-compete undertakings of a former employee
to demonstrate that the competitive activities of the former employee will harm one of a limited number of material interests of the
employer which have been recognized by the courts, such as the secrecy of a company&#8217;s confidential commercial information or the
protection of its intellectual property. If we cannot demonstrate that such interests will be harmed, we may be unable to prevent our
competitors from benefiting from the expertise of our former employees or consultants and our ability to remain competitive may be diminished.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, under the Israeli Patent Law, 5727-1967, or the Patent Law, inventions conceived by an employee in the course and as a result
of or arising from his or her employment with a company are regarded as &#8220;service inventions,&#8221; which belong to the employer,
absent a specific agreement between the employee and employer giving the employee service invention rights. The Patent Law also provides
that if there is no such agreement between an employer and an employee, the Israeli Compensation and Royalties Committee, or the Committee,
a body constituted under the Patent Law, shall determine whether the employee is entitled to remuneration for his or her inventions.
Case law clarifies that the right to receive consideration for &#8220;service inventions&#8221; can be waived by the employee and that
in certain circumstances, such waiver does not necessarily have to be explicit. The Committee will examine, on a case-by-case basis,
the general contractual framework between the parties, using interpretation rules of the general Israeli contract laws. Further, the
Committee has not yet determined one specific formula for calculating this remuneration, but rather uses the criteria specified in the
Patent Law. Although we generally enter into assignment-of-invention agreements with our employees pursuant to which such individuals
assign to us all rights to any inventions created in the scope of their employment or engagement with us, we may face claims demanding
remuneration in consideration for assigned inventions. As a consequence of such claims, we could be required to pay additional remuneration
or royalties to our current and/or former employees, or be forced to litigate such claims, which could negatively affect our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 43; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Any
lawsuits relating to infringement of intellectual property rights necessary to defend ourselves or enforce our rights will be costly
and time consuming.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may be required to initiate litigation to enforce our rights or defend our activities in response to alleged infringement of a third-party.
In addition, we may be sued by others who hold intellectual property rights and who claim that their rights are infringed by our product
candidates. These lawsuits can be very time consuming and costly. There is a substantial amount of litigation involving patent and other
intellectual property rights in the biotechnology and pharmaceutical industries generally.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
third-party may claim that we are using inventions claimed by their patents and may go to court to stop us from engaging in our normal
operations and activities, such as research, development, and the sale of any future products. Such lawsuits are expensive and would
consume time and other resources. There is a risk that such court will decide that we are infringing the third-party&#8217;s patents
and will order us to stop the activities claimed by the patents, redesign our products or processes to avoid infringement or obtain licenses,
which may not be available on commercially reasonable terms. In addition, there is a risk that a court will order us to pay the other
party damages for infringement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
there is no guarantee that any prevailing patent owner would offer us a license so that we could continue to engage in activities claimed
by the patent, or that such a license, if made available to us, could be acquired on commercially acceptable terms. In addition, third
parties may, in the future, assert other intellectual property infringement claims against us with respect to other product candidates,
technologies or other matters.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, our patents and patent applications could face challenges. Any of these challenges, if successful, could result in the invalidation
of, or in a narrowing of the scope of, any of our patents and patent applications subject to challenge. Any of these challenges, regardless
of their success, would likely be time consuming and expensive to defend and resolve and would divert our management&#8217;s time and
attention.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changes
in patent law could diminish the value of patents in general, thereby impairing our ability to protect Aramchol or any other
product candidate.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
is the case with other pharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining
and enforcing patents in the biopharmaceutical industry involve both technological and legal complexity. Therefore, obtaining and enforcing
pharmaceutical patents is costly, time-consuming, and inherently uncertain. In particular, the United States has recently enacted, and
is currently implementing, wide-ranging patent reform legislation. The United States Supreme Court has ruled on several patent cases
in recent years, and could do so again in the future, either narrowing the scope of patent protection available in certain circumstances
or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty regarding our ability to obtain
patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending
on decisions by applicable courts and legislatures in the countries in which we may pursue patent protection, including those of the
U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents and the interpretations of such laws could
change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that
we might obtain in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Obtaining
and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements
imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other
provisions during the patent process. There are situations in which noncompliance can result in abandonment or lapse of a patent or patent
application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might
be able to enter the market earlier than would otherwise have been the case.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 44; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Ownership of Our Ordinary Shares</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
business, operating results and growth rates may be adversely affected by current or future unfavorable economic and market conditions
and adverse developments with respect to financial institutions and associated liquidity risk.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business depends on the economic health of the global economies. If the conditions in the global economies remain uncertain or continue
to be volatile, or if they deteriorate, including as a result of the impact of military conflict, such as the war between Russia and
Ukraine, terrorism or other geopolitical events, our business, operating results and financial condition may be materially adversely
affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, increases in inflation raise our costs for commodities, labor, materials and services and other costs required to grow and
operate our business, and failure to secure these on reasonable terms may adversely impact our financial condition. Additionally, increases
in inflation, geopolitical developments and global supply chain
disruptions, have caused, and may in the future cause, global economic uncertainty and uncertainty about the interest rate environment,
which may make it more difficult, costly or dilutive for us to secure additional financing. A failure to adequately respond to these
risks could have a material adverse impact on our financial condition, results of operations or cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
can be no assurance that future credit and financial market instability and a deterioration in confidence in economic conditions will
not occur. Our general business strategy may be adversely affected by any such economic downturn, liquidity shortages, volatile business
environment or continued unpredictable and unstable market conditions. If the current equity and credit markets deteriorate, or if adverse
developments are experienced by financial institutions, it may cause short-term liquidity risk and also make any necessary debt or equity
financing more difficult, more costly, more onerous with respect to financial and operating covenants and more dilutive. Failure to secure
any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial
performance and stock price and could require us to alter our operating plans. In addition, there is a risk that one or more of our service
providers, financial institutions, manufacturers, suppliers and other partners may be adversely affected by the foregoing risks, which
could directly affect our ability to attain our operating goals on schedule and on budget.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
market price of our ordinary shares is volatile and you may sustain a complete loss of your investment</i></b><i>.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
our initial public offering, the trading price of our ordinary shares has been volatile and is likely to continue to be volatile. In
addition, the trading volume is and has been volatile and oftentimes relatively illiquid. The following factors, some of which are beyond
our control, in addition to other risk factors described in this section, may have a significant impact on the market price and trading
volume of our ordinary shares:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability to obtain the approvals necessary to commence
    further clinical trials; </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unsatisfactory or inconclusive
    results of clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    or termination of any clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse events in any
    clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements of regulatory
    approval or the failure to obtain it, or specific label indications or patient populations for its use, or changes or delays in the
    regulatory review process;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements of therapeutic
    innovations or new products by us or our competitors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse actions taken by
    regulatory agencies with respect to our clinical trials, manufacturing supply chain or sales and marketing activities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes or developments
    in laws or regulations applicable to our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any adverse changes to
    our relationship with manufacturers or suppliers;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any product liability actions
    or intellectual property infringement actions in which we may become involved;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements concerning
    our competitors or the pharmaceutical industry in general;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">achievement of expected
    product sales and profitability or our failure to meet expectations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our commencement of, or
    involvement in, litigation;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 45; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any major changes in our
    board of directors, management or other key personnel;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">legislation in the United
    States, Europe and other foreign countries relating to the sale or pricing of pharmaceuticals;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements by us of
    significant strategic partnerships, out-licensing, in-licensing, joint ventures, acquisitions or capital commitments;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expiration or terminations
    of licenses, research contracts or other collaboration agreements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">public concern as to the
    safety of drugs we, our licensees or others develop;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">success of research and
    development projects;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">variations in our and our
    competitors&#8217; results of operations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in earnings estimates,
    cash flow guidance, or recommendations by securities analysts;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developments by our licensees,
    if any;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">future issuances of ordinary
    shares or other securities; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">natural disasters and political
    and economic instability, including wars, terrorism, political unrest, results of certain elections and votes, emergence of a pandemic,
    or other widespread health emergencies (or concerns over the possibility of such an emergency), boycotts, adoption or expansion of
    government trade restrictions, and other business restrictions.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
factors and any corresponding price fluctuations may materially and adversely affect the market price and trading volume of our ordinary
shares and result in substantial losses by our investors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the stock market in general, and the Nasdaq Capital Market and the market for biotechnology companies in particular, have experienced
extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of our Company
and that of small companies. Broad market and industry factors may negatively affect the market price of our ordinary shares, regardless
of our actual operating performance. Further, a systemic decline in the financial markets and related factors beyond our control may
cause our share price to decline rapidly and unexpectedly. Price volatility of our ordinary shares might be worse if the trading volume
of our ordinary shares is low. Following periods of market volatility or a material decrease in the value of our ordinary shares, shareholders
may institute securities class action litigation. If we were involved in securities litigation, it could have a substantial cost and
divert resources and attention of management from our business, even if we are successful. Future sales of our ordinary shares could
also reduce the market price of such stock. Any adverse determination in litigation could also subject us to significant liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
the liquidity of our ordinary shares has been limited, not only in terms of the number of shares that can be bought and sold at a given
price, but by delays in the timing of transactions and reduction in security analysts&#8217; and the media&#8217;s coverage of us, if
any. These factors may result in lower prices for our ordinary shares than might otherwise be obtained and could also result in a larger
spread between the bid and ask prices for our ordinary shares. In addition, without a large float, our ordinary shares are less liquid
than the stock of companies with broader public ownership and, as a result, the trading prices of our ordinary shares are more volatile.
In the absence of an active public trading market, an investor may be unable to liquidate its investment in our ordinary shares. Trading
of a relatively small volume of our ordinary shares may have a greater impact on the trading price of our stock than would be the case
if our public float were larger. We cannot predict the prices at which our ordinary shares will trade in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 46; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Sales
of a substantial number of our ordinary shares in the public market could cause our share price to fall.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of a substantial number of our ordinary shares in the public market, or the perception that these sales might occur, could depress the
market price of our ordinary shares and could impair our ability to raise capital through the sale of additional equity securities. We
are unable to predict the effect that sales may have on the prevailing market price of our ordinary shares. Sales of shares by our existing
shareholders would likely result in the supply of our ordinary shares far exceeding the demand for our ordinary shares and could have
a material adverse effect on the trading price of our ordinary shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Raising
additional capital would cause dilution to our existing shareholders, and may restrict our operations or require us to relinquish rights.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We will need to raise additional capital and may seek additional capital through a combination of private and
public equity offerings, &#8220;at-the-market&#8221; issuances, equity-linked and structured transactions, debt (straight, convertible,
or otherwise) financings, collaborations and licensing arrangements. To the extent that we raise additional capital through the sale
of equity or convertible debt securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences
that adversely affect your rights as a shareholder. Debt financing, if available, would result in increased fixed payment obligations
and may involve agreements that include covenants limiting or restricting our ability to take specific actions such as incurring debt,
making capital expenditures or declaring dividends. If we raise additional funds through collaboration, strategic alliance and licensing
arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams or product candidates,
or grant licenses on terms that are not favorable to us. Depending upon market liquidity at the time, additional sales of shares registered
at any given time could cause the trading price of our ordinary shares to decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
U.S. shareholders may suffer adverse tax consequences due to our expected classification as a passive foreign investment company.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Generally,
if for any taxable year 75% or more of our gross income is passive income, or at least 50% of the average value of our assets is attributable
to assets that are held for the production of, or produce, passive income, we would be characterized as a passive foreign investment
company, or PFIC, for U.S. federal income tax purposes. Based upon our review of our financial data, we believe that we were a PFIC for
our 2024 taxable year and expect to be a PFIC for the 2025 taxable year. Because PFIC status is determined annually and is based on our
income, assets and activities for the entire taxable year, it is not possible to determine with certainty whether we will be characterized
as a PFIC for the 2025 taxable year until after the close of the year, and there can be no assurance that we will not be classified as
a PFIC in any future year. If we were to be characterized as a PFIC for U.S. federal income tax purposes in any taxable year during which
a U.S. Holder (as defined below) owns ordinary shares, such U.S. Holder could face adverse U.S. federal income tax consequences. For
example, such U.S. Holder could be subject to additional taxes and interest charges upon certain distributions by us and any gain recognized
on a sale, exchange or other disposition of our shares, whether or not we continue to be characterized as a PFIC. Certain adverse consequences
of PFIC status can be mitigated if a U.S. Holder makes a &#8220;mark-to-market&#8221; election or an election to treat us as a qualified
electing fund, or QEF. Upon request, we expect to provide the information necessary for U.S. Holders to make &#8220;qualified electing
fund elections&#8221; if we are classified as a PFIC. There is no assurance, however, that we will have timely knowledge of our status
as a PFIC, or that the information that we provide will be adequate to allow U.S. Holders to make a QEF election Each investor is urged
to consult its tax advisor with respect to the application of the PFIC rules. See also &#8220;Item 10. Additional Information&#8212;E.
Taxation&#8212; Certain Material U.S. Federal Income Tax Considerations.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>


<!-- Field: Page; Sequence: 47; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
a United States person is treated as owning at least 10% of our ordinary shares, such holder may be subject to adverse U.S. federal income
tax consequences.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a United States person is treated as owning (directly, indirectly or constructively) at least 10% of the value or voting power of our
ordinary shares, such person may be treated as a &#8220;United States shareholder&#8221; with respect to each &#8220;controlled foreign
corporation&#8221; in our group (if any). A United States shareholder of a controlled foreign corporation may be required to annually
report and include in its U.S. taxable income its pro rata share of &#8220;Subpart F income,&#8221; &#8220;global intangible low-taxed
income&#8221; and investments in U.S. property by controlled foreign corporations, whether or not we make any distributions, and may
be subject to tax reporting obligations. An individual that is a United States shareholder with respect to a controlled foreign corporation
generally would not be allowed certain tax deductions or foreign tax credits that would be allowed to a United States shareholder that
is a U.S. corporation. A failure to comply with these reporting obligations may subject you to significant monetary penalties and may
prevent the statute of limitations with respect to your U.S. federal income tax return for the year for which reporting was due from
starting. We cannot provide any assurances that we will assist any shareholder in determining whether such shareholder is treated as
a United States shareholder with respect to any &#8220;controlled foreign corporation&#8221; in our group (if any) or furnish to any
United States shareholders information that may be necessary to comply with the aforementioned reporting and tax paying obligations.
A United States investor should consult its tax advisors regarding the potential application of these rules to its investment in our
ordinary shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
the securities analysts that currently cover our stock, or will do so in the future, or industry analysts do not publish or cease publishing
research or reports about us, our business or our market, or if they adversely change their recommendations or publish negative reports
regarding our business or our shares, our share price and trading volume could be negatively impacted.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading market for our ordinary shares is influenced by the research and reports that industry or securities analysts may publish about
us, our business, our market or our competitors. We do not have any control over these analysts and we cannot provide any assurance that
analysts will cover us or provide favorable coverage. If any of the analysts who do cover, or may cover us in the future, adversely change
their recommendation regarding our shares, or provide more favorable relative recommendations about our competitors, our share price
would likely decline. If any analyst who cover us cease coverage of our company or fail to regularly publish reports on us, we could
lose visibility in the financial markets, which in turn could negatively impact our share price or trading volume.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Because
we do not intend to declare cash dividends on our ordinary shares in the foreseeable future, shareholders must rely on appreciation of
the value of our ordinary shares for any return on their investment.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never declared or paid cash dividends on our ordinary shares. We currently anticipate that we will retain future earnings for the
development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends in the foreseeable
future. Moreover, the Israeli Companies Law, 5759-1999, or the Companies Law, imposes certain restrictions on our ability to declare
and pay dividends. See &#8220;Item 8. Financial Information&#8212;Consolidated Financial Statements and Other Financial Information&#8212;Dividend
Policy&#8221; for additional information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
requirements associated with being a public company require significant company resources and management attention.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to the reporting requirements of the Securities Exchange Act of 1934, or the Exchange Act, the Sarbanes-Oxley Act, the listing
requirements of the Nasdaq Capital Market, on which our ordinary shares are traded, and other applicable securities rules and regulations.
The Exchange Act requires that we file periodic reports with respect to our business and financial condition and maintain effective disclosure
controls and procedures and internal control over financial reporting. In addition, subsequent rules implemented by the SEC and the Nasdaq
Capital Market may also impose various additional requirements on public companies. As a result, we incurred and will continue to incur
additional legal, accounting and other expenses that we did not incur as a privately-held company, particularly since, as of December
31, 2020, we are no longer considered an &#8220;emerging growth company&#8221; as defined in the JOBS Act. Further, the need to establish
the corporate infrastructure demanded of a public company may divert management&#8217;s attention from implementing our development plans.
We have made and will continue to make changes to our corporate governance standards, compensation policy, disclosure controls and financial
reporting and accounting systems to meet our reporting obligations and applicable law. The measures we take, however, may not be sufficient
to satisfy our obligations as a public company, which could subject us to delisting of our ordinary shares, fines, sanctions and other
regulatory action and potentially civil litigation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 48; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>As
a &#8220;foreign private issuer,&#8221; we are permitted to and currently do follow certain home country corporate governance practices
instead of otherwise applicable SEC and Nasdaq Capital Market requirements, which may result in less protection than is accorded to investors
under rules applicable to domestic U.S. issuers.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a &#8220;foreign private issuer,&#8221; we are permitted to, and currently do, follow certain home country corporate governance practices
instead of those otherwise required under the Listing Rules of the Nasdaq Capital Market, or the Nasdaq Listing Rules, for domestic U.S.
issuers. For instance, we currently follow home country practice in Israel with regard to, among other things, director nomination procedure
and approval of compensation of officers. In addition, we may follow our home country law instead of the Nasdaq Listing Rules that require
that we obtain shareholder approval for certain dilutive events, such as the establishment or amendment of certain equity based compensation
plans, an issuance that will result in a change of control of the company, certain transactions other than a public offering involving
issuances of a 20% or greater interest in the company, and certain acquisitions of the stock or assets of another company. Following
our home country governance practices as opposed to the requirements that would otherwise apply to a U.S. company listed on the Nasdaq
Capital Market may provide less protection to you than what is accorded to investors under the Nasdaq Listing Rules applicable to domestic
U.S. issuers. See &#8220;Item 16G. Corporate Governance.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, as a &#8220;foreign private issuer,&#8221; we are exempt from the rules and regulations under the Exchange Act related to the
furnishing and content of proxy statements and certain individual executive compensation information, and our officers, directors and
principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange
Act. Furthermore, foreign private issuers are not required to file their annual report on Form 20-F until 120 days after the end of each
fiscal year, while U.S. domestic issuers that are accelerated filers are required to file their annual report on Form 10-K within 75
days after the end of each fiscal year and U.S. domestic issuers that are large accelerated filers are required to file their annual
report on Form 10-K within 60 days after the end of each fiscal year. Additionally, as a &#8220;foreign private issuer,&#8221; we are
also not subject to the requirements of Regulation FD (Fair Disclosure) promulgated under the Exchange Act. These exemptions and leniencies
reduce the frequency and scope of information and protections to which you are entitled as an investor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
our ordinary shares become a &#8220;penny stock,&#8221; it may be more difficult for investors to sell their ordinary shares, and the
market price of our ordinary shares may be adversely affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ordinary shares could become a &#8220;penny stock&#8221; if, among other things, the share price is below $5.00 per share, we are not
listed on a national securities exchange or we have not met certain net tangible asset or average revenue requirements. Broker-dealers
who sell penny stocks must provide purchasers of these stocks with a standardized risk-disclosure document prepared by the SEC. This
document provides information about penny stocks and the nature and level of risks involved in investing in the penny-stock market. A
broker must also give a purchaser, orally or in writing, bid and offer quotations and information regarding broker and salesperson compensation,
make a written determination that the penny stock is a suitable investment for the purchaser, and obtain the purchaser&#8217;s written
agreement to the purchase. Broker-dealers must also provide customers that hold penny stock in their accounts with such broker-dealer
a monthly statement containing price and market information relating to the penny stock. If a penny stock is sold to an investor in violation
of the penny stock rules, the investor may be able to cancel its purchase and get its money back.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
applicable, the penny stock rules may make it difficult for investors to sell their ordinary shares. Because of the rules and restrictions
applicable to a penny stock, there is less trading in penny stocks and the market price of our ordinary shares may be adversely affected.
Also, many brokers choose not to participate in penny stock transactions. Accordingly, investors may not always be able to resell their
ordinary shares publicly at times and prices that they feel are appropriate and the market price of our ordinary shares may be adversely
affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 49; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Inflation
could adversely affect our business and results of operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2022, 2023 and 2024, the economy in the United States and global markets encountered a material increase in the level of inflation. The
impact geopolitical developments, such as the Russia-Ukraine conflict and the security situation in Israel, and global supply chain disruptions
had and continue to increase uncertainty in the outlook of near-term and long-term economic activity, including whether inflation will
continue and how long, and at what rate. Increases in inflation raise our costs for commodities, labor, materials and services and other
costs required to grow and operate our business, and failure to secure these on reasonable terms may adversely impact our financial condition.
Additionally, increases in inflation, along with the uncertainties surrounding geopolitical developments and global supply chain disruptions,
have caused, and may in the future cause, global economic uncertainty and uncertainty about the interest rate environment, which may
make it more difficult, costly or dilutive for us to secure additional financing. A failure to adequately respond to these risks could
have a material adverse impact on our financial condition, results of operations or cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Israeli Law and Our Operations in Israel</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
headquarters and other significant operations are located in Israel and, therefore, our results may be adversely affected by political,
economic and military instability in Israel.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
executive office is located in Ramat Gan, Israel. In addition, certain of our key employees, officers and directors are residents of
Israel. Accordingly, political, economic and military conditions in the Middle East may affect our business directly. Since the establishment
of the State of Israel in 1948, a number of armed conflicts have occurred between Israel and its neighboring countries and terrorist
organizations active in the region, including Hamas (an Islamist militia and political group in the Gaza Strip) and Hezbollah (an Islamist
militia and political group in Lebanon).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2023, Hamas terrorists infiltrated Israel&#8217;s southern border from the Gaza Strip and conducted a series of attacks on civilian
and military targets. Hamas also launched extensive rocket attacks on Israeli population and industrial centers located along Israel&#8217;s
border with the Gaza Strip and in other areas within the State of Israel. These attacks resulted in extensive deaths, injuries and kidnapping
of civilians and soldiers. Following the attack, Israel&#8217;s security cabinet declared war against Hamas and a military campaign against
these terrorist organizations commenced in parallel to their continued rocket and terror attacks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, since the commencement of these events, there have been continued hostilities along Israel&#8217;s northern border with Lebanon
(with the Hezbollah terror organization) and on other fronts from various extremist groups in the region, such as the Houthis in Yemen
and various rebel militia groups in Syria and Iraq. Israel has carried out a number of targeted strikes on sites belonging to these terror
organizations. In October 2024, Israel began limited ground operations against Hezbollah in Lebanon, culminating in a ceasefire
agreed to between Israel and Lebanon in November 2024, the results of which are uncertain. In addition, Iran recently launched direct
attacks on Israel involving hundreds of drones and missiles and has threatened to continue to attack Israel. These situations may potentially
escalate in the future to more violent events which may affect Israel and us. Such clashes may escalate in the future into a greater
regional conflict.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Israeli security cabinet&#8217;s declaration of war against Hamas and possible hostilities with other organizations,
several hundred thousand Israeli military reservists were drafted to perform immediate military service. Although many of such military
reservists have since been released, they may be called up for additional reserve duty, depending on developments in the war in Gaza
and along Israel&#8217;s other borders. While none of our employees in Israel have been called to active military duty, we rely on service
providers located in Israel and have entered into certain agreements with Israeli counterparties. Employees of such service providers
or contractual counterparties may be called for service in the current or future wars or other armed conflicts with Hamas as well as
the other pending or future armed conflicts in which Israel is or may become engaged, and such persons may be absent for an extended
period of time. As a result, our operations may be disrupted by such absences, which disruption may materially and adversely affect our
business and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
our executive offices are located in Ramat Gan, Israel, which is not near Israel&#8217;s borders where the main hostilities have taken
place and none of our employees have been called into military reserve duty, to help mitigate the effects of Israel&#8217;s war with
Hamas, we took several measures, including work-from-home measures and have a business continuity plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 50; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disruptions
that could severely impact our business, clinical trials, and supply chains, include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limitations
    on employee resources that would otherwise be focused on the conduct of our business including because of military reserve duty call-ups
    in the future that impact our employees and the affect the current security situation in Israel on the productivity of our employees
    and external partners;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in necessary interactions with vendors, local regulators, and other important agencies and contractors due to limitations in employee
    resources; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">impacts
    from prolonged remote work arrangements, such as increased cybersecurity risks and strains on our business continuity plans.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
intensity and duration of the current security situation in Israel is difficult to predict, as are such war&#8217;s economic implications
on the Company&#8217;s business and operations, on Israel&#8217;s economy in general, on the trading price of shares of our ordinary
shares and could impact our ability to raise additional capital on a timely basis or at all. These events may be intertwined with wider
macroeconomic indications of a deterioration of Israel&#8217;s economic standing that may involve further downgrade in Israel&#8217;s
credit rating by rating agencies, which may have a material adverse effect on the Company and its ability to effectively conduct its
operations. If the ceasefire declared collapses or a new war commences or hostilities expand to other fronts, our operations may be adversely
affected. The impact of the current war between Israel and Hamas may also have the effect of heightening many of the other risks described
in the See &#8220;Item 3. Key Information&#8212;Risk Factors&#8221; in this annual report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, some countries around the world restrict doing business with Israel and Israeli companies, and additional countries may impose
restrictions on doing business with Israel and Israeli companies if hostilities in Israel or political instability in the region continue
or increase. In addition, there have been increased efforts by countries, activists and organizations to cause companies and consumers
to boycott Israeli goods and services. In addition, in January 2024 the International Court of Justice, or ICJ, issued an interim ruling
in a case filed by South Africa against Israel in December 2023, making allegations of genocide amid and in connection with the war in
Gaza, and ordered Israel, among other things, to take measures to prevent genocidal acts, prevent and punish incitement to genocide,
and take steps to provide basic services and humanitarian aid to civilians in Gaza. There are concerns that companies and businesses
will terminate, and may have already terminated, certain commercial relationships with Israeli companies following the ICJ decision.
The foregoing efforts by countries, activists and organizations, particularly if they become more widespread, as well as the ICJ rulings
and future rulings and orders of other tribunals against Israel (if handed), may materially and adversely impact our business, clinical
trials, and supply chains.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
following Hamas&#8217; attack on Israel and Israel&#8217;s security cabinet declaration of war against Hamas, the Houthi movement, which
controls parts of Yemen has launched attacks on Israeli-controlled or owned ships in the Red Sea, resulting in shipping companies rerouting
their cargo ships or ceasing shipments to Israel in the case of the latter. The hostilities with Hamas, Hezbollah, the Houthi movement
and other terrorist organizations, include and may include terror, missile and drone attacks. In the event that our facilities are damaged
as a result of hostile actions, or hostilities otherwise disrupt our ongoing operations, our ability to deliver or provide products and
services in a timely manner to meet our contractual obligations towards customers and vendors could be materially and adversely affected.
Any hostilities involving Israel or the interruption or curtailment of trade between Israel and its present trading partners could have
a material adverse effect on our business and could make it more difficult for us to raise capital. Our insurance policies do not cover
losses that may occur as a result of events associated with war and terrorism. Although the Israeli government currently covers the reinstatement
value of direct damages that are caused by terrorist attacks or acts of war, we cannot assure you that this government coverage will
be maintained or that it will sufficiently cover our potential damages. Any losses or damages incurred by us could have a material adverse
effect on our business. Any armed conflicts or political instability in the region would likely negatively affect business conditions
and could harm our results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finally,
political conditions within Israel may affect our operations. Israel has held five general elections between 2019 and 2022, and prior
to October 2023, the Israeli government pursued extensive changes to Israel&#8217;s judicial system, which sparked extensive political
debate and unrest. In response to such initiative, many individuals, organizations and institutions, both within and outside of Israel,
voiced concerns that the proposed changes may negatively impact the business environment in Israel including due to reluctance of foreign
investors to invest or transact business in Israel, as well as to increased currency fluctuations, downgrades in credit rating, increased
interest rates, increased volatility in security markets and other changes in macroeconomic conditions. If such changes to Israel&#8217;s
judicial system are again pursued by the government and approved by the parliament, this may have an adverse effect on our business,
our results of operations and our ability to raise additional funds, if deemed necessary by our management and board of directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 51; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Exchange
rate fluctuations between the U.S. dollar and the New Israeli Shekel currencies may negatively affect our earnings.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
functional currency is the U.S. dollar. We incur expenses in U.S. dollars and New Israeli Shekels, or NIS. As a result, we are exposed
to the risks that the NIS may appreciate relative to the U.S. dollar, or, if either the NIS devalues relative to the U.S. dollar, that
the inflation rate in Israel may exceed such rate of devaluation of the NIS, or that the timing of such devaluation may lag behind inflation
in Israel. In any such event, the U.S. dollar cost of our operations in Israel would increase and our U.S. dollar-denominated results
of operations would be adversely affected. The average exchange rate for the year ended December 31, 2024 was $1.00 = NIS 3.647 We cannot
predict any future trends in the rate of inflation in Israel or the rate of devaluation, if any, of the NIS against the U.S. dollar.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Provisions
of Israeli law and our articles of association, or Articles, may delay, prevent or otherwise impede a merger with, or an acquisition
of, our company, which could prevent a change of control, even when the terms of such a transaction are favorable to us and our shareholders.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Companies Law regulates, among others, mergers, requires tender offers for acquisitions of shares above specified thresholds, requires
special approvals for transactions involving directors, officers or significant shareholders and regulates other matters that may be
relevant to such types of transactions. See &#8220;Item 10. Additional Information&#8212;B. &#8212;Mergers and Acquisitions under Israeli
Law&#8221; for additional information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
Israeli tax considerations may make potential transactions unappealing to us or to our shareholders whose country of residence does not
have a tax treaty with Israel exempting such shareholders from Israeli tax. See &#8220;Item 10. Additional Information&#8212;E. Taxation&#8212;Certain
Israeli Tax Considerations&#8221; for additional information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
the classification of our Board into three classes with terms of approximately three years each, per our Articles, the requirement of
affirmative vote of at least 75% of the voting rights of the Company represented personally or by proxy and voting thereon at a general
meeting in order to amend or replace our Articles, together with the other provisions of the Articles and Israeli law, could deter or
delay potential future merger, acquisition, tender or takeover offers, proxy contests or changes in control or management of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>It
may be difficult to enforce a judgment of a United States court against us, our officers, directors and the Israeli experts named in
this annual report in Israel or the United States, to assert United States securities laws claims in Israel or to serve process on our
officers, directors and these experts.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
were and continue to be organized in Israel. Most of our executive officers and directors reside outside of the United States, and all
of our assets and most of the assets of these persons are located outside of the United States. Therefore, a judgment obtained against
us, or any of these persons, including a judgment based on the civil liability provisions of the U.S. federal securities laws, may not
be collectible in the United States and may not necessarily be enforced by an Israeli court. It also may be difficult to effect service
of process on these persons in the United States or to assert U.S. securities law claims in original actions instituted in Israel. Additionally,
it may be difficult for an investor, or any other person or entity, to initiate an action with respect to United States securities laws
in Israel. Israeli courts may refuse to hear a claim based on an alleged violation of United States securities laws reasoning that Israel
is not the most appropriate forum in which to bring such a claim. In addition, even if an Israeli court agrees to hear a claim, it may
determine that Israeli law and not United States law is applicable to the claim. If United States law is found to be applicable, the
content of applicable United States law must be proven as a fact by expert witnesses, which can be a time consuming and costly process.
Certain matters of procedure will also be governed by Israeli law. There is little binding case law in Israel that addresses the matters
described above. As a result of the difficulty associated with enforcing a judgment against us in Israel, our shareholders may not be
able to collect any damages awarded by either a United States or foreign court.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>


<!-- Field: Page; Sequence: 52; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Your
rights, liabilities and responsibilities as a shareholder will be governed by Israeli law and differ in some material respects from those
under U.S. </i>law.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
we are an Israeli company, the rights and responsibilities of our shareholders are governed by our Articles and Israeli law. These rights,
liabilities and responsibilities differ in some material respects from the rights, liabilities and responsibilities of shareholders in
a U.S. corporation. In particular, a shareholder of an Israeli company has a duty to act in good faith towards the company and other
shareholders and to refrain from abusing his, her or its power in the company, including, among other things, when voting at the general
meeting of shareholders on certain matters. Israeli law provides that these duties are applicable to shareholder votes on, among other
things, amendments to a company&#8217;s articles of association, increases in a company&#8217;s authorized share capital, mergers and
interested party transactions requiring shareholder approval. In addition, a controlling shareholder, a shareholder who knows that it
possesses the power to determine the outcome of a shareholders&#8217; vote or a shareholder who has the power to appoint or prevent the
appointment of a director or executive officer in the company, has a duty of fairness towards the company. However, Israeli law does
not define the substance of this duty of fairness. There is little case law available to assist in understanding the implications of
these provisions that govern shareholder behavior. These provisions may be interpreted to impose additional obligations and liabilities
on holders of our ordinary shares that are not typically imposed on shareholders of U.S. corporations. See &#8220;Item 10. Additional
Information&#8212;B Memorandum and Articles of Association&#8212;Shareholder Duties&#8221; for additional information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Any
of the risk factors referred to above could significantly and negatively affect our business, results of operations or financial condition,
which may reduce our ability to pay dividends and lower the trading price of our ordinary shares. The risks referred to above are not
the only ones that may exist. Additional risks not currently known by us or that we deem immaterial may also impair our business operation</i>s.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_001"></span>ITEM
4. Information on the Company.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.
Historical Background and Corporate Structure</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Galmed
Pharmaceuticals Ltd., was incorporated in Israel on July 31, 2013 as a privately held company and is governed by the Companies Law. However,
our business has been operating since 2000 under a different group of companies established in the same year, or the Group. Originally,
we operated under the parent company, GHI. GHI held all of the equity rights in and to Galmed 2000 Inc., a holdings company incorporated
in the British Virgin Islands, or GTTI. GTTI held all of the equity rights in and to Galmed International Limited, a company incorporated
in Malta, or GIL (other than 0.1% of the share capital held by GHI). GIL held all of the equity rights in and to Galmed Medical Research
Ltd., an Israeli company, or GMR. Our intellectual property was held by GIL. The research and development was conducted by GMR as a service
to GIL on a cost plus basis. GIL was responsible for all product development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 2, 2014, we underwent the Reorganization, pursuant to which all of our intangible assets (including our intellectual property)
were transferred from GIL to Galmed Research and Development Ltd., or GRD. The Reorganization was effectuated by share transfers and
asset transfers, resulting in the Company as the parent company and 100% equity-owner of the following companies: (1) GRD, which holds
all the Group&#8217;s intellectual property, including the Company&#8217;s patent portfolio; (2) GIL, which is an inactive company; and
(3) GTTI, which was liquidated in 2017. GIL held GMR, which became an inactive company in 2015 and was liquidated in February 2019. The
Reorganization was conducted in order to simplify our capital structure, reduce our operating cost and to improve our ability to raise
funds. Immediately prior to the Reorganization, all our shareholders collectively held 9,739 ordinary shares of GHI. In connection with
the Reorganization, and in accordance with the Tax Pre-Ruling, we issued to all such shareholders ordinary shares, such that upon the
Reorganization all our shareholders collectively held 7,099,731 of our ordinary shares, in the same proportion among all shareholders,
which reflected a ratio of 729 of our ordinary shares for each ordinary share of GHI. In July 2023, GRD established a new wholly-owned
subsidiary incorporated under the laws of England and Wales called Galmed Therapeutics UK Limited, or Galmed UK.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 53; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a diagram of our corporate structure (following GTTI&#8217;s liquidation and the incorporation of Galmed UK):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img src="vi_001.jpg" alt=""/><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 18, 2014, we completed our initial public offering and since then have been listed on the Nasdaq Capital Market under the symbol
&#8220;GLMD&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
principal executive offices and registered office in Israel is located at c/o Meitar Law Offices, 16 Abba Hillel Road, Ramat Gan, Israel
5250608 and our telephone number is +972-3-693-8448. Our lease at our prior principal executive offices expired on March 21, 2024. We
did not extend the lease and are currently headquartered in Ramat Gan, Israel while we are in the process of searching for a new permanent
location for our principal executive offices. Our website address is http://www.galmedpharma.com. The information contained on, or that
can be accessed through, our website is neither a part of nor incorporated into this annual report. We have included our website address
in this annual report solely as an inactive textual reference. Puglisi &amp; Associates, or Puglisi, serves as our authorized representative
in the United States for certain limited matters. Puglisi&#8217;s address is 850 Library Avenue, Newark, Delaware 19711.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SEC maintains an internet site that contains reports, proxy and information statements and other information regarding issuers that file
electronically with the SEC at http://sec.gov. We use our website (http://www.galmedpharma.com) as a channel of distribution of Company
information. The information we post through this channel may be deemed material. Accordingly, investors should monitor our website,
in addition to following our press releases, SEC filings and public conference calls and webcasts. The contents of our website are not,
however, a part of this annual report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than as described in &#8220;Item 5. Operating and Financial Review and Prospects&#8212;Contractual Obligations&#8221;, we have not had
any material commitments for capital expenditures, including any anticipated material acquisition of plant and equipment or interests
in other companies, since January 1, 2014. Additionally, we have not had any material capital divestitures since January 1, 2014.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.
Business Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a biopharmaceutical company focused on the development of Aramchol. Historically, we have focused almost exclusively on
developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis,
PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">We are currently seeking to advance
the development of Aramchol for oncological indications outside of NASH and fibrosis. <span style="background-color: white">In addition, as
part of our growth strategy, we are actively pursuing opportunities to expand and diversify our product pipeline specifically targeting
cardiometabolic indications and other innovative product candidates that align with our core expertise in drug development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>


<!-- Field: Page; Sequence: 54; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aramchol, our lead product candidate,
is a synthetic conjugate of 3-amino cholic acid, or a type of modified bile acid, and arachidic acid, or a type of saturated fatty acid,
which in its non-synthetic forms, is naturally occurring. The conjugated molecule acts upon important metabolic pathways, reducing fat
accumulation in the liver, improving fatty acid oxidation and regulating the transport of cholesterol. The ability of Aramchol to decrease
liver fat content may also reduce the inflammation and fibrosis in the liver and the risk of cardiovascular complications associated
with NASH. Pre-clinical studies suggest Aramchol&#8217;s effect on fibrosis is also direct via collagen production from human hepatic
stellate cells. We believe that Aramchol&#8217;s ability to reduce liver fat and liver fibrosis and the safety profile observed to date
will enable it to be a treatment for all stages of NASH in patients who are overweight or obese and have pre diabetes or type II diabetes
mellitus and prevent the hepatic complications associated therewith.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2019, we initiated our Phase 3 ARMOR Study to evaluate the efficacy and safety of Aramchol in subjects with NASH and fibrosis.
The ARMOR Study was originally comprised of two parts, a randomized, double-blind, placebo-controlled histology-based registrational
part and a clinically based part where subjects will continue with the same treatment for approximately five years. In December 2020,
we announced the addition of a 150-patient open label part to the ARMOR Study and suspended randomization of new patients into the double-blind,
placebo-controlled histology-based registrational part of ARMOR as all enrolled patients were transitioned to the open label part.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2022, we announced our plan to expand into new anti-fibrotic indications to maximize the potential of Aramchol while at the same
time discontinuing the open label part of its ARMOR Study having reached its objectives. Simultaneously, we initiated a cost reduction
plan and at various times in the past have conducted a strategic review process. Following the discontinuation of our open label part of the ARMOR
Study, we do not currently expect to initiate the second part of the ARMOR Study in the near term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2023, we announced the initiation of a new clinical program to evaluate Aramchol meglumine for the treatment of PSC, a rare disease
for which there is no approved treatment. Currently, we do not have plans to continue the development of Aramchol for this indication.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During 2024, we entered into a collaboration agreement with the Massy Cancer
Center at Virginia Commonwealth University according to which we aim to investigate the effect of adding Aramchol to prevent drug resistance
to standard-of-care oncology agents in the treatment of hepatoma (hepatocellular carcinoma, or HCC), cholangiocarcinoma and colorectal
cancer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Non-Alcoholic
Fatty Liver Disease (NAFLD) / Non-Alcoholic Steato-Hepatitis (NASH)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is estimated that the global prevalence of NAFLD, the precondition to NASH, is approximately 25% in the general population and much higher
in certain high risk groups. This disease is also now recognized as one of the most common liver disorders, and a significant growing
public health problem. In the US alone, 80 - 100 million people are said to be affected by NAFLD, and its prevalence is rapidly growing
in parallel with metabolic syndromes, particularly obesity and diabetes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NAFLD
is characterized by the accumulation of fat of 5% or greater in the liver of people who drink alcohol only in moderation, or not at all.
There may be numerous causes of NAFLD, however, the disease is mostly associated with a high fat, fructose-rich diet. Although NAFLD
is generally asymptomatic, it is a major risk factor for liver inflammation (NASH) and scarring (fibrosis and cirrhosis). In addition,
NAFLD is also associated with metabolic syndrome and cardiovascular disease. Currently, NAFLD can only be managed through lifestyle improvements,
such as weight reduction and physical activity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NASH
is an emerging world crisis impacting an estimated 3% to 5% of the U.S. population and an estimated 2% to 4% globally, and is associated
with increased risk of liver cirrhosis, liver failure, hepatocellular cancer, as well as metabolic and cardiovascular diseases. The major
characteristics of NASH are elevated liver fat, inflammation, ballooning and fibrosis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 55; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">However,
despite the growing need, there are currently no approved therapeutic treatments for NASH. Modification of risk factors, such as obesity
and hyperlipidemia, and proper diabetic control is generally recommended for the treatment of NASH, and the standard of care includes
lifestyle changes to promote weight loss, including low-calorie, low-fat diets and physical activity. Although weight loss can be potentially
significant in delaying the progression of NASH, studies have shown that, for most individuals, it is generally very difficult to maintain
over the long-term, even following bariatric surgery.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date there is only one drug, Madrigal&#8217;s Rezdiffra (resmetirom), approved by the FDA for the treatment of NASH.
Even though certain drugs, such as insulin sensitizers and antihyperlipidemic agents, are prescribed for some NASH patients, they
are not approved for the treatment of NASH and their efficacy has not been proven in adequate and well-controlled clinical
studies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently,
it is impossible to predict which of the NAFLD patients will deteriorate to NASH as it is unclear what causes NASH to develop. Researchers
are now focusing on several factors that may contribute to the development of NASH. Therefore, lifestyle changes are recommended for
all patients with NAFLD.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is an exceptionally wide range of estimates regarding the potential commercial market for NASH. This uncertainty stems from (i) the overall
size of the patient population, (ii) the percentage of the addressable market that will be diagnosed and, subsequently, seek treatment,
(iii) the ultimate cost of the therapies, (iv) the number of approved drugs for NASH and their profile, and (v) uncertainty regarding
the regulatory approval process. Some of these factors cannot be known until NASH drugs begin to hit the market or biomarkers replacing
the biopsy diagnosis are validated. Independent estimates generally estimate a commercial multi billion market in developed countries,
though we do not endorse any estimates, which are based on a number of different underlying assumptions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aramchol
for NASH</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Overview</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
product candidate, Aramchol, is a first-in-class synthetic fatty acid-bile acid conjugate molecule, or FABAC, molecule that we are developing
for oral treatment for NASH in patients who are overweight or obese and have prediabetes or type II diabetes mellitus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Early
in its development, Aramchol&#8217;s ability to modulate hepatic lipid metabolism was observed and validated in numerous pre-clinical
trials with different animal species. Mice fed a high fat diet and treated with Aramchol did not develop fatty liver as compared to non-treated
mice. In these early studies, we also observed that the mechanism of this effect was not a result of malabsorption of fat in the intestines
because the FABAC-treated mice gained weight throughout the test periods to a similar degree to the control mice. This led us to conclude
that FABAC therapy triggers a beneficial modulation of intra-hepatic lipid metabolism and reduces liver fat content.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
<i>in-vitro</i> and in vivo studies, Aramchol down regulates the SCD1 enzyme, an enzyme recognized as playing an important role in the
metabolism of fatty acids. The SCD1 enzyme is essentially the gateway that regulates the use and storage of fat in the body by converting
saturated fatty acids to monounsaturated fatty acids. Experimental animal studies showed that complete inhibition of the SCD1 enzyme
protects against diet-induced obesity, hepatic steatosis, or fatty liver, and insulin resistance by instructing the body to use, rather
than store, all fatty acids. However, various animal studies have indicated that such complete SCD1 enzyme inhibition has mechanism based
serious side effects, such as atherosclerosis, and eye and skin disorders. As observed by us in our pre-clinical and clinical studies
performed to date, and subsequently published in the European Journal of Gastroenterology and Hepatology and Archives of Medical Research
in 2008 and 2010 respectively, one of Aramchol&#8217;s unique characteristics is that it down regulates the SCD1 enzyme but does not
inhibit it completely &#8211; a partial effect. To date, side effects that have been observed in animals with knock out of SCD1 have
not been observed in our toxicology and clinical studies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
better understand the role of Aramchol in NASH, we analyzed the effect of Aramchol in MCD diet model. The aim of this study was to investigate
Aramchol&#8217;s mechanism of action and its effect on fibrosis using the methionine- and choline-deficient (MCD) diet model of NASH.
We collected liver and serum from mice fed a MCD diet containing 0.1% methionine (0.1MCD) for four weeks, which developed steatohepatitis
and fibrosis, as well as mice receiving a control diet; the metabolomes and proteomes were determined. 0.1MCD fed mice were given Aramchol
(5mg/kg/day for the last 2 weeks); liver samples were analyzed histologically. Aramchol administration was found to reduce features of
steatohepatitis and fibrosis in 0.1MCD fed mice. Aramchol downregulated the SCD1 enzyme, a key enzyme involved in triglyceride biosynthesis
whose loss enhances fatty acid &#946;-oxidation. In addition, Aramchol increased the flux through the transsulfuration pathway, leading
to a rise in glutathione (GSH) and GSH/GSSG ratio, the main cellular antioxidant that maintains intracellular redox status. Comparison
of the serum metabolomic pattern between 0.1MCD-fed mice and patients with NAFLD showed a substantial overlap. These findings were published
in Hepatology Communications, Vol. 1, No. 9, 2017.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 56; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the effect of Aramchol on fibrosis was first reported we further analyzed the direct effect of Aramchol on collagen production and reported
down regulation of collagen production from the hepatic stellate cells (HSCs) by Aramchol. With that we could conclude that Aramchol
has potential direct effect on collagen production and therefore reduces fibrosis indirectly by down regulation of steatosis by reducing
the sequence of events but also directly affecting collagen producing cells. These findings were published in Hepatology Communications,
Vol. 1, No. 9, 2017.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
findings led us to further analyze the effect of Aramchol using the Thiocatemide (TAA) rat model. TAA is the most commonly used toxic
agents to induce liver fibrosis. Repeated IP injections of TAA leads to sever fibrosis / cirrhosis. Among all models for fibrosis, the
TAA model share multiple characteristics with human liver fibrosis and is considered to best predict efficacy in humans. Results demonstrated
that treatment with Aramchol 5mg/kg, significantly prevented TAA induced fibrosis in a dose dependent manner. These findings were presented
at EASL, Amsterdam in April 2017 (The anti Fibrotic effect of Aramchol on liver Fibrosis in TAA animal model).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Phase
1 Single and Multiple-Dose Study of Aramchol in Healthy Male Volunteers (NCT00776841)</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aramchol
was evaluated in two Phase 1 clinical trials (under a single protocol) to study its safety, tolerability and PK profile in healthy volunteers,
in both single and multiple dose administrations. The first Phase 1 clinical trial was an escalating single-dose trial conducted in 17
healthy subjects testing Aramchol doses ranging from 30 mg to 900 mg, performed in one center in Israel. The subsequent Phase 1 clinical
trial was a repeated-dose trial conducted over four days in 25 healthy subjects testing repeated daily doses of Aramchol of 30 mg and
300 mg, performed in one center in Israel. The profiles for the groups were similar and the maximal plasma concentration of Aramchol
increased with the higher doses. The PK profile demonstrated that Aramchol is suitable at each dose for once-daily administration and
there were neither significant adverse events observed in either Phase 1 trial nor any notable changes in biochemical, hematologic, cardiovascular
or other safety parameters.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Phase
2a Trial: Aramchol Treatment in NAFLD or NASH Patients (NCT01094158)</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2012, we completed a 60 patient multi-center, randomized, double-blind, placebo-controlled Phase 2a clinical trial of Aramchol
in patients with NAFLD or NASH between the ages of 18 and 75 in 12 centers in Israel. The Phase 2a study results were published in July
2014 in the peer-reviewed Clinical Gastroenterology and Hepatology Journal. The trial was performed in patients with either NAFLD or
NASH, which design was deemed acceptable by the FDA in 2007 at a pre-IND scientific advisory meeting. The trial&#8217;s primary efficacy
endpoint was a reduction in liver fat content, and did not consider inflammation or fibrosis, which can be diagnosed only by liver biopsy.
We believe that the short study duration of three months of treatment followed by a one-month follow-up period did not warrant repeated
biopsies. The trial evaluated the effects on liver fat content of 100 mg and 300 mg once-daily doses of Aramchol compared to a placebo.
At the end of the three month treatment period, statistically significant reductions in liver fat concentration as measured by MRS were
observed in the 300 mg patient group. Specifically, a 12.57% mean liver fat content reduction was observed in the 300 mg group, as compared
to a mean reduction of 2.89% in the 100 mg group and a mean increase of 6.39% in the placebo-treated patients. These results indicate
that the effects of Aramchol are dose-dependent, as demonstrated in the graph below, which presents the results with respect to the 57
patients who successfully completed the entire treatment period (three patients were excluded from data analysis because of one protocol
violation and two withdrawal consents).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 57; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Relative
Change in MRS from Baseline after Three Months of Treatment</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img src="vi_002.jpg" alt=""/><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table above shows that the primary endpoint of the study was attained. The study demonstrated a statistically significant, dose dependent
reduction in fat content in the livers of patients treated with Aramchol, with a 19% difference between the 300 mg dose group and the
placebo group, while the difference between the 100 mg dose group and the placebo group was not statistically significant. Notably, the
minimal effective dose of Aramchol for fat reduction has been defined.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no statistically significant differences among the three treatment groups for any of the secondary end points. There was a non-statistically
significant trend of mild weight reduction (P=.1) in the high dose Aramchol group. Serum adiponectin levels increased (0.2 &#177; 1.7
&#956;g/mL) in the high-dose Aramchol group but decreased in the low-dose (-0.3 &#177; 1.5 &#956;g/mL) and placebo groups (-0.7 &#177;_1.3
&#956;gg/mL) (P= 0.88 for trend of dose-response relationship by linear regression). FMD increased non-statistically significantly by 1.28%
&#177; 2.92% in the high-dose group, by 0.34% &#177;3.54% in the low-dose group, and by 0.46% &#177; 2.28% in the placebo group.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
frequency of adverse events was similar in all treatment groups, and none of them were considered to be related to the treatment. All
adverse events in the active treatment arms were mild or moderate and none were serious. None of the patients withdrew as a result of
adverse events. The following table shows the most frequent adverse events (occurring in &#8805; 2 patients in any group) in the study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center">Placebo</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center">Aramchol 100mg/d</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center">Aramchol 300mg/d</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(N=20)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(N=20)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(N=20)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">MedDRA</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">No.</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">No.</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">No.</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">No.</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">No.</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">No.</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">preferred term</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Events</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Subjects</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Events</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Subjects</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Events</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Subjects</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 19%; text-align: left">Abdominal pain</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">2</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">2</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">10</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">2</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">1</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">5</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">1</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">1</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">5</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Abdominal pain</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>upper</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Constipation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Asthenia</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Back pain</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Musculoskeletal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>pain</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Upper</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">respiratory tract</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>infection</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10</td><td style="text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 58; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
results of our Phase 2a clinical trial of Aramchol in the peer-reviewed Clinical Gastroenterology and Hepatology Journal were published
in December 2014. The trial manuscript, entitled &#8220;The Fatty Acid-Bile Acid Conjugate Aramchol Reduced Liver Fat Content in Patients
with Nonalcoholic Fatty Liver Disease,&#8221; provides the full report of the Phase 2a trial, which was completed in January 2012 and
presented at the 47<sup>th </sup>Annual Meeting of the European Association for the Study of the Liver in 2012. Based on this Phase 2a
proof-of-concept results, we established a development plan that we believe may confirm: (i) the good safety profile of Aramchol, (ii)
the optimal dose of Aramchol, and (iii) efficacy on steatosis as well as fibrosis in patients with NASH.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Pharmacokinetics
of Single and Multiple Escalating Doses of Aramchol and Food Effect in Healthy Volunteers (NCT02374437)</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 28, 2014, we commenced PK and food effect studies of Aramchol. In written correspondence from December 2013 regarding a requested
pre-IND meeting, the FDA recommended that we conduct such studies prior to commencing our Phase 2b ARREST Study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted the food effect and PK study at the Sourasky Medical Center in Tel Aviv, Israel involving 66 healthy volunteers to evaluate
the PK of Aramchol following single and multiple escalating doses (200 mg, 400 mg and 600 mg), as well as to evaluate the effect of a
high-fat, high-calorie meal on the PK of Aramchol following a single dose in healthy volunteers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
results showed dose-related, but less than dose-proportional, increases in the mean Aramchol plasma concentrations, or Cmax, area under
the curve, or AUC, (0-t), and AUC (inf) of 200 mg, 400 mg and 600 mg doses administered under fasting conditions or following a light
meal, both at single and repeated dose administration. Cmax and AUC are metrics used to indicate the significance of a drug&#8217;s exposure.
Steady-state was achieved by 144 hours (day seven). Administration of Aramchol after a high-fat, high-calorie meal afforded a 2.6 fold
increase in exposure, as measured by Cmax, AUC(0-t), and AUC(inf) compared to the fasting group.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
serious adverse events or deaths occurred during the study. Adverse events were equally distributed between placebo and Aramchol doses,
were mild (with only one moderate adverse event) and the majority defined unrelated to Aramchol. The PK study provides additional safety
data to further support existing safety data from our pre-clinical studies and our Phase 1 and Phase 2a clinical trials of Aramchol.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Pharmacokinetics
of Single and Multiple Escalating Doses of Aramchol Administered under Fed Conditions in Healthy Chinese Volunteers (NCT 02803996)</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2016, we performed the Chinese PK Study involving Chinese patients who are domiciled in the United States. We enrolled 66 patients in
this study, consisting of two parts. In part A, 32 subjects received a single escalating dose; Part B enrolled 34 subjects which received
a multiple escalating dose. Dr. Evelyn Darius served as the Study Investigator. No safety signal was identified in this study and we
deemed no changes were required in the enrollment of Chinese patients into the ARREST Study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Phase
2b ARREST Study for Aramchol (NCT 02279524)</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2014, the FDA granted Fast Track designation status to Aramchol for the treatment of NASH. Fast Track designation may accelerate
the development process and may expedite the review of drugs that show promise in treating serious, life-threatening medical conditions
for which no other drug either exists or is as effective.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 59; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 1, 2015, we began our ARREST Study. The ARREST Study was a Phase 2b, multicenter, global, randomized, double-blind, placebo
controlled study to evaluate the efficacy and safety and of two doses of Aramchol for the treatment of NASH in patients who are overweight
or obese and have pre diabetes or type II diabetes mellitus. In order to be eligible to participate in the ARREST Study, patients had
to be affected by NASH, as diagnosed by a biopsy centrally read (steatosis &#8805;1 + inflammation &#8805;1 + ballooning &#8805;1, total activity
NAS score of 4 or more), have a fibrosis stage of 1-3, be overweight or obese as measured by a Body Mass Index between 25 and 40 or waist
circumference between 88cm to 200cm for women, and between 102cm to 200cm for men, and who are pre diabetic or type II diabetic. We targeted
this specific population as it is at the greatest risk of developing NASH and its complications. We have generated data from animal models
that lead us to believe that Aramchol targets all three main pathologies of the disease: steatosis, inflammation and fibrosis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
total of 247 patients (approximately one third in the US, one third in Latin America and one third in Europe and Israel) with liver biopsy-proven
NASH who were overweight or obese and had pre-diabetes or type II diabetes mellitus were randomized. Patients were randomized in a ratio
of 2:2:1 (600mg, 400mg and placebo) taking once-daily oral Aramchol (in the Aramchol treatment arms) or a placebo (in the placebo arm).
The treatment part of the trial was 12 months in duration and patients completing this phase were observed for a three month follow-up
period. In February 2017, we completed randomization of the ARREST Study. Baseline histology of patients enrolled into the ARREST study
demonstrated a population with advanced disease, with 60% having stage 2 and 3 fibrosis and 70% have NAS&gt;5 at baseline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
primary endpoint of the study was the change from baseline to end of study in liver triglycerides ratio as measured by magnetic resonance
spectroscopy, or MRS (Aramchol 600mg vs. placebo). Secondary endpoints, demonstrated through biopsy, included fibrosis improvement by
at least one stage or more without worsening of NASH (defined by an increase of inflammation and or ballooning) and NASH resolution (defined
by ballooning score 0 and inflammation score 0-1 at termination) without worsening of fibrosis. Other secondary endpoints included improvement
(2 points or more) in NASH activity index, as measured by NAS or SAF, without worsening fibrosis and change in baseline to week 52/termination
in ALT (U/L).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 12, 2018, we announced top-line results of the ARREST Study and on November 13, 2018 an oral abstract presentation of one-year results
of the ARREST Study was presented during a Late Breaking Abstract Oral Session at The Liver Meeting&#174; 2018 during the American Association
for the Study of Liver Diseases 2018 Annual Meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Of
the 247 patients, 48 patients were in the placebo arm, 101 patients in the Aramchol 400mg arm and 98 in the Aramchol 600mg treatment
arm. The majority of subjects completed 52 weeks of treatment and 13 weeks of follow up (89.1%, 89.8%, 85.4% in the 400 mg, 600 mg and
placebo arms, respectively). The leading cause of discontinuation was consent withdrawal and early termination due to adverse events;
the incidence of early termination due to AEs was very low and similar across study arms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patients
in the ARREST study were planned to undergo MRS, and a liver biopsy at baseline and week 52, which were centrally read, blinded to treatment
allocation. The statistical analysis plan included pre-defined analysis sets: (i) a full analysis set for MRI (FAS -&#8212; MRI): all
intent to treat, or ITT, patients with baseline and at least one second MRS. 214 patients were included in this analysis set (41 in placebo;
90 in Aramchol 400mg; and 83 in Aramchol 600mg); and (ii) a full analysis set for liver biopsy (FAS -&#8212; biopsy): all ITT patients
with baseline and a second biopsy. 198 patients were included in this analysis set (40 in placebo; 80 in Aramchol 400mg; and 78 in Aramchol
600mg).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Results
from the study showed a statistically significant reduction in liver fat by MRS with Aramchol 400mg vs. placebo (p=0.0450) and not with
600mg (p=0.0655) and thus did not reach the primary endpoint of the study. In a post-hoc analysis, a cutoff of 5% absolute reduction
in liver fat was used as a surrogate for potentially clinically meaningful MRI reduction. In this responder&#8217;s analysis, a dose-response
could be observed; the responder rate was 47.0%, 36.7% and 24.2%, in the Aramchol 600mg, 400mg and placebo arms, respectively. The proportion
of the Aramchol 600mg arm compared to placebo was statistically-significant (p=0.0279).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Results
for the two biopsy endpoints, which may currently constitute a primary endpoint for a Phase 3 trial to support an FDA marketing application,
demonstrated the following: (i) significantly more patients treated with Aramchol 600mg vs. placebo achieved NASH resolution without
worsening of fibrosis (16.7% vs. 5.0%; p=0.0514); and (ii) a higher proportion of patients showed at least one-point improvement in fibrosis
score without worsening of NASH in Aramchol 600mg vs. placebo (29.5% vs. 17.5%; p=0.2110).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 60; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statistically
significant reductions in live enzymes alanine transaminase (ALT) and aspartate transaminase (AST) were demonstrated in both Aramchol
arms vs. placebo (p&#8804;0.0002) and (p&lt;0.0001), respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Secondary
endpoints based on NAS and SAF activity score, &#8805;2 points improvement, showed a higher proportion of patients with improvement in the
Aramchol arms (600mg&gt;400mg&gt;placebo; P&gt;0.05).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exploratory
endpoints of glycemic parameters showed statistically significant reductions in HbA1c with both Aramchol arms vs. placebo (p&lt;0.007)
implying a potential effect on glycemic control.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
52 weeks of treatment, Aramchol continued to show a favorable safety and tolerability profile. Serious adverse events were reported in
12.5%, 8.9% and 9.2% of patients in placebo, Aramchol 400mg and 600mg arms, respectively. No clustering of event type or atypical events
for the studied population was reported in either Aramchol arms. Severe adverse events were reported in 10.4%, 6.9%, and 6.1% of patients
in placebo, Aramchol 400mg, and 600mg arms, respectively. Early terminations due to adverse events occurred in 4.2%, 3.0% and 4.1% in
placebo, Aramchol 400mg and 600mg arms, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the most frequent adverse events.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img src="vi_003.jpg" alt=""/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>


<!-- Field: Page; Sequence: 61; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the ARREST results:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Aramchol</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Aramchol</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Placebo</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">400 mg</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">600 mg</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">MRS- &#8211;Absolute change from baseline in mean liver fat (1)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">(0.09</td><td style="width: 1%; text-align: left">)%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">(3.41</td><td style="width: 1%; text-align: left">)%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">(3.18</td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">P=0.0450</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">P=0.0655</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">MRS responders- Reduction of&#8201; &#8805;5% in absolute change from baseline (1)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24.4</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">36.7</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">47.0</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">P=0.0878</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">P=0.0279</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">NASH resolution without worsening of fibrosis (2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.5</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16.7</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">P=0.4955</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">P=0.0514</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">NASH resolution (2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.5</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12.5</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19.2</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">P=0.2237</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">P=0.0462</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Fibrosis improvement (&#8805;1 stage) without worsening of NASH (2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17.5</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21.3</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29.5</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">P=0.8425</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">P=0.2110</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Progression to Cirrhosis (Post-Hoc Analysis) worsening of NASH (2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.5</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.5</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.3</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">P=0.5693</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">P=0.1008</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">ALT (U/L) Change from baseline (3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">+11.82</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-12.0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(17.3</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">P=0.0002</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">P&lt;0.0001</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">AST (U/L) Change from baseline (3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">+6.67</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7.20</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(10.83</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">p=0.0011</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">p&lt;.0001</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">HbA1C Change from baseline (4)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">+0.32</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.04</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.13</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">p=0.0061</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">p=0.0008</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Placebo
    N=41; 400mg N=90, 600mg N=83; Mixed Effect Model Repeat Measurement (MMRM) adjusted mean changes from baseline; p-values for comparison
    of active treatment arm vs. placebo.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Placebo
    N=40, 400mg N=80, 600mg N=78; Baseline adjusted logistic regression; p-values for comparison of active treatment arm vs. placebo.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Placebo
    N=47, 400mg N=100, 600mg N=98; MMRM adjusted mean changes from baseline; p-values for comparison of active treatment arm vs. placebo.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Placebo
    N=47, 400mg N=98, 600mg N=96; MMRM adjusted mean changes from baseline; p-values for comparison of active treatment arm vs. placebo.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Dose
Splitting Pharmcokinetic Study (NCT03774173)</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the dose response pattern observed in the ARREST Study, we recently conducted a Phase 1, open-label, crossover PK study to
assess whether dose splitting of Aramchol 600mg to twice daily 300mg will significantly increase plasma levels. 16 healthy subjects took
part in two study periods. Eight subjects received each regimen in the first period and the alternate regimen in the second period. A
PK profile was obtained over the dosing interval at steady state on day ten of each period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Results
of the study showed that the administration of Aramchol 300 mg twice daily resulted in 24-hour plasma concentrations significantly greater
than those observed with the administration of Aramchol 600 mg once daily. (P&lt;0.0001). The average plasma levels (exposure) were 53%
higher and exposure was greater in all 16 subjects with the twice daily dosing. The treatment in both dosing regimens were similar in
terms of safety and were well tolerated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>First
in Human Aramchol Meglumine Pharmcokinetic Study</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2020, we announced new data from a Phase 1, first in human study that compared Aramchol meglumine to Aramchol acid.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 62; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Armachol
acid and Aramchol megluine was administered twice daily to 12 subjects. Below is a summary of the results:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img src="vi_004.jpg" alt=""/><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
initial results demonstrated that the new salt form of Aramchol meglumine has a plasma PK profile that is very similar to Aramchol acid.
It also showed that the administration of both forms resulted in the same form of Aramchol in the blood, regardless of which drug product
is administered and that less Aramchol meglumine is needed for the same exposure of Aramchol acid in the blood.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Phase
3 ARMOR Study for Aramchol</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2019, we initiated the ARMOR Study, a Phase 3 pivotal study of Aramchol for the treatment of NASH, following a successful End-of-Phase
2 meeting with the FDA in April 2019 in which we reached general agreement on key aspects of the Phase 3 development and registration
plan for Aramchol. The ARMOR Study was originally comprised of two parts, a randomized, double-blind, placebo-controlled histology -based
registrational part where 1200 subjects will be treated with Aramchol or matching placebo for 52 weeks and a clinically based part where
subjects will continue with the same treatment for approximately five years, taking into consideration draft guidance issued by the FDA
in December 2018 entitled &#8220;Noncirrhotic Nonalcoholic Steatohepatitis with Liver Fibrosis: Developing Drugs for Treatment&#8221;,
or the &#8220;December Guidance&#8221;. The histology-based data is intended to serve as the basis for the submission of a marketing
authorization application under regulatory provisions of Sub-part H accelerated/conditional approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
light of the rapid development of the Aramchol meglumine program and due to the delays resulting from the COVID-19 pandemic, in December
2020, we announced the addition of an open label part to the ARMOR Study and temporarily suspended randomization of new patients into
the double-blind, placebo-controlled histology-based registrational phase of ARMOR as currently enrolled patients are transitioned to
the open label part.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 63; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Part
One: Open Label Study</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
first part, an open-label study, was originally designed to evaluate treatment response kinetics, pharmacokinetics and safety of twice
daily administration of Aramchol 300mg in approximately 150 subjects with NASH and liver fibrosis stage 1-3 (F1 capped at 30 subjects),
subjects with NASH who may or may not be overweight, and subjects with NASH who may or may not have type 2 diabetes or be pre-diabetic.
Patients were randomized (1:1:1) into three groups with post-baseline liver biopsy being performed at 24 weeks, 48 weeks, or 72 weeks,
respectively. A second post-baseline liver biopsy was conducted after one year for subjects whose post-baseline liver biopsy at week
24, 48 or 72 does not show at least one stage improvement in fibrosis. The open label part was being conducted at approximately 50 selected
sites in the U.S., and around the world which have been less affected by the COVID-19 pandemic.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
open label study enrolled 157 subjects. Fifty-one (51) subjects underwent post-baseline biopsies prior to study discontinuation (28 subjects
at &lt;48 weeks and 23 subjects at &#8805;48 weeks). The study was designed to assess the safety, pharmacokinetics (PK) and efficacy kinetics
as a function of treatment duration. Three independent pathologists and three different histopathology reading methodologies were used
to assess the antifibrotic effect of Aramchol: fibrosis stage based on NASH CRN; ranked assessment (improvement/worsening/stable) of
paired (pre- and post-baseline) biopsies, blinded to sequence; and an automated and continuous score of Fibrosis Composite Severity (FCS),
using FibroNest&#8482;, a quantitative AI digital pathology image analysis method. Noninvasive tests (NITs) included imaging (fibroscan)
and biomarkers (liver enzymes, FIB-4, Pro-C3 and ELF).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aramchol
treatment resulted in a high proportion of subjects showing fibrosis improvement based on all three biopsy reading methodologies, with
a larger treatment effect with longer duration of therapy. Following a treatment duration of 48 weeks or more, improvement in fibrosis
was demonstrated in 39% of subjects according to NASH CRN and 61% of subjects according to ranked assessment. At Week 48 AI demonstrated
fibrosis improvement in 100% of subjects when responders were defined by an absolute reduction of the FCS score &gt;0.3, 65% when responders
were defined by a relative reduction of &gt;25%, and a statistically significant reduction from baseline in mean FCS score (p&lt;0.0001).
NASH resolution without worsening of fibrosis was demonstrated in 26.5% of subjects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fibroscan,
ALT, AST, and FIB4 were analyzed using MMRM, based on all subjects (N=154). Fibroscan results were consistent, with an improvement in
fibrosis showing a mean absolute reduction from baseline to week 72 of 2.5 kPa (p&lt;0.0001). At Week 72, ALT was reduced by 22 U/L (p&lt;0.0001),
AST was reduced by 18 U/L (p&lt;0.0001), and FIB-4 was reduced by 0.30 (p&lt;0.0001).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 64; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pro-C3
and ELF were analyzed for 43 subjects at week 24 showing reduction in both Pro-C3 levels (p&lt;0.0001) and ELF (p=0.0038).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Open Label part demonstrated the good safety profile of Aramchol 300mg BID including long-term follow up. The incidence of serious adverse
events (SAEs) was consistent with the population (10.4%) and early discontinuation rates due to adverse events (AEs) were low (4.5%).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Part
Two: Histology-Based and Clinically-Based Study</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
second part of the ARMOR Study is a randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of Aramchol
300 mg BID to support regulatory approval, with both a histology-based phase and a clinically-based phase. As was designed, a total
of 2000 subjects with NASH and liver fibrosis stage 2 and 3 who are overweight and are either pre-diabetic or have type 2 diabetes would
be randomized 2:1 to receive Aramchol 300mg BID or matching placebo. In the histology-based phase, we intend to treat 1000 subjects with
Aramchol or matching placebo for 72 weeks until the second biopsy. The histology-based data is intended to serve as the basis for the
submission of a Sub-part H marketing authorization application under regulatory provisions of accelerated/conditional approval. The primary
histology-based endpoint is NASH resolution without worsening of fibrosis or fibrosis improvement without NASH worsening. In the clinically-based
phase, all subjects will continue with the same treatment assignment for up to seven years until study completion to confirm clinical
efficacy. We may announce end-of-study at the time when a total of 380 subjects have experienced at least one pre-specified clinical
event or at five years from last subject randomization, whichever comes first. The primary clinically-based endpoint is expected to be
based on clinical events including all-cause mortality, histological progression to cirrhosis, MELD score &gt;15, and hepatic decompensation
events (e.g., hepatic encephalopathy, variceal bleeding, ascites). If the clinical trial results in the histology-based phase are positive,
we planned to submit an NDA for Sub-part H accelerated/conditional approval to the FDA. As discussed elsewhere, we suspended the initiation
of the double-blind placebo-controlled histology-based registrational part of ARMOR.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a depiction of part two of the ARMOR Study:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form20-f_005.jpg" alt=""/>&#160;</span></p>


<!-- Field: Page; Sequence: 65; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">In August 2021, we announced that
the FDA agreed with our plan to use Aramchol meglumine (in lieu of Aramchol free acid) in our ARMOR Study without the need to conduct
additional nonclinical and clinical studies other than planned limited pharmacology studies relating to Aramchol meglumine. In addition,
the Medicines and Healthcare products Regulatory Agency, or MHRA, the pharmaceuticals regulator in the UK, also agreed with our plan to
proceed with our proposed clinical studies with Aramchol meglumine in lieu of Aramchol free acid without the need to repeat nonclinical
and clinical studies other than planned limited pharmacology studies relating to Aramchol meglumine.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">In November 2021, we announced
positive interim data on the open label part of the ARMOR Study showing clinically significant effect on fibrosis improvement based on
histology in the first 16 patients. Subsequently in November 2021, we announced that new analyses of biomarkers corroborate this effect
showing statistically significant reductions in biomarkers associated with liver fibrosis including ALT, AST, Fib-4 and ProC-3. Reductions
of a similar magnitude were seen in a cohort of the first 20 patients for which paired biopsy have been analyzed and a cohort of 50 patients
for which biomarker data was analyzed based on all available data at that time. In addition, we reported that Aramchol continues to show
excellent safety and tolerability profile. Data support that a higher dose of Aramchol could provide statistically and clinically meaningful
effect on fibrosis in the double-blind placebo controlled part for submission of the ARMOR Study to support an NDA under Sub-part H.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">In April 2022, we announced further
positive interim data on the open label part of the ARMOR Study showing robust fibrosis improvement across multimodality histological
assessment. Results of post baseline biopsies performed either at 24 weeks or at 48 weeks from 46 subjects with NASH and F1-3 that received
Aramchol support the anti-fibrotic effect of Aramchol and reinforce the favorable safety profile of Aramchol.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">In May 2022, we announced the discontinuation
of the open label part of our ARMOR Study having reached its objectives and in January 2023, we announced full results from the open label
part of the ARMOR Study. Following the discontinuation of our open label part of the ARMOR Study, we do not currently expect to initiate
the second part of the ARMOR Study.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amilo-5MER</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2020, we announced significant progress in the development of Amilo-5MER, a 5 amino acid synthetic peptide MTADV (Methionine,
Threonine, Alanine, Aspartic acid, Valine). The 5 amino acids sequence of Amilo-5MER is homologue to a specific MTADV sequence in the
human CD44 variant found in synovial fluid cells from joints of rheumatoid arthritis, or RA patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amilo-5MER
was being developed through a research collaboration between us and the Hebrew University of Jerusalem. The molecule originated in the
laboratory of Prof. David Naor, from the Lautenberg Center for Immunology and Cancer Research, Faculty of Medicine, The Hebrew University.
Prof. Naor and his team were the first to publish this specific sequence in the prestigious scientific communication Journal of Clinical
Investigation 1.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amilo-5MER
binds to three pro-inflammatory amyloid proteins, Serum Amyloid A, or SAA, Transthyretin and Apolipoprotein B with high affinity. The
first two are known to be active only in their aggregated forms. By binding to SAA, Amilo-5MER interferes with SAA aggregation and therefor
inhibits the destructive autocrine, self-amplifying cytokine loop that causes additional inflammatory reaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SAA
constitutes acute phase reactants, whose concentration in serum rise rapidly in response to acute stimuli such as infection and trauma.
An elevated concentration of SAA was identified in sera of patients with multiple autoimmune diseases and more recently, an outstanding
increase of SAA was also detected in COVID-19 infected patients2-3. SAA in its aggregated form, is a potent and rapid inducer of cytokine
secretion (particularly Interleukin 6 (IL-6). IL-6 plays an important role in chronic inflammation and is implicated in the pathogenesis
of many autoimmune diseases, such as Multiple Sclerosis, or MS, RA, Inflammatory Bowel Disease, or IBD and acute COVID 19. Interference
with SAA polymerization and aggregation is a valid target to prevent chronic inflammatory conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amilo-5MER
has been shown to significantly reduce chronic inflammation in animal models of RA, IBD and MS (research work supported by a grant to
Prof. Naor from the National Multiple Sclerosis Society (NMSS) of the USA). Amilo-5MER provides a unique mechanism of action to interfere
with this vicious cycle, enabling a specific treatment for chronic inflammatory diseases. Data generated from multiple in-vitro, in-vivo
and human ex-vivo models have shown that Amilo-5MER significantly improves clinical symptoms. Histological improvements and reduction
of pro-inflammatory cytokine secretion were also observed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amilo-5MER
is considered a New Chemical Entity. As such, it is eligible for NCE patent protection until July 2034. Patents have been granted and
maintained in the US (US 1061181937), Europe (EP 3169343) and Australia (AU 2015291151) and have been allowed in Japan (JP 6671363).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2021, we dosed the first subject in our first in human Phase 1 trial of Amilo-5MER for the treatment of chronic inflammatory diseases.
The trial was a three-part, single center, double-blind, randomized, placebo-controlled first in human study of single ascending doses
(Part 1) and multiple doses (Part 2) of Amilo-5MER in young healthy adult male subjects and a single dose cohort in healthy elderly male
and female subjects (Part 3). Overall, 55 healthy male and female subjects were enrolled in the study. Cohorts of 8 subjects were randomized
to receive Amilo-5MER or placebo by subcutaneous injection in a ratio of 6:2. In Part 1, cohorts of young male adults received single
ascending doses of 10, 30, 90, 180 and 360 mg; in Part 2, a single cohort received doses of 180 mg BID for 5 consecutive days and in
Part 3 a single cohort of healthy elderly male and female subjects received a single dose of 180 mg. The primary objectives of the trial
were to evaluate the safety, tolerability, and pharmacokinetics of Amilo-5MER. In January 2022, we announced results in which all doses
of Amilo-5MER were well tolerated with no clinically significant adverse events and none considered related to the investigational product.
All subjects completed the study as per protocol. Overall exposure to Amilo-5MER increased with an increase in dose, with statistically
significant dose proportionality over the 10 mg to 360 mg dose range.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are currently not pursuing the development of Amilo-5MER.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 66; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Additional
Pre-clinical and Clinical Studies Required for Regulatory Submissions</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Toxicology
Studies</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
the completion of the Phase 2a study, pre-clinical toxicology studies have been conducted to support our clinical programs and
regulatory submissions. These studies were performed in compliance with the EMA&#8217;s ICH M3 (R2) guidelines. The toxicity program
for Aramchol included repeat dose studies of up to six months in rats and up to nine months in dogs by oral administration, the intended
route of administration in the clinical trials and beyond. The dose level of 1000 mg/kg/day in rats and 1500 mg/kg/day in dogs, which
is the maximal feasible dose in both species showed no side effect and therefore the highest dose of the study was selected as the no-observed-adverse-effect-level,
or NOAEL. There were no observations noted in the rat study. The findings in the dog study were limited to changes in plasma lipids,
including decreases in total blood cholesterol levels, LDL, HDL and phospholipids, and a slight increase in the size of the adrenal glands,
which were considered to be an extension of the primary pharmacology of Aramchol and non-toxic effects, and skin scales from week 13
onwards in all Aramchol-treated groups, with a dose-related incidence. After six months this was not accompanied by any microscopic alteration
of the skin and therefore considered not toxicologically relevant. Results from the study show that after nine months the presence of
scales in all Aramchol-treated groups was accompanied by minor test item-related microscopic findings in the skin: Hyperkeratosis of
the epidermis, correlating to the scales, and keratin plugs in the hair follicles (in males at 750/500 and 1500 mg/kg). After a 12-week
treatment-free recovery period, fewer scales were noted and microscopically there was partial recovery. As these findings were minor
and no clinical symptoms like scratching were noted, these findings were considered not adverse.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aramchol
was non-mutagenic in vitro in the Ames test and chromosomal aberrations test, each of which is a test to determine whether the subject
chemical can cause mutations in the DNA of an organism. In addition, in bone marrow micronucleus test in male rats at a 2000 mg/kg oral
dose (the maximum recommended dose in accordance with ICH S2 (R1)), Aramchol was not clastogenic, meaning it did not give rise to or
induce disruption or breakages of chromosomes, nor was it aneugenic, meaning it did not cause the number of chromosomes in the nucleus
of a cell to not be an exact multiple of the monoploid number of a particular species.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Embryo-fetal
development toxicity was assessed in rats and rabbits. No maternal or fetal development toxicity was observed in either species. The
NOAEL for maternal and development toxicity was at least 1000 mg/kg in rats and 750 mg/kg in rabbits (the maximum feasible dose in both
species).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
maximum tolerated doses were reached in the studies. Over 50-fold safety margin exposure was achieved in dogs but not in rats. However,
for rats, at least three of the four ICH M3(R2) safety margin criteria were met, and for dogs all four criteria were met. Blood tests
revealed a decrease in total blood cholesterol levels, including LDL, HDL and phospholipids, and there was a slight increase in the size
of the adrenal glands of the dogs, which WIL Research assessed as a physiologic compensatory response to the decrease in blood cholesterol
levels. WIL Research did not consider the decrease in blood cholesterol levels or the physiologic response of the adrenal glands as a
toxic effect, but rather as a pharmacodynamic effect, which is a biochemical and physiological effect of the drug on the body. Based
on the above, it was concluded that the overall safety data for Aramchol is sufficient to support the proposed Phase 2b clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we have conducted carcinogenicity studies to identify whether Aramchol has any tumorigenic potential upon long-term administration
in support of any future NDAs or MAAs. Under FDA guidance, we are required to perform two studies, one in rats and the other in mice.
The carcinogenicity study in rats is a two-year study which was initiated in February 2020 and finalized during 2022. There were no significant
adverse findings reported over the course of the study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aramchol
for the Treatment of Other Indications</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 14, 2018, we announced topline results from the investigator initiated ARRIVE Study for HIV associated lipodystrophy and NAFLD
patients. HIV patients have advanced liver disease which is a major cause for morbidity and mortality. ARRIVE, a Phase 2a, investigator
initiated clinical trial conducted at the University of California</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 67; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">San
Diego by Professor Rohit Loomba was a randomized, double-blinded, placebo-controlled, 12 weeks, proof-of-concept study that evaluated
the safety and efficacy of Aramchol at 600mg/day versus placebo in 50 patients with HIV-associated lipodystrophy and NAFLD. The primary
end point of successful therapy was improvement in hepatic steatosis at 12 weeks, as measured by MRI-PDFF. Secondary endpoints were improvement
in total body fat, metabolic profile, and liver biochemistry. Liver biopsies were not included as part of the evaluation in this pilot
trial. The trial showed no difference between HIV patients receiving Aramchol for 12 weeks when compared with HIV patients in the placebo
arm. Aramchol showed a favorable safety and tolerability profile. Although the pathology (fatty liver) is similar to &#8220;garden variety&#8221;
NASH, the pathogenesis involved in the HIV lipodystrophy and NAFLD is different and multi factorial including the effect of the virus
itself and the anti-HIV medications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 13, 2014, we announced the first administration of Aramchol in a proof-of-concept Phase 2a clinical trial for the treatment
of newly formed cholesterol gallstones following bariatric surgery. The primary end-point was to prove that Aramchol dissolves newly
formed gallbladder gallstones following bariatric surgery. Patients were to be assigned to one of three treatment arms; 400mg tablets,
600mg tablets and placebo. Only 9 patients were enrolled, and 7 patients completed the study. Due to poor patient recruitment and change
in Company focus, we decided to terminate the study on October 1, 2015. We currently believe that it is unlikely that we will revive
another study in cholesterol gallstones.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2022, we announced results showing significant effects of Aramchol in pre-clinical model of both lung and gastrointestinal (GI)
fibrosis. Fibrosis is a common complication of chronic inflammation and can affect all organs and tissues. To date, only limited anti-fibrotic
drugs are approved or are in development, most of which have restricting side effects. Aramchol is a partial inhibitor of SCD1 with distinctive,
direct, anti-fibrotic activity demonstrated in several pre-clinical models. Treatment with Aramchol resulted in statistically significant
fibrosis improvement in a validated bleomycin model of lung fibrosis (IPF), comparable to Pirfenidone which is the gold standard treatment.
Findings were seen across all important indicators for the severity of fibrosis including hydroxyproline (a marker for collagen deposition
in the fibrotic tissue) P&lt; 0.05, Ashcroft score P &lt; 0.005, % CPA (Percentage Collagen Proportionate Area of the lung) P &lt; 0.001,
and immunohistochemistry (type I collagen and a SMA) P &lt; 0.005 for both staining. Statistically significant improvements were also
demonstrated in a validated DSS model of inflammatory bowel disease (IBD). Dextran sulfate sodium (DSS) induced colitis model is widely
used because of its similarities with human ulcerative colitis. Clinical improvements were statistically significant at least by p value
&lt; 0.05 while in histological score (based on inflammation and colon structural changes) significance was as low as p<span style="text-decoration: underline">&lt;</span>0.01.
Aramchol was found to be the most effective compound tested. Control groups included 5-ASA and local steroids which are the gold standards
for current treatment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2023, we announced the initiation of a new clinical program to evaluate Aramchol meglumine for the treatment of PSC, a rare disease
for which there is no approved treatment. Currently, we do not have plans to continue the development of Aramchol for this indication.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">In connection with our ongoing evaluation of Aramchol meglumine we have
been conducting a bioavailability study to transition to Aramchol meglumine and to determine the optimal doses allowing Aramchol meglumine&#8217;s
further clinical development in Phase 2 studies. The bioavailability study consists of two parts comparing single doses of Aramchol acid
and Aramchol meglumine in healthy volunteers. We expect the second part of the study to be completed in the second half of 2025. Preliminary
results from the first part of the study show that Aramchol meglumine suspension 400 mg dose had an area under the curve (AUC) which is
almost twice those obtained Aramchol acid tablets. Accordingly, we believe that once daily 200 mg is the optimal dose for future clinical
trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">During 2024, we entered into a collaboration agreement with the Massy Cancer
Center at Virginia Commonwealth University according to which we aim to investigate the effect of adding Aramchol to prevent drug resistance
to standard-of-care oncology agents in the treatment of hepatoma (hepatocellular carcinoma, or HCC), cholangiocarcinoma and colorectal
cancer.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Strategic
Collaborations, Research Arrangements and other Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Samil
Pharma. Co., Ltd.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 28, 2016, we entered into a license agreement, referred to herein as the Samil Agreement, with Samil for the commercialization of
Aramchol (with the option to manufacture) in the Republic of Korea, or the Territory.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the terms of the Samil Agreement, the Company has granted Samil an exclusive licence, or the Samil License, for fatty liver indications
including NASH, or the Field of Use, in the Republic of Korea, or the Territory to such information concerning Aramchol as may be required
to support Samil&#8217;s applications for regulatory approvals, or the Licensed Information, and the patents for the import, marketing,
use, sale, offer for sale, commercialisation and distribution (and, if the option is exercised, manufacture) of Aramchol in tablet form,
or any other physical form as may be produced or manufactured by or on behalf of Galmed or by a third party for Galmed and, if the option
set out below is exercised, any products within the Field of Use, the development, manufacture or sale of which is based, in whole or
in part, on, or involves the use of, the Licensed Information or covered under any patent, or the Product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 68; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Samil License shall remain in force with respect to each Product (if the Samil Agreement is not early terminated) until the later of:
(i) the date of expiry in the Territory of the last of any patent covering such Product or any formulation, dosing or administration
form thereof; and (ii) the date of expiry of a period of 20 years commencing on the date of first commercial sale by Samil or a sublicensee
of such Product in the Territory.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the signing of the Samil Agreement, Samil paid the Company a gross upfront fee of approximately $2.1 million and in September 2018, we
received a milestone payment of $1.5 million. Samil has also agreed to pay additional clinical and regulatory-based milestone payments,
which may aggregate to an additional $4.5 million, as well as tiered, double-digit royalties payable on sales (lower if sales of a generic
equivalent commence in the Territory).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of the Samil Agreement, following the first achievement of US$25 million of net sales in any calendar year following the
first commercial sale of the Product in the Territory, Samil shall have the option to request that the Licensed Information include methods
for the formulation of Aramchol from its API, to allow for the manufacture of Aramchol by Samil; provided, however, that we shall have
the option, to widen the definition of the Licensed Information as aforesaid at any time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
shall be entitled, at our option: (i) to modify the Samil License with respect to any Product so that it is non-exclusive only; or (ii)
to terminate the Samil License hereunder, with respect to any Product if: (a) a first purchasing order from Samil for at least one Product
shall not have been placed by 6 months following the grant of the Korean Ministry of Food and Drug Safety new drug approval; or (b) commercial
sale of such Product having commenced and either (i) there shall be a period of 1 year during which no sales of any Product shall take
place, or (ii) within 1 year of such commencement, aggregate sales of Products shall not have reached a reasonable level, as determined
by the joint development committee, in each case, except as a result of force majeure or other factors beyond the control of Samil. Further,
we shall be entitled to terminate the Samil Agreement if Samil challenges the validity of any of the patents. If any such challenge is
unsuccessful, Samil shall (in addition to our right to terminate) pay us liquidated damages in the amounts of US $8,000,000. Either party
may terminate the Samil Agreement (i) upon the other party&#8217;s material breach if such party fails to cure such breach within 30
days, or, in the case of failure by Samil to pay any amount due from Samil to us pursuant to or in connection with the Samil Agreement
14 days after receiving written notice thereof, or (ii) upon customary events such as the granting of a winding-up order if such order
or act is not cancelled within 60 days.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event that we do not achieve the primary endpoint as defined in the study protocol, or Successful Completion, of the ARREST Study,
we shall as soon as practicable notify Samil of the non-achievement of such Successful Completion, and within 60 days thereof, notify
Samil in writing either:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
that we have decided not to develop the Licensed Information further for the Field of Use, or the Cessation Notice, or (ii) that we intend
to continue with such development notwithstanding the non-achievement of such Successful Completion, or the Licensor Continuation Notice.
Also, in the event that we do not achieve the Successful Completion of the potential Phase 3 Study, we shall, as soon as practicable,
notify Samil accordingly, or the Notice of Non-Success. Samil shall thereafter have the option, by notice in writing served to us within
45 days of Samil&#8217;s receipt of either a Cessation Notice, a Licensor Continuation Notice or a Notice of Non-Success, as applicable,
to indicate its intention either: (i) to terminate the Samil License, or (ii) to continue research and development of the Licensed Information
in the Field of Use in the Territory, or the Licensee Continuation Notice. In the event Samil shall serve a Licensee Continuation Notice
following the service of a Cessation Notice or a Notice of Non-Success, any such continuation by Samil shall be subject to the entry
by Samil into a written agreement with us as to the terms and conditions which would govern such continued research and development,
which would be carried out according to Samil&#8217;s own development plan and at its sole expense. In the event Samil serves a Licensee
Continuation Notice following the service of a Licensor Continuation Notice, or Agreed Continuation, the Samil Agreement shall continue
in accordance with its terms. In August 2018, Samil sent a Licensee Continuation Notice to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
following the Successful Completion of the ARREST Study or Agreed Continuation following non-achievement of Successful Completion of
the ARREST Study, Samil shall, for a period of 90 days following the date of written notification to it by us of such Successful Completion
or following the date of Agreed Continuation following non-achievement of Successful Completion, have the option to require that the
Territory be extended to include Vietnam, or the Extension Option. In the event that Samil exercises its Extension Option, the parties
shall conduct negotiations in good faith for up to 30 days thereafter in order to agree on milestone payments which would replace those
set out in the Samil Agreement. In the event that agreement is not reached in such regard within such period, the Extension Option shall
terminate. Discussions for the extension of the Samil License to Vietnam are ongoing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 69; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Amilo
5-MER</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into a research and option agreement with Yissum, the tech transfer company of the Hebrew University with respect to our
Amilo-5MER, a 5 amino acid synthetic peptide MTADV (Methionine, Threonine, Alanine, Aspartic acid, Valine). Under this agreement, we
are able to research and initially develop Amilo-5MER, are required to fund the initial research and have been granted an exclusive option
to negotiate and enter into a definitive license agreement with Yissum for Amilo-5MER upon certain pre-agreed upon terms and such other
terms to be agreed upon.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the success in the Phase 1 study, we exercised our option and on June 28, 2021, we entered into a license agreement with
Yissum pursuant to which Yissum granted us a worldwide, exclusive and irrevocable license to develop and commercialize Amilo-5MER. In
November, 2021, the grant of the license took effect when it was approved by the Israel Innovation Authority. Under the license agreement,
we are responsible for carrying out the development and commercialization of Amilo-5MER and the prosecution and maintenance of the licensed
patents under the license agreement. In consideration for the grant of the license, we have agreed to pay to Yissum an upfront license
fee of $100,000, payments of up to $950,000 upon meeting certain regulatory milestones, single digit royalties on any future net sales
and a share of any sublicense fees. Unless earlier terminated, the license will continue in effect on a product-by-product and country-by-country
basis until the later of (i) the expiration of the last to expire patent covering the licensed technology in such country, (ii) the expiration
of any exclusivity on Amilo-5MER granted by a regulatory body in such country, and (iii) 15 years from the first commercial sale in such
country. The license agreement may be terminated early for material breach or bankruptcy. In addition, we may terminate the license agreement
without cause upon 90 days prior written notice to Yissum and Yissum may terminate the license agreement upon written notice to us under
certain limited circumstances. We are currently not pursuing the development of Amilo-5MER.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Onkai</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2023, we entered into the OnKai Agreement for a $1.5 million equity investment in OnKai, a US-based technology company developing
an AI-based platform to advance healthcare for underserved populations across the United States by facilitating alignment between healthcare
stakeholders. The signing of the definitive agreement followed an announcement that we made in January 2023 that we had entered into
a non-binding termsheet for an equity investment in OnKai. The OnKai Agreement provided that we will invest $1.5 million in exchange
for series seed preferred shares of OnKai (which is in addition to a $1.5 million investment that was made by us in OnKai through a SAFE
and which converted at a 15% discount into series seed preferred shares upon consummation of the Investment Round). Our investment in
OnKai was part of an approximately $6.0 million Investment Round with other investors that was led by us of which SAFE notes of approximately
$3.8 million were converted into preferred shares. On June 19, 2023, the Investment Round closed. Following the Investment Round, we
hold approximately 23.9% of the outstanding share capital of OnKai on an as-converted and fully and our Chief Executive Officer and director,
Allen Baharaff serves as a board member of OnKai. In 2024, we assigned our investment in Onkai to one of our wholly-owned subsidiaries
in Israel, Galtopa Therapeutics Ltd.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the OnKai Agreement, our wholly-owned subsidiary, GRD entered into the OnKai Services Agreement with OnKai. The OnKai
Services Agreement provides that GRD shall on a non-exclusive basis (i) provide support services to OnKai relating to finance, business
development, strategic planning, execution and others; and (ii) lend its experience to OnKai in building a strategy and for the development
of treatments for the underserved and that OnKai shall on a non-exclusive basis (i) take part in plan preparation to serve GDR&#8217;s
vision of developing drugs for the underserved population and (ii) when relevant, design a process on the clinical trial dashboard that
could potentially serve GDR&#8217;s future trial. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 70; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 15, 2024, we entered into a bridge loan agreement with OnKai pursuant to which we made a loan in an aggregate amount of $250,000
to OnKai payable by January 1, 2028. The loan bears interest at an annual rate of 15%. In addition, in connection with the OnKai Services Agreement,
we paid OnKai $150,000 for OnKai to assist the Company in (i) identifying and preparing eligible sites for the Company&#8217;s future
clinical trials and (ii) preparing and submitting applications for clinical and research grants in respect of such future clinical trials,
including preparing reimbursement strategies. In the event that we are awarded a clinical or research grant, OnKai agreed to repay us
the $150,000 that we initially paid to OnKai.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OnKai
is developing a proprietary technology, a &#8220;smart grid&#8221;, that maps local clinics serving millions of underserved Americans
and streams to these clinics resources, including funding, specialists, training, and access to clinical studies. This is intended to
facilitate faster clinical trial enrollment and provide clinical trials as a healthcare option in these communities by bringing novel
medications, such as access to orphan drugs, to communities in need. We believe that it will potentially benefit in the future from enhanced
access to a pool of clinical trial participants for the advancement of our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2024, management, based on fair value estimation, assessed
the qualitative aspects of the Onkai equity investment and macroeconomic factors and determined that an impairment should be recognized
in amount of $1.1 million.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Competition</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
pharmaceutical industry is characterized by rapidly evolving technology, intense competition and a highly risky, costly and lengthy research
and development process. Adequate protection of intellectual property, successful product development, adequate funding and retention
of skilled, experienced and professional personnel are among the many factors critical to success in the pharmaceutical industry.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
operate in a competitive sector. Several companies are working on technologies, therapeutic targets or drug or biomarker candidates that
aim to treat or diagnose the same diseases or identify the same patient population as our product candidates. While we believe that our
drug candidates and diagnostic solutions, combined with our expertise and know-how, provide us with competitive advantages, we face potential
competition from various sources, including pharmaceutical and biotechnology companies, as well as from academic institutions, governmental
agencies and public and private research institutions. We anticipate that we will face intense and increasing competition as new drugs
and therapies enter the market and advanced technologies become available. In some indications, off-label use of non-approved drugs can
also be considered as competition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Companies,
including Inventiva Pharma, Cirius Therapeutics and Novo Nordisk A/S, have molecules currently in Phase 3 clinical development. Additionally,
there are a host of other potential competitors in earlier stages of clinical development relative to us for the treatment of NASH. Eli
Lilly and Company, Pfizer, Novartis, Bristol-Myers Squibb, Novo Nordisk A/S, Merck, Viking Therapeutics, Inc., Metacrine, Inc., Poxel
SA, Can-Fite BioPharma, 89bio, Inc., Sagimet Biosciences Inc. Terns, Inc., AstraZeneca and Hepanova Inc. and others.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2022, Madrigal announced positive topline results from its pivotal Phase 3 MAESTRO-NASH biopsy clinical trial of resmetirom,
a liver-directed selective thyroid hormone receptor agonist. MAESTRO-NASH, in which Madrigal reported that it achieved both liver histological
improvement endpoints that FDA proposed as reasonably likely to predict clinical benefit to support accelerated approval for the treatment
NASH with liver fibrosis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2024, Madrigal announced FDA approval of Rezdiffra (resmetirom) for the treatment of NASH with moderate to advanced liver fibrosis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
the foregoing, see &#8220;Item 3. Key Information&#8212;Risk Factors&#8212;Risks Related to Our Business, Industry and Regulatory Requirements&#8212;Our
market is subject to intense competition. If we are unable to compete effectively, Aramchol or any other product candidate that we develop
may be rendered noncompetitive or obsolete&#8221; and &#8220;Item 3. Key Information&#8212;Risk Factors&#8212;Risks Related to Our Business,
Industry and Regulatory Requirements&#8212;We are developing Aramchol for the treatment of NASH, an indication for which there are no
approved products, and there is significant uncertainty regarding the regulatory approval process. This makes it difficult to predict
the timing and costs of the clinical development of Aramchol for the treatment of NASH.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 71; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intellectual
Property and Patent Strategy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
proprietary nature of, and protection for, Aramchol or  any other product candidate and our discovery programs for new indications,
processes and know-how are important to our business. We own patent rights to Aramchol and Amilo-5MER in various jurisdictions worldwide,
including within and outside of Israel. We have sought patent protection in the United States and internationally for Aramchol and Amilo-5MER,
our discovery programs, and any other inventions to which we have rights, where available and when appropriate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have granted patents and pending patent applications in various jurisdictions relating to (1) the composition of matter of Aramchol meglumine
as well as a wide range of other salts, or the CoM Patent; (2) a method for treating/inhibiting hepatic fibrosis and non-hepatic fibrosis
associated or non-associated with NASH or NAFLD, or the Hepatic Fibrosis Patent; and (3) a method of treating dysbiosis, or the Dysbiosis
Patent. In addition, we have pending patent applications for Aramchol meglumine and other salts, including a granted U.S. patent for
low dose composition of Aramchol (US 10,849,911 B2) and other salts. We have been allowed or granted patents for Aramchol and other salts
which includes claims for the treatment of fatty liver in Europe and certain other countries. The CoM Patent application was granted
in the United States, Brazil and India. The CoM Patent that was granted in the United States and the expected term is December2034,.The
Hepatic Fibrosis Patent has been granted in United States (US 11,197,870 B2), Europe, Australia, Japan, Canada, Hong-Kong and in Israel
and has an expected term in each jurisdiction of 2037. The Dysbiosis Patent was granted in U.S., Israel, Brazil and Mexico and has an
expected term in US of 2038 and of 2037 in Israel and Mexico; and was allowed in Brazil. In addition, patent applications were granted
in Israel relating to Aramchol use in hepatic fibrosis treatment, optionally associated with NAFLD and NASH ; and in Canada, Japan, Israel
and Mexico relating to Aramchol use to treat pulmonary and/or dermal fibrosis. Also, a patent was granted in Mexico and Europe relating
to Aramchol use for inhibition of fibrosis in NAFLD patients (having fibrosis score of zero (0)). We also have granted patentsfor combination
therapy for the treatment of liver disease in Canada, Europe, and Mexico.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have an exclusive license to a US granted patent directed to Amilo-5MER and anti-inflammatory compositions thereof On 2023 our collaborator,
YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD was granted a new patent (US 11,560, 417 B2, a division
of US 10,611,819 B2) for using the 5MER for the treatment of inflammatory diseases which has an expected term until 2035. An additional
divisional patent application is pending (<span style="text-decoration: underline">US20230212261A1</span>).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
policy is to pursue, maintain and defend patent rights, whether developed internally or licensed from third parties, and to protect the
technology, inventions and improvements that are commercially important to the development of our business. We also rely on trade secrets
that may be important to the development of our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Patent
Portfolio for Aramchol and Aramchol Meglumine</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
patent portfolio for Aramchol contains eight patent families including pending patent applications and granted patents directed to composition
of matter, manufacturing methods and methods of use.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
first patent family discloses and claims additional FABACs with different conjugation moieties, as well as the use of these and the compounds
disclosed in the first patent family above, including Aramchol, in the treatment of fatty liver, reduction of serum cholesterol and treatment
of hyperglycemia and diabetes. All patents in this family are expired (term ended).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
patent family directed to topical uses of FABAC compounds (anti-acne) was granted in Europe and maintained in Germany, France, Italy,
the Netherlands and the United Kingdom. Expected term is 2033.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
patent family discloses and claims second generation FABAC salt compounds include Aramchol meglumine. This patent family includes Granted
U.S., Brazil, India, Europe (maintained in Albania, Austria, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, Greece,
Hungary, Iceland, Italy, Latvia, Lithuania, Macedonia, Malta, Norway, Poland, Portugal, Romania, San Marino, Serbia, Slovakia, Slovenia,
Spain, Sweden, The Netherlands, Turkey, Belgium, France, Germany, Ireland, Luxembourg, Malta, Monaco, Switzerland and United Kingdom),
China, Hong Kong, Macau, Canada, Israel, Korea, Japan, and Australia patents. If the appropriate maintenance, renewal, annuity or other
governmental fees are paid, the expected term for this patent family is December 2034.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 72; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
patent family having one U.S. patent application, discloses and claims compositions comprising low doses of the second generation FABAC
compounds Aramchol meglumine and other salts which was granted by the USPTO. When the appropriate maintenance, renewal, annuity or other
governmental fees are paid, the expected term for this patent family is December 2034.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
family is directed to treatment for modulating gut microbiota and/or dysbiosis using Aramchol. This patent family includes a granted
patents in Israel, U.S., Brazil and in Mexico; and pending foreign patent applications in Canada, China, Europe, Hong Kong and Japan.
Expected term for this patent family is 2037, expect for U.S. where the term is 2038.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent
families are directed to uses of Aramchol and Aramchol meglumine for treating and inhibiting fibrosis. The families have pending patent
applications in in Australia, Brazil, Canada, China, Europe, Hong-Kong, Israel, Japan, Korea, Mexico and US. It was granted in Australia,
Canada, Europe, Hong-Kong, Japan and Mexico; and the treatment of pulmonary fibrosis was granted in Canada, Israel, Mexico and Japan
(also dermal fibrosis in Japan). Expected term of this patent family is 2037. Additionally, a U.S. patent application directed to a method
for treating hepatic fibrosis non-associated with non-alcoholic fatty acid liver disease &#8211; was granted, and the expected term is
2037. In addition, a US application have been filed and claims the treatment of pulmonary, kidney, dermal, gastro intestinal and heart
fibrosis by Aramchol. The improved bio-availability of Aramchol is supported by the pharmacological model based on the preclinical and
the ARREST data. Also, treatment and inhibition of fibrosis by a regimen of 300 mg of Aramchol twice daily is pending in Australia and
granted in Israel. Expected term of this patent family is 2039.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
patent family is directed to a combination therapy of aramchol and MGL3196 for treating fatty liver disease; and has a PCT application
which entered National Phase in: Australia, Brazil, Canada, China, Europe, Hong Kong, Israel, India, Japan, Korea, Mexico and U.S. It
was granted in Canada, Europe, Hong-Kong and Mexico. Expected term for this patent family is 2039.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Patent
Portfolio for Amilo-5MER</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
patent portfolio for Amilo-5MER contains two patent families including pending patent applications and granted patents directed to composition
of matter and methods of use.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
t patent family is directed to Amilo-5MER and anti-inflammatory compositions thereof. Galmed Research and Development Ltd. has an exclusive
license to the U.S. granted patent within this family, and the expected term of this U.S. patent is 2035. Galmed Research and Development
Ltd. has also exclusive licenses to the corresponding granted patents in Europe, Australia, Japan, China, Canada, Korea and India. The
corresponding applications in Brazil are pending. The non-US expected patent term is 2035. A divisional application claiming the use
of Amilo-5MER for the treatment of inflammatory diseases was granted in 2023. An additional divisional patent application is pending
(US20230212261A1).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
patent family is directed to peptides for treating acute respiratory distress syndrome. This family includes a pending PCT international
patent application. Galmed Research and Development Ltd. is a co-applicant in this PCT application with Yissum. The expected patent term
for this patent family is 2041.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial success will depend in part on obtaining and maintaining patent protection and trade secret protection of our current and
other product candidates and the methods used to develop and manufacture them, as well as successfully defending these patents against
third-party challenges. Our ability to stop third parties from making, using, selling, offering to sell or importing our products depends
on the extent to which we have rights under valid and enforceable patents or trade secrets that cover these activities. We believe that
our patents provide broad and comprehensive coverage of Aramchol and the Amilo-5MER and uses thereof. However, the patent positions of
biopharmaceutical companies, such as ourselves, are generally uncertain and involve complex legal and factual questions. Our ability
to maintain and solidify our proprietary position for the technology will depend on our success in obtaining effective claims and enforcing
those claims once granted. There is no certainty that any of the Company&#8217;s pending patent applications will result in the issuance
of any patents. The issued patents and those that may be issued in the future, may be challenged, narrowed, circumvented or found to
be invalid or unenforceable, which could limit our ability to stop competitors from marketing related products or the length of term
of patent protection that we may have for our products. In addition, our competitors may independently develop similar technologies or
duplicate any technology developed by us, and the rights granted under any issued or future patents may not provide us with any meaningful
competitive advantages against these competitors. Furthermore, because of the extensive time required for development, testing and regulatory
review of a potential product, before any of our products can be commercialized, any related patent may expire or remain in force for
only a short period following commercialization, thereby reducing any advantage of such patent. For more risks associated with the protection
of our licensed intellectual property, see &#8220;Item 3. Key Information&#8212; Risk Factors&#8212;Risks Related to Our Intellectual
Property.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 73; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trade
Secrets</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to patents, we rely on trade secrets and know-how to develop and maintain our competitive position. Trade secrets and know-how
can be difficult to protect. We seek to protect our proprietary processes, in part, by confidentiality agreements and invention assignment
agreements with our employees, consultants, scientific advisors, contractors and commercial partners. These agreements are designed to
protect our proprietary information. We also seek to preserve the integrity and confidentiality of our data, trade secrets and know-how
by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we
have confidence in these individuals, organizations and systems, such agreements or security measures may be breached, and we may not
have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors
or others.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Seasonality</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business and operations are generally not affected by seasonal fluctuations or factors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Raw
Materials and Suppliers</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that the raw materials that we require to manufacture Aramchol are readily available commodities commonly used in the pharmaceutical
industry.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Manufacturing</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not own or operate manufacturing facilities for the production of Aramchol or any other product candidate, nor do we have plans to
develop our own manufacturing operations in the foreseeable future. We currently rely on third-party contract manufacturers for all of
our required raw materials, API and finished product for our non-clinical research and clinical trials. We do not have long term agreements
with any of these third parties. We also do not have any current contractual relationships for the manufacture of commercial supplies
of Aramchol if it is approved. If Aramchol or any other product candidate are approved by any regulatory agency, we intend to enter into
agreements with a third-party contract manufacturer or collaboration partner and one or more back-up manufacturers for the commercial
production of those products. Development and commercial quantities of any products that we develop will need to be manufactured in facilities,
and by processes, that comply with the requirements of the FDA and the regulatory agencies of other jurisdictions in which we are seeking
approval. We currently employ internal resources to manage our manufacturing contractors. The relevant manufacturers of our drug substance
and drug products for our current pre-clinical and clinical trials have advised us that they are compliant with both cGMP and, cGLP.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
can be no assurance that Aramchol, if approved, can be manufactured in sufficient commercial quantities, in compliance with regulatory
requirements and at an acceptable cost. We and our contract manufacturers are, and will be, subject to extensive governmental regulation
in connection with the manufacture of any pharmaceutical products or medical devices. We and our contract manufacturers must ensure that
all of the processes, methods and equipment are compliant with cGMP and cGLP for drugs on an ongoing basis, as mandated by the FDA and
other regulatory authorities, and conduct extensive audits of vendors, contract laboratories and suppliers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contract
Research Organizations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
outsource certain clinical trial activities to CROs. Our clinical CROs comply with guidelines from the International Conference on Harmonisation
of Technical Requirements for Registration of Pharmaceuticals for Human Use, which attempt to harmonize the FDA, the EMA, and the Pharmaceuticals
and Medical Devices Agency of Japan regulations and guidelines. We create and implement the drug development plans and manage the CROs
according to the specific requirements of the drug candidate under development. To the extent clinical research is overseen by the CROs
(or directly by us), compliance with certain federal regulations, including but not limited to 21 C.F.R. parts 50, 54, 56, 58 and 312,
which pertain to, among other things, IRBs, informed consent, financial conflicts of interest by investigators, correct administration
of treatment, follow up of adverse events, good laboratory practices and submitting IND applications, may be required.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 74; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Marketing,
Sales and Commercialization</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
our stage of development, we do not have any internal sales, marketing or distribution infrastructure or capabilities. In the event we
receive regulatory approval for any product candidate we intend, where appropriate, to pursue commercialization relationships, including
strategic alliances and licensing, with pharmaceutical companies and other strategic partners, which are equipped to market and/or sell
our product candidates through their well-developed sales, marketing and distribution organizations in order to gain access to global
markets. In addition, we may out-license some or all of our worldwide patent rights to more than one party to achieve the fullest development,
marketing and distribution of any products we develop. Over the longer term, we may consider ultimately building an internal marketing,
sales and commercial infrastructure. See &#8220;Item 4. Information on the Company&#8212; Business Overview&#8212;Strategic Collaborations,
Research Arrangements and other Material Agreements&#8212;Samil Pharm Co.&#8221; for information regarding the license agreement we entered
with Samil for the commercialization of Aramchol (with an option to manufacture) for the treatment of fatty liver indications including
NASH, in the Republic of Korea.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Environmental
Matters</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We,
our agents and our service providers, including our manufacturers, may be subject to various environmental, health and safety laws and
regulations, including those governing air emissions, water and wastewater discharges, noise emissions, the use, management and disposal
of hazardous, radioactive and biological materials and wastes and the cleanup of contaminated sites. We believe that our business, operations
and facilities, including, to our knowledge, those of our agents and service providers, are being operated in compliance in all material
respects with applicable environmental and health and safety laws and regulations. All information with respect to any chemical substance
is filed and stored as a Material Safety Data Sheet, as required by applicable environmental regulations. Based on information currently
available to us, we do not expect environmental costs and contingencies to have a material adverse effect on us. However, significant
expenditures could be required in the future if we, our agents or our service providers are required to comply with new or more stringent
environmental or health and safety laws, regulations or requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Government
Regulation and Product Approval</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Governmental
authorities in the United States and in other countries extensively regulate, among other things, the research, development, testing,
manufacture, labeling, packaging, promotion, storage, advertising, distribution, marketing and export and import of products such as
those we are developing. Aramchol or any other product candidate must be approved by the FDA through the NDA process before they may
be legally marketed in the United States and by the Committee on Human Medicinal Products, or CHMP, via the EMA and European Commission
through the MAA process before they may be legally marketed in Europe, or MHRA through its authorization procedures before they may be
legally marketed in the UK. Aramchol or any other product candidate will be subject to similar requirements in other countries prior
to marketing in those countries. The process of obtaining regulatory approvals and the subsequent compliance with applicable federal,
state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 75; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>United
States Government Regulation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">NDA
Approval Processes</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act, or the FDCA, and implementing regulations
and guidance documents. Failure to comply with the applicable U.S. requirements at any time during the product development process or
approval process, or after approval, may subject an applicant to administrative or judicial sanctions, any of which could have a material
adverse effect on us. These sanctions could include refusal to approve pending applications, withdrawal of an approval, imposition of
a clinical hold, issuance of warning letters, product seizures, total or partial suspension of production or distribution, injunctions,
fines, disgorgement, and civil or criminal penalties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
process required by the FDA before a drug may be marketed in the United States generally involves the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">completion
    of pre-clinical laboratory tests, animal studies and formulation studies conducted according to GLPs, or other applicable regulations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
    to the FDA of an IND application, which must become effective before human clinical trials may begin;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">performance
    of adequate and well-controlled human clinical trials according to GCPs, to establish the safety and efficacy of the proposed drug
    for its intended use;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
    to the FDA of an NDA;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
    completion of an FDA inspection of the manufacturing facility or facilities at which the product is produced to assess compliance
    with cGMPs to assure that the facilities, methods and controls are adequate to preserve the drug&#8217;s identity, strength, quality
    and purity;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
    completion of FDA inspections of clinical sites and GLP toxicology studies; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
    review and approval of the NDA.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
testing and approval process requires substantial time, effort and financial resources, and we cannot be certain that any approvals for
Aramchol or any other product candidate will be granted on a timely basis, if at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
a product candidate is identified for development, it enters the pre-clinical testing stage. Pre-clinical tests include laboratory evaluations
of product chemistry, toxicity and formulation, as well as animal studies. An IND sponsor must submit the results of the pre-clinical
tests, together with manufacturing information and analytical data, to the FDA as part of the IND. Some pre-clinical testing may continue
after the IND is submitted. In addition to including the results of the pre-clinical studies, the IND will also include a clinical trial
protocol detailing, among other things, the objectives of the clinical trial, the parameters to be used in monitoring safety and, depending
on the phase of the study, the effectiveness criteria to be evaluated. The IND automatically becomes effective 30 days after receipt
by the FDA, unless the FDA, within the 30-day time period, places the IND on clinical hold. In such a case, the IND sponsor and the FDA
must resolve any outstanding concerns before clinical trials can begin. A clinical hold may occur at any time during the life of an IND,
due to safety concerns or non-compliance, and may affect one or more specific studies or all studies conducted under the IND.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
clinical trials must be conducted under the supervision of one or more qualified investigators in accordance with the FDA&#8217;s GCP
regulations. These regulations include the requirement that all research subjects provide informed consent. Further, an IRB must review
and approve the plan for any clinical trial, including the informed consent document, before it commences at any institution. An IRB
considers, among other things, whether the risks to individuals participating in the trials are minimized and are reasonable in relation
to anticipated benefits. The IRB also approves the investigator brochure and other information about the trial distributed by the sponsor
and the consent form that must be provided to each trial subject or his or her legal representative and must monitor the study until
completed. All clinical trials must be conducted under protocols detailing the objectives of the trial, dosing procedures, research subject
inclusion and exclusion criteria and the safety and effectiveness criteria to be evaluated. Each protocol must be submitted to the FDA
as part of the IND, and progress reports detailing the status of the clinical trials must be submitted to the FDA annually. Sponsors
must also report within set timeframes to FDA serious and unexpected adverse reactions, any clinically important increase in the rate
of a serious suspected adverse reaction over that listed in the protocol or investigation brochure, or any findings from other studies
or animal or in-vitro testing that suggest a significant risk in humans exposed to the drug. Sponsors must also report to FDA certain
amendments to the protocol and other essential information concerning the IND that does not fall within the scope of other required reports.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 76; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Human
clinical trials are typically conducted in three sequential phases that may overlap or be combined:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Phase
    1. </i>The drug is initially introduced into healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism,
    distribution and elimination. In the case of some products for severe or life-threatening diseases, such as cancer, especially when
    the product may be inherently too toxic to ethically administer to healthy volunteers, the initial human testing is often conducted
    in patients.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Phase
    2. </i>Clinical trials are performed on a limited patient population intended to identify possible adverse effects and risks, to
    preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Phase
    3. </i>Clinical trials are undertaken to further evaluate dosage, clinical efficacy and safety in an expanded patient population
    at geographically dispersed clinical study sites. Phase 3 clinical trials are conducted to provide sufficient data for the statistically
    valid evidence of safety and efficacy.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Phase
    4. </i>The FDA may require that the sponsor conduct additional clinical trials following new drug approval. The purpose of these
    trials, known as Phase 4 studies, is to monitor long-term risks and benefits, study different dosage levels or evaluate safety and
    effectiveness. In recent years, the FDA has increased its reliance on these trials. Phase 4 studies usually involve thousands of
    participants. Phase 4 studies also may be initiated by the company sponsoring the new drug to gain broader market value for an approved
    drug.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Human
clinical trials are inherently uncertain and Phase 1, Phase 2, Phase 3 and Phase 4 testing may not be successfully completed. The FDA
or the sponsor may suspend a clinical trial at any time for a variety of reasons, including a finding that the research subjects or patients
are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution
if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with
unexpected serious harm to patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the development of a new drug, sponsors are given opportunities to meet with the FDA at certain points. These points are typically prior
to the submission of an IND, at the end of Phase 2 and before an NDA is submitted. Meetings at other times may also be requested. These
meetings can provide an opportunity for the sponsor to share information about the data gathered to date and for the FDA to provide advice
on the next phase of development. Sponsors typically use the meeting at the end of Phase 2 to discuss their Phase 2 clinical results
and present their plans for the pivotal Phase 3 clinical trial that they believe will support the approval of the NDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concurrent
with clinical trials, sponsors usually complete any remaining animal safety studies and also develop additional information about the
chemistry and physical characteristics of the drug and finalize a process for manufacturing commercial quantities of the product in accordance
with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the drug and the manufacturer
must develop methods for testing the quality, purity and potency of the drug. Additionally, appropriate packaging must be selected and
tested and stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration over
its proposed shelf-life.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
results of product development, pre-clinical studies and clinical trials, along with descriptions of the manufacturing process, analytical
tests and other control mechanisms, proposed labeling and other relevant information are submitted to the FDA as part of an NDA requesting
approval to market the product for one or more specified indications. The submission of an NDA is subject to the payment of an application
fee, but a waiver of such fees may be obtained under specified circumstances. We will seek a waiver of these fees as a small business
submitting its first human drug application to the FDA. If the waiver is granted it would not extend to establishment or product fees.
The FDA reviews all NDAs submitted to ensure that they are sufficiently complete for substantive review before it accepts them for filing.
It may request additional information rather than accept an NDA for filing. In this event, the NDA must be resubmitted with the additional
information. The resubmitted application also is subject to review before the FDA accepts it for filing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 77; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
the submission is accepted for filing, the FDA begins an in-depth review. The FDA may refuse to approve an NDA if the applicable statutory
and regulatory criteria are not satisfied or may require additional clinical or other data. Even if such data are submitted, the FDA
may ultimately decide that the NDA does not satisfy the criteria for approval. The FDA reviews an NDA to determine, among other things,
whether a product is safe and effective for its intended use and whether its manufacturing is cGMP-compliant. The FDA may refer the NDA
to an advisory committee for review and recommendation as to whether the application should be approved and under what conditions. The
FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations. Before approving an NDA,
the FDA will typically inspect the facility or facilities where the product is manufactured and tested. The FDA will also inspect selected
clinical sites that participated in the clinical studies and may inspect the testing facilities that performed the GLP toxicology studies
cited in the NDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Expedited
Review and Approval</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA has various specific programs, including Fast Track, Breakthrough Therapy, Priority Review, and Accelerated Approval, which, in different
ways, are each intended to expedite the process for reviewing and approving drugs. Even if a drug qualifies for one or more of these
programs, the FDA may later decide that the drug no longer meets the conditions for qualification or that the time period for FDA review
or approval will be shortened. Generally, drugs that are eligible for these programs are those for serious or life-threatening conditions,
those with the potential to address unmet medical needs and those that offer meaningful benefits over existing treatments. For example,
Fast Track is a process designed to facilitate the development and expedite the review of drugs to treat serious or life-threatening
diseases or conditions and fill unmet medical needs, and Breakthrough Therapy designation is designed to expedite the development and
review of drugs that are intended to treat a serious condition where preliminary clinical evidence indicates that the drug may demonstrate
substantial improvement over available therapy on a clinically significant endpoint(s). Priority review is designed to give drugs that
offer major advances in treatment or provide a treatment where no adequate therapy exists an initial review within six months as compared
to a standard review time of ten months. Although Fast Track, Breakthrough Therapy designation and priority review do not affect the
standards for approval, the FDA will attempt to facilitate early and frequent meetings with a sponsor of a Fast Track or Breakthrough
Therapy designated drug and expedite review of the application for a drug designated for priority review. The FDA will also provide Breakthrough
Therapy designated drugs intensive guidance on an efficient drug development program and provide these drug developers with an organizational
commitment from the FDA involving senior managers. Since sponsors can design clinical trials in a number of ways, in providing its guidance
for drugs designated as breakthrough therapies, the FDA will seek to ensure that the sponsor of the product designated as a breakthrough
therapy receives timely advice and interactive communications in order to help the sponsor design and conduct a development program as
efficiently as possible. During these interactions, the FDA may suggest, or a sponsor can propose, alternative clinical trial designs
(e.g., adaptive designs, an enrichment strategy, use of historical controls) that may result in smaller trials or more efficient trials
that require less time to complete. Such trial designs could also help minimize the number of patients exposed to a potentially less
efficacious treatment (i.e., the control group treated with available therapy). On September 23, 2014, the FDA granted Fast Track designation
status to Aramchol for the treatment of patients who are overweight or obese and have pre diabetes or type II diabetes mellitus with
NASH.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
Approval, which is described in 21 C.F.R. &#167; 314.500 <i>et seq</i>., provides for approval of a new drug that is intended to treat
a serious or life-threatening disease or condition and that fills an unmet medical need based on a surrogate endpoint. A surrogate endpoint
is a laboratory measurement or physical sign used as an indirect or substitute measurement representing a clinically meaningful outcome.
To be used in accelerated approval, a surrogate endpoint must be &#8220;reasonably likely, based on epidemiologic, therapeutic, pathophysiologic,
or other evidence to predict benefit on irreversible morbidity or mortality.&#8221; The term &#8220;reasonably likely&#8221; implies
that some uncertainty remains about the relationship of the surrogate to the clinical benefit to the patient. Therefore, accelerated
approval is typically contingent on a sponsor&#8217;s agreement to conduct additional post-approval studies to verify and describe the
drug&#8217;s clinical benefit. Accelerated Approval does not change the standards for approval, but by allowing a demonstration of efficacy
based on a surrogate endpoint may expedite the approval process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 78; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">FDA
Guidance</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2018, the FDA issued &#8220;Noncirrhotic Nonalcoholic Steatohepatitis with Liver Fibrosis: Developing Drugs for Treatment&#8221;,
or &#8220;the December Guidance&#8221;. The December Guidance, though nonbinding on the FDA or us, is intended to assist sponsors in
the clinical development of drugs for the treatment of noncirrhotic NASH with liver fibrosis, describes the FDA&#8217;s current thinking
regarding the necessary components of a drug development program for noncirrhotic NASH with liver fibrosis and identifies knowledge gaps
that represent important challenges in the development of drugs for the indication. According to the FDA, the ultimate goal of NASH treatment
is to slow the progress of, halt, or reverse disease progression and improve clinical outcomes (i.e., prevent progression to cirrhosis
and cirrhosis complications, reduce the need for liver transplantation, and improve survival). Because of the slow progression of NASH
and the time required to conduct a trial that would evaluate clinical endpoints such as progression to cirrhosis or survival, the FDA
recommends sponsors consider the following liver histological improvements as endpoints reasonably likely to predict clinical benefit
to support accelerated approval under the regulations:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Resolution
    of steatohepatitis on overall histopathological reading and no worsening of liver fibrosis on NASH CRN fibrosis score. Resolution
    of steatohepatitis is defined as absent fatty liver disease or isolated or simple steatosis without steatohepatitis and a NAS score
    of 0&#8211;1 for inflammation, 0 for ballooning, and any value for steatosis; or</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Improvement
    in liver fibrosis greater than or equal to one stage (NASH CRN fibrosis score) and no worsening of steatohepatitis (defined as no
    increase in NAS for ballooning, inflammation, or steatosis)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
according to the FDA, for NASH drugs approved on the basis of liver histology under the accelerated approval pathway, randomized, double-blind,
placebo-controlled clinical trials designed to describe and verify the drug&#8217;s clinical benefit should be underway at the time of
submission of the marketing application. Clinical benefit can be verified by demonstrating superiority to placebo in delaying disease
progression measured by a composite endpoint.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
EMA also issued a reflection paper to provide guidance on drug development in the field of NASH. However, the EMA indicated, among other
things, that both resolution of NASH without worsening of fibrosis and improvement in fibrosis without worsening of NASH would both be
required as intermediate endpoints for demonstrating statistical significance for stage 2 and 3 fibrosis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
also &#8220;Item 3. Key Information&#8212;Risk Factors&#8212;Risk Factors&#8212;Risks Related to Our Business, Industry and Regulatory
Requirements - We are developing Aramchol for the treatment of NASH, an indication for which there are no approved products, and there
is significant uncertainty regarding the regulatory approval process. This makes it difficult to predict the timing and costs of the
clinical development of Aramchol for the treatment of NASH.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Patent
Term Restoration and Marketing Exclusivity</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depending
upon the timing, duration and specifics of FDA approval of the use of Aramchol or any other product candidate, U.S. patents may be eligible
for limited patent term extension under the Hatch-Waxman Act. The Hatch-Waxman Act permits a patent restoration term of up to five years
as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration
cannot extend the remaining term of a patent beyond a total of 14 years from the product&#8217;s approval date. The patent term restoration
period is generally one-half the time between the effective date of an IND, and the submission date of an NDA, plus the time between
the submission date of an NDA and the approval of that application. Only one patent applicable to an approved drug is eligible for the
extension and the application for extension must be made prior to expiration of the patent. The USPTO, in consultation with the FDA,
reviews and approves the application for any patent term extension or restoration. In the future, we intend to apply for restorations
of patent term for some of our currently owned patents to add patent life beyond their current expiration date, depending on the expected
length of clinical trials and other factors involved in the submission of the relevant NDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 79; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market
exclusivity provisions under the FDCA can also delay the submission or the approval of certain applications. The FDCA provides a five-year
period of non-patent marketing exclusivity within the United States to the first applicant to gain approval of an NDA for a new chemical
entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety,
which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not accept
for review an abbreviated new drug application, or ANDA, or a 505(b)(2) NDA submitted by another company for another version of such
drug where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application
may be submitted after four years if it contains a certification of patent invalidity or non-infringement. The FDCA also provides three
years of marketing exclusivity for an NDA, 505(b)(2) NDA or supplement to an approved NDA if new clinical investigations, other than
bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the
application, for example, for new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the
conditions associated with the new clinical investigations and does not prohibit the FDA from approving ANDAs for drugs containing the
original active agent. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA; however, an applicant
submitting a full NDA would be required to conduct or obtain a right of reference to all of the pre-clinical studies and adequate and
well-controlled clinical trials necessary to demonstrate safety and effectiveness.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Post-approval
Requirements</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
an approval is granted, the FDA, European authorities and other regulatory authorities may withdraw the approval if compliance with regulatory
requirements is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems
with a product may result in restrictions on the product or even complete withdrawal of the product from the market. After approval,
some types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims,
are subject to further regulatory authority review and approval. Some of these modifications, especially adding indications, would likely
require additional clinical studies. In addition, the FDA may require testing and surveillance programs to monitor the effect of approved
products that have been commercialized, and the FDA has the power to prevent or limit further marketing of a product based on the results
of these post-marketing programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
drug product manufactured or distributed by us pursuant to FDA approvals are subject to continuing regulation by the FDA, including,
among other things record-keeping requirements; cGMPs; reporting of adverse experiences with the drug; providing the FDA with updated
safety and efficacy information; drug sampling and distribution requirements; notifying the FDA and gaining its approval of specified
manufacturing or labeling changes; and complying with FDA promotion and advertising requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drug
manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments
with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and some state agencies for compliance
with cGMP and other laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely, and expect to continue to rely, on third parties for the production of clinical and commercial quantities of Aramchol. Future FDA
and state inspections may identify compliance issues at the facilities of our contract manufacturers that may disrupt production or distribution,
or require substantial resources to correct.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, legislation is drafted, introduced and passed in Congress that could significantly change the statutory provisions governing
the approval, manufacturing and marketing of products regulated by the FDA. In addition, FDA regulations and guidance are often revised
or reinterpreted by the agency in ways that may significantly affect our business and our products. It is impossible to predict whether
legislative changes will be enacted, or FDA regulations, guidance or interpretations changed or what the impact of such changes, if any,
may be. In particular, it is unknown whether any of the provisions of the 2016 21<sup>st</sup> Century Cures Act that are intended to
accelerate drug approval will result in any change in the current approval pathway for Aramchol.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 80; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Affordable Care Act (discussed in greater detail below), the Centers for Medicare &amp; Medicaid Services (CMS) is required to
collect and publish information reported by applicable manufacturers about payments and other transfers of value manufacturers have made
to physicians and teaching hospitals. Such a law, when applicable to our products, could increase the company&#8217;s regulatory liability
through the imposition of additional reporting and regulatory requirements. There are also an increasing number of state laws that require
manufacturers to make similar reports to states on pricing and marketing information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Reimbursement</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
face uncertainties over the pricing of pharmaceutical products. Sales of Aramchol or any other product candidate will depend, in part,
on the extent to which the costs of Aramchol or any other product candidate will be covered by third-party payors, such as federal health
programs, commercial insurance and managed care organizations. These third-party payors are increasingly challenging the prices charged
for medical products and services. Additionally, the containment of healthcare costs has become a priority of federal and state governments
and the prices of drugs have been a focus in this effort. The U.S. government, state legislatures, foreign governments and third party
payors have shown significant interest in implementing cost-containment programs, including price controls, pricing transparency disclosure
obligations, restrictions on reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-containment
measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit our net
revenue and results. If these third-party payors do not consider Aramchol or any other product candidate to be cost-effective compared
to other therapies, they may not cover Aramchol or any other product candidate after approved as a benefit under their plans or, if they
do, the level of payment may not be sufficient to allow us to sell Aramchol or any other product candidate on a profitable basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Medicare Modernization Act imposed new requirements for the distribution and pricing of prescription drugs for Medicare beneficiaries
under Part D. Under Part D, Medicare beneficiaries may enroll in prescription drug plans offered by private entities that provide coverage
of outpatient prescription drugs. Part D prescription drug plan sponsors are not required to pay for all covered Part D drugs, and each
drug plan can develop its own drug formulary that identifies which drugs it will cover and at what tier or level. However, Part D prescription
drug formularies must include drugs within each therapeutic category and class of covered Part D drugs, though not necessarily all the
drugs in each category or class. The Centers for Medicare &amp; Medicaid Services published a final rule in 2014 implementing the Medicare
Modernization Act. Contrary to the proposed rule, which would have enabled Part D plans to offer fewer drugs, the final rule maintained
the existing six protected classes of drug categories, but stated that some of the proposals not included in the final rule could still
be finalized in the future, which would impact payor formulary and coverage decisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
American Recovery and Reinvestment Act of 2009 provides funding for the federal government to compare the effectiveness of different
treatments for the same illness. A plan for the research will be developed by the Department of Health and Human Services, the Agency
for Healthcare Research and Quality and the National Institutes for Health, and periodic reports on the status of the research and related
expenditures will be made to Congress. Although the results of the comparative effectiveness studies are not intended to mandate coverage
policies for public or private payors, it is not clear what effect, if any, the research will have on the sales of any product, if any
such product or the condition that it is intended to treat is the subject of a study. It is also possible that comparative effectiveness
research demonstrating benefits in a competitor&#8217;s product could adversely affect the sales of Aramchol or any other product candidate.
If third-party payors do not consider Aramchol or any other product candidate to be cost-effective compared to other available therapies,
they may not cover Aramchol or any other product candidate as a benefit under their plans or, if they do, the level of payment may not
be sufficient to allow us to sell Aramchol or any other product candidate on a profitable basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Affordable Care Act, enacted in March 2010, has had a significant impact on the health care industry. Some of the key changes made to
date pursuant to the Affordable Care Act include an expansion of coverage for the uninsured, the creation of insurance marketplaces and
increased protection of insureds with new benefits, rights and protections. With regard to pharmaceutical products, among other things,
the Affordable Care Act made major changes to the Medicare prescription drug program, which helped reduce drug costs for seniors and
increased rebates and other costs for the pharmaceutical industry.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 81; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
have been judicial and congressional challenges to the Affordable Care Act. In December 2017, Congress passed and then the President
Trump signed into law tax reform legislation that made significant changes to the Affordable Care Act including the repeal of the &#8220;individual
mandate&#8221; that was in place to strongly encourage broad participation in the health insurance markets. On December 14, 2018, a federal
district court in Texas ruled that the PPACA is unconstitutional as a result of the Tax Cuts and Jobs Act, the federal income tax reform
legislation previously passed by Congress and signed by President Trump on December 22, 2017, that eliminated the individual mandate
portion of the PPACA. The case, Texas, et al, v. United States of America, et al., (N.D. Texas), is an outlier, but in 2019, the Fifth
Circuit Court of Appeals subsequently upheld the lower court decision which was then appealed to the United States Supreme Court. The
U.S. Supreme Court declined to hear the appeal on an expedited basis and so no decision is expected until sometime in 2021 before the
end of the Supreme Court&#8217;s current term. We are not able to state with any certainty what will be impact of this court decision
on our business pending further court action and possible appeals. Given these changes and other statements of political leaders, we
cannot predict the ultimate impact on the Affordable Care Act and the subsequent effect on the pharmaceutical industry at this time.
In November 2020, Joseph Biden was elected President and, in January 2021, the Democratic Party obtained control of the Senate. As a
result of these electoral developments, it is unlikely that continued legislative efforts will be pursued to repeal PPACA. Instead, it
is possible that executive and regulatory initiatives, as well as legislation, will be pursued to enhance or reform PPACA. We are not
able to state with certainty what the impact of potential legislation will be on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, in some non-U.S. jurisdictions, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements
governing drug pricing vary widely from country to country. For example, the EU provides options for its member states to restrict the
range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal
products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct
or indirect controls on the profitability of the company placing the medicinal product on the market. There can be no assurance that
any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing
arrangements for Aramchol or any other product candidate. Historically, products launched in the EU do not follow price structures
of the United States and generally tend to be significantly lower.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Healthcare
Fraud and Abuse Laws</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the U.S., the research, development, testing, manufacturing, handling, storage, distribution, sale and promotion of drug products and
medical devices are potentially subject to regulation by various federal, state and local authorities in addition to the FDA, including
the Centers for Medicare &amp; Medicaid Services, other divisions of the U.S. Department of Health and Human Services (e.g., the Office
of Inspector General), the U.S. Department of Justice, state Attorneys General, and other state and local government agencies. For example,
sales, marketing and scientific/educational grant programs must comply with the fraud and abuse provisions applicable to pharmaceutical
manufacturers, including the federal &#8220;Anti-Kickback Statute&#8221;, the Civil Monetary Penalty Statute, the Stark Law, the federal
False Claims Act, as amended, state and federal &#8220;Physician Payment Sunshine Act&#8221; laws and regulations, the privacy regulations
promulgated under the Health Insurance Portability and Accountability Act, or HIPAA, and similar state laws. Pricing and rebate programs
must comply with the Medicaid Drug Rebate Program requirements of the Omnibus Budget Reconciliation Act of 1990, as amended, and the
Veterans Health Care Act of 1992, as amended. If products are made available to authorized users of the Federal Supply Schedule of the
General Services Administration, additional laws and requirements apply. All of these activities are also potentially subject to federal
and state consumer protection and unfair competition laws. Some of these health care laws include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Anti- Kickback Statute makes it illegal for any person, including a prescription drug manufacturer (or a party acting on its behalf)
to knowingly and willfully solicit, receive, offer, or pay any remuneration that is intended to induce the referral of business, including
the purchase, order, or prescription of a particular drug, for which payment may be made under a federal healthcare program, such as
Medicare or Medicaid.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
federal False Claims Act prohibits anyone from knowingly presenting, conspiring to present, making a false statement in order to present,
or causing to be presented, for payment to federal programs (including Medicare and Medicaid) claims for items or services, including
drugs, that are false or fraudulent, claims for items or services not provided as claimed, or claims for medically unnecessary items
or services. This law also prohibits anyone from knowingly underpaying an obligation owed to a federal program. Increasingly, U.S. federal
agencies are requiring nonmonetary remedial measures, such as corporate integrity agreements in False Claims Act settlements. The U.S.
Department of Justice announced in 2016 its intent to follow the &#8220;Yates Memo,&#8221; taking a far more aggressive approach in pursuing
individuals as False Claims Act defendants in addition to the corporations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 82; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Physician Payment Sunshine Act, enacted in 2010 as part of the Affordable Care Act, requires certain manufacturers of pharmaceuticals
and medical devices to annually report certain payments and other transfers of value to physicians (defined to include doctors, dentists,
optometrists, podiatrists and chiropractors) and teaching hospitals, as well as investment interests held by physicians and their immediate
family members. Effective January 1, 2022, covered manufacturers will also be required to report on payments and other transfers of value
to physician assistants, nurse practitioners or clinical nurse specialists, anesthesiologist assistants, certified registered nurse anesthetists,
and certified nurse-midwives during the previous year. In recent years, several states in the United States have also enacted legislation
requiring pharmaceutical companies to file periodic reports with the state, make periodic public disclosures on sales, marketing, pricing,
clinical trials and other activities, and/or register their sales representatives, as well as establish marketing compliance programs.
These laws may affect our sales, marketing, and other promotional activities by imposing administrative and compliance burdens on us.
Failure to meet these requirements, to the extent they are applicable to our activities, could also result in a variety of governmental
sanctions that could have a material adverse effect on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our operations are found to be in violation of any of the foregoing or other applicable health care laws and regulations, we may be subject
to penalties, including significant administrative, civil and criminal penalties, monetary damages, disgorgement, imprisonment, the curtailment
or restructuring of our operations, loss of eligibility to obtain approvals from the FDA, or exclusion from participation in government
contracting, healthcare reimbursement or other government programs, including Medicare and Medicaid.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>European
Economic Area</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to approval in the United States, we currently intend to seek regulatory approval of Aramchol in the EU. As such, a summary
of the EU regulatory processes follows below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
medicinal product may only be placed on the market in the European Economic Area, or the EEA, composed of the 27 EU member states of
the EU, plus Norway, Iceland and Lichtenstein, when a marketing authorization has been obtained according to the applicable EU and/or
member state law. A marketing authorization may either be granted in a national procedure, or in a coordinated procedure of several member
states pursuant to Directive 2001/83/EC, as amended January 1, 2025, or an authorization has been granted under the centralized procedure
in accordance with Regulation (EC) No. 726/2004, as amended on January 28, 2022. There are essentially three community procedures created
under prevailing European pharmaceutical legislation that, if successfully completed, allow an applicant to place a medicinal product
on the market in the respective EU or EEA member states.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
withdrawal of the United Kingdom (UK) from the EU took effect on January 1, 2021, and there are 27 member states remaining in the EU.
As of January 1, 2021, the UK is a &#8220;third country&#8221; with regard to the EU (subject to the terms of the EU UK Trade Agreement)
and EU law ceased to apply directly in the UK. However, the UK has retained the EU medicines regulatory regime with certain modifications
as standalone UK legislation. Therefore, the UK regulatory regime is currently similar to EU regulations, but under new legislation,
the Medicines and Medical Devices Act 2021, the UK may adopt changed regulations that may diverge from the EU legislative regime for
medicines and their research, development and commercialization. In order to market a medicinal product in the UK, a license or marketing
authorization must be obtained from the UK Medicines and Healthcare Products Regulatory Agency (MHRA). The UK legislation includes multiple
assessment routes for applications for medicinal products, including a 150-day national assessment or a rolling review application. Further,
and for a transitional period until 31 December 2022, the MHRA may rely on a decision taken by the European Commission on the approval
of a new marketing authorization in the centralized procedure. In addition, the MHRA has the power to have regard to marketing authorizations
approved in EU member states through the decentralized and mutual recognition procedures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 83; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Centralized
Procedure</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulation
726/2004/EC, as amended, governs the centralized procedure when a marketing authorization is granted by the European Commission, acting
in its capacity as the European Licensing Authority on the advice of the EMA. That authorization is valid throughout the entire EEA on
the basis of a single marketing authorization. The EMA is the administrative body responsible for coordinating the existing scientific
resources available in the member states for evaluation, supervision and pharmacovigilance of medicinal products. Certain medicinal products,
as described in the Annex to Regulation 726/2004, must be authorized centrally. These are products that are developed by means of certain
biotechnological processes in accordance with Paragraph 1 to the Annex to the Regulation. Medicinal products for human use containing
a new active substance that, on the date of effectiveness of the Regulation, was not authorized in the European Union, and for which
the therapeutic indication is the treatment of acquired immune deficiency syndrome, or AIDS, cancer, neurodegenerative disorder or diabetes,
autoimmune diseases and other immune dysfunctions and viral diseases must also be authorized centrally. Finally, all medicinal products
that are designated as orphan medicinal products pursuant to Regulation 141/2000 and Advanced Therapy Medicinal Products (ATMP) according
to Reg. (EC) No. 1394/2007. An applicant may also opt for assessment through the centralized procedure if the medicinal product contains
a new active substance which was not authorized in the EU when Reg. (EC) No. 726/2004 entered into force, or if the applicant can show
that the medicinal product constitutes a significant therapeutic, scientific or technical innovation or that the granting of authorization
centrally is in the interests of patients at the EEA level. For each application submitted to the EMA for scientific assessment, the
EMA is required to ensure that the opinion of the Committee for Medicinal Products for Human Use, or CHMP, is given within 210 days after
receipt of a valid application (or within 150 days by means of an accelerated procedure (excluding clock stops) the review period can
be extended). This 210 day period does not include the time that the applicant needs to answer any questions raised during the application
procedure, the so-called &#8216;clock stop&#8217; period. If the opinion is positive, the EMA is required to send the opinion to the
European Commission, which is responsible for preparing the draft decision granting a marketing authorization. This draft decision may
differ from the CHMP opinion, stating reasons for diverging from the CHMP opinion. The draft decision is sent to the applicant and the
member states, after which the European Commission takes a final decision. If the initial opinion of the CHMP is negative, the applicant
is afforded an opportunity to seek a re-examination of the opinion. In that case, the applicant may, within 15 days after receipt of
the opinion, give written notice to EMA that he wishes to request a re-examination of the opinion. The applicant is then required to
forward the detailed grounds for request within 60 days after receipt of the opinion. The CHMP is required to re-examine its opinion
within 60 days following receipt of the request by the applicant. All CHMP refusals and the reasons for refusal are made public on the
EMA website. Without a centralized marketing authorization it is prohibited to place a medicinal product that must be authorized centrally
on the market in the EU. Once a centralized marketing authorization has been granted by the European Commission, it is valid in all EEA
States for 5 years on a renewable basis. Marketing authorizations for medicinal products for veterinary use that fall within the scope
of article 42(2) Regulation (EU) 2019/6, as amended January 28, 2022, are also granted through a centralized procedure, in accordance
with the relevant provisions of this regulation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Mutual
Recognition and Decentralized Procedures</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
the exception of products that are authorized centrally, the competent authorities of the member states are responsible for granting
marketing authorizations for medicinal products placed on their national markets. If the applicant for a marketing authorization intends
to market the same medicinal product in more than one member state, the applicant may seek an authorization progressively in the community
under the mutual recognition or decentralized procedure. Mutual recognition procedure, or MRP is used if the medicinal product has already
been authorized in a member state. In this case, the holder of this marketing authorization requests the member state where the authorization
has been granted to act as reference member state by preparing an assessment report on the product or, if necessary, to update any existing
assessment report that is then used to facilitate mutual recognition of the existing authorization in the other member states in which
approval is sought (the so-called concerned member state(s)). The reference member state must prepare an updated assessment report within
90 days of receipt of a valid application. This report together with the approved Summary of Product Characteristics, the SmPC (which
sets out the conditions of use of the product), and a labeling and package leaflet are sent to the concerned member states for their
consideration. The concerned member states are required to approve the assessment report, the SmPC and the labeling and package leaflet
within 90 days of receipt of these documents. The reference member state shall record the agreement of all parties, close the procedure
and inform the applicant accordingly. Each member state in which an application has been submitted shall adopt a decision in conformity
with the approved documents, within 30 days after acknowledgement of the agreement. In most cases, the total procedural time of the MRP
is 180 days plus 30 days.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 84; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
decentralized procedure, or DCP, is used in cases where the medicinal product has not received a marketing authorization in the EU at
the time of application. The applicant requests a member state of its choice to act as reference member state to prepare an assessment
report that is then used to facilitate agreement with the concerned member states and the grant of a national marketing authorization
in all of these member states. In this procedure, the reference member state must prepare, for consideration by the concerned member
states, the draft assessment report, a draft SmPC and a draft of the labeling and package leaflet within 120 days after receipt of a
valid application. As in the case of mutual recognition, the concerned member states are required to approve these documents within 90
days of their receipt. The reference member state shall record the agreement of all parties, close the procedure and inform the applicant
accordingly. Each member state in which an application has been submitted shall adopt a decision in conformity with the approved documents,
within 30 days after acknowledgement of the agreement. In most cases the total time of the DCP will be 210 days plus 30 days.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
both MRP and DCP, if a concerned member state objects to the grant of a marketing authorization on the grounds of a potential serious
risk to public health, it shall give a detailed exposition of the reasons for its position with the reference member state, to the other
member states concerned and to the applicant. The points of disagreement are in the first instance referred to the co-ordination Group
on MRP and DCP to reach an agreement within 60 days of the communication of the points of disagreement. If member states fail to reach
an agreement, the reference Member State shall record the agreement, close the procedure and inform the applicant accordingly. If the
member states fail to reach an agreement within the 60-day period, then the matter is referred to the EMA and CHMP for arbitration. The
CHMP is required to deliver a reasoned opinion within 60 days of the date on which the matter is referred. The scientific opinion adopted
by the CHMP forms the basis for a binding European Commission decision. If the member states fail to reach an agreement within the 60-day
period, member states that have approved the assessment report, the draft summary of product characteristics and the labelling and package
leaflet of the reference Member State may, at the request of the applicant, authorize the medicinal product without waiting for the outcome
of the procedure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Irrespective
of whether the medicinal product is assessed centrally, de-centrally or through a process of mutual recognition, the medicinal product
must be manufactured in accordance with the principles of GMP for human use as set out in Directive 2001/83/EC and 2017/1572/EU and Delegated
Regulation 2017/1569 that have replaced Directive 2003/94/EC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directive
2017/1572/EU and Volume 4 of the rules governing medicinal products in the European Union govern GMP in the EU. Moreover, EU law requires
the clinical results in support of clinical safety and efficacy based upon clinical trials conducted in the EU to be in compliance with
the requirements of Regulation (EU) 536/2014, as amended on December 5, 2022, on clinical trials with medicinal products for human use
and Implementing Regulation 556/2017 on GCP-inspections which implement good clinical practice in the conduct of clinical trials on medicinal
products for human use. Clinical trials conducted outside the European community and used to support applications for marketing within
the EU must have been conducted in a way consistent with the principles set out in Regulation (EU) 536/2014 as regards the rights and
safety of the subject and the reliability and robustness of the data generated in the clinical trial. The conduct of a clinical trial
in the EU requires, pursuant to Regulation (E) 536/2017, authorization by the relevant national competent authority where a trial takes
place, and subject to the relevant national law, an ethics committee to have issued a favorable opinion in relation to the arrangements
for the trial. It also requires that the sponsor of the trial, or a person authorized to act on his behalf in relation to the trial,
be established in the community. In comparison to the former regime, Regulation (EU) 536/2014 further harmonizes EU law on clinical trials
and to some extent facilitates clinical trials conducted in more than one EU Member State. Under Regulation (EU) 536/2014, trial sponsors
submit their application for trial approval via an EU Portal, Clinical Trials Information System (CTIS). The approvals will still have
to be granted by the competent authorities of the EU Member States where a trial takes place, however, the procedure for approval is
conducted in a coordinated manner among the concerned EU Member States as provided under Regulation (EU) 536/2014. While the process
for the application and granting of the approvals is streamlined, it is still a complex process that can significantly delay the start
of a multinational clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
UK has not adopted Regulation (EU) 536/2014 with respect to clinical trials in the UK. Instead, the Medicines for Human Use (Clinical
Trials) Regulations 2004 applies with respect to clinical trials in the UK. The UK has adopted new legislation, the Medicines and Medical
Devices Act 2021 and has issued a consultation with respect to changes to clinical trial legislation to be made under this Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 85; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">National
Procedure</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
procedure is available for medicinal products that do not fall within the scope of mandatory centralized authorization. In addition,
the national procedure can only be used if the medicinal product does not already have a marketing authorization in another EEA state
or has already submitted an application for marketing authorization in one of the other member states of the EU/EEA and the application
is under consideration. Specific procedures and timelines differ between member states, but the duration of the procedure without clock-stop
time is generally 210 days and based on a risk/efficacy assessment by the competent authority of the member state concerned, followed
by determination of SmPC, package leaflet and label text/layout and subsequently grant of the marketing authorization. Marketing authorizations
granted on this basis are not mutually recognized by other member states, but the national marketing authorization can later be used
in an MRP to obtain marketing authorizations in other member states.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are various types of applications for marketing authorizations:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Full
    Applications</i>. A full application is one that is made under any of the community procedures described above and that &#8220;stands
    alone&#8221; in the sense that it contains all of the particulars and information required by Article 8(3) of Directive 2001/83 (as
    amended) to allow the competent authority to assess the quality, safety and efficacy of the product and in particular the balance
    between benefit and risk. Article 8(3)(i) in particular refers to the need to present the results of the applicant&#8217;s research
    on (i) pharmaceutical (physical-chemical, biological or microbiological) tests, (ii) pre-clinical (toxicological and pharmacological)
    studies and (iii) clinical trials in humans. The nature of these tests, studies and trials is explained in more detail in Annex I
    to Directive 2001/83/EC. Full applications would be required for products containing new active substances not previously approved
    by the competent authority, but may also be made for other products.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Abridged
    Applications</i>. Article 10 and 10(a) of Directive 2001/83/EC, as amended, contain exemptions from the requirement that the applicant
    has to provide the results of its own pre-clinical and clinical research. There are three regulatory routes for an applicant to seek
    an exemption from providing such results, namely (i) cross-referral to an innovator&#8217;s results without consent of the innovator,
    (ii) well established use according to published literature and (iii) consent to refer to an existing dossier of research results
    filed by a previous applicant.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Cross-referral
to Innovator&#8217;s Data</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Articles
10(1) of Directive 2001/83/EC provide the legal basis for an applicant to seek a marketing authorization on the basis that its product
is a generic medicinal product (a copy) of a reference medicinal product that has already been authorized, in accordance with community
provisions. A reference product is, in principle, an original product granted an authorization on the basis of a full dossier of particulars
and information. This is the main exemption used by generic manufacturers for obtaining a marketing authorization for a copy product.
The generic applicant is not required to provide the results of pre-clinical studies and of clinical trials if its product meets the
definition of a generic medicinal product and the applicable regulatory results protection period for the results submitted by the innovator
has expired. A generic medicinal product is defined as a medicinal product:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">having
    the same qualitative and quantitative composition in active substance as the reference medicinal product; having the same pharmaceutical
    form as the reference medicinal product; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">whose
    bioequivalence with the reference medicinal product has been demonstrated by appropriate bioavailability studies.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Applications
in respect of a generic medicinal product cannot be made before the expiry of the protection period. Where the reference product was
granted a national marketing authorization pursuant to an application made before October 30, 2005, the protection period is either six
years or 10 years, depending upon the election of the particular member state concerned. Regulation 726/2004, as amended, to Directive
2001/83/EC, as amended, provide for a harmonized protection period regardless of the approval route utilized. The harmonized protection
period is in total 10 years, including eight years of research data protection and two years of marketing protection. The effect is that
the originator&#8217;s results can be the subject of a cross-referral application after eight years, but any resulting authorization
cannot be exploited for a further two years. The rationale of this procedure is that the relevant particulars can, if the research data
protection period has expired, be found on the originator&#8217;s file and used for assessment of the generic medicinal product. The
10-year protection period can be extended to 11 years where, in the first eight years post-authorization, the holder of the authorization
obtains approval for a new therapeutic indication assessed as offering a significant clinical benefit in comparison with existing therapies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 86; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the copy product does not meet the definition of a generic medicinal product (as defined in article 10(2)(b) of the Regulation) or if
bioequivalence could not be demonstrated through bioavailability studies or in case of certain types of changes in the active substance(s)
or in the therapeutic indications, strength, pharmaceutical form or route of administration in relation to the reference medicinal product,
Article 10(3) of Directive 2001/83/EC provides that the results of the appropriate pre-clinical studies or clinical trials must be provided
by the applicant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where
a biological medicinal product which is similar to a reference biological product does not meet the conditions in the definition of generic
medicinal products, owing to, in particular, differences relating to raw materials or differences in manufacturing processes of the biological
medicinal product and the reference biological medicinal product, the results of appropriate pre-clinical tests or clinical trials relating
to these conditions must be provided ex. article 10(3) of the Regulation. The type and quantity of supplementary data to be provided
must comply with the relevant criteria stated in Annex I of the Regulation and the related detailed guidelines. In that case, the results
of other tests and trials from the reference medicinal product&#8217;s dossier shall not be provided.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Well-established
Medicinal Use</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
Article 10a of Directive 2001/83/EC, an applicant may, in substitution for the results of its own pre-clinical and clinical research,
present detailed references to published literature demonstrating that the active substance(s) of a product have a well- established
medicinal use within the community for at least ten years with recognized efficacy and an acceptable level of safety in terms of the
conditions set out in Annex I of Directive 2001/83/EC. In that event, the test and trial results shall be replaced by appropriate scientific
literature. The applicant is entitled to refer to a variety of different types of literature, including reports of clinical trials with
the same active substance(s) and epidemiological studies that indicate that the constituent or constituents of the product have an acceptable
safety/efficacy profile for a particular indication. However, use of the published literature exemption is restricted by stating that
in no circumstances active substances be treated as having a well- established use if they have been used for less than 10 years from
the first systematic and documented use of the substance as a medicinal product in the EU. Even after 10 years&#8217; systematic use,
the threshold for well-established medicinal use might not be met. European pharmaceutical law requires the competent authorities to
consider among other factors the period over which a substance has been used, the amount of patient use of the substance, the degree
of scientific interest in the use of the substance (as reflected in the scientific literature) and the coherence (consistency) of all
the scientific assessments. For this reason, different substances may reach the threshold for well-established use after different periods,
but the minimum period is 10 years. If the applicant seeks approval of an entirely new therapeutic use compared with that to which the
published literature refers, additional pre-clinical and/or clinical results would have to be provided.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Authorization
Holder&#8217;s Consent</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
Article 10c of Directive 2001/83/EC, following the grant of a marketing authorization the holder of such authorization may consent to
a competent authority utilizing the pharmaceutical, pre-clinical and clinical documentation that it submitted to obtain approval for
a medicinal product to assess a subsequent application relating to a medicinal product possessing the same qualitative and quantitative
composition with respect to the active substances and the same pharmaceutical form.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 87; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Law
Relating to Pediatric Research</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulation
(EC) 1901/2006 (as amended by Regulation (EC) 1902/2006 and Regulation (EU) 2019/5) was adopted on December 12, 2006. This Regulation,
as amended on January 28, 2019, governs the development of medicinal products for human use in order to meet the specific therapeutic
needs of the pediatric population (children aged 0 to 17 years). It requires any application for marketing authorization made after July
26, 2008 in respect of a medicinal product not authorized in the European Community on January 26, 2007 (the time the Regulation entered
into force), to include the studies performed in accordance with a pediatric investigation plan agreed by the Pediatric Committee of
the EMA, unless the product is subject to an agreed waiver or deferral or unless the product is excluded from the scope of Regulation
1901/2006 (generics, hybrid medicinal products, biosimilars, homeopathic and traditional (herbal) medicinal products and medicinal products
containing one or more active substances of well-established medicinal use) according to article 9 of Regulation (EC) 1901/2006, as amended
on January 28, 2019. Waivers can be granted in certain circumstances where pediatric studies are not required or desirable. Deferrals
can be granted in certain circumstances where the initiation or completion of pediatric studies should be deferred until appropriate
studies in adults have been performed. The EMA does not evaluate an application for market authorization that is not exempt from Regulation
(EC) 1901/2006, as amended, if there is no agreed PIP, deferral or waiver. Moreover, this regulation imposes the same obligation from
January 26, 2009 on an applicant seeking approval of a new indication, pharmaceutical form or route of administration for a product already
authorized and still protected by a supplementary protection certificate granted under Regulation EC 469/2009 and its precursor Regulation
(EEC) 1768/92 or by a patent that qualifies for the granting of such a supplementary protection certificate. The pediatric Regulation
(EC) 1901/2006 also provides, subject to certain conditions, a reward for performing such pediatric studies, regardless of whether the
pediatric results provided resulted in the grant of a pediatric indication. This reward comes in the form of an extension of six months
to the supplementary protection certificate granted in respect of the product, unless the product is subject to orphan drug designation,
in which case the 10-year market exclusivity period for such an orphan product is extended to 12 years. If any of the non-centralized
procedures for marketing authorization have been used, the six-month extension of the supplementary protection certificate is only granted
if the medicinal product is authorized in all member states. Where the product is no longer covered by a patent or supplementary protection
certificate, the applicant may make a separate application for a Pediatric Use Marketing Authorization, or PUMA, which, on approval,
will provide eight years&#8217; protection for data and 10 years&#8217; marketing protection for the pediatric results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Post-authorization
Obligations</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the pre-authorization phase, the applicant must provide a detailed pharmacovigilance plan that it intends to implement post- authorization.
An authorization to market a medicinal product in the EU carries with it an obligation to comply with many post- authorization organizational
and behavioral regulations relating to the marketing and other activities of authorization holders. These include requirements relating
to post-authorization efficacy studies, post-authorization safety studies, adverse event reporting and other pharmacovigilance requirements,
advertising, packaging and labeling, patient package leaflets, distribution and wholesale dealing. The regulations frequently operate
within a criminal law framework and failure to comply with the requirements may not only affect the authorization, but also can lead
to financial and other sanctions levied on the company in question and responsible officers. EU pharmacovigilance legislation has been
significantly modified by the Pharmacovigilance Directive, Dir. 2010/84/EC, as amended on January 20, 2011 which amended the legal framework
of pharmacovigilance for medicines marketed within the EU provided in Regulation (EC) No 726/2004 with respect to EU authorized medicinal
products and in Directive 2001/83/EC with respect to nationally authorized medicinal products (including those authorized through the
mutual recognition and decentralized systems). In addition, Commission Implementing Regulation (EU) No 520/2012 outlines the practical
details to be respected by marketing authorization holders, national competent authorities and the EMA, Regulation (EU) No 1027/2012
and Directive 2012/26/EU which further amended the pharmacovigilance legislation to further strengthen the protection of patient health
by allowing prompt notification and assessment of safety issues and Commission Delegated Regulation (EU) No 357/2014 on post-authorization
efficacy studies specifies the situations in which such studies may be required. Furthermore, EU good pharmacovigilance practice (GVP)
rules apply. With these amended pharmacovigilance requirements, the financial and organizational burden on market authorization holders
is significant, such as the obligation to maintain a pharmacovigilance system master file that applies to all holders of marketing authorizations
granted in accordance with Directive 2001/83/EC, as amended on January 1, 2025, or Regulation (EC) No 726/2004, as amended on January
28, 2022. Marketing authorization holders must furthermore collect data on adverse events associated with use of the authorized product
outside the scope of the authorization. Pharmacovigilance for biological products and medicines with a new active substance is even stricter,
as their authorization is subject to additional monitoring activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 88; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
authorization granted by member state authorities, which within three years of its granting is not followed by the actual placing on
the market of the authorized product in the authorizing member state, ceases to be valid (Art. 24 (4) Directive 2001/83/EC). When an
authorized product previously placed on the market in the authorizing member state is no longer actually present on the market for a
period of three consecutive years, the authorization for that product shall cease to be valid (Art. 24 (5) Directive 2001/83/EC). The
same two three-year periods apply to authorizations granted by the European Commission based on the centralized procedure (Art. 14 (4)
and (5) Regulation (EC) 726/2004).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
Countries</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to regulations in the United States, the EU, the UK and Israel, we are subject to a variety of other regulations governing clinical
trials and commercial sales and distribution of drugs in other countries. Whether or not Aramchol or any other product candidate receive
approval from the FDA, approval of such product candidates must be obtained by the comparable regulatory authorities of countries other
than the United States before we can commence clinical trials or marketing of the product in those countries. The approval process varies
from jurisdiction to jurisdiction, and the time may be longer or shorter than that required for FDA approval. The requirements governing
the conduct of clinical trials and product licensing vary greatly from country to country.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
requirements that we and our collaborators must satisfy to obtain regulatory approval by government agencies in other countries prior
to commercialization of Aramchol or any other product candidate in such countries can be rigorous, costly and uncertain. In the European
countries, UK, Canada and Australia, regulatory requirements and approval processes are similar in principle to those in the United States.
Additionally, depending on the type of drug for which approval is sought, there are currently two potential tracks for marketing approval
in the European countries: mutual recognition and the centralized procedure. These review mechanisms may ultimately lead to approval
in all EU countries, but each method grants all participating countries some decision-making authority in product approval. The UK has
a separate review period but for a transitional period until 31 December 2022, may rely on approvals under the EU mutual recognition
and/or centralized procedure. Foreign governments also have stringent post-approval requirements including those relating to manufacture,
labeling, reporting, record keeping and marketing. Failure to substantially comply with these on-going requirements could lead to government
action against the product, us and/or our representatives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Related
Matters</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, legislation is drafted, introduced and passed in governmental bodies that could significantly change the statutory provisions
governing the approval, manufacturing and marketing of products regulated by the FDA, MHRA or EMA and other applicable regulatory bodies
to which we are subject. In addition, regulations and guidance are often revised or reinterpreted by the national agency in ways that
may significantly affect our business and our therapeutic candidates. It is impossible to predict whether such legislative changes will
be enacted, whether FDA, MHRA or EMA regulations, guidance or interpretations will change, or what the impact of such changes, if any,
may be. We may need to adapt our business and therapeutic candidates and products to changes that occur in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.
Organizational Structure</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
&#8220;Item 4. Information on the Company&#8212;Historical Background and Corporate Structure&#8221; above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.
Description of Property and Facilities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
principal executive offices and registered office in Israel is located at 16 Abba Hillel Road, Ramat Gan, Israel 5250608 and our telephone
number is +972-3-693-8448.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_002"></span>ITEM
4A. Unresolved Staff Comments.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 89; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_003"></span>ITEM
5. Operating and Financial Review and Prospects.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial
statements and related notes that appear elsewhere in this annual report. In addition to historical financial information, the following
discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results could differ materially
from those discussed in the forward-looking statements. Factors that could cause or contribute to these differences include those discussed
below and elsewhere in this prospectus, particularly in the sections titled &#8220;Risk Factors&#8221; and &#8220;Cautionary Note Regarding
Forward-Looking Statements.&#8221; Our discussion and analysis for the year ended December 31, 2023 can be found in our Annual Report
on Form 20-F for the fiscal year ended December 31, 2023, filed with the SEC on April 4, 2024 (File No. 001-36345).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are currently seeking to advance the development of Aramchol for oncological
indications outside of NASH and fibrosis. In addition, as part of our growth strategy, we are actively pursuing opportunities to expand and
diversify our product pipeline specifically targeting cardiometabolic indications and other innovative product candidates that align with
our core expertise in drug development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, we have not generated revenue from the sale of any product, excluding the licensing revenue we recorded in connection with the
Samil Agreement, and we do not expect to generate any significant revenue other than the amortization of the upfront payments under the
license agreement with Samil and of the subsequent royalties and/or milestones that may be earned in connection with the Samil Agreement
or potential other license Agreements, unless and until we commercialize Aramchol, or license the product to additional third parties.
As of December 31, 2024, we had an accumulated deficit of approximately $200.5 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
financing activities are described below under &#8220;Liquidity and Capital Resources.&#8221; Obtaining approval of an NDA, MMA, or other
similar application is an extensive, lengthy, expensive and uncertain process, and the FDA, EMA, MHRA and other regulatory agencies may
delay, limit or deny approval of Aramchol or any other product candidate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial
Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, we have funded our operations primarily through proceeds from private placements and public offerings. At December 31, 2024, we
had current assets of $16.1 &#160;&#160;million, which is mainly comprised of cash and cash equivalents of $4.7 million, restricted cash
of $0.1 million, short-term deposits of $3.5 million and short-term marketable securities of $7.2 million. This compares with current
assets of $13.2 million at December 31, 2023 which is mainly comprised of cash and cash equivalents of $2.9 million, restricted
cash of $0.1 million, short-term deposits of $2.3 million and short-term marketable securities of $7.5 million. &#160;&#160;We
believe that such existing funds will be sufficient to continue our business and operations as currently conducted for more than 12 months
from the date of issuance of this annual report. However, significant additional funding will be necessary to fund our ongoing research and development work and to advance our product candidates through regulatory approval and into
commercialization, if approved. We intend to obtain additional funding through debt or equity financings,
governmental grants or through entering into collaborations, strategic alliances or license agreements to increase the funds available
to support our operating and capital needs. Although we have been successful in raising capital in the past, there is no assurance that
we will be successful in obtaining additional financing on terms acceptable to us. If funds are not available, we may be required to
delay, reduce the scope of or eliminate research or development plans for, or commercialization efforts with respect to Aramchol, and/or our other pre-clinical and clinical programs. This may raise substantial doubts about our ability to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 90; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Costs
and Operating Expenses</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
current costs and operating expenses consist of two components: (i) research and development expenses; and (ii) general and administrative
expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Research
and Development Expenses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
research and development expenses consist primarily of outsourced development expenses, salaries and related personnel expenses and
fees paid to external service providers, patent-related legal fees, costs of pre-clinical studies and clinical trials and drug and
laboratory supplies. We account for all research and development expenses as they are incurred. We expect our research and
development expense to remain one of our primary expenses in the near future as we continue to develop Aramchol.
Increases or decreases in research and development expenditures are primarily attributable to the number and/or duration of the
pre-clinical and clinical studies that we conduct.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that a substantial amount of our research and development expense in the future will be incurred in support of our current and
anticipated pre-clinical and clinical development projects. Due to the inherently unpredictable nature of pre-clinical and clinical development
studies, we are unable to estimate with any certainty the costs we will
incur in the continued development of Aramchol and other product candidate.
Clinical development timelines, the probability of success and development costs can differ materially from expectations. We currently
expect to continue testing Aramchol in pre-clinical studies for toxicology, safety and efficacy, and to conduct additional clinical trials
for Aramchol.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 29.15pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
lengthy process of completing clinical trials and seeking regulatory approval for Aramchol requires the expenditure of substantial resources.
Any failure or delay in completing clinical trials, or in obtaining regulatory approvals, could cause a delay in generating product revenue
and cause our research and development expenses to increase and, in turn, have a material adverse effect on our operations. Because of
the factors set forth above, we are not able to estimate with any certainty when we would recognize any net cash inflows from our projects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 29.15pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>General
and Administrative Expenses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses consist primarily of compensation for employees in executive and operational roles, including finance/accounting,
legal and other operating positions in connection with our activities. Our other significant general and administrative expenses include
non-cash stock-based compensation costs and facilities costs (including the rental expense for our offices in Tel Aviv, Israel), professional
fees for outside accounting and legal services, travel costs, investors relations, insurance premiums and depreciation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses also consist of costs associated with being a public company, including expenses related to services associated
with maintaining compliance with The Nasdaq Capital Market and SEC requirements, directors and officers insurance, increased legal and
accounting costs and investor relations costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Financial
Income, Net</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
financial income, net consists mainly of interest income from marketable debt securities, change in fair value of convertible note and
foreign currency gains. Our financial expense consists of fees associated with banking activities and losses from realization of marketable
debt securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Financial
expenses in connection with SEPA</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
expenses in connection with the SEPA (as defined below) consists of one-time expenses that we incurred in establishing the SEPA, which
includes fees paid in cash and ordinary shares to the equity line provider.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Impairment
of Associate</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
impairment of associate consists of changes in the fair value of our investment in OnKai.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 91; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.
Results of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below provides our results of operations for the year ended December 31, 2024 as compared to the year ended December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(thousands)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Research and development expenses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">3,569</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">2,979</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">General and administrative expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,923</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,299</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,492</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,278</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Financial income, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(580</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(516</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Financial expenses in connection with SEPA</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">610</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Impairment of Associate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,145</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">6,912</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,517</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
                                            comprehensive loss:</span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
                                            unrealized gain on available for sale securities</span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(291</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(38</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Comprehensive loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">6,621</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">7,479</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Basic and diluted net loss per share from continuing operations</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">30.0</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">8.08</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Research
and Development Expenses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
research and development expenses amounted to approximately $3.0 million during the year ended December 31, 2024, representing a decrease
of approximately $0.6 million, or approximately 17%, compared to approximately $3.6 million for the year ended December 31, 2023. The
decrease primarily resulted from a decrease in clinical trial expenses in the amount of approximately $0.3 million as well as a decrease
in regulatory expenses of approximately $0.4 million, partially offset by an increase in salaries and benefits expenses of approximately
$0.3 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>General
and Administrative Expenses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
general and administrative expenses amounted to approximately $3.3 million for the year ended December 31, 2024, representing a decrease
of approximately $0.6 million, or 15%, compared to approximately $3.9 million for the year ended December 31, 2023. The decrease primarily
resulted from a decrease in insurance expenses of $0.3 million, as well as a decrease in non-cash stock based compensation expenses of
approximately $0.2 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Operating
Loss</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the foregoing research and development and general and administrative expenses, as well as our failure to generate substantial
operating revenues, our operating loss for the year ended December 31, 2024 was approximately $6.3 million, representing a decrease in
our operating loss of approximately $1.2 million, or approximately 16%, compared to approximately $7.5 million for the year ended December
31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Financial
Income, Net</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
financial income, net, for the year ended December 31, 2024 was approximately $0.5 million, representing a decrease of approximately
$0.1 million, compared to a financial income of approximately $0.6 million for the year ended December 31, 2023. The decrease primarily
resulted from no income from change in fair value of a convertible note, an income of $0.3 million during the year ended December 31,
2023. This was partially offset by an increase of interest income of $0.15 million during the year ended in 2024 as compared to such
loss for the comparable period in 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 92; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Financial
expenses in connection with SEPA</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2024, we incurred financial expenses of approximately $0.6 million in relation to the SEPA (as
defined below).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Impairment
of Associate</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
investment in Onkai is presented on in our consolidated financial statements at its fair value. As of December 31, 2024, management,
based on fair value estimation, assessed the qualitative aspects of the equity investment and macroeconomic factors and determined
that an impairment should be recognized in the amount of approximately $1.1 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Net
Loss</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
net loss for the year ended December 31, 2024 was approximately $7.5 million, representing an increase of approximately $0.6 million,
or approximately 9%, compared to approximately $6.9 million for the year ended December 31, 2023. The increase primarily resulted
from the above-mentioned financial expense in connection with SEPA and impairment of associate which was partly offset by a decrease
in research development expenses and general and administrative expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.
Liquidity and Capital Resources</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Overview</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, we have funded our operations primarily through proceeds from private placements and public offerings and we have incurred substantial
losses since our inception. As of December 31, 2024, we had an accumulated deficit of approximately $200.5 million and positive working
capital (current assets less current liabilities) of approximately $14.0 million. We expect that operating losses will continue for the
foreseeable future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, we had cash and cash equivalents of approximately $4.7 million, restricted cash of $0.1 million, short-term deposits
of $3.5 million and short-term marketable debt securities of approximately $7.2 million invested in accordance with our investment policy,
totaling approximately $15.5 million, as compared to cash and cash equivalents of approximately $2.9 million, restricted cash of $0.1
million, short-term deposits of $2.3 million and short-term marketable debt securities of approximately $7.5 million, totaling approximately
$12.8 million as of December 31, 2023&#160;&#160;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
generally enter into contracts in the ordinary course of business with CROs for clinical trials and clinical supply manufacturing and
with vendors for pre-clinical research studies and other services and products for operating purposes, which generally provide for termination
within 30 to 90 days of notice, and therefore are cancelable contracts and not included in the discussion above. We have included as
purchase obligations our commitments under agreements to the extent they are quantifiable and are not cancelable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than as described above, we did not have any material commitments for capital expenditures, including any anticipated material acquisition
of plant and equipment or interests in other companies, as of December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cash
Flow from Operating Activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
had negative cash flow from operating activities of approximately $5.9 million for the year ended December 31, 2024 as compared to a
negative cash flow from operating activities of approximately $6.1 million for the year ended December 31, 2023. The negative cash flow
from operating activities for the year ended December 31, 2024 was mainly attributable to our net loss of approximately $7.5 million,
as well as a decrease in trade payables of approximately $0.6 million, partially offset by non-cash stock based compensation expenses
of approximately $0.5 million and an impairment of an investment in associate of approximately $1.1 million and financial expenses in
connection with SEPA (as defined below) of approximately $0.6 million</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 93; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cash
Flow from Investing Activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
had negative cash flow from investing activities of approximately $1.1 million for the year ended December 31, 2024 as compared to a
positive cash flow from investing activities of approximately $0.8 million for the year ended December 31, 2023. The negative cash flow
from investing activities for the year ended December 31, 2024 was primarily due to a net investment of $1.3 million in short-term deposits,
partially offset by the net sale of marketable debt securities in the amount of approximately $0.4 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cash
Flow from Financing Activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
had positive cash flow from financing activities of approximately $8.8 &#160;&#160;million for the year ended December 31, 2024 as compared
to a positive cash flow from financing activities of $6.2 million for the year ended December 31, 2023. The positive cash flow from financing
activity for the year ended December 31, 2024 was due to net proceeds from warrant exercises and proceeds raised under the SEPA (as defined
below).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 26, 2021, we entered into a sales agreement, or the 2021 Sales Agreement, with Cantor Fitzgerald &amp; Co. and Canaccord Genuity
LLC as sales agents, or the 2021 Sale Agents, pursuant to which we may offer and sell our ordinary shares having an aggregate offering
price of up to $50.0 million, from time to time through the 2021 Sales Agents. Under the 2021 Sales Agreement, we were able to sell,
from time to time, up to approximately $50.0 million of additional ordinary shares subject to limitations under the Baby Shelf Rule.
As of December 31, 2024, we sold 7,721 ordinary shares under the 2021 Sales Agreement for total net proceeds of approximately $0.1 million.
We did not sell any ordinary shares under the 2021 Sales Agreement in 2024 and in August 2024, we terminated the 2021 Sales Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 14, 2023, we entered into a definitive securities purchase agreement with investors for the purchase and sale in a public offering
of (i) 31,667 of our ordinary shares, (ii) 435,000 pre-funded warrants to purchase 435,000 ordinary shares, or the Pre-Funded Warrants,
and (iii) 466,667 warrants to purchase 466,667 ordinary shares, or the Investor Warrants, at a purchase price of $15.00 per Share and
accompanying Investor Warrant and $14.988 per Pre-Funded Warrant and accompanying Investor Warrant. The net proceeds to the offering
were approximately $6.5 million before deducting estimated offering expenses payable by us. As of the date hereof, all Pre-Funded Warrants
have been exercised into 435,000 ordinary shares and 293,333 Investor Warrants have been exercised into 293,333 ordinary shares for a
total net proceeds of approximately of $4.4 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 30, 2024, we entered into a Standby Equity Purchase Agreement, (or the &#8220;SEPA&#8221;), with YA II PN, LTD., a Cayman Islands
exempt limited partnership, or YA. Pursuant to the SEPA, we have the right, but not the obligation, to sell to YA from time to time,
each such occurrence, an Advance, up to $10.0 million, or the Initial Commitment Amount, of our ordinary shares, during the 36 months
following the execution of the SEPA, subject to the restrictions and satisfaction of the conditions in the SEPA. On October 21, 2024,
we and YA entered into an amendment to the SEPA to increase the Initial Commitment Amount to $20.0 million of our ordinary shares. At
our option, the ordinary shares would be purchased by YA from time to time at a price equal to 97% of the lowest of the three daily VWAPs
(as hereinafter defined) during a three consecutive trading day period commencing on the date that we, subject to certain limitations,
deliver a notice to YA that we are committing YA to purchase such ordinary shares, or the Advance Shares. We may also specify a certain
minimum acceptable price per share in each Advance. &#8220;VWAP&#8221; means, for any trading day, the daily volume weighted average
price of our ordinary shares for such trading day on the Nasdaq Stock Market during regular trading hours as reported by Bloomberg L.P.
As consideration for YA irrevocable commitment to purchase our ordinary shares up to the Initial Commitment Amount, we agreed to issue
31,566 ordinary shares, or the Commitment Shares, to YA and also paid a $15,000 structuring fee to an affiliate of YA. The Commitment
Shares shall be issued in four equal installments, of which 7,892 Commitment Shares were issued on the date of execution of the SEPA
and the remaining 23,674 Commitment Shares will be issued in three equal installments 90 calendar days following the due date of the
immediately preceding installment until all four installments have been issued. As of the date of this Annual Report, we have issued
an aggregate of 607,450 ordinary shares to YA consisting of (i) 23,675 ordinary shares that we issued to YA as consideration for YA&#8217;s
irrevocable commitment to purchase our ordinary shares up to the Commitment Amount and (ii) 583,775 ordinary shares represented that
we sold to YA as Advance Shares for aggregate gross proceeds of approximately $4.4 million. Since December 31, 2024, we have issued an
aggregate of 7,892 ordinary shares to YA as part of the Commitment Shares and an aggregate of 25,000 ordinary shares that we sold to
YA as Advance Shares for aggregate gross proceeds of approximately $0.1 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 94; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 14, 2025, we entered into a Capital on Demand Sales Agreement, or the 2024 Sales Agreement, with JonesTrading Institutional
Serviecs LLC, or JonesTrading. Pursuant to the 2024 Sales Agreement, we may offer and sell our ordinary shares having an aggregate offering
price of up to $8.1 million, from time to time through JonesTrading. JonesTrading will receive a commission equal to 3.0% of the gross
proceeds from the sale of the ordinary shares and will be reimbursed for certain specified expenses in connection with entering into
the Sales Agreement. As of the date hereof and since December 31, 2024, we sold 541,996 of our ordinary shares for aggregate net proceeds
of approximately $1.5 million pursuant to the 2024 Sales Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Current
Outlook</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we provide no assurance, we believe that our existing funds will be sufficient to continue our business and operations as currently conducted
for more than 12 months from the date of issuance of this Report on Form 6-K. However, significant additional funding will be necessary
to fund ongoing research and development work, to advance our product candidates through
regulatory approval and into commercialization, if approved. We intend to obtain additional
funding through debt or equity financings, governmental grants or through entering into collaborations, strategic alliances or license
agreements to increase the funds available to support our operating and capital needs. Although we have been successful in raising capital
in the past, there is no assurance that we will be successful in obtaining additional financing on terms acceptable to us. If funds are
not available, we may be required to delay, reduce the scope of or eliminate research or development plans for, or commercialization
efforts with respect to Aramchol, and/or our other pre-clinical and clinical programs. This may raise substantial doubts about
our ability to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
extent of our future capital requirements will depend on many other factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    progress and costs of our pre-clinical studies, clinical trials and other research and development activities;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    regulatory pathway of Aramchol any other product candidate;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope, prioritization and number of our clinical trials and other collaboration research and development programs;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    amount of revenues and contributions we receive under future licensing, development and commercialization arrangements with respect
    to Aramchol or any other product candidate;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs of the development and expansion of our operational infrastructure;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs and timing of obtaining regulatory approval for Aramchol or any other product candidate;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ability of us, or our collaborators, to achieve development milestones, marketing approval and other events or developments under
    our potential future licensing agreements;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs of filing, prosecuting, enforcing and defending patent claims and other intellectual property rights;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs and timing of securing manufacturing arrangements for clinical or commercial production;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs of contracting with third parties to provide sales and marketing capabilities for us;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs of acquiring or undertaking development and commercialization efforts for any future products, product candidates or platforms;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    magnitude of our general and administrative expenses;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    cost that we may incur under future in- and out-licensing arrangements relating to Aramchol or any other product candidate;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">market
    conditions;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to main the listing of our ordinary shares on The Nasdaq Capital Market;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to identify, evaluate and complete any strategic alternative that yields value for our shareholders; and</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    impact of the security situation in Israel, which may exacerbate the magnitude of the factors discussed above.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 95; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.
Research and Development, Patents and Licenses</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
information concerning our research and development policies and a description of the amount spent during each of the last three fiscal
years on company-sponsored research and development activities, see &#8220;Item 5. Operating and Financial Review and Prospects&#8212;Results
of Operations.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.
Trend Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a development stage company and it is not possible for us to predict with any degree of accuracy the outcome of our research, development
or commercialization efforts. As such, it is not possible for us to predict with any degree of accuracy any known trends, uncertainties,
demands, commitments or events that are reasonably likely to have a material effect on our net sales or revenues, income from continuing
operations, profitability, liquidity or capital resources, or that would cause reported financial information to not necessarily be indicative
of future operating results or financial conditions. However, to the extent possible, certain trends, uncertainties, demands, commitments
and events are in this &#8220;Operating and Financial Review and Prospects.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E.
Critical Accounting Policies and Estimates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
prepare our financial statements in accordance with U.S. GAAP. In doing so, we must make estimates and assumptions that affect our reported
amounts of assets, liabilities and expenses, as well as related disclosure of contingent assets and liabilities. In some cases, we could
reasonably have used different accounting policies and estimates. Changes in the accounting estimates are reasonably likely to occur
from period to period. Accordingly, actual results could differ materially from our estimates. To the extent that there are material
differences between these estimates and actual results, our financial condition or results of operations will be affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
our significant accounting policies are described in more detail in the notes to our audited consolidated financial statements appearing
elsewhere in this Annual Report on Form 20-F we believe that the following accounting policies are those most critical to the judgments
and estimates used in the preparation of our consolidated financial statements:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accounting
for stock-based compensation:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
grant equity-based awards under share-based compensation plans. We estimate the fair value of share-based payment awards using the Black-Scholes
option valuation model. The Black-Scholes option valuation model requires the input of subjective assumptions, including price volatility
of the underlying stock, risk-free interest rate, dividend yield, and expected life of the option. Share-based compensation expense is
based on awards ultimately expected to vest, and therefore is reduced by expected forfeitures. Changes in assumptions used under the
Black-Scholes option valuation model could materially affect our net loss and net loss per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accounting
for Marketable Debt Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
debt securities are classified as available-for-sale and recorded at fair value. We determine the appropriate classification of investments
in debt securities at the acquisition date and re-evaluates the classification at each balance sheet date. Unrealized gains and losses
during the year, net of the related tax effect applicable to available-for-sale are excluded from income and reflected in other comprehensive
income (loss) as a separate component of shareholders&#8217; equity until realized. As the result of the adoption of Accounting Standards
Update (&#8220;ASU&#8221;) 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instrument
(&#8220;ASU 2016-13&#8221;) we assess the need at each period end to record an allowance for credit loss. Any portion of the market decline
related to debt securities that is believed to arise from factors other than credit is recorded as a component of other comprehensive
income (loss) rather than against income.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 96; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accounting
for Investment in Associate at Fair Value</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We,
through our wholly-owned subsidiary in Israel, Galtopa Therapeutics Ltd., hold an equity investment of a privately-owned company Onkai,
over which have the ability to exercise significant influence, but not control. The investment was included as a non-current asset in
our balance sheet as of December 31, 2024. We have elected the fair value option allowed by Accounting Standards Codification 825, Financial
Instruments, with respect to this investment because our management believes this approach will better reflect the economics of our equity
interest. Under the fair value option, the investment is remeasured at fair value (level 3) at each reporting period with changes in
fair value, if any, recorded in the statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aa_001"></span>ITEM
6. Directors, Senior Management and Employees.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.
Directors and Senior Management.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set
forth below is information concerning the directors, senior management and executive officers of the Company as of March 21, 2025, the
latest practicable date for inclusion in this annual report. The business address for each of our directors, senior management and corporate
officers is c/o Galmed Pharmaceuticals Ltd., c/o Meitar Law Offices, 16 Abba Hillel Silver Rd. Ramat Gan, 5250608.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 34%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 52%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allen
    Baharaff</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President
    and Chief Executive Officer, Class II Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Liat Hayardeny</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Scientist Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Doron
    Cohen</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yohai
    Stenzler</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Accounting Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Guy
    Nehemya</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Operating Officer and Data Protection Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
    Sidransky, M.D.<sup>(1)(2)(3)(4)(5)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lead
    Independent Director and Chairman of the R&amp;D Committee, Chairman of our Nomination Committee, Chairman of our Remuneration Committee,
    and Class III director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shmuel
    Nir<sup>(2)(3)(4)(5)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class
    I Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amir
    Poshinski<sup>(2)(3)(4)(5)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
    of our Audit Committee, Class III director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Carol
    L. Brosgart, M.D. <sup>(1) (2)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">73</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class
    I Director</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    member of our research &amp; development committee.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent
    director under applicable Nasdaq Capital Market and SEC rules, as affirmatively determined by our Board.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    member of our audit committee.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    member of our remuneration committee.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    member of our nomination committee.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 97; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Allen
Baharaff</i>, our President and Chief Executive Officer of our Board, co-founded the Group in 2000, served as the Chief Financial Officer
of GHI from 2000 until January 2015, and has served as our Chief Executive Officer since January 2012 and as our President since March
2015. Previously, he held a senior executive position at Isramex Projects Ltd., an energy project financing company, and Managing Director
of T+M Trusteeship &amp; Management Services (Israel) Ltd., a subsidiary of a Swiss company providing trust and similar services. Since
2005, Mr. Baharaff serves as a Director of the Rubin Museum. Since October 2023, Allen serves as a director of Onkai Inc, a private US-based
technology company Mr. Baharaff holds a Bachelor of Science degree in economics from the London School of Economics, University of London
and LLB and MA degrees from Cambridge University. Since 1993, Mr. Baharaff has been a member of the Israel Bar Association.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Dr.
Liat Hayardeny</i>, our Chief Scientific Officer joined the Company in September 2016 bringing more than 17 years of experience in drug
development at all stages as part of Teva Pharmaceuticals&#8217; global Research and Development Division. Prior to joining Galmed, Dr.
Hayardeny served as Teva&#8217;s Senior Director and Head of Research Scientific Affairs. In that capacity, Dr. Hayardeny established
the scientific positioning of Teva&#8217;s innovative compounds. Additionally, Dr. Hayardeny was responsible for Teva&#8217;s relationship
with institutions of higher education; managing Teva&#8217;s global research collaborations and publications. Dr. Hayardeny holds a Ph.D.
from Sackler School of Medicine and an MBA from Recanati Business School at Tel Aviv University.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Doron
Cohen, </i>our Chief Financial Officer, joined the Company in February 2022, after providing the Company consulting services, including
with respect to management of the Company&#8217;s funds, since 2018. Mr. Cohen brings more than twenty-five years of experience in the
global financial markets, including significant experience on the buy side of life sciences companies. Since 2016, Mr. Cohen has served
as Chief Executive Officer at Tangram Strategic Ltd., a boutique investment firm offering strategic solutions in economic &amp; financial
research, risk and regulation. Before that, between 1992 and 2017, Mr. Cohen served as Research Director at Gems Investments Research
Ltd., an investment research company. During his tenure there, he provided research to hedge funds and managed three teams of analysts,
focusing on investment research, operations research, and risk analysis. Prior to that from 1990 to 1992, Mr. Cohen served as Director
of Public Relations at the World Union of Jewish Students. Since October 2023, Doron serves as the interim CFO of Onkai Inc, a private
US-based technology company Mr. Cohen holds a Master of Science degree in management from Boston University, and a Bachelor&#8217;s degree
in philosophy and political science from the University of New South Wales.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Yohai
Stenzler</i>, our Chief Accounting Officer, has served in such capacity since February 2022. Mr. Stenzler joined the Company in June
2014 as the Company&#8217;s corporate controller, and later on served as the Company&#8217;s Director of Finance. Between February 2017
to February 2022, Mr. Stenzler served as our Chief Financial Officer. Mr. Stenzler has six years of financial management experience as
an accountant at the real estate department at Ernst &amp; Young LLP, where he was involved in financing, taxes, auditing, advising and
accounting of public and private companies, both domestic and international. Mr. Stenzler is a certified CPA and holds a MBA in Finance
from Recanati Business School at Tel Aviv University, and a BA in Economics and Accounting from Ben-Gurion University of the Negev.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Guy
Nehemya</i>, our Chief Operating Officer and Data Protection Officer, has served in each role since January 2019 and March 2021, respectively.
Between March 2017 and January 2019, Mr. Nehemya served as our Vice President, Operations. Mr. Nehemya joined the Company in October
2013 as the Company&#8217;s Director of Operations, after completing his internship at Agmon, Rosenberg, HaCohen &amp; Co. Law Offices.
Mr. Nehemya was a key member of management during the Company&#8217;s initial public offering and execution thereof. Mr. Nehemya holds
a LL.B. from the College of Management and is currently completing his MBA degree at the IDC Herzliya. Mr. Nehemya has been a member
of the Israeli Bar Association since 2012.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 98; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>David
Sidransky, M.D.</i>, the chairman of our Nomination, Remuneration and R&amp;D Committees, joined our Board in June 2014, originally as
an external director. Dr. Sidransky is a renowned oncologist and research scientist named and profiled by TIME magazine in 2001 as one
of the top physicians and scientists in America, recognized for his work with early detection of cancer. He serves as the Director of
the Head and Neck Cancer Research Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University. He is a Professor
of Oncology, Otolaryngology, Cellular &amp; Molecular Medicine, Urology, Genetics, and Pathology at Johns Hopkins University and Hospital.
Dr. Sidransky has written over 600 peer-reviewed publications and has contributed to more than 60 cancer reviews and chapters. Dr. Sidransky
is a founder of a number of biotechnology companies and holds numerous biotechnology patents. He has been the recipient of many awards
and honors, including the 1997 Sarstedt International prize from the German Society of Clinical Chemistry, 1998 Alton Ochsner Award Relating
Smoking and Health by the American College of Chest Physicians and the 2004 Hinda Rosenthal Award and 2017 Team Award presented by the
American Association of Cancer Research. Dr. Sidransky has served as Vice Chairman of the Board of Directors of ImClone. He is Chairman
of the Board of Ayala Pharma (Nasdaq: AYLA), and is a lead director at Champions Oncology and on the board of directors of Ascentage
Pharma and Nectin Therapeutics (Nasdaq: AAPG). He previously served on the board of director of Orgensis Inc. (Nasdaq ORGS. He is serving
and has served on scientific advisory boards of corporations and institutions, including Amgen, MedImmune, Roche and Veridex, LLC (a
Johnson &amp; Johnson diagnostic company), among others. In addition, Dr. Sidransky served as Director of American Association for Cancer
Research from 2005 to 2008. Dr. Sidransky received his B.A. from Brandeis University and his M.D. from the Baylor College of Medicine.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Shmuel
Nir</i>, a director of the Company since 2007, serves as President and Chief Executive Officer of Tushia Consulting Engineers Ltd., an
investment and management services company. From January 2001 to January 2016, Mr. Nir served as Chairman of the board of directors of
Matan Digital Printers Ltd. From March 1998 to January 2008, he served as President and Chief Executive Officer of Macpell Industries
Ltd., a leading industrial group. Between January 1991 and March 1998, Mr. Nir was an Executive Vice President of Operations at Macpell
Industries Ltd. and President and Chief Executive Officer of two of its subsidiaries, New Net Industries Ltd. and New Net Assets Ltd.
Prior to January 1991, Mr. Nir had held various positions with Intel Corporation in Jerusalem, Israel and Tefen Management Consulting.
Between 1999 and 2006, Mr. Nir served as managing partner at Spring Venture Capital Fund. Mr. Nir holds a B.Sc. in Industrial Engineering
and Management from the Technion - Israel Institute of Technology in Haifa, which was awarded in 1989.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Amir
Poshinski</i>, joined our Board in June 2020. Mr. Poshinski is an entrepreneur with over 20 years&#8217; management and leadership experience
across multiple industries, including technology, biotechnology, banking and real estate. Mr. Poshinski is the owner of DAP Holdings,
through which he has acted since 2010 as a management consultant and strategic advisor to global companies. Mr. Poshinski currently serves
as a member of the advisory board of Benson Oak Ventures, a venture focused fund, as well as several other private companies. Prior to
2010, Mr. Poshinski served as Deputy CEO of Primsa Investment House, which at the time was Israel&#8217;s largest investment house, Deputy
CEO of Discount Mortgage Bank, the real estate lending arm of one of Israel&#8217;s largest banks, VP of Marketing at Comverse, a telecommunications
software company that was listed on Nasdaq, VP Marketing, Sales and Advertising of Mifal Hapayis, Israel&#8217;s national lottery, and
VP and Deputy CEO of the Economic Company of the Israeli Local Authorities Association. Mr. Poshinski previously served on the board
of directors of each of TAS-AGT (a TATA joint venture), Excellence Nessuah Mutual Funds, and Therapix Biosciences (Nasdaq: TRPX) as well
as several other private companies. Mr. Poshinski holds a B.A. in Business Administration and Marketing from the New York Institute of
Technology.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Carol
L. Brosgart, M.D. </i>joined our Board on June 7, 2017. Since 2022 Dr. Brosgart also serves on the Board of of Eradivir Biotech and Merlin
Biotech. Dr. Brosgart previously served on the board of directors of (i) Abivax, a biotechnology company, headquartered in Paris, working
on HIV Cure and inflammatory diseases, (ii) Intrivo Diagnostic, (iii) Mirum Pharmaceuticals Inc. (Nasdaq: MIRM), where she previously
served as a clinical consultant and still current served as a scientific advisor, (iv) Tobira Therapeutics&#8217;s Board of Directors
from 2009 until it was acquired by Allergan in 2016, (v) Juvaris, a vaccine company acquired by Bayer, and (vi) Renovaro BioSciences
(f/k/a) Enochian BioSciences, a company focusing on a cure for HIV. Dr. Brosgart previously served as a consultant to Theravance Biopharma,
Inc. (Nasdaq: TBPH). Dr. Brosgart served on the scientific advisory board of Immgenuity Inc. and previously served on the scientific
advisory board of Hepion Pharmaceuticals Inc. (Nasdaq: HEPA). Dr. Brosgart current serves on the board of directors of the Hepatitis
B Foundation and previously served on the board of directors of Berkeley Community Scholars and the San Francisco AIDS Foundation. Dr.
Brosgart has previously consulted (i) Dynavax Technologies Corp (Nasdaq: DVAX), Moderna Inc. (Nasdaq: MRNA), (iii) Mirum Pharmaceuticals
Inc. (Nasdaq: MIRM), (iv) Pardes Biosciences Inc. (Nasdaq: PRDS), and (v) Hepion Pharmaceuticals Inc. (Nasdaq: HEPA). Dr. Brosgart received
a B.S. in Community Medicine from the University of California, Berkeley and received an M.D. from the University of California, San
Francisco. Her residency training was in pediatrics, public health and preventive medicine at UCSF and UC Berkeley School of Public Health.
She has published extensively in the areas of HIV, HBV, CMV, and liver disease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 99; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no family relationships between any director or executive officer. There are no arrangements or understandings with major shareholders,
customers, suppliers or others, pursuant to which any director or executive officer was selected as a director or member of senior management,
as the case may be.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Scientific
Advisory Board</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
seek advice from our Scientific Advisory Board generally on scientific and medical matters. Our Scientific Advisory Board includes the
following: Professor Vlad Ratziu from the University Pierre et Marie Curie in Paris, France and coordinator of the EU FP7 FLIP consortium;
Professor Scott Friedman from the Icahn School of Medicine at Mount Sinai in New York, United States; Professor Arun Sanyal, from the
Virginia Commonwealth University in Richmond, Virginia; Professor Jose Mato, from CIC bioGUNE Spain; and Professor Shomron Ben-Horin,
Chief of the Gastroenterology Department at Sheba Medical Center.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.
Compensation.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Certain
Approvals Required for Office Holders&#8217; Compensation of the Companies Law</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Companies Law, the Company is required to adopt a compensation policy regarding the terms of office and employment of its Office
Holders (as such terms are defined below), which includes exemption and release of the Office Holders from liability for breach of his
or her duty of care to the Company, an undertaking to indemnify the Office Holder, post factum indemnification or insurance; any grant,
payment, remuneration, compensation, or other benefit provided in connection with termination of service; and any benefit, other payment
or undertaking to provide any payment as aforesaid, or the Terms of Office and Employment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s current amended and restated compensation policy with respect to the terms of office and employment of the Company&#8217;s
Office Holders, or the Compensation Policy, was adopted by the Board on May 30, 2023, and will remain in effect for a period of three
years according to the Companies Law, unless replaced prior. The Compensation Policy was approved in accordance with the mechanism set
forth in the Companies Law, which allows the Board to approve the Compensation Policy, notwithstanding the resolution of the general
meeting on May 11, 2023, provided that the remuneration committee and thereafter the Board have concluded, following further and detailed
discussion of the matter and for specified reasons, that such approval is in the Company&#8217;s best interests. To that end, the remuneration
committee and our Bord considered the results of the general meeting vote, details of the Compensation Policy and its alignment with
the Company&#8217;s compensation philosophy and other relevant considerations and thereafter determined that the approval of the Compensation
Policy is in the best interest of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
term &#8216;Office Holder&#8217; as defined in the Companies Law includes a general manager, chief business manager, deputy general manager,
vice general manager, any other person fulfilling or assuming the responsibilities of any of the foregoing positions without regard to
such person&#8217;s title, as well as a director, or a manager directly subordinate to the general manager or the chief executive officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Companies Law, arrangements between the Company and its Office Holders must generally be approved by the remuneration committee
and the Board and be consistent with the Compensation Policy. However, under certain circumstances, the Company may approve an arrangement
that is not consistent with the Compensation Policy, if such arrangement is approved by a majority of the Company&#8217;s shareholders,
provided that (i) such majority includes a majority of the votes cast by shareholders who are not controlling shareholders and who do
not have a personal interest in the matter, present and voting (abstentions are disregarded), or (ii) the votes cast by shareholders
who are not controlling shareholders and who do not have a personal interest in the matter who were present and voted against the arrangement
constitute two percent or less of the voting power of the company, or the Special Majority.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 100; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
terms of office and employment of directors (including an officer who is a director but is not a controlling shareholder) further require
the approval of the shareholders by a simple majority in addition to the approval of the Remuneration Committee and the Board, in that
order, and under certain circumstances, a Special Majority; with respect to a chief executive officer who is not also a director or an
officer who is a controlling shareholder, the approval of the shareholders must be made by the Special Majority. In addition, under certain
circumstances, a company may be temporarily exempt from receiving the shareholders&#8217; approval with respect to the terms of office
and employment of a non-affiliated candidate for chief executive officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
certain circumstances, if the terms of office and employment of Office Holders (who are not directors or controlling shareholders) are
not approved by the shareholders, where such approval is required, the remuneration committee and the Board may subsequently override
the resolution of the shareholders following a new discussion of the matter and for specified reasons. In addition, amendment of terms
of office and employment of Office Holders (who are not directors or controlling shareholders) requires the approval of the remuneration
committee only, if the remuneration committee determines that the amendment is not material.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Aggregate
Executive Compensation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate compensation, including share-based compensation, paid by us to all of our Office Holders as a group, with respect to the year
ended December 31, 2024, was approximately $3.05 million. This amount includes approximately $0.3 million set aside or accrued to provide
pension, severance, retirement, vacation or similar benefits or expenses, but does not include business travel, relocation, professional
and business association dues and expenses reimbursed to Office Holders, and other benefits commonly reimbursed or paid by companies
in our industry. In addition to the five current members of the Board (including the Company&#8217;s President and Chief Executive Officer),
the Company considers four other individuals, namely, the Company&#8217;s directors that are members of the audit and remuneration committees,
Chief Financial Officer, Chief Accounting Officer and the Chief Operating Officer, to have been Office Holders in 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, options to purchase 17,228 of our ordinary shares granted to our Office Holders as a group were outstanding, of
which options to purchase 16,439 of our ordinary shares have vested, with a weighted average exercise price of $517.4 per ordinary share
and 178,055 restricted share units, or RSUs granted to our Office Holders were outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
outstanding equity-based awards granted to our Office Holders, see below under &#8220;Item 6. Directors, Senior Management and Employees&#8212;E.
Share Ownership&#8212;Certain Information Concerning Equity Awards to Office Holders.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 101; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Individual
Compensation of Covered Executives</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the compensation granted to the five most highly compensated Office Holders during or with respect to the
year ended December 31, 2024. All amounts reported in the table reflect the cost to the Company, as recognized in its financial statements
for the year ended December 31, 2024. The five individuals for whom disclosure is provided are referred to herein as &#8220;Covered Executives.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Information Regarding the</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Covered Executives</p></td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="22" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation for Services<sup>(1)</sup></b></span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Base</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Benefits and</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Cash</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Equity-Based</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Salary</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Perquisites</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Bonus</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Compensation</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Other</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name and Principal Position<sup>(1)</sup></b></span></td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)<sup>(2)</sup></b></span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)<sup>(3)</sup></b></span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)<sup>(4)</sup></b></span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)<sup>(5)</sup></b></span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Allen Baharaff (President and Chief Executive Officer)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">553,275</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">149,885</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">723,956</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">242,420</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">40,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">1,709,536</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Yohai Stenzler (Chief Accounting Officer)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">168,586</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">51,118</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">78,403</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">55,883</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">353,991</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Guy Nehemya (Chief Operating Officer and Data Protection Officer)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">168,586</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">47,358</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">78,403</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">55,883</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">350,230</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Doron Cohen (Chief Financial Officer)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">146,455</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">37,527</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">68,111</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">43,153</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">295,246</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Amir Poshinski / Shmuel Nir/ David Sidransky (Directors)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22,854</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">72,854</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    above-mentioned executives are all full-time employee of the Company. Cash compensation amounts denominated in currencies other than
    the Dollar were converted into Dollars at an exchange rate of NIS 3.69= $1.00, which reflects the average conversion rate for fiscal
    year ended December 31, 2024.</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amounts
    reported in this column include benefits and perquisites, including those mandated by applicable law. Such benefits and perquisites
    may include, to the extent applicable to the Covered Executives, payments, contributions and/or allocations for savings funds, pension,
    severance, vacation, car allowance, risk insurance (e.g., life, disability, accident), telephone, convalescence pay, payments for
    social security and other benefits and perquisites consistent with the Company&#8217;s policies.</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amounts
    reported in this column represent the expense recorded in the Company&#8217;s financial statements for the year ended December 31,
    2024 with respect to equity-based compensation. Assumptions and key variables used in the calculation of such amounts are discussed
    in Note 10 to the Financial Statements. For outstanding equity-based awards granted to Covered Executives see below under &#8220;Item
    6. Directors, Senior Management and Employees&#8212;E. Share Ownership&#8212;Certain Information Concerning Equity Awards to Office
    Holders.&#8221;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amounts
    reported in this column refer to the cash bonuses provided by the Company with respect to 2024, which have been provided for in the
    Company&#8217;s financial statements for the year ended December 31, 2024 (including if such bonuses were paid in 2025). They exclude
    bonuses paid in 2023 which were provided for in the Company&#8217;s financial statements for previous years. Cash bonuses are paid
    in accordance with the Company&#8217;s 2023 Annual Cash Bonus Plan and are intended to promote the Company&#8217;s work plan and
    business strategy by rewarding officers for achievement of the Company&#8217;s business and financial goals through teamwork and
    collaboration. Key performance indicators which are factored into cash bonus determinations are based both on personal</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amounts
    reported in this column include payments made with respect to the year 2024 and recorded in the financial statements for the year
    ended December 31, 2024 relating to directors&#8217; fees.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>


<!-- Field: Page; Sequence: 102; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Compensation
of Directors</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
approved by our shareholders at our 2020 annual meeting of shareholders, in connection with their services as directors of the Company,
each of our directors from time to time, is entitled to an annual payment of $40,000, plus value-added tax, or VAT, if applicable, and
with respect to an expert external director (if applicable), $50,000 plus VAT, payable quarterly at the end of each quarter, and, upon
first becoming a member of the Board. As approved by our shareholders at our 2023 special meeting of shareholders, (i) each of our non-management
directors, except Dr. Carol L. Brosgart, received a grant of RSUs to purchase 75,000 ordinary shares, or the Director RSUs. The
Director RSUs were granted under the 2013 Plan and (ii) our director, Dr. Carol L. Brosgart, received a grant of options to purchase
75,000 ordinary shares, or the Director Options. The Director Options were granted under the 2013 Plan at an exercise price equal to
$0.92, the closing price of our Ordinary Shares on the Nasdaq Stock Market on August 6, 2023, the day prior to the meeting of the Board
approving such grant. The Director RSUs and the Director Options vest over a period of three years, such that Director RSUs and the Director
Options will vest with respect to 1/3 of the underlying Ordinary Shares on the first anniversary of the grant (i.e., the date of the
Board&#8217;s approval on August 7, 2023), and thereafter, Director RSUs and the Director Options will vest with respect to the additional
2/3 of the underlying ordinary shares on an equally quarterly basis, provided that each non-management director continues to serve as
a director of us or our affiliates throughout each such vesting date. All unvested options held by a non-management director in office
will automatically vest and become exercisable upon the consummation of a Transaction, as such term is defined in the 2013 Plan. The
grant is subject to the execution by each director of an option agreement with us confirming the terms and conditions applying to the
grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board has determined that each of Mr. Nir, Mr. Poshinski, and Dr. Sidransky are entitled to receive compensation equivalent to what an
&#8216;expert external director&#8217; would have received. See also &#8220;Item 6. Directors, Senior Management and Employees&#8212;C.
Board Practices&#8212;External Directors&#8221; and &#8220;Item 7. Major Shareholders and Related Party Transactions&#8212;C. Related
Party Transactions&#8221; below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the outstanding equity-based awards granted to our directors, see below under &#8220;Item 6. Directors, Senior Management and Employees&#8212;E.
Share Ownership&#8212;Certain Information Concerning Equity Awards to Office Holders.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employment
Agreements and Arrangements with Directors and Related Parties</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
entered into written employment agreements with each of our executive officers. These agreements provide for notice periods of varying
duration for termination of the agreement by us or by the relevant executive officer, during which time the executive officer will continue
to receive base salary and benefits. These agreements also contain customary provisions regarding non-competition, confidentiality of
information and assignment of inventions. However, the enforceability of the non-competition and assignment of inventions provisions
may be limited under applicable law. See &#8220;Item 3. Key Information&#8212;Risk Factors&#8212;Risks Related to Our Business, Industry
and Regulatory Requirements.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employment
Agreement with Our President and Chief Executive Officer</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 30, 2013, we entered into a personal employment agreement with our controlling shareholder, Mr. Allen Baharaff who serves as
our president and chief executive officer and as the chairman of our Board, as amended on March 15, 2016, July 20, 2017, August 1, 2019,
and August 30, 2021 which provides that Mr. Baharaff&#8217;s terms of office and employment are for an undefined term, subject to re-approval
under the Companies Law and termination in accordance with the terms of the employment agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the current terms of his employment agreement, Mr. Baharaff is entitled to a gross monthly salary of NIS 170,000, following shareholder
approval which was obtained at our 2021 annual meeting of shareholders. In addition, Mr. Baharaff will be entitled to an annual cash
bonus based on achievement of qualitative and quantitative performance goals and objectives. As approved at our 2021 annual meeting of
shareholders the annual cash bonus amount may be of up to six times Mr. Baharaff&#8217;s monthly base salary, and the actual bonus paid
in a given year shall be determined based on the achievement of certain qualitative and quantitative performance goals and objectives
set by our remuneration committee and Board, which effective as of January 1, 2022, does not require further shareholder approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 103; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Baharaff is also entitled to receive the following bonuses (i) upon execution of a Strategic Agreement (as defined below), and subject
to the discretion of the Board, a cash bonus in an amount of up to twelve times his monthly base salary. A &#8220;Strategic Agreement&#8221;
means: a license agreement or any other strategic agreement (i.e. research and development, manufacture, distribution, etc.) for the
U.S., Europe, Japan or China; (ii) upon consummation of a fund raising (excluding funds received from a Strategic Agreement), and, subject
to the discretion of the Board, a cash bonus in an amount of up to ten times his monthly base salary if the funds received by the Company
are between $8 Million to $10 million and up to twelve times his monthly base salary if the funds received by the Company are $10 million
or more; (iv) upon a Change of Control Event (as defined below), and, subject to the discretion of the Board, a cash bonus in an amount
of up to twelve times his monthly base salary, a &#8220;Change of Control Event&#8221; means: (a) the acquisition of the Company by another
entity or individual or group of individuals by means of any transaction or series of related transactions (including, without limitation,
any reorganization, merger, share purchase or consolidation), unless the Company&#8217;s shareholders of record as constituted immediately
prior to any such transaction will, immediately after such transaction (by virtue of securities issued as consideration for the Company&#8217;s
share capital, assets or otherwise) hold more than 50% of the voting power of the surviving or acquiring entity; or (b) a sale of all
or substantially all of the assets of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Baharaff will also be entitled to the following equity based compensation: (i) in the event that our options are cashed-out upon a Change
of Control Event, all unvested options granted to Mr. Baharaff will vest immediately prior to the consummation of the Change of Control
Event; (ii) if upon a Change of Control Event (a) Mr. Baharaff&#8217;s employment as chief executive officer of the Company or the surviving
entity is terminated within twelve months as of the Change of Control Event, and (b) unvested options are replaced for new options of
the surviving entity as part of the Change of Control Event with a vesting schedule and terms identical to the replaced options, or the
Replacement Options, then (x) all unvested Replacement Options granted to Mr. Baharaff will vest immediately prior to the termination
of Mr. Baharaff&#8217;s employment, and (y) Mr. Baharaff&#8217;s Replacement Options will be exercisable until the earlier of (a) two
years from termination, and (b) expiration of the Replacement Options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Baharaff will also receive other benefits required under Israeli law or that are customary for senior executives in Israel such as confidentiality,
reimbursement of expenses, payment for absence days, sick leave, pension and/or a manager&#8217;s insurance policy and study fund.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Baharaff is also entitled to accumulate vacation days for no more than two years. As approved at our 2021 annual meeting of shareholders,
unused accumulated vacation days that exceed the number of vacation days that may be accumulated over a two-year period (currently, 48
vacation days) shall be redeemed once a year, on March 1, provided that the redemption will not result in the number of accumulated vacation
days following the redemption being less than 48 days, or as otherwise required by law. Accumulated vacation days shall also be redeemed
in the event of termination of employment of Mr. Baharaff.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Baharaff&#8217;s employment agreement is terminable by either party upon six months prior written notice, or Prior Notice Period, and
contains customary provisions regarding noncompetition, confidentiality of information and assignment of inventions. Upon termination,
provided such termination was not for cause, Mr. Baharaff shall be entitled, in addition to the Prior Notice Period, to a payment in
an amount of up to twelve times his monthly base salary, to be paid in twelve equal monthly installments, in exchange for Mr. Baharaff&#8217;s
undertaking not to compete with the Company for a period of twelve months, or Non-Compete Grant. Other than in case of resignation by
Mr. Baharaff, excluding resignation for a Good Reason Event (as defined below), or termination for cause: (i) all Mr. Baharaff&#8217;s
unvested options will vest upon termination; and (ii) unexercised options granted to Mr. Baharaff may be exercised until the earlier
of (a) two years from his termination, and (b) expiration of his options. A &#8220;Good Reason Event&#8221; means: any of the following
events, provided that the event is effected by the Company without the written consent of Mr. Baharaff: (i) a material reduction or adverse
change in Mr. Baharaff&#8217;s authority, duties or responsibilities; (ii) a reduction in Mr. Baharaff&#8217;s monthly base salary, other
than a reduction of no more than 10% of his then current monthly base salary as part of an across the board reduction in all salaries
for employees of the Company; (iii) a material breach by the Company of Mr. Baharaff&#8217;s employment agreement or any other agreements
pertaining directly to Mr. Baharaff&#8217;s compensation or employment or (iv) death, disability or severe illness. Upon termination
for cause by the Company, Mr. Baharaff shall not be entitled to any Prior Notice Period, Non-Compete Grant or any other payment, and
any unvested outstanding equity awards shall terminate immediately upon the date of such termination for cause.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
cash bonuses granted to Mr. Baharaff see &#8220;Item 6. Directors, Senior Management and Employees&#8212; B. Compensation&#8212;Individual
Compensation of Covered Executives.&#8221; For outstanding equity-based awards granted to Mr. Baharaff see below under &#8220;Item 6.
Directors, Senior Management and Employees&#8212;E. Share Ownership&#8212;Certain Information Concerning Equity Awards to Office Holders.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 104; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.
Board Practices.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are incorporated in Israel, and, therefore, we are subject to various corporate governance practices under Israeli law relating to such
matters as external directors (if required), independent directors, audit committees, remuneration committees and internal auditors.
These Israeli law requirements are in addition to the requirements of the Nasdaq Listing Rules and other relevant provisions of U.S.
securities laws. Under such Nasdaq Listing Rules, a foreign private issuer may generally follow its home country practices for corporate
governance in lieu of such comparable listing rules&#8217; requirements, except for certain matters such as composition and responsibilities
of the audit committee and the SEC-mandated standards for the independence of its members. See below under &#8220;Item 16G. Corporate
Governance&#8221; for further information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Membership
of the Board</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Articles provide that the minimum number of members of the Board is three and the maximum number of members is eleven. The Board is presently
comprised of five members. Pursuant to regulations <span style="background-color: white">promulgated under the Companies Law,</span>
or the Relief Regulations, companies with no controlling shareholder whose shares are listed for trading on specified exchanges outside
of Israel, including the Nasdaq Capital Market, may adopt exemptions from various corporate governance requirements of the Companies
Law so long as the company satisfies the applicable foreign country laws and regulations, including applicable stock exchange rules,
that apply to companies organized in that country relating to the appointment of independent directors and the composition of audit and
remuneration committees. Such exemptions include an exemption from the requirement to appoint external directors and the requirement
that an external director be a member of the audit and remuneration committees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2020, our Board adopted this exemption , and our directors then in office who were elected and classified as an external director,
were no longer classified as such under the Companies Law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
minimum and maximum number of directors may be changed, at any time and from time to time, by a majority vote of our directors then in
office, provided that no decrease in the number of directors shall shorten the term of any incumbent director. Under our Articles, the
Board consists of three classes of directors which are appointed for fixed terms of office in accordance with the Companies Law and our
Articles, with one class being elected each year for a term of approximately three years by our shareholders at our annual general meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors
so elected cannot be removed from office by the shareholders until the expiration of their term of office. The directors do not receive
any benefits upon the expiration of their term of office.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
three classes of directors are Class I Directors, Class II Directors and Class III Directors. Shmuel Nir and Dr. Carol Brosgart serve
as our Class I Directors until the close of the annual general meeting to be held in 2027; Allen Baharaff serves as our Class II Director
until the close of the annual general meeting to be held in 2025; and Dr. David Sidransky and Amir Poshinski serve as our Class III Directors
until the close of the annual general meeting to be held in 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with the Articles, any vacancies on the Board of, including unfilled positions, may be filled by a vote of a majority of the
directors then in office, and each director chosen in this manner would hold office until the next annual general meeting of the Company
(or until the earlier termination of his or her appointment as provided for in the Companies Law or the Articles).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
amendment of our Articles regarding the election of directors, as described above, requires the affirmative vote of at least 75% of the
voting rights in the Company, represented personally or by proxy and voting thereon at a general meeting. See &#8220;Item 6. Directors,
Senior Management and Employees&#8212;C. Board Practices&#8212;External Directors&#8221; for a description of the procedure for the election
of external directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
nominee for service as a director in a public company may not be elected without submitting a declaration to the company, prior to election,
specifying that he or she has the requisite qualifications to serve as a director, independent director or external director (if required),
as applicable, and the ability to devote the appropriate time to performing his or her duties as such.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 105; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
director, who ceases to meet the statutory requirements to serve as a director, external director or independent director, as applicable,
must notify the company to that effect immediately and his or her service as a director will expire upon submission of such notice.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Alternate
Directors</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Articles provide, as allowed by the Companies Law, that any director may, subject to the conditions set thereto, appoint a person as
an alternate to act in his place, to remove the alternate and appoint another in his place and to appoint an alternate in place of an
alternate whose office is vacated for any reason whatsoever. Under the Companies Law, a person who is not qualified to be appointed as
a director, a person who is already serving as a director or a person who is already serving as an alternate director for another director,
may not be appointed as an alternate director. Nevertheless, a director who is already serving as a director may be appointed as an alternate
director for a member of a committee of the board of directors so long as he or she is not already serving as a member of such committee.
A person who is not qualified to be appointed as an independent director, pursuant to the Companies Law, may not be appointed as an alternate
director of an independent director qualified as such under the Companies Law. Unless the appointing director limits the time or scope
of the appointment, the appointment is effective for all purposes until the appointing director ceases to be a director or terminates
the appointment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>External
Directors</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Generally,
unless a regulatory relief is available, under the Companies Law and the regulations promulgated pursuant thereto, Israeli companies
whose shares have been offered to the public, or that are publicly traded outside of Israel, which we refer to as a public company, are
required to appoint at least two natural persons as &#8220;external directors.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
the Relief Regulations, companies with shares traded on certain U.S. stock exchanges, including Nasdaq, which do not have a &#8220;controlling
shareholder,&#8221; may, subject to certain conditions, &#8220;opt out&#8221; from the Companies Law requirements to appoint external
directors and related Companies Law rules concerning the composition of the audit committee and remuneration committee of the board of
directors. In accordance with these regulations, in March 2020, our Board elected to &#8220;opt out&#8221; from the Companies Law requirement
to appoint external directors and related Companies Law rules concerning the composition of the audit committee and remuneration committee
of our Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Director
Independence</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
our &#8220;opt-out&#8221; of the requirement to have external directors serving on our Board, we comply with the director independence
requirements and the audit committee and the remuneration committee composition requirements under U.S. laws (including applicable Nasdaq
Capital Market rules) applicable to U.S. domestic issuers. Our Board has undertaken a review of the independence of each director. Based
on information provided by each director concerning their background, employment and affiliations, our Board has determined that Mr.
Nir, Mr. Poshinski, Dr. Sidransky, and Dr. Brosgart do not have a relationship that would interfere with the exercise of independent
judgment in carrying out the responsibilities of a director and that each of these directors is &#8220;independent&#8221; as that term
is defined under the listing standards of the Nasdaq. In making these determinations, our Board considered the current and prior relationships
that each non-employee director has with our company and all other facts and circumstances our Board deemed relevant in determining their
independence, including the beneficial ownership of our capital shares by each non-employee director.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Committees
of the Board</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Articles also provide that the Board may delegate any, or all, of its powers to one or more committees of the Board, and may entrust
to and confer upon a &#8220;managing director&#8221; such of its powers as it deems appropriate. However, the Companies Law provides
that certain powers and authorities (for example, the power to approve the financial statements) may not be delegated and may be exercised
only by the Board. Notwithstanding the foregoing, we currently do, and intend to continue to, comply with the corporate governance requirements
of the Nasdaq Capital Market, except to the extent indicated elsewhere in this annual report, including as set forth under &#8220;Item
16G. Corporate Governance&#8221; below. The Companies Law requires public companies such as the Company to appoint an audit committee
and a remuneration committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 106; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Audit
Committee</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Companies Law requires public companies to appoint an audit committee comprised of at least three directors, including all of the external
directors, if any the majority of whom must be independent directors under the Companies Law. The Companies Law further stipulates that
the following may not be members of the audit committee: (i) the chairman of the board of directors; (ii) any director employed by or
providing services on an ongoing basis to the company, to a controlling shareholder of the company or an entity controlled by a controlling
shareholder of the company; (iii) a director whose livelihood mainly depends on a controlling shareholder; and (iv) a controlling shareholder
or any relative of a controlling shareholder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Companies Law further requires that: (i) the chairperson of the audit committee must be an external director; (ii) generally, any person
who is not entitled to be a member of the audit committee may not attend the audit committee&#8217;s meetings and voting sessions, unless
such person was invited by the chairperson of the committee for the purpose of presenting a specific subject matter thereof; and (iii)
the quorum required for the convening of meetings of the audit committee and for adopting resolutions by the audit committee is a majority
of the members of the audit committee, provided that the majority of the members present are independent directors and at least one of
them is an external director. As noted, under the Relief Regulation, companies with no controlling shareholder whose shares are listed
for trading on specified exchanges outside of Israel, including the Nasdaq Capital Market, may adopt exemptions from various corporate
governance requirements of the Companies Law so long as the company satisfies the applicable foreign country laws and regulations, including
applicable stock exchange rules, that apply to companies organized in that country relating to the appointment of independent directors
and the composition of audit and remuneration committees. Such exemptions include an exemption from the requirement to appoint external
directors and the requirement that an external director be a member of certain committees. In accordance with these Regulations, we elected
to &#8220;opt out&#8221; from such requirements of the Companies Law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
responsibilities of the audit committee under the Companies Law include: (i) identifying flaws in the management of a company&#8217;s
business and making recommendations to the board of directors as to how to correct them; (ii) with respect to certain actions involving
conflicts of interest and with respect to certain related party transactions, deciding whether such actions are material actions and
whether such transactions are extraordinary transactions, respectively, all for the purpose of approving such actions or transactions;
(iii) reviewing and deciding whether to approve certain related party transactions and certain actions involving conflicts of interest;
(iv) reviewing the internal auditor&#8217;s work program; (v) examining the company&#8217;s internal control structure and processes,
the performance of the internal auditor and whether the internal auditor has at his or her disposal the tools and resources required
to perform his or her duties, considering, inter alia, the special needs of the company and its size; (vi) examining the independent
auditor&#8217;s scope of work as well as the independent auditor&#8217;s fees and providing its recommendations to the appropriate corporate
organ; (vii) providing for arrangements as to the manner in which the company will deal with employee complaints with respect to deficiencies
in the management of the company&#8217;s business and the protection to be provided to such employees; and (viii) with respect to related
party transactions with a controlling shareholder, regardless of whether such transactions are extraordinary transactions, that prior
to entering into such transaction, to establish the requirement of having a competitive process under the supervision of the audit committee
or any individual, committee or body on its behalf and according to criteria established by the audit committee and to determine procedures
for approving certain related party transactions with a controlling shareholder, which were determined by the audit committee to be non-extraordinary
transactions, but which are not negligible transactions. In addition, the audit committee is required to supervise the manner the Company
implements the requirements of the Privacy Protection Law, 1981 and the Privacy Protection Regulations (Data Security), 2017.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board has adopted an audit committee charter setting forth the responsibilities of the audit committee consistent with the rules of the
SEC and the Nasdaq Listing Rules, as well as the requirements for such committee under the Companies Law, as described below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audit committee oversees the accounting and financial reporting processes of the Company. It also provides assistance to the Board in
fulfilling its legal and fiduciary obligations with respect to matters involving the accounting, auditing, financial reporting and internal
control functions of the Company. In carrying out its duties, our audit committee meets with management at least once a quarter, at which
time, among other things, it reviews, and either approves or disapproves, the financial results of the Company for the immediately preceding
calendar quarter and conveys its conclusions in this regard to the Board. Our audit committee also monitors generally the services provided
by the Company&#8217;s independent auditors to ensure their independence and reviews all audit and non-audit services provided by them.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 107; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board has resolved to delegate to the audit committee the power to pre-approve non-auditing services rendered by the Company&#8217;s
independent auditors without the need for further approval by our Board. As such, on March 15, 2016, our audit committee approved the
adoption of a pre-approval policy, such that the Chairman of the audit committee is authorized to pre-approve any engagement of our independent
auditors during a period of twelve months from the date of such approval, for the provision of non-auditing services, for fees not to
exceed $20,000, and any such engagement which exceeds $20,000 shall require a pre-approval by the entire audit committee. Once services
have been pre-approved, our management must then report to the audit committee on a periodic basis regarding the extent of services actually
provided in accordance with the pre-approval policy, and regarding the fees for the services performed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s independent and internal auditors also report regularly to our audit committee, and our audit committee discusses with
the Company&#8217;s independent auditors the quality, not just the acceptability, of the accounting principles, the reasonableness of
significant judgments and the clarity of disclosures in the Company&#8217;s financial statements, as and when it deems it appropriate
to do so.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the provisions of the Sarbanes-Oxley Act, the audit committee is directly responsible for the appointment, compensation and oversight
of the work of the company&#8217;s independent auditors. However, under Israeli law, the appointment of independent auditors and their
compensation require the approval of the shareholders of a public company. Pursuant to Israeli law, the shareholders may delegate the
authority to determine the compensation of the independent auditors to the board of directors. In addition, pursuant to the Companies
Law, the audit committee is required to examine the independent auditors&#8217; fees and to provide its recommendations with respect
thereto to the appropriate corporate body. Accordingly, the appointment of our independent auditors is required to be approved and recommended
to the shareholders by our audit committee and Board and approved by the shareholders. The compensation of the independent auditors for
audit services is required to be approved and recommended to the Board by our audit committee and approved by the Board. The Board has
delegated its authority to approve the compensation of independent auditors for non-auditing services to the audit committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Nir, Mr. Poshinski and Dr. Sidransky are the current members of our audit committee, with Mr. Poshinski serving as chairperson. Each
of our audit committee members are &#8220;independent directors&#8221; in accordance with the Nasdaq Capital Market corporate governance
requirements, as affirmatively determined by our Board. In addition, our Board has affirmatively determined that Mr. Poshinski also qualifies
as an audit committee financial expert pursuant to the applicable SEC rules, and accordingly has the necessary financial sophistication
as required by the Nasdaq Capital Market rules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Remuneration
Committee</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Companies Law requires public companies to appoint a remuneration committee comprised of at least three directors, including all of the
external directors, who must generally also constitute a majority of the members. All other members of the committee, who are not external
directors, must be directors who receive compensation consistent with that of external directors and that is in compliance with the compensation
related regulations promulgated under the Companies Law. In addition, the chairperson of the remuneration committee must be an external
director. As noted, under the Relief Regulations, we elected to &#8220;opt out&#8221; from such requirements of the Companies Law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Companies Law further stipulates that directors who are not qualified to serve on the audit committee, as described above, may not serve
on the remuneration committee either and that similar to the audit committee, generally, any person who is not entitled to be a member
of the remuneration committee may not attend the remuneration committee&#8217;s meetings. Our Board has adopted a remuneration committee
charter setting forth the responsibilities of our remuneration committee, as described below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 108; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
responsibilities of the remuneration committee under the Companies Law include: (i) making recommendations to the board of directors
with respect to the approval of the compensation policy and any extensions thereto; (ii) periodically reviewing the implementation of
the compensation policy and providing the board of directors with recommendations with respect to any amendments or updates thereto;
(iii) reviewing and resolving whether or not to approve transactions with respect to the terms of office and employment of Office Holders;
and (iv) resolving, under certain circumstances prescribed under the Companies Law, whether or not to exempt a transaction with a candidate
for chief executive officer who meets non-affiliation criteria from shareholder approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
remuneration committee also oversees the administration of the Company&#8217;s various compensation plans and arrangements, in particular,
the incentive compensation, deferred compensation and equity based plans of the Company (and to the extent appropriate, of the subsidiaries
of the Company) and assists the Board in fulfilling its responsibilities relating to the compensation of directors, the Chief Executive
Officer and other Office Holders of the Company. In carrying out these duties, our remuneration committee meets on an ad hoc basis. Under
the Companies Law, our remuneration committee may need to seek the approval of the Board and the shareholders for certain compensation
decisions as described above. Each member of our remuneration committee is an &#8220;independent director&#8221; in accordance with the
Nasdaq Capital Market corporate governance requirements, as affirmatively determined by our Board. Mr. Nir, Mr. Poshinksi and Dr. Sidransky
are the current members of our remuneration committee, with Dr. Sidransky serving as chairperson.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Compensation
Policy</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
approved by our shareholders, and as required by the Companies Law, we have adopted a Compensation Policy regarding the terms of office
and employment of our &#8220;office holders&#8221; (as defined under the Companies Law, which includes directors, the CEO, other executive
officers and any other managers directly subordinate to the CEO), including cash compensation, equity-based awards, releases from liability,
indemnification and insurance, severance and other benefits. Each of the named executive officers is an &#8220;office holder&#8221; within
the meaning of the Companies Law. The Compensation Policy is reviewed from time to time by our remuneration committee and our Board to
ensure its appropriateness, and is required to be brought at least once every three years to our shareholders for approval. See &#8220;Item
6. Directors, Senior Management and Employees &#8212; B. Compensation &#8212; Certain Approvals Required for Office Holders&#8217; Compensation
of the Companies Law&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
current Compensation Policy was approved and adopted on May 30, 2023 and will be in effect for a period of three years until May 29,
2026, unless replaced in accordance with the Companies Law prior. The Compensation Policy links pay to performance and aligns our executive
officers&#8217; interests with those of the Company and of our shareholders. It allows us to provide meaningful incentives that reflect
both our short and long-term goals and performance, as well as the executive officers&#8217; individual performance and impact on shareholder
value, while providing compensation that is competitive in the global marketplace in which we recruit talent and is designed to reduce
incentives for our executive officers to take excessive risks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Compensation Policy emphasizes each executive officer&#8217;s individual characteristics (such as his or her respective position, education,
scope of responsibilities and contribution to the attainment of our goals) as the basis for compensation variation among executive officers,
taking into account the internal ratios between compensation of our executive officers and directors and other employees of the Company.
Pursuant to the Compensation Policy, the compensation that may be granted to an executive officer may include: base salary and benefits,
annual cash bonuses and other cash bonuses (such as retention and special bonuses), as well as equity-based compensation, retirement
and termination of employment benefits, change of control provisions and other benefits. The cash bonuses that may be granted under the
Compensation Policy are limited to a maximum amount linked to the executive officer&#8217;s base salary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Compensation Policy, an annual cash bonus that will be awarded to executive officers (other than the CEO) will be based on performance
objectives and a discretionary evaluation of the executive officer&#8217;s overall performance by the CEO and may be subject to minimum
thresholds. The remuneration committee and the Board will determine any applicable minimum thresholds that must be met for entitlement
to the annual cash bonus (all or any portion thereof) and the formula for calculating any annual cash bonus payout on the basis of, but
not limited to, company and individual objectives. Notwithstanding the above, we may determine that, with respect to any executive officer
subordinated to the CEO, which does not serve as a director, a portion or all of his or her annual cash bonus will be based on the evaluation
of the CEO.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 109; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Compensation Policy provides that the annual bonus awarded to the Company&#8217;s CEO will be mainly based on measurable objectives of
the Company, subject to a minimum threshold on the basis of, but not limited to, company and personal objectives. 30% or less of the
annual cash bonus granted to the Company&#8217;s CEO may be based on a discretionary evaluation of the CEO&#8217;s overall performance
by the remuneration committee and the Board. The measurable objectives will be determined annually by the remuneration committee and
the Board at the commencement of each calendar year, or upon engagement, in case of newly hired CEO, or in other special circumstances
as set forth in the Compensation Policy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
equity-based compensation under the Compensation Policy for our executive officers is designed in a manner intended to attract and retain
officers and align their interests with shareholders&#8217; interests to maximize creation of long-term economic value for the Company,
and to strengthen the retention and the motivation of executive officers in the long term. Equity-based awards may be granted from time
to time in the form of options and/or other equity- based awards, such as RSUs in accordance with our 2013 Plan as may be updated from
time to time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Compensation Policy contains compensation recovery provisions in the event of accounting restatement, which would allow us, under certain
conditions, to recover bonuses or performance-based equity paid in excess of what would have been paid under the financial statements,
as restated. The Compensation Policy also contains provisions that allow us to exculpate, indemnify and insure our executive officers
and directors subject to certain updated limitations set forth in the Compensation Policy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Compensation Policy also governs the compensation of our non-management Board members and provides that our directors will be entitled
to an annual cash fee retainer, which shall not exceed US$100,000 plus VAT, or the Maximum Amount, and with respect to an Expert External
Director, as defined in the compensation related regulations promulgated under the Companies Law, plus 33% to the Maximum Amount. Our
non-management Board members may also receive equity awards up to the limits set forth in the Compensation Policy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nominating
Committee</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Nasdaq Capital Market corporate governance requires each company adopting a nominating committee to certify that it has adopted a formal
written charter or board resolution, as applicable, addressing the nominations process and such related matters as may be required under
U.S. federal securities laws. Although not required as a foreign private issuer to adopt a nominating committee, we have decided to follow
such requirement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board has adopted a nominating committee charter setting forth the responsibilities of the nominating committee consistent with the Nasdaq
Listing Rules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
nominating committee is responsible for identifying individuals qualified to be appointed as board members, and recommending to the Board
appropriate director nominees for election at the general meeting of shareholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent
director oversight of nominations enhances investor confidence in the selection of well-qualified director nominees, as well as independent
nominees as required by the rules. The Nasdaq Capital Market listing rule is also intended to provide flexibility for a company to choose
an appropriate board structure and reduce resource burdens, while ensuring that independent directors approve all nominations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Nir, Mr. Poshinski, and Dr. Sidransky are the current members of our nominating committee, with Dr. Sidransky serving as chairperson.
Nasdaq Capital Market Listing Rule 5605(e) requires that our nominating committee be comprised solely of independent directors unless
the nominating committee is comprised of at least three members and the Board determines that such non-independent director&#8217;s membership,
which shall not be longer than two years, is required by the best interests of the Company and our shareholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 110; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>R&amp;D
Committee</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
R&amp;D Committee, which was established by the Board on May 2014, advises and assists the Board in its oversight of our research and
development programs, including the rationale and timeline of clinical trials and other studies, as well as market surveys in connection
therewith. The R&amp;D Committee operates in accordance with the purposes and objectives determined by the Board from time to time. Dr.
Sidransky, Dr. Brosgart and Mr. Baharaff are the current members of our R&amp;D Committee, with Dr. Sidransky serving as chairperson.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Internal
Auditor</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law, the board of directors of an Israeli public company must appoint an internal auditor recommended by the audit committee
and nominated by the board of directors. The role of the internal auditor is to examine, among other things, our compliance with applicable
law and orderly business procedures. An internal auditor should comply with the requirements of the Companies Law and the Internal Audit
Law, 5752-1992, and may not be:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    person (or a relative of a person) who holds more than 5% of the Company&#8217;s outstanding shares or voting rights;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    person (or a relative of a person) who has the power to appoint a director or the general manager of the Company;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    Office Holder, including a director, of the Company (or a relative thereof); or</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    member of the Company&#8217;s independent accounting firm, or anyone on his or her behalf.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Israeli law, an internal auditor&#8217;s tenure cannot be terminated without his or her consent, nor can he or she be suspended from
such position unless the board of directors of the company has so resolved following the recommendations of the company&#8217;s audit
committee and, after providing the internal auditor with the opportunity to present his or her position to the board of directors of
the company and to the audit committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 2, 2024, our Board re-appointed Zachi Refaeli, CPA, from Ernst &amp; Young Israel - Kost Forer Gabbay &amp; Kasierer, Tel Aviv,
Israel, as the Company&#8217;s internal auditor for a period of two years, effective as of April 2, 2026. Mr. Refaeli has been serving
as the Company&#8217;s internal auditor since January 12, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Exculpation
and Indemnification of Directors and Officers</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law, a company may not exculpate an Office Holder from liability for a breach of the duty of loyalty. An Israeli company
may exculpate an Office Holder in advance from liability to the company, in whole or in part, for damages caused to the company as a
result of a breach of the duty of care but only if a provision authorizing such exculpation is included in its articles of association.
Our Articles include such a provision. The Company may not exculpate in advance a director from liability arising out of a prohibited
dividend or distribution to shareholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law, and the Israeli Securities Law, 5738&#8212;1968, or the Securities Law, a company may indemnify, or undertake in advance
to indemnify, an Office Holder for the following liabilities and expenses, imposed on Office Holder or incurred by Office Holder due
to acts performed by him or her as an Office Holder, provided its articles of association include a provision authorizing such indemnification:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    monetary liability incurred by or imposed on him or her in favor of another person pursuant to a judgment, including a settlement
    or arbitrator&#8217;s award approved by a court. However, if an undertaking to indemnify an Office Holder with respect to such liability
    is provided in advance, then such an undertaking must be limited to events which, in the opinion of the board of directors, can be
    foreseen based on the company&#8217;s activities when the undertaking to indemnify is given, and to an amount or according to criteria
    determined by the board of directors as reasonable under the circumstances, and such undertaking shall detail the abovementioned
    foreseen events and amount or criteria;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 111; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reasonable
    litigation expenses, including attorneys&#8217; fees, incurred by the Office Holder as a result of an investigation or proceeding
    instituted against him or her by an authority authorized to conduct such investigation or proceeding, provided that (i) no indictment
    was filed against such Office Holder as a result of such investigation or proceeding; and (ii) no financial liability was imposed
    upon him or her as a substitute for the criminal proceeding as a result of such investigation or proceeding or, if such financial
    liability was imposed, it was imposed with respect to an offense that does not require proof of criminal intent or as a monetary
    sanction;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    monetary liability imposed on him or her in favor of an injured party at an Administrative Procedure (as defined below) pursuant
    to Section 52(54)(a)(1)(a) of the Securities Law;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses
    incurred by an office holder or certain compensation payments made to an injured party that were instituted against an office holder
    in connection with an Administrative Procedure under the Securities Law, including reasonable litigation expenses and reasonable
    attorneys&#8217; fees; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reasonable
    litigation expenses, including attorneys&#8217; fees, incurred by the Office Holder or imposed by a court in proceedings instituted
    against him or her by the company, on its behalf, or by a third-party, or in connection with criminal proceedings in which the Office
    Holder was acquitted, or as a result of a conviction for an offense that does not require proof of criminal intent.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
    &#8220;Administrative Procedure&#8221; is defined as a procedure pursuant to chapters H3 (Monetary Sanction by the Israeli Securities
    Authority), H4 (Administrative Enforcement Procedures of the Administrative Enforcement Committee) or I1 (Arrangement to prevent
    Procedures or Interruption of procedures subject to conditions) to the Securities Law.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law and the Securities Law, a company may insure an Office Holder against the following liabilities incurred for acts performed
by him or her as an Office Holder if and to the extent provided in the company&#8217;s articles of association:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    breach of the duty of loyalty to the company, provided that the Office Holder acted in good faith and had a reasonable basis to believe
    that such act would not prejudice the company;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    breach of the duty of care to the company or to a third-party;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    monetary liability imposed on the Office Holder in favor of a third-party;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    monetary liability imposed on the office holder in favor of an injured party at an Administrative Procedure pursuant to Section 52(54)
    (a)(1)(a) of the Securities Law; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses
    incurred by an office holder in connection with an Administrative Procedure instituted against him or her, including reasonable litigation
    expenses and reasonable attorneys&#8217; fees.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nevertheless,
under the Companies Law, a company may not indemnify, exculpate or insure an Office Holder against any of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    breach of the duty of loyalty, except for indemnification and insurance for a breach of the duty of loyalty to the company in the
    event Office Holder acted in good faith and had a reasonable basis to believe that the act would not prejudice the company;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    breach of the duty of care committed intentionally or recklessly, excluding a breach arising out of the negligent conduct of the
    Office Holder;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    act or omission committed with intent to derive unlawful personal benefit; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    fine, monetary sanction, penalty or forfeit levied against the Office Holder.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 112; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law, exculpation, indemnification and insurance of Office Holders require the approval of the remuneration committee, board
of directors and, in certain circumstances, the shareholders, as described above under &#8220;Item 6<b>&#8212;</b>Directors, Senior Management
and Employees&#8212;B. Compensation.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Articles permit us to exculpate, indemnify and insure our Office Holders to the fullest extent permitted by the Companies Law. Each of
our Office Holders have entered into an indemnification agreement with us, exculpating them, to the fullest extent permitted by Israeli
law, from liability to us for damages caused to us as a result of a breach of the duty of care and undertaking to indemnify them to the
fullest extent permitted by Israeli law, including with respect to liabilities resulting from certain acts performed by such Office Holders
in their capacity as an Office Holder of the Company, our subsidiaries or our affiliates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the opinion of the SEC, indemnification of directors and Office Holders for liabilities arising under the Securities Act, however, is
against public policy and therefore unenforceable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Agreements
with Directors</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than a written agreement with our President, Chief Executive Officer and Chairman, as detailed in &#8220;Item 6. Directors, Senior Management
and Employees&#8212;B. Compensation&#8212;Employment Agreements and Arrangements with Directors and Related Parties&#8212;Employment
Agreement with Our President, Chief Executive Officer and Chairman of the Board,&#8221; we do not have written agreements with any director
providing for benefits upon the termination of his or her services with our Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.
Employees.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, we had six employees, of which three were full-time employees and three were part-time employees. Three of our
employees were involved in our clinical and product development operations and three served in general and administrative capacities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
none of our employees are party to any collective bargaining agreements or represented by any labor unions, certain provisions of the
Israeli labor laws and certain collective bargaining agreements between the Histadrut (General Federation of Labor in Israel) and the
Coordination Bureau of Economic Organizations (including the Industrialists&#8217; Associations) are applicable to our employees by order
of the Israel Ministry of Economics. These provisions primarily concern the length of the workday, minimum daily wages for professional
workers, pension fund benefits for all employees, insurance for work-related accidents, procedures for dismissing employees, determination
of severance pay and other conditions of employment. We generally provide our employees with benefits and working conditions beyond the
required minimums. We have never experienced any employment-related work stoppages and believe our relationship with our employees is
favorable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E.
Share Ownership.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information regarding beneficial ownership of our ordinary shares as of March 21 2025, the latest practicable
date for inclusion in this annual report, held by our directors and executive officers, individually and as a group and beneficial owners
of more than 5% of our outstanding shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficial
ownership is determined in accordance with the rules of the SEC and includes voting or investment power with respect to ordinary shares.
Ordinary shares issuable under share options, warrants or other conversion rights currently exercisable or that are exercisable within
60 days after March 21, 2025 are deemed outstanding for the purpose of computing the percentage ownership of the person holding the options,
or other conversion rights, but are not deemed outstanding for the purpose of computing the percentage ownership of any other person.
Percentage of shares beneficially owned is based <span>o</span>n 2,258,034 ordinary shares outstanding
on March 21, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as otherwise indicated, and subject to applicable community property laws, the persons named in the table have sole voting and investment
power and the right to receive the economic benefit of ownership with respect to all ordinary shares held by that person.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 113; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise stated, the address for our directors and senior management is Galmed Pharmaceuticals Ltd., c/o Meitar Law Offices, 16 Abba
Hillel Road, Ramat Gan, Israel 5250608.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of ordinary</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Percentage of ordinary</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">shares beneficially</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">shares beneficially</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>owned<sup>(1)</sup></b></span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">owned</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">More than 5% Holders</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 56%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CVI Investments, Inc. <sup>(2)</sup></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right">167,258</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right">6.9</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Directors and Executive Officers</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allen Baharaff<sup>(3)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">46,444</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.0</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shmuel Nir<sup>(4)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,893</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. David Sidransky<sup>(5)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,622</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Carol L. Brosgart<sup>(6)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,491</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Liat Hayardeny<sup>(7)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,110</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yohai Stenzler<sup>(8)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,184</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Guy Nehemya<sup>(9)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,073</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amir Poshinski<sup>(10)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,401</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Doron Cohen<sup>(11)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,402</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">All directors and executive officers as a group (9 persons)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">82,620</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.6</td><td style="text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*Less
than 1%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
All options included are either currently exercisable or will be exercisable within 60 days of March 21, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
Based upon information contained in a Schedule 13G/A filed by the shareholder on November 12, 2024. Shares beneficially owned consist
of 167,258 ordinary shares issuable upon the exercise of warrants. The warrants are subject to a beneficial ownership limitation of 9.99%,
which such limitation restricts the holder from exercising that portion of the warrants that would result in the holder and its affiliates
owning, after exercise, a number of ordinary share in excess of the beneficial ownership limitation. Heights Capital Management, Inc.,
the authorized agent of CVI Investments, Inc. (&#8220;CVI&#8221;), has discretionary authority to vote and dispose of the shares held
by CVI and may be deemed to be the beneficial owner of these shares. Martin Kobinger, in his capacity as Investment Manager of Heights
Capital Management, Inc., may also be deemed to have investment discretion and voting power over the shares held by CVI. Mr. Kobinger
disclaims any such beneficial ownership of the shares. The principal business address of CVI is c/o Heights Capital Management, Inc.,
101 California Street, Suite 3250, San Francisco, California 94111.&#160;&#160;&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
Consists of (i) 36,935 ordinary shares held by Mr. Baharaff; and (ii) options to purchase 9,509 ordinary shares that are currently exercisable
within 60 days as of March 21, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
Consists of (i) 3,165 ordinary shares held by Mr. Nir; and (ii) 230 ordinary shares are held through Tushia Consulting Engineers Ltd.,
of which Shmuel Nir is its controlling shareholder and (iii) 498 ordinary shares issuable upon the exercise of options that are currently
exercisable or will be exercisable within 60 days as of March 21, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)
Consists of (i) 3,124 ordinary shares held by Dr. Sidransky; and (ii) 498 ordinary shares issuable upon the exercise of options that
are currently exercisable or will be exercisable within 60 days as of March 21, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)
Consists of 3,491 ordinary shares issuable upon the exercise of options that are currently exercisable or will be exercisable within
60 days as of March 21, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)
Consists of 1,110 ordinary shares issuable upon the exercise of options that are currently exercisable or will be exercisable within
60 days as of March 21, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)
Consists of (i) 6,282 ordinary shares held by Mr. Stenzler; and (ii) 902 ordinary shares issuable upon the exercise of options that are
currently exercisable or will be exercisable within 60 days as of March 21, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 114; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)
Consists of (i) 6,282 ordinary shares held by Mr. Nehemya; and (ii) 791 ordinary shares issuable upon the exercise of options that are
currently exercisable or will be exercisable within 60 days as of March 21, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10)
Consists of (i) 3,124 ordinary shares held by Mr. Poshinski; and (ii) 277 ordinary shares issuable upon the exercise of options that
are currently exercisable or will be exercisable within 60 days as of March 21, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11)
Consists of (i) 6,250 ordinary shares held by Mr. Cohen and (ii) 152 ordinary shares issuable upon the exercise of options that are currently
exercisable or will be exercisable within 60 days as of March 21, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Change
in Control</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
our knowledge, (i) we are not directly or indirectly owned or controlled by another corporation, by any foreign government or by any
other natural or legal person severally or jointly, except as disclosed in the above table regarding our major shareholders, and (ii)
there are no arrangements which would result in our change in control at a subsequent date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Significant
Changes in the Ownership of Major Shareholders</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
our knowledge, other than as disclosed in the table above, our other filings with the SEC and this annual report, there has been no significant
change in the percentage ownership held by any major shareholder since January 1, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Major
Shareholders Voting Rights</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
major shareholders do not have different voting rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Record
Holders</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
our knowledge, as of March 21, 2025, we had 8 holders of record of our ordinary shares with a U.S. address, Cede &amp; Co., the nominee
of The Depository Trust Company. This holder held in the aggregate 2,247,758 ordinary shares, or 99.5% of our outstanding ordinary shares
as of March 21, 2025. The number of record holders in the United States is not representative of the number of beneficial holders of
our ordinary shares nor is it representative of where such beneficial holders are resident since many of these ordinary shares were held
by brokers or other nominees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>2013
Incentive Share Option Plan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
maintain one equity-based incentive plan, our 2013 Plan. As of March 21, 2025, the latest practicable date for inclusion in this annual
report, a total of 500,000 shares were reserved for issuance under our 2013 Plan, of which (1) options to purchase 19,022 ordinary were
issued and outstanding thereunder (i.e., were granted but not canceled, expired or exercised); (2) RSUs to purchase 159,791 ordinary
shares were issued and outstanding; (3) options to purchase 6,050 ordinary shares were exercised and 36,884 ordinary shares were issued
upon vesting of RSUs; (4) options to purchase 17,500 ordinary shares and RSUs to purchase 197,500 ordinary shares were approved
by our Board and are subject to shareholders approval, and (5) 62,489 shares remain unallocated for future equity awards pursuant to
our 2013 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 12, 2024, the board approved a grant of options to purchase 17,500 of our ordinary shares and a grant of 197,500 restricted
share units, subject to the approval of the Company&#8217;s shareholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
2013 Plan, which was adopted by our Board on September 2, 2013, and approved by our shareholders in December 30, 2013 (as amended on
March 30, 2015, May 11, 2015, August 30, 2018 and August 7, 2023), will be in effect until October 4, 2026 and provides for the grant
of options to purchase our ordinary shares and the issuance of RSUs to our officers, directors, employees, service providers and consultants.
Our 2013 Plan provides for such equity-based compensation under various and different tax regimes, including those detailed below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 115; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2013 Plan is administered by our Board, which, on its own or upon the recommendation of our remuneration committee or any other similar
committee of the Board, shall determine, subject to applicable law, the identity of grantees of awards and various terms of the grant.
Consistent with our Compensation Policy, the 2013 Plan provides for granting options to purchase our ordinary shares pursuant to Section
102 of the Israeli Income Tax Ordinance, or the Ordinance, under the capital gains route, to directors, officers and employees who are
Israeli residents holding (or have a right to hold or to purchase) less than 10% of our total share capital and do not have a right to
receive 10% or more of the Company&#8217;s profits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
102 of the Ordinance allows Israeli employees, directors and officers, who are not controlling shareholders to receive favorable tax
treatment for compensation in the form of shares or options. However, under this route we are not allowed to deduct any expense with
respect to the issuance of the options or shares. Israeli non-employee service providers, consultants and shareholders who hold 10% or
more of our total share capital or are otherwise controlling shareholders, may be granted options pursuant to Section 3(i) of the Ordinance,
which does not provide for similar tax benefits. In order to comply with the terms of the capital gains route pursuant to Section 102
of the Ordinance, the granted options as well as the ordinary shares issued upon exercise of these options and other shares received
subsequently following any realization of rights with respect to such options (such as share dividends and share splits), must be granted
to a trustee for the benefit of the relevant grantee and should be held by the trustee for at least two years after the date of the grant.
If such options or shares are sold by the trustee or are transferred to the grantee before the end of the two-year period, then the grantee
would be taxed at top marginal rates upon selling the shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
residents, or deemed residents, of the United States, the 2013 Plan provides grants, which are pursuant to Section 422 of the Internal
Revenue Code of 1986, as amended, or the Code, as incentive stock options, or ISOs, and any other participants which do not qualify for
ISOs, as non-statutory stock options, or NSOs, pursuant to the Code.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
422 of the Code allows employees, directors and officers, who are non-controlling shareholders (e.g., less than 10% shareholders) and
are considered residents of the United States or those who are deemed to be residents of the United States for purposes of the payment
of tax, or are otherwise subject to taxation in the United States with respect to the grant of awards, to receive favorable tax treatment
for compensation in the form of shares or ISOs. 10% shareholders or persons which are not service providers will receive NSOs, which
do not entitle them to receive similar tax benefits. Section 422(b) of the Code provides for the ISO track such that the individual does
not have to pay ordinary income tax (nor employment taxes) on the difference between the exercise price and the fair market value of
the shares issued (however, the holder may have to pay U.S. alternative minimum tax instead). However, if the shares are held for one
year from the date of exercise and two years from the date of grant, then the profit (if any) made on sale of the shares is taxed as
long-term capital gain. Section 422 of the Code requires that any grant of awards shall not be made at a price which is less than 100%
of the fair market value of such awards on the date of the grant, all pursuant to the terms of Section 409A of the Code. However, under
this ISO track, we are not allowed to deduct any expense with respect to the issuance of the options or shares. In order to comply with
the terms of the ISO track, the option granted thereunder must meet the requirements of Section 422 of the Code when granted and at all
times until the exercise thereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
and RSUs granted under the 2013 Plan will vest in accordance with the vesting dates as determined by the Board following the recommendation
of the remuneration committee or any other similar committee of the Board with respect to each grant. Generally, options that are not
exercised within ten years from the grant date expire, unless otherwise determined by the Board and the remuneration committee, as applicable,
provided, however, that, pursuant to our Compensation Policy, any equity-based awards to Office Holders must include both a gradual vesting
period of at least three years from the date of grant, and an exercise period of no more than ten years from the date of grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 116; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
such date or dates designated in the applicable award agreement, unless earlier forfeited, subject to the receipt of any approvals required
from any relevant tax authority, we shall settle each RSU upon vesting by delivering one ordinary share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
case of termination for reasons of disability or death, the grantee or his legal successor may exercise options that have vested prior
to termination within a period of twelve months from the date of disability or death. If we terminate a grantee&#8217;s employment or
service for cause, all of the grantee&#8217;s vested and unvested unexercised options will expire and terminate on the date of termination.
If a grantee&#8217;s employment or service is terminated for any other reason, the grantee may exercise his or her vested options within
90 days of the date of termination or within a longer period under specified circumstances determined by our Board. Any expired or unvested
options shall return to the option pool reserved under the 2013 Plan for reissuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of grantee&#8217;s termination prior to a vesting date by reason of such grantee&#8217;s death or disability, all of such grantee&#8217;s
RSUs shall immediately become vested as of the date of such termination. In the event of a grantee&#8217;s termination for cause prior
to settlement, all of such grantee&#8217;s RSUs shall immediately be forfeited for no consideration as of the date of such termination.
If a grantee&#8217;s employment or service is terminated for any other reason, (1) all vesting with respect to such grantee&#8217;s RSUs
shall cease, (2) all of such grantee&#8217;s unvested RSUs shall immediately be forfeited for no consideration as of the date of such
termination, and (3) to the extent not already settled, all of such grantee&#8217;s vested RSUs shall be settled in accordance with the
settlement schedule set forth in the applicable award agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of a merger or consolidation of our company subsequent to which we would no longer exist as a legal entity, or a sale of all,
or substantially all, of our ordinary shares or assets or other transaction having a similar effect on us, or a Transaction, any unexercised
options then outstanding will be cancelled. Notwithstanding the foregoing, the Board, or the relevant committee of the Board, may determine
that the options will not be cancelled but will be assumed or substituted for an appropriate number of the same type of shares or other
securities of the successor company as were distributed to the Company or the shareholders in connection with the Transaction. In addition,
the Board, or the relevant committee of the Board, may determine to include in certain option agreements either a clause that provides
for acceleration of vesting of all or part of the unvested options in the event of a Transaction or the occurrence of another event or
a clause which provides that if the optionee&#8217;s employment with the successor company is terminated by the successor company without
cause within a certain period, not to exceed two years from the closing of such Transaction, all or part of the unvested options shall
be accelerated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 117; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Certain
Information Concerning Equity Awards to Office Holders</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables set forth information, as of March 21, 2025 concerning all outstanding equity awards to Office Holders as of such date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Name of Office Holder</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Date of grant</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise price per</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>share ($)*</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares subject</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>to the option</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares vested and</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>unexercised</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>unvested</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Schedule date of expiration</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 16%; text-align: left">Allen Baharaff</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 30, 2013</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NIS 1.80</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">1,399</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">1,399</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 15%; text-align: right">Dec-12-2028</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 30, 2013</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NIS 1.80</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">466</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">466</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">Dec-12-2028</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 4, 2016</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">988.2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">777</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">777</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">Feb-04-2026</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 4, 2016</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,069.2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">944</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">944</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">Feb-04-2026</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 10, 2018</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,080.8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,222</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,222</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">Jul-10-2028</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 17, 2019</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">921.6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,222</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,222</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">Dec-17-2029</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 10, 2020</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">599.4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,222</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,222</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">Nov-17-2030</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Shmuel Nir</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 11, 2015</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">988.2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">55</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">55</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">May-11-2025</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 4, 2016</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,069.2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">166</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">166</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">Feb-04-2026</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 10, 2018</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,080.8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">166</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">166</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">Jul-10-2028</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 15, 2021</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">558</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">111</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">111</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">Jul-10-2031</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Amir Poshinski</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 13, 2020</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">858.6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">166</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">166</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">August 13, 2030</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 15, 2021</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">558</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">111</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">111</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">Jul-10-2031</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">David Sidransky</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 11, 2015</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">988.2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">55</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">55</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">May-11-2025</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 4, 2016</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,069.2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">166</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">166</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">Feb-04-2026</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 10, 2018</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,080.8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">166</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">166</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">Jul-10-2028</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 15, 2021</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">558</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">111</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">111</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">Jul-10-2031</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dr. Liat Hayardeny</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 6, 2016</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">68.4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">222</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">222</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">Sep-06-2026</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 31, 2017</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">68.4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">222</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">222</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">Jan-31-2026</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 10, 2018</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">68.4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">222</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">222</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">Jul-10-2028</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 17, 2019</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">68.4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">222</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">222</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">Dec-17-2029</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 10, 2020</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">68.4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">222</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">222</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">Nov-10-2030</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Yohai Stenzler</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 3, 2016</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">68.4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">125</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">125</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">Jan-03-2026</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 7, 2017</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">68.4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">111</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">111</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">Nov-07-2020</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 10, 2018</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">68.4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">222</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">222</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">Jul-10-2028</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 17, 2019</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">68.4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">222</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">222</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">Dec-17-2029</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 10, 2020</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">68.4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">222</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">222</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">Nov-10-2030</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">68.4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Guy Nehemya</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 3, 2016</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">68.4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">125</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">125</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">Jan-03-2026</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 10, 2018</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">68.4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">222</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">222</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">Jul-10-2028</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 17, 2019</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">68.4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">222</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">222</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">Dec-17-2029</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 10, 2020</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">68.4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">222</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">222</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">Nov-10-2030</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Carol L. Brosgart (**)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 25, 2017</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">876.6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">111</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">111</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">Apr-25-2027</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 10, 2018</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,080.8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">166</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">166</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">Jul-10-2028</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 15, 2021</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">558</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">111</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">111</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">Jul-10-2031</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 7, 2023</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">12.6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,2500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,188</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,062</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">Augt-7-2033</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Doron Cohen</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 23, 2022</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">68.4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">222</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">152</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">70</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">Feb-23-2032</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(*)
All exercise prices are in USD unless otherwise specified.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(**)
On November 12, 2024, the board approved Dr. Brosgart a grant of options to purchase 17,500 of our ordinary shares with an exercise price
of $2.88. the grant is subject to the approval of the Company&#8217;s shareholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 118; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->118<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RSUs</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Name of Office</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">subject to</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Holder</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Date of grant</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">the RSUs</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">vested</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">unvested</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Allen Baharaff (*)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aug-7-2023</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">53,333</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">17,778</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">35,555</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Shmuel Nir (*)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Feb-04-2016</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">41</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">41</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aug-7-2023</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,250</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,083</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,167</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">David Sidransky (*)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Feb-04-2016</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">41</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">41</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aug-7-2023</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,250</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,083</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,167</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Amir Poshinski (*)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aug-7-2023</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,250</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,083</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,167</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Yohai Stenzler</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jan-03-2016</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aug-7-2023</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,167</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,333</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nov-12-2024</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Guy Nehemya</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jan-03-2016</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aug-7-2023</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,167</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,333</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nov-12-2024</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Doron Cohen</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aug-7-2023</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,167</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,333</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nov-12-2024</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35,000</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(*)
On November 12, 2024, the board approved a grant of 197,500 restricted share units to each of its directors, which is subject to the
approval of the Company&#8217;s shareholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">co</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F.
Disclosure of a registrant&#8217;s action to recover erroneously awarded compensation.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
was no erroneously awarded compensation that was required to be recovered pursuant to the Galmed Pharmaceuticals Ltd. Executive Officer
Clawback Policy during the fiscal year ended December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 119; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->119<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aa_002"></span>ITEM
7. Major Shareholders and Related Party Transactions.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.
Major Shareholders.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as set forth in &#8220;Item 6. Directors, Senior Management and Employees&#8212;E. Share Ownership,&#8221; to the best of our knowledge,
no other person who we know beneficially owns 5% or more of the Company&#8217;s ordinary shares outstanding as of March 21, 2025, the
latest practicable date for inclusion in this annual report. None of our shareholders has different voting rights from other shareholders.
Other than as described herein, to the best of our knowledge, we are not owned or controlled, directly or indirectly, by another corporation,
by any foreign government or by any natural person or legal persons, severally or jointly, and we are not aware of any arrangement that
may, at a subsequent date, result in a change of control of our company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.
Related Party Transactions.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary description of the material terms of those transactions with related parties to which we, or our subsidiaries,
are party and which were in effect since January 1, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Financing
Agreement with GRD</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have provided financing to GRD from time to time, pursuant to which the Company and GRD have executed several capital notes for an aggregate
outstanding principal amount of approximately $153.0 million. The par value of such notes is in NIS, and they bear no interest nor repayment
date; provided, however, that no repayment shall be made before the fifth anniversary from the issuance date of each note.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Agreements
with Directors and Officers</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Employment
and Consulting Agreements</i>. We have entered into written employment or consulting agreements with certain of our Office Holders. These
agreements provide for notice periods of varying duration for termination of the agreement by us or by the relevant Office Holder, during
which time the Office Holder will continue to receive base salary and benefits. We have also entered into customary non-competition,
confidentiality of information and ownership of inventions arrangements with these Office Holders. However, the enforceability of the
noncompetition provisions may be limited under applicable law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Options.
</i>Since our inception, we have granted options to purchase our ordinary shares to certain of our Office Holders. Such option agreements
may contain acceleration provisions upon certain merger, acquisition, or change of control transactions. See also &#8220;Item 6. Directors,
Senior Management and Employees&#8212;E. Share Ownership&#8221;. We describe our 2013 Plan under &#8220;Item 6. Directors, Senior Management
and Employees&#8212;B. Compensation&#8212; 2013 Incentive Share Option Plan.&#8221; If the relationship between us and an Office Holder
is terminated except for &#8220;cause&#8221; (as defined in the 2013 Plan and/or the applicable option award agreement), options that
are vested will generally remain exercisable for 90 days after such termination; provided, however, that prior to the date of such termination,
our remuneration committee may authorize an extension of the terms of all or part of the vested options beyond the date of such termination
for a period not to exceed the period during which the options by their terms would otherwise have been exercisable, and provided further
that the vested options may lose their status as incentive stock options and/or approved 102 options if such extension extends beyond
the maximum extension authorized by the Ordinance or the Code, as applicable<i>.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>RSUs.
</i>We have granted RSUs to certain of our Office Holders. Such award agreements may contain acceleration provisions upon certain merger,
acquisition, or change of control transactions. See also &#8220;Item 6. Directors, Senior Management and Employees&#8212;E. Share Ownership.&#8221;
We describe our 2013 Plan under &#8220;Item 6. Directors, Senior Management and Employees&#8212;B. Compensation&#8212;2013 Incentive
Share Option Plan.&#8221; If the relationship between us and an Office Holder is terminated, RSUs that are vested shall be settled in
accordance with the settlement schedule set forth in the applicable award agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 120; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->120<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>OnKai</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2023, we entered into the OnKai Agreement for a $1.5 million equity investment in OnKai, a US-based technology company developing
an AI-based platform to advance healthcare for underserved populations across the United States by facilitating alignment between healthcare
stakeholders. The signing of the definitive agreement followed an announcement that we made in January 2023 that we had entered into
a non-binding termsheet for an equity investment in OnKai. The OnKai Agreement provided that we will invest $1.5 million in exchange
for series seed preferred shares of OnKai (which is in addition to a $1.5 million investment that was made by us in OnKai through a SAFE
and which converted at a 15% discount into series seed preferred shares upon consummation of the Investment Round). Our investment in
OnKai was part of an approximately $6 million Investment Round with other investors that was led by us of which SAFE notes of approximately
$3.8 million were converted into preferred shares. On June 19, 2023, the Investment Round closed. Following the Investment Round, we
hold approximately 23.9% of the outstanding share capital of OnKai on an as-converted and fully and our Chief Executive Officer and director,
Allen Baharaff serves as a board member of OnKai. In 2024, we assigned our investment in Onkai to one our our wholly-owned subsidiaries
in Israel, Galtopa Therapeutics Ltd. In connection with the OnKai Agreement, our wholly-owned subsidiary, GRD entered into the OnKai
Services Agreement with OnKai. The OnKai Services Agreement provides that GRD shall on a non-exclusive basis (i) provide support services
to OnKai relating to finance, business development, strategic planning, execution and others; and (ii) lend its experience to OnKai in
building a strategy and for the development of treatments for the underserved and that OnKai shall on a non-exclusive basis (i) take
part in plan preparation to serve GDR&#8217;s vision of developing drugs for the underserved population and (ii) when relevant, design
a process on the clinical trial dashboard that could potentially serve GDR&#8217;s future trial. On October 15, 2024, we entered into
a bridge loan agreement with OnKai pursuant to which we made a loan in an aggregate amount of $250,000 to OnKai payable by January 1,
2028. The loan bears interest at an annual rate of 15%. In addition, in connection with the OnKai Services Agreement, we paid OnKai $150,000
for OnKai to assist the Company in (i) identifying and preparing eligible sites for the Company&#8217;s future clinical trials and (ii)
preparing and submitting applications for clinical and research grants in respect of such future clinical trials, including preparing
reimbursement strategies. In the event that we are awarded a clinical or research grant, OnKai agreed to repay us the $150,000 that we
initially paid to OnKai.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.
Interests of Experts and Counsel.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aa_003"></span>ITEM
8. Financial Information.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.
Consolidated Financial Statements and Other Financial Information.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
&#8220;Item 18. Financial Statements&#8221; for a list of all financial statements filed as part of this annual report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Legal
Matters</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are neither party to any legal or arbitration proceedings, including those relating to bankruptcy, receivership or similar proceedings
and those involving any third-party, nor any governmental proceedings pending or known to be contemplated, which may have, or have had
in the recent past, significant effects on the Company&#8217;s financial position or profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Dividend
Policy</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never declared or paid any cash dividends on our ordinary shares and do not anticipate paying any cash dividends in the foreseeable
future. Payment of cash dividends, if any, in the future will be at the discretion of our Board and will depend on then-existing conditions,
including our financial condition, operating results, contractual restrictions, capital requirements, business prospects and other factors
our Board may deem relevant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment
of dividends may also be subject to Israeli withholding taxes. See &#8220;Item 10. Additional Information&#8212;E. Taxation&#8212;Certain
Israeli Tax Considerations&#8221; for additional information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 121; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->121<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.
Significant Changes.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than as otherwise described in this Annual Report on Form 20-F and as set forth below, no significant change has occurred in our operations
since the date of our consolidated financial statements included in this Annual Report on Form 20-F.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aa_004"></span>ITEM
9. The Offer and Listing.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.
Offer and Listing Details</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ordinary shares have been listed on the Nasdaq Capital Market under the symbol &#8220;GLMD&#8221; since March 13, 2014. Prior to that
date, there was no public trading market for our ordinary shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.
Plan of Distribution</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.
Market for Ordinary Shares</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ordinary shares are listed on the Nasdaq Capital Market under the symbol &#8220;GLMD.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.
Selling Shareholders</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E.
Dilution</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F.
Expenses of the issue</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aa_005"></span>ITEM
10. Additional Information.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.
Share Capital.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.
Memorandum and Articles of Association.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
registration number is 51-495351-2. At the 2014 annual general meeting of shareholders, our shareholders adopted our Articles, which
became effective on the consummation of our initial public offering in the United States in March 2014. Under Section 2 of our Articles,
the purpose of the Company is to engage in any lawful activity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information set forth in Exhibit 2.1 of this Annual Report is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.
Material Contracts</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
a description of our material agreements relating to our strategic collaborations and research arrangements and other material agreements,
please refer to &#8220;Item 4.B. Information on the Company&#8212;Business Overview&#8212;Strategic Collaborations, Research Arrangements
and other Material Agreements.&#8221; &#8220;and &#8220;Item 7.B &#8220;Related Party Transactions&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 122; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->122<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employment
Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
&#8220;Item 6. Directors, Senior Management and Employees&#8212;B. Compensation&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.
Exchange Controls.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no Israeli government laws, decrees, regulations or other legislation that restrict or that affect our export or import of capital,
including the availability of cash and cash equivalents for use by us and our wholly-owned subsidiaries, or the remittance of dividends,
interest or other payments to non-resident holders of our securities, except for ownership by nationals of certain countries that are,
or have been, declared as enemies of Israel or otherwise as set forth under &#8220;Item 10. Additional Information&#8212;E. Taxation.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E.
Taxation.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following description is not intended to constitute a complete analysis of all tax consequences relating to the ownership or disposition
of our ordinary shares. You should consult your own tax advisor concerning the tax consequences of your particular situation, as well
as any tax consequences that may arise under the laws of any state, local, foreign, including Israel, or other taxing jurisdiction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Certain
Israeli Tax Considerations</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a brief summary of the material Israeli income tax laws applicable to us. This section also contains a discussion of material
Israeli tax consequences concerning the ownership and disposition of our ordinary shares. This summary does not discuss all the aspects
of Israeli tax law that may be relevant to a particular investor in light of his or her personal investment circumstances or to some
types of investors subject to special treatment under Israeli law. Examples of this kind of investor include residents of Israel or investors
in securities who are subject to special tax regimes not covered in this discussion. To the extent that the discussion is based on new
tax legislation that has not yet been subject to judicial or administrative interpretation, we cannot assure you that the appropriate
tax authorities or the courts will accept the views expressed in this discussion. This summary is based on laws and regulations in effect
as of the date hereof and does not take into account possible future amendments which may be under consideration.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>General
Corporate Tax Structure in Israel</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israeli
resident companies (as defined below), such as the Company, are generally subject to corporate tax at the rate of 23% on their taxable
income, as of January 1, 2018 (23% in 2024). However, the effective tax rate payable by a company that derives income from a Preferred
Enterprise or a Technology Enterprise, as discussed below, may be considerably less.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital
gains derived by an Israeli resident company are generally subject to tax at the same rate as the corporate tax rate. Under Israeli tax
legislation, a corporation will be considered an &#8220;Israeli resident&#8221; if it meets one of the following: (i) it was incorporated
in Israel; or (ii) the control and management of its business are exercised in Israel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Law
for the Encouragement of Industry (Taxes), 5729-1969</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Law for the Encouragement of Industry (Taxes), 5729-1969, which we refer to as the Industry Encouragement Law, provides several tax benefits
for &#8220;Industrial Companies,&#8221; which are defined as Israeli resident-companies which were incorporated in Israel, of which 90%
or more of their income in any tax year, other than income from certain government loans, is derived from an &#8220;Industrial Enterprise&#8221;
that it owns and located in Israel or in the &#8220;Area&#8221;, in accordance with the definition under Section 3A of the Israeli Tax
Ordinance. An &#8220;Industrial Enterprise&#8221; is defined as an enterprise whose principal activity in a given tax year is industrial
production. Eligibility for benefits under the Industry Encouragement Law is not contingent upon approval of any governmental authority.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>


<!-- Field: Page; Sequence: 123; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->123<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tax benefits, among others, are available to Industrial Companies:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">amortization
    over an eight year period of the cost of purchasing a patent, rights to use a patent and rights to know-how, which are used for the
    development or advancement of the company, commencing in the year in which such rights were first exercised;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">under
    limited conditions, an election to file consolidated tax returns with related Industrial Companies controlled by it; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">deductions
    of expenses related to a public offering in equal amounts over a three year period commencing on the year of the offering.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that we qualify as an &#8220;Industrial Company&#8221; within the meaning of the Industry Encouragement Law. There can be no
assurance that we will continue to qualify as an Industrial Company in the future or that the benefits described above will be available
to us at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Law
for the Encouragement of Capital Investments, 5719-1959</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Law for the Encouragement of Capital Investments, 5719-1959, which we refer to as the Investment Law, provides certain incentives for
capital investments in production facilities (or other eligible assets) by &#8220;Industrial Enterprises&#8221; (as defined under the
Investment Law). Generally, an investment program that is implemented in accordance with the provisions of the Investment Law, is entitled
to benefits. These benefits may include cash grants from the Israeli government and tax benefits, based upon, among other things, the
geographic location in Israel of the facility in which the investment is made. In order to qualify for these incentives, an Approved
Enterprise, a Beneficiary Enterprise or a Preferred Enterprise is required to comply with the requirements of the Investment Law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Investment Law was significantly amended effective April 1, 2005, further amended as of January 1, 2011, or the 2011 Amendment, and as
of January 1, 2017, or the 2017 Amendment. The 2011 Amendment introduced new benefits to replace those granted in accordance with the
provisions of the Investment Law in effect prior to the 2011 Amendment. However, companies entitled to benefits under the Investment
Law as in effect up to January 1, 2011 were entitled to choose to continue to enjoy such benefits, provided that certain conditions are
met, or elect instead, irrevocably, to forego such benefits and elect the benefits of the 2011 Amendment. The 2017 Amendment introduces
new benefits for Technological Enterprises, alongside the existing tax benefits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following discussion is a summary of the Investment Law following its most recent amendments:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Tax
Benefits Under the 2011 Amendment</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2011 Amendment canceled the availability of the benefits granted to Industrial Companies under the Investment Law prior to 2011 and,
instead, introduced new benefits for income generated by a &#8220;Preferred Company&#8221; through its &#8220;Preferred Enterprise&#8221;
(as such terms are defined in the Investment Law) as of January 1, 2011.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
definition of a Preferred Company includes a company incorporated in Israel that is not fully owned by a governmental entity, and that
has, among other things, a Preferred Enterprise and is controlled and managed from Israel. Pursuant to the 2011 Amendment, beginning
in 2014 and in each year thereafter until 2016, a Preferred Company may only be entitled to a reduced corporate tax rate of 16% with
respect to its preferred income derived by its Preferred Enterprise, unless the Preferred Enterprise is located in a specified development
zone, in which case the rate will be 9%. Pursuant to the 2017 Amendment, in 2017 and thereafter, the corporate tax rate for Preferred
Enterprise which is located in a specified development zone was reduced to 7.5%, while the reduced corporate tax rate for other development
zones remains 16%. Income derived by a Preferred Company from a &#8220;Special Preferred Enterprise&#8221; (as such term is defined in
the Investment Law) would be entitled, during a benefit period of ten years, to further reduced tax rates of 8%, or 5% if the Special
Preferred Enterprise is located in a certain development zone. As of January 1, 2017, the definition for &#8216;Special Preferred Enterprise&#8217;
includes less stringent conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>


<!-- Field: Page; Sequence: 124; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->124<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of January 1, 2014, dividends paid to Israeli shareholders out of income attributed to a Preferred Enterprise or to a Special Preferred
Enterprise are generally subject to withholding tax at source at the rate of 20% (in the case of non-Israeli shareholders - subject to
the receipt in advance of a valid certificate from the ITA allowing for a reduced tax rate, 20%, or such a lower tax rate as may be provided
under an applicable tax treaty). However, if such dividends are paid to an Israeli company, no tax is required to be withheld (although,
if such dividends are subsequently distributed to individuals or a non-Israeli company, the aforesaid will apply).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>New
Tax benefits under the 2017 Amendment</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2017 Amendment was enacted as part of the Economic Efficiency Law that was published on December 29, 2016, and is effective as of January
1, 2017. The 2017 Amendment provides new tax benefits for two types of &#8220;Technology Enterprises&#8221;, as described below, and
is in addition to the other existing tax beneficial programs under the Investment Law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2017 Amendment provides that a technology company satisfying certain conditions will qualify as a &#8220;Preferred Technology Enterprise&#8221;
and will thereby enjoy a reduced corporate tax rate of 12% on income that qualifies as &#8220;Preferred Technology Income&#8221;, as
defined in the Investment Law. The tax rate is further reduced to 7.5% for a Preferred Technology Enterprise located in development zone
A. In addition, a Preferred Technology Company will enjoy a reduced corporate tax rate of 12% on capital gain derived from the sale of
certain &#8220;Benefitted Intangible Assets&#8221; (as defined in the Investment Law) to a related foreign company if the Benefitted
Intangible Assets were acquired from a foreign company on or after January 1, 2017 for at least NIS 200 million (approximately $56 million),
and the sale receives prior approval from the National Authority for Technological Innovation (previously known as the Israeli Office
of the Chief Scientist), to which we refer as IIA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2017 Amendment further provides that a technology company satisfying certain conditions will qualify as a &#8220;Special Preferred Technology
Enterprise&#8221; and will thereby enjoy a reduced corporate tax rate of 6% on &#8220;Preferred Technology Income&#8221; regardless of
the company&#8217;s geographic location within Israel. In addition, a Special Preferred Technology Enterprise will enjoy a reduced corporate
tax rate of 6% on capital gain derived from the sale of certain &#8220;Benefitted Intangible Assets&#8221; to a related foreign company
if the Benefitted Intangible Assets were either developed by the Special Preferred Technology Enterprise or acquired from a foreign company
on or after January 1, 2017, and the sale received prior approval from IIA. A Special Preferred Technology Enterprise that acquires Benefitted
Intangible Assets from a foreign company for more than NIS 500 million will be eligible for these benefits for at least ten years, subject
to certain approvals as specified in the Investment Law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends
distributed by a Preferred Technology Enterprise or a Special Preferred Technology Enterprise to Israeli shareholders, paid out of Preferred
Technology Income, are subject to withholding tax at source at the rate of 20% (in the case of non-Israeli shareholders - subject to
the receipt in advance of a valid certificate from the ITA allowing for a reduced tax rate, 20%, or such lower rate as may be provided
in an applicable tax treaty). However, if such dividends are paid to an Israeli company, no tax is required to be withheld (although,
if such dividends are subsequently distributed to individuals or a non-Israeli company, the aforesaid will apply). If such dividends
are distributed to a foreign parent company holding, alone or together with other foreign companies, at least 90% of the shares of the
distributing company and other conditions are met, the withholding tax rate will be 4% (or a lower rate under a tax treaty, if applicable,
subject to the receipt in advance of a valid certificate from the ITA allowing for a reduced tax rate).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
examining the impact of the 2017 Amendment, we submitted a request to receive a tax ruling from the Israel Tax Authority to be recognized
as a Preferred Technology Enterprise and we received a tax ruling from the Israel Tax Authority granting GRD a Preferred Technology Enterprise
status, subject to terms and conditions determined in the tax ruling. The tax ruling was valid from 2018 until the tax year ending in
2022. There is no assurance that GRD will continue to meet all the terms and conditions required under the tax ruling and the Investment
Law that will allow it to enjoy any tax benefits under the Investment Law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 125; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->125<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Taxation
of Our Israeli Individual Shareholders on Receipt of Dividends</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israeli
residents who are individuals are generally subject to Israeli income tax for dividends paid on our ordinary shares (other than bonus
shares or share dividends) at a rate of 25%, or 30% if the recipient of such dividend is a Substantial Shareholder (as defined below)
at the time of distribution or at any time during the preceding 12-month period. However, dividends distributed from taxable income accrued
from Preferred Enterprise or Preferred Technology Enterprise to Israeli individuals are subject to withholding tax at the rate of 20%.
However, if such dividends are distributed to an Israeli company, no tax is imposed (although, if such dividends are subsequently distributed
to individuals or a non-Israeli company, withholding tax at a rate of 20% or such lower rate as may be provided in an applicable tax
treaty (subject to the receipt in advance of a valid certificate from the Israel Tax Authority (&#8220;ITA&#8221;) allowing for a reduced
tax rate will apply). An average rate will be set in case the dividend is distributed from mixed types of income (regular and preferred
income).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
&#8220;Substantial Shareholder&#8221; is generally a person who alone, or together with his or her relative or another person who collaborates
with him or her on a regular basis, holds, directly or indirectly, at least 10% of any of the &#8220;means of control&#8221; of a corporation.
&#8220;Means of control&#8221; generally include the right to vote, receive profits, nominate a director or an officer, receive assets
upon liquidation or instruct someone who holds any of the aforesaid rights regarding the manner in which he or she is to exercise such
right(s), all regardless of the source of such right.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
respect to individuals, the term &#8220;Israeli resident&#8221; is generally defined under Israeli tax legislation as a person whose
center of life is in Israel. The Israeli Tax Ordinance (as amended by Amendment Law No. 132 of 2002), states that in order to determine
the center of life of an individual, consideration will be given to the individual&#8217;s family, economic and social connections, including:
(i) place of permanent residence; (ii) place of residential dwelling of the individual and the individual&#8217;s immediate family; (iii)
place of the individual&#8217;s regular or permanent occupation or the place of his or her permanent employment; (iv) place of the individual&#8217;s
active and substantial economic interests; (v) place of the individual&#8217;s activities in organizations, associations and other institutions.
The center of life of an individual will be presumed to be in Israel if: (i) the individual was present in Israel for 183 days or more
in the tax year; or (ii) the individual was present in Israel for 30 days or more in the tax year, and the total period of the individual&#8217;s
presence in Israel in that tax year and the two previous tax years is 425 days or more. Such presumption may be rebutted either by the
individual or by the assessing officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payers
of dividends on our ordinary shares, including the Israeli stockbroker effectuating the transaction, or the financial institution through
which the securities are held, are generally required, subject to any of the foregoing exemptions, reduced tax rates and the demonstration
of a shareholder regarding his, her or its foreign residency, to withhold tax upon the distribution of dividend at the rate of 25% (whether
the recipient is a Substantial Shareholder or not), so long as the shares are registered with a nominee company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Taxation
of Israeli Resident Corporations on Payment of Dividends</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israeli
resident corporations are generally exempt from Israeli corporate income tax with respect to dividends paid on ordinary shares of Israeli
resident corporations as long as the profits out of which the dividends were paid were derived in Israel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Capital
Gains Taxes Applicable to Israeli Resident Shareholders</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
income tax rate applicable to real capital gains derived by an Israeli individual resident from the sale of shares that were purchased
after January 1, 2012, whether listed on a stock exchange or not, is 25%. However, if such shareholder is considered a Substantial Shareholder
at the time of sale or at any time during the preceding 12 month period and/or claims a deduction for interest and linkage differences
expenses in connection with the purchase and holding of such shares, such gain will be taxed at the rate of 30%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
capital gains derived by an individual shareholder who is a dealer or trader in securities, or to whom such income is otherwise taxable
as ordinary business income, are taxed in Israel at their marginal rates applicable to business income (up to 50% in 2023 and 2024, including
Excess Tax as detailed below).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the sale of securities traded on a stock exchange, a detailed return, including a computation of the tax due, must be filed and an advanced
payment must be paid on January 31 and July 31 of every tax year in respect of sales of securities made within the previous six months.
However, if all tax due was withheld at source according to applicable provisions of the Israeli Tax Ordinance and regulations promulgated
thereunder, the aforementioned return is not required to be filed and no advance payment must be paid. Capital gain is also reportable
on the annual income tax return.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 126; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->126<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Taxation
of Non-Israeli Shareholders on Receipt of Dividends</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Israeli
residents are generally subject to Israeli income tax on the receipt of dividends paid on our ordinary shares at the rate of 25% (or
30% for individuals, if such person is a Substantial Shareholder at the time he or she receives the dividend or on any date in the 12
months preceding such date), or 20% if the dividend is distributed from income attributed to Preferred Enterprise unless a lower rate
is provided under an applicable tax treaty between Israel and the shareholder&#8217;s country of residence and provided that a certificate
from the Israel Tax Authority allowing for a reduced withholding tax rate is obtained in advance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
non-Israeli resident who has dividend income derived from or accrued in Israel, from which the full amount of tax was withheld at source,
is generally exempt from the duty to file tax returns in Israel in respect of such income; provided that (i) such income was not derived
from a business conducted in Israel by the taxpayer, (ii) the taxpayer has no other taxable sources of income in Israel with respect
to which a tax return is required to be filed, and (iii) the taxpayer is not obligated to pay excess tax (as further explained below).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
example, under the Convention Between the Government of the United States of America and the Government of Israel with Respect to Taxes
on Income, as amended, or the U.S.-Israel Tax Treaty, Israeli withholding tax on dividends paid to a U.S. resident for treaty purposes
may not, in general, exceed 25%, subject to certain conditions. Where the recipient is a U.S. corporation owning 10% or more of the voting
shares of the paying corporation during the part of the paying corporation&#8217;s taxable year which precedes the date of payment of
the dividend and during the entirety of its prior taxable year (if any), the Israeli tax withheld may not exceed 12.5%, subject to certain
conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payers
of dividends on our ordinary shares, including the Israeli stockbroker effectuating the transaction, or the financial institution through
which the securities are held, are generally required, subject to any of the foregoing exemptions, reduced tax rates and the demonstration
of a shareholder regarding his, her or its foreign residency, to withhold tax upon the distribution of dividend at the rate of 25% (whether
the recipient is a Substantial Shareholder or not), so long as the shares are registered with a nominee company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Capital
Gains Income Taxes Applicable to Non-Israeli Shareholders</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Israeli
resident shareholders are generally exempt from Israeli capital gains tax on any gains derived from the sale, exchange or disposition
of our ordinary shares, provided that such shareholders did not acquire their shares prior to January 1, 2009 or acquired their shares
after the Company was listed for trading on NASDAQ and such gains were not derived from a permanent business or business activity of
such shareholders in Israel. These provisions dealing with capital gain are not applicable to a person whose gains from selling or otherwise
disposing of the shares are deemed to be business income. However, non-Israeli corporations will not be entitled to the foregoing exemptions
if an Israeli resident (i) has a controlling interest of more than 25% in such non-Israeli corporation or (ii) is the beneficiary of
or is entitled to 25% or more of the revenues or profits of such non-Israeli corporation, whether directly or indirectly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, a sale of securities by a non-Israeli resident may be exempt from Israeli capital gains tax under the provisions of an applicable
tax treaty. For example, under the U.S.-Israel Tax Treaty, the sale, exchange or disposition of our ordinary shares by a shareholder
who is a U.S. resident (for purposes of the U.S.-Israel Tax Treaty) holding the ordinary shares as a capital asset and is entitled to
claim the benefits afforded to such a resident by the U.S.-Israel Tax Treaty, or a Treaty U.S. Resident, is generally exempt from Israeli
capital gains tax unless: (i) such Treaty U.S. Resident is an individual and was present in Israel for 183 days or more in the aggregate
during the relevant taxable year; (ii) such Treaty U.S. Resident holds, directly or indirectly, shares representing 10% or more of our
voting power of the Company during any part of the 12 month period preceding such sale, exchange or disposition, subject to certain conditions;
(iii) the capital gains arising from such sale, exchange or disposition are attributable to a permanent establishment of the Treaty U.S.
Resident maintained in Israel, subject to certain conditions; (iv) the capital gains arising from such sale, exchange or disposition
is attributed to real estate located in Israel; or (v) the capital gains arising from such sale, exchange or disposition is attributed
to royalties. In any such case, the sale, exchange or disposition of our ordinary shares would be subject to Israeli tax, to the extent
applicable. However, under the U.S.-Israel Tax Treaty, such Treaty U.S. Resident would be permitted to claim a credit for such taxes
against U.S. federal income tax imposed on any gain from such sale, exchange or disposition, under the circumstances and subject to the
limitations specified in the U.S.-Israel Income Tax Treaty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 127; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->127<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regardless
of whether shareholders may be liable for Israeli income tax on the sale of our ordinary shares, the payment of the consideration may
be subject to withholding of Israeli tax at the source. Accordingly, shareholders may be required to demonstrate that they are exempt
from tax on their capital gains in order to avoid withholding at source at the time of sale. Specifically, in transactions involving
a sale of all of the shares of an Israeli resident company, in the form of a merger or otherwise, the Israel Tax Authority may require
from shareholders who are not liable for Israeli tax to sign declarations in forms specified by this authority or obtain a specific exemption
from the Israel Tax Authority to confirm their status as non-Israeli resident, and, in the absence of such declarations or exemptions,
may require the purchaser of the shares to withhold taxes at source.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Excess
Tax</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Individuals
who are subject to tax in Israel are also subject to an additional tax at a rate of 3% on annual income exceeding a certain threshold
(NIS 721,560 for 2024), which amount is generally linked to the annual change in the Israeli consumer price index (with the exception
that based on Israeli new legislation such amount, and certain other statutory amounts will not be linked to the Israeli consumer price
index for the years 2025-2027), including, but not limited to, dividends, interest and capital gains.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to new legislation, in effect as of January 1, 2025, an additional 2% excess tax is imposed on Capital-Sourced Income (defined as income
from any source other than employment income, business income or income from &#8220;personal effort&#8221;), to the extent that the Individual&#8217;s
Capital Sourced Income exceeds the specified threshold of NIS 721,560 (and regardless of the employment/business income amount of such
individual). This new excess tax applies, among other things, to income from capital gains, dividends, interest, rental income, or the
sale of real property.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Estate
and Gift Tax</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israeli
law presently does not impose estate or gift taxes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Certain
Material U.S. Federal Income Tax Considerations</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a general summary of certain material U.S. federal income tax consequences relating to the purchase, ownership and disposition
of our ordinary shares by U.S. Holders (as defined below). This summary is based on the Code, the regulations of the U.S. Department
of the Treasury issued pursuant to the Code, or the Treasury Regulations, the income tax treaty between the United States and Israel,
or the U.S.-Israel Tax Treaty, and administrative and judicial interpretations thereof, all as in effect on the date hereof and all of
which are subject to change, possibly with retroactive effect, or to different interpretation. No ruling has been sought from the Internal
Revenue Service, or the IRS, with respect to any U.S. federal income tax consequences described below, and there can be no assurance
that the IRS or a court will not take a contrary position. This summary is no substitute for consultation by prospective investors with
their own tax advisors and does not constitute tax advice. This summary applies only to U.S. Holders that hold our ordinary shares as
capital assets for U.S. federal income tax purposes (generally, property held for investment) and does not address all of the tax considerations
that may be relevant to specific U.S. Holders in light of their particular circumstances or to U.S. Holders subject to special treatment
under U.S. federal income tax law (including, without limitation, banks, insurance companies, tax-exempt entities, retirement plans,
regulated investment companies, partnerships, dealers in securities, brokers, real estate investment trusts, grantor trusts, certain
former citizens or residents of the United States, persons who acquire our ordinary shares as part of a straddle, hedge, conversion transaction
or other integrated investment, persons who acquire our ordinary shares through the exercise or cancellation of employee stock options
or otherwise as compensation for their services, persons that have a &#8220;functional currency&#8221; other than the U.S. dollar, persons
that own (or are deemed to own, indirectly, or by attribution) 10% or more of our shares (by vote or value), or persons that mark their
securities to market for U.S. federal income tax purposes). This summary does not address any U.S. state or local or non-U.S. tax considerations,
any U.S. federal estate, gift or alternative minimum tax considerations, or any U.S. federal tax consequences other than U.S. federal
income tax consequences.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 128; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->128<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
used in this summary, the term &#8220;U.S. Holder&#8221; means a beneficial owner of our ordinary shares that is, for U.S. federal income
tax purposes, (i) an individual citizen or resident of the United States, (ii) a corporation, or other entity taxable as a corporation
for U.S. federal income tax purposes, created or organized in or under the laws of the United States, any state thereof, or the District
of Columbia, (iii) an estate the income of which is subject to U.S. federal income tax regardless of its source, or (iv) a trust with
respect to which a court within the United States is able to exercise primary supervision over its administration and one or more U.S.
persons have the authority to control all of its substantial decisions, or that has a valid election in effect under applicable Treasury
Regulations to be treated as a &#8220;United States person.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an entity or arrangement treated as a partnership for U.S. federal income tax purposes holds our ordinary shares, the tax treatment of
such entity or arrangement treated as a partnership and each person treated as a partner thereof generally will depend upon the status
and activities of the entity and such person. A holder that is treated as a partnership for U.S. federal income tax purposes should consult
its own tax advisor regarding the U.S. federal income tax considerations applicable to it and its partners of the purchase, ownership
and disposition of our ordinary shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prospective
investors should be aware that this summary does not address the tax consequences to investors who are not U.S. Holders. Prospective
investors should consult their own tax advisors as to the particular tax considerations applicable to them relating to the purchase,
ownership and disposition of our ordinary shares, including the applicability of U.S. federal, state and local tax laws and non-U.S.
tax laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Taxation
of U.S. Holders</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Distributions</i>.
Subject to the discussion below under &#8220;Passive Foreign Investment Company,&#8221; a U.S. Holder that receives a distribution with
respect to an ordinary share generally will be required to include the amount of such distribution in gross income as a dividend (without
reduction for any Israeli tax withheld from such distribution) when actually or constructively received to the extent of the U.S. Holder&#8217;s
pro rata share of our current and/or accumulated earnings and profits (as determined under U.S. federal income tax principles). Any distributions
in excess of our earnings and profits will be applied against and will reduce (but not below zero) the U.S. Holder&#8217;s tax basis
in its ordinary shares, and, to the extent they exceed that tax basis, will be treated as gain from the sale or exchange of our ordinary
shares. We do not intend to calculate our earnings and profits under U.S. federal income tax principles. Therefore, a U.S. Holder should
expect that a distribution will be reported as a dividend even if that distribution would otherwise be treated as a non-taxable return
of capital or as capital gain under the rules described above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
noted above, we do not anticipate paying any cash dividends in the foreseeable future. If we were to pay dividends, we expect to pay
such dividends in NIS. A dividend paid in NIS, including the amount of any Israeli taxes withheld, will be includible in a U.S. Holder&#8217;s
income at a U.S. dollar amount calculated by reference to the exchange rate in effect on the date such dividend is received, regardless
of whether the payment is in fact converted into U.S. dollars. If the dividend is converted to U.S. dollars on the date of receipt, a
U.S. Holder generally will not recognize a foreign currency gain or loss. However, if the U.S. Holder converts the NIS into U.S. dollars
on a later date, the U.S. Holder must include, in computing its income, any gain or loss resulting from any exchange rate fluctuations.
The gain or loss will be equal to the difference between (i) the U.S. dollar value of the amount included in income when the dividend
was received and (ii) the amount received on the conversion of the NIS into U.S. dollars. Such gain or loss generally will be ordinary
income or loss and will be U.S. source income or loss for U.S. foreign tax credit purposes. U.S. Holders should consult their own tax
advisors regarding the tax consequences to them if we pay dividends in NIS or any other non-U.S. currency.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to certain significant conditions and limitations, any Israeli taxes paid on or withheld from distributions from us and not refundable
to a U.S. Holder may be credited against the U.S. Holder&#8217;s U.S. federal income tax liability or, alternatively, may be deducted
from the U.S. Holder&#8217;s taxable income. However, as a result of recent changes to the U.S. foreign tax credit rules, a withholding
tax may need to satisfy certain additional requirements in order to be considered a creditable tax for a U.S. Holder. We have not determined
whether these requirements have been met and, accordingly, no assurance can be given that any withholding tax on dividends paid by us
will be creditable. The election to deduct, rather than credit, foreign taxes, is made on a year-by-year basis and applies to all foreign
taxes paid by a U.S. Holder or withheld from a U.S. Holder that year. Dividends paid on our ordinary shares generally will constitute
income from sources outside the United States and be categorized as &#8220;passive category income&#8221; or, in the case of some U.S.
Holders, as &#8220;general category income&#8221; for U.S. foreign tax credit purposes. Because the rules governing foreign tax credits
are complex, U.S. Holders should consult their own tax advisors regarding the availability of foreign tax credits in their particular
circumstances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 129; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->129<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends
paid on our ordinary shares will not be eligible for the &#8220;dividends-received&#8221; deduction generally allowed to corporate U.S.
Holders with respect to dividends received from U.S. corporations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
distributions treated as dividends that are received by an individual U.S. Holder from a &#8220;qualified foreign corporation&#8221;
may be classified as &#8220;qualified dividend income,&#8221;<b><span style="text-decoration: line-through">&#8201;&#8212;&#8201;</span></b>&#8201;which is generally
taxed at the lower applicable long term capital gains rates provided certain holding period and other requirements are satisfied. A non-U.S.
corporation (other than a PFIC for the taxable year in which the dividend is paid or the preceding taxable year) generally will be considered
to be a qualified foreign corporation (i) if it is eligible for the benefits of a comprehensive tax treaty with the United States which
the Secretary of Treasury of the United States determines is satisfactory for purposes of this provision and which includes an exchange
of information program, or (ii) with respect to any dividend it pays on stock which is readily tradable on an established securities
market in the United States. We will not be a qualified foreign corporation if we are a PFIC for the taxable year in which we pay a dividend
or for the preceding taxable year. As discussed below under &#8220;Passive Foreign Investment Company,&#8221; we believe that we were
a PFIC for our 2024 taxable year and expect to be a PFIC for the 2025 taxable year. Because the PFIC determination is highly fact intensive,
there can be no assurance that we will not be a PFIC in 2025 or for any other taxable year. Our ordinary shares will generally be considered
to be readily tradable on an established securities market in the United States if they are listed on the Nasdaq Capital Market, as we
intend our ordinary shares will be. U.S. Holders should consult their own tax advisors regarding the availability of the lower rate for
dividends paid with respect to our ordinary shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
additional 3.8% &#8220;net investment income tax&#8221; (described below) may apply to dividends received by certain U.S. Holders who
meet certain modified adjusted gross income thresholds.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Sale,
Exchange or Other Taxable Disposition of Ordinary Shares</i>. Subject to the discussion under &#8220;Passive Foreign Investment Company&#8221;
below, a U.S. Holder generally will recognize capital gain or loss upon the sale, exchange, or other taxable disposition of our ordinary
shares in an amount equal to the difference between the amount realized on the sale, exchange, or other taxable disposition and the U.S.
Holder&#8217;s adjusted tax basis (determined under U.S. federal income tax rules) in such ordinary shares. This capital gain or loss
will be long-term capital gain or loss if the U.S. Holder&#8217;s holding period in our ordinary shares exceeds one year. Preferential
tax rates for long-term capital gain (currently, with a maximum rate of 20%) will apply to individual U.S. Holders. The deductibility
of capital losses is subject to limitations. The gain or loss generally will be income or loss from sources within the United States
for U.S. foreign tax credit purposes, subject to certain possible exceptions under the U.S.-Israel Tax Treaty. The additional 3.8% &#8220;net
investment income tax&#8221; (described below) may apply to gains recognized upon the sale, exchange, or other taxable disposition of
our ordinary shares by certain U.S. Holders who meet certain modified adjusted gross income thresholds.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
Holders should consult their own tax advisors regarding the U.S. federal income tax consequences of receiving currency other than U.S.
dollars upon the disposition of their ordinary shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Passive
Foreign Investment Company. </i>In general, a non-U.S. corporation will be treated as a PFIC for U.S. federal income tax purposes in
any taxable year in which either (i) at least 75% of its gross income is &#8220;passive income,&#8221; or (ii) on average at least 50%
of its assets by value produce passive income or are held for the production of passive income. Passive income for this purpose generally
includes, among other things, certain dividends, interest, royalties, rents and gains from commodities and securities transactions and
from the sale or exchange of property that gives rise to passive income. Passive income also includes amounts derived by reason of the
temporary investment of funds, including those raised in a public offering. Assets that produce or are held for the production of passive
income may include cash, even if held as working capital or raised in a public offering, as well as marketable debt securities and other
assets that may produce passive income. In determining whether a non-U.S. corporation is a PFIC, a proportionate share of the income
and assets of each corporation in which it owns, directly or indirectly, at least a 25% interest (by value) is taken into account.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
foreign corporation&#8217;s PFIC status is an annual determination that is based on tests that are factual in nature, and our status
for any year will depend on our income, assets, and activities for such year. Based upon our review of our financial data, we believe
that we were a PFIC for our 2024 taxable year and expect to be a PFIC for the 2025 taxable year. Because PFIC status is determined annually
and is based on our income, assets and activities for the entire taxable year, it is not possible to determine with certainty whether
we will be characterized as a PFIC for the 2025 taxable year until after the close of the year, and there can be no assurance that we
will not be classified as a PFIC in any future year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 130; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->130<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Default
PFIC Rules</i>. If we are a PFIC for any tax year, a U.S. Holder who does not make a timely &#8220;qualified electing fund&#8221; election,
or &#8220;QEF election&#8221; or a mark-to-market election (as described below), referred to in this summary as a &#8220;Non-Electing
U.S. Holder,&#8221; will be subject to special rules with respect to (i) any &#8220;excess distribution&#8221; (generally, the portion
of any distributions received by the Non-Electing U.S. Holder on the ordinary shares in a taxable year in excess of 125% of the average
annual distributions received by the Non-Electing U.S. Holder in the three preceding taxable years, or, if shorter, the Non-Electing
U.S. Holder&#8217;s holding period for the ordinary shares), and (ii) any gain realized on the sale or other disposition of such ordinary
shares. Under these rules:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    excess distribution or gain would be allocated ratably over the Non-Electing U.S. Holder&#8217;s holding period for such ordinary
    shares;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    amount allocated to the current taxable year and any year prior to us becoming a PFIC would be taxed as ordinary income; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    amount allocated to each of the other taxable years would be subject to tax at the highest rate of tax in effect for the applicable
    class of taxpayer for that year, and an interest charge for the deemed deferral benefit would be imposed with respect to the resulting
    tax attributable to each such other taxable year.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a Non-Electing U.S. Holder who is an individual dies while owning our ordinary shares, the Non-Electing U.S. Holder&#8217;s successor
would be ineligible to receive a step-up in tax basis of such ordinary shares. Non-Electing U.S. Holders should consult their tax advisors
regarding the application of the &#8220;net investment income tax&#8221; (described below) to their specific situation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent a distribution on our ordinary shares does not constitute an excess distribution to a Non-Electing U.S. Holder, such Non-Electing
U.S. Holder generally will be required to include the amount of such distribution in gross income as a dividend to the extent of our
current and/or accumulated earnings and profits (as determined for U.S. federal income tax purposes) that are not allocated to excess
distributions. The tax consequences of such distributions are discussed above under &#8220;Taxation of U.S. Holders&#8212;Distributions.&#8221;
Each U.S. Holder is encouraged to consult its own tax advisor with respect to the appropriate U.S. federal income tax treatment of any
distribution on our ordinary shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are treated as a PFIC for any taxable year during the holding period of a Non-Electing U.S. Holder, we will continue to be treated
as a PFIC for all succeeding years during which the Non-Electing U.S. Holder is treated as a direct or indirect Non-Electing U.S. Holder
even if we are not a PFIC for such years. A U.S. Holder is encouraged to consult its tax advisor with respect to any available elections
that may be applicable in such a situation, including the &#8220;deemed sale&#8221; election of Section 1298(b)(1) of the Code (which
will be taxed under the adverse tax rules described above).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
U.S. Holder that owns (or is deemed to own) shares in a PFIC during any taxable year of the U.S. Holder generally is required to file
an IRS Form 8621 with such U.S. Holder&#8217;s U.S. federal income tax return and provide such other information as the IRS may require.
Failure to file IRS Form 8621 for each applicable taxable year may result in substantial penalties and result in the U.S. Holder&#8217;s
taxable</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may invest in the equity of foreign corporations that are PFICs or may own subsidiaries that are PFICs (any such entity, a &#8220;lower-tier
PFIC&#8221;). If we are classified as a PFIC, under attribution rules, U.S. Holders will be subject to the PFIC rules with respect to
their indirect ownership interests in such lower-tier PFICs, such that a disposition by us of the shares of the lower-tier PFIC or receipt
by us of a distribution from the lower-tier PFIC generally will be treated as a deemed disposition of such shares or the deemed receipt
of such distribution by the U.S. Holder, subject to taxation under the PFIC rules even though the U.S. Holder does not receive any proceeds
from those dispositions or distributions. There can be no assurance that a U.S. Holder will be able to make a QEF election with respect
to any lower-tier PFICs in which we invest. Each U.S. Holder is encouraged to consult its own tax advisor with respect to tax consequences
of an investment by us in a lower-tier PFIC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i></i></span></p>


<!-- Field: Page; Sequence: 131; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->131<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>QEF
Election</i>. Certain adverse consequences of PFIC status can be mitigated for holders of our ordinary shares if a U.S. Holder makes
a QEF election. A U.S. Holder who makes a timely QEF election, referred to in this disclosure as an &#8220;Electing U.S. Holder,&#8221;
with respect to us must report for U.S. federal income tax purposes its pro rata share of our ordinary earnings and net capital gain,
if any, for our taxable year that ends with or within the taxable year of the Electing U.S. Holder. The &#8220;net capital gain&#8221;
of a PFIC is the excess, if any, of the PFIC&#8217;s net long-term capital gains over its net short-term capital losses. The amount so
included in income generally will be treated as ordinary income to the extent of such Electing U.S. Holder&#8217;s allocable share of
the PFIC&#8217;s ordinary earnings and as long-term capital gain to the extent of such Electing U.S. Holder&#8217;s allocable share of
the PFIC&#8217;s net capital gains. Such Electing U.S. Holder generally will be required to translate such income into U.S. dollars based
on the average exchange rate for the PFIC&#8217;s taxable year with respect to the PFIC&#8217;s functional currency. Such income generally
will be treated as income from sources outside the United States for U.S. foreign tax credit purposes. Amounts previously included in
income by such Electing U.S. Holder under the QEF rules generally will not be subject to tax when they are distributed to such Electing
U.S. Holder. The Electing U.S. Holder&#8217;s tax basis in our ordinary shares generally will increase by any amounts so included under
the QEF rules and decrease by any amounts not included in income when distributed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
Electing U.S. Holder will be subject to U.S. federal income tax on such amounts for each taxable year in which we are a PFIC, regardless
of whether such amounts are actually distributed to such Electing U.S. Holder. However, an Electing U.S. Holder may, subject to certain
limitations, elect to defer payment of current U.S. federal income tax on such amounts, subject to an interest charge. If an Electing
U.S. Holder is an individual, any such interest will be treated as non-deductible &#8220;personal interest.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
net operating losses or net capital losses of a PFIC will not pass through to the Electing U.S. Holder and will not offset any ordinary
earnings or net capital gain of a PFIC recognized by Electing U.S. Holder in subsequent years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">So
long as an Electing U.S. Holder&#8217;s QEF election with respect to us is in effect with respect to the entire holding period for our
ordinary shares, any gain or loss recognized by such Electing U.S. Holder on the sale, exchange or other disposition of such shares generally
will be long-term capital gain or loss if such Electing U.S. Holder has held such shares for more than one year at the time of such sale,
exchange or other disposition. Preferential tax rates for long-term capital gain (currently, a maximum rate of 20%) will apply to individual
U.S. Holders. The deductibility of capital losses is subject to limitations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, a U.S. Holder must make a QEF election on or before the due date for filing its income tax return for the first year to which
the QEF election is to apply. A U.S. Holder makes a QEF election by completing the relevant portions of and filing IRS Form 8621 in accordance
with the instructions thereto. Upon request, we expect to provide U.S. Holders with the information needed to complete IRS Form 8621
(which form would be required to be filed with the IRS on an annual basis by the U.S. Holder) and to make and maintain a valid QEF election
for any year in which we are a PFIC. There is no assurance, however, that we will have timely knowledge of our status as a PFIC or the
status of a lower-tier PFIC, or that the information that we provide will be adequate to allow U.S. Holders to make a QEF election. A
QEF election will not apply to any taxable year during which we are not a PFIC, but will remain in effect with respect to any subsequent
taxable year in which we become a PFIC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
U.S. Holder should consult its own tax advisor with respect to the advisability of, the tax consequences of, and the procedures for making
a QEF election with respect to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Mark-to-Market
Election</i>. Alternatively, if our ordinary shares are treated as &#8220;marketable stock,&#8221; a U.S. Holder would be allowed to
make a &#8220;mark-to-market&#8221; election with respect to our ordinary shares, provided the U.S. Holder completes and files IRS Form
8621 in accordance with the relevant instructions and related Treasury Regulations. If that election is made, the U.S. Holder generally
would include as ordinary income in each taxable year the excess, if any, of the fair market value of our ordinary shares at the end
of the taxable year over such holder&#8217;s adjusted tax basis in such ordinary shares. The U.S. Holder would also be permitted an ordinary
loss in respect of the excess, if any, of the U.S. Holder&#8217;s adjusted tax basis in our ordinary shares over their fair market value
at the end of the taxable year, but only to the extent of the net amount previously included in income as a result of the mark-to- market
election. A U.S. Holder&#8217;s tax basis in our ordinary shares would be adjusted to reflect any such income or loss amount. Gain realized
on the sale, exchange or other disposition of our ordinary shares would be treated as ordinary income, and any loss realized on the sale,
exchange or other disposition of our ordinary shares would be treated as ordinary loss to the extent that such loss does not exceed the
net mark-to-market gains previously included in income by the U.S. Holder, and any loss in excess of such amount will be treated as capital
loss. Amounts treated as ordinary income will not be eligible for the favorable tax rates applicable to qualified dividend income or
long-term capital gains.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 132; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->132<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Generally,
stock will be considered marketable stock if it is &#8220;regularly traded&#8221; on a &#8220;qualified exchange&#8221; within the meaning
of applicable Treasury Regulations. A class of stock is regularly traded on an exchange during any calendar year during which such class
of stock is traded, other than in de minimis quantities, on at least 15 days during each calendar quarter. To be marketable stock, our
ordinary shares must be regularly traded on a qualifying exchange (i) in the United States that is registered with the SEC or a national
market system established pursuant to the Exchange Act or (ii) outside the United States that is properly regulated and meets certain
trading, listing, financial disclosure and other requirements. Our ordinary shares are expected to constitute &#8220;marketable stock&#8221;
as long as they remain listed on the Nasdaq Capital Market and are regularly traded.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
mark-to-market election will not apply to our ordinary shares held by a U.S. Holder for any taxable year during which we are not a PFIC,
but will remain in effect with respect to any subsequent taxable year in which we become a PFIC. Such election will not apply to any
lower-tier PFIC that we own. Each U.S. Holder is encouraged to consult its own tax advisor with respect to the availability and tax consequences
of a mark-to-market election with respect to our ordinary shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
U.S. Holder should consult its own tax adviser with respect to the applicability of the &#8220;net investment income tax&#8221; (discussed
below) where a mark-to-market election is in effect.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, U.S. Holders should consult their tax advisors regarding the IRS information reporting and filing obligations that may arise
as a result of the ownership of ordinary shares in a PFIC, including IRS Form 8621, Information Return by a Shareholder of a Passive
Foreign Investment Company or Qualified Electing Fund.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
U.S. federal income tax rules relating to PFICs, QEF elections, and mark-to market elections are complex. U.S. Holders are urged to consult
their own tax advisors with respect to the purchase, ownership and disposition of our ordinary shares, any elections available with respect
to such ordinary shares and the IRS information reporting obligations with respect to the purchase, ownership and disposition of our
ordinary shares.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Certain
Reporting Requirements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
U.S. Holders may be required to file IRS Form 926, Return by U.S. Transferor of Property to a Foreign Corporation and IRS Form 5471,
Information Return of U.S. Persons With Respect to Certain Foreign Corporations, reporting transfers of cash or other property to us
and information relating to the U.S. Holder and us. Substantial penalties may be imposed upon a U.S. Holder that fails to comply. See
also the discussion regarding Form 8621, Information Return by a Shareholder of a Passive Foreign Investment Company or Qualified Electing
Fund, above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, certain U.S. Holders must report information on IRS Form 8938, Statement of Specified Foreign Financial Assets, with respect
to their investments in certain &#8220;specified foreign financial assets,&#8221; which would include an investment in our ordinary shares,
if the aggregate value of all of those assets exceeds $50,000 on the last day of the taxable year (and in some circumstances, a higher
threshold). This reporting requirement applies to individuals and certain U.S. entities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
Holders who fail to report required information could become subject to substantial penalties. U.S. Holders should consult their tax
advisors regarding the possible implications of these reporting requirements arising from their investment in our ordinary shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 133; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->133<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Backup
Withholding Tax and Information Reporting Requirements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Generally,
information reporting requirements will apply to distributions on our ordinary shares or proceeds on the disposition of our ordinary
shares paid within the United States (and, in certain cases, outside the United States) to U.S. Holders other than certain exempt recipients,
such as corporations. Furthermore, backup withholding (currently at 24%) may apply to such amounts if the U.S. Holder fails to (i) provide
a correct taxpayer identification number, (ii) report interest and dividends required to be shown on its U.S. federal income tax return,
or (iii) make other appropriate certifications in the required manner. U.S. Holders who are required to establish their exempt status
generally must provide such certification on IRS Form W-9.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Backup
withholding is not an additional tax. Amounts withheld as backup withholding from a payment may be credited against a U.S. Holder&#8217;s
U.S. federal income tax liability and such U.S. Holder may obtain a refund of any excess amounts withheld by filing the appropriate claim
for refund with the IRS and furnishing any required information in a timely manner.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Medicare
Tax on Investment Income</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
U.S. persons, including individuals, estates and trusts, will be subject to an additional 3.8% Medicare tax, or &#8220;net investment
income tax,&#8221; on unearned income. For individuals, the additional net investment income tax applies to the lesser of (i) &#8220;net
investment income&#8221; or (ii) the excess of &#8220;modified adjusted gross income&#8221; over $200,000 ($250,000 if married and filing
jointly or $125,000 if married and filing separately). &#8220;Net investment income&#8221; generally equals the taxpayer&#8217;s gross
investment income reduced by the deductions that are allocable to such income. Investment income generally includes, among other things,
passive income such as interest, dividends, annuities, royalties, rents, and capital gains. U.S. Holders are urged to consult their own
tax advisors regarding the implications of the additional net investment income tax resulting from their ownership and disposition of
our ordinary shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>THE
DISCUSSION ABOVE IS A GENERAL SUMMARY. IT DOES NOT COVER ALL TAX MATTERS THAT MAY BE OF IMPORTANCE TO A PROSPECTIVE INVESTOR. EACH PROSPECTIVE
INVESTOR IS URGED TO CONSULT ITS OWN TAX ADVISOR ABOUT THE TAX CONSEQUENCES RELATING TO THE PURCHASE, OWNERSHIP AND DISPOSITION OF OUR
ORDINARY SHARES IN LIGHT OF THE INVESTOR&#8217;S OWN CIRCUMSTANCES, INCLUDING THE CONSEQUENCES OF ANY PROPOSED CHANGE IN APPLICABLE LAWS.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F.
Dividends and Paying Agents.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>G.
Statements by Experts.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>H.
Documents on Display.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SEC maintains an Internet website that contains reports and other information regarding issuers that file electronically with the SEC.
You may read and copy this annual report, including the related exhibits and schedules, and any document we file with the SEC at http://www.sec.gov.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a &#8220;foreign private issuer,&#8221; we are subject to the information reporting requirements of the Exchange Act that are applicable
to foreign private issuers, and under those requirements file reports with the SEC. Those other reports or other information may be inspected
without charge at the locations described above. As a &#8220;foreign private issuer,&#8221; we are exempt from the rules under the Exchange
Act related to the furnishing and content of proxy statements, and our officers, directors and principal shareholders will be exempt
from the reporting and &#8220;short-swing&#8221; profit recovery provisions contained in Section 16 of the Exchange Act with respect
to their purchases and sales of ordinary shares. Furthermore, as a &#8220;foreign private issuer,&#8221; we are also not subject to the
requirements of Regulation FD (Fair Disclosure) promulgated under the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 134; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->134<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
maintain a corporate website at http://www.galmedpharma.com. Information contained on, or that can be accessed through, our website is
not incorporated by reference into this annual report and does not constitute a part of this annual report. We have included our website
address in this annual report solely as an inactive textual reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>I.
Subsidiary Information.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>J.
Annual Report to Security Holders</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aa_006"></span>ITEM
11. Quantitative and Qualitative Disclosures About Market Risk.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Quantitative
and Qualitative Disclosure About Market Risk</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are exposed to market risks in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial
position, results of operations or cash flows due to adverse changes in financial market prices and rates, including interest rates and
foreign exchange rates, of financial instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Foreign
Currency Exchange Risk</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
foreign currency exposures give rise to market risk associated with exchange rate movements of the Euro and NIS mainly against the U.S.
dollar because a large portion of our expenses are denominated in Euros and NIS. Our Euro expenses consist principally of payments made
to sub-contractors and consultants for pre-clinical studies, clinical trials and other research and development activities. Our NIS expenses
consist principally of payments made to employees, subcontractors and consultants for pre-clinical studies, clinical trials, professional
services, other research and development activities and general and administrative activities. We anticipate that a large portion of
our expenses will continue to be denominated in currencies other than the U.S. dollar. Our financial position, results of operations
and cash flow are subject to fluctuations due to changes in foreign currency exchange rates. Our results of operations and cash flow
are, therefore, subject to fluctuations due to changes in foreign currency exchange rates and may be adversely affected in the future
due to changes in foreign exchange rates. Approximately 35% of our expected expenses are denominated in NIS. Changes of 5% and 10% in
the U.S. dollar to NIS exchange rate will increase/decrease our operation expenses by 1.75% and 3.5%, respectively. Approximately 10%
of our expected expenses are denominated in Euros. Changes of 5% and 10% in the U.S. dollar to Euro exchange rate, will increase/decrease
our operation expenses by 0.5% and 1.0%, respectively. To date, fluctuations in the exchange rates have not materially affected our results
of operations or financial condition for the periods under review.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, we have not engaged in hedging our foreign currency exchange risk. In the future, we may enter into formal currency hedging transactions
to decrease the risk of financial exposure from fluctuations in the exchange rates of our principal operating currencies. These measures,
however, may not adequately protect us from the material adverse effects of such fluctuations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Interest
Rate Risk</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
primary exposure to market risk is interest income sensitivity, which is affected by changes in the general level of U.S. interest rates.
We currently do not hedge interest rate exposure. Because of the short-term maturities of our cash equivalents and investment securities,
we do not believe that an increase in market rates would have any significant impact on the realized value of our investment securities.
If a 10% change in interest rates were to have occurred on December 31, 2024, this change would not have had a material effect on the
fair value of our investment portfolio as of that date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 135; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->135<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Liquidity</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not believe that our cash and cash equivalents and available for sale investments have significant risk of default or illiquidity.
While we believe our cash, cash equivalents and available for sale investments do not contain excessive risk, we cannot provide absolute
assurance that in the future our investments will not be subject to adverse changes in market value. In addition, we maintain significant
amounts of cash and cash equivalents at one or more financial institutions that are in excess of federally insured limits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aa_007"></span>ITEM
12. Description of Securities Other Than Equity Securities.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.
Debt Securities.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.
Warrants and Rights.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.
Other Securities.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.
American Depositary Shares.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aa_008"></span>PART
II</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aa_009"></span>ITEM
13. Defaults, Dividend Arrearages and Delinquencies.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aa_010"></span>ITEM
14. Material Modifications to the Rights of Security Holders and Use of Proceeds.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aa_011"></span>ITEM
15. Controls and Procedures.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Disclosure
Controls and Procedures</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
performed an evaluation of the effectiveness of our disclosure controls and procedures that are designed to ensure that information required
to be disclosed in this annual report and filed with the SEC is recorded, processed, summarized and reported timely within the time period
specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures
designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange
Act, is accumulated and communicated to the issuer&#8217;s management, including its principal executive and principal financial officers,
or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. There can be no assurance
that our disclosure controls and procedures will detect or uncover all failures of persons within our Company to disclose information
otherwise required to be set forth in our reports. Nevertheless, our disclosure controls and procedures are designed to provide reasonable
assurance of achieving the desired control objectives. Based on our evaluation, our management, including our President, Chief Executive
Officer and Chairman and Chief Accounting Officer, have concluded that our disclosure controls and procedures (as defined in Rules 13a-15(e)
and 15(d)-15(e) of the Exchange Act) as of the end of the period covered by this annual report are effective at such reasonable assurance
level.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 136; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->136<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Management&#8217;s
Annual Report on Internal Control over Financial Reporting</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management is responsible for establishing and maintaining adequate internal control over our financial reporting. Internal control over
financial reporting is defined in Rule 13a-15(f) or 15d-15(f) promulgated under the Exchange Act as a process designed by, or under the
supervision of, the company&#8217;s principal executive and principal financial officers and effected by the company&#8217;s board of
directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation
of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies
and procedures that:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pertain
    to the maintenance of records that in reasonable detail accurately and fairly reflect the transaction and dispositions of the assets
    of the company;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide
    reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with
    generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with
    authorizations of management and directors of the company; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide
    reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the company&#8217;s
    assets that could have a material effect on the financial statements.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation
of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that
the degree of compliance with the policies or procedures may deteriorate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management assessed the effectiveness of our internal control over financial reporting as of December 31, 2024. In making this assessment,
our management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal
Control-Integrated Framework (2013). Based on that assessment, our management concluded that as of December 31, 2024, our internal control
over financial reporting was effective.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changes
in Internal Controls Over Financial Reporting</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no changes in our internal control over financial reporting that occurred during the year ended December 31, 2024 that have materially
affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aa_012"></span>ITEM
16. [RESERVED]</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aa_013"></span>ITEM
16A. Audit Committee Financial Expert.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board has determined that Mr. Poshinski qualifies as an audit committee financial expert pursuant to the applicable SEC rules and that
Mr. Poshinski is &#8220;independent&#8221; in accordance with the Nasdaq Capital Market corporate governance requirements. For information
relating to Mr. Poshinski&#8217;s qualifications and experience, see &#8220;Item 6. Directors, Senior Management and Employees&#8212;A.
Directors and Senior Management.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aa_014"></span>ITEM
16B. Code of Ethics.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have adopted a Code of Business Conduct and Ethics applicable to all of our directors and employees, including our President, Chief Executive
Officer and Chairman, Chief Financial Officer, controller or principal accounting officer or other persons performing similar functions,
which is a &#8220;code of ethics&#8221; as defined in Item 16B of Form 20-F promulgated by the SEC and as required by the Nasdaq Listing
Rules, which refers to Section 406(c) of the Sarbanes-Oxley Act. Section 406(c) of the Sarbanes-Oxley Act provides that a &#8220;code
of ethics&#8221; means such standards as are reasonably necessary to promote (i) honest and ethical conduct, including the ethical handling
of actual or apparent conflicts of interest between personal and professional relationships; (ii) full, fair, accurate, timely and understandable
disclosure in the periodic reports required to be filed by the issuer; and (iii) compliance with applicable governmental rules and regulation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 137; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->137<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
full text of the Code of Business Conduct and Ethics is posted on our website at www.galmedpharma.com. Information contained on, or that
can be accessed through, our website does not constitute a part of this prospectus and is not incorporated by reference herein. We will
provide a copy of such code of ethics without charge upon request by mail or by telephone. If we make any amendment to the Code of Business
Conduct and Ethics or grant any waivers, including any implicit waiver, from a provision of the Code of Business Conduct and Ethics,
we will disclose the nature of such amendment or waiver on our website to the extent required by the rules and regulations of the SEC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aa_015"></span>ITEM
16C. Principal Accountant Fees and Services.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brightman
Almagor Zohar &amp; Co., a Firm in the Deloitte Global Network, an independent registered public accounting firm, served as our independent
public accountants for the fiscal years ended December 31, 2024 and 2023, for which audited financial statements appear in this annual
report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the aggregate fees for professional services rendered by such accountants to us during their respective term
as our principal accountants in 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(US$ in thousands)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(US$ in thousands)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Audit Fees (1)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">170</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">160</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Tax and incentives Fees (2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold"><b>Total</b></td><td><b>&#160;</b></td>
    <td style="text-align: left"><b>&#160;</b></td><td style="text-align: right"><b>178</b></td><td style="text-align: left"><b>&#160;</b></td><td><b>&#160;</b></td>
    <td style="text-align: left"><b>&#160;</b></td><td style="text-align: right"><b>160</b></td><td style="text-align: left"><b>&#160;</b></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    professional services rendered in connection with the audit of our annual financial statements and the review of our interim financial
    statements, including consents and comfort letters for registration statement filings.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
    fees consist of services related to obtaining a tax rulings.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Audit
Committee Pre-Approval Policies and Procedures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
of our audit committee&#8217;s main roles is to assist the board of directors in fulfilling its responsibility for oversight of the quality
and integrity of the accounting, auditing and reporting practices of the Company. The audit committee oversees the appointment, compensation,
and oversight of the public accounting firm engaged to prepare or issue an audit report on the financial statements of the Company. Our
Board has delegated to the audit committee the power to pre-approve non-auditing services rendered by the Company&#8217;s independent
auditors without the need for further approval by the board of directors. As such, our audit committee has adopted a pre-approval policy
for the engagement of our independent registered public accounting firm to perform certain audit and non-audit services. Pursuant to
this policy, which is designed to assure that such engagements do not impair the independence of our auditors, the audit committee pre-approves
annually a list of specific audit and non-audit services in the categories of audit services, audit-related services, tax services and
other services that may be performed by our independent registered public accounting firm. The last pre-approval policy was adopted by
our audit committee on April 2, 2024 for a period of twelve months. Since its establishment in May 2014, the audit committee has approved
all of the audit-related fees, tax fees and all other fees. If a type of service that is to be provided by our auditors has not received
such general pre-approval, it will require specific pre-approval by our audit committee. The policy prohibits retention of the independent
registered public accounting firm to perform the prohibited non-audit functions defined in applicable SEC rules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aa_016"></span>ITEM
16D. Exemptions from the Listing Standards for Audit Committees.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 138; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->138<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aa_017"></span>ITEM
16E. Purchases of Equity Securities by the Issuer and Affiliated Purchasers.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aa_018"></span>ITEM
16F. Change in Registrant&#8217;s Certifying Accountant.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aa_019"></span>ITEM
16G. Corporate Governance.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
shares are listed on the Nasdaq Capital Market under the symbol &#8220;GLMD.&#8221; In addition to the corporate governance requirements
of the Sarbanes-Oxley Act and the related rules implemented by the SEC, we must comply with the Nasdaq Listing Rules. Under those Nasdaq
Listing Rules, we may elect to follow certain corporate governance practices permitted under the Companies Law in lieu of compliance
with corresponding corporate governance requirements otherwise imposed by the Nasdaq Listing Rules for U.S. domestic issuers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with Israeli law and practice, and subject to the exemption set forth in Rule 5615 of the Nasdaq Listing Rules, we follow
the provisions of the Companies Law, rather than the Nasdaq Listing Rules, with respect to the following requirements:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Distribution
    of certain reports to shareholders</i>. As opposed to the Nasdaq Listing Rules, which require listed issuers to make certain reports,
    such as annual reports, interim reports and quarterly reports, available to shareholders in one of a number of specific manners,
    Israeli law does not require us to distribute periodic reports directly to shareholders, and the generally accepted business practice
    in Israel is not to distribute such reports to shareholders, but to make such reports available through a public website. In addition
    to making such reports available on a public website, we plan to make our audited financial statements available to our shareholders
    at our offices and will only mail such reports to shareholders upon request. As a foreign private issuer, we are generally exempt
    from the SEC&#8217;s proxy solicitation rules. See &#8220;Item 10. Additional Information&#8212;Documents on Display&#8221; for a
    description of our Exchange Act reporting obligations.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Quorum</i>.
    While the Nasdaq Listing Rules require that the quorum for purposes of any meeting of the holders of a listed company&#8217;s common
    voting stock be no less than 33.33% of the company&#8217;s outstanding common voting stock, under Israeli law, a company is entitled
    to determine in its articles of association the number of shareholders and percentage of holdings required for a quorum at a shareholders
    meeting. Our articles of association provide that a quorum of two or more shareholders holding at least 33.33% of the voting rights
    in person or by proxy is required for commencement of business at a general meeting. However, the quorum set forth in our articles
    of association with respect to an adjourned meeting consists of any two shareholders present in person or by proxy even if, between
    them, they represent shares conferring 33.33% or less of the voting rights of the Company.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Nomination
    of directors</i>. With the exception of directors elected by our Board due to vacancy, our directors are elected by an annual meeting
    of our shareholders to hold office until the next annual meeting following three years from his or her election. See &#8220;Item
    6. Directors, Senior Management and Employees&#8212;C. Board Practices.&#8221; The nominations for directors, which are presented
    to our shareholders by our Board, are made by the nominating committee itself, in accordance with the provisions of Nasdaq Capital
    Market Listing Rule 5605(e), our Articles and the Companies Law.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 139; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->139<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Compensation
    of officers</i>. We follow the provisions of the Companies Law with respect to matters in connection with the composition and responsibilities
    of our remuneration committee, Office Holder compensation and any required approval by the shareholders of such compensation. Israeli
    law and our Articles do not require that the independent members of our Board, or a remuneration committee composed solely of independent
    members of our Board, determine an executive officer&#8217;s compensation, as is generally required under the Nasdaq Listing Rules
    with respect to the Chief Executive Officer and all other executive officers of a company. Instead, remuneration of Office Holders
    is determined and approved by our remuneration committee, and in general, by our Board as well, and in certain circumstances, by
    our shareholders, as detailed above. The requirements for shareholder approval of any Office Holder compensation, and the relevant
    majority or Special Majority for such approval, are all as set forth in the Companies Law. Thus, we seek shareholder approval for
    all corporate actions with respect to Office Holder compensation requiring such approval under the requirements of the Companies
    Law, including for our Compensation Policy and for certain Office Holder Compensation, rather than seeking approval for such corporate
    actions in accordance with Nasdaq Listing Rules. All members of our remuneration committee are independent directors under applicable
    Nasdaq Capital Market and SEC rules, as affirmatively determined by our Board. See &#8220;Item 6. Directors, Senior Management and
    Employees&#8212;B. Compensation.&#8221;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Independent
    directors</i>. Although Israeli law does not require that a majority of the directors serving on our Board be &#8220;independent,&#8221;
    as defined under Nasdaq Capital Market Listing Rule 5605(a)(2), but rather requires we have at least two external directors who meet
    the requirements of the Companies Law, as described above under &#8220;Item 6. Directors, Senior Management and Employees&#8212;C.
    Board Practices&#8212;External Directors.&#8221;, following our &#8220;opt-out&#8221; of the requirement to appoint external directors,
    a majority of our Board is independent based on the Nasdaq Capital Market rules. We are required, however, to ensure that all members
    of our audit committee are &#8220;independent&#8221; under the applicable Nasdaq Capital Market and SEC criteria for independence
    (as we cannot exempt ourselves from compliance with that SEC independence requirement, despite our status as a foreign private issuer).
    Our independent directors&#8217; conduct regularly scheduled meetings at which only such independent directors are present, as required
    by the Nasdaq Listing Rules. Our Board has affirmatively determined that each of Mr. Nir, Mr. Poshinski, Dr. Sidransky and Dr. Brosgart
    qualifies as &#8220;independent&#8221; under the Nasdaq Capital Market independence standards.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Shareholder
    approval</i>. We will seek shareholder approval for all corporate actions requiring such approval under requirements of the Companies
    Law, rather than seeking approval for corporate actions in accordance with Nasdaq Capital Market Listing Rule 5635. In particular,
    under this Nasdaq Capital Market rule, shareholder approval is generally required for: (i) an acquisition of shares or assets of
    another company that involves the issuance of 20% or more of the acquirer&#8217;s shares or voting rights or if a director, officer
    or 5% shareholder has greater than a 5% interest in the target company or the consideration to be received; (ii) the issuance of
    shares leading to a change of control; (iii) adoption or amendment of equity compensation arrangements; and (iv) issuances of 20%
    or more of the shares or voting rights (including securities convertible into, or exercisable for, equity) of a listed company via
    a private placement (or via sales by directors, officers or 5% shareholders) if such equity is issued (or sold) at below the greater
    of the book or market value of shares. By contrast, under the Companies Law, shareholder approval is required for, among other things:
    (i) transactions with directors concerning the terms of their service or indemnification, exemption and insurance for their service
    (or for any other position that they may hold at a company), for which approvals of the remuneration committee, board of directors
    and shareholders are all required, (ii) Extraordinary Transactions with controlling shareholders of publicly held companies, which
    require the special approval described under &#8220;Item 6. Directors, Senior Management and Employees&#8212;C. Board Practices&#8212;Approval
    of Related Party Transactions under Israeli Law&#8212; Transactions with Controlling Shareholders,&#8221; and (iii) terms of office
    and employment or other engagement of the controlling shareholder of the Company or such controlling shareholder&#8217;s relative,
    which require the special approval described under &#8220;Item 6. Directors, Senior Management and Employees&#8212;B. Compensation&#8221;
    and &#8220;Item 6. Directors, Senior Management and Employees&#8212;C. Board Practices&#8212; Approval of Related Party Transactions
    under Israeli Law.&#8221; In addition, under the Companies Law, a merger requires approval of the shareholders of each of the merging
    companies. See also &#8220;Compensation of officers&#8221; above.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aa_020"></span>ITEM
16H. Mine Safety Disclosure.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 140; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->140<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aa_021"></span>ITEM
16I. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aa_022"></span>ITEM
16J. Insider Trading Policies.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have <span id="xdx_904_eecd--InsiderTrdPoliciesProcAdoptedFlag_dbT_c20240101__20241231_zlO7um6DW4mj" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBQb2xpY2llcyBhbmQgUHJvY2VkdXJlcwA_"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000052" name="ecd:InsiderTrdPoliciesProcAdoptedFlag">adopted</ix:nonNumeric></span> a statement of trading policies that governs the trading in our securities by our directors, officers and certain other
covered persons, and which is reasonably designed to promote compliance with applicable insider trading laws, rules and regulations,
and any listing standards applicable to the Company. A copy of the Insider Trading Policy is included as Exhibit 11.2 to this annual
report. <span style="background-color: white">In addition, with regard to any trading in our own securities, it is our policy to comply
with the federal securities laws and the applicable exchange listing requirements.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aa_023"></span>ITEM
16K. Cybersecurity.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_986_ecyd--CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_iB_c20240101__20241231_gBFCRMPFAIAMT-XI_zx2nbOpqOK04" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" continuedAt="ConU000056-01" escape="true" id="Fact000056" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have developed and maintain a cybersecurity risk management program, consisting of cybersecurity policies, procedures, compliance and
awareness programs to mitigate risk and to ensure compliance with security, availability and confidentiality trust principles. <span id="xdx_903_ecyd--CybersecurityRiskManagementProcessesIntegratedTextBlock_c20240101__20241231_zgk7LVvGPvGd" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000057" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock">The cybersecurity
process has been integrated into our overall risk management system and process, and is solely internally managed. Management is responsible
for identifying risks that threaten achievement of the control activities stated in the management&#8217;s description of the services
organizations systems. Management has implemented a process for identifying relevant risks that could affect the organization&#8217;s
ability to provide secure and reliable service to its users. In addition, we maintain cybersecurity insurance.</ix:nonNumeric></span> The risk assessment occurs
as business needs change, and covers identification of risks that could act against the company&#8217;s objectives as well as specific
risks related to a compromise to the security of data. See &#8220;Item 3.D Risk Factors&#8212; Risks Related to Information Technology,
Intellectual Property and Data Security and Privacy&#8212;If we or our third-party service providers experience a security breach, data
loss or other compromise, including if unauthorized parties obtain access to our customers&#8217; data, our reputation may be harmed,
demand for our products and services may be reduced, and we may incur significant liabilities.&#8221;</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_C0D_gBFCRMPFAIAMT-XI_zoobIIZ0g8R"><ix:continuation continuedAt="ConU000056-02" id="ConU000056-01">&#160;</ix:continuation></span></span></p>

<div id="xdx_C0D_gBFCRMPFAIAMT-XI_z4QVWSMaLk3g"><ix:continuation continuedAt="ConU000056-03" id="ConU000056-02"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_dbT_c20240101__20241231_zvVjYnBRuX9j" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000058" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">The
oversight of cybersecurity threats is undertaken by our IT external provider, who holds over 25 years of experience, and is supported
by management. Our audit committee is responsible for cybersecurity oversight and monitoring risk. Management informs the audit and remuneration
committee of such risk at committee meetings.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbT_c20240101__20241231_zviIkgx3w7Ve" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000059" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">As
of the date of this report, we are not aware of any material risks from cybersecurity threats that have materially affected or are reasonably
likely to materially affect us, including our business strategy, results of operations or financial condition.</ix:nonNumeric></span></span></p>

</ix:continuation></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_C06_gBFCRMPFAIAMT-XI_zqMP3qYAAvA"><ix:continuation id="ConU000056-03">&#160;</ix:continuation></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aa_024"></span>PART
III</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aa_025"></span>ITEM
17. Financial Statements.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have responded to Item 18 in lieu of responding to this item.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 141; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->141<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aa_026"></span>ITEM
18. Financial Statements.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
refer to the financial statements beginning on page F-1. The following financial statements, financial statement schedules and related
notes are filed as part of this annual report, together with the report of the independent registered public accounting firm.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#aF_001">Report of Independent Registered Public Accounting Firm</a> (PCAOB ID: <span id="xdx_905_edei--AuditorFirmId_c20240101__20241231_za9mN5Mp4Fi1"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000060" name="dei:AuditorFirmId">1197</ix:nonNumeric></span>)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#aF_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Balance Sheets</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#aF_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Operations</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#aF_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Comprehensive Loss</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#aF_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Changes in Stockholders&#8217; Equity</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#aF_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Cash Flows</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#aF_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to Consolidated Financial Statements</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-8</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 142; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->142<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="finlog_001.jpg" alt=""/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aF_001"></span>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the shareholders and the Board of Directors of Galmed Pharmaceuticals Ltd.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Opinion
on the Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--AuditorOpinionTextBlock_c20240101__20241231_z4gtT6UbcnCl"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000061" name="dei:AuditorOpinionTextBlock">We
have audited the accompanying consolidated balance sheets of Galmed Pharmaceuticals Ltd. and subsidiaries (the &#8220;Company&#8221;)
as of December 31, 2024 and 2023, the related consolidated statements of operations, comprehensive loss, changes in stockholders&#8217;
equity and cash flows, for each of the three years in the period ended December 31, 2024, and the related notes (collectively referred
to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in
all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and
its cash flows for each of the three years in the period ended December 31, 2024, in conformity with accounting principles generally
accepted in the United States of America.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis
for Opinion</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion
on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public
Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company
in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission
and the PCAOB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud.
Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether
due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence
regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles
used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.
We believe that our audits provide a reasonable basis for our opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Audit Matter</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
critical audit matter communicated below is a matter arising from the current-period audit of the financial statements that was communicated
or required to be communicated to the audit committee and that (1) relates to accounts or disclosures that are material to the financial
statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters
does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit
matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Marketable
Debt Securities Classified as Available-for-Sale&#8211; Refer to Note 3 to the consolidated financial statements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Critical
Audit Matter Description</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company invests its excess cash primarily in available-for-sale marketable debt securities. Investments in marketable debt securities
classified as available-for-sale are reported at fair value in the financial statements. The investments totaled approximately $7.2 million
on December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 143; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
identified the investments in marketable debt securities classified as available-for-sale as a critical audit matter because of the magnitude
of these investments and due to the increased extent of audit effort in relation to our audit as a whole.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>How
the Critical Audit Matter Was Addressed in the Audit</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audit procedures related to the Company&#8217;s investments in marketable debt securities classified as available-for-sale included the
following, among others:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    assessed the accuracy and completeness of the quantities of marketable debt securities held by the Company as of December 31, 2024
    by comparing the Company&#8217;s investment report to the custodians&#8217; balance confirmations.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    obtained independent estimates of the fair value of the investments in marketable debt securities classified as available-for-sale
    held by the Company as of December 31, 2024 and compared our estimates to the Company&#8217;s estimates.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    agreed the recorded values of investments in marketable debt securities classified as available-for-sale to the fair values indicated
    in the custodians&#8217; balance confirmations.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>/s/
Brightman Almagor Zohar &amp; Co.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_907_edei--AuditorName_c20240101__20241231_zZK4rEsWgR69"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000062" name="dei:AuditorName">Brightman
Almagor Zohar &amp; Co.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certified
Public Accountants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A
Firm in the Deloitte Global Network</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_edei--AuditorLocation_c20240101__20241231_zWVIFKXrMEc2"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000063" name="dei:AuditorLocation">Tel
Aviv, Israel</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
2, 2025</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have served as the Company&#8217;s auditor since 2013.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 144; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aF_002"></span>GALMED
PHARMACEUTICALS LTD.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated
Balance Sheet</b>s</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>U.S.
Dollars in thousands, except share data and per share data</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_308_111_pn3n3_zxb2GcRrd06l" summary="xdx: Statement - Consolidated Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20241231_z8AUBhDiFDO5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20231231_zsdRIDJMiY09" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Note</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AssetsAbstract_iB_zGOJvLspGrg7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Assets</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AssetsCurrentAbstract_i01B_zzI1tyqJm4hg" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Current assets</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maACzrxv_zQwhiTQscSCe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 54%; text-align: left">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 8%; text-align: center">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2024-12-31" id="Fact000071" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,652</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-12-31" id="Fact000072" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,861</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--RestrictedCashCurrent_i02I_pn3n3_maACzrxv_zjwpQw4SSZn7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted cash</td><td>&#160;</td>
    <td style="text-align: center">10</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RestrictedCashCurrent" contextRef="AsOf2024-12-31" id="Fact000074" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">121</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RestrictedCashCurrent" contextRef="AsOf2023-12-31" id="Fact000075" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">117</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DepositsAssetsCurrent_i02I_maACzrxv_zPYK4KTVWTS" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Short-term deposits</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepositsAssetsCurrent" contextRef="AsOf2024-12-31" id="Fact000077" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,496</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepositsAssetsCurrent" contextRef="AsOf2023-12-31" id="Fact000078" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,253</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--MarketableSecuritiesCurrent_i02I_maACzrxv_zbUy0y1vtfNa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Marketable debt securities</td><td>&#160;</td>
    <td style="text-align: center">3</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:MarketableSecuritiesCurrent" contextRef="AsOf2024-12-31" id="Fact000080" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,183</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:MarketableSecuritiesCurrent" contextRef="AsOf2023-12-31" id="Fact000081" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,528</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OtherReceivablesNetCurrent_i02I_maACzrxv_zXbNyfGiHFK7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other receivables</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt">4</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherReceivablesNetCurrent" contextRef="AsOf2024-12-31" id="Fact000083" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">672</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherReceivablesNetCurrent" contextRef="AsOf2023-12-31" id="Fact000084" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">480</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AssetsCurrent_i02TI_maAz1Kh_mtACzrxv_ztCmHAqiQJF7" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-left: 10pt">Total current assets</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2024-12-31" id="Fact000086" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16,124</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2023-12-31" id="Fact000087" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13,239</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_maANzeLV_z1MXDOlzdGt2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating lease right-of-use assets</td><td>&#160;</td>
    <td style="text-align: center">5</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0089">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-12-31" id="Fact000090" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">42</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_i01I_pn3n3_maANzeLV_zRYgkrntmAS4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Property and equipment, net</td><td>&#160;</td>
    <td style="text-align: center">6</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0092">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-12-31" id="Fact000093" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">83</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_i01I_maANzeLV_ziZbyqx1gpo8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Investment in associate at fair value</td><td>&#160;</td>
    <td style="text-align: center">7</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" contextRef="AsOf2024-12-31" id="Fact000095" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,119</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" contextRef="AsOf2023-12-31" id="Fact000096" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,265</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OtherAssetsNoncurrent_i01I_maANzeLV_zoXlxgQYxTg7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loan to associate</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt">7</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2024-12-31" id="Fact000098" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">257</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0099">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AssetsNoncurrent_i01TI_mtANzeLV_maAz1Kh_zB53XO6VmB8a" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Total non-current assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2024-12-31" id="Fact000101" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,376</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2023-12-31" id="Fact000102" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,390</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--Assets_i01TI_mtAz1Kh_ztnXYnxww8vl" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Total assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-12-31" id="Fact000104" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">18,500</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-12-31" id="Fact000105" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16,629</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_z0ICJJLLhvJ7" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Liabilities and stockholders&#8217; equity</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LiabilitiesCurrentAbstract_i01B_zAFlrDkxDHfg" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Current liabilities</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AccountsPayableCurrent_i02I_maCzBey_zLi9NSdfYDX2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Trade payables</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2024-12-31" id="Fact000113" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,308</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2023-12-31" id="Fact000114" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,879</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OtherLoansPayableCurrent_i02I_maCzBey_zwXvSIX3pWSd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other payables</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt">8</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherLoansPayableCurrent" contextRef="AsOf2024-12-31" id="Fact000116" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">865</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherLoansPayableCurrent" contextRef="AsOf2023-12-31" id="Fact000117" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">871</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LiabilitiesCurrent_i02TI_mtCzBey_maLASEzugD_zsDQdB6spLu6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-left: 10pt">Total current liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000119" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,173</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000120" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,750</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--CommitmentsAndContingencies_iI_maLASEzugD_zCIRmbRG5Ib2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Commitments and contingencies liabilities</td><td>&#160;</td>
    <td style="text-align: center">10</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0122">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0123">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--StockholdersEquityAbstract_iB_zxXedMPzaNA8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Stockholders&#8217; equity</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--CommonStockValue_i01I_maSEzsbJ_z4Uw7UcvA1xb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Ordinary shares, par value NIS <span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_uILSPShares_c20241231_zJcOAh3jg4g6" title="Ordinary shares, par value"><span id="xdx_903_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_uILSPShares_c20231231_zBpkDlA0dgec" title="Ordinary shares, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31" id="Fact000131" format="ixt:numdotdecimal" decimals="INF" unitRef="ILSPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31" id="Fact000133" format="ixt:numdotdecimal" decimals="INF" unitRef="ILSPShares">1.80</ix:nonFraction></ix:nonFraction></span>
    </span>per share; Authorized <span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20241231_zWn5bTKi3s7k" title="Ordinary shares, authorized"><span id="xdx_90B_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20231231_zwmqS6RDcULj" title="Ordinary shares, authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact000135" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-12-31" id="Fact000137" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000,000</ix:nonFraction></ix:nonFraction></span></span>
    shares; Issued and outstanding: <span id="xdx_90C_eus-gaap--CommonStockSharesIssued_iI_pid_c20241231_zAXoPzUirHt8" title="Ordinary shares, issued"><span id="xdx_90E_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20241231_zmvy6SPuJua3" title="Ordinary shares, outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-12-31" id="Fact000139" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-12-31" id="Fact000141" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,664,884</ix:nonFraction></ix:nonFraction></span></span>
    and <span id="xdx_900_eus-gaap--CommonStockSharesIssued_iI_pid_c20231231_zfWVe6fmXak5" title="Ordinary shares, issued"><span id="xdx_905_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20231231_zjtZev47dESd" title="Ordinary shares, outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-12-31" id="Fact000143" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-12-31" id="Fact000145" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">573,741</ix:nonFraction></ix:nonFraction></span></span> shares as of December
    31, 2024 and December 31, 2023, respectively <span id="xdx_F46_zZ4iVKUFUfwk">(*)</span></td><td>&#160;</td>
    <td style="text-align: center">11</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2024-12-31" id="Fact000128" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">742</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-12-31" id="Fact000129" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">209</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AdditionalPaidInCapital_i01I_maSEzsbJ_zLnh6Pskghh7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2024-12-31" id="Fact000147" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">216,470</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2023-12-31" id="Fact000148" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">207,076</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_i01I_maSEzsbJ_zSl4Bu3vWYEi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Accumulated other comprehensive loss</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2024-12-31" id="Fact000150" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">416</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2023-12-31" id="Fact000151" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">454</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--RetainedEarningsAccumulatedDeficit_i01I_maSEzsbJ_zuo9LKuBi3mk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Accumulated deficit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-12-31" id="Fact000153" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">200,469</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-12-31" id="Fact000154" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">192,952</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--StockholdersEquity_i01TI_mtSEzsbJ_maLASEzugD_zEByzVELKSpb" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-left: 10pt">Total stockholders&#8217; equity</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000156" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16,327</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000157" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13,879</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LiabilitiesAndStockholdersEquity_iTI_mtLASEzugD_zOLzsjsEcHP4" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Total liabilities and stockholders&#8217; equity</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000159" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">18,500</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000160" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16,629</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span id="xdx_F09_zPHSplGVVVv7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(*)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F11_zwzUOSiM26J5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000161" xml:lang="en-US">Retroactively
    adjusted to reflect the <span id="xdx_903_eus-gaap--StockholdersEquityReverseStockSplit_c20240101__20241231_ztGOQ4rE0CZ9" title="Reverse stock split"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000163" name="us-gaap:StockholdersEquityReverseStockSplit">12-1 reverse split</ix:nonNumeric></span> that was effected in August 2024 (see Note 11(A)(3))</ix:footnote></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accompanying
notes are an integral part of the consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 145; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aF_003"></span>GALMED
PHARMACEUTICALS LTD.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated
Statements of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>U.S.
Dollars in thousands, except share data and per share data</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_307_113_pn3n3_zDTxkCc99av1" summary="xdx: Statement - Consolidated Statements of Operations" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20240101__20241231_zMf8h3hoyrU9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20230101__20231231_zfA8ROfulY3k" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20220101__20221231_znW25bL8lYu4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ResearchAndDevelopmentExpense_maCzm97_zjlbBqIBphSj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left">Research and development expenses</td><td style="width: 2%">&#160;</td>
    <td style="width: 8%; text-align: center">12</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000165" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,979</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31" id="Fact000166" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,569</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31" id="Fact000167" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,995</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--GeneralAndAdministrativeExpense_maCzm97_ztiIMs1UDES4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">General and administrative expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt">13</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000169" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,299</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-012023-12-31" id="Fact000170" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,923</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-01-012022-12-31" id="Fact000171" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,656</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingExpenses_iT_mtCzm97_msNILzBBR_zbQhTlxX42h3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-left: 10pt">Total operating loss</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2024-01-01to2024-12-31" id="Fact000173" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,278</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2023-01-012023-12-31" id="Fact000174" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,492</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2022-01-012022-12-31" id="Fact000175" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17,651</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OtherNonoperatingIncomeExpense_iN_di_maNILzBBR_z7z6lS8xsywa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Financial loss (income), net</td><td>&#160;</td>
    <td style="text-align: center">14</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000177" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">516</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2023-01-012023-12-31" id="Fact000178" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">580</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2022-01-012022-12-31" id="Fact000179" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">215</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--FinancialExpenses_msNILzBBR_z8gskbkoy4x9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Financial expenses related to SEPA</td><td>&#160;</td>
    <td style="text-align: center">11</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GLMD:FinancialExpenses" contextRef="From2024-01-01to2024-12-31" id="Fact000181" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">610</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0182">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0183">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--ImpairmentOnAssociate_msNILzBBR_zwe7KI3RpUrg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Impairment on associate</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt">7</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="GLMD:ImpairmentOnAssociate" contextRef="From2024-01-01to2024-12-31" id="Fact000185" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,145</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0186">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0187">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetIncomeLoss_iNT_di_mtNILzBBR_zHMLiG8agvB6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-left: 10pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000189" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">7,517</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000190" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,912</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31" id="Fact000191" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">17,866</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Basic and diluted net loss per share <span id="xdx_F4B_zxBcGrFyexX6">(*)</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_907_eus-gaap--EarningsPerShareBasic_pid_c20240101__20241231_fKCop_zEjtbae9FJB" title="Basic, net loss per share" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><span id="xdx_903_eus-gaap--EarningsPerShareDiluted_pid_c20240101__20241231_fKCop_zy8E84xbtK9" title="Diluted, net loss per share" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-01-01to2024-12-31" id="Fact000193" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-01-01to2024-12-31" id="Fact000195" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.08</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_904_eus-gaap--EarningsPerShareBasic_pid_c20230101__20231231_fKCop_zf5XhwCQMZm3" title="Basic, net loss per share" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><span id="xdx_90A_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20231231_fKCop_zL0er74iaG5a" title="Diluted, net loss per share" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-01-012023-12-31" id="Fact000197" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-01-012023-12-31" id="Fact000199" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">30.00</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_909_eus-gaap--EarningsPerShareBasic_pid_c20220101__20221231_fKCop_ziV4SbZmrmi2" title="Basic, net loss per share" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><span id="xdx_905_eus-gaap--EarningsPerShareDiluted_pid_c20220101__20221231_fKCop_zudxiWPNyuc1" title="Diluted, net loss per share" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-01-012022-12-31" id="Fact000201" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2022-01-012022-12-31" id="Fact000203" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">127.80</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Weighted-average number of shares outstanding used in computing basic and diluted net loss per share
    <span id="xdx_F49_z4L2DgxRUzxi">(*)</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240101__20241231_fKCop_z6inZLsAKcl3" title="Weighted average number of shares outstanding used in computing net loss per share, basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><span id="xdx_906_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240101__20241231_fKCop_zVIFP0pDml5j" title="Weighted average number of shares outstanding used in computing net loss per share, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-01-01to2024-12-31" id="Fact000205" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-01-01to2024-12-31" id="Fact000207" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">930,822</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230101__20231231_fKCop_zNWCRRBeNmB1" title="Weighted average number of shares outstanding used in computing net loss per share, basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230101__20231231_fKCop_zf0z1YGKNo2d" title="Weighted average number of shares outstanding used in computing net loss per share, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-012023-12-31" id="Fact000209" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-012023-12-31" id="Fact000211" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">230,795</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20220101__20221231_fKCop_zhoZ77NROgla" title="Weighted average number of shares outstanding used in computing net loss per share, basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20220101__20221231_fKCop_zTa1q2mdIuUc" title="Weighted average number of shares outstanding used in computing net loss per share, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-01-012022-12-31" id="Fact000213" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2022-01-012022-12-31" id="Fact000215" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">139,682</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span id="xdx_F05_zisJUZiQ9NYh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(*)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1B_zStl5gbd3eI7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000216" xml:lang="en-US">Retroactively
    adjusted to reflect the <span id="xdx_908_eus-gaap--StockholdersEquityReverseStockSplit_c20240101__20241231_zsT0zUcMI9de" title="Reverse stock split"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000218" name="us-gaap:StockholdersEquityReverseStockSplit">12-1 reverse split</ix:nonNumeric></span> that was affected in August 2024 (see Note 11(A)(3))</ix:footnote></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accompanying
notes are an integral part of the consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 146; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aF_004"></span>GALMED
PHARMACEUTICALS LTD.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated
Statements of Comprehensive Loss</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>U.S.
Dollars in thousands, except share data and per share data</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_306_113_pn3n3_zdxW7DWo6m43" summary="xdx: Statement - Consolidated Statements of Comprehensive Loss" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20240101__20241231_zZKfx17A0QJk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20230101__20231231_zlH1PxRLSxk9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20220101__20221231_zPumwaRILps8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLoss_iN_di_maCzhrw_zoqkLIwOLjXc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; font-weight: bold; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000220" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">7,517</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000221" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,912</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31" id="Fact000222" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">17,866</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OtherComprehensiveIncomeLossTaxAbstract_iB_z1mZD5xA1q66" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other comprehensive loss:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DebtSecuritiesAvailableForSaleUnrealizedGainLoss_i01N_di_maCzhrw_zSqtIBKIdiMc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Net unrealized loss (gain) on available for sale securities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000228" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">38</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" contextRef="From2023-01-012023-12-31" id="Fact000229" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">291</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" contextRef="From2022-01-012022-12-31" id="Fact000230" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">574</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_i01NT_di_mtCzhrw_zI0xUOYsB3m4" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-left: 10pt">Comprehensive loss</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="From2024-01-01to2024-12-31" id="Fact000232" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">7,479</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="From2023-01-012023-12-31" id="Fact000233" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,621</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="From2022-01-012022-12-31" id="Fact000234" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">18,440</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accompanying
notes are an integral part of the consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 147; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aF_005"></span>GALMED
PHARMACEUTICALS LTD.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Statements
of Changes in Stockholders&#8217; Equity</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>U.S.
Dollars in thousands, except share data and per share data</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_300_114_pn3n3_z8mQyxIvbuKe" summary="xdx: Statement - Statements of Changes in Stockholders' Equity" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_4B8_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_z6Q3qbZLp0Pa" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_4BA_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zvxoPV68rjog" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4B4_us-gaap--StatementEquityComponentsAxis_us-gaap--AccumulatedOtherComprehensiveIncomeMember_z5CDdQpssEWi" style="font-weight: bold; text-align: center">Accumulated</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_4BE_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zCLDgJvGjqO1" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_4BD_zAzZQLLaKB2g" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Additional</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">other</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Ordinary shares (**)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">paid-in</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">comprehensive</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Accumulated</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_F5B_z30zEeWv7F56" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">capital</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">income (loss)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">deficit</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_43A_c20220101__20221231_eus-gaap--StockholdersEquity_iS_z7dNChNA5iF3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-weight: bold">Balance - December 31, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharesOutstanding_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKCoqKQ_____zujW88pbYLr9" title="Balance, shares" style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" id="Fact000242" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">293,682</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" id="Fact000236" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">70</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000237" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">198,772</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000238" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">171</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" id="Fact000239" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">168,174</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" id="Fact000240" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30,497</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_zFbcF2I9tkB1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0244">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000245" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,296</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0246">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0247">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" contextRef="From2022-01-012022-12-31" id="Fact000248" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,296</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zkNVaQjOXwG6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of ordinary shares in ATM offering net of issuance costs of $<span id="xdx_906_eus-gaap--PaymentsOfStockIssuanceCosts_pn3n3_c20220101__20221231_zAZAcStMTAP3" title="Stock issuance cost"><ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2022-01-012022-12-31" id="Fact000256" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKCoqKQ_____zwyGxppTtO37" title="Issuance of ordinary shares in at-the-market (&quot;ATM&quot;) offering, net of issuance costs, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="Fact000258" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">643</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0250">-</span></span><span id="xdx_F29_zm2kSdVnHvI">(*)</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000251" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">70</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0252">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0253">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-12-31" id="Fact000254" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">70</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_zc5afgdWsRmg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Unrealized loss from marketable debt securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0260">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0261">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000262" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">574</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0263">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="From2022-01-012022-12-31" id="Fact000264" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">574</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetIncomeLoss_zulfyQxx2Vp2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0266">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0267">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0268">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="Fact000269" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">17,866</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31" id="Fact000270" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">17,866</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_434_c20230101__20231231_eus-gaap--StockholdersEquity_iS_zHyUCHjm2qvb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance - December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKCoqKQ_____zX6oTtqEbep9" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000278" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">294,325</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000272" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">70</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000273" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">200,138</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000274" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">745</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" id="Fact000275" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">186,040</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" id="Fact000276" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13,423</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--StockIssuedDuringPeriodValueOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts_z2nxnhdMrYP1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of ordinary shares, pre-funded warrants, and warrants net of issuance costs of $<span id="xdx_904_ecustom--WarrantsNetOfIssuanceCosts_pn3n3_c20230101__20231231_zwygpA02HEh8" title="Warrants net of issuance costs"><ix:nonFraction name="GLMD:WarrantsNetOfIssuanceCosts" contextRef="From2023-01-012023-12-31" id="Fact000286" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">756</ix:nonFraction>
    </span>thousand <span id="xdx_F4F_zS3UE94YLBdi">(***)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--StockIssuedDuringPeriodSharesOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKCoqKSgqKiop_z9IHGJrZNN2" title="Issuance of ordinary shares, pre-funded warrants, and warrants net of issuance costs, shares" style="text-align: right"><ix:nonFraction name="GLMD:StockIssuedDuringPeriodSharesOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000288" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">31,667</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GLMD:StockIssuedDuringPeriodValueOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000280" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GLMD:StockIssuedDuringPeriodValueOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000281" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,169</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0282">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0283">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GLMD:StockIssuedDuringPeriodValueOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts" contextRef="From2023-01-012023-12-31" id="Fact000284" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,185</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--ExerciseOfPrefundedWarrants_zb57XbFRZPed" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise of Pre-funded warrants <span id="xdx_F4D_zRFFgsngKHoj">(***)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--ExerciseOfPrefundedWarrantsShares_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKCoqKSgqKiop_zS29K9j6J7H5" title="Exercise of Pre-funded warrants, shares" style="text-align: right"><ix:nonFraction name="GLMD:ExerciseOfPrefundedWarrantsShares" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000296" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">247,749</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GLMD:ExerciseOfPrefundedWarrants" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000290" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">123</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="GLMD:ExerciseOfPrefundedWarrants" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000291" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">123</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0292">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0293">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0294">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_zVM5xaFcJGuf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0298">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000299" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">892</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0300">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0301">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" contextRef="From2023-01-012023-12-31" id="Fact000302" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">892</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_zWwCClvHsike" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Unrealized gain on marketable debt securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0304">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0305">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000306" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">291</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0307">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="From2023-01-012023-12-31" id="Fact000308" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">291</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetIncomeLoss_zoKHKdkUIwz1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0310">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0311">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0312">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="Fact000313" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,912</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000314" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,912</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_438_c20240101__20241231_eus-gaap--StockholdersEquity_iS_z6IQHOx0RVwl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Balance - December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharesOutstanding_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKCoqKQ_____zgBMfINJuxS" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000322" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">573,741</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000316" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">209</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000317" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">207,076</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000318" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">454</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000319" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">192,952</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000320" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13,879</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_436_c20240101__20241231_eus-gaap--StockholdersEquity_iS_ziljQMjAIPCb" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Balance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharesOutstanding_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKCoqKQ_____zpvRy0lnCXxh" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000330" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">573,741</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000324" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">209</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000325" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">207,076</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000326" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">454</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000327" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">192,952</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000328" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13,879</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_zFMMgwpshoW7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of ordinary shares in relation to SEPA <span id="xdx_F44_zH2EYzMnCpu7">(****)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKCoqKSgqKioqKQ_____zFA7Wgk5VYg9" title="Issuance of ordinary shares in relation to SEPA, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000338" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">558,775</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000332" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">272</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000333" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,654</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0334">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0335">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2024-01-01to2024-12-31" id="Fact000336" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,926</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--StockIssuedDuringPeriodValueOther_z8lOrF7WTUih" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Issuance of SEPA Commitment Shares <span id="xdx_F47_zdyKztlkpgnh">(****)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesOther_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKCoqKSgqKioqKQ_____zvS92AvwTZtc" title="Issuance of SEPA Commitment Shares, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000346" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,784</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000340" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000341" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">62</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-01-01to2024-12-31" id="Fact000344" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">70</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--ExerciseOfPrefundedWarrants_zPvNwtM82J2g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise of Pre-funded warrants <span id="xdx_F40_zMK2P34AhgQ9">(***)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--ExerciseOfPrefundedWarrantsShares_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKCoqKSgqKiop_zoWDS99342Hd" title="Exercise of Pre-funded warrants, shares" style="text-align: right"><ix:nonFraction name="GLMD:ExerciseOfPrefundedWarrantsShares" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000354" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">186,723</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GLMD:ExerciseOfPrefundedWarrants" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000348" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">92</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="GLMD:ExerciseOfPrefundedWarrants" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000349" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">92</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0352">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_zIZUjA6jnh16" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise of RSUs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKCoqKQ_____zHkVlV4PkeO1" title="Exercise of RSUs, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000362" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">36,528</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000356" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">18</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000357" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">18</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0360">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--StockIssuedDuringPeriodValueExerciseOfWarrants_zsdz8geuoVbc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise of Warrants <span id="xdx_F4D_zvooLTDic3mk">(***)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--StockIssuedDuringPeriodSharesExerciseOfWarrants_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKCoqKSgqKiop_zpvJKshTQyVc" title="Exercise of Warrants, shares" style="text-align: right"><ix:nonFraction name="GLMD:StockIssuedDuringPeriodSharesExerciseOfWarrants" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000370" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">293,333</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GLMD:StockIssuedDuringPeriodValueExerciseOfWarrants" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000364" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">143</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GLMD:StockIssuedDuringPeriodValueExerciseOfWarrants" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000365" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,257</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GLMD:StockIssuedDuringPeriodValueExerciseOfWarrants" contextRef="From2024-01-01to2024-12-31" id="Fact000368" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,400</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_zHmzd0E6pswh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0372">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000373" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">531</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0374">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0375">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" contextRef="From2024-01-01to2024-12-31" id="Fact000376" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">531</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_z3rGdeSwVULd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Unrealized gain from marketable debt securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0378">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0379">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000380" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">38</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0381">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="From2024-01-01to2024-12-31" id="Fact000382" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">38</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetIncomeLoss_z4SD97au6CId" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0384">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0385">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0386">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="Fact000387" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">7,517</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000388" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">7,517</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_432_c20240101__20241231_eus-gaap--StockholdersEquity_iE_zxaseuY4cE42" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; font-weight: bold">Balance - December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td id="xdx_98C_eus-gaap--SharesOutstanding_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKCoqKQ_____ze74ugsZxJ7h" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000396" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,664,884</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000390" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">742</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000391" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">216,470</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000392" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">416</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember" id="Fact000393" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">200,469</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000394" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16,327</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr id="xdx_437_c20240101__20241231_eus-gaap--StockholdersEquity_iE_zBGqrS4Fl3Dg" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; font-weight: bold">Balance </td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td id="xdx_984_eus-gaap--SharesOutstanding_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKCoqKQ_____z4DsOeI44SAe" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000404" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,664,884</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000398" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">742</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000399" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">216,470</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000400" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">416</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember" id="Fact000401" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">200,469</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000402" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16,327</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span id="xdx_F0C_z9kxHTJpDk91" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(*)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F15_zZQzByx1HXib" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000405" xml:lang="en-US">Represents
    amounts less than $1</ix:footnote></span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span id="xdx_F02_z9Ar2i66d3zf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(**)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F16_zNYQhN1oCV7b" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000406" xml:lang="en-US">Retroactively
    adjusted to reflect the <span id="xdx_90E_eus-gaap--StockholdersEquityReverseStockSplit_c20240101__20241231_zflb9DMjyxOc" title="Reverse stock split"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000408" name="us-gaap:StockholdersEquityReverseStockSplit">12-1 reverse split</ix:nonNumeric></span> that was effected in August 2024 (see Note 11(A)(3))</ix:footnote></span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span id="xdx_F04_z3TRMhp99fPl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(***)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F12_zMoOOtcsbu9g" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000409" xml:lang="en-US">See
    also Note 11(A)(4)</ix:footnote></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F05_zWDLu7lsNHG3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(****)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1C_zoKwMJGyKHI5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000410" xml:lang="en-US">See
    also Note 11(A)(5)</ix:footnote></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accompanying
notes are an integral part of the consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 148; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aF_006"></span>GALMED
PHARMACEUTICALS LTD.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated
Statements of Cash Flows</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>U.S.
Dollars in thousands, except share data and per share data</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30B_112_pn3n3_z2tWBLDDdSFk" summary="xdx: Statement - Consolidated Statements of Cash Flows" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20240101__20241231_zcxmAsDeUUH" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20230101__20231231_z56OiiJwz7Wb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20220101__20221231_z2I6rnd3acfk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zkWZ8vieDQHc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash flow from operating activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NetIncomeLoss_i01_maNCPBUze3g_zUI8EKfyuas7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Net loss for the year</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000416" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">7,517</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000417" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,912</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31" id="Fact000418" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">17,866</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zR7t8xKWKjy4" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Adjustments required to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DepreciationAndAmortization_i02_maNCPBUze3g_zwhSeyyDAkM3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2024-01-01to2024-12-31" id="Fact000424" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">83</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2023-01-012023-12-31" id="Fact000425" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">31</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2022-01-012022-12-31" id="Fact000426" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">35</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AmortizationOfDebtDiscountPremium_i02_maNCPBUze3g_zIUply3vC0Kf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Amortization of discount (premium) on marketable debt securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2024-01-01to2024-12-31" id="Fact000428" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">17</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2023-01-012023-12-31" id="Fact000429" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2022-01-012022-12-31" id="Fact000430" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--GainLossOnSaleOfInvestments_i02N_di_msNCPBUze3g_z6FBpH8dTjuc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gain on sale of marketable debt securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainLossOnSaleOfInvestments" contextRef="From2024-01-01to2024-12-31" id="Fact000432" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">12</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainLossOnSaleOfInvestments" contextRef="From2023-01-012023-12-31" id="Fact000433" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">13</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainLossOnSaleOfInvestments" contextRef="From2022-01-012022-12-31" id="Fact000434" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">523</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--FinancialExpenses_i02_maNCPBUze3g_zptvRTYzYsNb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Finance expenses related to SEPA <span id="xdx_F4C_zztmVlTYD3e4">(***)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GLMD:FinancialExpenses" contextRef="From2024-01-01to2024-12-31" id="Fact000436" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">610</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0437">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0438">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--ProceedsFinanceLeaseInterestExpenseIncome_i02_maNCPBUze3g_z29Pu0z9obwc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance expenses (income)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GLMD:ProceedsFinanceLeaseInterestExpenseIncome" contextRef="From2024-01-01to2024-12-31" id="Fact000440" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GLMD:ProceedsFinanceLeaseInterestExpenseIncome" contextRef="From2023-01-012023-12-31" id="Fact000441" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="GLMD:ProceedsFinanceLeaseInterestExpenseIncome" contextRef="From2022-01-012022-12-31" id="Fact000442" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">36</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_ecustom--DecreaseInShorttermDeposits_i02N_di_msNCPBUze3g_zA2S1ZMQXG43" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Decrease in short-term deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GLMD:DecreaseInShorttermDeposits" contextRef="From2024-01-01to2024-12-31" id="Fact000444" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">7</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="GLMD:DecreaseInShorttermDeposits" contextRef="From2023-01-012023-12-31" id="Fact000445" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">53</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0446">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--IncomeLossFromEquityMethodInvestments_i02N_di_msNCPBUze3g_ziAWdvfJrzP4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest income from loan to associate <span id="xdx_F41_zyZytRDeA55i">(**)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="From2024-01-01to2024-12-31" id="Fact000448" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0449">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0450">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--ShareBasedCompensation_i02_maNCPBUze3g_zdH64ZlOEl7f" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-01to2024-12-31" id="Fact000452" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">531</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-12-31" id="Fact000453" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">892</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-12-31" id="Fact000454" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,296</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OtherAssetImpairmentCharges_i02_maNCPBUze3g_zUdjc4SABBv" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Impairment of Associate <span id="xdx_F47_zHmHj43evujk">(**)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherAssetImpairmentCharges" contextRef="From2024-01-01to2024-12-31" id="Fact000456" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,145</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0457">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0458">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--ChangeInFairValueConvertibleNote_i02N_di_msNCPBUze3g_z6qoDxjJz394" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Change in fair value convertible note</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="GLMD:ChangeInFairValueConvertibleNote" contextRef="From2023-01-012023-12-31" id="Fact000461" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">265</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0462">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B_zMytZTIlETnb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IncreaseDecreaseInAccountsAndOtherReceivables_i03N_di_msNCPBUze3g_zMFttnK7Apu7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Decrease (increase) in other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" contextRef="From2024-01-01to2024-12-31" id="Fact000468" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">192</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" contextRef="From2023-01-012023-12-31" id="Fact000469" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">345</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" contextRef="From2022-01-012022-12-31" id="Fact000470" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">300</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--IncreaseDecreaseInAccountsPayableTrade_i03_maNCPBUze3g_zfHCkyqUr5Df" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Decrease in trade payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="From2024-01-01to2024-12-31" id="Fact000472" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">571</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="From2023-01-012023-12-31" id="Fact000473" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">681</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="From2022-01-012022-12-31" id="Fact000474" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,311</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--IncreaseDecreaseInOtherAccountsPayable_i03_maNCPBUze3g_zdI16sYE5rAj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Increase (decrease) in other payables</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" contextRef="From2024-01-01to2024-12-31" id="Fact000476" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">35</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" contextRef="From2023-01-012023-12-31" id="Fact000477" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">468</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" contextRef="From2022-01-012022-12-31" id="Fact000478" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">440</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i02T_mtNCPBUze3g_maCCERCzRBC_zxWR9uozsVVb" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-left: 10pt">Net cash used in operating activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-01-01to2024-12-31" id="Fact000480" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,880</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-01-012023-12-31" id="Fact000481" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,137</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-01-012022-12-31" id="Fact000482" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">18,501</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_z1drik1HHiba" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Cash flow from investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_di_msNCPBUzIK2_zRWjWw2Abs4l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Purchase of property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0488">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0489">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2022-01-012022-12-31" id="Fact000490" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_ecustom--PaymentsForInvestmentInAvailableForSaleSecurities_i01N_di_msNCPBUzIK2_zi3SBkFc7kVd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Investment in available for sale securities,</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="GLMD:PaymentsForInvestmentInAvailableForSaleSecurities" contextRef="From2024-01-01to2024-12-31" id="Fact000492" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,115</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="GLMD:PaymentsForInvestmentInAvailableForSaleSecurities" contextRef="From2023-01-012023-12-31" id="Fact000493" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,133</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="GLMD:PaymentsForInvestmentInAvailableForSaleSecurities" contextRef="From2022-01-012022-12-31" id="Fact000494" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,373</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_ecustom--PaymentsForProceedsFromInvestmentInConvertibleNote_i01N_di_msNCPBUzIK2_zupSrXUucZ74" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Investment in Convertible note <span id="xdx_F43_zFi4qmE3M2J8">(**)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0496">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0497">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="GLMD:PaymentsForProceedsFromInvestmentInConvertibleNote" contextRef="From2022-01-012022-12-31" id="Fact000498" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,500</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--PaymentsToAcquireBusinessesGross_i01N_di_msNCPBUzIK2_zsSkAp0iz7Oh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Loan to associate <span id="xdx_F4B_zHRSq7c5vzU8">(**)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireBusinessesGross" contextRef="From2024-01-01to2024-12-31" id="Fact000500" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">250</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0501">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0502">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--PaymentsForProceedsFromInvestmentInAssociate_i01N_di_msNCPBUzIK2_zjyfuOQHNm7l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Investment in Associate <span id="xdx_F47_zw4w0WigQRLi">(**)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0504">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="GLMD:PaymentsForProceedsFromInvestmentInAssociate" contextRef="From2023-01-012023-12-31" id="Fact000505" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,500</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0506">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_i01_maNCPBUzIK2_zmIQxsFCPj9c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Proceeds from sale of available for sale securities,</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" contextRef="From2024-01-01to2024-12-31" id="Fact000508" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,504</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" contextRef="From2023-01-012023-12-31" id="Fact000509" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,633</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" contextRef="From2022-01-012022-12-31" id="Fact000510" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">21,440</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--PaymentsForProceedsFromOtherDeposits_i01N_di_msNCPBUzIK2_zu4kqBob2Dfi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Proceeds from (investment in) short-term deposits, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsForProceedsFromOtherDeposits" contextRef="From2024-01-01to2024-12-31" id="Fact000512" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,250</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsForProceedsFromOtherDeposits" contextRef="From2023-01-012023-12-31" id="Fact000513" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,200</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0514">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_mtNCPBUzIK2_maCCERCzRBC_zVz4ltNxKg88" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Net cash provided by (used in) investing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2024-01-01to2024-12-31" id="Fact000516" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,111</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2023-01-012023-12-31" id="Fact000517" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">800</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2022-01-012022-12-31" id="Fact000518" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17,563</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zddZNnHHdy6i" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Cash flow from financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_maNCPBUzrcP_zVLWg8bXYcL4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of ordinary shares in at-the-market offering, net of issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0524">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0525">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2022-01-012022-12-31" id="Fact000526" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">70</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ProceedsFromIssuanceOfCommonStock_maNCPBUzrcP_z7PyT94P2Vrf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Issuance of ordinary shares in relation to SEPA <span id="xdx_F43_ztlB1K6AQTSi">(***)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-01-01to2024-12-31" id="Fact000528" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,386</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0529">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0530">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--IssuanceOfOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts_iN_di_msNCPBUzrcP_zh16fpTwJfp4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of ordinary shares, pre-funded warrants, and warrants net of issuance costs <span id="xdx_F43_zeTQMPRdmGPl">(****)</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="GLMD:IssuanceOfOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts" contextRef="From2024-01-01to2024-12-31" id="Fact000532" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,400</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="GLMD:IssuanceOfOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts" contextRef="From2023-01-012023-12-31" id="Fact000533" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,185</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--NetCashProvidedByUsedInFinancingActivities_iT_mtNCPBUzrcP_maCCERCzRBC_zcmPe2anMpi7" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-left: 10pt">Net cash provided by financing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2024-01-01to2024-12-31" id="Fact000536" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,786</ix:nonFraction><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-01-012023-12-31" id="Fact000537" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,185</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2022-01-012022-12-31" id="Fact000538" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">70</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_mtCCERCzRBC_zEPUcD8RJzpb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Increase (decrease) in cash, cash equivalents and restricted cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2024-01-01to2024-12-31" id="Fact000540" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,795</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2023-01-012023-12-31" id="Fact000541" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">848</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2022-01-012022-12-31" id="Fact000542" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">868</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iS_zCd9x0PIJJgk" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Cash and cash equivalents and restricted cash at the beginning of the year</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-12-31" id="Fact000544" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,978</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-12-31" id="Fact000545" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,130</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2021-12-31" id="Fact000546" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,998</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iE_zvOvoFV7OLxd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash, cash equivalents and restricted cash at the end of the year</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2024-12-31" id="Fact000548" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,773</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-12-31" id="Fact000549" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,978</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-12-31" id="Fact000550" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,130</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zUjgSFJOsLQj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Supplemental disclosure of cash flow information:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--InterestPaidNet_i01_z2YvXnJGcbC" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cash received from interest</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2024-01-01to2024-12-31" id="Fact000556" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">503</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2023-01-012023-12-31" id="Fact000557" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">376</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2022-01-012022-12-31" id="Fact000558" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">297</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NoncashInvestingAndFinancingItemsAbstract_i01B_zkXXNbUhb6C7" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Non-cash investing and financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--ConversionOfConvertibleNoteIntoInvestmentInAssociate_i02_z33VNLYyxDk1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Conversion of convertible note into investment in associate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0564">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GLMD:ConversionOfConvertibleNoteIntoInvestmentInAssociate" contextRef="From2023-01-012023-12-31" id="Fact000565" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,765</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0566">-</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(*)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
    amount less than $1</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F03_z8UcQNrHFxtg" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(**)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F12_zIMAOJrMp2Cf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000567" xml:lang="en-US">See
    also Note 7</ix:footnote></span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F04_zsthyXomKXF" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(***)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1D_zyqurW6NWWK9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000568" xml:lang="en-US">See
    also Note 11(A)(5)</ix:footnote></span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F06_zMzfFh565Zck" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(****)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F15_ztE8fM8zYg92" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000569" xml:lang="en-US">See
    also Note 11(A)(4)</ix:footnote></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of the consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 149; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aF_007"></span>GALMED
PHARMACEUTICALS LTD.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000571" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p id="xdx_809_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zbP61AUVdI0f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
1 &#8211; <span id="xdx_825_zP36nn1Cx8rc">General</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Galmed
Pharmaceuticals Ltd. (the &#8220;Company&#8221;) was incorporated in Israel on <span id="xdx_903_edei--EntityIncorporationDateOfIncorporation_c20240101__20241231_zNXhuVNnOKOk" title="Date of incorporation"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:datemonthdayyearen" id="Fact000573" name="dei:EntityIncorporationDateOfIncorporation">July 31, 2013</ix:nonNumeric></span> and commenced operations on <span id="xdx_903_eus-gaap--OperationsCommencedDate1_c20240101__20241231_zAhbMXbA6BI3" title="Date of commenced operations"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:datemonthdayyearen" id="Fact000575" name="us-gaap:OperationsCommencedDate1">February 2,
2014</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company holds three wholly-owned subsidiaries, Galmed International Ltd., which is incorporated in Malta, and Galmed Research and Development
Ltd. (&#8220;GRD&#8221;) and Galtopa Therapeutics Ltd., both of which are incorporated in Israel. In July 2023, GRD established a new
wholly-owned subsidiary incorporated under the laws of England and Wales called Galmed Therapeutics UK Limited.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a biopharmaceutical company focused on the development of Aramchol. The Company has focused almost exclusively on developing
Aramchol for the treatment of liver disease and previously was developing Aramchol for Primary Sclerosing Cholangitis,
or PSC. The Company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.
<span style="background-color: white">In addition, as part of the Company&#8217;s growth strategy, the Company is actively pursuing opportunities
to expand and diversify its product pipeline specifically targeting cardiometabolic indications and other innovative product candidates
that align with the Company&#8217;s core expertise in drug development.</span>. The Company has an operating history limited to pre-clinical
and clinical drug development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company funded its research and development programs and operations to date primarily through proceeds from private placements and public
offerings. The Company currently has no products approved for marketing and has not generated any revenue from product sales to date.
As of December 31, 2024, the Company had cash and cash equivalents of $<span id="xdx_901_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20241231_zXqkWGsftd87" title="Cash and cash equivalents"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2024-12-31" id="Fact000577" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.7</ix:nonFraction></span> million, restricted cash of $<span id="xdx_907_eus-gaap--RestrictedCashCurrent_iI_pn5n6_c20241231_zXmnhDowRwce" title="Restricted cash"><ix:nonFraction name="us-gaap:RestrictedCashCurrent" contextRef="AsOf2024-12-31" id="Fact000579" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span> million, short-term deposits
of $<span id="xdx_902_eus-gaap--DepositsAssetsCurrent_iI_pn5n6_c20241231_zm4jTcWIOW8" title="Short-term deposits"><ix:nonFraction name="us-gaap:DepositsAssetsCurrent" contextRef="AsOf2024-12-31" id="Fact000581" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.5</ix:nonFraction></span> million and marketable debt securities of $<span id="xdx_909_eus-gaap--ShortTermInvestments_iI_pn5n6_c20241231_zsVKsQGfeYYk" title="Marketable securities debt"><ix:nonFraction name="us-gaap:ShortTermInvestments" contextRef="AsOf2024-12-31" id="Fact000583" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">7.2</ix:nonFraction></span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has incurred operating losses in each year since inception. The Company&#8217;s loss attributable to holders of its ordinary
shares for the years ended December 31, 2022, 2023, and 2024 was approximately $<span id="xdx_905_eus-gaap--ProfitLoss_pn5n6_c20220101__20221231_zUahAWqL4XP8" title="Profit loss"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-01-012022-12-31" id="Fact000585" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">17.9</ix:nonFraction></span> million, $<span id="xdx_905_eus-gaap--ProfitLoss_pn5n6_c20230101__20231231_zk1X3rszzmHl" title="Profit loss"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-01-012023-12-31" id="Fact000587" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">6.9</ix:nonFraction></span> million, and $<span id="xdx_905_eus-gaap--ProfitLoss_pn5n6_c20240101__20241231_zYN8a5pCEaDi" title="Profit loss"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000589" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">8.0</ix:nonFraction></span> million, respectively.
As of December 31, 2024, the Company had an accumulated deficit of $<span id="xdx_900_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20241231_zJvmeL5xUFU9" title="Retained earnings accumulated deficit"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-12-31" id="Fact000591" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">200.5</ix:nonFraction></span> million. Substantially all of its operating losses resulted
from costs incurred in connection with the Company&#8217;s development program and from general and administrative costs associated with
its operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will need to raise substantial, additional capital to fund its operations and to develop Aramchol for, and beyond
its current development stage and any future commercialization, as well as any additional indications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the Company&#8217;s current operating plan, the Company&#8217;s management currently estimates that its cash position will support
its current operations as currently conducted for more than 12 months from the date of issuance of these financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000593" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_806_eus-gaap--SignificantAccountingPoliciesTextBlock_zFO5Oe2Wqqrc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2 &#8211; <span id="xdx_822_zYZLUn7eiPMi">Significant Accounting Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000595" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_848_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zgAG2X9Y5v77" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_z8rvBjjyI7xb">Basis of presentation</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements have been prepared in accordance with United States Generally Accepted Accounting Principles (&#8220;U.S.
GAAP&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000597" name="us-gaap:UseOfEstimates"><p id="xdx_84A_eus-gaap--UseOfEstimates_z0kO2pZpw4p8" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_znJjOyCAGxob">Use of estimates</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities as of the date of the financial statements, and the reported amounts of expenses
during the reporting period. Actual results could differ from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 150; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GALMED
PHARMACEUTICALS LTD.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2 &#8211; Significant Accounting Policies (Cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000599" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"><p id="xdx_844_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zMTom8fPyiR" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zvAm7mmhDgL8">Financial statement in U.S. dollars</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
functional currency of the Company and its subsidiaries is the U.S dollar (the &#8220;dollar&#8221;), because the dollar is the currency
of the primary economic environment in which the Company and its subsidiaries operate and expect to continue operating in the foreseeable
future. Transactions and balances denominated in dollars are presented in their original amounts. Non-dollar denominated transactions
and balances have been re-measured to dollars in accordance with the provisions of ASC 830, &#8220;Foreign Currency Matters.&#8221; All
transaction gains and losses from re-measurement of monetary balance sheet items denominated in non-dollar currencies are reflected in
the statement of operations as financial income or expenses, as appropriate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000601" name="us-gaap:ConsolidationPolicyTextBlock"><p id="xdx_842_eus-gaap--ConsolidationPolicyTextBlock_zhleHKi1imec" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zamApzJTutkh">Principles of consolidation</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries: Galmed Research and Development
Ltd., Galmed International Ltd., Galtopa Therapeutics Ltd and Galmed Therapeutics UK Limited. All intercompany balances and transactions
have been eliminated upon consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000603" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_840_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zqH5FRoAuZ1e" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zLhKQzbTkWh8">Cash and cash equivalents</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
equivalents are short-term, highly liquid investments that are readily convertible into cash with maturities of three months or less
as of the date acquired.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000605" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"><p id="xdx_841_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zyW1iWSTYwhb" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zRHhT8coz6O8">Restricted Cash</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
that is held for a specific purpose and is not available for immediate or general business use due to external restrictions is classified
in the Company&#8217;s consolidated balance sheets as restricted cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000607" name="GLMD:ShortTermDepositsPolicyTextBlock"><p id="xdx_84B_ecustom--ShortTermDepositsPolicyTextBlock_z6Lb1A38Pww7" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>G.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zKQgtsmvZrR1">Short-term deposits</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bank
deposits with maturities of more than three months but less than one year are included in short-term bank deposits. Such short-term deposits
are stated at cost which approximates fair market value. Interest rates on the Company&#8217;s short-term deposits were between <span id="xdx_90A_eus-gaap--InvestmentInterestRate_iI_dp_c20241231__srt--RangeAxis__srt--MinimumMember_zrnKAFKsFb8b" title="Short-Term deposits interest rate"><ix:nonFraction name="us-gaap:InvestmentInterestRate" contextRef="AsOf2024-12-31_srt_MinimumMember" id="Fact000609" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.06</ix:nonFraction></span>%-<span id="xdx_90A_eus-gaap--InvestmentInterestRate_iI_dp_c20241231__srt--RangeAxis__srt--MaximumMember_zvKFU0wY1879" title="Short-Term deposits interest rate"><ix:nonFraction name="us-gaap:InvestmentInterestRate" contextRef="AsOf2024-12-31_srt_MaximumMember" id="Fact000611" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6.63</ix:nonFraction></span>%
during the year ended December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000613" name="us-gaap:MarketableSecuritiesPolicy"><p id="xdx_84E_eus-gaap--MarketableSecuritiesPolicy_zZuUPur3p6sf" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>H.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_zeDj7pNOxf15">Marketable debt securities</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company invests most of its excess cash primarily in debt securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for its investments in investment grade debt securities in accordance with ASC 320 &#8220;Investments - Debt and Equity
Securities&#8221;. Management determines the appropriate classification of its investments in debt securities at the time of purchase
and re-evaluates such determinations at each balance sheet date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marketable
debt securities are considered to be available for sale and are carried at fair value on the consolidated balance sheet. Unrealized gains
and losses net of tax, if any, are reported in a separate component of stockholders&#8217; equity in accumulated other comprehensive
income (&#8220;OCI&#8221;). Gains and losses are recognized when realized, on a specific identification basis, in the Company&#8217;s
consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the adoption of ASC 326, current expected credit losses on the Company&#8217;s marketable grade debt securities are recorded, if expected,
through an allowance for current expected credit losses. The amount of allowance for current expected credit losses is limited to the
amount that the fair value is less than the amortized cost basis. Any remaining unrealized losses are included in accumulated other comprehensive
loss in stockholders&#8217; equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Company intends to sell the debt security (that is, it has decided to sell the security), or more likely than not will be required
to sell the security before recovery of its amortized cost basis, any allowance for current expected credit losses is written off and
the amortized cost basis shall be written down to the debt security&#8217;s fair value at the reporting date with any incremental impairment
reported in earnings. Based on management&#8217;s assessment, the Company does not intend to sell its securities for less than amortized
cost; therefore, an allowance for current expected credit losses has not been recorded as of December 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 151; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GALMED
PHARMACEUTICALS LTD.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2 &#8211; Significant Accounting Policies (Cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000615" name="us-gaap:ConcentrationRiskCreditRisk"><p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_zR0yP4KaGEUj" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>I.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_z6MELlxtEgSl">Concentrations of credit risk</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments which potentially subject the Company to credit risk consist primarily of cash, cash equivalents, marketable debt securities
and short-term deposits. The Company hold these investments in highly-rated financial institutions, and, by policy, limit the amounts
of credit exposure to any one financial institution. These amounts at times may exceed federally insured limits. The Company has not
experienced any credit losses in such accounts and does not believe we are exposed to any significant credit risk on these funds. The
Company has no off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts, or other
hedging arrangements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000617" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p id="xdx_848_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zT95vhA3yXBd" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>J.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_zZqdSXymQ8A">Property and equipment</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000619" name="GLMD:ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentTableTextBlock"><p id="xdx_899_ecustom--ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentTableTextBlock_zwrlmrQPQTvl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated
useful lives of the assets. The annual depreciation rates are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_zu3C94eWLw65">Schedule of Depreciation Rates for Property, Plant and Equipment</span></span></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 93%; border-collapse: collapse; margin-left: 0.5in">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>%</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office
    furniture and equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentSalvageValuePercentage_iI_pid_dp_uPure_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndEquipmentMember_zdsLcXWNG2oj" title="Property and equipment, depreciation, percentage"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage" contextRef="AsOf2024-12-31_srt_MinimumMember_custom_OfficeFurnitureAndEquipmentMember" id="Fact000621" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7</ix:nonFraction></span>&#8211;<span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentSalvageValuePercentage_iI_pid_dp_uPure_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndEquipmentMember_z0H6Yi6QX3He" title="Property and equipment, depreciation, percentage"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage" contextRef="AsOf2024-12-31_srt_MaximumMember_custom_OfficeFurnitureAndEquipmentMember" id="Fact000623" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">16</ix:nonFraction></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computer
    software and electronic equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentSalvageValuePercentage_iI_pid_dp_uPure_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerSoftwareElectronicEquipmentMember_zonOslvEYeMl" title="Property and equipment, depreciation, percentage"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage" contextRef="AsOf2024-12-31_srt_MinimumMember_custom_ComputerSoftwareElectronicEquipmentMember" id="Fact000625" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">15</ix:nonFraction></span>&#8211;<span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentSalvageValuePercentage_iI_pid_dp_uPure_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerSoftwareElectronicEquipmentMember_zN9gwrrdvISk" title="Property and equipment, depreciation, percentage"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage" contextRef="AsOf2024-12-31_srt_MaximumMember_custom_ComputerSoftwareElectronicEquipmentMember" id="Fact000627" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">33</ix:nonFraction></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold
    improvements</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentDepreciationMethodExtensibleEnumeration_iI_dxL_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zpQO8BQbJZv3" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2024%23UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember"><span style="-sec-ix-hidden: xdx2ixbrl0628">Shorter
    of the remaining lease term or useful life</span></span></span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AE_zgIUUXRcts4j" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded depreciation expenses in a total of approximately $<span id="xdx_903_eus-gaap--Depreciation_pn4n6_c20240101__20241231_zK6bs281Zfbi" title="Depreciation expenses"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2024-01-01to2024-12-31" id="Fact000630" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD">0.08</ix:nonFraction></span> million, $<span id="xdx_907_eus-gaap--Depreciation_pn4n6_c20230101__20231231_z8IKX3h04Tt1" title="Depreciation expenses"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2023-01-012023-12-31" id="Fact000632" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD">0.03</ix:nonFraction></span> million and $<span id="xdx_90A_eus-gaap--Depreciation_pn4n6_c20220101__20221231_zf8relcGANAi" title="Depreciation expenses"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2022-01-012022-12-31" id="Fact000634" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD">0.06</ix:nonFraction></span> million for the years ended
December 31, 2024, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000636" name="us-gaap:CompensationRelatedCostsPolicyTextBlock"><p id="xdx_84C_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zrrGTnJytw75" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>K.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zeP9cVpNefX2">Severance pay</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company employees are included under section 14 of the Severance Compensation Act, 1963 (&#8220;Section 14&#8221;) in Israel for a portion
of their salaries. According to Section 14, these employees are entitled to monthly deposits at a rate of <span id="xdx_90B_ecustom--MonthlyDepositsOfEmployeesPercentageOnMonthlySalary_pid_dp_uPure_c20240101__20241231_zggLAPYGX5qe" title="Monthly deposits percentage"><ix:nonFraction name="GLMD:MonthlyDepositsOfEmployeesPercentageOnMonthlySalary" contextRef="From2024-01-01to2024-12-31" id="Fact000638" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8.33</ix:nonFraction></span>% of their monthly salary,
contributed on their behalf with insurance companies. Under the Severance Compensation Act, 1963, payments in accordance with Section
14 release the Company from any future severance payments to those employees. Therefore, the Company does not recognize a liability for
severance pay due to these employees and the deposits under Section 14 are not recorded as an asset in the Company&#8217;s consolidated
balance sheets. The Company&#8217;s contributions to the defined contribution plans are charged to the consolidated statements of operations
as and when the services are received from the Company&#8217;s employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 152; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GALMED
PHARMACEUTICALS LTD.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2 &#8211; Significant Accounting Policies (Cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000640" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_842_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z3XvbzKcrp1c" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>L.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_z7Ci3ZnFql9k">Fair value of financial instruments</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
estimated fair value of financial instruments was determined by the Company using available market information and valuation methodologies.
Considerable judgment is required in estimating fair values. Accordingly, the estimates may not be indicative of the amounts the Company
could realize in a current market exchange.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following methods and assumptions were used by the Company in estimating its fair value disclosures for financial instruments:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts of cash and cash equivalents, short-term deposits, other accounts receivables, trade payables and other trade payables
approximate their fair value due to the short-term maturity of such instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
value is an exit price representing the amount that would be received upon selling an asset or that would be paid to transfer a liability
in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based
on assumptions used by market participants in pricing an asset or a liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
three-tier fair-value hierarchy was established as a basis for considering such assumptions and for inputs used in the valuation methodologies
in measuring fair value:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2 - Other inputs that are directly or indirectly observable in the marketplace; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3 - Unobservable inputs that are supported by little or no market activity</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when
measuring fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000642" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"><p id="xdx_898_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zOB5ODJGcNJ8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of the Company&#8217;s assets measured at fair value on a recurring basis by level within the fair value hierarchy are as
follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B3_zO8puHwV0nw7" style="display: none">Schedule of Assets Measured at Fair Value on Recurring Basis</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_ztWBlCt5Mr04" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_ze1DC6ihqWdf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zeNz5iE4EnBj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zlPtLLioYWOe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center"/><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zwGbeKQwQqJh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Corporate bonds</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0644">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member_us-gaap_CorporateDebtSecuritiesMember" id="Fact000645" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,367</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0646">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_CorporateDebtSecuritiesMember" id="Fact000647" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,367</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zCUvvjcAExU8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Treasury bills</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0649">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member_us-gaap_USTreasurySecuritiesMember" id="Fact000650" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">533</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0651">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USTreasurySecuritiesMember" id="Fact000652" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">533</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember_zPv2QFGWJita" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Mutual funds</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member_us-gaap_MutualFundMember" id="Fact000654" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,283</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0655">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0656">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_MutualFundMember" id="Fact000657" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,283</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__custom--InvestmentInAssociateMember_zGGIL9wP0cQe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Investment in associate</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0659">-</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0660">-</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member_custom_InvestmentInAssociateMember" id="Fact000661" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,119</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_custom_InvestmentInAssociateMember" id="Fact000662" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,119</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_zbmirx9aLf74" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Total</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member" id="Fact000664" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,283</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member" id="Fact000665" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,900</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member" id="Fact000666" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,119</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember" id="Fact000667" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,302</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zLK9o7TRzH3f" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zcyjbxTQ8IF7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zpg9gx3TYEvh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_znCRBj3zweN7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>Fair</b> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value</b></span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zvg8XcErWjm" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Corporate bonds</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0669">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member_us-gaap_CorporateDebtSecuritiesMember" id="Fact000670" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,969</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0671">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_CorporateDebtSecuritiesMember" id="Fact000672" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,969</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zYCkcRLGM1fe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Treasury bills</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0674">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member_us-gaap_USTreasurySecuritiesMember" id="Fact000675" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">409</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0676">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USTreasurySecuritiesMember" id="Fact000677" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">409</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember_z6XGAWOuzlRk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Mutual funds</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member_us-gaap_MutualFundMember" id="Fact000679" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,150</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0680">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0681">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_MutualFundMember" id="Fact000682" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,150</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__custom--InvestmentInAssociateMember_zFeOz1hUX6Ce" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Investment in associate</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0684">-</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0685">-</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member_custom_InvestmentInAssociateMember" id="Fact000686" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,265</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_custom_InvestmentInAssociateMember" id="Fact000687" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,265</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_z6FQkSJwzSW1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Total</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member" id="Fact000689" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,150</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member" id="Fact000690" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,378</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member" id="Fact000691" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,265</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember" id="Fact000692" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,793</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_zIXA0OEOeNXl" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><b>Derivative instrument</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-size: 10pt">Under ASC 815-40,
contracts that are not indexed to the Company&#8217;s own equity are classified as liabilities recorded at fair value, as such, the Company
classifies the SEPA Agreement entered into (see Note 11A(5)) as a derivative instrument measured at fair value at each reporting period,
as settlement provisions under this agreement are not indexed to the Company&#8217;s own equity.</span><span style="font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 18pt"></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000694" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy"><p id="xdx_848_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zE5ODiPqkVT5" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>M.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span><span id="xdx_86D_zTToCDHGG1ga">Accounting for stock-based compensation</span></span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for share-based compensation under ASC 718, Compensation - Stock Compensation (&#8220;ASC 718&#8221;), which requires
the measurement and recognition of compensation expense based on estimated fair values for all share-based payment awards made to employees,
non-employee consultants and directors, including options and restricted share units (&#8220;RSUs&#8221;) based on the fair value of
the awards on the date of grant. ASC 718 requires companies to estimate the fair value of equity-based payment awards on the date of
grant using an option-pricing model. The expense for share-based compensation cost is recognized over the requisite service period of
each individual grant using the straight-line method for service-based awards. Forfeitures are accounted for as they occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 153; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GALMED
PHARMACEUTICALS LTD.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2 &#8211; Significant Accounting Policies (Cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>M.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accounting for stock-based compensation (Cont.)</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company calculates the fair value of RSUs based on the fair value on the closing trading price of the underlying shares at the date of
grant and estimates the fair value of stock options granted using a <span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDescription_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zr03dAoCGCpk" title="Black scholes option pricing model"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockMember" id="Fact000696" name="GLMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDescription">Black-Scholes option-pricing model</ix:nonNumeric></span>. The option-pricing model requires
a number of assumptions, the most significant of which are the expected stock-price volatility and the expected option term (the time
from the grant date until the options are exercised or expire).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s calculations of the expected volatility were based upon actual historical stock-price movements over the period, which
was equal to the expected option term. The expected option term was calculated for options granted to employees and directors in accordance
with ASC-718-10-S99, using the &#8220;simplified&#8221; method, and grants to non-employees were based on the contractual term. Historically,
the Company has not paid dividends, and has no foreseeable plans to do so. The risk-free interest rate is based on the yield from U.S.
Treasury zero-coupon bonds with an equivalent term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000698" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_843_eus-gaap--ResearchAndDevelopmentExpensePolicy_zsmgn5zbkeyk" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>N.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zmrDVWBlDJG2">Research and development expenses</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses are charged to the statements of operations as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000700" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_zWvuoFjtfIN7" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>O.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_zibACiF6s8o1">Income taxes</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes in accordance with ASC 740, Income Taxes (&#8220;ASC 740&#8221;), using the liability method whereby
deferred tax assets and liability account balances are determined based on the differences between financial reporting and the tax basis
for assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected
to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to the amounts that are more likely-than-not
to be realized. As of December 31, 2024 and 2023, the Company recorded a full valuation allowance against its deferred tax assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company applies a more-likely-than-not recognition threshold to uncertain tax positions based on the technical merits of the income tax
positions taken. The Company does not recognize a tax benefit unless it is more likely than not that the tax position will be sustained
upon examination, including resolution of any related appeals or litigation processes, based on the technical merits of the position.
The tax benefit that is recorded for these positions is measured at the largest amount of benefit that is greater than 50% likely of
being realized upon ultimate settlement. As of December 31, 2024 and 2023, no liability for unrecognized tax benefits was recorded due
to immateriality.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000702" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_84C_eus-gaap--EarningsPerSharePolicyTextBlock_zn8UeKVGd4ol" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>P.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zFxI6g2aD1Z1">Basic and diluted net loss per share</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
net loss per share is computed based on the weighted-average number of shares outstanding during each year. Diluted net loss per share
is computed based on the weighted-average number of shares outstanding during each year, plus the dilutive potential of the ordinary
shares considered outstanding during the year, in accordance with ASC 260-10, &#8220;Earnings Per Share.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
outstanding stock options, RSUs, prefunded-warrants and warrants were excluded from the calculation of the diluted loss per share
for the years ended December 31, 2024, 2023 and 2022, because all such securities have an anti-dilutive effect.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 154; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GALMED
PHARMACEUTICALS LTD.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2 &#8211; Significant Accounting Policies (Cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000704" name="us-gaap:LesseeLeasesPolicyTextBlock"><p id="xdx_84C_eus-gaap--LesseeLeasesPolicyTextBlock_ztJF6bSmuRqc" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Q.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_z81fguYtUhG4">Leases</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for leases in accordance with ASC 842 &#8220;Leases.&#8221; Arrangements that are determined to be operating leases
at inception are recognized as right-of-use operating lease assets and lease liabilities in the balance sheets at lease commencement.
The Company recognizes a lease liability at the present value of the lease payments to be made over the lease term, and concurrently
recognizes a right-of-use asset at the same amount of the liability, adjusted for any prepaid or accrued lease payments, plus initial
direct costs incurred in respect of the lease. The Company uses its incremental borrowing rate based on the information available at
the commencement date to determine the present value of the lease payments. The subsequent measurement depends on whether the lease is
classified as a finance lease or an operating lease. During the reporting periods, the Company has only operating leases. Lease terms
include options to extend the lease when it is reasonably certain that the Company will exercise that option. Lease expenses for operating
leases are recognized on a straight-line basis over the lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has made a policy election not to capitalize leases with a term of 12 months or less. The Company made has also made a policy
election to include lease and non-lease components as a single lease component.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payments
for variable lease costs are expensed as incurred and are not included in the operating lease right-of-use assets and lease liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with ASC 360-10, management reviews operating lease assets for impairment whenever events or changes in circumstances indicate
that the carrying amount of an asset may not be recoverable based on estimated future undiscounted cash flows. If so indicated, an impairment
loss would be recognized for the difference between the carrying amount of the asset and its fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000706" name="us-gaap:InvestmentPolicyTextBlock"><p id="xdx_849_eus-gaap--InvestmentPolicyTextBlock_z0Yq6MBcXBu1" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>R.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zWIp43wKc5ib">Investment in Associate at Fair Value</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company holds an equity investment of a privately-owned company, Onkai Inc. (&#8220;Onkai&#8221;), over which it has the ability to exercise
significant influence, but not control. The investment was included as a non-current asset in the balance sheet as of December 31, 2024.
The Company has elected the fair value option allowed by ASC 825, Financial Instruments, with respect to this investment because management
believes this approach will better reflect the economics of its equity interest. Under the fair value option, the investment is remeasured
at fair value (level 3) at each reporting period with changes in fair value, if any, recorded in the statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, management, based on fair value estimation, assessed the qualitative aspects of the equity investment and macroeconomic
factors and determined that an impairment should be recognized in amount of $1.1 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000708" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_845_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z7VU98c1aeO3" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>S.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zrB96f2tbo9">Recently adopted accounting pronouncements</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, new accounting pronouncements are issued by FASB, or other standard setting bodies and adopted by the Company as of the
specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have
a material impact on our financial position or results of operations upon adoption.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The ASU expands
public entities&#8217; segment disclosures by requiring disclosure of significant segment expenses that are regularly reviewed by the
chief operating decision maker (&#8220;CODM&#8221;) and included within each reported measure of segment profit or loss, an amount and
description of its composition for other segment items, and interim disclosures of a reportable segment&#8217;s profit or loss and assets.
The ASU also allows, in addition to the measure that is most consistent with U.S. GAAP, the disclosure of additional measures of segment
profit or loss that are used by the CODM in assessing segment performance and deciding how to allocate resources. The ASU is effective
for the Company&#8217;s Annual Report on Form 20-F for the fiscal year ended December 31, 2024, and subsequent interim periods, with
early adoption permitted. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000710" name="GLMD:NewAccountingPronouncementsNotYetEffectivePolicyTextBlock"><p id="xdx_84A_ecustom--NewAccountingPronouncementsNotYetEffectivePolicyTextBlock_zXeQR5BViNok" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>T.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_zsQbYWN4vhzh">Accounting pronouncements not yet effective</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, the FASB issued ASU 2024-03, &#8220;Income Statement&#8211;Reporting Comprehensive Income&#8211;Expense Disaggregation
Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses&#8221; (&#8220;ASU 2024-03&#8221;), which requires the disaggregation
of certain expenses in the financial statements notes, to provide enhanced transparency into the expense captions presented on the face
of the consolidated statement of operations. ASU 2024-03 is effective for annual reporting periods beginning January 1, 2027 and interim
periods beginning January 1, 2028 and may be applied either prospectively or retrospectively. The Company is currently evaluating the
impact that ASU 2024-03 will have on its related disclosures, and the transition method.</span></p>

</ix:nonNumeric><p id="xdx_851_z2X5hTML8xEi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 155; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GALMED
PHARMACEUTICALS LTD.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000712" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock"><p id="xdx_807_eus-gaap--CashCashEquivalentsAndMarketableSecuritiesTextBlock_z5ElUcWHzoDj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
3 &#8211; <span id="xdx_828_zM8Eu57ykDzl">Marketable debt securities</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000714" name="us-gaap:MarketableSecuritiesTextBlock"><p id="xdx_891_eus-gaap--MarketableSecuritiesTextBlock_ziorsCGksSsk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the Company&#8217;s marketable debt securities as of December 31, 2024 and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zLSGCQ7oRRSc">Schedule of Marketable Debt Securities</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Gross</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Gross</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Amortized</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Unrealized</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Unrealized</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Estimated</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Cost</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Gains</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Losses</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="6" style="text-align: center">(in thousands)</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Corporate bonds</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20241231__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_z5pGNXVo15m1" title="Amortized Cost" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="AsOf2024-12-31_us-gaap_CorporateDebtSecuritiesMember" id="Fact000716" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,529</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20240101__20241231__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zxu3sadovbg1" title="Gross Unrealized Gains" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" contextRef="From2024-01-012024-12-31_us-gaap_CorporateDebtSecuritiesMember" id="Fact000718" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20240101__20241231__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zZhrqtyHu77i" title="Gross Unrealized Losses" style="width: 11%; text-align: right">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" contextRef="From2024-01-012024-12-31_us-gaap_CorporateDebtSecuritiesMember" id="Fact000720" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">171</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20241231__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zMkO1mcWkvQh" title="Estimated Fair Value" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="AsOf2024-12-31_us-gaap_CorporateDebtSecuritiesMember" id="Fact000722" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,367</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Treasury bills</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20241231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zlnpOESAfzBe" title="Amortized Cost" style="text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="AsOf2024-12-31_us-gaap_USTreasurySecuritiesMember" id="Fact000724" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">530</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20240101__20241231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zW8dGQ697sa1" title="Gross Unrealized Gains" style="text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" contextRef="From2024-01-012024-12-31_us-gaap_USTreasurySecuritiesMember" id="Fact000726" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20240101__20241231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zgJ5wvhkh6g1" title="Gross Unrealized Losses" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0728">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20241231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zHdxs25KFZ0c" title="Estimated Fair Value" style="text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="AsOf2024-12-31_us-gaap_USTreasurySecuritiesMember" id="Fact000730" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">533</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Mutual funds</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20241231__us-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember_z3opYpITlijf" title="Amortized Cost" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="AsOf2024-12-31_us-gaap_MutualFundMember" id="Fact000732" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,540</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20240101__20241231__us-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember_zMKHIuurUWhi" title="Gross Unrealized Gains" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" contextRef="From2024-01-012024-12-31_us-gaap_MutualFundMember" id="Fact000734" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">23</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20240101__20241231__us-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember_zA5nio4FBf8a" title="Gross Unrealized Losses" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" contextRef="From2024-01-012024-12-31_us-gaap_MutualFundMember" id="Fact000736" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">280</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20241231__us-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember_zn5Ey2cwU955" title="Estimated Fair Value" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="AsOf2024-12-31_us-gaap_MutualFundMember" id="Fact000738" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,283</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total short-term investments</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20241231_zbZiAMju3MH2" title="Amortized Cost" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="AsOf2024-12-31" id="Fact000740" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,599</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20240101__20241231_zbEGM5h03LV" title="Gross Unrealized Gains" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" contextRef="From2024-01-01to2024-12-31" id="Fact000742" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">35</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20240101__20241231_zgkIQrNH6ZUa" title="Gross Unrealized Losses" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000744" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">451</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20241231_zyoIMognowkb" title="Estimated Fair Value" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="AsOf2024-12-31" id="Fact000746" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,183</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Gross</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Gross</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Amortized</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Unrealized</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Unrealized</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Estimated</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Cost</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Gains</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Losses</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="6" style="text-align: center">(in thousands)</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Corporate bonds</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zwMu8yQc0E5j" title="Amortized Cost" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="AsOf2023-12-31_us-gaap_CorporateDebtSecuritiesMember" id="Fact000748" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,123</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zpHunG4JoUD1" title="Gross Unrealized Gains" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" contextRef="From2023-01-012023-12-31_us-gaap_CorporateDebtSecuritiesMember" id="Fact000750" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_z6syK3HtY8V7" title="Gross Unrealized Losses" style="width: 11%; text-align: right">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" contextRef="From2023-01-012023-12-31_us-gaap_CorporateDebtSecuritiesMember" id="Fact000752" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">160</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zbs0K82Z1RP8" title="Estimated Fair Value" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="AsOf2023-12-31_us-gaap_CorporateDebtSecuritiesMember" id="Fact000754" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,969</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Treasury bills</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zwBHrXpb881a" title="Amortized Cost" style="text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="AsOf2023-12-31_us-gaap_USTreasurySecuritiesMember" id="Fact000756" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">400</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_z54lJKA8hhQ4" title="Gross Unrealized Gains" style="text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" contextRef="From2023-01-012023-12-31_us-gaap_USTreasurySecuritiesMember" id="Fact000758" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zfUhQ8ISTWRl" title="Gross Unrealized Losses" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0760">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zlWOlNyvzLQ8" title="Estimated Fair Value" style="text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="AsOf2023-12-31_us-gaap_USTreasurySecuritiesMember" id="Fact000762" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">409</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Mutual funds</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember_zIge1392z3Ce" title="Amortized Cost" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="AsOf2023-12-31_us-gaap_MutualFundMember" id="Fact000764" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,459</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember_zqFwdqgwBlVd" title="Gross Unrealized Gains" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" contextRef="From2023-01-012023-12-31_us-gaap_MutualFundMember" id="Fact000766" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember_zYSUBOil9V18" title="Gross Unrealized Losses" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" contextRef="From2023-01-012023-12-31_us-gaap_MutualFundMember" id="Fact000768" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">310</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember_zRKOzt5MpGBl" title="Estimated Fair Value" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="AsOf2023-12-31_us-gaap_MutualFundMember" id="Fact000770" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,150</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total short-term investments</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20231231_zV8pgetGHb0b" title="Amortized Cost" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="AsOf2023-12-31" id="Fact000772" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,982</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20230101__20231231_zUN73WatyXV3" title="Gross Unrealized Gains" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" contextRef="From2023-01-012023-12-31" id="Fact000774" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20230101__20231231_zqKOliB3p1o7" title="Gross Unrealized Losses" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" contextRef="From2023-01-012023-12-31" id="Fact000776" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">470</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20231231_zjdC2HKyqqfi" title="Estimated Fair Value" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="AsOf2023-12-31" id="Fact000778" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,528</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

</ix:nonNumeric><p id="xdx_8AA_zGAD9W5tvry3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
contractual maturities of the aforementioned corporate bonds and treasury bills are less than one year for the year ended December 31,
2024 and one year and a half of the aforementioned corporate bonds for the year ended December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000780" name="us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"><p id="xdx_802_eus-gaap--LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_zPYLXOV76QC6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
4&#8211; <span id="xdx_822_zEg71KFV39pc">Other Receivables</span></b></span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000782" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"><p id="xdx_894_eus-gaap--ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_zU0YQQcu491b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zcVwmyobPA67">Schedule
of Other  Receivables</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20241231_z2qPXrmPFB2e" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20231231_zROnT5sZLdv6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(in thousands)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--PrepaidExpenseCurrent_iI_pn3n3_maRNCz4tF_zH9Wg5qgz80b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Prepaid expenses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2024-12-31" id="Fact000784" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">463</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2023-12-31" id="Fact000785" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">315</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--GrantsReceivable_iI_pn3n3_maRNCz4tF_zAx1QN4A0UNb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Government institutions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GrantsReceivable" contextRef="AsOf2024-12-31" id="Fact000787" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">76</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GrantsReceivable" contextRef="AsOf2023-12-31" id="Fact000788" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">47</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OtherReceivables_iI_pn3n3_maRNCz4tF_zoSnRg0fmu44" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Other receivables</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherReceivables" contextRef="AsOf2024-12-31" id="Fact000790" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">133</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherReceivables" contextRef="AsOf2023-12-31" id="Fact000791" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">118</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--ReceivablesNetCurrent_iTI_pn3n3_mtRNCz4tF_zZtiDosvOvsg" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ReceivablesNetCurrent" contextRef="AsOf2024-12-31" id="Fact000793" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">672</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ReceivablesNetCurrent" contextRef="AsOf2023-12-31" id="Fact000794" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">480</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_zipfSQigaL46" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000796" name="us-gaap:LesseeOperatingLeasesTextBlock"><p id="xdx_80E_eus-gaap--LesseeOperatingLeasesTextBlock_zPcnNDdcyjS4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
5&#8211; <span id="xdx_820_ztU7bvZE5ZOk">Leases</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company leased, approximately <span id="xdx_907_eus-gaap--AreaOfLand_iI_uSqft_c20241231_zycON41sONN3" title="Area of land under operating lease agreement"><ix:nonFraction name="us-gaap:AreaOfLand" contextRef="AsOf2024-12-31" id="Fact000798" format="ixt:numdotdecimal" decimals="INF" unitRef="Sqft">590</ix:nonFraction></span>
square meters at a facility located in Tel-Aviv, Israel. The lease expired on <span id="xdx_905_eus-gaap--LeaseExpirationDate1_dd_c20240101__20241231_zCEVOnSUJprb" title="Lease expiry date"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:datemonthdayyearen" id="Fact000800" name="us-gaap:LeaseExpirationDate1">March
21, 2024</ix:nonNumeric></span>. The Company did not extend the lease and the Company&#8217;s employees are currently working remotely while
management is in the process of searching for a new permanent location for its principal executive offices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 33pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2024, 2023 and 2022, the Company recorded lease expenses in its statement of operations in the amount of $<span id="xdx_908_eus-gaap--OperatingLeaseExpense_pn4n6_c20240101__20241231_zS30WNBUgOdh" title="Lease expense"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000802" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD">0.04</ix:nonFraction></span> million, $<span id="xdx_909_eus-gaap--OperatingLeaseExpense_pn5n6_c20230101__20231231_zZ06hxuMApCi" title="Lease expense"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2023-01-012023-12-31" id="Fact000804" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span> million,
and $<span id="xdx_906_eus-gaap--OperatingLeaseExpense_pn5n6_c20220101__20221231_z52qwBH9wZyk" title="Lease expense"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2022-01-012022-12-31" id="Fact000806" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span> million respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 33pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2024, the Company&#8217;s operating lease right-of-use assets and current lease liabilities for operating leases totaled
$<span id="xdx_906_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_dxL_c20241231_ziUqPvO1Q6s" title="Operating lease right of use assets::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0808">0</span></span> thousand and $<span id="xdx_906_eus-gaap--OperatingLeaseLiability_iI_pn3n3_c20241231_ztFVQuUMbKji" title="Operating lease liability"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2024-12-31" id="Fact000810" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">0</ix:nonFraction></span> thousand, respectively, while at December 31, 2023, the Company&#8217;s operating lease assets and lease liabilities
(both the current and non-current portion) for operating leases totaled $<span id="xdx_909_eus-gaap--OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_iI_dxL_c20231231_z3SsKMWRQrI4" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2024%23OperatingLeaseRightOfUseAsset"><span style="-sec-ix-hidden: xdx2ixbrl0811">42</span></span> thousand and $<span id="xdx_90A_eus-gaap--OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_iI_dxL_c20231231_zLNPd3S9HBFk" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2024%23OperatingLeaseLiability"><span style="-sec-ix-hidden: xdx2ixbrl0812">41</span></span> thousand, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000814" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><p id="xdx_809_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zXUoc069fT8b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
6 &#8211; <span id="xdx_828_zDOgqzCMV6Wa">Property and equipment, net</span></b></span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000816" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><p id="xdx_897_eus-gaap--PropertyPlantAndEquipmentTextBlock_zk2Ns6bbY8W3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BF_z81lMRSFFPlc">Schedule of Property and Equipment</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20241231_zNetz5pICHLb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20231231_zIY10BIZmWNl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="6" style="text-align: center">(in thousands)</td><td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--MachineryAndEquipmentGross_iI_pn3n3_maPPAEGzWKA_zZY4PcHfFz3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Medical equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:MachineryAndEquipmentGross" contextRef="AsOf2024-12-31" id="Fact000818" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">737</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:MachineryAndEquipmentGross" contextRef="AsOf2023-12-31" id="Fact000819" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">737</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FurnitureAndFixturesGross_iI_pn3n3_maPPAEGzWKA_zWkuntSH1YE2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Office furniture and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FurnitureAndFixturesGross" contextRef="AsOf2024-12-31" id="Fact000821" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">55</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FurnitureAndFixturesGross" contextRef="AsOf2023-12-31" id="Fact000822" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">55</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--CapitalizedComputerSoftwareGross_iI_pn3n3_maPPAEGzWKA_zDn4IKV7adRc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Computer software and electronic equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CapitalizedComputerSoftwareGross" contextRef="AsOf2024-12-31" id="Fact000824" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">75</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CapitalizedComputerSoftwareGross" contextRef="AsOf2023-12-31" id="Fact000825" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">75</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LeaseholdImprovementsGross_iI_pn3n3_maPPAEGzWKA_zroB6QTOVs47" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Leasehold improvements</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LeaseholdImprovementsGross" contextRef="AsOf2024-12-31" id="Fact000827" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">236</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LeaseholdImprovementsGross" contextRef="AsOf2023-12-31" id="Fact000828" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">235</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iTI_pn3n3_mtPPAEGzWKA_maPPAENzlLK_z45bbBTi5Ove" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, gross</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31" id="Fact000830" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,103</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31" id="Fact000831" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,102</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENzlLK_z52HQWbqdROc" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Less - Accumulated depreciation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2024-12-31" id="Fact000833" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,103</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2023-12-31" id="Fact000834" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,019</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzlLK_zIAZEi5e5nvk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Net book value</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0836">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-12-31" id="Fact000837" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">83</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_zHWWNp4z3VEj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 156; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GALMED
PHARMACEUTICALS LTD.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000839" name="us-gaap:InvestmentTextBlock"><p id="xdx_80B_eus-gaap--InvestmentTextBlock_zhyu9jLzwbQi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
</b>7 &#8211; <b><span id="xdx_82A_zvpI9q6cojjk">Investment in an Associate</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 4, 2023, the Company entered into a definitive agreement (the &#8220;Agreement&#8221;) for a $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_pn5n6_c20230504__20230504__srt--TitleOfIndividualAxis__custom--OnkaiIncMember_zE9FyBZ1mqsd" title="Additional investment on convertible safe notes"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-05-042023-05-04_custom_OnkaiIncMember" id="Fact000841" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.5</ix:nonFraction></span> million equity investment in OnKai,
a US-based technology company developing an AI-based platform to advance healthcare for underserved populations across the United States
by facilitating alignment between healthcare stakeholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Previously,
in November, 2022 the Company invested $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_pn5n6_c20221130__20221130__srt--TitleOfIndividualAxis__custom--OnkaiIncMember_zZnppgv1Ugb9"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-11-302022-11-30_custom_OnkaiIncMember" id="Fact000842" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.5</ix:nonFraction></span> million in OnKai through a Simple Agreement for Future Equity (&#8220;SAFE&#8221;) which
converted at a <span id="xdx_902_ecustom--CapitalStockDiscountRate_pid_dp_uPure_c20221130__20221130__srt--TitleOfIndividualAxis__custom--OnkaiIncMember_zKvOliJu4sU2" title="Capital discount rate"><ix:nonFraction name="GLMD:CapitalStockDiscountRate" contextRef="From2022-11-302022-11-30_custom_OnkaiIncMember" id="Fact000844" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">15</ix:nonFraction></span>% discount into series seed preferred shares upon closing of the Investment Round (as defined below). The Company recorded
in its statement of operations a change in the fair value of the convertible note (the SAFE) which totaled $<span id="xdx_903_eus-gaap--GainLossOnInvestments_pn5n6_c20230101__20231231__srt--TitleOfIndividualAxis__custom--OnkaiIncMember_zm3wFEXeZ8V3" title="Investments"><ix:nonFraction name="us-gaap:GainLossOnInvestments" contextRef="From2023-01-012023-12-31_custom_OnkaiIncMember" id="Fact000846" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.3</ix:nonFraction></span> million for the year
ended December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s investment in OnKai was part of an approximately $<span id="xdx_903_eus-gaap--PaymentsToAcquireInvestments_pn5n6_c20240101__20241231_zidFFboeH9a2" title="Investment"><ix:nonFraction name="us-gaap:PaymentsToAcquireInvestments" contextRef="From2024-01-01to2024-12-31" id="Fact000848" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">6.0</ix:nonFraction></span>
million investment round (the &#8220;Investment Round&#8221;) with other investors that was led by the Company of which SAFEs of
approximately $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_pn5n6_c20240101__20241231__srt--TitleOfIndividualAxis__custom--OnkaiIncMember_zMHZm85sS704" title="Value conversion"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2024-01-012024-12-31_custom_OnkaiIncMember" id="Fact000850" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.8</ix:nonFraction></span>
were converted into preferred shares of Onkai upon the consummation of the Investment Round. On June 19, 2023, the Investment Round
closed. Following the closing of the Investment Round, the Company holds <span id="xdx_90F_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20230619__srt--TitleOfIndividualAxis__custom--OnkaiIncMember_zNwP2aCoSVq6" title="Shares owned"><ix:nonFraction name="us-gaap:InvestmentOwnedBalanceShares" contextRef="AsOf2023-06-19_custom_OnkaiIncMember" id="Fact000852" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,223,535</ix:nonFraction></span>
preferred shares which comprised approximately <span id="xdx_906_eus-gaap--InvestmentOwnedPercentOfNetAssets_iI_pid_dp_uPure_c20230619__srt--TitleOfIndividualAxis__custom--OnkaiIncMember_zKReVlMpSMhh" title="Shares owned percentage"><ix:nonFraction name="us-gaap:InvestmentOwnedPercentOfNetAssets" contextRef="AsOf2023-06-19_custom_OnkaiIncMember" id="Fact000854" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">24</ix:nonFraction></span>%
of the outstanding share capital of OnKai on an as-converted basis as of December 31, 2023 and December 31, 2024. The Company&#8217;s Chief Executive
Officer and director, Allen Baharaff, serves as one of three board members of OnKai.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the terms of the Agreement, during the three-year period following the closing of the Investment Round the Company will have the right
to merge with OnKai subject to the approval of the boards of directors of each of the Company and OnKai. The Company was granted certain
customary pre-emptive rights as well as registration rights, first refusal rights, co-sale, a board seat, and certain customary protective
provisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Agreement, the Company&#8217;s wholly-owned subsidiary, GRD, entered into a services agreement (the &#8220;Services
Agreement&#8221;) with OnKai. The Services Agreement provides that GRD will on a non-exclusive basis (i) provide support services to
OnKai relating to finance, business development, strategic planning, execution and others; and (ii) lend its experience to OnKai in building
a strategy and for the development of treatments for the underserved and that OnKai shall on a non-exclusive basis (i) take part in plan
preparation to serve GRD&#8217;s vision of developing drugs for the underserved population and (ii) when relevant, design a process on
the clinical trial dashboard that could potentially serve GDR&#8217;s future trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the above mentioned Services Agreement, the Company recorded reimbursement of expenses of $<span id="xdx_901_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20240101__20241231__srt--ProductOrServiceAxis__us-gaap--AdministrativeServiceMember_zGLhk4NLGCW1" title="Management fee income"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-01-012024-12-31_us-gaap_AdministrativeServiceMember" id="Fact000856" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">48</ix:nonFraction></span> thousand and $<span id="xdx_90D_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20230101__20231231__srt--ProductOrServiceAxis__us-gaap--AdministrativeServiceMember_zX20bJ6t8rIf" title="Management fee income"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-012023-12-31_us-gaap_AdministrativeServiceMember" id="Fact000858" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12</ix:nonFraction></span> thousand
in general and administrative expenses in its statement of operations for the years ended December 31, 2024 and December 31, 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 15, 2024, the Company entered into a bridge loan agreement with OnKai pursuant to which the Company made a loan in an aggregate
amount of $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_c20241015__us-gaap--TypeOfArrangementAxis__custom--BridgeLoanAgreementMember_zHFvVvvt3Inl" title="Loan amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2024-10-15_custom_BridgeLoanAgreementMember" id="Fact000860" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span> to OnKai payable by January 1, 2028. The loan bears interest at an annual rate of <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20241015__us-gaap--TypeOfArrangementAxis__custom--BridgeLoanAgreementMember_zBZnWTlmFfz7" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="AsOf2024-10-15_custom_BridgeLoanAgreementMember" id="Fact000862" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">15</ix:nonFraction></span>%. In addition, in connection with the
Services Agreement, the Company paid OnKai $<span id="xdx_900_eus-gaap--ProceedsFromOtherDebt_c20241015__20241015__us-gaap--TypeOfArrangementAxis__custom--ServicesAgreementMember_zW7OMRMGGNvi" title="Proceeds from debt"><ix:nonFraction name="us-gaap:ProceedsFromOtherDebt" contextRef="From2024-10-152024-10-15_custom_ServicesAgreementMember" id="Fact000864" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,000</ix:nonFraction></span> for OnKai to assist the Company in (i) identifying and preparing eligible sites for
the Company&#8217;s future clinical trials and (ii) preparing and submitting applications for clinical and research grants in respect
of such future clinical trials, including preparing reimbursement strategies. In the event that Onkai is awarded a clinical or research
grant, OnKai agreed to repay the Company the $<span id="xdx_90F_eus-gaap--RepaymentsOfDebt_c20241015__20241015__us-gaap--TypeOfArrangementAxis__custom--ServicesAgreementMember_zszqb1F8osV3" title="Repayments of debt"><ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="From2024-10-152024-10-15_custom_ServicesAgreementMember" id="Fact000866" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,000</ix:nonFraction></span> that it initially paid to OnKai.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, management, based on fair value estimation, assessed the qualitative aspects of the equity investment and macroeconomic
factors and determined that an impairment should be recognized in amount of $<span id="xdx_90F_eus-gaap--AssetImpairmentCharges_pn5n6_c20240101__20241231_zbmoMGPcwJ1e" title="Impairment charges"><ix:nonFraction name="us-gaap:AssetImpairmentCharges" contextRef="From2024-01-01to2024-12-31" id="Fact000868" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.1</ix:nonFraction></span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attached
is a summarized un-audited financial information of Onkai:</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000870" name="GLMD:ScheduleOfBalanceSheetsTableTextBlock"><p id="xdx_89D_ecustom--ScheduleOfBalanceSheetsTableTextBlock_zupYrJFyreB" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span><span id="xdx_8B7_zLCxDACqeusf" style="display: none">Schedule
of Balance Sheets</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Balance
sheet as of December 31, 2024</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 0.75in">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_490_20241231__srt--TitleOfIndividualAxis__custom--OnkaiIncMember_zXUwPwrBovBb" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(in thousands)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AssetsCurrent_iI_pn3n3_msSEzDrf_zOzTqQ0pVvV9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">Current assets</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2024-12-31_custom_OnkaiIncMember" id="Fact000872" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">105</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AssetsNoncurrent_iI_pn3n3_msSEzDrf_zt5GQthFEbv5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Non-current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2024-12-31_custom_OnkaiIncMember" id="Fact000874" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LiabilitiesCurrent_iI_pn3n3_maSEzDrf_zobY668MRGo8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2024-12-31_custom_OnkaiIncMember" id="Fact000876" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">324</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--LiabilitiesNoncurrent_iI_pn3n3_maSEzDrf_zMXlZzwTppjg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Non-current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesNoncurrent" contextRef="AsOf2024-12-31_custom_OnkaiIncMember" id="Fact000878" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,665</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--StockholdersEquity_iNTI_pn3n3_di_mtSEzDrf_zkyvyScp2BRj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Equity</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_custom_OnkaiIncMember" id="Fact000880" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,881</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_zI1eLcJpUXbl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Statement
of operations for the year ended December 31, 2024:</span></b></span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000882" name="GLMD:ScheduleOfStatementOfOperationsTableTextBlock"><p id="xdx_894_ecustom--ScheduleOfStatementOfOperationsTableTextBlock_z2gmHRwAhNka" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B6_zPHAEsrbXx7d" style="display: none">Schedule of Statement of Operations</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20240101__20241231__srt--TitleOfIndividualAxis__custom--OnkaiIncMember_zkDMtB6dour2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(in thousands)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OperatingExpenses_pn3n3_msNILzGpU_z2RKoKHX4gFj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%; text-align: left">Total operating loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2024-01-012024-12-31_custom_OnkaiIncMember" id="Fact000884" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,485</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--NonoperatingIncomeExpense_pn3n3_maNILzGpU_zEeHcD4uNTQd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Financial expenses, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2024-01-012024-12-31_custom_OnkaiIncMember" id="Fact000886" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeTaxExpenseBenefit_pn3n3_msNILzGpU_zt7bQ6wUrWck" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Income tax</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2024-01-012024-12-31_custom_OnkaiIncMember" id="Fact000888" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">22</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--NetIncomeLoss_iNT_pn3n3_di_mtNILzGpU_zZzVj1WqR7h9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Net Loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_custom_OnkaiIncMember" id="Fact000890" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,537</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_z44tMFV77x" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 157; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GALMED
PHARMACEUTICALS LTD.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000892" name="us-gaap:OtherLiabilitiesDisclosureTextBlock"><p id="xdx_80B_eus-gaap--OtherLiabilitiesDisclosureTextBlock_zBeFeMlSalod" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
8 &#8211; <span id="xdx_820_zKXRHV6iQQz7">Other Payables</span></b></span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000894" name="us-gaap:OtherLiabilitiesTableTextBlock"><p id="xdx_89D_eus-gaap--OtherLiabilitiesTableTextBlock_zaNda3wGO549" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BF_zMZzMlssmlv1">Schedule
of Other Payables</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%; margin-left: 0.75in">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20241231_zYN49w91ZZ6c" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20231231_z6YGup8Lcp3a" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(in thousands)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--EmployeeRelatedLiabilitiesCurrentAndNoncurrent_iI_pn3n3_maOLzBhJ_zRyT3YMRNj1k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Employees and related</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent" contextRef="AsOf2024-12-31" id="Fact000896" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">603</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent" contextRef="AsOf2023-12-31" id="Fact000897" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">571</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--CompensatedAbsencesLiability_iI_pn3n3_maOLzBhJ_zxo0qSQeVIYi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued Vacation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CompensatedAbsencesLiability" contextRef="AsOf2024-12-31" id="Fact000899" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">256</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CompensatedAbsencesLiability" contextRef="AsOf2023-12-31" id="Fact000900" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">259</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--ShorttermLeaseObligation_iI_pn3n3_maOLzBhJ_z2yrk2VWa5g7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Short-term lease obligation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0902">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GLMD:ShorttermLeaseObligation" contextRef="AsOf2023-12-31" id="Fact000903" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">41</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OtherNotesPayable_iI_pn3n3_maOLzBhJ_zymGl44N1hgb" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherNotesPayable" contextRef="AsOf2024-12-31" id="Fact000905" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0906">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OtherLiabilities_iTI_pn3n3_mtOLzBhJ_zCDUx68QUafg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Other Payables</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilities" contextRef="AsOf2024-12-31" id="Fact000908" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">865</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilities" contextRef="AsOf2023-12-31" id="Fact000909" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">871</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_zCSbzujzOc39" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000911" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_809_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zWtBRc2Sjgnb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
9 &#8211; <span id="xdx_824_za6jximPdAh6">Related Parties</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    of December 31, 2024, and 2023, the Company had an accrual in the amount of approximately $<span id="xdx_906_eus-gaap--OtherLiabilitiesCurrent_iI_pn5n6_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersAndDirectorsMember_zeNcBHrV6v97" title="Due to related parties"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2024-12-31_custom_OfficersAndDirectorsMember" id="Fact000913" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.5</ix:nonFraction></span> million and $<span id="xdx_906_eus-gaap--OtherLiabilitiesCurrent_iI_pn5n6_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersAndDirectorsMember_zBLnwBX6TO6a" title="Due to related parties"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2023-12-31_custom_OfficersAndDirectorsMember" id="Fact000915" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.6</ix:nonFraction></span> million, respectively,
    pursuant to an employment agreements with its officers and directors&#8217; fee. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    of December 31, 2024, the Company had a receivable balance of $<span id="xdx_909_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember_zdNvTrPxdjI5" title="Related party services, balance amount"><ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2024-01-012024-12-31_custom_ServiceAgreementMember" id="Fact000917" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">25</ix:nonFraction></span> thousand, pursuant to a service agreement with OnKai and a long
    term loan balance of $<span id="xdx_90A_eus-gaap--LongTermDebt_iI_pn3n3_c20241231__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember_zpHttbkQw4D8" title="Long term loan"><ix:nonFraction name="us-gaap:LongTermDebt" contextRef="AsOf2024-12-31_custom_ServiceAgreementMember" id="Fact000919" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">257</ix:nonFraction></span> thousand (see note 7).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
    2024, 2023 and 2022, the Company recorded salary expenses, stock-based compensation expenses and directors&#8217; fees to its related
    parties in the amount of $<span id="xdx_908_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn5n6_c20240101__20241231_z9ryINkykqE5" title="Related party transaction, expenses"><ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2024-01-01to2024-12-31" id="Fact000921" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.1</ix:nonFraction></span> million, $<span id="xdx_904_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn5n6_c20230101__20231231_z5NRUIqp1o0a" title="Related party transaction, expenses"><ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2023-01-012023-12-31" id="Fact000923" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.8</ix:nonFraction></span> million and $<span id="xdx_90F_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn5n6_c20220101__20221231_zRkDcOZDvtlj" title="Related party transaction, expenses"><ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2022-01-012022-12-31" id="Fact000925" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.8</ix:nonFraction></span> million respectively. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
    2024, the Company recorded reimbursement of expenses pursuant to the service agreement with OnKai. And as well recorded research
    and development expenses in connection with the service agreement with Onkai (see note 7)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000927" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_802_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zmpvnPBgCCW6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
10 </b>&#8211; <b><span id="xdx_82B_zIc8BnQjewvf">Commitments and Contingencies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    of December 31, 2024, the Company recorded a pledge on its short-term deposit in favor of its bank in the amount of approximately
    $<span id="xdx_902_ecustom--BankLienOnMarketableSecurities_pn3n3_c20240101__20241231_zy8yr6jZNaNb" title="Bank lien on marketable securities"><ix:nonFraction name="GLMD:BankLienOnMarketableSecurities" contextRef="From2024-01-01to2024-12-31" id="Fact000929" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">121</ix:nonFraction></span> thousand to secure the Company&#8217;s commitments to the bank</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company enters into contracts in the ordinary course of business with contract research organizations for clinical trials and clinical
    supply manufacturing and with vendors for non-clinical research studies and other services and products for operating purposes, which
    generally provide for termination upon 30 to 90 days&#8217; notice or less, and therefore are cancelable contracts and not considered
    as commitment or purchase obligations.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    June 28, 2021, the Company entered into a license agreement with Yissum Research Development Company of the Hebrew University of
    Jerusalem (&#8220;Yissum&#8221;) pursuant to which Yissum granted to the Company a worldwide, exclusive and irrevocable license to
    develop and commercialize Amilo-5Mer. Under the license agreement, the Company is responsible for carrying out the development and
    commercialization of Amilo-5Mer and the prosecution and maintenance of the licensed patents under the license agreement. In consideration
    for the grant of the license, the Company paid Yissum an upfront license fee of $<span id="xdx_907_ecustom--UpfrontLicenseFee_pn3n3_c20210627__20210628_zymwOabmFZc2" title="Upfront license fee"><ix:nonFraction name="GLMD:UpfrontLicenseFee" contextRef="From2021-06-272021-06-28" id="Fact000931" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">100</ix:nonFraction></span> thousand which was included in research and
    development expenses for the period ended December 31, 2021. In addition, the Company may be required to make payments of up to $<span id="xdx_902_ecustom--PaymentsToRegulatoryMilestones_pn3n3_c20210627__20210628__srt--RangeAxis__srt--MaximumMember_zGjq0FD7O9g3" title="Payments to regulatory milestones"><ix:nonFraction name="GLMD:PaymentsToRegulatoryMilestones" contextRef="From2021-06-272021-06-28_srt_MaximumMember" id="Fact000933" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">950</ix:nonFraction></span>
    thousand upon meeting certain regulatory milestones and may be entitled to pay single digit royalties on any future net sales and
    a share of any sublicense fees. The Company is not currently pursuing the development of Amilo-5MER.</span></td></tr>
  </table>
<!-- Field: Split-Segment; Name: 01 -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 158; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GALMED
PHARMACEUTICALS LTD.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000935" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock"><p id="xdx_80A_eus-gaap--ShareholdersEquityAndShareBasedPaymentsTextBlock_z3FCK3TRwFLk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
11 &#8211; <span id="xdx_826_zOM8itOHtfd8">Stockholders&#8217; equity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ordinary
    shares</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ordinary
    shares confer upon the holders the right to receive notice to participate and vote in general meetings of the Company and the right
    to receive dividends, if declared.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    March 26, 2021, the Company entered into a Sales Agreement (the &#8220;2021 Sales Agreement&#8221;) with Cantor Fitzgerald &amp; Co. and Canaccord
    Genuity LLC, as sales agents, pursuant to which the Company may offer and sell ordinary shares &#8220;at the market&#8221; having an
    aggregate offering price of up to $<span id="xdx_90A_ecustom--MaximumAmountOfSharesToBeIssued_iI_pn5n6_c20210326__us-gaap--TypeOfArrangementAxis__custom--NewSalesAgreementMember_zuIBLx74F6pd" title="Aggregate offering price"><ix:nonFraction name="GLMD:MaximumAmountOfSharesToBeIssued" contextRef="AsOf2021-03-26_custom_NewSalesAgreementMember" id="Fact000937" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">50.0</ix:nonFraction></span>
    million from time to time through the sales agents. During 2022, the Company sold <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--NewSalesAgreementMember_zyAcvZIKVssi" title="Additional ordinary shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-01-012022-12-31_custom_NewSalesAgreementMember" id="Fact000939" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">643</ix:nonFraction></span>
    ordinary shares under its ATM program for total net proceeds of approximately $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--NewSalesAgreementMember_zDjOISA2j37g" title="Proceeds from sale of ordinary shares"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2022-01-012022-12-31_custom_NewSalesAgreementMember" id="Fact000941" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span>
    million. The Company did not sell any ordinary shares the 2021 Sales Agreement in 2023 and 2024 and in August 2024, the Company
    terminated the 2021 Sales Agreement in connection with its entry into the 2024 Sales Agreement (as defined below). See Note
    11(A)(6).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    May 15, 2023, the Company effected a reverse share split of the Company&#8217;s ordinary shares at the ratio of <span id="xdx_905_eus-gaap--StockholdersEquityReverseStockSplit_c20230515__20230515__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z4YdwSTmVXGg" title="Reverse stock split"><ix:nonNumeric contextRef="From2023-05-152023-05-15_us-gaap_CommonStockMember" id="Fact000943" name="us-gaap:StockholdersEquityReverseStockSplit">1-for-15</ix:nonNumeric></span>, such that
    each fifteen (15) ordinary shares, par value NIS <span id="xdx_902_eus-gaap--CommonStockNoParValue_iI_pid_uILSPShares_c20230515__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5yOgznQn6l8" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockNoParValue" contextRef="AsOf2023-05-15_us-gaap_CommonStockMember" id="Fact000945" format="ixt:numdotdecimal" decimals="INF" unitRef="ILSPShares">0.01</ix:nonFraction></span> per share, were consolidated into one (1) ordinary share, par value NIS <span id="xdx_90D_eus-gaap--SaleOfStockPricePerShare_iI_pid_uILSPShares_c20230515__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_znbayBOH7ZW1" title="Share price"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2023-05-15_us-gaap_CommonStockMember" id="Fact000947" format="ixt:numdotdecimal" decimals="INF" unitRef="ILSPShares">0.15</ix:nonFraction></span>.
    On August 29, 2024 the Company effected an additional reverse share split of the Company&#8217;s ordinary shares at the ratio of
    <span id="xdx_90A_eus-gaap--StockholdersEquityReverseStockSplit_c20240829__20240829__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ziNUIBHTH2Ol" title="Reverse stock split"><ix:nonNumeric contextRef="From2024-08-292024-08-29_us-gaap_CommonStockMember" id="Fact000949" name="us-gaap:StockholdersEquityReverseStockSplit">1-for-12</ix:nonNumeric></span>, such that each twelve (12) ordinary shares, par value NIS <span id="xdx_908_eus-gaap--CommonStockNoParValue_iI_pid_uILSPShares_c20240829_zefy5ShkOKu8" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockNoParValue" contextRef="AsOf2024-08-29" id="Fact000951" format="ixt:numdotdecimal" decimals="INF" unitRef="ILSPShares">0.15</ix:nonFraction></span> per share, were consolidated into one (1) ordinary share,
    par value NIS <span id="xdx_903_eus-gaap--CommonStockNoParValue_iI_pid_uILSPShares_c20240829__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zbpGZoM4psik" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockNoParValue" contextRef="AsOf2024-08-29_us-gaap_CommonStockMember" id="Fact000953" format="ixt:numdotdecimal" decimals="INF" unitRef="ILSPShares">1.80</ix:nonFraction></span> per share. As a result, all share and per share amounts prior to the reverse share split were adjusted retroactively
    for all periods presented in these consolidated financial statements.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
                                            July 18, 2023, the Company sold to investors in a public offering (i) <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230718__20230718_z5dLrsBqjnlh"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-07-182023-07-18" id="Fact000954" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">31,666</ix:nonFraction></span> ordinary shares,
                                            (ii) <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20230718__us-gaap--SubsidiarySaleOfStockAxis__custom--PrefundedWarrantsMember_zhrJw6vAsFHb" title="Stock and warrants issued during period shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2023-07-18_custom_PrefundedWarrantsMember" id="Fact000956" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">435,000</ix:nonFraction></span> pre-funded warrants to purchase <span id="xdx_904_eus-gaap--ConversionOfStockSharesIssued1_pid_c20230718__20230718__us-gaap--SubsidiarySaleOfStockAxis__custom--PrefundedWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zG0emCgmWM7d" title="Class of Warrant or Right, Number of Securities Called by Warrants or Rights"><ix:nonFraction name="us-gaap:ConversionOfStockSharesIssued1" contextRef="From2023-07-182023-07-18_custom_PrefundedWarrantsMember_us-gaap_CommonStockMember" id="Fact000958" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">435,000</ix:nonFraction></span> ordinary shares (the &#8220;Pre-Funded
                                            Warrants&#8221;), and (iii) <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20230718__us-gaap--SubsidiarySaleOfStockAxis__custom--InvestorWarrantsMember_zGNZfI0MzSI8" title="Stock and warrants issued during period shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2023-07-18_custom_InvestorWarrantsMember" id="Fact000960" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">466,666</ix:nonFraction></span> warrants to purchase <span id="xdx_900_eus-gaap--ConversionOfStockSharesIssued1_pid_c20230718__20230718__us-gaap--SubsidiarySaleOfStockAxis__custom--InvestorWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkRP9ftiEyd3" title="Class of Warrant or Right, Number of Securities Called by Warrants or Rights"><ix:nonFraction name="us-gaap:ConversionOfStockSharesIssued1" contextRef="From2023-07-182023-07-18_custom_InvestorWarrantsMember_us-gaap_CommonStockMember" id="Fact000962" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">466,666</ix:nonFraction></span> ordinary shares (the &#8220;Investor
                                            Warrants&#8221;), at a purchase price of $<span id="xdx_90A_eus-gaap--SharePrice_iI_pid_c20230718__us-gaap--SubsidiarySaleOfStockAxis__custom--InvestorWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zifjnMTEABl8" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-07-18_custom_InvestorWarrantsMember_us-gaap_CommonStockMember" id="Fact000964" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">15.0</ix:nonFraction></span> per share and accompanying Investor Warrant
                                            and $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230718__us-gaap--SubsidiarySaleOfStockAxis__custom--InvestorWarrantsMember_zYB6Q8b5T7bd" title="Exercise price of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-07-18_custom_InvestorWarrantsMember" id="Fact000966" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">14.99</ix:nonFraction></span> per Pre-Funded Warrant and accompanying Investor Warrant. The aggregate gross
                                            proceeds were $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20230718__20230718__us-gaap--SubsidiarySaleOfStockAxis__custom--InvestorWarrantsMember_zaueRm6PB0Yf" title="Gross proceeds stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-07-182023-07-18_custom_InvestorWarrantsMember" id="Fact000968" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">7.0</ix:nonFraction></span> million ($<span id="xdx_903_eus-gaap--PaymentsOfDebtIssuanceCosts_pn5n6_c20230718__20230718__us-gaap--SubsidiarySaleOfStockAxis__custom--InvestorWarrantsMember_zjAFNxgUx9F3" title="Issuance costs"><ix:nonFraction name="us-gaap:PaymentsOfDebtIssuanceCosts" contextRef="From2023-07-182023-07-18_custom_InvestorWarrantsMember" id="Fact000970" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">6.2</ix:nonFraction></span> million net of issuance costs).</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Pre-Funded Warrants are immediately exercisable at an exercise price of $<span id="xdx_900_eus-gaap--WarrantExercisePriceIncrease_pid_c20240101__20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--PrefundedWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHFQmA7DV567" title="Exercise price of warrants"><ix:nonFraction name="us-gaap:WarrantExercisePriceIncrease" contextRef="From2024-01-012024-12-31_custom_PrefundedWarrantsMember_us-gaap_CommonStockMember" id="Fact000972" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span> per ordinary share. As of December 31, 2024, all of
    the Pre-Funded Warrants have been exercised.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Investor Warrants have an exercise price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230718__us-gaap--SubsidiarySaleOfStockAxis__custom--PrefundedWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zIJtkgQmK9Kk" title="Exercise price of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-07-18_custom_PrefundedWarrantsMember_us-gaap_CommonStockMember" id="Fact000974" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">15</ix:nonFraction></span> per ordinary share, are immediately exercisable, and may be exercised until July
    18, 2028. During September 2024, a total of <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230718__us-gaap--SubsidiarySaleOfStockAxis__custom--PrefundedWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zNxvBFQ1XSqb" title="Investor warrants, shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2023-07-18_custom_PrefundedWarrantsMember_us-gaap_CommonStockMember_us-gaap_InvestorMember" id="Fact000976" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">293,333</ix:nonFraction></span> Investor Warrants have been exercised into <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230718__us-gaap--SubsidiarySaleOfStockAxis__custom--PrefundedWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zzwyImVjepic" title="Warrant exercised, shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-07-18_custom_PrefundedWarrantsMember_us-gaap_CommonStockMember_us-gaap_InvestorMember" id="Fact000978" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">293,333</ix:nonFraction></span> ordinary shares for a total
    net proceeds of $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20230718__20230718_z2m0qxYSYGs3" title="Proceeds from sale of ordinary shares"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-07-182023-07-18" id="Fact000980" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.4</ix:nonFraction></span> million. As of December 31, 2024 a total of <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231_zXcJV7Ee1euk" title="Warrants are outstanding"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31" id="Fact000982" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">173,333</ix:nonFraction></span> warrants are outstanding.</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
                                            August 30, 2024, the Company entered into a Standby Equity Purchase Agreement (the &#8220;SEPA&#8221;)
                                            with YA II PN, LTD., a Cayman Islands exempt limited partnership (&#8220;YA&#8221;). Pursuant
                                            to the SEPA, the Company have the right, but not the obligation, to sell to YA from time
                                            to time, each such occurrence, an Advance, up to $<span id="xdx_906_eus-gaap--OtherCommitment_iI_pn5n6_c20240830__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember_zpF3iro49RRd" title="Commitment amount"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2024-08-30_custom_StandbyEquityPurchaseAgreementMember" id="Fact000984" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">10.0</ix:nonFraction></span> million (the &#8220;Commitment Amount&#8221;),
                                            of the Company ordinary shares, during the 36 months following the execution of the SEPA,
                                            subject to the restrictions and satisfaction of the conditions in the SEPA. On October 21,
                                            2024, the Company and YA entered into an amendment to the SEPA to increase the Amount of
                                            the commitment to $<span id="xdx_90A_eus-gaap--OtherCommitment_iI_pn5n6_c20241021__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember__srt--RangeAxis__srt--MaximumMember_zgrykBHimNQ4" title="Commitment amount"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2024-10-21_custom_StandbyEquityPurchaseAgreementMember_srt_MaximumMember" id="Fact000986" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">20.0</ix:nonFraction></span> million of the Company&#8217;s ordinary shares.</span></p>
                                                         <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    consideration for YA&#8217;s irrevocable commitment to purchase the Company&#8217;s ordinary shares up to the Commitment Amount, the
    Company agreed to issue <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240830__20240830_zxVC6KB6S9Z8" title="Issuance of ordinary shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-08-302024-08-30" id="Fact000988" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">31,566</ix:nonFraction></span>
    ordinary shares (the &#8220;Commitment Shares&#8221;) to YA and also paid a $<span id="xdx_906_eus-gaap--DebtInstrumentFeeAmount_iI_pn3n3_c20240830_zvYDdhcYQmfk" title="Structuring fee"><ix:nonFraction name="us-gaap:DebtInstrumentFeeAmount" contextRef="AsOf2024-08-30" id="Fact000990" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15,000</ix:nonFraction></span>
    structuring fee to an affiliate of YA. The Commitment Shares shall be issued in four equal installments every 90 calendar days. As
    of December 31, 2024, the Company issued a total of <span id="xdx_909_ecustom--CommitmentShare_iI_pid_c20241231_zWCvhxvb1D4c" title="Commitment share"><ix:nonFraction name="GLMD:CommitmentShare" contextRef="AsOf2024-12-31" id="Fact000992" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,784</ix:nonFraction></span>
    Commitment Share. The Commitment Shares and structuring fee were recorded as expense in &#8220;Finance expenses related to
    SEPA&#8221;, in amounts of $<span id="xdx_906_ecustom--ProceedsFinanceLeaseInterestExpenseIncome_pn3n3_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember_zV8tH734tCI4" title="Finance expenses"><ix:nonFraction name="GLMD:ProceedsFinanceLeaseInterestExpenseIncome" contextRef="From2024-01-012024-12-31_custom_StandbyEquityPurchaseAgreementMember" id="Fact000994" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">70</ix:nonFraction></span>
    thousand and $<span id="xdx_907_ecustom--ProceedsFinanceLeaseInterestExpenseIncome_pn3n3_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember_zjKxAUajMR21" title="Finance expenses"><ix:nonFraction name="GLMD:ProceedsFinanceLeaseInterestExpenseIncome" contextRef="From2023-01-012023-12-31_custom_StandbyEquityPurchaseAgreementMember" id="Fact000996" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15</ix:nonFraction></span>
    thousand, respectively.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company evaluated the contract that includes the right to require YA to purchase shares of common stock in the future (&#8220;put
    right&#8221;) considering the guidance in ASC 815-40, &#8220;Derivatives and Hedging &#8212; Contracts on an Entity&#8217;s Own Equity&#8221;
    and concluded that it is an equity-linked contract that does not qualify for equity classification, and therefore requires fair value
    accounting and thus meet the definition of a derivative liability. Accordingly, the put right will be measured at fair value at each
    reporting period, and changes in its fair value will be recognized in the consolidated statement of operations. The Put right is
    measured under level 2 of the Fair Value hierarchy. The Company analyzed the terms of the freestanding put right and concluded that
    it has an immaterial value as of December 31, 2024.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    of December 31, 2024, the Company has issued an aggregate of <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--CaymanIslandsExemptLimitedPartnershipMember_zObevxSNdBxd" title="Issuance of shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember_custom_CaymanIslandsExemptLimitedPartnershipMember" id="Fact000998" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">574,559</ix:nonFraction></span>
    ordinary shares to YA for aggregate gross proceeds of approximately $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--CaymanIslandsExemptLimitedPartnershipMember_zXLAHct5ROG4" title="Gross proceeds stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember_custom_CaymanIslandsExemptLimitedPartnershipMember" id="Fact001000" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.0</ix:nonFraction></span>
    million (<span id="xdx_90E_eus-gaap--PaymentsOfDebtIssuanceCosts_pn5n6_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--CaymanIslandsExemptLimitedPartnershipMember_zmCl3Bc9fVf8" title="Issuance costs"><ix:nonFraction name="us-gaap:PaymentsOfDebtIssuanceCosts" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember_custom_CaymanIslandsExemptLimitedPartnershipMember" id="Fact001002" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.4</ix:nonFraction></span>
    million net of issuance costs). The Company recorded expenses in the amount of $<span id="xdx_904_eus-gaap--OtherExpenses_pn5n6_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--CaymanIslandsExemptLimitedPartnershipMember_zFXAoviBi0U" title="Other expenses"><ix:nonFraction name="us-gaap:OtherExpenses" contextRef="From2024-01-012024-12-31_custom_CaymanIslandsExemptLimitedPartnershipMember" id="Fact001004" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.6</ix:nonFraction></span> million in &#8220;finance
expenses related to SEPA&#8221; (including the commitment shares and structuring fee, as detailed above)</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    November 14, 2024, the Company entered into a Capital on Demand Sales Agreement (the &#8220;2024 Sales Agreement&#8221;) with JonesTrading
    Institutional Serviecs LLC, (&#8220;JonesTrading). Pursuent to the 2024 Sales Agreement, the Company may offer and sell ordinary
    shares having an aggregate offering price of up to $<span id="xdx_909_ecustom--MaximumAmountOfSharesToBeIssued_iI_pn5n6_c20241114__us-gaap--TypeOfArrangementAxis__custom--DemandSalesAgreementMember_zSabuyPzzcj7" title="Aggregate offering price"><ix:nonFraction name="GLMD:MaximumAmountOfSharesToBeIssued" contextRef="AsOf2024-11-14_custom_DemandSalesAgreementMember" id="Fact001006" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">8.1</ix:nonFraction></span>
    million, from time to time through JonesTrading. Subsequent to the balance sheet date, As of March 21 2025, the Company sold <span id="xdx_903_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20250320__20250321__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentySalesAgreementMember_zoAyVA0fTTbj" title="Sale of stock"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2025-03-202025-03-21_custom_TwoThousandAndTwentySalesAgreementMember" id="Fact001008" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">541,996</ix:nonFraction></span>
    ordinary shares pursuant to the 2024 Sales Agreement, for a total consideration of approximately $<span id="xdx_90E_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn5n6_c20250320__20250321__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentySalesAgreementMember_zThrcRtSe0c6" title="Total consideration"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2025-03-202025-03-21_custom_TwoThousandAndTwentySalesAgreementMember" id="Fact001010" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.5</ix:nonFraction></span>
    million</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 159; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GALMED
PHARMACEUTICALS LTD.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
11 &#8211; Stockholders&#8217; equity (Cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock-based
    compensation</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company has an equity-based incentive plan, the 2013 Incentive Share Option Plan (the &#8220;2013 Plan&#8221;). As of December 31,
    2023, based on the latest amendment to the plan from August 7, 2023, a total of <span id="xdx_90D_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20231231__us-gaap--PlanNameAxis__custom--IncentiveShareOptionPlan2013Member_z31sbmaJg3n7" title="Shares reserved for future issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2023-12-31_custom_IncentiveShareOptionPlan2013Member" id="Fact001012" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500,000</ix:nonFraction></span> ordinary shares were reserved for issuance
    under the 2013 Plan, of which a total of <span id="xdx_900_ecustom--CommonStockCapitalSharesReservedForFutureIssuanceUnallocated_iI_pid_c20231231__us-gaap--PlanNameAxis__custom--IncentiveShareOptionPlan2013Member_zSR43I9Tutrk" title="Shares reserved for future issuance"><ix:nonFraction name="GLMD:CommonStockCapitalSharesReservedForFutureIssuanceUnallocated" contextRef="AsOf2023-12-31_custom_IncentiveShareOptionPlan2013Member" id="Fact001014" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">63,253</ix:nonFraction></span> ordinary shares remain reserved, but unallocated for future equity awards. The 2013
    Plan, which was adopted by the Board on September 2, 2013, and approved by the Company&#8217;s shareholders on December 30, 2013
    (as was amended by the Board and the Company&#8217;s shareholders on March 30, 2015, May 11, 2015, August 30, 2018, August 7, 2023
    and November 12, 2024 respectively), provides for the grant of options to purchase the ordinary shares and the issuance of RSUs to
    the Company&#8217;s officers, directors, employees, service providers and consultants. The 2013 Plan provides for such equity-based
    compensation under various and different tax regimes.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    February 2022, the Company granted options to purchase <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220201__20220228_z9iMdpyD6jv4" title="Options granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-02-012022-02-28" id="Fact001016" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">222</ix:nonFraction></span> ordinary shares of the Company to one of its officers. The options are
    exercisable at $<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20220228_zGuXqR4gjd12" title="Options exercisable per share"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-02-28" id="Fact001018" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">288</ix:nonFraction></span> per share, have a <span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220201__20220228_zV0xDydsDAoe" title="Contractual term"><ix:nonNumeric contextRef="From2022-02-012022-02-28" format="ixt-sec:duryear" id="Fact001020" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">10</ix:nonNumeric></span>-year term and vest over a period of <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dt_c20220201__20220228_zSyNs9DbPHLk" title="Vest period"><ix:nonNumeric contextRef="From2022-02-012022-02-28" format="ixt-sec:durwordsen" id="Fact001022" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">four years</ix:nonNumeric></span>.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    March 23, 2023, the Company received a ruling from the Israel Tax Authority (&#8220;ITA&#8221;) confirming the repricing of certain
    stock options. This repricing was accounted for as a modification of a share-based payment award. The incremental compensation expense
    recognized as a result of the modification during the year ended December 31, 2023 was approximately $<span id="xdx_908_eus-gaap--OtherExpenses_pn5n6_c20230101__20231231_zPVzMPSSUXq1" title="Compensation expense"><ix:nonFraction name="us-gaap:OtherExpenses" contextRef="From2023-01-012023-12-31" id="Fact001024" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span> million.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    August 2023, the Company granted <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230801__20230831__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zqYmJKhfUsS1" title="Options granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-08-012023-08-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001026" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">109,583</ix:nonFraction></span> RSUs and <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230801__20230831_ztF5u6aejao1" title="Options granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-08-012023-08-31" id="Fact001028" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,250</ix:nonFraction></span> options to purchase <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230801__20230831_zRP4q85JGoGc" title="Options granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-08-012023-08-31" id="Fact001030" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,250</ix:nonFraction></span> ordinary shares of the Company to its officers
    and directors. The options are exercisable at $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20230831_zFukQF5Jfxob" title="Options exercisable per share"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2023-08-31" id="Fact001032" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.05</ix:nonFraction></span> per share and have a 10-year term. The options and RSUs vest over a period of
    three years. The aggregate grant date fair value of such RSUs and options was approximately $<span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_pn5n6_c20230801__20230831_zr6uZ6slH8af" title="Aggregate grant fair value"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" contextRef="From2023-08-012023-08-31" id="Fact001034" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.9</ix:nonFraction></span> million.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    September 2023, the Company extended the exercise period of <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230901__20230930__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zxgTuRsRp0eh" title="Options granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-09-012023-09-30_srt_ChiefExecutiveOfficerMember" id="Fact001036" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,805</ix:nonFraction></span> options with an exercise price of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_uILSPShares_c20230930__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zLMNLRGisRid" title="Options granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2023-09-30_srt_ChiefExecutiveOfficerMember" id="Fact001038" format="ixt:numdotdecimal" decimals="INF" unitRef="ILSPShares">0.15</ix:nonFraction></span> NIS previously granted to
    the Company&#8217;s Chief Executive Officer (and director), by approximately five years to December 31, 2028. the exercise period
    represented a modification in accordance with ASC 718. The Incremental compensation expense on the modification date was less than
    $<span id="xdx_903_eus-gaap--OtherExpenses_pn3n3_c20230901__20230930__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zDdQdiOt2FHa" title="Compensation expense"><ix:nonFraction name="us-gaap:OtherExpenses" contextRef="From2023-09-012023-09-30_srt_ChiefExecutiveOfficerMember" id="Fact001040" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></span> thousand.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    November 12, 2024, the Company&#8217;s board of directors approved the grant of <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20241112__20241112__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_znlp37Xlhtei" title="Options granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2024-11-122024-11-12_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001042" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">302,500</ix:nonFraction></span> RSUs and <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20241112__20241112_zS6adLTyhUqj" title="Options granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2024-11-122024-11-12" id="Fact001044" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">17,500</ix:nonFraction></span> options to purchase <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20241112__20241112_zLUFvm1v4Kzh" title="Options granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2024-11-122024-11-12" id="Fact001046" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">17,500</ix:nonFraction></span>
    ordinary shares of the Company to its officers and directors. The options and <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_pid_c20241112__20241112__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember_zD33oZrvMhLl" title="Restricted stock unit options"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2024-11-122024-11-12_us-gaap_OptionMember" id="Fact001048" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">197,500</ix:nonFraction></span> of the RSUs are subject to the approval
    of the Company&#8217;s shareholders. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 160; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GALMED
PHARMACEUTICALS LTD.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
11 &#8211; Stockholders&#8217; equity (Cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock-based
    compensation (Cont.)</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    summary of the status of the Company&#8217;s outstanding options as of December 31, 2024 and 2023 and changes during the years then
    ended are presented below:</span></td></tr>
  </table>
<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001050" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zguewmEJvuXf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none"><span id="xdx_8B4_zZ6l0CFM7hFc">Summary
of Status of Company's Option Plans and Changes</span></span></span></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 96%; border-collapse: collapse; margin-left: 0.25in">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="6" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="6" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023
    (*)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
    of</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>average</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
    of</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>average</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>share</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>exercise</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>share</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>exercise</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>options</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>price</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>options</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>price</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options
    outstanding at beginning of year</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zWLAnmky41Ye" title="Number of share options, Beginning" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember94762828" id="Fact001052" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,277</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zPy4aA2aXj48" title="Weighted average exercise price, Beginning" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember94762828" id="Fact001054" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">460</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zCnRDwTCWP91" title="Number of share options, Beginning" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-12-31_us-gaap_EmployeeStockOptionMember94762828" id="Fact001056" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,973</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_z2SpChuqlEQ7" title="Weighted average exercise price, Beginning" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_us-gaap_EmployeeStockOptionMember94762828" id="Fact001058" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">654</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Granted</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zu7PmuIAJeM6" title="Number of share options, Granted" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1060">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zClQp5lDQYJa" title="Weighted average exercise price, Granted" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1062">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zkw6Zng0TR4i" title="Number of share options, Granted" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember94762843" id="Fact001064" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,250</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zxH0vhVFriKe" title="Weighted average exercise price, Granted" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember94762843" id="Fact001066" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.6</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Forfeited</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240101__20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zIdJ4i6OqQAb" title="Number of share options, Forfeited" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember94762828" id="Fact001068" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,041</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zdvWLtcaz6of" title="Weighted average exercise price, Forfeited" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember94762828" id="Fact001070" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">94</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20230101__20231231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zFEWnAg1SZzk" title="Number of share options, Forfeited" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember94762843" id="Fact001072" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,351</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zMVt6qpJBCxb" title="Weighted average exercise price, Forfeited" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember94762843" id="Fact001074" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">441.6</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding
    at end of year</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zW2ejCxeWnMg" title="Number of share options, Ending" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember94762843" id="Fact001076" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">19,236</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zWBsxNgW3OE7" title="Weighted average exercise price, Ending" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember94762843" id="Fact001078" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">321</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zjjWoaIFNMvc" title="Number of share options, Ending" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember94762828" id="Fact001080" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,277</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_z4GB1kLPmpXb" title="Weighted average exercise price, Ending" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember94762828" id="Fact001082" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">460</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options
    exercisable at year end</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20240101__20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zIm8Sf8sRbn2" title="Number of share options exercisable, Ending" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember94762843" id="Fact001084" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,966</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zXZBLkzawzW" title="Weighted average exercise price, Options exercisable, Ending" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember94762843" id="Fact001086" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">413</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zwGHpJuCoFfi" title="Number of share options exercisable, Ending" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember94762828" id="Fact001088" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,269</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zxUQD2xG0Rr5" title="Weighted average exercise price, Options exercisable, Ending" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember94762828" id="Fact001090" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">670.56</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AC_z2dNKr9MSFmj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following assumptions were used for the fiscal year 2023 grants:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">dividend
    yield of <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zHzPfW3WoVGg" title="Dividend yield"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zBpYfMwPjME2" title="Dividend yield"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zWKVpxKXNBW3" title="Dividend yield"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember" id="Fact001092" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember" id="Fact001094" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember" id="Fact001096" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span>% for all periods.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">risk-free
    interest rate between <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zt3cgo0Wcrc5" title="Risk-free interest rate, minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember" id="Fact001098" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.80</ix:nonFraction></span>% and <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zMcDuzUootQ1" title="Risk-free interest rate, maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember" id="Fact001100" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.34</ix:nonFraction></span>% for the fiscal year 2021, <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zBgWm4RUQehb" title="Risk-free interest rate, maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember" id="Fact001102" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.94</ix:nonFraction></span>% for the fiscal year 2022 and <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgnGUuUnDK67" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember" id="Fact001104" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.16</ix:nonFraction></span>% for the fiscal year 2023.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    expected life between <span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zAvlkqxYP6Qk" title="Expected life, term"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zGQYzpbpfF37" title="Expected life, term"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zDpef0XgM2Ag" title="Expected life, term"><ix:nonNumeric contextRef="From2024-01-012024-12-31_srt_MinimumMember_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" id="Fact001106" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"><ix:nonNumeric contextRef="From2023-01-012023-12-31_srt_MinimumMember_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" id="Fact001108" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"><ix:nonNumeric contextRef="From2022-01-012022-12-31_srt_MinimumMember_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" id="Fact001110" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></span></span></span> and <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zsp8CSencube" title="Expected life, term"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zprI5R4wrxd" title="Expected life, term"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zAa9rslQSijc" title="Expected life, term"><ix:nonNumeric contextRef="From2021-01-012021-12-31_srt_MaximumMember_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" id="Fact001112" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"><ix:nonNumeric contextRef="From2022-01-012022-12-31_srt_MaximumMember_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" id="Fact001114" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"><ix:nonNumeric contextRef="From2023-01-012023-12-31_srt_MaximumMember_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" id="Fact001116" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6.25</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></span></span></span> years for all periods.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and
    a volatility rate ranging between <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgYQTc14SXkb" title="Volatility rate, minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember" id="Fact001118" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">64</ix:nonFraction></span>% and <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zcRexkOB0Tg8" title="Volatility rate, maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember" id="Fact001120" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">81</ix:nonFraction></span>% for the fiscal year 2021, <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z6MXtW14SqDj" title="Volatility rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember" id="Fact001122" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">65</ix:nonFraction></span>% for the fiscal year 2022 and <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zbSiVoN1E86a" title="Volatility rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember" id="Fact001124" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">108</ix:nonFraction></span>% for the fiscal year
    2023.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, and 2023, the weighted-average remaining contractual term of the outstanding options, excluding the <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zaBOz755R9vh" title="Options, granted"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z9mUVh2GntT9" title="Options, granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember" id="Fact001126" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember" id="Fact001128" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">270</ix:nonFraction></ix:nonFraction></span></span> options
granted in 2002 that have no expiration date, is <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zyLnTWWW9lP9" title="Contractual term"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" id="Fact001130" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">3.82</ix:nonNumeric></span> and <span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zOwH39SJhGbc" title="Contractual term"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" id="Fact001132" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">6.24</ix:nonNumeric></span> years, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average grant date fair value of the options granted during the years ended December 31, 2023 and 2022 is $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z11vaQxD2b14" title="Weighted average grant date fair value"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember" id="Fact001134" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.63</ix:nonFraction></span>, and $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zJp1Ym5fk6D6" title="Weighted average grant date fair value"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember" id="Fact001136" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.68</ix:nonFraction></span> respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, a total of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231_zCqS9JBKENj9" title="Options, exercisable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2024-12-31" id="Fact001138" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,805</ix:nonFraction></span> outstanding and exercisable options are &#8220;in the money&#8221; with aggregate intrinsic value
of $<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231_zWCgm6i9TNIa" title="Options, intrinsic value"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2024-12-31" id="Fact001140" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5</ix:nonFraction></span> thousand; while as of December 31, 2023 a total of <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20231231_z0xfbf8T2Veb" title="Options, exercisable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2023-12-31" id="Fact001142" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">21,654</ix:nonFraction></span> outstanding and exercisable options were &#8220;in the money&#8221; with
aggregate intrinsic value of $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20231231_zA1tCaWBSXK7" title="Options, intrinsic value"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2023-12-31" id="Fact001144" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></span> thousand.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unrecognized compensation expense calculated under the fair-value method for stock options expected to vest as of December 31, 2024,
2023 and 2022 is approximately $<span id="xdx_90D_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn4n6_c20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zFD26POnPyJj" title="Unrecognized share based compensation"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember" id="Fact001146" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD">0.03</ix:nonFraction></span> million, $<span id="xdx_901_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn5n6_c20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zXcWvYIyAxl1" title="Unrecognized share based compensation"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember" id="Fact001148" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.3</ix:nonFraction></span> million, and $<span id="xdx_900_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn5n6_c20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zlF8WAAWeDJe" title="Unrecognized share based compensation"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2022-12-31_us-gaap_EmployeeStockOptionMember" id="Fact001150" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.9</ix:nonFraction></span> million, respectively, and is expected to be recognized over a weighted-average
period of <span id="xdx_905_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z5UPKpAmrl8l" title="Unrecognized compensation, term"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" id="Fact001152" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">1.0</ix:nonNumeric></span> years, <span id="xdx_902_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zAXDUWAP1LH5" title="Unrecognized compensation, term"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" id="Fact001154" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">0.3</ix:nonNumeric></span> years and <span id="xdx_904_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z25Gmt71VKYk" title="Unrecognized compensation, term"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" id="Fact001156" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">1.41</ix:nonNumeric></span> years, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended 2024, 2023 and 2022, the Company recorded a total of $<span id="xdx_904_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zErVATd19F99" title="Allocated stock based compensation"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember" id="Fact001158" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.5</ix:nonFraction></span> million, $<span id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zZeCj8Charwk" title="Allocated stock based compensation"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember" id="Fact001160" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.8</ix:nonFraction></span> million, and $<span id="xdx_906_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zdomHhxA0e71" title="Allocated stock based compensation"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember" id="Fact001162" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.3</ix:nonFraction></span> million of stock-based compensation
expenses, in connection with the above-mentioned options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 161; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GALMED
PHARMACEUTICALS LTD.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
11 &#8211; Stockholders&#8217; equity (Cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock-based
    compensation (Cont.)</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 7, 2023, the Company issued a total of <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230807__20230807__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zTbmiCwd4id1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-08-072023-08-07_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001163" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">109,583</ix:nonFraction></span> RSUs. Upon vesting, each RSU will settle for the issuance of one ordinary
share. The RSUs vest over <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dt_c20230807__20230807__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zuZx4nS6qzA8"><ix:nonNumeric contextRef="From2023-08-072023-08-07_us-gaap_RestrictedStockUnitsRSUMember" format="ixt-sec:durwordsen" id="Fact001164" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">three years</ix:nonNumeric></span>. On November 12, 2024, the Company&#8217;s board of directors approved the grant of <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20241112__20241112__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zaFJOQy2HjXa" title="Share based compensation granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2024-11-122024-11-12_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001166" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">302,500</ix:nonFraction></span> of
which <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther_pid_c20241112__20241112__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zGV9l8VREFHg" title="Share based compensation subject to company shareholders"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther" contextRef="From2024-11-122024-11-12_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001168" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">197,500</ix:nonFraction></span> are subject to the approval of the Company&#8217;s shareholders. As of December 31, 2024, <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pid_c20241112__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zSykou31asH" title="Share based compensation vested"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2024-11-12_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001170" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">36,528</ix:nonFraction></span> of the RSUs were
vested. With respect to the above-mentioned RSUs, the Company recorded stock-based compensation expenses in the amount of $<span id="xdx_90C_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn5n6_c20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zC3yIoqCf9Gb" title="Unrecognized compensation expense"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001172" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.3</ix:nonFraction></span>
million and $<span id="xdx_902_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn5n6_c20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zUnzjyPnxm21" title="Unrecognized compensation expense"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001174" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span> million for the years ended December 31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average grant date fair value of the RSUs granted during the year ended December 31, 2024 and 2023 was $<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJfBjosh3Wkb" title="Weighted average grant date fair value"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001176" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.02</ix:nonFraction></span> and $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z4dpZgmi1oZ7" title="Weighted average grant date fair value"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001178" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.63</ix:nonFraction></span>,
respectively</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unrecognized compensation expense calculated for RSUs expected to vest as of December 31, 2024 and 2023 is approximately $<span id="xdx_909_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn5n6_c20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zdlVElp3wGO3" title="Unrecognized share based compensation"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001180" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.7</ix:nonFraction></span>
million and $<span id="xdx_909_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn5n6_c20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z9zM8efXAc11" title="Unrecognized share based compensation"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001182" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.7</ix:nonFraction></span> million, respectively and is expected to be recognized over a weighted-average period of <span id="xdx_905_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zRQfdQO5GAY6" title="Unrecognized compensation, term"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt-sec:duryear" id="Fact001184" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">2.11</ix:nonNumeric></span> years and <span id="xdx_907_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zTrA9d7Yk4s1" title="Unrecognized compensation, term"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt-sec:duryear" id="Fact001186" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">2.5</ix:nonNumeric></span> years, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001188" name="us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"><p id="xdx_809_eus-gaap--ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_zZk84PJrZwaa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
12 &#8211; <span id="xdx_825_zS06Ih1Y0sv7">Research and Development Expenses</span></b></span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001190" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock"><p id="xdx_890_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock_ziuRnOx0P0rf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none"><span id="xdx_8B8_zv2MOaxIgHVk">Schedule of Research and Development Expenses</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(in thousands)</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Chemistry and formulation studies</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__custom--ChemistryAndFormulationStudiesMember_zDsfi0ig8y67" title="Research and development expense" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-12-31_custom_ChemistryAndFormulationStudiesMember" id="Fact001192" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">696</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--ChemistryAndFormulationStudiesMember_zyE8JQIQubG9" title="Research and development expense" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31_custom_ChemistryAndFormulationStudiesMember" id="Fact001194" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">573</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__custom--ChemistryAndFormulationStudiesMember_zOlTd1YZTYmc" title="Research and development expense" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31_custom_ChemistryAndFormulationStudiesMember" id="Fact001196" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,448</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Salaries</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__custom--SalariesMember_zpI82J099YY5" title="Research and development expense" style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-12-31_custom_SalariesMember" id="Fact001198" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">982</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--SalariesMember_zeDn0J9ezjF6" title="Research and development expense" style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31_custom_SalariesMember" id="Fact001200" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">676</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__custom--SalariesMember_ztdz1oqsyw1l" title="Research and development expense" style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31_custom_SalariesMember" id="Fact001202" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,692</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__custom--StockBasedCompensationMember_z8wj4qyB3dd6" title="Research and development expense" style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-12-31_custom_StockBasedCompensationMember" id="Fact001204" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">112</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--StockBasedCompensationMember_z8goXa8TdSV7" title="Research and development expense" style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31_custom_StockBasedCompensationMember" id="Fact001206" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">243</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__custom--StockBasedCompensationMember_zl26bsC9nsoj" title="Research and development expense" style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31_custom_StockBasedCompensationMember" id="Fact001208" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">383</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and preclinical studies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__custom--ResearchAndPreclinicalStudiesMember_zm8txvyA7r6h" title="Research and development expense" style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-12-31_custom_ResearchAndPreclinicalStudiesMember" id="Fact001210" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">255</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--ResearchAndPreclinicalStudiesMember_z4n5cQkWnNFe" title="Research and development expense" style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31_custom_ResearchAndPreclinicalStudiesMember" id="Fact001212" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">460</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__custom--ResearchAndPreclinicalStudiesMember_zkCJ2CZk1hNl" title="Research and development expense" style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31_custom_ResearchAndPreclinicalStudiesMember" id="Fact001214" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,346</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Clinical studies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__custom--ClinicalStudiesMember_z28YOLCpUlZ6" title="Research and development expense" style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-12-31_custom_ClinicalStudiesMember" id="Fact001216" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">291</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--ClinicalStudiesMember_zX0SYvubDGq9" title="Research and development expense" style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31_custom_ClinicalStudiesMember" id="Fact001218" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">616</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__custom--ClinicalStudiesMember_zDn6uGm2gOYg" title="Research and development expense" style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31_custom_ClinicalStudiesMember" id="Fact001220" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,532</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Regulatory and other expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__custom--RegulatoryAndOtherExpensesMember_zsuWlwnT3cOf" title="Research and development expense" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-12-31_custom_RegulatoryAndOtherExpensesMember" id="Fact001222" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">643</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--RegulatoryAndOtherExpensesMember_zRXUnXXn2lg9" title="Research and development expense" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31_custom_RegulatoryAndOtherExpensesMember" id="Fact001224" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,001</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__custom--RegulatoryAndOtherExpensesMember_zrwxLZ03siza" title="Research and development expense" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31_custom_RegulatoryAndOtherExpensesMember" id="Fact001226" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">594</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20240101__20241231_zha7UvacKc6e" title="Research and development expense" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-01to2024-12-31" id="Fact001228" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,979</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20230101__20231231_zdKICeaB44Gf" title="Research and development expense" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31" id="Fact001230" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,569</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20220101__20221231_zIs0giyR4hz5" title="Research and development expense" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31" id="Fact001232" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,995</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_zxp9NFzOR6xk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001234" name="GLMD:GeneralAndAdministrativeExpensesDisclosureTextBlock"><p id="xdx_801_ecustom--GeneralAndAdministrativeExpensesDisclosureTextBlock_zinLv9zPo5l2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
13 &#8211; <span id="xdx_82E_z9pCqip28Azk">General and Administrative Expenses</span></b></span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001236" name="GLMD:GeneralAndAdministrativeExpensesTableTextBlock"><p id="xdx_896_ecustom--GeneralAndAdministrativeExpensesTableTextBlock_zc3DZSOklY" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none"><span id="xdx_8B8_z6s0KlLNaH92">Schedule of General and Administrative Expenses</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">(in thousands)</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Stock-based compensation</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__custom--StockBasedCompensationMember_z1dA2h3OIgi4" title="General and administrative expenses" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-01-012024-12-31_custom_StockBasedCompensationMember" id="Fact001238" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">419</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--StockBasedCompensationMember_z6Pr0SVLyUP2" title="General and administrative expenses" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-012023-12-31_custom_StockBasedCompensationMember" id="Fact001240" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">649</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__custom--StockBasedCompensationMember_zA3NEe6Nuc8c" title="General and administrative expenses" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-01-012022-12-31_custom_StockBasedCompensationMember" id="Fact001242" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">913</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__custom--ProfessionalFeeMember_zEQ1jAH6MHrh" title="General and administrative expenses" style="text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-01-012024-12-31_custom_ProfessionalFeeMember" id="Fact001244" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">896</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--ProfessionalFeeMember_zUUUZQfcKdk4" title="General and administrative expenses" style="text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-012023-12-31_custom_ProfessionalFeeMember" id="Fact001246" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">908</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__custom--ProfessionalFeeMember_z2WpLiFfOKPa" title="General and administrative expenses" style="text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-01-012022-12-31_custom_ProfessionalFeeMember" id="Fact001248" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,084</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Salaries and benefits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__custom--SalariesAndBenefitsMember_zoS20LYjqApa" title="General and administrative expenses" style="text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-01-012024-12-31_custom_SalariesAndBenefitsMember" id="Fact001250" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,478</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--SalariesAndBenefitsMember_zkv5dJOEydng" title="General and administrative expenses" style="text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-012023-12-31_custom_SalariesAndBenefitsMember" id="Fact001252" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,428</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__custom--SalariesAndBenefitsMember_zL5geAw4doO3" title="General and administrative expenses" style="text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-01-012022-12-31_custom_SalariesAndBenefitsMember" id="Fact001254" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,164</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Rent and office-maintenance fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__custom--RentAndOfficeMaintenanceFeesMember_zNl2NqVBOnQ7" title="General and administrative expenses" style="text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-01-012024-12-31_custom_RentAndOfficeMaintenanceFeesMember" id="Fact001256" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">117</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--RentAndOfficeMaintenanceFeesMember_z6kOQICm3hGg" title="General and administrative expenses" style="text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-012023-12-31_custom_RentAndOfficeMaintenanceFeesMember" id="Fact001258" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">261</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__custom--RentAndOfficeMaintenanceFeesMember_z7jXRxaxz2L8" title="General and administrative expenses" style="text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-01-012022-12-31_custom_RentAndOfficeMaintenanceFeesMember" id="Fact001260" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">401</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Insurance and other expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__custom--InsuranceAndOtherExpensesMember_zVjfrOB9y13a" title="General and administrative expenses" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-01-012024-12-31_custom_InsuranceAndOtherExpensesMember" id="Fact001262" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">389</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--InsuranceAndOtherExpensesMember_zgfeDWFmEPG" title="General and administrative expenses" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-012023-12-31_custom_InsuranceAndOtherExpensesMember" id="Fact001264" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">677</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__custom--InsuranceAndOtherExpensesMember_zIGcJJGXstW1" title="General and administrative expenses" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-01-012022-12-31_custom_InsuranceAndOtherExpensesMember" id="Fact001266" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,094</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20240101__20241231_z0U5gSchMxMf" title="General and administrative expenses" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-01-01to2024-12-31" id="Fact001268" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,299</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20230101__20231231_z9uSjw6MrGWb" title="General and administrative expenses" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-012023-12-31" id="Fact001270" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,923</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20220101__20221231_zzhwtv32kYGl" title="General and administrative expenses" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-01-012022-12-31" id="Fact001272" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,656</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_zqt2b8ey4TF2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 162; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GALMED
PHARMACEUTICALS LTD.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001274" name="us-gaap:RevenueFromContractWithCustomerTextBlock"><p id="xdx_805_eus-gaap--RevenueFromContractWithCustomerTextBlock_zvXR9B4dAAMi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
14 &#8211; <span id="xdx_82B_zBBfoUfcBbai">Financial income, net</span></b></span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001276" name="us-gaap:ScheduleOfOtherNonoperatingIncomeByComponentTextBlock"><p id="xdx_89A_eus-gaap--ScheduleOfOtherNonoperatingIncomeByComponentTextBlock_zFdcfS2Q25A4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none"><span id="xdx_8BE_ziOFMcPvD306">Schedule of Financial Income, Net</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20240101__20241231_zzb1ucyZ33Ie" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20230101__20231231_zDfH2kZowrVd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20220101__20221231_zcqyslIm7Gfh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">(in thousands)</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_408_ecustom--BankFees_iN_pn3n3_di_msONIEz4mj_zKZr1V4vqB77" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Bank fees</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="GLMD:BankFees" contextRef="From2024-01-01to2024-12-31" id="Fact001278" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">15</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="GLMD:BankFees" contextRef="From2023-01-012023-12-31" id="Fact001279" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">11</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="GLMD:BankFees" contextRef="From2022-01-012022-12-31" id="Fact001280" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">22</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--InterestIncome_pn3n3_maONIEz4mj_zwhCBrfac05h" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="GLMD:InterestIncome" contextRef="From2024-01-01to2024-12-31" id="Fact001282" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">503</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="GLMD:InterestIncome" contextRef="From2023-01-012023-12-31" id="Fact001283" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">375</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="GLMD:InterestIncome" contextRef="From2022-01-012022-12-31" id="Fact001284" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">297</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--DebtSecuritiesAvailableForSaleGainLoss_pn3n3_maONIEz4mj_zKDn9fGmekm4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss from sale of marketable debt securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleGainLoss" contextRef="From2024-01-01to2024-12-31" id="Fact001286" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleGainLoss" contextRef="From2023-01-012023-12-31" id="Fact001287" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleGainLoss" contextRef="From2022-01-012022-12-31" id="Fact001288" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">526</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--ChangeInFairValueOfConvertibleNote_pn3n3_maONIEz4mj_z5zWTc7hC6qb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Change in fair value of convertible note</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1290">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="GLMD:ChangeInFairValueOfConvertibleNote" contextRef="From2023-01-012023-12-31" id="Fact001291" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">265</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1292">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--ForeignCurrencyTransactionGainLossBeforeTax_pn3n3_maONIEz4mj_zY7KEqP1G7p9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Foreign currency (gains) losses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2024-01-01to2024-12-31" id="Fact001294" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">40</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2023-01-012023-12-31" id="Fact001295" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">36</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2022-01-012022-12-31" id="Fact001296" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">36</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--OtherNonoperatingIncomeExpense_iNT_pn3n3_di_mtONIEz4mj_zy0VsQvvfJy4" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
    income net</span></span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2024-01-01to2024-12-31" id="Fact001298" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">516</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2023-01-012023-12-31" id="Fact001299" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">580</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2022-01-012022-12-31" id="Fact001300" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">215</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_zqoB0Hagb4Oa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001302" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_80E_eus-gaap--IncomeTaxDisclosureTextBlock_ziq34bF35CA5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
15 &#8211; <span id="xdx_82A_zd8W2oqR6btg">Income Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>General</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is assessed for tax purposes on an unconsolidated basis. Each of the Company&#8217;s subsidiaries is subject to the tax rules
prevailing in its country of incorporation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate
    Taxation</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israeli
Companies:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Israeli corporate income tax rate is <span id="xdx_900_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_c20210101__20211231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--IsraelTaxAuthorityMember_zacWVWJ0Kuvh" title="Effective income tax rate reconciliation, at federal statutory income tax rate, percent"><span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_c20230101__20231231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--IsraelTaxAuthorityMember_zpR4dLOqKd95" title="Effective income tax rate reconciliation, at federal statutory income tax rate, percent"><span id="xdx_905_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_c20240101__20241231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--IsraelTaxAuthorityMember_zXR7aP9oeTj8" title="Effective income tax rate reconciliation, at federal statutory income tax rate, percent"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2021-01-012021-12-31_us-gaap_IsraelTaxAuthorityMember" id="Fact001304" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2023-01-012023-12-31_us-gaap_IsraelTaxAuthorityMember" id="Fact001306" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2024-01-012024-12-31_us-gaap_IsraelTaxAuthorityMember" id="Fact001308" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">23</ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span>% for the years 2022, 2023 and 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 7, 2018, the Israeli Tax Authority issued a ruling granting the Company&#8217;s Israeli subsidiary, Galmed Research and Development
Ltd, a &#8220;Preferred Technological Enterprise&#8221; status as defined under the Encouragement of Capital Investment Law -1959 (the
&#8220;Approval&#8221;). The grant of the status means that the Company&#8217;s Israeli subsidiary will be subject to a reduced Israeli
corporate tax rate that will range between 6%-12% on any future taxable &#8220;technological income&#8221; which includes sales, licenses
and royalties from its IP protected products. The tax ruling applies for five years until the end of 2022 and may be extended for further
periods subject to meeting certain requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maltese
subsidiary:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxable
income of Maltese companies was subject to tax at the rate of <span id="xdx_909_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_c20220101__20221231__us-gaap--IncomeTaxAuthorityNameAxis__custom--MalteseSubsidiaryMember_zB4ZoEgTIg2l" title="Effective income tax rate reconciliation, at federal statutory income tax rate, percent"><span id="xdx_909_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_c20230101__20231231__us-gaap--IncomeTaxAuthorityNameAxis__custom--MalteseSubsidiaryMember_z85g1bxroSua" title="Effective income tax rate reconciliation, at federal statutory income tax rate, percent"><span id="xdx_901_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_c20240101__20241231__us-gaap--IncomeTaxAuthorityNameAxis__custom--MalteseSubsidiaryMember_z1GdRFr0UtX9" title="Effective income tax rate reconciliation, at federal statutory income tax rate, percent"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2022-01-012022-12-31_custom_MalteseSubsidiaryMember" id="Fact001310" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2023-01-012023-12-31_custom_MalteseSubsidiaryMember" id="Fact001312" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2024-01-012024-12-31_custom_MalteseSubsidiaryMember" id="Fact001314" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">35</ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span>% for the years 2022, 2023, and 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net
    Operating Loss Carry forward</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, the Company had approximately $<span id="xdx_905_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20241231_zmFPUDl5IPGj" title="Operating loss carry forwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2024-12-31" id="Fact001316" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">175.4</ix:nonFraction></span> million net-operating-loss carry forwards, consisting of approximately $<span id="xdx_905_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MalteseSubsidiaryMember_zZJsUzBwRXfj" title="Operating loss carry forwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2024-12-31_custom_MalteseSubsidiaryMember" id="Fact001318" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">11.7</ix:nonFraction></span>
million of Maltese net-operating-loss carry forwards and approximately $<span id="xdx_90E_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--IsraeliSubsidiaryMember_zk55bgRB31m4" title="Operating loss carry forwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2024-12-31_custom_IsraeliSubsidiaryMember" id="Fact001320" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">163.7</ix:nonFraction></span> million Israeli net-operating-loss carry forward. Additionally,
the Company had approximately $<span id="xdx_908_eus-gaap--DeferredTaxAssetsCapitalLossCarryforwards_iI_pn5n6_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--IsraeliSubsidiaryMember_zg2XFBzTJUk3" title="Deferred tax assets, capital loss carry forwards"><ix:nonFraction name="us-gaap:DeferredTaxAssetsCapitalLossCarryforwards" contextRef="AsOf2024-12-31_custom_IsraeliSubsidiaryMember" id="Fact001322" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.1</ix:nonFraction></span> million of capital loss carry forward from the sale of marketable debt securities in Israel. The Maltese
and the Israeli loss carry forwards have no expiration date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 163; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GALMED
PHARMACEUTICALS LTD.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
15 &#8211; Income Taxes (Cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Deferred
    income taxes</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, the significant components of the Company&#8217;s deferred tax assets are net operating loss carryforward in the
amount of $<span id="xdx_90B_eus-gaap--DeferredTaxAssetsCapitalLossCarryforwards_iI_pn5n6_c20241231_zUwB0TMHz5Ui" title="Deferred tax assets, capital loss carry forwards"><ix:nonFraction name="us-gaap:DeferredTaxAssetsCapitalLossCarryforwards" contextRef="AsOf2024-12-31" id="Fact001324" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">175.4</ix:nonFraction></span> million. and research and development expenses in the amount of $<span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_pn5n6_c20240101__20241231__us-gaap--RegulatoryAssetAxis__us-gaap--DeferredIncomeTaxChargesMember_zxXlc8rOZYpa" title="Research and development expenses"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-12-31_us-gaap_DeferredIncomeTaxChargesMember" id="Fact001326" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.3</ix:nonFraction></span> million. The Company has evaluated the positive
and negative evidence bearing upon its ability to realize the deferred tax assets. Management has considered the Company&#8217;s history
of cumulative net losses incurred since inception and its lack of commercialization of any products or generation of any revenue from
product sales since inception and has concluded that it is more likely than not that the Company will not realize the benefits of the
deferred tax assets. Accordingly, a full valuation allowance has been established against the deferred tax assets as of December 31,
2024. Management reevaluates the positive and negative evidence at each reporting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Tax
    assessment</b>s</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Israeli subsidiaries received final tax assessments through the year ended December 31, 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Effective
    tax expense</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001328" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><p id="xdx_893_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_z8W8nOrww3Vd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of the Company&#8217;s effective tax expense to the Company&#8217;s theoretical statutory tax benefit is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zpOBbrXmcaTk" style="display: none">Schedule of Effective Income Tax Rate Reconciliation</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20240101__20241231_zI43QpEYMOXb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20230101__20231231_ziaulpg56Iz9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20220101__20221231_zj3jy4F0oDhi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(in thousands)</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn3n3_ztAHqONZnqb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left; padding-bottom: 2.5pt">Loss before taxes on income, as reported in the consolidated statements of operations</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2024-01-01to2024-12-31" id="Fact001330" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,517</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2023-01-012023-12-31" id="Fact001331" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,912</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2022-01-012022-12-31" id="Fact001332" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17,866</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_zbKWAnV5rC57" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Statutory tax rate</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2024-01-01to2024-12-31" id="Fact001334" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">23</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2023-01-012023-12-31" id="Fact001335" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">23</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2022-01-012022-12-31" id="Fact001336" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_maITEBzSAa_zQqEaK4ogOW2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Theoretical tax benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="From2024-01-01to2024-12-31" id="Fact001338" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,729</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="From2023-01-012023-12-31" id="Fact001339" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,590</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="From2022-01-012022-12-31" id="Fact001340" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,144</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_maITEBzSAa_zd1KL1KEkRdk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Losses and other items for which a valuation allowance was provided or benefit from loss carry forwards</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2024-01-01to2024-12-31" id="Fact001342" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,729</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2023-01-012023-12-31" id="Fact001343" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,590</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2022-01-012022-12-31" id="Fact001344" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,144</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3n3_mtITEBzSAa_ztV1u2QHBqcg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Actual tax expense</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1346">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1347">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1348">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zwk492MKDilb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001350" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_80A_eus-gaap--SubsequentEventsTextBlock_ztFYymnC2Hq6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
16 &#8211; <span id="xdx_821_zXWHEo3Q1xt8">Subsequent events</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent
                                            to the balance sheet date, as of March 21 2025, the Company sold <span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20250320__20250321__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentySalesAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zaZXSo3sUEd4" title="Sale of stock"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2025-03-202025-03-21_custom_TwoThousandAndTwentySalesAgreementMember_us-gaap_SubsequentEventMember" id="Fact001352" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">541,996</ix:nonFraction></span> ordinary shares
                                            pursuant to the 2024 Sales Agreement with JonesTrading, for a total consideration of approximately
                                            $<span id="xdx_908_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn5n6_c20250320__20250321__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentySalesAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zxjZbnqiJy1f" title="Total consideration"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2025-03-202025-03-21_custom_TwoThousandAndTwentySalesAgreementMember_us-gaap_SubsequentEventMember" id="Fact001354" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.5</ix:nonFraction></span> million. See note 11(A)(6).</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent
                                                                                                                                                                                                       to the balance sheet date, as of March 21, 2025 the Company has issued an aggregate of <span id="xdx_907_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20250320__20250321__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--CaymanIslandsExemptLimitedPartnershipMember_z5ltgpUVk3gg" title="Sale of stock"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2025-03-202025-03-21_us-gaap_SubsequentEventMember_custom_CaymanIslandsExemptLimitedPartnershipMember" id="Fact001356" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,891</ix:nonFraction></span>
                                                                                                                                                                                                       ordinary shares to YA as part of the Commitment Shares and an aggregate of <span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20250320__20250321__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentySalesAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--CaymanIslandsExemptLimitedPartnershipMember_zNMbZ3TyF7Aj" title="Sale of stock"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2025-03-202025-03-21_custom_TwoThousandAndTwentySalesAgreementMember_us-gaap_SubsequentEventMember_custom_CaymanIslandsExemptLimitedPartnershipMember" id="Fact001358" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000</ix:nonFraction></span>
                                                                                                                                                                                                       ordinary shares that we sold to YA as Advance Shares for aggregate gross proceeds of approximately $<span id="xdx_904_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn3n3_c20250321__20250321__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentySalesAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z9GrfEhogdBi" title="Commitment share,value"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2025-03-212025-03-21_custom_TwoThousandAndTwentySalesAgreementMember_us-gaap_SubsequentEventMember" id="Fact001360" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">75</ix:nonFraction></span>
                                                                                                                                                                                                       thousand. See note 11(A)(5).&#160;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001362" name="us-gaap:SegmentReportingDisclosureTextBlock"><p id="xdx_80B_eus-gaap--SegmentReportingDisclosureTextBlock_zEySMl5bj5ye" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
17 &#8211; <span id="xdx_82F_znQxEJ8yPQw8">Segment Reporting</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
280, &#8220;Segment Reporting&#8221;, establishes standards for reporting information about operating segments. Operating segments are
defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief
operating decision maker (&#8220;CODM&#8221;) in deciding how to allocate resources and in assessing performance. The Company manages
its business on the basis of <span id="xdx_905_eus-gaap--NumberOfReportableSegments_dc_uInteger_c20240101__20241231_zT41MWE2qx35" title="Number of reportable segments"><ix:nonFraction name="us-gaap:NumberOfReportableSegments" contextRef="From2024-01-01to2024-12-31" id="Fact001364" format="ixt-sec:numwordsen" decimals="INF" unitRef="Integer">one</ix:nonFraction></span> reportable segment and unit. The Company&#8217;s chief operating decision maker is the chief executive
officer of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
CODM assesses the performance of the Company and decides how to allocate resources based on the operating results available that is also
reported within the Consolidated Statements of Operations. The measure of segment assets that is reviewed by the CODM is reported within
the Balance Sheet as Total assets.</span></p>

</ix:nonNumeric><p id="xdx_815_zRGdoNOX9UX3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 164; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aa_027"></span>ITEM
19. Exhibits.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    No.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1595353/000149315223021672/ex3-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Articles of Association of Galmed Pharmaceuticals Ltd. (19)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex2-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description of Securities Registered under Section 12 of the Exchange Act*</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1595353/000114420414012612/v367917_ex10-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Indemnification Agreement (1)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1595353/000114420415020787/v406342_ex99-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Galmed Pharmaceuticals Ltd. 2013 Incentive Share Option Plan as anemded on October 4, 2023 (4)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1595353/000114420414006610/v367324_ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registration and Information Rights Agreement, dated December 2013, by and among Galmed Pharmaceuticals Ltd., Shirat HaChaim Ltd., David &amp; Debora Goldfarb, Medgal S.A. and G. Yarom Medical Research Ltd. (2)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1595353/000114420414006610/v367324_ex10-8.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Personal Employment Agreement, dated December 23, 2013, by and between Galmed Medical Research Ltd. and Allen Baharaff (2)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1595353/000114420418014234/tv487506_ex4-6.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment No.1 to Employment Agreement by and between Galmed Research and Development Ltd. and Allen Baharaff (10)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1595353/000110465920032166/tm206796d1_ex4-6.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment No.2 to Employment Agreement by and between Galmed Research and Development Ltd. and Allen Baharaff(12)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1595353/000149315222011729/ex4-7.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment No.3 to Employment Agreement by and between Galmed Research and Development Ltd. And Allen Baharaff(13)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1595353/000149315223021672/ex10-8.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation Policy of Galmed Pharmaceuticals Ltd.(5)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1595353/000114420417016148/v462263_ex4-8.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease, dated March 22, 2015, between Galmed Research and Development Ltd. and Mintz K. Construction Company Ltd.(8)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1595353/000114420417016148/v462263_ex4-9.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Addendum to Lease, dated February 27, 2017, between Galmed Research and Development Ltd. and Mintz K. Construction Company Ltd. (8)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1595353/000114420419013601/tv515440_ex4-9.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Addendum to Lease, dated August 8, 2018, between Galmed Research and Development Ltd. and Mintz K. Construction Company Ltd.(11)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1595353/000110465921038205/tmb-20201231xex4d11.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Addendum to Lease, dated March 11, 2021, between Galmed Research and Development Ltd. and Mintz K. Construction Company Ltd.(12)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.13</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1595353/000149315221006920/ex1-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales Agreement, dated March 26, 2021, among Galmed Pharmaceuticals Ltd., Cantor Fitzgerald &amp; Co. and Canaccord Genuity LLC.(9)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.14</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1595353/000149315223024790/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Securities Purchase Agreement (14)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.15</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1595353/000149315223024790/ex10-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Placement Agency Agreement (15)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;4.16</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1595353/000149315223024790/ex10-3.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Pre-Funded Warrant (16)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.17</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1595353/000149315223024790/ex10-4.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Warrant (17)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.18</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1595353/000149315223024790/ex10-5.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Placement Agent Warrant (18)</span></a></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 165; Options: NewSection; Value: 143 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->143<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.19</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1595353/000149315224034594/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Standby Equity Purchase Agreement dated August 30, 2024, by and between Galmed Pharmaceuticals Ltd. and YA II PN, LTD. (20)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.20</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1595353/000149315224041775/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Amendment to Standby Equity Purchase Agreement dated October 21, 2024, by and between Galmed Pharmaceuticals Ltd. and YA II PN, LTD. (21)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.21</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1595353/000149315224046092/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital on Demand&#8482; Sales Agreement, dated November 14, 2024, by and between Galmed Pharmaceuticals Ltd. and JonesTrading Institutional Services LLC. (22)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex8-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">List of subsidiaries of Galmed Pharmaceuticals Ltd.* </span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1595353/000114420416089349/v434576_ex11-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Code of Business Conduct and Ethics of Galmed Pharmaceuticals Ltd.(7)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex11-2.htm">Insider Trading Policy*</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex12-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Chief Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex12-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Chief Accounting Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex13-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Chief Executive Officer and Chief Accounting Officer pursuant to Exchange Act Rules 13a-14(b) and 15d-14(b) and 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex15-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Brightman Almagor Zohar &amp; Co.*</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">97.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1595353/000149315224013203/ex97-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Officer Clawback Policy (23)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Instance Document*</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Schema Document*</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Calculation Linkbase Document*</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Definition Linkbase Document*</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Label Linkbase Document*</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Presentation Linkbase Document*</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    herein by reference to Amendment No. 1 to the Registration Statement on Form F-1, filed with the SEC on February 28, 2014.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    herein by reference to the Registration Statement on Form F-1, filed with the SEC on February 6, 2014.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    herein by reference to the Company&#8217;s Report on Form 6-K filed with the SEC on June 1, 2016.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    herein by reference to Exhibit A to the Company&#8217;s Report on Form 6-K filed with the SEC on April 2, 2015.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    herein by reference to Exhibit 10.8 to the Company&#8217;s Registration Statement on Form F-1 filed with the SEC on June 16, 2023.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    herein by reference to the Company&#8217;s Annual Report on Form 20-F filed with the SEC on March 31, 2015.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 166; Value: 143 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->144<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    herein by reference to the Company&#8217;s Annual Report on Form 20-F filed with the SEC on March 22, 2016.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    herein by reference to the Company&#8217;s Annual Report on Form 20-F filed with the SEC on March 23, 2017.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    herein by reference to Exhibit 1.1 to the Company&#8217;s Report on Form 6-K filed with the SEC on March 26, 2021.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    herein by reference to the Company&#8217;s Annual Report on Form 20-F filed with the SEC on March 13, 2018.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    herein by reference to the Company&#8217;s Annual Report on Form 20-F filed with the SEC on March 13, 2019.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    herein by reference to the Company&#8217;s Annual Report on Form 20-F filed with the SEC on March 18, 2021.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(13)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    herein by reference to the Company&#8217;s Annual Report on Form 20-F filed with the SEC on May 2, 2022.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(14)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    herein by reference to Exhibit 10.1 to the Company&#8217;s Report on Form 6-K filed with the SEC on July 18, 2023.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(15)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    herein by reference to Exhibit 10.2 to the Company&#8217;s Report on Form 6-K filed with the SEC on July 18, 2023.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(16)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    herein by reference to Exhibit 10.3 to the Company&#8217;s Report on Form 6-K filed with the SEC on July 18, 2023.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(17)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    herein by reference to Exhibit 10.4 to the Company&#8217;s Report on Form 6-K filed with the SEC on July 18, 2023.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(18)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    herein by reference to Exhibit 10.5 to the Company&#8217;s Report on Form 6-K filed with the SEC on July 18, 2023.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(19)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    herein by reference to Exhibit 3.1 to the Company&#8217;s Registration Statement on Form F-1 filed with the SEC on October 21, 2024.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(20)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    herein by reference to Exhibit 10.1 to the Company&#8217;s Report on Form 6-K filed with the SEC on August 30, 2024.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(21)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    herein by reference to Exhibit 10.1 to the Company&#8217;s Report on Form 6-K filed with the SEC on October 21, 2024.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(22)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    herein by reference to Exhibit 10.1 to the Company&#8217;s Report on Form 6-K filed with the SEC on November 14, 2024.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(23)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    herein by reference to the Company&#8217;s Annual Report on Form 20-F filed with the SEC on April 4, 2024.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*Filed
herewith.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 167; Value: 143 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->145<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized
the undersigned to sign this annual report on its behalf.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GALMED
    PHARMACEUTICALS LTD.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>By:</i></span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Allen Baharaff</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allen
    Baharaff</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President,
    Chief Executive Officer and Chairman</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
April 2, 2025</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 168; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->146<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>ex2-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
2.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DESCRIPTION
OF SECURITIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
descriptions of the securities contained herein summarize the material terms and provisions of the ordinary shares of Galmed Pharmaceuticals
Ltd. (the &ldquo;Company&rdquo;, &ldquo;we&rdquo;, &ldquo;our&rdquo; or &ldquo;us&rdquo;), registered under Section 12 of the Securities
Exchange Act of 1934.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>General</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
registered share capital of the Company is NIS 90,000,000 divided into 50,000,000 ordinary shares, NIS 1.80 par value per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
Nasdaq Capital Market</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ordinary shares are listed on the Nasdaq Capital Market under the symbol &ldquo;GLMD&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Memorandum
and Articles of Association</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
registration number is 51-495351-2. At the 2014 annual general meeting of shareholders, our shareholders adopted our Articles of
Association (the &ldquo;Original Articles&rdquo;), which became effective on the consummation of our initial public offering in the
United States in March 2014. At the 2023 annual general meeting of shareholders, our shareholders approved a proposal to grant our
Board of Directors (the &ldquo;Board&rdquo;) discretionary authority to effect a reverse share split of our ordinary shares in the
range of up to 1:15 within 12 months of the 2023 annual general meeting of shareholders, and to amend the Original Articles
accordingly. On May 15, 2023, following the approval of our Board, we effected a 1-for-15 reverse share split of our authorized
ordinary shares, including our issued and outstanding ordinary shares, and the par value of each share was accordingly increased
from NIS 0.01 per share to NIS 0.15 per share and adopted our Amended and Restated Articles of Association (the &ldquo;Amended
Articles&rdquo;). On August 29, 2024, following the approval of our Board, we effected a 1-for-12 reverse share split of our
authorized ordinary shares, including our issued and outstanding ordinary shares, and the par value of each share was accordingly
increased from NIS 0.15 per share to NIS 1.80 per share and adopted our Amended and Restated Articles of Association (the
&ldquo;Articles&rdquo;). Under Section 2 of our Articles, the purpose of the Company is to engage in any lawful activity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Election
of Directors</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board consists of three classes of directors, with one class being elected each year by shareholders at the Company&rsquo;s annual general
meeting for a term of approximately three years. In accordance with our Articles, directors so elected cannot be removed from office
by the shareholders until the expiration of their term of office. Ordinary shares do not have cumulative voting rights. As a result,
the holders of ordinary shares that represent a simple majority of the voting power represented at a shareholders&rsquo; meeting and
voting at the meeting have the power to elect all of the directors put forward for election.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
our Articles, a director shall vacate his or her office if that director dies; is declared bankrupt; is declared to be legally incompetent;
resigns such office by notice in writing given to the Company; is not re-elected by the shareholders upon expiration of his or her term
at the relevant annual general meeting of shareholders; <FONT STYLE="background-color: white">or otherwise as provided in the Israeli
Companies Law, 5759-1999 (the &ldquo;Companies Law&rdquo;).</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Articles provide that a director may, by written notice to the Company, appoint another person to serve as an alternate director provided
that such appointment is approved by a majority of the directors then in office, and that such appointing director may remove such alternate
director. Any alternate director shall be entitled to notice of meetings of the Board and of relevant committees and to attend and vote
accordingly, except that the alternate has no standing at any meeting at which the appointing director is present or at which the appointing
director is not entitled to participate as provided in the Companies Law. A person who is not qualified to be appointed as a director,
or a person who already serves as a director or an alternate director, may not be appointed as an alternate director.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
the appointing director limits the time or scope of the appointment, the appointment is effective for all purposes until the earlier
of (i) the appointing director ceasing to be a director; (ii) the appointing director terminating the appointment; or (iii) the occurrence,
with respect to the alternate, of any of the circumstances under which a director shall vacate his or her office. The appointment of
an alternate director does not in itself diminish the responsibility of the appointing director as a director. An alternate director
is solely responsible for his or her actions and omissions and is not deemed an agent of the appointing director. At present, there are
no effective appointments of alternate directors for our Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Borrowing
Powers</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board may from time to time, and at its reasonable discretion, borrow or secure the payment of any sum or sums of money for reasonable
Company purposes. The directors may raise or secure the repayment of such sum or sums in such manner, at such times and upon such terms
and conditions in all respects as they see fit and, in particular, by issuing bonds, perpetual or redeemable debentures, debenture stock
or any mortgages, charges or other securities on the undertaking of the whole or any part of the property of the Company, both present
and future, including current uncalled capital and called but unpaid capital.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Fiduciary
Duties of Directors and Executive Officers</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Companies Law codifies the fiduciary duties that Office Holders (as defined in the Companies Law) owe to a company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
Office Holder&rsquo;s fiduciary duties consist of a duty of care and a duty of loyalty. The duty of care requires an Office Holder to
act with the level of care with which a reasonable Office Holder in the same position would have acted under the same circumstances.
The duty of loyalty requires that an Office Holder act in good faith and in the best interests of a company. The duty of care includes
a duty to use reasonable means to obtain:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">information
    on the advisability of a given action brought for his or her approval or performed by virtue of his or her position; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
    other important information pertaining to these actions.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
duty of loyalty requires an Office Holder to act in good faith and for the benefit of a company, and includes a duty to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refrain
    from any conflict of interest between the performance of his or her duties to the company and his or her other duties or personal
    affairs;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refrain
    from any activity that is competitive with the company;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refrain
    from exploiting any business opportunity of the company to receive a personal gain for himself or herself or others; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disclose
    to the company any information or documents relating to the company&rsquo;s affairs which the Office Holder received as a result
    of his or her position as an Office Holder.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Disclosure
of Personal Interests of an Office Holder</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Companies Law requires that an Office Holder promptly disclose to the board of directors any personal interest that he or she may have
concerning any existing or proposed transaction with a company, as well as any substantial information or document with respect thereof.
An interested Office Holder&rsquo;s disclosure must be made promptly and, in any event, no later than the first meeting of the board
of directors at which the transaction is considered.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law, a &ldquo;personal interest&rdquo; includes an interest of any person in an action or transaction of a company, including
a personal interest of one&rsquo;s relative or of a corporate body in which such person or a relative of such person is a 5% or greater
shareholder, director or general manager or in which he or she has the right to appoint at least one director or the general manager,
but excluding a personal interest stemming from one&rsquo;s ownership of shares in a company. A personal interest furthermore includes
the personal interest of a person for whom the Office Holder holds a voting proxy or the interest of the Office Holder with respect to
his or her vote on behalf of the shareholder for whom he or she holds a proxy, even if such shareholder itself has no personal interest
in the approval of the matter. An Office Holder is not, however, obliged to disclose a personal interest if it derives solely from the
personal interest of a relative of such Office Holder in a transaction that is not considered an extraordinary transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law, an extraordinary transaction is defined as any of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    transaction other than in the ordinary course of business;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    transaction that is not on market terms; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    transaction that may have a material impact on a company&rsquo;s profitability, assets or liabilities.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Approval
Procedure</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an Office Holder has a personal interest in a transaction, approval by the board of directors is required for the transaction, unless
the articles of association of a company provide for a different method of approval. Our Articles do not provide for any such different
method of approval. Further, so long as an Office Holder has disclosed his or her personal interest in a transaction, the board of directors
may approve an action by the Office Holder that would otherwise be deemed a breach of the duty of loyalty. However, a company may not
approve a transaction or action that is adverse to such company&rsquo;s interest or that is not performed by the Office Holder in good
faith. Approval first by a company&rsquo;s audit committee and subsequently by the board of directors is required for an extraordinary
transaction in which an Office Holder has a personal interest. Arrangements regarding the Office Holders&rsquo; terms of office and employment
(which includes compensation, indemnification or insurance) generally require the approval of the remuneration committee, board of directors
and, in certain circumstances, the shareholders, in that order, and must generally be consistent with the Company&rsquo;s Compensation
Policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Generally,
a person who has a personal interest in a matter which is considered at a meeting of the board of directors or the audit committee may
not be present at such a meeting or vote on that matter unless a majority of the directors or members of the audit committee have a personal
interest in the matter, or unless the chairman of the audit committee or board of directors (as applicable) determines that he or she
should be present in order to present the transaction that is subject to approval. Generally, if a majority of the members of the audit
committee and the board of directors (as applicable) has a personal interest in the approval of a transaction, then all directors may
participate in discussions of the audit committee and/or the board of directors on such transaction and the voting on approval thereof,
but shareholder approval is also required for such transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Transactions
with Controlling Shareholders</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Israeli law, the disclosure requirements regarding personal interests that apply to directors and executive officers also apply to
a controlling shareholder of a public company. In the context of a transaction involving a controlling shareholder or an officer who
is a controlling shareholder of a company, a controlling shareholder also includes any shareholder who holds 25% or more of the voting
rights if no other shareholder holds more than 50% of the voting rights. Two or more shareholders with a personal interest in the approval
of the same transaction are deemed to be a single shareholder and may be deemed a controlling shareholder for the purpose of approving
such transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Extraordinary
transactions, including private placement transactions, with a controlling shareholder or in which a controlling shareholder has a personal
interest, and engagements with a controlling shareholder or his or her relative, directly or indirectly, including through a corporation
under his or her control, regarding the company&rsquo;s receipt of services from the controlling shareholder, and if such controlling
shareholder is also an office holder or an employee of the company, regarding his or her terms of service or employment, require the
approval of the audit committee or remuneration committee, the board of directors and the shareholders of a company by a Special Majority,
in that order.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Arrangements
regarding the terms of office and employment of a controlling shareholder who is an Office Holder, and the terms of employment of a controlling
shareholder who is an employee of a company, require the approval of the remuneration committee, board of directors and the shareholders
by a Special Majority, in that order, with respect to Office Holders&rsquo; compensation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent that any such transaction with a controlling shareholder is for a period extending beyond three years, approval is required
once every three years, unless, with respect to extraordinary transactions with a controlling shareholder or in which a controlling shareholder
has a personal interest, the audit committee determines that the duration of the transaction is reasonable given the circumstances related
thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Dividends
and Dividend Policy</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends
may be distributed only out of profits available for dividends as determined by the Companies Law, provided that there is no reasonable
concern that the distribution will prevent the Company from being able to meet its existing and anticipated obligations when they become
due. Under the Companies Law, the distribution amount is further limited to the greater of retained earnings or earnings generated over
the two most recent years legally available for distribution. In the event that we do not have retained earnings or earnings generated
over the two most recent years legally available for distribution, we may seek the approval of the court in order to distribute a dividend.
The court may approve our request if it is convinced that there is no reasonable concern that the payment of a dividend will prevent
us from satisfying our existing and foreseeable obligations as they become due.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Generally,
under the Companies Law, the decision to distribute dividends and the amount to be distributed is made by a company&rsquo;s board of
directors. The Articles provide that the Board may from time to time declare, and cause the Company to pay, such dividends as may appear
to it to be justified by the profits of the Company and that the Board has the authority to determine the time for payment of such dividends
and the record date for determining the shareholders entitled to receive such dividends, provided the date is not before the date of
the resolution to distribute the dividend. Declaration of dividends does not require shareholder approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to our Articles, subject to the rights of holders of shares with limited or preferred rights, ordinary shares shall confer upon the holders
thereof equal rights to receive dividends and to participate in the distribution of the assets of the Company upon its winding-up, in
proportion to the amount paid up or credited as paid up on account of the nominal value of the shares held by them respectively and in
respect of which such dividends are being paid or such distribution is being made, without regard to any premium paid in excess of the
nominal value, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never declared or paid any cash dividends on our ordinary shares and do not anticipate paying any cash dividends in the foreseeable
future. Payment of cash dividends, if any, in the future will be at the discretion of our Board and will depend on then-existing conditions,
including our financial condition, operating results, contractual restrictions, capital requirements, business prospects and other factors
our Board may deem relevant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment
of dividends may also be subject to Israeli withholding taxes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Transfer
of Shares</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ordinary
shares which have been fully paid-up are transferable by submission of a proper instrument of transfer to the Company or its transfer
agent together with the certificate of the shares to be transferred and such other evidence, if any, as the directors may require to
prove the rights of the intending transferor in the transferred shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ordinary shares that are fully paid for are issued in registered form and may be freely transferred under our Articles, unless the transfer
is restricted or prohibited by applicable law or the rules of a stock exchange on which the shares are traded. The ownership or voting
of our ordinary shares by non-residents of Israel is not restricted in any way by our Articles or the laws of the State of Israel, except
for ownership by nationals of some countries that are, or have been, declared as enemies of Israel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Shareholder
Meetings</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Articles provide that an annual general meeting must be held at least once in every calendar year, not later than 15 months after the
last preceding annual general meeting, at such time and place as may be determined by the Board. The Board may, in its discretion, convene
additional shareholder meetings and, pursuant to the Companies Law, must convene a meeting upon the demand of two directors or one quarter
of the directors then in office or upon the demand of the holder or holders of 10% of the Company&rsquo;s issued share capital and 1%
of its voting rights or upon the demand of the holder or holders of 10% of its voting rights. All demands for shareholder meetings must
set forth the items to be considered at that meeting. Pursuant to the Companies Law, the holder or holders of 1% of the Company&rsquo;s
voting rights may request the inclusion of an item on the agenda of a future shareholder meeting, provided the item is appropriate for
discussion at a shareholder meeting, and if such item relates to the appointment of a director, the holder or holders shall hold at 5%
of the Company&rsquo;s voting rights in order to make such request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to regulations promulgated pursuant to the Companies Law and governing the terms of notice and publication of shareholder meetings of
public companies, or the General Meeting Regulations, holder(s) of one percent or more of the Company&rsquo;s voting rights may propose
any matter appropriate for deliberation at a shareholder meeting to be included on the agenda of a shareholder meeting, generally by
submitting a proposal within seven days of publicizing the convening of a shareholder meeting, or, if the Company publishes a preliminary
notice at least 21 days prior to publicizing the convening of a meeting (stating its intention to convene such meeting and the agenda
thereof), within 14 days of such preliminary notice. Any such proposal must further comply with the information requirements under applicable
law and the Articles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Companies Law and regulations promulgated thereunder with respect to the convening of general meetings in a public company, shareholder
meetings generally require prior notice of not less than 21 days, and for certain matters specified in the Companies Law, not less than
35 days. The function of the annual general meeting is to elect directors in accordance with the Articles, receive and consider the profit
and loss account, the balance sheet and the ordinary reports and accounts of the directors and auditors, appoint auditors and fix their
remuneration and transact any other business which under the Articles or applicable law may be transacted by the shareholders of a company
in general meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Articles determine that the quorum required for either an annual (regular) or an extraordinary (special) general meeting of shareholders
consists of at least two shareholders present in person or by proxy holding shares comprising in the aggregate more than 33.33% of the
voting rights of the Company. If a meeting is convened by the Board upon the demand of shareholders or upon the demand of less than 50%
of the directors then in office or directly by such shareholders or directors and no quorum is present within half an hour from the time
appointed, it shall be cancelled. If a meeting is otherwise called and no quorum is present within such time, the meeting is adjourned
to the same day one week later at the same time and place or at such other time and place as the Board may determine and specify in the
notice of the general meeting and it shall not be necessary to give notice of such adjournment. If a quorum is not present within half
an hour from the time stated for such adjourned meeting, any two shareholders present in person or by proxy at such meeting shall constitute
a quorum even if, between them, they represent shares conferring 33.33% or less of the voting rights of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Generally,
under the Companies Law and the Articles, shareholder resolutions are deemed adopted if approved by the holders of a simple majority
of the voting rights represented at a meeting and voting unless a different majority is required by law or pursuant to the Articles.
The Companies Law provides that resolutions on certain matters, such as amending a company&rsquo;s articles of association, assuming
the authority of the board of directors in certain circumstances, appointing auditors, appointing external directors (if applicable),
approving certain transactions, increasing or decreasing the registered share capital and approving most mergers must be made by the
shareholders at a general meeting. A company may determine in its articles of association certain additional matters in respect of which
resolutions by the shareholders in a general meeting will be required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Access
to Corporate Records</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law, all shareholders generally have the right to review minutes of our general meetings, our shareholder register and
register of significant shareholders (as defined in the Companies Law), our articles of association, our financial statements, other
documents as provided in the Companies Law, and any document we are required by law to file publicly with the Israeli Companies Registrar.
Any shareholder who specifies the purpose of its request may request to review any document in our possession that relates to: (i) any
action or transaction with a related party which requires shareholder approval under the Companies Law; or (ii) the approval, by the
board of directors, of an action in which an office holder has a personal interest. We may deny a request to review a document if we
determine that the request was not made in good faith, or if such denial is necessary to protect our interest or protect a trade secret
or patent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Shareholder
Duties</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Companies Law, a shareholder has a duty to act in good faith and in a customary manner toward a company and other shareholders
and to refrain from abusing his or her power in the company, including, among other things, in voting at the general meeting of shareholders
and at class shareholder meetings with respect to the following matters:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    amendment to the company&rsquo;s articles of association;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    increase of the company&rsquo;s authorized share capital;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    merger; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; direction: ltr; unicode-bidi: embed"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approval
    of interested party transactions and acts of Office Holders that require shareholder approval.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, a shareholder also has a general duty to refrain from discriminating against other shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
shareholders have a further duty of fairness toward a company. These shareholders include any controlling shareholder, any shareholder
who knows that it has the power to determine the outcome of a shareholder vote or a shareholder class vote and any shareholder who has
the power to appoint or to prevent the appointment of an Office Holder of the company or other power towards the company. The Companies
Law does not define the substance of this duty of fairness, except to state that the remedies generally available upon a breach of contract
will also apply in the event of a breach of the duty to act with fairness, taking the shareholder&rsquo;s position in the company into
account.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Mergers
and Acquisitions under Israeli Law</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(i)
Merger</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Companies Law permits merger transactions if approved by each party&rsquo;s board of directors, and, unless certain requirements described
under the Companies Law are met, a majority of each party&rsquo;s shareholders, by a majority of each party&rsquo;s shares that are voted
on the proposed merger at a shareholders&rsquo; meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
board of directors of a merging company is required pursuant to the Companies Law to discuss and determine whether in its opinion there
exists a reasonable concern that as a result of a proposed merger, the surviving company will not be able to satisfy its obligations
towards its creditors, taking into account the financial condition of the merging companies. If the board of directors has determined
that such a concern exists, it may not approve a proposed merger. Following the approval of the board of directors of each of the merging
companies, the boards of directors must jointly prepare a merger proposal for submission to the Israeli Registrar of Companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of the shareholder vote, unless a court rules otherwise, the merger will not be deemed approved if a majority of the shares
voting at the shareholders meeting (excluding abstentions) that are held by parties other than the other party to the merger, any person
who holds 25% or more of the means of control of the other party to the merger or any one on their behalf including their relatives or
corporations controlled by any of them, vote against the merger. In addition, if the non-surviving entity of the merger has more than
one class of shares, the merger must be approved by each class of shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the transaction would have been approved but for the separate approval of each class of shares or the exclusion of the votes of certain
shareholders as provided above, a court may still rule that the company has approved the merger upon the request of holders of at least
25% of the voting rights of a company, if the court holds that the merger is fair and reasonable, taking into account the appraisal of
the merging companies&rsquo; value and the consideration offered to the shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law, each merging company must send a copy of the proposed merger plan to its secured creditors. Unsecured creditors are
entitled to receive notice of the merger, as provided by the regulations promulgated under the Companies Law. Upon the request of a creditor
of either party to the proposed merger, the court may delay or prevent the merger if it concludes that there exists a reasonable concern
that, as a result of the merger, the surviving company will be unable to satisfy the obligations of the target company. The court may
also give instructions in order to secure the rights of creditors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, a merger may not be completed unless at least 50 days have passed from the date that a proposal for approval of the merger
was filed with the Israeli Registrar of Companies and 30 days from the date that shareholder approval of both merging companies was obtained.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(ii)
Special Tender Offer</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Companies Law provides that an acquisition of shares of an Israeli public company must be made by means of a special tender offer if
as a result of the acquisition the purchaser would become a holder of 25% or more of the voting rights in the company. This rule does
not apply if there is already another holder of 25% or more of the voting rights in the company. Similarly, the Companies Law provides
that an acquisition of shares in a public company must be made by means of a special tender offer if as a result of the acquisition the
purchaser would become a holder of more than 45% of the voting rights in the company, if there is no other shareholder of the company
who holds more than 45% of the voting rights in the company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
requirements do not apply if the acquisition (i) occurs in the context of a private offering, on the condition that the shareholders&rsquo;
meeting approved the acquisition as a private offering whose purpose is to give the acquirer at least 25% of the voting rights in the
company if there is no person who holds at least 25% of the voting rights in the company, or as a private offering whose purpose is to
give the acquirer 45% of the voting rights in the company, if there is no person who holds 45% of the voting rights in the company; (ii)
was from a shareholder holding at least 25% of the voting rights in the company and resulted in the acquirer becoming a holder of at
least 25% of the voting rights in the company; or (iii) was from a holder of more than 45% of the voting rights in the company and resulted
in the acquirer becoming a holder of more than 45% of the voting rights in the company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
special tender offer may be consummated only if (i) at least 5% of the voting power attached to the company&rsquo;s outstanding shares
will be acquired by the offeror and (ii) the special tender offer is accepted by a majority of the votes of those offerees who gave notice
of their position in respect of the offer; in counting the votes of offerees, the votes of a holder of control in the offeror, a person
who has personal interest in acceptance of the special tender offer, a holder of at least 25% of the voting rights in the company, or
any person acting on their or on the offeror&rsquo;s behalf, including their relatives or companies under their control, are not taken
into account.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event that a special tender offer is made, a company&rsquo;s board of directors is required to express its opinion on the advisability
of the offer or shall abstain from expressing any opinion if it is unable to do so, provided that it gives the reasons for its abstention.
In addition, the board of directors must disclose any personal interest each of member of the board of directors have in the offer or
stems therefrom.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
office holder in a target company who, in his or her capacity as an office holder, performs an action the purpose of which is to cause
the failure of an existing or foreseeable special tender offer or is to impair the chances of its acceptance, is liable to the potential
purchaser and shareholders for damages resulting from his acts, unless such office holder acted in good faith and had reasonable grounds
to believe he or she was acting for the benefit of the company. However, office holders of the target company may negotiate with the
potential purchaser in order to improve the terms of the special tender offer, and may further negotiate with third parties in order
to obtain a competing offer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a special tender offer was accepted by a majority of the shareholders who announced their stand on such offer, then shareholders who
did not respond to the special offer or had objected to the special tender offer may accept the offer within four days of the last day
set for the acceptance of the offer. In the event that a special tender offer is accepted, then the purchaser or any person or entity
controlling it and any corporation controlled by them shall refrain from making a subsequent tender offer for the purchase of shares
of the target company and may not execute a merger with the target company for a period of one year from the date of the offer, unless
the purchaser or such person or entity undertook to effect such an offer or merger in the initial special tender offer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(iii)
Full Tender Offer</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law, a person may not acquire shares in a public company if, after the acquisition, he will hold more than 90% of the shares
or more than 90% of any class of shares of that company, unless a tender offer is made to purchase all of the shares or all of the shares
of the particular class. The Companies Law also provides, subject to certain exceptions, that as long as a shareholder in a public company
holds more than 90% of the company&rsquo;s shares or of a class of shares, that shareholder shall be precluded from purchasing any additional
shares unless tendering an offer to purchase all of the outstanding shares of the company or the applicable class of the shares. If the
shareholders who do not respond to or accept the offer hold less than 5% of the issued and outstanding share capital of the company or
of the applicable class of the shares, and more than half of the shareholders who do not have a personal interest in the offer accept
the offer, all of the shares that the acquirer offered to purchase will be transferred to the acquirer by operation of law. However,
a tender offer will be accepted if the shareholders who do not accept it hold less than 2% of the issued and outstanding share capital
of the company or of the applicable class of the shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
a successful completion of such a full tender offer, any shareholder that was an offeree in such tender offer, whether such shareholder
accepted the tender offer or not, has the right, within six months from the date of acceptance of the tender offer, to petition the court
to determine that the tender offer was for less than fair value and that the fair value should be paid as determined by the court. However,
under certain conditions, the purchaser may provide in its offer that an offeree who accepted the tender offer will not be entitled to
such rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the conditions set forth above are not met, the purchaser may not acquire additional shares of the company from shareholders who accepted
the tender offer to the extent that following such acquisition, the purchaser would own more than 90% of the company&rsquo;s issued and
outstanding share capital.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Anti-Takeover
Measures under Israeli Law</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Companies Law allows us to create and issue shares having rights different from those attached to our ordinary shares, including shares
providing certain preferred rights, distributions or other matters and shares having preemptive rights. As of the date hereof, no preferred
shares are authorized under our Articles. In the future, if we do authorize, create and issue a specific class of preferred shares, such
class of shares, depending on the specific rights that may be attached to it, may have the ability to frustrate or prevent a takeover
or otherwise prevent our shareholders from realizing a potential premium over the market value of their ordinary shares. The authorization
and designation of a class of preferred shares will require an amendment to our Articles, which requires the affirmative vote of at least
75% of the voting rights of the Company represented personally or by proxy and voting thereon at a general meeting at which a quorum
is present. The convening of the general meeting, the shareholders entitled to participate and the majority vote required to be obtained
at such a meeting will be subject to the requirements set forth in the Articles and the Companies Law as described above in &ldquo;&mdash;
Shareholder Meetings.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, certain provisions of the Articles may have the effect of rendering more difficult or discouraging an acquisition of the Company
deemed undesirable by the Board. The classification of the Board into three classes with terms of approximately three years each, may
make it more difficult for shareholders who oppose the policies of the Board to remove a majority of the then current directors from
office quickly. It may also, in some circumstances, together with the other provisions of the Articles and Israeli law, deter or delay
potential future merger, acquisition, tender or takeover offers, proxy contests or changes in control or management of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Changes
in Capital</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Articles enable us to increase or reduce our share capital. Any such changes are subject to the provisions of the Companies Law and must
be approved by a resolution duly passed by our shareholders at a general meeting by voting on such change in the capital. In addition,
transactions that have the effect of reducing capital, such as the declaration and payment of dividends in the absence of sufficient
retained earnings or profits and an issuance of shares for less than their nominal value (under certain circumstances), require the approval
of both our Board and an Israeli court.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Changes
in Shareholder Rights</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to our Articles, if at any time the share capital is divided into different classes of shares, the Company may by shareholder resolution,
unless otherwise provided by the terms of issue of the shares of that class, modify, convert, broaden, add or otherwise alter the rights,
privileges, advantages, restrictions and provisions related or unrelated at that time to the shares of any class with the sanction of
a resolution passed by a simple majority of those present, personally or by proxy, and voting thereon at a separate general meeting of
the holders of the shares of that class. Such majority approval is consistent with Israeli law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 8; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-8.1
<SEQUENCE>3
<FILENAME>ex8-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
8.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Subsidiaries
    of Galmed Pharmaceuticals Ltd.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jurisdiction
    of Incorporation</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Galmed
    International Ltd.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Malta</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Galmed
    Research and Development Ltd.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Israel</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Galtopa
    Therapeutics Ltd.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Israel</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Galmed
    Therapeutics UK Limited*</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>England
    and Wales</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OnKai,
    Inc.**</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
Wholly-owned subsidiary of Galmed Research and Development Ltd.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">**
Partially-owned subsidiary of Galtopa Therapeutics Ltd.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-11.2
<SEQUENCE>4
<FILENAME>ex11-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
11.2</B></FONT></P>

<P STYLE="margin-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">GALMED
PHARMACEUTICALS LTD.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">POLICY
STATEMENT ON INSIDE INFORMATION AND INSIDER TRADING</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the course of your service for or employment with Galmed Pharmaceuticals, Ltd. (&ldquo;<B>Galmed</B>&rdquo;) and its subsidiaries, including
Galmed Research and Development Ltd., Galmed International Limited, Galmed 2000 Inc. and Galmed Medical Research Ltd., you are likely
to use or have access to information about Galmed that is not generally available to the public. Because of your relationship with Galmed,
you have certain responsibilities under the U.S federal securities laws with respect to inside information. The purpose of this Policy
Statement on Inside Information and Insider Trading (this &ldquo;<B>Policy Statement</B>&rdquo;) is to outline Galmed&rsquo;s policies
regarding the protection of &ldquo;<B>inside information</B>&rdquo; and trading and &ldquo;<B>tipping</B>&rdquo;, as well as the expected
standards of conduct of Galmed directors, &ldquo;<B>management insiders</B>&rdquo;, &ldquo;<B>financial insiders</B>&rdquo;, &ldquo;<B>systems
insiders</B>&rdquo;, or &ldquo;<B>other insiders</B>&rdquo; (as each term is defined below) with respect to these highly sensitive matters.
The Policy Statement explains your obligations under the law and Galmed&rsquo;s policies. You should read this Policy Statement carefully
and comply with it at all times.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>I. <U>SUMMARY OF POLICY
STATEMENT</U></B></FONT></P>



<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
avoid the appearance of impropriety, all rules set forth in this Policy Statement will apply not only to you, but also to all members
of your family who reside in the same household.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Galmed&rsquo;s
policy regarding securities trading can be summarized by four important rules:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
                                            may not trade in securities of Galmed at any time that you possess material, non-public information
                                            (what is described below as &ldquo;<B>inside information</B>&rdquo;) about Galmed.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
                                            may not convey to any other person (&ldquo;<B>tip</B>&rdquo;) inside information about Galmed.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assuming
                                            that you do not possess inside information about Galmed, if you are (a) a member of the Board
                                            of Directors of Galmed, a management insider, financial insider, systems insider, or other
                                            insider, you may trade in securities of Galmed <I><U>only</U></I> during the period beginning
                                            24 hours after the public release of Galmed&rsquo;s quarterly and annual earnings and ending
                                            on the tenth day following the end of the third month of Galmed&rsquo;s fiscal quarter (the
                                            &ldquo;<B>trading window</B>&rdquo;), and (b) a member of the Board of Directors of Galmed
                                            or a management insider, you may trade in securities of Galmed <I><U>only</U></I> after,
                                            and only during the period of time as to which, you have obtained clearance from Galmed&rsquo;s
                                            Chief Financial Officer (or in his or her absence, the Chief Operating Officer or the Chief
                                            Executive Officer) that such transaction would not violate this Policy Statement (Galmed&rsquo;s
                                            Chief Financial Officer must obtain approval from the Chief Executive Officer for his or
                                            her own trades); <U>however</U>, trading windows and &ldquo;<B>blackout periods</B>&rdquo;
                                            (as defined below) will not apply, and pre-clearance will not be required with respect to,
                                            trading pursuant to the Rule 10b5-1 arrangements described in <U>Annex A</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            term &ldquo;<B>management insider</B>&rdquo; means (i) Galmed&rsquo;s Chief Executive Officer,
                                            Chief Medical Officer, Chief Operating Officer, Chief Financial Officer and Secretary, and
                                            other similarly situated individuals holding similar positions within its subsidiaries with
                                            access to inside information regarding Galmed or any of its subsidiaries, and (ii) the following
                                            Corporate or Divisional officers of Galmed: Vice President &ndash; Regulatory, Vice President
                                            &ndash; Drug Development and Vice President &ndash; Corporate Development (or in his or her
                                            absence, the individual performing similar functions for Galmed).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            term &ldquo;<B>financial insider</B>&rdquo; means Galmed&rsquo;s Chief Operating Officer,
                                            Treasurer, if any, Controller, Internal Auditor, bookkeeper or any other similarly situated
                                            individuals with access to inside information due to their financial and/or accounting permissions
                                            and who are given written notice from the Chief Financial Officer that such persons are deemed
                                            to be &ldquo;financial insiders&rdquo;, which status shall continue until a contrary written
                                            notice shall have been issued by the Chief Financial Officer.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            term &ldquo;<B>systems insider</B>&rdquo; means any accounting systems manager, computer
                                            systems manager or other similarly situated individuals with access to inside information
                                            due to their systems permissions and who are given written notice from the Chief Financial
                                            Officer that such persons are deemed to be &ldquo;systems insiders&rdquo;, which status shall
                                            continue until a contrary written notice shall have been issued by the Chief Financial Officer.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            term &ldquo;<B>other insider</B>&rdquo; means other employees or other individuals, as determined
                                            by the Chief Financial Officer, who are asked to work on sensitive projects or transactions,
                                            or who gain access to inside information in connection with a specific project or transaction,
                                            and who are given written notice from the Chief Financial Officer that such persons are deemed
                                            to be &ldquo;other insiders&rdquo;, which status shall continue until a contrary written
                                            notice shall have been issued by the Chief Financial Officer. The Chief Financial Officer
                                            shall provide this Policy Statement to all such &ldquo;other insiders.&rdquo;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing rules are only a summary. You must comply with all of the policies set forth below in Section III, which contains Galmed&rsquo;s
complete Policy Statement on inside information and insider trading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>II. <U>INSIDE
INFORMATION</U></B></FONT></P>



<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal">A. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>What
is Inside Information?</U></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inside
information is material information about Galmed that is not available to the public. Information generally becomes available to the
public when it has been disclosed by Galmed or third parties in a press release or other public statement or filing, including, without
limitation, any public filing with the Securities and Exchange Commission (the &ldquo;<B>SEC</B>&rdquo;) or the Israeli Securities Authority,
or a posting on the Galmed website. In general, information is considered to have been made available to the public 24 hours after the
formal release of the information. In other words, there is a presumption that the public needs 24 hours to receive and absorb such information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal">B. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>What
is Material Information?</U></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a general rule, information about Galmed is material if it could reasonably be expected to affect someone&rsquo;s decision to buy, hold,
or sell securities of Galmed. For example, information generally is considered to be material if its disclosure to the public would be
reasonably likely to affect (1) an investor&rsquo;s decision to buy or sell the securities of the company to which the information relates,
or (2) the market price of that company&rsquo;s securities. While it is not possible to identify in advance all information that will
be deemed to be material, some examples of such information would include the following: earnings and other financial information; regulatory
approvals and rejections; study and test results and analysis; major or otherwise material collaborations, partnerships or licensing
transactions; major acquisitions or dispositions; governmental investigations; class action lawsuits; and changes in senior management.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
can sometimes be difficult to know whether information would be considered material. The determination of whether information is material
is almost always clearer after the fact, when the effect of that information on the market can be quantified. Although you may have information
about Galmed that you do not consider to be material, federal regulators and others may conclude (with the benefit of hindsight) that
such information was material. Therefore, trading in securities of Galmed when you possess non-public information about Galmed can be
risky. When doubt exists, the information should be presumed to be material. <B>If you are unsure whether information of which you are
aware is material or non-public, you should consult with Galmed&rsquo;s Chief Financial Officer.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal">C. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>What
is the Penalty for Insider Trading?</U></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading
on inside information is a crime. The seriousness of insider trading is reflected in the penalties that it carries. Galmed and its directors,
management insiders, financial insiders, systems insiders and other insiders may be liable. If an individual&rsquo;s insider trading
is found to be a willful violation of SEC insider trading rules, he or she may be penalized up to $5,000,000 or imprisoned for up to
20 years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SEC also has the authority to seek a civil monetary penalty of up to three times the amount of the profit gained or loss avoided as a
result of an individual&rsquo;s insider trading. In addition, civil enforcement actions by the SEC are not subject to the statute of
limitations. The SEC may also impose control person liability on Galmed for up to the greater of $1,000,000 or three times the amount
of profit gained or loss avoided by insider trading. &ldquo;<B>Profit gained</B>&rdquo; or &ldquo;<B>loss avoided</B>&rdquo; is defined
as the difference between the purchase or sale price of the security and its value as measured by the trading price of the security a
reasonable period after public dissemination of the nonpublic information. The SEC is authorized to pay a bounty of between 10% and 30%
of the monetary sanctions collected in actions brought by the SEC and related actions brought by other regulatory and law enforcement
authorities to persons who provided the information leading to the imposition of such penalty. In addition to civil penalties, the SEC
may seek other relief such as an injunction against future violations and disgorgement of profits resulting from illegal trading. Finally,
private parties may bring actions against any person purchasing or selling a security while in the possession of inside information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
director, management insider, financial insider, systems insider or other insider who violates the prohibitions against insider trading
or knows of such violation by any other persons must report the violation immediately to Galmed&rsquo;s Chief Financial Officer. Upon
learning of any such violations, Galmed will determine appropriate action.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SEC, the U.S. Department of Justice and the Financial Industry Regulatory Authority have committed large staffs, computer investigative
techniques, and other resources to the detection and prosecution of insider trading cases. Criminal prosecution and the imposition of
fines and/or imprisonment is commonplace.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
all of these reasons, both you and Galmed have a significant interest in ensuring that insider trading is scrupulously avoided.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal">D. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>How
Should Material Information be Safeguarded?</U></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
material information relating to Galmed or its business has been disclosed to the general public, it must be kept in strict confidence.
Such information should be discussed only with persons who are employed by or represent Galmed who have a &ldquo;need to know&rdquo;
and should be confined to as small a group as possible. The utmost care and circumspection must be exercised at all times. Therefore,
conversations in public places, such as elevators, restaurants, and airplanes, as well as conversations on mobile phones, should be limited
to matters that do not involve information of a sensitive or confidential nature. In addition, you should not transmit sensitive or confidential
information through the Internet (including on public or personal blogs and social media sites) or any electronic mail system that is
not secure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
ensure Galmed&rsquo;s confidences are protected to the maximum extent possible, no individuals other than specifically authorized personnel
may release material information to the public or respond to inquiries from the media, analysts, or others outside Galmed. If you are
contacted by the media or by an analyst seeking information about Galmed, refer the call to Galmed&rsquo;s Chief Financial Officer (or
in his or her absence, the individual performing similar functions for Galmed).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, to avoid improper conduct or the appearance of impropriety, directors and management insiders and, in appropriate circumstances,
financial insiders, systems insiders and other insiders, will be prohibited by Galmed from buying or selling securities of Galmed during
times when Galmed is most likely to have inside information available; these additional black-out periods will be imposed because these
persons generally have access to financial or other sensitive information about Galmed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
occasion, it may be necessary for legitimate business reasons to disclose inside information to persons outside Galmed. Such persons
might include legal advisors, financial advisors, commercial bankers, investment bankers, or other companies seeking to engage in a joint
goal with Galmed. In such circumstances, the information should not be conveyed until an express understanding has been reached that
such information is not to be used for trading purposes and may not be further disclosed other than for legitimate business reasons.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>III. <U>STATEMENT OF POLICY</U></B></FONT></P>



<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1. For
purposes of this Policy Statement, all references to &ldquo;you&rdquo; shall mean you, as well as any family members that reside in the
same household as you.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2. You
may not buy or sell the securities of Galmed when you are in possession of inside information about Galmed or during a blackout period.
The insider trading rules apply both to securities purchases and securities sales, regardless of how or from whom the inside information
has been obtained.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3. Assuming
that you do not possess inside information about Galmed, if you are (a) a member of the Board of Directors of Galmed, a management insider,
financial insider, systems insider, or other insider, you may trade in securities of Galmed <I><U>only</U></I> during the trading window,
and (b) a member of the Board of Directors of Galmed or a management insider, you may trade in securities of Galmed <I><U>only</U></I>
after, and only during the period of time as to which, you have obtained clearance from Galmed&rsquo;s Chief Financial Officer (or in
his or her absence, the Chief Operating Officer or the Chief Executive Officer) that such transaction would not violate this Policy Statement
(Galmed&rsquo;s Chief Financial Officer must obtain approval from the Chief Executive Officer for his or her own trades); <U>however</U>,
blackout periods will not apply, and pre-clearance will not be required with respect to, trading pursuant to the Rule 10b5-1 arrangements
described in <U>Annex A</U>. A form of Request for Approval to Trade in the Securities of Galmed Pharmaceuticals Ltd. is attached for
your convenience. Of course, even if you receive clearance, you may make such trades only so long as you are not trading in violation
of the policy set forth in paragraph 2 above. Notwithstanding the foregoing, you may exercise your vested Galmed stock options at any
time, but you may not sell the underlying securities purchased upon exercise except in accordance with this Policy Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4. Galmed
from time to time may impose a trading freeze on all directors and management insiders and, in appropriate circumstances, on financial
insiders, systems insiders and other insiders, due to a significant unannounced corporate development. These trading freezes, known as
&ldquo;<B>blackout periods,</B>&rdquo; may vary in length.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5. You
may not tip inside information to any other person by providing them with inside information about Galmed or assisting them in any way.
The concept of unlawful tipping includes passing on such information to friends, family members or acquaintances under circumstances
that suggest that you were trying to help them make a profit or avoid a loss. You may, of course, provide such information to other Galmed
employees or representatives on a &ldquo;need to know&rdquo; basis in the course of performing your job with Galmed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6. All
inquiries for information about Galmed from any representative of the press or other media, an analyst, or other persons outside of Galmed
(other than publicly available information that an employee is authorized to disseminate in the ordinary course of his or her duties)
must be directed to Galmed&rsquo;s Chief Financial Officer (or in his or her absence, the individual performing similar functions for
Galmed).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7. You
must observe the foregoing policies and procedures at all times. Your failure to do so will be grounds for disciplinary action, up to
and including dismissal. You must promptly report to Galmed&rsquo;s Chief Financial Officer any trading in securities of Galmed by Galmed
personnel or disclosure of inside information by Galmed personnel that you have reason to believe may violate this Policy Statement or
the securities laws of the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8. This
Policy Statement also applies to trading in the securities of other issuers that are vendors, customers, or other business partners of
Galmed as to which a person subject to this Policy Statement becomes aware of inside information in the course of his or her duties for
Galmed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IV. <U>ADDITIONAL PROHIBITED TRANSACTIONS</U></B></FONT></P>



<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Galmed
considers it improper and inappropriate for any Galmed insider to engage in short-term or speculative transactions in Galmed&rsquo;s
securities. It therefore is Galmed&rsquo;s policy that Galmed directors, management insiders, financial insiders, systems insiders and
other insiders may not engage in any of the following transactions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Publicly
Traded Options. </B>A transaction in publicly-traded options to purchase or sell Galmed securities is, in effect, a bet on the short-term
movement of such Galmed securities and therefore may create the appearance that you are trading based on material nonpublic information.
Transactions in options also may focus your attention on short-term performance at the expense of Galmed&rsquo;s long-term objectives.
Accordingly, transactions in options, puts, calls or other derivatives of Galmed securities, on an exchange or in any other organized
market, are prohibited by this Policy Statement. Option positions arising from certain types of hedging transactions are governed by
the section below captioned &ldquo;Hedging Transactions.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Short
Sales. </B>Short sales of Galmed securities (i.e., the sale of a security that the seller does not own) evidence an expectation on the
part of the seller that the securities will decline in value and therefore signal to the market that the seller does not have confidence
in Galmed or its prospects. In addition, short sales may reduce the seller&rsquo;s incentive to seek to improve Galmed&rsquo;s performance.
For these reasons, short sales of Galmed&rsquo;s securities are prohibited by this Policy Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Hedging
Transactions. </B>Certain forms of hedging or monetization transactions with respect to Galmed&rsquo;s securities, such as prepaid variable
forwards, equity swaps and collars, allow an insider to lock in much of the value of his or her stock holdings, often in exchange for
all or part of the potential for upside appreciation in the stock. These transactions allow the insider to continue to own the covered
securities, but without the full risks and rewards of ownership. When that occurs, the insider may no longer have the same objectives
as Galmed&rsquo;s other shareholders. Therefore, these transactions are prohibited under this Policy Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Margin
Accounts and Pledges. </B>Securities held in a margin account may be sold by the broker without the customer&rsquo;s consent if the customer
fails to meet a margin call. Similarly, securities pledged (or hypothecated) as collateral for a loan may be sold in foreclosure if the
borrower defaults on the loan. Because a margin sale or foreclosure sale may occur at a time when the pledgor is aware of material nonpublic
information or otherwise is not permitted to trade in Galmed securities, Galmed directors, management insiders, financial insiders systems
insiders and other insiders are prohibited from holding Galmed securities in a margin account or pledging Galmed securities as collateral
for a loan. An exception to this prohibition may be granted where a person wishes to pledge Galmed securities as collateral for a loan
(not including margin debt) and clearly demonstrates the financial capacity to repay the loan without resort to the pledged securities
or if the pledge is effected under a Rule 10b5-1 trading plan established in accordance with <U>Annex A</U>. Any person who wishes to
pledge Galmed securities as collateral for a loan must submit a request for approval to the Chief Financial Officer at least ten business
days prior to the proposed execution of documents evidencing the proposed pledge.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>V. <U>CERTIFICATION</U></B></FONT></P>



<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
must sign, date, and return the attached Certification stating that you received Galmed&rsquo;s Policy Statement regarding insider trading
and the preservation of the confidentiality of inside information and related procedures, and you agree to comply with it. Please note
that you are bound by the Policy Statement whether or not you sign the Certification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CERTIFICATION</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
hereby certify that I:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">have
                                            read and understand the Policy Statement on Inside Information and Insider Trading for Directors,
                                            Management Insiders, Financial Insiders, Systems Insiders and Other Insiders and related
                                            procedures, a copy of which was distributed with this Certificate;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">have
                                            complied with the policies and procedures set forth in the Policy Statement;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">will
                                            continue to comply with the policies and procedures set forth in the Policy Statement;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">will
                                            request from the Chief Financial Officer prior clearance of all proposed acquisitions or
                                            dispositions of securities of Galmed as required by the Policy Statement; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">will
                                            engage in acquisitions or dispositions of securities of Galmed only on the dates permitted.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 8%">Signature:&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 42%">&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify">&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify">Name:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify">&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify">Title:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify">&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify">Date:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>






<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>REQUEST
FOR CLEARANCE TO TRADE</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Request
for Clearance to Trade<BR>
in the Securities of Galmed Pharmaceuticals Ltd.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of Insider: ___________________________________</FONT></TD>
  <TD STYLE="text-align: justify; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 60pt; text-align: justify">Print
Name</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
hereby request clearance for me (or a member of my immediate family or household) to execute the following transaction or transactions
relating to the securities of Galmed Pharmaceutics Ltd.:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR
INFORMATIONAL PURPOSES ONLY:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Type
of transaction (circle one):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PURCHASE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OPEN
MARKET SALE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SALE
OF SHARES ISSUED UPON EXERCISE OF OPTIONS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OTHER</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of Shares:</FONT> _________________________________</TD>
  <TD STYLE="text-align: justify; width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify">Other
(please explain): ______________________________</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: left; width: 70%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of beneficial owner if other than yourself _______________________________</FONT></TD>
  <TD STYLE="text-align: justify; width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Relationship of beneficial owner to you</FONT> ____________________________________</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature: _____________________________________</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT>
_____________________</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
authorization is valid only during the &ldquo;trading window&rdquo; and until the commencement of a &ldquo;blackout period,&rdquo; each
as defined in Galmed&rsquo;s Policy Statement on Inside Information and Insider Trading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD>Approved by:</TD>
  <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 12%">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 34%">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 49%">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THIS
IS NOT AN AUTHORIZATION FROM THE INSIDER TO TRADE THE SECURITIES DESCRIBED ABOVE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>ANNEX
A</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SEC
Rule 10b5-1 Trading Arrangements</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rule
10b5-1 promulgated under the Exchange Act of 1934, as amended (&ldquo;<B>Rule 10b5-1</B>&rdquo;), protects individuals from insider trading
liability under Rule 10b-5 for transactions under a previously established contract, plan or instruction that satisfies the requirements
of Rule 10b5-1. Rule 10b5-1 presents an opportunity for insiders to establish arrangements to sell (or purchase) securities of Galmed
without the sometimes arbitrary restrictions imposed by trading windows and blackout periods&mdash;even when there is undisclosed material
information. Such 10b5-1 arrangements may include blind trusts, other trusts, pre-scheduled stock option exercises and sales, pre-arranged
trading instructions, and other brokerage and third party arrangements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potential
Pitfalls</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">First,
the arrangement must satisfy the requirements of Rule 10b5-1. The plan must be documented, bona fide and previously established (at a
time when the insider did not possess inside information) and must specify the price, amount and date of trades or provide a formula
or mechanism to be followed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second,
Rule 10b5-1 only provides an &ldquo;affirmative defense&rdquo; (which must be proven) in the event there is an insider-trading lawsuit.
It does not prevent someone from bringing a lawsuit, and it does not prevent the media from writing about the sales.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board of Directors has provided in Galmed&rsquo;s Policy Statement on Inside Information and Insider Trading (the &ldquo;<B>Policy Statement</B>&rdquo;)
to permit transactions that comply with Rule 10b5-1. Galmed does not want to impede your ability to engage in sales or purchases of securities
of Galmed (e.g., for financial and estate planning purposes). However, in order to reduce the risk of litigation and bad press, and to
preserve the hard-earned good name of our company and our people, we are adopting procedural requirements that are essentially an extension
of Galmed&rsquo;s current pre-clearance procedure for transactions in securities of Galmed:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Galmed
must pre-approve any plan, arrangement, trading instructions, etc. involving potential sales (or purchases) of securities of Galmed or
option exercises, sales, etc. (including, but not limited to, blind trusts, discretionary accounts with banks or brokers, limit orders,
hedging strategies, etc.).</B> You must still adhere to this prior approval procedure even where, for example, you are assured that a
major law firm has blessed the trading arrangement that a brokerage firm or bank may be suggesting. (Note that the actual transactions
effected pursuant to a pre-approved plan will <U>not</U> be subject to Galmed&rsquo;s trading window, blackout periods or pre-clearance
procedures for transactions in securities of Galmed.)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will want to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Review
                                            Proposed Arrangement</U>. We must satisfy ourselves that the arrangement will not place Galmed&rsquo;s
                                            good name or yours in jeopardy.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 76.5pt; text-align: justify; text-indent: -.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 76.5pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 76.5pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Add
                                            Additional Safeguards</U>. To reduce exposure, we will need to make sure, for example, that
                                            at the time you enter into an arrangement (or at any time that you wish to terminate or modify
                                            a prior instruction or plan), there is no material information about Galmed that has not
                                            been publicly disclosed. If there is undisclosed material information (even if you are not
                                            aware of it), you would need to wait until that information has been disclosed. It may also
                                            be advisable that there be an interval between establishment of the plan and the first transaction.
                                            In general, the plans should also be established only during Galmed&rsquo;s released trading
                                            window periods (the period beginning 24 hours after the public release of Galmed&rsquo;s
                                            earnings and ending on the tenth day following the end of the third month of each fiscal
                                            quarter).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 76.5pt; text-align: justify; text-indent: -.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Consider
                                            a Public Announcement</U>. We will consider in each case whether public announcement of a
                                            trading plan should be made (via press release, web site, etc.). In addition, when applicable,
                                            a statement should be included in your Form 144, if applicable, indicating that sales are
                                            pursuant to a pre-existing plan.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 76.5pt; text-align: justify; text-indent: -.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Establish
                                            Rule 144 and other Procedures</U>. Also, we will need to establish a procedure with whomever
                                            is handling your transactions to ensure compliance with SEC Rule 144, if applicable, at the
                                            time of any sale.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 76.5pt; text-align: justify; text-indent: -.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
of the Opportunities</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
pre-arranged trading program (in which your instructions are irrevocable), properly structured, can be a safer way to insulate insiders
from potential insider trading liability than our current system of trading windows and blackout periods.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>An
Ongoing Periodic Sale Program</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
a trading plan, for example, it becomes clearer to the investing public (and potential plaintiffs) that your sales are simply part of
a pre-established plan and are not being prompted by your knowledge of current developments within Galmed, or your feelings about Galmed&rsquo;s
prospects. Indeed, for some insiders who may have been reluctant to sell any securities for fear of the message it might send to the
market, Rule 10b5-1 may well present an opportunity to establish an acceptable diversification program. Pre-arranged sales over a period
of time would also reduce any argument by a plaintiff&rsquo;s attorney that there was incentive at a particular time for Galmed to manipulate
earnings or disclosures in connection with a sale.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Stock
Option Exercises and Sales</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
program could include instructions for periodic exercise and same-day sales of your stock options, which could be conditioned on a minimum
stock price established in your instructions. For example, you could specify that sales be limited to the number of shares necessary
to cover the option exercise price and taxes dues.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Discretionary
Accounts and Other Arrangements with Brokers</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
true discretionary account (like a blind trust where the trustee has complete discretion) should satisfy Rule 10b5-1. Good-till-canceled
orders, as well as limit orders, should also work (as long as the instruction is not changed at a time when there is undisclosed material
inside information). While discretionary accounts might work in theory, Galmed would not be inclined to approve such an arrangement where
the broker has a close relationship with the client that could undermine the affirmative defense in the event of litigation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Pledging
Company Stock to Secure Margin or Other Loans</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Problems
often arise when there is a margin maintenance call and the broker seeks to liquidate the collateral. The broker&rsquo;s sales would
be attributable to the insider under Rule 144, if this rule is applicable to you. While a margin sale by the broker may be attributable
to the insider under Rule 10b-5, the pledge arrangement may fall within Rule 10b5-1, provided at the time of the pledge the insider irrevocably
instructs the broker to sell the shares in the event of a margin call (without substituting other collateral). Any pledges will be subject
to our pre-clearance policy and must be approved on a case-by-case basis. See Section IV of the Policy Statement for additional information
on margin accounts and pledges.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Put
and Call Options and Other Hedging Transactions</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Policy Statement prohibits our insiders from engaging in put and call options and other hedging transactions involving securities of
Galmed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Frequently
Asked Questions on Insider Trading</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Transactions
Subject to the Policy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Does
the Policy Statement apply to the exercise of employee stock options?</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise of employee stock options is exempt from this Policy Statement because the exercise price of an option is fixed at the time
of grant and does not fluctuate with the market. As a result, you may always adopt an &ldquo;exercise and hold&rdquo; strategy<I>. However,
the sale of the underlying stock is subject to the Policy Statement.</I> Thus, the use of Galmed stock to pay the exercise price of an
option and a &ldquo;cashless exercise&rdquo; of an option are also subject to the Policy Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Does
this Policy Statement apply to the sale of restricted stock?</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes,
the Policy Statement applies to the sale of restricted stock even if you are selling shares to satisfy your tax obligations to Galmed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tipping</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>What
is tipping?</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tipping
refers to the transmission of material non-public information from an insider to another person. Sometimes this involves a deliberate
conspiracy in which the tipper passes on information in exchange for a portion of the &ldquo;tippee&rsquo;s&rdquo; illegal trading profits.
Even if there is no expectation of profit, however, a tipper can have liability if he or she has reason to know that the information
may be misused.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Materiality</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>I
know all sorts of things about Galmed. How do I know what&rsquo;s &ldquo;material&rdquo;?</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Supreme Court of the United States says that information is material if a reasonable investor would consider it important in deciding
whether to buy or sell a security. At Galmed we have determined that our quarterly and annual earnings information is material. Other
information is evaluated by management on a case-by-case basis but could include the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
                                            investigations;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
                                            changes in earnings, financial results and/or financial condition and financial guidance;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">stock
                                            splits;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
                                            in senior management;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
                                            approvals and rejections;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">study
                                            and test results and analysis;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">major
                                            or otherwise material collaborations, partnerships or licensing transactions;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
                                            mergers, acquisitions, reorganizations, dispositions of assets or joint ventures; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
                                            increases or decreases in the amount of outstanding securities or indebtedness.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you are at all unsure about whether you have material inside information, the safe approach is to discuss it with Galmed&rsquo;s Chief
Financial Officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
Considerations</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>My
spouse is employed by a publicly traded corporation and we own stock in my spouse&rsquo;s employer. Does the Policy Statement prohibit
us from trading in stock of my spouse&rsquo;s employer?</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Policy Statement would not prohibit you or your spouse from trading in securities of your spouse&rsquo;s employer. However, you should
carefully review the insider trading policy of your spouse&rsquo;s employer to be sure that you are complying with both policies in all
of your trades. Furthermore, you should <U>never</U> trade in the securities of any company while in possession of inside information
about such company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enforcement
Practices</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>I
only own a few hundred shares. The SEC doesn&rsquo;t go after small fish like me?</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SEC has prosecuted numerous cases involving relatively small amounts of shares and/or money.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>If
I pass information to others but don&rsquo;t trade myself, no one will be able to figure it out, so this is ok, right?</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SEC has sophisticated and ingenious methods for identifying unusual trading patterns and tracing them to their source. They have the
ability to subpoena telephone records, bank and brokerage statements, personal files, electronic mail files, and anything else that may
help them to make a case. The SEC has the resources to establish the connection to you.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further
Information</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Who
should I contact if I have questions regarding Galmed&rsquo;s insider trading policy or the Policy Statement?</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
contact Galmed&rsquo;s Chief Financial Officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Where
do I go for the most current version of Galmed&rsquo;s insider trading policy or the Policy Statement?</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
contact Galmed&rsquo;s Chief Financial Officer.</FONT></P>

<P STYLE="margin-right: 0pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-right: 0pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 12; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-right: 0pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>5
<FILENAME>ex12-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 12.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">I, Allen Baharaff, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">1. I have reviewed this annual
report on Form 20-F of Galmed Pharmaceuticals Ltd. (the &ldquo;Company&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2. Based on my knowledge, this
report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made,
in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3. Based on my knowledge, the
financial statements, and other financial information included in this report, fairly present in all material respects the financial condition,
results of operations and cash flows of the Company as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4. The Company&rsquo;s other certifying
officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)
and 15d-15(e) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company
and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.75in">(a) Designed such disclosure
controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material
information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly
during the period in which this report is being prepared;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.75in">(b) Designed such internal control
over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable
assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
with generally accepted accounting principles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.75in">(c) Evaluated the effectiveness
of the Company&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the
disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.75in">(d) Disclosed in this report
any change in the Company&rsquo;s internal control over financial reporting that occurred during the period covered by the annual report
that has materially affected, or is reasonably likely to materially affect, the Company&rsquo;s internal control over financial reporting;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5. The Company&rsquo;s other certifying
officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company&rsquo;s
auditors and the audit committee of the Company&rsquo;s board of directors (or persons performing the equivalent functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.75in">(a) All significant deficiencies
and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely
affect the Company&rsquo;s ability to record, process, summarize and report financial information; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.75in">(b) Any fraud, whether or not
material, that involves management or other employees who have a significant role in the Company&rsquo;s internal control over financial
reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1pt; width: 3%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 47%"><I>/s/ Allen Baharaff </I></TD>
    <TD STYLE="padding-bottom: 1pt; width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Allen Baharaff</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>President and Chief Executive Officer</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Date: April 2, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.2
<SEQUENCE>6
<FILENAME>ex12-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
12.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Yohai Stenzler, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 35.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
I have reviewed this annual report on Form 20-F of Galmed Pharmaceuticals Ltd. (the &ldquo;Company&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 35.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the
period covered by this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 35.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 35.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
The Company&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e) and internal control over financial reporting (as defined in Exchange Act Rules
13a-15(f) and 15d-15(f)) for the Company and have:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within
those entities, particularly during the period in which this report is being prepared;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted accounting principles;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Evaluated the effectiveness of the Company&rsquo;s disclosure controls and procedures and presented in this report our conclusions about
the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Disclosed in this report any change in the Company&rsquo;s internal control over financial reporting that occurred during the period
covered by the annual report that has materially affected, or is reasonably likely to materially affect, the Company&rsquo;s internal
control over financial reporting; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 35.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
The Company&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the Company&rsquo;s auditors and the audit committee of the Company&rsquo;s board of directors (or persons performing the
equivalent functions):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the Company&rsquo;s ability to record, process, summarize and report financial information; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company&rsquo;s internal
control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Yohai Stenzler </I></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yohai
    Stenzler</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Accounting Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
April 2, 2025</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.1
<SEQUENCE>7
<FILENAME>ex13-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
13.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18
U.S.C. SECTION 1350,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AS
ADOPTED PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the annual report of Galmed Pharmaceuticals Ltd. (the &ldquo;Company&rdquo;) on Form 20-F for the period ending December
31, 2024, as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), the undersigned hereby
certify that to the best of our knowledge:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of
    the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Allen Baharaff </I></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allen
    Baharaff</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President
    and Chief Executive Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Yohai Stenzler </I></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yohai
    Stenzler</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Accounting Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
April 2, 2025</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
certification set forth above is being furnished as an exhibit solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and is
not being filed as part of the annual report on Form 20-F for the period ended December 31, 2024, or as a separate disclosure document
of the Company or the certifying officers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.1
<SEQUENCE>8
<FILENAME>ex15-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
15.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
consent to the incorporation by reference in Registration Statements Nos. 333-206292, 333-227441 and 333-284163 on Form S-8 and
Registration Statements No. 333-272722 and No. 333-283241 on Form F-3 of our report dated April 2, 2025, relating to the
consolidated financial statements of Galmed Pharmaceuticals Ltd., appearing in this Annual Report on Form 20-F for the year ended
December 31, 2024.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Brightman
    Almagor Zohar &amp; Co.</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brightman
    Almagor Zohar &amp; Co.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certified
    Public Accountants</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Firm in the Deloitte Global Network</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tel Aviv, Israel</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 2, 2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>form20-f_005.jpg
<TEXT>
begin 644 form20-f_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &" NX# 2(  A$! Q$!_\0
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MS_\  )__ "(>VI_S+\35HK*^WO\ W'_[\2?X4?;W_N/_ -^)/\*.;^[/_P
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M[O\ Z=/RZGP]]M_;_/71?V8O;_B<>/3_ .V'%'VS]O[_ * G[,7_ (./'O\
M\@U]PF?3PP0W-J',;3!#-!N,*;-\H7.3&OF)N?&U=Z9(W#*F6Q!P9[8$KN ,
ML.2N0N[K]W<0,],D#J15?6(_R?E_F)Y))_\ ,=C?_ J/ZTSX=^V?M_?] 3]F
M+_P<>/?_ )!H^V?M_?\ 0$_9B_\ !QX]_P#D&ON4&U;!#Q$%BJD-$0Q'4 C/
M(.00<$$'CIEK262$!YH(RWW0[Q(6ZGY0V"P(!((R#@X/!H^L1_D?X?YB_L.7
M_0?C?_ J/_RL^'/MG[?W_0$_9B_\''CW_P"0:/MG[?W_ $!/V8O_  <>/?\
MY!K[CCDLI55XIH)%<$HR/$RN S(2C#(8!U925)&012"6R(W+-;N.3\LL)R!G
M<<[L87!+'/ !STH^L1_D?X?YA_8<O^@_&_\ @5'_ .5GP[]L_;^_Z G[,7_@
MX\>__(-'VS]O[_H"?LQ?^#CQ[_\ (-?<$=QILQQ#=6DI +'RYX'PHY).TG Q
MSD]LGL:<9+($@S09569AOB)554.S,!DA0I#%C@ %>?F&3ZQ'^1_A_F']AR_Z
M#\;_ .!4?_E9\._;/V_O^@)^S%_X./'O_P @T?;/V_O^@)^S%_X./'O_ ,@U
M]RYM"I<20[0NXMOBVA?[Q/0+[YQ2;[/('FP9(! WQ$D,0H./0E@ >A) [TOK
M$/Y?R_S#^PY?]!^-_P# J/\ \K/AO[9^W]_T!/V8O_!QX]_^0:/MG[?W_0$_
M9B_\''CW_P"0:^Y3]FPS!HB$)#8:/Y2" 022 ,%@#DC!('4@49M<D!X200&&
MY"5R=HX'(.\JO(QSCKBG]8C_ "/\/\Q_V'+_ *#\;_X%1_\ E9\-?;/V_O\
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M_9B_\''CW_Y!H^V?M^_] 3]F+_P<>/?_ ) K[C62R<X2>W8[0^%DA8["2 ^
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;;UOU8'Q=+_P6CTW6/A/\ OB#X2^!UQI=W\7OBMX[^$?B_Q#\2M8U/P#\)?
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M5-MIIZ<LY17^&#Y8WU>O*E=[MZNS=A:***T- HHHH **** "B@'(R.AY%-+
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M*RLI'#*5..#A@0<$8(.#U'(JN+. *1Y:_-R5YV*V,$H#]P$#!"XSU(SS4?\
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M%_%G6_V,?VO43XVZ9\?O!?B'XY_L)WW@3X8?#_PO^W/KGAGX2^+],^*&H_\
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M_D%^'W[.WQ)^(OQ(_91^%_B#PI^T1#^Q=?\ [</QRD^%WA7Q%JWQ)TJ_T_\
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M^Q&<U\1? G/_  T=^V,2!QXJ^$^6R. O@1R<G)P1@M^1QDXK[9F;,+Y&?E<
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M3<XN4IR7NII)1T=TKVMYOK^>B;LFS^SM;W3B@=+BW"A2%(91\N""$!P67Y<
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M*^-'QX^$/PJ^ /Q=\-?L[>,_&NG_ +,-Y:_"&[^&O@/QAI>O:9\6M,TOQ/\
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MZE;7!8]+NHMV\[>Q]3[9^V2?\]K;\C_\51]LD_Y[6W_CW_Q5?%/_  L#]LL
M9_9L^'///_)9+7_YE:0_$']LKM^S;\./Q^,=J?\ W5A4?4<?_P!!F#_\$KY_
M:_I[A_;=#_H'S'[G_P#*3[7^V2?\]K;_ ,>_^*H^V2?\]K;_ ,>_^*KXG_X6
M#^V7_P!&V_#C_P /%;?_ #+4?\+!_;+_ .C;?AQ_X>*V_P#F6H^HX_\ Z#,)
M_P""5_\ )"_MRA_T"YD_E_\ <S[8^V2?\]K;_P >_P#BJ/MDG_/:V_\ 'O\
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MWDZDXPC&ZNG*4FE%-7E>36FNBNUT1ACZ;0.W;J,CGU//3V-*((Q_#GV/3O\
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M .&D?V7?'6C:9;>;XP\$0?\ "=>#;N!2+U-2T&U%S<:?"Z 3$ZMIXG@= 29
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M[SQAX^AN[[P)X>T#PW=QP1Z_X/>#4H]1M5L;:YCC1%7ZXTO]E']ICP3^U_\
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M?$:S\*?#3PQ\.O$=S\4M+O;?3+[4_B7X;2/Q_P#$9-9N[RRO;2/Q++<76@W
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M_HOW[4O_ (>6;_Y44?\ #(H_Z+]^U+_X>6;_ .5%?;6U1V'\_P"=(0H!) P
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MQ?\ \D>'?\,C#_HO_P"U+V'_ "6:;J>@_P"01W[>M'_#(HX_XO\ ?M2\]/\
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M]/C_ /M2D=,GXS3$G''.-(P,8Z>N11_PR*/^B_?M2_\ AY9O_E17VUM' P"
M,<\G_/7/O1@>@_(5E[?%NW[R#]8/]3H>4X%_\N;>DI?_ "1\2_\ #(H_Z+]^
MU+_X>6;_ .5%'_#(H_Z+]^U+_P"'EF_^5%?;6!Z#\A1@>@_(4_;XO_GY3_\
M &+^R<#_ ,^OQE_\D?$O_#(H_P"B_?M2_P#AY9O_ )44?\,BC_HOW[4O_AY9
MO_E17VU@>@_(48'H/R%'M\7_ ,_*?_@##^R<#_SZ_&7_ ,D?$G_#(RC_ )N
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M_97;>CC]HG]J(.C*5?\ X7$A8;95FQAM(VE9'4+*C?NY8V>*4-$S(WVCL08
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MNM7JC18[$MO_ &"I9+_GY%^]?JU%:?B[;V/P;_82_9S\;>'/VH_^">?BF/\
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MW5K*-.$=+:[NUK[+IZ&4\PQJ6F655O\ %4C+>UK::V6DMK[JU[+])O[7M<$
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MH **** $()(.2,=AWZ=?\]Z.<]\#IR.<\_IC'/K]:6B@ _#^7^/^<_7!110
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M%QAKM?,MYX!%!LC*B0?9C'Y&QR.<8. 08QMYQZ$?D.:^19;S7&_:QN;-]?\
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MB@R,@8SS]W^B@_E_]<'EPCH O&#M< G&-H;:,-C+D$$;<D=6./Q<_P"']?\
MP34_Z+#XA_\ "*U'_P"2J/\ A_7_ ,$T_P#HL7B$?]R5J/\ 2Y-/^R,3_P!
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M:?\ T6+Q!V_YDG4/3(_Y>>X!/N,]J/[/QO\ T"8G_P %?_;C^O4?^?\ 0_\
M!B_^0/VEVQ?\])/^_G_U_P"7XXI-L7]^3_OO_P"O7XN?\/ZO^":A/_)8?$'/
M_4DZE@_3_2..GMW]Z3_A_5_P33_Z+%X@_P#"*U+_ .2*%E^.>V$Q#7E3W_\
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M*/[.QW_0'B?_  4O_E@?7Z'_ $$T/_!D?_D3]I-L7]^3_OO_ .O1MB_OR?\
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M[;=U\_RNFNQ[L_XE:U]9>O\ R[I[+336_P#EU=1116XPHHHH **** "BBB@
MHHHH **** "BBB@ HHHH @N?]5V^_%U)'_+1>A'(/H1R.HY%?FMX/^$'@O\
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MU/YH0!P#M.T!26(!([\F0,"HV@G'RD#! W4_.<?ZO/7 &[(.>P<G&<=/4DX
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M1RQ[R_\  W_\B+ZMA?[_ -R(?-B_YY_JO_Q5'FQ?\\_U7_XJIO)'][_QU?\
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M%JSUKXB7^A0?#?4/$(\(:7XKU"^U"ZL]-TF]\1LICT6QENFM_M=T_P D,4;
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M_GG^J_\ Q5'FQ?\ //\ 5?\ XJIO)'][_P =7_"CR1_>_P#'5_PHY(?S3_\
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MK-HVDRH57VU=DU%J[N[)7W>C[O>X'] ?]I6GRDR[0SK&"RLN)'+!48,H*O\
M+DJ<%0<G IRW]L_1^=TBX8%21$=KN >2@/1NC $@XK\1]8_X*76OPL^#_P
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M61_[C:T^J5E_RX:_[F*)T?7\M7_,QH_^"JGS^TKG-B0#^!L_3'Z=O\:7SO\
M8:NC_P"$"^(?;P/XQ_\ !#K)_P#<8*/^$"^(G_0C^,?_  0:S_\ *VE]4JO_
M )</_P **/\ F'U_+?\ H94/_!<__DCG/._V&H\[_8:NC_X0+XB?]"/XQ_\
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MRD_X0'XB=O OC ?]P'60<>__ !*Z:P=7I0=_^PBE;[WO]P?7\MO_ ,C+#_\
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MLH7N)'M+B59I'=:_)\^!O'*X\[P9XNC8$;4'AG7I0(\C#_)IBJ1P<J.1@9!
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M5K6Z_6J=_2UK??9HKZ_EEE_PI4+_ /7NI=?C8YWSO]AJ/._V&KHQX ^(6.?
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MI/IW_A6OP_\ ^A'\#_\ A.:'_P#(%'_"M?A__P!"/X'_ /"<T/\ ^0*^8O\
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MM>VE*ZOY)[>A]+GX:_#X@[/!W@AG R%/A71!D_-QG['QD#JV ."<=:/^%:>
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MP_\ ^A'\#_\ A.:'_P#(%?,7_":_MP?]$U_98_\ #M?$3_YA*/\ A-?VX/\
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MM_$/_P"8&C_A,OVW?^B9?LO#K_S5OXAX/I_S(!/^>W6CZIF'_0QC_P"%4?\
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M<>O-2T4!=]W][_S&[%[*OY 9_$#CU_"FE!SD]>G'(7))YZ_Q%23_  X%24$
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MF@#'3_/^>]%%')%[Q7W""BBBER0_EC]P!1111R0_EC]P!1113Y(K[,?N7_!
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M_9N(_P"?E'_P*/\ \F6LYPG_ $\^<7^A]5^9'_ST3_OI?\:/,C_YZ)_WTO\
MC7RI_P -,>*_^C-OVJO_  D_!7_S5T?\-,>*_P#HS;]JK_PD_!7_ ,U=']FX
MC_GY1_\  H__ "P?]LX3_IY_X"SZK\R/_GHG_?2_XT>9'_ST3_OI?\:^5/\
MAICQ7_T9M^U5_P"$GX*_^:NC_AICQ7_T9M^U5_X2?@K_ .:NC^S<1_S\H_\
M@4?_ )8']LX3_IY_X"SZK\R/_GHG_?2_XT>9'_ST3_OI?\:^5/\ AICQ7_T9
MM^U5_P"$GX*_^:NC_AICQ7_T9M^U5_X2?@K_ .:NC^S<1_S\H_\ @4?_ )8'
M]LX3_IY_X"SZK\R/_GHG_?2_XT>9'_ST3_OI?\:^5/\ AICQ7_T9M^U5_P"$
MGX*_^:NC_AICQ7_T9M^U5_X2?@K_ .:NC^S<1_S\H_\ @4?_ )8']LX3_IY_
MX"SZK\R/_GHG_?2_XT>9'_ST3_OI?\:^5/\ AICQ7_T9M^U5_P"$GX*_^:NC
M_AICQ7_T9M^U5_X2?@K_ .:NC^S<1_S\H_\ @4?_ )8']LX3_IY_X"SZK\R/
M_GHG_?2_XT>9'_ST3_OI?\:^5/\ AICQ7_T9M^U5_P"$GX*_^:NC_AICQ7_T
M9M^U5_X2?@K_ .:NC^S<1_S\H_\ @4?_ )8']LX3_IY_X"SZK\R/_GHG_?2_
MXT>9'_ST3_OI?\:^5/\ AICQ7_T9M^U5_P"$GX*_^:NC_AICQ7_T9M^U5_X2
M?@K_ .:NC^S<1_S\H_\ @4?_ )8']LX3_IY_X"SZK\R/_GHG_?2_XT>9'_ST
M3_OI?\:^5/\ AICQ7_T9M^U5_P"$GX*_^:NC_AICQ7_T9M^U5_X2?@K_ .:N
MC^S<1_S\H_\ @4?_ )8']LX3_IY_X"SZK\R/_GHG_?2_XT>9'_ST3_OI?\:^
M5/\ AICQ7_T9M^U5_P"$GX*_^:NC_AICQ7_T9M^U5_X2?@K_ .:NC^S<1_S\
MH_\ @4?_ )8']LX3_IY_X"SZK\R/_GHG_?2_XT>9'_ST3_OI?\:^5/\ AICQ
M7_T9M^U5_P"$GX*_^:NC_AICQ7_T9M^U5_X2?@K_ .:NC^S<1_S\H_\ @4?_
M )8']LX3_IY_X"SZK\R/_GHG_?2_XT>9&1]]/IO7KVYSC/IS7RI_PTOXK_Z,
MW_:J_P#"3\%__-72?\-,>*^#_P ,<_M4]N/^$3\% @XY_P"9K((;D<8Z@\#(
MI/+<0]ZE'73XH^73VFO]:KJ?VSA5TJ;-Z0?3_/IZ??\ 4S%.""& <;CG=D;)
M,$XR!RVW.,@_A7F'QGBT^;X-_%-=8AO)M&/@+Q2=133"HU2>S72Q]JCLBZR(
M+EHBXMWE1D\PJ2&&17E*?M)>+'!/_#'G[4Z'(&#X7\$(3G.2P/BU?E[D@$C@
MYSMW>=?%_P#:6\;)\*_B*NG?LM?M.^'+]?!GB1[?7[_PUX*MK#2)QIX9+^^N
M5\52O!:6;)Y\DBQ22+%'(RQ29VUKAL'B54<7[%QYXQO[17WBKV;L]WHFUTN>
M=F6>X18*NN6M:+D[J#^S!RNDM]FGV7GJO=K?X?>$?BM^S5'\)]<BU8?#WXH_
M ^7X>:Q;2SO9:Y'X3\8>";C0+Y8[F-<V^JQVFHJJ75LB>5=/'*4V!A3]$_9\
M^'.A_LXZ;^RS8VFLR?"33/A7_P *?L[.YUJ2;Q,_@?\ LDZ$\,FMRQM(=;:T
M)*7("A)55E 4'/C7P_\ VEO&#^ _ KW/[*O[3NLW;>$M!>;6;'PYX2FMM4E_
MLBP,VH1RS^,@LL5U(RR6DLMO;2,C.4C"D@]BW[2OBQ2"O['O[5#J5RNWPEX)
M<]!C+?\ "5J<@@D8R.VT]:53 XAXFLKTHIS=Y*HHN+CT2?NN_7WO2Q.79[@)
M4U)>W<IX/#2Y71Y8JTKZ.^N[7+T?3J?+/Q!_X(__ +''Q$MM M-7'QFT.UT/
MX,>&?@%K=IX.^+.N>&(?'_PS\(W27_A#1?B'!IZ"/Q@N@:E ;NU2[VP0W #I
M&1G=ZCXR_P"";_[,OBSXE>!_BO WQ5\$>-O!7@KPA\.[Z^^'/Q/U_P %P_$#
MP;X'DA;PSH/Q(M-(:$>*[&S,,;J+I\R!3"Q57)/J'_#2_BS.!^QM^U._7<S>
M$O!66^4G.!XMXPWR#(.0V2.*D'[3'BS/'[&_[5!7'WO^$4\%XRI(Y \6 Y/L
M2!G'<X;P%>+TJP_\&QOZM>T9WO.<)):*K9;/D>M]-G:W3T6YY)H/_!-C]G#P
MA\5+OXH^"O$'Q[\$VM[XVB^)>L?"/PA\<?%_A_X)Z[XQA:0G7K[X=6,T6F2W
M4MS<W,]S:*T<>H7$TL]UYCX8<)_PZ,_8T/Q4/Q8GT[XL76H3?%F?XXZYX-NO
MBGKC_##Q5\2I[B*[LO$7B7P'(7T/5+S2;J*-M.,T#26:K_K'."/I<_M,>+#C
M_C#?]JG([#PEX,(ZYZMXMX /('?G/. 4_P"&E_%A&3^QS^U3G_L4?!?Y\>+/
M88 !'/(&,4?4L3_S^AY_O8V_]+%_:V%[55_VY_P?UN>*:]_P2Y_9%\0?'+Q%
M\=K[1OB&+GQ9\3K3XW^+/A1;?$'68O@5XK^,EI9V]C%\4=:^%18Z#+XC-M9V
MUK!+)'*TSVD<]P"ZHX_0V,H) ?W2(%1$BCPD=K'$"L<**#C!4J21D(%"+A.!
M\N?\-+^+"V3^QO\ M58&>!X3\%<GG!_Y&TG.#CG'RY."Q.7?\-,>+._[&_[5
M/_A*>#,X[#'_  E('IW_ !-1_9V(N[U:;3[2B]//][^:-%G.$[5/_ 7^6K_(
M^J_,C_OI_P!]+_C1YD?_ #T3_OI?\:^5/^&F/%?_ $9M^U5_X2?@K_YJZ/\
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MNC^S<1_S\H_^!1_^6!_;.$_Z>?\ @+/JOS(_^>B?]]+_ (T>9'_ST3_OI?\
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MC'(;(P>%R>.@7!(YYZ9X_++]@'XJV^A>'_C+H'BSX0^/?AG<^+_VJ_CAXR\
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M/^>K?DO_ ,31_9H_YZM^2_\ Q-:E%'+_ 'JG_@R?_P D'L*/_/FE_P" 1_\
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M"C_SZI_^ 1_^1,O^S1_SU;\E_P#B:/[-'_/5OR7_ .)K4HHY?[U3_P &3_\
MD@]A1_Y\TO\ P"/_ ,B9?]FC_GJWY+_\31_9H_YZM^2__$UJ44<O]ZI_X,G_
M /)!["C_ ,^:7_@$?_D3+_LT?\]6_)?_ (FC^S1_SU;\E_\ B:U**.7^]4_\
M&3_^2#V%'_GS2_\  (__ ")E_P!FC_GJWY+_ /$T?V:/^>K?DO\ \36I11R_
MWJG_ (,G_P#)!["C_P ^:7_@$?\ Y$R_[-'_ #U;\E_^)H_LT?\ /5OR7_XF
MM2BCE_O5/_!D_P#Y(/84?^?-+_P"/_R)E_V:/^>K?DO_ ,31_9H_YZM^2_\
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MC_GJWY+_ /$T?V:/^>K?DO\ \36I11R_WJG_ (,G_P#)!["C_P ^:7_@$?\
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M %N#S_3\: "C/3WX_0G^E%4KJZ6UPQCDE+;B%CRS[5V%B /X5 +,,] ?[Q%
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M1:!?RFVT_6/B9XV\.>!].U6^C5Y9--TR]\2ZEIMM?7WE+N-I9O/=A#YBPM@
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MMB6W,T*L3D,2#W)5G!]SO8D\L2V:+Y2T.-I<[U(16968 ]%P""P'S -A212
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MKZ9#813!999+M6M([<,TH,6:_&S_ (*/?"CQQIGA_P#;+\<?M=_'CXT>)?\
M@G9J?P:7QU>?#'P;XB\&>#5N_$T>K:5X=M_V3M4LM-\)ZEX^U'PY\7-5N]$@
M@\6Z/J%O=K;ZIJVAWNH:1-)!JR_2OP=_:Y^$W[5W[&/Q5GT>PT_Q7K?PO^%B
M_#[XQ_#OP'?^,;#P9;>/=/\ !MI=>)/AA\//'.O:6-2\76WA1U70K_Q5IMAJ
MKI>1MBY/V@J>JF_>AV5K676ZW?:U_GMN<6._W6M'77G7HW":OTNDG>V^FFN_
MZ+> S=)X$\%QZA>6=_?GPCHC7FH:<T+:=J-\;;3!?7FGO:10V-U:2R8E@GL(
MQ:&-E,9"LH/IMATGZD^8>GMMZ'GD>G.>"#W/DWPJ:&3X>>#O(TZYTF!_ &@2
M6VG7CW%U<:9:QZ=9_9=+-[=06MQ=R:;E(I+B6W@>1E#O$&) ]?L0 F0H#%49
MV'=F16.[H,YR>AZXR,$5C-_O:_E.+M:UKM[:;.__  R%@XVI8>=]'AZ5+EZM
MTX_$^GO=DM%9:O5W<8SCJ<G&>_\ 2EIKDA6P0#M;!/8[3@_@>3[9J@K(?E\P
MNRA<[')8Y7.=N<]>OH/I4G<:-%5X#RXP_1#ELXY+\#//&.>W(Q5@\?\ UZ #
MKTHK.#*H7<9%&%W,6*HHP>2>@7C QU) %/@D1Y/W<GF!0X8*^\*05!!Y/(/!
M[9(./0 O57NYEM[6YN'FB@2"WFF>>=TC@A6.-G::9Y'CC2*,*7D>1T14#%W5
M02+&>WK44Y @F)V$"*0D2*6C(",3YBKRR?WE R5R!R: /'KOXU_#73] T;Q?
M>?%#X9V7@[Q5(B>#O%=YXY\+6OA?Q0KQ.\0\-^(;G5+?2=?EG2*>XD32[F[\
MA('4&0J3766_C;1I](/B.WUG0[KPRVF3:VGBBVU.RF\+R:)!:_:KG7#KZ3G2
MTTB&*.6XFU$W1M8H0"S8^:OYE_A%^SIX^T'XL_'C]CC6_@OJL'P'_P""=%U^
MUO\ &+]D_76\*W6H^$-5TO\ :/M[KXE? KP9X/DU.SU:U\3WGPCT_P"(&N>"
M!9"/4KF&ZT:*":/S3**V_#/C?]J[0_B3\%? UK<?M&>+=%\1?L97-AXF^%%E
MX!\0^"_AC\*;B/X):W)+XGUB >$;_P"%WQ$36?%;66FW&E,UGXZTK6C_ &7#
MIK021[:4;J]TM;:W_JRZOH3*7*M(\S_E5KO[]/Q/Z3M$\5VOB?1-.\3>%M5T
M;Q-X?U6."^TG7O#NHV6N:%K.EW#%8+K3=6TVXNK.]C<G?Y]K)+$\>#&Q<%!Q
M?A_]H#X-^*/'=]\,?#_QC^$?B#XCZ6][_:GP]\/_ !(\&ZSX]L!8JWVLW7A#
M3M;NM?MH[(X:[-U8126ZJ!-&@)(_ ;_@GK\/_'?A3]J+]BSXA?%=?VDO#>H_
M$7_@G!\/_#>G6,=IXETOX0M\4/#6KWMQXP\'>//"^F:3#X4\*W%AHLEOJUAI
M>L1:5JEQJH^UK<-)((%^8?V:_AUX_MO'/_!3;P3\.M5U;X0?M5^)M7_:D\:_
ML]SZ3^QK>^'?B'%XLT9K?Q5X6U[3?VR9=,4ZWX4\<7>B0^%K_P !?;S]OT76
M-1ALI1)+MDIP2YO?3VM9/5O335VY>M[=5T;8G>*E;>*E;=ZJ]MM^A_7LLS;V
M1=[NK&,':2-P )#D9P.#@].^/1!+<#@*QY/+12=.3P=IR/X5QUXZ5_+)\5_C
MO_P4,^)'P)\$?M#1^)OCO\"?A!\??C)KNJ^,[.T\%_$Z[\>? ;P%X;\%Z;X>
M\$:;:^'?AA;)\3/#VC>,_B%;ZIJFH26NG7<<PD@AUA/L4I8?7/PD\%_M>_%G
MXE_$+0_'G[2W[2>DKX+_ &&/A7??#[6- L=7^$/@_P 6_&[Q?I_Q(LM7\<:U
MX=UZRDU&?7],M[+PJUWX>U&]PMY!)KUT([RY!C7)O><5;J[OJE9+KOWTW:!.
M[:LU97^1^[\DURL<C1H)94B=Q"/E9C@^6J@@D%B!G@E>^":X7P=\2/#/CNZU
M2'PCXI\*>*X- OM2T77KGPIK^D>)8-%\1:>;47/AW5;C0KR_ATO7;5)_M-YH
MU^]MJ,$3Q.;=DW,GX0_LP?%+_@H'^U_^PS^TI\8O!VH6]A\?O'4]E\ OA1X'
M\<>,9='\!:+'\*XK+P5\6/'VC:G#874>DZ_X^NQXDU2QUV.WO4COVTZYC:98
M J^'_L@?#_\ :@_9F_8+_P""LWA+PO\  )_V9_&OA7Q7\0];^!\?PB\3:E\0
M/%E]X\_X5MHT5WJGAO7=4T6RO_&5W#J]M!=VOC PW3^(=2N];5( +'9(.&]I
M1=K7M?1Z7WMHK[Z[/16U;=K=;W_ _J*:2964%F4$!558V+9."N[)X.#@\=1P
M>H#'GN%&Y4+ AB#M8F-1C<K!<DXP#D<@ C!8[:_F&TZ7]O/X=?%_X@77A_XY
M?MC?$'3?AS\?/V-M)\"^'/'UQ)K?@GQ;X>^,GPO.H_&9_$<L7@R!M9\-Z5XH
M9(HH)-2AT;P;<Y0RV]P!7D5O\7/^"D5_#XV;PEXV_;''BS1OV??CU)^VA%X[
M\*:A8^&?A/\ 'Q/&VF0?LY6G[,MM?:!:VYDO/#8\5O>P_#*XU_0-0L+/1;KQ
M)?O=-$5;I[/VD$K_ -[1^=KV6NM[@G=)[7/ZRUO;QAN6-W&TRO"+=UF52NY4
M1BVTO,?G5&'FK&"3'Z\YX.^('A;QV?$T7A3Q3H'B:Y\&>([WP;XM30KU+]O#
MOBK2X+:XO_#^J10Y:UU6TCOH'N;67$D*2Q;P-V:_F3^,OP]^.']G6\?Q?^)W
M[<_C_P"&W[/7[8W[,7C2U\;^'=<\1/\ $Z+P/\2/A@;GXAWL3^#-%BU3Q)I'
MASQN]O:0V6FVMY9>%;:YN;2YM-[R25VWA?P_^T7\+?CI\1?BE\,/&W[2FA:#
M\8O^"AOQZ\)^(O#5GX6U#6_ $GPJO?V>/"VL^'?BM=_#V'0I;S5?&O\ PDUO
M +;Q5=7EC-J^HV<>D2PVDEF?,I4+_P#+R#TOL];=%>6CLTVK:W3%)\L7*S=N
MBW_K5?U<_IRC+[?GZ\8(# D'@$@@$'CYACCOCK4M?C5_P27^('QT\<?#SXS6
M_P 5-6^.WC/2?#7CNRT[P+\6OC$/%FGK\18VTS/B+4/"7A[XAZ-I?CCPK9:=
MK&ZSU#1=5GU72-.O8WA\/?Z $!_9!!Q&68EP@/W@03C#-PJ@GYOO!5[8502*
MQ>DG'JE>_3>WYCB^9)[75]27^O2BJURR*$WR",9.,MMR>./RW<]NO0&H R$C
M]X2#C;AV)8'<1@#/. IQP<,._% S0H^O'7^?'YCGVJ.+.Q<YZ8P>HY/4]^,#
M'&,?A0=^!W.!G!QSE<]!Z;L=LXX] 3=DWV'!P<\@#. 21AN.HYYYR/J#0&!/
M'S<D$C! ( /)SW!&.M9MP&$F?,$?#<-(45BOS%U^8?=W$D$'C()P,BU:AEB
M)W<L=V3@\].<D>XQ@$'K05IRWYE?K'JOGMY6WV+5%'^?SHH$9,UA'<77VDS2
MQS*CQ?*ZA3"0,0M&W)590ERK J5F&0V#BOP\_P""F7[.\OC;Q=I?[37[1WQS
M\<>!?V6?V4=.A\7?#GX9_ FVGC^*WC?XP^)9'\,K)-JDD$K_ -O:DNH#P]X4
MMM$/VZ*[U$3)+;2G</V]GD(N&R[JP*)M#E07<97)!4[BH=@O)*C))"@UQ?Q$
M\ ^$OB;\/O%7@#QMX=M/$_A3Q?H=_I.N:5,#&EY:W$3!VCGA>&>SO;=_+NM/
MU*TGM[VPO(H+VRN8KJ"-P+7^MOZ0Y6233O=)M+=7=K=GM?3HT?G5_P $K?VC
MO@_\6/A;XM^$'PK\#>,OAOJG[/L^@+XO\ >-?B--\7/$WAI?BE+XBUW1;7Q7
MXMGNI]7LOB"LNAZY'XT\#^(([?6/"=XEL&C>UOK=W_3F^:22\TYW>*)Q*C1R
M%HV1L3@;,"6.<D;B[)M*  ^9A02O\SO[<Z?M+_LU?%5O"G@*6U^&'P%U'4?A
M5\0OA[\9WTT^&M)\&:?\*= CT[XL_'K]HK]H#0[RV\7_ !'^*VDIJ&D>$/ W
MP9^)&E^(K;XNZ)KPM-)6?5]&GG7]COV/?VUOAS^V7X=U;7O".B^/M O/#6L1
M:=?:%\2_ /B'P)XDU?1+HH/#/Q!T[2=>TK3O*\.^.(([C6+&WM9[_P"PPO#;
M7?D.X))0E[EM5SPO:]U>5M=5TNVMK)\S1E5=J=1ZZ1;LG9WLK6:3:^6JMHF]
M'I?L6S^'Y?@I<GPE8ZK9Z)_PNC]H9Y[?4YX+_4!KS?''QM%K5S%-:.]K;Z?J
M-Y>2ZII-FS)<P:85VH0&:ONU0 J@<@  'U %?$W[)>I:IJGPOO9=<\4:9XYO
MH?BM\;]./B;3+P7VGPZ;;?&GX@VNG^$Q?FRLI!JOA"T$&F75J;;9&BPV\=].
ML:[?MA?NKQC@>H/Y'I^O]3=9<N(J+1Q48-22^*Z=_NM:W2WI?DRV3EA*;<91
M=YVC+5VYFU?1?\-K=WT7/(XX.>?0^_L>>?7 [U7D@221B6?+*%."1LVE&!4_
MPD]-RG//'3A)@2RC)'RR'C_MF![D#))_$=*IR3*&8N[!]A+HC*I7" _=.#QE
M3N)'WL'BH.YM[)<S[)K]3\F/^"CW[,WPU^)=D_[0W[2^I^+/B9^SW^S5\.M<
M\9K^RWH?F:1HGC+XG6MY<7&F>/-6US3;NTO/M<,4JV-I8O=1VEC$SW%PFQ66
MN _X):_M.Z;K$_CK]GX_LU?#_P#93M/ /ACPOX\M/"?@Z\U@>'M*F^(U[*^B
M>'_$>L:U!#I.H^+M=LY+36K.]T35=1AUNVNI9H,^6Q'[0ZOI.D:CI6HV&I:;
MI^H:?J%G<VVHV-]:PW5G?6E\C1WEM>6\\4\5Q;W<;O'<QRQR++&S*X(-?SE_
M\%/OV:/CWX"\*7T?PN\=^&_AW^Q+?>$;;PQXTL];M],7X1_LB>#;22:[\8_&
MFZ^'X@G\3_$SXA6#SV^I?"&Z\,ZYIOB'PSXUBTF/284LT,54FFDK;Z)W>BO?
M;2^M]7?==D,_I#M)GF1BP9'78KJXVR*Y0%@\9R4^8Y4$G<FU@<-FOFKXVS>)
M=.U_X,/X?UW0-"ANOCSX.M_$*ZS/IUM-X@\/W]KJT-[H.AKJ$$DD^N7,JV]Q
M%:Z>8KZ2"TDFBF !4_*W[#G[6?C?XD^%O#_@OXX_"WXD? '7H+'1;;X+WGQV
MU[2++QQ^T'X L=-LM-T7Q]JVG&_CO4^(FNVEO'XC\8>"4LH9M&O-3%O))+(K
MJ/H_X_C3S=_ &;5?"VK^+91^TG\-3I3Z??36Z>&+Z7^V;>#QAJ:VUO>"_L-)
MB=[2>TG>WA=M32:6:%82ZZT4XSFV].22TU5[2_&R\UH]3S<S@YTJ4=%_M-%W
M=VGRU(2M9:-M)K6R7>VI]56L85U8-_"J%<C!"QJ1@YY(8$'&00/K5\X ZD<]
MO7\*H6XYM\8YC9\?PYP,8 X '&,< <#"\5?7)&2,$YSR3W]^V.?Z5S+2=5?]
M/'^2_5.]_P#(]'1J,K64HQDM=4G%*U[6NN6S:5AU%%%4,****  ^W/3^?/Y#
MGWKYW^,7[1WP_P#@O\2/V>/ACXV@\2PZK^TQX^UWX9_#[6=,TB&\\,VGB_1/
M!VK^-X])\6:Q-J%JVAR:]I6AZE!X<\BRU274M2M9;7R8%5IU^B*^&/\ @H+^
MS=XM_:>^ <_A'X8ZYHWA;XU^"?&7@SXM_ ?QAX@-XND>$?BEX)OKM+'6+I[+
M=.J77AW6?$.B2!%RUOJLX(;&V@"_\//VSOAI\2?&LGA;P[X8\<VVA0:K\4-'
MNOB3X@G^%VA^"(KSX074%KXKG:+4/B>GCR?2S+.S6&O6G@6YT5TMKI[[4-.$
M.#UGB/\ :\^"OAV?0=<7Q)I7B/X9ZS\-OB=\4I_C5X2\9_"[Q#\--$\-?"A=
M)3Q(=3N+/XA?\)?>O<?VH$L]4\+^#?$?A:SNK232_$GB/P_J]]HFGZI^7?B7
M_@ECXTO1\"$,_P -/&=M\.?V.?V@_@9\1M/\13ZWI<7CGXD?&_5=.\3:O?-K
M.F02:QI_AZXU:/45DOSYTD DCWV\L0:)LSX0_P#!,'XOV6D_ *Q^+.H_L_ZF
MOPZ^!G[?GPDU31/"_@W25\.Z+:_M4#X,VWP]LK#2;7PWI&@^*(_#\'PT<>+]
M7?0-.FU:5+:2[BOKVXEE;1*E9:RO;5:*\MW:5G97[[I69GSN]K:7MYI7/UU^
M'G[7'[./Q7\%?"_Q[\/?C#\/O$>A_&K26U7X4VZ>,?#&DZ[X[:*WM[F^TC0-
M!U[6-*U2Y\0:0EQ''KNB/:QW^AW):VU:*RG0QUY!/^WA\,[[]J3Q/^REX1^'
M/QY^(WBWX>3_  ]TSXT?$+P!\.[+6_A5\"/$GQ5\+6WC?P!X:^)VO3>);#Q+
M:WGB'P3>:5XI_MGPMX0\6>#=)TS5[2'7O%&E:FE]IUG^4/AK_@EI^TA8WO[#
M<D'A_P#8\\':S^S9X6\&> /B#XMT/1KS77\3>#? OBF+5F.C>$M1\)-81^)_
M'%I;I?WWBS2;S0/$=AK'G)J6K:OI\KV;?3?[1_[!OQF^,G[;FD_'OP#>_"'X
M':;I[>&M,U']H#X;:]\0]!_:%\:_"K3/ ESHWB'X*?$[P39R1?#KXCZ:?$^M
M:KJ'A[Q)K4%U?^&?#%YHND:>]M+I3 RE&_O-M>6EM=-;7UUZ:VZZHJ3:6A]?
M_&O]MKX+?!*?P2USXE\$>+QK/QMT7X'^,I]"^)W@&RM_A+K&NZ-K7B'^TOB5
MJ6HZJND^&H;/3=!FN;K2]?U#0=1:/RS8B]!=1]$WWQT^"OAZQ\)ZUK?Q:^&N
ME:5\0KV#3_A_J^K>/?!VDZ=X^N;\6_\ 95MX*O\ 4M;L[/Q7)>^=%;V*>'YM
M0:[F;$8.Y2?Q.^$__!+CQMH/PU^"/P5^)/PZ_8]M_!OP9_:&^%WCSQ'K/@GP
MRTFM_M%>!_ @\:R7^I?'NSU30;?3?%7B:_N_$>F7]GIFJ1:RC74=^;BY>.<^
M9X+XI_X(F_&^X\,_ 70+;4_@OXUT'X=>!?CG\)M9\ ZUK.I^#_#WAKPI\1OV
ME_B'\:O#>J^!+S3_  ;X@FLCI_A#QMIGARYTO2H]!NK"+1[.RTK5[.RMH887
MRPZ-I=;V_"RT7W_+8(NZ]&?NG\8?VJ/A[\./B=\*?A4SZ9XA\;?$_P ;6_A"
M?0K'Q5X:@\3?#RWDT'4_$%KXR\5^%9KJXUV#P[-9:;+/!//:6<! 26ZF@B=7
M&)\?/VNOA/\ !3X.:O\ &73M<\/_ !.TZPT71O%6E:!X%\;^%KC4_$_A/7/$
MMKH">*O#3)<W[:AX:CU"\2277+*TN+&\D$BVER\.)C^:O@G_ ()8_%/P=^UY
MX=^+4=O^S?JW@/1?CI>?&1_BCJNB:S>?M-C1M:^%X^']Q\+K;QA>V,MS/X-\
M.E0^@6VJZO+&]@WEK9I,\CMY)\/_ /@DU^U;H_PZ\/?##Q7XS^ 0T+X-_LRR
M?LP?"C6?#<WBJ'6M<\-:1\:3\0M-\6>-#?VL<.EWFJZ$EM8W.BZ$\NEZ7J"R
MQ0JL.%!^Z25W*^M[6MY6O]S>ZWU*/WZT3XL?#:Y\66/@D>./!-O\2+[PO8>+
M$^%Y\8^%S\0Y='U2SCNX]4'A(ZE#KK6&6:%-0EL(;*=HFEC=>E>NVURERH>/
M<5*(^XHP1A(H=#')S#,-I^<PR2*C H6R*_ ?P'_P2Q^)?A7]N^']H[Q!XA\$
M>-/!%K\6K;XQ:9XLO/%7B/1?B?X=OH/"\/ARY\%)I&D>'+?^W]%BGWO:6]WX
MK'AN2 P&?1'FPR?O;IX<B65P4>1U+QNP:6-@6!25A\A.W!*( %9CW J+);.]
M]7_P?ZT U*JW2221-''PSG"G=C!P#N)ZX !&T?>]1FK1Y![>XZTA ZXR1G'K
MSUQZ9H ^$?\ @H)\)/%OQ<_9(^,7P]\"^&=&\9?$#Q'X9LD\)>$-4U6+1M-\
M87^@>*?#OB>;PA>3/JFC2:Q9:UIVB7WF>%+_ %&+PYXE:(Z1XCEATR=W/Y:_
M\$M_A+\>-#^-'B_Q)\6/&7Q]^'GBO3?"^NQZK\ /BOX2^'NBVGC+P=K>LRZ'
MX%\>_8/ ?Q$\>VW@K3[&+1YY/!WP[TQ;&/PK9E[:77-1@(0?T,:ZNZ*-L%FR
M\9CR?WD+K$TL9Q\P&41CC!&S(9<G/P%\0?V8(?B9^TWXH^('CJ/Q1'X'G^%/
M@KP]X<U/PQ\1/%'@V\?Q#I.NZM?ZM#>Q>%]7TR6ZBBLKFWD1[I)TD<F+:>'7
MJPL8-5_;5/8TG&W.VDG[O1OS;ZINUEW/#SS&8^E2P5'*<!#,<9_:&'JUJ%2:
MH1C@X-NI*%:5DIV^&24E!Z2B[V7TW\5/A!X9^+?@>Y\*>+]%L[V)?,U7PQJE
M_9V^HWO@KQ@-&U72=(\<Z,DJLMOXET%=:O;O3+R&(-:3QQM!L=FE3X!_X):?
MLK_#7X%^&O$GQ,\">,M:UZX\7V4OPYU71K6QFT?P7!J'PW\4ZSI6N^)K*RN-
M:\1W%SXC\4:]#=:EK%_JOB"[O!--<0V=O9V+"VB^B9/V,?@K(K6[7OQF.Z.0
MR7(^/OQ?6 JIVLJ,OB]45BP!:-46/:""-O%>)?L[?L&^$M!^'4%A\33\2K'Q
MK/XH\=:A>V?A[XV?$JQTU--O/%FK77AZ:.#1?%%I9122>')---T3"MQ<732S
M3M)(Q:J@LN=*<:F/=W=+EH..BZ+WKNZ6C6[5^J/-KYQGWURE2H9/35*="I5J
M*5=5)QDG[JYDH^[&[7,HM2:\KO\ 3?7+6TUJVFT[4K*WU'2=3M9K"_TW4(EN
M+2X@FAN8YH+J!3)'<6M_:SSPW$<Q5 8HTV/YOR^!_L]W/P57PYXF\._ OP':
M> _#/@OQ[K_@S4M!T3PQI?A+3Y/%.@21#4;^&UT1[FVG@9I4,-SJ<MG=2?=D
MMX\J&\YE_8F^"8?:+GXQRJT49EE_X7Q\87: P3LMO",^+^/.-_=R2[2"OV=>
M/FKQ;X(_L!>"-'M_'J>/8/B9:3ZE\4_&>L>%GT_XU?%&V,WA>^N+<Z;<WHL?
M%,$5Q?.L;,]SJ"3WI)'[T  !JGE?LJG+CI\\(Q=.U*7+?F2O)7=_=VNUMU%4
MS;B&&*H4EDL)TY\SJM5;RA"RL^9*\$Y:*\7S-<KY7O\ =OQB^'/@3XP?"WQO
M\+_BKH)\1?#SQGH5UI/BW097FAAU72"J7,UHTEE?031[W@5I&$T"2D!7D57+
M#S_]DC3/@7I'P=\/WG[/'@'2O /PVUZ.XN=*TG2/#FEZ%<R3Z3<W.@W=[K1T
MV]U+^T+V:XTN3R;FZU*_O!:+"DLB\1KY]J7[#WP6>RNUBO\ XQ"X-M*;<R?'
MOXNR(;@Q.+=727Q?)$X:5DC*3+)&P8B1'4,*\5_9Y_8+\#:/\'/!NG_$P_%+
M3_&]M::FNO:;I7QQ^)MA96\MSXAUFZM$AM='\506*+]BGA8F*)&9VS*6<EJB
MV6?5:LWCY>WI.DOX#4;3=I/EN[ZZ1=VG>R75;5<QX@AF&'I1RRC+!U:=64FJ
MJ]HI07,HJH]O=M=>S?-T:=T_N;XN_"S2OC%X+\8>#]4O;[PZ_BG0-?\ #ECX
MPT1;5/&'A*'Q'I4.AZM?>&=1N8;A])O+JSA,3-:R(DT+ W$9D9POXO?\$KOV
M7/VF?@]\2OB/XDT_X@>'[?\ 9;L?B#JWP_\ !>C>*?$^L?$_XD^+OAM\,(-4
M\,>&K2S@B-AX,^%+Q^*9=5UK7%TM=8O]6DVVTT]K%^Z'Z2K^Q#\#E9(Y;[XR
MJ?,!1T^/OQE1I,NK@KY7C-?N ^60 I&W').X^1?!/]@_P)I7A%--\=CXIV.O
MKXJ\:31P:7\;/BCIUM'IUWXDU&XT6Y$&F^*HH'N+O2);7[5+,&>:1I9IRT[N
M3JWERC)/'/FC%)+V#V2UTYM[*RV;>MFVC-YEQ![;"..44G0KNJIMUES*4$[.
M+45HFMM;][*\OT\%XB@CRYB >/ECZ'G'^L'W>G//3KS33>+N_P!7.!G)RL1
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M3K9.E1G3J.=15[<LE**A=J+Y5RMMIIN3T5DG?]2S>J1_J9U/S !HT!]B<R9
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MSQV<$08(FU20<9)Y QW)[<>PXJO:ZK97D4<UO<1S1RQ+.DL9+120N%9)(WP
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MMOE^"V'U3[1<5W46[\J[1OJULWJ1+!&N?E!R<\\X]AZ#U]3R:#!&?X3TQ@'
MP.@ &!4U%"TU6GH)I2WU]?Z\BH;.%\K(@9&'0GH=Q(''< D$@\Y(J/\ LVR
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MLS*QCR4)(RS$?,"#P20<^A&,X(Y JY10VVG&[M;:[M_E^ _F_O*GV&V[1XX
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MI8QU859U545/V,[PC.CAF^:Z7*YU'6FXZ^]*H[W<C[SW#U'YT9'J/S%?!O\
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MZV%HHHH-0HHHH **** "BBB@ HHHH *8V<'ZC'3IQ_\ 7]_3M3Z:<_-P#R,
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MP#?>#;;2]"\2ZMX*N=.#V][)<Z<&E1\/^*<_[;7@75_V,_AAH&D>*?A7>_\
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M8,T;LR@+EGMH7D9ATRS'>6;D[@0=Q:M2U&$/8_)D9SR47N?KT!QR<9K)M/\
M52>ADB/3O]CML9]\\ _3CJ*UK?/..@*[OKY:$?7V].*PB_C7:<DNEK.6EOP]
M=3Z9*TIZO7V;Z65Z47;;[GU33]+0& !Z#%%%%,84444 %%%% !1110 4444
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MYI(;N:T"=7^S[^SS^UW\0A\+OA[\5=-^//AOX4C]OSQ#XF$.A7_CSP)I>F_
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M\0NZ(W[)/[52*=Q\QO &DYW')<';XH&06P3@#)P"!@@?73P1J[A;($ L%90
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)DP^*'K+]3__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>vi_001.jpg
<TEXT>
begin 644 vi_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %! NX# 2(  A$! Q$!_\0
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M?\1!/[(?_1)OVH__  W?A3_YNZ_EBR__ #WF_P"^W_\ CE&7_P">\W_?;_\
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M** "BBB@ KP?]I'_ )-Z_: _[(K\5_\ U"M>KWBO!_VD?^3>OV@/^R*_%?\
M]0K7JTH_[U@?^QCE_P#ZF4#'$_[MBO\ L%Q/_J/6/\\3P)_R)?A/_L6/#_\
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MM#[S?A_*O\HK;KLE^G^9_:T9*:;6EN_K8=11104%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !7@_[2/_ ";U^T!_V17X
MK_\ J%:]7O%>#_M(_P#)O7[0'_9%?BO_ .H5KU:4?]ZP/_8QR[_U,PYCB?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^-S<219GQ>^ G@CPM\+/$?B?PEIFJVWB'P/9_LE>(M;O;KQ!%K.FW/AOXY^
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M:2:[/ND?E]N3G)!]^#_(<=.]+E/;\O\ ZU?J'_PY:_X*)]_!G[/W_AYM3_\
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MQ^799>>3VY^AZ=!@YSC]3Z>H_L_.H_:3_9H<DA5_:!^%S?,K+P/$<*LP!&2
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %18!+?,4P<G:0 >>2<@
M\],D8[=.\M-VJ>WZG_&DTFFFMU9/JO0>G4A9<Y!/'L1^F.??^?%1^4OJW_?1
MJUL7T_4_XT;%]/U/^-8QH4XW3C[6[;YJLI75_LJSMRK=>;8-K^6+\W=/\+E7
MRE]6_P"^C1Y2^K?]]&K6Q?3]3_C1L7T_4_XU7LJ7_/BE_P"!3_S%_P!N0_\
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MA4$WQ-^-T8RO[-6N2*0=I7XJ?#0$^G!U#@D?B",>A*C=MWG3^4DOSD:GT62
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M@3(YQU3XG>$57J>,&4'/J<4?\)_\9._P&N<?]E/\(8Q_W_Z8H]G4_GI??_\
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MZ'_"OGS_ (63\9_^C<]9_P##H_#?_P"3ZL#XB_& @9_9YUX$@''_  LCX<D
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MBNO$&O327.M:TEWH2:E97-S+#<:UJ:MIMI%$]+6;Z[2?E_>'\OP7_P B>R_
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M)Y/FSTOI.G/R>L:DDM5M=/R/]'@7=J,YGMLD_P#/S#Z ?\]!2_;+7_GO;?\
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MK::6Y7>[6EDC@S3'8?+,OQ>8XF->5+!TG6DJ#2G9-)WNU=-/;76[Z'[J"3+
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MGIPW2:\L1ET4]%T>,NNWFTWLT+_B(?"-[O-\0_+EK-_^F/U[=C^I[S(O6/\
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M?7L6]N@J0#'I^&?ZD_ICJ<YXQ&O#)_P/^2U-7^J-7^+4]8?^FX'\9P_ATO\
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M)-Z>[=W2TZ>=M3$J#S&W8P,;]N=IZ;L==W7\.M;MQX1\>VAUH3>!O&4,WAN
MZCKMI<>'KQ)],L9K:[U6PFU&.6&"2UAN--M!*SI%@QO(RL5YK9^(_P .M=^%
M_B.W\+^(;O2[J\NO#?A7Q5!=:3</<0#3/%6B3^(M-M;J9QNM]6BLA#;ZA"I(
M%PLD.3A:Z:>:8'$8VC@,/C<)5Q&(C4>'5'$TJWMG2@JDX1C1G*4&H6:E4M![
M+5.V4J%:%)UIX:OR1E9WIN%K;N]1137I=K=Z''!LD#!&?48_SWIU01%B 6Y)
MYY/(ZXX.#T/)P?\ ">NZ$N:-VUS7:G'5N$HMIPDWHVK7TTM)=;F?N6BZ<E)2
MBF[?9D[WB_-66VFI _WG^D?_ *&*_=__ (-\E ^.7[6_)^;X;_!K/M_Q,O$/
M2OPA?&[Z@9_#D9_GS_A7[P?\&^&&^.G[70/('P\^#JC_ '?[1\1X'T   ]@*
M_%/I#?\ )KL]?:>"_P#4G#GWWA?KQIEL%HZ5.O5;Z-5*59)+S76^G8_JG7[Z
M_4_^@M4]0+]]?J?_ $%JGK_.4_K(**** "BBB@ HHHH **** "BBB@ HHHH
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M!?3+\^EU]K!>7\*G_F;</W3]1_Z M2U%#]T_4?\ H"U+7\G4_P"'3_Z]T_\
MTW _;GJ[]U'_ -)B%%%%6(**** "BBB@ HHHH **** "OYT_^#AS_DF'[*?_
M &6[Q'_ZAL]?T65_.G_P<.?\DP_93_[+=XC_ /4-GK[OPN_Y./P9_P!CFG_Z
M;F?,\9?\DKGO_8#+_P!*B?S.K]Y/^!_R6IJ@!P5.,XW\?]\5(K[L\$8QU(/7
M/I]*_P!4:O\ %J>L?_3<#^,X?PZ7_7M?^EU!DBL6X&1A>X[,21R?0_3M73^
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M@ZWK-SJ&D>%UU&?4QH5G<RR2RVIO[@F2_FN)E%]<W4I4>=<F&V@ABA"#$4$
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M",X)S]6_#W]F[1/'/A'X<:EJWB36M!\3?$;PU^TCX^M(8UT6]TJV\%_ K2;
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M2Z ^5&K6X)P<F#4N-HZ_\>'7CG_)I1K^@L3C6+4'''[C4=S,!PH!LOF)YQW
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MFY\NM#^:3?S['0*<CZ<?3VSW^O>EKG_^$I\/_P#05M_^_&I?_(%'_"4^'_\
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M5:?\.G_@@ONA%/\ %,_;&TW=:K3\$E^:844458@HHHH **** "BBB@ HHHH
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MMO\ ]_F_^-4OVB+_ )ZP?]_3_P#$4.K4@[03:>K:<=]O^?B[(I1FUI1K;_\
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MO4I<@9VX^K1K^LKQ)^&_/H#@X Y/1<^N'B?'I_J99@._WBN>P.#@7/LH5O\
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M'O\ @WZ#1?LD_&,,"=W[6?Q9B^Y(H!AL/"T6X,Z!'#D$C8S8 (/;/[Q0@J[
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M?A5_T2WX<_\ A#^&?_E71_PI7X5?]$M^'/\ X0_AG_Y5UZU11]8Q7_0;C_\
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M(?RTO_!%'_Y \E_X4K\*O^B6_#G_ ,(?PS_\JZ/^%*_"K_HEOPY_\(;PS_\
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M,8![Y8G]!Z<5)2!0HP!@=:6AZO\ K]"XQ44HQO9;7=WU>K]6PHHHI#"BBB@
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MX5_('^=)Y:?W15_ZP<2)66=YO9;7SW.;V\_]J'_9&3_]"O!?+#TO_E9^<_\
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M/J-#N/ZWYI?^'47_  3I_P"C//@]_P""*;_Y.K]&/+3^Z*/+3^Z*/]8>)/\
MH=YO_P"'W.?_ )I#^R,G_P"A9@__  GH_P#RL_.?_AU%_P $Z?\ HSSX/?\
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M&0,'<<D#J<=KJ>6Z@KR,#N<C(!&1G()!!P><$'H:G_B,'B=_T66:_P#@4/\
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MCR7_ '<,>UG+.H_=[BB(!'M:??\ %?YHJZ[K[U_F6Z*;O7U_0_X4;U]?T/\
MA2]M#O\ C'_Y(+KNOO7^8ZBF[U]?T/\ A1O7U_0_X4>VAW_&/_R077=?>O\
M,=13=Z^OZ'_"C>OK^A_PH]M#O^,?_D@NNZ^]?YCJ*;O4=3C\Z4,K9P0<=<5<
M9*2NMKM=.GHW^8SX[_;E^*/C'X(_L??M+?&/X=W]II/CWX9_!WQMXQ\(ZC?V
M%IJMA8Z]H>D7]UIUQ=Z9J#I97]NEQ;1>=;7$L:RH7"R1R,DJ?RB1_P#!6_\
MX*1K% '_ &A_"QD%O;>:[_ ?X;!I'-O')N51JA+[S*WFS@J'9(QY:\&OZ@O^
M"G) _P"">/[:! "G_AG;XG 8Z@?\([JV1VQP3T/.>.M?PU6^=J 8P(+<#J<?
MZ+;\ 9P!].M?U;]&S@[AKB; <2/B/),!FM3"XJ$,+#$8>->5.,H1DH492J14
M$T[N]_M=3\0\5.(,TR7,,KH9?C<3A?;X24Y1HU.2-2HG;FE^[DG*R=FFO0_1
M8?\ !73_ (*0)P?VAO"Q).?^2#_#KI@#'&K+W!/3O1_P]X_X*.CK^T-X6_\
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M^$7AO%KFX(R^/5-X6C%6[W>(CMIJKK;4T_UWXL>V;8YZVTKMZ]M*._EOY'Z
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MK\/F?H9_P]V_X*.CK^T-X6_'X#?#8?\ N4%'_#W?_@HY_P!'#>%?_##?#?\
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M(****!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4C'"L1U )'X"EIDAPCGT1C^0-)[/T?Y,:U:7=I?>TOU*KSR@R@!<H5"
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MC,OBA_X=3P+_ %TVOYO^>Y;\%'] ?YT?BW_?/_V-2_HQ^%;NU#B17NTJ>/\
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M]K)[23Y>5*+UO8%XM<8J]H94K[WH_EKIML?TAK_P<->'B<?\,9_%'H3S\5/
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M_P#*RGG_ (.%O#X!/_#&'Q2&!GGXM?#4@>^%1Y#Z[5B:3L(RWRU_-UEO0_\
MCW^-#*,,=W."<'&>A/.?\/RJ)?1C\,96Y<-G4&O^@7/7CF_\:E2I^R7\K3?.
M[K3ENS_B+?&7\N4_^"?^"?T?'_@X:T#@+^QE\4-QW;?^+K_#U02D;OAGGL[>
M-%.W;N,A.2,(PR5_97]B#]JG3OVS_P!GCPI^T#I'@G6?AU:>*M1\3::?"'B#
M5-.UO4M,G\,>(=1T"=I-6T=4TZ\CNWL?M$9MAMB63RV)=6K^"RVS]HA^;)$@
MQC QGY3SR>02.AX//'!_L,_X(:$G_@G'\*'.6=_&?QA+M@L6(^)WB9<L202<
M +DD\  < 8_%/'#PBX2\/N'<JQ^04,\I8C%YB\/4KXW$QJ8=PM)NG&"3E[1*
M*M?1W=DTKGZ#X<<;9[Q1FN.P>:1PZAA\-"LI8>"A3O+:W7FWYM6KVT1]!_\
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ME;56W3/TA\+?L:^&K&S\3^&-:35H=5^('A?]G&;0]7\30>$/$?C'X0ZCXO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ME_'I?X:W_IEGV?\ \$T?^4B?[(O_ &.?C#_U5&NU_=A'_K&_WQ_Z!%7\)_\
MP31_Y2)_LB_]CGXP_P#54:[7]V$?,C$=-XY[?<BK_/[Z3W_)?4_^Q-A?_4_&
M']+^$7_)+Q_[#\1_Z8PY97^+_>/]*=35_B_WC_2G5_/C_1?E$_6'N_E^2"BB
MBD(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'\[W_!-2&1?^"B'[(Y:"90GC;QH"Q#[1L^&>MQ)G=;QCE< G>,GGT4_W80
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MPX5_;4_Z+;^RU_X"?%;_ .9*C_B8'PF_Z*-_^$V(_P#F8/\ B%_&?_0GJ?\
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MWX_S%%%?R='I_A_0_9R2H7^\?P_D***WCM'T8#:***H HHHH **** "BBB@
MHHHH **** "BBB@ J0??C_X!_.BBA_#+T7ZB[?/\BVG^OE^J_P#H)JS117/A
M]JG_ %\?Y(%L@HHHKH&%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %5)>OXM_,445,_A?R_,"*K%%%33Z_+]3.
MILO7] HHHK0S"BBB@ HHHH **** "BBB@ HHHH'U^:_-!1110(*:_P!QO]UO
EY&BB@:W7JOS(/XX_]_\ ]E:K%M]QO]]O_0FHHH-8?"OG^9__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>vi_002.jpg
<TEXT>
begin 644 vi_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &Q MH# 2(  A$! Q$!_\0
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MPLO4^^B#I[]:/^%F:@#C^Q#^M>@?8+7D_9TX[8I386@_Y=T_[YH \_/Q,O\
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MO7N#_9S?I2?VUKP'_'@PQUX%=9GVHP,\]^: .3_MK7L<Z<3[$"C^W-=_Z!S
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MI:* "DP*6B@ QSFBBB@ Q28I:* $Q2T44 %)@8Q2T4 %%%% "8]Z-HI:* $
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MY&:7_A.(O^?5^F: .PW>XHW=.:X[_A.(^]J]+_PFT>3_ *+)Q0!V .11DUR
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M -B8^E G3H2!2"9/NYZ]J %\J(C'E+@>U CCR<1J#_NTGF)C_"CS4/1QG.*
M%,<9!^12<8Z5S/A[3)[+7-2F>,)'*?E]#712W4<2%Y'"+UR>U4!XATE!M^VQ
M9_WAUH U!C'S $_2GJ?4C-5XKF*:,/&RE3W!J3S8\\XXZ4 39![T9J'SD ZX
MI?/3KGCUS0!+FC-1><F,YX^M'G)ZT 39I,U%YZX_^O1YR>OZT 39HJ'SEZ?U
MH$Z>N* )>M-'"X%,$R^H_P *#*H!)(X% '(>/,[=//3$HZ5LZM_R*\V.!Y/;
MZ5B>/'!CT\AL SC\ZV]6 'A>89'^I]?:@#&^&9 \'IG_ )^'S^E=I7%_#/\
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MUH =E!W%&Y/;TIODKD\<8]:7R5YPOMUH 7<E)E#SQS2&%2>GZT>2,]#SSUH
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MX_$UV7DJ.Q_ UQ<@'_"?],_N0/YT =KO X!_&EWH?<TU84X_QI?(7)."/QH
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MUBVNM@NX)Y!UC% '>#!'6D*9Z@''<U3TR[DN[))9XMCG@KZ5?^4=\]^M #2
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MOFIZ* (/L_ ^<T?9^/OFIZ* (/L_^V:#;D_QD5/10!!]G/\ ?-'V<_WS4]%
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M6>2,UN>"[>YM[VW6=2&,>3N]*[.?PSI]Y>)=3QEV4C&36?POBT(J@!4P![4
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M >OX/3!Y///2EZCI]>>E>/&7QL>EV<GKS1Y_C7C_ $TX[>U 'L(!ZX/K0 0
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M3\Y.T\BN \/G%A-M/_+9LUW^KD_V7/P/NUP&@$&QGQ_SU('MS0!J@MUS0"V
M,T YX[FESG! ]CS0 !VXYY[4N]E&3P!P-W>HGDBB&'<#/7G%#W,4:L[L "<@
ML>M $WF'/4=/PS306(&,X]:BCECD3=&P=2<D@Y_"B6>*VYFD"*W3)H E\PD=
M1^%)N/0GYO2HOML"()&E3;G@YXI8[N&4XBE0L>RG- $V6'))P".O%9,__(TV
M9'][UK4/W^1^%94G_(S6?N>: /2D.5!R,8J0$8ZU&@_=+P#P.#3\>U #ATI,
M>].%% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 TY'3FO/_&S!?$&F
M,2 .0?SKT$UYOX^MS<ZOI\&\@L#AA_.@"'7I=3^R_P#$J >0]U.<5SWAGQ1>
MW>K2Z7J0*S1G&<=:753?^$],D>RWW,SC@8K%\+7EW:07%]-9LUY(6<DCIGM0
M!K>+?%=UI&H"VA8)\N06. :I+X^NFT-9F7;,S85FX!Y]:RO$UK?ZS<0WMW:M
MY.S&P+S26'AV5?"\L=U$Y52#&N.1W% &@OBB\O(+C3]0($C1EE^E=MX8Y\/V
MI .=G4]S7FNE^';FWBN-5N2P4)M4,*](\-Y_L&V)& 5H V,@ G\/K2G'3)/%
M-W9SZ$<TOKS]?>@ P1DX.!UQ3)LK:S=SM/3Z4_)]<8-,EQ]EF&W!"&@"Q\/C
M_P 2V;'!!(_6NQ!).>>E<?\ #YF.F2ACGYOZUUX4>G!H =R!SU-.Q0!2T )B
MC'O2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 TCWH .,$T[&:* &]#C!I,G
M'3\*=BEH 3'O32<=!D^E.(XIC#/7@_SH -PSGGZUQ<ASX^ R/]4/YFNKO;HV
MMNTRKN*C[OK7F;Z[?'Q2+Y;!]NW:1CI0!ZIGKUI=P'&><9JKI]T;NS29DVLW
M48JT 0N!U]Z %R>>,TJ\CIBA??K3@* $Q3?FSU_2GTF* &C.0/SIV/>EP**
M$Q1BEHH 3%,.<G!&#4E,&W'% '&>/?NZ=S_RVK:U4'_A%I<Y_P!5_2L7Q[RN
MG#&?W_.*VM4Y\+S<9_<]_I0!C?#//_"'I_U\/_2NS_&N,^&?_(GH,G_CX?\
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M <4 .HIHD4T;Q0 ZBF[QFC>* '44W>,9HW@#- #J*;N&<4;Q0 ZBF[A2[A0
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MP>F?^>[_ -*[/F@#SWXM<>&H>,$W(Q^E=-X:'_%-6F.<QC [US7Q9&?#</\
MU\C^E=-X: _X1RTYQ^[% &#XA%]*DB7$4,B[L1JS8K.L_P"V=)2)C86T$&>H
M89JWXZT.[O[N&[COFMXXQSS@$UD6Z6US)#%<ZX9%# %<_I0!Z9;N9+:)V.2R
M@EEZ587/3%5[6-$LX8XV^15POTJPG'7B@!%PP! X]Z=M'3%(!E>1@T!@2,4
M9/B/_D7KD]]M1^&/^0)#Z;>U/\1\^'KC![4WPN?^)'"<=J -H 8I<<4F>#Q2
M]J # HQ2T9H 3 II[]AZT[--/0T 4=6S_9<_'\)K@/#^/[/EP<_O6.?^!&O0
M-6YTJ?\ W:\_T 8L9L<?O3UH UNAZ=.<T@Z<8SCG_P"M1TR.3Q01\QQTQQ0
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MXFTZ6.Z94DZJ#B@#N7N$0#>Z@D=":57# ,&!!/45Y]>_:-:UF]B69HUM5W
MXKHO"EP\VD[96)9"1DT 6O$G_(!N!MP0*;X8(_L6'GL/I5/Q?J4=GHLR."68
M5/X6G4Z%"V/EVYH WL$#H,TN2 !UJ+[0O'6FB=1@C- $^3QD<TF<X^4U']H4
M\4@N!^9H F!P/NXI#DG@=N]1?:!GVI//7H: *^K G2+@8 .VN!T YL91@_ZT
M\=ASZUWFKS+_ &5<<_PUP7A\@V$QZ8F8?J: -8?G0"2!^5'IGTH!SCWZ^QH
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M+VKG.P<#BC:H/" 'UH $Y R<$=:D&!3,'/' [TISG@4 .XHXIF3U -+DYZ4
M.XHXS3<]\<49R,@4 .R*,BF\XZ4<YZ&@!])D4W/M29XZ&@!^11D4S)[ THR>
MU #N*.*;G':DRW'% #\BCBF\]"*!GKB@!W%'%-R?0T9Z<4 .HR*9DYZ'%+D\
M\4 /S29%-S[4'MQ0 [(HXIO/I1SSQ0 [BC(IN?:@_2@!V11D4S)QR.E+^% #
MN*.*;D\<4#/I0 ZCBFY.,XYHYQTH =D4<4W)]*,GTH =Q1D4S)ZD&@DXX!H
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M"EHH 3%&!Z4M% "8%&!Z4M% "8'I1@4M% "8'I2XHHH 3%&!2T4 )@48I:*
M$P,T8%+10 F!2X%%% "8%&!Z4M% "8%&!Z4M% "8HP*6B@!,#THP*6B@!,#T
MHP*6B@ P/2DP*6B@!,"C%+10 F!1@4M% "8'I1@4M% ##D-[5R.K'_BK+,]B
ME=>>OM7(:P/^*LLSD?<- '7+]P"G  4U<[1FGYH 3 I<"BC- "8%&!Z4N129
M% !@48%+1F@!,#THQ2T9% "8XIN..!BG'I3 01P<\T <=X[Z:?QSYPQ6UJA/
M_",S-QDP_P!*QO'6=MAZ^<,=ZV-5_P"17E[?N>GX4 8_PS(_X0Z/K_KW_I79
MUQGPS_Y$]"!G_2'_ *5V?% 'GWQ9&?#D/_7R/Z5T_AK_ )%RS_ZYBN7^+1QX
M<@_Z^1_2NH\-?\BY9_\ 7,4 ;0Z_A0V<<4G<?2D))]L&@!-V>>U&X9&?SIC$
M@< X'7CI7+:[K6I:9*)/(!M<\L&ZT =6&XSP33L]\8%<9<^+I)MBZ=;/*4&Y
MQCH*Z#2-135+);@ AQ]X'L: (_$7R^'[H ]J9X8.-#A.#P*/$\JKH5RC,H.W
MN<9IOA9@="@Y4Y& ,T ;H.!3<D$=,=Z3>O\ %D?6EW#DY'3UH 7)Z$4$^U-_
MX&/SHSGG<!]30 [)].*4'CI3,C& PX[YHSQC<.>^>E #L\CB@D^E-SCG<#CM
MFC//WQ@^] #LGTI=V!S^-,R/4<]LTN_TP?QH #@Y!YIDF3'T!['<.*=N7!.X
M#U)J.<_N7(;C!Z4 ,2.!LA4CZX.%%3 8X P.U<IX8U)#/J$=S<JK+)E=S=!7
M2?VA:=1<H?QH L]>,T[<,54^WV@'_'Q'GMDT&^M1S]HCQ]: +FX>M)O%5?MM
MH0<7$?\ WT.*/M]H?^7B/\Z +>X>M!8#O53[=: \W$?/;(H^W6F!BXCQZ[A0
M!;W#GFDWC.*J"^M,_P#'Q&<]MPI3?6G(^T1_7- %O</6C</6J?VZU&#]HC'I
MR.:7[=:]KB//^\* +6X>M&X>M5/M]H1_Q\Q\=\T&_M,_\?"8[\T 7-PI-X Z
MU5^W6NW'VB/C@G<*07UID9N(_P Z +>\9I=PJG]NM.]Q&/QI?MUK][[1'@>X
MZT 6]P]:-P]:IB]M#G%Q&?\ @0H^WVG>YCXZ<T 7-P]:3<*J_;K4<_:(^>V1
M2?;K3'%PGUW#I0!<W#UI-X]:J"^M/^?B//L1S1]NM<D?:(_?F@"YN'K2;QZ^
MU5!?6IX^T)GUS2B^M.?](3UZT 6PP-)O'K57[=:8)^TQ >[ 4?;K3C%S#D]!
MN% %O<*3>/6JAO[3I]H3W.12_;;7 /VB/\Z +98#O2%P.IJI]NM.GVF/WYH-
M]:8!^T)CZB@"WO'K2[AFJ@OK3/\ Q\1YQTR!2?;K3&/M*?G0!<W#UI-PJH;Z
MU!!-Q&/3D4HOK4YQ<)^= %O</6DW#UJK]OM,\W$>>G6D-]:9YN(\?4&@"YN%
M)O7UJI]NM<<7$?'4[A1]NM.HN(R?3/>@"YN&<9HW#UJG]NM.1]ICX]^]'VZU
MSG[1&/3YA0!<W"DWKZU5^VVG(%Q'_P!]#BD^W6G!-S'QZ&@"WO'K2[A5/[=:
M _\ 'Q'],BE^VVF/^/B/W^89H M;AZTI8#O53[=:$_\ 'Q'GZTGVZTY!N(_S
MH M[A2[AZU4^W6G7[1&,_P"U2?;K3G%Q'G_>% %S<*-P]:J?;[3_ )^8_P Z
M#?6@.3<1_P#?0/% %K.3D9KC]8"GQ?:#/\ /ZUTPOK48_P!)CQ_O"N5U.YAE
M\5VGES*[;,97ZT =D"2O':E#>M,!&SL:4-@8R">U #]PI"<\@9XI-_T_.F[A
MZGU&>* '@G'2ER>>*9O'7./K1N'3//0T .S[49.>G%-W _Q'TH!S_%S0 [/3
MY:,GTXIN0?XO>C(_O4 .S[4G)X(Q1D9Z].?PI-P(XQ^= ''^/ ,:=Q_RVZFM
MG5?^17FQP/*[?2L;QVV5TX\<3=?RK:U4?\4O-_UQ_I0!B_#/'_"'H?\ IX?^
ME=GBN,^&?_(GIP>+A_Z5V>..IH \_P#BS_R+D'_7R/Z5T_AK_D7+/_KF*YCX
ML\^'(,<?Z2._TKI_#7_(N6?_ %S% &S_ (4A^Z<TO^%-/89_&@#(O["\FNQ+
M%.1&#RN:Y#Q#JS7FJ)8-')Y,7WCC@UZ&PS[9&*KMIMK)DO""QZ],T <$0^D7
M]TXB;R[E (R!75>%;22#2_WRD;R3@^]:[P6\BKNB1@OW<CI4B(   <#V- '/
M>+].6\T660G&U>F:G\+QI_84 [8&?>IO$@QH4_'1>*9X7)_L*'GTZT :QA7/
M)H,*\]ZFPI[4NT4 0>0N>E'D+D8[5,5&*15'/O0!#Y"@#^=!A49/45.5&>]&
MP$8Q0!#]G7BD\A?QJ<@<T@4?Y% $/DKNP>U MU]#D>]3%1^?6@*"#0!$84P>
M](85*\XP14^T4F/R[4 <Y/X1L9[DRJ"A?EL4W_A#K//\7_?1KI@#W-+M% ',
MGP?:' );KGAJ/^$.M?[S=<_>KIMHI,<GO0!S/_"'V>/F=O48-!\'VG7+=<_>
MKIBHQP.>U&W/44 <S_PA]F/XFSD_Q4H\'V?'S-_WU72E?2D"@GKP* .:_P"$
M/M./F;O_ !4?\(?9@8#-]=U=-@$=*3&3[=Z .:/@^S&<,V3VW4'PA:<\M_WU
M73!>>3G-+M'I0!S'_"'V?9F('?=1_P (?9CC<QQSRU=,5]/PH"C'K0!S/_"'
M69&"S<?[5+_PA]F<?,W(_O5TQ44W'O0!S1\(69/5N./O4G_"'V?=V'''S5TX
M4=*"HQ0!S7_"'VA!RS?@U)_PB%I@_,WK]ZNE"^_UI=B^G:@#F?\ A#[,$G<V
M?3=1_P (?:#'S-Q_M5T^T>E&T?IB@#F/^$0M!C+-_P!]4#PA9XX9N>^XUTC
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M.#P/;UH R/$A']@7)'IWIOA?YM#A'J,T_P 1_P#( N>,<?6F>%_^0)",\D4
M;B\BEIJG Z&ES0 M%)FESF@ HHHH ***,T %%)D4N<T %%%% !BBDSS1N^M
M"T44F0* %HI,T9% "T8HHH **** "BBDS0 M%)F@G% "T4F:,T +129%&: %
MQ129HW"@!::V>.:7-(>2/:@!GWCU^E8_B:W:Z\.7<()WO'A<5M$\]!C%,V*Z
M[6&0>: . T?PC<W&FV:75RQB0?=]JZ:7PY93,7W,&''7K6SL 7:!QCC;2X&
M/;MUH YB_P#"BR-'):2F.9.C9YI;;PP;2S$27!WLV92>]=-M.>/UZTH0Y]?J
M: ./D\%H]QM%R?()W,N>]-U#PC=W6I17"W9"0C"(>E=@5Y;"G)%*0=HQR?4T
M <E=^$Y+EX[A;DI,J[6V_P 0K;T;28](L_LZG))R6/>M+'0GCM@4NTD=AF@
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M_:(3\HZ@]C5S[3$#CSDS7&^'@PM]5DA!$)W&/_ZU<_+:75SI=S?&ZF$BR[<
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MW^LH U;/1M,LG+1! 6&#S38=#TN"Z\] GF9W<GO65_P@-N#G^UM2_P"_M"^
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MBNUR*Q_#V@VWAW2$TZTDD:%&+@OR>:V-HH C_P"6E ZK110 X]Z0?='T-%%
M#4^XOTIPZCZT44 %)W%%%  >M)_"/I110 O84O8_6BB@!!_2E;[OX"BB@!O\
M+5(*** &>OUIP_I110 B]Z!]T?2BB@!K??;_ ':D[444 ,]*#]TT44 */Z4-
MU6BB@ [GZT@_K110 #O2GH?I110 J?>-+110 R/[YI6Z444 'K]:0=*** $[
MM]:7L?\ =HHH .P^E+_RT;Z"BB@!'^\?I2^O^[110 C?=I3_  _0T44 -'W/
MPI4Z)]***  ]&IH[_6BB@!P[TO\ $M%%  O;ZT@[444 '8_0T#I^%%%  W0_
M2D/7\***  =6^HIQZ&BB@ /W12-T/THHH /\!1V/T-%% #3]\_2GCH*** $'
M2E7[QHHH 0_UH/4_[M%%  .M(>A^E%% "_X4O>BB@!!U%*.@HHH 0]J<O044
M4 )2_P#+0_2BB@!C]33NYHHH %Z?A31UHHH <?NFFCO110 J]*&ZT44 *>G_
;  &D_A6BB@ -(>A^M%% #C]W\*>.E%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>vi_003.jpg
<TEXT>
begin 644 vi_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %K Q4# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH ***9DXI, .,5A3^*].@NI;8^8SQ':VU<\UN$#!^E<QH&UKG5B47/VG'(Y
M-<]>K[.-QQ5RS_PF&G_\\YO^^:3_ (2_3_[DW_?-:6U/^>:_D*-J_P#/-/R%
M>;_:!?(9O_"7Z?\ W)O^^:/^$OT__GG/_P!\UI;5_P">2?D*-J_\\T_(4?VB
M/D,W_A+]/_N3?]\T?\)?I_\ SSF_[YK3VJ?^6:?D*/+0_P#+-?R%+^T6'(9G
M_"7Z?_SSG_[XH_X2[3_^><W_ 'S6EL3_ )YK^0I=B?\ /-?R%-8^0<AF_P#"
M7V'_ #SF_P"^:/\ A+[#_GG-_P!\UHA$_P">:_D*-B?\\U_(4?7V+D,[_A+[
M#_GG/_WS1_PF&G_W)O\ OFM+:O:-?R%&U.\:?D*/[08^0S?^$OT_^Y-_WS2?
M\)?8?\\YO^^:TMJ=?+3\A0%0C_5I^0I_79-70<AF_P#"7V'_ #SF_P"^*/\
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M(*G>-/R%*40C_5)_WR*I8]MZ"Y1FF:O;:K"TEL6PIP01TK27I7->&0!<ZD
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MVK>,(-.U6UMEPT<G+MCH*VUUBQ>:&!9QYDXS&I[UQ7B%[635M'O)H$BBE +
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MO#57H-21<N=/MKN2-YXU=HSE2>U++8VTMXET\0\]!A6QVJC_ &=XB_Z"D/\
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M>XN9%I-)LX[5[585\E^2N*P]?\/S:BVFVENJQV<,FZ11WQ6G_9_B+_H)P_\
M?ND_L[Q#_P!!.'_OV*I8:JA71K*%10JC"J, 4[-8_P#9WB'_ *"</_?L4O\
M9OB+_H*0_P#?NL_J51NY7.C7Q28%9/\ 9WB(?\Q.'_OW1_9WB+_H)P_]^Z/J
M,^PN=&N>M ZUD?V=XB_Z"</_ '[IK:=XCP<:I#G_ *YT?4:B8<R'^&_^/G4A
M_P!-JZ->E8NB:3/IB3FXG$\DK9) Q6RO KW*2<8I,S>XZBC-)FMA"T4F110
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MW?\ :ME_SV7\Z7^U;+_GLOYUP@Z9QQ2 #(P3[4[(1W?]JV0_Y;+^=*-6LO\
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M4UW'RGU/_;^E'_E]A_[[%']OZ5T^VP_]]"OE@2RG_EM+_P!]4>;-C(GEP/\
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MS\T(S]:A6VG9%98G*GGI6@+JWGT.2=Y56<IL_P!ZJ!O(_*4>?=IA<84 C^=
MR>QT\WC,6?RU7U[TV&UCD@GN'8B&*3R_E&235G39[*22WC=Y5VY.6& :=8SJ
MEK=26!CED:?[DQPN,]:8B);&$74EONW.4WK6=T!!'(-:]NT#:\\D+ GRR96S
ME5..@K'4[B[$?>.:!#N]!H'- ZT(+V 5A7'_ !\/6Z.>*PKG_CXDQ7SN=*\3
MV,L7O$.:*2EKY$^D5A,4N*,^U&:5QZ!BG1H7D5%&2QQ3>M7M*GMK2Z,MSN*[
M2%P,X/K6]!*4TF8UFXQ;B6+O1&M1;A7W-,VW'O3I=&B\F?[-<"6>VP)4QTS6
MBU[ID-M8R).[MYI;#<GGUJ(B+23J=Z\T;+<L#& V<_A7M^PI7/']O596&A1E
M53[2/M+)O\OVK'BB>5S'&C,X)&T#O73NL*WR:HT\0B\@#&><XK%T&<#6#*[
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MGH5C/XTH:X_N)^= "RP0S@"6-7 .0&'2G"-5 "C '84S-Q_<3\Z-US_<3\Z
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M_P"^:KZCB"?KE Y6XGENIQ)*<E1M4#H!4>.,5UI\"7!ZW@/_  &C_A!9L_\
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M3317,>4<T8/I7K'_  I*?_H+C_OBC_A2<P_YBH_[XH^M0"Z/)NA]J]3^"O\
MQ_WO^[4W_"DIP>-67'NE=-X*\%/X0U&0/=+/YR\$#%8UZ\)1LA-G>M13J*\R
MQ!7N_P#CVESZ5&]S!:VBR7$R11A1EG.!4EX<6LAZ\=*\M^*DK'5/#-G<RM'I
MTLR^?M. ?8U0'I=GJ=CJ!9;2ZCF(ZA35T=1@<5Y[XNN;'PGX:GO=!6&.[D"Q
MJZMG:#W(KG8M6UWPSK^DP/K+:E#JEIYTB,N#&V.W/ H ]ES[4@)/:O!/[>\6
M#2H_$3:[NB2^\H6PBXV[L8)S6O?:_J]MX^":QJ<]I87#(+0VPW1MG^]Z4 >O
M//"H=C*N$&6P>GUI+.\@O[<3VS[XR<9Q7B^AVVH)XS\5.VM2,+>-F$;CA^/3
M-5X/$FNR^&_#45GJB6;WTSQS2^7D=2,]: />/PIK,$4LQ  '4]J\8L?$NIZ9
M%KNE:GX@::.V(\J]2/!)/\(YZUG:=K>KWTGB'1/[4NFMEM/.BDG \T<9/3M0
M![=<ZA:6T*2S3JD;G ;J":LJV[! _P#KUX-;3:AIOPWTVX_M0W;3WJ+B0?<&
MX<=:U[S5=<\0ZWX@>#7/[,ATF,>5"J#+D#J<GI2 ]ER?2C..*\.3Q5XFU^^T
M73K?519FZB822>7G.!UZUV/PMUC4]1T_5;/4[H74EA>O L^,%P/:F!Z$.113
M0>*=0 4444 (1FEHHH *0BEHH K7O%N0/45*@^1?I45]_P >Y^HJ9/N+]* '
M8%&*!TI: $Q1BEHH  ,"F'IBGU&_('.* (;BZ@M(C)<3)$@[N<4RUO[6_C+V
MLZRJIY*UYI\59+]]>T"SLVBQ+)PDQ(0G/>M;X>^(KC4[W5](O;&WM[G3Y KO
M;?<?\*0'6?VY9'5VTQ9E-RJ[F7^Z/>IX-0L[F1D@NHI7C^\%8';]:\Z\'1+J
M/CGQ0UR3]_R\YP0/:J?@*UM-.^)_BBPMYLVR*A4.^[L,T@/35US2VN1;"_@\
MXG 3=R:N23QPQ-+*P1%Y+-TKQO7K?3O%7C:QTW01%"+&7S+FZ$F-W/W?K7HW
MB%%U70+[2;2\A%V8MO)^[Z9YJ@-"/6=-N-_D7D4I12Q5#DX%+I&L6>MVGVJQ
ME$D(8J3Z$5YEX1U*;P]XFM?#.J:1:>=+$=EW;S;B1[BM/X6$Q:GXIM$_X]XK
M[]VN>!GF@#TW&:,4+TI: $Q1BEHH ;BEQ2T4 12C]R^?2HK49ME]*FF_U+_2
MH;/_ (]E_&@"<BC!]:=01[TK )BDP?6G8]Z-OO18!I!'>BG8HP*+(!E%/Q1@
M4K(!,4A%.Q[T8]Z+ ,QVK/DUO2XK@V[W\ F!QLW<Y]*T3QGGM7B.K17_ ((U
M34M<O+*QU+3[FZ#']]MDB^@YS1RH#V>:XBAMWGD<+$B[F;MBL^W\1:5/817O
MVR-()F*QLYQN(-8'C;4?.^&UQ?6R,JS0JP7H5!%<OJ/AN]O_  GX3GTK[)(M
MF@E>"X?:)<CI3T0'HUQXBTNTM%NWN4,+-L#CIFM6-EE19$.589!KQ\Z_:^(O
MAWK4+::EC/8L5=4.Y=P]#7H?@BXDN/!NFRRY+F$9)HL@.@P*2E'>G8HL@&8H
MQ3\"C%%D SF@+3\48]Z+(!F/:EQ[T[%&/>BR ;TI<<4N*7%%@(W'!^E067,!
M_P!XU8?[IJO9?ZG\30!9 S1MI0,4M,!N*-M.HI6 ;BC;3J* &[3GBD;H?:GT
MQSV_7TH JW5];648:ZN(X0>FX]:6TO;:]C,EM<1S(#@E#G%>9_%.21M5TN/3
M_P![J8),<$C8C<>]2?!Z53;ZQ'<;EU%+@FXB4Y12?[II(#OFURP35&TYIU%P
MJ[F7T%/M]8TV[G\F"]A>7L@;DUY3%)!<:CXSN;Z:2+9\BNG+*,=JY[PI+<P^
M,/#AUM1#:E)!92P/\TQ[;Q3L![]<7<%G"9+F5(D]6-4G\0:8NG2WR7D<MO#]
M]HSG;]:I>(=5T*'1;B]U&:*X@AR"H;JWI7!^!M&,NC^)-6E\N&SU&-FBM,[O
M+4#@FA@>L6=W#?6D5S;N'AE4,K ]JL@5P?PFN)9O MN)"2(W95.>V:[P=: $
M(.:3::?118!NTT;:=118!NVC;3J*+ -QQ5)Q_P 32#_<:K]49.-5A_W#18"X
M311CGK10!!>?\>LGTK*UOPWI_B72X[34(]Z 95AP5/J*U;S_ (]9/857BNY#
M&H\GC'!S3 YRQ^&^CV=E<VKO/<1SC!\U\X^E/TCX>Z/I%X;I3+/-Y?EHTK9V
MKC&!71?;91_RP/YBC[;)_P \#^= &(? NCG2/[,\H_9_-\[&?XLYJ"?X=Z1<
MZO'?3/-)Y;!EB9LJ".E=']MD_P">)_,4?;9,?Z@_G0!S\W@/29-=EU9?,269
M-DBJW##WKF?$OPV%T^A6&GH5TVTD+28;!4GJ17HOVR8\>0>?4TGVJ3)(AQCK
MSUH YF'X:Z#%HT^FM&\B3,':1FRV?7-6-*^'^CZ5-//&)))IX?)D=SDE<8K>
M-Y)Q^X/YTOVV3_GB: .9MOAKHMM9&T_>O#YPF56;A6!SQ3M8^'6CZOJDE^YE
MADE 641M@2#WKI/MLG_/$TOVR3_GBWYB@#(@\&Z3;WUG=Q0[9+1"D>.@!JYH
MGAVQT WALE*_:YC-)_O'K5K[;)_SQ/YT?;9?^>!_.@"X!3ZH?;9?^>'ZT?;9
M?^>'ZT 7Z*H?;9?^>'ZT?;9?^>'ZT 7Z*H?;9?\ GA^M'VV7_GA^M %^BJ'V
MV7_GA^M'VV7_ )X?K0!-??\ 'N?J*F3[B_2LR[O)3 <PGJ.]3+>R;1B#MZT
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MY#D\9H ])@GBN8$F@;?$XW(U25QGPLO)+OP+:B5MQB)0'V'%=I[^M !1110
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MU'S_ //-J '44WY_^>;4?/\ \\VH =13/G_YYM2_O/\ GDU $5T,P'ZU*HP
M/]FH+HR" _NVZBIAO(!$3=* 'CI13/G_ .>;4?/_ ,\VH ?13?G_ .>;4?/_
M ,\VH =2&D^?_GFU)\__ #R:A *P5E96 96&"*XC7/A7X>U<0-# +9XYO-=E
M/W_8UVWS_P#/-J7YO^>34AW,#Q1HHOO!=UIEJ@^2+]TH]JY>V\(7NNZ/H>I+
M.]CJEC#Y1W#((^E>C$R=H6R.]+F3M$<>M"N(X6R^'+V=F1%JLT5S+/YLTB<;
M^>E.\0>!-2UN:2#^W)DTZ8C? 0#P*[@;\$^4PHW.1S$QI@>=:CX9D?Q)X?TF
MU@;^S=/ <R'ID5Z,<$C'ZTW+G)\EB?YT9<MDQL&]!VH </6EIOS]/+:D^?\
MYYM2 ?13?G_YYM1\_P#SS:F ZBF?/_SS:C+_ //-J !S^[?W%1VO_'NOXT]]
MXC;]V>E1VID-NO[IN] $XI:9\_\ SR:CY_\ GFU #Z*;\_\ SS:CY_\ GFU
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MNGZ[X6U664^;=*L4ZAOE;/>O5%(XI")!1113&%%%% !1110 R;B%_I4-F?\
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M5_ML/]X_E1]MA_O'\J )92?)?Z5#9G_1E_&DDO(#&PW'IZ5%:W<'V9>3W[4
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M_GWC_*L.]\=^'M.OTL;O44CGD(" J?F)]Z2]\?>'--U!;&ZOQ'/P.5..>G-
M&[]@M>OV>/\ [YI186O>WC_[YJ2*5)D62,[E89##H14U %;^S[3_ )]X_P#O
MFC^S[3_GWC_*K-% %;^S[3_GWC_*C^S[3_GWC_*K-% %;^S[3_GWC_*C^S[3
M_GWC_*K-% %;^S[3_GWC_*C^S[3_ )]X_P JLT4 5O[/M/\ GWC_ "H_L^T_
MY]X_RJS10!G7EC:K;G$"=1VJ9+&UV+_HZ=/2G7W^H/U%3)]Q?I0!7^P6G_/N
MGY4[^S[3_GWC_*K(Z44 5O[/M/\ GWC_ "H_L^T_Y]X_RJS10!6_LZT_Y]X_
MRH^P6G7[/'^56:#0!5^PVG_/O'^5)]BM.GV>/\JG9L#BO+?$_CSQ5X7U.VN+
MW2[4:3<7(@0JY+G)ZXH ]*^PV@/$$8SUPM'V"TSG[/'^59'B+7?[+\)W.JJI
M5_*R@_VB*P#XONO#WPZL]3OU^T:E<)NCA[N3T_"D!VYL;7O;Q_E338V@Y\B/
M'TKGO /B>Y\6>&UU&[MTMYBQ5D4YQ6%XX\6>+/#4TE];Z9:MHT+*I=W(=L\=
M* ._%A:_\^\>#S]VE%A:?\^\?Y5P4_B^[B\0Z!=$E--U- K(PP5<UZ&,Y -
M$7V"T_Y]X_RH^P6G_/O'^560/6C I@5_[/M/^?>/\J/[/M/^?>/\JLT4 5O[
M/M/^?>/\J/[/M/\ GW3\JLT4 4I+&U$3_P"CIT]*CL[*U-LO[A._:KTW^I?Z
M5!9_\>JT +]@M#_R[Q_E1_9]I_S[Q_E5@4M %;^S[3_GWC_*C^S[3_GWC_*K
M-% %;^S[3_GWC_*C^S[3_GWC_*K-% %;^S[3_GWC_*C^S[3_ )]X_P JLT4
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M_P ^\?Y59HH K?V?:?\ /O'^5']GVG_/O'^56:* *OV"TS_Q[Q_E1]@M,?\
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MW=W8::CR,TRX">@%>M?\([9C76U<#$[KM=?X6^M:<-M#;AC#"D8;[VU<9HV
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M)_ST8TOV&/\ O'\ZR?#_ (RTGQ)YJVCLDL7WXI1M8?G6VMS V=LT1P<<,.M
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M&^B^&9H(+^<B:=@J(JD\T ;/V-/[['\:/L:]I&K-USQ;I/AW2TO[^?9%( 4
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MD*-NIE2/M8&/]FJ-AXIT;5=8GTJRNDENX#B11VJ37?$6E^&K-+K4Y]B,VU%
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.PN,5HT4 -^E%.HH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>vi_004.jpg
<TEXT>
begin 644 vi_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $+ NX# 2(  A$! Q$!_\0
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M,/O:[:@=RUC-@?\ D;N0.@SD^G3+E^(_A6,+\VJR[USE-%U%>N>NZ#<"<#/
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M_@PJU_J7B*]TZ[*SZX2NDZ [13PQ,ZD, ?K7,A51AF.6 ZXX"L>V?0?YYJ-
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MED;8D1WG! /W_P"Z> #QCJ#:OKH6L3W(0AHT4B/;A7:(E\;#\K2$3'  +D*
M,@(*33H5CMT5V>1YW:>Y>7<S"?[RC>Y)VC("]A@+C&10<\JG-)P2:LFVWZV6
MWG>^OI<9?W$\=G?R1SS#RK:4H?,<L#M*@@Y/?(S@8VYSSQ#IRPP6D2PY#2(D
MKLTC,TLDD8=V=B<\9;[OJ<\XQHNL)B=)8T:%U(FC9 T;J5Y#IMVLH#<;N%/)
M((4G$TOSHEGL[M5FGL+ET1PP)FM)DE:U=F.?,5!"R GA<<#/0L9SJ*'+=-\T
MK*UM//\ '\#29Y00HWY4Y4![@IC(8$9E!R<#([9'7YJD$D[!EE9P'^4+YLXX
M)YQ^\[<C@\^@&<?B7_P4S_:K^+/P:_:2_9(^#WA+]M;3?V)/AY\5O _Q>\3>
M.?'VH? _P]\<[[7=5\'Z9%<^'=(L++Q-I&KV^C1F>1Y;R\MU3S(XQ'([$[3X
M5^S+_P %9_B-HGPBDL_CQJL'[0WC/Q[^V%\5/@!^QS\8&\-:1^RMI'[3?PF^
M&_@;P3XEUGXR>)-*\9/H/A?P?I&FZYKFK^'(M:6"RTW7IK4S:+"C%KEQ/7;:
MVMWY[Z6Z=V^MCI]E!QN[\UKN_+:]KKK>SNEJK/5)G]$DH=5RA<L' ),T_"X<
M$'YSCYMO8]".^:C0RA3F290".DTA'S#_ &R3P1@D<=P#7XK_  ]_X+,_#KX]
M^-?@C\,/@%\$?B[\1/&?QG\$_$KQGXH?2=4\.V>G_ S2?A-KEQX6\<7_ (MU
M._U--)U9M#\13Z++IMOX7N)%\7:9>^7'!>*40^8?L^_\%<=:U']E/X3^.6^'
MGQE_:[\9Z1^S;XE_:4_:*^(&@:'X$^%5YX/^%>E>/_%VAQZ_?>#=,O[/0)O&
M%OX>\,76IP>$O!<4$NIZ5IO]H6S276HW*U?.ET?3JNV^KOY?\.<]3#RY&U).
M[2LHS[MV3Y6G*R<K*^B;TLS]^,.6#>=)P#@D@\'!R21DG);&<$8..*8S, 6,
MLS<J<&:8#YBJDX5U5B"<Y*D$CIQD_@;^UM_P6'NM.^&?[0$W[&/PO^)/Q/U/
MX/?!_P#9U^)'CKXY0:3H%]X ^%)_:<M].\3_  MLY?"7B35Y]0\3:PW@O4+C
M5_&UIHR"U\)6QTTZC;SYC6+]FKGXK>"_ O@#PIXP^+/C_P &>!]-U;P_X:N+
MSQ)XP\0:;X:TBZUG4O#NG:K?&VNM0DM]/C2ZFN7EM8%8+;[72W2,,H"=2]K:
M/7\+/L[;^O7;?!4)M/5*UM6I*_-S6MI_=>MVNVJ:7I<A* E3*V_<"/-F'''/
M^L('WL'D =!NZTU02 ?WHRQX,TO.6).<2=,C(^7.,YX S\R_M,1_M%^*_A?H
M%K^R-\3_ (9_#G7/$&KZ)<^(/CAXWL-,\;:'X-^$]X3>:UXT\,:!J=ZGASQ+
MK\5HD9TA]<;^RC!(T[M)$-M?*7_!+?\ :,^.'[0_@;]H"_\ BOX_T_XZ^!_A
M?^T!XB^%OP)_:@L/ 5C\*[#]HGP-H>FV,^K^,H/!^AI;:++:^'/%:7GA6#Q'
MHMM%HWB.*"[GT]IH)<R:4ZM1VBFEKIJ]>:_E;?YV5S6&%4HWDXWN[O76RTUN
MKV3Z):V6K9^I*EMK!9906SP993M// _>8(!R%!R,*0P/4L8.P",\HY[.S9VX
M/4D8SWR!@=#R=JKL 8 @9)YW[L=0IWL26( R&)W-G<2<\ QGYE!!Q\YP1@#N
MQ'.[C'.?48P3Z27*UY6;U6K25[?/;J<^*IK7W7HK)NVFUGW_ .&W;()D"@-N
M=B2.KG;]]1T'&/FR<YY [<4Y1@,N20"1T'0X<YP,<;B.F-HYZ9IEP%/E ;3F
M=,X()*[22"!U7< 2#P.!C&*<P0%LJ,ACP5Y/.% &.F  NT8ZYR>FGM%V?WHX
M/9ONOQ&.I;K+)DD8QM'#':2/E/<[N><CT)JC)%')OAN,S0R8B>%]AW"1VARI
MVY5TQYBLIW!@2 ><WR8P#\P'49W<@Y(W#H0>X/&.#QUKFM3U%=,M9KB7S)9(
M6%K;, SL]Q<GRHV##YF>(R;D;G8064Y&:F33M96MT]7TM]_0RJQ:AJTW=O1/
M:R3WZWZ=D-T*XN([:>R%U++'9:C/I\$QD9E%J%MY%1F)(?89"H/&,XSZ^X68
M L(,D'A,LO()V=N>F/?V[9/B6FV0T^QBM?\ EH6DGN6&=TUS,(7$DS<&6;:5
M3=(6D_=[<G;7N&FJ/LL(V@8C7@#'("CM^74^G:O(S/X%IV^>K/;X:J)>UIV=
M[W3NK*SFWI:^M]_(\MU1&_M:Y7 ),F\<XRI5E4]<<YY!&1@'UHCX&,8*@ @]
M>YSQQR"#QWSP*GU)"VK7#@_<98\8X8;2P.>QX/MR*K-)L0L,''4?2/=^N*[L
M-\$]_A7YK^O4\K$K_::[M_)MV]VX,!YZGN/)Y_[:-4AC8S%U QYCYZ=?-0G(
M/7A3Z\CU/+(U,I64Y0KM)3@Y*LI )SC_ ):#\1VJTA)!8_Q$L!Z!_FQGOC=U
MK85/>2\E^8U]P"J@^=P2@R "N 6()X7U&03GMSPNP(L2\;@LA(QQRR%0#R6'
M\(.2>>::KEKF-,<1HXSGKU7I_P !JQ)C<F.ZN?UC_P :#0BW9W*!\PP.,8P1
MG/([<X^F#UX:1M^8JH!P22W&  58@_,.!TZ[C@X/%*/ORD<X"G'OM/'N3CMR
M>G6FB#+JQ<MEHQC8'_UFP' ;KA6Y'M]T#HT[:]M?P9[&"DTH)*/O**O;6R5M
M'WU\^_0;YD<<3SR30106L3W%Q--,D4,$$!26:::60K''%$BL[R2,J(@)8@*:
MY3P?\5OA?\0M(U?Q#X ^)'@/QQX>\/75WI_B/Q!X2\7:%KVB>'+W38)+N_M-
M>U/3[Z6UTBXL[0-=3PWKQ/#;(9G41X8_EA_P72_:ID_9-_X)D?M">*-/U5]%
M\=?%#3M#^ _@&YLT>>]@\1?%'4;+0=7OK.V@1[R[_L/PU=:IJ+K9Q279$#&W
MC:8*#_/5_P $R_''[*?[.O[5G[:7[#G['_CR3XD? 3]K7_@E[I'Q5LXWT_QM
MI%CI_P"U5\&?AKXPT'XH^';6+QYH&BW][J'B*PN[SQ#J;:/:W-J(M2TJS$\M
M]I]U!;^57DU.RU5UI9^5O1[Z/=Z:LG#X2GB*V(YI2@W)R3NDM+)K57=U:]KV
MO?M?^VJ;XK_"VV\"V/Q-NOB3X%MOAGJD<+Z=\1+CQ5HL/@B^2]N5M+-[7Q,]
MX-*G6[NG6WMFBG99IMT:'<.*WB?XO?"?P%;:3?\ C_XG_#SX?V>N/MT*?QUX
MT\.^$1K;>6N3HXU[4;(ZG&A<Q/)9+,BR1398I$9&_C6\;MX?U+_@T#_9KTN"
MXT74Y[_5/@7I,-A'>65X]WXAF_:2(DT7R?M)F75HL32W.GJJ720I-MA\K>1]
M@?L]_LJ?LJ_\% ?^"IW_  5D7]O?P#X:^,/B3]F;4?@7\&O@/\&?BWK-ZWAC
MX3? )?@KX1OC\1_!OA"^U!(-%M/&<]NGC2Z\2648MY)M;O=68VJ7BR#)5&EH
MK7;W\N7KM]KY6\].MY935_WKE;?E:NM6OOLKV6KU3UW_ *G(-1L;M([FUNK:
M[MKN**ZM+FTN;6[M[JTN$+VUY;3V<T\4]G<(0T%U&S0SA6,4C%6 W]QP& )#
M<C)/0],C;P<'I[ <8K\K/^"=I_8C^!?['7A7P1^R]^U9I/Q6_9T^'7CGQ_X+
M\%^,?B%\1K:XAT'6[+6#/J?PGTCQ!XH&F3G2_"5Y.;/1M/VWL-E82HPNQ;R1
M/)^BU]\2O NGZWH_A>\\8>![/Q#K<%M/HN@:AXQ\/66O:M;7</FV4FEZ5/>B
MZU)+Q5,EG-9)+:7=N1+;73X*UHJG6ZM^/W/^M>FAQRPM>G)QIQYH+X;J[U]Y
MJZ:3=V^E^FMM.]5MQ*@DL@)8XP JD;L9(S@#W)P>F<59P0=Q[*V??+;E_#;@
M9KX0_:]_X**?LP?L)S>$(/VBO$GBK2+KQMI?B/Q%:6/@OP-XB\?:AX?\#^$)
M[.#QI\3?&=EX=M;J;PS\.?##:GIHU'Q)?8A4M>&*.6.T9E^@_B_^T'\(/@'\
M)=<^/?Q<\>^&_!WP<\.>'D\3ZG\0KR_6XT2;1[G3SJ5C+HGV+[3<^(I]7@V2
MZ19:3'<75_!=PRPJ7\V-5S)-W>]].^MM.]MM-?S6U"A64)2LDK/F7:Z3M9N\
M=$]]KIZ]?:+CB"0 ](\'_ON.KB8VKS_"N?88_P#UFORT\<?\%@/V)_ ?PI^
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M=J;,Y"87)_BZODKT'#@$9/.0>@H_KT-TE%65[7OJ[[V\EV) P "D'(P,8/7
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M-NZ35W.>VG9+6[VVVM6>.0D/Y*A5 ).\'  9CQU))(([YSD@  P2'*A^0$E
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M;0.AC?\ ?9AY+*GRDGS'#$$9^9?EP,X4EP>X#*/K48)<\@<;^A/4NWTZX/\
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MS^. ,^G3UI+A3&L;\G;E<<Y^8*N!P2%(/0\8SSD\K+G]W*-N<J-N>#M9F)R
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M!R 3QCG[N>>,]>N!4,:D,IVMD Y)R ?E/.3GJ<=!G!-2.S$*8T,BL2"5R>.
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M^" ''PF_;Q'<?\%/OVNLCOSXHLL?RH _?JBBB@ HHHH **** "BBB@ HHHH
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M"#R0.<]SR.()41#'L7&2N1\S9R)"W7)&2!C!&.W&35HG)QQPO0<XR5P<8Y
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M6UM=6?S_ *[Z'/WKG4-1TW1C&WV*W8:SJL@? 1\A+:Q++\R!F8L51E#;3O#
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MT&*@C!&=P )D5AC!RC0ML.?<#)!Z=*GZ4$F=<.ZJ@,C0Q-=1K).N=T4+*Q#
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MG-8_)MIDGM8=J^']AAMIXTN+>+'EPW*+<QJLX$E?J\L+,6D$?#.0&R 3]\G
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M9[9 Z=:F50H"J, = .W>JEM]^7_KI+_-*N5DW=W-DK*P4444AA1110 4444
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M>%I].B6S>?4(M=@N$C_L[0X;D'5) N8KE;F *S1!G^D[U6951'1)&:%=SAF
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M57LN?2+Y5>\M8WM;6Z=Y:>2>FWR+\=/VB_BQ\,/B)H'P]^%'[$'Q]_:CGO\
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MB_A70;#14U%+1/(M5NUMX2+@VKV_FQ2$AE9@@P 3)Z3OWJ(E :257WL#A=V
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MIFG2(\IVERH5X?C#^T1\*_@+\)OB?\;_ (H>(8]#^&_P;\,:MXQ^(NN62?\
M"02>'] T:U-Y>7<FE:"=0U>>4P)*8+2&Q:ZE>"=!$ICR?Y"?@E\/_B9^S?\
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MQ17LNH>&&M83,_\ 3K?J\RH$*D9$L98A-LL3!D8NP(4JPS@@YP5QGFOY=_\
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M,\[1ZGT!R!0;DK'NS\Q .2 .H'K@#/3'U)X!P$R;2NOZ_K_AB0AE#9VG!8G
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MZW$%KR6SS@+C/.,RMGK_ +H_*K9VA69L9W/R3SG+*/KQP!_ABJ=K]YO]T?\
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M[I8=9GEW+%U*B7+*EAVXTE[1*,97O:"IIQO=7N3V3_9Y[?RW:)!-$5"HNTE
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MU:&SLM4U6P%S%:0V^GV=Y<A[9&K3^ _[5'['?Q]\;>)?A9\$OBG\)OB'XO\
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M\)K%/'VCV>LPVFIV6A>//]*\4Z1I\D$0M+'4?LML3;Q+CT/XY_'3]CGXX_\
M!%S]CS]G/X-^+/A+\<?VS-9^&'['.A_ ?X;?!?4O#'B/XT>"/B]HEYX,:X\8
M2:=X9FDU_P $V'@E[&_U#Q;J&K7>G6]OI]K>C4][7'EW(!_8]'+'D1[U\U$0
MNA92ZC)0%@O !8,,@!200.F!-_D?Y_\ UUQ7ABQOK2QT:'7&2XUM-"T6WU2X
M\TS/-?6VF6XOI6F0A)'DU 3R"1"1)O,H.7KM: "BBB@ HHHH *XS5/\ D(:%
M_P!A$_\ I')79UQNI_\ (1T'_L)?^VCT ;6K$QP#8XC!9(^2H1A(^W:^ZWN@
M$)P&Q"S<C8T>"]?S1_\ !1/P_P#M%Z1^V7H.D>%/V@OC[\<I_''PSUGQ%X)_
M9F^'?[#7[)?QG3X7>%=,U4V&H:QJ7COXO^#-;M-.T;6-3MI+5;D:/-XCO-]O
MIXE2UE,Q_IGOB5B'&2S!%&5!+R?NT50XPS$MD#*[L;=RDC/\WO\ P6-UGX20
M_M._L?:+XK\+_P#"/>+-3\>? 3X?:Q\99/VC_&_P!U*R^$7QQ_:/\"_"KQMX
M8^&]MX+\0>'8_&GC;2+'Q5?>*F3Q'<S:/H6CZ?<ZI/\ 9?+%U$ ?I3_P3L\#
M^)? '[+W@?0?$UM\9K'QC?>(O&?B;Q%8_'#PEX$\ _$"TO\ Q!KE[J)@NO!/
MPULK'P-X;\/QF=;?3=*T&UB5-+AM54^8K%?IS]IOXWV_[.7P ^*WQRO-#O?%
MEM\-O!]UXF3PYI=Q+9W>N7B7%C::;I=M>I:7\MH+N_G2-K@65VT,$IE-M.$*
M-\G?\$NO&<'C/]D'PO<Z1IUR$\*?$3XJ> +K65^+?B3XV^'O&EUX-\=:_H4W
MQ#\'_%;QO>77B+QAX0\7QVJZCHUQJ=[)):+-+9 A+.'?]G?&?X76GQC^%WC+
MX:WNL^(O#</BS3H+>'Q!X.U*/2?$FC:AI]UI]]I&JZ-=SP75@;G3KVQCO(+>
M]M)[*Y:&*&XA9)MR@'Y>^(?^"F_C:U\#:/K^E?!WPKXU\0Z9\._%7QI^-^B_
M#_XT#4],^$_P;\(ZMI^CZM<V^LWWA?3K[7/B5#)>7=S?^&[W3M+M;/3-"NGC
MEDFNTQL>)_\ @I1XJTF\\4JGP5OM6\-ZGX@\?>'OV:O$>E_$2*&?X]^*O 7Q
M%\-_"W4]!\1:=%HD-Q\-+"Z\5^*;+7-+U?S=:MQX=T#5[>YM89;FW\WH]0_X
M)4^!=<TJXMK_ .+?QNM/%/B^;Q'%\=?B!IVJ>&;'7OVA/"WC'4+#4/%/P^\=
M6<&C2Z5I7A6_;2[2SMX_#=M8S06$^I1,SO>.S=/XB_X)D> -?U_XC7]Q\2OC
M#'H?C(^)=4\ >%+;6=!M?#_[.GB;Q?XRT7XB^(_%GP7CLM!M[NRU>^\9>&=&
MN8[+7[G4+&'3DN;5587+T :GA/\ X*4_ /1? [^)_P!J#XC?#S]E7Q7X?^+G
MC?X(>+_"'Q \?Z?<:='\1_AY>HVMVGA7Q/)#ID&LZ%J5E+%>P7D]G%):VDR)
M*@>-V;XD_P"#>7Q#H?BWX!?MF^,O#&J6.L>$_%/_  4I_:O\0^'/$&DW'GZ7
MX@T&_P#$5M)9:M:3'S(Y;*Z0>9$\$K1L(U*E5!#?H_\ #/\ 8)^ 6A> -.\$
M?$SX=^%OVB+JY\<>(_BEXL\>?'WP3X.\:^+/%'Q*\6W'VOQ#XPNHKS1I-(L+
MS462&RDM=/M(;86<*#8^6C;\WO\ @@-HVA>&/V?OVV]$\-VECH>AZ!_P4T_:
MUT_2- LH8K71-$TZS\3V,-CINF:;"8;33;&*(@):VB)$ OEJC X)NTEN]$N[
M[>HTF]E?9:;W>R^?]6/Z!Y[NVC,>Z>%&:1XP/.0;I$A>Z= 21EEMX99V'58H
MW<@*#A1-"0)!,I4L=HW CY6YR0<<8!X.>U?DU^TG_P %'/@Y^SO^TK\.?V;_
M !OX_P#@_I.N^.#=13'QE\1+CPUK&AO)H-YK^B)?^&TTW["LWC6\M8O"GAXP
MW+SZG<7R6FX)<.!^G&F17,^G07"P2V]M)&9/):43",2'S!Y9R7:$@YA\T*RH
MR[E!-&-H8O!4Z%2>%KQCC+\DG3DXM+W5*#7,M4[WNNB:5TWT8G"8K"86GBJV
M'JPIUE/V<IP:C-0;3Y'>5[6UM&^O6Z9U2;'(D"1L"YVN)2<E6PVWY2"1SP/H
M?2K0DMU;(:,-("<Y4,X&"3ZD#<,^A/-?&'Q[_:E\&? /Q9\//"GB'0M3UC4O
MB+J2Z/H5_9>)?"&@C3[V<2NL5W9^)]<TJ]2UG2WF9=6AM9=/WE8TO4GD$8^E
MM/FM[N)KSR;D?:/+<Q0K)/R;);F));B.,Q3,D?F*MQ9O/9S[E(F;((KV56%'
M#UJE.I"EB%:C5E3FH57'W9<DG%<W+)-2VLUN]&\I4:T*,*\Z52%*HDXSE%J+
M;479/6_Q*^B_R[B2>-1P4/#$DLH"A0"2=W& #D^@'/6HEG@.V7S5"L%8?,-F
MU@"K;@<$%2&!  (Q]3\:?M&?M9?!G]F9/#<7Q9U=]#'BR64:3;R7&FB_=[:Z
MM[0R&VN)Q>?8#/<1)=75L6@M8W4W(0."/?\ PEK=KXL\-Z!XAT^X:XT/7=+M
MM<LC&9YT>QU6,7]HT$\<.RYA:&XC$,L3&WDB\M[>66 I,]U\-B:-&%9T*OLY
MRY83Y&XRT;NI)R3O9[)KSZ%U,)C84J=;ZI7=&K-1C5Y/<::;NI<UNG;_ ('J
M#2Q;21,@!QGYAC)8#CGID_AWXZ.\Q$(!<8'RG<<<G)/IS[=NG4U\D_'K]I+X
M3?LU^&M.\1?%G5]3T/3M<U!=)LGMK.:^NWO)?G2&".YDMYD=UPK.A*QJ2Q(0
M.Z^J_"_XD^$OBCX4\/\ C;P;J U/POXETB'5-!OV0R"YT^64HLBW$ FMIT,D
M<J[X[B4^8A5L<&N.M3Q:P\:TL/75)U5>I[*:ALK+FM9Z-RLE:W?<UJX'%4:,
M,1*A65"HE)U>1\BELX\W-)*V]NSYMF[>P1/'R/,#$-Q\P.1C /'(ZD8..?;%
M.:6+YE\U00K C(R#CK]1V'?->-?%/XP?#GX*^$[CQS\2_$,7AKPO9RV\%WK+
MVNHWL=L]TWEVJ30Z?:W,ZFYD5TB;RV4ONR<+DS^ _B3X-^*OA>T\9^ ]9?6_
M#VJ1W,FGZ@EE=Q"5[<;7_P!%EC%R'C<J&#Q*0"-Y3%;SHUUAHXRE1JSI5)J,
MJBIMP51*\H<VR=M;<L;=3'ZOB'2>(5&HZ*O>KR-T[Z[R3MT>EM4F>K1R1,2$
MEWL.2<X.!CIS@8]?7C'7,_FH>#(H)4MC<.5)P..,@X(')R>_8_)/[47Q]T']
MF7X1^*?B[XPOO#>F>&_#+Z<MS?>+/%=CX$\.NU[.E@8)M?U1'LK"<W;&.U6Y
M,:W-TUO;PR-)*H'A7[,?[?\ \ /CY\+;[XJ7/Q4^"_A'2+#6YM O6/QH\#^(
M=-TNZMK>"[-K>ZXFIVL<5RL%Y;S-;O&P9+B.2"292Y7HI8+%U\)+'+#573@F
MXRC3;BVVDE>^MVUIRZ:KW78Z893F-7 3Q\:%2I0@X)RIPO!\\XQLFI<UTI7:
MY=EK;9_I#+<PJ0IF57) V;UW-A3GC=D;05+'W!^ZP(JJ[)#(9&;<R2^6&=OG
M)!QM!8Y('S'N..0*_);]KC_@IM^Q[\+?@%\7?&NB_%[PG\8]8\)^$[N^'P]^
M%7BT_P#"1^(=]Y:0V]M9^(M+BEAT>47$BR)>SW4431!MKE ,_G5_P3#_ ."P
M.D?'GP;X^T#P[^RE^U;XL\;>%-<TZUDMO"E[J/QAM=;GULO=VGF^,=1N+;0?
M!5E;6TD5I=G4]2@MP\<DLTMO!ND7LP^0YIBLHJYO&C5H4Z,U"?M(*,9QN[<M
MYMOETORQ=G*/O/WE'LPO#N8XG!5\PHTJD</0Y?;RG!*&K:C%.=2+34D^9I):
MJ[T:7],'B#54T[1;Z]-M>7IL;:2\-EIB3SZG=+:H\S06D5LRS7%Q(J?NX4.Y
MSA,9;GPSX,?M&^&/C:_B)_#'A;XG>&[30+AXKNY^(GA2\\%V-U?6MQY%]:6%
MW<-<3SW%HP*O:K B':/-*DL:^&OC%\</^"C_ (^^&'Q'L?@Q^P[J'POUF_\
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M]'?XR-X]\2ZA\1[6_P# WB=M>\%Z[H_PZOV\!GQ!J!M[==0U".Y\/6_EC^S
M9B45T"/A@,CP^+P..Q,\?AYU,#!N-+VCC.?)>UDU!RNU9VN^:<$T[I/# 9+1
MQV7X_%3QE!RP4)RA!347-QO9+F4&];K:34I035FD_P"QRQ8M:69DWJQB_>K*
MX,L9\KE)BORF1&.U\87>IVJ%(%2WMQY=N^PAI&7;&BMEBSD*"H&20-V[(Y&
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MEQZ_]N7_ / TOS/TQ@SA1_=2)B?4[77'ZD]^F*=<?ZIOHW_HMZ2#O_USB_\
M9Z6X_P!4WT;_ -%O0:B6O5CZ*,_]_7.?T-6F3>F,XQ(6'&>4D+#\..3V&356
MVSB7U\O]=\M7<#@=0Q7=R0""0&R/<.3QC&<YXY4I6M\_ZU".DUYI_C+_ #8#
M]Y K#(X5<#G.R/ /(ZG=SQC"CCDFJNHKML+HYSFTU,=L BPN^1@#J<9]<=>]
M6W8JLB+E52 N ""%8+C@G!Z# R<#&>IJI??-ILA;YBUCJ&X\<YT^Y)(QTY&3
MP.<C.,U$V_95&MO=]=%>_73\_0[^;ECBIO55,&J"2:NI5%+E<D[6@KIO=Z:)
MV3?^;[^QM^]\(_&MB<9_:P_:#7 _[&BVP>>_(R/45]>!-J-@GHO)P/X5(&/7
M;\I'L"3UKY$_8S'_ !1WQMQG_D[']H09'][_ (2>T!QTXSGG/(SU(-?74),B
ML'.06P1D#.%SS@# X /)XQVKX;V4G=WC\5U>ZWE)KIK:S7Z:'^#7TP%R^+/%
MR<=%FN6I_P#;M'#IZ]%H[>M[;B0GYK2,$[I)XD/08$D.S(/'(4]/3!Y[_M'_
M ,&PL(3]@_XNIN8F']M#X[MDXP<0:-""3@XW*Q;(Z,N!QG/XMVQ)%F<\&\C.
M3C@JS1KD],;0 ".3G/!Z?M1_P;!?\F)_&88.T?MI?'3 ] 1H6<$]>20<CCFN
M_*K?6ZD=VJ$]=;?Q*:V>KU?EV/Z\_9]S4L'QMIOC<(]ELTM^G6W_  Y_2$1D
M$#@ET&>NW)CR,=P>XXR,CHU22Q+NR2<[=I;C/RLG3C')P??OVPR,9,9/=@3G
MU\L$9Q_M*I^HQ[5.VW!;()P>><GE20> >@&2!C@D9KW_ /[7\%'_ "/]*XW5
M5I)O5+3IM;[BNZ[!N!R=_P!TCCA6;<2!G (Z=,9  ZTZ $JTI(W(&0+V/R^3
MNR1G) X]SC'JLOW%Z\/AB>.=C@GV#>^*6W8A A^Z4$G4\O@OZ==W/!XX&.E'
M]?D=ZOU335EM9JW*GHE9WLW9M:6ZZ$<KO+M)S$4.4* GY\' .<,!N(),;QR*
M 2DB&O/-(^$GP[\->*O$_C?PA\/O /A'XB>-\-XS\9:-X0T;3/$7BMQEE?Q!
MK^G6=KJVJ*)7,QCO+R8O,L<DDCD.9/2+N1U7Y=Y)1OD09+L%9L(2&"EVPH+
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M=L/B/XF\'Z/>VWC;XA_#'PZMG:7FG_"XWESX6N?.1QH<EM'*)?'=,^ 'Q/\
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MIOMBRE.U9)G=!(9"&FF?GD%",IYD;JS%4=@MNX1D#D9 !_)+X+_8^\2?#/\
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MR$ *P%P2C<\;]H8D!22:<8<KWOHEM_78#4HK-&JV39"7%L[ $[5O+1F( )X
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M.L5OJ0N%:55*H=CR?K 691'GIY=NV.<%FDPQZX)..G(R 3DU_)%INEZ3?_\
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MQ*@# &X_-CTS_P#7.:OT ,1"O5BWRA>0HX4L<\ <G=@]L 8 Y)?110 4444
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M  ;>?\$WKJ,W#7_[8,AE=I/,?]L[X],9,[5,FY?'&661@S[I-LN25<#"K7Z
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MCXFOX;32]/T:/=)K2Q)/8W$UM,TCQ))M_KLM=>L+RTL);35K.Y74[*RN=/N
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M\??#SQ_X?AB37/!'CO0]0 GL=8TZ.:TGM+NVDGTO5]-GMM1T^>YM9X9W\_\
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MRQ,DV]9.^N]X2?;OJ>?ZF!_:%Z>WF=^1@1/C@_UJ!L>1L(!W*"0!R=A9CMY
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M7,,UK'H:WAEB\V2/<D$I4 ]DHI!D@$C!(&1G.#CD9[X/&>]+0 4444 %%%%
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MF$E_+)SF,'9R3MS@A8=,MH<[8$^5@T8#2?NR ,>669MA'3<F&QD"@H_F$O\
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MV1C[CIL<\-O(98Y/-!VL9I%=I<D?OFV;@';[TF "\A9JUVC#8YZ?WOG'Y/N
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M]_C/3[I!]:N^8&@,JC@QL^&&#PI."/J,'MC- $U%4Y;AHXX7V@^8 6&X  E
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M>])+YHRJ L&;>7+L&!/RE 2?NX09&3Z]<&@.=I+ ;OF)&1C=RV.N2/<<=/7
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MU-4LY!#J6FJDXGV'S;J! 9KB">0 2,FQ'CV@@$90\&KT3I?QI,50PWMJCJ@
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MY\$_#[PQ;:;<>'_%4_B[2O MM:^ O$FLW]B_A]-;E:ZMT>TB\O\ 0O\ 8O\
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ME)HXF\JUF2,%LDZJ]E>^V[NN_P#P/O,9;RVO?:VMTX62=][<W?X?,^A_&_\
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M=ISO;75TTM;=[?@02@+/(%&%\I1CL5:9L@@]B#G_ .M7JFFDK9VY'_/).O\
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M110 4444 %%%% !1110 4444 %-;IT).>,=0?7\.M.J"X8J@(_OKGC/'.?\
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M::VCFC,R1[A&\D8<Y;C^26U^//QOTS4(?V:/%/[2_C[X8_L;^(?VQ?A;\/\
MXB_&O2?VGM-^/'QE^#.@:U\./%/B:^^%FJ?M(>&O#5CX7\/^%/'?BW2M)V:Q
M'<S:GH6GPR6IU.)$N8[K@? GQ2\5R?M%?M%>&_AA^U#\1_VL_"W[.GQ+_:H\
M$_LF_%/Q;J=QXM\4Z#+;_L;V?B2;PGINMZ7:Q3^)+GP#XZ34M"\,>([832>,
M)=*TWQ")95OE8U!W?9V;V>^EKO3YIZVVZLG$8:E&]6\>7X;1M?FD[*T>B_F:
M=EV=^4_L=A=+K5[R_DC<6]LEO::2@@B\TNK0PW]PMLNYT"7MRUCAD&Z2UN"
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MWZXS_/G'3VKDG4;6RW7?S,:JE)\[:TMHKVU5NOR_R(X//ZG:RKC.2,+SD\9
M3H!Q@$ [<C-/!4C/SD#'($A'S=.<=>W?GH<$9NWEO#';AD0JQ+9(=\G!7&?F
MYZGKUSS4211JA(7!&0.6(_UI3H21]TD9(SWZ@$82JM-+E3NGNVMOD8^RE4^W
MRVTT3:=W;75=O+<K%0Q&=W!)P=X)R, @'@[1\W'(ZX'(J9)I@N/+?=N;@J02
M, @A6.0#UQ@<DX'! E9%!0XY D(Z_P#/-3_, X/%2.BBXP!_"OKGI)U/4]!U
M[9'0G,^W?\J^]_Y&\,/:*3J-M-W=EK9M=6WT(%F^;;M(W,H;C;][9N.1@C@9
M.>ZDD\5,6W$E68C!^X<D[G).>1@# .?7 [\65C1G<%00&4#J, ^5Z8Y^=L'J
M,\'@8MZ?#$0V4!S'(3UQPL>.,X'WCT'.>:7MW_*OO?\ D=^&BHM;O1Z.UFK1
MO??>_8RN!D,TN<X'L><^N", CVR#SE1*LX5<!,X'&Y06/KDGD\G'&<#U&2-V
M.V@)?,2_?'J.HD/8^PI_V:#8Q\I<A<CKUV@^OK2=:^G*N^_;Y'79;J$4W:[3
M=[7M:UN^O34Q/E880R$G:%.6P./O'(Y&,GUSSUPP1HW7.YF'/][ .._0 #CC
MTXZ5K-%'M8[1G<!^'F1C^1(_&FQ0Q.Y#(& SC)/]Y!Z^A-"K-:<J[[OR-(RY
M8_"I:WU;5DW9)6T=N6^NMV9@QC!;.&&"220#SD''OVP0QSGCB:*4EP&5BOED
M%B6()$3*3D\9RH8$<$D,""V*T'BC4@*@ V@X]SS_ %JO(B@.0,968GKC[T@Z
M=.@'&,<4I5>:^EF[ZW[]=D8RA><I=Y-M;KHFD[WMI^(Q201M<IU^8[G7:R]\
MY '90 &'![\2$S$#;*'&<97Y<< 8YQUX&!V ]A4MNBD8(!   SS_ ,LMWYY[
M]< #H !::- J@*!GD]>N!SU]^/0\CD"LAMN-FOYHK7S=BB#N7+,2V#D[SC.2
M!C#8(P "1WR,9!J4$AT(+$>8&SG(Z'.>F!]3ST]:B6&)E#,N2SC/S, ?G9>@
M( X &0/?J2:G^SQ;0=O/ED_>?J& '\7IVZ4[]/Q_KT.ETTXPJ.37Q*R2M]G=
MW7?3U)HCU;/8=7)7)]26VCOD<;<'/LYD\S!#$8^7 8C/ ;/'4G> 3ZCWJ&"*
M,(V%Q^]C7[S="CL>_7/?KCC..*5B4("D@%02!W.YAGZX 'T K.4W%V271]>Q
MT%D+@ $D[1CAF'&3@'!'..OU!H0!B5!/(^;]XW /."<D G&.H()QZXJ>8Y."
MQQN4?@=N1^IJU#PTV /]7'V_Z:&LO\V_O=_U&M&O5?H2LQ*.%9D P<B,DG?N
M./E&6QDY' Y SGFK4))3EBY!P2000< D$$ Y&?3H:C !,@/(7&,D\9=P>>O0
M ?A4L8 !QZ_T _D *#<DHHHH **** "BBB@ KBM6>3^U=( 5#&FLLNXA3C-L
M0!NP2"H/3/RC' KM:\?^(4TUGKO@D6L\]N+G6Y#.L4\J+*2A4[D#[2""00
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M?H.E0I:Z5HGBQI=)D_X2+1M*M8X[;2]-U;[?:Z9;0I#90VZHBKZ@O0_[S_\
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#'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>finlog_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 finlog_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ; ) # 2(  A$! Q$!_\0
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M+D6VGZW93SGI&LHW'Z ]:X3X_?\ (F67_7X/_06KQ_QCH_AK1I+.;POX@;4
MV?-# J\;#&&!P.#^F*[+QCKUQXB^"&A7MVYDN5N_)E<]6*AAD^Y&* .@_9Z_
MY FM?]?$?_H)KT_5O%.@Z$ZQZIJUI:2-R$DD 8_AUKQ;X4:TWAWX;^+=60 R
M6S(T8/3>5(7]2*XGP=X<N_B-XPDM[R_D5W1[BXN6&]L @?GDB@#ZBTGQ)HNO
M!O[*U.UNRGWA%("1]1UK@?C#X<LM?.D_;/$.GZ1Y/F[?MC8\S.WI],?K7C7B
M'2[_ .&GCHP65\QFMBLL,ZC:64C/(_0BNS^-.J+K>@>$-45=HNK>27;Z$A,B
M@#N?!QTSP5\,KG_BHM/N8_-F,5Y$X$?F%>%&>_'2O*?!OCW6+KQ[I4^O>(;C
M["LK&4S3E8@-K8R!@=<5U'A+PP/%7P-EM#=&V\B]EN=VS=G:O3J*\L\*Z$/$
MOBBQT8S^0+IRGF[=VW"D]/PH ^GO$OC+28?!5_J5AK=HK/#*EI.DJG=,%) 7
MU.<<5XO\./'5_)X]M[CQ'XBG^QB*3<;JX(C!V\<9Q79^)/A6-/\ A<UA_:Q?
M^RWGO]_DX\SY/NXSQTZUX_X(\+CQAXFAT<W7V42([^;LW8VC/3(H ^N[&_M-
M3LX[RQN8[BVD&4EC;<K?0UBWGCSPII]RUM=:_8QS*<,GF@D'WQ7G/Q"FN?AW
M\+M-\-V5Z[S7#M$UPJ[#Y8^9L<\9R!],UYGX.T'PGJMC=S^(_$9TV8-L@B1"
M2>,[VX/'.,>QI@?56GZE8ZK:K=:?=PW4#=)(7##]*M5\M_"K6[G0OB+;6-M=
M>;97<QMY=N=D@YVL!]<&OJ2@#XK\/ZC'I'B+3M1E1GCM;F.9E7J0K X'Y5Z+
M\0?C#_PE6B-H^F6,EK;2L#/)*X+. <A0!T&>OTJK_P (IHG_ #Y?^17_ ,:[
MGP+X \+7,WGW&D13.G*^9([+G_=)P?RI 8WP-\&W#R7?B*\C:.!X6M[7<,;]
MWWF'L!Q^)KRVYT^+0O%\ECKEM,;>WN2EQ'&VUV3/53].17V3'&D4:QQHJ(HP
MJJ, #T K@?BEX8T74M#DU*[L(Y+V%<)."5;'H2",_C0!YO+9_!>.U\X7VIR-
MC/E)OW_3E<?K6K\4-$TO0/A7I5KHYE-C)>">,R/N)WH3UKS_ ,(Z'INIZ_%;
M7EMYL)DP5WL./P->X?$?1=/D\':=8-;C[+;R(L48=AM 4@<YSTH \Z^&VD3:
M[\*_&.G6ZEIY2C1J/XF4;@/Q*XKF_A9XIL_!WC%KG5/,CM98'@D8(28SD$$C
MKU7'XU[/\)=,L],T[4TM(?+5YD+#<3GY?<UROQG\,:+:[-3M[".*\G),LB$K
MO/J0#C/OB@#SKXC>(;?QCXYFO-+222!E2"#*X:3'&<=>2:ZCXN:9+HWA+P5I
MLW^MM[5T?_>PF?UKI_@UX8T5X#JSV$;WT1_=RN2VSW )P#[XK8^+>DV6IG2O
MMD/F;/,V_.RXSM]#[4 5?@_&TWPCO(D&7>2X51ZDJ*\2\%:O;>'?&VFZG?"3
M[/;3$R;!E@"".GXU](_#"QMM/\(^1:Q^7']H=MNXGGCUKR'XM>'M*TWQ8396
M:0?:#YD@1C@L>2<9P/PH ]6F\6Z=XX\ ^)9-&6=DAMI8<RIM+,8R>!FO OAM
MXBL?"WC6UU/4?,%JJ.CF-=Q&Y2 <?6OH+X8:-I^E^$4^QVXC^TMOFRQ;><8[
MD]J\6^(OA[2M+\;26UC9K! [9**S8YZXYX_"@#J?BMJ,'CKP)8^(]'CG:SL;
MQX9/,3#88 ;L<\9 'XUPW@>/P#<VT\/BU[RWN0^Z*:)CL9,=" "00<_G7T+X
M)T/3+'P5!8P6B"UG4M+$Y+ARW7.XGK7AOQ,\-:/HGB%H=-LEMXV.2JNQ'X9/
M% ';>"= ^&FH^*X_^$=FU":]L0+E7D<JG! QR 3UKN)?&HCU(Q?9A]F5]I;/
MS8Z9_P#K5R?P;\.Z5;PR:K%:!;W:8_-WL?E/48)QV]*Z2;3[0^-EA,*^6QWE
4<G!/6O/Q\ZT5#V3M=V,YMZ6/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>15
<FILENAME>glmd-20241231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaCKObP9z5Z8iekhvWB0bRl6zyoveSvwhiUQq7WWYRMF -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:GLMD="http://galmedpharma.com/20241231" elementFormDefault="qualified" targetNamespace="http://galmedpharma.com/20241231">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://galmedpharma.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://galmedpharma.com/role/BalanceSheets" id="BalanceSheets">
          <link:definition>00000002 - Statement - Consolidated Balance Sheets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://galmedpharma.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://galmedpharma.com/role/StatementsOfOperations" id="StatementsOfOperations">
          <link:definition>00000004 - Statement - Consolidated Statements of Operations</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://galmedpharma.com/role/StatementsOfOperationsParenthetical" id="StatementsOfOperationsParenthetical">
          <link:definition>00000005 - Statement - Consolidated Statements of Operations (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://galmedpharma.com/role/StatementsOfComprehensiveLoss" id="StatementsOfComprehensiveLoss">
          <link:definition>00000006 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://galmedpharma.com/role/StatementsOfChangesInStockholdersEquity" id="StatementsOfChangesInStockholdersEquity">
          <link:definition>00000007 - Statement - Statements of Changes in Stockholders' Equity</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://galmedpharma.com/role/StatementsOfChangesInStockholdersEquityParenthetical" id="StatementsOfChangesInStockholdersEquityParenthetical">
          <link:definition>00000008 - Statement - Statements of Changes in Stockholders' Equity (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://galmedpharma.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
          <link:definition>00000009 - Statement - Consolidated Statements of Cash Flows</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://galmedpharma.com/role/General" id="General">
          <link:definition>999017 - Disclosure - General</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://galmedpharma.com/role/SignificantAccountingPolicies" id="SignificantAccountingPolicies">
          <link:definition>999018 - Disclosure - Significant Accounting Policies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://galmedpharma.com/role/MarketableDebtSecurities" id="MarketableDebtSecurities">
          <link:definition>999019 - Disclosure - Marketable debt securities</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://galmedpharma.com/role/OtherReceivables" id="OtherReceivables">
          <link:definition>999020 - Disclosure - Other Receivables</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://galmedpharma.com/role/Leases" id="Leases">
          <link:definition>999021 - Disclosure - Leases</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://galmedpharma.com/role/PropertyAndEquipmentNet" id="PropertyAndEquipmentNet">
          <link:definition>999022 - Disclosure - Property and equipment, net</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://galmedpharma.com/role/InvestmentInAssociate" id="InvestmentInAssociate">
          <link:definition>999023 - Disclosure - Investment in an Associate</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://galmedpharma.com/role/OtherPayables" id="OtherPayables">
          <link:definition>999024 - Disclosure - Other Payables</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://galmedpharma.com/role/RelatedParties" id="RelatedParties">
          <link:definition>999025 - Disclosure - Related Parties</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://galmedpharma.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
          <link:definition>999026 - Disclosure - Commitments and Contingencies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://galmedpharma.com/role/StockholdersEquity" id="StockholdersEquity">
          <link:definition>999027 - Disclosure - Stockholders&#8217; equity</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://galmedpharma.com/role/ResearchAndDevelopmentExpenses" id="ResearchAndDevelopmentExpenses">
          <link:definition>999028 - Disclosure - Research and Development Expenses</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://galmedpharma.com/role/GeneralAndAdministrativeExpenses" id="GeneralAndAdministrativeExpenses">
          <link:definition>999029 - Disclosure - General and Administrative Expenses</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://galmedpharma.com/role/FinancialIncomeNet" id="FinancialIncomeNet">
          <link:definition>999030 - Disclosure - Financial income, net</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://galmedpharma.com/role/IncomeTaxes" id="IncomeTaxes">
          <link:definition>999031 - Disclosure - Income Taxes</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://galmedpharma.com/role/SubsequentEvents" id="SubsequentEvents">
          <link:definition>999032 - Disclosure - Subsequent events</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://galmedpharma.com/role/SegmentReporting" id="SegmentReporting">
          <link:definition>999033 - Disclosure - Segment Reporting</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://galmedpharma.com/role/SignificantAccountingPoliciesPolicies" id="SignificantAccountingPoliciesPolicies">
          <link:definition>999034 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://galmedpharma.com/role/SignificantAccountingPoliciesTables" id="SignificantAccountingPoliciesTables">
          <link:definition>999035 - Disclosure - Significant Accounting Policies (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://galmedpharma.com/role/MarketableDebtSecuritiesTables" id="MarketableDebtSecuritiesTables">
          <link:definition>999036 - Disclosure - Marketable debt securities (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://galmedpharma.com/role/OtherReceivablesTables" id="OtherReceivablesTables">
          <link:definition>999037 - Disclosure - Other Receivables (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://galmedpharma.com/role/PropertyAndEquipmentNetTables" id="PropertyAndEquipmentNetTables">
          <link:definition>999038 - Disclosure - Property and equipment, net (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://galmedpharma.com/role/InvestmentInAssociateTables" id="InvestmentInAssociateTables">
          <link:definition>999039 - Disclosure - Investment in an Associate (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://galmedpharma.com/role/OtherPayablesTables" id="OtherPayablesTables">
          <link:definition>999040 - Disclosure - Other Payables (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://galmedpharma.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
          <link:definition>999041 - Disclosure - Stockholders&#8217; equity (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://galmedpharma.com/role/ResearchAndDevelopmentExpensesTables" id="ResearchAndDevelopmentExpensesTables">
          <link:definition>999042 - Disclosure - Research and Development Expenses (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://galmedpharma.com/role/GeneralAndAdministrativeExpensesTables" id="GeneralAndAdministrativeExpensesTables">
          <link:definition>999043 - Disclosure - General and Administrative Expenses (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://galmedpharma.com/role/FinancialIncomeNetTables" id="FinancialIncomeNetTables">
          <link:definition>999044 - Disclosure - Financial income, net (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://galmedpharma.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
          <link:definition>999045 - Disclosure - Income Taxes (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://galmedpharma.com/role/GeneralDetailsNarrative" id="GeneralDetailsNarrative">
          <link:definition>999046 - Disclosure - General (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://galmedpharma.com/role/ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentDetails" id="ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentDetails">
          <link:definition>999047 - Disclosure - Schedule of Depreciation Rates for Property, Plant and Equipment (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://galmedpharma.com/role/ScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails" id="ScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails">
          <link:definition>999048 - Disclosure - Schedule of Assets Measured at Fair Value on Recurring Basis (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://galmedpharma.com/role/SignificantAccountingPoliciesDetailsNarrative" id="SignificantAccountingPoliciesDetailsNarrative">
          <link:definition>999049 - Disclosure - Significant Accounting Policies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://galmedpharma.com/role/ScheduleOfMarketableDebtSecuritiesDetails" id="ScheduleOfMarketableDebtSecuritiesDetails">
          <link:definition>999050 - Disclosure - Schedule of Marketable Debt Securities (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://galmedpharma.com/role/ScheduleOfOtherReceivablesDetails" id="ScheduleOfOtherReceivablesDetails">
          <link:definition>999051 - Disclosure - Schedule of Other Receivables (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://galmedpharma.com/role/LeasesDetailsNarrative" id="LeasesDetailsNarrative">
          <link:definition>999052 - Disclosure - Leases (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://galmedpharma.com/role/ScheduleOfPropertyAndEquipmentDetails" id="ScheduleOfPropertyAndEquipmentDetails">
          <link:definition>999053 - Disclosure - Schedule of Property and Equipment (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://galmedpharma.com/role/ScheduleOfBalanceSheetsDetails" id="ScheduleOfBalanceSheetsDetails">
          <link:definition>999054 - Disclosure - Schedule of Balance Sheets (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://galmedpharma.com/role/ScheduleOfStatementOfOperationsDetails" id="ScheduleOfStatementOfOperationsDetails">
          <link:definition>999055 - Disclosure - Schedule of Statement of Operations (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://galmedpharma.com/role/InvestmentInAssociateDetailsNarrative" id="InvestmentInAssociateDetailsNarrative">
          <link:definition>999056 - Disclosure - Investment in an Associate (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://galmedpharma.com/role/ScheduleOfOtherPayablesDetails" id="ScheduleOfOtherPayablesDetails">
          <link:definition>999057 - Disclosure - Schedule of Other Payables (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://galmedpharma.com/role/RelatedPartiesDetailsNarrative" id="RelatedPartiesDetailsNarrative">
          <link:definition>999058 - Disclosure - Related Parties (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://galmedpharma.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
          <link:definition>999059 - Disclosure - Commitments and Contingencies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://galmedpharma.com/role/SummaryOfStatusOfCompanysOptionPlansAndChangesDetails" id="SummaryOfStatusOfCompanysOptionPlansAndChangesDetails">
          <link:definition>999060 - Disclosure - Summary of Status of Company's Option Plans and Changes (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://galmedpharma.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
          <link:definition>999061 - Disclosure - Stockholders&#8217; equity (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://galmedpharma.com/role/ScheduleOfResearchAndDevelopmentExpensesDetails" id="ScheduleOfResearchAndDevelopmentExpensesDetails">
          <link:definition>999062 - Disclosure - Schedule of Research and Development Expenses (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://galmedpharma.com/role/ScheduleOfGeneralAndAdministrativeExpensesDetails" id="ScheduleOfGeneralAndAdministrativeExpensesDetails">
          <link:definition>999063 - Disclosure - Schedule of General and Administrative Expenses (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://galmedpharma.com/role/ScheduleOfFinancialIncomeNetDetails" id="ScheduleOfFinancialIncomeNetDetails">
          <link:definition>999064 - Disclosure - Schedule of Financial Income, Net (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://galmedpharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" id="ScheduleOfEffectiveIncomeTaxRateReconciliationDetails">
          <link:definition>999065 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://galmedpharma.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
          <link:definition>999066 - Disclosure - Income Taxes (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://galmedpharma.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
          <link:definition>999067 - Disclosure - Subsequent events (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://galmedpharma.com/role/SegmentReportingDetailsNarrative" id="SegmentReportingDetailsNarrative">
          <link:definition>999068 - Disclosure - Segment Reporting (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="glmd-20241231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="glmd-20241231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="glmd-20241231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="glmd-20241231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://xbrl.sec.gov/cyd/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd" />
    <element id="GLMD_OfficeFurnitureAndEquipmentMember" name="OfficeFurnitureAndEquipmentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GLMD_ComputerSoftwareElectronicEquipmentMember" name="ComputerSoftwareElectronicEquipmentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GLMD_InvestmentInAssociateMember" name="InvestmentInAssociateMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GLMD_OnkaiIncMember" name="OnkaiIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GLMD_BridgeLoanAgreementMember" name="BridgeLoanAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GLMD_ServicesAgreementMember" name="ServicesAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GLMD_OfficersAndDirectorsMember" name="OfficersAndDirectorsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GLMD_ServiceAgreementMember" name="ServiceAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GLMD_NewSalesAgreementMember" name="NewSalesAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GLMD_PrefundedWarrantsMember" name="PrefundedWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GLMD_InvestorWarrantsMember" name="InvestorWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GLMD_StandbyEquityPurchaseAgreementMember" name="StandbyEquityPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GLMD_CaymanIslandsExemptLimitedPartnershipMember" name="CaymanIslandsExemptLimitedPartnershipMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GLMD_DemandSalesAgreementMember" name="DemandSalesAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GLMD_TwoThousandAndTwentySalesAgreementMember" name="TwoThousandAndTwentySalesAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GLMD_IncentiveShareOptionPlan2013Member" name="IncentiveShareOptionPlan2013Member" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GLMD_ChemistryAndFormulationStudiesMember" name="ChemistryAndFormulationStudiesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GLMD_SalariesMember" name="SalariesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GLMD_StockBasedCompensationMember" name="StockBasedCompensationMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GLMD_ResearchAndPreclinicalStudiesMember" name="ResearchAndPreclinicalStudiesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GLMD_ClinicalStudiesMember" name="ClinicalStudiesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GLMD_RegulatoryAndOtherExpensesMember" name="RegulatoryAndOtherExpensesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GLMD_ProfessionalFeeMember" name="ProfessionalFeeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GLMD_SalariesAndBenefitsMember" name="SalariesAndBenefitsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GLMD_RentAndOfficeMaintenanceFeesMember" name="RentAndOfficeMaintenanceFeesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GLMD_InsuranceAndOtherExpensesMember" name="InsuranceAndOtherExpensesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GLMD_MalteseSubsidiaryMember" name="MalteseSubsidiaryMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GLMD_IsraeliSubsidiaryMember" name="IsraeliSubsidiaryMember" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GLMD_FinancialExpenses" name="FinancialExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GLMD_ImpairmentOnAssociate" name="ImpairmentOnAssociate" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GLMD_StockIssuedDuringPeriodValueOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts" name="StockIssuedDuringPeriodValueOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GLMD_StockIssuedDuringPeriodSharesOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts" name="StockIssuedDuringPeriodSharesOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="GLMD_ExerciseOfPrefundedWarrants" name="ExerciseOfPrefundedWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GLMD_ExerciseOfPrefundedWarrantsShares" name="ExerciseOfPrefundedWarrantsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="GLMD_StockIssuedDuringPeriodValueExerciseOfWarrants" name="StockIssuedDuringPeriodValueExerciseOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GLMD_StockIssuedDuringPeriodSharesExerciseOfWarrants" name="StockIssuedDuringPeriodSharesExerciseOfWarrants" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="GLMD_WarrantsNetOfIssuanceCosts" name="WarrantsNetOfIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GLMD_ProceedsFinanceLeaseInterestExpenseIncome" name="ProceedsFinanceLeaseInterestExpenseIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GLMD_DecreaseInShorttermDeposits" name="DecreaseInShorttermDeposits" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GLMD_ChangeInFairValueConvertibleNote" name="ChangeInFairValueConvertibleNote" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GLMD_PaymentsForInvestmentInAvailableForSaleSecurities" name="PaymentsForInvestmentInAvailableForSaleSecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GLMD_PaymentsForProceedsFromInvestmentInConvertibleNote" name="PaymentsForProceedsFromInvestmentInConvertibleNote" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GLMD_PaymentsForProceedsFromInvestmentInAssociate" name="PaymentsForProceedsFromInvestmentInAssociate" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GLMD_IssuanceOfOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts" name="IssuanceOfOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GLMD_ConversionOfConvertibleNoteIntoInvestmentInAssociate" name="ConversionOfConvertibleNoteIntoInvestmentInAssociate" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GLMD_DisclosureLeasesAbstract" name="DisclosureLeasesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="GLMD_DisclosureGeneralAndAdministrativeExpensesAbstract" name="DisclosureGeneralAndAdministrativeExpensesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="GLMD_GeneralAndAdministrativeExpensesDisclosureTextBlock" name="GeneralAndAdministrativeExpensesDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="GLMD_ShortTermDepositsPolicyTextBlock" name="ShortTermDepositsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="GLMD_NewAccountingPronouncementsNotYetEffectivePolicyTextBlock" name="NewAccountingPronouncementsNotYetEffectivePolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="GLMD_ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentTableTextBlock" name="ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="GLMD_ScheduleOfBalanceSheetsTableTextBlock" name="ScheduleOfBalanceSheetsTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="GLMD_ScheduleOfStatementOfOperationsTableTextBlock" name="ScheduleOfStatementOfOperationsTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="GLMD_GeneralAndAdministrativeExpensesTableTextBlock" name="GeneralAndAdministrativeExpensesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="GLMD_MonthlyDepositsOfEmployeesPercentageOnMonthlySalary" name="MonthlyDepositsOfEmployeesPercentageOnMonthlySalary" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="GLMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDescription" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="GLMD_CapitalStockDiscountRate" name="CapitalStockDiscountRate" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="GLMD_ShorttermLeaseObligation" name="ShorttermLeaseObligation" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GLMD_BankLienOnMarketableSecurities" name="BankLienOnMarketableSecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GLMD_UpfrontLicenseFee" name="UpfrontLicenseFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GLMD_PaymentsToRegulatoryMilestones" name="PaymentsToRegulatoryMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GLMD_MaximumAmountOfSharesToBeIssued" name="MaximumAmountOfSharesToBeIssued" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GLMD_CommitmentShare" name="CommitmentShare" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="GLMD_CommonStockCapitalSharesReservedForFutureIssuanceUnallocated" name="CommonStockCapitalSharesReservedForFutureIssuanceUnallocated" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="GLMD_BankFees" name="BankFees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GLMD_InterestIncome" name="InterestIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GLMD_ChangeInFairValueOfConvertibleNote" name="ChangeInFairValueOfConvertibleNote" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GLMD_InterestIncomeFromShorttermDeposits" name="InterestIncomeFromShorttermDeposits" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GLMD_InvestorRelationsAndBusinessDevelopmentExpensesMember" name="InvestorRelationsAndBusinessDevelopmentExpensesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>16
<FILENAME>glmd-20241231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://galmedpharma.com/role/Cover" xlink:href="glmd-20241231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/BalanceSheets" xlink:href="glmd-20241231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/BalanceSheetsParenthetical" xlink:href="glmd-20241231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/StatementsOfOperations" xlink:href="glmd-20241231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/StatementsOfOperationsParenthetical" xlink:href="glmd-20241231.xsd#StatementsOfOperationsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/StatementsOfComprehensiveLoss" xlink:href="glmd-20241231.xsd#StatementsOfComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/StatementsOfChangesInStockholdersEquity" xlink:href="glmd-20241231.xsd#StatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/StatementsOfChangesInStockholdersEquityParenthetical" xlink:href="glmd-20241231.xsd#StatementsOfChangesInStockholdersEquityParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/StatementsOfCashFlows" xlink:href="glmd-20241231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#MaterialCybersecurityIncidentDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/General" xlink:href="glmd-20241231.xsd#General" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/SignificantAccountingPolicies" xlink:href="glmd-20241231.xsd#SignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/MarketableDebtSecurities" xlink:href="glmd-20241231.xsd#MarketableDebtSecurities" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/OtherReceivables" xlink:href="glmd-20241231.xsd#OtherReceivables" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/Leases" xlink:href="glmd-20241231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/PropertyAndEquipmentNet" xlink:href="glmd-20241231.xsd#PropertyAndEquipmentNet" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/InvestmentInAssociate" xlink:href="glmd-20241231.xsd#InvestmentInAssociate" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/OtherPayables" xlink:href="glmd-20241231.xsd#OtherPayables" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/RelatedParties" xlink:href="glmd-20241231.xsd#RelatedParties" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/CommitmentsAndContingencies" xlink:href="glmd-20241231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/StockholdersEquity" xlink:href="glmd-20241231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/ResearchAndDevelopmentExpenses" xlink:href="glmd-20241231.xsd#ResearchAndDevelopmentExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/GeneralAndAdministrativeExpenses" xlink:href="glmd-20241231.xsd#GeneralAndAdministrativeExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/FinancialIncomeNet" xlink:href="glmd-20241231.xsd#FinancialIncomeNet" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/IncomeTaxes" xlink:href="glmd-20241231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/SubsequentEvents" xlink:href="glmd-20241231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/SegmentReporting" xlink:href="glmd-20241231.xsd#SegmentReporting" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/SignificantAccountingPoliciesPolicies" xlink:href="glmd-20241231.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/SignificantAccountingPoliciesTables" xlink:href="glmd-20241231.xsd#SignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/MarketableDebtSecuritiesTables" xlink:href="glmd-20241231.xsd#MarketableDebtSecuritiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/OtherReceivablesTables" xlink:href="glmd-20241231.xsd#OtherReceivablesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/PropertyAndEquipmentNetTables" xlink:href="glmd-20241231.xsd#PropertyAndEquipmentNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/InvestmentInAssociateTables" xlink:href="glmd-20241231.xsd#InvestmentInAssociateTables" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/OtherPayablesTables" xlink:href="glmd-20241231.xsd#OtherPayablesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/StockholdersEquityTables" xlink:href="glmd-20241231.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/ResearchAndDevelopmentExpensesTables" xlink:href="glmd-20241231.xsd#ResearchAndDevelopmentExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/GeneralAndAdministrativeExpensesTables" xlink:href="glmd-20241231.xsd#GeneralAndAdministrativeExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/FinancialIncomeNetTables" xlink:href="glmd-20241231.xsd#FinancialIncomeNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/IncomeTaxesTables" xlink:href="glmd-20241231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/GeneralDetailsNarrative" xlink:href="glmd-20241231.xsd#GeneralDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentDetails" xlink:href="glmd-20241231.xsd#ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/ScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="glmd-20241231.xsd#ScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/SignificantAccountingPoliciesDetailsNarrative" xlink:href="glmd-20241231.xsd#SignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/ScheduleOfMarketableDebtSecuritiesDetails" xlink:href="glmd-20241231.xsd#ScheduleOfMarketableDebtSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/ScheduleOfOtherReceivablesDetails" xlink:href="glmd-20241231.xsd#ScheduleOfOtherReceivablesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/LeasesDetailsNarrative" xlink:href="glmd-20241231.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:href="glmd-20241231.xsd#ScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/ScheduleOfBalanceSheetsDetails" xlink:href="glmd-20241231.xsd#ScheduleOfBalanceSheetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/ScheduleOfStatementOfOperationsDetails" xlink:href="glmd-20241231.xsd#ScheduleOfStatementOfOperationsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/InvestmentInAssociateDetailsNarrative" xlink:href="glmd-20241231.xsd#InvestmentInAssociateDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/ScheduleOfOtherPayablesDetails" xlink:href="glmd-20241231.xsd#ScheduleOfOtherPayablesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/RelatedPartiesDetailsNarrative" xlink:href="glmd-20241231.xsd#RelatedPartiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="glmd-20241231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/SummaryOfStatusOfCompanysOptionPlansAndChangesDetails" xlink:href="glmd-20241231.xsd#SummaryOfStatusOfCompanysOptionPlansAndChangesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/StockholdersEquityDetailsNarrative" xlink:href="glmd-20241231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/ScheduleOfResearchAndDevelopmentExpensesDetails" xlink:href="glmd-20241231.xsd#ScheduleOfResearchAndDevelopmentExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/ScheduleOfGeneralAndAdministrativeExpensesDetails" xlink:href="glmd-20241231.xsd#ScheduleOfGeneralAndAdministrativeExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/ScheduleOfFinancialIncomeNetDetails" xlink:href="glmd-20241231.xsd#ScheduleOfFinancialIncomeNetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:href="glmd-20241231.xsd#ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/IncomeTaxesDetailsNarrative" xlink:href="glmd-20241231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/SubsequentEventsDetailsNarrative" xlink:href="glmd-20241231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/SegmentReportingDetailsNarrative" xlink:href="glmd-20241231.xsd#SegmentReportingDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaapRestrictedCashCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapRestrictedCashCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="loc_us-gaapDepositsAssetsCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapDepositsAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapMarketableSecuritiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaapOtherReceivablesNetCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapOtherReceivablesNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:label="loc_us-gaapInvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapInvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLoansPayableCurrent" xlink:label="loc_us-gaapOtherLoansPayableCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherLoansPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_FinancialExpenses" xlink:label="loc_GLMDFinancialExpenses" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_GLMDFinancialExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_ImpairmentOnAssociate" xlink:label="loc_GLMDImpairmentOnAssociate" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_GLMDImpairmentOnAssociate" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/StatementsOfOperationsParenthetical" xlink:title="00000005 - Statement - Consolidated Statements of Operations (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/StatementsOfComprehensiveLoss" xlink:title="00000006 - Statement - Consolidated Statements of Comprehensive Loss">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:label="loc_us-gaapDebtSecuritiesAvailableForSaleUnrealizedGainLoss" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaapDebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000007 - Statement - Statements of Changes in Stockholders&apos; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/StatementsOfChangesInStockholdersEquityParenthetical" xlink:title="00000008 - Statement - Statements of Changes in Stockholders&apos; Equity (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/StatementsOfCashFlows" xlink:title="00000009 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfInvestments" xlink:label="loc_us-gaapGainLossOnSaleOfInvestments" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainLossOnSaleOfInvestments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_FinancialExpenses" xlink:label="loc_GLMDFinancialExpenses" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_GLMDFinancialExpenses" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_ProceedsFinanceLeaseInterestExpenseIncome" xlink:label="loc_GLMDProceedsFinanceLeaseInterestExpenseIncome" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_GLMDProceedsFinanceLeaseInterestExpenseIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_DecreaseInShorttermDeposits" xlink:label="loc_GLMDDecreaseInShorttermDeposits" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_GLMDDecreaseInShorttermDeposits" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaapIncomeLossFromEquityMethodInvestments" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncomeLossFromEquityMethodInvestments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetImpairmentCharges" xlink:label="loc_us-gaapOtherAssetImpairmentCharges" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapOtherAssetImpairmentCharges" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_ChangeInFairValueConvertibleNote" xlink:label="loc_GLMDChangeInFairValueConvertibleNote" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_GLMDChangeInFairValueConvertibleNote" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsAndOtherReceivables" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsAndOtherReceivables" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableTrade" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableTrade" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccountsPayable" />
      <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_PaymentsForInvestmentInAvailableForSaleSecurities" xlink:label="loc_GLMDPaymentsForInvestmentInAvailableForSaleSecurities" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_GLMDPaymentsForInvestmentInAvailableForSaleSecurities" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_PaymentsForProceedsFromInvestmentInConvertibleNote" xlink:label="loc_GLMDPaymentsForProceedsFromInvestmentInConvertibleNote" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_GLMDPaymentsForProceedsFromInvestmentInConvertibleNote" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaapPaymentsToAcquireBusinessesGross" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireBusinessesGross" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_PaymentsForProceedsFromInvestmentInAssociate" xlink:label="loc_GLMDPaymentsForProceedsFromInvestmentInAssociate" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_GLMDPaymentsForProceedsFromInvestmentInAssociate" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaapProceedsFromSaleOfAvailableForSaleSecuritiesDebt" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromOtherDeposits" xlink:label="loc_us-gaapPaymentsForProceedsFromOtherDeposits" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsForProceedsFromOtherDeposits" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_IssuanceOfOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts" xlink:label="loc_GLMDIssuanceOfOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_GLMDIssuanceOfOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000015 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure" />
    <link:calculationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000016 - Disclosure - Material Cybersecurity Incident Disclosure" />
    <link:calculationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/General" xlink:title="999017 - Disclosure - General" />
    <link:calculationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/SignificantAccountingPolicies" xlink:title="999018 - Disclosure - Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/MarketableDebtSecurities" xlink:title="999019 - Disclosure - Marketable debt securities" />
    <link:calculationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/OtherReceivables" xlink:title="999020 - Disclosure - Other Receivables" />
    <link:calculationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/Leases" xlink:title="999021 - Disclosure - Leases" />
    <link:calculationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/PropertyAndEquipmentNet" xlink:title="999022 - Disclosure - Property and equipment, net" />
    <link:calculationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/InvestmentInAssociate" xlink:title="999023 - Disclosure - Investment in an Associate" />
    <link:calculationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/OtherPayables" xlink:title="999024 - Disclosure - Other Payables" />
    <link:calculationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/RelatedParties" xlink:title="999025 - Disclosure - Related Parties" />
    <link:calculationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/CommitmentsAndContingencies" xlink:title="999026 - Disclosure - Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/StockholdersEquity" xlink:title="999027 - Disclosure - Stockholders&#8217; equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/ResearchAndDevelopmentExpenses" xlink:title="999028 - Disclosure - Research and Development Expenses" />
    <link:calculationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/GeneralAndAdministrativeExpenses" xlink:title="999029 - Disclosure - General and Administrative Expenses" />
    <link:calculationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/FinancialIncomeNet" xlink:title="999030 - Disclosure - Financial income, net" />
    <link:calculationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/IncomeTaxes" xlink:title="999031 - Disclosure - Income Taxes" />
    <link:calculationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/SubsequentEvents" xlink:title="999032 - Disclosure - Subsequent events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/SegmentReporting" xlink:title="999033 - Disclosure - Segment Reporting" />
    <link:calculationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/SignificantAccountingPoliciesPolicies" xlink:title="999034 - Disclosure - Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/SignificantAccountingPoliciesTables" xlink:title="999035 - Disclosure - Significant Accounting Policies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/MarketableDebtSecuritiesTables" xlink:title="999036 - Disclosure - Marketable debt securities (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/OtherReceivablesTables" xlink:title="999037 - Disclosure - Other Receivables (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/PropertyAndEquipmentNetTables" xlink:title="999038 - Disclosure - Property and equipment, net (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/InvestmentInAssociateTables" xlink:title="999039 - Disclosure - Investment in an Associate (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/OtherPayablesTables" xlink:title="999040 - Disclosure - Other Payables (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/StockholdersEquityTables" xlink:title="999041 - Disclosure - Stockholders&#8217; equity (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/ResearchAndDevelopmentExpensesTables" xlink:title="999042 - Disclosure - Research and Development Expenses (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/GeneralAndAdministrativeExpensesTables" xlink:title="999043 - Disclosure - General and Administrative Expenses (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/FinancialIncomeNetTables" xlink:title="999044 - Disclosure - Financial income, net (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/IncomeTaxesTables" xlink:title="999045 - Disclosure - Income Taxes (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/GeneralDetailsNarrative" xlink:title="999046 - Disclosure - General (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentDetails" xlink:title="999047 - Disclosure - Schedule of Depreciation Rates for Property, Plant and Equipment (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/ScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:title="999048 - Disclosure - Schedule of Assets Measured at Fair Value on Recurring Basis (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/SignificantAccountingPoliciesDetailsNarrative" xlink:title="999049 - Disclosure - Significant Accounting Policies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/ScheduleOfMarketableDebtSecuritiesDetails" xlink:title="999050 - Disclosure - Schedule of Marketable Debt Securities (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/ScheduleOfOtherReceivablesDetails" xlink:title="999051 - Disclosure - Schedule of Other Receivables (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaapReceivablesNetCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapReceivablesNetCurrent" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrantsReceivable" xlink:label="loc_us-gaapGrantsReceivable" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapReceivablesNetCurrent" xlink:to="loc_us-gaapGrantsReceivable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivables" xlink:label="loc_us-gaapOtherReceivables" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapReceivablesNetCurrent" xlink:to="loc_us-gaapOtherReceivables" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/LeasesDetailsNarrative" xlink:title="999052 - Disclosure - Leases (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:title="999053 - Disclosure - Schedule of Property and Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MachineryAndEquipmentGross" xlink:label="loc_us-gaapMachineryAndEquipmentGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:to="loc_us-gaapMachineryAndEquipmentGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="loc_us-gaapFurnitureAndFixturesGross" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:to="loc_us-gaapFurnitureAndFixturesGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedComputerSoftwareGross" xlink:label="loc_us-gaapCapitalizedComputerSoftwareGross" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:to="loc_us-gaapCapitalizedComputerSoftwareGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="loc_us-gaapLeaseholdImprovementsGross" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:to="loc_us-gaapLeaseholdImprovementsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/ScheduleOfBalanceSheetsDetails" xlink:title="999054 - Disclosure - Schedule of Balance Sheets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/ScheduleOfStatementOfOperationsDetails" xlink:title="999055 - Disclosure - Schedule of Statement of Operations (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/InvestmentInAssociateDetailsNarrative" xlink:title="999056 - Disclosure - Investment in an Associate (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/ScheduleOfOtherPayablesDetails" xlink:title="999057 - Disclosure - Schedule of Other Payables (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilities" xlink:label="loc_us-gaapOtherLiabilities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrentAndNoncurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilities" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensatedAbsencesLiability" xlink:label="loc_us-gaapCompensatedAbsencesLiability" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilities" xlink:to="loc_us-gaapCompensatedAbsencesLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_ShorttermLeaseObligation" xlink:label="loc_GLMDShorttermLeaseObligation" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilities" xlink:to="loc_GLMDShorttermLeaseObligation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNotesPayable" xlink:label="loc_us-gaapOtherNotesPayable" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilities" xlink:to="loc_us-gaapOtherNotesPayable" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/RelatedPartiesDetailsNarrative" xlink:title="999058 - Disclosure - Related Parties (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999059 - Disclosure - Commitments and Contingencies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/SummaryOfStatusOfCompanysOptionPlansAndChangesDetails" xlink:title="999060 - Disclosure - Summary of Status of Company&apos;s Option Plans and Changes (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/StockholdersEquityDetailsNarrative" xlink:title="999061 - Disclosure - Stockholders&#8217; equity (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/ScheduleOfResearchAndDevelopmentExpensesDetails" xlink:title="999062 - Disclosure - Schedule of Research and Development Expenses (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/ScheduleOfGeneralAndAdministrativeExpensesDetails" xlink:title="999063 - Disclosure - Schedule of General and Administrative Expenses (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/ScheduleOfFinancialIncomeNetDetails" xlink:title="999064 - Disclosure - Schedule of Financial Income, Net (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_BankFees" xlink:label="loc_GLMDBankFees" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:to="loc_GLMDBankFees" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_InterestIncome" xlink:label="loc_GLMDInterestIncome" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:to="loc_GLMDInterestIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleGainLoss" xlink:label="loc_us-gaapDebtSecuritiesAvailableForSaleGainLoss" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:to="loc_us-gaapDebtSecuritiesAvailableForSaleGainLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_ChangeInFairValueOfConvertibleNote" xlink:label="loc_GLMDChangeInFairValueOfConvertibleNote" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:to="loc_GLMDChangeInFairValueOfConvertibleNote" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:title="999065 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/IncomeTaxesDetailsNarrative" xlink:title="999066 - Disclosure - Income Taxes (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/SubsequentEventsDetailsNarrative" xlink:title="999067 - Disclosure - Subsequent events (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/SegmentReportingDetailsNarrative" xlink:title="999068 - Disclosure - Segment Reporting (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>17
<FILENAME>glmd-20241231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://galmedpharma.com/role/Cover" xlink:href="glmd-20241231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/BalanceSheets" xlink:href="glmd-20241231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/BalanceSheetsParenthetical" xlink:href="glmd-20241231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/StatementsOfOperations" xlink:href="glmd-20241231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/StatementsOfOperationsParenthetical" xlink:href="glmd-20241231.xsd#StatementsOfOperationsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/StatementsOfComprehensiveLoss" xlink:href="glmd-20241231.xsd#StatementsOfComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/StatementsOfChangesInStockholdersEquity" xlink:href="glmd-20241231.xsd#StatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/StatementsOfChangesInStockholdersEquityParenthetical" xlink:href="glmd-20241231.xsd#StatementsOfChangesInStockholdersEquityParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/StatementsOfCashFlows" xlink:href="glmd-20241231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#MaterialCybersecurityIncidentDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/General" xlink:href="glmd-20241231.xsd#General" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/SignificantAccountingPolicies" xlink:href="glmd-20241231.xsd#SignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/MarketableDebtSecurities" xlink:href="glmd-20241231.xsd#MarketableDebtSecurities" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/OtherReceivables" xlink:href="glmd-20241231.xsd#OtherReceivables" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/Leases" xlink:href="glmd-20241231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/PropertyAndEquipmentNet" xlink:href="glmd-20241231.xsd#PropertyAndEquipmentNet" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/InvestmentInAssociate" xlink:href="glmd-20241231.xsd#InvestmentInAssociate" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/OtherPayables" xlink:href="glmd-20241231.xsd#OtherPayables" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/RelatedParties" xlink:href="glmd-20241231.xsd#RelatedParties" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/CommitmentsAndContingencies" xlink:href="glmd-20241231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/StockholdersEquity" xlink:href="glmd-20241231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/ResearchAndDevelopmentExpenses" xlink:href="glmd-20241231.xsd#ResearchAndDevelopmentExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/GeneralAndAdministrativeExpenses" xlink:href="glmd-20241231.xsd#GeneralAndAdministrativeExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/FinancialIncomeNet" xlink:href="glmd-20241231.xsd#FinancialIncomeNet" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/IncomeTaxes" xlink:href="glmd-20241231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/SubsequentEvents" xlink:href="glmd-20241231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/SegmentReporting" xlink:href="glmd-20241231.xsd#SegmentReporting" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/SignificantAccountingPoliciesPolicies" xlink:href="glmd-20241231.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/SignificantAccountingPoliciesTables" xlink:href="glmd-20241231.xsd#SignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/MarketableDebtSecuritiesTables" xlink:href="glmd-20241231.xsd#MarketableDebtSecuritiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/OtherReceivablesTables" xlink:href="glmd-20241231.xsd#OtherReceivablesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/PropertyAndEquipmentNetTables" xlink:href="glmd-20241231.xsd#PropertyAndEquipmentNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/InvestmentInAssociateTables" xlink:href="glmd-20241231.xsd#InvestmentInAssociateTables" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/OtherPayablesTables" xlink:href="glmd-20241231.xsd#OtherPayablesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/StockholdersEquityTables" xlink:href="glmd-20241231.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/ResearchAndDevelopmentExpensesTables" xlink:href="glmd-20241231.xsd#ResearchAndDevelopmentExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/GeneralAndAdministrativeExpensesTables" xlink:href="glmd-20241231.xsd#GeneralAndAdministrativeExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/FinancialIncomeNetTables" xlink:href="glmd-20241231.xsd#FinancialIncomeNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/IncomeTaxesTables" xlink:href="glmd-20241231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/GeneralDetailsNarrative" xlink:href="glmd-20241231.xsd#GeneralDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentDetails" xlink:href="glmd-20241231.xsd#ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/ScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="glmd-20241231.xsd#ScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/SignificantAccountingPoliciesDetailsNarrative" xlink:href="glmd-20241231.xsd#SignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/ScheduleOfMarketableDebtSecuritiesDetails" xlink:href="glmd-20241231.xsd#ScheduleOfMarketableDebtSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/ScheduleOfOtherReceivablesDetails" xlink:href="glmd-20241231.xsd#ScheduleOfOtherReceivablesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/LeasesDetailsNarrative" xlink:href="glmd-20241231.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:href="glmd-20241231.xsd#ScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/ScheduleOfBalanceSheetsDetails" xlink:href="glmd-20241231.xsd#ScheduleOfBalanceSheetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/ScheduleOfStatementOfOperationsDetails" xlink:href="glmd-20241231.xsd#ScheduleOfStatementOfOperationsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/InvestmentInAssociateDetailsNarrative" xlink:href="glmd-20241231.xsd#InvestmentInAssociateDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/ScheduleOfOtherPayablesDetails" xlink:href="glmd-20241231.xsd#ScheduleOfOtherPayablesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/RelatedPartiesDetailsNarrative" xlink:href="glmd-20241231.xsd#RelatedPartiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="glmd-20241231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/SummaryOfStatusOfCompanysOptionPlansAndChangesDetails" xlink:href="glmd-20241231.xsd#SummaryOfStatusOfCompanysOptionPlansAndChangesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/StockholdersEquityDetailsNarrative" xlink:href="glmd-20241231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/ScheduleOfResearchAndDevelopmentExpensesDetails" xlink:href="glmd-20241231.xsd#ScheduleOfResearchAndDevelopmentExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/ScheduleOfGeneralAndAdministrativeExpensesDetails" xlink:href="glmd-20241231.xsd#ScheduleOfGeneralAndAdministrativeExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/ScheduleOfFinancialIncomeNetDetails" xlink:href="glmd-20241231.xsd#ScheduleOfFinancialIncomeNetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:href="glmd-20241231.xsd#ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/IncomeTaxesDetailsNarrative" xlink:href="glmd-20241231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/SubsequentEventsDetailsNarrative" xlink:href="glmd-20241231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/SegmentReportingDetailsNarrative" xlink:href="glmd-20241231.xsd#SegmentReportingDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosureWithAdditionalMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosureWithAdditionalMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpTable" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsToCompensation" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpAdjustmentsToCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TabularListsByExecutiveCategory" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TabularListsByExecutiveCategory" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TabularListMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TabularListMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpExecutiveCategoriesOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpAdjustmentsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#IndividualsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTypeOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TradingArrangmentsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ForgoneRecoveries" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ForgoneRecoveries" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/OutstandingRecoveries" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#OutstandingRecoveries" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardsCloseToMnpiDisc" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardsCloseToMnpiDisc" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsByInd" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangemenstByInd" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/Defaults" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#Defaults" xlink:type="simple" />
    <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd#eedm" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesLineItems" xlink:label="loc_deiEntityAddressesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesTable" xlink:label="loc_deiEntityAddressesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_deiEntityAddressesAddressTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_deiEntityAddressesTable" xlink:to="loc_deiEntityAddressesAddressTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain" xlink:label="loc_deiAddressTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiEntityAddressesAddressTypeAxis" xlink:to="loc_deiAddressTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain" xlink:label="loc_deiAddressTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiEntityAddressesAddressTypeAxis" xlink:to="loc_deiAddressTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember" xlink:label="loc_deiBusinessContactMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiAddressTypeDomain" xlink:to="loc_deiBusinessContactMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentType_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAmendmentFlag_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAmendmentDescription_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentRegistrationStatement_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentAnnualReport_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentQuarterlyReport_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentTransitionReport_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentShellCompanyReport_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate_40" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentPeriodStartDate_40" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentPeriodEndDate_40" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus_40" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFiscalYearFocus_40" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate_40" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityFileNumber_40" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityRegistrantName_40" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCentralIndexKey_40" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityPrimarySicNumber_40" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber_40" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode_40" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine1_40" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine2_40" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine3_40" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressCityOrTown_40" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressStateOrProvince_40" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressCountry_40" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressPostalZipCode_40" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCountryRegion_40" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCityAreaCode_40" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiLocalPhoneNumber_40" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiExtension_40" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiWrittenCommunications_40" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSolicitingMaterial_40" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiPreCommencementTenderOffer_40" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer_40" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurity12bTitle_40" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiNoTradingSymbolFlag_40" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiTradingSymbol_40" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurityExchangeName_40" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurity12gTitle_40" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurityReportingObligation_40" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAnnualInformationForm_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityVoluntaryFilers_40" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCurrentReportingStatus_40" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent_40" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityFilerCategory_40" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntitySmallBusiness_40" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany_40" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityExTransitionPeriod_40" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentAccountingStandard_40" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber_40" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityShellCompany_40" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityPublicFloat_40" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent_40" xlink:type="arc" order="55" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding_40" xlink:type="arc" order="56" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock_40" xlink:type="arc" order="57" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelName" xlink:label="loc_deiContactPersonnelName_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiContactPersonnelName_40" xlink:type="arc" order="58" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelEmailAddress" xlink:label="loc_deiContactPersonnelEmailAddress_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiContactPersonnelEmailAddress_40" xlink:type="arc" order="59" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_deiIcfrAuditorAttestationFlag_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiIcfrAuditorAttestationFlag_40" xlink:type="arc" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_deiDocumentFinStmtErrorCorrectionFlag_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFinStmtErrorCorrectionFlag_40" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAuditorFirmId_40" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock" xlink:label="loc_deiAuditorOpinionTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAuditorOpinionTextBlock_40" xlink:type="arc" order="63" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAuditorName_40" xlink:type="arc" order="64" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAuditorLocation_40" xlink:type="arc" order="65" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations" />
    <link:definitionLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/StatementsOfOperationsParenthetical" xlink:title="00000005 - Statement - Consolidated Statements of Operations (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/StatementsOfComprehensiveLoss" xlink:title="00000006 - Statement - Consolidated Statements of Comprehensive Loss" />
    <link:definitionLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000007 - Statement - Statements of Changes in Stockholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_StockIssuedDuringPeriodValueOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts" xlink:label="loc_GLMDStockIssuedDuringPeriodValueOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GLMDStockIssuedDuringPeriodValueOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_StockIssuedDuringPeriodSharesOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts" xlink:label="loc_GLMDStockIssuedDuringPeriodSharesOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GLMDStockIssuedDuringPeriodSharesOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_ExerciseOfPrefundedWarrants" xlink:label="loc_GLMDExerciseOfPrefundedWarrants_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GLMDExerciseOfPrefundedWarrants_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_ExerciseOfPrefundedWarrantsShares" xlink:label="loc_GLMDExerciseOfPrefundedWarrantsShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GLMDExerciseOfPrefundedWarrantsShares_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_60" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_60" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_60" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_60" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_60" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:label="loc_GLMDStockIssuedDuringPeriodValueExerciseOfWarrants_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GLMDStockIssuedDuringPeriodValueExerciseOfWarrants_60" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="loc_GLMDStockIssuedDuringPeriodSharesExerciseOfWarrants_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GLMDStockIssuedDuringPeriodSharesExerciseOfWarrants_60" xlink:type="arc" order="19" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/StatementsOfChangesInStockholdersEquityParenthetical" xlink:title="00000008 - Statement - Statements of Changes in Stockholders&apos; Equity (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/StatementsOfCashFlows" xlink:title="00000009 - Statement - Consolidated Statements of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000015 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000016 - Disclosure - Material Cybersecurity Incident Disclosure" />
    <link:definitionLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/General" xlink:title="999017 - Disclosure - General" />
    <link:definitionLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/SignificantAccountingPolicies" xlink:title="999018 - Disclosure - Significant Accounting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/MarketableDebtSecurities" xlink:title="999019 - Disclosure - Marketable debt securities" />
    <link:definitionLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/OtherReceivables" xlink:title="999020 - Disclosure - Other Receivables" />
    <link:definitionLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/Leases" xlink:title="999021 - Disclosure - Leases" />
    <link:definitionLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/PropertyAndEquipmentNet" xlink:title="999022 - Disclosure - Property and equipment, net" />
    <link:definitionLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/InvestmentInAssociate" xlink:title="999023 - Disclosure - Investment in an Associate" />
    <link:definitionLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/OtherPayables" xlink:title="999024 - Disclosure - Other Payables" />
    <link:definitionLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/RelatedParties" xlink:title="999025 - Disclosure - Related Parties" />
    <link:definitionLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/CommitmentsAndContingencies" xlink:title="999026 - Disclosure - Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/StockholdersEquity" xlink:title="999027 - Disclosure - Stockholders&#8217; equity" />
    <link:definitionLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/ResearchAndDevelopmentExpenses" xlink:title="999028 - Disclosure - Research and Development Expenses" />
    <link:definitionLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/GeneralAndAdministrativeExpenses" xlink:title="999029 - Disclosure - General and Administrative Expenses" />
    <link:definitionLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/FinancialIncomeNet" xlink:title="999030 - Disclosure - Financial income, net" />
    <link:definitionLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/IncomeTaxes" xlink:title="999031 - Disclosure - Income Taxes" />
    <link:definitionLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/SubsequentEvents" xlink:title="999032 - Disclosure - Subsequent events" />
    <link:definitionLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/SegmentReporting" xlink:title="999033 - Disclosure - Segment Reporting" />
    <link:definitionLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/SignificantAccountingPoliciesPolicies" xlink:title="999034 - Disclosure - Significant Accounting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/SignificantAccountingPoliciesTables" xlink:title="999035 - Disclosure - Significant Accounting Policies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/MarketableDebtSecuritiesTables" xlink:title="999036 - Disclosure - Marketable debt securities (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/OtherReceivablesTables" xlink:title="999037 - Disclosure - Other Receivables (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/PropertyAndEquipmentNetTables" xlink:title="999038 - Disclosure - Property and equipment, net (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/InvestmentInAssociateTables" xlink:title="999039 - Disclosure - Investment in an Associate (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/OtherPayablesTables" xlink:title="999040 - Disclosure - Other Payables (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/StockholdersEquityTables" xlink:title="999041 - Disclosure - Stockholders&#8217; equity (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/ResearchAndDevelopmentExpensesTables" xlink:title="999042 - Disclosure - Research and Development Expenses (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/GeneralAndAdministrativeExpensesTables" xlink:title="999043 - Disclosure - General and Administrative Expenses (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/FinancialIncomeNetTables" xlink:title="999044 - Disclosure - Financial income, net (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/IncomeTaxesTables" xlink:title="999045 - Disclosure - Income Taxes (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/GeneralDetailsNarrative" xlink:title="999046 - Disclosure - General (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentDetails" xlink:title="999047 - Disclosure - Schedule of Depreciation Rates for Property, Plant and Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_OfficeFurnitureAndEquipmentMember" xlink:label="loc_GLMDOfficeFurnitureAndEquipmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_GLMDOfficeFurnitureAndEquipmentMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_ComputerSoftwareElectronicEquipmentMember" xlink:label="loc_GLMDComputerSoftwareElectronicEquipmentMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_GLMDComputerSoftwareElectronicEquipmentMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" xlink:label="loc_us-gaapPropertyPlantAndEquipmentSalvageValuePercentage_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentSalvageValuePercentage_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDepreciationMethodExtensibleEnumeration" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDepreciationMethodExtensibleEnumeration_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDepreciationMethodExtensibleEnumeration_60" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/ScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:title="999048 - Disclosure - Schedule of Assets Measured at Fair Value on Recurring Basis (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaapFairValueByMeasurementFrequencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaapFairValueMeasurementsRecurringMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:to="loc_us-gaapFairValueMeasurementsRecurringMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaapCorporateDebtSecuritiesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapCorporateDebtSecuritiesMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaapUSTreasurySecuritiesMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapUSTreasurySecuritiesMember_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MutualFundMember" xlink:label="loc_us-gaapMutualFundMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapMutualFundMember_80" xlink:type="arc" order="83" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_InvestmentInAssociateMember" xlink:label="loc_GLMDInvestmentInAssociateMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_GLMDInvestmentInAssociateMember_120" xlink:type="arc" order="123" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaapAssetsFairValueDisclosure_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapAssetsFairValueDisclosure_410" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/SignificantAccountingPoliciesDetailsNarrative" xlink:title="999049 - Disclosure - Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentInterestRate" xlink:label="loc_us-gaapInvestmentInterestRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapInvestmentInterestRate_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDepreciation_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_MonthlyDepositsOfEmployeesPercentageOnMonthlySalary" xlink:label="loc_GLMDMonthlyDepositsOfEmployeesPercentageOnMonthlySalary_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_GLMDMonthlyDepositsOfEmployeesPercentageOnMonthlySalary_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDescription" xlink:label="loc_GLMDShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDescription_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_GLMDShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDescription_70" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/ScheduleOfMarketableDebtSecuritiesDetails" xlink:title="999050 - Disclosure - Schedule of Marketable Debt Securities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:label="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:label="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaapCorporateDebtSecuritiesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapCorporateDebtSecuritiesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaapUSTreasurySecuritiesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapUSTreasurySecuritiesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MutualFundMember" xlink:label="loc_us-gaapMutualFundMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapMutualFundMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaapAvailableForSaleDebtSecuritiesAmortizedCostBasis_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapAvailableForSaleDebtSecuritiesAmortizedCostBasis_170" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:label="loc_us-gaapAvailableForSaleDebtSecuritiesGrossUnrealizedGain_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapAvailableForSaleDebtSecuritiesGrossUnrealizedGain_170" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:label="loc_us-gaapAvailableForSaleDebtSecuritiesGrossUnrealizedLoss_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapAvailableForSaleDebtSecuritiesGrossUnrealizedLoss_170" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaapAvailableForSaleSecuritiesDebtSecurities_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapAvailableForSaleSecuritiesDebtSecurities_170" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/ScheduleOfOtherReceivablesDetails" xlink:title="999051 - Disclosure - Schedule of Other Receivables (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/LeasesDetailsNarrative" xlink:title="999052 - Disclosure - Leases (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:title="999053 - Disclosure - Schedule of Property and Equipment (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/ScheduleOfBalanceSheetsDetails" xlink:title="999054 - Disclosure - Schedule of Balance Sheets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_OnkaiIncMember" xlink:label="loc_GLMDOnkaiIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_GLMDOnkaiIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsCurrent_20" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsNoncurrent_20" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesCurrent_20" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesNoncurrent_20" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_20" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/ScheduleOfStatementOfOperationsDetails" xlink:title="999055 - Disclosure - Schedule of Statement of Operations (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_OnkaiIncMember" xlink:label="loc_GLMDOnkaiIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_GLMDOnkaiIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingExpenses_20" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNonoperatingIncomeExpense_20" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit_20" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_20" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/InvestmentInAssociateDetailsNarrative" xlink:title="999056 - Disclosure - Investment in an Associate (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_OnkaiIncMember" xlink:label="loc_GLMDOnkaiIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_GLMDOnkaiIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdministrativeServiceMember" xlink:label="loc_us-gaapAdministrativeServiceMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapAdministrativeServiceMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_BridgeLoanAgreementMember" xlink:label="loc_GLMDBridgeLoanAgreementMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GLMDBridgeLoanAgreementMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_ServicesAgreementMember" xlink:label="loc_GLMDServicesAgreementMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GLMDServicesAgreementMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_CapitalStockDiscountRate" xlink:label="loc_GLMDCapitalStockDiscountRate_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GLMDCapitalStockDiscountRate_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaapGainLossOnInvestments_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGainLossOnInvestments_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaapPaymentsToAcquireInvestments_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsToAcquireInvestments_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentOwnedBalanceShares" xlink:label="loc_us-gaapInvestmentOwnedBalanceShares_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInvestmentOwnedBalanceShares_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentOwnedPercentOfNetAssets" xlink:label="loc_us-gaapInvestmentOwnedPercentOfNetAssets_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInvestmentOwnedPercentOfNetAssets_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense_110" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_110" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage_110" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromOtherDebt" xlink:label="loc_us-gaapProceedsFromOtherDebt_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromOtherDebt_110" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaapRepaymentsOfDebt_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRepaymentsOfDebt_110" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaapAssetImpairmentCharges_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetImpairmentCharges_110" xlink:type="arc" order="11" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/ScheduleOfOtherPayablesDetails" xlink:title="999057 - Disclosure - Schedule of Other Payables (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/RelatedPartiesDetailsNarrative" xlink:title="999058 - Disclosure - Related Parties (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_OfficersAndDirectorsMember" xlink:label="loc_GLMDOfficersAndDirectorsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_GLMDOfficersAndDirectorsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_ServiceAgreementMember" xlink:label="loc_GLMDServiceAgreementMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GLMDServiceAgreementMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapOtherLiabilitiesCurrent_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaapLongTermDebt_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapLongTermDebt_80" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999059 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLossContingenciesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_BankLienOnMarketableSecurities" xlink:label="loc_GLMDBankLienOnMarketableSecurities_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GLMDBankLienOnMarketableSecurities_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_UpfrontLicenseFee" xlink:label="loc_GLMDUpfrontLicenseFee_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GLMDUpfrontLicenseFee_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_PaymentsToRegulatoryMilestones" xlink:label="loc_GLMDPaymentsToRegulatoryMilestones_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GLMDPaymentsToRegulatoryMilestones_40" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/SummaryOfStatusOfCompanysOptionPlansAndChangesDetails" xlink:title="999060 - Disclosure - Summary of Status of Company&apos;s Option Plans and Changes (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityEquityTable" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_60" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/StockholdersEquityDetailsNarrative" xlink:title="999061 - Disclosure - Stockholders&#8217; equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_NewSalesAgreementMember" xlink:label="loc_GLMDNewSalesAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GLMDNewSalesAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_StandbyEquityPurchaseAgreementMember" xlink:label="loc_GLMDStandbyEquityPurchaseAgreementMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GLMDStandbyEquityPurchaseAgreementMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_CaymanIslandsExemptLimitedPartnershipMember" xlink:label="loc_GLMDCaymanIslandsExemptLimitedPartnershipMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GLMDCaymanIslandsExemptLimitedPartnershipMember_240" xlink:type="arc" order="242" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_DemandSalesAgreementMember" xlink:label="loc_GLMDDemandSalesAgreementMember_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GLMDDemandSalesAgreementMember_260" xlink:type="arc" order="261" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_TwoThousandAndTwentySalesAgreementMember" xlink:label="loc_GLMDTwoThousandAndTwentySalesAgreementMember_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GLMDTwoThousandAndTwentySalesAgreementMember_270" xlink:type="arc" order="271" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_PrefundedWarrantsMember" xlink:label="loc_GLMDPrefundedWarrantsMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_GLMDPrefundedWarrantsMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_InvestorWarrantsMember" xlink:label="loc_GLMDInvestorWarrantsMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_GLMDInvestorWarrantsMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaapInvestorMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapInvestorMember_160" xlink:type="arc" order="163" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_190" xlink:type="arc" order="192" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_440" xlink:type="arc" order="441" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_IncentiveShareOptionPlan2013Member" xlink:label="loc_GLMDIncentiveShareOptionPlan2013Member_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_GLMDIncentiveShareOptionPlan2013Member_280" xlink:type="arc" order="281" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_320" xlink:type="arc" order="321" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_400" xlink:type="arc" order="401" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srtChiefExecutiveOfficerMember_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefExecutiveOfficerMember_350" xlink:type="arc" order="351" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionMember" xlink:label="loc_us-gaapOptionMember_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapOptionMember_390" xlink:type="arc" order="391" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_MaximumAmountOfSharesToBeIssued" xlink:label="loc_GLMDMaximumAmountOfSharesToBeIssued_610" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_GLMDMaximumAmountOfSharesToBeIssued_610" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_610" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_610" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_610" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_610" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit_610" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit_610" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockNoParValue" xlink:label="loc_us-gaapCommonStockNoParValue_610" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockNoParValue_610" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_610" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_610" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_610" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_610" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1_610" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapConversionOfStockSharesIssued1_610" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_610" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharePrice_610" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_610" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_610" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfDebtIssuanceCosts_610" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPaymentsOfDebtIssuanceCosts_610" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantExercisePriceIncrease" xlink:label="loc_us-gaapWarrantExercisePriceIncrease_610" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapWarrantExercisePriceIncrease_610" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_610" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_610" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_610" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_610" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaapOtherCommitment_610" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapOtherCommitment_610" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="loc_us-gaapDebtInstrumentFeeAmount_610" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapDebtInstrumentFeeAmount_610" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_CommitmentShare" xlink:label="loc_GLMDCommitmentShare_610" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_GLMDCommitmentShare_610" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_ProceedsFinanceLeaseInterestExpenseIncome" xlink:label="loc_GLMDProceedsFinanceLeaseInterestExpenseIncome_610" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_GLMDProceedsFinanceLeaseInterestExpenseIncome_610" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpenses" xlink:label="loc_us-gaapOtherExpenses_610" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapOtherExpenses_610" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_610" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_610" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_610" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_610" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_610" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_610" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_CommonStockCapitalSharesReservedForFutureIssuanceUnallocated" xlink:label="loc_GLMDCommonStockCapitalSharesReservedForFutureIssuanceUnallocated_610" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_GLMDCommonStockCapitalSharesReservedForFutureIssuanceUnallocated_610" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_610" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_610" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_610" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_610" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_610" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_610" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_610" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_610" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_610" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_610" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_610" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_610" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_610" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_610" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_610" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_610" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_610" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_610" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_610" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_610" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_610" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_610" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_610" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_610" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_610" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_610" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_610" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_610" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_610" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_610" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_610" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_610" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_610" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_610" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_610" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_610" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_610" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_610" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_610" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_610" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_610" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_610" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther_610" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther_610" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_610" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_610" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_610" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_610" xlink:type="arc" order="46" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/ScheduleOfResearchAndDevelopmentExpensesDetails" xlink:title="999062 - Disclosure - Schedule of Research and Development Expenses (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_ChemistryAndFormulationStudiesMember" xlink:label="loc_GLMDChemistryAndFormulationStudiesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_GLMDChemistryAndFormulationStudiesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_SalariesMember" xlink:label="loc_GLMDSalariesMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_GLMDSalariesMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_StockBasedCompensationMember" xlink:label="loc_GLMDStockBasedCompensationMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_GLMDStockBasedCompensationMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_ResearchAndPreclinicalStudiesMember" xlink:label="loc_GLMDResearchAndPreclinicalStudiesMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_GLMDResearchAndPreclinicalStudiesMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_ClinicalStudiesMember" xlink:label="loc_GLMDClinicalStudiesMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_GLMDClinicalStudiesMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_RegulatoryAndOtherExpensesMember" xlink:label="loc_GLMDRegulatoryAndOtherExpensesMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_GLMDRegulatoryAndOtherExpensesMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_220" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/ScheduleOfGeneralAndAdministrativeExpensesDetails" xlink:title="999063 - Disclosure - Schedule of General and Administrative Expenses (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_StockBasedCompensationMember" xlink:label="loc_GLMDStockBasedCompensationMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_GLMDStockBasedCompensationMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_ProfessionalFeeMember" xlink:label="loc_GLMDProfessionalFeeMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_GLMDProfessionalFeeMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_SalariesAndBenefitsMember" xlink:label="loc_GLMDSalariesAndBenefitsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_GLMDSalariesAndBenefitsMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_RentAndOfficeMaintenanceFeesMember" xlink:label="loc_GLMDRentAndOfficeMaintenanceFeesMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_GLMDRentAndOfficeMaintenanceFeesMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_InsuranceAndOtherExpensesMember" xlink:label="loc_GLMDInsuranceAndOtherExpensesMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_GLMDInsuranceAndOtherExpensesMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense_190" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/ScheduleOfFinancialIncomeNetDetails" xlink:title="999064 - Disclosure - Schedule of Financial Income, Net (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:title="999065 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/IncomeTaxesDetailsNarrative" xlink:title="999066 - Disclosure - Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityNameAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityNameAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IsraelTaxAuthorityMember" xlink:label="loc_us-gaapIsraelTaxAuthorityMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:to="loc_us-gaapIsraelTaxAuthorityMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_MalteseSubsidiaryMember" xlink:label="loc_GLMDMalteseSubsidiaryMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:to="loc_GLMDMalteseSubsidiaryMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_MalteseSubsidiaryMember" xlink:label="loc_GLMDMalteseSubsidiaryMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_GLMDMalteseSubsidiaryMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_IsraeliSubsidiaryMember" xlink:label="loc_GLMDIsraeliSubsidiaryMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_GLMDIsraeliSubsidiaryMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RegulatoryAssetAxis" xlink:label="loc_us-gaapRegulatoryAssetAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapRegulatoryAssetAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RegulatoryAssetDomain" xlink:label="loc_us-gaapRegulatoryAssetDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRegulatoryAssetAxis" xlink:to="loc_us-gaapRegulatoryAssetDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RegulatoryAssetDomain" xlink:label="loc_us-gaapRegulatoryAssetDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRegulatoryAssetAxis" xlink:to="loc_us-gaapRegulatoryAssetDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxChargesMember" xlink:label="loc_us-gaapDeferredIncomeTaxChargesMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRegulatoryAssetDomain" xlink:to="loc_us-gaapDeferredIncomeTaxChargesMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsCapitalLossCarryforwards_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsCapitalLossCarryforwards_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_110" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/SubsequentEventsDetailsNarrative" xlink:title="999067 - Disclosure - Subsequent events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_TwoThousandAndTwentySalesAgreementMember" xlink:label="loc_GLMDTwoThousandAndTwentySalesAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GLMDTwoThousandAndTwentySalesAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_CaymanIslandsExemptLimitedPartnershipMember" xlink:label="loc_GLMDCaymanIslandsExemptLimitedPartnershipMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GLMDCaymanIslandsExemptLimitedPartnershipMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_CaymanIslandsExemptLimitedPartnershipMember" xlink:label="loc_GLMDCaymanIslandsExemptLimitedPartnershipMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_GLMDCaymanIslandsExemptLimitedPartnershipMember_20" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_50" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/SegmentReportingDetailsNarrative" xlink:title="999068 - Disclosure - Segment Reporting (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" order="1000" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationMethodDomain" xlink:label="loc_us-gaapDepreciationMethodDomain" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember" xlink:label="loc_us-gaapUsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDepreciationMethodDomain" xlink:to="loc_us-gaapUsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember" xlink:type="arc" order="1001" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaapLiabilitiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" order="1002" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>18
<FILENAME>glmd-20241231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_EntityAddressesAddressTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesAddressTypeAxis_lbl" xml:lang="en-US">Entity Addresses, Address Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember" xlink:label="dei_BusinessContactMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_BusinessContactMember_lbl" xml:lang="en-US">Business Contact [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Restricted Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_OfficeFurnitureAndEquipmentMember" xlink:label="GLMD_OfficeFurnitureAndEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_OfficeFurnitureAndEquipmentMember" xlink:to="GLMD_OfficeFurnitureAndEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GLMD_OfficeFurnitureAndEquipmentMember_lbl" xml:lang="en-US">Office Furniture and Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_ComputerSoftwareElectronicEquipmentMember" xlink:label="GLMD_ComputerSoftwareElectronicEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_ComputerSoftwareElectronicEquipmentMember" xlink:to="GLMD_ComputerSoftwareElectronicEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GLMD_ComputerSoftwareElectronicEquipmentMember_lbl" xml:lang="en-US">Computer Software and Electronic Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US">Financial Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xml:lang="en-US">US Treasury Securities [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MutualFundMember" xlink:label="us-gaap_MutualFundMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MutualFundMember" xlink:to="us-gaap_MutualFundMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MutualFundMember_lbl" xml:lang="en-US">Mutual Fund [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_InvestmentInAssociateMember" xlink:label="GLMD_InvestmentInAssociateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_InvestmentInAssociateMember" xlink:to="GLMD_InvestmentInAssociateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GLMD_InvestmentInAssociateMember_lbl" xml:lang="en-US">Investment In Associate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title and Position [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_OnkaiIncMember" xlink:label="GLMD_OnkaiIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_OnkaiIncMember" xlink:to="GLMD_OnkaiIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GLMD_OnkaiIncMember_lbl" xml:lang="en-US">Onkai Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdministrativeServiceMember" xlink:label="us-gaap_AdministrativeServiceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdministrativeServiceMember" xlink:to="us-gaap_AdministrativeServiceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdministrativeServiceMember_lbl" xml:lang="en-US">Administrative Service [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_BridgeLoanAgreementMember" xlink:label="GLMD_BridgeLoanAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_BridgeLoanAgreementMember" xlink:to="GLMD_BridgeLoanAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GLMD_BridgeLoanAgreementMember_lbl" xml:lang="en-US">Bridge Loan Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_ServicesAgreementMember" xlink:label="GLMD_ServicesAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_ServicesAgreementMember" xlink:to="GLMD_ServicesAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GLMD_ServicesAgreementMember_lbl" xml:lang="en-US">Services Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_OfficersAndDirectorsMember" xlink:label="GLMD_OfficersAndDirectorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_OfficersAndDirectorsMember" xlink:to="GLMD_OfficersAndDirectorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GLMD_OfficersAndDirectorsMember_lbl" xml:lang="en-US">Officers And Directors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_ServiceAgreementMember" xlink:label="GLMD_ServiceAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_ServiceAgreementMember" xlink:to="GLMD_ServiceAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GLMD_ServiceAgreementMember_lbl" xml:lang="en-US">Service Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_NewSalesAgreementMember" xlink:label="GLMD_NewSalesAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_NewSalesAgreementMember" xlink:to="GLMD_NewSalesAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GLMD_NewSalesAgreementMember_lbl" xml:lang="en-US">New Sales Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_PrefundedWarrantsMember" xlink:label="GLMD_PrefundedWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_PrefundedWarrantsMember" xlink:to="GLMD_PrefundedWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GLMD_PrefundedWarrantsMember_lbl" xml:lang="en-US">Prefunded Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_InvestorWarrantsMember" xlink:label="GLMD_InvestorWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_InvestorWarrantsMember" xlink:to="GLMD_InvestorWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GLMD_InvestorWarrantsMember_lbl" xml:lang="en-US">Investor Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestorMember" xlink:label="us-gaap_InvestorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestorMember" xlink:to="us-gaap_InvestorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestorMember_lbl" xml:lang="en-US">Investor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_StandbyEquityPurchaseAgreementMember" xlink:label="GLMD_StandbyEquityPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_StandbyEquityPurchaseAgreementMember" xlink:to="GLMD_StandbyEquityPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GLMD_StandbyEquityPurchaseAgreementMember_lbl" xml:lang="en-US">Standby Equity Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_CaymanIslandsExemptLimitedPartnershipMember" xlink:label="GLMD_CaymanIslandsExemptLimitedPartnershipMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_CaymanIslandsExemptLimitedPartnershipMember" xlink:to="GLMD_CaymanIslandsExemptLimitedPartnershipMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GLMD_CaymanIslandsExemptLimitedPartnershipMember_lbl" xml:lang="en-US">Cayman Islands Exempt Limited Partnership [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_DemandSalesAgreementMember" xlink:label="GLMD_DemandSalesAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_DemandSalesAgreementMember" xlink:to="GLMD_DemandSalesAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GLMD_DemandSalesAgreementMember_lbl" xml:lang="en-US">Demand Sales Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_TwoThousandAndTwentySalesAgreementMember" xlink:label="GLMD_TwoThousandAndTwentySalesAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_TwoThousandAndTwentySalesAgreementMember" xlink:to="GLMD_TwoThousandAndTwentySalesAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GLMD_TwoThousandAndTwentySalesAgreementMember_lbl" xml:lang="en-US">Two Thousand And Twenty Sales Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_IncentiveShareOptionPlan2013Member" xlink:label="GLMD_IncentiveShareOptionPlan2013Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_IncentiveShareOptionPlan2013Member" xlink:to="GLMD_IncentiveShareOptionPlan2013Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GLMD_IncentiveShareOptionPlan2013Member_lbl" xml:lang="en-US">Incentive Share Option Plan2013 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US">Chief Executive Officer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionMember" xlink:label="us-gaap_OptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionMember" xlink:to="us-gaap_OptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionMember_lbl" xml:lang="en-US">Options Held [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityEquityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityAxis_lbl" xml:lang="en-US">Option Indexed to Issuer's Equity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_ChemistryAndFormulationStudiesMember" xlink:label="GLMD_ChemistryAndFormulationStudiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_ChemistryAndFormulationStudiesMember" xlink:to="GLMD_ChemistryAndFormulationStudiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GLMD_ChemistryAndFormulationStudiesMember_lbl" xml:lang="en-US">Chemistry And Formulation Studies [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_SalariesMember" xlink:label="GLMD_SalariesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_SalariesMember" xlink:to="GLMD_SalariesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GLMD_SalariesMember_lbl" xml:lang="en-US">Salaries [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_StockBasedCompensationMember" xlink:label="GLMD_StockBasedCompensationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_StockBasedCompensationMember" xlink:to="GLMD_StockBasedCompensationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GLMD_StockBasedCompensationMember_lbl" xml:lang="en-US">Stock Based Compensation [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_ResearchAndPreclinicalStudiesMember" xlink:label="GLMD_ResearchAndPreclinicalStudiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_ResearchAndPreclinicalStudiesMember" xlink:to="GLMD_ResearchAndPreclinicalStudiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GLMD_ResearchAndPreclinicalStudiesMember_lbl" xml:lang="en-US">Research And Preclinical Studies [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_ClinicalStudiesMember" xlink:label="GLMD_ClinicalStudiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_ClinicalStudiesMember" xlink:to="GLMD_ClinicalStudiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GLMD_ClinicalStudiesMember_lbl" xml:lang="en-US">Clinical Studies [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_RegulatoryAndOtherExpensesMember" xlink:label="GLMD_RegulatoryAndOtherExpensesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_RegulatoryAndOtherExpensesMember" xlink:to="GLMD_RegulatoryAndOtherExpensesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GLMD_RegulatoryAndOtherExpensesMember_lbl" xml:lang="en-US">Regulatory And Other Expenses [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_ProfessionalFeeMember" xlink:label="GLMD_ProfessionalFeeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_ProfessionalFeeMember" xlink:to="GLMD_ProfessionalFeeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GLMD_ProfessionalFeeMember_lbl" xml:lang="en-US">Professional Fees [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_SalariesAndBenefitsMember" xlink:label="GLMD_SalariesAndBenefitsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_SalariesAndBenefitsMember" xlink:to="GLMD_SalariesAndBenefitsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GLMD_SalariesAndBenefitsMember_lbl" xml:lang="en-US">Salaries And Benefits [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_RentAndOfficeMaintenanceFeesMember" xlink:label="GLMD_RentAndOfficeMaintenanceFeesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_RentAndOfficeMaintenanceFeesMember" xlink:to="GLMD_RentAndOfficeMaintenanceFeesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GLMD_RentAndOfficeMaintenanceFeesMember_lbl" xml:lang="en-US">Rent And Office Maintenance Fees [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_InsuranceAndOtherExpensesMember" xlink:label="GLMD_InsuranceAndOtherExpensesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_InsuranceAndOtherExpensesMember" xlink:to="GLMD_InsuranceAndOtherExpensesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GLMD_InsuranceAndOtherExpensesMember_lbl" xml:lang="en-US">Insurance And Other Expenses [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IsraelTaxAuthorityMember" xlink:label="us-gaap_IsraelTaxAuthorityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IsraelTaxAuthorityMember" xlink:to="us-gaap_IsraelTaxAuthorityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IsraelTaxAuthorityMember_lbl" xml:lang="en-US">Israel Tax Authority [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_MalteseSubsidiaryMember" xlink:label="GLMD_MalteseSubsidiaryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_MalteseSubsidiaryMember" xlink:to="GLMD_MalteseSubsidiaryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GLMD_MalteseSubsidiaryMember_lbl" xml:lang="en-US">Maltese Subsidiary [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_IsraeliSubsidiaryMember" xlink:label="GLMD_IsraeliSubsidiaryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_IsraeliSubsidiaryMember" xlink:to="GLMD_IsraeliSubsidiaryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GLMD_IsraeliSubsidiaryMember_lbl" xml:lang="en-US">Israeli Subsidiary [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RegulatoryAssetAxis" xlink:label="us-gaap_RegulatoryAssetAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RegulatoryAssetAxis" xlink:to="us-gaap_RegulatoryAssetAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RegulatoryAssetAxis_lbl" xml:lang="en-US">Regulatory Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxChargesMember" xlink:label="us-gaap_DeferredIncomeTaxChargesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxChargesMember" xlink:to="us-gaap_DeferredIncomeTaxChargesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxChargesMember_lbl" xml:lang="en-US">Deferred Income Tax Charge [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesTable" xlink:label="dei_EntityAddressesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesTable" xlink:to="dei_EntityAddressesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesTable_lbl" xml:lang="en-US">Entity Addresses [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesLineItems" xlink:label="dei_EntityAddressesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesLineItems" xlink:to="dei_EntityAddressesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesLineItems_lbl" xml:lang="en-US">Entity Addresses [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelName" xlink:label="dei_ContactPersonnelName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelName" xlink:to="dei_ContactPersonnelName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_ContactPersonnelName_lbl" xml:lang="en-US">Contact Personnel Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelEmailAddress" xlink:label="dei_ContactPersonnelEmailAddress" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelEmailAddress" xlink:to="dei_ContactPersonnelEmailAddress_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_ContactPersonnelEmailAddress_lbl" xml:lang="en-US">Contact Personnel Email Address</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorOpinionTextBlock" xlink:to="dei_AuditorOpinionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorOpinionTextBlock_lbl" xml:lang="en-US">Auditor Opinion [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xml:lang="en-US">Restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="us-gaap_DepositsAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsCurrent" xlink:to="us-gaap_DepositsAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsCurrent_lbl" xml:lang="en-US">Short-term deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xml:lang="en-US">Marketable debt securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xml:lang="en-US">Other receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:label="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:to="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_lbl" xml:lang="en-US">Investment in associate at fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Loan to associate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">Total non-current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Trade payables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLoansPayableCurrent" xlink:label="us-gaap_OtherLoansPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLoansPayableCurrent" xlink:to="us-gaap_OtherLoansPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLoansPayableCurrent_lbl" xml:lang="en-US">Other payables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Ordinary shares, par value NIS 1.80 per share; Authorized 50,000,000 shares; Issued and outstanding: 1,664,884 and 573,741 shares as of December 31, 2024 and December 31, 2023, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Ordinary shares, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Ordinary shares, authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Ordinary shares, issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Ordinary shares, outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Reverse stock split</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Financial loss (income), net</link:label>
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_FinancialExpenses" xlink:label="GLMD_FinancialExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_FinancialExpenses" xlink:to="GLMD_FinancialExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GLMD_FinancialExpenses_lbl" xml:lang="en-US">Financial expenses related to SEPA</link:label>
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_ImpairmentOnAssociate" xlink:label="GLMD_ImpairmentOnAssociate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_ImpairmentOnAssociate" xlink:to="GLMD_ImpairmentOnAssociate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GLMD_ImpairmentOnAssociate_lbl" xml:lang="en-US">Impairment on associate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Basic, net loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Diluted, net loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average number of shares outstanding used in computing net loss per share, basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average number of shares outstanding used in computing net loss per share, diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl" xml:lang="en-US">Other comprehensive loss:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_lbl" xml:lang="en-US">Net unrealized loss (gain) on available for sale securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of ordinary shares in ATM offering net of issuance costs of $2</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of ordinary shares in at-the-market ("ATM") offering, net of issuance costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US">Unrealized gain from marketable debt securities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_StockIssuedDuringPeriodValueOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts" xlink:label="GLMD_StockIssuedDuringPeriodValueOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_StockIssuedDuringPeriodValueOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts" xlink:to="GLMD_StockIssuedDuringPeriodValueOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GLMD_StockIssuedDuringPeriodValueOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts_lbl" xml:lang="en-US">Issuance of ordinary shares, pre-funded warrants, and warrants net of issuance costs of $756 thousand</link:label>
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_StockIssuedDuringPeriodSharesOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts" xlink:label="GLMD_StockIssuedDuringPeriodSharesOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_StockIssuedDuringPeriodSharesOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts" xlink:to="GLMD_StockIssuedDuringPeriodSharesOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GLMD_StockIssuedDuringPeriodSharesOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts_lbl" xml:lang="en-US">Issuance of ordinary shares, pre-funded warrants, and warrants net of issuance costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_ExerciseOfPrefundedWarrants" xlink:label="GLMD_ExerciseOfPrefundedWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_ExerciseOfPrefundedWarrants" xlink:to="GLMD_ExerciseOfPrefundedWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GLMD_ExerciseOfPrefundedWarrants_lbl" xml:lang="en-US">Exercise of Pre-funded warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_ExerciseOfPrefundedWarrantsShares" xlink:label="GLMD_ExerciseOfPrefundedWarrantsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_ExerciseOfPrefundedWarrantsShares" xlink:to="GLMD_ExerciseOfPrefundedWarrantsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GLMD_ExerciseOfPrefundedWarrantsShares_lbl" xml:lang="en-US">Exercise of Pre-funded warrants, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xml:lang="en-US">Issuance of ordinary shares in relation to SEPA</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US">Issuance of ordinary shares in relation to SEPA, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Issuance of SEPA Commitment Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Issuance of SEPA Commitment Shares, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US">Exercise of RSUs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Exercise of RSUs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:label="GLMD_StockIssuedDuringPeriodValueExerciseOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:to="GLMD_StockIssuedDuringPeriodValueExerciseOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GLMD_StockIssuedDuringPeriodValueExerciseOfWarrants_lbl" xml:lang="en-US">Exercise of Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="GLMD_StockIssuedDuringPeriodSharesExerciseOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:to="GLMD_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GLMD_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl" xml:lang="en-US">Exercise of Warrants, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Stock issuance cost</link:label>
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_WarrantsNetOfIssuanceCosts" xlink:label="GLMD_WarrantsNetOfIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_WarrantsNetOfIssuanceCosts" xlink:to="GLMD_WarrantsNetOfIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GLMD_WarrantsNetOfIssuanceCosts_lbl" xml:lang="en-US">Warrants net of issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flow from operating activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_4_lbl" xml:lang="en-US">Net loss for the year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments required to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Amortization of discount (premium) on marketable debt securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfInvestments" xlink:label="us-gaap_GainLossOnSaleOfInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfInvestments" xlink:to="us-gaap_GainLossOnSaleOfInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfInvestments_lbl" xml:lang="en-US">Gain on sale of marketable debt securities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_FinancialExpenses" xlink:to="GLMD_FinancialExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="GLMD_FinancialExpenses_2_lbl" xml:lang="en-US">Finance expenses related to SEPA</link:label>
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_ProceedsFinanceLeaseInterestExpenseIncome" xlink:label="GLMD_ProceedsFinanceLeaseInterestExpenseIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_ProceedsFinanceLeaseInterestExpenseIncome" xlink:to="GLMD_ProceedsFinanceLeaseInterestExpenseIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GLMD_ProceedsFinanceLeaseInterestExpenseIncome_lbl" xml:lang="en-US">Finance expenses (income)</link:label>
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_DecreaseInShorttermDeposits" xlink:label="GLMD_DecreaseInShorttermDeposits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_DecreaseInShorttermDeposits" xlink:to="GLMD_DecreaseInShorttermDeposits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="GLMD_DecreaseInShorttermDeposits_lbl" xml:lang="en-US">Decrease in short-term deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xml:lang="en-US">Interest income from loan to associate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetImpairmentCharges" xlink:label="us-gaap_OtherAssetImpairmentCharges" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetImpairmentCharges" xlink:to="us-gaap_OtherAssetImpairmentCharges_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetImpairmentCharges_lbl" xml:lang="en-US">Impairment of Associate</link:label>
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_ChangeInFairValueConvertibleNote" xlink:label="GLMD_ChangeInFairValueConvertibleNote" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_ChangeInFairValueConvertibleNote" xlink:to="GLMD_ChangeInFairValueConvertibleNote_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="GLMD_ChangeInFairValueConvertibleNote_lbl" xml:lang="en-US">Change in fair value convertible note</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_lbl" xml:lang="en-US">Decrease (increase) in other receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xml:lang="en-US">Decrease in trade payables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable_lbl" xml:lang="en-US">Increase (decrease) in other payables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flow from investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_PaymentsForInvestmentInAvailableForSaleSecurities" xlink:label="GLMD_PaymentsForInvestmentInAvailableForSaleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_PaymentsForInvestmentInAvailableForSaleSecurities" xlink:to="GLMD_PaymentsForInvestmentInAvailableForSaleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="GLMD_PaymentsForInvestmentInAvailableForSaleSecurities_lbl" xml:lang="en-US">Investment in available for sale securities,</link:label>
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_PaymentsForProceedsFromInvestmentInConvertibleNote" xlink:label="GLMD_PaymentsForProceedsFromInvestmentInConvertibleNote" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_PaymentsForProceedsFromInvestmentInConvertibleNote" xlink:to="GLMD_PaymentsForProceedsFromInvestmentInConvertibleNote_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="GLMD_PaymentsForProceedsFromInvestmentInConvertibleNote_lbl" xml:lang="en-US">Investment in Convertible note</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xml:lang="en-US">Loan to associate</link:label>
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_PaymentsForProceedsFromInvestmentInAssociate" xlink:label="GLMD_PaymentsForProceedsFromInvestmentInAssociate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_PaymentsForProceedsFromInvestmentInAssociate" xlink:to="GLMD_PaymentsForProceedsFromInvestmentInAssociate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="GLMD_PaymentsForProceedsFromInvestmentInAssociate_lbl" xml:lang="en-US">Investment in Associate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_lbl" xml:lang="en-US">Proceeds from sale of available for sale securities,</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromOtherDeposits" xlink:label="us-gaap_PaymentsForProceedsFromOtherDeposits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromOtherDeposits" xlink:to="us-gaap_PaymentsForProceedsFromOtherDeposits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForProceedsFromOtherDeposits_lbl" xml:lang="en-US">Proceeds from (investment in) short-term deposits, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flow from financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Issuance of ordinary shares in at-the-market offering, net of issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Issuance of ordinary shares in relation to SEPA</link:label>
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_IssuanceOfOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts" xlink:label="GLMD_IssuanceOfOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_IssuanceOfOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts" xlink:to="GLMD_IssuanceOfOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="GLMD_IssuanceOfOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts_lbl" xml:lang="en-US">Issuance of ordinary shares, pre-funded warrants, and warrants net of issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Increase (decrease) in cash, cash equivalents and restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Cash and cash equivalents and restricted cash at the beginning of the year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xml:lang="en-US">Cash, cash equivalents and restricted cash at the end of the year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash received from interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Non-cash investing and financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_ConversionOfConvertibleNoteIntoInvestmentInAssociate" xlink:label="GLMD_ConversionOfConvertibleNoteIntoInvestmentInAssociate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_ConversionOfConvertibleNoteIntoInvestmentInAssociate" xlink:to="GLMD_ConversionOfConvertibleNoteIntoInvestmentInAssociate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GLMD_ConversionOfConvertibleNoteIntoInvestmentInAssociate_lbl" xml:lang="en-US">Conversion of convertible note into investment in associate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable" xlink:label="ecd_PvpTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTable" xlink:to="ecd_PvpTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTable_lbl" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis" xlink:label="ecd_ExecutiveCategoryAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ExecutiveCategoryAxis" xlink:to="ecd_ExecutiveCategoryAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ExecutiveCategoryAxis_lbl" xml:lang="en-US">Executive Category [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="ecd_IndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_IndividualAxis" xlink:to="ecd_IndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_IndividualAxis_lbl" xml:lang="en-US">Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis" xlink:label="ecd_AdjToCompAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAxis" xlink:to="ecd_AdjToCompAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAxis_lbl" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis" xlink:label="ecd_MeasureAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureAxis" xlink:to="ecd_MeasureAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureAxis_lbl" xml:lang="en-US">Measure [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock" xlink:label="ecd_PvpTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTableTextBlock" xlink:to="ecd_PvpTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTableTextBlock_lbl" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName" xlink:label="ecd_CoSelectedMeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureName" xlink:to="ecd_CoSelectedMeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureName_lbl" xml:lang="en-US">Company Selected Measure Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="ecd_PeerGroupIssuersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupIssuersFnTextBlock" xlink:to="ecd_PeerGroupIssuersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupIssuersFnTextBlock_lbl" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="ecd_ChangedPeerGroupFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ChangedPeerGroupFnTextBlock" xlink:to="ecd_ChangedPeerGroupFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ChangedPeerGroupFnTextBlock_lbl" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt" xlink:label="ecd_PeoTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoTotalCompAmt" xlink:to="ecd_PeoTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoTotalCompAmt_lbl" xml:lang="en-US">PEO Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="ecd_PeoActuallyPaidCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoActuallyPaidCompAmt" xlink:to="ecd_PeoActuallyPaidCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoActuallyPaidCompAmt_lbl" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="ecd_AdjToPeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToPeoCompFnTextBlock" xlink:to="ecd_AdjToPeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToPeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock" xlink:label="ecd_TabularListTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TabularListTableTextBlock" xlink:to="ecd_TabularListTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TabularListTableTextBlock_lbl" xml:lang="en-US">Tabular List, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt" xlink:label="ecd_TotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnAmt" xlink:to="ecd_TotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnAmt_lbl" xml:lang="en-US">Total Shareholder Return Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_5_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_5_lbl" xml:lang="en-US">Net Income (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt" xlink:label="ecd_CoSelectedMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureAmt" xlink:to="ecd_CoSelectedMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureAmt_lbl" xml:lang="en-US">Company Selected Measure Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt" xlink:label="ecd_OtherPerfMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OtherPerfMeasureAmt" xlink:to="ecd_OtherPerfMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OtherPerfMeasureAmt_lbl" xml:lang="en-US">Other Performance Measure, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt" xlink:label="ecd_AdjToCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAmt" xlink:to="ecd_AdjToCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAmt_lbl" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName" xlink:label="ecd_PeoName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoName" xlink:to="ecd_PeoName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoName_lbl" xml:lang="en-US">PEO Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName" xlink:label="ecd_MeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureName" xlink:to="ecd_MeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xml:lang="en-US">Non-GAAP Measure Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="ecd_Additional402vDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Additional402vDisclosureTextBlock" xlink:to="ecd_Additional402vDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Additional402vDisclosureTextBlock_lbl" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="ecd_PnsnBnftsAdjFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PnsnBnftsAdjFnTextBlock" xlink:to="ecd_PnsnBnftsAdjFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PnsnBnftsAdjFnTextBlock_lbl" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable" xlink:label="ecd_ErrCompRecoveryTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompRecoveryTable" xlink:to="ecd_ErrCompRecoveryTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompRecoveryTable_lbl" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis" xlink:label="ecd_RestatementDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDateAxis" xlink:to="ecd_RestatementDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDateAxis_lbl" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate" xlink:label="ecd_RestatementDeterminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDeterminationDate" xlink:to="ecd_RestatementDeterminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDeterminationDate_lbl" xml:lang="en-US">Restatement Determination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt" xlink:label="ecd_AggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompAmt" xlink:to="ecd_AggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompAmt_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="ecd_ErrCompAnalysisTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompAnalysisTextBlock" xlink:to="ecd_ErrCompAnalysisTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompAnalysisTextBlock_lbl" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="ecd_OutstandingAggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingAggtErrCompAmt" xlink:to="ecd_OutstandingAggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingAggtErrCompAmt_lbl" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName" xlink:label="ecd_ForgoneRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_ForgoneRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName" xlink:label="ecd_OutstandingRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_OutstandingRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="ecd_OutstandingRecoveryCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryCompAmt" xlink:to="ecd_OutstandingRecoveryCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryCompAmt_lbl" xml:lang="en-US">Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xml:lang="en-US">Restatement does not require Recovery</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="ecd_AwardsCloseToMnpiDiscTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTable" xlink:to="ecd_AwardsCloseToMnpiDiscTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTable_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="ecd_AwardTmgMnpiDiscTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiDiscTextBlock" xlink:to="ecd_AwardTmgMnpiDiscTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiDiscTextBlock_lbl" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="ecd_AwardTmgMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMethodTextBlock" xlink:to="ecd_AwardTmgMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMethodTextBlock_lbl" xml:lang="en-US">Award Timing Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="ecd_AwardTmgPredtrmndFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgPredtrmndFlag" xlink:to="ecd_AwardTmgPredtrmndFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgPredtrmndFlag_lbl" xml:lang="en-US">Award Timing Predetermined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xml:lang="en-US">Award Timing MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="ecd_MnpiDiscTimedForCompValFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MnpiDiscTimedForCompValFlag" xlink:to="ecd_MnpiDiscTimedForCompValFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MnpiDiscTimedForCompValFlag_lbl" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="ecd_AwardsCloseToMnpiDiscIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="ecd_AwardUndrlygSecuritiesAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardUndrlygSecuritiesAmt" xlink:to="ecd_AwardUndrlygSecuritiesAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardUndrlygSecuritiesAmt_lbl" xml:lang="en-US">Underlying Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice" xlink:label="ecd_AwardExrcPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardExrcPrice" xlink:to="ecd_AwardExrcPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardExrcPrice_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue" xlink:label="ecd_AwardGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardGrantDateFairValue" xlink:to="ecd_AwardGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardGrantDateFairValue_lbl" xml:lang="en-US">Fair Value as of Grant Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="ecd_UndrlygSecurityMktPriceChngPct" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_UndrlygSecurityMktPriceChngPct" xlink:to="ecd_UndrlygSecurityMktPriceChngPct_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_UndrlygSecurityMktPriceChngPct_lbl" xml:lang="en-US">Underlying Security Market Price Change</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable" xlink:label="ecd_TradingArrByIndTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TradingArrByIndTable" xlink:to="ecd_TradingArrByIndTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TradingArrByIndTable_lbl" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis" xlink:label="ecd_TradingArrAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TradingArrAxis" xlink:to="ecd_TradingArrAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TradingArrAxis_lbl" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName" xlink:label="ecd_TrdArrIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_TrdArrIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle" xlink:label="ecd_TrdArrIndTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndTitle" xlink:to="ecd_TrdArrIndTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndTitle_lbl" xml:lang="en-US">Title</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate" xlink:label="ecd_TrdArrAdoptionDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrAdoptionDate" xlink:to="ecd_TrdArrAdoptionDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrAdoptionDate_lbl" xml:lang="en-US">Adoption Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate" xlink:label="ecd_TrdArrTerminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrTerminationDate" xlink:to="ecd_TrdArrTerminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrTerminationDate_lbl" xml:lang="en-US">Termination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate" xlink:label="ecd_TrdArrExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrExpirationDate" xlink:to="ecd_TrdArrExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrExpirationDate_lbl" xml:lang="en-US">Expiration Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration" xlink:label="ecd_TrdArrDuration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrDuration" xlink:to="ecd_TrdArrDuration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrDuration_lbl" xml:lang="en-US">Arrangement Duration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="ecd_InsiderTradingPoliciesProcLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingPoliciesProcLineItems" xlink:to="ecd_InsiderTradingPoliciesProcLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingPoliciesProcLineItems_lbl" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xml:lang="en-US">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Third Party Engaged [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xml:lang="en-US">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board of Directors Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Role of Management [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentAbstract" xlink:label="cyd_MaterialCybersecurityIncidentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentAbstract" xlink:to="cyd_MaterialCybersecurityIncidentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentAbstract_lbl" xml:lang="en-US">Material Cybersecurity Incident [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentNatureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentNatureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentNatureTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Nature [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentScopeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentScopeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentScopeTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Scope [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentTimingTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentTimingTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentTimingTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Timing [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">General</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_lbl" xml:lang="en-US">Marketable debt securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesAbstract" xlink:label="us-gaap_ReceivablesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_ReceivablesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesAbstract_lbl" xml:lang="en-US">Receivables [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl" xml:lang="en-US">Other Receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_DisclosureLeasesAbstract" xlink:label="GLMD_DisclosureLeasesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_DisclosureLeasesAbstract" xlink:to="GLMD_DisclosureLeasesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GLMD_DisclosureLeasesAbstract_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="us-gaap_InvestmentsAllOtherInvestmentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract_lbl" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTextBlock" xlink:label="us-gaap_InvestmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTextBlock" xlink:to="us-gaap_InvestmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentTextBlock_lbl" xml:lang="en-US">Investment in an Associate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="us-gaap_OtherLiabilitiesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract_lbl" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_OtherLiabilitiesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">Other Payables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ResearchAndDevelopmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentAbstract_lbl" xml:lang="en-US">Research and Development [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:to="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_lbl" xml:lang="en-US">Research and Development Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_DisclosureGeneralAndAdministrativeExpensesAbstract" xlink:label="GLMD_DisclosureGeneralAndAdministrativeExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_DisclosureGeneralAndAdministrativeExpensesAbstract" xlink:to="GLMD_DisclosureGeneralAndAdministrativeExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GLMD_DisclosureGeneralAndAdministrativeExpensesAbstract_lbl" xml:lang="en-US">General And Administrative Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_GeneralAndAdministrativeExpensesDisclosureTextBlock" xlink:label="GLMD_GeneralAndAdministrativeExpensesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_GeneralAndAdministrativeExpensesDisclosureTextBlock" xlink:to="GLMD_GeneralAndAdministrativeExpensesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GLMD_GeneralAndAdministrativeExpensesDisclosureTextBlock_lbl" xml:lang="en-US">General and Administrative Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xml:lang="en-US">Financial income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent events</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">Segment Reporting</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Financial statement in U.S. dollars</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US">Restricted Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_ShortTermDepositsPolicyTextBlock" xlink:label="GLMD_ShortTermDepositsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_ShortTermDepositsPolicyTextBlock" xlink:to="GLMD_ShortTermDepositsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="GLMD_ShortTermDepositsPolicyTextBlock_lbl" xml:lang="en-US">Short-term deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xml:lang="en-US">Marketable debt securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentrations of credit risk</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US">Severance pay</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair value of financial instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Accounting for stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and development expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Basic and diluted net loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xml:lang="en-US">Investment in Associate at Fair Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently adopted accounting pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_NewAccountingPronouncementsNotYetEffectivePolicyTextBlock" xlink:label="GLMD_NewAccountingPronouncementsNotYetEffectivePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_NewAccountingPronouncementsNotYetEffectivePolicyTextBlock" xlink:to="GLMD_NewAccountingPronouncementsNotYetEffectivePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GLMD_NewAccountingPronouncementsNotYetEffectivePolicyTextBlock_lbl" xml:lang="en-US">Accounting pronouncements not yet effective</link:label>
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentTableTextBlock" xlink:label="GLMD_ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentTableTextBlock" xlink:to="GLMD_ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GLMD_ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentTableTextBlock_lbl" xml:lang="en-US">Schedule of Depreciation Rates for Property, Plant and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US">Schedule of Assets Measured at Fair Value on Recurring Basis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="us-gaap_MarketableSecuritiesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesTextBlock" xlink:to="us-gaap_MarketableSecuritiesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesTextBlock_lbl" xml:lang="en-US">Schedule of Marketable Debt Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl" xml:lang="en-US">Schedule of Other Receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_ScheduleOfBalanceSheetsTableTextBlock" xlink:label="GLMD_ScheduleOfBalanceSheetsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_ScheduleOfBalanceSheetsTableTextBlock" xlink:to="GLMD_ScheduleOfBalanceSheetsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GLMD_ScheduleOfBalanceSheetsTableTextBlock_lbl" xml:lang="en-US">Schedule of Balance Sheets</link:label>
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_ScheduleOfStatementOfOperationsTableTextBlock" xlink:label="GLMD_ScheduleOfStatementOfOperationsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_ScheduleOfStatementOfOperationsTableTextBlock" xlink:to="GLMD_ScheduleOfStatementOfOperationsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GLMD_ScheduleOfStatementOfOperationsTableTextBlock_lbl" xml:lang="en-US">Schedule of Statement of Operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesTableTextBlock" xlink:label="us-gaap_OtherLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesTableTextBlock" xlink:to="us-gaap_OtherLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Other Payables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Summary of Status of Company's Option Plans and Changes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock_lbl" xml:lang="en-US">Schedule of Research and Development Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_GeneralAndAdministrativeExpensesTableTextBlock" xlink:label="GLMD_GeneralAndAdministrativeExpensesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_GeneralAndAdministrativeExpensesTableTextBlock" xlink:to="GLMD_GeneralAndAdministrativeExpensesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GLMD_GeneralAndAdministrativeExpensesTableTextBlock_lbl" xml:lang="en-US">Schedule of General and Administrative Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeByComponentTextBlock" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeByComponentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherNonoperatingIncomeByComponentTextBlock" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeByComponentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeByComponentTextBlock_lbl" xml:lang="en-US">Schedule of Financial Income, Net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="dei_EntityIncorporationDateOfIncorporation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationDateOfIncorporation" xlink:to="dei_EntityIncorporationDateOfIncorporation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationDateOfIncorporation_lbl" xml:lang="en-US">Date of incorporation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperationsCommencedDate1" xlink:label="us-gaap_OperationsCommencedDate1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperationsCommencedDate1" xlink:to="us-gaap_OperationsCommencedDate1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperationsCommencedDate1_lbl" xml:lang="en-US">Date of commenced operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermInvestments_lbl" xml:lang="en-US">Marketable securities debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Profit loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xml:lang="en-US">Retained earnings accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" xlink:label="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" xlink:to="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage_lbl" xml:lang="en-US">Property and equipment, depreciation, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDepreciationMethodExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentDepreciationMethodExtensibleEnumeration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDepreciationMethodExtensibleEnumeration" xlink:to="us-gaap_PropertyPlantAndEquipmentDepreciationMethodExtensibleEnumeration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDepreciationMethodExtensibleEnumeration_lbl" xml:lang="en-US">Property, Plant and Equipment, Depreciation Method [Extensible Enumeration]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentInterestRate" xlink:label="us-gaap_InvestmentInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentInterestRate" xlink:to="us-gaap_InvestmentInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentInterestRate_lbl" xml:lang="en-US">Short-Term deposits interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_MonthlyDepositsOfEmployeesPercentageOnMonthlySalary" xlink:label="GLMD_MonthlyDepositsOfEmployeesPercentageOnMonthlySalary" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_MonthlyDepositsOfEmployeesPercentageOnMonthlySalary" xlink:to="GLMD_MonthlyDepositsOfEmployeesPercentageOnMonthlySalary_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GLMD_MonthlyDepositsOfEmployeesPercentageOnMonthlySalary_lbl" xml:lang="en-US">Monthly deposits percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDescription" xlink:label="GLMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDescription" xlink:to="GLMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GLMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDescription_lbl" xml:lang="en-US">Black scholes option pricing model</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable_lbl" xml:lang="en-US">Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:label="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_lbl" xml:lang="en-US">Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xml:lang="en-US">Amortized Cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_lbl" xml:lang="en-US">Gross Unrealized Gains</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_lbl" xml:lang="en-US">Gross Unrealized Losses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xml:lang="en-US">Estimated Fair Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrantsReceivable" xlink:label="us-gaap_GrantsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantsReceivable" xlink:to="us-gaap_GrantsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrantsReceivable_lbl" xml:lang="en-US">Government institutions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivables" xlink:label="us-gaap_OtherReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherReceivables_lbl" xml:lang="en-US">Other receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesNetCurrent" xlink:to="us-gaap_ReceivablesNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfLand" xlink:to="us-gaap_AreaOfLand_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AreaOfLand_lbl" xml:lang="en-US">Area of land under operating lease agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xml:lang="en-US">Lease expiry date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Lease expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xml:lang="en-US">Operating lease right of use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US">Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MachineryAndEquipmentGross" xlink:label="us-gaap_MachineryAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentGross" xlink:to="us-gaap_MachineryAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MachineryAndEquipmentGross_lbl" xml:lang="en-US">Medical equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="us-gaap_FurnitureAndFixturesGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesGross" xlink:to="us-gaap_FurnitureAndFixturesGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesGross_lbl" xml:lang="en-US">Office furniture and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedComputerSoftwareGross" xlink:label="us-gaap_CapitalizedComputerSoftwareGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedComputerSoftwareGross" xlink:to="us-gaap_CapitalizedComputerSoftwareGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalizedComputerSoftwareGross_lbl" xml:lang="en-US">Computer software and electronic equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="us-gaap_LeaseholdImprovementsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsGross" xlink:to="us-gaap_LeaseholdImprovementsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsGross_lbl" xml:lang="en-US">Leasehold improvements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property and equipment, gross</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less - Accumulated depreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xml:lang="en-US">Net book value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Current assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_2_lbl" xml:lang="en-US">Non-current assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Non-current liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Total operating loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Financial expenses, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Value conversion</link:label>
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_CapitalStockDiscountRate" xlink:label="GLMD_CapitalStockDiscountRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_CapitalStockDiscountRate" xlink:to="GLMD_CapitalStockDiscountRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GLMD_CapitalStockDiscountRate_lbl" xml:lang="en-US">Capital discount rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnInvestments" xlink:label="us-gaap_GainLossOnInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnInvestments" xlink:to="us-gaap_GainLossOnInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnInvestments_lbl" xml:lang="en-US">Investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInvestments" xlink:to="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xml:lang="en-US">Investment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentOwnedBalanceShares" xlink:label="us-gaap_InvestmentOwnedBalanceShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentOwnedBalanceShares" xlink:to="us-gaap_InvestmentOwnedBalanceShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentOwnedBalanceShares_lbl" xml:lang="en-US">Shares owned</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentOwnedPercentOfNetAssets" xlink:label="us-gaap_InvestmentOwnedPercentOfNetAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentOwnedPercentOfNetAssets" xlink:to="us-gaap_InvestmentOwnedPercentOfNetAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentOwnedPercentOfNetAssets_lbl" xml:lang="en-US">Shares owned percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_2_lbl" xml:lang="en-US">Management fee income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Loan amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US">Interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromOtherDebt" xlink:label="us-gaap_ProceedsFromOtherDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromOtherDebt" xlink:to="us-gaap_ProceedsFromOtherDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromOtherDebt_lbl" xml:lang="en-US">Proceeds from debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xml:lang="en-US">Repayments of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xml:lang="en-US">Impairment charges</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Employees and related</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensatedAbsencesLiability" xlink:label="us-gaap_CompensatedAbsencesLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensatedAbsencesLiability" xlink:to="us-gaap_CompensatedAbsencesLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensatedAbsencesLiability_lbl" xml:lang="en-US">Accrued Vacation</link:label>
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_ShorttermLeaseObligation" xlink:label="GLMD_ShorttermLeaseObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_ShorttermLeaseObligation" xlink:to="GLMD_ShorttermLeaseObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GLMD_ShorttermLeaseObligation_lbl" xml:lang="en-US">Short-term lease obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNotesPayable" xlink:label="us-gaap_OtherNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNotesPayable" xlink:to="us-gaap_OtherNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNotesPayable_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilities" xlink:label="us-gaap_OtherLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilities" xlink:to="us-gaap_OtherLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherLiabilities_lbl" xml:lang="en-US">Other Payables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Related Party Transaction [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Due to related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xml:lang="en-US">Related party transaction, expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US">Long term loan</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US">Loss Contingencies [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_BankLienOnMarketableSecurities" xlink:label="GLMD_BankLienOnMarketableSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_BankLienOnMarketableSecurities" xlink:to="GLMD_BankLienOnMarketableSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GLMD_BankLienOnMarketableSecurities_lbl" xml:lang="en-US">Bank lien on marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_UpfrontLicenseFee" xlink:label="GLMD_UpfrontLicenseFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_UpfrontLicenseFee" xlink:to="GLMD_UpfrontLicenseFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GLMD_UpfrontLicenseFee_lbl" xml:lang="en-US">Upfront license fee</link:label>
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_PaymentsToRegulatoryMilestones" xlink:label="GLMD_PaymentsToRegulatoryMilestones" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_PaymentsToRegulatoryMilestones" xlink:to="GLMD_PaymentsToRegulatoryMilestones_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GLMD_PaymentsToRegulatoryMilestones_lbl" xml:lang="en-US">Payments to regulatory milestones</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityEquityTable" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityEquityTable" xlink:to="us-gaap_OptionIndexedToIssuersEquityEquityTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityTable_lbl" xml:lang="en-US">Option Indexed to Issuer's Equity, Equity [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:label="us-gaap_OptionIndexedToIssuersEquityLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:to="us-gaap_OptionIndexedToIssuersEquityLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityLineItems_lbl" xml:lang="en-US">Option Indexed to Issuer's Equity [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of share options, Beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of share options, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of share options, Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Number of share options, Ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price, Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of share options exercisable, Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Options exercisable, Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_MaximumAmountOfSharesToBeIssued" xlink:label="GLMD_MaximumAmountOfSharesToBeIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_MaximumAmountOfSharesToBeIssued" xlink:to="GLMD_MaximumAmountOfSharesToBeIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GLMD_MaximumAmountOfSharesToBeIssued_lbl" xml:lang="en-US">Aggregate offering price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Issuance of shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xml:lang="en-US">Gross proceeds stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockNoParValue" xlink:label="us-gaap_CommonStockNoParValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockNoParValue" xlink:to="us-gaap_CommonStockNoParValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockNoParValue_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Share price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US">Stock and warrants issued during period shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xml:lang="en-US">Issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantExercisePriceIncrease" xlink:label="us-gaap_WarrantExercisePriceIncrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceIncrease" xlink:to="us-gaap_WarrantExercisePriceIncrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantExercisePriceIncrease_lbl" xml:lang="en-US">Exercise price of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrants are outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Warrant exercised, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitment" xlink:label="us-gaap_OtherCommitment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitment" xlink:to="us-gaap_OtherCommitment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitment_lbl" xml:lang="en-US">Commitment amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="us-gaap_DebtInstrumentFeeAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFeeAmount" xlink:to="us-gaap_DebtInstrumentFeeAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFeeAmount_lbl" xml:lang="en-US">Structuring fee</link:label>
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_CommitmentShare" xlink:label="GLMD_CommitmentShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_CommitmentShare" xlink:to="GLMD_CommitmentShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GLMD_CommitmentShare_lbl" xml:lang="en-US">Commitment share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_ProceedsFinanceLeaseInterestExpenseIncome" xlink:to="GLMD_ProceedsFinanceLeaseInterestExpenseIncome_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="GLMD_ProceedsFinanceLeaseInterestExpenseIncome_2_lbl" xml:lang="en-US">Finance expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpenses" xlink:label="us-gaap_OtherExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherExpenses_lbl" xml:lang="en-US">Compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Sale of stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Total consideration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Shares reserved for future issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_CommonStockCapitalSharesReservedForFutureIssuanceUnallocated" xlink:label="GLMD_CommonStockCapitalSharesReservedForFutureIssuanceUnallocated" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_CommonStockCapitalSharesReservedForFutureIssuanceUnallocated" xlink:to="GLMD_CommonStockCapitalSharesReservedForFutureIssuanceUnallocated_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="GLMD_CommonStockCapitalSharesReservedForFutureIssuanceUnallocated_lbl" xml:lang="en-US">Shares reserved for future issuance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xml:lang="en-US">Options, granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Options granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Contractual term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Vest period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_lbl" xml:lang="en-US">Aggregate grant fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Restricted stock unit options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US">Risk-free interest rate, maximum</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected life, term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US">Volatility rate, minimum</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US">Volatility rate, maximum</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Volatility rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xml:lang="en-US">Options, exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Options, intrinsic value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Unrecognized compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Unrecognized compensation, term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Allocated stock based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Share based compensation granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther_lbl" xml:lang="en-US">Share based compensation subject to company shareholders</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Share based compensation vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Unrecognized share based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xml:lang="en-US">Research and development expense</link:label>
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_BankFees" xlink:label="GLMD_BankFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_BankFees" xlink:to="GLMD_BankFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="GLMD_BankFees_lbl" xml:lang="en-US">Bank fees</link:label>
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_InterestIncome" xlink:label="GLMD_InterestIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_InterestIncome" xlink:to="GLMD_InterestIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GLMD_InterestIncome_lbl" xml:lang="en-US">Interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleGainLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleGainLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleGainLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleGainLoss_lbl" xml:lang="en-US">Loss from sale of marketable debt securities</link:label>
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_ChangeInFairValueOfConvertibleNote" xlink:label="GLMD_ChangeInFairValueOfConvertibleNote" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_ChangeInFairValueOfConvertibleNote" xlink:to="GLMD_ChangeInFairValueOfConvertibleNote_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GLMD_ChangeInFairValueOfConvertibleNote_lbl" xml:lang="en-US">Change in fair value of convertible note</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US">Foreign currency (gains) losses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Financial income net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Loss before taxes on income, as reported in the consolidated statements of operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Statutory tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Theoretical tax benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Losses and other items for which a valuation allowance was provided or benefit from loss carry forwards</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Actual tax expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2_lbl" xml:lang="en-US">Effective income tax rate reconciliation, at federal statutory income tax rate, percent</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Operating loss carry forwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_lbl" xml:lang="en-US">Deferred tax assets, capital loss carry forwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2_lbl" xml:lang="en-US">Commitment share,value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US">Number of reportable segments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_MaximumAmountOfSharesToBeIssued" xlink:to="GLMD_MaximumAmountOfSharesToBeIssued_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GLMD_MaximumAmountOfSharesToBeIssued_doc" xml:lang="en-US">The maximum number of shares to be issued in the offering.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_NewSalesAgreementMember" xlink:to="GLMD_NewSalesAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GLMD_NewSalesAgreementMember_doc" xml:lang="en-US">New Sales Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_PrefundedWarrantsMember" xlink:to="GLMD_PrefundedWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GLMD_PrefundedWarrantsMember_doc" xml:lang="en-US">Prefunded Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_InvestorWarrantsMember" xlink:to="GLMD_InvestorWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GLMD_InvestorWarrantsMember_doc" xml:lang="en-US">Investor Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_ExerciseOfPrefundedWarrants" xlink:to="GLMD_ExerciseOfPrefundedWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GLMD_ExerciseOfPrefundedWarrants_doc" xml:lang="en-US">Exercise of Pre-funded warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_StockIssuedDuringPeriodValueOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts" xlink:to="GLMD_StockIssuedDuringPeriodValueOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GLMD_StockIssuedDuringPeriodValueOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts_doc" xml:lang="en-US">Stock issued during period value ordinary shares prefunded warrants and warrants net of issuance costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_WarrantsNetOfIssuanceCosts" xlink:to="GLMD_WarrantsNetOfIssuanceCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GLMD_WarrantsNetOfIssuanceCosts_doc" xml:lang="en-US">Warrants net of issuance costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:to="GLMD_StockIssuedDuringPeriodValueExerciseOfWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GLMD_StockIssuedDuringPeriodValueExerciseOfWarrants_doc" xml:lang="en-US">Exercise of warrants, value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_StockIssuedDuringPeriodSharesOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts" xlink:to="GLMD_StockIssuedDuringPeriodSharesOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GLMD_StockIssuedDuringPeriodSharesOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts_doc" xml:lang="en-US">Stock issued during period shares ordinary shares prefunded warrants and warrants net of issuance costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_ExerciseOfPrefundedWarrantsShares" xlink:to="GLMD_ExerciseOfPrefundedWarrantsShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GLMD_ExerciseOfPrefundedWarrantsShares_doc" xml:lang="en-US">Exercise of Pre-funded warrants, shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:to="GLMD_StockIssuedDuringPeriodSharesExerciseOfWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GLMD_StockIssuedDuringPeriodSharesExerciseOfWarrants_doc" xml:lang="en-US">Exercise of warrants, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_ProceedsFinanceLeaseInterestExpenseIncome" xlink:to="GLMD_ProceedsFinanceLeaseInterestExpenseIncome_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GLMD_ProceedsFinanceLeaseInterestExpenseIncome_doc" xml:lang="en-US">Finance expenses (income).</link:label>
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_InterestIncomeFromShorttermDeposits" xlink:label="GLMD_InterestIncomeFromShorttermDeposits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_InterestIncomeFromShorttermDeposits" xlink:to="GLMD_InterestIncomeFromShorttermDeposits_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GLMD_InterestIncomeFromShorttermDeposits_doc" xml:lang="en-US">Interest income from short-term deposits.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_ChangeInFairValueConvertibleNote" xlink:to="GLMD_ChangeInFairValueConvertibleNote_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GLMD_ChangeInFairValueConvertibleNote_doc" xml:lang="en-US">Change in fair value convertible note.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_PaymentsForInvestmentInAvailableForSaleSecurities" xlink:to="GLMD_PaymentsForInvestmentInAvailableForSaleSecurities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GLMD_PaymentsForInvestmentInAvailableForSaleSecurities_doc" xml:lang="en-US">Payments for investment in available for sale securities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_PaymentsForProceedsFromInvestmentInConvertibleNote" xlink:to="GLMD_PaymentsForProceedsFromInvestmentInConvertibleNote_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GLMD_PaymentsForProceedsFromInvestmentInConvertibleNote_doc" xml:lang="en-US">Payments for proceeds from investment in convertible note.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_PaymentsForProceedsFromInvestmentInAssociate" xlink:to="GLMD_PaymentsForProceedsFromInvestmentInAssociate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GLMD_PaymentsForProceedsFromInvestmentInAssociate_doc" xml:lang="en-US">payments for proceeds from investment in associate.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_IssuanceOfOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts" xlink:to="GLMD_IssuanceOfOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GLMD_IssuanceOfOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts_doc" xml:lang="en-US">Issuance of ordinary shares, pre-funded warrants, and warrants net of issuance costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_ConversionOfConvertibleNoteIntoInvestmentInAssociate" xlink:to="GLMD_ConversionOfConvertibleNoteIntoInvestmentInAssociate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GLMD_ConversionOfConvertibleNoteIntoInvestmentInAssociate_doc" xml:lang="en-US">Conversion of convertible note into investment in associate.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_DecreaseInShorttermDeposits" xlink:to="GLMD_DecreaseInShorttermDeposits_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GLMD_DecreaseInShorttermDeposits_doc" xml:lang="en-US">Decrease in short term deposits.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_CommitmentShare" xlink:to="GLMD_CommitmentShare_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GLMD_CommitmentShare_doc" xml:lang="en-US">Commitment share.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentTableTextBlock" xlink:to="GLMD_ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GLMD_ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentTableTextBlock_doc" xml:lang="en-US">Schedule Of Depreciation Rates For Property Plant And Equipment [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_OfficeFurnitureAndEquipmentMember" xlink:to="GLMD_OfficeFurnitureAndEquipmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GLMD_OfficeFurnitureAndEquipmentMember_doc" xml:lang="en-US">Office Furniture and Equipment [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_ComputerSoftwareElectronicEquipmentMember" xlink:to="GLMD_ComputerSoftwareElectronicEquipmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GLMD_ComputerSoftwareElectronicEquipmentMember_doc" xml:lang="en-US">Computer Software and Electronic Equipment [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_MonthlyDepositsOfEmployeesPercentageOnMonthlySalary" xlink:to="GLMD_MonthlyDepositsOfEmployeesPercentageOnMonthlySalary_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GLMD_MonthlyDepositsOfEmployeesPercentageOnMonthlySalary_doc" xml:lang="en-US">Collection of monthly deposits from the employees on their monthly salary for severance pay.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_IncentiveShareOptionPlan2013Member" xlink:to="GLMD_IncentiveShareOptionPlan2013Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GLMD_IncentiveShareOptionPlan2013Member_doc" xml:lang="en-US">Incentive Share Option Plan2013 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_CommonStockCapitalSharesReservedForFutureIssuanceUnallocated" xlink:to="GLMD_CommonStockCapitalSharesReservedForFutureIssuanceUnallocated_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GLMD_CommonStockCapitalSharesReservedForFutureIssuanceUnallocated_doc" xml:lang="en-US">Common stock capital shares reserved for future issuance unallocated.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDescription" xlink:to="GLMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GLMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDescription_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award fair value assumptions.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_OnkaiIncMember" xlink:to="GLMD_OnkaiIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GLMD_OnkaiIncMember_doc" xml:lang="en-US">Onkai Inc [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_CapitalStockDiscountRate" xlink:to="GLMD_CapitalStockDiscountRate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GLMD_CapitalStockDiscountRate_doc" xml:lang="en-US">Capital stock discount rate.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_ShorttermLeaseObligation" xlink:to="GLMD_ShorttermLeaseObligation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GLMD_ShorttermLeaseObligation_doc" xml:lang="en-US">Short term lease obligation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_OfficersAndDirectorsMember" xlink:to="GLMD_OfficersAndDirectorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GLMD_OfficersAndDirectorsMember_doc" xml:lang="en-US">Officers And Directors [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_ServiceAgreementMember" xlink:to="GLMD_ServiceAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GLMD_ServiceAgreementMember_doc" xml:lang="en-US">Service Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_BankLienOnMarketableSecurities" xlink:to="GLMD_BankLienOnMarketableSecurities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GLMD_BankLienOnMarketableSecurities_doc" xml:lang="en-US">These lines are represents that lien on marketable securities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_UpfrontLicenseFee" xlink:to="GLMD_UpfrontLicenseFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GLMD_UpfrontLicenseFee_doc" xml:lang="en-US">Upfront License Fee.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_PaymentsToRegulatoryMilestones" xlink:to="GLMD_PaymentsToRegulatoryMilestones_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GLMD_PaymentsToRegulatoryMilestones_doc" xml:lang="en-US">Payments to regulatory milestones.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_ChemistryAndFormulationStudiesMember" xlink:to="GLMD_ChemistryAndFormulationStudiesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GLMD_ChemistryAndFormulationStudiesMember_doc" xml:lang="en-US">Chemistry And Formulation Studies [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_SalariesMember" xlink:to="GLMD_SalariesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GLMD_SalariesMember_doc" xml:lang="en-US">Salaries [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_StockBasedCompensationMember" xlink:to="GLMD_StockBasedCompensationMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GLMD_StockBasedCompensationMember_doc" xml:lang="en-US">Stock Based Compensation [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_ResearchAndPreclinicalStudiesMember" xlink:to="GLMD_ResearchAndPreclinicalStudiesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GLMD_ResearchAndPreclinicalStudiesMember_doc" xml:lang="en-US">Research And Preclinical Studies [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_ClinicalStudiesMember" xlink:to="GLMD_ClinicalStudiesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GLMD_ClinicalStudiesMember_doc" xml:lang="en-US">Clinical Studies [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_RegulatoryAndOtherExpensesMember" xlink:to="GLMD_RegulatoryAndOtherExpensesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GLMD_RegulatoryAndOtherExpensesMember_doc" xml:lang="en-US">Regulatory And Other Expenses [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_ProfessionalFeeMember" xlink:to="GLMD_ProfessionalFeeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GLMD_ProfessionalFeeMember_doc" xml:lang="en-US">Professional Fees [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_SalariesAndBenefitsMember" xlink:to="GLMD_SalariesAndBenefitsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GLMD_SalariesAndBenefitsMember_doc" xml:lang="en-US">Salaries And Benefits [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_RentAndOfficeMaintenanceFeesMember" xlink:to="GLMD_RentAndOfficeMaintenanceFeesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GLMD_RentAndOfficeMaintenanceFeesMember_doc" xml:lang="en-US">Rent And Office Maintenance Fees [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_InvestorRelationsAndBusinessDevelopmentExpensesMember" xlink:label="GLMD_InvestorRelationsAndBusinessDevelopmentExpensesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_InvestorRelationsAndBusinessDevelopmentExpensesMember" xlink:to="GLMD_InvestorRelationsAndBusinessDevelopmentExpensesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GLMD_InvestorRelationsAndBusinessDevelopmentExpensesMember_doc" xml:lang="en-US">Investor Relations And Business Development Expenses [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_InsuranceAndOtherExpensesMember" xlink:to="GLMD_InsuranceAndOtherExpensesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GLMD_InsuranceAndOtherExpensesMember_doc" xml:lang="en-US">Insurance And Other Expenses [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_BankFees" xlink:to="GLMD_BankFees_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GLMD_BankFees_doc" xml:lang="en-US">Amount of expense classified as bank fees.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_InterestIncome" xlink:to="GLMD_InterestIncome_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GLMD_InterestIncome_doc" xml:lang="en-US">Interest income</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_ChangeInFairValueOfConvertibleNote" xlink:to="GLMD_ChangeInFairValueOfConvertibleNote_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GLMD_ChangeInFairValueOfConvertibleNote_doc" xml:lang="en-US">Change in fair value of convertible note.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_MalteseSubsidiaryMember" xlink:to="GLMD_MalteseSubsidiaryMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GLMD_MalteseSubsidiaryMember_doc" xml:lang="en-US">Maltese Subsidiary [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_IsraeliSubsidiaryMember" xlink:to="GLMD_IsraeliSubsidiaryMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GLMD_IsraeliSubsidiaryMember_doc" xml:lang="en-US">Israeli Subsidiary [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_FinancialExpenses" xlink:to="GLMD_FinancialExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GLMD_FinancialExpenses_doc" xml:lang="en-US">Financial expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_BridgeLoanAgreementMember" xlink:to="GLMD_BridgeLoanAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GLMD_BridgeLoanAgreementMember_doc" xml:lang="en-US">Bridge Loan Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_ServicesAgreementMember" xlink:to="GLMD_ServicesAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GLMD_ServicesAgreementMember_doc" xml:lang="en-US">Services Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember" xlink:label="us-gaap_UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember" xlink:to="us-gaap_UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember_lbl" xml:lang="en-US">Useful Life, Shorter of Lease Term or Asset Utility [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_3_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_3_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_5_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_5_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_3_lbl" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_2_lbl" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Gain (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2_lbl" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfInvestments" xlink:to="us-gaap_GainLossOnSaleOfInvestments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfInvestments_2_lbl" xml:lang="en-US">Gain (Loss) on Sale of Investments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_DecreaseInShorttermDeposits" xlink:to="GLMD_DecreaseInShorttermDeposits_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GLMD_DecreaseInShorttermDeposits_3_lbl" xml:lang="en-US">DecreaseInShorttermDeposits</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_2_lbl" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_ChangeInFairValueConvertibleNote" xlink:to="GLMD_ChangeInFairValueConvertibleNote_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GLMD_ChangeInFairValueConvertibleNote_3_lbl" xml:lang="en-US">ChangeInFairValueConvertibleNote</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts and Other Receivables</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_PaymentsForInvestmentInAvailableForSaleSecurities" xlink:to="GLMD_PaymentsForInvestmentInAvailableForSaleSecurities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GLMD_PaymentsForInvestmentInAvailableForSaleSecurities_3_lbl" xml:lang="en-US">PaymentsForInvestmentInAvailableForSaleSecurities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_PaymentsForProceedsFromInvestmentInConvertibleNote" xlink:to="GLMD_PaymentsForProceedsFromInvestmentInConvertibleNote_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GLMD_PaymentsForProceedsFromInvestmentInConvertibleNote_3_lbl" xml:lang="en-US">PaymentsForProceedsFromInvestmentInConvertibleNote</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_2_lbl" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_PaymentsForProceedsFromInvestmentInAssociate" xlink:to="GLMD_PaymentsForProceedsFromInvestmentInAssociate_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GLMD_PaymentsForProceedsFromInvestmentInAssociate_3_lbl" xml:lang="en-US">PaymentsForProceedsFromInvestmentInAssociate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromOtherDeposits" xlink:to="us-gaap_PaymentsForProceedsFromOtherDeposits_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForProceedsFromOtherDeposits_2_lbl" xml:lang="en-US">Payments for (Proceeds from) Other Deposits</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_IssuanceOfOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts" xlink:to="GLMD_IssuanceOfOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GLMD_IssuanceOfOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts_3_lbl" xml:lang="en-US">IssuanceOfOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryIndName_2_lbl" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryIndName_2_lbl" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndName_2_lbl" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, and Marketable Securities [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_2_lbl" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2_lbl" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_2_lbl" xml:lang="en-US">Shareholders' Equity and Share-Based Payments [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_2_lbl" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_ShortTermDepositsPolicyTextBlock" xlink:to="GLMD_ShortTermDepositsPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GLMD_ShortTermDepositsPolicyTextBlock_2_lbl" xml:lang="en-US">ShortTermDepositsPolicyTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesPolicy_2_lbl" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_2_lbl" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_2_lbl" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_2_lbl" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherReceivables_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivables_2_lbl" xml:lang="en-US">Other Receivables [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesNetCurrent" xlink:to="us-gaap_ReceivablesNetCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesNetCurrent_2_lbl" xml:lang="en-US">Receivables, Net, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_2_lbl" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilities" xlink:to="us-gaap_OtherLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilities_2_lbl" xml:lang="en-US">Other Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_2_lbl" xml:lang="en-US">Share Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceIncrease" xlink:to="us-gaap_WarrantExercisePriceIncrease_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantExercisePriceIncrease_2_lbl" xml:lang="en-US">Warrant, Exercise Price, Increase</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_CommonStockCapitalSharesReservedForFutureIssuanceUnallocated" xlink:to="GLMD_CommonStockCapitalSharesReservedForFutureIssuanceUnallocated_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GLMD_CommonStockCapitalSharesReservedForFutureIssuanceUnallocated_3_lbl" xml:lang="en-US">CommonStockCapitalSharesReservedForFutureIssuanceUnallocated</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GLMD_BankFees" xlink:to="GLMD_BankFees_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GLMD_BankFees_3_lbl" xml:lang="en-US">Bank Fees</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>19
<FILENAME>glmd-20241231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://galmedpharma.com/role/Cover" xlink:href="glmd-20241231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/BalanceSheets" xlink:href="glmd-20241231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/BalanceSheetsParenthetical" xlink:href="glmd-20241231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/StatementsOfOperations" xlink:href="glmd-20241231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/StatementsOfOperationsParenthetical" xlink:href="glmd-20241231.xsd#StatementsOfOperationsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/StatementsOfComprehensiveLoss" xlink:href="glmd-20241231.xsd#StatementsOfComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/StatementsOfChangesInStockholdersEquity" xlink:href="glmd-20241231.xsd#StatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/StatementsOfChangesInStockholdersEquityParenthetical" xlink:href="glmd-20241231.xsd#StatementsOfChangesInStockholdersEquityParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/StatementsOfCashFlows" xlink:href="glmd-20241231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#MaterialCybersecurityIncidentDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/General" xlink:href="glmd-20241231.xsd#General" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/SignificantAccountingPolicies" xlink:href="glmd-20241231.xsd#SignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/MarketableDebtSecurities" xlink:href="glmd-20241231.xsd#MarketableDebtSecurities" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/OtherReceivables" xlink:href="glmd-20241231.xsd#OtherReceivables" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/Leases" xlink:href="glmd-20241231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/PropertyAndEquipmentNet" xlink:href="glmd-20241231.xsd#PropertyAndEquipmentNet" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/InvestmentInAssociate" xlink:href="glmd-20241231.xsd#InvestmentInAssociate" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/OtherPayables" xlink:href="glmd-20241231.xsd#OtherPayables" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/RelatedParties" xlink:href="glmd-20241231.xsd#RelatedParties" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/CommitmentsAndContingencies" xlink:href="glmd-20241231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/StockholdersEquity" xlink:href="glmd-20241231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/ResearchAndDevelopmentExpenses" xlink:href="glmd-20241231.xsd#ResearchAndDevelopmentExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/GeneralAndAdministrativeExpenses" xlink:href="glmd-20241231.xsd#GeneralAndAdministrativeExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/FinancialIncomeNet" xlink:href="glmd-20241231.xsd#FinancialIncomeNet" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/IncomeTaxes" xlink:href="glmd-20241231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/SubsequentEvents" xlink:href="glmd-20241231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/SegmentReporting" xlink:href="glmd-20241231.xsd#SegmentReporting" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/SignificantAccountingPoliciesPolicies" xlink:href="glmd-20241231.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/SignificantAccountingPoliciesTables" xlink:href="glmd-20241231.xsd#SignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/MarketableDebtSecuritiesTables" xlink:href="glmd-20241231.xsd#MarketableDebtSecuritiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/OtherReceivablesTables" xlink:href="glmd-20241231.xsd#OtherReceivablesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/PropertyAndEquipmentNetTables" xlink:href="glmd-20241231.xsd#PropertyAndEquipmentNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/InvestmentInAssociateTables" xlink:href="glmd-20241231.xsd#InvestmentInAssociateTables" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/OtherPayablesTables" xlink:href="glmd-20241231.xsd#OtherPayablesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/StockholdersEquityTables" xlink:href="glmd-20241231.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/ResearchAndDevelopmentExpensesTables" xlink:href="glmd-20241231.xsd#ResearchAndDevelopmentExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/GeneralAndAdministrativeExpensesTables" xlink:href="glmd-20241231.xsd#GeneralAndAdministrativeExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/FinancialIncomeNetTables" xlink:href="glmd-20241231.xsd#FinancialIncomeNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/IncomeTaxesTables" xlink:href="glmd-20241231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/GeneralDetailsNarrative" xlink:href="glmd-20241231.xsd#GeneralDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentDetails" xlink:href="glmd-20241231.xsd#ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/ScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="glmd-20241231.xsd#ScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/SignificantAccountingPoliciesDetailsNarrative" xlink:href="glmd-20241231.xsd#SignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/ScheduleOfMarketableDebtSecuritiesDetails" xlink:href="glmd-20241231.xsd#ScheduleOfMarketableDebtSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/ScheduleOfOtherReceivablesDetails" xlink:href="glmd-20241231.xsd#ScheduleOfOtherReceivablesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/LeasesDetailsNarrative" xlink:href="glmd-20241231.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:href="glmd-20241231.xsd#ScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/ScheduleOfBalanceSheetsDetails" xlink:href="glmd-20241231.xsd#ScheduleOfBalanceSheetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/ScheduleOfStatementOfOperationsDetails" xlink:href="glmd-20241231.xsd#ScheduleOfStatementOfOperationsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/InvestmentInAssociateDetailsNarrative" xlink:href="glmd-20241231.xsd#InvestmentInAssociateDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/ScheduleOfOtherPayablesDetails" xlink:href="glmd-20241231.xsd#ScheduleOfOtherPayablesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/RelatedPartiesDetailsNarrative" xlink:href="glmd-20241231.xsd#RelatedPartiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="glmd-20241231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/SummaryOfStatusOfCompanysOptionPlansAndChangesDetails" xlink:href="glmd-20241231.xsd#SummaryOfStatusOfCompanysOptionPlansAndChangesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/StockholdersEquityDetailsNarrative" xlink:href="glmd-20241231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/ScheduleOfResearchAndDevelopmentExpensesDetails" xlink:href="glmd-20241231.xsd#ScheduleOfResearchAndDevelopmentExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/ScheduleOfGeneralAndAdministrativeExpensesDetails" xlink:href="glmd-20241231.xsd#ScheduleOfGeneralAndAdministrativeExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/ScheduleOfFinancialIncomeNetDetails" xlink:href="glmd-20241231.xsd#ScheduleOfFinancialIncomeNetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:href="glmd-20241231.xsd#ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/IncomeTaxesDetailsNarrative" xlink:href="glmd-20241231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/SubsequentEventsDetailsNarrative" xlink:href="glmd-20241231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://galmedpharma.com/role/SegmentReportingDetailsNarrative" xlink:href="glmd-20241231.xsd#SegmentReportingDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesTable" xlink:label="loc_deiEntityAddressesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesLineItems" xlink:label="loc_deiEntityAddressesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesTable" xlink:to="loc_deiEntityAddressesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_deiEntityAddressesAddressTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesTable" xlink:to="loc_deiEntityAddressesAddressTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain" xlink:label="loc_deiAddressTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesAddressTypeAxis" xlink:to="loc_deiAddressTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember" xlink:label="loc_deiBusinessContactMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiAddressTypeDomain" xlink:to="loc_deiBusinessContactMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelName" xlink:label="loc_deiContactPersonnelName" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiContactPersonnelName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelEmailAddress" xlink:label="loc_deiContactPersonnelEmailAddress" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiContactPersonnelEmailAddress" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_deiIcfrAuditorAttestationFlag" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiIcfrAuditorAttestationFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_deiDocumentFinStmtErrorCorrectionFlag" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFinStmtErrorCorrectionFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId" />
      <link:presentationArc order="620" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAuditorFirmId" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock" xlink:label="loc_deiAuditorOpinionTextBlock" />
      <link:presentationArc order="630" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAuditorOpinionTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName" />
      <link:presentationArc order="640" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAuditorName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation" />
      <link:presentationArc order="650" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAuditorLocation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaapRestrictedCashCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapRestrictedCashCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="loc_us-gaapDepositsAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapDepositsAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapMarketableSecuritiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaapOtherReceivablesNetCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapOtherReceivablesNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:label="loc_us-gaapInvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapInvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLoansPayableCurrent" xlink:label="loc_us-gaapOtherLoansPayableCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherLoansPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_FinancialExpenses" xlink:label="loc_GLMDFinancialExpenses" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_GLMDFinancialExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_ImpairmentOnAssociate" xlink:label="loc_GLMDImpairmentOnAssociate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_GLMDImpairmentOnAssociate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/StatementsOfOperationsParenthetical" xlink:title="00000005 - Statement - Consolidated Statements of Operations (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/StatementsOfComprehensiveLoss" xlink:title="00000006 - Statement - Consolidated Statements of Comprehensive Loss">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossTaxAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossTaxAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:label="loc_us-gaapDebtSecuritiesAvailableForSaleUnrealizedGainLoss" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherComprehensiveIncomeLossTaxAbstract" xlink:to="loc_us-gaapDebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherComprehensiveIncomeLossTaxAbstract" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000007 - Statement - Statements of Changes in Stockholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_StockIssuedDuringPeriodValueOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts" xlink:label="loc_GLMDStockIssuedDuringPeriodValueOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GLMDStockIssuedDuringPeriodValueOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_StockIssuedDuringPeriodSharesOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts" xlink:label="loc_GLMDStockIssuedDuringPeriodSharesOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GLMDStockIssuedDuringPeriodSharesOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_ExerciseOfPrefundedWarrants" xlink:label="loc_GLMDExerciseOfPrefundedWarrants" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GLMDExerciseOfPrefundedWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_ExerciseOfPrefundedWarrantsShares" xlink:label="loc_GLMDExerciseOfPrefundedWarrantsShares" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GLMDExerciseOfPrefundedWarrantsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:label="loc_GLMDStockIssuedDuringPeriodValueExerciseOfWarrants" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GLMDStockIssuedDuringPeriodValueExerciseOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="loc_GLMDStockIssuedDuringPeriodSharesExerciseOfWarrants" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GLMDStockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/StatementsOfChangesInStockholdersEquityParenthetical" xlink:title="00000008 - Statement - Statements of Changes in Stockholders&apos; Equity (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_WarrantsNetOfIssuanceCosts" xlink:label="loc_GLMDWarrantsNetOfIssuanceCosts" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_GLMDWarrantsNetOfIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/StatementsOfCashFlows" xlink:title="00000009 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfInvestments" xlink:label="loc_us-gaapGainLossOnSaleOfInvestments" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainLossOnSaleOfInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_FinancialExpenses" xlink:label="loc_GLMDFinancialExpenses" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_GLMDFinancialExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_ProceedsFinanceLeaseInterestExpenseIncome" xlink:label="loc_GLMDProceedsFinanceLeaseInterestExpenseIncome" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_GLMDProceedsFinanceLeaseInterestExpenseIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_DecreaseInShorttermDeposits" xlink:label="loc_GLMDDecreaseInShorttermDeposits" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_GLMDDecreaseInShorttermDeposits" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaapIncomeLossFromEquityMethodInvestments" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncomeLossFromEquityMethodInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetImpairmentCharges" xlink:label="loc_us-gaapOtherAssetImpairmentCharges" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapOtherAssetImpairmentCharges" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_ChangeInFairValueConvertibleNote" xlink:label="loc_GLMDChangeInFairValueConvertibleNote" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_GLMDChangeInFairValueConvertibleNote" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsAndOtherReceivables" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsAndOtherReceivables" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableTrade" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableTrade" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccountsPayable" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccountsPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_PaymentsForInvestmentInAvailableForSaleSecurities" xlink:label="loc_GLMDPaymentsForInvestmentInAvailableForSaleSecurities" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_GLMDPaymentsForInvestmentInAvailableForSaleSecurities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_PaymentsForProceedsFromInvestmentInConvertibleNote" xlink:label="loc_GLMDPaymentsForProceedsFromInvestmentInConvertibleNote" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_GLMDPaymentsForProceedsFromInvestmentInConvertibleNote" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaapPaymentsToAcquireBusinessesGross" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireBusinessesGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_PaymentsForProceedsFromInvestmentInAssociate" xlink:label="loc_GLMDPaymentsForProceedsFromInvestmentInAssociate" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_GLMDPaymentsForProceedsFromInvestmentInAssociate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaapProceedsFromSaleOfAvailableForSaleSecuritiesDebt" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromOtherDeposits" xlink:label="loc_us-gaapPaymentsForProceedsFromOtherDeposits" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsForProceedsFromOtherDeposits" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_IssuanceOfOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts" xlink:label="loc_GLMDIssuanceOfOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_GLMDIssuanceOfOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_ConversionOfConvertibleNoteIntoInvestmentInAssociate" xlink:label="loc_GLMDConversionOfConvertibleNoteIntoInvestmentInAssociate" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_GLMDConversionOfConvertibleNoteIntoInvestmentInAssociate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:title="995410 - Disclosure - Pay vs Performance Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems" xlink:label="loc_ecdPayVsPerformanceDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable" xlink:label="loc_ecdPvpTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis" xlink:label="loc_ecdExecutiveCategoryAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdExecutiveCategoryAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember" xlink:label="loc_ecdAllExecutiveCategoriesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdExecutiveCategoryAxis" xlink:to="loc_ecdAllExecutiveCategoriesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis" xlink:label="loc_ecdAdjToCompAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdAdjToCompAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember" xlink:label="loc_ecdAllAdjToCompMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAdjToCompAxis" xlink:to="loc_ecdAllAdjToCompMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis" xlink:label="loc_ecdMeasureAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdMeasureAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock" xlink:label="loc_ecdPvpTableTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName" xlink:label="loc_ecdCoSelectedMeasureName" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdCoSelectedMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="loc_ecdNamedExecutiveOfficersFnTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdNamedExecutiveOfficersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="loc_ecdPeerGroupIssuersFnTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeerGroupIssuersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="loc_ecdChangedPeerGroupFnTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdChangedPeerGroupFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt" xlink:label="loc_ecdPeoTotalCompAmt" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="loc_ecdPeoActuallyPaidCompAmt" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoActuallyPaidCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="loc_ecdAdjToPeoCompFnTextBlock" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdAdjToPeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="loc_ecdNonPeoNeoAvgTotalCompAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="loc_ecdAdjToNonPeoNeoCompFnTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdAdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:presentationArc order="2140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" />
      <link:presentationArc order="2150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" />
      <link:presentationArc order="2160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock" xlink:label="loc_ecdTabularListTableTextBlock" />
      <link:presentationArc order="2170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTabularListTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt" xlink:label="loc_ecdTotalShareholderRtnAmt" />
      <link:presentationArc order="2180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="loc_ecdPeerGroupTotalShareholderRtnAmt" />
      <link:presentationArc order="2190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdPeerGroupTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="2200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt" xlink:label="loc_ecdCoSelectedMeasureAmt" />
      <link:presentationArc order="2210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdCoSelectedMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt" xlink:label="loc_ecdOtherPerfMeasureAmt" />
      <link:presentationArc order="2220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdOtherPerfMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt" xlink:label="loc_ecdAdjToCompAmt" />
      <link:presentationArc order="2230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdAdjToCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName" xlink:label="loc_ecdPeoName" />
      <link:presentationArc order="2240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdPeoName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName" xlink:label="loc_ecdMeasureName" />
      <link:presentationArc order="2250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="loc_ecdNonGaapMeasureDescriptionTextBlock" />
      <link:presentationArc order="2260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdMeasureName" xlink:to="loc_ecdNonGaapMeasureDescriptionTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="loc_ecdAdditional402vDisclosureTextBlock" />
      <link:presentationArc order="2270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdAdditional402vDisclosureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="loc_ecdPnsnBnftsAdjFnTextBlock" />
      <link:presentationArc order="2280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPnsnBnftsAdjFnTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:title="995440 - Disclosure - Recovery of Erroneously Awarded Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems" xlink:label="loc_ecdRecoveryOfErrCompDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable" xlink:label="loc_ecdErrCompRecoveryTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdErrCompRecoveryTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis" xlink:label="loc_ecdRestatementDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdRestatementDateAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate" xlink:label="loc_ecdRestatementDeterminationDate" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdRestatementDeterminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt" xlink:label="loc_ecdAggtErrCompAmt" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="loc_ecdErrCompAnalysisTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdErrCompAnalysisTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="loc_ecdOutstandingAggtErrCompAmt" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdOutstandingAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="loc_ecdAggtErrCompNotYetDeterminedTextBlock" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdAggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName" xlink:label="loc_ecdForgoneRecoveryIndName" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName" xlink:label="loc_ecdOutstandingRecoveryIndName" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="loc_ecdOutstandingRecoveryCompAmt" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:title="995443 - Disclosure - Award Timing Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems" xlink:label="loc_ecdAwardTmgDiscLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="loc_ecdAwardsCloseToMnpiDiscTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_ecdIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="loc_ecdAwardTmgMnpiDiscTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiDiscTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="loc_ecdAwardTmgMethodTextBlock" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="loc_ecdAwardTmgPredtrmndFlag" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgPredtrmndFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="loc_ecdAwardTmgMnpiCnsdrdFlag" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiCnsdrdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="loc_ecdMnpiDiscTimedForCompValFlag" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdMnpiDiscTimedForCompValFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="loc_ecdAwardsCloseToMnpiDiscIndName" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="loc_ecdAwardUndrlygSecuritiesAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardUndrlygSecuritiesAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice" xlink:label="loc_ecdAwardExrcPrice" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardExrcPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue" xlink:label="loc_ecdAwardGrantDateFairValue" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="loc_ecdUndrlygSecurityMktPriceChngPct" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdUndrlygSecurityMktPriceChngPct" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="995445 - Disclosure - Insider Trading Arrangements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="loc_ecdInsiderTradingArrLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable" xlink:label="loc_ecdTradingArrByIndTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTradingArrByIndTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis" xlink:label="loc_ecdTradingArrAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdTradingArrByIndTable" xlink:to="loc_ecdTradingArrAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember" xlink:label="loc_ecdAllTradingArrangementsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdTradingArrAxis" xlink:to="loc_ecdAllTradingArrangementsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdTradingArrByIndTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="loc_ecdMtrlTermsOfTrdArrTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdMtrlTermsOfTrdArrTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName" xlink:label="loc_ecdTrdArrIndName" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle" xlink:label="loc_ecdTrdArrIndTitle" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="loc_ecdRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="loc_ecdNonRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate" xlink:label="loc_ecdTrdArrAdoptionDate" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrAdoptionDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="loc_ecdRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="loc_ecdNonRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate" xlink:label="loc_ecdTrdArrTerminationDate" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrTerminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate" xlink:label="loc_ecdTrdArrExpirationDate" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrExpirationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration" xlink:label="loc_ecdTrdArrDuration" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrDuration" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:title="995447 - Disclosure - Insider Trading Policies and Procedures">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="loc_ecdInsiderTradingPoliciesProcLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000015 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="loc_cydCybersecurityRiskManagementProcessesIntegratedFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementProcessesIntegratedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="loc_cydCybersecurityRiskManagementProcessesIntegratedTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="loc_cydCybersecurityRiskManagementThirdPartyEngagedFlag" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementThirdPartyEngagedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="loc_cydCybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="loc_cydCybersecurityRiskBoardOfDirectorsOversightTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="loc_cydCybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="loc_cydCybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="loc_cydCybersecurityRiskRoleOfManagementTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskRoleOfManagementTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000016 - Disclosure - Material Cybersecurity Incident Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentAbstract" xlink:label="loc_cydMaterialCybersecurityIncidentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentNatureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentNatureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentScopeTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentScopeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentTimingTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentTimingTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/General" xlink:title="999017 - Disclosure - General">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/SignificantAccountingPolicies" xlink:title="999018 - Disclosure - Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/MarketableDebtSecurities" xlink:title="999019 - Disclosure - Marketable debt securities">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaapCashAndCashEquivalentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="loc_us-gaapCashCashEquivalentsAndMarketableSecuritiesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/OtherReceivables" xlink:title="999020 - Disclosure - Other Receivables">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesAbstract" xlink:label="loc_us-gaapReceivablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:label="loc_us-gaapLoansNotesTradeAndOtherReceivablesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapReceivablesAbstract" xlink:to="loc_us-gaapLoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/Leases" xlink:title="999021 - Disclosure - Leases">
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_DisclosureLeasesAbstract" xlink:label="loc_GLMDDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeasesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GLMDDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeasesTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/PropertyAndEquipmentNet" xlink:title="999022 - Disclosure - Property and equipment, net">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/InvestmentInAssociate" xlink:title="999023 - Disclosure - Investment in an Associate">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTextBlock" xlink:label="loc_us-gaapInvestmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" xlink:to="loc_us-gaapInvestmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/OtherPayables" xlink:title="999024 - Disclosure - Other Payables">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="loc_us-gaapOtherLiabilitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaapOtherLiabilitiesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapOtherLiabilitiesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/RelatedParties" xlink:title="999025 - Disclosure - Related Parties">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/CommitmentsAndContingencies" xlink:title="999026 - Disclosure - Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/StockholdersEquity" xlink:title="999027 - Disclosure - Stockholders&#8217; equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapShareholdersEquityAndShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/ResearchAndDevelopmentExpenses" xlink:title="999028 - Disclosure - Research and Development Expenses">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaapResearchAndDevelopmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:label="loc_us-gaapResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentAbstract" xlink:to="loc_us-gaapResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/GeneralAndAdministrativeExpenses" xlink:title="999029 - Disclosure - General and Administrative Expenses">
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_DisclosureGeneralAndAdministrativeExpensesAbstract" xlink:label="loc_GLMDDisclosureGeneralAndAdministrativeExpensesAbstract" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_GeneralAndAdministrativeExpensesDisclosureTextBlock" xlink:label="loc_GLMDGeneralAndAdministrativeExpensesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GLMDDisclosureGeneralAndAdministrativeExpensesAbstract" xlink:to="loc_GLMDGeneralAndAdministrativeExpensesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/FinancialIncomeNet" xlink:title="999030 - Disclosure - Financial income, net">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaapRevenueFromContractWithCustomerAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaapRevenueFromContractWithCustomerTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/IncomeTaxes" xlink:title="999031 - Disclosure - Income Taxes">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/SubsequentEvents" xlink:title="999032 - Disclosure - Subsequent events">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/SegmentReporting" xlink:title="999033 - Disclosure - Segment Reporting">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaapSegmentReportingDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapSegmentReportingDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/SignificantAccountingPoliciesPolicies" xlink:title="999034 - Disclosure - Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConsolidationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaapCashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_ShortTermDepositsPolicyTextBlock" xlink:label="loc_GLMDShortTermDepositsPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_GLMDShortTermDepositsPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="loc_us-gaapMarketableSecuritiesPolicy" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapMarketableSecuritiesPolicy" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaapLesseeLeasesPolicyTextBlock" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapLesseeLeasesPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="loc_us-gaapInvestmentPolicyTextBlock" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapInvestmentPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_NewAccountingPronouncementsNotYetEffectivePolicyTextBlock" xlink:label="loc_GLMDNewAccountingPronouncementsNotYetEffectivePolicyTextBlock" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_GLMDNewAccountingPronouncementsNotYetEffectivePolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/SignificantAccountingPoliciesTables" xlink:title="999035 - Disclosure - Significant Accounting Policies (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentTableTextBlock" xlink:label="loc_GLMDScheduleOfDepreciationRatesForPropertyPlantAndEquipmentTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_GLMDScheduleOfDepreciationRatesForPropertyPlantAndEquipmentTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaapScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/MarketableDebtSecuritiesTables" xlink:title="999036 - Disclosure - Marketable debt securities (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaapCashAndCashEquivalentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="loc_us-gaapMarketableSecuritiesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsAbstract" xlink:to="loc_us-gaapMarketableSecuritiesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/OtherReceivablesTables" xlink:title="999037 - Disclosure - Other Receivables (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesAbstract" xlink:label="loc_us-gaapReceivablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="loc_us-gaapScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapReceivablesAbstract" xlink:to="loc_us-gaapScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/PropertyAndEquipmentNetTables" xlink:title="999038 - Disclosure - Property and equipment, net (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/InvestmentInAssociateTables" xlink:title="999039 - Disclosure - Investment in an Associate (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_ScheduleOfBalanceSheetsTableTextBlock" xlink:label="loc_GLMDScheduleOfBalanceSheetsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" xlink:to="loc_GLMDScheduleOfBalanceSheetsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_ScheduleOfStatementOfOperationsTableTextBlock" xlink:label="loc_GLMDScheduleOfStatementOfOperationsTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" xlink:to="loc_GLMDScheduleOfStatementOfOperationsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/OtherPayablesTables" xlink:title="999040 - Disclosure - Other Payables (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="loc_us-gaapOtherLiabilitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesTableTextBlock" xlink:label="loc_us-gaapOtherLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapOtherLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/StockholdersEquityTables" xlink:title="999041 - Disclosure - Stockholders&#8217; equity (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/ResearchAndDevelopmentExpensesTables" xlink:title="999042 - Disclosure - Research and Development Expenses (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaapResearchAndDevelopmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/GeneralAndAdministrativeExpensesTables" xlink:title="999043 - Disclosure - General and Administrative Expenses (Tables)">
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_DisclosureGeneralAndAdministrativeExpensesAbstract" xlink:label="loc_GLMDDisclosureGeneralAndAdministrativeExpensesAbstract" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_GeneralAndAdministrativeExpensesTableTextBlock" xlink:label="loc_GLMDGeneralAndAdministrativeExpensesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GLMDDisclosureGeneralAndAdministrativeExpensesAbstract" xlink:to="loc_GLMDGeneralAndAdministrativeExpensesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/FinancialIncomeNetTables" xlink:title="999044 - Disclosure - Financial income, net (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaapRevenueFromContractWithCustomerAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeByComponentTextBlock" xlink:label="loc_us-gaapScheduleOfOtherNonoperatingIncomeByComponentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapScheduleOfOtherNonoperatingIncomeByComponentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/IncomeTaxesTables" xlink:title="999045 - Disclosure - Income Taxes (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/GeneralDetailsNarrative" xlink:title="999046 - Disclosure - General (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="loc_deiEntityIncorporationDateOfIncorporation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_deiEntityIncorporationDateOfIncorporation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperationsCommencedDate1" xlink:label="loc_us-gaapOperationsCommencedDate1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOperationsCommencedDate1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaapRestrictedCashCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapRestrictedCashCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="loc_us-gaapDepositsAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapDepositsAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaapShortTermInvestments" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapShortTermInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentDetails" xlink:title="999047 - Disclosure - Schedule of Depreciation Rates for Property, Plant and Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_OfficeFurnitureAndEquipmentMember" xlink:label="loc_GLMDOfficeFurnitureAndEquipmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_GLMDOfficeFurnitureAndEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_ComputerSoftwareElectronicEquipmentMember" xlink:label="loc_GLMDComputerSoftwareElectronicEquipmentMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_GLMDComputerSoftwareElectronicEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" xlink:label="loc_us-gaapPropertyPlantAndEquipmentSalvageValuePercentage" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentSalvageValuePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDepreciationMethodExtensibleEnumeration" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDepreciationMethodExtensibleEnumeration" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDepreciationMethodExtensibleEnumeration" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/ScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:title="999048 - Disclosure - Schedule of Assets Measured at Fair Value on Recurring Basis (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaapFairValueByMeasurementFrequencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByMeasurementFrequencyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaapFairValueMeasurementsRecurringMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:to="loc_us-gaapFairValueMeasurementsRecurringMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaapCorporateDebtSecuritiesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapCorporateDebtSecuritiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaapUSTreasurySecuritiesMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapUSTreasurySecuritiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MutualFundMember" xlink:label="loc_us-gaapMutualFundMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapMutualFundMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_InvestmentInAssociateMember" xlink:label="loc_GLMDInvestmentInAssociateMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_GLMDInvestmentInAssociateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaapAssetsFairValueDisclosure" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapAssetsFairValueDisclosure" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/SignificantAccountingPoliciesDetailsNarrative" xlink:title="999049 - Disclosure - Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentInterestRate" xlink:label="loc_us-gaapInvestmentInterestRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapInvestmentInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_MonthlyDepositsOfEmployeesPercentageOnMonthlySalary" xlink:label="loc_GLMDMonthlyDepositsOfEmployeesPercentageOnMonthlySalary" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_GLMDMonthlyDepositsOfEmployeesPercentageOnMonthlySalary" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDescription" xlink:label="loc_GLMDShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDescription" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_GLMDShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDescription" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/ScheduleOfMarketableDebtSecuritiesDetails" xlink:title="999050 - Disclosure - Schedule of Marketable Debt Securities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaapCashAndCashEquivalentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:label="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsAbstract" xlink:to="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:label="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaapCorporateDebtSecuritiesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapCorporateDebtSecuritiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaapUSTreasurySecuritiesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapUSTreasurySecuritiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MutualFundMember" xlink:label="loc_us-gaapMutualFundMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapMutualFundMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaapAvailableForSaleDebtSecuritiesAmortizedCostBasis" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:label="loc_us-gaapAvailableForSaleDebtSecuritiesGrossUnrealizedGain" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapAvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:label="loc_us-gaapAvailableForSaleDebtSecuritiesGrossUnrealizedLoss" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapAvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaapAvailableForSaleSecuritiesDebtSecurities" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapAvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/ScheduleOfOtherReceivablesDetails" xlink:title="999051 - Disclosure - Schedule of Other Receivables (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesAbstract" xlink:label="loc_us-gaapReceivablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapReceivablesAbstract" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrantsReceivable" xlink:label="loc_us-gaapGrantsReceivable" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapReceivablesAbstract" xlink:to="loc_us-gaapGrantsReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivables" xlink:label="loc_us-gaapOtherReceivables" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapReceivablesAbstract" xlink:to="loc_us-gaapOtherReceivables" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaapReceivablesNetCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapReceivablesAbstract" xlink:to="loc_us-gaapReceivablesNetCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/LeasesDetailsNarrative" xlink:title="999052 - Disclosure - Leases (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_DisclosureLeasesAbstract" xlink:label="loc_GLMDDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfLand" xlink:label="loc_us-gaapAreaOfLand" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GLMDDisclosureLeasesAbstract" xlink:to="loc_us-gaapAreaOfLand" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaapLeaseExpirationDate1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GLMDDisclosureLeasesAbstract" xlink:to="loc_us-gaapLeaseExpirationDate1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GLMDDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GLMDDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GLMDDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GLMDDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:label="loc_us-gaapOperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GLMDDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:title="999053 - Disclosure - Schedule of Property and Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MachineryAndEquipmentGross" xlink:label="loc_us-gaapMachineryAndEquipmentGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapMachineryAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="loc_us-gaapFurnitureAndFixturesGross" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapFurnitureAndFixturesGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedComputerSoftwareGross" xlink:label="loc_us-gaapCapitalizedComputerSoftwareGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapCapitalizedComputerSoftwareGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="loc_us-gaapLeaseholdImprovementsGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapLeaseholdImprovementsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/ScheduleOfBalanceSheetsDetails" xlink:title="999054 - Disclosure - Schedule of Balance Sheets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_OnkaiIncMember" xlink:label="loc_GLMDOnkaiIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_GLMDOnkaiIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/ScheduleOfStatementOfOperationsDetails" xlink:title="999055 - Disclosure - Schedule of Statement of Operations (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_OnkaiIncMember" xlink:label="loc_GLMDOnkaiIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_GLMDOnkaiIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/InvestmentInAssociateDetailsNarrative" xlink:title="999056 - Disclosure - Investment in an Associate (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_OnkaiIncMember" xlink:label="loc_GLMDOnkaiIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_GLMDOnkaiIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtProductOrServiceAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdministrativeServiceMember" xlink:label="loc_us-gaapAdministrativeServiceMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapAdministrativeServiceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_BridgeLoanAgreementMember" xlink:label="loc_GLMDBridgeLoanAgreementMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GLMDBridgeLoanAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_ServicesAgreementMember" xlink:label="loc_GLMDServicesAgreementMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GLMDServicesAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_CapitalStockDiscountRate" xlink:label="loc_GLMDCapitalStockDiscountRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GLMDCapitalStockDiscountRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaapGainLossOnInvestments" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGainLossOnInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaapPaymentsToAcquireInvestments" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsToAcquireInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentOwnedBalanceShares" xlink:label="loc_us-gaapInvestmentOwnedBalanceShares" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInvestmentOwnedBalanceShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentOwnedPercentOfNetAssets" xlink:label="loc_us-gaapInvestmentOwnedPercentOfNetAssets" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInvestmentOwnedPercentOfNetAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromOtherDebt" xlink:label="loc_us-gaapProceedsFromOtherDebt" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromOtherDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaapRepaymentsOfDebt" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRepaymentsOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaapAssetImpairmentCharges" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetImpairmentCharges" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/ScheduleOfOtherPayablesDetails" xlink:title="999057 - Disclosure - Schedule of Other Payables (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="loc_us-gaapOtherLiabilitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrentAndNoncurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensatedAbsencesLiability" xlink:label="loc_us-gaapCompensatedAbsencesLiability" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapCompensatedAbsencesLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_ShorttermLeaseObligation" xlink:label="loc_GLMDShorttermLeaseObligation" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_GLMDShorttermLeaseObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNotesPayable" xlink:label="loc_us-gaapOtherNotesPayable" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapOtherNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilities" xlink:label="loc_us-gaapOtherLiabilities" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapOtherLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/RelatedPartiesDetailsNarrative" xlink:title="999058 - Disclosure - Related Parties (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_OfficersAndDirectorsMember" xlink:label="loc_GLMDOfficersAndDirectorsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_GLMDOfficersAndDirectorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_ServiceAgreementMember" xlink:label="loc_GLMDServiceAgreementMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GLMDServiceAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaapLongTermDebt" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapLongTermDebt" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999059 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLossContingenciesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapLossContingenciesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_BankLienOnMarketableSecurities" xlink:label="loc_GLMDBankLienOnMarketableSecurities" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GLMDBankLienOnMarketableSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_UpfrontLicenseFee" xlink:label="loc_GLMDUpfrontLicenseFee" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GLMDUpfrontLicenseFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_PaymentsToRegulatoryMilestones" xlink:label="loc_GLMDPaymentsToRegulatoryMilestones" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GLMDPaymentsToRegulatoryMilestones" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/SummaryOfStatusOfCompanysOptionPlansAndChangesDetails" xlink:title="999060 - Disclosure - Summary of Status of Company&apos;s Option Plans and Changes (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityEquityTable" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/StockholdersEquityDetailsNarrative" xlink:title="999061 - Disclosure - Stockholders&#8217; equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_NewSalesAgreementMember" xlink:label="loc_GLMDNewSalesAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GLMDNewSalesAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_StandbyEquityPurchaseAgreementMember" xlink:label="loc_GLMDStandbyEquityPurchaseAgreementMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GLMDStandbyEquityPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_CaymanIslandsExemptLimitedPartnershipMember" xlink:label="loc_GLMDCaymanIslandsExemptLimitedPartnershipMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GLMDCaymanIslandsExemptLimitedPartnershipMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_DemandSalesAgreementMember" xlink:label="loc_GLMDDemandSalesAgreementMember" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GLMDDemandSalesAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_TwoThousandAndTwentySalesAgreementMember" xlink:label="loc_GLMDTwoThousandAndTwentySalesAgreementMember" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GLMDTwoThousandAndTwentySalesAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_PrefundedWarrantsMember" xlink:label="loc_GLMDPrefundedWarrantsMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_GLMDPrefundedWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_InvestorWarrantsMember" xlink:label="loc_GLMDInvestorWarrantsMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_GLMDInvestorWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaapInvestorMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapInvestorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtRangeAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapPlanNameAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_IncentiveShareOptionPlan2013Member" xlink:label="loc_GLMDIncentiveShareOptionPlan2013Member" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_GLMDIncentiveShareOptionPlan2013Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAwardTypeAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtTitleOfIndividualAxis" order="80" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srtChiefExecutiveOfficerMember" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefExecutiveOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="90" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionMember" xlink:label="loc_us-gaapOptionMember" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_MaximumAmountOfSharesToBeIssued" xlink:label="loc_GLMDMaximumAmountOfSharesToBeIssued" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_GLMDMaximumAmountOfSharesToBeIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockNoParValue" xlink:label="loc_us-gaapCommonStockNoParValue" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockNoParValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapConversionOfStockSharesIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfDebtIssuanceCosts" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPaymentsOfDebtIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantExercisePriceIncrease" xlink:label="loc_us-gaapWarrantExercisePriceIncrease" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapWarrantExercisePriceIncrease" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaapOtherCommitment" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapOtherCommitment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="loc_us-gaapDebtInstrumentFeeAmount" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapDebtInstrumentFeeAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_CommitmentShare" xlink:label="loc_GLMDCommitmentShare" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_GLMDCommitmentShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_ProceedsFinanceLeaseInterestExpenseIncome" xlink:label="loc_GLMDProceedsFinanceLeaseInterestExpenseIncome" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_GLMDProceedsFinanceLeaseInterestExpenseIncome" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpenses" xlink:label="loc_us-gaapOtherExpenses" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapOtherExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_CommonStockCapitalSharesReservedForFutureIssuanceUnallocated" xlink:label="loc_GLMDCommonStockCapitalSharesReservedForFutureIssuanceUnallocated" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_GLMDCommonStockCapitalSharesReservedForFutureIssuanceUnallocated" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/ScheduleOfResearchAndDevelopmentExpensesDetails" xlink:title="999062 - Disclosure - Schedule of Research and Development Expenses (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaapResearchAndDevelopmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_ChemistryAndFormulationStudiesMember" xlink:label="loc_GLMDChemistryAndFormulationStudiesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_GLMDChemistryAndFormulationStudiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_SalariesMember" xlink:label="loc_GLMDSalariesMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_GLMDSalariesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_StockBasedCompensationMember" xlink:label="loc_GLMDStockBasedCompensationMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_GLMDStockBasedCompensationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_ResearchAndPreclinicalStudiesMember" xlink:label="loc_GLMDResearchAndPreclinicalStudiesMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_GLMDResearchAndPreclinicalStudiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_ClinicalStudiesMember" xlink:label="loc_GLMDClinicalStudiesMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_GLMDClinicalStudiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_RegulatoryAndOtherExpensesMember" xlink:label="loc_GLMDRegulatoryAndOtherExpensesMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_GLMDRegulatoryAndOtherExpensesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/ScheduleOfGeneralAndAdministrativeExpensesDetails" xlink:title="999063 - Disclosure - Schedule of General and Administrative Expenses (Details)">
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_DisclosureGeneralAndAdministrativeExpensesAbstract" xlink:label="loc_GLMDDisclosureGeneralAndAdministrativeExpensesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GLMDDisclosureGeneralAndAdministrativeExpensesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_StockBasedCompensationMember" xlink:label="loc_GLMDStockBasedCompensationMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_GLMDStockBasedCompensationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_ProfessionalFeeMember" xlink:label="loc_GLMDProfessionalFeeMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_GLMDProfessionalFeeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_SalariesAndBenefitsMember" xlink:label="loc_GLMDSalariesAndBenefitsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_GLMDSalariesAndBenefitsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_RentAndOfficeMaintenanceFeesMember" xlink:label="loc_GLMDRentAndOfficeMaintenanceFeesMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_GLMDRentAndOfficeMaintenanceFeesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_InsuranceAndOtherExpensesMember" xlink:label="loc_GLMDInsuranceAndOtherExpensesMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_GLMDInsuranceAndOtherExpensesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/ScheduleOfFinancialIncomeNetDetails" xlink:title="999064 - Disclosure - Schedule of Financial Income, Net (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaapRevenueFromContractWithCustomerAbstract" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_BankFees" xlink:label="loc_GLMDBankFees" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_GLMDBankFees" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_InterestIncome" xlink:label="loc_GLMDInterestIncome" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_GLMDInterestIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleGainLoss" xlink:label="loc_us-gaapDebtSecuritiesAvailableForSaleGainLoss" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapDebtSecuritiesAvailableForSaleGainLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_ChangeInFairValueOfConvertibleNote" xlink:label="loc_GLMDChangeInFairValueOfConvertibleNote" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_GLMDChangeInFairValueOfConvertibleNote" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:title="999065 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/IncomeTaxesDetailsNarrative" xlink:title="999066 - Disclosure - Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapOperatingLossCarryforwardsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityNameAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IsraelTaxAuthorityMember" xlink:label="loc_us-gaapIsraelTaxAuthorityMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:to="loc_us-gaapIsraelTaxAuthorityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_MalteseSubsidiaryMember" xlink:label="loc_GLMDMalteseSubsidiaryMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:to="loc_GLMDMalteseSubsidiaryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_MalteseSubsidiaryMember" xlink:label="loc_GLMDMalteseSubsidiaryMember_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_GLMDMalteseSubsidiaryMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_IsraeliSubsidiaryMember" xlink:label="loc_GLMDIsraeliSubsidiaryMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_GLMDIsraeliSubsidiaryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RegulatoryAssetAxis" xlink:label="loc_us-gaapRegulatoryAssetAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapRegulatoryAssetAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RegulatoryAssetDomain" xlink:label="loc_us-gaapRegulatoryAssetDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRegulatoryAssetAxis" xlink:to="loc_us-gaapRegulatoryAssetDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxChargesMember" xlink:label="loc_us-gaapDeferredIncomeTaxChargesMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRegulatoryAssetDomain" xlink:to="loc_us-gaapDeferredIncomeTaxChargesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsCapitalLossCarryforwards" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsCapitalLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/SubsequentEventsDetailsNarrative" xlink:title="999067 - Disclosure - Subsequent events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_TwoThousandAndTwentySalesAgreementMember" xlink:label="loc_GLMDTwoThousandAndTwentySalesAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GLMDTwoThousandAndTwentySalesAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_CaymanIslandsExemptLimitedPartnershipMember" xlink:label="loc_GLMDCaymanIslandsExemptLimitedPartnershipMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GLMDCaymanIslandsExemptLimitedPartnershipMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_deiLegalEntityAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="glmd-20241231.xsd#GLMD_CaymanIslandsExemptLimitedPartnershipMember" xlink:label="loc_GLMDCaymanIslandsExemptLimitedPartnershipMember_2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_GLMDCaymanIslandsExemptLimitedPartnershipMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://galmedpharma.com/role/SegmentReportingDetailsNarrative" xlink:title="999068 - Disclosure - Segment Reporting (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaapNumberOfReportableSegments" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapNumberOfReportableSegments" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesLineItems', window );"><strong>Entity Addresses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentRegistrationStatement', window );">Document Registration Statement</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentShellCompanyReport', window );">Document Shell Company Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36345<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">GALMED
PHARMACEUTICALS LTD.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001595353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">L3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">16
Abba Hillel Road<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Ramat Gan<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">5250608<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary shares, par
    value NIS 0.15 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GLMD<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAccountingStandard', window );">Document Accounting Standard</a></td>
<td class="text">U.S. GAAP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">1,654,428<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">1197<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorOpinionTextBlock', window );">Auditor Opinion [Text Block]</a></td>
<td class="text">We
have audited the accompanying consolidated balance sheets of Galmed Pharmaceuticals Ltd. and subsidiaries (the &#8220;Company&#8221;)
as of December 31, 2024 and 2023, the related consolidated statements of operations, comprehensive loss, changes in stockholders&#8217;
equity and cash flows, for each of the three years in the period ended December 31, 2024, and the related notes (collectively referred
to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in
all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and
its cash flows for each of the three years in the period ended December 31, 2024, in conformity with accounting principles generally
accepted in the United States of America.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Brightman
Almagor Zohar & Co.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Tel
Aviv, Israel<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesLineItems', window );"><strong>Entity Addresses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">16
Abba Hillel Road<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Ramat
Gan<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">5250608<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">+972.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">693.8448<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Allen
Baharaff<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelEmailAddress', window );">Contact Personnel Email Address</a></td>
<td class="text">ab@galmedpharma.com<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorOpinionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X<br> -Number 210<br> -Section 2<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorOpinionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelEmailAddress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Email address of contact personnel.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelEmailAddress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAccountingStandard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAccountingStandard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:accountingStandardItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a registration statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentShellCompanyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentShellCompanyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 4,652<span></span>
</td>
<td class="nump">$ 2,861<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">121<span></span>
</td>
<td class="nump">117<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsCurrent', window );">Short-term deposits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,496<span></span>
</td>
<td class="nump">2,253<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,183<span></span>
</td>
<td class="nump">7,528<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">672<span></span>
</td>
<td class="nump">480<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16,124<span></span>
</td>
<td class="nump">13,239<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Investment in associate at fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,119<span></span>
</td>
<td class="nump">3,265<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Loan to associate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">257<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,376<span></span>
</td>
<td class="nump">3,390<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">18,500<span></span>
</td>
<td class="nump">16,629<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Trade payables</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,308<span></span>
</td>
<td class="nump">1,879<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLoansPayableCurrent', window );">Other payables</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">865<span></span>
</td>
<td class="nump">871<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,173<span></span>
</td>
<td class="nump">2,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary shares, par value NIS 1.80 per share; Authorized 50,000,000 shares; Issued and outstanding: 1,664,884 and 573,741 shares as of December 31, 2024 and December 31, 2023, respectively</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">742<span></span>
</td>
<td class="nump">209<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">216,470<span></span>
</td>
<td class="nump">207,076<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(416)<span></span>
</td>
<td class="num">(454)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(200,469)<span></span>
</td>
<td class="num">(192,952)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16,327<span></span>
</td>
<td class="nump">13,879<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 18,500<span></span>
</td>
<td class="nump">$ 16,629<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Retroactively
    adjusted to reflect the <span id="xdx_903_eus-gaap--StockholdersEquityReverseStockSplit_c20240101__20241231_ztGOQ4rE0CZ9" title="Reverse stock split">12-1 reverse split</span> that was effected in August 2024 (see Note 11(A)(3))</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity method investee and investment in and advance to affiliate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLoansPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term loans classified as other, payable within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLoansPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - &#8362; / shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value</a></td>
<td class="nump">&#8362; 1.80<span></span>
</td>
<td class="nump">&#8362; 1.80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, authorized</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, issued</a></td>
<td class="nump">1,664,884<span></span>
</td>
<td class="nump">573,741<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares, outstanding</a></td>
<td class="nump">1,664,884<span></span>
</td>
<td class="nump">573,741<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">12-1 reverse split<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,979<span></span>
</td>
<td class="nump">$ 3,569<span></span>
</td>
<td class="nump">$ 12,995<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,299<span></span>
</td>
<td class="nump">3,923<span></span>
</td>
<td class="nump">4,656<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,278<span></span>
</td>
<td class="nump">7,492<span></span>
</td>
<td class="nump">17,651<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Financial loss (income), net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(516)<span></span>
</td>
<td class="num">(580)<span></span>
</td>
<td class="nump">215<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GLMD_FinancialExpenses', window );">Financial expenses related to SEPA</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">610<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GLMD_ImpairmentOnAssociate', window );">Impairment on associate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,145<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 7,517<span></span>
</td>
<td class="nump">$ 6,912<span></span>
</td>
<td class="nump">$ 17,866<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic, net loss per share</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 8.08<span></span>
</td>
<td class="nump">$ 30.00<span></span>
</td>
<td class="nump">$ 127.80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted, net loss per share</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 8.08<span></span>
</td>
<td class="nump">$ 30.00<span></span>
</td>
<td class="nump">$ 127.80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of shares outstanding used in computing net loss per share, basic</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">930,822<span></span>
</td>
<td class="nump">230,795<span></span>
</td>
<td class="nump">139,682<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of shares outstanding used in computing net loss per share, diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">930,822<span></span>
</td>
<td class="nump">230,795<span></span>
</td>
<td class="nump">139,682<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See
    also Note 11(A)(5)</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Retroactively
    adjusted to reflect the <span id="xdx_908_eus-gaap--StockholdersEquityReverseStockSplit_c20240101__20241231_zsT0zUcMI9de" title="Reverse stock split">12-1 reverse split</span> that was affected in August 2024 (see Note 11(A)(3))</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GLMD_FinancialExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GLMD_FinancialExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GLMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GLMD_ImpairmentOnAssociate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GLMD_ImpairmentOnAssociate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GLMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations (Parenthetical)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">12-1 reverse split<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 7,517<span></span>
</td>
<td class="nump">$ 6,912<span></span>
</td>
<td class="nump">$ 17,866<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss', window );">Net unrealized loss (gain) on available for sale securities</a></td>
<td class="num">(38)<span></span>
</td>
<td class="num">(291)<span></span>
</td>
<td class="nump">574<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss</a></td>
<td class="nump">$ 7,479<span></span>
</td>
<td class="nump">$ 6,621<span></span>
</td>
<td class="nump">$ 18,440<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Statements of Changes in Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>AOCI Attributable to Parent [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 70<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 198,772<span></span>
</td>
<td class="num">$ (171)<span></span>
</td>
<td class="num">$ (168,174)<span></span>
</td>
<td class="nump">$ 30,497<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">293,682<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,296<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,296<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of ordinary shares in ATM offering net of issuance costs of $2</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">70<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of ordinary shares in at-the-market ("ATM") offering, net of issuance costs, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">643<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain from marketable debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="num">(574)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(574)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(17,866)<span></span>
</td>
<td class="num">(17,866)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 70<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">200,138<span></span>
</td>
<td class="num">(745)<span></span>
</td>
<td class="num">(186,040)<span></span>
</td>
<td class="nump">13,423<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">294,325<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">892<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">892<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain from marketable debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="nump">291<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">291<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(6,912)<span></span>
</td>
<td class="num">(6,912)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GLMD_StockIssuedDuringPeriodValueOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts', window );">Issuance of ordinary shares, pre-funded warrants, and warrants net of issuance costs of $756 thousand</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">$ 16<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">6,169<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,185<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GLMD_StockIssuedDuringPeriodSharesOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts', window );">Issuance of ordinary shares, pre-funded warrants, and warrants net of issuance costs, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[3]</sup></td>
<td class="nump">31,667<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GLMD_ExerciseOfPrefundedWarrants', window );">Exercise of Pre-funded warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">$ 123<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(123)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GLMD_ExerciseOfPrefundedWarrantsShares', window );">Exercise of Pre-funded warrants, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[3]</sup></td>
<td class="nump">247,749<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 209<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">207,076<span></span>
</td>
<td class="num">(454)<span></span>
</td>
<td class="num">(192,952)<span></span>
</td>
<td class="nump">13,879<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">573,741<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">531<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">531<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain from marketable debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(7,517)<span></span>
</td>
<td class="num">(7,517)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GLMD_ExerciseOfPrefundedWarrants', window );">Exercise of Pre-funded warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">$ 92<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(92)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GLMD_ExerciseOfPrefundedWarrantsShares', window );">Exercise of Pre-funded warrants, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[3]</sup></td>
<td class="nump">186,723<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of ordinary shares in relation to SEPA</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">$ 272<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,654<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,926<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of ordinary shares in relation to SEPA, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[4]</sup></td>
<td class="nump">558,775<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of SEPA Commitment Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">$ 8<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of SEPA Commitment Shares, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[4]</sup></td>
<td class="nump">15,784<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Exercise of RSUs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 18<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(18)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Exercise of RSUs, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">36,528<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GLMD_StockIssuedDuringPeriodValueExerciseOfWarrants', window );">Exercise of Warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">$ 143<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GLMD_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Exercise of Warrants, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[3]</sup></td>
<td class="nump">293,333<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 742<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 216,470<span></span>
</td>
<td class="num">$ (416)<span></span>
</td>
<td class="num">$ (200,469)<span></span>
</td>
<td class="nump">$ 16,327<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,664,884<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Retroactively
    adjusted to reflect the <span id="xdx_90E_eus-gaap--StockholdersEquityReverseStockSplit_c20240101__20241231_zflb9DMjyxOc" title="Reverse stock split">12-1 reverse split</span> that was effected in August 2024 (see Note 11(A)(3))</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Represents
    amounts less than $1</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">See
    also Note 11(A)(4)</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">See
    also Note 11(A)(5)</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GLMD_ExerciseOfPrefundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise of Pre-funded warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GLMD_ExerciseOfPrefundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GLMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GLMD_ExerciseOfPrefundedWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise of Pre-funded warrants, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GLMD_ExerciseOfPrefundedWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GLMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GLMD_StockIssuedDuringPeriodSharesExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise of warrants, shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GLMD_StockIssuedDuringPeriodSharesExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GLMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GLMD_StockIssuedDuringPeriodSharesOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares ordinary shares prefunded warrants and warrants net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GLMD_StockIssuedDuringPeriodSharesOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GLMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GLMD_StockIssuedDuringPeriodValueExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise of warrants, value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GLMD_StockIssuedDuringPeriodValueExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GLMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GLMD_StockIssuedDuringPeriodValueOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value ordinary shares prefunded warrants and warrants net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GLMD_StockIssuedDuringPeriodValueOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GLMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to additional paid-in capital (APIC) for recognition and exercise of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Changes in Stockholders' Equity (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GLMD_WarrantsNetOfIssuanceCosts', window );">Warrants net of issuance costs</a></td>
<td class="nump">$ 756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GLMD_WarrantsNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GLMD_WarrantsNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GLMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flow from operating activities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the year</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (7,517)<span></span>
</td>
<td class="num">$ (6,912)<span></span>
</td>
<td class="num">$ (17,866)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments required to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">83<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of discount (premium) on marketable debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(17)<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfInvestments', window );">Gain on sale of marketable debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="nump">523<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GLMD_FinancialExpenses', window );">Finance expenses related to SEPA</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">610<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GLMD_ProceedsFinanceLeaseInterestExpenseIncome', window );">Finance expenses (income)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="num">(36)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GLMD_DecreaseInShorttermDeposits', window );">Decrease in short-term deposits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7<span></span>
</td>
<td class="num">(53)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Interest income from loan to associate</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(7)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">531<span></span>
</td>
<td class="nump">892<span></span>
</td>
<td class="nump">1,296<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetImpairmentCharges', window );">Impairment of Associate</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">1,145<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GLMD_ChangeInFairValueConvertibleNote', window );">Change in fair value convertible note</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(265)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables', window );">Decrease (increase) in other receivables</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(192)<span></span>
</td>
<td class="nump">345<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Decrease in trade payables</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(571)<span></span>
</td>
<td class="num">(681)<span></span>
</td>
<td class="num">(2,311)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayable', window );">Increase (decrease) in other payables</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">35<span></span>
</td>
<td class="nump">468<span></span>
</td>
<td class="num">(440)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(5,880)<span></span>
</td>
<td class="num">(6,137)<span></span>
</td>
<td class="num">(18,501)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flow from investing activities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GLMD_PaymentsForInvestmentInAvailableForSaleSecurities', window );">Investment in available for sale securities,</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(5,115)<span></span>
</td>
<td class="num">(4,133)<span></span>
</td>
<td class="num">(2,373)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GLMD_PaymentsForProceedsFromInvestmentInConvertibleNote', window );">Investment in Convertible note</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,500)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Loan to associate</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(250)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GLMD_PaymentsForProceedsFromInvestmentInAssociate', window );">Investment in Associate</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text"> <span></span>
</td>
<td class="num">(1,500)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Proceeds from sale of available for sale securities,</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,504<span></span>
</td>
<td class="nump">8,633<span></span>
</td>
<td class="nump">21,440<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherDeposits', window );">Proceeds from (investment in) short-term deposits, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,250)<span></span>
</td>
<td class="num">(2,200)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,111)<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="nump">17,563<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flow from financing activities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Issuance of ordinary shares in at-the-market offering, net of issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of ordinary shares in relation to SEPA</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">4,386<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GLMD_IssuanceOfOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts', window );">Issuance of ordinary shares, pre-funded warrants, and warrants net of issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">4,400<span></span>
</td>
<td class="nump">6,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,786<span></span>
</td>
<td class="nump">6,185<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,795<span></span>
</td>
<td class="nump">848<span></span>
</td>
<td class="num">(868)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents and restricted cash at the beginning of the year</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,978<span></span>
</td>
<td class="nump">2,130<span></span>
</td>
<td class="nump">2,998<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash at the end of the year</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,773<span></span>
</td>
<td class="nump">2,978<span></span>
</td>
<td class="nump">2,130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash received from interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">503<span></span>
</td>
<td class="nump">376<span></span>
</td>
<td class="nump">297<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GLMD_ConversionOfConvertibleNoteIntoInvestmentInAssociate', window );">Conversion of convertible note into investment in associate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,765<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See
    also Note 11(A)(5)</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">See
    also Note 7</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">See
    also Note 11(A)(4)</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GLMD_ChangeInFairValueConvertibleNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value convertible note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GLMD_ChangeInFairValueConvertibleNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GLMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GLMD_ConversionOfConvertibleNoteIntoInvestmentInAssociate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of convertible note into investment in associate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GLMD_ConversionOfConvertibleNoteIntoInvestmentInAssociate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GLMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GLMD_DecreaseInShorttermDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in short term deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GLMD_DecreaseInShorttermDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GLMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GLMD_FinancialExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GLMD_FinancialExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GLMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GLMD_IssuanceOfOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of ordinary shares, pre-funded warrants, and warrants net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GLMD_IssuanceOfOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GLMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GLMD_PaymentsForInvestmentInAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments for investment in available for sale securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GLMD_PaymentsForInvestmentInAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GLMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GLMD_PaymentsForProceedsFromInvestmentInAssociate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>payments for proceeds from investment in associate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GLMD_PaymentsForProceedsFromInvestmentInAssociate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GLMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GLMD_PaymentsForProceedsFromInvestmentInConvertibleNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments for proceeds from investment in convertible note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GLMD_PaymentsForProceedsFromInvestmentInConvertibleNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GLMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GLMD_ProceedsFinanceLeaseInterestExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance expenses (income).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GLMD_ProceedsFinanceLeaseInterestExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GLMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from deposits classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (7,517)<span></span>
</td>
<td class="num">$ (6,912)<span></span>
</td>
<td class="num">$ (17,866)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have developed and maintain a cybersecurity risk management program, consisting of cybersecurity policies, procedures, compliance and
awareness programs to mitigate risk and to ensure compliance with security, availability and confidentiality trust principles. <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_903_ecyd--CybersecurityRiskManagementProcessesIntegratedTextBlock_c20240101__20241231_zgk7LVvGPvGd">The cybersecurity
process has been integrated into our overall risk management system and process, and is solely internally managed. Management is responsible
for identifying risks that threaten achievement of the control activities stated in the management&#8217;s description of the services
organizations systems. Management has implemented a process for identifying relevant risks that could affect the organization&#8217;s
ability to provide secure and reliable service to its users. In addition, we maintain cybersecurity insurance.</span> The risk assessment occurs
as business needs change, and covers identification of risks that could act against the company&#8217;s objectives as well as specific
risks related to a compromise to the security of data. See &#8220;Item 3.D Risk Factors&#8212; Risks Related to Information Technology,
Intellectual Property and Data Security and Privacy&#8212;If we or our third-party service providers experience a security breach, data
loss or other compromise, including if unauthorized parties obtain access to our customers&#8217; data, our reputation may be harmed,
demand for our products and services may be reduced, and we may incur significant liabilities.&#8221;</span>&#160;<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90A_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_dbT_c20240101__20241231_zvVjYnBRuX9j">The
oversight of cybersecurity threats is undertaken by our IT external provider, who holds over 25 years of experience, and is supported
by management. Our audit committee is responsible for cybersecurity oversight and monitoring risk. Management informs the audit and remuneration
committee of such risk at committee meetings.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90C_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbT_c20240101__20241231_zviIkgx3w7Ve">As
of the date of this report, we are not aware of any material risks from cybersecurity threats that have materially affected or are reasonably
likely to materially affect us, including our business strategy, results of operations or financial condition.</span></span></p>

&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text">The cybersecurity
process has been integrated into our overall risk management system and process, and is solely internally managed. Management is responsible
for identifying risks that threaten achievement of the control activities stated in the management&#8217;s description of the services
organizations systems. Management has implemented a process for identifying relevant risks that could affect the organization&#8217;s
ability to provide secure and reliable service to its users. In addition, we maintain cybersecurity insurance.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">General</a></td>
<td class="text"><p id="xdx_809_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zbP61AUVdI0f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
1 &#8211; <span id="xdx_825_zP36nn1Cx8rc">General</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Galmed
Pharmaceuticals Ltd. (the &#8220;Company&#8221;) was incorporated in Israel on <span id="xdx_903_edei--EntityIncorporationDateOfIncorporation_c20240101__20241231_zNXhuVNnOKOk" title="Date of incorporation">July 31, 2013</span> and commenced operations on <span id="xdx_903_eus-gaap--OperationsCommencedDate1_c20240101__20241231_zAhbMXbA6BI3" title="Date of commenced operations">February 2,
2014</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company holds three wholly-owned subsidiaries, Galmed International Ltd., which is incorporated in Malta, and Galmed Research and Development
Ltd. (&#8220;GRD&#8221;) and Galtopa Therapeutics Ltd., both of which are incorporated in Israel. In July 2023, GRD established a new
wholly-owned subsidiary incorporated under the laws of England and Wales called Galmed Therapeutics UK Limited.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a biopharmaceutical company focused on the development of Aramchol. The Company has focused almost exclusively on developing
Aramchol for the treatment of liver disease and previously was developing Aramchol for Primary Sclerosing Cholangitis,
or PSC. The Company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.
<span style="background-color: white">In addition, as part of the Company&#8217;s growth strategy, the Company is actively pursuing opportunities
to expand and diversify its product pipeline specifically targeting cardiometabolic indications and other innovative product candidates
that align with the Company&#8217;s core expertise in drug development.</span>. The Company has an operating history limited to pre-clinical
and clinical drug development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company funded its research and development programs and operations to date primarily through proceeds from private placements and public
offerings. The Company currently has no products approved for marketing and has not generated any revenue from product sales to date.
As of December 31, 2024, the Company had cash and cash equivalents of $<span id="xdx_901_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20241231_zXqkWGsftd87" title="Cash and cash equivalents">4.7</span> million, restricted cash of $<span id="xdx_907_eus-gaap--RestrictedCashCurrent_iI_pn5n6_c20241231_zXmnhDowRwce" title="Restricted cash">0.1</span> million, short-term deposits
of $<span id="xdx_902_eus-gaap--DepositsAssetsCurrent_iI_pn5n6_c20241231_zm4jTcWIOW8" title="Short-term deposits">3.5</span> million and marketable debt securities of $<span id="xdx_909_eus-gaap--ShortTermInvestments_iI_pn5n6_c20241231_zsVKsQGfeYYk" title="Marketable securities debt">7.2</span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has incurred operating losses in each year since inception. The Company&#8217;s loss attributable to holders of its ordinary
shares for the years ended December 31, 2022, 2023, and 2024 was approximately $<span id="xdx_905_eus-gaap--ProfitLoss_pn5n6_c20220101__20221231_zUahAWqL4XP8" title="Profit loss">17.9</span> million, $<span id="xdx_905_eus-gaap--ProfitLoss_pn5n6_c20230101__20231231_zk1X3rszzmHl" title="Profit loss">6.9</span> million, and $<span id="xdx_905_eus-gaap--ProfitLoss_pn5n6_c20240101__20241231_zYN8a5pCEaDi" title="Profit loss">8.0</span> million, respectively.
As of December 31, 2024, the Company had an accumulated deficit of $<span id="xdx_900_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20241231_zJvmeL5xUFU9" title="Retained earnings accumulated deficit">200.5</span> million. Substantially all of its operating losses resulted
from costs incurred in connection with the Company&#8217;s development program and from general and administrative costs associated with
its operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will need to raise substantial, additional capital to fund its operations and to develop Aramchol for, and beyond
its current development stage and any future commercialization, as well as any additional indications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the Company&#8217;s current operating plan, the Company&#8217;s management currently estimates that its cash position will support
its current operations as currently conducted for more than 12 months from the date of issuance of these financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text"><p id="xdx_806_eus-gaap--SignificantAccountingPoliciesTextBlock_zFO5Oe2Wqqrc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2 &#8211; <span id="xdx_822_zYZLUn7eiPMi">Significant Accounting Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_848_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zgAG2X9Y5v77" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_z8rvBjjyI7xb">Basis of presentation</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements have been prepared in accordance with United States Generally Accepted Accounting Principles (&#8220;U.S.
GAAP&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84A_eus-gaap--UseOfEstimates_z0kO2pZpw4p8" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_znJjOyCAGxob">Use of estimates</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities as of the date of the financial statements, and the reported amounts of expenses
during the reporting period. Actual results could differ from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GALMED
PHARMACEUTICALS LTD.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<div style="margin: 0pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2 &#8211; Significant Accounting Policies (Cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_844_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zMTom8fPyiR" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zvAm7mmhDgL8">Financial statement in U.S. dollars</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
functional currency of the Company and its subsidiaries is the U.S dollar (the &#8220;dollar&#8221;), because the dollar is the currency
of the primary economic environment in which the Company and its subsidiaries operate and expect to continue operating in the foreseeable
future. Transactions and balances denominated in dollars are presented in their original amounts. Non-dollar denominated transactions
and balances have been re-measured to dollars in accordance with the provisions of ASC 830, &#8220;Foreign Currency Matters.&#8221; All
transaction gains and losses from re-measurement of monetary balance sheet items denominated in non-dollar currencies are reflected in
the statement of operations as financial income or expenses, as appropriate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_842_eus-gaap--ConsolidationPolicyTextBlock_zhleHKi1imec" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zamApzJTutkh">Principles of consolidation</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries: Galmed Research and Development
Ltd., Galmed International Ltd., Galtopa Therapeutics Ltd and Galmed Therapeutics UK Limited. All intercompany balances and transactions
have been eliminated upon consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_840_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zqH5FRoAuZ1e" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zLhKQzbTkWh8">Cash and cash equivalents</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
equivalents are short-term, highly liquid investments that are readily convertible into cash with maturities of three months or less
as of the date acquired.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zyW1iWSTYwhb" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zRHhT8coz6O8">Restricted Cash</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
that is held for a specific purpose and is not available for immediate or general business use due to external restrictions is classified
in the Company&#8217;s consolidated balance sheets as restricted cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_ecustom--ShortTermDepositsPolicyTextBlock_z6Lb1A38Pww7" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>G.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zKQgtsmvZrR1">Short-term deposits</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bank
deposits with maturities of more than three months but less than one year are included in short-term bank deposits. Such short-term deposits
are stated at cost which approximates fair market value. Interest rates on the Company&#8217;s short-term deposits were between <span id="xdx_90A_eus-gaap--InvestmentInterestRate_iI_dp_c20241231__srt--RangeAxis__srt--MinimumMember_zrnKAFKsFb8b" title="Short-Term deposits interest rate">5.06</span>%-<span id="xdx_90A_eus-gaap--InvestmentInterestRate_iI_dp_c20241231__srt--RangeAxis__srt--MaximumMember_zvKFU0wY1879" title="Short-Term deposits interest rate">6.63</span>%
during the year ended December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84E_eus-gaap--MarketableSecuritiesPolicy_zZuUPur3p6sf" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>H.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_zeDj7pNOxf15">Marketable debt securities</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company invests most of its excess cash primarily in debt securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for its investments in investment grade debt securities in accordance with ASC 320 &#8220;Investments - Debt and Equity
Securities&#8221;. Management determines the appropriate classification of its investments in debt securities at the time of purchase
and re-evaluates such determinations at each balance sheet date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marketable
debt securities are considered to be available for sale and are carried at fair value on the consolidated balance sheet. Unrealized gains
and losses net of tax, if any, are reported in a separate component of stockholders&#8217; equity in accumulated other comprehensive
income (&#8220;OCI&#8221;). Gains and losses are recognized when realized, on a specific identification basis, in the Company&#8217;s
consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the adoption of ASC 326, current expected credit losses on the Company&#8217;s marketable grade debt securities are recorded, if expected,
through an allowance for current expected credit losses. The amount of allowance for current expected credit losses is limited to the
amount that the fair value is less than the amortized cost basis. Any remaining unrealized losses are included in accumulated other comprehensive
loss in stockholders&#8217; equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Company intends to sell the debt security (that is, it has decided to sell the security), or more likely than not will be required
to sell the security before recovery of its amortized cost basis, any allowance for current expected credit losses is written off and
the amortized cost basis shall be written down to the debt security&#8217;s fair value at the reporting date with any incremental impairment
reported in earnings. Based on management&#8217;s assessment, the Company does not intend to sell its securities for less than amortized
cost; therefore, an allowance for current expected credit losses has not been recorded as of December 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GALMED
PHARMACEUTICALS LTD.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<div style="margin: 0pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2 &#8211; Significant Accounting Policies (Cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_zR0yP4KaGEUj" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>I.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_z6MELlxtEgSl">Concentrations of credit risk</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments which potentially subject the Company to credit risk consist primarily of cash, cash equivalents, marketable debt securities
and short-term deposits. The Company hold these investments in highly-rated financial institutions, and, by policy, limit the amounts
of credit exposure to any one financial institution. These amounts at times may exceed federally insured limits. The Company has not
experienced any credit losses in such accounts and does not believe we are exposed to any significant credit risk on these funds. The
Company has no off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts, or other
hedging arrangements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_848_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zT95vhA3yXBd" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>J.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_zZqdSXymQ8A">Property and equipment</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_899_ecustom--ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentTableTextBlock_zwrlmrQPQTvl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated
useful lives of the assets. The annual depreciation rates are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_zu3C94eWLw65">Schedule of Depreciation Rates for Property, Plant and Equipment</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 93%; border-collapse: collapse; margin-left: 0.5in">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>%</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office
    furniture and equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentSalvageValuePercentage_iI_pid_dp_uPure_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndEquipmentMember_zdsLcXWNG2oj" title="Property and equipment, depreciation, percentage">7</span>&#8211;<span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentSalvageValuePercentage_iI_pid_dp_uPure_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndEquipmentMember_z0H6Yi6QX3He" title="Property and equipment, depreciation, percentage">16</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computer
    software and electronic equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentSalvageValuePercentage_iI_pid_dp_uPure_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerSoftwareElectronicEquipmentMember_zonOslvEYeMl" title="Property and equipment, depreciation, percentage">15</span>&#8211;<span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentSalvageValuePercentage_iI_pid_dp_uPure_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerSoftwareElectronicEquipmentMember_zN9gwrrdvISk" title="Property and equipment, depreciation, percentage">33</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold
    improvements</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentDepreciationMethodExtensibleEnumeration_iI_dxL_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zpQO8BQbJZv3" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2024%23UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember"><span style="-sec-ix-hidden: xdx2ixbrl0628">Shorter
    of the remaining lease term or useful life</span></span></span></td></tr>
  </table>
<p id="xdx_8AE_zgIUUXRcts4j" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded depreciation expenses in a total of approximately $<span id="xdx_903_eus-gaap--Depreciation_pn4n6_c20240101__20241231_zK6bs281Zfbi" title="Depreciation expenses">0.08</span> million, $<span id="xdx_907_eus-gaap--Depreciation_pn4n6_c20230101__20231231_z8IKX3h04Tt1" title="Depreciation expenses">0.03</span> million and $<span id="xdx_90A_eus-gaap--Depreciation_pn4n6_c20220101__20221231_zf8relcGANAi" title="Depreciation expenses">0.06</span> million for the years ended
December 31, 2024, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84C_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zrrGTnJytw75" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>K.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zeP9cVpNefX2">Severance pay</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company employees are included under section 14 of the Severance Compensation Act, 1963 (&#8220;Section 14&#8221;) in Israel for a portion
of their salaries. According to Section 14, these employees are entitled to monthly deposits at a rate of <span id="xdx_90B_ecustom--MonthlyDepositsOfEmployeesPercentageOnMonthlySalary_pid_dp_uPure_c20240101__20241231_zggLAPYGX5qe" title="Monthly deposits percentage">8.33</span>% of their monthly salary,
contributed on their behalf with insurance companies. Under the Severance Compensation Act, 1963, payments in accordance with Section
14 release the Company from any future severance payments to those employees. Therefore, the Company does not recognize a liability for
severance pay due to these employees and the deposits under Section 14 are not recorded as an asset in the Company&#8217;s consolidated
balance sheets. The Company&#8217;s contributions to the defined contribution plans are charged to the consolidated statements of operations
as and when the services are received from the Company&#8217;s employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GALMED
PHARMACEUTICALS LTD.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<div style="margin: 0pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2 &#8211; Significant Accounting Policies (Cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_842_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z3XvbzKcrp1c" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>L.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_z7Ci3ZnFql9k">Fair value of financial instruments</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
estimated fair value of financial instruments was determined by the Company using available market information and valuation methodologies.
Considerable judgment is required in estimating fair values. Accordingly, the estimates may not be indicative of the amounts the Company
could realize in a current market exchange.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following methods and assumptions were used by the Company in estimating its fair value disclosures for financial instruments:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts of cash and cash equivalents, short-term deposits, other accounts receivables, trade payables and other trade payables
approximate their fair value due to the short-term maturity of such instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
value is an exit price representing the amount that would be received upon selling an asset or that would be paid to transfer a liability
in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based
on assumptions used by market participants in pricing an asset or a liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
three-tier fair-value hierarchy was established as a basis for considering such assumptions and for inputs used in the valuation methodologies
in measuring fair value:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2 - Other inputs that are directly or indirectly observable in the marketplace; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3 - Unobservable inputs that are supported by little or no market activity</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when
measuring fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_898_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zOB5ODJGcNJ8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of the Company&#8217;s assets measured at fair value on a recurring basis by level within the fair value hierarchy are as
follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B3_zO8puHwV0nw7" style="display: none">Schedule of Assets Measured at Fair Value on Recurring Basis</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_ztWBlCt5Mr04" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_ze1DC6ihqWdf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zeNz5iE4EnBj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zlPtLLioYWOe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center"></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zwGbeKQwQqJh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Corporate bonds</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0644">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">2,367</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0646">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">2,367</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zCUvvjcAExU8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Treasury bills</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0649">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">533</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0651">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">533</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember_zPv2QFGWJita" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Mutual funds</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,283</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0655">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0656">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,283</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__custom--InvestmentInAssociateMember_zGGIL9wP0cQe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Investment in associate</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0659">-</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0660">-</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,119</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,119</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_zbmirx9aLf74" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Total</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">4,283</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">2,900</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">2,119</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">9,302</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zLK9o7TRzH3f" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zcyjbxTQ8IF7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zpg9gx3TYEvh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_znCRBj3zweN7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>Fair</b> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value</b></span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zvg8XcErWjm" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Corporate bonds</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0669">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,969</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0671">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,969</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zYCkcRLGM1fe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Treasury bills</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0674">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">409</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0676">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">409</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember_z6XGAWOuzlRk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Mutual funds</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,150</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0680">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0681">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,150</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__custom--InvestmentInAssociateMember_zFeOz1hUX6Ce" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Investment in associate</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0684">-</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0685">-</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,265</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,265</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_z6FQkSJwzSW1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Total</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">5,150</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">2,378</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">3,265</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">10,793</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A7_zIXA0OEOeNXl" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><b>Derivative instrument</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-size: 10pt">Under ASC 815-40,
contracts that are not indexed to the Company&#8217;s own equity are classified as liabilities recorded at fair value, as such, the Company
classifies the SEPA Agreement entered into (see Note 11A(5)) as a derivative instrument measured at fair value at each reporting period,
as settlement provisions under this agreement are not indexed to the Company&#8217;s own equity.</span><span style="font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 18pt"></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_848_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zE5ODiPqkVT5" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>M.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span><span id="xdx_86D_zTToCDHGG1ga">Accounting for stock-based compensation</span></span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for share-based compensation under ASC 718, Compensation - Stock Compensation (&#8220;ASC 718&#8221;), which requires
the measurement and recognition of compensation expense based on estimated fair values for all share-based payment awards made to employees,
non-employee consultants and directors, including options and restricted share units (&#8220;RSUs&#8221;) based on the fair value of
the awards on the date of grant. ASC 718 requires companies to estimate the fair value of equity-based payment awards on the date of
grant using an option-pricing model. The expense for share-based compensation cost is recognized over the requisite service period of
each individual grant using the straight-line method for service-based awards. Forfeitures are accounted for as they occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GALMED
PHARMACEUTICALS LTD.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<div style="margin: 0pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2 &#8211; Significant Accounting Policies (Cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>M.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accounting for stock-based compensation (Cont.)</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company calculates the fair value of RSUs based on the fair value on the closing trading price of the underlying shares at the date of
grant and estimates the fair value of stock options granted using a <span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDescription_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zr03dAoCGCpk" title="Black scholes option pricing model">Black-Scholes option-pricing model</span>. The option-pricing model requires
a number of assumptions, the most significant of which are the expected stock-price volatility and the expected option term (the time
from the grant date until the options are exercised or expire).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s calculations of the expected volatility were based upon actual historical stock-price movements over the period, which
was equal to the expected option term. The expected option term was calculated for options granted to employees and directors in accordance
with ASC-718-10-S99, using the &#8220;simplified&#8221; method, and grants to non-employees were based on the contractual term. Historically,
the Company has not paid dividends, and has no foreseeable plans to do so. The risk-free interest rate is based on the yield from U.S.
Treasury zero-coupon bonds with an equivalent term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p id="xdx_843_eus-gaap--ResearchAndDevelopmentExpensePolicy_zsmgn5zbkeyk" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>N.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zmrDVWBlDJG2">Research and development expenses</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses are charged to the statements of operations as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_zWvuoFjtfIN7" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>O.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_zibACiF6s8o1">Income taxes</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes in accordance with ASC 740, Income Taxes (&#8220;ASC 740&#8221;), using the liability method whereby
deferred tax assets and liability account balances are determined based on the differences between financial reporting and the tax basis
for assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected
to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to the amounts that are more likely-than-not
to be realized. As of December 31, 2024 and 2023, the Company recorded a full valuation allowance against its deferred tax assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company applies a more-likely-than-not recognition threshold to uncertain tax positions based on the technical merits of the income tax
positions taken. The Company does not recognize a tax benefit unless it is more likely than not that the tax position will be sustained
upon examination, including resolution of any related appeals or litigation processes, based on the technical merits of the position.
The tax benefit that is recorded for these positions is measured at the largest amount of benefit that is greater than 50% likely of
being realized upon ultimate settlement. As of December 31, 2024 and 2023, no liability for unrecognized tax benefits was recorded due
to immateriality.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84C_eus-gaap--EarningsPerSharePolicyTextBlock_zn8UeKVGd4ol" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>P.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zFxI6g2aD1Z1">Basic and diluted net loss per share</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
net loss per share is computed based on the weighted-average number of shares outstanding during each year. Diluted net loss per share
is computed based on the weighted-average number of shares outstanding during each year, plus the dilutive potential of the ordinary
shares considered outstanding during the year, in accordance with ASC 260-10, &#8220;Earnings Per Share.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
outstanding stock options, RSUs, prefunded-warrants and warrants were excluded from the calculation of the diluted loss per share
for the years ended December 31, 2024, 2023 and 2022, because all such securities have an anti-dilutive effect.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GALMED
PHARMACEUTICALS LTD.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<div style="margin: 0pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2 &#8211; Significant Accounting Policies (Cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p id="xdx_84C_eus-gaap--LesseeLeasesPolicyTextBlock_ztJF6bSmuRqc" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Q.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_z81fguYtUhG4">Leases</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for leases in accordance with ASC 842 &#8220;Leases.&#8221; Arrangements that are determined to be operating leases
at inception are recognized as right-of-use operating lease assets and lease liabilities in the balance sheets at lease commencement.
The Company recognizes a lease liability at the present value of the lease payments to be made over the lease term, and concurrently
recognizes a right-of-use asset at the same amount of the liability, adjusted for any prepaid or accrued lease payments, plus initial
direct costs incurred in respect of the lease. The Company uses its incremental borrowing rate based on the information available at
the commencement date to determine the present value of the lease payments. The subsequent measurement depends on whether the lease is
classified as a finance lease or an operating lease. During the reporting periods, the Company has only operating leases. Lease terms
include options to extend the lease when it is reasonably certain that the Company will exercise that option. Lease expenses for operating
leases are recognized on a straight-line basis over the lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has made a policy election not to capitalize leases with a term of 12 months or less. The Company made has also made a policy
election to include lease and non-lease components as a single lease component.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payments
for variable lease costs are expensed as incurred and are not included in the operating lease right-of-use assets and lease liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with ASC 360-10, management reviews operating lease assets for impairment whenever events or changes in circumstances indicate
that the carrying amount of an asset may not be recoverable based on estimated future undiscounted cash flows. If so indicated, an impairment
loss would be recognized for the difference between the carrying amount of the asset and its fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_849_eus-gaap--InvestmentPolicyTextBlock_z0Yq6MBcXBu1" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>R.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zWIp43wKc5ib">Investment in Associate at Fair Value</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company holds an equity investment of a privately-owned company, Onkai Inc. (&#8220;Onkai&#8221;), over which it has the ability to exercise
significant influence, but not control. The investment was included as a non-current asset in the balance sheet as of December 31, 2024.
The Company has elected the fair value option allowed by ASC 825, Financial Instruments, with respect to this investment because management
believes this approach will better reflect the economics of its equity interest. Under the fair value option, the investment is remeasured
at fair value (level 3) at each reporting period with changes in fair value, if any, recorded in the statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, management, based on fair value estimation, assessed the qualitative aspects of the equity investment and macroeconomic
factors and determined that an impairment should be recognized in amount of $1.1 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_845_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z7VU98c1aeO3" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>S.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zrB96f2tbo9">Recently adopted accounting pronouncements</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, new accounting pronouncements are issued by FASB, or other standard setting bodies and adopted by the Company as of the
specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have
a material impact on our financial position or results of operations upon adoption.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The ASU expands
public entities&#8217; segment disclosures by requiring disclosure of significant segment expenses that are regularly reviewed by the
chief operating decision maker (&#8220;CODM&#8221;) and included within each reported measure of segment profit or loss, an amount and
description of its composition for other segment items, and interim disclosures of a reportable segment&#8217;s profit or loss and assets.
The ASU also allows, in addition to the measure that is most consistent with U.S. GAAP, the disclosure of additional measures of segment
profit or loss that are used by the CODM in assessing segment performance and deciding how to allocate resources. The ASU is effective
for the Company&#8217;s Annual Report on Form 20-F for the fiscal year ended December 31, 2024, and subsequent interim periods, with
early adoption permitted. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84A_ecustom--NewAccountingPronouncementsNotYetEffectivePolicyTextBlock_zXeQR5BViNok" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>T.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_zsQbYWN4vhzh">Accounting pronouncements not yet effective</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, the FASB issued ASU 2024-03, &#8220;Income Statement&#8211;Reporting Comprehensive Income&#8211;Expense Disaggregation
Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses&#8221; (&#8220;ASU 2024-03&#8221;), which requires the disaggregation
of certain expenses in the financial statements notes, to provide enhanced transparency into the expense captions presented on the face
of the consolidated statement of operations. ASU 2024-03 is effective for annual reporting periods beginning January 1, 2027 and interim
periods beginning January 1, 2028 and may be applied either prospectively or retrospectively. The Company is currently evaluating the
impact that ASU 2024-03 will have on its related disclosures, and the transition method.</span></p>

<p id="xdx_851_z2X5hTML8xEi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GALMED
PHARMACEUTICALS LTD.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<div style="margin: 0pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable debt securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Marketable debt securities</a></td>
<td class="text"><p id="xdx_807_eus-gaap--CashCashEquivalentsAndMarketableSecuritiesTextBlock_z5ElUcWHzoDj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
3 &#8211; <span id="xdx_828_zM8Eu57ykDzl">Marketable debt securities</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_891_eus-gaap--MarketableSecuritiesTextBlock_ziorsCGksSsk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the Company&#8217;s marketable debt securities as of December 31, 2024 and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zLSGCQ7oRRSc">Schedule of Marketable Debt Securities</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Gross</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Gross</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Amortized</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Unrealized</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Unrealized</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Estimated</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Cost</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Gains</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Losses</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="6" style="text-align: center">(in thousands)</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Corporate bonds</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20241231__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_z5pGNXVo15m1" style="width: 11%; text-align: right" title="Amortized Cost">2,529</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20240101__20241231__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zxu3sadovbg1" style="width: 11%; text-align: right" title="Gross Unrealized Gains">9</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20240101__20241231__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zZhrqtyHu77i" style="width: 11%; text-align: right" title="Gross Unrealized Losses">(171</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20241231__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zMkO1mcWkvQh" style="width: 11%; text-align: right" title="Estimated Fair Value">2,367</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Treasury bills</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20241231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zlnpOESAfzBe" style="text-align: right" title="Amortized Cost">530</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20240101__20241231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zW8dGQ697sa1" style="text-align: right" title="Gross Unrealized Gains">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20240101__20241231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zgJ5wvhkh6g1" style="text-align: right" title="Gross Unrealized Losses"><span style="-sec-ix-hidden: xdx2ixbrl0728">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20241231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zHdxs25KFZ0c" style="text-align: right" title="Estimated Fair Value">533</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Mutual funds</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20241231__us-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember_z3opYpITlijf" style="border-bottom: Black 1pt solid; text-align: right" title="Amortized Cost">4,540</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20240101__20241231__us-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember_zMKHIuurUWhi" style="border-bottom: Black 1pt solid; text-align: right" title="Gross Unrealized Gains">23</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20240101__20241231__us-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember_zA5nio4FBf8a" style="border-bottom: Black 1pt solid; text-align: right" title="Gross Unrealized Losses">(280</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20241231__us-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember_zn5Ey2cwU955" style="border-bottom: Black 1pt solid; text-align: right" title="Estimated Fair Value">4,283</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total short-term investments</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20241231_zbZiAMju3MH2" style="border-bottom: Black 2.5pt double; text-align: right" title="Amortized Cost">7,599</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20240101__20241231_zbEGM5h03LV" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross Unrealized Gains">35</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20240101__20241231_zgkIQrNH6ZUa" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross Unrealized Losses">(451</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20241231_zyoIMognowkb" style="border-bottom: Black 2.5pt double; text-align: right" title="Estimated Fair Value">7,183</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Gross</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Gross</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Amortized</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Unrealized</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Unrealized</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Estimated</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Cost</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Gains</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Losses</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="6" style="text-align: center">(in thousands)</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Corporate bonds</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zwMu8yQc0E5j" style="width: 11%; text-align: right" title="Amortized Cost">2,123</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zpHunG4JoUD1" style="width: 11%; text-align: right" title="Gross Unrealized Gains">6</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_z6syK3HtY8V7" style="width: 11%; text-align: right" title="Gross Unrealized Losses">(160</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zbs0K82Z1RP8" style="width: 11%; text-align: right" title="Estimated Fair Value">1,969</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Treasury bills</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zwBHrXpb881a" style="text-align: right" title="Amortized Cost">400</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_z54lJKA8hhQ4" style="text-align: right" title="Gross Unrealized Gains">9</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zfUhQ8ISTWRl" style="text-align: right" title="Gross Unrealized Losses"><span style="-sec-ix-hidden: xdx2ixbrl0760">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zlWOlNyvzLQ8" style="text-align: right" title="Estimated Fair Value">409</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Mutual funds</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember_zIge1392z3Ce" style="border-bottom: Black 1pt solid; text-align: right" title="Amortized Cost">5,459</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember_zqFwdqgwBlVd" style="border-bottom: Black 1pt solid; text-align: right" title="Gross Unrealized Gains">1</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember_zYSUBOil9V18" style="border-bottom: Black 1pt solid; text-align: right" title="Gross Unrealized Losses">(310</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember_zRKOzt5MpGBl" style="border-bottom: Black 1pt solid; text-align: right" title="Estimated Fair Value">5,150</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total short-term investments</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20231231_zV8pgetGHb0b" style="border-bottom: Black 2.5pt double; text-align: right" title="Amortized Cost">7,982</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20230101__20231231_zUN73WatyXV3" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross Unrealized Gains">16</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20230101__20231231_zqKOliB3p1o7" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross Unrealized Losses">(470</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20231231_zjdC2HKyqqfi" style="border-bottom: Black 2.5pt double; text-align: right" title="Estimated Fair Value">7,528</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p id="xdx_8AA_zGAD9W5tvry3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
contractual maturities of the aforementioned corporate bonds and treasury bills are less than one year for the year ended December 31,
2024 and one year and a half of the aforementioned corporate bonds for the year ended December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Receivables<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock', window );">Other Receivables</a></td>
<td class="text"><p id="xdx_802_eus-gaap--LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_zPYLXOV76QC6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
4&#8211; <span id="xdx_822_zEg71KFV39pc">Other Receivables</span></b></span></p>

<p id="xdx_894_eus-gaap--ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_zU0YQQcu491b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zcVwmyobPA67">Schedule
of Other  Receivables</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20241231_z2qPXrmPFB2e" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20231231_zROnT5sZLdv6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(in thousands)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--PrepaidExpenseCurrent_iI_pn3n3_maRNCz4tF_zH9Wg5qgz80b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Prepaid expenses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">463</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">315</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--GrantsReceivable_iI_pn3n3_maRNCz4tF_zAx1QN4A0UNb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Government institutions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">76</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">47</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OtherReceivables_iI_pn3n3_maRNCz4tF_zoSnRg0fmu44" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Other receivables</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">133</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">118</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--ReceivablesNetCurrent_iTI_pn3n3_mtRNCz4tF_zZtiDosvOvsg" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">672</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">480</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AE_zipfSQigaL46" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for claims held for amounts due to entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/310-10/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GLMD_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--LesseeOperatingLeasesTextBlock_zPcnNDdcyjS4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
5&#8211; <span id="xdx_820_ztU7bvZE5ZOk">Leases</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company leased, approximately <span id="xdx_907_eus-gaap--AreaOfLand_iI_uSqft_c20241231_zycON41sONN3" title="Area of land under operating lease agreement">590</span>
square meters at a facility located in Tel-Aviv, Israel. The lease expired on <span id="xdx_905_eus-gaap--LeaseExpirationDate1_dd_c20240101__20241231_zCEVOnSUJprb" title="Lease expiry date">March
21, 2024</span>. The Company did not extend the lease and the Company&#8217;s employees are currently working remotely while
management is in the process of searching for a new permanent location for its principal executive offices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 33pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2024, 2023 and 2022, the Company recorded lease expenses in its statement of operations in the amount of $<span id="xdx_908_eus-gaap--OperatingLeaseExpense_pn4n6_c20240101__20241231_zS30WNBUgOdh" title="Lease expense">0.04</span> million, $<span id="xdx_909_eus-gaap--OperatingLeaseExpense_pn5n6_c20230101__20231231_zZ06hxuMApCi" title="Lease expense">0.2</span> million,
and $<span id="xdx_906_eus-gaap--OperatingLeaseExpense_pn5n6_c20220101__20221231_z52qwBH9wZyk" title="Lease expense">0.2</span> million respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 33pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2024, the Company&#8217;s operating lease right-of-use assets and current lease liabilities for operating leases totaled
$<span id="xdx_906_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_dxL_c20241231_ziUqPvO1Q6s" title="Operating lease right of use assets::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0808">0</span></span> thousand and $<span id="xdx_906_eus-gaap--OperatingLeaseLiability_iI_pn3n3_c20241231_ztFVQuUMbKji" title="Operating lease liability">0</span> thousand, respectively, while at December 31, 2023, the Company&#8217;s operating lease assets and lease liabilities
(both the current and non-current portion) for operating leases totaled $<span id="xdx_909_eus-gaap--OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_iI_dxL_c20231231_z3SsKMWRQrI4" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2024%23OperatingLeaseRightOfUseAsset"><span style="-sec-ix-hidden: xdx2ixbrl0811">42</span></span> thousand and $<span id="xdx_90A_eus-gaap--OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_iI_dxL_c20231231_zLNPd3S9HBFk" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2024%23OperatingLeaseLiability"><span style="-sec-ix-hidden: xdx2ixbrl0812">41</span></span> thousand, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GLMD_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GLMD_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GLMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and equipment, net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and equipment, net</a></td>
<td class="text"><p id="xdx_809_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zXUoc069fT8b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
6 &#8211; <span id="xdx_828_zDOgqzCMV6Wa">Property and equipment, net</span></b></span></p>

<p id="xdx_897_eus-gaap--PropertyPlantAndEquipmentTextBlock_zk2Ns6bbY8W3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BF_z81lMRSFFPlc">Schedule of Property and Equipment</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20241231_zNetz5pICHLb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20231231_zIY10BIZmWNl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="6" style="text-align: center">(in thousands)</td><td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--MachineryAndEquipmentGross_iI_pn3n3_maPPAEGzWKA_zZY4PcHfFz3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Medical equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">737</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">737</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FurnitureAndFixturesGross_iI_pn3n3_maPPAEGzWKA_zWkuntSH1YE2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Office furniture and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">55</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">55</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--CapitalizedComputerSoftwareGross_iI_pn3n3_maPPAEGzWKA_zDn4IKV7adRc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Computer software and electronic equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">75</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LeaseholdImprovementsGross_iI_pn3n3_maPPAEGzWKA_zroB6QTOVs47" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Leasehold improvements</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">236</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">235</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iTI_pn3n3_mtPPAEGzWKA_maPPAENzlLK_z45bbBTi5Ove" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, gross</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,103</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,102</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENzlLK_z52HQWbqdROc" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Less - Accumulated depreciation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,103</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,019</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzlLK_zIAZEi5e5nvk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Net book value</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0836">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">83</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AB_zHWWNp4z3VEj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GALMED
PHARMACEUTICALS LTD.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<div style="margin: 0pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment in an Associate<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTextBlock', window );">Investment in an Associate</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--InvestmentTextBlock_zhyu9jLzwbQi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
</b>7 &#8211; <b><span id="xdx_82A_zvpI9q6cojjk">Investment in an Associate</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 4, 2023, the Company entered into a definitive agreement (the &#8220;Agreement&#8221;) for a $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_pn5n6_c20230504__20230504__srt--TitleOfIndividualAxis__custom--OnkaiIncMember_zE9FyBZ1mqsd" title="Additional investment on convertible safe notes">1.5</span> million equity investment in OnKai,
a US-based technology company developing an AI-based platform to advance healthcare for underserved populations across the United States
by facilitating alignment between healthcare stakeholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Previously,
in November, 2022 the Company invested $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_pn5n6_c20221130__20221130__srt--TitleOfIndividualAxis__custom--OnkaiIncMember_zZnppgv1Ugb9">1.5</span> million in OnKai through a Simple Agreement for Future Equity (&#8220;SAFE&#8221;) which
converted at a <span id="xdx_902_ecustom--CapitalStockDiscountRate_pid_dp_uPure_c20221130__20221130__srt--TitleOfIndividualAxis__custom--OnkaiIncMember_zKvOliJu4sU2" title="Capital discount rate">15</span>% discount into series seed preferred shares upon closing of the Investment Round (as defined below). The Company recorded
in its statement of operations a change in the fair value of the convertible note (the SAFE) which totaled $<span id="xdx_903_eus-gaap--GainLossOnInvestments_pn5n6_c20230101__20231231__srt--TitleOfIndividualAxis__custom--OnkaiIncMember_zm3wFEXeZ8V3" title="Investments">0.3</span> million for the year
ended December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s investment in OnKai was part of an approximately $<span id="xdx_903_eus-gaap--PaymentsToAcquireInvestments_pn5n6_c20240101__20241231_zidFFboeH9a2" title="Investment">6.0</span>
million investment round (the &#8220;Investment Round&#8221;) with other investors that was led by the Company of which SAFEs of
approximately $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_pn5n6_c20240101__20241231__srt--TitleOfIndividualAxis__custom--OnkaiIncMember_zMHZm85sS704" title="Value conversion">3.8</span>
were converted into preferred shares of Onkai upon the consummation of the Investment Round. On June 19, 2023, the Investment Round
closed. Following the closing of the Investment Round, the Company holds <span id="xdx_90F_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20230619__srt--TitleOfIndividualAxis__custom--OnkaiIncMember_zNwP2aCoSVq6" title="Shares owned">1,223,535</span>
preferred shares which comprised approximately <span id="xdx_906_eus-gaap--InvestmentOwnedPercentOfNetAssets_iI_pid_dp_uPure_c20230619__srt--TitleOfIndividualAxis__custom--OnkaiIncMember_zKReVlMpSMhh" title="Shares owned percentage">24</span>%
of the outstanding share capital of OnKai on an as-converted basis as of December 31, 2023 and December 31, 2024. The Company&#8217;s Chief Executive
Officer and director, Allen Baharaff, serves as one of three board members of OnKai.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the terms of the Agreement, during the three-year period following the closing of the Investment Round the Company will have the right
to merge with OnKai subject to the approval of the boards of directors of each of the Company and OnKai. The Company was granted certain
customary pre-emptive rights as well as registration rights, first refusal rights, co-sale, a board seat, and certain customary protective
provisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Agreement, the Company&#8217;s wholly-owned subsidiary, GRD, entered into a services agreement (the &#8220;Services
Agreement&#8221;) with OnKai. The Services Agreement provides that GRD will on a non-exclusive basis (i) provide support services to
OnKai relating to finance, business development, strategic planning, execution and others; and (ii) lend its experience to OnKai in building
a strategy and for the development of treatments for the underserved and that OnKai shall on a non-exclusive basis (i) take part in plan
preparation to serve GRD&#8217;s vision of developing drugs for the underserved population and (ii) when relevant, design a process on
the clinical trial dashboard that could potentially serve GDR&#8217;s future trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the above mentioned Services Agreement, the Company recorded reimbursement of expenses of $<span id="xdx_901_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20240101__20241231__srt--ProductOrServiceAxis__us-gaap--AdministrativeServiceMember_zGLhk4NLGCW1" title="Management fee income">48</span> thousand and $<span id="xdx_90D_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20230101__20231231__srt--ProductOrServiceAxis__us-gaap--AdministrativeServiceMember_zX20bJ6t8rIf" title="Management fee income">12</span> thousand
in general and administrative expenses in its statement of operations for the years ended December 31, 2024 and December 31, 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 15, 2024, the Company entered into a bridge loan agreement with OnKai pursuant to which the Company made a loan in an aggregate
amount of $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_c20241015__us-gaap--TypeOfArrangementAxis__custom--BridgeLoanAgreementMember_zHFvVvvt3Inl" title="Loan amount">250,000</span> to OnKai payable by January 1, 2028. The loan bears interest at an annual rate of <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20241015__us-gaap--TypeOfArrangementAxis__custom--BridgeLoanAgreementMember_zBZnWTlmFfz7" title="Interest rate">15</span>%. In addition, in connection with the
Services Agreement, the Company paid OnKai $<span id="xdx_900_eus-gaap--ProceedsFromOtherDebt_c20241015__20241015__us-gaap--TypeOfArrangementAxis__custom--ServicesAgreementMember_zW7OMRMGGNvi" title="Proceeds from debt">150,000</span> for OnKai to assist the Company in (i) identifying and preparing eligible sites for
the Company&#8217;s future clinical trials and (ii) preparing and submitting applications for clinical and research grants in respect
of such future clinical trials, including preparing reimbursement strategies. In the event that Onkai is awarded a clinical or research
grant, OnKai agreed to repay the Company the $<span id="xdx_90F_eus-gaap--RepaymentsOfDebt_c20241015__20241015__us-gaap--TypeOfArrangementAxis__custom--ServicesAgreementMember_zszqb1F8osV3" title="Repayments of debt">150,000</span> that it initially paid to OnKai.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, management, based on fair value estimation, assessed the qualitative aspects of the equity investment and macroeconomic
factors and determined that an impairment should be recognized in amount of $<span id="xdx_90F_eus-gaap--AssetImpairmentCharges_pn5n6_c20240101__20241231_zbmoMGPcwJ1e" title="Impairment charges">1.1</span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attached
is a summarized un-audited financial information of Onkai:</span></p>

<p id="xdx_89D_ecustom--ScheduleOfBalanceSheetsTableTextBlock_zupYrJFyreB" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span><span id="xdx_8B7_zLCxDACqeusf" style="display: none">Schedule
of Balance Sheets</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Balance
sheet as of December 31, 2024</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 0.75in">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_490_20241231__srt--TitleOfIndividualAxis__custom--OnkaiIncMember_zXUwPwrBovBb" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(in thousands)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AssetsCurrent_iI_pn3n3_msSEzDrf_zOzTqQ0pVvV9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">Current assets</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">105</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AssetsNoncurrent_iI_pn3n3_msSEzDrf_zt5GQthFEbv5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Non-current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LiabilitiesCurrent_iI_pn3n3_maSEzDrf_zobY668MRGo8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">324</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--LiabilitiesNoncurrent_iI_pn3n3_maSEzDrf_zMXlZzwTppjg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Non-current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,665</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--StockholdersEquity_iNTI_pn3n3_di_mtSEzDrf_zkyvyScp2BRj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Equity</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,881</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  </table>

<p id="xdx_8A5_zI1eLcJpUXbl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Statement
of operations for the year ended December 31, 2024:</span></b></span></p>

<p id="xdx_894_ecustom--ScheduleOfStatementOfOperationsTableTextBlock_z2gmHRwAhNka" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B6_zPHAEsrbXx7d" style="display: none">Schedule of Statement of Operations</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20240101__20241231__srt--TitleOfIndividualAxis__custom--OnkaiIncMember_zkDMtB6dour2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(in thousands)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OperatingExpenses_pn3n3_msNILzGpU_z2RKoKHX4gFj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%; text-align: left">Total operating loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">2,485</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--NonoperatingIncomeExpense_pn3n3_maNILzGpU_zEeHcD4uNTQd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Financial expenses, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeTaxExpenseBenefit_pn3n3_msNILzGpU_zt7bQ6wUrWck" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Income tax</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">22</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--NetIncomeLoss_iNT_pn3n3_di_mtNILzGpU_zZzVj1WqR7h9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Net Loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">2,537</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AA_z44tMFV77x" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GALMED
PHARMACEUTICALS LTD.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<div style="margin: 0pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 321<br> -Publisher FASB<br> -URI https://asc.fasb.org/321/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 325<br> -Publisher FASB<br> -URI https://asc.fasb.org/325/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Payables<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureTextBlock', window );">Other Payables</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--OtherLiabilitiesDisclosureTextBlock_zBeFeMlSalod" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
8 &#8211; <span id="xdx_820_zKXRHV6iQQz7">Other Payables</span></b></span></p>

<p id="xdx_89D_eus-gaap--OtherLiabilitiesTableTextBlock_zaNda3wGO549" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BF_zMZzMlssmlv1">Schedule
of Other Payables</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%; margin-left: 0.75in">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20241231_zYN49w91ZZ6c" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20231231_z6YGup8Lcp3a" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(in thousands)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--EmployeeRelatedLiabilitiesCurrentAndNoncurrent_iI_pn3n3_maOLzBhJ_zRyT3YMRNj1k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Employees and related</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">603</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">571</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--CompensatedAbsencesLiability_iI_pn3n3_maOLzBhJ_zxo0qSQeVIYi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued Vacation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">256</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">259</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--ShorttermLeaseObligation_iI_pn3n3_maOLzBhJ_z2yrk2VWa5g7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Short-term lease obligation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0902">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">41</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OtherNotesPayable_iI_pn3n3_maOLzBhJ_zymGl44N1hgb" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">6</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0906">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OtherLiabilities_iTI_pn3n3_mtOLzBhJ_zCDUx68QUafg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Other Payables</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">865</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">871</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AD_zCSbzujzOc39" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Parties</a></td>
<td class="text"><p id="xdx_809_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zWtBRc2Sjgnb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
9 &#8211; <span id="xdx_824_za6jximPdAh6">Related Parties</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    of December 31, 2024, and 2023, the Company had an accrual in the amount of approximately $<span id="xdx_906_eus-gaap--OtherLiabilitiesCurrent_iI_pn5n6_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersAndDirectorsMember_zeNcBHrV6v97" title="Due to related parties">0.5</span> million and $<span id="xdx_906_eus-gaap--OtherLiabilitiesCurrent_iI_pn5n6_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersAndDirectorsMember_zBLnwBX6TO6a" title="Due to related parties">0.6</span> million, respectively,
    pursuant to an employment agreements with its officers and directors&#8217; fee. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    of December 31, 2024, the Company had a receivable balance of $<span id="xdx_909_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember_zdNvTrPxdjI5" title="Related party services, balance amount">25</span> thousand, pursuant to a service agreement with OnKai and a long
    term loan balance of $<span id="xdx_90A_eus-gaap--LongTermDebt_iI_pn3n3_c20241231__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember_zpHttbkQw4D8" title="Long term loan">257</span> thousand (see note 7).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
    2024, 2023 and 2022, the Company recorded salary expenses, stock-based compensation expenses and directors&#8217; fees to its related
    parties in the amount of $<span id="xdx_908_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn5n6_c20240101__20241231_z9ryINkykqE5" title="Related party transaction, expenses">3.1</span> million, $<span id="xdx_904_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn5n6_c20230101__20231231_z5NRUIqp1o0a" title="Related party transaction, expenses">2.8</span> million and $<span id="xdx_90F_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn5n6_c20220101__20221231_zRkDcOZDvtlj" title="Related party transaction, expenses">2.8</span> million respectively. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
    2024, the Company recorded reimbursement of expenses pursuant to the service agreement with OnKai. And as well recorded research
    and development expenses in connection with the service agreement with Onkai (see note 7)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p id="xdx_802_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zmpvnPBgCCW6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
10 </b>&#8211; <b><span id="xdx_82B_zIc8BnQjewvf">Commitments and Contingencies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    of December 31, 2024, the Company recorded a pledge on its short-term deposit in favor of its bank in the amount of approximately
    $<span id="xdx_902_ecustom--BankLienOnMarketableSecurities_pn3n3_c20240101__20241231_zy8yr6jZNaNb" title="Bank lien on marketable securities">121</span> thousand to secure the Company&#8217;s commitments to the bank</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company enters into contracts in the ordinary course of business with contract research organizations for clinical trials and clinical
    supply manufacturing and with vendors for non-clinical research studies and other services and products for operating purposes, which
    generally provide for termination upon 30 to 90 days&#8217; notice or less, and therefore are cancelable contracts and not considered
    as commitment or purchase obligations.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    June 28, 2021, the Company entered into a license agreement with Yissum Research Development Company of the Hebrew University of
    Jerusalem (&#8220;Yissum&#8221;) pursuant to which Yissum granted to the Company a worldwide, exclusive and irrevocable license to
    develop and commercialize Amilo-5Mer. Under the license agreement, the Company is responsible for carrying out the development and
    commercialization of Amilo-5Mer and the prosecution and maintenance of the licensed patents under the license agreement. In consideration
    for the grant of the license, the Company paid Yissum an upfront license fee of $<span id="xdx_907_ecustom--UpfrontLicenseFee_pn3n3_c20210627__20210628_zymwOabmFZc2" title="Upfront license fee">100</span> thousand which was included in research and
    development expenses for the period ended December 31, 2021. In addition, the Company may be required to make payments of up to $<span id="xdx_902_ecustom--PaymentsToRegulatoryMilestones_pn3n3_c20210627__20210628__srt--RangeAxis__srt--MaximumMember_zGjq0FD7O9g3" title="Payments to regulatory milestones">950</span>
    thousand upon meeting certain regulatory milestones and may be entitled to pay single digit royalties on any future net sales and
    a share of any sublicense fees. The Company is not currently pursuing the development of Amilo-5MER.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GALMED
PHARMACEUTICALS LTD.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<div style="margin: 0pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">Stockholders&#8217; equity</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--ShareholdersEquityAndShareBasedPaymentsTextBlock_z3FCK3TRwFLk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
11 &#8211; <span id="xdx_826_zOM8itOHtfd8">Stockholders&#8217; equity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ordinary
    shares</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ordinary
    shares confer upon the holders the right to receive notice to participate and vote in general meetings of the Company and the right
    to receive dividends, if declared.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    March 26, 2021, the Company entered into a Sales Agreement (the &#8220;2021 Sales Agreement&#8221;) with Cantor Fitzgerald &amp; Co. and Canaccord
    Genuity LLC, as sales agents, pursuant to which the Company may offer and sell ordinary shares &#8220;at the market&#8221; having an
    aggregate offering price of up to $<span id="xdx_90A_ecustom--MaximumAmountOfSharesToBeIssued_iI_pn5n6_c20210326__us-gaap--TypeOfArrangementAxis__custom--NewSalesAgreementMember_zuIBLx74F6pd" title="Aggregate offering price">50.0</span>
    million from time to time through the sales agents. During 2022, the Company sold <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--NewSalesAgreementMember_zyAcvZIKVssi" title="Additional ordinary shares">643</span>
    ordinary shares under its ATM program for total net proceeds of approximately $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--NewSalesAgreementMember_zDjOISA2j37g" title="Proceeds from sale of ordinary shares">0.1</span>
    million. The Company did not sell any ordinary shares the 2021 Sales Agreement in 2023 and 2024 and in August 2024, the Company
    terminated the 2021 Sales Agreement in connection with its entry into the 2024 Sales Agreement (as defined below). See Note
    11(A)(6).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    May 15, 2023, the Company effected a reverse share split of the Company&#8217;s ordinary shares at the ratio of <span id="xdx_905_eus-gaap--StockholdersEquityReverseStockSplit_c20230515__20230515__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z4YdwSTmVXGg" title="Reverse stock split">1-for-15</span>, such that
    each fifteen (15) ordinary shares, par value NIS <span id="xdx_902_eus-gaap--CommonStockNoParValue_iI_pid_uILSPShares_c20230515__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5yOgznQn6l8" title="Common stock, par value">0.01</span> per share, were consolidated into one (1) ordinary share, par value NIS <span id="xdx_90D_eus-gaap--SaleOfStockPricePerShare_iI_pid_uILSPShares_c20230515__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_znbayBOH7ZW1" title="Share price">0.15</span>.
    On August 29, 2024 the Company effected an additional reverse share split of the Company&#8217;s ordinary shares at the ratio of
    <span id="xdx_90A_eus-gaap--StockholdersEquityReverseStockSplit_c20240829__20240829__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ziNUIBHTH2Ol" title="Reverse stock split">1-for-12</span>, such that each twelve (12) ordinary shares, par value NIS <span id="xdx_908_eus-gaap--CommonStockNoParValue_iI_pid_uILSPShares_c20240829_zefy5ShkOKu8" title="Common stock, par value">0.15</span> per share, were consolidated into one (1) ordinary share,
    par value NIS <span id="xdx_903_eus-gaap--CommonStockNoParValue_iI_pid_uILSPShares_c20240829__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zbpGZoM4psik" title="Common stock, par value">1.80</span> per share. As a result, all share and per share amounts prior to the reverse share split were adjusted retroactively
    for all periods presented in these consolidated financial statements.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
                                            July 18, 2023, the Company sold to investors in a public offering (i) <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230718__20230718_z5dLrsBqjnlh">31,666</span> ordinary shares,
                                            (ii) <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20230718__us-gaap--SubsidiarySaleOfStockAxis__custom--PrefundedWarrantsMember_zhrJw6vAsFHb" title="Stock and warrants issued during period shares">435,000</span> pre-funded warrants to purchase <span id="xdx_904_eus-gaap--ConversionOfStockSharesIssued1_pid_c20230718__20230718__us-gaap--SubsidiarySaleOfStockAxis__custom--PrefundedWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zG0emCgmWM7d" title="Class of Warrant or Right, Number of Securities Called by Warrants or Rights">435,000</span> ordinary shares (the &#8220;Pre-Funded
                                            Warrants&#8221;), and (iii) <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20230718__us-gaap--SubsidiarySaleOfStockAxis__custom--InvestorWarrantsMember_zGNZfI0MzSI8" title="Stock and warrants issued during period shares">466,666</span> warrants to purchase <span id="xdx_900_eus-gaap--ConversionOfStockSharesIssued1_pid_c20230718__20230718__us-gaap--SubsidiarySaleOfStockAxis__custom--InvestorWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkRP9ftiEyd3" title="Class of Warrant or Right, Number of Securities Called by Warrants or Rights">466,666</span> ordinary shares (the &#8220;Investor
                                            Warrants&#8221;), at a purchase price of $<span id="xdx_90A_eus-gaap--SharePrice_iI_pid_c20230718__us-gaap--SubsidiarySaleOfStockAxis__custom--InvestorWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zifjnMTEABl8" title="Share price">15.0</span> per share and accompanying Investor Warrant
                                            and $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230718__us-gaap--SubsidiarySaleOfStockAxis__custom--InvestorWarrantsMember_zYB6Q8b5T7bd" title="Exercise price of warrants">14.99</span> per Pre-Funded Warrant and accompanying Investor Warrant. The aggregate gross
                                            proceeds were $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20230718__20230718__us-gaap--SubsidiarySaleOfStockAxis__custom--InvestorWarrantsMember_zaueRm6PB0Yf" title="Gross proceeds stock">7.0</span> million ($<span id="xdx_903_eus-gaap--PaymentsOfDebtIssuanceCosts_pn5n6_c20230718__20230718__us-gaap--SubsidiarySaleOfStockAxis__custom--InvestorWarrantsMember_zjAFNxgUx9F3" title="Issuance costs">6.2</span> million net of issuance costs).</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Pre-Funded Warrants are immediately exercisable at an exercise price of $<span id="xdx_900_eus-gaap--WarrantExercisePriceIncrease_pid_c20240101__20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--PrefundedWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHFQmA7DV567" title="Exercise price of warrants">0.001</span> per ordinary share. As of December 31, 2024, all of
    the Pre-Funded Warrants have been exercised.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Investor Warrants have an exercise price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230718__us-gaap--SubsidiarySaleOfStockAxis__custom--PrefundedWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zIJtkgQmK9Kk" title="Exercise price of warrants">15</span> per ordinary share, are immediately exercisable, and may be exercised until July
    18, 2028. During September 2024, a total of <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230718__us-gaap--SubsidiarySaleOfStockAxis__custom--PrefundedWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zNxvBFQ1XSqb" title="Investor warrants, shares">293,333</span> Investor Warrants have been exercised into <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230718__us-gaap--SubsidiarySaleOfStockAxis__custom--PrefundedWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zzwyImVjepic" title="Warrant exercised, shares">293,333</span> ordinary shares for a total
    net proceeds of $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20230718__20230718_z2m0qxYSYGs3" title="Proceeds from sale of ordinary shares">4.4</span> million. As of December 31, 2024 a total of <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231_zXcJV7Ee1euk" title="Warrants are outstanding">173,333</span> warrants are outstanding.</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
                                            August 30, 2024, the Company entered into a Standby Equity Purchase Agreement (the &#8220;SEPA&#8221;)
                                            with YA II PN, LTD., a Cayman Islands exempt limited partnership (&#8220;YA&#8221;). Pursuant
                                            to the SEPA, the Company have the right, but not the obligation, to sell to YA from time
                                            to time, each such occurrence, an Advance, up to $<span id="xdx_906_eus-gaap--OtherCommitment_iI_pn5n6_c20240830__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember_zpF3iro49RRd" title="Commitment amount">10.0</span> million (the &#8220;Commitment Amount&#8221;),
                                            of the Company ordinary shares, during the 36 months following the execution of the SEPA,
                                            subject to the restrictions and satisfaction of the conditions in the SEPA. On October 21,
                                            2024, the Company and YA entered into an amendment to the SEPA to increase the Amount of
                                            the commitment to $<span id="xdx_90A_eus-gaap--OtherCommitment_iI_pn5n6_c20241021__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember__srt--RangeAxis__srt--MaximumMember_zgrykBHimNQ4" title="Commitment amount">20.0</span> million of the Company&#8217;s ordinary shares.</span></p>
                                                         <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    consideration for YA&#8217;s irrevocable commitment to purchase the Company&#8217;s ordinary shares up to the Commitment Amount, the
    Company agreed to issue <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240830__20240830_zxVC6KB6S9Z8" title="Issuance of ordinary shares">31,566</span>
    ordinary shares (the &#8220;Commitment Shares&#8221;) to YA and also paid a $<span id="xdx_906_eus-gaap--DebtInstrumentFeeAmount_iI_pn3n3_c20240830_zvYDdhcYQmfk" title="Structuring fee">15,000</span>
    structuring fee to an affiliate of YA. The Commitment Shares shall be issued in four equal installments every 90 calendar days. As
    of December 31, 2024, the Company issued a total of <span id="xdx_909_ecustom--CommitmentShare_iI_pid_c20241231_zWCvhxvb1D4c" title="Commitment share">15,784</span>
    Commitment Share. The Commitment Shares and structuring fee were recorded as expense in &#8220;Finance expenses related to
    SEPA&#8221;, in amounts of $<span id="xdx_906_ecustom--ProceedsFinanceLeaseInterestExpenseIncome_pn3n3_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember_zV8tH734tCI4" title="Finance expenses">70</span>
    thousand and $<span id="xdx_907_ecustom--ProceedsFinanceLeaseInterestExpenseIncome_pn3n3_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember_zjKxAUajMR21" title="Finance expenses">15</span>
    thousand, respectively.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company evaluated the contract that includes the right to require YA to purchase shares of common stock in the future (&#8220;put
    right&#8221;) considering the guidance in ASC 815-40, &#8220;Derivatives and Hedging &#8212; Contracts on an Entity&#8217;s Own Equity&#8221;
    and concluded that it is an equity-linked contract that does not qualify for equity classification, and therefore requires fair value
    accounting and thus meet the definition of a derivative liability. Accordingly, the put right will be measured at fair value at each
    reporting period, and changes in its fair value will be recognized in the consolidated statement of operations. The Put right is
    measured under level 2 of the Fair Value hierarchy. The Company analyzed the terms of the freestanding put right and concluded that
    it has an immaterial value as of December 31, 2024.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    of December 31, 2024, the Company has issued an aggregate of <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--CaymanIslandsExemptLimitedPartnershipMember_zObevxSNdBxd" title="Issuance of shares">574,559</span>
    ordinary shares to YA for aggregate gross proceeds of approximately $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--CaymanIslandsExemptLimitedPartnershipMember_zXLAHct5ROG4" title="Gross proceeds stock">5.0</span>
    million (<span id="xdx_90E_eus-gaap--PaymentsOfDebtIssuanceCosts_pn5n6_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--CaymanIslandsExemptLimitedPartnershipMember_zmCl3Bc9fVf8" title="Issuance costs">4.4</span>
    million net of issuance costs). The Company recorded expenses in the amount of $<span id="xdx_904_eus-gaap--OtherExpenses_pn5n6_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--CaymanIslandsExemptLimitedPartnershipMember_zFXAoviBi0U" title="Other expenses">0.6</span> million in &#8220;finance
expenses related to SEPA&#8221; (including the commitment shares and structuring fee, as detailed above)</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    November 14, 2024, the Company entered into a Capital on Demand Sales Agreement (the &#8220;2024 Sales Agreement&#8221;) with JonesTrading
    Institutional Serviecs LLC, (&#8220;JonesTrading). Pursuent to the 2024 Sales Agreement, the Company may offer and sell ordinary
    shares having an aggregate offering price of up to $<span id="xdx_909_ecustom--MaximumAmountOfSharesToBeIssued_iI_pn5n6_c20241114__us-gaap--TypeOfArrangementAxis__custom--DemandSalesAgreementMember_zSabuyPzzcj7" title="Aggregate offering price">8.1</span>
    million, from time to time through JonesTrading. Subsequent to the balance sheet date, As of March 21 2025, the Company sold <span id="xdx_903_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20250320__20250321__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentySalesAgreementMember_zoAyVA0fTTbj" title="Sale of stock">541,996</span>
    ordinary shares pursuant to the 2024 Sales Agreement, for a total consideration of approximately $<span id="xdx_90E_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn5n6_c20250320__20250321__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentySalesAgreementMember_zThrcRtSe0c6" title="Total consideration">1.5</span>
    million</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GALMED
PHARMACEUTICALS LTD.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<div style="margin: 0pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
11 &#8211; Stockholders&#8217; equity (Cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock-based
    compensation</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company has an equity-based incentive plan, the 2013 Incentive Share Option Plan (the &#8220;2013 Plan&#8221;). As of December 31,
    2023, based on the latest amendment to the plan from August 7, 2023, a total of <span id="xdx_90D_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20231231__us-gaap--PlanNameAxis__custom--IncentiveShareOptionPlan2013Member_z31sbmaJg3n7" title="Shares reserved for future issuance">500,000</span> ordinary shares were reserved for issuance
    under the 2013 Plan, of which a total of <span id="xdx_900_ecustom--CommonStockCapitalSharesReservedForFutureIssuanceUnallocated_iI_pid_c20231231__us-gaap--PlanNameAxis__custom--IncentiveShareOptionPlan2013Member_zSR43I9Tutrk" title="Shares reserved for future issuance">63,253</span> ordinary shares remain reserved, but unallocated for future equity awards. The 2013
    Plan, which was adopted by the Board on September 2, 2013, and approved by the Company&#8217;s shareholders on December 30, 2013
    (as was amended by the Board and the Company&#8217;s shareholders on March 30, 2015, May 11, 2015, August 30, 2018, August 7, 2023
    and November 12, 2024 respectively), provides for the grant of options to purchase the ordinary shares and the issuance of RSUs to
    the Company&#8217;s officers, directors, employees, service providers and consultants. The 2013 Plan provides for such equity-based
    compensation under various and different tax regimes.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    February 2022, the Company granted options to purchase <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220201__20220228_z9iMdpyD6jv4" title="Options granted">222</span> ordinary shares of the Company to one of its officers. The options are
    exercisable at $<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20220228_zGuXqR4gjd12" title="Options exercisable per share">288</span> per share, have a <span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220201__20220228_zV0xDydsDAoe" title="Contractual term">10</span>-year term and vest over a period of <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dt_c20220201__20220228_zSyNs9DbPHLk" title="Vest period">four years</span>.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    March 23, 2023, the Company received a ruling from the Israel Tax Authority (&#8220;ITA&#8221;) confirming the repricing of certain
    stock options. This repricing was accounted for as a modification of a share-based payment award. The incremental compensation expense
    recognized as a result of the modification during the year ended December 31, 2023 was approximately $<span id="xdx_908_eus-gaap--OtherExpenses_pn5n6_c20230101__20231231_zPVzMPSSUXq1" title="Compensation expense">0.1</span> million.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    August 2023, the Company granted <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230801__20230831__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zqYmJKhfUsS1" title="Options granted">109,583</span> RSUs and <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230801__20230831_ztF5u6aejao1" title="Options granted">6,250</span> options to purchase <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230801__20230831_zRP4q85JGoGc" title="Options granted">6,250</span> ordinary shares of the Company to its officers
    and directors. The options are exercisable at $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20230831_zFukQF5Jfxob" title="Options exercisable per share">1.05</span> per share and have a 10-year term. The options and RSUs vest over a period of
    three years. The aggregate grant date fair value of such RSUs and options was approximately $<span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_pn5n6_c20230801__20230831_zr6uZ6slH8af" title="Aggregate grant fair value">0.9</span> million.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    September 2023, the Company extended the exercise period of <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230901__20230930__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zxgTuRsRp0eh" title="Options granted">1,805</span> options with an exercise price of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_uILSPShares_c20230930__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zLMNLRGisRid" title="Options granted">0.15</span> NIS previously granted to
    the Company&#8217;s Chief Executive Officer (and director), by approximately five years to December 31, 2028. the exercise period
    represented a modification in accordance with ASC 718. The Incremental compensation expense on the modification date was less than
    $<span id="xdx_903_eus-gaap--OtherExpenses_pn3n3_c20230901__20230930__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zDdQdiOt2FHa" title="Compensation expense">1</span> thousand.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    November 12, 2024, the Company&#8217;s board of directors approved the grant of <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20241112__20241112__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_znlp37Xlhtei" title="Options granted">302,500</span> RSUs and <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20241112__20241112_zS6adLTyhUqj" title="Options granted">17,500</span> options to purchase <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20241112__20241112_zLUFvm1v4Kzh" title="Options granted">17,500</span>
    ordinary shares of the Company to its officers and directors. The options and <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_pid_c20241112__20241112__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember_zD33oZrvMhLl" title="Restricted stock unit options">197,500</span> of the RSUs are subject to the approval
    of the Company&#8217;s shareholders. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GALMED
PHARMACEUTICALS LTD.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<div style="margin: 0pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
11 &#8211; Stockholders&#8217; equity (Cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock-based
    compensation (Cont.)</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    summary of the status of the Company&#8217;s outstanding options as of December 31, 2024 and 2023 and changes during the years then
    ended are presented below:</span></td></tr>
  </table>
<p id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zguewmEJvuXf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none"><span id="xdx_8B4_zZ6l0CFM7hFc">Summary
of Status of Company's Option Plans and Changes</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 96%; border-collapse: collapse; margin-left: 0.25in">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="6" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="6" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023
    (*)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
    of</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>average</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
    of</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>average</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>share</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>exercise</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>share</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>exercise</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>options</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>price</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>options</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>price</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options
    outstanding at beginning of year</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zWLAnmky41Ye" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Number of share options, Beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20,277</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zPy4aA2aXj48" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted average exercise price, Beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">460</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zCnRDwTCWP91" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Number of share options, Beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14,973</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_z2SpChuqlEQ7" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted average exercise price, Beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">654</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Granted</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zu7PmuIAJeM6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of share options, Granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1060">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zClQp5lDQYJa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, Granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1062">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zkw6Zng0TR4i" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of share options, Granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,250</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zxH0vhVFriKe" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, Granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Forfeited</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240101__20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zIdJ4i6OqQAb" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of share options, Forfeited"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,041</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zdvWLtcaz6of" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, Forfeited"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">94</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20230101__20231231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zFEWnAg1SZzk" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of share options, Forfeited"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11,351</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zMVt6qpJBCxb" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, Forfeited"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">441.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding
    at end of year</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zW2ejCxeWnMg" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of share options, Ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19,236</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zWBsxNgW3OE7" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, Ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">321</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zjjWoaIFNMvc" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of share options, Ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20,277</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_z4GB1kLPmpXb" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, Ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">460</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options
    exercisable at year end</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20240101__20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zIm8Sf8sRbn2" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of share options exercisable, Ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14,966</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zXZBLkzawzW" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, Options exercisable, Ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">413</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zwGHpJuCoFfi" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of share options exercisable, Ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13,269</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zxUQD2xG0Rr5" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, Options exercisable, Ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">670.56</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p id="xdx_8AC_z2dNKr9MSFmj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following assumptions were used for the fiscal year 2023 grants:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">dividend
    yield of <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zHzPfW3WoVGg" title="Dividend yield"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zBpYfMwPjME2" title="Dividend yield"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zWKVpxKXNBW3" title="Dividend yield">0.00</span></span></span>% for all periods.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">risk-free
    interest rate between <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zt3cgo0Wcrc5" title="Risk-free interest rate, minimum">0.80</span>% and <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zMcDuzUootQ1" title="Risk-free interest rate, maximum">1.34</span>% for the fiscal year 2021, <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zBgWm4RUQehb" title="Risk-free interest rate, maximum">1.94</span>% for the fiscal year 2022 and <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgnGUuUnDK67" title="Risk-free interest rate">4.16</span>% for the fiscal year 2023.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    expected life between <span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zAvlkqxYP6Qk" title="Expected life, term"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zGQYzpbpfF37" title="Expected life, term"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zDpef0XgM2Ag" title="Expected life, term">5</span></span></span> and <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zsp8CSencube" title="Expected life, term"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zprI5R4wrxd" title="Expected life, term"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zAa9rslQSijc" title="Expected life, term">6.25</span></span></span> years for all periods.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and
    a volatility rate ranging between <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgYQTc14SXkb" title="Volatility rate, minimum">64</span>% and <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zcRexkOB0Tg8" title="Volatility rate, maximum">81</span>% for the fiscal year 2021, <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z6MXtW14SqDj" title="Volatility rate">65</span>% for the fiscal year 2022 and <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zbSiVoN1E86a" title="Volatility rate">108</span>% for the fiscal year
    2023.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, and 2023, the weighted-average remaining contractual term of the outstanding options, excluding the <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zaBOz755R9vh" title="Options, granted"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z9mUVh2GntT9" title="Options, granted">270</span></span> options
granted in 2002 that have no expiration date, is <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zyLnTWWW9lP9" title="Contractual term">3.82</span> and <span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zOwH39SJhGbc" title="Contractual term">6.24</span> years, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average grant date fair value of the options granted during the years ended December 31, 2023 and 2022 is $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z11vaQxD2b14" title="Weighted average grant date fair value">0.63</span>, and $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zJp1Ym5fk6D6" title="Weighted average grant date fair value">0.68</span> respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, a total of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231_zCqS9JBKENj9" title="Options, exercisable">1,805</span> outstanding and exercisable options are &#8220;in the money&#8221; with aggregate intrinsic value
of $<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231_zWCgm6i9TNIa" title="Options, intrinsic value">5</span> thousand; while as of December 31, 2023 a total of <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20231231_z0xfbf8T2Veb" title="Options, exercisable">21,654</span> outstanding and exercisable options were &#8220;in the money&#8221; with
aggregate intrinsic value of $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20231231_zA1tCaWBSXK7" title="Options, intrinsic value">1</span> thousand.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unrecognized compensation expense calculated under the fair-value method for stock options expected to vest as of December 31, 2024,
2023 and 2022 is approximately $<span id="xdx_90D_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn4n6_c20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zFD26POnPyJj" title="Unrecognized share based compensation">0.03</span> million, $<span id="xdx_901_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn5n6_c20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zXcWvYIyAxl1" title="Unrecognized share based compensation">0.3</span> million, and $<span id="xdx_900_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn5n6_c20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zlF8WAAWeDJe" title="Unrecognized share based compensation">0.9</span> million, respectively, and is expected to be recognized over a weighted-average
period of <span id="xdx_905_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z5UPKpAmrl8l" title="Unrecognized compensation, term">1.0</span> years, <span id="xdx_902_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zAXDUWAP1LH5" title="Unrecognized compensation, term">0.3</span> years and <span id="xdx_904_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z25Gmt71VKYk" title="Unrecognized compensation, term">1.41</span> years, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended 2024, 2023 and 2022, the Company recorded a total of $<span id="xdx_904_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zErVATd19F99" title="Allocated stock based compensation">0.5</span> million, $<span id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zZeCj8Charwk" title="Allocated stock based compensation">0.8</span> million, and $<span id="xdx_906_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zdomHhxA0e71" title="Allocated stock based compensation">1.3</span> million of stock-based compensation
expenses, in connection with the above-mentioned options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GALMED
PHARMACEUTICALS LTD.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<div style="margin: 0pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
11 &#8211; Stockholders&#8217; equity (Cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock-based
    compensation (Cont.)</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 7, 2023, the Company issued a total of <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230807__20230807__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zTbmiCwd4id1">109,583</span> RSUs. Upon vesting, each RSU will settle for the issuance of one ordinary
share. The RSUs vest over <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dt_c20230807__20230807__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zuZx4nS6qzA8">three years</span>. On November 12, 2024, the Company&#8217;s board of directors approved the grant of <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20241112__20241112__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zaFJOQy2HjXa" title="Share based compensation granted">302,500</span> of
which <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther_pid_c20241112__20241112__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zGV9l8VREFHg" title="Share based compensation subject to company shareholders">197,500</span> are subject to the approval of the Company&#8217;s shareholders. As of December 31, 2024, <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pid_c20241112__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zSykou31asH" title="Share based compensation vested">36,528</span> of the RSUs were
vested. With respect to the above-mentioned RSUs, the Company recorded stock-based compensation expenses in the amount of $<span id="xdx_90C_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn5n6_c20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zC3yIoqCf9Gb" title="Unrecognized compensation expense">0.3</span>
million and $<span id="xdx_902_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn5n6_c20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zUnzjyPnxm21" title="Unrecognized compensation expense">0.1</span> million for the years ended December 31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average grant date fair value of the RSUs granted during the year ended December 31, 2024 and 2023 was $<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJfBjosh3Wkb" title="Weighted average grant date fair value">3.02</span> and $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z4dpZgmi1oZ7" title="Weighted average grant date fair value">0.63</span>,
respectively</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unrecognized compensation expense calculated for RSUs expected to vest as of December 31, 2024 and 2023 is approximately $<span id="xdx_909_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn5n6_c20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zdlVElp3wGO3" title="Unrecognized share based compensation">0.7</span>
million and $<span id="xdx_909_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn5n6_c20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z9zM8efXAc11" title="Unrecognized share based compensation">0.7</span> million, respectively and is expected to be recognized over a weighted-average period of <span id="xdx_905_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zRQfdQO5GAY6" title="Unrecognized compensation, term">2.11</span> years and <span id="xdx_907_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zTrA9d7Yk4s1" title="Unrecognized compensation, term">2.5</span> years, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Development Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock', window );">Research and Development Expenses</a></td>
<td class="text"><p id="xdx_809_eus-gaap--ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_zZk84PJrZwaa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
12 &#8211; <span id="xdx_825_zS06Ih1Y0sv7">Research and Development Expenses</span></b></span></p>

<p id="xdx_890_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock_ziuRnOx0P0rf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none"><span id="xdx_8B8_zv2MOaxIgHVk">Schedule of Research and Development Expenses</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(in thousands)</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Chemistry and formulation studies</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__custom--ChemistryAndFormulationStudiesMember_zDsfi0ig8y67" style="width: 14%; text-align: right" title="Research and development expense">696</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--ChemistryAndFormulationStudiesMember_zyE8JQIQubG9" style="width: 14%; text-align: right" title="Research and development expense">573</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__custom--ChemistryAndFormulationStudiesMember_zOlTd1YZTYmc" style="width: 14%; text-align: right" title="Research and development expense">2,448</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Salaries</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__custom--SalariesMember_zpI82J099YY5" style="text-align: right" title="Research and development expense">982</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--SalariesMember_zeDn0J9ezjF6" style="text-align: right" title="Research and development expense">676</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__custom--SalariesMember_ztdz1oqsyw1l" style="text-align: right" title="Research and development expense">1,692</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__custom--StockBasedCompensationMember_z8wj4qyB3dd6" style="text-align: right" title="Research and development expense">112</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--StockBasedCompensationMember_z8goXa8TdSV7" style="text-align: right" title="Research and development expense">243</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__custom--StockBasedCompensationMember_zl26bsC9nsoj" style="text-align: right" title="Research and development expense">383</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and preclinical studies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__custom--ResearchAndPreclinicalStudiesMember_zm8txvyA7r6h" style="text-align: right" title="Research and development expense">255</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--ResearchAndPreclinicalStudiesMember_z4n5cQkWnNFe" style="text-align: right" title="Research and development expense">460</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__custom--ResearchAndPreclinicalStudiesMember_zkCJ2CZk1hNl" style="text-align: right" title="Research and development expense">1,346</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Clinical studies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__custom--ClinicalStudiesMember_z28YOLCpUlZ6" style="text-align: right" title="Research and development expense">291</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--ClinicalStudiesMember_zX0SYvubDGq9" style="text-align: right" title="Research and development expense">616</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__custom--ClinicalStudiesMember_zDn6uGm2gOYg" style="text-align: right" title="Research and development expense">6,532</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Regulatory and other expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__custom--RegulatoryAndOtherExpensesMember_zsuWlwnT3cOf" style="border-bottom: Black 1pt solid; text-align: right" title="Research and development expense">643</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--RegulatoryAndOtherExpensesMember_zRXUnXXn2lg9" style="border-bottom: Black 1pt solid; text-align: right" title="Research and development expense">1,001</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__custom--RegulatoryAndOtherExpensesMember_zrwxLZ03siza" style="border-bottom: Black 1pt solid; text-align: right" title="Research and development expense">594</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20240101__20241231_zha7UvacKc6e" style="border-bottom: Black 2.5pt double; text-align: right" title="Research and development expense">2,979</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20230101__20231231_zdKICeaB44Gf" style="border-bottom: Black 2.5pt double; text-align: right" title="Research and development expense">3,569</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20220101__20221231_zIs0giyR4hz5" style="border-bottom: Black 2.5pt double; text-align: right" title="Research and development expense">12,995</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AD_zxp9NFzOR6xk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/985-20/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General and Administrative Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GLMD_DisclosureGeneralAndAdministrativeExpensesAbstract', window );"><strong>General And Administrative Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GLMD_GeneralAndAdministrativeExpensesDisclosureTextBlock', window );">General and Administrative Expenses</a></td>
<td class="text"><p id="xdx_801_ecustom--GeneralAndAdministrativeExpensesDisclosureTextBlock_zinLv9zPo5l2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
13 &#8211; <span id="xdx_82E_z9pCqip28Azk">General and Administrative Expenses</span></b></span></p>

<p id="xdx_896_ecustom--GeneralAndAdministrativeExpensesTableTextBlock_zc3DZSOklY" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none"><span id="xdx_8B8_z6s0KlLNaH92">Schedule of General and Administrative Expenses</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">(in thousands)</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Stock-based compensation</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__custom--StockBasedCompensationMember_z1dA2h3OIgi4" style="width: 14%; text-align: right" title="General and administrative expenses">419</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--StockBasedCompensationMember_z6Pr0SVLyUP2" style="width: 14%; text-align: right" title="General and administrative expenses">649</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__custom--StockBasedCompensationMember_zA3NEe6Nuc8c" style="width: 14%; text-align: right" title="General and administrative expenses">913</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__custom--ProfessionalFeeMember_zEQ1jAH6MHrh" style="text-align: right" title="General and administrative expenses">896</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--ProfessionalFeeMember_zUUUZQfcKdk4" style="text-align: right" title="General and administrative expenses">908</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__custom--ProfessionalFeeMember_z2WpLiFfOKPa" style="text-align: right" title="General and administrative expenses">1,084</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Salaries and benefits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__custom--SalariesAndBenefitsMember_zoS20LYjqApa" style="text-align: right" title="General and administrative expenses">1,478</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--SalariesAndBenefitsMember_zkv5dJOEydng" style="text-align: right" title="General and administrative expenses">1,428</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__custom--SalariesAndBenefitsMember_zL5geAw4doO3" style="text-align: right" title="General and administrative expenses">1,164</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Rent and office-maintenance fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__custom--RentAndOfficeMaintenanceFeesMember_zNl2NqVBOnQ7" style="text-align: right" title="General and administrative expenses">117</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--RentAndOfficeMaintenanceFeesMember_z6kOQICm3hGg" style="text-align: right" title="General and administrative expenses">261</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__custom--RentAndOfficeMaintenanceFeesMember_z7jXRxaxz2L8" style="text-align: right" title="General and administrative expenses">401</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Insurance and other expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__custom--InsuranceAndOtherExpensesMember_zVjfrOB9y13a" style="border-bottom: Black 1pt solid; text-align: right" title="General and administrative expenses">389</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--InsuranceAndOtherExpensesMember_zgfeDWFmEPG" style="border-bottom: Black 1pt solid; text-align: right" title="General and administrative expenses">677</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__custom--InsuranceAndOtherExpensesMember_zIGcJJGXstW1" style="border-bottom: Black 1pt solid; text-align: right" title="General and administrative expenses">1,094</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20240101__20241231_z0U5gSchMxMf" style="border-bottom: Black 2.5pt double; text-align: right" title="General and administrative expenses">3,299</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20230101__20231231_z9uSjw6MrGWb" style="border-bottom: Black 2.5pt double; text-align: right" title="General and administrative expenses">3,923</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20220101__20221231_zzhwtv32kYGl" style="border-bottom: Black 2.5pt double; text-align: right" title="General and administrative expenses">4,656</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A4_zqt2b8ey4TF2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GALMED
PHARMACEUTICALS LTD.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<div style="margin: 0pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GLMD_DisclosureGeneralAndAdministrativeExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GLMD_DisclosureGeneralAndAdministrativeExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GLMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GLMD_GeneralAndAdministrativeExpensesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GLMD_GeneralAndAdministrativeExpensesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GLMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial income, net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Financial income, net</a></td>
<td class="text"><p id="xdx_805_eus-gaap--RevenueFromContractWithCustomerTextBlock_zvXR9B4dAAMi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
14 &#8211; <span id="xdx_82B_zBBfoUfcBbai">Financial income, net</span></b></span></p>

<p id="xdx_89A_eus-gaap--ScheduleOfOtherNonoperatingIncomeByComponentTextBlock_zFdcfS2Q25A4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none"><span id="xdx_8BE_ziOFMcPvD306">Schedule of Financial Income, Net</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20240101__20241231_zzb1ucyZ33Ie" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20230101__20231231_zDfH2kZowrVd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20220101__20221231_zcqyslIm7Gfh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">(in thousands)</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_408_ecustom--BankFees_iN_pn3n3_di_msONIEz4mj_zKZr1V4vqB77" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Bank fees</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">15</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">11</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">22</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--InterestIncome_pn3n3_maONIEz4mj_zwhCBrfac05h" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(503</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(375</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(297</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--DebtSecuritiesAvailableForSaleGainLoss_pn3n3_maONIEz4mj_zKDn9fGmekm4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss from sale of marketable debt securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">526</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--ChangeInFairValueOfConvertibleNote_pn3n3_maONIEz4mj_z5zWTc7hC6qb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Change in fair value of convertible note</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1290">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(265</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1292">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--ForeignCurrencyTransactionGainLossBeforeTax_pn3n3_maONIEz4mj_zY7KEqP1G7p9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Foreign currency (gains) losses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(40</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">36</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(36</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--OtherNonoperatingIncomeExpense_iNT_pn3n3_di_mtONIEz4mj_zy0VsQvvfJy4" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
    income net</span></span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(516</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(580</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">215</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AE_zqoB0Hagb4Oa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--IncomeTaxDisclosureTextBlock_ziq34bF35CA5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
15 &#8211; <span id="xdx_82A_zd8W2oqR6btg">Income Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>General</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is assessed for tax purposes on an unconsolidated basis. Each of the Company&#8217;s subsidiaries is subject to the tax rules
prevailing in its country of incorporation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate
    Taxation</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israeli
Companies:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Israeli corporate income tax rate is <span id="xdx_900_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_c20210101__20211231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--IsraelTaxAuthorityMember_zacWVWJ0Kuvh" title="Effective income tax rate reconciliation, at federal statutory income tax rate, percent"><span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_c20230101__20231231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--IsraelTaxAuthorityMember_zpR4dLOqKd95" title="Effective income tax rate reconciliation, at federal statutory income tax rate, percent"><span id="xdx_905_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_c20240101__20241231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--IsraelTaxAuthorityMember_zXR7aP9oeTj8" title="Effective income tax rate reconciliation, at federal statutory income tax rate, percent">23</span></span></span>% for the years 2022, 2023 and 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 7, 2018, the Israeli Tax Authority issued a ruling granting the Company&#8217;s Israeli subsidiary, Galmed Research and Development
Ltd, a &#8220;Preferred Technological Enterprise&#8221; status as defined under the Encouragement of Capital Investment Law -1959 (the
&#8220;Approval&#8221;). The grant of the status means that the Company&#8217;s Israeli subsidiary will be subject to a reduced Israeli
corporate tax rate that will range between 6%-12% on any future taxable &#8220;technological income&#8221; which includes sales, licenses
and royalties from its IP protected products. The tax ruling applies for five years until the end of 2022 and may be extended for further
periods subject to meeting certain requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maltese
subsidiary:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxable
income of Maltese companies was subject to tax at the rate of <span id="xdx_909_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_c20220101__20221231__us-gaap--IncomeTaxAuthorityNameAxis__custom--MalteseSubsidiaryMember_zB4ZoEgTIg2l" title="Effective income tax rate reconciliation, at federal statutory income tax rate, percent"><span id="xdx_909_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_c20230101__20231231__us-gaap--IncomeTaxAuthorityNameAxis__custom--MalteseSubsidiaryMember_z85g1bxroSua" title="Effective income tax rate reconciliation, at federal statutory income tax rate, percent"><span id="xdx_901_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_c20240101__20241231__us-gaap--IncomeTaxAuthorityNameAxis__custom--MalteseSubsidiaryMember_z1GdRFr0UtX9" title="Effective income tax rate reconciliation, at federal statutory income tax rate, percent">35</span></span></span>% for the years 2022, 2023, and 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net
    Operating Loss Carry forward</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, the Company had approximately $<span id="xdx_905_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20241231_zmFPUDl5IPGj" title="Operating loss carry forwards">175.4</span> million net-operating-loss carry forwards, consisting of approximately $<span id="xdx_905_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MalteseSubsidiaryMember_zZJsUzBwRXfj" title="Operating loss carry forwards">11.7</span>
million of Maltese net-operating-loss carry forwards and approximately $<span id="xdx_90E_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--IsraeliSubsidiaryMember_zk55bgRB31m4" title="Operating loss carry forwards">163.7</span> million Israeli net-operating-loss carry forward. Additionally,
the Company had approximately $<span id="xdx_908_eus-gaap--DeferredTaxAssetsCapitalLossCarryforwards_iI_pn5n6_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--IsraeliSubsidiaryMember_zg2XFBzTJUk3" title="Deferred tax assets, capital loss carry forwards">3.1</span> million of capital loss carry forward from the sale of marketable debt securities in Israel. The Maltese
and the Israeli loss carry forwards have no expiration date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GALMED
PHARMACEUTICALS LTD.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<div style="margin: 0pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
15 &#8211; Income Taxes (Cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Deferred
    income taxes</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, the significant components of the Company&#8217;s deferred tax assets are net operating loss carryforward in the
amount of $<span id="xdx_90B_eus-gaap--DeferredTaxAssetsCapitalLossCarryforwards_iI_pn5n6_c20241231_zUwB0TMHz5Ui" title="Deferred tax assets, capital loss carry forwards">175.4</span> million. and research and development expenses in the amount of $<span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_pn5n6_c20240101__20241231__us-gaap--RegulatoryAssetAxis__us-gaap--DeferredIncomeTaxChargesMember_zxXlc8rOZYpa" title="Research and development expenses">3.3</span> million. The Company has evaluated the positive
and negative evidence bearing upon its ability to realize the deferred tax assets. Management has considered the Company&#8217;s history
of cumulative net losses incurred since inception and its lack of commercialization of any products or generation of any revenue from
product sales since inception and has concluded that it is more likely than not that the Company will not realize the benefits of the
deferred tax assets. Accordingly, a full valuation allowance has been established against the deferred tax assets as of December 31,
2024. Management reevaluates the positive and negative evidence at each reporting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Tax
    assessment</b>s</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Israeli subsidiaries received final tax assessments through the year ended December 31, 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Effective
    tax expense</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_893_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_z8W8nOrww3Vd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of the Company&#8217;s effective tax expense to the Company&#8217;s theoretical statutory tax benefit is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zpOBbrXmcaTk" style="display: none">Schedule of Effective Income Tax Rate Reconciliation</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20240101__20241231_zI43QpEYMOXb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20230101__20231231_ziaulpg56Iz9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20220101__20221231_zj3jy4F0oDhi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(in thousands)</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn3n3_ztAHqONZnqb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left; padding-bottom: 2.5pt">Loss before taxes on income, as reported in the consolidated statements of operations</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">7,517</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">6,912</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">17,866</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_zbKWAnV5rC57" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Statutory tax rate</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">23</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">23</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">12</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_maITEBzSAa_zQqEaK4ogOW2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Theoretical tax benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,729</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,590</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,144</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_maITEBzSAa_zd1KL1KEkRdk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Losses and other items for which a valuation allowance was provided or benefit from loss carry forwards</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,729</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,590</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(2,144</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3n3_mtITEBzSAa_ztV1u2QHBqcg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Actual tax expense</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1346">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1347">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1348">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A1_zwk492MKDilb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent events</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--SubsequentEventsTextBlock_ztFYymnC2Hq6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
16 &#8211; <span id="xdx_821_zXWHEo3Q1xt8">Subsequent events</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent
                                            to the balance sheet date, as of March 21 2025, the Company sold <span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20250320__20250321__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentySalesAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zaZXSo3sUEd4" title="Sale of stock">541,996</span> ordinary shares
                                            pursuant to the 2024 Sales Agreement with JonesTrading, for a total consideration of approximately
                                            $<span id="xdx_908_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn5n6_c20250320__20250321__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentySalesAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zxjZbnqiJy1f" title="Total consideration">1.5</span> million. See note 11(A)(6).</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent
                                                                                                                                                                                                       to the balance sheet date, as of March 21, 2025 the Company has issued an aggregate of <span id="xdx_907_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20250320__20250321__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--CaymanIslandsExemptLimitedPartnershipMember_z5ltgpUVk3gg" title="Sale of stock">7,891</span>
                                                                                                                                                                                                       ordinary shares to YA as part of the Commitment Shares and an aggregate of <span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20250320__20250321__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentySalesAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--CaymanIslandsExemptLimitedPartnershipMember_zNMbZ3TyF7Aj" title="Sale of stock">25,000</span>
                                                                                                                                                                                                       ordinary shares that we sold to YA as Advance Shares for aggregate gross proceeds of approximately $<span id="xdx_904_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn3n3_c20250321__20250321__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentySalesAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z9GrfEhogdBi" title="Commitment share,value">75</span>
                                                                                                                                                                                                       thousand. See note 11(A)(5).&#160;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--SegmentReportingDisclosureTextBlock_zEySMl5bj5ye" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
17 &#8211; <span id="xdx_82F_znQxEJ8yPQw8">Segment Reporting</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
280, &#8220;Segment Reporting&#8221;, establishes standards for reporting information about operating segments. Operating segments are
defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief
operating decision maker (&#8220;CODM&#8221;) in deciding how to allocate resources and in assessing performance. The Company manages
its business on the basis of <span id="xdx_905_eus-gaap--NumberOfReportableSegments_dc_uInteger_c20240101__20241231_zT41MWE2qx35" title="Number of reportable segments">one</span> reportable segment and unit. The Company&#8217;s chief operating decision maker is the chief executive
officer of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
CODM assesses the performance of the Company and decides how to allocate resources based on the operating results available that is also
reported within the Consolidated Statements of Operations. The measure of segment assets that is reviewed by the CODM is reported within
the Balance Sheet as Total assets.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><p id="xdx_848_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zgAG2X9Y5v77" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_z8rvBjjyI7xb">Basis of presentation</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements have been prepared in accordance with United States Generally Accepted Accounting Principles (&#8220;U.S.
GAAP&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--UseOfEstimates_z0kO2pZpw4p8" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_znJjOyCAGxob">Use of estimates</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities as of the date of the financial statements, and the reported amounts of expenses
during the reporting period. Actual results could differ from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GALMED
PHARMACEUTICALS LTD.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<div style="margin: 0pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2 &#8211; Significant Accounting Policies (Cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Financial statement in U.S. dollars</a></td>
<td class="text"><p id="xdx_844_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zMTom8fPyiR" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zvAm7mmhDgL8">Financial statement in U.S. dollars</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
functional currency of the Company and its subsidiaries is the U.S dollar (the &#8220;dollar&#8221;), because the dollar is the currency
of the primary economic environment in which the Company and its subsidiaries operate and expect to continue operating in the foreseeable
future. Transactions and balances denominated in dollars are presented in their original amounts. Non-dollar denominated transactions
and balances have been re-measured to dollars in accordance with the provisions of ASC 830, &#8220;Foreign Currency Matters.&#8221; All
transaction gains and losses from re-measurement of monetary balance sheet items denominated in non-dollar currencies are reflected in
the statement of operations as financial income or expenses, as appropriate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of consolidation</a></td>
<td class="text"><p id="xdx_842_eus-gaap--ConsolidationPolicyTextBlock_zhleHKi1imec" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zamApzJTutkh">Principles of consolidation</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries: Galmed Research and Development
Ltd., Galmed International Ltd., Galtopa Therapeutics Ltd and Galmed Therapeutics UK Limited. All intercompany balances and transactions
have been eliminated upon consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text"><p id="xdx_840_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zqH5FRoAuZ1e" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zLhKQzbTkWh8">Cash and cash equivalents</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
equivalents are short-term, highly liquid investments that are readily convertible into cash with maturities of three months or less
as of the date acquired.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><p id="xdx_841_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zyW1iWSTYwhb" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zRHhT8coz6O8">Restricted Cash</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
that is held for a specific purpose and is not available for immediate or general business use due to external restrictions is classified
in the Company&#8217;s consolidated balance sheets as restricted cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GLMD_ShortTermDepositsPolicyTextBlock', window );">Short-term deposits</a></td>
<td class="text"><p id="xdx_84B_ecustom--ShortTermDepositsPolicyTextBlock_z6Lb1A38Pww7" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>G.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zKQgtsmvZrR1">Short-term deposits</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bank
deposits with maturities of more than three months but less than one year are included in short-term bank deposits. Such short-term deposits
are stated at cost which approximates fair market value. Interest rates on the Company&#8217;s short-term deposits were between <span id="xdx_90A_eus-gaap--InvestmentInterestRate_iI_dp_c20241231__srt--RangeAxis__srt--MinimumMember_zrnKAFKsFb8b" title="Short-Term deposits interest rate">5.06</span>%-<span id="xdx_90A_eus-gaap--InvestmentInterestRate_iI_dp_c20241231__srt--RangeAxis__srt--MaximumMember_zvKFU0wY1879" title="Short-Term deposits interest rate">6.63</span>%
during the year ended December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable debt securities</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--MarketableSecuritiesPolicy_zZuUPur3p6sf" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>H.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_zeDj7pNOxf15">Marketable debt securities</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company invests most of its excess cash primarily in debt securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for its investments in investment grade debt securities in accordance with ASC 320 &#8220;Investments - Debt and Equity
Securities&#8221;. Management determines the appropriate classification of its investments in debt securities at the time of purchase
and re-evaluates such determinations at each balance sheet date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marketable
debt securities are considered to be available for sale and are carried at fair value on the consolidated balance sheet. Unrealized gains
and losses net of tax, if any, are reported in a separate component of stockholders&#8217; equity in accumulated other comprehensive
income (&#8220;OCI&#8221;). Gains and losses are recognized when realized, on a specific identification basis, in the Company&#8217;s
consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the adoption of ASC 326, current expected credit losses on the Company&#8217;s marketable grade debt securities are recorded, if expected,
through an allowance for current expected credit losses. The amount of allowance for current expected credit losses is limited to the
amount that the fair value is less than the amortized cost basis. Any remaining unrealized losses are included in accumulated other comprehensive
loss in stockholders&#8217; equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Company intends to sell the debt security (that is, it has decided to sell the security), or more likely than not will be required
to sell the security before recovery of its amortized cost basis, any allowance for current expected credit losses is written off and
the amortized cost basis shall be written down to the debt security&#8217;s fair value at the reporting date with any incremental impairment
reported in earnings. Based on management&#8217;s assessment, the Company does not intend to sell its securities for less than amortized
cost; therefore, an allowance for current expected credit losses has not been recorded as of December 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GALMED
PHARMACEUTICALS LTD.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<div style="margin: 0pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2 &#8211; Significant Accounting Policies (Cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of credit risk</a></td>
<td class="text"><p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_zR0yP4KaGEUj" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>I.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_z6MELlxtEgSl">Concentrations of credit risk</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments which potentially subject the Company to credit risk consist primarily of cash, cash equivalents, marketable debt securities
and short-term deposits. The Company hold these investments in highly-rated financial institutions, and, by policy, limit the amounts
of credit exposure to any one financial institution. These amounts at times may exceed federally insured limits. The Company has not
experienced any credit losses in such accounts and does not believe we are exposed to any significant credit risk on these funds. The
Company has no off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts, or other
hedging arrangements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and equipment</a></td>
<td class="text"><p id="xdx_848_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zT95vhA3yXBd" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>J.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_zZqdSXymQ8A">Property and equipment</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_899_ecustom--ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentTableTextBlock_zwrlmrQPQTvl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated
useful lives of the assets. The annual depreciation rates are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_zu3C94eWLw65">Schedule of Depreciation Rates for Property, Plant and Equipment</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 93%; border-collapse: collapse; margin-left: 0.5in">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>%</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office
    furniture and equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentSalvageValuePercentage_iI_pid_dp_uPure_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndEquipmentMember_zdsLcXWNG2oj" title="Property and equipment, depreciation, percentage">7</span>&#8211;<span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentSalvageValuePercentage_iI_pid_dp_uPure_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndEquipmentMember_z0H6Yi6QX3He" title="Property and equipment, depreciation, percentage">16</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computer
    software and electronic equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentSalvageValuePercentage_iI_pid_dp_uPure_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerSoftwareElectronicEquipmentMember_zonOslvEYeMl" title="Property and equipment, depreciation, percentage">15</span>&#8211;<span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentSalvageValuePercentage_iI_pid_dp_uPure_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerSoftwareElectronicEquipmentMember_zN9gwrrdvISk" title="Property and equipment, depreciation, percentage">33</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold
    improvements</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentDepreciationMethodExtensibleEnumeration_iI_dxL_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zpQO8BQbJZv3" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2024%23UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember"><span style="-sec-ix-hidden: xdx2ixbrl0628">Shorter
    of the remaining lease term or useful life</span></span></span></td></tr>
  </table>
<p id="xdx_8AE_zgIUUXRcts4j" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded depreciation expenses in a total of approximately $<span id="xdx_903_eus-gaap--Depreciation_pn4n6_c20240101__20241231_zK6bs281Zfbi" title="Depreciation expenses">0.08</span> million, $<span id="xdx_907_eus-gaap--Depreciation_pn4n6_c20230101__20231231_z8IKX3h04Tt1" title="Depreciation expenses">0.03</span> million and $<span id="xdx_90A_eus-gaap--Depreciation_pn4n6_c20220101__20221231_zf8relcGANAi" title="Depreciation expenses">0.06</span> million for the years ended
December 31, 2024, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Severance pay</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zrrGTnJytw75" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>K.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zeP9cVpNefX2">Severance pay</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company employees are included under section 14 of the Severance Compensation Act, 1963 (&#8220;Section 14&#8221;) in Israel for a portion
of their salaries. According to Section 14, these employees are entitled to monthly deposits at a rate of <span id="xdx_90B_ecustom--MonthlyDepositsOfEmployeesPercentageOnMonthlySalary_pid_dp_uPure_c20240101__20241231_zggLAPYGX5qe" title="Monthly deposits percentage">8.33</span>% of their monthly salary,
contributed on their behalf with insurance companies. Under the Severance Compensation Act, 1963, payments in accordance with Section
14 release the Company from any future severance payments to those employees. Therefore, the Company does not recognize a liability for
severance pay due to these employees and the deposits under Section 14 are not recorded as an asset in the Company&#8217;s consolidated
balance sheets. The Company&#8217;s contributions to the defined contribution plans are charged to the consolidated statements of operations
as and when the services are received from the Company&#8217;s employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GALMED
PHARMACEUTICALS LTD.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<div style="margin: 0pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2 &#8211; Significant Accounting Policies (Cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair value of financial instruments</a></td>
<td class="text"><p id="xdx_842_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z3XvbzKcrp1c" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>L.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_z7Ci3ZnFql9k">Fair value of financial instruments</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
estimated fair value of financial instruments was determined by the Company using available market information and valuation methodologies.
Considerable judgment is required in estimating fair values. Accordingly, the estimates may not be indicative of the amounts the Company
could realize in a current market exchange.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following methods and assumptions were used by the Company in estimating its fair value disclosures for financial instruments:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts of cash and cash equivalents, short-term deposits, other accounts receivables, trade payables and other trade payables
approximate their fair value due to the short-term maturity of such instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
value is an exit price representing the amount that would be received upon selling an asset or that would be paid to transfer a liability
in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based
on assumptions used by market participants in pricing an asset or a liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
three-tier fair-value hierarchy was established as a basis for considering such assumptions and for inputs used in the valuation methodologies
in measuring fair value:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2 - Other inputs that are directly or indirectly observable in the marketplace; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3 - Unobservable inputs that are supported by little or no market activity</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when
measuring fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_898_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zOB5ODJGcNJ8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of the Company&#8217;s assets measured at fair value on a recurring basis by level within the fair value hierarchy are as
follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B3_zO8puHwV0nw7" style="display: none">Schedule of Assets Measured at Fair Value on Recurring Basis</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_ztWBlCt5Mr04" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_ze1DC6ihqWdf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zeNz5iE4EnBj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zlPtLLioYWOe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center"></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zwGbeKQwQqJh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Corporate bonds</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0644">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">2,367</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0646">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">2,367</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zCUvvjcAExU8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Treasury bills</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0649">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">533</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0651">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">533</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember_zPv2QFGWJita" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Mutual funds</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,283</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0655">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0656">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,283</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__custom--InvestmentInAssociateMember_zGGIL9wP0cQe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Investment in associate</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0659">-</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0660">-</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,119</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,119</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_zbmirx9aLf74" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Total</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">4,283</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">2,900</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">2,119</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">9,302</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zLK9o7TRzH3f" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zcyjbxTQ8IF7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zpg9gx3TYEvh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_znCRBj3zweN7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>Fair</b> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value</b></span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zvg8XcErWjm" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Corporate bonds</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0669">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,969</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0671">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,969</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zYCkcRLGM1fe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Treasury bills</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0674">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">409</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0676">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">409</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember_z6XGAWOuzlRk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Mutual funds</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,150</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0680">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0681">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,150</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__custom--InvestmentInAssociateMember_zFeOz1hUX6Ce" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Investment in associate</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0684">-</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0685">-</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,265</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,265</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_z6FQkSJwzSW1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Total</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">5,150</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">2,378</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">3,265</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">10,793</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A7_zIXA0OEOeNXl" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><b>Derivative instrument</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-size: 10pt">Under ASC 815-40,
contracts that are not indexed to the Company&#8217;s own equity are classified as liabilities recorded at fair value, as such, the Company
classifies the SEPA Agreement entered into (see Note 11A(5)) as a derivative instrument measured at fair value at each reporting period,
as settlement provisions under this agreement are not indexed to the Company&#8217;s own equity.</span><span style="font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 18pt"></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Accounting for stock-based compensation</a></td>
<td class="text"><p id="xdx_848_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zE5ODiPqkVT5" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>M.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span><span id="xdx_86D_zTToCDHGG1ga">Accounting for stock-based compensation</span></span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for share-based compensation under ASC 718, Compensation - Stock Compensation (&#8220;ASC 718&#8221;), which requires
the measurement and recognition of compensation expense based on estimated fair values for all share-based payment awards made to employees,
non-employee consultants and directors, including options and restricted share units (&#8220;RSUs&#8221;) based on the fair value of
the awards on the date of grant. ASC 718 requires companies to estimate the fair value of equity-based payment awards on the date of
grant using an option-pricing model. The expense for share-based compensation cost is recognized over the requisite service period of
each individual grant using the straight-line method for service-based awards. Forfeitures are accounted for as they occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GALMED
PHARMACEUTICALS LTD.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<div style="margin: 0pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2 &#8211; Significant Accounting Policies (Cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>M.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accounting for stock-based compensation (Cont.)</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company calculates the fair value of RSUs based on the fair value on the closing trading price of the underlying shares at the date of
grant and estimates the fair value of stock options granted using a <span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDescription_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zr03dAoCGCpk" title="Black scholes option pricing model">Black-Scholes option-pricing model</span>. The option-pricing model requires
a number of assumptions, the most significant of which are the expected stock-price volatility and the expected option term (the time
from the grant date until the options are exercised or expire).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s calculations of the expected volatility were based upon actual historical stock-price movements over the period, which
was equal to the expected option term. The expected option term was calculated for options granted to employees and directors in accordance
with ASC-718-10-S99, using the &#8220;simplified&#8221; method, and grants to non-employees were based on the contractual term. Historically,
the Company has not paid dividends, and has no foreseeable plans to do so. The risk-free interest rate is based on the yield from U.S.
Treasury zero-coupon bonds with an equivalent term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development expenses</a></td>
<td class="text"><p id="xdx_843_eus-gaap--ResearchAndDevelopmentExpensePolicy_zsmgn5zbkeyk" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>N.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zmrDVWBlDJG2">Research and development expenses</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses are charged to the statements of operations as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_zWvuoFjtfIN7" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>O.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_zibACiF6s8o1">Income taxes</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes in accordance with ASC 740, Income Taxes (&#8220;ASC 740&#8221;), using the liability method whereby
deferred tax assets and liability account balances are determined based on the differences between financial reporting and the tax basis
for assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected
to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to the amounts that are more likely-than-not
to be realized. As of December 31, 2024 and 2023, the Company recorded a full valuation allowance against its deferred tax assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company applies a more-likely-than-not recognition threshold to uncertain tax positions based on the technical merits of the income tax
positions taken. The Company does not recognize a tax benefit unless it is more likely than not that the tax position will be sustained
upon examination, including resolution of any related appeals or litigation processes, based on the technical merits of the position.
The tax benefit that is recorded for these positions is measured at the largest amount of benefit that is greater than 50% likely of
being realized upon ultimate settlement. As of December 31, 2024 and 2023, no liability for unrecognized tax benefits was recorded due
to immateriality.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and diluted net loss per share</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--EarningsPerSharePolicyTextBlock_zn8UeKVGd4ol" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>P.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zFxI6g2aD1Z1">Basic and diluted net loss per share</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
net loss per share is computed based on the weighted-average number of shares outstanding during each year. Diluted net loss per share
is computed based on the weighted-average number of shares outstanding during each year, plus the dilutive potential of the ordinary
shares considered outstanding during the year, in accordance with ASC 260-10, &#8220;Earnings Per Share.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
outstanding stock options, RSUs, prefunded-warrants and warrants were excluded from the calculation of the diluted loss per share
for the years ended December 31, 2024, 2023 and 2022, because all such securities have an anti-dilutive effect.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GALMED
PHARMACEUTICALS LTD.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<div style="margin: 0pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2 &#8211; Significant Accounting Policies (Cont.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--LesseeLeasesPolicyTextBlock_ztJF6bSmuRqc" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Q.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_z81fguYtUhG4">Leases</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for leases in accordance with ASC 842 &#8220;Leases.&#8221; Arrangements that are determined to be operating leases
at inception are recognized as right-of-use operating lease assets and lease liabilities in the balance sheets at lease commencement.
The Company recognizes a lease liability at the present value of the lease payments to be made over the lease term, and concurrently
recognizes a right-of-use asset at the same amount of the liability, adjusted for any prepaid or accrued lease payments, plus initial
direct costs incurred in respect of the lease. The Company uses its incremental borrowing rate based on the information available at
the commencement date to determine the present value of the lease payments. The subsequent measurement depends on whether the lease is
classified as a finance lease or an operating lease. During the reporting periods, the Company has only operating leases. Lease terms
include options to extend the lease when it is reasonably certain that the Company will exercise that option. Lease expenses for operating
leases are recognized on a straight-line basis over the lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has made a policy election not to capitalize leases with a term of 12 months or less. The Company made has also made a policy
election to include lease and non-lease components as a single lease component.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payments
for variable lease costs are expensed as incurred and are not included in the operating lease right-of-use assets and lease liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with ASC 360-10, management reviews operating lease assets for impairment whenever events or changes in circumstances indicate
that the carrying amount of an asset may not be recoverable based on estimated future undiscounted cash flows. If so indicated, an impairment
loss would be recognized for the difference between the carrying amount of the asset and its fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investment in Associate at Fair Value</a></td>
<td class="text"><p id="xdx_849_eus-gaap--InvestmentPolicyTextBlock_z0Yq6MBcXBu1" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>R.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zWIp43wKc5ib">Investment in Associate at Fair Value</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company holds an equity investment of a privately-owned company, Onkai Inc. (&#8220;Onkai&#8221;), over which it has the ability to exercise
significant influence, but not control. The investment was included as a non-current asset in the balance sheet as of December 31, 2024.
The Company has elected the fair value option allowed by ASC 825, Financial Instruments, with respect to this investment because management
believes this approach will better reflect the economics of its equity interest. Under the fair value option, the investment is remeasured
at fair value (level 3) at each reporting period with changes in fair value, if any, recorded in the statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, management, based on fair value estimation, assessed the qualitative aspects of the equity investment and macroeconomic
factors and determined that an impairment should be recognized in amount of $1.1 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently adopted accounting pronouncements</a></td>
<td class="text"><p id="xdx_845_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z7VU98c1aeO3" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>S.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zrB96f2tbo9">Recently adopted accounting pronouncements</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, new accounting pronouncements are issued by FASB, or other standard setting bodies and adopted by the Company as of the
specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have
a material impact on our financial position or results of operations upon adoption.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The ASU expands
public entities&#8217; segment disclosures by requiring disclosure of significant segment expenses that are regularly reviewed by the
chief operating decision maker (&#8220;CODM&#8221;) and included within each reported measure of segment profit or loss, an amount and
description of its composition for other segment items, and interim disclosures of a reportable segment&#8217;s profit or loss and assets.
The ASU also allows, in addition to the measure that is most consistent with U.S. GAAP, the disclosure of additional measures of segment
profit or loss that are used by the CODM in assessing segment performance and deciding how to allocate resources. The ASU is effective
for the Company&#8217;s Annual Report on Form 20-F for the fiscal year ended December 31, 2024, and subsequent interim periods, with
early adoption permitted. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GLMD_NewAccountingPronouncementsNotYetEffectivePolicyTextBlock', window );">Accounting pronouncements not yet effective</a></td>
<td class="text"><p id="xdx_84A_ecustom--NewAccountingPronouncementsNotYetEffectivePolicyTextBlock_zXeQR5BViNok" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>T.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_zsQbYWN4vhzh">Accounting pronouncements not yet effective</span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, the FASB issued ASU 2024-03, &#8220;Income Statement&#8211;Reporting Comprehensive Income&#8211;Expense Disaggregation
Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses&#8221; (&#8220;ASU 2024-03&#8221;), which requires the disaggregation
of certain expenses in the financial statements notes, to provide enhanced transparency into the expense captions presented on the face
of the consolidated statement of operations. ASU 2024-03 is effective for annual reporting periods beginning January 1, 2027 and interim
periods beginning January 1, 2028 and may be applied either prospectively or retrospectively. The Company is currently evaluating the
impact that ASU 2024-03 will have on its related disclosures, and the transition method.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GLMD_NewAccountingPronouncementsNotYetEffectivePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GLMD_NewAccountingPronouncementsNotYetEffectivePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GLMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GLMD_ShortTermDepositsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GLMD_ShortTermDepositsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GLMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 12<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GLMD_ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentTableTextBlock', window );">Schedule of Depreciation Rates for Property, Plant and Equipment</a></td>
<td class="text"><p id="xdx_899_ecustom--ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentTableTextBlock_zwrlmrQPQTvl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated
useful lives of the assets. The annual depreciation rates are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_zu3C94eWLw65">Schedule of Depreciation Rates for Property, Plant and Equipment</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 93%; border-collapse: collapse; margin-left: 0.5in">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>%</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office
    furniture and equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentSalvageValuePercentage_iI_pid_dp_uPure_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndEquipmentMember_zdsLcXWNG2oj" title="Property and equipment, depreciation, percentage">7</span>&#8211;<span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentSalvageValuePercentage_iI_pid_dp_uPure_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndEquipmentMember_z0H6Yi6QX3He" title="Property and equipment, depreciation, percentage">16</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computer
    software and electronic equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentSalvageValuePercentage_iI_pid_dp_uPure_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerSoftwareElectronicEquipmentMember_zonOslvEYeMl" title="Property and equipment, depreciation, percentage">15</span>&#8211;<span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentSalvageValuePercentage_iI_pid_dp_uPure_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerSoftwareElectronicEquipmentMember_zN9gwrrdvISk" title="Property and equipment, depreciation, percentage">33</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold
    improvements</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentDepreciationMethodExtensibleEnumeration_iI_dxL_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zpQO8BQbJZv3" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2024%23UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember"><span style="-sec-ix-hidden: xdx2ixbrl0628">Shorter
    of the remaining lease term or useful life</span></span></span></td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Assets Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><p id="xdx_898_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zOB5ODJGcNJ8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of the Company&#8217;s assets measured at fair value on a recurring basis by level within the fair value hierarchy are as
follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B3_zO8puHwV0nw7" style="display: none">Schedule of Assets Measured at Fair Value on Recurring Basis</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_ztWBlCt5Mr04" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_ze1DC6ihqWdf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zeNz5iE4EnBj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zlPtLLioYWOe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center"></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zwGbeKQwQqJh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Corporate bonds</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0644">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">2,367</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0646">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">2,367</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zCUvvjcAExU8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Treasury bills</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0649">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">533</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0651">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">533</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember_zPv2QFGWJita" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Mutual funds</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,283</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0655">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0656">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,283</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__custom--InvestmentInAssociateMember_zGGIL9wP0cQe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Investment in associate</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0659">-</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0660">-</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,119</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,119</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_zbmirx9aLf74" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Total</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">4,283</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">2,900</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">2,119</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">9,302</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zLK9o7TRzH3f" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zcyjbxTQ8IF7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zpg9gx3TYEvh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_znCRBj3zweN7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>Fair</b> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value</b></span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zvg8XcErWjm" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Corporate bonds</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0669">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,969</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0671">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,969</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zYCkcRLGM1fe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Treasury bills</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0674">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">409</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0676">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">409</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember_z6XGAWOuzlRk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Mutual funds</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,150</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0680">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0681">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,150</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__custom--InvestmentInAssociateMember_zFeOz1hUX6Ce" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Investment in associate</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0684">-</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0685">-</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,265</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,265</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_z6FQkSJwzSW1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Total</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">5,150</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">2,378</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">3,265</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">10,793</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GLMD_ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Depreciation Rates For Property Plant And Equipment [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GLMD_ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GLMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable debt securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Schedule of Marketable Debt Securities</a></td>
<td class="text"><p id="xdx_891_eus-gaap--MarketableSecuritiesTextBlock_ziorsCGksSsk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the Company&#8217;s marketable debt securities as of December 31, 2024 and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zLSGCQ7oRRSc">Schedule of Marketable Debt Securities</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Gross</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Gross</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Amortized</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Unrealized</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Unrealized</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Estimated</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Cost</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Gains</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Losses</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="6" style="text-align: center">(in thousands)</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Corporate bonds</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20241231__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_z5pGNXVo15m1" style="width: 11%; text-align: right" title="Amortized Cost">2,529</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20240101__20241231__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zxu3sadovbg1" style="width: 11%; text-align: right" title="Gross Unrealized Gains">9</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20240101__20241231__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zZhrqtyHu77i" style="width: 11%; text-align: right" title="Gross Unrealized Losses">(171</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20241231__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zMkO1mcWkvQh" style="width: 11%; text-align: right" title="Estimated Fair Value">2,367</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Treasury bills</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20241231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zlnpOESAfzBe" style="text-align: right" title="Amortized Cost">530</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20240101__20241231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zW8dGQ697sa1" style="text-align: right" title="Gross Unrealized Gains">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20240101__20241231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zgJ5wvhkh6g1" style="text-align: right" title="Gross Unrealized Losses"><span style="-sec-ix-hidden: xdx2ixbrl0728">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20241231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zHdxs25KFZ0c" style="text-align: right" title="Estimated Fair Value">533</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Mutual funds</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20241231__us-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember_z3opYpITlijf" style="border-bottom: Black 1pt solid; text-align: right" title="Amortized Cost">4,540</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20240101__20241231__us-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember_zMKHIuurUWhi" style="border-bottom: Black 1pt solid; text-align: right" title="Gross Unrealized Gains">23</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20240101__20241231__us-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember_zA5nio4FBf8a" style="border-bottom: Black 1pt solid; text-align: right" title="Gross Unrealized Losses">(280</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20241231__us-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember_zn5Ey2cwU955" style="border-bottom: Black 1pt solid; text-align: right" title="Estimated Fair Value">4,283</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total short-term investments</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20241231_zbZiAMju3MH2" style="border-bottom: Black 2.5pt double; text-align: right" title="Amortized Cost">7,599</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20240101__20241231_zbEGM5h03LV" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross Unrealized Gains">35</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20240101__20241231_zgkIQrNH6ZUa" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross Unrealized Losses">(451</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20241231_zyoIMognowkb" style="border-bottom: Black 2.5pt double; text-align: right" title="Estimated Fair Value">7,183</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Gross</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Gross</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Amortized</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Unrealized</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Unrealized</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Estimated</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Cost</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Gains</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Losses</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="6" style="text-align: center">(in thousands)</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Corporate bonds</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zwMu8yQc0E5j" style="width: 11%; text-align: right" title="Amortized Cost">2,123</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zpHunG4JoUD1" style="width: 11%; text-align: right" title="Gross Unrealized Gains">6</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_z6syK3HtY8V7" style="width: 11%; text-align: right" title="Gross Unrealized Losses">(160</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zbs0K82Z1RP8" style="width: 11%; text-align: right" title="Estimated Fair Value">1,969</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Treasury bills</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zwBHrXpb881a" style="text-align: right" title="Amortized Cost">400</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_z54lJKA8hhQ4" style="text-align: right" title="Gross Unrealized Gains">9</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zfUhQ8ISTWRl" style="text-align: right" title="Gross Unrealized Losses"><span style="-sec-ix-hidden: xdx2ixbrl0760">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zlWOlNyvzLQ8" style="text-align: right" title="Estimated Fair Value">409</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Mutual funds</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember_zIge1392z3Ce" style="border-bottom: Black 1pt solid; text-align: right" title="Amortized Cost">5,459</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember_zqFwdqgwBlVd" style="border-bottom: Black 1pt solid; text-align: right" title="Gross Unrealized Gains">1</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember_zYSUBOil9V18" style="border-bottom: Black 1pt solid; text-align: right" title="Gross Unrealized Losses">(310</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember_zRKOzt5MpGBl" style="border-bottom: Black 1pt solid; text-align: right" title="Estimated Fair Value">5,150</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total short-term investments</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20231231_zV8pgetGHb0b" style="border-bottom: Black 2.5pt double; text-align: right" title="Amortized Cost">7,982</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20230101__20231231_zUN73WatyXV3" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross Unrealized Gains">16</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20230101__20231231_zqKOliB3p1o7" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross Unrealized Losses">(470</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20231231_zjdC2HKyqqfi" style="border-bottom: Black 2.5pt double; text-align: right" title="Estimated Fair Value">7,528</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Receivables (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Schedule of Other Receivables</a></td>
<td class="text"><p id="xdx_894_eus-gaap--ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_zU0YQQcu491b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zcVwmyobPA67">Schedule
of Other  Receivables</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20241231_z2qPXrmPFB2e" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20231231_zROnT5sZLdv6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(in thousands)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--PrepaidExpenseCurrent_iI_pn3n3_maRNCz4tF_zH9Wg5qgz80b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Prepaid expenses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">463</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">315</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--GrantsReceivable_iI_pn3n3_maRNCz4tF_zAx1QN4A0UNb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Government institutions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">76</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">47</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OtherReceivables_iI_pn3n3_maRNCz4tF_zoSnRg0fmu44" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Other receivables</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">133</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">118</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--ReceivablesNetCurrent_iTI_pn3n3_mtRNCz4tF_zZtiDosvOvsg" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">672</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">480</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and equipment, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><p id="xdx_897_eus-gaap--PropertyPlantAndEquipmentTextBlock_zk2Ns6bbY8W3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BF_z81lMRSFFPlc">Schedule of Property and Equipment</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20241231_zNetz5pICHLb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20231231_zIY10BIZmWNl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="6" style="text-align: center">(in thousands)</td><td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--MachineryAndEquipmentGross_iI_pn3n3_maPPAEGzWKA_zZY4PcHfFz3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Medical equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">737</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">737</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FurnitureAndFixturesGross_iI_pn3n3_maPPAEGzWKA_zWkuntSH1YE2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Office furniture and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">55</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">55</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--CapitalizedComputerSoftwareGross_iI_pn3n3_maPPAEGzWKA_zDn4IKV7adRc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Computer software and electronic equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">75</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LeaseholdImprovementsGross_iI_pn3n3_maPPAEGzWKA_zroB6QTOVs47" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Leasehold improvements</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">236</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">235</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iTI_pn3n3_mtPPAEGzWKA_maPPAENzlLK_z45bbBTi5Ove" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, gross</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,103</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,102</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENzlLK_z52HQWbqdROc" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Less - Accumulated depreciation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,103</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,019</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzlLK_zIAZEi5e5nvk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Net book value</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0836">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">83</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment in an Associate (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GLMD_ScheduleOfBalanceSheetsTableTextBlock', window );">Schedule of Balance Sheets</a></td>
<td class="text"><p id="xdx_89D_ecustom--ScheduleOfBalanceSheetsTableTextBlock_zupYrJFyreB" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span><span id="xdx_8B7_zLCxDACqeusf" style="display: none">Schedule
of Balance Sheets</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Balance
sheet as of December 31, 2024</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 0.75in">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_490_20241231__srt--TitleOfIndividualAxis__custom--OnkaiIncMember_zXUwPwrBovBb" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(in thousands)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AssetsCurrent_iI_pn3n3_msSEzDrf_zOzTqQ0pVvV9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">Current assets</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">105</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AssetsNoncurrent_iI_pn3n3_msSEzDrf_zt5GQthFEbv5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Non-current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LiabilitiesCurrent_iI_pn3n3_maSEzDrf_zobY668MRGo8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">324</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--LiabilitiesNoncurrent_iI_pn3n3_maSEzDrf_zMXlZzwTppjg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Non-current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,665</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--StockholdersEquity_iNTI_pn3n3_di_mtSEzDrf_zkyvyScp2BRj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Equity</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,881</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GLMD_ScheduleOfStatementOfOperationsTableTextBlock', window );">Schedule of Statement of Operations</a></td>
<td class="text"><p id="xdx_894_ecustom--ScheduleOfStatementOfOperationsTableTextBlock_z2gmHRwAhNka" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B6_zPHAEsrbXx7d" style="display: none">Schedule of Statement of Operations</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20240101__20241231__srt--TitleOfIndividualAxis__custom--OnkaiIncMember_zkDMtB6dour2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(in thousands)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OperatingExpenses_pn3n3_msNILzGpU_z2RKoKHX4gFj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%; text-align: left">Total operating loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">2,485</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--NonoperatingIncomeExpense_pn3n3_maNILzGpU_zEeHcD4uNTQd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Financial expenses, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeTaxExpenseBenefit_pn3n3_msNILzGpU_zt7bQ6wUrWck" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Income tax</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">22</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--NetIncomeLoss_iNT_pn3n3_di_mtNILzGpU_zZzVj1WqR7h9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Net Loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">2,537</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GLMD_ScheduleOfBalanceSheetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GLMD_ScheduleOfBalanceSheetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GLMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GLMD_ScheduleOfStatementOfOperationsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GLMD_ScheduleOfStatementOfOperationsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GLMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Payables (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesTableTextBlock', window );">Schedule of Other Payables</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--OtherLiabilitiesTableTextBlock_zaNda3wGO549" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BF_zMZzMlssmlv1">Schedule
of Other Payables</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%; margin-left: 0.75in">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20241231_zYN49w91ZZ6c" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20231231_z6YGup8Lcp3a" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(in thousands)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--EmployeeRelatedLiabilitiesCurrentAndNoncurrent_iI_pn3n3_maOLzBhJ_zRyT3YMRNj1k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Employees and related</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">603</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">571</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--CompensatedAbsencesLiability_iI_pn3n3_maOLzBhJ_zxo0qSQeVIYi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued Vacation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">256</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">259</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--ShorttermLeaseObligation_iI_pn3n3_maOLzBhJ_z2yrk2VWa5g7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Short-term lease obligation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0902">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">41</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OtherNotesPayable_iI_pn3n3_maOLzBhJ_zymGl44N1hgb" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">6</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0906">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OtherLiabilities_iTI_pn3n3_mtOLzBhJ_zCDUx68QUafg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Other Payables</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">865</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">871</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Status of Company's Option Plans and Changes</a></td>
<td class="text"><p id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zguewmEJvuXf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none"><span id="xdx_8B4_zZ6l0CFM7hFc">Summary
of Status of Company's Option Plans and Changes</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 96%; border-collapse: collapse; margin-left: 0.25in">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="6" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="6" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023
    (*)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
    of</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>average</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
    of</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>average</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>share</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>exercise</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>share</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>exercise</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>options</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>price</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>options</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>price</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options
    outstanding at beginning of year</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zWLAnmky41Ye" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Number of share options, Beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20,277</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zPy4aA2aXj48" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted average exercise price, Beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">460</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zCnRDwTCWP91" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Number of share options, Beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14,973</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_z2SpChuqlEQ7" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted average exercise price, Beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">654</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Granted</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zu7PmuIAJeM6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of share options, Granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1060">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zClQp5lDQYJa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, Granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1062">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zkw6Zng0TR4i" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of share options, Granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,250</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zxH0vhVFriKe" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, Granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Forfeited</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240101__20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zIdJ4i6OqQAb" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of share options, Forfeited"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,041</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zdvWLtcaz6of" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, Forfeited"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">94</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20230101__20231231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zFEWnAg1SZzk" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of share options, Forfeited"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11,351</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zMVt6qpJBCxb" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, Forfeited"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">441.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding
    at end of year</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zW2ejCxeWnMg" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of share options, Ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19,236</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zWBsxNgW3OE7" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, Ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">321</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zjjWoaIFNMvc" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of share options, Ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20,277</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_z4GB1kLPmpXb" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, Ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">460</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options
    exercisable at year end</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20240101__20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zIm8Sf8sRbn2" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of share options exercisable, Ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14,966</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zXZBLkzawzW" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, Options exercisable, Ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">413</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zwGHpJuCoFfi" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of share options exercisable, Ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13,269</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zxUQD2xG0Rr5" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, Options exercisable, Ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">670.56</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Development Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock', window );">Schedule of Research and Development Expenses</a></td>
<td class="text"><p id="xdx_890_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock_ziuRnOx0P0rf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none"><span id="xdx_8B8_zv2MOaxIgHVk">Schedule of Research and Development Expenses</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(in thousands)</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Chemistry and formulation studies</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__custom--ChemistryAndFormulationStudiesMember_zDsfi0ig8y67" style="width: 14%; text-align: right" title="Research and development expense">696</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--ChemistryAndFormulationStudiesMember_zyE8JQIQubG9" style="width: 14%; text-align: right" title="Research and development expense">573</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__custom--ChemistryAndFormulationStudiesMember_zOlTd1YZTYmc" style="width: 14%; text-align: right" title="Research and development expense">2,448</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Salaries</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__custom--SalariesMember_zpI82J099YY5" style="text-align: right" title="Research and development expense">982</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--SalariesMember_zeDn0J9ezjF6" style="text-align: right" title="Research and development expense">676</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__custom--SalariesMember_ztdz1oqsyw1l" style="text-align: right" title="Research and development expense">1,692</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__custom--StockBasedCompensationMember_z8wj4qyB3dd6" style="text-align: right" title="Research and development expense">112</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--StockBasedCompensationMember_z8goXa8TdSV7" style="text-align: right" title="Research and development expense">243</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__custom--StockBasedCompensationMember_zl26bsC9nsoj" style="text-align: right" title="Research and development expense">383</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and preclinical studies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__custom--ResearchAndPreclinicalStudiesMember_zm8txvyA7r6h" style="text-align: right" title="Research and development expense">255</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--ResearchAndPreclinicalStudiesMember_z4n5cQkWnNFe" style="text-align: right" title="Research and development expense">460</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__custom--ResearchAndPreclinicalStudiesMember_zkCJ2CZk1hNl" style="text-align: right" title="Research and development expense">1,346</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Clinical studies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__custom--ClinicalStudiesMember_z28YOLCpUlZ6" style="text-align: right" title="Research and development expense">291</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--ClinicalStudiesMember_zX0SYvubDGq9" style="text-align: right" title="Research and development expense">616</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__custom--ClinicalStudiesMember_zDn6uGm2gOYg" style="text-align: right" title="Research and development expense">6,532</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Regulatory and other expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__custom--RegulatoryAndOtherExpensesMember_zsuWlwnT3cOf" style="border-bottom: Black 1pt solid; text-align: right" title="Research and development expense">643</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--RegulatoryAndOtherExpensesMember_zRXUnXXn2lg9" style="border-bottom: Black 1pt solid; text-align: right" title="Research and development expense">1,001</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__custom--RegulatoryAndOtherExpensesMember_zrwxLZ03siza" style="border-bottom: Black 1pt solid; text-align: right" title="Research and development expense">594</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20240101__20241231_zha7UvacKc6e" style="border-bottom: Black 2.5pt double; text-align: right" title="Research and development expense">2,979</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20230101__20231231_zdKICeaB44Gf" style="border-bottom: Black 2.5pt double; text-align: right" title="Research and development expense">3,569</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20220101__20221231_zIs0giyR4hz5" style="border-bottom: Black 2.5pt double; text-align: right" title="Research and development expense">12,995</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements. Include also the amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others. Aggregation of similar arrangements by type may be appropriate. Include also the amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others. Aggregation of similar arrangements by type may be appropriate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General and Administrative Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GLMD_DisclosureGeneralAndAdministrativeExpensesAbstract', window );"><strong>General And Administrative Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GLMD_GeneralAndAdministrativeExpensesTableTextBlock', window );">Schedule of General and Administrative Expenses</a></td>
<td class="text"><p id="xdx_896_ecustom--GeneralAndAdministrativeExpensesTableTextBlock_zc3DZSOklY" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none"><span id="xdx_8B8_z6s0KlLNaH92">Schedule of General and Administrative Expenses</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">(in thousands)</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Stock-based compensation</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__custom--StockBasedCompensationMember_z1dA2h3OIgi4" style="width: 14%; text-align: right" title="General and administrative expenses">419</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--StockBasedCompensationMember_z6Pr0SVLyUP2" style="width: 14%; text-align: right" title="General and administrative expenses">649</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__custom--StockBasedCompensationMember_zA3NEe6Nuc8c" style="width: 14%; text-align: right" title="General and administrative expenses">913</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__custom--ProfessionalFeeMember_zEQ1jAH6MHrh" style="text-align: right" title="General and administrative expenses">896</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--ProfessionalFeeMember_zUUUZQfcKdk4" style="text-align: right" title="General and administrative expenses">908</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__custom--ProfessionalFeeMember_z2WpLiFfOKPa" style="text-align: right" title="General and administrative expenses">1,084</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Salaries and benefits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__custom--SalariesAndBenefitsMember_zoS20LYjqApa" style="text-align: right" title="General and administrative expenses">1,478</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--SalariesAndBenefitsMember_zkv5dJOEydng" style="text-align: right" title="General and administrative expenses">1,428</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__custom--SalariesAndBenefitsMember_zL5geAw4doO3" style="text-align: right" title="General and administrative expenses">1,164</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Rent and office-maintenance fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__custom--RentAndOfficeMaintenanceFeesMember_zNl2NqVBOnQ7" style="text-align: right" title="General and administrative expenses">117</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--RentAndOfficeMaintenanceFeesMember_z6kOQICm3hGg" style="text-align: right" title="General and administrative expenses">261</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__custom--RentAndOfficeMaintenanceFeesMember_z7jXRxaxz2L8" style="text-align: right" title="General and administrative expenses">401</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Insurance and other expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__custom--InsuranceAndOtherExpensesMember_zVjfrOB9y13a" style="border-bottom: Black 1pt solid; text-align: right" title="General and administrative expenses">389</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--InsuranceAndOtherExpensesMember_zgfeDWFmEPG" style="border-bottom: Black 1pt solid; text-align: right" title="General and administrative expenses">677</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__custom--InsuranceAndOtherExpensesMember_zIGcJJGXstW1" style="border-bottom: Black 1pt solid; text-align: right" title="General and administrative expenses">1,094</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20240101__20241231_z0U5gSchMxMf" style="border-bottom: Black 2.5pt double; text-align: right" title="General and administrative expenses">3,299</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20230101__20231231_z9uSjw6MrGWb" style="border-bottom: Black 2.5pt double; text-align: right" title="General and administrative expenses">3,923</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20220101__20221231_zzhwtv32kYGl" style="border-bottom: Black 2.5pt double; text-align: right" title="General and administrative expenses">4,656</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GLMD_DisclosureGeneralAndAdministrativeExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GLMD_DisclosureGeneralAndAdministrativeExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GLMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GLMD_GeneralAndAdministrativeExpensesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GLMD_GeneralAndAdministrativeExpensesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GLMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial income, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeByComponentTextBlock', window );">Schedule of Financial Income, Net</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--ScheduleOfOtherNonoperatingIncomeByComponentTextBlock_zFdcfS2Q25A4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none"><span id="xdx_8BE_ziOFMcPvD306">Schedule of Financial Income, Net</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20240101__20241231_zzb1ucyZ33Ie" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20230101__20231231_zDfH2kZowrVd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20220101__20221231_zcqyslIm7Gfh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">(in thousands)</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_408_ecustom--BankFees_iN_pn3n3_di_msONIEz4mj_zKZr1V4vqB77" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Bank fees</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">15</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">11</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">22</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--InterestIncome_pn3n3_maONIEz4mj_zwhCBrfac05h" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(503</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(375</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(297</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--DebtSecuritiesAvailableForSaleGainLoss_pn3n3_maONIEz4mj_zKDn9fGmekm4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss from sale of marketable debt securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">526</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--ChangeInFairValueOfConvertibleNote_pn3n3_maONIEz4mj_z5zWTc7hC6qb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Change in fair value of convertible note</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1290">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(265</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1292">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--ForeignCurrencyTransactionGainLossBeforeTax_pn3n3_maONIEz4mj_zY7KEqP1G7p9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Foreign currency (gains) losses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(40</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">36</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(36</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--OtherNonoperatingIncomeExpense_iNT_pn3n3_di_mtONIEz4mj_zy0VsQvvfJy4" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
    income net</span></span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(516</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(580</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">215</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeByComponentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the detailed components of other nonoperating income. May include methodology, assumptions and amounts for: (a) dividends, (b) interest on securities, (c) profits on securities (net of losses), and (d) miscellaneous other income items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeByComponentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><p id="xdx_893_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_z8W8nOrww3Vd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of the Company&#8217;s effective tax expense to the Company&#8217;s theoretical statutory tax benefit is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zpOBbrXmcaTk" style="display: none">Schedule of Effective Income Tax Rate Reconciliation</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20240101__20241231_zI43QpEYMOXb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20230101__20231231_ziaulpg56Iz9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20220101__20221231_zj3jy4F0oDhi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(in thousands)</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn3n3_ztAHqONZnqb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left; padding-bottom: 2.5pt">Loss before taxes on income, as reported in the consolidated statements of operations</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">7,517</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">6,912</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">17,866</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_zbKWAnV5rC57" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Statutory tax rate</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">23</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">23</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">12</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_maITEBzSAa_zQqEaK4ogOW2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Theoretical tax benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,729</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,590</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,144</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_maITEBzSAa_zd1KL1KEkRdk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Losses and other items for which a valuation allowance was provided or benefit from loss carry forwards</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,729</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,590</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(2,144</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3n3_mtITEBzSAa_ztV1u2QHBqcg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Actual tax expense</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1346">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1347">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1348">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Date of incorporation</a></td>
<td class="text">Jul. 31,  2013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperationsCommencedDate1', window );">Date of commenced operations</a></td>
<td class="text">Feb.  02,  2014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 4,652<span></span>
</td>
<td class="nump">$ 2,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">121<span></span>
</td>
<td class="nump">117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsCurrent', window );">Short-term deposits</a></td>
<td class="nump">3,496<span></span>
</td>
<td class="nump">2,253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Marketable securities debt</a></td>
<td class="nump">7,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Profit loss</a></td>
<td class="nump">8,000<span></span>
</td>
<td class="nump">6,900<span></span>
</td>
<td class="nump">$ 17,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings accumulated deficit</a></td>
<td class="nump">$ 200,469<span></span>
</td>
<td class="nump">$ 192,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationDateOfIncorporation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when an entity was incorporated</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationDateOfIncorporation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperationsCommencedDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the operations of the entity commenced, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperationsCommencedDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Depreciation Rates for Property, Plant and Equipment (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDepreciationMethodExtensibleEnumeration', window );">Property, Plant and Equipment, Depreciation Method [Extensible Enumeration]</a></td>
<td class="text">Useful Life, Shorter of Lease Term or Asset Utility [Member]<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Office Furniture and Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage', window );">Property and equipment, depreciation, percentage</a></td>
<td class="nump">7.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Computer Software and Electronic Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage', window );">Property and equipment, depreciation, percentage</a></td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Office Furniture and Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage', window );">Property and equipment, depreciation, percentage</a></td>
<td class="nump">16.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Computer Software and Electronic Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage', window );">Property and equipment, depreciation, percentage</a></td>
<td class="nump">33.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDepreciationMethodExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates method of allocating cost over useful life in systematic and rational manner for property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDepreciationMethodExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stated as a percentage, the estimated or actual value of the asset at the end of its useful life or when it is no longer serviceable (cannot be used for its original purpose) divided by its [historical] capitalized cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=GLMD_OfficeFurnitureAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=GLMD_OfficeFurnitureAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=GLMD_ComputerSoftwareElectronicEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=GLMD_ComputerSoftwareElectronicEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Assets Measured at Fair Value on Recurring Basis (Details) - Fair Value, Recurring [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">$ 9,302<span></span>
</td>
<td class="nump">$ 10,793<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">2,367<span></span>
</td>
<td class="nump">1,969<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">US Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">533<span></span>
</td>
<td class="nump">409<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Mutual Fund [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">4,283<span></span>
</td>
<td class="nump">5,150<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Investment In Associate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">2,119<span></span>
</td>
<td class="nump">3,265<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">4,283<span></span>
</td>
<td class="nump">5,150<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 1 [Member] | Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 1 [Member] | US Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 1 [Member] | Mutual Fund [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">4,283<span></span>
</td>
<td class="nump">5,150<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 1 [Member] | Investment In Associate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">2,900<span></span>
</td>
<td class="nump">2,378<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 2 [Member] | Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">2,367<span></span>
</td>
<td class="nump">1,969<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 2 [Member] | US Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">533<span></span>
</td>
<td class="nump">409<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 2 [Member] | Mutual Fund [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 2 [Member] | Investment In Associate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">2,119<span></span>
</td>
<td class="nump">3,265<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 3 [Member] | Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 3 [Member] | US Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 3 [Member] | Mutual Fund [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 3 [Member] | Investment In Associate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">$ 2,119<span></span>
</td>
<td class="nump">$ 3,265<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MutualFundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MutualFundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=GLMD_InvestmentInAssociateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=GLMD_InvestmentInAssociateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expenses</a></td>
<td class="nump">$ 80<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="nump">$ 60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GLMD_MonthlyDepositsOfEmployeesPercentageOnMonthlySalary', window );">Monthly deposits percentage</a></td>
<td class="nump">8.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GLMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDescription', window );">Black scholes option pricing model</a></td>
<td class="text">Black-Scholes option-pricing model<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentInterestRate', window );">Short-Term deposits interest rate</a></td>
<td class="nump">5.06%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentInterestRate', window );">Short-Term deposits interest rate</a></td>
<td class="nump">6.63%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GLMD_MonthlyDepositsOfEmployeesPercentageOnMonthlySalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collection of monthly deposits from the employees on their monthly salary for severance pay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GLMD_MonthlyDepositsOfEmployeesPercentageOnMonthlySalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GLMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GLMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award fair value assumptions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GLMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GLMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of interest on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Marketable Debt Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 7,599<span></span>
</td>
<td class="nump">$ 7,982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Gross Unrealized Gains</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Gross Unrealized Losses</a></td>
<td class="num">(451)<span></span>
</td>
<td class="num">(470)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">7,183<span></span>
</td>
<td class="nump">7,528<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">2,529<span></span>
</td>
<td class="nump">2,123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Gross Unrealized Gains</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Gross Unrealized Losses</a></td>
<td class="num">(171)<span></span>
</td>
<td class="num">(160)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">2,367<span></span>
</td>
<td class="nump">1,969<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">US Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">530<span></span>
</td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Gross Unrealized Gains</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Gross Unrealized Losses</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">533<span></span>
</td>
<td class="nump">409<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MutualFundMember', window );">Mutual Fund [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">4,540<span></span>
</td>
<td class="nump">5,459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Gross Unrealized Gains</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Gross Unrealized Losses</a></td>
<td class="num">(280)<span></span>
</td>
<td class="num">(310)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 4,283<span></span>
</td>
<td class="nump">$ 5,150<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MutualFundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MutualFundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Other Receivables (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">$ 463<span></span>
</td>
<td class="nump">$ 315<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrantsReceivable', window );">Government institutions</a></td>
<td class="nump">76<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Other receivables</a></td>
<td class="nump">133<span></span>
</td>
<td class="nump">118<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Total</a></td>
<td class="nump">$ 672<span></span>
</td>
<td class="nump">$ 480<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due from parties in nontrade transactions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details Narrative)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GLMD_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area of land under operating lease agreement | ft&#178;</a></td>
<td class="nump">590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiry date</a></td>
<td class="text">Mar. 21,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Lease expense</a></td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Operating lease right of use assets<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Operating lease liability<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GLMD_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GLMD_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GLMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MachineryAndEquipmentGross', window );">Medical equipment</a></td>
<td class="nump">$ 737<span></span>
</td>
<td class="nump">$ 737<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FurnitureAndFixturesGross', window );">Office furniture and equipment</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareGross', window );">Computer software and electronic equipment</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseholdImprovementsGross', window );">Leasehold improvements</a></td>
<td class="nump">236<span></span>
</td>
<td class="nump">235<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">1,103<span></span>
</td>
<td class="nump">1,102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less - Accumulated depreciation</a></td>
<td class="num">(1,103)<span></span>
</td>
<td class="num">(1,019)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net book value</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 83<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FurnitureAndFixturesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FurnitureAndFixturesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseholdImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseholdImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MachineryAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MachineryAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Balance Sheets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Current assets</a></td>
<td class="nump">$ 16,124<span></span>
</td>
<td class="nump">$ 13,239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Non-current assets</a></td>
<td class="nump">2,376<span></span>
</td>
<td class="nump">3,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current liabilities</a></td>
<td class="nump">2,173<span></span>
</td>
<td class="nump">2,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Equity</a></td>
<td class="num">(16,327)<span></span>
</td>
<td class="num">$ (13,879)<span></span>
</td>
<td class="num">$ (13,423)<span></span>
</td>
<td class="num">$ (30,497)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=GLMD_OnkaiIncMember', window );">Onkai Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Current assets</a></td>
<td class="nump">105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Non-current assets</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current liabilities</a></td>
<td class="nump">324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Non-current liabilities</a></td>
<td class="nump">1,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Equity</a></td>
<td class="num">$ (1,881)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=GLMD_OnkaiIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=GLMD_OnkaiIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Statement of Operations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating loss</a></td>
<td class="nump">$ 6,278<span></span>
</td>
<td class="nump">$ 7,492<span></span>
</td>
<td class="nump">$ 17,651<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">7,517<span></span>
</td>
<td class="nump">$ 6,912<span></span>
</td>
<td class="nump">$ 17,866<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=GLMD_OnkaiIncMember', window );">Onkai Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating loss</a></td>
<td class="nump">2,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Financial expenses, net</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax</a></td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 2,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=GLMD_OnkaiIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=GLMD_OnkaiIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment in an Associate (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 15, 2024</div></th>
<th class="th"><div>May 04, 2023</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 19, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Management fee income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,299,000<span></span>
</td>
<td class="nump">$ 3,923,000<span></span>
</td>
<td class="nump">$ 4,656,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GLMD_BridgeLoanAgreementMember', window );">Bridge Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Loan amount</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Interest rate</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GLMD_ServicesAgreementMember', window );">Services Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromOtherDebt', window );">Proceeds from debt</a></td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt</a></td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_AdministrativeServiceMember', window );">Administrative Service [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Management fee income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,000<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=GLMD_OnkaiIncMember', window );">Onkai Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Value conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="nump">$ 3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GLMD_CapitalStockDiscountRate', window );">Capital discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Shares owned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,223,535<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedPercentOfNetAssets', window );">Shares owned percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GLMD_CapitalStockDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capital stock discount rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GLMD_CapitalStockDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GLMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of investment owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedPercentOfNetAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of investment owned to net assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedPercentOfNetAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromOtherDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from debt classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromOtherDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=GLMD_BridgeLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=GLMD_BridgeLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=GLMD_ServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=GLMD_ServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_AdministrativeServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_AdministrativeServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=GLMD_OnkaiIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=GLMD_OnkaiIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Other Payables (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent', window );">Employees and related</a></td>
<td class="nump">$ 603<span></span>
</td>
<td class="nump">$ 571<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensatedAbsencesLiability', window );">Accrued Vacation</a></td>
<td class="nump">256<span></span>
</td>
<td class="nump">259<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GLMD_ShorttermLeaseObligation', window );">Short-term lease obligation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNotesPayable', window );">Other</a></td>
<td class="nump">6<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Other Payables</a></td>
<td class="nump">$ 865<span></span>
</td>
<td class="nump">$ 871<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GLMD_ShorttermLeaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short term lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GLMD_ShorttermLeaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GLMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensatedAbsencesLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability accrued for the employer's obligation related to an employee's right to receive compensation for future absences that have been earned by employee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483070/710-10-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensatedAbsencesLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term notes payable classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related party transaction, expenses</a></td>
<td class="nump">$ 3,100<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GLMD_ServiceAgreementMember', window );">Service Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related party transaction, expenses</a></td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long term loan</a></td>
<td class="nump">257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GLMD_OfficersAndDirectorsMember', window );">Officers And Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Due to related parties</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=GLMD_ServiceAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=GLMD_ServiceAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GLMD_OfficersAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GLMD_OfficersAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 28, 2021</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GLMD_BankLienOnMarketableSecurities', window );">Bank lien on marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GLMD_UpfrontLicenseFee', window );">Upfront license fee</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GLMD_PaymentsToRegulatoryMilestones', window );">Payments to regulatory milestones</a></td>
<td class="nump">$ 950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GLMD_BankLienOnMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>These lines are represents that lien on marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GLMD_BankLienOnMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GLMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GLMD_PaymentsToRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments to regulatory milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GLMD_PaymentsToRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GLMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GLMD_UpfrontLicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront License Fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GLMD_UpfrontLicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GLMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Status of Company's Option Plans and Changes (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 12, 2024</div></th>
<th class="th"><div>Aug. 31, 2023</div></th>
<th class="th"><div>Feb. 28, 2022</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityLineItems', window );"><strong>Option Indexed to Issuer's Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of share options, Granted</a></td>
<td class="nump">17,500<span></span>
</td>
<td class="nump">6,250<span></span>
</td>
<td class="nump">222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of share options exercisable, Ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,805<span></span>
</td>
<td class="nump">21,654<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, Options exercisable, Ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.05<span></span>
</td>
<td class="nump">$ 288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityLineItems', window );"><strong>Option Indexed to Issuer's Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of share options, Beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,277<span></span>
</td>
<td class="nump">14,973<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 460<span></span>
</td>
<td class="nump">$ 654<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of share options, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 12.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of share options, Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,041)<span></span>
</td>
<td class="num">(11,351)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94<span></span>
</td>
<td class="nump">$ 441.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of share options, Ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,236<span></span>
</td>
<td class="nump">20,277<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 321<span></span>
</td>
<td class="nump">$ 460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of share options exercisable, Ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,966<span></span>
</td>
<td class="nump">13,269<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, Options exercisable, Ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 413<span></span>
</td>
<td class="nump">$ 670.56<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; equity (Details Narrative)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="7">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 21, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 12, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 30, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 29, 2024 </div>
<div>&#8362; / shares</div>
</th>
<th class="th">
<div>Aug. 07, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 18, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 15, 2023 </div>
<div>&#8362; / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 28, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th" colspan="2">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th" colspan="2">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th" colspan="2">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th">
<div>Nov. 14, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 21, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>&#8362; / shares</div>
</th>
<th class="th">
<div>Mar. 26, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds stock | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,386<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12-1 reverse split<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Common stock, par value | &#8362; / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants are outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">173,333<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Structuring fee | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GLMD_CommitmentShare', window );">Commitment share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,784<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GLMD_ProceedsFinanceLeaseInterestExpenseIncome', window );">Finance expenses | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">6<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (36)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Compensation expense | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 100<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,250<span></span>
</td>
<td class="nump">222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options granted | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.05<span></span>
</td>
<td class="nump">$ 288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Contractual term</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vest period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested', window );">Aggregate grant fair value | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options, exercisable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,805<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">21,654<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options, intrinsic value | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_OptionMember', window );">Options Held [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Restricted stock unit options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Compensation expense | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options granted | &#8362; / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">302,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vest period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.02<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0.63<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 100<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation, term</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">2 years 1 month 9 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Share based compensation granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">302,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther', window );">Share based compensation subject to company shareholders</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Share based compensation vested</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized share based compensation | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 700<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">270<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Contractual term</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 9 months 25 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">6 years 2 months 26 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1.94%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1.34%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4.16%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Volatility rate, minimum</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">64.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Volatility rate, maximum</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">81.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">108.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">65.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0.63<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0.68<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 300<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 900<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation, term</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">3 months 18 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">1 year 4 months 28 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated stock based compensation | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 800<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=GLMD_IncentiveShareOptionPlan2013Member', window );">Incentive Share Option Plan2013 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">500,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GLMD_CommonStockCapitalSharesReservedForFutureIssuanceUnallocated', window );">Shares reserved for future issuance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">63,253<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life, term</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life, term</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">5 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">5 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=GLMD_PrefundedWarrantsMember', window );">Prefunded Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Stock and warrants issued during period shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">435,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=GLMD_InvestorWarrantsMember', window );">Investor Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds stock | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Stock and warrants issued during period shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">466,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Issuance costs | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">643<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1-for-12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1-for-15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Common stock, par value | &#8362; / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 1.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Share price | &#8362; / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Prefunded Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">435,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceIncrease', window );">Exercise price of warrants | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Prefunded Warrants [Member] | Investor [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants are outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">293,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant exercised, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">293,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Investor Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">466,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GLMD_NewSalesAgreementMember', window );">New Sales Agreement [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GLMD_MaximumAmountOfSharesToBeIssued', window );">Aggregate offering price | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">643<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds stock | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 100<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GLMD_StandbyEquityPurchaseAgreementMember', window );">Standby Equity Purchase Agreement [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Commitment amount | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GLMD_ProceedsFinanceLeaseInterestExpenseIncome', window );">Finance expenses | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 15<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GLMD_StandbyEquityPurchaseAgreementMember', window );">Standby Equity Purchase Agreement [Member] | Maximum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Commitment amount | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GLMD_CaymanIslandsExemptLimitedPartnershipMember', window );">Cayman Islands Exempt Limited Partnership [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Compensation expense | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GLMD_CaymanIslandsExemptLimitedPartnershipMember', window );">Cayman Islands Exempt Limited Partnership [Member] | Common Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">574,559<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds stock | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Issuance costs | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,400<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GLMD_DemandSalesAgreementMember', window );">Demand Sales Agreement [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GLMD_MaximumAmountOfSharesToBeIssued', window );">Aggregate offering price | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GLMD_TwoThousandAndTwentySalesAgreementMember', window );">Two Thousand And Twenty Sales Agreement [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">541,996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Total consideration | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="22"></td></tr>
<tr><td colspan="22"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See
    also Note 11(A)(5)</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Retroactively
    adjusted to reflect the <span id="xdx_90E_eus-gaap--StockholdersEquityReverseStockSplit_c20240101__20241231_zflb9DMjyxOc" title="Reverse stock split">12-1 reverse split</span> that was effected in August 2024 (see Note 11(A)(3))</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GLMD_CommitmentShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitment share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GLMD_CommitmentShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GLMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GLMD_CommonStockCapitalSharesReservedForFutureIssuanceUnallocated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock capital shares reserved for future issuance unallocated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GLMD_CommonStockCapitalSharesReservedForFutureIssuanceUnallocated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GLMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GLMD_MaximumAmountOfSharesToBeIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares to be issued in the offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GLMD_MaximumAmountOfSharesToBeIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GLMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GLMD_ProceedsFinanceLeaseInterestExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance expenses (income).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GLMD_ProceedsFinanceLeaseInterestExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GLMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other increase (decrease) in number of shares reserved for issuance under non-option equity instrument agreements that is not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantExercisePriceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share increase in exercise price of warrant. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantExercisePriceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_OptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_OptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=GLMD_IncentiveShareOptionPlan2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=GLMD_IncentiveShareOptionPlan2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=GLMD_PrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=GLMD_PrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=GLMD_InvestorWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=GLMD_InvestorWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=GLMD_NewSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=GLMD_NewSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=GLMD_StandbyEquityPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=GLMD_StandbyEquityPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=GLMD_CaymanIslandsExemptLimitedPartnershipMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=GLMD_CaymanIslandsExemptLimitedPartnershipMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=GLMD_DemandSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=GLMD_DemandSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=GLMD_TwoThousandAndTwentySalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=GLMD_TwoThousandAndTwentySalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Research and Development Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">$ 2,979<span></span>
</td>
<td class="nump">$ 3,569<span></span>
</td>
<td class="nump">$ 12,995<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=GLMD_ChemistryAndFormulationStudiesMember', window );">Chemistry And Formulation Studies [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">696<span></span>
</td>
<td class="nump">573<span></span>
</td>
<td class="nump">2,448<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=GLMD_SalariesMember', window );">Salaries [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">982<span></span>
</td>
<td class="nump">676<span></span>
</td>
<td class="nump">1,692<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=GLMD_StockBasedCompensationMember', window );">Stock Based Compensation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">112<span></span>
</td>
<td class="nump">243<span></span>
</td>
<td class="nump">383<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=GLMD_ResearchAndPreclinicalStudiesMember', window );">Research And Preclinical Studies [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">255<span></span>
</td>
<td class="nump">460<span></span>
</td>
<td class="nump">1,346<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=GLMD_ClinicalStudiesMember', window );">Clinical Studies [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">291<span></span>
</td>
<td class="nump">616<span></span>
</td>
<td class="nump">6,532<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=GLMD_RegulatoryAndOtherExpensesMember', window );">Regulatory And Other Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">$ 643<span></span>
</td>
<td class="nump">$ 1,001<span></span>
</td>
<td class="nump">$ 594<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=GLMD_ChemistryAndFormulationStudiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=GLMD_ChemistryAndFormulationStudiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=GLMD_SalariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=GLMD_SalariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=GLMD_StockBasedCompensationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=GLMD_StockBasedCompensationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=GLMD_ResearchAndPreclinicalStudiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=GLMD_ResearchAndPreclinicalStudiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=GLMD_ClinicalStudiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=GLMD_ClinicalStudiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=GLMD_RegulatoryAndOtherExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=GLMD_RegulatoryAndOtherExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of General and Administrative Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">$ 3,299<span></span>
</td>
<td class="nump">$ 3,923<span></span>
</td>
<td class="nump">$ 4,656<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=GLMD_StockBasedCompensationMember', window );">Stock Based Compensation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">419<span></span>
</td>
<td class="nump">649<span></span>
</td>
<td class="nump">913<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=GLMD_ProfessionalFeeMember', window );">Professional Fees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">896<span></span>
</td>
<td class="nump">908<span></span>
</td>
<td class="nump">1,084<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=GLMD_SalariesAndBenefitsMember', window );">Salaries And Benefits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">1,478<span></span>
</td>
<td class="nump">1,428<span></span>
</td>
<td class="nump">1,164<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=GLMD_RentAndOfficeMaintenanceFeesMember', window );">Rent And Office Maintenance Fees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">117<span></span>
</td>
<td class="nump">261<span></span>
</td>
<td class="nump">401<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=GLMD_InsuranceAndOtherExpensesMember', window );">Insurance And Other Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">$ 389<span></span>
</td>
<td class="nump">$ 677<span></span>
</td>
<td class="nump">$ 1,094<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=GLMD_StockBasedCompensationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=GLMD_StockBasedCompensationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=GLMD_ProfessionalFeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=GLMD_ProfessionalFeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=GLMD_SalariesAndBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=GLMD_SalariesAndBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=GLMD_RentAndOfficeMaintenanceFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=GLMD_RentAndOfficeMaintenanceFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=GLMD_InsuranceAndOtherExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=GLMD_InsuranceAndOtherExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Financial Income, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GLMD_BankFees', window );">Bank fees</a></td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GLMD_InterestIncome', window );">Interest income</a></td>
<td class="num">(503)<span></span>
</td>
<td class="num">(375)<span></span>
</td>
<td class="num">(297)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleGainLoss', window );">Loss from sale of marketable debt securities</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="nump">526<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GLMD_ChangeInFairValueOfConvertibleNote', window );">Change in fair value of convertible note</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(265)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency (gains) losses</a></td>
<td class="num">(40)<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="num">(36)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Financial income net</a></td>
<td class="num">$ (516)<span></span>
</td>
<td class="num">$ (580)<span></span>
</td>
<td class="nump">$ 215<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GLMD_BankFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense classified as bank fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GLMD_BankFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GLMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GLMD_ChangeInFairValueOfConvertibleNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of convertible note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GLMD_ChangeInFairValueOfConvertibleNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GLMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GLMD_InterestIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest income</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GLMD_InterestIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GLMD_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481839/830-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Effective Income Tax Rate Reconciliation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before taxes on income, as reported in the consolidated statements of operations</a></td>
<td class="nump">$ 7,517<span></span>
</td>
<td class="nump">$ 6,912<span></span>
</td>
<td class="nump">$ 17,866<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory tax rate</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Theoretical tax benefit</a></td>
<td class="nump">$ 1,729<span></span>
</td>
<td class="nump">$ 1,590<span></span>
</td>
<td class="nump">$ 2,144<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Losses and other items for which a valuation allowance was provided or benefit from loss carry forwards</a></td>
<td class="num">(1,729)<span></span>
</td>
<td class="num">(1,590)<span></span>
</td>
<td class="num">(2,144)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Actual tax expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Effective income tax rate reconciliation, at federal statutory income tax rate, percent</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carry forwards</a></td>
<td class="nump">$ 175,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards', window );">Deferred tax assets, capital loss carry forwards</a></td>
<td class="nump">175,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">2,979<span></span>
</td>
<td class="nump">$ 3,569<span></span>
</td>
<td class="nump">$ 12,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RegulatoryAssetAxis=us-gaap_DeferredIncomeTaxChargesMember', window );">Deferred Income Tax Charge [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GLMD_MalteseSubsidiaryMember', window );">Maltese Subsidiary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carry forwards</a></td>
<td class="nump">11,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GLMD_IsraeliSubsidiaryMember', window );">Israeli Subsidiary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carry forwards</a></td>
<td class="nump">163,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards', window );">Deferred tax assets, capital loss carry forwards</a></td>
<td class="nump">$ 3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_IsraelTaxAuthorityMember', window );">Israel Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Effective income tax rate reconciliation, at federal statutory income tax rate, percent</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=GLMD_MalteseSubsidiaryMember', window );">Maltese Subsidiary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Effective income tax rate reconciliation, at federal statutory income tax rate, percent</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsCapitalLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RegulatoryAssetAxis=us-gaap_DeferredIncomeTaxChargesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RegulatoryAssetAxis=us-gaap_DeferredIncomeTaxChargesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GLMD_MalteseSubsidiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GLMD_MalteseSubsidiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GLMD_IsraeliSubsidiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GLMD_IsraeliSubsidiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_IsraelTaxAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_IsraelTaxAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=GLMD_MalteseSubsidiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=GLMD_MalteseSubsidiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent events (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 21, 2025</div></th>
<th class="th"><div>Mar. 21, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GLMD_TwoThousandAndTwentySalesAgreementMember', window );">Two Thousand And Twenty Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">541,996<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Commitment share,value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GLMD_TwoThousandAndTwentySalesAgreementMember', window );">Two Thousand And Twenty Sales Agreement [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">541,996<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Commitment share,value</a></td>
<td class="nump">$ 75<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GLMD_TwoThousandAndTwentySalesAgreementMember', window );">Two Thousand And Twenty Sales Agreement [Member] | Subsequent Event [Member] | Cayman Islands Exempt Limited Partnership [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GLMD_CaymanIslandsExemptLimitedPartnershipMember', window );">Cayman Islands Exempt Limited Partnership [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,891<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=GLMD_TwoThousandAndTwentySalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=GLMD_TwoThousandAndTwentySalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=GLMD_CaymanIslandsExemptLimitedPartnershipMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=GLMD_CaymanIslandsExemptLimitedPartnershipMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=GLMD_CaymanIslandsExemptLimitedPartnershipMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=GLMD_CaymanIslandsExemptLimitedPartnershipMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>Integer</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>85
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( +* @EI&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( +* @EJVA++ \@   "L"   1
M9&]C4')O<',O8V]R92YX;6S-DL%.PS ,AE\%Y=XZ33>0HJX7$">0D)@$XA8E
MWA;1I%%BU.[M:</6@> !.,;^\_FSY$8'J?N(3[$/&,EBNAI=YY/48<,.1$$"
M)'U IU(Y)?S4W/71*9J><0]!Z7>U1Q"<7X-#4D:1@AE8A(7(VL9HJ2,JZN,)
M;_2"#Q^QRS"C 3MTZ"E!55; VGEB.(Y= Q? #".,+GT5T"S$7/T3FSO 3LDQ
MV24U#$,YU#DW[5#!Z^/#<UZWL#Z1\AJG7\E*.@;<L//DE_KV;GO/6L'%NN"K
M@HNMX)*O9;UZFUU_^%V$76_LSOXSXYMOQF?!MH%?=]%^ E!+ P04    " "R
M@():F5R<(Q &  "<)P  $P   'AL+W1H96UE+W1H96UE,2YX;6SM6EMSVC@4
M?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.'X416(UL>621A'^_1S80RY8-[9)-
MNIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X8-DOV]:[MR_>X%<R)!%!,!FGK_#
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M"CS<_N\-L,+$CN'MB[\!4$L#!!0    ( +* @EK_W%-R: @  "@C   8
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M 8-S<2' O?G*;F]V@8U0N$RKM3;*0;B?KI>GR#);3!#Q-\CA;*@A'TNMC.'
M@HV,E?+0*IMJYS.D1L,P]"&$/C=!.9\?X*YZ/+I^)%&9I!K2GTAK!AAV&[^M
M -.BUVHNY_D#W$MO;/URFL<I9!SK @RYDM+FO> ^JA+K5\/;7%7[_TI&@8L'
M >[%:RM>IS(CX\M&%ES!\XX/,107"0+<;]<H'XLTM]9Y8J^:7'"8<LTVPN4^
ML\Z"@L^F1A:<FU[ ,2QYNZ;,HH]%K@1/$^OZII3#>#%B*\/*9&8WE&?PPP/,
M]8S&K-0I;)MA8Z"3'H%)3U0Y56F24IG"4OC5J+_[Y<CW!R>K96O/O)/?.M3*
M7;*8F9VMJ]D:$3@(]BR:9-R"O*%2]=RQ$J)@U2X*LCS3#\D6IMP/?>3"I+A5
M_J-(FD-#L-I"\ 1BNP'Q#D\Z[*_2+&7SV)BJ!9EQ\0*M9F!R1N.%>8(!T0O)
M&%DR*JV2N514915F2M<_=F3/2F[V(1?:V"06W+Y,>&9\:=Y(,)CX24<+ A;9
ML->;'L_6Z\;UO;9D#V(Q$:4$0]@94AFNM3FQE6=8?S.:2K[<@UYU*+A7V/Y
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M +_/!&1ZJQ/S@/7',>?_ U!+ P04    " "R@():7PI#;_$%  " %P  &
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M?M.^? B]KK"V&!%GH(:1G8/VN,0X31)N^CM0*PK*DQFHHY@6'&J'%:A%:^#
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MGS0&,+X20C_?F FV3??E_U!+ P04    " "R@():1F>BNN("  "2"   &
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M_WZ59>SU3=G X6+ZU?\!4$L#!!0    ( +* @EH6\Q0BB0(  ,@&   8
M>&PO=V]R:W-H965T<R]S:&5E=#@N>&ULK55=;YLP%/TK%JNV5MH*@22=N@2I
M23MM#Y6B9ET?ICTX<!.L@DWM2]+^^UT;PI*.9JNT%_#7.3[G&A]&&Z7O30:
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M\BIZ^:5@&WW7^ID5!5OKCRM*$LJ5@'R^9-+RZHMZP?Y_")C]!5!+ P04
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MH<GL]1(C,S33$#C=Q@N\U\ZW0YPV_OT!$Q+\_D%K=PQ"@>E%*W\!4$L#!!0
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M,RYX;6R-5]MRVS80?==7["B93CNCZF8G3N/+C"^YM4GJL9OFH=,'B%R1F(
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MG+:2E-OH,:MA%\_>L&6OS,DD DR&)EEG>-$:SK]C.)O3!V=C&>B5S3G?!YB
M14]EOJ5R,7\4\8JS,1W,1C2?S@\?P3OH73M(> ??P?O=%\KJ?Y1D?T27S@9G
M=*Y:,=B<KCT'MK$=<$MZK:VRF5:&;C'(4%X,]-?Y(D0/[?S]4(A: H</$Y!Z
M>AEJE?'IL):]_(J'9S\\F3V?'C_BWF'OWN%CZ(]E[E'#AVE]=)$',_KAR8OY
M;'9,'3B]4:;B?'!=*E1 QDW4F3*!WL=\3#_&DI/!?'I\Z:I:V4UZFQW_1&L5
M2-O,^=IYQ#+'"[T+7K$A!/O7QFRZ3,\.Z#4O?(.&0//1  .']$?)@PZ02F?R
M0+'TS+3&B]G\[-86@*%9!)UKY36'4<>3WMG(WJ:,@KRP',%*9R7I;_E\4":J
M49)"9WZ#:"B/U3)VQ2NTK%ID,&C][7Q]<W/5^]D91U<KH>U5G6(4NKT7+I8B
MK9:#\OR=H(S!O(T*M'\ =VZNB$-4"Z-1VCDILKP>/.S_9A^S035ZDM08M0ZR
M^2M;&.$I?Y^5X4#(H>'>ZSW>GWZC][K20!KOY0'Q4[30KMY3 F7=]-*A5P$+
MR96M\_O8"8-SKZH,Y!,D]:F%1K9V8.)")+[+3!/0IA$)0'4PVA:#+00L6N\B
MCJ"XW<# Q%.ND;[ R5$H>Z5=$P D6KQ'HCVD:Z_E+*+;S+!W0>8O,:=LH:,.
MHX$LN;W<YXU09(WWV!K@@?F+6$5'*E^A?_!C 4A[.J3+N"+%3]L<OZ)7I*J)
MR"C+^H_GMV^3&TN]$%IA/(! 5)[KMIG!HUKY!!WOF:7B/3H.5*"50'C2N"(7
MF]'NHI3)=!2"?=WXT A]5T,_L;' YS" ,WQ7;S632W"#7L(4#;'V+F^R2+6N
M63H+A9HSO11O !B5+S@*8J9\KEW%$#':;K;GJ:"B,I R;:U;*6'3 V>8E38M
M/$H5(0U=6)R*<.@A7R%]%K;LD3"I+\I]4^PF8%_(2RF0/+GB=\M]-V.@4B!C
M'5% =[P1%R&&>5&-%G]+[YJB%(N,&9UJZ5TE\ZNTSJ!2VG,D:;)!/6<#MURR
M1XC"OJSN-26%8=TV(+"M\;@":5$/-O[21E@@VZ61BM2OI?X%"MIGV_"63!O7
MD$J_<V$\.$^] 6<N5PLD8GON[FNE5#GR$=H(I0?^VL WDWR"_5,Z'!_1=#RC
M@_$S.AK/]YMW>PJ(8WT<0=RX$%AFB!6BOT$2"*67I>[(M<1Z+S1]KL605(Q>
M+QIICBSNR D!?0H;2:J#["Q*>A#0J3CT_4)V"<0I^?_U>C[J^JZX*5%(/2.%
M_0Z9CE(J3VEV-/Z%GN/OQ7B*55,XO.OL6AN#-@UXD/)*Q"@].BH;<:<8]=4K
M75/5.N(7"T6.+>][F0D+R5.KR+WFT5)<\,;9?"!FG6KVY(L]B[8+MH*/#4H$
MG;IB+]>;_DH$']>X#LNO+-PAN%.L8[I 3\T'76?_IORZ_>^S"]';T8-K*V5!
M+%&\%SN.N11B.>11[<DG$5J-MI=N9BFNH4D-:L_EW8CMMN0,L8'@M_4B_0'0
MEG!CK=H;:ZJ+U*:E2D4X(32I=[<-%:E;]I?!T%\&Q_30M6VR<_E&A(OTB2%]
MJ;&QO8?WH_U7S'E[>;]?WGX"?4#WU'#'\!*FT_'1LR'Y]K.B?<$](UWE<:_
MAT%Z+/$EQEX68'[I<(WK7F2#_MON[%]02P,$%     @ LH""6@9@55/'&@
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M4#W6D:9'B@@%)S56MX'RT$M@0,+Z0E>?D_#I!#DWL!O$C6I(V$77,F7E$4R
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M>N="5M^"I;*4# +S/,$AJ*[_P>I,[J"ABJTUPYX+AWHYK8Z2_- BY(9]96@
M1S=4LJ-=\BXC6AV3V(E/7ZQSX7741QY1@W)$31X9%_&M<BZ^?+6G..R+]E$V
MD@I0XP3LB%=I"J/E>MT)< _FA;:P-TP&@G9T .T@Z*,:C)5.7 UODYFFU91_
M8F<NTK&J# 2H-=FZ8K.]@5WN)QY[S4CZ-UO]V51#)H7N5@A1J.A/4F8JLRP0
M=%3<RBDXCCG9M@_C#3&809)L9PD':M-L.8S5?CHH#B>!=EUV/O 5-HA' /7
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M_O(1CC^9@QOSQ319P;>H\%AV]R>''$@26@=>XJS#@9[*C.Z@I",]BQ-R?SQ
MQ!JBW>"5"G>-.3*C*QC;HI4^MCM<LCXW'+)4T]G!18RA3/+N= PWB 9G)>$L
MBB,<D9UE 7$I?PZV0B:CK8@!92.E40</$7PXF6.O<J<1E"RB9;;M\X[*BD@%
M_?(ICY2.^WE8=M$'9N_8-)RQ@92%)B<G]9V7CFY7(@.BV]KG;*Q<.?%3G"QN
ME#(I_%-)RU'F">1>9]%DW88\>\9?\,B"28(4'O3Z)6)V1BZ:=7 3LDS$4U5C
MOE9'-:W"^G(@#PHLJ>]%8\#*UN%T+H_$@Z@<",0]=B_-/B3H\\60V9X!/LQK
MA?M9<4?P [$A;N-<AS;.L-\V4 SD4-;7-EI_^\/?5=-4UKOC229W!\Q=MTK5
M+]5G75"Y8-R/W]-7?9& E5**^6[<F>%W#HZ-B]B%)!X)A*D&C)SWTKT<8A$7
MD&I73HX W&G;RS K#*F2'T 10IWRSN=F9X?NF0 V[A[?86ERVZ>YTDOFF&7V
M,(VBJ#?]<$8J&N$=&^?H17R?) 1ZO:(D;HK2NL8/C8M0P.W21;KO&!KW7+!P
M]TYMN+/C&2I%L+%KPYU$)75>LI<>,N\^DTN&':Q[TAZ>WS_;RQ)T(T6-FW#^
MADA(L!R+SER2I-0N.<6MV*I$R6T$J)\7(OQDN-NQDLJP12L=.\T\Z2O!1VK
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M&8_&'CX+/#7)L@#6UP:QM />H'^\GOX#4$L#!!0    ( +* @EI8R7?-BP(
M (T%   9    >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;(U4[T_;,!#]GK_B
M%!#:I$%^-"T=M)%:8-JDL5548Q^F?7"2:V/AQ)GM4/K?[YR$K*!2[4,3W_G>
M\[M<GR<;J1YTCFC@J1"EGKJY,=6%Y^DTQX+I,UEA23LKJ0IF*%1K3U<*6=:
M"N&%OC_R"L9+-YXTN86*)[(V@I>X4*#KHF!J.T<A-U,W<)\3=WR=&YOPXDG%
MUKA$\Z-:*(J\GB7C!9::RQ(4KJ;N++B81[:^*;CGN-$[:["=)%(^V.!+-G5]
M*P@%IL8R,'H]XA4*88E(QI^.T^V/M,#=]3/[IZ9WZB5A&J^D^,DSDT_=L0L9
MKE@MS)W<?,:NGZ'E2Z70S1,V;6WDNY#6VLBB Y."@I?MFSUUWV$','X+$':
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M9C\5KGMM=(-@FWC#SVW >R%^5GB@D>,-6%]8Q+(9L(/AR3?]&U!+ P04
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MK&'T<C\2<X_B,\1@RK+HM #>].[P9G2$-_MQ8%DBK"0B14-.^-S ;FZ=,G:
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M2WU8+O 6Q58$\/_,8/2T#^)@_5YV^A]02P,$%     @ LH""6J7A8U]K @
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MU\=18,H6.';NH!E@,[7--+V,/E&0+XO,#L3< )=(L#:)E>81TBTVJEE7X#/
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M[(2THT<+BBWC\BO1!%RR1,5:AV.3JNP(F).MGM51QI!?A[N.M@4$)I1^'T&
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M@0/@]V4%\F4_X +^[<O/_P]02P,$%     @ LH""6C+$#H0A!   \@D  !D
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MYK(!A>N9OXBOKC-K[PR^<MSI QEL)H643W;S:SGS(TL(!:Z,16"T/.,2A;!
M1./;'M/O0UK'0_D5_:/+G7(IF,:E%+_STE0S?^Q#B6O6"O-9[G[!?3ZYQ5M)
MH=T_[#K;=.+#JM5&UGMG8E#SIEO9]WT=#AS&T1L.R=XA<;R[0([E#3-L/E5R
M!\I:$YH57*K.F\CQQC;EP2CZRLG/S.^8>D+#"H&42V% XZI5W'#4,'BT:GT^
M#0T%LN;A:@]ZW8$F;X#&"=S)QE0:;IL2RQ\!0F+8TTQ>:5XG)Q%O<'4):1Q
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M:NEZCM:&5:MJ=LV5I4E8+7/Z]*!V ;2_4,IN#5>@^9@EOP%02P,$%     @
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MNF?CT ;9MZU^H473M8JET-1XNFE.G1ZE.4#VE1!ZMS !AG]'\@=02P,$%
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M5RY3?6OJ-T:N;3M82H/-Q2XK[.:@R #O2RG-;D,!]O^'[!=02P,$%     @
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MP<L:2&. SW="Z,>)V:"Y_BW_ U!+ P04    " "R@():97506TT#   9#@
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M.;N!M!O,_50(_3JQQXGJ-#C^!U!+ P04    " "R@():U*M3N90&  #^/@
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MTS3F@\S2GL-[.R-!\>QY%C>T8C[S6O)8HXX/L\YE_""DRG<_"EW&Q:0FJZ#
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M:*#>GS,FWP^*#G9;JV?_ U!+ P04    " "R@():%'?8YZX"  "]!P  &0
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MC# [LGDLFHX6E:VWB=!8O6TSQ_<5I G ^:40^KEC2GCW8L=_ 5!+ P04
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M"RC5 DIK 65Z9(%!M<"@O8!\9(%AM<#PW!%&U0*C]@*C(PN,JP7&YZ[29;7
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M]['#^#2-+OU'(NX0)AZU=[BC_4=4TU!-1S4#U4Q4LU#-1C4'U5Q4\U#-1[4
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M1S=3#*MLVZEVHL7.-A@;H;$TV6&)'2A(8X#?"X%WH)N8#?J>-OD/4$L#!!0
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M1P?%;$$WJ;KEVS]8-:&AX44\E<6_:%NU]1P4;:3B616L1Y E>?F7/E:)V G
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MW X+O1;LZX(Q[:U2(8L166B=O_/]8K9@*2TNLIQ)@R292JDV737WBUPQ&A=
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MP .&!$'Y'MQY'_F;]Y3?_/]P_ =02P,$%     @ LH""6I>*NQS     $P(
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M751%<>WVW<EOBN?[UR'WKW)>_@=02P,$%     @ LH""6M))O&T1 @  %R8
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M/-];KH^_++].3M[>"\[IMJ(^_P502P,$%     @ LH""6L"(;73I 0  ?B4
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M#P72AP;IHP#IXQRDCPN0/BY!^N 3E$901.4HI'(44SD*JAQ%58["*D=QE:/
MRE%D%2BR"A19!8JL D56@2*K0)%5H,@J4&05*+(*%%DEBJP215:)(JM$D56B
MR"I19)4HLDH4626*K!)%5H4BJT*15:'(JE!D52BR*A19%8JL"D56A2*K0I%5
MH\BJ4635*+)J%%DUBJP:15:-(JM&D56CR*I19"U09"U09"U09"U09"W^4]9G
M:Y=_'#\\\];4W2&?#7^[FKT!4$L! A0#%     @ LH""6D;'34B5    S0
M !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M" "R@():MH2RP/(    K @  $0              @ '#    9&]C4')O<',O
M8V]R92YX;6Q02P$"% ,4    " "R@():F5R<(Q &  "<)P  $P
M    @ 'D 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( +* @EK_
MW%-R: @  "@C   8              " @24(  !X;"]W;W)K<VAE971S+W-H
M965T,2YX;6Q02P$"% ,4    " "R@():7PI#;_$%  " %P  &
M    @('#$   >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @
MLH""6D9GHKKB @  D@@  !@              ("!ZA8  'AL+W=O<FMS:&5E
M=',O<VAE970S+GAM;%!+ 0(4 Q0    ( +* @EK&C!:NOP0  -81   8
M          " @0(:  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4
M    " "R@():CH^Q"BD"  #$!   &               @('W'@  >&PO=V]R
M:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ LH""6A:#)B4& P  >PD
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M965T,3 N>&UL4$L! A0#%     @ LH""6CRE,S@1 @  W00  !D
M     ("!1CP  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( +* @EH&#M.0<P(  &T%   9              "
M@1II  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ LH""
M6KNQ!]2< @  U 4  !D              ("!Q&L  'AL+W=O<FMS:&5E=',O
M<VAE970Q-RYX;6Q02P$"% ,4    " "R@():X+ABF ,#  "*!@  &0
M        @(&7;@  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0
M   ( +* @EI<L1YII@8  ,@.   9              " @=%Q  !X;"]W;W)K
M<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ LH""6EC)=\V+ @  C04
M !D              ("!KG@  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q0
M2P$"% ,4    " "R@():_<I*-R #   9!P  &0              @(%P>P
M>&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( +* @EI>3V%6
MHP0  /X)   9              " @<=^  !X;"]W;W)K<VAE971S+W-H965T
M,C(N>&UL4$L! A0#%     @ LH""6A4+([9*"P  ;QP  !D
M ("!H8,  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " "R
M@():/]"^C-@"  !D!@  &0              @($BCP  >&PO=V]R:W-H965T
M<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( +* @EJIP%"X 0,  )$&   9
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M970R.2YX;6Q02P$"% ,4    " "R@():Z,]"O5D<  ")60  &0
M    @($WI0  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    (
M +* @EHRQ Z$(00  /()   9              " @<?!  !X;"]W;W)K<VAE
M971S+W-H965T,S$N>&UL4$L! A0#%     @ LH""6M9AYM-1 P  IP<  !D
M             ("!'\8  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"
M% ,4    " "R@():DT?[Y6T"  !B!0  &0              @(&GR0  >&PO
M=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( +* @EH[5>YIR@(
M "D&   9              " @4O,  !X;"]W;W)K<VAE971S+W-H965T,S0N
M>&UL4$L! A0#%     @ LH""6J'$/>#< @  V 8  !D              ("!
M3,\  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    " "R@():
MP!&T5(@"  "%!0  &0              @(%?T@  >&PO=V]R:W-H965T<R]S
M:&5E=#,V+GAM;%!+ 0(4 Q0    ( +* @EIM]O%9^P(  'T&   9
M      " @1[5  !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%
M  @ LH""6NDWR*_2 @  1P8  !D              ("!4-@  'AL+W=O<FMS
M:&5E=',O<VAE970S."YX;6Q02P$"% ,4    " "R@():IVHZ:L,"   K!@
M&0              @(%9VP  >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+
M 0(4 Q0    ( +* @EK!R*PVZ@(  #T&   9              " @5/>  !X
M;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ LH""6ETEI,-)
M P  / <  !D              ("!=.$  'AL+W=O<FMS:&5E=',O<VAE970T
M,2YX;6Q02P$"% ,4    " "R@():_"MO2M$#   *#@  &0
M@('TY   >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( +*
M@EIE=5!;30,  !D.   9              " @?SH  !X;"]W;W)K<VAE971S
M+W-H965T-#,N>&UL4$L! A0#%     @ LH""6M2K4[F4!@  _CX  !D
M         ("!@.P  'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4
M    " "R@():I"6BR]<#   O$P  &0              @(%+\P  >&PO=V]R
M:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( +* @EK&FD,5A00  !D6
M   9              " @5GW  !X;"]W;W)K<VAE971S+W-H965T-#8N>&UL
M4$L! A0#%     @ LH""6FA>IX%_ @  QP8  !D              ("!%?P
M 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4    " "R@():@M8H
MU($#   D#@  &0              @('+_@  >&PO=V]R:W-H965T<R]S:&5E
M=#0X+GAM;%!+ 0(4 Q0    ( +* @EIR+J>-  ,  "()   9
M  " @8," 0!X;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @
MLH""6K]\]$18 P  1A$  !D              ("!N@4! 'AL+W=O<FMS:&5E
M=',O<VAE970U,"YX;6Q02P$"% ,4    " "R@():VMJ9M#H#  "R#   &0
M            @(%)"0$ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4
M Q0    ( +* @EI&9D^XA 4  &8M   9              " @;H, 0!X;"]W
M;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @ LH""6A1WV.>N @
MO0<  !D              ("!=1(! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX
M;6Q02P$"% ,4    " "R@():7Z.G8U #  #[#@  &0              @(%:
M%0$ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( +* @EK)
MQ8V*Y@(  %L)   9              " @>$8 0!X;"]W;W)K<VAE971S+W-H
M965T-34N>&UL4$L! A0#%     @ LH""6@-"N$XC!0  ""$  !D
M     ("!_AL! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( +* @EK9JEQ7B0,  ,$*   9              "
M@4U1 0!X;"]W;W)K<VAE971S+W-H965T-C$N>&UL4$L! A0#%     @ LH""
M6E>?V;<+!0  P"0  !D              ("!#54! 'AL+W=O<FMS:&5E=',O
M<VAE970V,BYX;6Q02P$"% ,4    " "R@():+#1N6U,#  "D$   &0
M        @(%/6@$ >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0
M   ( +* @EHHF+R_(0(  *4$   9              " @=E= 0!X;"]W;W)K
M<VAE971S+W-H965T-C0N>&UL4$L! A0#%     @ LH""6FD,)VE3 P  3!0
M  T              ( !,6 ! 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " "R
M@():EXJ[',     3 @  "P              @ &O8P$ 7W)E;',O+G)E;'-0
M2P$"% ,4    " "R@():CA8GHCX%  !.*@  #P              @ &89 $
M>&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ LH""6M))O&T1 @  %R8  !H
M             ( ! VH! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L!
M A0#%     @ LH""6L"(;73I 0  ?B4  !,              ( !3&P! %M#
G;VYT96YT7U1Y<&5S72YX;6Q02P4&     $@ 2 "O$P  9FX!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>217</ContextCount>
  <ElementCount>299</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>56</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galmedpharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galmedpharma.com/role/BalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galmedpharma.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galmedpharma.com/role/StatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Consolidated Statements of Operations (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galmedpharma.com/role/StatementsOfOperationsParenthetical</Role>
      <ShortName>Consolidated Statements of Operations (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galmedpharma.com/role/StatementsOfComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Statement - Statements of Changes in Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galmedpharma.com/role/StatementsOfChangesInStockholdersEquity</Role>
      <ShortName>Statements of Changes in Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Statement - Statements of Changes in Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galmedpharma.com/role/StatementsOfChangesInStockholdersEquityParenthetical</Role>
      <ShortName>Statements of Changes in Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galmedpharma.com/role/StatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>999017 - Disclosure - General</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galmedpharma.com/role/General</Role>
      <ShortName>General</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>999018 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galmedpharma.com/role/SignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>999019 - Disclosure - Marketable debt securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galmedpharma.com/role/MarketableDebtSecurities</Role>
      <ShortName>Marketable debt securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>999020 - Disclosure - Other Receivables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galmedpharma.com/role/OtherReceivables</Role>
      <ShortName>Other Receivables</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>999021 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galmedpharma.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>999022 - Disclosure - Property and equipment, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galmedpharma.com/role/PropertyAndEquipmentNet</Role>
      <ShortName>Property and equipment, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>999023 - Disclosure - Investment in an Associate</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galmedpharma.com/role/InvestmentInAssociate</Role>
      <ShortName>Investment in an Associate</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>999024 - Disclosure - Other Payables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galmedpharma.com/role/OtherPayables</Role>
      <ShortName>Other Payables</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>999025 - Disclosure - Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galmedpharma.com/role/RelatedParties</Role>
      <ShortName>Related Parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>999026 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galmedpharma.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>999027 - Disclosure - Stockholders??? equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galmedpharma.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders??? equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>999028 - Disclosure - Research and Development Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galmedpharma.com/role/ResearchAndDevelopmentExpenses</Role>
      <ShortName>Research and Development Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>999029 - Disclosure - General and Administrative Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galmedpharma.com/role/GeneralAndAdministrativeExpenses</Role>
      <ShortName>General and Administrative Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>999030 - Disclosure - Financial income, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galmedpharma.com/role/FinancialIncomeNet</Role>
      <ShortName>Financial income, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>999031 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galmedpharma.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>999032 - Disclosure - Subsequent events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galmedpharma.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>999033 - Disclosure - Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galmedpharma.com/role/SegmentReporting</Role>
      <ShortName>Segment Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>999034 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galmedpharma.com/role/SignificantAccountingPoliciesPolicies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://galmedpharma.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>999035 - Disclosure - Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galmedpharma.com/role/SignificantAccountingPoliciesTables</Role>
      <ShortName>Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://galmedpharma.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>999036 - Disclosure - Marketable debt securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galmedpharma.com/role/MarketableDebtSecuritiesTables</Role>
      <ShortName>Marketable debt securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://galmedpharma.com/role/MarketableDebtSecurities</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>999037 - Disclosure - Other Receivables (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galmedpharma.com/role/OtherReceivablesTables</Role>
      <ShortName>Other Receivables (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://galmedpharma.com/role/OtherReceivables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>999038 - Disclosure - Property and equipment, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galmedpharma.com/role/PropertyAndEquipmentNetTables</Role>
      <ShortName>Property and equipment, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://galmedpharma.com/role/PropertyAndEquipmentNet</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>999039 - Disclosure - Investment in an Associate (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galmedpharma.com/role/InvestmentInAssociateTables</Role>
      <ShortName>Investment in an Associate (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://galmedpharma.com/role/InvestmentInAssociate</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>999040 - Disclosure - Other Payables (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galmedpharma.com/role/OtherPayablesTables</Role>
      <ShortName>Other Payables (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://galmedpharma.com/role/OtherPayables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>999041 - Disclosure - Stockholders??? equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galmedpharma.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders??? equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://galmedpharma.com/role/StockholdersEquity</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>999042 - Disclosure - Research and Development Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galmedpharma.com/role/ResearchAndDevelopmentExpensesTables</Role>
      <ShortName>Research and Development Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://galmedpharma.com/role/ResearchAndDevelopmentExpenses</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>999043 - Disclosure - General and Administrative Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galmedpharma.com/role/GeneralAndAdministrativeExpensesTables</Role>
      <ShortName>General and Administrative Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://galmedpharma.com/role/GeneralAndAdministrativeExpenses</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>999044 - Disclosure - Financial income, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galmedpharma.com/role/FinancialIncomeNetTables</Role>
      <ShortName>Financial income, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://galmedpharma.com/role/FinancialIncomeNet</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>999045 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galmedpharma.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://galmedpharma.com/role/IncomeTaxes</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>999046 - Disclosure - General (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galmedpharma.com/role/GeneralDetailsNarrative</Role>
      <ShortName>General (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://galmedpharma.com/role/GeneralAndAdministrativeExpensesTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>999047 - Disclosure - Schedule of Depreciation Rates for Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galmedpharma.com/role/ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentDetails</Role>
      <ShortName>Schedule of Depreciation Rates for Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>999048 - Disclosure - Schedule of Assets Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galmedpharma.com/role/ScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Schedule of Assets Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>999049 - Disclosure - Significant Accounting Policies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galmedpharma.com/role/SignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>Significant Accounting Policies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://galmedpharma.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>999050 - Disclosure - Schedule of Marketable Debt Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galmedpharma.com/role/ScheduleOfMarketableDebtSecuritiesDetails</Role>
      <ShortName>Schedule of Marketable Debt Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>999051 - Disclosure - Schedule of Other Receivables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galmedpharma.com/role/ScheduleOfOtherReceivablesDetails</Role>
      <ShortName>Schedule of Other Receivables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>999052 - Disclosure - Leases (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galmedpharma.com/role/LeasesDetailsNarrative</Role>
      <ShortName>Leases (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://galmedpharma.com/role/Leases</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>999053 - Disclosure - Schedule of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galmedpharma.com/role/ScheduleOfPropertyAndEquipmentDetails</Role>
      <ShortName>Schedule of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>999054 - Disclosure - Schedule of Balance Sheets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galmedpharma.com/role/ScheduleOfBalanceSheetsDetails</Role>
      <ShortName>Schedule of Balance Sheets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>999055 - Disclosure - Schedule of Statement of Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galmedpharma.com/role/ScheduleOfStatementOfOperationsDetails</Role>
      <ShortName>Schedule of Statement of Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>999056 - Disclosure - Investment in an Associate (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galmedpharma.com/role/InvestmentInAssociateDetailsNarrative</Role>
      <ShortName>Investment in an Associate (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://galmedpharma.com/role/InvestmentInAssociateTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>999057 - Disclosure - Schedule of Other Payables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galmedpharma.com/role/ScheduleOfOtherPayablesDetails</Role>
      <ShortName>Schedule of Other Payables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>999058 - Disclosure - Related Parties (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galmedpharma.com/role/RelatedPartiesDetailsNarrative</Role>
      <ShortName>Related Parties (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://galmedpharma.com/role/RelatedParties</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>999059 - Disclosure - Commitments and Contingencies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galmedpharma.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>Commitments and Contingencies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://galmedpharma.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>999060 - Disclosure - Summary of Status of Company's Option Plans and Changes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galmedpharma.com/role/SummaryOfStatusOfCompanysOptionPlansAndChangesDetails</Role>
      <ShortName>Summary of Status of Company's Option Plans and Changes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>999061 - Disclosure - Stockholders??? equity (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galmedpharma.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>Stockholders??? equity (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://galmedpharma.com/role/StockholdersEquityTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>999062 - Disclosure - Schedule of Research and Development Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galmedpharma.com/role/ScheduleOfResearchAndDevelopmentExpensesDetails</Role>
      <ShortName>Schedule of Research and Development Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>999063 - Disclosure - Schedule of General and Administrative Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galmedpharma.com/role/ScheduleOfGeneralAndAdministrativeExpensesDetails</Role>
      <ShortName>Schedule of General and Administrative Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>999064 - Disclosure - Schedule of Financial Income, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galmedpharma.com/role/ScheduleOfFinancialIncomeNetDetails</Role>
      <ShortName>Schedule of Financial Income, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>999065 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galmedpharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Schedule of Effective Income Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>999066 - Disclosure - Income Taxes (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galmedpharma.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>Income Taxes (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://galmedpharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>999067 - Disclosure - Subsequent events (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galmedpharma.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>Subsequent events (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://galmedpharma.com/role/SubsequentEvents</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>999068 - Disclosure - Segment Reporting (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://galmedpharma.com/role/SegmentReportingDetailsNarrative</Role>
      <ShortName>Segment Reporting (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://galmedpharma.com/role/SegmentReporting</ParentRole>
      <Position>64</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="20-F" isDefinitelyFs="true" isUsgaap="true" original="form20-f.htm">form20-f.htm</File>
    <File>glmd-20241231.xsd</File>
    <File>glmd-20241231_cal.xml</File>
    <File>glmd-20241231_def.xml</File>
    <File>glmd-20241231_lab.xml</File>
    <File>glmd-20241231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>finlog_001.jpg</File>
    <File>form20-f_005.jpg</File>
    <File>vi_001.jpg</File>
    <File>vi_002.jpg</File>
    <File>vi_003.jpg</File>
    <File>vi_004.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="666">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="45">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="1">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>91
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form20-f.htm": {
   "nsprefix": "GLMD",
   "nsuri": "http://galmedpharma.com/20241231",
   "dts": {
    "inline": {
     "local": [
      "form20-f.htm"
     ]
    },
    "schema": {
     "local": [
      "glmd-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "glmd-20241231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "glmd-20241231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "glmd-20241231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "glmd-20241231_pre.xml"
     ]
    }
   },
   "keyStandard": 262,
   "keyCustom": 37,
   "axisStandard": 20,
   "axisCustom": 0,
   "memberStandard": 25,
   "memberCustom": 28,
   "hidden": {
    "total": 106,
    "http://galmedpharma.com/20241231": 23,
    "http://fasb.org/us-gaap/2024": 80,
    "http://xbrl.sec.gov/dei/2024": 3
   },
   "contextCount": 217,
   "entityCount": 1,
   "segmentCount": 56,
   "elementCount": 576,
   "unitCount": 8,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 666,
    "http://xbrl.sec.gov/dei/2024": 45,
    "http://xbrl.sec.gov/cyd/2024": 4,
    "http://xbrl.sec.gov/ecd/2024": 1
   },
   "report": {
    "R1": {
     "role": "http://galmedpharma.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://galmedpharma.com/role/BalanceSheets",
     "longName": "00000002 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://galmedpharma.com/role/BalanceSheetsParenthetical",
     "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "ILSPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "ILSPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://galmedpharma.com/role/StatementsOfOperations",
     "longName": "00000004 - Statement - Consolidated Statements of Operations",
     "shortName": "Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "GLMD:ImpairmentOnAssociate",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://galmedpharma.com/role/StatementsOfOperationsParenthetical",
     "longName": "00000005 - Statement - Consolidated Statements of Operations (Parenthetical)",
     "shortName": "Consolidated Statements of Operations (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "link:footnote",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R6": {
     "role": "http://galmedpharma.com/role/StatementsOfComprehensiveLoss",
     "longName": "00000006 - Statement - Consolidated Statements of Comprehensive Loss",
     "shortName": "Consolidated Statements of Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://galmedpharma.com/role/StatementsOfChangesInStockholdersEquity",
     "longName": "00000007 - Statement - Statements of Changes in Stockholders' Equity",
     "shortName": "Statements of Changes in Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://galmedpharma.com/role/StatementsOfChangesInStockholdersEquityParenthetical",
     "longName": "00000008 - Statement - Statements of Changes in Stockholders' Equity (Parenthetical)",
     "shortName": "Statements of Changes in Stockholders' Equity (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2022-01-012022-12-31",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-01-012022-12-31",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://galmedpharma.com/role/StatementsOfCashFlows",
     "longName": "00000009 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DepreciationAndAmortization",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "unique": true
     }
    },
    "R10": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R11": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://galmedpharma.com/role/General",
     "longName": "999017 - Disclosure - General",
     "shortName": "General",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://galmedpharma.com/role/SignificantAccountingPolicies",
     "longName": "999018 - Disclosure - Significant Accounting Policies",
     "shortName": "Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://galmedpharma.com/role/MarketableDebtSecurities",
     "longName": "999019 - Disclosure - Marketable debt securities",
     "shortName": "Marketable debt securities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://galmedpharma.com/role/OtherReceivables",
     "longName": "999020 - Disclosure - Other Receivables",
     "shortName": "Other Receivables",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://galmedpharma.com/role/Leases",
     "longName": "999021 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://galmedpharma.com/role/PropertyAndEquipmentNet",
     "longName": "999022 - Disclosure - Property and equipment, net",
     "shortName": "Property and equipment, net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://galmedpharma.com/role/InvestmentInAssociate",
     "longName": "999023 - Disclosure - Investment in an Associate",
     "shortName": "Investment in an Associate",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:InvestmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:InvestmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://galmedpharma.com/role/OtherPayables",
     "longName": "999024 - Disclosure - Other Payables",
     "shortName": "Other Payables",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://galmedpharma.com/role/RelatedParties",
     "longName": "999025 - Disclosure - Related Parties",
     "shortName": "Related Parties",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://galmedpharma.com/role/CommitmentsAndContingencies",
     "longName": "999026 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://galmedpharma.com/role/StockholdersEquity",
     "longName": "999027 - Disclosure - Stockholders\u2019 equity",
     "shortName": "Stockholders\u2019 equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://galmedpharma.com/role/ResearchAndDevelopmentExpenses",
     "longName": "999028 - Disclosure - Research and Development Expenses",
     "shortName": "Research and Development Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://galmedpharma.com/role/GeneralAndAdministrativeExpenses",
     "longName": "999029 - Disclosure - General and Administrative Expenses",
     "shortName": "General and Administrative Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "GLMD:GeneralAndAdministrativeExpensesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "GLMD:GeneralAndAdministrativeExpensesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://galmedpharma.com/role/FinancialIncomeNet",
     "longName": "999030 - Disclosure - Financial income, net",
     "shortName": "Financial income, net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://galmedpharma.com/role/IncomeTaxes",
     "longName": "999031 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://galmedpharma.com/role/SubsequentEvents",
     "longName": "999032 - Disclosure - Subsequent events",
     "shortName": "Subsequent events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://galmedpharma.com/role/SegmentReporting",
     "longName": "999033 - Disclosure - Segment Reporting",
     "shortName": "Segment Reporting",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://galmedpharma.com/role/SignificantAccountingPoliciesPolicies",
     "longName": "999034 - Disclosure - Significant Accounting Policies (Policies)",
     "shortName": "Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "30",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://galmedpharma.com/role/SignificantAccountingPoliciesTables",
     "longName": "999035 - Disclosure - Significant Accounting Policies (Tables)",
     "shortName": "Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "GLMD:ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "GLMD:ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://galmedpharma.com/role/MarketableDebtSecuritiesTables",
     "longName": "999036 - Disclosure - Marketable debt securities (Tables)",
     "shortName": "Marketable debt securities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://galmedpharma.com/role/OtherReceivablesTables",
     "longName": "999037 - Disclosure - Other Receivables (Tables)",
     "shortName": "Other Receivables (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://galmedpharma.com/role/PropertyAndEquipmentNetTables",
     "longName": "999038 - Disclosure - Property and equipment, net (Tables)",
     "shortName": "Property and equipment, net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://galmedpharma.com/role/InvestmentInAssociateTables",
     "longName": "999039 - Disclosure - Investment in an Associate (Tables)",
     "shortName": "Investment in an Associate (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "GLMD:ScheduleOfBalanceSheetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InvestmentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "GLMD:ScheduleOfBalanceSheetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InvestmentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://galmedpharma.com/role/OtherPayablesTables",
     "longName": "999040 - Disclosure - Other Payables (Tables)",
     "shortName": "Other Payables (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:OtherLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:OtherLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://galmedpharma.com/role/StockholdersEquityTables",
     "longName": "999041 - Disclosure - Stockholders\u2019 equity (Tables)",
     "shortName": "Stockholders\u2019 equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://galmedpharma.com/role/ResearchAndDevelopmentExpensesTables",
     "longName": "999042 - Disclosure - Research and Development Expenses (Tables)",
     "shortName": "Research and Development Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://galmedpharma.com/role/GeneralAndAdministrativeExpensesTables",
     "longName": "999043 - Disclosure - General and Administrative Expenses (Tables)",
     "shortName": "General and Administrative Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "GLMD:GeneralAndAdministrativeExpensesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "GLMD:GeneralAndAdministrativeExpensesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "GLMD:GeneralAndAdministrativeExpensesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "GLMD:GeneralAndAdministrativeExpensesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://galmedpharma.com/role/FinancialIncomeNetTables",
     "longName": "999044 - Disclosure - Financial income, net (Tables)",
     "shortName": "Financial income, net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeByComponentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeByComponentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://galmedpharma.com/role/IncomeTaxesTables",
     "longName": "999045 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://galmedpharma.com/role/GeneralDetailsNarrative",
     "longName": "999046 - Disclosure - General (Details Narrative)",
     "shortName": "General (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "dei:EntityIncorporationDateOfIncorporation",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "dei:EntityIncorporationDateOfIncorporation",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://galmedpharma.com/role/ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentDetails",
     "longName": "999047 - Disclosure - Schedule of Depreciation Rates for Property, Plant and Equipment (Details)",
     "shortName": "Schedule of Depreciation Rates for Property, Plant and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31_srt_MinimumMember_custom_OfficeFurnitureAndEquipmentMember",
      "name": "us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "GLMD:ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_srt_MinimumMember_custom_OfficeFurnitureAndEquipmentMember",
      "name": "us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "GLMD:ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://galmedpharma.com/role/ScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails",
     "longName": "999048 - Disclosure - Schedule of Assets Measured at Fair Value on Recurring Basis (Details)",
     "shortName": "Schedule of Assets Measured at Fair Value on Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueOfFinancialInstrumentsPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueOfFinancialInstrumentsPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://galmedpharma.com/role/SignificantAccountingPoliciesDetailsNarrative",
     "longName": "999049 - Disclosure - Significant Accounting Policies (Details Narrative)",
     "shortName": "Significant Accounting Policies (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:Depreciation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-4",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:Depreciation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-4",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://galmedpharma.com/role/ScheduleOfMarketableDebtSecuritiesDetails",
     "longName": "999050 - Disclosure - Schedule of Marketable Debt Securities (Details)",
     "shortName": "Schedule of Marketable Debt Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://galmedpharma.com/role/ScheduleOfOtherReceivablesDetails",
     "longName": "999051 - Disclosure - Schedule of Other Receivables (Details)",
     "shortName": "Schedule of Other Receivables (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://galmedpharma.com/role/LeasesDetailsNarrative",
     "longName": "999052 - Disclosure - Leases (Details Narrative)",
     "shortName": "Leases (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:AreaOfLand",
      "unitRef": "Sqft",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:AreaOfLand",
      "unitRef": "Sqft",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://galmedpharma.com/role/ScheduleOfPropertyAndEquipmentDetails",
     "longName": "999053 - Disclosure - Schedule of Property and Equipment (Details)",
     "shortName": "Schedule of Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:MachineryAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:MachineryAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://galmedpharma.com/role/ScheduleOfBalanceSheetsDetails",
     "longName": "999054 - Disclosure - Schedule of Balance Sheets (Details)",
     "shortName": "Schedule of Balance Sheets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:AssetsCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_custom_OnkaiIncMember",
      "name": "us-gaap:AssetsCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "GLMD:ScheduleOfBalanceSheetsTableTextBlock",
       "us-gaap:InvestmentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://galmedpharma.com/role/ScheduleOfStatementOfOperationsDetails",
     "longName": "999055 - Disclosure - Schedule of Statement of Operations (Details)",
     "shortName": "Schedule of Statement of Operations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:OperatingExpenses",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31_custom_OnkaiIncMember",
      "name": "us-gaap:OperatingExpenses",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "GLMD:ScheduleOfStatementOfOperationsTableTextBlock",
       "us-gaap:InvestmentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://galmedpharma.com/role/InvestmentInAssociateDetailsNarrative",
     "longName": "999056 - Disclosure - Investment in an Associate (Details Narrative)",
     "shortName": "Investment in an Associate (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:PaymentsToAcquireInvestments",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:InvestmentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:PaymentsToAcquireInvestments",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:InvestmentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://galmedpharma.com/role/ScheduleOfOtherPayablesDetails",
     "longName": "999057 - Disclosure - Schedule of Other Payables (Details)",
     "shortName": "Schedule of Other Payables (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:OtherLiabilitiesTableTextBlock",
       "us-gaap:OtherLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:OtherLiabilitiesTableTextBlock",
       "us-gaap:OtherLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://galmedpharma.com/role/RelatedPartiesDetailsNarrative",
     "longName": "999058 - Disclosure - Related Parties (Details Narrative)",
     "shortName": "Related Parties (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://galmedpharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "longName": "999059 - Disclosure - Commitments and Contingencies (Details Narrative)",
     "shortName": "Commitments and Contingencies (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "GLMD:BankLienOnMarketableSecurities",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "GLMD:BankLienOnMarketableSecurities",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://galmedpharma.com/role/SummaryOfStatusOfCompanysOptionPlansAndChangesDetails",
     "longName": "999060 - Disclosure - Summary of Status of Company's Option Plans and Changes (Details)",
     "shortName": "Summary of Status of Company's Option Plans and Changes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "From2024-11-122024-11-12",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_EmployeeStockOptionMember94762828",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative",
     "longName": "999061 - Disclosure - Stockholders\u2019 equity (Details Narrative)",
     "shortName": "Stockholders\u2019 equity (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "From2024-08-302024-08-30",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-08-302024-08-30",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://galmedpharma.com/role/ScheduleOfResearchAndDevelopmentExpensesDetails",
     "longName": "999062 - Disclosure - Schedule of Research and Development Expenses (Details)",
     "shortName": "Schedule of Research and Development Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31_custom_ChemistryAndFormulationStudiesMember",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock",
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://galmedpharma.com/role/ScheduleOfGeneralAndAdministrativeExpensesDetails",
     "longName": "999063 - Disclosure - Schedule of General and Administrative Expenses (Details)",
     "shortName": "Schedule of General and Administrative Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31_custom_StockBasedCompensationMember",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "GLMD:GeneralAndAdministrativeExpensesTableTextBlock",
       "GLMD:GeneralAndAdministrativeExpensesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://galmedpharma.com/role/ScheduleOfFinancialIncomeNetDetails",
     "longName": "999064 - Disclosure - Schedule of Financial Income, Net (Details)",
     "shortName": "Schedule of Financial Income, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "GLMD:BankFees",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeByComponentTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "GLMD:BankFees",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeByComponentTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://galmedpharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails",
     "longName": "999065 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "shortName": "Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://galmedpharma.com/role/IncomeTaxesDetailsNarrative",
     "longName": "999066 - Disclosure - Income Taxes (Details Narrative)",
     "shortName": "Income Taxes (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://galmedpharma.com/role/SubsequentEventsDetailsNarrative",
     "longName": "999067 - Disclosure - Subsequent events (Details Narrative)",
     "shortName": "Subsequent events (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "From2025-03-202025-03-21_custom_TwoThousandAndTwentySalesAgreementMember",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-03-202025-03-21_custom_TwoThousandAndTwentySalesAgreementMember_us-gaap_SubsequentEventMember",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "unique": true
     }
    },
    "R64": {
     "role": "http://galmedpharma.com/role/SegmentReportingDetailsNarrative",
     "longName": "999068 - Disclosure - Segment Reporting (Details Narrative)",
     "shortName": "Segment Reporting (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "Integer",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "Integer",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://galmedpharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade payables",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r672"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://galmedpharma.com/role/ScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less - Accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r134",
      "r494"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "presentation": [
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r149",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://galmedpharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated other comprehensive loss",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r14",
      "r65",
      "r138",
      "r489",
      "r521",
      "r522"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "presentation": [
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r149",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://galmedpharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r7",
      "r14",
      "r390",
      "r393",
      "r435",
      "r517",
      "r518",
      "r818",
      "r819",
      "r820",
      "r827",
      "r828",
      "r829",
      "r830"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r751"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://galmedpharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r672",
      "r962"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://galmedpharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r538",
      "r827",
      "r828",
      "r829",
      "r830",
      "r898",
      "r963"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://galmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions",
     "crdr": "credit",
     "presentation": [
      "http://galmedpharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation",
        "documentation": "Amount of increase (decrease) to additional paid-in capital (APIC) for recognition and exercise of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://galmedpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments required to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdministrativeServiceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdministrativeServiceMember",
     "presentation": [
      "http://galmedpharma.com/role/InvestmentInAssociateDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Administrative Service [Member]",
        "documentation": "Administrative assistance, including, but not limited to, accounting, tax, legal, regulatory filing, and share registration of managed fund and investment account of independent third party, and related and affiliated entity."
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r718",
      "r729",
      "r743",
      "r769"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r721",
      "r732",
      "r746",
      "r772"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r757"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r764"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r722",
      "r733",
      "r747",
      "r764",
      "r773",
      "r777",
      "r785"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "auth_ref": [
      "r783"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Allocated stock based compensation",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r337",
      "r343"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://galmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://galmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfDebtDiscountPremium",
     "crdr": "debit",
     "calculation": {
      "http://galmedpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of discount (premium) on marketable debt securities",
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r73",
      "r282",
      "r908"
     ]
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://galmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "us-gaap_AreaOfLand": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AreaOfLand",
     "presentation": [
      "http://galmedpharma.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Area of land under operating lease agreement",
        "documentation": "Area of land held."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://galmedpharma.com/role/InvestmentInAssociateDetailsNarrative",
      "http://galmedpharma.com/role/RelatedPartiesDetailsNarrative",
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative",
      "http://galmedpharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r381"
     ]
    },
    "us-gaap_AssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetImpairmentCharges",
     "crdr": "debit",
     "presentation": [
      "http://galmedpharma.com/role/InvestmentInAssociateDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment charges",
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r30"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://galmedpharma.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets [Default Label]",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r116",
      "r136",
      "r161",
      "r186",
      "r192",
      "r198",
      "r201",
      "r242",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r383",
      "r387",
      "r412",
      "r484",
      "r567",
      "r642",
      "r643",
      "r672",
      "r690",
      "r860",
      "r861",
      "r914"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://galmedpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://galmedpharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://galmedpharma.com/role/ScheduleOfBalanceSheetsDetails": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/BalanceSheets",
      "http://galmedpharma.com/role/ScheduleOfBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "verboseLabel": "Current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r140",
      "r161",
      "r242",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r383",
      "r387",
      "r412",
      "r672",
      "r860",
      "r861",
      "r914"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://galmedpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://galmedpharma.com/role/ScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r400",
      "r401",
      "r661"
     ]
    },
    "us-gaap_AssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://galmedpharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://galmedpharma.com/role/ScheduleOfBalanceSheetsDetails": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/BalanceSheets",
      "http://galmedpharma.com/role/ScheduleOfBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current assets",
        "label": "Non-current assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r242",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r383",
      "r387",
      "r412",
      "r860",
      "r861",
      "r914"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://galmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://galmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r702",
      "r704",
      "r725"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://galmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r702",
      "r704",
      "r725"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://galmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r702",
      "r704",
      "r725"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://galmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r799"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "presentation": [
      "http://galmedpharma.com/role/ScheduleOfMarketableDebtSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r250",
      "r483"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesGrossUnrealizedGain",
     "crdr": "credit",
     "presentation": [
      "http://galmedpharma.com/role/ScheduleOfMarketableDebtSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross Unrealized Gains",
        "documentation": "Amount of unrealized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesGrossUnrealizedLoss",
     "crdr": "debit",
     "presentation": [
      "http://galmedpharma.com/role/ScheduleOfMarketableDebtSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gross Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss",
        "documentation": "Amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "presentation": [
      "http://galmedpharma.com/role/ScheduleOfMarketableDebtSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimated Fair Value",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r211",
      "r250",
      "r400",
      "r478",
      "r661",
      "r664",
      "r840",
      "r902",
      "r903",
      "r904"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r781"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "auth_ref": [
      "r776"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://galmedpharma.com/role/SignificantAccountingPoliciesDetailsNarrative",
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r308",
      "r309",
      "r310",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "GLMD_BankFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://galmedpharma.com/20241231",
     "localname": "BankFees",
     "crdr": "debit",
     "calculation": {
      "http://galmedpharma.com/role/ScheduleOfFinancialIncomeNetDetails": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/ScheduleOfFinancialIncomeNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Bank fees",
        "documentation": "Amount of expense classified as bank fees.",
        "label": "Bank Fees"
       }
      }
     },
     "auth_ref": []
    },
    "GLMD_BankLienOnMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://galmedpharma.com/20241231",
     "localname": "BankLienOnMarketableSecurities",
     "crdr": "credit",
     "presentation": [
      "http://galmedpharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bank lien on marketable securities",
        "documentation": "These lines are represents that lien on marketable securities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://galmedpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "GLMD_BridgeLoanAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galmedpharma.com/20241231",
     "localname": "BridgeLoanAgreementMember",
     "presentation": [
      "http://galmedpharma.com/role/InvestmentInAssociateDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bridge Loan Agreement [Member]",
        "documentation": "Bridge Loan Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://galmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r704",
      "r725"
     ]
    },
    "GLMD_CapitalStockDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://galmedpharma.com/20241231",
     "localname": "CapitalStockDiscountRate",
     "presentation": [
      "http://galmedpharma.com/role/InvestmentInAssociateDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital discount rate",
        "documentation": "Capital stock discount rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalizedComputerSoftwareGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CapitalizedComputerSoftwareGross",
     "crdr": "debit",
     "calculation": {
      "http://galmedpharma.com/role/ScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer software and electronic equipment",
        "documentation": "Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software."
       }
      }
     },
     "auth_ref": [
      "r256",
      "r631"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://galmedpharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/BalanceSheets",
      "http://galmedpharma.com/role/GeneralDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r132",
      "r633"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://galmedpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://galmedpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r98"
     ]
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "presentation": [
      "http://galmedpharma.com/role/MarketableDebtSecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Marketable debt securities",
        "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]",
        "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r839"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://galmedpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents and restricted cash at the beginning of the year",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at the end of the year",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r78",
      "r159"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://galmedpharma.com/role/StatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) in cash, cash equivalents and restricted cash",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r78"
     ]
    },
    "GLMD_CaymanIslandsExemptLimitedPartnershipMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galmedpharma.com/20241231",
     "localname": "CaymanIslandsExemptLimitedPartnershipMember",
     "presentation": [
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative",
      "http://galmedpharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cayman Islands Exempt Limited Partnership [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GLMD_ChangeInFairValueConvertibleNote": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://galmedpharma.com/20241231",
     "localname": "ChangeInFairValueConvertibleNote",
     "crdr": "credit",
     "calculation": {
      "http://galmedpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in fair value convertible note",
        "documentation": "Change in fair value convertible note.",
        "label": "ChangeInFairValueConvertibleNote"
       }
      }
     },
     "auth_ref": []
    },
    "GLMD_ChangeInFairValueOfConvertibleNote": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://galmedpharma.com/20241231",
     "localname": "ChangeInFairValueOfConvertibleNote",
     "crdr": "credit",
     "calculation": {
      "http://galmedpharma.com/role/ScheduleOfFinancialIncomeNetDetails": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/ScheduleOfFinancialIncomeNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of convertible note",
        "documentation": "Change in fair value of convertible note."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r755"
     ]
    },
    "GLMD_ChemistryAndFormulationStudiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galmedpharma.com/20241231",
     "localname": "ChemistryAndFormulationStudiesMember",
     "presentation": [
      "http://galmedpharma.com/role/ScheduleOfResearchAndDevelopmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chemistry And Formulation Studies [Member]",
        "documentation": "Chemistry And Formulation Studies [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ChiefExecutiveOfficerMember",
     "presentation": [
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer [Member]"
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://galmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price of warrants",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r287"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "presentation": [
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock and warrants issued during period shares",
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant exercised, shares",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r287"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants are outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "GLMD_ClinicalStudiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galmedpharma.com/20241231",
     "localname": "ClinicalStudiesMember",
     "presentation": [
      "http://galmedpharma.com/role/ScheduleOfResearchAndDevelopmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical Studies [Member]",
        "documentation": "Clinical Studies [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "GLMD_CommitmentShare": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://galmedpharma.com/20241231",
     "localname": "CommitmentShare",
     "presentation": [
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitment share",
        "documentation": "Commitment share."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://galmedpharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and contingencies liabilities",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r103",
      "r487",
      "r553"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://galmedpharma.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r262",
      "r263",
      "r627",
      "r853",
      "r855"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares reserved for future issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "GLMD_CommonStockCapitalSharesReservedForFutureIssuanceUnallocated": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://galmedpharma.com/20241231",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuanceUnallocated",
     "presentation": [
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Shares reserved for future issuance",
        "documentation": "Common stock capital shares reserved for future issuance unallocated.",
        "label": "CommonStockCapitalSharesReservedForFutureIssuanceUnallocated"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://galmedpharma.com/role/StatementsOfChangesInStockholdersEquity",
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r680",
      "r681",
      "r682",
      "r684",
      "r685",
      "r686",
      "r687",
      "r827",
      "r828",
      "r830",
      "r898",
      "r959",
      "r963"
     ]
    },
    "us-gaap_CommonStockNoParValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockNoParValue",
     "presentation": [
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value",
        "documentation": "Face amount per share of no-par value common stock."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://galmedpharma.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary shares, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://galmedpharma.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary shares, authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r554"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://galmedpharma.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary shares, issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://galmedpharma.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary shares, outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r57",
      "r554",
      "r573",
      "r963",
      "r964"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://galmedpharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary shares, par value NIS 1.80 per share; Authorized 50,000,000 shares; Issued and outstanding: 1,664,884 and 573,741 shares as of December 31, 2024 and December 31, 2023, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r488",
      "r672"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "us-gaap_CompensatedAbsencesLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensatedAbsencesLiability",
     "crdr": "credit",
     "calculation": {
      "http://galmedpharma.com/role/ScheduleOfOtherPayablesDetails": {
       "parentTag": "us-gaap_OtherLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/ScheduleOfOtherPayablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Vacation",
        "documentation": "Amount of liability accrued for the employer's obligation related to an employee's right to receive compensation for future absences that have been earned by employee."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "presentation": [
      "http://galmedpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Severance pay",
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r92"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://galmedpharma.com/role/StatementsOfComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/StatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r95",
      "r144",
      "r146",
      "r151",
      "r479",
      "r502"
     ]
    },
    "GLMD_ComputerSoftwareElectronicEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galmedpharma.com/20241231",
     "localname": "ComputerSoftwareElectronicEquipmentMember",
     "presentation": [
      "http://galmedpharma.com/role/ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer Software and Electronic Equipment [Member]",
        "documentation": "Computer Software and Electronic Equipment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://galmedpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentrations of credit risk",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r120"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://galmedpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principles of consolidation",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r635"
     ]
    },
    "dei_ContactPersonnelEmailAddress": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelEmailAddress",
     "presentation": [
      "http://galmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Email Address",
        "documentation": "Email address of contact personnel."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://galmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "GLMD_ConversionOfConvertibleNoteIntoInvestmentInAssociate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://galmedpharma.com/20241231",
     "localname": "ConversionOfConvertibleNoteIntoInvestmentInAssociate",
     "crdr": "credit",
     "presentation": [
      "http://galmedpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of convertible note into investment in associate",
        "documentation": "Conversion of convertible note into investment in associate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockSharesIssued1",
     "presentation": [
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r23",
      "r24"
     ]
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://galmedpharma.com/role/ScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails",
      "http://galmedpharma.com/role/ScheduleOfMarketableDebtSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Corporate Debt Securities [Member]",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r654",
      "r656",
      "r661",
      "r673",
      "r678",
      "r956"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://galmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://galmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r712",
      "r795"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r712",
      "r795"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r714",
      "r797"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r714",
      "r797"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r707",
      "r790"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r708",
      "r791"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r708",
      "r791"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r706",
      "r789"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r709",
      "r792"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r711",
      "r794"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r711",
      "r794"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r712",
      "r795"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r713",
      "r796"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r710",
      "r793"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://galmedpharma.com/role/InvestmentInAssociateDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r279",
      "r425",
      "r426",
      "r650",
      "r651",
      "r671"
     ]
    },
    "us-gaap_DebtInstrumentFeeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFeeAmount",
     "crdr": "debit",
     "presentation": [
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Structuring fee",
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://galmedpharma.com/role/InvestmentInAssociateDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest rate",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r285",
      "r425",
      "r426",
      "r671"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleGainLoss",
     "crdr": "credit",
     "calculation": {
      "http://galmedpharma.com/role/ScheduleOfFinancialIncomeNetDetails": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/ScheduleOfFinancialIncomeNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss from sale of marketable debt securities",
        "documentation": "Amount of unrealized and realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r821",
      "r822"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedGainLoss",
     "crdr": "credit",
     "calculation": {
      "http://galmedpharma.com/role/StatementsOfComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/StatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net unrealized loss (gain) on available for sale securities",
        "label": "Debt Securities, Available-for-Sale, Unrealized Gain (Loss)",
        "documentation": "Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r842",
      "r843"
     ]
    },
    "us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable",
     "presentation": [
      "http://galmedpharma.com/role/ScheduleOfMarketableDebtSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Table]",
        "documentation": "Disclosure of information about allowance for credit loss on investment in debt security measured at amortized cost (held-to-maturity)."
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems",
     "presentation": [
      "http://galmedpharma.com/role/ScheduleOfMarketableDebtSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "GLMD_DecreaseInShorttermDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://galmedpharma.com/20241231",
     "localname": "DecreaseInShorttermDeposits",
     "crdr": "credit",
     "calculation": {
      "http://galmedpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Decrease in short-term deposits",
        "documentation": "Decrease in short term deposits.",
        "label": "DecreaseInShorttermDeposits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxChargesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxChargesMember",
     "presentation": [
      "http://galmedpharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Charge [Member]",
        "documentation": "Rate action of a regulator resulting in capitalization or accrual of income taxes."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r112",
      "r113",
      "r114"
     ]
    },
    "us-gaap_DeferredTaxAssetsCapitalLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsCapitalLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://galmedpharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax assets, capital loss carry forwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "GLMD_DemandSalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galmedpharma.com/20241231",
     "localname": "DemandSalesAgreementMember",
     "presentation": [
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Demand Sales Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepositsAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepositsAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://galmedpharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/BalanceSheets",
      "http://galmedpharma.com/role/GeneralDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-term deposits",
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter."
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://galmedpharma.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation expenses",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r31"
     ]
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://galmedpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r31"
     ]
    },
    "GLMD_DisclosureGeneralAndAdministrativeExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://galmedpharma.com/20241231",
     "localname": "DisclosureGeneralAndAdministrativeExpensesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "General And Administrative Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "GLMD_DisclosureLeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://galmedpharma.com/20241231",
     "localname": "DisclosureLeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://galmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://galmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r702",
      "r704",
      "r725"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://galmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r702",
      "r704",
      "r725",
      "r765"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://galmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://galmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://galmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://galmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://galmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://galmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r691"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://galmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://galmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://galmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r750"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://galmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://galmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r694"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://galmedpharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic, net loss per share",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r177",
      "r179",
      "r181",
      "r182",
      "r183",
      "r185",
      "r376",
      "r380",
      "r397",
      "r398",
      "r480",
      "r503",
      "r637"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://galmedpharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Diluted, net loss per share",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r179",
      "r181",
      "r182",
      "r183",
      "r185",
      "r376",
      "r380",
      "r397",
      "r398",
      "r480",
      "r503",
      "r637"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://galmedpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic and diluted net loss per share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r184"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "presentation": [
      "http://galmedpharma.com/role/IncomeTaxesDetailsNarrative",
      "http://galmedpharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statutory tax rate",
        "verboseLabel": "Effective income tax rate reconciliation, at federal statutory income tax rate, percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r352",
      "r367",
      "r658"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrentAndNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://galmedpharma.com/role/ScheduleOfOtherPayablesDetails": {
       "parentTag": "us-gaap_OtherLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/ScheduleOfOtherPayablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employees and related",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r924"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized compensation expense",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r338"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized compensation, term",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r338"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized share based compensation",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative",
      "http://galmedpharma.com/role/SummaryOfStatusOfCompanysOptionPlansAndChangesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://galmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://galmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://galmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://galmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://galmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://galmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://galmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://galmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesLineItems",
     "presentation": [
      "http://galmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesTable",
     "presentation": [
      "http://galmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Table]",
        "documentation": "Container of address information for the entity"
       }
      }
     },
     "auth_ref": [
      "r693"
     ]
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://galmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r697"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://galmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r693"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://galmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://galmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://galmedpharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://galmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r693"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://galmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r802"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://galmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://galmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r693"
     ]
    },
    "dei_EntityIncorporationDateOfIncorporation": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationDateOfIncorporation",
     "presentation": [
      "http://galmedpharma.com/role/GeneralDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Date of incorporation",
        "documentation": "Date when an entity was incorporated"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://galmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://galmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r798"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://galmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://galmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://galmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r693"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://galmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r693"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://galmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r693"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://galmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r693"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://galmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://galmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r800"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://galmedpharma.com/role/StatementsOfChangesInStockholdersEquity",
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r128",
      "r148",
      "r149",
      "r150",
      "r163",
      "r164",
      "r165",
      "r167",
      "r172",
      "r174",
      "r176",
      "r187",
      "r243",
      "r244",
      "r257",
      "r288",
      "r365",
      "r366",
      "r373",
      "r374",
      "r375",
      "r377",
      "r379",
      "r380",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r396",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r427",
      "r429",
      "r435",
      "r500",
      "r517",
      "r518",
      "r519",
      "r538",
      "r598"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r718",
      "r729",
      "r743",
      "r769"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r715",
      "r726",
      "r740",
      "r766"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "GLMD_ExerciseOfPrefundedWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://galmedpharma.com/20241231",
     "localname": "ExerciseOfPrefundedWarrants",
     "crdr": "credit",
     "presentation": [
      "http://galmedpharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of Pre-funded warrants",
        "documentation": "Exercise of Pre-funded warrants."
       }
      }
     },
     "auth_ref": []
    },
    "GLMD_ExerciseOfPrefundedWarrantsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://galmedpharma.com/20241231",
     "localname": "ExerciseOfPrefundedWarrantsShares",
     "presentation": [
      "http://galmedpharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of Pre-funded warrants, shares",
        "documentation": "Exercise of Pre-funded warrants, shares."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://galmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://galmedpharma.com/role/ScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r400",
      "r401",
      "r408",
      "r661"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://galmedpharma.com/role/ScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r400",
      "r401",
      "r408",
      "r661"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://galmedpharma.com/role/ScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r281",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r399",
      "r401",
      "r402",
      "r403",
      "r404",
      "r407",
      "r408",
      "r410",
      "r448",
      "r449",
      "r450",
      "r650",
      "r651",
      "r654",
      "r655",
      "r656",
      "r661",
      "r664"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://galmedpharma.com/role/ScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r400",
      "r401",
      "r402",
      "r404",
      "r661",
      "r903",
      "r906"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://galmedpharma.com/role/ScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r281",
      "r299",
      "r304",
      "r401",
      "r408",
      "r448",
      "r654",
      "r655",
      "r656",
      "r661"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://galmedpharma.com/role/ScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r281",
      "r299",
      "r304",
      "r401",
      "r402",
      "r408",
      "r449",
      "r650",
      "r651",
      "r654",
      "r655",
      "r656",
      "r661"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://galmedpharma.com/role/ScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r281",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r401",
      "r402",
      "r403",
      "r404",
      "r408",
      "r450",
      "r650",
      "r651",
      "r654",
      "r655",
      "r656",
      "r661",
      "r664"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://galmedpharma.com/role/ScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r400",
      "r401",
      "r402",
      "r404",
      "r661",
      "r903",
      "r906"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://galmedpharma.com/role/ScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r281",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r399",
      "r401",
      "r402",
      "r403",
      "r404",
      "r407",
      "r408",
      "r410",
      "r448",
      "r449",
      "r450",
      "r650",
      "r651",
      "r654",
      "r655",
      "r656",
      "r661",
      "r664"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://galmedpharma.com/role/ScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r661",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r906"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://galmedpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of financial instruments",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "GLMD_FinancialExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://galmedpharma.com/20241231",
     "localname": "FinancialExpenses",
     "crdr": "debit",
     "calculation": {
      "http://galmedpharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      },
      "http://galmedpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/StatementsOfCashFlows",
      "http://galmedpharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial expenses related to SEPA",
        "verboseLabel": "Finance expenses related to SEPA",
        "documentation": "Financial expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://galmedpharma.com/role/ScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails",
      "http://galmedpharma.com/role/ScheduleOfMarketableDebtSecuritiesDetails",
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r251",
      "r252",
      "r253",
      "r283",
      "r286",
      "r395",
      "r411",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r501",
      "r648",
      "r661",
      "r662",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r673",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r845",
      "r846",
      "r847",
      "r848",
      "r899",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://galmedpharma.com/role/ScheduleOfFinancialIncomeNetDetails": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/ScheduleOfFinancialIncomeNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign currency (gains) losses",
        "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r414",
      "r415",
      "r416",
      "r417",
      "r595"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://galmedpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial statement in U.S. dollars",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r413"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r722",
      "r733",
      "r747",
      "r773"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r722",
      "r733",
      "r747",
      "r773"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r722",
      "r733",
      "r747",
      "r773"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r722",
      "r733",
      "r747",
      "r773"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r722",
      "r733",
      "r747",
      "r773"
     ]
    },
    "us-gaap_FurnitureAndFixturesGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesGross",
     "crdr": "debit",
     "calculation": {
      "http://galmedpharma.com/role/ScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office furniture and equipment",
        "documentation": "Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "us-gaap_GainLossOnInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnInvestments",
     "crdr": "credit",
     "presentation": [
      "http://galmedpharma.com/role/InvestmentInAssociateDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments",
        "documentation": "Amount of realized and unrealized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r74",
      "r803"
     ]
    },
    "us-gaap_GainLossOnSaleOfInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnSaleOfInvestments",
     "crdr": "credit",
     "calculation": {
      "http://galmedpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gain on sale of marketable debt securities",
        "label": "Gain (Loss) on Sale of Investments",
        "documentation": "The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://galmedpharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/InvestmentInAssociateDetailsNarrative",
      "http://galmedpharma.com/role/ScheduleOfGeneralAndAdministrativeExpensesDetails",
      "http://galmedpharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative expenses",
        "verboseLabel": "Management fee income",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r577"
     ]
    },
    "GLMD_GeneralAndAdministrativeExpensesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://galmedpharma.com/20241231",
     "localname": "GeneralAndAdministrativeExpensesDisclosureTextBlock",
     "presentation": [
      "http://galmedpharma.com/role/GeneralAndAdministrativeExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "GLMD_GeneralAndAdministrativeExpensesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://galmedpharma.com/20241231",
     "localname": "GeneralAndAdministrativeExpensesTableTextBlock",
     "presentation": [
      "http://galmedpharma.com/role/GeneralAndAdministrativeExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of General and Administrative Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GrantsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GrantsReceivable",
     "crdr": "debit",
     "calculation": {
      "http://galmedpharma.com/role/ScheduleOfOtherReceivablesDetails": {
       "parentTag": "us-gaap_ReceivablesNetCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/ScheduleOfOtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Government institutions",
        "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants."
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://galmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r702",
      "r704",
      "r725"
     ]
    },
    "GLMD_ImpairmentOnAssociate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://galmedpharma.com/20241231",
     "localname": "ImpairmentOnAssociate",
     "crdr": "debit",
     "calculation": {
      "http://galmedpharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment on associate"
       }
      }
     },
     "auth_ref": []
    },
    "GLMD_IncentiveShareOptionPlan2013Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galmedpharma.com/20241231",
     "localname": "IncentiveShareOptionPlan2013Member",
     "presentation": [
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incentive Share Option Plan2013 [Member]",
        "documentation": "Incentive Share Option Plan2013 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "presentation": [
      "http://galmedpharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss before taxes on income, as reported in the consolidated statements of operations",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r108",
      "r115",
      "r481",
      "r497",
      "r638",
      "r642",
      "r831",
      "r833",
      "r834",
      "r835",
      "r836"
     ]
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromEquityMethodInvestments",
     "crdr": "credit",
     "calculation": {
      "http://galmedpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest income from loan to associate",
        "label": "Income (Loss) from Equity Method Investments",
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r67",
      "r107",
      "r186",
      "r193",
      "r201",
      "r241",
      "r496"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://galmedpharma.com/role/ScheduleOfGeneralAndAdministrativeExpensesDetails",
      "http://galmedpharma.com/role/ScheduleOfResearchAndDevelopmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r260",
      "r261",
      "r405",
      "r406",
      "r409",
      "r514",
      "r516",
      "r582",
      "r631",
      "r663",
      "r929"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://galmedpharma.com/role/ScheduleOfGeneralAndAdministrativeExpensesDetails",
      "http://galmedpharma.com/role/ScheduleOfResearchAndDevelopmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r261",
      "r405",
      "r406",
      "r409",
      "r514",
      "r516",
      "r582",
      "r631",
      "r663",
      "r929"
     ]
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityNameAxis",
     "presentation": [
      "http://galmedpharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority, Name [Axis]",
        "documentation": "Information by name of taxing authority."
       }
      }
     },
     "auth_ref": [
      "r358",
      "r896"
     ]
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityNameDomain",
     "presentation": [
      "http://galmedpharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": [
      "r358",
      "r896"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://galmedpharma.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r348",
      "r352",
      "r355",
      "r356",
      "r357",
      "r359",
      "r362",
      "r368",
      "r370",
      "r371",
      "r372",
      "r533",
      "r658"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://galmedpharma.com/role/ScheduleOfStatementOfOperationsDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      },
      "http://galmedpharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails",
      "http://galmedpharma.com/role/ScheduleOfStatementOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income tax",
        "totalLabel": "Actual tax expense",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r126",
      "r175",
      "r176",
      "r186",
      "r194",
      "r201",
      "r351",
      "r352",
      "r369",
      "r505",
      "r658"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://galmedpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r349",
      "r350",
      "r359",
      "r360",
      "r361",
      "r364",
      "r530"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://galmedpharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Losses and other items for which a valuation allowance was provided or benefit from loss carry forwards",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r354",
      "r658",
      "r895"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://galmedpharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Theoretical tax benefit",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r658"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsAndOtherReceivables",
     "crdr": "credit",
     "calculation": {
      "http://galmedpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Decrease (increase) in other receivables",
        "label": "Increase (Decrease) in Accounts and Other Receivables",
        "documentation": "The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "crdr": "debit",
     "calculation": {
      "http://galmedpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Decrease in trade payables",
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://galmedpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://galmedpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) in other payables",
        "documentation": "Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r722",
      "r733",
      "r747",
      "r764",
      "r773",
      "r777",
      "r785"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "auth_ref": [
      "r783"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r705",
      "r788"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r705",
      "r788"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r705",
      "r788"
     ]
    },
    "GLMD_InsuranceAndOtherExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galmedpharma.com/20241231",
     "localname": "InsuranceAndOtherExpensesMember",
     "presentation": [
      "http://galmedpharma.com/role/ScheduleOfGeneralAndAdministrativeExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insurance And Other Expenses [Member]",
        "documentation": "Insurance And Other Expenses [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GLMD_InterestIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://galmedpharma.com/20241231",
     "localname": "InterestIncome",
     "crdr": "credit",
     "calculation": {
      "http://galmedpharma.com/role/ScheduleOfFinancialIncomeNetDetails": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/ScheduleOfFinancialIncomeNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income",
        "documentation": "Interest income"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://galmedpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash received from interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r157",
      "r158"
     ]
    },
    "GLMD_InvestmentInAssociateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galmedpharma.com/20241231",
     "localname": "InvestmentInAssociateMember",
     "presentation": [
      "http://galmedpharma.com/role/ScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment In Associate [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentInterestRate",
     "presentation": [
      "http://galmedpharma.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term deposits interest rate",
        "documentation": "Rate of interest on investment."
       }
      }
     },
     "auth_ref": [
      "r604",
      "r605",
      "r610",
      "r611",
      "r612",
      "r613",
      "r622",
      "r623",
      "r682",
      "r841",
      "r844"
     ]
    },
    "us-gaap_InvestmentOwnedBalanceShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentOwnedBalanceShares",
     "presentation": [
      "http://galmedpharma.com/role/InvestmentInAssociateDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares owned",
        "documentation": "Number of shares of investment owned."
       }
      }
     },
     "auth_ref": [
      "r540",
      "r544",
      "r606",
      "r616",
      "r624",
      "r682"
     ]
    },
    "us-gaap_InvestmentOwnedPercentOfNetAssets": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentOwnedPercentOfNetAssets",
     "presentation": [
      "http://galmedpharma.com/role/InvestmentInAssociateDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares owned percentage",
        "documentation": "Percentage of investment owned to net assets."
       }
      }
     },
     "auth_ref": [
      "r541",
      "r542",
      "r543",
      "r607",
      "r615",
      "r617",
      "r618",
      "r625",
      "r682",
      "r960"
     ]
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentPolicyTextBlock",
     "presentation": [
      "http://galmedpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment in Associate at Fair Value",
        "documentation": "Disclosure of accounting policy for investment in financial asset."
       }
      }
     },
     "auth_ref": [
      "r504",
      "r526",
      "r527",
      "r528",
      "r529",
      "r608",
      "r609"
     ]
    },
    "us-gaap_InvestmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentTextBlock",
     "presentation": [
      "http://galmedpharma.com/role/InvestmentInAssociate"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment in an Associate",
        "documentation": "The entire disclosure for investment."
       }
      }
     },
     "auth_ref": [
      "r804",
      "r805",
      "r839"
     ]
    },
    "us-gaap_InvestmentsAllOtherInvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsAllOtherInvestmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, All Other Investments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
     "crdr": "debit",
     "calculation": {
      "http://galmedpharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment in associate at fair value",
        "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate."
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "us-gaap_InvestorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestorMember",
     "presentation": [
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investor [Member]",
        "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value."
       }
      }
     },
     "auth_ref": [
      "r910",
      "r911"
     ]
    },
    "GLMD_InvestorWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galmedpharma.com/20241231",
     "localname": "InvestorWarrantsMember",
     "presentation": [
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investor Warrants [Member]",
        "documentation": "Investor Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IsraelTaxAuthorityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IsraelTaxAuthorityMember",
     "presentation": [
      "http://galmedpharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Israel Tax Authority [Member]",
        "documentation": "Designated tax department of the government of Israel."
       }
      }
     },
     "auth_ref": []
    },
    "GLMD_IsraeliSubsidiaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galmedpharma.com/20241231",
     "localname": "IsraeliSubsidiaryMember",
     "presentation": [
      "http://galmedpharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Israeli Subsidiary [Member]",
        "documentation": "Israeli Subsidiary [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GLMD_IssuanceOfOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://galmedpharma.com/20241231",
     "localname": "IssuanceOfOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://galmedpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Issuance of ordinary shares, pre-funded warrants, and warrants net of issuance costs",
        "documentation": "Issuance of ordinary shares, pre-funded warrants, and warrants net of issuance costs.",
        "label": "IssuanceOfOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseExpirationDate1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseExpirationDate1",
     "presentation": [
      "http://galmedpharma.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease expiry date",
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsGross",
     "crdr": "debit",
     "calculation": {
      "http://galmedpharma.com/role/ScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold improvements",
        "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://galmedpharma.com/role/ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r434"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://galmedpharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://galmedpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r433"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://galmedpharma.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r428"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://galmedpharma.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r104",
      "r491",
      "r672",
      "r826",
      "r849",
      "r907"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://galmedpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and stockholders\u2019 equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://galmedpharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      },
      "http://galmedpharma.com/role/ScheduleOfBalanceSheetsDetails": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/BalanceSheets",
      "http://galmedpharma.com/role/ScheduleOfBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "verboseLabel": "Current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r131",
      "r161",
      "r242",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r384",
      "r387",
      "r388",
      "r412",
      "r672",
      "r860",
      "r914",
      "r915"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://galmedpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://galmedpharma.com/role/ScheduleOfBalanceSheetsDetails": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/ScheduleOfBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current liabilities",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r52",
      "r53",
      "r54",
      "r55",
      "r161",
      "r242",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r384",
      "r387",
      "r388",
      "r412",
      "r860",
      "r914",
      "r915"
     ]
    },
    "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
     "presentation": [
      "http://galmedpharma.com/role/OtherReceivables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Receivables",
        "documentation": "The entire disclosure for claims held for amounts due to entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses."
       }
      }
     },
     "auth_ref": [
      "r425",
      "r837"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://galmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "presentation": [
      "http://galmedpharma.com/role/RelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long term loan",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r102",
      "r280",
      "r284",
      "r650",
      "r651",
      "r671",
      "r925"
     ]
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://galmedpharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r264",
      "r265",
      "r266",
      "r269",
      "r344",
      "r649",
      "r856",
      "r857"
     ]
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://galmedpharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Table]",
        "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation."
       }
      }
     },
     "auth_ref": [
      "r264",
      "r265",
      "r266",
      "r269",
      "r344",
      "r649",
      "r856",
      "r857"
     ]
    },
    "us-gaap_MachineryAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MachineryAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://galmedpharma.com/role/ScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Medical equipment",
        "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "GLMD_MalteseSubsidiaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galmedpharma.com/20241231",
     "localname": "MalteseSubsidiaryMember",
     "presentation": [
      "http://galmedpharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maltese Subsidiary [Member]",
        "documentation": "Maltese Subsidiary [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://galmedpharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable debt securities",
        "documentation": "Amount of investment in marketable security, classified as current."
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesPolicy",
     "presentation": [
      "http://galmedpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Marketable debt securities",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment classified as marketable security."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesTextBlock",
     "presentation": [
      "http://galmedpharma.com/role/MarketableDebtSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Marketable Debt Securities",
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets."
       }
      }
     },
     "auth_ref": []
    },
    "cyd_MaterialCybersecurityIncidentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r736",
      "r737"
     ]
    },
    "cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r736",
      "r738"
     ]
    },
    "cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r736",
      "r739"
     ]
    },
    "cyd_MaterialCybersecurityIncidentNatureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentNatureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Nature [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r736",
      "r739"
     ]
    },
    "cyd_MaterialCybersecurityIncidentScopeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentScopeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Scope [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r736",
      "r739"
     ]
    },
    "cyd_MaterialCybersecurityIncidentTimingTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentTimingTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Timing [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r736",
      "r739"
     ]
    },
    "GLMD_MaximumAmountOfSharesToBeIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://galmedpharma.com/20241231",
     "localname": "MaximumAmountOfSharesToBeIssued",
     "crdr": "credit",
     "presentation": [
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate offering price",
        "documentation": "The maximum number of shares to be issued in the offering."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://galmedpharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://galmedpharma.com/role/ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentDetails",
      "http://galmedpharma.com/role/SignificantAccountingPoliciesDetailsNarrative",
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r265",
      "r266",
      "r267",
      "r268",
      "r306",
      "r344",
      "r404",
      "r476",
      "r513",
      "r515",
      "r523",
      "r545",
      "r546",
      "r604",
      "r610",
      "r613",
      "r614",
      "r622",
      "r628",
      "r629",
      "r647",
      "r652",
      "r657",
      "r664",
      "r665",
      "r669",
      "r670",
      "r675",
      "r862",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name"
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://galmedpharma.com/role/ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentDetails",
      "http://galmedpharma.com/role/SignificantAccountingPoliciesDetailsNarrative",
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r265",
      "r266",
      "r267",
      "r268",
      "r306",
      "r344",
      "r404",
      "r476",
      "r513",
      "r515",
      "r523",
      "r545",
      "r546",
      "r604",
      "r610",
      "r613",
      "r614",
      "r622",
      "r628",
      "r629",
      "r647",
      "r652",
      "r657",
      "r664",
      "r665",
      "r669",
      "r675",
      "r862",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "GLMD_MonthlyDepositsOfEmployeesPercentageOnMonthlySalary": {
     "xbrltype": "percentItemType",
     "nsuri": "http://galmedpharma.com/20241231",
     "localname": "MonthlyDepositsOfEmployeesPercentageOnMonthlySalary",
     "presentation": [
      "http://galmedpharma.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Monthly deposits percentage",
        "documentation": "Collection of monthly deposits from the employees on their monthly salary for severance pay."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "us-gaap_MutualFundMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MutualFundMember",
     "presentation": [
      "http://galmedpharma.com/role/ScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails",
      "http://galmedpharma.com/role/ScheduleOfMarketableDebtSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mutual Fund [Member]",
        "documentation": "Regulated investment instrument that pools funds from multiple investors to invest principally in a portfolio of securities and money market instruments to match the investment objective."
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://galmedpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r156"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://galmedpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flow from financing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://galmedpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r156"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://galmedpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flow from investing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://galmedpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r79",
      "r80"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://galmedpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flow from operating activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://galmedpharma.com/role/StatementsOfComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      },
      "http://galmedpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://galmedpharma.com/role/StatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://galmedpharma.com/role/ScheduleOfStatementOfOperationsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/ScheduleOfStatementOfOperationsDetails",
      "http://galmedpharma.com/role/StatementsOfCashFlows",
      "http://galmedpharma.com/role/StatementsOfChangesInStockholdersEquity",
      "http://galmedpharma.com/role/StatementsOfComprehensiveLoss",
      "http://galmedpharma.com/role/StatementsOfOperations",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Net loss",
        "negatedLabel": "Net loss",
        "label": "Net loss",
        "verboseLabel": "Net loss for the year",
        "terseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r80",
      "r109",
      "r129",
      "r143",
      "r145",
      "r150",
      "r161",
      "r166",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r175",
      "r176",
      "r180",
      "r242",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r376",
      "r380",
      "r398",
      "r412",
      "r499",
      "r575",
      "r596",
      "r597",
      "r688",
      "r860"
     ]
    },
    "GLMD_NewAccountingPronouncementsNotYetEffectivePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://galmedpharma.com/20241231",
     "localname": "NewAccountingPronouncementsNotYetEffectivePolicyTextBlock",
     "presentation": [
      "http://galmedpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting pronouncements not yet effective"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://galmedpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recently adopted accounting pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "GLMD_NewSalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galmedpharma.com/20241231",
     "localname": "NewSalesAgreementMember",
     "presentation": [
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Sales Agreement [Member]",
        "documentation": "New Sales Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://galmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://galmedpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash investing and financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://galmedpharma.com/role/ScheduleOfStatementOfOperationsDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/ScheduleOfStatementOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial expenses, net",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://galmedpharma.com/role/SegmentReportingDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of reportable segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r639",
      "r646",
      "r832"
     ]
    },
    "GLMD_OfficeFurnitureAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galmedpharma.com/20241231",
     "localname": "OfficeFurnitureAndEquipmentMember",
     "presentation": [
      "http://galmedpharma.com/role/ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office Furniture and Equipment [Member]",
        "documentation": "Office Furniture and Equipment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GLMD_OfficersAndDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galmedpharma.com/20241231",
     "localname": "OfficersAndDirectorsMember",
     "presentation": [
      "http://galmedpharma.com/role/RelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Officers And Directors [Member]",
        "documentation": "Officers And Directors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GLMD_OnkaiIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galmedpharma.com/20241231",
     "localname": "OnkaiIncMember",
     "presentation": [
      "http://galmedpharma.com/role/InvestmentInAssociateDetailsNarrative",
      "http://galmedpharma.com/role/ScheduleOfBalanceSheetsDetails",
      "http://galmedpharma.com/role/ScheduleOfStatementOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Onkai Inc [Member]",
        "documentation": "Onkai Inc [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://galmedpharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      },
      "http://galmedpharma.com/role/ScheduleOfStatementOfOperationsDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/ScheduleOfStatementOfOperationsDetails",
      "http://galmedpharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating loss",
        "label": "Total operating loss",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://galmedpharma.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r909"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://galmedpharma.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://galmedpharma.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://galmedpharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/BalanceSheets",
      "http://galmedpharma.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease right-of-use assets",
        "verboseLabel": "Operating lease right of use assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://galmedpharma.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset."
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://galmedpharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating loss carry forwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://galmedpharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://galmedpharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Disclosure of information about operating loss carryforward. Includes, but is not limited to, tax authority, amount and expiration date of operating loss carryforward, and likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "us-gaap_OperationsCommencedDate1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperationsCommencedDate1",
     "presentation": [
      "http://galmedpharma.com/role/GeneralDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Date of commenced operations",
        "documentation": "Date the operations of the entity commenced, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OptionIndexedToIssuersEquityEquityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OptionIndexedToIssuersEquityEquityAxis",
     "presentation": [
      "http://galmedpharma.com/role/SummaryOfStatusOfCompanysOptionPlansAndChangesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Indexed to Issuer's Equity [Axis]",
        "documentation": "Information by type of options indexed to an issuer's equity."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r38",
      "r39",
      "r97"
     ]
    },
    "us-gaap_OptionIndexedToIssuersEquityEquityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OptionIndexedToIssuersEquityEquityTable",
     "presentation": [
      "http://galmedpharma.com/role/SummaryOfStatusOfCompanysOptionPlansAndChangesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Indexed to Issuer's Equity, Equity [Table]",
        "documentation": "Disclosure of information about option contract issued and indexed to equity, classified as equity. Includes, but is not limited to, strike price, number of shares, indexed share, and settlement date."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r38",
      "r39",
      "r97"
     ]
    },
    "us-gaap_OptionIndexedToIssuersEquityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OptionIndexedToIssuersEquityLineItems",
     "presentation": [
      "http://galmedpharma.com/role/SummaryOfStatusOfCompanysOptionPlansAndChangesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Indexed to Issuer's Equity [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OptionIndexedToIssuersEquityTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OptionIndexedToIssuersEquityTypeDomain",
     "presentation": [
      "http://galmedpharma.com/role/SummaryOfStatusOfCompanysOptionPlansAndChangesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OptionMember",
     "presentation": [
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Held [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific commodity, or financial or equity instrument, at a specified price during a specified period (an American option) or at a specified date (a European option) which were purchased or otherwise acquired, excluding options written (for which a premium was received)."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r563",
      "r568",
      "r585",
      "r591",
      "r619",
      "r620",
      "r621",
      "r680",
      "r681"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://galmedpharma.com/role/General"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r94",
      "r524",
      "r525"
     ]
    },
    "us-gaap_OtherAssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetImpairmentCharges",
     "crdr": "debit",
     "calculation": {
      "http://galmedpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Associate",
        "documentation": "The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value."
       }
      }
     },
     "auth_ref": [
      "r824",
      "r851"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://galmedpharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan to associate",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "us-gaap_OtherCommitment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitment",
     "crdr": "credit",
     "presentation": [
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitment amount",
        "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossTaxAbstract",
     "presentation": [
      "http://galmedpharma.com/role/StatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive loss:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://galmedpharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrealized gain from marketable debt securities",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r142",
      "r240"
     ]
    },
    "us-gaap_OtherExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherExpenses",
     "crdr": "debit",
     "presentation": [
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation expense",
        "documentation": "Amount of expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r70"
     ]
    },
    "us-gaap_OtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://galmedpharma.com/role/ScheduleOfOtherPayablesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/ScheduleOfOtherPayablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other Payables",
        "label": "Other Liabilities",
        "documentation": "Amount of liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r485",
      "r549",
      "r550",
      "r690",
      "r926",
      "r961"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://galmedpharma.com/role/RelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Due to related parties",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r672"
     ]
    },
    "us-gaap_OtherLiabilitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://galmedpharma.com/role/OtherPayables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Payables",
        "documentation": "The entire disclosure for other liabilities."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r53",
      "r852"
     ]
    },
    "us-gaap_OtherLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesTableTextBlock",
     "presentation": [
      "http://galmedpharma.com/role/OtherPayablesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Other Payables",
        "documentation": "Tabular disclosure of other liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLoansPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLoansPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://galmedpharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other payables",
        "documentation": "Amount of long-term loans classified as other, payable within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r551",
      "r552"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://galmedpharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      },
      "http://galmedpharma.com/role/ScheduleOfFinancialIncomeNetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/ScheduleOfFinancialIncomeNetDetails",
      "http://galmedpharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Financial loss (income), net",
        "negatedTotalLabel": "Financial income net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "us-gaap_OtherNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://galmedpharma.com/role/ScheduleOfOtherPayablesDetails": {
       "parentTag": "us-gaap_OtherLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/ScheduleOfOtherPayablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other",
        "documentation": "Amount of long-term notes payable classified as other."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r102",
      "r925"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "us-gaap_OtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherReceivables",
     "crdr": "debit",
     "calculation": {
      "http://galmedpharma.com/role/ScheduleOfOtherReceivablesDetails": {
       "parentTag": "us-gaap_ReceivablesNetCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/ScheduleOfOtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other receivables",
        "label": "Other Receivables [Default Label]",
        "documentation": "Amount due from parties in nontrade transactions, classified as other."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r562",
      "r643",
      "r927"
     ]
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://galmedpharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other receivables",
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://galmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r720",
      "r731",
      "r745",
      "r771"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r723",
      "r734",
      "r748",
      "r774"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r723",
      "r734",
      "r748",
      "r774"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "auth_ref": [
      "r752"
     ]
    },
    "GLMD_PaymentsForInvestmentInAvailableForSaleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://galmedpharma.com/20241231",
     "localname": "PaymentsForInvestmentInAvailableForSaleSecurities",
     "crdr": "credit",
     "calculation": {
      "http://galmedpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Investment in available for sale securities,",
        "documentation": "Payments for investment in available for sale securities.",
        "label": "PaymentsForInvestmentInAvailableForSaleSecurities"
       }
      }
     },
     "auth_ref": []
    },
    "GLMD_PaymentsForProceedsFromInvestmentInAssociate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://galmedpharma.com/20241231",
     "localname": "PaymentsForProceedsFromInvestmentInAssociate",
     "crdr": "credit",
     "calculation": {
      "http://galmedpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Investment in Associate",
        "documentation": "payments for proceeds from investment in associate.",
        "label": "PaymentsForProceedsFromInvestmentInAssociate"
       }
      }
     },
     "auth_ref": []
    },
    "GLMD_PaymentsForProceedsFromInvestmentInConvertibleNote": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://galmedpharma.com/20241231",
     "localname": "PaymentsForProceedsFromInvestmentInConvertibleNote",
     "crdr": "credit",
     "calculation": {
      "http://galmedpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Investment in Convertible note",
        "documentation": "Payments for proceeds from investment in convertible note.",
        "label": "PaymentsForProceedsFromInvestmentInConvertibleNote"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForProceedsFromOtherDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForProceedsFromOtherDeposits",
     "crdr": "credit",
     "calculation": {
      "http://galmedpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Proceeds from (investment in) short-term deposits, net",
        "label": "Payments for (Proceeds from) Other Deposits",
        "documentation": "Amount of cash (inflow) outflow from deposits classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfDebtIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance costs",
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://galmedpharma.com/role/StatementsOfChangesInStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock issuance cost",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireBusinessesGross",
     "crdr": "credit",
     "calculation": {
      "http://galmedpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loan to associate",
        "label": "Payments to Acquire Businesses, Gross",
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r378"
     ]
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireInvestments",
     "crdr": "credit",
     "presentation": [
      "http://galmedpharma.com/role/InvestmentInAssociateDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment",
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://galmedpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "GLMD_PaymentsToRegulatoryMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://galmedpharma.com/20241231",
     "localname": "PaymentsToRegulatoryMilestones",
     "crdr": "debit",
     "presentation": [
      "http://galmedpharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to regulatory milestones",
        "documentation": "Payments to regulatory milestones."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r755"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r755"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://galmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://galmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "GLMD_PrefundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galmedpharma.com/20241231",
     "localname": "PrefundedWarrantsMember",
     "presentation": [
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prefunded Warrants [Member]",
        "documentation": "Prefunded Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://galmedpharma.com/role/ScheduleOfOtherReceivablesDetails": {
       "parentTag": "us-gaap_ReceivablesNetCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/ScheduleOfOtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r254",
      "r255",
      "r634"
     ]
    },
    "GLMD_ProceedsFinanceLeaseInterestExpenseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://galmedpharma.com/20241231",
     "localname": "ProceedsFinanceLeaseInterestExpenseIncome",
     "crdr": "debit",
     "calculation": {
      "http://galmedpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/StatementsOfCashFlows",
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance expenses (income)",
        "verboseLabel": "Finance expenses",
        "documentation": "Finance expenses (income)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "calculation": {
      "http://galmedpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of ordinary shares in at-the-market offering, net of issuance costs",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://galmedpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/StatementsOfCashFlows",
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of ordinary shares in relation to SEPA",
        "label": "Gross proceeds stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromOtherDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromOtherDebt",
     "crdr": "debit",
     "presentation": [
      "http://galmedpharma.com/role/InvestmentInAssociateDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from debt",
        "documentation": "Amount of cash inflow from debt classified as other."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "crdr": "debit",
     "calculation": {
      "http://galmedpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from sale of available for sale securities,",
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r153",
      "r208",
      "r239"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://galmedpharma.com/role/InvestmentInAssociateDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r204",
      "r477",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r632",
      "r653",
      "r674",
      "r675",
      "r676",
      "r677",
      "r679",
      "r858",
      "r859",
      "r863",
      "r928",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r957",
      "r958"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://galmedpharma.com/role/InvestmentInAssociateDetailsNarrative"
     ],
     "auth_ref": [
      "r204",
      "r477",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r632",
      "r653",
      "r674",
      "r675",
      "r676",
      "r677",
      "r679",
      "r858",
      "r859",
      "r863",
      "r928",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r957",
      "r958"
     ]
    },
    "GLMD_ProfessionalFeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galmedpharma.com/20241231",
     "localname": "ProfessionalFeeMember",
     "presentation": [
      "http://galmedpharma.com/role/ScheduleOfGeneralAndAdministrativeExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Professional Fees [Member]",
        "documentation": "Professional Fees [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "presentation": [
      "http://galmedpharma.com/role/GeneralDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit loss",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r143",
      "r145",
      "r155",
      "r161",
      "r166",
      "r172",
      "r175",
      "r176",
      "r242",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r376",
      "r380",
      "r382",
      "r385",
      "r386",
      "r398",
      "r412",
      "r481",
      "r498",
      "r537",
      "r575",
      "r596",
      "r597",
      "r659",
      "r660",
      "r689",
      "r820",
      "r860"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://galmedpharma.com/role/ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r434"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDepreciationMethodExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDepreciationMethodExtensibleEnumeration",
     "presentation": [
      "http://galmedpharma.com/role/ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Depreciation Method [Extensible Enumeration]",
        "documentation": "Indicates method of allocating cost over useful life in systematic and rational manner for property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r258"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://galmedpharma.com/role/PropertyAndEquipmentNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r121",
      "r124",
      "r125"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://galmedpharma.com/role/ScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Property and equipment, gross",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r133",
      "r495"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://galmedpharma.com/role/ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentDetails",
      "http://galmedpharma.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r434"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://galmedpharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://galmedpharma.com/role/ScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/BalanceSheets",
      "http://galmedpharma.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net",
        "totalLabel": "Net book value",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r434",
      "r482",
      "r495",
      "r672"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://galmedpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r121",
      "r124",
      "r493"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentSalvageValuePercentage",
     "presentation": [
      "http://galmedpharma.com/role/ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, depreciation, percentage",
        "documentation": "Stated as a percentage, the estimated or actual value of the asset at the end of its useful life or when it is no longer serviceable (cannot be used for its original purpose) divided by its [historical] capitalized cost."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://galmedpharma.com/role/PropertyAndEquipmentNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Property and Equipment",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://galmedpharma.com/role/ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r434"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://galmedpharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://galmedpharma.com/role/ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentDetails",
      "http://galmedpharma.com/role/SignificantAccountingPoliciesDetailsNarrative",
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r265",
      "r266",
      "r267",
      "r268",
      "r298",
      "r306",
      "r333",
      "r334",
      "r335",
      "r344",
      "r404",
      "r451",
      "r460",
      "r476",
      "r513",
      "r515",
      "r523",
      "r545",
      "r546",
      "r604",
      "r610",
      "r613",
      "r614",
      "r622",
      "r628",
      "r629",
      "r647",
      "r652",
      "r657",
      "r664",
      "r665",
      "r669",
      "r670",
      "r675",
      "r682",
      "r854",
      "r862",
      "r903",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://galmedpharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://galmedpharma.com/role/ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentDetails",
      "http://galmedpharma.com/role/SignificantAccountingPoliciesDetailsNarrative",
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "auth_ref": [
      "r265",
      "r266",
      "r267",
      "r268",
      "r298",
      "r306",
      "r333",
      "r334",
      "r335",
      "r344",
      "r404",
      "r451",
      "r460",
      "r476",
      "r513",
      "r515",
      "r523",
      "r545",
      "r546",
      "r604",
      "r610",
      "r613",
      "r614",
      "r622",
      "r628",
      "r629",
      "r647",
      "r652",
      "r657",
      "r664",
      "r665",
      "r669",
      "r670",
      "r675",
      "r682",
      "r854",
      "r862",
      "r903",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921"
     ]
    },
    "us-gaap_ReceivablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReceivablesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://galmedpharma.com/role/ScheduleOfOtherReceivablesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/ScheduleOfOtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Receivables, Net, Current",
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value."
       }
      }
     },
     "auth_ref": [
      "r672"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "auth_ref": [
      "r715",
      "r726",
      "r740",
      "r766"
     ]
    },
    "GLMD_RegulatoryAndOtherExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galmedpharma.com/20241231",
     "localname": "RegulatoryAndOtherExpensesMember",
     "presentation": [
      "http://galmedpharma.com/role/ScheduleOfResearchAndDevelopmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Regulatory And Other Expenses [Member]",
        "documentation": "Regulatory And Other Expenses [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RegulatoryAssetAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RegulatoryAssetAxis",
     "presentation": [
      "http://galmedpharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Regulatory Asset [Axis]",
        "documentation": "Information by type of regulatory asset."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r45",
      "r111"
     ]
    },
    "us-gaap_RegulatoryAssetDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RegulatoryAssetDomain",
     "presentation": [
      "http://galmedpharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate action of a regulator resulting in capitalization of costs incurred."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://galmedpharma.com/role/IncomeTaxesDetailsNarrative",
      "http://galmedpharma.com/role/RelatedPartiesDetailsNarrative",
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r305",
      "r439",
      "r440",
      "r486",
      "r492",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r572",
      "r574",
      "r603"
     ]
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "crdr": "debit",
     "presentation": [
      "http://galmedpharma.com/role/RelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related party transaction, expenses",
        "documentation": "Amount of transactions with related party during the financial reporting period."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r439"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://galmedpharma.com/role/RelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r578",
      "r579",
      "r582"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://galmedpharma.com/role/IncomeTaxesDetailsNarrative",
      "http://galmedpharma.com/role/RelatedPartiesDetailsNarrative",
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r305",
      "r439",
      "r440",
      "r486",
      "r492",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r572",
      "r574",
      "r603",
      "r913"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://galmedpharma.com/role/RelatedParties"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Parties",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r436",
      "r437",
      "r438",
      "r440",
      "r441",
      "r534",
      "r535",
      "r536",
      "r580",
      "r581",
      "r582",
      "r601",
      "r602"
     ]
    },
    "GLMD_RentAndOfficeMaintenanceFeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galmedpharma.com/20241231",
     "localname": "RentAndOfficeMaintenanceFeesMember",
     "presentation": [
      "http://galmedpharma.com/role/ScheduleOfGeneralAndAdministrativeExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rent And Office Maintenance Fees [Member]",
        "documentation": "Rent And Office Maintenance Fees [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepaymentsOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfDebt",
     "crdr": "credit",
     "presentation": [
      "http://galmedpharma.com/role/InvestmentInAssociateDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayments of debt",
        "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation."
       }
      }
     },
     "auth_ref": [
      "r823"
     ]
    },
    "us-gaap_ResearchAndDevelopmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock",
     "presentation": [
      "http://galmedpharma.com/role/ResearchAndDevelopmentExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Research and Development Expenses",
        "documentation": "Tabular disclosure of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements. Include also the amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others. Aggregation of similar arrangements by type may be appropriate. Include also the amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others. Aggregation of similar arrangements by type may be appropriate."
       }
      }
     },
     "auth_ref": [
      "r893",
      "r894"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://galmedpharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/IncomeTaxesDetailsNarrative",
      "http://galmedpharma.com/role/ScheduleOfResearchAndDevelopmentExpensesDetails",
      "http://galmedpharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development expenses",
        "verboseLabel": "Research and development expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r346",
      "r631",
      "r642",
      "r922"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://galmedpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and development expenses",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r345"
     ]
    },
    "GLMD_ResearchAndPreclinicalStudiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galmedpharma.com/20241231",
     "localname": "ResearchAndPreclinicalStudiesMember",
     "presentation": [
      "http://galmedpharma.com/role/ScheduleOfResearchAndDevelopmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research And Preclinical Studies [Member]",
        "documentation": "Research And Preclinical Studies [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
     "presentation": [
      "http://galmedpharma.com/role/ResearchAndDevelopmentExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expenses",
        "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r630"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r716",
      "r727",
      "r741",
      "r767"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r717",
      "r728",
      "r742",
      "r768"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r724",
      "r735",
      "r749",
      "r775"
     ]
    },
    "us-gaap_RestrictedCashCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashCurrent",
     "crdr": "debit",
     "calculation": {
      "http://galmedpharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/BalanceSheets",
      "http://galmedpharma.com/role/GeneralDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r813",
      "r825"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://galmedpharma.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://galmedpharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/BalanceSheets",
      "http://galmedpharma.com/role/GeneralDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "negatedLabel": "Retained earnings accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r87",
      "r490",
      "r520",
      "r522",
      "r532",
      "r555",
      "r672"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://galmedpharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r163",
      "r164",
      "r165",
      "r167",
      "r172",
      "r174",
      "r176",
      "r243",
      "r244",
      "r257",
      "r365",
      "r366",
      "r373",
      "r374",
      "r375",
      "r377",
      "r379",
      "r380",
      "r389",
      "r391",
      "r392",
      "r394",
      "r396",
      "r427",
      "r429",
      "r517",
      "r519",
      "r538",
      "r963"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://galmedpharma.com/role/FinancialIncomeNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial income, net",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "GLMD_SalariesAndBenefitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galmedpharma.com/20241231",
     "localname": "SalariesAndBenefitsMember",
     "presentation": [
      "http://galmedpharma.com/role/ScheduleOfGeneralAndAdministrativeExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Salaries And Benefits [Member]",
        "documentation": "Salaries And Benefits [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GLMD_SalariesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galmedpharma.com/20241231",
     "localname": "SalariesMember",
     "presentation": [
      "http://galmedpharma.com/role/ScheduleOfResearchAndDevelopmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Salaries [Member]",
        "documentation": "Salaries [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative",
      "http://galmedpharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total consideration",
        "verboseLabel": "Commitment share,value",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative",
      "http://galmedpharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of stock",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share price",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "presentation": [
      "http://galmedpharma.com/role/OtherReceivablesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Other Receivables",
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r64"
     ]
    },
    "GLMD_ScheduleOfBalanceSheetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://galmedpharma.com/20241231",
     "localname": "ScheduleOfBalanceSheetsTableTextBlock",
     "presentation": [
      "http://galmedpharma.com/role/InvestmentInAssociateTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Balance Sheets"
       }
      }
     },
     "auth_ref": []
    },
    "GLMD_ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://galmedpharma.com/20241231",
     "localname": "ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentTableTextBlock",
     "presentation": [
      "http://galmedpharma.com/role/SignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Depreciation Rates for Property, Plant and Equipment",
        "documentation": "Schedule Of Depreciation Rates For Property Plant And Equipment [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://galmedpharma.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r658",
      "r895"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://galmedpharma.com/role/SignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Assets Measured at Fair Value on Recurring Basis",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r900",
      "r901"
     ]
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeByComponentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfOtherNonoperatingIncomeByComponentTextBlock",
     "presentation": [
      "http://galmedpharma.com/role/FinancialIncomeNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Financial Income, Net",
        "documentation": "Tabular disclosure of the detailed components of other nonoperating income. May include methodology, assumptions and amounts for: (a) dividends, (b) interest on securities, (c) profits on securities (net of losses), and (d) miscellaneous other income items."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://galmedpharma.com/role/ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentDetails",
      "http://galmedpharma.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r434"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://galmedpharma.com/role/RelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r41",
      "r578",
      "r579",
      "r582"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://galmedpharma.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Status of Company's Option Plans and Changes",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r11",
      "r91"
     ]
    },
    "GLMD_ScheduleOfStatementOfOperationsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://galmedpharma.com/20241231",
     "localname": "ScheduleOfStatementOfOperationsTableTextBlock",
     "presentation": [
      "http://galmedpharma.com/role/InvestmentInAssociateTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Statement of Operations"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://galmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r692"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://galmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r696"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://galmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r695"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://galmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r701"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://galmedpharma.com/role/SegmentReporting"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r186",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r195",
      "r196",
      "r197",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r639",
      "r640",
      "r641",
      "r642",
      "r644",
      "r645",
      "r646"
     ]
    },
    "GLMD_ServiceAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galmedpharma.com/20241231",
     "localname": "ServiceAgreementMember",
     "presentation": [
      "http://galmedpharma.com/role/RelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Service Agreement [Member]",
        "documentation": "Service Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GLMD_ServicesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galmedpharma.com/20241231",
     "localname": "ServicesAgreementMember",
     "presentation": [
      "http://galmedpharma.com/role/InvestmentInAssociateDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Services Agreement [Member]",
        "documentation": "Services Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://galmedpharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted stock unit options",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r324"
     ]
    },
    "GLMD_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://galmedpharma.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDescription",
     "presentation": [
      "http://galmedpharma.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Black scholes option pricing model",
        "documentation": "Share based compensation arrangement by share based payment award fair value assumptions."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r334"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Volatility rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r333"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Volatility rate, maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Volatility rate, minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r335"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free interest rate, maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free interest rate, minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "presentation": [
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share based compensation granted",
        "documentation": "Net number of non-option equity instruments granted to participants."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther",
     "presentation": [
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share based compensation subject to company shareholders",
        "documentation": "Other increase (decrease) in number of shares reserved for issuance under non-option equity instrument agreements that is not separately disclosed."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative",
      "http://galmedpharma.com/role/SummaryOfStatusOfCompanysOptionPlansAndChangesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Number of share options exercisable, Ending",
        "label": "Options, exercisable",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r314"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative",
      "http://galmedpharma.com/role/SummaryOfStatusOfCompanysOptionPlansAndChangesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted average exercise price, Options exercisable, Ending",
        "label": "Options granted",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r314"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://galmedpharma.com/role/SummaryOfStatusOfCompanysOptionPlansAndChangesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of share options, Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r318"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative",
      "http://galmedpharma.com/role/SummaryOfStatusOfCompanysOptionPlansAndChangesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of share options, Granted",
        "verboseLabel": "Options, granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r316"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average grant date fair value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r326"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options, intrinsic value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://galmedpharma.com/role/SummaryOfStatusOfCompanysOptionPlansAndChangesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of share options, Beginning",
        "periodEndLabel": "Number of share options, Ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r312",
      "r313"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://galmedpharma.com/role/SummaryOfStatusOfCompanysOptionPlansAndChangesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average exercise price, Beginning",
        "periodEndLabel": "Weighted average exercise price, Ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r312",
      "r313"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share based compensation vested",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://galmedpharma.com/role/SignificantAccountingPoliciesDetailsNarrative",
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r308",
      "r309",
      "r310",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://galmedpharma.com/role/SummaryOfStatusOfCompanysOptionPlansAndChangesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, Forfeited",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r318"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://galmedpharma.com/role/SummaryOfStatusOfCompanysOptionPlansAndChangesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, Granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r316"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://galmedpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting for stock-based compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r307",
      "r311",
      "r330",
      "r331",
      "r332",
      "r333",
      "r336",
      "r339",
      "r340",
      "r341",
      "r342"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharePrice",
     "presentation": [
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share price",
        "label": "Share Price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested",
     "crdr": "debit",
     "presentation": [
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate grant fair value",
        "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected life, term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r332"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contractual term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vest period",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock",
     "presentation": [
      "http://galmedpharma.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stockholders\u2019 equity",
        "label": "Shareholders' Equity and Share-Based Payments [Text Block]",
        "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP)."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r89"
     ]
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://galmedpharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, shares",
        "periodEndLabel": "Balance, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "GLMD_ShortTermDepositsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://galmedpharma.com/20241231",
     "localname": "ShortTermDepositsPolicyTextBlock",
     "presentation": [
      "http://galmedpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Short-term deposits",
        "label": "ShortTermDepositsPolicyTextBlock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://galmedpharma.com/role/GeneralDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable securities debt",
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r106",
      "r817"
     ]
    },
    "GLMD_ShorttermLeaseObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://galmedpharma.com/20241231",
     "localname": "ShorttermLeaseObligation",
     "crdr": "credit",
     "calculation": {
      "http://galmedpharma.com/role/ScheduleOfOtherPayablesDetails": {
       "parentTag": "us-gaap_OtherLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/ScheduleOfOtherPayablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-term lease obligation",
        "documentation": "Short term lease obligation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://galmedpharma.com/role/SignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r160"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://galmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r699"
     ]
    },
    "GLMD_StandbyEquityPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galmedpharma.com/20241231",
     "localname": "StandbyEquityPurchaseAgreementMember",
     "presentation": [
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Standby Equity Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://galmedpharma.com/role/StatementsOfChangesInStockholdersEquity",
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r57",
      "r61",
      "r62",
      "r128",
      "r148",
      "r149",
      "r150",
      "r163",
      "r164",
      "r165",
      "r167",
      "r172",
      "r174",
      "r176",
      "r187",
      "r243",
      "r244",
      "r257",
      "r288",
      "r365",
      "r366",
      "r373",
      "r374",
      "r375",
      "r377",
      "r379",
      "r380",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r396",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r427",
      "r429",
      "r435",
      "r500",
      "r517",
      "r518",
      "r519",
      "r538",
      "r598"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://galmedpharma.com/role/InvestmentInAssociateDetailsNarrative",
      "http://galmedpharma.com/role/ScheduleOfBalanceSheetsDetails",
      "http://galmedpharma.com/role/ScheduleOfGeneralAndAdministrativeExpensesDetails",
      "http://galmedpharma.com/role/ScheduleOfResearchAndDevelopmentExpensesDetails",
      "http://galmedpharma.com/role/ScheduleOfStatementOfOperationsDetails",
      "http://galmedpharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r164",
      "r165",
      "r187",
      "r429",
      "r477",
      "r526",
      "r539",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r554",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r563",
      "r564",
      "r565",
      "r566",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r574",
      "r576",
      "r577",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r598",
      "r683"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://galmedpharma.com/role/InvestmentInAssociateDetailsNarrative",
      "http://galmedpharma.com/role/ScheduleOfBalanceSheetsDetails",
      "http://galmedpharma.com/role/ScheduleOfGeneralAndAdministrativeExpensesDetails",
      "http://galmedpharma.com/role/ScheduleOfResearchAndDevelopmentExpensesDetails",
      "http://galmedpharma.com/role/ScheduleOfStatementOfOperationsDetails",
      "http://galmedpharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r164",
      "r165",
      "r187",
      "r207",
      "r429",
      "r477",
      "r526",
      "r539",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r554",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r563",
      "r564",
      "r565",
      "r566",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r574",
      "r576",
      "r577",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r598",
      "r683"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r719",
      "r730",
      "r744",
      "r770"
     ]
    },
    "GLMD_StockBasedCompensationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galmedpharma.com/20241231",
     "localname": "StockBasedCompensationMember",
     "presentation": [
      "http://galmedpharma.com/role/ScheduleOfGeneralAndAdministrativeExpensesDetails",
      "http://galmedpharma.com/role/ScheduleOfResearchAndDevelopmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Based Compensation [Member]",
        "documentation": "Stock Based Compensation [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "presentation": [
      "http://galmedpharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of ordinary shares in relation to SEPA, shares",
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r57",
      "r87"
     ]
    },
    "GLMD_StockIssuedDuringPeriodSharesExerciseOfWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://galmedpharma.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesExerciseOfWarrants",
     "presentation": [
      "http://galmedpharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of Warrants, shares",
        "documentation": "Exercise of warrants, shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://galmedpharma.com/role/StatementsOfChangesInStockholdersEquity",
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of ordinary shares in at-the-market (\"ATM\") offering, net of issuance costs, shares",
        "verboseLabel": "Issuance of shares",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r56",
      "r57",
      "r87",
      "r531",
      "r598",
      "r626"
     ]
    },
    "GLMD_StockIssuedDuringPeriodSharesOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://galmedpharma.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts",
     "presentation": [
      "http://galmedpharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of ordinary shares, pre-funded warrants, and warrants net of issuance costs, shares",
        "documentation": "Stock issued during period shares ordinary shares prefunded warrants and warrants net of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesOther",
     "presentation": [
      "http://galmedpharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of SEPA Commitment Shares, shares",
        "documentation": "Number of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://galmedpharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of RSUs, shares",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r87"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "crdr": "credit",
     "presentation": [
      "http://galmedpharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of ordinary shares in relation to SEPA",
        "documentation": "Value of stock issued pursuant to acquisitions during the period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r57",
      "r61",
      "r62",
      "r87"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://galmedpharma.com/role/InvestmentInAssociateDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value conversion",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r57",
      "r61",
      "r62",
      "r87"
     ]
    },
    "GLMD_StockIssuedDuringPeriodValueExerciseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://galmedpharma.com/20241231",
     "localname": "StockIssuedDuringPeriodValueExerciseOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://galmedpharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of Warrants",
        "documentation": "Exercise of warrants, value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://galmedpharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of ordinary shares in ATM offering net of issuance costs of $2",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r56",
      "r57",
      "r87",
      "r538",
      "r598",
      "r626",
      "r689"
     ]
    },
    "GLMD_StockIssuedDuringPeriodValueOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://galmedpharma.com/20241231",
     "localname": "StockIssuedDuringPeriodValueOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://galmedpharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of ordinary shares, pre-funded warrants, and warrants net of issuance costs of $756 thousand",
        "documentation": "Stock issued during period value ordinary shares prefunded warrants and warrants net of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueOther",
     "crdr": "credit",
     "presentation": [
      "http://galmedpharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of SEPA Commitment Shares",
        "documentation": "Value of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "crdr": "credit",
     "presentation": [
      "http://galmedpharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of RSUs",
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r56",
      "r57",
      "r87"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://galmedpharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      },
      "http://galmedpharma.com/role/ScheduleOfBalanceSheetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://galmedpharma.com/role/BalanceSheets",
      "http://galmedpharma.com/role/ScheduleOfBalanceSheetsDetails",
      "http://galmedpharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "negatedTotalLabel": "Equity",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r61",
      "r62",
      "r82",
      "r556",
      "r573",
      "r599",
      "r600",
      "r672",
      "r690",
      "r826",
      "r849",
      "r907",
      "r963"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://galmedpharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityReverseStockSplit",
     "presentation": [
      "http://galmedpharma.com/role/BalanceSheetsParenthetical",
      "http://galmedpharma.com/role/StatementsOfChangesInStockholdersEquityParenthetical",
      "http://galmedpharma.com/role/StatementsOfOperationsParenthetical",
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reverse stock split",
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://galmedpharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r424",
      "r443"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://galmedpharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r424",
      "r443"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://galmedpharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r424",
      "r443"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://galmedpharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r424",
      "r443"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://galmedpharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r424",
      "r443"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://galmedpharma.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r442",
      "r444"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://galmedpharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r763"
     ]
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://galmedpharma.com/role/InvestmentInAssociateDetailsNarrative",
      "http://galmedpharma.com/role/ScheduleOfBalanceSheetsDetails",
      "http://galmedpharma.com/role/ScheduleOfStatementOfOperationsDetails",
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r838",
      "r912"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://galmedpharma.com/role/InvestmentInAssociateDetailsNarrative",
      "http://galmedpharma.com/role/ScheduleOfBalanceSheetsDetails",
      "http://galmedpharma.com/role/ScheduleOfStatementOfOperationsDetails",
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r755"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://galmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://galmedpharma.com/role/ScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails",
      "http://galmedpharma.com/role/ScheduleOfMarketableDebtSecuritiesDetails",
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r283",
      "r286",
      "r395",
      "r411",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r501",
      "r661",
      "r662",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r673",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r845",
      "r846",
      "r847",
      "r848",
      "r899",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "GLMD_TwoThousandAndTwentySalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://galmedpharma.com/20241231",
     "localname": "TwoThousandAndTwentySalesAgreementMember",
     "presentation": [
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative",
      "http://galmedpharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand And Twenty Sales Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://galmedpharma.com/role/InvestmentInAssociateDetailsNarrative",
      "http://galmedpharma.com/role/RelatedPartiesDetailsNarrative",
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative",
      "http://galmedpharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r381"
     ]
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://galmedpharma.com/role/ScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails",
      "http://galmedpharma.com/role/ScheduleOfMarketableDebtSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Treasury Securities [Member]",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r636",
      "r654",
      "r656",
      "r661",
      "r923"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r782"
     ]
    },
    "GLMD_UpfrontLicenseFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://galmedpharma.com/20241231",
     "localname": "UpfrontLicenseFee",
     "crdr": "debit",
     "presentation": [
      "http://galmedpharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Upfront license fee",
        "documentation": "Upfront License Fee."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://galmedpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r29",
      "r118",
      "r119",
      "r122",
      "r123"
     ]
    },
    "us-gaap_WarrantExercisePriceIncrease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantExercisePriceIncrease",
     "presentation": [
      "http://galmedpharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exercise price of warrants",
        "label": "Warrant, Exercise Price, Increase",
        "documentation": "Per share increase in exercise price of warrant. Excludes change due to standard antidilution provision."
       }
      }
     },
     "auth_ref": [
      "r287"
     ]
    },
    "GLMD_WarrantsNetOfIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://galmedpharma.com/20241231",
     "localname": "WarrantsNetOfIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://galmedpharma.com/role/StatementsOfChangesInStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants net of issuance costs",
        "documentation": "Warrants net of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://galmedpharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average number of shares outstanding used in computing net loss per share, diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r183"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://galmedpharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average number of shares outstanding used in computing net loss per share, basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r183"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://galmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r801"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "63",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-63"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "710",
   "SubTopic": "10",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483070/710-10-25-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-4"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "320",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-5"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "980",
   "SubTopic": "340",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478742/980-340-50-2"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "980",
   "SubTopic": "715",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478574/980-715-50-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "83",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480647/815-10-15-83"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-3"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "980",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477711/980-340-25-1"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "980",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478742/980-340-50-1"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "980",
   "SubTopic": "405",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477571/980-405-25-1"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "980",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479068/980-740-25-1"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "980",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479068/980-740-25-2"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-11"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "12",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-12"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/985-20/tableOfContent"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-17"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 6-K",
   "Section": "General Instruction",
   "Subsection": "B"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05",
   "Subsection": "Instruction",
   "Paragraph": "2"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05",
   "Subsection": "a"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "321",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/321/tableOfContent"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "325",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/325/tableOfContent"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/310-10/tableOfContent"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405/tableOfContent"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>92
<FILENAME>0001641172-25-002362-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001641172-25-002362-xbrl.zip
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M!^DPF-._!49GE]% T_-90/^O)],XG4]H"L$LRL?!/U4\T6%P,E:T,0-=Y-%
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MH3*$T644DBEF H0_.8 FC\'DCB3[ AH-*1>+N5G\^YIV@9<KM63(5S$\:XS
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M.,U!*@JO.! JXW&"_/DK#F]%900K_L1M_-((R:WPH'5H&K+E,])_#"=?D'5
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M*2BD_<M1=5/$N;$5ABJ>F\B _OY(JQCQ+#+>/6'W0M]2/M$.U"*Z8$#:X\@
MW15$#)!9Z@<)W*!J\&<1N319^C/=MS)M]F4P2B]UED!SXM7A$CE$LY?!(%:D
M<]F"+V#P%71A!7Q.]"$C17I)1.-66<R/3GIOTH)Z)$(!-@0JR?E=4%*$D '=
M2Q#319+.H*E;S_XBV?2US]/<+95(A(N5*8=GN&H8CVVS-"=V2@HP_6.FYD:*
M*I%/7I;M#ND"=L1TX'I9X7N.W?@C6P7:LB4+J?0G2M2B8026W8UA!HS&9:4I
MJ\RUY(IE6\@K\78+7^(Y#K.R9 D>^S#\)7I5V,U.:63T24X,(U[*F$[; *Y5
MRBW;K66>I4Q]LS/VYE7%AU>5R_+&^? TJT%IZJ)5]HXD3V0NYN#;L-72H@\
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MIXZE6K<"<C==1D")6 L&7'V8)YC8["IBJ1.P;Q6,R :>X@>7X2.F>I%SJ'_
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M)->$5I-.ZNDD9;:$ POE(DF',%4YR6$\B559@]%8=35+<'>&XEM-%$OVSI+
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M?J;H ^!(<6JXR]-67IYVE;J^(NZ7 QX9"61$6BX2TFZ%:"\US="KS.U;E@K
M@_[LH5&&Z:#@9')G9)6U!NYQ6=0C$-7W'[Z0Z,7!T>EY[VWOH&EOOFW&5I5K
M #=")PB)X#M69\^+3$1?63H!XXOSIZ5D'3X-A]_IU4J$BPKY4JQ2RO@DHKH
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M1LS-,IY.9#R4GR%[/L"-.>E!JF:(4TN66X6RD'./GHSK1DCLA'H0"<*,@UQ
MYXABSDR>\_U<Y&R^'W1+(*.9%M$0:L%7<MA&L#,LY$HL&0 J20#O6Q917+&
M?8GPUEK\L(OI4L6%LE4XM*5J5$+(K\HC8)CF>A(X8_LXF)GOBO3Z381/ V'@
M3_=.$ SN/E#['[_^_,NO]3:T#Q#'(-,CE$"EV9J(:;9BS_H9EKOMWD?!_C.<
M48/BV-#A%M*AH8&YD#)9$ZQ/+$HCT$HB?SM> Q()E' .S9-:9Y*RMHDE>/7[
M"+F<R4 W)-V0=$/27T724GZZ#C&;*9GHC31M2*\AO:^:IA6*ZZJT $L #'!E
M@S:DV)!B0XK?P\!TG:XD_3O3?TC=R&,5CIN_KC5Z=CQ[UF2L;TW&^@9>U48H
M-D+QGDW#(EQ7'J+Z5IO<]^C0?U4\-]%C%8H-1384>4?3Y*:HZU$D&8J</#1#
M^G89I&7]@+0&92&E@$&7Z QH(8PN%T<#M$E>*&)L"+@AX(: OTL 9:*SD: ?
M#?XL(A-9NLUTFHU4$OW;$7(8F6EJ_YIK+HS1.9/T'VF4Y $@&( 9^1*2N2'G
MAIP;<OX>Y!PE Z1(:8%RU>X/%BA%31A?C<@W+7*3*VE9Y>,& )T@U/U<AXDV
MYMMT(GAPA+PQ28.]8;M5]KG/.:FRD*85DDOI$M[P#">S>2WS%H'F.K829VBA
M;-"H*.)D<R#/%<8@L8[+$1<ZN1V,(TWS>%O&T(^'='-U]FVSH)N<Y_H:;*ZA
M:VJE+)#,)B]IPXGU5>_UAWF[16H4BF*1^"E5QZ&%^7:=+U'CH)'/FDVM'<7.
MCID.TEGB"G&38#(/9*B2$.UXV7Z @LK5X%(.B:;=*BS^C"NIB-S8*"6Y<NPF
MR?K+5O$-DJR7SKI"_W2GSH+ 0?;;B[AT"7P4(?_)%??,E8[SN(*2VFX-2!H-
MBYAN<J8O(SVKP;R5!3PRV1N^P)G:TG"W:GNK7$^FN31!(8E$^N]8AHQ$V2%)
MR+7UKJ]3J(%#761@BI,TT_Z,@U>?7B=8!KI/R<-.7ZKO!3 A!Q8;<L9(>X!L
M2E'MY&JPEL5JNR6BF)%6[=M-?=##8@M'."YIO4ADE,$I-6CZ.'UO3MT#W"%Q
M$4@]%0SIU7&1A!EJP[GZ6P VT8T-N!F)91YY,$IMPU\S@4(\1.,.!I2>Z$9Z
M/406(B5"=(XHMT2G&.*Z*(=)BHG.2"YP$8P/="<8U)<:3;CXC,6N-5Z; )OP
M.TD3_?C8[8.^PK!9>UPD7"N4 LPJI+/4-X5I1<\BD2=SH^-A!^6]=*8E3*N#
MOQU&(R@) &TO\DY@4EO!3'?BHA-D $EOB/\A7N@:\9MT.D:+W@&7P\'J(7)'
M4B(Q@8G.Q^CUCN+Q"%.AJ8$9%$EA"K\T7.7$_"UN)OTXL*W7)[9N/D+;J8+$
M/<L/VVV*VT.5K?<8/FB:ZD31TF,]'>/&99HLLI!6TE?)A?3<8UQBY'Z4_8X1
M\>):>@7!$V/A-, @S](D&@!3NOQ9XM=S+GVE9XQ5<">*3,2QCJ?EE">*>R&
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M8430XG>02:L$3V0^8TOIY@".+43L/22]!7S3"?:Y@%C"IJL J!"'/03 NR\
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ML0SQ^KX^YCUAH$,?FL.79_I _0]02P,$%     @ LH""6I2=[_M:!P  @RX
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M&'2*^729\WFRU2BK>SPSFU>A[#H4($[14YZO=9:B 0C<6!K23&<!1.P:H@W
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MG.'")9?(K:WE-3JXDAGNJC+1N/CV8.QTN<#<#_-6LT6FH /XOMU2+2M4?T-
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M&;AV=6LUB"&$(  ;VT9R(LM,-SZ=I_]GCH=D_^F3',1[/B#-W=7(';BO<P3
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M*;>BXLUAL0*7G=F6P,DG,Y(F5(KFYBF:-*M%13*11-:4":DI\#.N70%<.YR
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M,O5LYW+D@I#"040AC+L5V21*_MQR]%)&B6ID4.SB)>IF=5'>G>)DGP&=40*
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M?)RF/TGO_=QEV%0^R,>7-!]4D@]6?HDU-[2D;.M791)4QR*HDH]9?'1H!MG
MTT%JA0[&N+IOXY\.UK.MSY8C.8^EY$C.>'6QFIG%_0:FZ;<O[-X>1^/Z2A':
MUU<H.4)J\-?,G-:F3*O%!%*9P@MVMKO[2IF>\[MKYKP:#WS.=->D3N5>K$Z=
M=F,CJYL]0_6VKSD'8'DSJ_LB&4,4I9,_I9+5QV//O0X]\WO]^>0ZA&7#KY_\
MB(!HF-O$<^'7()^FGIOS.F/X>\M&Z7+?6<D5L&:1=;)(]F)X;\7Q^_;!=O<P
M^4EO>R4T@]R-);WUS'=6X:W3"^KCN&7\V\SBK"(*KN6G*FIS=9N=&%1OMSL'
MR4_UD8F\ 8+4+VN I+^S$@,$7Z <FDN?#R+7XM8?##V < ,N$:ZC?F!;-O.G
MZ+M<#$AB4D[-G"FOSPA);_@+2-,C6[^A.G9%3+%I>KYV"DS !7O^Z]%?Q3-^
M=>JK>!E>I_9Z(DMHY55)Y:5Y^!7S<(5UJ^:^5ZJ\'DL]TIZ$]B0>C;A6+S]*
M^\.:BRMQ')?$C_$GZC#3;%II-EV&B&4RH]5WLFRPJ5)#UQ$)'@?LEFOUIV*O
M+B/?'+'@U>2\+C#W=5X:)4@<*ZF3:6]W.\NPP6:D<;X88RQ"3)5R2O.5FMW5
M5F4<"'@@^5--KRQS8KIX9L1*0':R&KX^2_HB>N_1>B!]$%;F(*RP+_P8D)5F
MHXJR4;4@*A9H&93W5B6#';'IF+EG@0-K'9S<\_$D_&R/;>G2N-P/1O:D_GQ6
M"2_R(69?8A^TZESH!'XEG*V9:C6UNYWM3@P^>\QA&:W75'HT?\;K\R%Q1U9G
MR>]155L[_BG6(S=WWLW(BP)8CYYKW=S!!*:OB146G?_:-(C<N:4TB-SC5=YN
M90ZC,]?$^=WRZQ'S^<4$H\>7H):[[<X&]"#&F9RS,<_<Z#\VX;5%Q%<,!M#=
M;G=5]2K\5%LP #F/I<1*SGAU8E6[)4UQ7FYQ5I)0=*"B"!CW2MR_*QZ$OFV"
MX4>^S5?7#H.KZZ_UUSR].^9;>'IE_;@'Y[O.F,'!\C$#VLF5AIZR3%,?V:KP
MXB8Y!?5:TNS5\<%*#TIXP6',>8=XB8PW@D<CFP_ 5S4CM!XDPEA]%=4#,(KX
MT0.S7:>:.GR")!VN]!9*L\B:622K&0Y7?*N&SGXW^4D;,I4R9.2N+!NS2W]G
M%8'@'-/4Y]2MX>+&$BE<^_H+X*.-V](3U9*WV+7CR7CB>%/.27EM"J?,4=5S
MYZJO5A9KO:&912<T/(H$J)FE"LQ2223 3LPL'<TL%6*6SA.8I?/R:2.4CFZ[
M2;;T9K)/48YX>M:/LLE&\FA-3"7-HZ^81VMBH6D>?<4\6A/#<*;T[/7PZ%+U
M8!O)HY6T1^?H4<VCKY-'*ZE'Y]BCFD=?)X]6RQ[-==W:2#ZL XNLHRNCWNSU
M;_;J\JKCU%^]V579[.[*-CN3E?HV^4EG %4J TCNRI)G?^8[JZK:T\EB:V>5
MF;J][NJ.A;S!IS>]$IO^LH:?WO3U;_H:>F_K[:^235"3.U3--%5BFDH&D1:.
M*QSNOMWO'JRK'K4<=A'S.7,M?L^M&^\L""+N!P(G1_R[VKYH=0(/FAO6SPTK
MCTP\(=E=\T45KBMJ9IX\PDV[.YJ;M-WRU,LOS4/K/ZE6%R1Y%!D/MM &9V#:
M<ZU3SQ]'#L/5N XCR^8;T&WHS#6],8\A'S][)LTO#8RWP KH@VHAA%K-3)5F
MIFJ=4W.3W30SU8&9*IF5-A^"G3G,?R5LDYVK/KH6 U?7#**/HX>.(\T@^HAY
MI,L'^)(?6< M1)2'16>;D8:V +L\,'-]_"S8VT,S3X68IV9'DV:>*C%/O8ZM
M*QYPYILC\#$O?6XZMFN;S'E%7O8""Z /L84.,<U*%6:E>AUIFI4JS$KU.N".
M7A_S%$Y9'V*+W6%I=M$'U1*W5)I=]&&TC+<UQ%L\C^[T+L(1]T_NT6]]'9SS
MV.SU$;6@GZ69J(),5*^#2S-1)9FH7L?9I>\->("+SYQ3SE\#YQ1.61]<"QU<
MFEWT$;7$$:7911]&3\CQ@Q/](W?YP Y?A2DS=]KZ4%HJ\T^SC3Z<GI /J-E&
M'U)+!0#=$%U.:MWXA=GP3>PUQN&P?Q7\\_C\];&U8!!0,U)%&:E>!YEFI,HR
M4KV.MC,WB'Q<N=<84'YD\OI06^A0TRQ401:JUW&F6:B"+%3)@VQ^C\BSP&?<
MN6'WO2@<>3[,>5.8)SVG<S;.P0+.F_?:^*:2[7GFXS1IOJD(WU3RR)J/%J?Y
MIB)\4TEK>:ZI\X4Y(0_X==0/;,MF_H9S#5DX<^:L+9N%_"O-,>OGF)J<39IC
M*L,QU3J5<OB2F\LG5]R!);,N8;6G-^!5!\Q$=SOX.$U_4BV^><G&&_GP+QES
M]JOF@#EKL'$<\*A'<\P'W/>Y%>O:HQ'SAYL0A$MEC@<!#[,.S</3U@=(FGGV
MMML[V_!?]5.L2&[NO)N1%P7,M7JN=7,'TYY>,X<'O:'/*?(IUBUF-A0W_B."
M#TYNXT_KS&/8L.-BT/-][#.+PZ14S**K\RBS+4-0;H5G&XH4;L':^%VRUE+\
M+IGP)?G]0?Z-"TS9=,S<L\"!#0].[OEX$GZVQ[8\?%SN!R-[4G^67Q&'E25U
M2^R"YOH7U/*O3$I>R\&P" D6M]]]YD/FG- &:F$M2U@[VB1[O9*W6GY?S@4I
ME]\CUQ;,_O7Z.,^)8\Z"R.<?[,#;[7;>OH-'U%#JH\SX.%;QX-?@\/%@WOAR
M\O3,$U\ I%T6O\2R;X'[9Q84OWD>C;F/3NL,KRT^]SQY!6.FWGC,76]LNX^\
M\]'UR+^T8%CU<7KZ"^S3CT$X;Y>BT'\7P.=/W*$SX+WAK+93H\A$'7KFB6^X
MA&<?9K$)_/A4\C]?KY;!X 6O@,%@EH]IF7D+D1_\%_O^G<]%\P<T78P!'-=7
M?!# P<W,$ _![L&6$7KR;YX7NE[(\>_[G:TWBPYQ^.PA#G<*A^AV]A<?8N_Y
M0[Q]_A#%:['$$-UVY_E#/'LYN^UG+V>W_>SE[+:?OYR=YR]GY_G+V7GZ<MY;
M]UT;Y1KLFG;A*+NP68L2LMN=,\3B<]DK5AG+#/'V^4,<S!W"R/QZN/"(A_LE
MC[C3??9B[^S,V_(EAEALI3KMA4?<76REEAAQ;[?LM=]__MJ_G;OV3R5J/HLM
M.L1N>^Y*+2XZ\^:UN*P<%&O5189(Z;.#>7NTW"C%ZGFIZ<Q;U"6TQ_,7];"4
M13TL95'G6&3+CO+L==W9G:>]EABBV(I8;BX[>T]?UU@G/7\Y]HL-B:6&>/Z*
M[LQ9BR4T_LX<!EM@B-2F[,Q9T25'F;.HRTQGCF9?YE2=HT&6&6*.!EEFB*>O
MJ#JBYHCLWO[;)39E=X[4+CG*')-YD5'4=/:*MW990HJ]H65'*65IYY@ARX[R
M]!FII3U\^G3D$'OMIV]P,I>].4[WLJ,4J\5E1RF6P*46I5BA+4O(T]E$;? <
MM;@'9] 2G+8SC].6&V4>LST^BEK7.=&RY0C9FQ,P6W*4.9[A,M.9<XSO[2]L
M">S-.<:3(=[0&($7^28/X"_TAQ%G%EX>_?+&LF\_-!J-7R9&$$X=_NO6P'/#
M=T:G/0F-&WO, ^.<WQE7WIBY3?&'IG'-?7OPWA@S?VB[[PQ\-/[_>P/O;[:9
M8P_A(Y.[(0;4_^L_.OOM][^\F7Q8^:OD2_[7]K9Q:G/'>F=<10[?OF1#;FQO
M?_@%)JS>+T;=#KT)C:Q>L]WWPM ;R[_=V58X0BK;_[F5^7;?\V$-Q;<_.LS\
M;NP"58'GV-9[0WZH1A*?=UI[R1,X^>W _C>'L2=ALD2X(?+?J3F\R4SB.8OX
MR'0+ES28,#?]ONT!&]O.]-UC;TS/L8V3_*4?S[,/L\1Q/\SABH.J3^A 3NCK
M^=G-R7'C^J9W<W*]0?.Z/CGZ>G5V<W9RW>B='QLG_SKZK7?^Z<0XNOCRY>SZ
M^NSB_/')=JL^V:Z<[!\,]*L[##VWV3AN';6,;GMO]_#Q"=9#[)3,;01?8D/U
MAA@1K^O@1/YVV#[YQBUN;V\?>V8TEED5WTS,AFYWVIUOW_"G3G>G\^W?XW_<
M[GW\>/@___[X%PP'9Z'KN71A:9N&S#Z T_377*9\Z"69U5LB\T8<P&V\67 9
MYKI@7E/Z_5L?NNWM4SIODW<D_/1Z6*N< _ZO* CMP;34XRC'11]S7'3%AW80
M^F1_Q>@=Q6RU<_5/_\^/UP$<UT]FJP%P-@M_W;+OPW=]SW,X<P?,"7B.X?:+
M&*Z05-R>P[>[N^_G,&$#Q.GJY-/9]<U5[P84ND&'V)>3\QOC\NO5]=<>_'!S
M8<!)0)]VNC_U?S8NKHR?AO"?4^/FMQ,C.262$Z)W=(,?=PYW=DMD\\6LOQHR
M]DK,K(LKO?25T"F=G$[IN6[$G"L^\?PYJN1?T71R\>?N'ZR]6Z8J"?THKTG>
M%FF2-(%2@>P_I$!ZY^=?>Y^-JY/+BZLY>F,'E49G[R=+JXWGT-[J[MGNZAF8
M3*Q&..+&P Y,YAA3SGR#NQ:WC,=.S$O*Z3P1"9_%[#WZ_=,/UPK__.W/42GL
M;>%A!]\;66R*E'(WQ^4'15R>(716:O?DO(XB'P8,3VDA_H31'YQ:__ZH^WW_
MH'?_J?RIS4SK,#VM>71N?3CFIDA%QI+ 0B%NSNQJ7F<EPY["7X+BR;=[@^#R
MQX]/X[_;I1C6W7;1ON5(V:**Q[DV]JI-[PU2+B]^,![E73:LT[;1?GWH</PR
M#(:[7\8W?S]^NV([N]LI=.QR5"YB8H-U?7Y]1D>A/B6U<?U:EOX%=,AI3H=<
MC[CC''EC>&KZD!:YF5[_]>6W+R=GGX:KUB+=(BTR2^<B>N3ZMY//GS'^>MD[
M_U.KDA<PN%_"WD8SK>$-#([%7H;/?T2V;[M#(QS9@1$@HP!+$J? A\@JQK?<
M/WKCUK)Q*4<IC*T"0U2UT4WMS$;E_C%0ZD+/@($>>5)'BZLV$]@ST-]CFUJ^
M-4YMAQOG7FO&DWHK#RA1ZHR/@5ZG\O?"8^G?[NWG^_O]2>_IQFWF\-E)'SYY
M&K *M[.]L[^SNZ<O*>IS_S4O!".V5]T#N"%BXQ6SV8GU.[NV_G7U#V]0#IOM
MSK)9EHZM#Y]ZG[^<'#<N?^M=?>D=G7R].3OJ?;XV/M\<MS:<^7ZQ/_QT<@]+
MU< U,N"D3];&8'#$3[B)=>^68<.VAH%ACI@/-/P,Z[(1"U!S9^_\3:^^UC$R
M'X4L1!(9VIEHKR0<^%__<=#MO'T?D  #!X(Y<N(.'3L8:?ZKW$S0!PRENY _
M!KJ98P!Q['QP%I+[X",O<D-_>N19<TZ%;GC1W9O:7>NL%)]X.^#F.VX-F3_Q
MO5M3O#T?Q.[NS9X<#Y*^]4$@-6Y<:!<%]>^1;P>6;2I)M=,K87@^_&_(7/O?
M]+L6S\K-I, X.\Y(9<^R?!X$\C^?;9=WBF4QVO]TYTZ'?_VQ=UB.A;8_*V<%
MQ&Q]Z.PW>OT^,WZS'8<[,&]F+7QKM%\TUR/X\<*_\>[<XIG^\^:W[U=O3[RO
MDY)LT;=S9YJ0LO7ABH&>,CXQ=^D[L>R00C,53^UT=_+UDWE]& 2\-(4J]2C.
M<$:7'LR?N?C6(\ISL2E?>D'(G/^Q)_-/DN&7_7_\\?W@[]&>6<Z>'LZ=68::
MK0][W;WV?OM@(T\'.6,\&"8^' WVA#D&O^=F%-JWZ%=@&\1 'PN5F\D#Q\(1
M/ M,?LG]P'-=[LSUV;_-"B)7JELAB,F'/D8!Z'(4>AI;XKO]N]]I_Y/]N#^Y
MW-]90BA3"-$P^+?"L;/"NI.YMB^:X-:''APN;N,C T>7#0:;[O_W/US"-A&^
M78.YEG$TLOG .(DE5S0P]3=HO@M9!H]:0<_G^4[G^N;'IPNO'7U?+<]W2C>O
M:GQ6S>[_WA,LP^?O_N7Y7[_=_'7;NQKNKW;WNXN;G(UE3,[B97O Y'S^FAU-
MOEO_Z/2.=J=[I:_9$K;L3L'%Q?-LV9.GV;+/7U'_T]$_[GK_N._<=U;+A05!
M^#4;R>L^ADZVQ\QVWLT4"^W-L;Y.\'&Y9JN2K]\._GYQNSLX^OLRKM$3N&'O
M(2LL/=&M#ZS_?X;,&7-K O;8F+5,;[SYO''#"QAC5S$&[J_/V0K5PN@L_'KW
M/W?_^OIYF53A)S!")O*3GMC6A__O\&VWM3-GKUOSC#CL7NQ<CCSWH:OLYR_0
MES_^-?S[N']T=+[B!<H$C/*3V_JP?[C3.MC=?07J\I3=OVL(GFC)6;_=F.G9
M'WY"W[/9 ,'G$]S@IB'.!P-\LC>>;P!#!/88$SE<VGK\NR%9%F]M9;J>(7G)
M$-I4QULJ-Q.\)0/?VK=#FP<-GZXZN<\MO$$)/://C=3?)I$?1'@3#Y_ M^BF
M1=0YRJO2GAFVZNN,%>UJR/K Y"9W'/BK:;O#7[?:6_3[A%F6^GWI^:6 ,F+\
M"]-S'#8)@!SU$T$K_Q+ZRX]_R_W0!NVL%DMPE(1J_B6T<K@<.>B-+/#&4C/:
MV?_/%U!/-W;H<)H+YH(R<V28#@N"C'H)K9G9+CX;N;GQPG12Z";=E<\PQX@%
M,RE]W[JKGQ7NF\]P66DVU]-QWW-^R@7A]:XM)6T'+[%K: MDA(W?FR/L$&*
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MP(Z:\'Y=T9$V4P8&#4+"D3H?.=U5YP Z"0GRBGBB"0PNI,980&I<3T'N@&2
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M6%CLEE*K>_AA2AXI3J)E? 2.BA[>D(00N8D-X@-2)[CQ4P[*U"1_ 5SU&?;
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M96KKE;'4,7PKSGN\>!)5I%-I"XB04:K+5R.6Q%10P;=O&5479!8\/BG)^&5
MG"^>)R'$6H3! ,[G#9?%AZL1.KH:H<1JA,XKK$;8O$#(2CJ-S@F(HPIV/'>X
M3<T<"YODR:NG>4%\HRB(WWAN$%\%' 88+$A"#>#/@"..QX6()P\$'EO*@2#+
MD,ZZ?GK"JFUBGBZ^1-Q7A_.J=-1<1'[C$<X5MC+BT0M_.=?I,06H)Y).4@&
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M6HPJ'+KKN5NZ[8)&]/1QAHG]\NHC+/;%UTV< ]_1]7+9M$ 45OMW%O\8-]5
M@VG[_"W73!SBRH5&X"0HMK-B^3IGQMO"=<NV7$!2%HW OAE1.[K%0^DCH@(
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MQ\7Y.$]H/R[*9M>Q4=59O?V6FQ;2)#5KV.!T\:XIP;C*7FEDO2%. @I":62
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M8:)YB0[7K Y)PL.X],UL<W,0!G3S;6@)68S(C-\EE?&F2N3);'^-=*_U0SE
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M#1V]?>F=(QHPL&:(?VLIYFJH[GD9]=W48D]F:K&/2"WVY#.D%KM_!\#'IP9
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ME)AR0/N16"/$1%2GF8U5N7*!>ZFF#=B[Y:9NJF9M[;)Q96BCV#58PUX]-KZ
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MBX#7%C]!T,;1Z>GAP/ -2!X0=AJQ6:OV;2)DGI]1C4S&YGIN_+_;_%=.=:_
M8<&S;(HO?GIG,1=YS8+.UKI6-CV:E3_HJ!DTWOE/'84BV.CCQ\"/,NYG#AO&
M6&>\E3F;8+==I=^Z93X(O2/];]-/2)NJM>9]SJGS_E!*%>LHR6K>+X\6^T?\
M'XDTC;&H)1:@-B5.HB&$$V)TC.+I/+]#57G;:W4 TS+^@!NM.;,WO'A];07_
M!T$1XUZ7L/H]U[UWIT2_FE.B'S$E^M6<$IU3HN_\H.M*D.')L<8[4G8'\7X]
M[8_Y*=VO(#8%!F]<!"$9#5*/1AHWY< !LQHQR1Q@X8X#D[YX'CYJQ0$U/K1/
M%F", +V*^#L"T69)U,LAKM?-WC\X<**0'WG4#RC"C^(J=Q;A8VEBM%!I_'LQ
M@W@],9[1FB[VP1*+>I$B$NH[HRE2'X3$(+92XJ+,(BVCN%K4HUGA0DQ@^;Z,
M 2.ZWF2TQ''I-9@0-YQQ:^HQ\&\*0<[92:E8J*J3:"ESMD(-]]!IW?H)<]2B
M-@R).LA@3WPE1T7N^7E_.8I="$)>]#YG!U@EN,M[;<:CH4=I[,<U.%4ZW72C
M/&(M&#?'@1',4=!C@$2@*TC4O1]S#@@(MW0SA>*Y"7^4/H.D0#*.&%X\7W/J
M27Y5!Q^PR(2H8=S44EB\E(AC6O0X:J2T&ZJ_QJ)H\H-'3 M>.BEXB*D';,![
M[(WIQIX?8V>()7$\OO_^@'T4!4Y.$'[$%'G;G-U*#0V/D.0 0Q3.%+\+#;A\
M$ \O3 P:%1S[\3Q(+<Y5>HWA;)'VZ5NE3IDH, IT14)YW3EII,!'?N?C%7AR
M/"W)\2HS\_XQL8D$C?J>CM5>?&G#3PAGWV(?^D!YV\@SN$BN\IB[!>K+-X1(
MHLF:BO%KX.5$<W,OB3Z$J^BSJ4TA>)'5>*1C]@<V+^U1F5FV&F1N5L<?Z9O.
MCIYSE;X>%XWG$7T3X.=;KLX@\S+U@E\NQ:RDL?O>7ZNF#0SL:E8=9Q$.FAE,
MK",^*^#"M;)#;=JCJI/QC*!Q0LM \$;6>MP,49J1;<JU<N8L-5IT. ,D*?G$
M,8:)437%K$ Q!<%*^A.$6C>.,AX](S3^T%B\F/HL-WZ 0:_\UZ<Y:S[UF1BB
M%W&TXC":\<'?,@IFG QZ_)]SZ>VNP_W4%NN_U"C]TXWQ<KJYYSY3J/0.ZN""
MY\&JR*J\'GV,[\?^N\O9>4K6>8[JMW809D'YC4=U.4H'Q,99X,N+JURKO6\/
MNY]EZ>)'-2N=LUN2SU7IQ,V +(BA'5F7ULMX%J2+']6L<<YN23Y7C8/(VR-O
MY7P#,V<6FTL?U:Q?SFY)/E?]4KNRESZRJ,I0_O3ZL'U27EU-"I/BB"X\B7?O
MLI(_<>Y "%=.)3]"/0RG4'S,G*MK\C@)Y[OW' ?T@:9GJ.HCP?ISGH++:SHT
M_]3VDHEF=01YP_F'D#T$R"7MAAV7KM/MW1)&- SJ+#0FM6<>\.-+*U.UPX^B
M_R$5I&0'/&;?BTO33H% 08;"S^P&9#I++4E:,[XE9&0/RPU.3_)$BBLY2G'E
M!<V)(&S^R5P74HA5U\3XU5%"[6#A.5.G9<JX-B( ?E>N:O+=+PYS?B067.D8
MI=;:4>6%)P76M*\ <SO^@(FUB:NUW(EA9%$J6IJ5,_-&QKU_D0<4>=<2U) _
M*U<12W0V@D^O7>UI3D_L )+!1JLZ(1Y!$%N(*LGN<G\R;2^?ZU<A?&_B,5=C
MY+GBKTI^W@PA.A-,BT"(0KZ]2YJA1P7"! 2MUXKB<4Y6=ICFVD_@R2+4GE'F
M1I(P@X+.29Q?U E3N4:== ("HA).%/\W0QU\]TMV5$4S:DPQ0A]R(5O4]734
M_D8EZ2IY42O8(QZ)/G_$S<PGVJD6.EQIAC*B,6TOCGT2RU[+*ENW=#14C/L8
MLY",; QN\.T+=..#HVG]^+QY8L2XT3?<6GED:#@H8!7I*738\5Q/W"V8-[M$
M9C_VJ@W6_+ZEF2@RD4I4?Y[AG_FNG#P-M5EDZ+T -A%_*Q#'!G["IRZ;G5@%
M?$K+R;GRLX)5!SP,*=:.%J\3V,0^M0/TF%D)TP390?6J,HWL(W3P/3]'[BX]
M^<-<>O(12T_^,)>>W(/3\1/ JU? \)M2%6T('<#$&77OR]09H,F.9(7VR/R/
MJ)(@&U,+LVKLCCODHI;]H!-R5%8!6YY=/ : +D^T 4]EO(SFC!LZVW'K4".^
M5'=J:?=$Y VA,#MT_N4R##YSDJC&0NK*F7 J\^A?[N]&?L&'='G$B0@]KS;B
M;I#*G-DZ/+-#ZF\N$6YJ[0@>E8$>2)F6]&92;"I5I5",--K# JEWBC1(5S0H
M1(]6(IAD3 1SP%O.)JCD-#V/=UNN-TI+; PHAR]25J 9>1F_^X*1E[_!#K^<
M</G/$0?H==V7C_Y2+M\NR"KD$;]1OB-2T)MR4>($FR)<>ELWM](YU,K1I$-7
MQU4:/3,!-6!WY_]BQ^I&?N2^PA)D1<7>=JB5U,>X7ZH]#X3C]_8+LR8N\VXC
M/Z=ORUH(8%%/8,2 MSF:JPI/B[ZK$-HP'#UMFTM[4_AQ?+W2HWGJ!M^/K)4[
M91@2^2K1%B4ZK /.W1IVJ3<'HB$>[2V=><K'PZYSIHC2P/LZ9A'CWFA6VA%S
M+?$PC,/\*OVK;SN@;XQ9"6 J- /\1]*5G=2/<F,9G*LW/.M"28#UJUPA)#?]
M*8GPTM#(9'B<"%>5L(*_*9N*"V1Z+=TTPBQ/I.KYB,3%%69@[FDA\5-9&87S
M:Q^ PT+%D=4DZR*'3E/C376A' M:8-IRN$+4?N875DMC4,^$*,9>ZRU;3W?$
M(GY4FW""O'[+; T\%N;E;)BBZHU;#BVF^UK./PO)>Q9?+HB)(K0<(NMH<,I@
M#,\_+[=1OQR(7A?)7J>6&<LR9SIX$+(0$7/NW2OJ*81AU9'%68G@\_DY5&S2
M\CBT4XYT$3AX\I+V=)5^S_<^P]6R-$PO?8TWT'![H_@[&A^/Z^WAN#0:TBD?
M,.("[E>:"N9ME99R'(<J=[DU6AKO)ZZ>Y7$$JC\K%><8AU"&QG4;(K+R*A0.
ML0UP0"H&K"9LTP4"YCOM&X,B(F4>@3)!.4A$#4:#M7%TS(=J\G3PEM&C,;:B
MS6_K5/H_0/=)Z0[W-@F/U]T?V5HD^_02F-BMFNS,WPT/@,>A8?Y_#"#<V6LJ
M)@R&12P,93I;>@8'^V^..[B@H7Y6ZW29)E>D-'F\HCB%GIUVX/?/KK/W-[Z4
MOLXL*W 0B7?$!,KR1Q *R#NDCG%O$=VH^1P& @;'B#5KXDC@=X27;_.W_&)Y
MY]'KF7*1BVRY-:P\#U97R[WDV"'4(U "N7*6*O7='6?2P3#0;XLTOXYA;)B6
MZ%E,IA#^>=.4PE!9.&-?R+1AEMT/7G@RI00P8L.A&4MI$=S>&-AM)</\'9@^
M3%JV0VD?F+ZB1I6>[#Z7PX.)^Y7@BJS)KJ_<@CGAC=NJ;W@4BU9--VE6"T*_
M35ZM#L_C./%;@46$;O+'KC^]2<+D1*&9WBC3!$Q<?&,/LTCI2_="EH7+O3SR
M:.ABF%U\&$^+(HR+7=FJ+.A?,A48O[1! N*237_U:7G.1%XC:0Z1!G_JIP^"
M"379#NAAO"V.C*RX8Z&2A!UM#1E&M#WN>F J!#5L#A98>;Y8^3BC&T,!R%#[
M$I#CQZG(5?FMK F+G"W3B25B!\1[7Y&HI])GJHF<$YU&6,.V6V"*L/EJUP1T
M@5I<8KQQ:JZI(WG"-\&*5Q*!4,).RF#7M+(Y>K=FRSE?MTZ] 9(+B!^:'PM1
M3Q>U.'CN8 F:,OLSM/;2J8#6S5 O)1OUY(O'?^ RON"S:!]F; ;=?/\?I[9?
MNFV3^:T7A!6-R"$\:Z%:OG&2V0/[&YP[</X(QUQH\,;#Z'CTA5N1JY#K]\14
M"Y+&DQF0:G)<'_K*,:^^LM3#MXZ0%!ISFZJL7P0J.G':@D</V1,IZUL'=Z;(
MM_G:&<&-&=Q1O)<\D\ZW36-.:Y9]\0U&6IS[1HRX#*((L\Q'#$8QI3A2>YY5
MU'![Z"PV]@1#=S+UX\5Y K&>G[?0!PSS*7E;4/*Y?N]]>NA'=T#KZUE^3-L:
M%UY@7, 4BN/E O<#0O6>P]BS&4JSC#S4=O-RVW4\$&%R6@ ^<Z2^#@@FOHE>
MKOD%'H<;@7M\;W(H4@\)B@(E=-4V:LNS\)X2YW6_H35;YVLE3/1SPV/1G>)K
MZ6V?D*AUWU@S._#$R]T@I^1J6M^_+R:E5>$W5<R#>"U=]EZIXOELS=K9_;B,
M=;I,]T.B-6],;7?30=^3\5VH?QJ=67EJ.*L=?2/1UF$7<[ZOF%^\]<9?'2,W
MY#A1>P[!HEYXG4=&?SAC.&RK9J#&C,.3V=6P5\@Q==L*TPOZ=#;+@9^A7R9U
M;_G6&4<,.N:J=7L\P/<<'/V?5F/5#8RWP.PMP-2JA%W-^>-@NQ[TS345+I/"
M=E\V,OQ^1Q3[[PIT^7H&NGQ$H,O7GR'094Z\_DX'[\PQ<W@,/^,HX$MUD7G(
MK[S7]=?\UL"K_^LZHZIM.M__&?T$ 2\J?3S1.]N1[Z:MW!'CYQ1@\&/RN_)K
MF>:TT,<-WH 3OS5D'GQ@9!2=[-('CQ]^<&@R\PFOU4&LQ!R3PWB)@)IRKM#@
M%]^"RG4J6*AQK=N<Y._!DX?'*6 #;>$G;2H8!^E\[C1,"/= 9&Q(\5[)J#BY
M.ZH6FDKJ">"6=0B3CQT_*DYKT3<]?3@1WKLS[?<-7OG@RX<,,=/E((L*';TE
MWT42 $\?RUC'_8M^(ZMCUM S-.9,-/0/DDU^ 59-E,R)CJ:=8E$F;)CK)4/Z
M[2?MO_'X3W_Z RN]'UZ\NK[.M%2&-%C+S6^U%I#U=@A:K8Z2%\'KTGZ:I$H-
M&J,4E[J%Y>^ UZ7=<N/$J2F<@>'V$_Z%J9'L.&GR+F_/(M__O,,W#OV_PU?*
M#IRE[% A>H_I6*M^DW8TY57>'N9N)K5C-H6;*1J-W==.&^CFTBEC!*.QN.*H
M95Q[-V!FE/;@IRZUTR+R95ZSSY&PL]<;<R3L0A2\*F28P(+?TO[>/&"O\4.<
M^F>WW-1H@23Z^3M25<V6MC/4Y#.KT-+[H/P?_/#BY^^>_?#0D/2F^4>4M6C*
MIJBAGIQTMMQVKME5EKTJ1/>4?".4@&AY+:T#/II,>06:*3J(CJAN6W:=.@C!
MB@6/?R'5Z&S[>+)H_Y%9P%R1FN,$4YS^%K@_Y])\>NL0'#7BN%[YKT. @(XC
M_LW&^Z&CNQ)(F>_,@"3DW_(.2(B>OI4#F8PUU%Z)DE?8VZ+0?ST'KISA%;(F
MVDRZB^=3RQ7"$'W?/QF1X*?P()P$GBIT+R>\)"6K_-8S^[*9W[%9OG#K7!(>
M*#\,#4E&C5._S%B^*G33;?WJ9^J5^(^/DJP1_7&W138KW&:IR_"N/P^U2Y]^
M(:^RS''49823SU&?[?>9&1Z+KM>=,R-9ZI2,#0S8;N\4A\].!EY8MO'3(J%T
MO^X84\RW6L"4WPC#6OMTV<8!HD$\4Y_1Y%V4TZ'.$N8_Q9+13 \/4"K/7!-F
ML6@PB;X0D>0YDCLXH=SZ&->$WW6!I'G;B5#MYW BS"?W9:S3Y9S<L6OVRC+;
MZ2MQ"R2)-=38AB[6]5Z)V)$T I)'#0 +IZB?T/$P8F-E<I?*0 =CW'_,"<+C
M$/2!08XRG^3V;"3/-F55M"YT+S]T-2T'GHW",[6<EVH(/.-,@ S(PYO^(]_N
MOAG5"V ^);[TX-G+-P]'27BV+<2G\5VJ(YX0F!0KG:4;)%X.0 4/T/*]]FTU
M$11#EDW*'/E0[RR+U>P >NA;_B7=-469RS_$$]Z48*24ZLF'8L_ <(!JW30=
M]VCJ1*,WMS6-:%/NM%,W<"+J1M)LN([9NBL^?Z*16A'%4=/J<>-O.83*+:.5
MP([)HDHRL)6* C7IZ'0?K-ZBY :-#D>YT=ML&2M3ZX(9+.8[*]3G@5B'],?6
M\-/.S;%X,J\*([L.: )4)D"I\,$+!\!,V4EQ*@^FYC:]//]L9O"=;2 @D+^S
M)TO;FU<PIQ,1K RR5Q!C#L_DK4;VG&,+D3M\T7_*0_2^WIY2A(O#4!YMR^*6
M9HI.X*$-?55I@R+[RNTVYV#D_0Q&GJL1,F>O_L__$T^+RV6%A\28GC!@[H2K
MX:]\0<K,G]6XP2>>Q,MQO^9HO @%$%< <6U60!=V\B[?;XI4(!>-N39PC'#A
M%_0C%Y69QQJHML8]D40]UDW]2 <WZY%[JD<NRL.9LS$GQOI*V.D.XQT\W@!6
M#A#R*"#%S!DEV]*6?15[@W5*'%33,M$Q^T <\[A*?V*]T07]IR.2;.PI>/(!
M?P<;,>-K#;'M_8";ID(R:3S^]5 6W$;=&ZD8O[O)ZSZZC,>"2^V;MT,E^&D)
M<$[4B'SCB2SA QV8GL'(_"<\!DN&3'D-X?)).YSS1@;!!H*Z+DH,R2#&O5&%
M&(D$+XA\U&'82M#O4>CJ.+H8F+GB'K;,TL)WB,F/IH& OB/A+R<=?P#NC2#Y
MM_E>/V_5NYH+10*,P6E#.@N,H9IDZ'0!E[GVH_.+[E!Q/ >0+D!)7?109Y$Z
MSZ%>SADM](SI=P/*+.F9O]3<[UH 4R[];V:!K20'\TJKYDGMOO9D.QP5^^_G
MKUYSX=7C)]^$/Z7?_<+56_])LZ%_O$7FKFAVRC3XDOP"KN^"VD7=T]9)*'_I
MHW&-7O450BV/_^A?)SD;?G&<#M3+O^2K_T#^RM#*844G=U,S'$\M!?\M(_LD
M7[9-UXWFA(?!\Z*A)#G%Y*SXL6GIW,C2%V2N&XW%7TNWW- 1TO4.2;1]8/@0
MTLM;21'^2FO(0]XI@0K-\U%NR+(9 <*F29/,F*VU1%>!#_0,_CZC[_6-7/T*
M^QSH=>OR] '^]N3K@R_S?*!3W^AS-:/O?!@77%JFY^ASBK);5DUG42%Z;!AW
M?*P;\31JC[,#$X8+ZGRJ)KQ #,0X!3I^OTX$F&M[8>GFF9(DYV>+RO_CC,K_
MB*C\/\ZH_#D\<A]0^9_4V)H#LI'II>SL?R%!+IJM42.@P-U.R5_^XB,,[M=2
MVV,<6VVP?9X^3I^[I9SE3[YX\H7P%<%*8K!\"<YVJ:!O!?MN1ST0'M;R_2\<
M\1#O&[XUVU9RACZ@/^)I#]G\DL;O>=J6W5O.Q0+RN6:--^*4C.GD2Z$C<$P1
MRATHJNK()#N(BW#K]]F7/GN)ONBASB)UGD/]Y K]8FS[GQ7GBO_W#!QP35N7
M>?K,H(ZO-'2J50S>77[V[-7UJ$TQ.WAC#,,7$Z#:^"7V[-<,^O/#,-8KOOK5
MZ^N T1380%DS'U2H=HLPC:/W/TT?M&[E6@5(T%@P:G(JUXPDB$;BT7E^$-Z3
M5D0B[E^R:RPP5PV2N\I%](5E.^EY9L"ZI*#@C'"PDRZJ(17],.1E($K%R^C&
MBB<@W)$O\-R-,-><>#]W9NC0(0CA#<S!F/=%JDY"D>"(F;&+!M.EMV#OSF,"
M*YX?=GT#K6/D T/V0I7<3E## @Z2(SNZ-JU*:\P6#57ATGX4B'7<&=[PZ98X
M>H"[1ND<75>Y0>&GF0T+=P3NYY3_!^F6,!4%:V?A"\,M0@_#KYF0\"C*=0U;
M9I\^>/:*1#'B7#>+*?,O]GP$0AFKLD%3[4<Q+6P<,F(G)EUC9):%09L0O!K[
MILC;0KG?=(@[)ND%]/6O\,89U.M3#SY;Q2O",*MHKXQ6X) G?I)2/BPT6!0L
MC14D\,&PP]3\^]?95U]\P11#4BLC*QY80RURA/_W[T_\Q9**\9>181FM20 ;
M,TI *G=.BG.@#>)/9W'1'3R2\M&.16,9)4S3S66<2O1@^[2O[,.6K'HR_I>'
MF*.<2\J)]%;5@@[/I+VD*SLFIO6#X#?G:='\KZMU-C0*QY^[RX6_J>6$E'6_
MX2YU6AD5 <%-_0)/SY+N"E\1YAT SFSR'P^1Z6)K>TD*_&*J2<G,)YE["2XM
MB2\RFI]]A&:!DBW/ %4W!N67PR=D#;L8A@+Q0[J0KUR \(X[!OJI09"N;Z5A
M%;-#,X\76E;5:PCIN+-5H&!2#OKCB9%7CGP0S] 5U?+%LCK9_\I0Y;RF06"S
M<&0P'&]I%2"B2%&LS,C^WLI26/,M2><N&NDUT;SE&@Q4P'$Q2+1Q0;S(D$I,
M,$W!>LU'[+,7KZX?+?(NT$0^**_<52H_-?'PO!OYHK[)K=0DLAH>CAKQL)EU
M,<;1<>3HLL9_/=Z*S) 7ZX$2D*NMUMRK-B@M9:Z)@%6XB@\[TQ XZ7C',?].
M:)/P8(3FPJ/^I\2W1T8E#^8P^\.54O_S[#E.Q;O-RJ?RV&<DZVU>-",3]<&S
MR?N'*KKYF9:6+H<^'DG\D.E1C)[R2Y]OILWD![],#L+'4)Z./N-GFJON>!Q0
M;B/>\ <_/W_UYNY1?2E/_(F6 UOT<&Q@D'CPTUT3Q,,(#_J>)K@L\O1YN0;<
M.OT6&I^N%GL]??#]\V]?WST@CTYY2:*9UY%?<3SI+W\^F/9$;4YZYD_+OL'4
MZ6,?JDDIW08AB0=6'1\-X:3YL/-%6?GDD.F;M<,9PX/Q9A#+J8JA_P__TR_^
M-UXS717_(Z9-2$?YBP^/+$]F-75.20#MMSBKWG%&14IQCG3,0YV#9Y_/.LW!
MLY!MB2QZ:PYR*[TDHAX,T.HONC9W53D5$?@KG/['?_KCX_2!\JF^>O5795)]
MF)FW/>[C%@(;"[5B.#32]+[GYKO?^SJVVO@\-H/C(>)\7_OA>#LDNB,:GT2%
MXB@17AQ!5#4==,=0KK56?!]-P;6]PKIRZ7$?>Y T)[DZ,,VM^4G'X1'VU,O.
MC%I8NUNZ$!?COPVCVN(?BB9A%JJE7>VQOQI$:SF3GHV@GN1QU6O)A/514)76
M$B;RU!Q*2W"F\RX%PUI 2"6.@F:L0WN4Q1I57GN'</:Q3B6%/SFZ0'5 CY)V
M1$-H$%G@O8G2G+HA(0^WW'!&^[9;8-QOC[PE0\QX<*Z'-7U*,*8YZG+ &B#7
M\# >,TCMR5=^'UW; -+'3\.&NIYH(!%?J>'O3D=\[9W\W&]4CN%Z2FX?QE(.
M:\[C]I;-99J@MI;>S[+Y1S&\J'6XYZSK\EI;&WB*_:A-\S[=D*7/HP>1 O?!
MH4U!YG+/;1V.:V]M[B?4Z=4!E<1H)DKTG 9-=B>1YTC[2+.!EB.6JEJ@BD9J
M1PUOK4_8^\S!P *Q;0ITW8DVND5X.!ZJ(=D,LM*4W!7#T[$K\Y^53 (<!V 0
M]T63^#H]=,0)B(2W)_# -M'VS<'A/%0V83@DB2*?IPW_SP#7]J<9U_81<6U_
MFG%M,ZYMQK7=UX%?DB.'\"!R9B&#5@8P >PIB=R]RXEZ%1B>7GO/9$0=%CP-
MG,)RI!YC[_PH1KCZAP9J4-/NNU^F'+*4"QX8(Z$6(J<Y.739.C V2 _*D6\4
MY9/,#(V8O:X"-(.1>9S;94=7'!B%5[#SHC:%V@V9<N&BM29H2L1.$VN0FRCA
MY>HI'_9BGEV:WVO\WY/U/&BL>:)BE:SH[#@B ?N1/(78[X=TD".!-1=S-R^V
M95UV/; ;H / 59EFR'V>,11\5'FG39/$$Y!@B+12L Z;><>/,!)5'\*^2G_9
MP36*3?DQ!=K(N=(-'IP.V/9@!3A C<:3,.5*Q./'99-NOR5%QAOXH2]0B:(*
M50"W<M9=&T <38"X%L#0Q"9_O@41K:]2(6FHC!7ZQQ=OYAWVNZ/NVGQ7<J8%
M N8KBG*FOU&NBIYLMU+PS]ZG?^&5O:6*R*78I,T.Q=E#+51UPJ($%D .2S&]
M^=#Z G.-8XD\><"USWZYFZ;BWM#7+U(4:'7+?.<\N,?:1J6%VVKAM:;45OR2
MCG/&OC&V-?V61E@JC=J'1<-OFJ;R=6!KFIJ-DFH6#CO"&XGPU_NH50M-=<9O
M!5".HR;T8-8P(W;USDBO^!M!WH5*=OJ\/O!YRO<)D"6)P[HX*,.G(A P?AQ'
M=*29GW 2T<9MQ,&6TO4=^8+N"@?HK1NA9B2((KST5L#']]'(]%C6FG7K0:@!
M9F%CSF_QWQIA964%.+^MO_WH4/"'%&<.Z+Q<7G*+OOPJ_9LV/V;.E)Z3@3?.
MPE5>#@*1@I"[U#=EVTA/MVYH6U(TA8C+5?H3C=XRB=*Z$Z$1'6^1[WHEZ@HL
M#?$JV-C-)O$3S3:-F!?<F4P9!4RTF'8+PH (B$\B6WA$M#A'4&I!4"TA?R1.
M5ZF>=\R/3<-M5)L:@BT?36%1=KQ?>W(.L[@5G]8.TLA,^4<2PYO"/F0JN\K(
MOBC!"@.-[4;:^+.B_MW&_Y/8XBC_??RU@2P\\B2FE_4_DBQSL_.?CW]4S0(2
M,P^T+=R-JX!G]8WHU4QFO5*X7=7LL:MX'%%]C&<17S7+0?J_EKD\ RD,,8@"
ME!9O9_MBW8R< [KO>[=H(WC-'Q0MP9'5+[]0<!U] %H2:GB71V&!45\.#'S1
MY2[UI8NJV13C BX?N;\.1L6+V*A@[$T?NIZ242K"ZFT,U->/V W5=OUII<_[
M,RDNG)!,*JR*\/$3VRVLZR63L"K;3@AJ6K=Q-7=-Y88V0 =5P*N@54!+I_IM
MT[[UW2YC)/8*HXL+ZG\1^?;#MC(!-92E+@TVB#?W'\<C4ZR;N>UTU2OM=^?0
MR<'WMV&=#?N#S)HO^6$OTK_212WB 5-)F2=^7QFJZBLE(&XZ7R$G&9@1)K9U
M(YP\/Y6,(6X^HT]?<$SB#W$6>,PWP*?Q"/2=:<T;QR(8X<--7 -;#X@,Z'!G
M@XPMP>B"+-T,VUQ:OW1PSD=,XTOZ+V8?5W@5>M^RSW?"C/4FW@JCE&7=-N0S
M=J.5?/:S4EV"Q8W-B/)7\G9ZMZ912E+9> S^*W %9:HQ!<R_A8DGO\+K+!>#
M$)'&!L28XHB7V;HL%:/&@C? QG\GP$9^O0#7U5&,(,[&>SKE[::^VY#%?"2/
M9>Q(M.F>_N'+;YY^E7WQQ1?X_\S$P(CQKV$2+#W/@%0Y!)ZHOL$6HGU3%;<P
M=Y5J%+U[& U^[-"*,[N+Q/V%$A/YZ(UN0,VUA?$Q+G\\O,?_^O#8I!\\:Q^3
MPI.-V#(S12E3[-"1 X1095>YO-"^LG$/62%K0%ZU*6SGRDFH5%Q,]A#3TY/%
MRJ1:LLM@DGFZD,!:$A0,BZ66#?A$+\E:+AO?."A.>7&E#QC$VO0=FUF&$6_H
M3[J9Q04[N9]-M_J/(AM:.%$R=3FZ_C!RQ&R/4X!A\;G&80])=1]C%;7NQVC
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M( MN];=?/R7F7T$$GN<E(^."N'NI<76>O#>"(SO##6P))P--K]?Y<%PG_M(
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M$F]9PA6(F ,>B8<ZT-QK,E2'1M1#[SY*S/(GO_G\]R.S_&..WVM79OBZ%#6
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M<O<&:F16A6B<EZSM/FE@'8,U3#=(BSIIBV"4CIR).S+:J07<D'.H/Z/L"('
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M>B?B&R',%BW((PPZR6A3 =0BPQ<O%U<]U$6D+G.H5ZH6M:N5W&A6C=W92IT
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M[G-##$V18J9?2S$+SJ"RB62[<:_Q%%*I,Q2+(U2G8+2!%1)ZX1^H>A?MHUF
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MNM#SR"#O;%EJCUNL/#J#"C/JGR#B;C*5ZWMVQFS_I/Q&/4,F_W::&8U]D4N
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MDMA%(!PAC^%XP S?#',9A;O%=L%/9?<V>QH:".JCF;RSD\_3\Y+<+'2[L7)
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MAZJ33&4"F$/8;=!G'MZRH^0?*R:E9<ONAJI$XJ*<.]"YM*X4E;8Z,M<286*
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MT>5,ZFIHW!W,MP,E: 13!#*1<N+_IM\29RUSV:)RKPMDY4:(R:I' *2VPQ_
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M\J _#'U?%3=_>]5AC!T]DTV-! !J4P3JMKX23M&87L[MZ(6N IP#ADSL!HZ
MNFU1AO2$*:7EN0Q-Q-^4>8'37+<M<9HUONANT'ED3[EM[OA?@==:D$!34FO!
M7 C+0CE9%UZ/C]JV#_2X7%@@.0F(T6W,8_/8>G;!]2&,_\T%H]@J2IGF=K=K
M2\%R)_CO/.P7;RWXI?>5MB9P%23_W ;.L2:7OT"GWX\::ZFN- )ST(YXB6>0
MDUB "\Y&9D"'CTK'=%#.U("#09Q$UZO9R<,8<+4BMD/<-@SY]$-'*H/JBT^)
MW9O(2LYM7N11E)&5(NF[Y;_F^J@@"E:2F%[5_)LB,>SA2D:<UMDW]U77-MS-
M%<J1G+I$:1@VIXWG*$HH+4 I$+9-WA8+$*_X^2-D%85P9,879*@6_QXK32@(
MQ$VTPDPWX6F)%'4G-C6?OU$(T0";RS9U^_!^:4#?@;W_*\V(C>2W;#7\@+ON
M?HC97>WE^TO!BN$%;/2+N)%! R\A^O>-;K_U10FGN3OXSBCYI$_-G$#*I[9K
MQMX-55I$R4E1D WEK;DC@$_PR5 &1J.#ILU=O!)1:6*W)CK]5#T6>_#Y?4MR
MYRT8D._$5$8!BR4:7(#!+-Y!A'XHX'[(_H0/D]U-"_$TY2+AH%?^F/G=OFZ/
MGF HI*:#6Y1C60=E]K&+B%/C3A^=Q+RB]&7STA<NI-#%_%U5EF"G?(/(?F2F
MS'A$"@MXF[VL&LF5)]5Z&L0F"QHG)L<(WO'IEY_]'MG=(]E=T>VH=(_-VEZ8
MW=;2YZ4TOO$@4CR[\=7=%JPYHHJAFC;%+8-CWL'G/0RBNRN:ZI]ZL+EU3J:)
M;"9$3!Z,TC_#-O791P6^J@9IP/D3'W<A/3!J,C%,ESSG3\4_"YAF5^T_IJ_]
MV?]SA5&A;?(D]YHG_<6OBJ9M/GZW-_Z'XDF^DYD^;]P+.)HHT^A@YB)/01HI
M\5C5!Z[/86D.^; >C%^X7)J,0XRQ'"N*ESIH"#E(7B?X+944E1X.!<;?,<N'
MW5E5T;CDE!^P/@@SM#PF2J/5!9C?6T1>1PXMHKKHVC4&I\WCU,C9MWNMN^'$
M(V$1D45+QE;4=^R%I--S,JO@FXQFA;J/^W#1L='RHQG]H<4[.D*^@5G+QFF4
MOCAL>SS:?Q^"5GA5E4VQWPL-M2Z3>(!M7592SBT%LXPY1*_))YNE_O8:[FW,
MDP>TBP<LUT*^ = =LM0-!0B"NBV0/O.NT6\Y=BF"D&2IRF)TH35/<%]@AMC7
MXHE477#7R[!S0?WI$KUOXNE%R;QM)6.ZM,/=JW*BM?$L55I3S\D[NE57>)-&
ML=F"MTP7$QZ2F8.;-6V7Z"4ZP7)9N8_">8Z7GDB?%6.^%UL]XZ#:T&(A#:<=
MX;"8W?_/WKLVMVTMVZ+?\2M0V=>KI#HD(U+O^&15R;(=*\MR7):S4N?3+I $
M2<0@P(V'9*Y??WMT]WP I&0[6[8IA77OV<L1@8GY[-F/T3UBOG'Y1BS;E[3O
M#7L%4<FUT\+_AP&SI#,-%?&0#HBY;%UC5\M"+]^+(OJ?GE$F9A$(-XH"9!)P
M/_A:B<C,F%D.$S!NT C*I(H%@)--7<S?'N"FPL%:GG<E'!A!0@W08U)$E=J7
M+=,P08P(L=/J5 12%^M4D!H2@8VD.-@$Z1<,IQ@+'<F*UJ0-X)TW^37GJ'L>
M4,\=(5X6X>-5W;2EL=(D,J6*)+K8FT34PF#E_G#)$.&,ADJ2DK\SIIU@*H(D
M99F8L/2,5YKS(S(9C>^7E-9;%X+U?&H=/)>O',2 J6JDV'-1(;4;OB/@+G!J
MY+!X"6^J]WH3"#*]*^Q$4)#,-%![2_-)QD%TS?((9".+ XBUW*U<?E0CO4 D
M*<L4^6[EHE&?VAJ#E:^B.40F4VN]_F"9L7QQS=\0B=J0.IV@1)D!VFIZU) I
M5Y<L^K0W5AL!VJ&X9MV4^:C&!:#>?.)(& 'C%"9TL8P9P6#?4G\Y69HIFI[.
M!*H!HD@<#O-<X+7.=X]<5WP#%7'*9*0=04RH V44<9UDLHA:=:&D)>I?C3#"
MV/)9YEG3?:U'$+-(_X22*;EQZVXVF3JYUE!XC', 2#Q:5(8UP3TOD'>'2E]Q
MR,6LM-,CG;R);?4[G:] <6M%N=Z])(W'&E1B^6'3OQP1*R^[64B-02D?:2]\
M8;ML%D._'=IO!U+(OT+*5\WRR&^BM1(3+C4J+9CT-$EOE-K4+.EHMDO'G]6V
MY;F_NI6QR[@L-Q<D419<LY2VO78+B2GG8^Z2,K3H-X;5QMDTFII8A$<IX!QS
MP]+@%".U$\;Q.) "/7S5T^%N59IID6MK2QH'$<^>*"5H>Q3;5&D7*5'DE@0&
ME#AO79PY^*PX\^,7H7^?RX)E32"TJ4W'X8KW><5U:*NQ"FDBHJ]MR:8R#4%6
MB4%R :G&Y2$$:-&'F)-D%=RZ7OBMB#R63*TKQ(AF^F46IPO+7B>.0=[JI;/B
M'0HX$HLB8 '!0K-"6-G<8*:(3B-TG!<?NC >NIS.:NOL6 D:.3>EJHVX>)$+
M_'=PKMT)H3O<VT+H[@]"=[BWA= ]BLC1MX"=_0VNM><>H$B8'Z0X&81Y"^7B
M@#.H?<ZA$/8FET:)<]@3*_SCGQ[;IEBWU9TP]85G6[A^\<@;LO66H3T-;Q7.
M/T"X>!+X\S^\1E;_H)+*B><O'L=>;W#OZ)33H^-3MQ@DO_]Z+[^RB/38E[B/
M9&L8?<TKM+NV6,<0<*A17;K"'!I16BF([32NH4L?6:OVL6+8K1?2F9:7C0MW
MN(/O]$H#7E1#R+<M[\(SFFX;GG<@"U>45NZ(U/O6^J>P;S-2BAL+S!?T1FSL
MKRA5-GDCKW;UL2[)PQ$NXSB-EO8H._8P1F6:RD?LU;F.LS'3F\!>34-;.;3T
M*RNC]&]1 6)%NBC75[! 8[0&),M8_/H^IUSB)!KWQ$HU9BC\.VR8[1G>N"5Y
M.&=8+EPYQ!QGI=N2*T_#OSC/JYB]*&%4%*@"T,HX,/!R.J3+(;R5>AD+[)G5
M\PJ)")9XXC9WB^>V]'>%&L2/U0KZ^[@Q.9$E8]"-XOG'M0ME?;9"EY1>7C,B
M3Z!.1?G_2+RAO"]O(E<[P (946]<>2/+0/7"<U<T79RAOG/=>=0[+CC=:I=!
MN,H!VS':IDEXMFF[FJG;2N -#,D WW#0O#W5U^-GD3P5+\ UTK)X7+$#T8B4
M"QI*J ,UGE(;Z=8XM08D^%:N;KCT%E_*-XCR!/-H5.1NGK*QF28I0<C5'I+<
M+=;:F: WN?B&H*&4451K7X"8E._W<7Z33<&GX%;4HKZ$!!=I'&Q&+,V_C";@
MEY>]+9$BUCA)8W4M"-2;4\N-D"ZM34./!%X4!>48>%L:O(0#;AE#5R:<U)X;
M=DX;7 W_V7>@,Y$0A_]\4,MM8:,UF=Q<)-[LCN9IP8?7P#<DB&8Y%<2%/W,S
M- EG@,32>13N04>=)UT4^3V.RU&1#)GX61!VK<*'^[WP7_%R#84/$B#"EZ*S
M>;RUC,5IE#O;1JL>U4B;D#-70I15>8$N<= ]+U)748+D I]Y(WV]L'7H0Q$L
MT8=F^7DBT7Z$Q0XSB 1MWJLO_0KX7?UC[+D5"@^6W4K)<$@T"T0*N/Z&*$HM
M;%0;;>?T*3JI3 3#'.HZNH[F1QH^S2;^D^NZU&7LC4"MI[)&Y1NP1@SSY2BO
M*CO8:9Z/FXF-K0[2B'Z-Z+R240?XEP!5A"A&Y_Z<Q!A+E%^Q]T9"QGMQ_FM'
MJO>-I78-)/4<U42XR"T#T9 NBA*#'!^_ E O/)O0@D46U>+R  Q/BJ*EY]$'
MOAO2-)ZZNXINBGS$K*)S+824\"*L(&T$\Q$ \Z'F9R'\*C8-=EUQK9R#H"Z(
M*.H',Y[KEW$5C2#9S=\9D%,S*3=J:E:V>I'I:H<Q)]QN6<4+;51*%N%.'S43
M3F<U'4(XU1*4$4X$[F;1R0ICX>NBD )?-/H1K95A5VYL#',2XC+@(L>FJ%/L
M$C7EHDUI2XZ7[O>QRT+A.Z]0>B M=CI+%BO0$_/=20,R3;L$MRK7!16J)(2V
MIGQ.OWC_MVAV##FSXCX8O@=]IUQ@-!T/8&*[(KNSY"51EZ3^R6V2TE;*1Q!B
M6&><&-S<K^!DGS%-SF[G;F#'G5&.X-8HQ_;2?%0C]6O<!NZ$L ZG^K$!LN;9
MZI7UJ52#VP&#'0\C32?D.O82IQU5&(X5;WM&4#/@UH)X5[,_NOI>*GR>I/$#
M%<TR06_'=RB6$$<FJ5F1R7AD(?E91E@4,<T[$[II!@,M9:YM*9D[\R_1'[3D
M>.Y=&:PE1ZZ250H"JD)TZ15LI$Z'Q5"OG9G >2IOR<&PX4<OU5W^6U[H&.RR
M6," --O<"]R[K*+SS<'RFM/!HY$%W<,(H8Y.22&/'/Z,M7D>4*PT3&6G;8*X
MH(YBSL3XR$36-DS=-CMH"D8OG]]:HRE2+-I>3XEGC=*FSS!)'B&6#R/TZ:JJ
M_ :L7%Y]/D;HB[?8L=E_ AK'A<#(AFFJ:P9&[K0V6S' P.ZPC6I<9:G-AF#[
M])8\P@5"65@=8^)KI$@[BNLRN-,N72D5(R^N+U#@%2,0)X!:_CU.'Z=CK+3I
MS&&&(2LG+9?<!F6WI:O#3N0<R;"U;]1!T";MO-%*TF:;SSW\K@]5%EX *8%H
MJ2SX\Z4JPJP=B]X36!9G@?[K7O8J4TN=""[+:<^7E3 %ZU8JQSH>ESSSQ\>F
M_G\E1J;?,T.$SF5#AK&E2!0))5%')7IP'&MF(+QD-D7 ])GF ZP%,L6H'Z%#
ML82#-(;:WQ9KW!7!^FTA3;>!K9]I<C3(XCW:=0V<^MY7S>0-W"Z<T4<;N>I;
M7.GC'2D(F%$A)G#;RDOOUJQ*%7^MS.Z&E\SE1C'GY03X5/6(AG%J"IT;>3K8
MZY^::DJ#CBF)F!>P39L)L;>(F45=L%'I$C@]]L>6/O1G/4[8-!&&1N-!I"DL
M/C2:L%,0C..A*<!89W @\+4L55U*J=8##S,IZ%7"9TM+3SH*!KY[&YGD;(?2
M8E>U7K'#G'VO/,-"QE A-=_Y5CO!=9Z,Y/Q[YIM"&81RQ0R;RU.Z@ZX6!1ZU
MA]VKBN.[TBUF0V.J9,#1M<XW"O5$2_$'C<*A\A\L-;5TIH\!<>:S9UOEGD]#
M[HC1,IS@2[51.:Q;F!MI.()= :-QT"CU4WJ_A-=<#=>(0ZL&F_I;3FTSDY8
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M"_6D/55@@S81%@9H?G#<VR,M9?^H=_R$)VYPT!L\Z:S7GM:X'-?H+2+*7?J
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M+^7%>@^H>4N"QN95NY[M71WH@C9<%9^'>XU*G  +@:T7L@YTV0KV51=5#C1
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M]_J'@]-^_U 3S[RH*#SCL;K>,9<[O[X-CXZ.^_M'^]L,GTW9G!=9<,FW@X4
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MLH#7<HO=^9Y\8^_SCXGD302Z9EN&L<V2%%<)(BN<Z.Q2W1M$7(,HU"KX"_]
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M!90$U^B0YCA05/$=8B>(&^,I#61KKT8>Z6!_P$04IO2/ZT!G;7.M;:2B:AO
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M! /D.M:ED>VV&[X%-RV=V[U#U)"<4>\FE5)=O0W-;_CQ27C^]BS<>1L7\$O
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MO$(1W/2>DR<*T!Z198RA??J(3!\A3"*[@D?+M,+F*,K=MQR+8 DHS"KK#VC
M-]^.^@Q>NWP7"+'SN@QR#K=6.+3X@%JT:M-68-P9(06BN["P__R(%\FC=Q\V
MZ 7.[#H89]^\:N?#6O@:A/ $1SL06B)&PH+9A[U&)#Y!B/X5E#V?L7;_]+[2
M3_6'LCIX2;?+R!HS>R4F$2[43_7W914E7R2J'>/\<_@'_58Y68PRB7\'A^?]
MN>+X(UEM?I3>5KJ\I+KRTU?ZS0T)72F5::RYB/(?,4<+AVTA+C23NVDVBE?N
MC!P2(R>WC"N?>Q)'W+M]2<[2J@*E'UBGL,P\6*,K#V_(.@ -+YO5@FF6WNW6
M7D1>2ADM#<+JXO480]HZSJRORP5K@'^6M;5@>I0'>,(B67TR?A&=GU4*!("W
M<NF<[L!-JRXC'F^<H:_SA.A7?I[N)S<=5!IBKF*FL^/0WQUK[8D+V,I@^T;>
M=,\7X8Z0?N7XZ7[ ,A*N2EXX37/8).C#ENG9R_S\],5S-FWD#624()HIG5Y*
MTKS_![74K%#EV-XX7O$3Z:@,QKRH6_HJC.LMB [)F_YI:-/US61HUQ%?/O8Z
MK:3Y\OB!G^SXH4J;UDM_+WP&B*=?AY58'I+MD=EB\MR]NMLIVLG^]NCX:_\J
MZV6M:\,K,9X]2*S%#SIY6NBEGYI[/E^A7]YQ_B+)*8V_QI$%7)/1$CQ\=/ST
M_]BZDEWAT2QBF<[+385>!O[HL#F;E]U1M+5H3#8@+,'>&VW$V67EEOGS7]@S
MH'OW$WI#<$$V:NG!I=2T178*+&K^;4DO*I=+G[7F?H4-4B=K9SU_]:Z0O>2Y
MK3QK>#/>^9RU5\0FCF^@QGRU/6JN\1,RM,G#J- 4  0)ZE\5J(_OFTW)_=3*
MC:/!SSME<KDS6N0NJL4I8.U(IA8WG +R#KY[^VR?/CT79$07R6=^R5A^9Q-?
M5$&N8@,OD80G>V9I98-X7W"U]$>>*Z.SY]*P9$BM6XEF1)BOJJ6+X8R>0XYH
MER4L#)V12S&,!'H1T8[896<)UT4EKBB!XM0M,"9T16HQ_.75Z&XZ5*N%L$'J
MT[>^X>S(KN=6KL;'%K*8L44@D01:'7G^1ZP/%+[(]*H6< S)3C!7FQ83E-)W
MS]YZTLBKRG*FP8S)A59\:DS!2@FKPO$96GA'-@ZM*VTJ'7+QKSG.I>#T40>'
M1=E=BC##'.%*KA8!A0>BXO%8+5*@_5ONT$7]O>G<KQX<TKF?+IW[U8-#.O?@
M9-ZF_/2?0/?F6ZP\*?)]K*BSMEK0P5LUY4YV4532;C;!_,-2?E6)3>P+U[0J
M"$'FAQ)(SKS^M()U<AW,M>3^+P^_UO@B'CCC\&3%X^QZJ8R%FSH@BZ=@,?*E
M1@'$/15&^ZP83@XP X%\XV\G&O2&1E2_KF$SNY,<@9$4T'N@AJV-<Z6M1$0)
M<[$%;3.G&KJJ=T'#ZN]'BBY+-687-&YXH&0#9ZC4XW^.Z<)&I 2:YN3X,'NI
MEN4U7-Z(*UC?7$1<:>'=K:O6,W1(%CRKFE.NF\*$:;:EO$;7,83W_1N8TRP>
M5Z%+'!(7>"/\2<8J^LT(50F6^Q72"#U/!\_D%D](W )TB@M&)QN,&W2CP]4/
M<3:$W[1G7;>&;7M!8DG[U6GM_9H,#VW4(.>J$]> GJJ!!4EA18;LZ1J\%V4M
MZ:8.IOC:X.Z=\X^AHTG>T1QS"5< ^ %V%W!WF!"OI\_I_%?B17 "2W*\J%VP
MDQ[QKDO;(*FGX3.>^;">RY<ENDV,[67IT>73D.8*[<@(! FB,*/1\-4VL08M
M5Z2E"$G:&6ZR8&AI([*HP5[A2R3#5)IV<TDG@-V#0NHRPM/H%;5#N.5GM].B
MBZ-TL7$_<[5;5AY5JF*'TTZNON1&S%EX;XEF8QQJ&2V*X$>J31G[4!ILM>P)
MO%O+[\T1P@&H^,^&Q/]E=_:O)EX_Y9OWS,TE8O7HQ,P->E=YH0$(WTQF65:M
M]*')P8SN&2R[CDZ"=E;]GZ&4^#?"UJR]//6)A+=V8\J2?Y^W#9H%-&MR^:TN
M70I3K!I>\<LUJ#%I)%JG844J+?WZHD;;6*[6"*;,26 =^C,(T#]KS?*),W*P
MG%S/9MXA(7=[]#O9Z]F&2;_G'"OF[G&+@=D[2/'-$=B> P#PJ^0*VG)3+58H
MSF]65Y(H"NJ?U:2H+MMK;0EV65U<TJ_:JONP!4-MUVNH'50.Z#-BEF4V+A?4
MV-1Q?KH@<0&MB[IN=1"XVU>/LOYY/TCWGXUK^VT1-U$VE9+$%$M[FIH(:G9K
M]2.SU7VHI--F""$N3*&C8[60?M%''1R6E5C-ZT9S%VL&S*CLFJ,4E'5A,\:4
M[5G[ RKPEMR/GUV&(\7UL;6TCY2C?<4=;6A[T5);>B-*FAD6%L["==-^,-Y$
MNR,57M6'S$Q.%O0%.K^20<1\. WWS=;.@,$&DLBK-B/A8#3_HBHO:O2.8:QB
MN?9=J_AYYMN&3ZT%;!P:[O997?G/W%1NIYG-T'(ORWAPDA+CL7!'\F8UJ&%*
M*S)C=>W;-_%EZJM.4(H?ZN;ZZ+*Y+KR5K#72R3JSF8@&AAW'/I8H>?(F:A8+
M&S9+T2B[&5!CNN,/C&X;AD#+O8,4X&V*"/SXL>6<9,::6X32-'N;HM330JC0
M6-#%95[IDB@/N8B,Z@I'R/O/\3,$9U2+>=R[-&'.DS6Y*@#J.9B"E 0IB-G.
MDRJ)HR2G#&,1O+,()?"'BT@6TWN1G$VT-6SHH&B?J964YG;X4T3'SHSC1_0Y
M"3WM@<AU?0;XE)P$G8^,:1BY%Y2@(:7U>S3L@^M_BR=TYN]"%%1"3IZ.ZE69
M2ZN0(C^KVHIN6Y)OYA[SS55#_Z<EF?0A/_WB7&LZUPTIZP&L6 %6YUN>/9IL
MB0;='U?C<M6DZ-O\4KOE*J&2YX:P0]9P$-+#3SL6(XE_&AL;DI2\,I#@9)=
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MUKT8^GQ=S=L&E=6E3^'Z[+HD>.S,WFP!>QQ(%GGE9E+%9K%EG^,<NL7#H$3
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MGPW9>2R,0*2E5Q3D!8XX'T>NWF]J(*G1J8.4*ECUF2+!>O[&KU#H! M)M!T
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M.Y!7F+<<DBI"V\5G-!2_AM*Z21<(.QT/VIS\:,#R0 ^QP[>F:<&R>16][A"
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MU<E&KHY:+_.VFDD\X^%)?G;\XOCM<8YE^.J;_-')X^,G#Q[D_U7]P\$"_1_
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M116#&1#I%W+Y@E'.6!4]+#W@<5!NL=K&!"1F3_N"#<2LS0S$6I+DR;6>;=V
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M9:N;^*0\+/2T\$0<$D.UQKRD5Y#LB/FR&0-. A$'SUJ"BO,279]Y;<AT['.
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M&?-^=3SMMO&,0W%#]Y"(3@HF4DS,R9,'1POPI9BFCI[+>!CP[TGW,NG@&%Z
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M]&5V'OR3)P+!E3AS2Z;D=43G#8[HR4CNGD Z__D*5=GTYW;+ICFORA)OUO/
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M7]V0E;T6H8,BH%E;4W$V:_5-M:(2DTL!TQHEJS.C $[!'1>KK4&J[GF;'X:
M D7*Q=5&-_O+I"X\ZU(7;C%UX5F7NM"52#]5K\ PL9$+YJE.3]D*HHRC"(K7
MT&KUB,ULD%4P+&&B"1)%TEV'M*F"18PH&V+B'""L/&M:KQ9*IJY9_L(MW"V-
M =QZE8=:][V I9SX6\.L ,MGW]_:WVX5Y-ODQ$5=T&OYI ..+X4@8N,)L=>0
M5/4&\[1Q**GDJ8Y%'ER-?$.K@ M+N8WCDJ@6N)B&'!:OJBH,W5S 0NNQ8CD.
M5BX'6.4>Q=L05(:($, 5SA9G[9$D;K4A4JT=<25+0#1HT]R*S&3',++P-$QA
MGS:,# FDM*Y):35J^PD)]<=#_-]'B#__$35/[P2K+] CAZCS?_]EU+'V#6'M
MI\#/1"/FXC/K9M-]@Q,"DCJ7OFGLG>'__O:_I*^?YID*8^#WC,+O*MMN"1M[
MP]PO<$85<D.=2NU)J1JE5P-#"#.R(-$?R+^L^ NQ+BXK9TZ3M;$^9\2NZ5?
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MEPW+M[4[8->XE;1EA=7!%848MBR4+?.E82CIM9<,:YHFJ$K]ZF]%VZLU43T
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MZ[V&8*/H(4%WVXS33F1MRG6\=9:Q-3CN;S3#V.YDU=,\>'O/'M&YNU]/PHI
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MUPE*,*'4@N@"NY9EV"/ &PO[V#+-*H$NF%6,_>OT[^*(6RY&8;[=IB3OVS1
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MD"'Z50P=C*%8,S OIU@4+W:)J3;'-TS](14#VM)_9>K=XRMRLI5C0G(!;K#
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M96F93%"0I]FO?C8;;0UV]X/!WK-@<'"P_?V7]G9[VL9A0H2\4*#DJ>GT\0F
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ML:1A$15%& :51[#2X$.ZB!)%0G?-4Y_"19E('9GSG,T&DJ2?4U.YT(GNS3M
MCX<E//7UZT3WG2W'^7Q1AC&;MU'&\KH3UK<GK/>>[MK=JL6+$I&E=9<)N\'[
M]'ANWE-?OTXFWMER#!<1]S,\2_-Y!-9LU,G%SHA]($\P6Y9$BUB70\3(KIB?
MG3GY"+;R\5S.I[Y^G>B\.WZELI2MR7<]_T66YC.5%>P+]K4SV =!VLG/'Z/T
MJ+,K;]>NO+5&N(\?H.7V4%ANLX/T9I[5.R02..7M<Z([@,P:$F4+QCJL-?;S
M*:)2Z2PXUGKK'3>D[NYA=P]OYQX.'L<]=,*<1*.V!:4GA@,I_T'E$_6G?R+=
M(KF1 F/XO3KQLS+&SR#@Z70:$6#<!;;N, C\A$R*M_Q%JK))^S5^\%.[F<=T
M,ZFZ;U3%[J#<*U5;>X^#@;4I$M0/[CJ=H3M#CXBJCMELW);<*K/9?[S,)G/3
MMCJ>\W2HZGC.QFW)K?*<@\?+<Q*;4'I?GI&' %%?WTSIJ&NF=(O-E(ZZ9DI_
M;>S_OT>">FH13Z-_<,-U@TRY#I52\R;R[P1P%7:F&'F4AC5OLK1<(ES_8'=W
M%P'WLPONCT/= &C$!H8)=J9]\_:4>]3A>](^\)\J*;%;T&"W?\"M8.<PD!T2
MJ5A%9![AJ79&&'";^;PV47Z.&A-X^)T>_NTB2LL\O@I\H'D>8A,BW3G =CI8
M"KXU=IO!7D:+\"L6W6%37MT@ #8L!(UQ=N4O^0^ZE7<RT\V*>%KOL1\!_E8'
MH7!%/O^?]_[G#,Y$&.;S:"G.\O>V=0%L\ 5V'/"WN)?2MOZLVVF).B6=7T9Y
M;OHC 3$7$;4(+G!XHB"/X#"IC!87Q^SYY[@PL"2[L/3OLY[!Q^7US[GED2F8
MT#42Y0BV_GV9A^5"AO _P@,HT@:[@[W IZ-7&6/BC$&MF_S39!S8_D[^;^?<
M4=@KPO$\2>,4%E3/I4(9]HO"$5^H,>P:CTBH<6/L$#KC!L=.1R(Z;TCVNS29
MP$YB.^ TQK=>Z6<"_[<$=CO+L6L4_(&?I&;N[]Z]X,T;RN RX(E:C+)H DS,
MOJK7HG]\O%=;3CS2HQ#61#FR'XGB384',]/I#'LLWP,'ZMAF.]M$#,PZ_J5F
MG<R'!*,06)!A1/].R2GN-D.!0W@>+@O>;>PFZH^P_RO>R 6VN:8NFOTCZ@5+
M?5.PTW7&YQ@[UF;ES'.#9D"1BF.8I9KQI5JJC-I5?0XO5+UYB6[4.HO3$;#@
M3SH61Y7#SJ OHXLHIZ;>9QEROB*EJ2"1W!4E\'$]S%(X?!D_*Y_)?6G\4RFM
M>ANJ"=)G/NZLVW"*7;F  9TFW,YTK% A*Z[H>W;IL4T[*"E1/D?.@(VZ[!B:
M-R.QL@R&GBA)T@N*6G"/4Q!=V'45=$!\ ]:Q\2'L](9]TM(DCU!IQ/XRE2&I
M(2LV!0,V[5&/,>Q_&A4EMQX'"N;1#-NC8N]R>O(YMZ!!^BHCR::8 "GIF:-4
M>H[1VBW+42SMW8#N*J6: 9[->R]['G&C<U"&8_BTY6WOPTDTQE;)) ^!6[\8
M,N/Z%(X5&AO^"]U11UZ"3?@,G&AX 2J@P],Z3O1PG(@0" E],/"1"5D6U-"N
M@A4LZ'4XRD0Y&@Q WDZQ=9^C&SA/@S3$OLWX:ZT@!-+\$%MSUCL)+JR.4FT#
M9<[Y%&]=(,H7<,!G/1**-"%FAKG#"HM+&.IJ9XIW=@5/Q$Y2<GFF9@&X;[)+
M:J79HS-"RKW^1B6P,= +<?PXF@I/016+]8W(*$;$M@.':*N9>O#3*JT4;Y)*
M9J M^N<%=IR: ;?26MLHA8?!'',;'F*(%9MJA=0@/#?O@&DKW,71:$1%- O@
M:3X2^%F4?Y'NW[.2N17H(&3!$9<-L'?C):HAH**PJ@PS/')G:/F[8=N6J1?^
MFW"1.PU:[5.>48:=>3D<CDX&<#+N@8Y-OHHP*8FN, M)!^=3&4[L:W#*@.^#
MCD4GB>CE4X?''!6](E0+.B?PV_@JAU/@3=,Q,K:9G[:2$CC='9U?TJ+QZN%
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MHM$G%$BI =-'P;J:)O',QD91#9@B07$ 3$%K44TQ]L9S0,!'3B*QP6VSJ1P
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M67$>4!(CWE=A1RW(NQDU05+41;)XKQNU$EW)0BZ:_0\OJ[]2J*5U>N$%6Y#
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MAPM$&60;U9R1V1%'LAM?ZA0+1691*HEJ@P:CYW;*N+?E6(I'W30I03T .^B
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M>@QWX.^=IVH0A+W;DB]5$!JC7\QP9]:S&>?&Q@9;!ISCX!UNG%M%<RT&8%U
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M1;=8JC@Z.A[2#H\F5#H8V/(FSMW+K@K+T?Z<[1HJDK/'A!$Y;)%UMH 6_BQ
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M_Z&9K3]Q@7D>Q"O^KX5I*_3[%0ED^S**$V^<#/51XIFF_\ 6Q,LHL0AO56%
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M?35B#SFS%,UBJBGO(@@6#!.O*UGC&3H"7I.HVWK8%=99-#1+,%P-;HEP!]S
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MF@ZD,-0.ENI#9)9XZZP>&2U9G7<U7S!K(K0%>)^1[5)=[HL4XHSB]"O90%7
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MZ *,L- ,ITX/>FC(^24G'MS<\Y Z$%'#'Z(%82"&&KAA7 ,5!2ET6..:@6E
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M\Q?,;(,M U</0.].HD[W]PB3,C_<YG,RSVU(/*64N0Z"7;K)N;J=<"N]%>@
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MW0/FUS@TP6 N@ O$#0OMO2?9I_G[0I=THVC/A\6N'$6[H8 YM_M3NI >]SU
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M.$9V5UNN'4,<P*/")@G.0*3SF6A=JUQ%"0NE 9316(Y7H-["AWOVP^F1@=U
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M!1"-K/K\P%\^J%%AGZ; WU6O&JCCRL?(.Z+C@E/8/0]CM58C_@$^V.GU "(
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ME R".BYM-_[K)H-P&)P0LBU ?VM[?6LE6J4=[HC](;$1)X!\RV5/]PO%>]5
M\98)Q7O50/$> !2OR:@T&95_GD6T:Y79:4N$>-?%))*,9H7>+*?[BT[H,*1*
M_!JB (@[2+M,JB.T*A1CX^>"PLVBX11\9F:@944?,*6\\I_!5G#J!JF49S0S
M?GFQ)LZQ,@Q1K'E$2R(E.!))4SOZGPO(2M$ANZAJB$2(ND$>&S(8\:B>%J\,
ME'BE"7"7(S6Z*=RA<$C50TV\1IV22.CY95/M:).IKX3$E;(23<) +YB!=52%
MQ' 853GP0G, WVX.8&JK2J/C %E/2BX/1_DD"M6DG$52GW'VG(,R3G\7?!%7
M?HGY6'> J-159A^XQKU:F<L(..7Y4QH8$V>]Z1!";5A^UYW142U8K@%U&5#?
M -+XL*N&0V5:#K %+&/K6^:4<I"F_H0'-GHHN@CE9(1_I52WF_DGD"E$A!/_
M#M^&V4I==@86-6R+&JP3<BJ;M6KP4P)3Y%'TI7K4ZNN4\$H2"]4C#="+QV7.
M]:5%TJD[_0)S*%U\4$$@X2 0S&'H0K#F66V2+?>H')[: V#@CK?8'=FNL^PV
M/ 16 N.'U@*().'9TWKP"E2X)-7HK4Z2%"]YC;0(,U?>&/>3ULH 1G$DU> W
M)/^54CT\N>$ :@!#N*+<"9FOEWU%RDG"!1Q)'$;1F<0.,Y;L+?;_>8RN5&/W
M-7;? [3[#@NV1"$.UDF 6.#L?#ZBA%,L1MN0 #;"!RNE(0LVLC1J-ZIH?1;P
M7>?NZ+J0F,17M;PJQV;"U97V*N%'6$#S4$&)<XMU2?) Y@.H[+$-IAGRY7F*
M037);,Q7,:1><+P :.B*DN=Q?V^/M%W*2Q8B;/S'?1F\?JP(S, *!\*Z\S#2
M\60MG>HN<SP7:WZ8-2(2CHJE(8B1N]UF5V.'HL+OAOEU6&M&F'R*N/,069R!
M?ZX386J#1H:Y(33:T'8+BC7_\+#ZUGK&=+#JT^>K0]U7>I!F#C<$CF(%#42_
M%X[@9A#0!L:5 X,!1V#+/<_5=.#1#M.$M1%@Q>=CZ+F !N4DQ%X8]9"?53HG
M1P4J![UU;/5+GR;NT   M+QW'O6GB<D08GJ28K,(3$([IMJTL&*W@=T."\<R
M!YI-^5M#I5)K9> Z12$,98"-"M]#6R>G8V'@[V5 $-'/0O4CV7#PF]=9FI^%
M&5UCI[/C(F>C^D XNZ5;9SWN2&]CGC3FR0,T3TZ,7TE:AUTK'9)"Y.1<%[3&
M_9SO4R[H3U[K_97?6^_TS;=J-K<0TCI&Y <(;5+#(JN4VJW7KD'UXE1'>@;
M%0S]_2!#V5._Y+"<8'DPB1CF>80K0[LRHCB.H(>($&=TD:+JD_YX(=,HM=>?
M:_R-YA/#EYNHE'E3 1>B%!M$AD3Y!!(Q(DL@\[>>.W,%M7*61=#\G'8IA$_H
MWH(<VIA YZ>)'CZ362%$IB\^-I'["'</=QDL3(T X#1T95SVN;5NR'WBJ?8)
MVUW^R%T"D2 I)G"-U7EIX$=4Q^Y&,;,,'H.'4EH-7JSJ >2\N+(4]@+7K>>*
MB8CDIF1>#1)%+F@$M58I1BB529/UXAS5Q !6GH:X6H5E\R_BD*U$,5#&2<@0
MJ!48A3*C\C"A\GPK&6SB?\6MS%=AYXFUB]8&+$VP>OKXQ%Q]:A5LEFXD,6K>
M>#$2B?LL_8)K0Y?C K*7YF0K<V%&.Z0<@Z"NE*W^-MEW2%E"PQ3L;I808%+]
M0)8B'!PP4YQ(F#&GU #4$HRD>29802*#8DWDY;,-.ASI]LR!51A%04IE,^/)
M9'HV\VT:!W#$P;F#(T]]524$+['K&=8$(OH /3S>WE6G;P\O0&X<B>KP:IEW
MCH5'OP 2Y""D\03PKBDW)PN5W(Q'T(OTM+2 TD@6SW(AG$^H?B7ESJ-$#FFL
MZSQP&,:79;8MZ"(C>VN\NF7Y<S6^G#!SRID]YEK0#TKL%R;MXC?5N>1'5"S-
MKK4T)W946K? U6U+]6FCFZAWB#H!2U\X#ML[;'\L,JOVH #G\TU8M/+C6@M0
M8]>+B%2=6Y-S)_M4"$0ZL0GU\5L[!G['BOS7GP'+ K#.055]\AQAIASY2*D_
M*T1BIQVJDF/BB<'?X+L"7M+WBB+!2B2DLD1.F-U*+>H#B!F1AB+X 7 :M->+
MG 8_M_QWD$<\"0>1.H%[NE5RPVK0L'[<+L3LQ7H#,5LBQ.S%>@,Q>S!2X_9%
M^R,;;DD3;10UT6'+TCY 3A5FZ+L><#3\%^7!YOV8;5_T8CYD4*LR 0C)F%!'
M#=5;H[;N?_'OX3JUB]?I%T1608P+W J\2=(1XJ[N2(%KIKW3VMG"T3^^S;MM
MVIQ/D8>9:[.K5_VKSZ_67WR.HEY_;8VW\C3KRR9"1X\.4; ?).'9YW[W]',/
MB-;7-]8W/G^&?VVT-S<^?TV.=J;#[;U/+X9_*3LH"?.<'CX^'TT^'[])OO[1
MOKKH;?XV^_.D,SG<3Z:]=O+ES]\/SW[[^9?S/]\DTS]GKW_MMJ_&?[23I#=[
M?=X=_GKV\>=?+OYH__:E__LO2>^R\QD"^E<_C-+1^ZGR&N,>NO]JQ8ZCP7^>
M'63I$,:SMKZA_G>2XK\WVFN;&\]\HA;XS[/X:O)#-TV3*!Q-LFGT#-?@0/G"
MZ^I_MMK/_)&R=_[S3"W&#]>NQ;.?F)O^?__M#$K./)2=ZAY1X.OR_1A+QQ14
M+L1012%N^017:.8. ZE3"F2%.;%9%</,,*CB]>"149^++IER0W<S4+:7^JV2
MH3.GL8'RUX?I)"HEF*W<=LP778:9A)?JX<0Q1HA;2 6C?J0V&Q"H23@'H9.<
M]A,%XBD@S8YZ_5B#/RH%"P5MJ:\80BKWKY!%WM_8:+7I@:7NWKYS@\IM#2^I
MV:03[&!L(9@'5 $[*VY/>CFRM@@)]V-N(DT#55\C:C5/@Y0'41]+=:VMA574
MT$MK;2(AL9 5M!-*1OT]>IGT1#3C9E$S_K?E[\X 84);/7LZ)J/6&R^W/T>]
MF=(;SD2/X_R+B5IB2Z@\CW)E8'?@_^?J+!_"62(&V,ZHCQ]6_SP]AVQ+?JKF
M]#I)>U\^QZ\K=<W9ZX/=XW<?#CJ'G7>G:[\??OYZU1YUC\9_'_UW_<4BRN?]
MUA_#WV:]]F]_*<4R[O_\Y>SC,/D:SEZ__^/3UOF?[=\F?W[:6C]\<S#]<_?U
M:5\IJ/Z;WT;1R>O]\/?W?W7?O/H*"JG3^?SY&^ ,WW;CJKJQLMCZ1I4(GXM'
MTZC?47IQ-QU]1!6XK3[WS(_R7CB&$$)91VZ+CE0;_\/M[/MM6#Q]Y<(EZ9CA
M_-#^BEH#^3U["K[R_;X #Y:$W)56/,O"82!D!\S#X7Y)%'H '^?^9X&M2 &D
M'%Z&6<3D5OA,(@%3.@!:/]&+40MHI%I1$\O[-,,7M=ZB9I6C08QKBQVWE*::
M8DL=I2?C,<*DBA;?Y@UN[B'V[H($@KF:E3;@V9>=M[]=O/EP\:9_Q]?P6R_!
MG(.^<].#7K%,SWZ" @WGM'AC^CSB"KH1<&#H[V&FG&R+"\14E,YC/LLA4T3\
MEO@<KB;)I;@'@0DCQ&/0]_HM.X<46ZW;D@B[;L7F4N+[<LG=8NX;$!SGL;H]
M%4DZ1*1<D!F#IFY?X!!FR#H35^#IPJP0=Y3RTNPL',5?R7;D2>;.N&&U;![;
M4.;OEZ; U2OV7'KI%/+/@P$6BIQ#ZMN\4$;HR8TB:QB97W#7(K9NU64$PTS2
MY^ICP&$SS8$(ULV4(1,NBQA75NB,>JO.:\"2'I0&*#5IV7OJZVJ N6%^@1YM
M.:-" A8"%U@>1VO!&7U8ZO)" %7PF1H<=_PK$?\@5RKV4N>:)2SG89Y CYYG
M]>NDK+ZZ9D"HRS:]GC%DZ\-)6"[MV&SM^7"5?+AR@BQM_XB_RW7*4CW.8H;S
M3Z/>^4BIO[-9X,&%2X"& -@+U#54_@[+PSWU0O]$1D"=*>.+L#?C=QP.8(NX
M?D<Y#%E_;8RI4=E;WG^@:;@";D,,<8=F4A#!AEYW,#,O2?/<I+3-4MC%0O'
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MW_G'TCI)0*&>+F]Q 6&%8C%?JL0/3ONCB,N2MB'B,2D'J^1%8?5@0B(![(W
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MPW8TECJ_F87Z[:@XK1N=\;9LEKE]_5$EL+V-^T#V:&+\I=N[)1:=J?<L>,(
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MUKB[:AP=/]R?'S4N6]SE?1-+H\Z7_5TQZ%(K9QLPC' F=D\\L=ORQ.X^KS,
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M>/3$F*8D0)Q )C$-=XZ5[PQ;I8?=X&59"(%#EJ/I"P><7Q[1) A)@S SI-8
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M)<1LI:2D5LI*2G:&%N6,%KNF(5B6]]18)-B*>:%2SLI[=H5/5N8!%C[@QGB
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M%6G*/]RMU$.?\9-(020\H2Q^IA-7\-]<H>"XQAC[2:/I(55:(3)SI9X!\9T
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MR(*8*4B6GN3$RPW8M$""1.APP3K(W;L"S%D?@5[UU3> 3,.W6,B'<EBZK_2
M"&>P>_'NH]( WA-^8@]O?IN$^C"BRL6_7,09W5P'T453X4##AR/-R6.<%2PD
MD1JZX1/[ /M(]V4=^E9JD0BAMTQEA$!&J0-XIXD%O;^<(;/,XRUS(6R9'TNF
MCLEJW2*3')<L-]#]_1YC[FQ/]=H#NOA^JI2,U&5>[]=.O]V>G2ZVIR>OYY6>
M(#7Y7]A./\16D.Q$TK'XPMM*1S:G&5A@8M>7GHQF(8V=T<J$7+EY$H&TAI0&
M0L& /J'%FT@I2-BVA+RLV9&C<^QMC&RLX'2BQ9015)W26K0)DLP#KKF0+7(;
M>F>>&VHCRS&60:6^@"*SH=8(:T5''6(5@)6P.<DY#X34?VPE@WJ+>#8Y#"&/
M7N#=")5B@<<.CN/2N.*,P_*,(P+MP'%OWI%^V2O&;VA:SD_80-I%GF2#8+XQ
M$?1VQ(PWEDS3*P/Q/I"#.R=GVCD7(Z=WL^-2E[U<81CB>,>R(KQD82\0'C-G
MVM#),:Z!(V#[#LG2"%MCI+IEA+G<\AJ$<GV\1>#<#<.G%CQVIT[C.S)F5JAH
M*&45#4PK&H2LHF&/A6MV2IY5-&05#5E%PY^SL_=;FNY>1<->$VQOLX:JQ;GF
M')<0[D67"'O*5O+(VI*[VE/[ZTFETQJ,[G[+650MO!&_;2^JUFQ/:WRW-_II
M/_1/2S"14,I2@78I?+#PZ%LCE%H4%JJ5!#<D1$GJAH$X7VV![QS5=SY-3T^=
M_"$L\.F+<G"P@E]!LY[A%M]1!QQND-X(1K< \8+0S8%S:O*%_[1:I:$WY[B<
ML_J(7&L[E\K&8 !^'SF4R=V'#FH) '"^%WSNQ#TJ&D(^,E9@7M4+.3\BUSI-
M*2QGP:1%AY<?3B\!G-#\9BQ620:5;FN37.#%@863A;KOMK 0]9U1!=(*\%,5
MX!:W'P0Y+D<DLQH^RC(6RTH(4">\J,*!I:3E: (YZ7<Q2_ ";.(EP\E\8+7!
MD\<1X1QZ&^V%@HUS;'J:QI@<CI&QA?ZXJ*K3OGV$]B^2JI&HA&3G: [YC$*T
M" .2OEV&2DH&"J$UZEC$T;<#G5H4-(1<<P!GW$?X9C^55"L7[)TF.2D4[@4$
MP6&F/.":LQ!KN'N9%4P)@.QV0X?SP]"N.. N/4:Q<O1,=59Y CG_KS9R4C<H
M+"2=0G6./27+T#$F)YQWVNR>Y[IO)D>Y;O4*_9D^W7VSEQ%(BPX<\'*.= CM
M4Z!>J)$)22:)XOM]C>&]1\$/_$?DD\0-B27%(0TY'3TA"\#@L#&GVN1(VU4,
MM"Z"UJ?@#<<+W "_HD]/\[%I%I0(Y.GP&DFSC."[<MZ[X,S:87%'KF/6A@H3
M3U(/#9V(5+()(>E(0USHQRPWY@T7X%00TNRQ%\E4B1QW*02*Q,WLTBTJ2SW%
MXB:5T2:-SDF$H[O#^GY>)RY0_IF0>5M^.-=S4=:CZ!PJXD=(U%2$##\5C:U%
MIAU)QL2B1#7)U:#E("60P_^0A'03LM6QV4G,/5DUY=$ 3L1D\H6BRMAJR'G*
M3Y9,DY0WSXPG27=LJX$T(2S8H8H-CFF!A:-:M(V@^Q942ZN6VWM+EJP^U]6,
M,19_YUW.,KRWD\HYWQ)RY !M;(PTQ7V7HT3=H[19/J27N;D >)*Y2"U#O G
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M6"7';Q,59I;R^FB01*B).PS?FQP9:FJL3 ;.)@-'R7#S=MQM/1^/=>EUF\C
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M&FL<4888>5<!%PVT1L?01!EI9LF0]0W;T\)?Z?.R..6=Q2A=292!CQA=%;$
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M)=/>###000L U'[)Z9*/)S?!%K*=FW%O%QA)HIYMHSX\Q%HJD*,+&78ZA[/
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M.;OR5)ILL/9"NIS4#&D7--NU@\+:)=>J.RM^3!]_#I9BDYB6FGY"7]64L3I
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M3UA C<UL6([-LENBCMY1_V%8N+F[1H/.UV"W5>UX-I>0!\@>AD^'"V4W+E#
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MIC<T+_@?1'TQ\H2ODZ+0J0]&F"P"MZ/2O%Q.#B>29C5P_[K&2!)KC$2U,9+
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MK<4/H]>0@T/@+E10@K_H>R\>SQ>2!GLBN^*,H:KPE)\TZTK??)P,;QH=Z\=
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M:FNT1F8:DPV-2>CF(ZU=^K6JY7.E4"TG]\]ZK<JL:[^MT3%N/SUWDS^XQP;
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M:!G"FGV^SH$>!VZZM#KD_RA]'KL\V$C&<*2/D73\%[$]J#G[E1<H"P0,P9N
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M 2PTXBDQ$%W24J2G)$IU:GY7_FC33(N!W@5&Q'/?,K]HA^&A;LJK):^FD97
MRZ7QDB?+55FX. +#4?H.H0[7)>CF.0Z@$S0]3 ROROO<#%_Z1(%OZZTDQE!2
M4)N?!PXA,RQM>-,QPIB7R*+9"T6!!87G!:IOU[3-^(T[B<(YDC<GHR>G4Z_<
M]Z0-E/F.WQ1]CV.<K9Z8I;IV8;Z*S_K2#)BFET=X6F!".T8%%E! VS36-7H
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MK\I0)[!G&\&H"I!^NG84NH)-4FRZ6,S3]D"&GFAN&JD./E16TK5<H[+KP]A
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MAO*--MV=U!U#<5E63]<6VK8(O1=TJI1+O*FO$C!_Q)WB*$$7G!3(!.9T9(3
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M6&>&*>LY*,QV],O/2\'XTM,TQ<"Z9[_R7_]JIM$3&KS1$YHE6M*;JVI\=0[
M_0<];%0O68T$J7H>JT5JS-Q:!9/+T$2X.N\@IN.0T>ZF@94^\H0KE4R3I_1/
MIE$Q1(2F!W;;/!]0VB]/$NU6Q(EP7*NG*JE^$4U6<MC3@_7SJY/NDX%ZY7I^
MB$&1J!=I2_2OB!DE$DP*/0AO<*5=8Z91E)((/N\Q?H6F,W-) G5I!@:2-)7
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M1B\/;^)0?3K-+;6BY*O4C;XEI1@_C*P7^C29[E\)M^@SX@%2*+<W!W1:D9R
M!U(]R( W9 C,4S'5+*DAT%=1GCR^.F,GT/KF(7,&+<@\!6\EH2*9)Z 4%$'W
M%<33#U#>0%.DC?2=X58X'T["1E8]0G>";@%);O:1O_L3;TKE3_9U<9.)+%)H
M;_SXMLS1H#]C6\'WGJ+(9(U*W5<=K'.^XO9^='9A;5#X51D6BE=V+\Z(6'%I
M"+#7.8*B )\"DG<V;JB:*[G@L8192EGIMY;39FRE-3<_-<3YD;XA,I<RQ0KV
MQ.N7W:XSVE"^:6+PTJ4CT/H\83'M",2#'B(?AM-#&&F&EH?_\,<XRTSM\"<B
MSU#L>N"&H24 _B;E?ERM1[$G4Y,R7?O\ %GN7KXX]]1Z_H97[@6JN3)J&@R<
M\QA")<&D,<>!<:;N&@9,C>_'1B\V:0QB9P_[D5<IRR\Y8Y_1D:R5@;AW(-V:
MM('0]KPZFI/PWFLZT[&EQ,5UV%WJRR!.[^>2QX5 6\:O;')[$EW?-FUF*KAT
M1V,X-DYB00=46-P?$_#E5_;@/)YD\D5*R*8@>3)/[U\C%S[8B5:YPM\F0OJR
MF:!]8WU9J5-%68:1EXW'1@<YKOJO333^KLIFU$P>9L!FTGDEC17.LI/\N4<>
M/?*]:L7)IC^@I?H()-=;U7VG^+PX[Y[IUXM]\JF=DULA;NQ15Z@O9])@1R G
M<7TIF<I6L>^:!=3N,>0[M")T_X U$4)LIP8=4:^Y/0Q:DC?8?$/X0DY(&O\%
M=0^<3[T,OB2[S??XA.B*WB L+?]E<JN>3+82R<R*(VQW@_,?ZFI!\IW2NY;.
MOG<;,1DPQD<>..FY1:0)I^HQ$$^ZF:%_9JCT*()Z:))I=!SY0Z$@FF)*))#C
M[E/4L:GQD1R7\,([^J[W?@DO4?QSEJAC5F8KE/I"B">?$8CY@U,I+0HLFLIA
M[@<4!VV96@<6O54X?6QI<KD9(=<P(VQNT#$;>*NBQ7)6Z??,&%HH]]-[/.!Y
MORG,8#*/61ORQXLY^@O5FP"(@7XC!>BZO$.0+07/8^:DDA5.B//4IMY:4>C8
MU<]'($@A7&E]#D4<1)PQ0I_$2+AEC-'OX(S):.?F3<>7XJ#T",Z9?;>\Z8[?
M_<2):6><I5(Y/OGQ[FK7@9A[3BCR#+.S-OC0AKR<MUG\]_R[C 6AN[= _Z^7
ML,FC>CD.!1?-]+G'I-_NLE'\["MMPF'O_WD_(8O_SJ4D)96QE2/6;1#P/'!K
MY>?T_;P[GC7;VI(;I&_D%QUU*:MUM4^5(M3FPQR8NTR[OX6[JQ[;:61]RI #
MT$6Q&&+R44:_V2(U\V^G/01055^K1$V!:()%!TH @-BXCF0(8SHJ[6NG)^JF
M QZ660\H),F-4@Q(J6^I'83Z>*;L*K4"[8]B\T2>HTSUCHK4+FU*>=;2-(2!
M&PY-A9V'%F11^ZB_"HD$^;SP&SX72NSX%G;&*YZ/<XK[1^5'^SJ5ARJ<D$V_
M)BO\Y5'/9P _!&FL^XC1[@(Z*"I#\02E_GGD@J2?6/EF_*\9IB3=(MP]U< ;
M*PY<-ZB!*/6+?"QNB>YW4!PMJA2R-S^7)SC>&L0U47V+<&&XMURKP$.XX;6?
M8E-IDPMEM]VS8I9 LI7G2H)_PUP>M*KOL#D^D907^V'5?,#AKHT_8DKPX?#0
MDXB7[J%:*7(=U_\DB?Q,U=>MCMA7M0C,OB-TK&!7TES^&M3(_-@U5>/>E<)_
M%0292=&#$"F[_KX!;,MT%$>A;D]:K(SNYU@SM/,/IC+LZ94(PH@/O"G%S^1G
MD"3'(^B! 6SN6ORKM(/1(;HJ# ^#;/E ^/G%.)FB-Z4$4HV-)+]S&IARENR6
M51FO2537Q[;4X:'91R"U[,.P2N^WG2NS#H(C@6;FY<K7&VT*%+5'SV]?ST^*
M"KDSU<P=J+.+\LH?#F6LLQ6X<<JG_FKA](_^;MP-"N!N2S-_U*VG),6S(K[2
MMA0RO#H#/@-^!6LI^>\Q"=H(W:M\_(-!>G-0R)8J>7X0:AVVPI%M),O$L3.W
M:5[ LYJA>6!$0"']^46FJ$IJFWP1W?_!B,8W:Q^WRSOMBB>_FNNL-U5MNGNO
MAB\L-?ZUG3F19M&>%+S=^FG7:/;P,7H;A]^"T.^#GV4QPQU1I$7Z?01+-KG9
M:",@#]HS(' ,LO5 #;6?708YC7I6M]CHUY<V1)*N/@+-V]^+, 4?@8S?0.B"
M&)3W07@\;9[_@/,;<N4(]!7:S)Q5HM-8.7 ("[PW^E^? 313A)^<>P0RP5-(
M1R!^X=8CT.6?J-X>1L,1Z \>*84B$%F;+CND5?UW;P1-KB-0%"MZ*6B0OX)W
MN-]"6/\,-/KW?RH_ K'$AECUO[_4$%& /:0%QI!D54HWM%VDC]QEC8>3-G($
M*O4!_(] \8FL3=]Z&96RM*7XFQ+S)(R>CFT]C_JA[L%*>$>@/4UR8*@&YVBT
M.%MJ07+6")(M*GQI5PFW? 0J^BA#Y[_Q@]Z'A\0B[B!ED;,%))H/X#=4/VC@
M<@1J_W0U[, FOE\#KQR(GFTE?/0M#1FTUZ=9%XE(#QKYQE-Z#^)<7DQKL)-K
M"XTP!:MJ8 NAQKG+#\=XWP99!G30<QO\EB/@N+"WC[,.3;:T\SS//<W\;0VY
MM.P)4V-^(N[3T8IOTZ\GEIM+IF3Y)H^J//R4,6%/[_X:<TOUR=4/-I+T9J6O
M'NI?S?45;<#2K?TPO(IL&JN,%G,26%Q.H6!WF-*VLI_Q[\X-*B?M.PG,FLLB
MLWU'DF*K[XJ,B'P47.'%YN@_'_7VSV^[?K2LE6.\KIL>R]U+0."45_[U??-P
M9/IB-@;QTV_+J/M0ZA$TJ=J1;-%P?6+_/6?N;]!'S)_KZZ K#9<;TRZ]-,R5
M#! @BLXX.^8^K_5ON__FHLIG^J#T&S-R8;) NLYY;>H2\/+0 [W?,A97>'*%
M)-V>&;J:=DJ@6WH[Z\?S %0OZM"#8KH^19EDC^2DJYO!#U9Z/X,B+NW6RD=^
M$[*V[^3-:K=2UMI$-DNU8O:PQ=/A<?.$0-WY*T'@^</7&31#M^%4V=9,X7@#
M77,EU2,0O/4)I\+)L6%1(X<HY6L(.49589RI[1V!5K.>I)12K\^2I(72-\NO
M+RJ^!$ORLZ 7*>^W/DN9PFQH4C/G!)(]%.#_I!\C0/782I9RT:S??<W C79]
M;FMIR;:_'@>M, 5@2&;7P10#*I.-:<PUZ)COJ:G+8?RUPOVMQ4RK>=B;AA,"
M%18M6BLM'')RPZXN9AH-/K(OC:A*D O.$$OY;3@1\NP)S_!GP=J/OZJYDR6
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M=I_:<@0Z]2"E9<*^0$NC^<IEB9&W5Z+<7\$,"Z^U/RH<A7X9,VMK*OGL#1L
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M^YD2:]I4\V.8)ED*5_V#IOM:UTWX*C^1PN96[C>;NK_Y</]6+Y?8V7[*''F
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M< -G-1/P##[BMW8<>.'9?&76 *+E*0@S[:SH?PH(5M35\'/2CA>NKU'TNT^
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M5YNH0O"!2>EDIOVL0HBRAN\>.!%V&&OW,?MQBEKQ^5(.V,-L$3VQ[6YE=-<
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MG-'-,N?>2V.-5'U/M:=?7QNW2S@9ZFL52MUHQ+F#[3SWP;TKDCO'4JY?_OK
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MTS"52_@]AJ_!VXDPHS.L(&VS?O9%QQ_IWQJ%G)LCM)X] 14N")*1\RF"%I\
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M45^7S_!(+/%?E!!OEB9?\']3(G7W^&.#J8./5'.7=WS/?^'FD+:U >FN+X=
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M&.C.W\--00[)^3\/#R"/4G>6*>D'$$ %^[]=U7(#T?_9+\>'X@,(S!,[QW,
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M#U)81__?Y=(R[O]?R_]?7LO_OQ+_6F(.47*O8OK#9^ -*S/F_62/DJ)$SI4
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MGJS.7F+9^*4D5%,WI,[;M"K#T5F-%*MJBIUNFR?13^Y)HC'[+UC*/\"]+0F
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M'$6H=_"L(['_G7+HNF[B4QHI:R>(@\*]:PY5VS'8?\_LA0+I 8<8>ZYAA4O
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MA)>9^]AIM82MGV:,E$F_?3M;^T3C :$K8T*F"/("1]-V;G)3&$ )4\/&(S6
M2.+P@W_PT,8>(=OT3X7N;J_P8Q1K,$ D.+J3&2;Z61<]$%8AM!8Q[_-L77T
M^=W3U,G$5-@S^L9(HW$*[$1_&+XC@.\%$J8DRKATBI><$*B"X^&,6ODC92&=
M!C%SAX2;7^\D-+$D-5_2=P'G@;_2#4)U-##SV"*KJJJH=@>)3PZ!S(I\.[,3
M.W,!7-/.$L8)]S*0Q3_\HCN>&)LWJ(O:I:ND.HQH'FI6; Z+@UDN\V@3SRFM
M&Z8R_ 2%,Z +C3$K-KULB_=1R=H>@JVED%F3X7>:8\+*]NF+QA>U[7#P720?
MY\BW()]+JVW?@:NN"ZC[N&;[E ;R\!9@(,TX--RK1$1EH.C"B"*R8^2<[7QZ
M"PACQ$I^CKX%Q&S$6 =V7V';E;H_QP1VFW8QKGDS*/3I9YP_P8H\^.)T%%.T
MN7P"\\%V]MX)V"'LFQ]H%/<=E);N7OA8 ?M8[ZA^0?>HK B%977__:RX:"2E
M1-TZQ=[E M+B=#YRD]Q.>&V(XYF&/<903/(VHV/'ZE#CX4;U%XBN*=PS5+2P
ME*XII=F,A+_X"=C?:TK3H6^I5;D/W93^\8G$"^KPH'\] Q_<KJ63(&",C2)U
M$640I2B -7^/_OTHG2*2/=CCB  KI>2D8*"5ICOC$4BVTYH34;GX?LY3M<U?
M1WL:!RHU-\W7[PZL2ZRA=.JXB0J@9!9^;60"LTP\J-_#5N1EH,;[GP<?L@U;
M1UK'XNPV:!/UWPUO6W+';8BEZJ#8ZYKVR=?B*7!/T,XIF+L!@CLKS^JG>,/?
M-TP$R,*TIP[RV%W:4Q%R?A"ION>-^D/GAH_%N<3Z;5,^O[5^_&8V<"$N.FE
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MA<PRC6?.)!L]YZ^Q]F) '#><];'V=MD3' 3[F>'5<?%CSIF4F6A>H?)R1F,
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M@IP5QE:,EO70?*LL"ADJU-J$K:"!UG!*\4>!T>;U/L.XWG^$PLSW2X9PXW*
M5X8E::*E3S?,=.0NBT=+LH&<C]?-H9/<0(:RDX-?X6%EXT8/ZMEXN8%>[7#
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MJWX?)=:+/)%!6C%)@U=4!,8S4LLT0&I)L$6U';-;0,VC.J[:UPGAS)P<B>V
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M*HB/,<2XOM9U$2*4B%E8$@^.IJ>F>58MJD2Q#Y6I'^%-L+%_X;&X66-[L[+
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M.YJ-N&[:K'?)VP2YB\AQSQD[AJ(8!4'\@D6V20;&<MZF;'MY M'O@QB4\LD
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M=@]R<W^OJ<+T9(H,6VN:;WK?[NV""'F>OLQ)XQR*)P942LM_U?M8,;=YO\N
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M@5%[7H^GA/"O-BIU/A%R ;C$CGX1,]Z1O _]P6!RQ]T"\O-!DXO6(%?"T @
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MJ1#$U5.<(F]4V*2#[36N27NX=WR5=6?K.&K5)W<ANEUEPM+=E[%H:J]=.Z[
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MKG**\J8CO#3Y1E,D.?D2#ZNNB4<^[[3-T!-*$LP:E!+ND<%ZCJ#/,'91Y.]
M[@ 5UDL G0HR?Y/__7;<U$Q&:0^F.<W'%!%QE89R,TMW]V74W]_8%<YOWW6.
M[CJ3=OME;!\&93[H#.]HM#!:K3(4QZE'WPW*!2E^;A?]LEB*VGU6P;U[CZV&
MRS*@R+JO NHNXN<Q[+^N]WZE8H2YY>B="PO]R=H'P4+ZN";WDEOR8NGX."QU
M/X)>5:CZ'YM#W4PZ /-LP.AM]*)14DS[+)RR->K?D93+<<U=LTD6VG9R;0Q<
MB>OT5_[:I^Z^W8%.7P*JV(]'T&4;,$:P%ND#1"2"=?#"<M#0Y2%6/D5<3LS_
M]45,1@WV^OHO>\T ?^*#"B\]H?(M=&I_]H?P#.TL05?=U9:YP1(>L+G;M\P5
MPQ5OGWFT^]E2#>-'G(EON]F@PNQ\NT_3G+X]_/L27@M[@F0<2>5SM,";;)(4
M1KC#7N$6.FK^9(0FH0]XS+XO (1K*G9W [=I JJ8A>Z J].4_#U/GM[) IS(
ME_J\U>_<2'^;M1V\#>K4&+SR*G 2<ALR7!!.9,LZ&T T226&&+,/.&](\*#\
M^Q6A+V! R!*4!CFC&HWRCT]%3AJ-H!8^U. MD?&(Q,.LLR?M]1AT7IR<KPV;
M+K*CL^"0ECT9*/7?G4+SGV:"']B+E.6K&HY*G:8GC]M0#V8NUR)A*3Y@DR")
MKF=8QDVI.,D0QP0$P]^%@C_>.R% VH@I>P.+.=D8BT<TS=X6'L6R/I8-ABH6
MU;5-,4T'M:7&X=[=?A>M.T7<RJWZA>L]?W4??MK:%FT3$0T)\E22X%XEYTUH
M6^5H"X2MB@T/.5+FN)FK6#'FESW_QB;S7-O:*6^\4#Q95O1*^OO6@OA5JF&\
M?M&WLFNVSK[5#)L9\+'%@TO !A!_-R\6PD,,7FR>I@?;8$>2Y6J7$ :8HT'X
M:XE/8$.,-SYO,PAL,'/XC1@CDM$\S>9E";FUV#1-;Q]1^:VI-DZ^0RVC$NDD
M\2>+I[WF:BBT\>C@A&!/? BD^\?(S><@JGA_I"X)KOH(Y<P0#]V<ONH9Y=^K
M,AW'C'CT_.90U)^2S4D!)+EDL].%>:[97G_OKR0=P"5CTRG?63CKW;[9UBRQ
M+27#1L4Z>KGFV^E>AW5_N6936<* UN=RCB_/P-_D/9>&)S^_:]YK!I7>\-^$
M#OC3$<,QP -DI7>>--@:7X(AH$!#4,H=UJ4]"?=*O )2NVJ#1#%T4;K_=HA4
M]&EU=Q&B.#.Y7A0BDFVJ(#WI+^C-H[37)8?U[^,7PC=O3L<IVY-; S?A"=P*
MB7]KV6VF2_;"ENVX'5.=VS[H1!NSK/;QY]2,@Q.S4,M]1 *UF^W+JE90(@)C
M!GH%9>XR)-B0I_Y[2P.+=VRR'(1>Q4OA1$@-$%X[+\05R2/?([ "]MEPL0#>
M6:3?V][ M/YG=?/[D+4PZ(V]^_:/A0L4XO1GOTD^KE_2;\ ;3O<=X4758'$]
M,@.H?:FTY9X*J=A+@-,7R%U&6J]9J>3_+HD94]\2'D:X(W/0776K"JD9&3[/
ML0\\CS@J0R5J5BU8FUJ5OE9H/<J/MIGM6#;?$U/?FUUL[I;[,6N&- VJ-&6K
M, W;_E"BI61M;1]D+5239:OBO7B1\S#QS9.4T8:R5Q_9!K;>$4>?GD&T+5]I
M<Q<*I@K<"PC2E.*RN!ZD[ZOAJIG6>)O"+YSI8S-4H%BR$=^^ >(%,\UTV7XB
M+W98'E1B0;@=_&0H1F>CFE]D 4U66R72Q2$9XDCM'#7^PI4W4\HQ?C58%BGF
MB-1^"/.\OZ7]3)=:L+<__26@8SW:GXHH3&KI CD36+WXA3&U:)'-9^41FX.Y
M3$0.K&0%RE8,>HW(C%48LC?I GW%#Z R$^5<E<,'_\$?_(V28O+ 2-U> :2B
MK+D[KK[S1>B,2>IB<?,E8!]M3-:[X%(.2/5\5C(7Q=8,STJQ($SOO=-/WT*O
MAQ<./YZ!*7@L@TNIA$R:F$;MM5$C=5(N=^*2W*Z]=Y46O%J2).#T4$EQ(RWM
M]VGM=@6."K,X L?[(Y(=&Q#IJL&H].B-"B*KOR4^-72CEM7+X5[/_%]H,K<_
M6@E2+([70D[SKN>S-_,<Q3O011>)^AZQ4FV,W!$89JZZD+]MM?%2FY.7I"%P
MP@DRGKY7EZXP7FYKR5:.WK,/EI#M[K2W-?2-EO>JU)Y8>VTSKU^D'%  7<N*
M"_3TC%93Z%Z:E&X#@^-U2@7+?K@+U;_4/-?8/F+ZN(%/1+-Q@=RGEQD#)H"O
M0!Q6:,-9 <8K$8GB'UFT1X;O:UN]X<QVU'US]94E-=VK^[H"?Y0NF* YX'V"
M5@OB);1)Y206HX,ZH0^*P&CW1&,[,Z@AC#]?1XJ9G.U-%%<[S=5::JD(G^;6
M?OW3832U+ "[J3?-:,'@Y[VT:%ES7>Y<0K]\3<BT /<@"]QUBE!):0B[B7-/
MSM[(ZP-V64.8P/*>&LW, H<8R8SZI%4W]G<!X^GQ=I+&<J?/L?%C@O2%QSH_
M+RZB8AUN$!2*$!3J-/+:/$CJ@>>5Q2-]RGICZ+3"JY'[R]T[]"PQ@1<6S9$6
M=[J>%_RN%*K>4I"H%1MKJ:UXQEM:*.K6ICN\>T^OL^5(1-2^=LO61L;"7LXW
M58O-K/C-_]YC8&8J<TU'8ZA]BF8YGR(C4NU8!G$+5?ZY(6$X0D!1X,MH7Q\9
MFEC.>'&^(T*".MC""F%-(T/ :^ [I$H(!7X$Q=#)F !^0#U0FW01LKQ%AE6O
M>=:M[>45J(9AC-5SW,%CLGO9LC+CN<CWKM/-&2H1('_@$@MG>2A^$[G$O5,^
MT+$+N6/VPDF0BDU9-5Y :.+>A'AU_<&$O![HN5=43-<)=>Z"Z,L,4(&5A2F]
M#U=@M^ZY[K57AS<*%6^__"KVV8K]O&E?5?I7>T-K/_9EP//A]9L4+1J"8?//
M/8R8*L35)3H\'QIQ;'TPSF_^GKW5G&797=NI2AT_,C/\?/OA-_8)=HM03]$1
M1+GA7)HIY+@K*]5OK*9#X'<K"0YU=0= ^]$_V%-?6&8P,CT^8;K^Y86A*!=@
M],7Q^+;?[)"!:#+('[3$;%\.Y)&5DIEQ\:PY4-6H7C%Z))53UJ Q%>#*+/C\
M4='X(R=2("G^A0XQ8LDIY,[PG-HYJ'._3_W]2+>:K($TC7P8Y!,=G714FLL9
M;Z%3L0877W!<U>#&:LPJOT3WPCK$8#ZD)<&DHGBHUC/C(RJ[YQW"4-:@8+%5
MY]O1L]^6I"ZXJ^AU!:)D-QO;@%BZRN =LY@] RVQ'6-QH9?+$SS7AJ5O5EJ0
MNBX!KJQI8)]9]GG] = OL/YQ/Z5/DHO[C!5'6@N&5WG[2(#?>/&1=@-O3-9W
M7M?,NN4 G?9$U9,IF9&K.2&I @NSTW"@<^/I_B!HFYV.-6&1E,E)V.?9[RFL
MV8>[A#2Z>Z-V?:&OE,5VFA>/3H[A([2$4,@H<YX$=E'O_A,!/9'B 8=(M^,)
MRA,*CQ=<NJ\\?:W.;Q>(9IR)U]]'&*\LXAY9O?;&CCRZ)6K?/^*H;:&H,I.0
M>JPHP&=[SYI!<W/_Q:S/SQ.W%[T9C+\D&-MW:3<IZ<-[3Y6H\EP_,E?\R@*,
MD:=;*%190#]#]AYD10$BV:+M6/%U;9V=#@K>DR(>S3%\IRUCN64?9 N&G1<(
M_7SHM7-U<F[]^0HV>O,20&0-WSQ*D.CBPL(<\=Y8E0$.[C58TD$3E#/"W7&^
M^D!N12PZ52S&IH\AF[X \C$W/#P,ZM500%TPNXL^Y/"P?]N!N$9>@-<E#L#I
M/,C4^& L:Y_#58Q_(AHR48IW[R\&SI]*\!C$0=^;SLZN/-1EFI9T[Q3/%#HX
MF)T6&!V$M</K#^I /ZK)?M#-\>\NE"[9C+S\*@SOIW1YM!M&_L5-JS_^N,GO
MXT;L;PR5L;%=U#-S3(<C;>J,;<3Z8HQ$C'G7=W2A&L<#QO"0[M&]^86SPZ;%
M*G4M8*O_04Z;/D1QQV?O.BM.PO]ZPQ=K<[:=:K9Q<ZYD>D#*W1E3.<'C8DE2
M/<@9SH=W<<#HI/?<Q=L.05BP<NE3.2@0P[Z-<9)_4Y%?_ZY&6P.\.8;W4TM6
M)IQ2_2$'%WV\MCJ26ZUDOV(I^)<G;C4HFK.E6!K2=1Q1J?WV>;>X^)2>(N%:
MW:G22/916M0K8Y%$-":YE5=8RMO1& _$*-/.3/V>Q[X3<"\OH5I?6-_'+I9@
M=1+AOO!?G?T71LG(2P CV %SF%,:$:S?.-,D(;FHB[VZO!OE4.27F[L<D]*2
MLF[X2?K1U4<LV>*>+,.-D>X3O N=A&?0/I"JP2:,EOADD>BY8>B.HGZ)^HGN
M8D61= ;6;W4L$$5\J[7OS#O_D$3H32:N;/+X":<_^?;I%4GF[->L^#35\%S&
MZU_+] &1P#9"[TGQ%6I W#SB5XN 4F.#O_$IW?.H+,T[_-J*_%V,ICK)_3'5
M_QSRJR8VI4:?EZ_R\1ZKN'B,'UX"!A(=Q79;RW:WCM- F*? )='GYH[I_'QB
M"3PP8^SU]O-?[A0Z3VFVN>SJKNOY+O''8*-QOTFYH4>O86RG$F(H7&SHEWW0
M#7!X^>["S"]\[#?)HU @G5=82POVULSP;D6!+C)%6D$U[2N5U>(ZA?[L.^2!
M3^/\R_H6"A%*I_?MO1O;BKNG5/F?!:I3*Y;(.PEV5OUZPTKC ]EYM]XHGZJR
M>.#PNLT*KP<_%4!([2%>-MTV&;F^$JQ..^Y!1BS#)EM9 1^>9MY_/?>Z''BD
M?3\[];"L+)HX3[BYO/[/M5N0L;#E[L[=,]PEH/'F 5FRFEB18FM0C\GN9UJW
MF6:?&+L_=FW<F#9#*T-WT-GUQ5L]_QJG*YI]@GY*@B&]O0(K%'S4/7K5OU#Q
MD0F<2.:AZS?J:7#:J?$ITH#^6]>_M/5?,W\*8*_P6]5EQ-1MUT]%N<^5!X_[
M!5?)^5G+[NJ$TO1 0WW.+65]PU9:@Q<'GJ9?-]LT,O(4_FJD/Q7T]/6=W]5%
M:#J$H>V/1BTV4^7_V0IR7<'9WJS]GJG&V+"Z$ZW=]D?5;;Z(WX%VI(V85I#D
MBY 4LW29!/&\MW>0'X#*_2M6BGW4][I8NV/Z/_:=%X909KSO [@R#!)@4?&W
M7OFH8L4S9N)-^Y)DD+V&7?0EN<Y9)9GO Z=672NXY=K_%)9$!6TU0HA2GA(2
M%9N^3[Q-<4U[<YXZQ1_BE:LV,Y5)*/V+JJ7/<TO6AQ ;\C2<4S4& ^I5<&14
M-2=(D6>B>FH_XX]&SFIBD% *SX[<Y%"7F@BXZ<^FE4ZZ;:PLU1XMVD_@;;G'
M'1K;I&$%8'0<KA-+UR$ &0,UFXJN@H<Q5-E%(T)]*ZC8-[:4&_2%5ZEH@/:J
MS%5MMK<TQ-G? 3@IWOX;("@E>'$)N*'_LO'-FX\O."<.'0+*VS@!:0'4G #W
MXJB*S+*DJDE5OBU1.33OY]7(==R?%%N1%T4K7A?>&\['A8M4)=K%P32SKV$-
M%6/48UQCA,H.TZBA92.T8^G^\3/(PO*FM#_>C7&Y(HR!%A_^Z;??!C(SQ:J"
MNJC<2)D>]76,8.6=ALY<>H;[2F-6F096G1UT5U))@?;KCMNY^H8)]9J/4K(@
M7,[ONZ@(*.X/Q,1$%4.*NP+F6 $*7]V!_0V;V</J?D7!Q>EOT]MJE':$X>%S
MI?#]<[Y0::6:/*+8D/<L4UC#\GJ_VG3Z)0!9%=I=0GU01C #9D^L0O@]7:*8
MQW7AF+<YKB^NK,N?<V[Q<D[<3H=ZQ7B(Y(+<0,M57")2&(*^'^10 \HRFB3O
MYF)F]_AUM7/ QYC\+8+4EA0^Q3Z1:_ECQI @UX6K>T;7L3'@QW8B]/@(OG0$
M7]YW$8F=S*DIK/F OUW3;.DP8 F5ZSQ65TK%U2R4&L;AGI&^!JGO2PT4L<4O
MEPLL)PY6<1Z_N\:IV?5%$A@X+H5^5G7G#;PA#VVA2=_FGQ@EX]N%4IM$O0*_
MH3%/3DY7;;[7V0YR.1</,!?HG8J M/<!KE)#:"E="F.S]9\'7@+$Y]I4%8R?
M:HHL\H;VH1)-T^&)K:';R[@3^0PZN4!'3/W-"39$)\/D)>"'RO[L 7X(Y)7^
M7*T$Y&:\W$S%ID"TG10ZN])LU7/$##D=X_1PE43L;65[K-<W3,&;7S09R)!R
MH%X'K,S,F8E1M]*?:#Z\AD"9A=+]<"JF-AFMK:?7C_C5CGXK"9(YK?@$J%37
MQBB*O/G(&_9<:2-N3.161FFFYZ-SOLZ@&CA&RC <W?G 2A41^F$XR!L9F)(9
M7MM@L.:@3W8?GB"8[=,*-HH<5!$L:=V?N[X!J_S(B:5Q2?5F9*T?I)G5?KOM
M(M@@&UMXZXFO"BZI<;;9WGB0 UB?AQ;U1JD%T?'81P_*7P)HB7+^-?MART[O
M/'$7+16,R1:'Y/6!J7=+*ZMCLA:$T61M0&U;5^P8091K;$RDD,0;\"!V]X=I
MDN8E(,]_)+#W@G@:_.,2 /.&M!IC5K#<_>[<C@\^KW=(N?GZ=N]Z>T.DGJ'L
M77"%,)N&CMF_L*6;N,\_FVKTEP\GS.;\>[AVPENXRXOV1FZ@<\M] U&>)9T-
MG2UIML;>LH;T;^KO40COV=/ARK/[.]0_(!&,Y!%X,U5FB0?NA]6NLE$.IE6G
M?BYD@B[$"EU=+8Y6-63O[JYI\F(1BQ PTY &U+;0/[PO ^@; T62#Z],3T&[
MTS9<!&IE9ZXWBLJX_.GE]'M9R44W'-WJH*@6+V=)DR>^4ZD&7%F3GYLICW&X
MN+%Q4IQ?+E@-WUX[1+AIU107=$L$;_XGP =B:DL'(;- WGPE9]0@AB:WK50F
MN]94IFMVO[>R*:K\-L[=,E/ T=AL7!7^VN9=,C78!A^.-$Y8OX&?]T;Y1J,<
MXY&8^:][ZM)UF$%EOMS".N^"LM4QU0*M%=VM,)I^GX!?B LFU]>=.@WNZ]<C
M(SYX\S*Q70(8:$85SPV8YQLM79(?446[TS71=SYPR;D&F BL-W.Y%D %F&*0
MQ88X70)"&=U%C,Q*[E:J6^EU#J/'Y7VCUT)G:HSTW-K2@DK+4RM-S>JE:^V-
MI/4_59XTK:0K[A3>6A2NT5;66\V:F"3(GYN;KYW<8:"1T>'E? C:_I@$%U%]
MFQ5@]/,Z>\1J^,LE@30 $X,B]75:KOWL6+.79I9/I97>1A5;)0;4Q$WH!DD'
M<,(>WB,JRNBL;#FH,59L1%1G(2;7SGS/+@&Q):=O?/N40#$V]_W&QH;OW3-:
M0%<8R*WFIMS]_/3_UO%M84[&I4B_9,T!PV.J:[-?,2A.4;@+9D3O+;AAUJXZ
MY83FWM??%MF^\NY*=H)8VN;'T;^5[^Q0R)N>>G(WR^?"]*HJ7L#^:!D<&^C)
MN7^2F#HEW#1>;Y7K.ET?^:.#YL$^ZX=1PGU@<>JJV#_E-Q.[)"X!] ALW&/^
M6S]]F@V*[H"8]OA!&'8<[/.J^EN7:%73-:T*N]&4F80(%W^))VW/#L,N 9BG
MC$ORBB_;\#/(B"WQW\,M_(+7G@73-#3LWB.D.5N__VCA\^[I)Y<]>_WA=?Q7
M.UM-U<"7M;A4J*R8Z[N[UK3F3SA\6.YKJC08BG-KQ?6GB<L2V4''6S[==)(
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M.>$>D9U5E>'@4-87N. !"RY][@UA2D(7Q?LM)"Z=4G!VK(#P&02R]XD%L<&
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M!_(%/.19* UI#< LN4 ,O.4]G!NYS;, :F,-("OY0"I=Z#U([7SI>0.Q&&P
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MO!>/<8N'H"Z]$RL?;=L9"C?6.K3UQB*-WCJ]/LDA=&(U9#2Z]-7ATH@CO8=
MB+/DD[]Y3$@H#'RJGZ)#G<$9:?,(7L3#SHB)[7=(.HV]#FIR;3V\C=^R>U=)
M$%GN8-#STO?01R06BXKR.&%$)]UL+GE73LJSX]A>G;_M(&^XK:J1\=?5*D!Y
MFE["@*XDV%*8H-G43*\A=3^?L1V-JK;L!!M\?>K8I<E?(&#AR2[@#)+Y+B -
MLE(SZM8R8T41>J95HL8]QXBW[1"[E^[209NNN8[*52DZ^2G.?G'UTA0+2<;Z
M)7TZ,K3WB)N7]MD0I'&1GXX@[<M"FA?[B07)>QK]8PHP)+_Y/U!+ P04
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MB]9*OCS2</F-XX,EG%7+[*]^LJI0+OSN(/]CN6@@:;H$.@Y^CC-)KHB'DLQ
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M;;5J/&UTR$X!5GEC?ODH"K>W"G63777.76$#3;4']S+R@Z? 3U&X&U:@G5:
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MDP2S037;9 0/(<'E'6=" 1SBX;WQ#%ELFILEYY02>DJ8 ^+)^5#7<YP730%
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M-6;G1C>V\,Q4AL(;%/B7T2F:!PD*581(JQE_[7$+=M0"@%39X\KSTED:\C5
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M@E?E7 J+6_([U+U%2HW:HVAEY(NQ]].$/!WX.,CY8#^L:6#_>+C"$Q2>1TD
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MJS1??:233Y)&*JM40KX(H0?8L$&6 $$%+2PI!U@KB!I)SR2X(YB1$-.*X(<
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M*9+.]801D_;-BVV25C@18*Y2=FMGRFXKK],CJE;$[2K>V.((OB6.11X&A]Q
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M(V,%P-' N"<!@B-:6+IA<?^N@#"Y\[9/61I?946D7V49R'C.F"?#&R7+ZP0
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M,LCYJGXCS(8+2B$0Q# A4UP]+&11(XQ^8^*^F7&=)[3O3+91IJ'$6, 7%]3
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M[7E@O2@("MGQ21>_#L>U?*:4H&5!AF$X+%MVD$&O<M9G=4\VK? S<+.C,JN
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MC(+!R>*";DP&(13>J[&4(WBQP2QG?+X2J*SNRZ+DU4\Y&3!P2$8-:$,Q)[1
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M175\,JN$2=:N!Z].V2[+@^&3 T@Y?3M[B HF#XU1=6[GQ?(65V)UW\UNE5Y
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MX5.%VZ+"Y5VT,V1!5LAYSW*K@BFEN>T+!6>+#9DRPRT,3O1Z5)-1 S'OC%"
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M_EJ]SXKXL[S$>8A28=7I(4V2MCCJLM%BB?JE(UX\HN6CY@6(OP'15Z#V'75
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M2K%>L]NCB_CS>;1)JR@3IRG8 CYYP>R*Z:LM:Z/-Z8E/>93Q7.1XX&KW+@S
M(.!P-B@2N\TN%.9E4D!J2\(CW83 +HIB$HK/V/_3#?V)_KGY$_W/$VV1]"__
M'U!+ P04    " "R@():C;W6N+%0  !$(04 %0   &=L;60M,C R-#$R,S%?
M<')E+GAM;.U];7/C.)+F]XNX_Z#KC9B8C=CJ>NONF9J7NY#?:GQK6S[;W7US
M7SIH$I*X11%JD')9\^L/ "F)(@D@01%,R.6-V&F7#8"9^22 1&8B\;?_];Q(
M1D^$93%-__[=^^_??3<B:4BC.)W]_;N?[]^,[T\O+[\;97F01D%"4_+W[U+Z
MW?_ZG__]OXWX__WM?[QY,[J(21+]971&PS>7Z93^=703+,A?1I])2EB04_;7
MT2]!LA*_H1=Q0MCHE"Z6"<D)_T/QX;^,?OK^W>/HS1O L+^0-*+LY[O+[;#S
M/%]F?WG[]NO7K]^G]"GX2MF7[/N0+F #WN=!OLJVH[U[?E?^7]'];TF<?OF+
M^)_'(",C+JXT^\MS%O_]._'=\K-?/WY/V>SMAW?OWK_]O]=7]^&<+((W<2K$
M%I+O-KW$*&W]WG_Z].FM_.NF::/E\R-+-M_X^'9#SG9D_M=8T[Y"21;_)9/D
M7=$PR"7JQL^,E"W$O]YLFKT1OWKS_L.;C^^_?\ZB[S;"EQ)D-"%W9#H2_^7H
M;;\Z"Y(%B9;S@"T" =I;T>#M*>4ZR:F57>>,3/_^W2Q91/P+'WYX_Z$8_]_V
M&N7K)=?-+!:J]=WH[0'?/@D2(:O[.2%Y9J*AM;$C6FX#1M)\3O(X#!(KPEI[
M]D>EF$)DP;^03::3I9CU7*^,HM/W<DV=E3 MAG!#MU@R&9F3-(N?R!7-K(2K
M[.R(UGF0SDAVF=[G-/PRITG$5_GSWU=QOK:BVCS,X/1W5AK;,1UQ%F3SBX1^
MM=.>>J<NM,E=(R/A]S/Z]#9<1^4JOW[D8B#ABG$YW,79E^L@#6;RP^,TNL_Y
M/".S]5F<A0G-5HSLD[W9]QMC"U;$#Y*G8J?H^*'^6+WF7V!QD.Q1<IF&<<1I
MZ(%#R_'[TZ_"S#-.AEJS'O4[GJ7QE,\=#F48TE6:<]/UEB9Q&!.SGD,Z]T?K
M=<"^D#QX3,@9><SO"Y0 9)KZ]4?AA"]$[(Z$)'X2GS-2IFK?'T57A%N61CKV
M6_7W]5M&^7:?K_DJ(5;KI5@Q;DAN(L?0K3_Z+M,GDN5B^,MTG&4TC/DZ8*).
MVZEG7;H-UG!%JC?NCY8[DG >([[70N9;>^O^J.$&V2*6 &1<0TZI7';XL1M
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M#CI9J#L?;V*]A6S0M])&G8+Q*I]3%O]K-Y&U^#4[86?>]P.<2AC^ 2;+P=J
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M_3$C16WWR;3AM3+,(,MAL&]HVF'824:^(ELJH(67UGH@]/N9O<!K$I37;C]
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M9%[3CHI@%317"BD.(>1QDM0)B4EV31:/K>\?\2[Z'O@BUZI-1?YZ/G8E1X=
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M%]H#"V0B<<4QUA;$^[$>Q"N[C\K^H[T!!HG0U,AO %./UJC;#U)8;/OA$Y&
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MJ3/5)]=V JY-?W*Q-AEUJY[T8N8>_1@OZJE/II5WR?3ONBB:'\,ZI>>@XGC
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MF0;!=_5H55&'E8DU#-?0Z3PFT_-G$JZ$25Z^N*GS:&@[0/?!_@L,=)%W S&
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M2S4'AJJ"[ZZKGB2,KBD;&2SB7.Q/FN!>O2$42=]]60H)H",C[81M'/*"D"+
MI49(V0&*E.].+(-$7!6IVZJ&RHDHZ[+56T&%[JW/J)4KIY+>1GAD&)Y<"=OJ
M,LT)EQPWO$2.:4FW @.+_N@7COM QUI>1VV@2C&5;.E>=-]O!@7:=Y]1*_?H
M>U2UBLC&]JEX&B_32F4#4/0%, I^[=7>0S)@V?D$^"GE#'-12\'?D9!P[J.)
M->*08?#N?CN#'"X]=,PKP=[38!GG05+HZ1T'@7&J+RB[6(F7\S9>+5!4'#H4
M%'O?'4B=I>C0K+6BY^>4GV7%!Y3)AH<-"07:6R?1X2)X 5;:M_.DN>\>JF&>
M-__V-/3%O9CVP7</'=[K:8@:^FCF]]'Z5<X[(BXS\-]S\U.^8;4*D@?"%A\,
MVCHT,?@O-?2HN3A('KT6_T(RP6X:":^'N-S_0,6O[$6BR37QB4:HSGOK,/90
MIL<^%8JD^,IM- G,PSQ(2V&-9S-&9ARR2\YZS)$*92IV(4,'>G\H0?COO" K
M>3^(^J'174PR(_\%HYMCAP,KVIH"_%=OD,WHCI@=KY)>!'%QI66<9:O%YA!1
M[$9GHI0#2:,[#H<#[81_&KVP'K9:VJ+TLO3Q+LZ^7#"R#?@*3LN*J0.II98"
M\ W%;TD[ 9A] TI:7-?'5-(-!5 E]3VV-#1F+U])$;43KI;>1L*&$Y5/^MCE
M.*BS85SYK@#?1*\>BGU,!^/BA^KU;3[_0D6-ND049!C<K#30 %7-%QO4ZHS;
M-Z&J@QJ7!AJ@JGH44:Q!<?L65!551S$+HQZ=<AZ_5K:F]-3":/*/9YS=K6"&
M2KP"$ +5UJ.(&PV/X-%K;B6%ITB6'R2]:O,IJ/:]V B0"86CUZ]*=L%^W-6=
MGFD^"=6W%QO:@:*"KG?;IRED?6'2SO -E8^&DN+EB^R!YD%2_;NH G)#\W^2
M_(Z$=);&_]+E;CC\)'K)YI[TSCDJ+U?O"L/B@K+R5Z*=Q@DY-!WHS][XKJ%:
M_-#5=KRYZ]+.<'F_5:UNT/Y0-?$]@F(G+W1X.^_W7-.++;^1:B3/-,941D??
MA*K1481!G.+R$E5/2GQ0Q2N_"%6[%QOB &)RO$H'3G5W[>R 4X#W4+@G2MD1
M,W0E=69J5IYCU-S1'>CS4/7T/9PQ*%HMNOFWMPWQ<9*_;/[:^L>]T<AS3M)H
M9QGLR7@6) L2+3E3B^![+I+B5O!]."?12I3&$-?D.3ES/KW.R!-)Z%),OTW9
MFS.2!W&RHUZ\KO?W[SY]^O3NIP^C-Z.S. L3FJT8X?_8C#FBT]%FU!&?GZ/*
MN*/-P*,_ED/_^W=83P"WL#U^S.1U)O7<,O7#>OZ$3P)!R-X+>6TOG>RW\^.9
M-Q@6C8=,]EFI5B5&!J&QX&B J+3U XQV55()OT)^M2(0#@#%DK^C37Q$R$[[
M,J:VTQ%!HN6C\OZ85]"8'K4T=/,#'H#:P;#JZ>E)5?6A.5G$?$E=\V7V@C)I
M.,6B<,XJBDFF?&A2EM@!=<5^! ^D8WN5@RPDXJ@DU'V0!,PD_GHC[!>MK 7=
MSJ4KD0JKNV&_ZP6L[8+]0(V]N $2<"3\BBEWRTC(.\1AD$#6&%!/]*<IK+&P
M$(BKJG,6("C:HE>0MU_:$01]1V9B!Z%R/]DK'FM0?%,W]+K6';0>)@IT3YW6
M^V'K!;"-A;J"2WT0K=FA(.Y[KCR'Z^WZ3%+"@H0S/(X6?(D0+H8\?B( ?]='
MG;^K'%>ZN_9'[LOCI5AT=A296-/XML1(709Z=7993,ZN0G[U?OGF:GGU?GD'
MR:OWZ]7[Y:57P!]O%Z)7X);1*<G$V[A!<D&(5NJ*MD?G\]+R[-B;R*V*$VY?
M3.,<YEAL:7]\3B\3[\Y._6DN#KG3:1R2:TX</YV(*O,<<].YW]SQ&/U=4'$X
MPN,RY>:U^**5$\;8Z_A<8$!!H+M@#"<AM7ED['@L;AB@!+Q+'2H>08N#I-#-
M&Y)KW"<_Z-PGVY%&Q5#_,>*#X:<(/9%T12XXKILRQ[_&^?QTE>6<1 ;)%0(.
MT.?Z=Q*D7\1BJUCH=G]&GAV6TJVN;'46[3V4GPI53F75W^B0MS&4NU!1,DO[
M>&*]$?:1X@!(VOE%WUO$\Z6[EX''3WPU$4Z$"\K$NV"?^<YYI7WM!MH?_%J:
M7\A9<NDV3#D7V>"7Z;:0PF1Z*G)N61Z+N^^TM7I+D<5A[@@NC>H7/E#V/)EM
M7&%(/$M/5WP!3L-UY6&]C0Z=D"EO\Q \JZ><U2#87H'#YET'>:%C+$\2-S2E
M2_F0HJ@2(%9\H[%NZ@=$TME5E\.0A$GE4#M%7CKP*IQZ/IV2,-_>MN"**HHW
MB1L0W)I/XN*$JCX3_*@[$VS'+L\$(S[Z2 P_VA\?^YBP97W'B?EHH.V$&:00
MJ\YF$L3IBJOR9%D^F5JN1EO227;^S"GF,Y.?WMA:GG#Y' C%]*%)4E00D5:A
M20Z./HI\P@$H1FMDQ"D$Z!L(9,D8YQ=$/-2;"!?*2J01[356JU,O@V,?P^SU
MID>9HNO'CJH]\K>_+O?4TL??65-Z_@SV ;#K6M.SG'W5GLTAZJRTNGB#<9:1
M/!,GJ@*D)*%?]2]I]S$V]D&T-SWI(%%_E&-?MP&(USM@GSL/@+&=]\Y)GKDG
M9Y**250>!VX"5H11VDX>/]5/'KLS1B53<[0=X_5L<9C78',N%K;M*1?JFINQ
MQ45Z?0ZGL:-/25 V\]'(&'Y&IYK$*W.*)ZBS'^ !E1,,X)5_6:%B=U[E<\KB
M?'T3+ @D*;2]SS%#IN/+DQS1.G&P%%%5+S_ ,JL@"*>>\D,/!RIC 4FJU"DS
MBS;\*'MXXVK0*%T=' /[CL*#UT&2<]G<KQZS.(H#IA:Z:*YL[8WA#A"XEA%/
MCE1W1)9?N@U87HU?92?KZE_TVXW-&'ZL:-VV'QL^*_XB?&!-FU!;6S^ LE=/
M#69N+RCTLL#]]@&\Q#E[.$&M.8"%33#@=!\IMJ\8*&9E:Z"0G;T6 !.R@5D/
M=H_M-7'A.S1M$RV-_5AFNNX'+0Q5',!>8&)>^UN;^X&+1K_T6/ARUMAXU[=F
MX^D\8#/-789M1I^^'_J]$JV6-=(3(4) 7\Q>3&#;%>86_L1!XMM]5+/PQ2/;
MQ1&+[W[HKA%F2:"O!XW(Z&FPC$6P#(Z=Q1#8"0C=H;26$SJRJ$6#G*4&=$?0
MMHP0:NXJ/PN1WU>"OB?^/Z!@\9\:::K;049$CN)/Q+C.GSE<K.Z!5$AFGQY3
MD9_6UGX</TQ8U,O*M+*"'P>NT=58#8R@7/D6\=6IF!Z4*Y]BNP]\[,FT\HZ&
MWH&B:'YTD"CX0(_@5B@252AN:!KL?E/U/IM.[]8#^0&A5AWKKZS9LNC&Z?[P
ME3[,Z2H+4O&\S,-7_O&UN/.8C6>,2%JT[F%X=^R35D?=K#J3;67EZIYHL%X$
MZ666<#K$Z\B+)5^4%W'I#$\)R^;Q4E_DUF8$['-5#\!UD!CZ$:N^'?!/Z3<W
M90<_UL;N%L>.$_28< MEIO" IHN?P-04S8R-+Z&"&FDF&T/1''N?,JJ8'A"'
MJUA&PN]G].EM1.("#O[##@7^C]^NR"Q(SM,\5B:\\%:-1GY.@[;UJ8WZ7L.5
M9A$7GU8N.KS)?@MDX;9)K"'3?8H=O?TRI-%DD832OS.S(="#[*'^TE$.7]\#
M<>%>%O$L7KOD_Q O%6:76;82P=&*,:A9]JU&P2Z@9G \U?>"#A+R"=93;L7'
M47G3^XZ$)'XBT<0:5\@PGFWS%LC"A?02WBT@,W',NR-+RD1D!A*L^',C6%$,
M,MJ.XE&PHL8?(%BA[($S?3<+34&0L)I*"C5'55T?[!77 $AM7IJYMXKZE7\1
M__,89(3_YO\#4$L#!!0    ( +* @EH@4+_9,N4  +;U   *    =FE?,# Q
M+FIP9\RZ=U13W;<VNA$0*TA'6E10NDB33FQ4%:0("D*4(DU FD1*(B+204!$
M:7D1D"9$NM30JQ#I4@,)O4A"#9#R;=_W=W[?'?><>\<=W[E_'#+6&$GVVG.M
MN>:<SWP>LNF_Z#/ &0,=?1V @8$!> R^ /H$<///I__6WQ\C_UT;#/1&@/T8
MP_4COQD9+@!'V!D8V1GHK0 $ !B8_YD _.N/X0@C$_-1EF/'3YP$)U2< 8XP
M,#(>86)D9F9B J\&@=<!)G9FCO-RUX]R&C]AN>#))1\<GWE,Y$9)$[=)/U%4
MP=;K]?$3/+Q\9_DO7A(3EY!45+JJK**J=O.6MHZNGKZ!J=E]<XL'#RWM[!V>
M.CHYNWC[^+[P@[_T#WD3^C8L/"(R(?%]TH?DCY]2/F=EYWS)S<LO*"TKKZBL
M^EY=T]S2VM;>T=G5/3 X-#PR^FML?!9/F)M?6%Q:7B%M;FWO[.Z1]P_^^,4
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M*2RANU36R.FFJX9752GLNBC$&^26F]-"N_#'NY^7S7<JT[ P"A,M%_.?_1@
MCP]6ROOG^*+ XUL$CZ\./1_F@]H:=S]JU+>_T8%;[5#$;WH>CAV;L5?\U'&'
M2/7$5F\DWF?[C &&R K%%Y+0 0%:$54D TU."$7[-[CJ7W=*#KS!<WD%^3\]
M4/&_?<1L5(&Y^AZ#-X<STL(>:=.!!.0G*(F7'$4+EL?6("D15$,Z\)_CGT6[
M</SOG$Q$@#GI3I&@ [U32.F'R/T-9>HN':!X16,H>ZFT0R1-59=B@ 60/U?#
M,9M&6VSD* JXRK5/CE-0VBU:+O(_[[/_OXH<Y@/G GOKEB-UGV4S47'R+IA\
M8)5A$N@ :1Q&D@ID$1))]^2N?X*9AOYKA6I'&IC4G9!A-LHM]L,+R'^=SS3<
M5 R-C@-V5Z#IOAD '7B]1.L"5]0Z#S\YNY!*Q.V^[=]!AF=(]]=!LES\Z4"P
MAI);UK@K_SKAX7AEB;<CX79/5,"+2V/V&0*WDT,O61R;DT=O/KX?T:->S<+T
MZ2+V&QUX.!B_O;J] QNC5%.SZ<#3]],OR>#2O5=N9CB,/NOWNE-'Z.GAR,U3
M<4_"DZ#]9<&;""&LPB,MSU8E.;X[]2.Y+%W=BP9)+B6F>PTLDL8F948?3'"W
M_.QITI["RE>;9B2?R/_ZV6:>JW_7VU7"+(<_/JX6X=1NXK)\:: ,^K.4@RGX
MQ;IU9I*Z[B5!C<#G>N.46-;!+H*R9$HF9ZSN=#P&L(<>6B,O[?9VTRY!/Q^)
M%/_K?\RH@^S&TX%$?^I?T+5(B@4=&)*R0</1+-1LY-PTQHGM\ *&FP[LG!@M
M-(!N/( <\H%9</#I6@<G;3V2#GQ[9$3+&H%B.1M1FQ?)1K2V.#8ZL%PJN;+Z
MGBA&B4!PTH$2NQ;PCF>1-35TP$9^8Y]W!KK&PDP'\CYZD[VY:7M@C7XK &=X
M/='FLK#K5QY3WG,]X&/FZL]075/H,%W&>J]2:MXYBJ7-G,I(HVJE9010Y;0&
M4LTF[2?R=X/2];XOX>KFN;FK@K:Y1_4O'4K1:ECS3L5T-LZ'K\;*ZWCI,V8N
M\O&)1K,Z%N_-3$?,;'!1;,B>LZAPR_K*X)DBU_;QJ^GX>MO?\\_6UK9O1UR4
M3N9-T.=XV!'PO))'6=E#X[8K:Z;BM#T"]O%*A^W2/%GPJ5I9\F6.-ZL%S]\4
MF!5VIN4<TY$XG"R@[21N!+&<4F^SO3+$^3XH1R<ML=RVVKS,SW"*&YV_L.3W
M7>_Y  ][S&8[KT\T%^1]F0IS\/@K#B/<HSDMB0'K[N+H[J/;W=+Q:=]\$MBE
M$W3L?.445.X-B(3:'(,@5U! !88/V7S1NQC.1):?I5VD^!'WP.,=@S]$0%S'
MA9.)64U5-+'Z6B(V0B1EPY*T&/RDJO3J-&38)_WR;Q!0> ?'FGCRO2YO!L0)
M(GI1IS1D/Z\(<P^-MBD?L#1C3R(&8-PZN5F5R9_A=* M8<E?K 7&L800)IU>
MJQP(?Q)RC^0P:3+1'>?)YS']E?>TQLTM?IJ<_2_+!_IFN5'ISZQ,S98>+ZJ:
MM'1[Y7(_W/2JKAY,&E95ZA$O7_=>7G[>(,(I&=]\OZ69Z\E+@WH;(V=CZYYX
M&4O7#[TY?D%&/V9>BJ#NL>4*[6-5-^Z51_%Q&+3SW6G&]3[GX?H4;']:.N$6
MNE[GEIS.;WDN!?8M1,(DK1UW\C(%YI>]A! G921GP?W:()P^,CK85K7TALQB
M>"_E/#&Q!<E)4<XDFUM+W:E/P3T:%6B]-/"$FNZIN8OZXB+Q65NKV/9M)8(5
MT8<[L8V)R. F\43D4JZ1LS)7A,7(\7_=SG9-4:RYCVGR(RXVO2"YHB*O\D^C
M6#,1-1F%Z)?"PC7#THH"7\)NE26YV=8X5MD4T*2(<Q(U[[,^%F2,IQ\W?B 9
M:3.08V"VAKH0&:?D--4]<G?E,=E#;GZA04CJ*AT(XOU\MPKC5.5VX(ZP%0W%
M,IVY9Y!J5E-WD9*IG'+,S/S=JSRS*G5]["7+OL%%YV=%HB\L$A;$+Y_*DSM5
M.EDTW-;2>O3HF.C]=\%)?-T%[&T[??+>6'2N33I89?&1U,OR)BT#Q4E)UOD8
M_$VCBEU_'\=@\>^&SY%/)E)M'KKN^N^ONK$8WYULP"P>T+AJP]"!B$OA/9\J
MGI9CC Q?\T2*%S#D8@[!CE4ZFA<(J%!SD$\3U!$_82>-YM%--C8!=* .<RCC
MCVR$[*L:C172^EAF/6BH&?1[ GI?!(ZBM2F!F,'+$R"H_"4HOF$L"KEO'D%[
MJWK!9^]E,G&3X(&5A)ZBN@R;FMSI0NVOBM$BZ,#JB7*M+02D&],MY5Y[\0#Y
MB5IT5N++R(>-U2=#QMK,S%S&U_Y'##AT780.7-HYO(8<XR:C02 SK[<AV; =
MZM&!KGK$3\BN-D**#JQPH\W?(Z>_07?E>C ["JQVH(LOVI"_+H.<R7@5LA@Q
M8[3/00$_V':$T8'M,6Y?WVZX@-0,]EA(7Z#<+$WWF7.\A05LM=V:#ER@L%!?
MS6!V.%F1K+:8:1)REQM&!PQ_2 AD$C2$KUAI^#3.+?[T\C]AJ=/.ZAU[>/UI
M1U !1D'0Y_[^1V)=O'6JZ]/UHJ1B<&S75H##8F !,CKGU\!'ODE2:&O@:2"%
MA=:)7*W*M)QVY9'00N&AIYP/ZFDYL[U"@;K%SM/"Q(5"D"1/7QA6G&)Y4:3Y
M(3AGQ>_UB*IHY6NK\&C7> +Z"!P]BXGH"*FSLQ/D7QHHM[89UU1UO_P,+1UX
MT^YH?DY12'VYR32LR\./R\]\9%7Q+:7^JY,[.UXX_:] 'PP1UG22C0%NT*^(
MA5@%W@"5S6-24GO\ETD788&?=; 95R3+G0RV(0\9=&P$/F+=G#:"_RUN^7MZ
M@)K!$[NL%[>$/H,8@;%2[ K;,RX/-D@9S5I+M6D=&Z%<],R>3)0-_EHG0SS?
MP _33/JJ,&YMLS2:(7TU92^\W$W=K)Q_Z+@T5C,CZSDS9H&O6(3$R_B14&@^
MNX&>2Y+S=7KL?,]09?\&>]KG516,?0Z\K2>!:]! _V+FSIFFN>_1IU6#')Z4
M^,JL7U1BL]/_DOK"^+Z2?IM-0$51'#8G9M*PR\UKU?7<Z_4/?7-%Z2UZWXHJ
M",<\'5]LJ03+7+YC(:N2P!61$VFF8R30(J#O[>'K]DSH_,>I,>OKP/<4"8>(
M2R]G]+(2\"K9<+?Y"[??GCQEW"4=WTH'LM5PZZC9DV@!N)C-@ ]6X"$YP("\
M3-S Q[4*J6%UOPT^(7T(GL&\;> GNC7CG%]L36?O6=1LA+57YSA5)5?QRCV$
MW:BRJ*HR'_637=S#5;R-P6./3Y%E\4PX=@VK+R[04UE$\US[FM#T[-$,F1)J
M82 WJ6;"NJRZRBJ@4#U5]NTT_S"%U[E0Y%-Y3^IV?["K3L*,HVXTY5JTF TJ
M3"7-^GC!>P?M^U'UJN.7[]_75W(XJWK9K'ZI?,,G]%2N>']'N$3[Y^$:X[L=
MNM,R8Q4>IOA*E,5A4/G=?'CU3I':%'.TR2I"@C8]($W0'4]1*^%O3\[5/O98
MD:JI6*@G\RGA\>[7D<W& >OOMZO%1G[;-B0:E_%:\%K.4_C3F^\\&7IL57WY
MA^770F]G.L!Y4CEA$]O[>NSWK#-SHL627QS2!?UV6I*8'*[!.&N%C4"<KAVF
M7,PB&]TE=SC/2DG4>7]>HO&1NR"M4^HMO >WIL^I)5$L,6]!;A 4T.J&E_*+
MLBRM'+8Y;77K=OJ%K2N(41I[,(*CUWF6^F!)F&-8B\>&'-5<97.V!'GF>EZ@
M.HSCP<JTR$^*[]7B<8?AC1B9NFOC'W+_FH##C+Y7UT:<JZT>8G?++I\+8R=I
M04X:5D!/<:L.HB7=TUU\)(?O[;FHQ0>BDZ?S11/O7K:J]WB)3IZO6Z%<O[1O
MXF7HZ6:]-"2-*K3X'2B7"_=N4RMZ<_ [R1F?F.WDOQCJLWZS[;F+_WQ#\BS5
MKXW1!'8"6[!2Y"VS$%4 .WUUX2[4TGFAIJ1T0.RU7E&1?:7TU(T)ZT%?)/N#
MWL*54=YXEU%+GMI")RW1T0I-W@?U@QYW[!O*W%YZL(037&.J7G189!R<Y='.
MX-LKD=ICS3V\"S^":[*$-6^<7H5R^:!..7U EGW=/9C'AI53Y0EM_*BF./[
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M-;?(C^38"A)$7RC^(<B6\-]8B(4P;6'1Q/E'UHG*]?4?1':^)..=P5NSQ.E
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M564PM7R1PV>VIJJDR@W%LQ N*>%J#MZR=L[1KUL(R"DW31_CJ !KF1M=%:I
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MK?=FH<0#2;2B;C/CWK);BEQ';KU"LML+FUNSRYYC ::!<QW-:1R7S'\14D$
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M@V$O04UEU7 7BTL!#(EQXS<ND6O[\!S-O"R-5_;J@58(?^LJ?0'1[2ZK&.Z
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MD[H,_-:JU3>/Z6K.%1#P#)V+486<I%IVV\<EUU4"NW/V$BK4LM5JY_G4EEB
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M,$+YEJ%U< G!TV?3W$!U-:@A],)3KY?7#,,-08.A@;=//SKB8[R<_G4]E5]
MO[>=!>!:;SJSE#+M..'A-_;91!'#I5[H,3$"-@YL1#>Z-SVSL$CTF7MBMI^T
M;>T *^-@+-.,6(""1,8<.^(C,@12H5B<S!+5E^RI-T>Y01$PH5]"^-!>H#M?
MH9<'J3:;G'0Q0BQU]=")XRM00(^_E 4(/C3J@@-O 3A^<M,M5_E8 .EFW7!,
M) LP^E9S?U9H'?_&2S U4VO7867,Q"H-W!_8EH=:RXN@,2#,R#'=6[CP"+;@
MW/;(QPU8TK[^7W\S6[4OQAAG&N;=FPMLBSNP=*BR.GAGKT*?6$)*H\E0(I+
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M8,TD!Q]79&O\82UX*O"WMK</7VHFWT#9S>D/X3G#1[<6;:_Y#7P*EA%Y\L9
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M<>O+:/M8]HVG_F^+^]Q,]=W'>@OZ[76N6T>[2MA8%&9:>6[;78FP*41,3#J
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MZ ]F+[>1S5I+BP?C59O[8MLHAGEE'J%F<43@)+-O/O5=V[GF,2^E2A7<N?9
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M6U&45%3J==K^^E<68#W4LO1]6X>LX?5$^V*8*=U*:MK'/TRS>;(N[9,UV.'
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M:H"'D*@!LW)^\,)/)709.VQ6"SJ!G$;LQ< ,)>*6?*ZRUEQ?4UV>E)Q>%EF
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MM :$/-]$GM%.Q!YAU_A!$'JOLQM6"PQ@,@D//?/0V<Y@ $@M:W/@/U+ 8G(
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MQC%$%-<O81B +-==KNDL!+N2X!I+/-?S";;++#"O=T/02@ '(8Z%0'^'?E<
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M%;9$BZ$G/Z!)^E7@2 E1J<'MY3)YJA'+@@L4H:(M2!'SE1+/(0'BHKK5B.6
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M\X;2F^B_T(05/,EX>A+^.7[4=1NU!Q8*VMCVNH,N1!X2I)[>H@O)A2"UK3%
ME0%,EP5ZGH_BD7?Y4/PG3H&O0^:YWO25<NN?(H;\YM&-^]@OB4G6L4@\ 5:[
M= &_.'5MK]@7&D*E<9,!-665M*RCL(.%*YS+#7\CZ] YBFE;35T,X#$F_6\;
M(+KD>6Q%._JA$7N<GQ3$0O5(^_:= 81_WECQ"_02PI,L<-33TXTF([<"?XH(
MKKG>2V#EK=T+*3\B=QYK.NF>G[(_1ILY9?VY"N_V3"]0Y'WBE]Y75/TEYOR[
M,8-LFG<F)_],>EQ/L&@!'G7QSQXSV_N#<R6"_^AQPF7FR<,&5"U"M=7,9%2M
MNJF/E;S%JO?+F&''HO+^/KHWL:7<)<9O1&]Y<43OXK;;G\!G<R#)'#$,-G3C
MZ;D&FB62:]FL'?QDW@@^P;)2#Y*F_*RL3[6^B*9_"F@[T&9?'ZK. TA?14+!
M!CV9$1Q*3Z^6^>K5\CTV[+C]+]#)'9/ZLJMW2;/Z>5[[MWO"6\H6YO<T%42_
MFBBTQER2RHS<4VG+S'OFK&[[R6\/^$W7\EI$S]T/.=RJ6W^!I_HD:48_28WK
M6=SCP(U';S*3!_"^EG&N6RXVM>7<4X'2%IAAZB*%UHX?6\)14>D3?[MS?GX7
ML^IX(N)/]5BZ5NX_W \S@%*E73<W!"BC:4?S&C:Z:P)]]W=?\WS0+3%M?J:1
MI&%^_6;,)?-]X=_/?YM?EQ,')J%F"[LH3E\%!=7F_?I?5(OT/C.KG2 M=,-G
M _8S "<6G8X:3']B\ZC)5F?QA)I9(AQ_ -<P$Q@*-HSA)S,R<,L<!+>62:4&
M)-:^7=:!U"=@-A4$ZQP$#'1VXA]83^UJ/ ML2@4+H"X>V7MGKW=*E)SI*R!G
MT/1$HTMU' _SO<82>\=G>SJ$"X/Z)\EU.8D(W'+/4U$ 5FM33W?CM[]=]L<%
MQ>912Y=SSD\3$F^$]FZZ1JX.6J*U\(15%,FXFZ;L=A DO*0BZ.OPXX)XI_[7
M'-R@LPR TVA](#K0)Q$(:KYZYD,<JW'4YV./+[6V"3")2KS6_TH#YS"0@01!
M(DS=1V(/CG[%V'*#3H/VD"MX2_LZ/?:G+2YR;7Q,VNFA":(GBQ KS_P)_#G.
M(_P-0<D$S;$4195.A'B"@QD QT'"-0;P^P#UR9YNM^V#>R"\'K36ML$ ?N*I
M6#_-GZ^45;J516.,9H=PAF'G\<3#/NX/&$!_%$N3OK.,1$9.O 6MQ?S#'!G+
MDU>LK_A#,=H:5U">FMMN3,TMR["T]L9K4A8IW$B$O0L<Q?*#SMW/4*RP5,!M
MTD1$K3!T:0@R^DA-;J!,L$(G"%6_I_K4^/(6G\19+UK)+#=U9C3DC-2I=AR$
M-^_H.S#5G>F0V'S-73PYQ78%V+__0GJ7NN^41':M+LR#GDP2JX!X3"E:[+KF
MY+"8)[EBSXP:U%U"6<:$V*.>ZC IT@>;Y47W?!]7GM/X8P[9;+P@0-A0GUYE
M]DB9[#>3XY9AA9N.9Z.5_75MY<VFE9L54G$'M%7+-S;0@:2.\S_.W1:YD=)R
MV)+[I4_[3TI9=K<2?^_'7K>$BQ<V*F:L3 P]?K^$)!WR(<PJ:MX0UXB9PXL%
MOMJ"JXY_C#C]7][Y^?_J8R)?7RQ\22QP;\+[$_4J&]KH5^?3NGO@:TX6B4\2
MQWOI>CBU#^W K?3KSR9=Q?E#5 *]SP(N[.,1OBU3N&4D#^_S[L'?0_@M*8"I
MFIX&N9.-3,!0^!CUK5QX-7K*B(WJIA]L0#;$$SGV=QLYR=P>7ME<69XEC2UV
M2F_+?^&1WS^N%]BH!PP_4O@NK[9FKG!NZ/6O^*%/TM0QQ-WCPA,D8Z! X_*.
M'"1E\$*XRIHHUZ0B<$D%X+OX4G3?%[]-.JH^D*_]ZT3TH]_[W=E-._+ND'GS
M"X3H:>)=H8<'LZ5,1JAY&GTZ/BK.2T--Y$]>,03H^2?TWGE]/O;[#@TC18XF
M+Q9R],[9F+Q(#BETT'+LV4)#?\FEVU7 S1@>)NFSHO!1W+/6[1LYQXO>*2LS
M/^(\,+FY>PA42UB=*,S?00Q#;9JK'60 [<.PZ\<'4JRCNK,:WX _\742*5B3
MIY=S55:L<V%4(#JL%X\H .)--9G')5F-)+W#3O1BFPJ\P46HNR&+."$@69I@
MTCNR)1)H@L[DHKZT;9B%G;N)SQA 9>ZD$6BC!)%U&<#A@U00CNHCQL+"1GO!
MM2_XY/6T)OPAU<#CH*J&F^FV''4P<JZ3<,T\]0S1R)]8LGUG@>;/3UB0-9K&
M*DY[>WXS'X*T:L_!M[(9 #-(:=E 0O<PNX\_'-5-#/I[*,S\IY[_=0UYN-UQ
M&(#-!7PR[)\ \8"7P%14)#B!ID?KT^2I%BO]RJ]O+TLABMG% &/'5B3O==?_
M=+][9-)@*YHH0\:N3:.I)QC FLY&T.[D'PKC;=$1+"/PT0KDP3XE7V8 P2$;
MAX<H\E0L PBS_HZ'"G S.SA+%I+5)98<-(F= 4AAJ0EH]HQ5537];.=[>.([
ML-%Z2K:X'4.OVSWN<0XIZO#!,4(53NAAH"(#"%6AYE*B^1HJ*:$)!\G6A!E9
M/K.D>J)TR/H9$RVI'ILKC5_6/N1]OBZ^9 ES"I"6[H30HS0DE^NNMQ"[&ZZP
MD=(_OU9+"6$Y>$QY[E %RW;=9HO <5*1RJUE-9&19)'DV-P<2E"4MO+\VNN^
M.1](&D--P+$_B$LXII84H7OF]I//K&X%0@YFE"_^NAJWS3YNU@3YE#5+44+-
M<#5SL-5\><M&*)[T:"@LO 62QS:)O%@GFWX/[NLS8 !H*V_H+WG"*NV<7 2*
MZO5/2+GQJ<Q9CNX%TYY6,AE!UO V UAR1/7$U@^N2MVZC#23Y;M 6Y;#N,[7
MK:/+.#&/VSO7'^Y:2&ZZ'21ITL5BYR"D<C>(H!A QCEJ!C7 C"2QV7>: ;P,
M@1!BINU UD'*1'80>OLFIA.VKA =O0!>CE 8GX@'0ZQHBC[Z/!E2 LD.-RM3
MC$RBM0=7LGA?Q&4I47)S=2^/2QD.H1 X*?P#3L@P?R,7L[NL] &6!R0M^" 9
M^^T;L/$*O#O\>6H&XF33[]A=)S, F>5M):K)D?'W-%=4/XAMCD5,R3J=I7;A
MSFP/6.BEZE;+(5/= )^<$ !E39%4 $YB>[F0T-Q=8'[.* *-V AAF^WMOKL@
MJM;8@R8UHWA"]_M2RTC]0:LA.J]HRS>2#.L5)F1 I9MNFDB& J/9,]B]/9X_
M<D][L8XE07GB&[:D9HOI!OOK3G"0QU",&^1HEKLC#A4J=:V43E?M0CAQ%\(2
M,"L=A:(J.UV:E%NR(VNZCU7 LOB& >9,5ZI]6M?X>=,*UZD3*J('&L1!._ >
MUW"V(;V$ =C'L@7^5-5Y[H4-LTB3Z@\P^(0]X!-LUE=6HW\-VR!RHM^3==C
M6L>L#R=:Y8\JU78)_95@)!/NY0@?E"FAO QT?GV\^:P\]LUZVY\CJB)<:H_
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MUPX[@JWT=5QXOBF7SJ^^.(OHA,KLOLVRPE$K)T^$&6]P&WZJ,.K>?35]<R%
M&JXU9@!]+V>S(#\,H1"1*#<I(,2M YM([)Q$B,OL%!?=7' :?'*8 12X;;7
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M47X&I8F-,1[("38-VK*N9^;&V2^;J+FEV#N]"BP;J0$0)QF8%DRXO]:\U>O
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MB"B6*HT#'(8<[)@I^86S!/X(NX@FL@Q)7ZXOT&"WM0G>=GKSJ6:W.]_^"9-
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M\O)N9J:R'I-INGFS;_2483Q+<^)VCN8KEQ ^68ZGCGDS1>:](F-^M?Z#=(@
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M-<RS+5KV3I\CO.3=VHRL><=/A]R>[5#]R&:F,6LXQ71VL<[(?<P(G(R:'Q
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MA]+\4!&@2V(:P'(YSS]$M,#\[0T^8FX;X(=T(;='C<%Z&X//_4#HB-;)F[+
MDS_8L?=B7FG@ IR,-7!@I1K?@8"4-<!UU<;FNW+BS-6 >ODEZF/29H37_23
MVD'8'-(R[UU_%_:/^M;[0O]S=KVO]+^'#R=IG3 #]JK5'T0 #_(1I?8B7L*F
MD^3;ZSK"<?4",M4@%:)*/;2P.@"S L:-@S&CUGDS\><('KSK1?1 $OE+2:7?
MCA-/ *BBP>[3U7<50E]X1GC&[\-9 =62-,04WH96N.;'^1_ R83_OFG@?VT=
M^-_>O9+#G] -FO>.)(/J\C8YJMTG.<W*R![R-I7=K,ZROE*3: 6X_T%PWB0
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M[DIQYEJNLWUH?DV9+@\_L79K]'RVAZ4 B&F%^9O"'G'R%1FP I?1FI)H&P&
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M( G%^%L ?*Y1H.?N#P%+R<T,82D9;+*[H^R%'X<1&3ZG_B#,L'@)K-OO> 6
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M()HE*[&+I#8)Y.R+AH\40TU1$SI1-BS0P> 6K9>' _5J?6%KXJXITD])>MB
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MP3I00&!??&/?R\WJGBN;+U3HK9//9OIJBV7(K :<$CB<)Z+,=F;Y/K;E6VA
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M\>W-Z3>?V1V]9K 25ICWK/&IK4K8-S&?_J+;?R!WPYNU?IB'X_0^^).$KW&
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M/* 2_WJ*RP'G);7929"BR\0H-7_PMP\K+TT7['^$F54-?BB QAPDART*0H1
MA."$A-$!\_D)(&8DY_O_ %!+ P04    " "R@():Z?BXLIB#  #$E   "@
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M41F^/'?68VVO?+':&)YN@P#U\4 #O1HGT0[)&O?C-A"@:< R'7X?!H9[]2%
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M?Y?R)N6/.@!\$""@&O$/WG3P9U^==SZ%]]QTU2VY_^Z'P?&4:8"8$F6 ;75
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MO,R, %D]N1;.=?HWS1EWJYQK2S%=B/,USALK@"'$ZLDKLKE_ _T7,,+J<"_
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M6N<=<#D[Y"89V[#ZRQ<+*BDGQF\(3<&[8;\^T5Y7 4> -J1/0XNO2TS!7Z/
M6&1^;J/$Q[0B&4[T.=T*7>$+2DT6Q&9\3<Q[:4NJ^#X.EV,TKC#F@K32L0[2
M# )D,XX ]5E U^$CI0A0<O?%V-T>#M^<4I3:VP^V+OK=]#@O=AN3G'[DWF4X
MWE#JE':#Y5L@0*)C1YE_V8QAI&1R6-_XL]6!]+D![D;_G+G#9;47$LSFMXL
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M??]I2!^PX6ZP:4C_P+05C:NYZ.60?5_NU0M[%2$DU:40+=W7=YV\9U$0("0
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MT'5&6"O!JH@M@-;*B$S_(&&[9_H=99/S5()RA6PL(_JR.YV?P(Y14[?M@M2
MJT#SQ2&>D+3(]SV#V C36D#E+],_J#"MR#BL"+323_%@=05I UU.4HHF].\*
MPOYOU?S?@:#93?#O@RDOVA!X,>+M*J^I3,XJT"% :LY1LWZ\TC:ZJ7\*_S\B
ML4Z).83?1>,_^<=NO'<NH7Q +\D^X+GV:5>>K 43$B3"G.UI>E>M]8G7YPT&
ME\B.V?(WUXO 7[X9=G7LZAT15J*$4>,X+]8KR>(;*0X3G 4K"^8>][VOY4B$
M$(U;9UF]*&"E-Y=.D=OH&8[O"_<MM6X^E"0[%!0[;EK=;:!8]TBPB^6Z^SJ7
M@8N_;WI$^?RI2;^KZ%,>64;;Q ^O,^^+B6-\CAE+[.(.*TOIC=IYM48MTS'J
MQPVE2@5N?T47$D4%#U;;_3JEW??TENI5@4YZ'77Q_S9/#)@RU:/@S[XC0+76
M8E.,X.&4WE39! -=]JZJ9=%U%/5Z0O]@D/]>HC5&A9J41I7F2\R\NE@!(O>]
M3SIB,2N-!$6[%BGB_:;5G@\:8UYOW)N/V!"G_HC62I![^/*SBM"VW6)&U[JW
M>Q&>RA";&+G5T.:D8PI/ :HU9>E]+.K5G)8EY?L;0FV!1?5$^2TY32_?IHED
MEWS#D]\0[^42TDJH:F57\)3E-4%]^?+'8[/*Z<7<300(WZU\V-%L"-Y'6ND6
M:AQNL6(&A/Q6Y;[C:O]NOB_DRU$OB\HKY4S/BI&]CT&MC#^&6NG.)^XRZN"A
M?/Y2++7/_V%71'4A9V^/3J8H5BI80RD>HQ#D&ET>70Y2E23\GYY(:'.742>Y
M!+MA9S;"C2=,6VI,,S2[_2@=<H^H'GU##KYY[CU#PN'-_$Q'M/*<?4"G)"63
ME2NO3+ YAR%AGX;D_-U6,FWE2/IPW2=YVQ'_.T3?=5R.N/&*K(WT<">I+Q@^
M4MHS9-O0=O.+HSUUS)W0U_E47A.VO0PM)6YBK)FCWL1QW+]<]/&8?ACZ0F")
M=BS%LXAXJ!Q\-^.9_)=(["Y+E'N#]]^<"-\YS5GY;'Y?:HN..B2;[LN9^X <
M?>0B0\0EJP!Z-?A=*?J P]?I*N[[["N."30V:PTL$Y.3\@];W2?CIA@LZ Z,
MSIZXB%.73P8FV"#_S*:Q=OM5Y#WR%3JR0MZ:-GCU<_(KB9AK7R53M*N3[4CM
MUWZ40,)_03:& &G.R7T>7IR!D$<@0"-=QSD[D*49,#DH-O9?_W?VSQ/I[NJ7
MPS;B.2X--2C':IM@< Y;QPH*TX8AQE+*O<KZ@J)TXLQ3'P.Q'>/WH',NRN6J
MH81[U"?T!<X\D?>(T&6/B8@*=^I/JB;M5W"0!/"2!;;T]T+<\.@79GI^XRK'
MWT$:F]8BR=O<R/+$>KX_4S$Y-6WS.#;AE?-*L7Z8MQV>>NWP]HZI#F/U4PJ^
M$?L)LGP=4FS<%8>8A4O:SUL+8KGX/ZQ7RN+CS=ECYT^*M?=CIN;.E95JPE<2
M'GP=1+',EM-5>C?8CW3[/R%NG[)3^YD9.^<JR#0G+],J$"#U\X1$N$Y"\!A,
M]C(!%*TVB*D+>I06?/-4.L8>''1;.OF&+LOPN&CCH0P"-&>G2E@B%Y@:8ZZL
M(4BT!FSB7+>FSH9F*?3R\[6[N!_^L!<HY SBGWRX&^:,&U+E?,><U9EHH)O>
M1P5#R4V8MY'/GNOC063\.LOSVJJ8W];.6%T3$LBVW=N1:[H'>)^8WHG$/<H2
MT/#1,$(6BT@[]__5\:)TA)TW%[^2IZ^67_2J'^,[-LCK0EH_.<9P\7)T=*+H
M83PJZ\C/SH(YHHW!35VT955#>;MGQ)9AN9=:9/.VCI50MN$=APRO[PQ(RX(B
M+_U$&>\NUKQE?%O5NO2*5U;?LKF[BP.*9?/0OIU.A<:DS3T9_I^]%5#_/.60
M. PV!,US:$]["M1KA0!-@W_Y\?H,2'L_0JY?0( DHS;TPX)?TSLNUO--&&KZ
MKZ+/87=ZJ1O8SU^?&R-2>@R7PV/^@!(@3FD$I=6*F]1H^UQ6T.-:"KJWS[>4
M26[9<D&@[G^F-4R]/R6YW/3.F&7QQ^L:RN9A%-HM G+0D=E^?(89P>8A+*SO
M:!"IGW*U&B8A.<(.5<R;Z;!WJFI_/5G4T]E$W3"R)Q@.Z29>JZ#%B6R?8O-)
M'D;JM'Y#$*LHZ[:U(3?;9[LB3[HN4.B(Z>D.QEKOR99DCB;3?=91)-MC_U)B
MD(Y9#-B3LR7X4<DK7"! :XEJ4 3HJ"<':5C]#>1B=?CU_^L[L>MWC< 6/EE1
M'-\ N^E-!4L("#R1PQ'BCW)5N<EB4N?W7''0CUI(]3:^ZA%P9>3[AC&@^!]O
MU<B54^!>%4Q]P/4RX1WR=TU-3:28]W>*Z/7/M19V],7[F]B3!>O&+,"0\3'[
MFS69%XUK46I4O_$(K=*N?GKH6N3A17+./#HM,IQJ)JG=#4O=E!<>WXQ]?"'M
MU$F_81BBD)1J]_FX)JI<FKJ<]<."70-E?5(\ODV9I L;W&Z0B>)B0^D XRTO
MNX,U+7PZGF?CPQP2:)^UFF)?.;HYM%?ZR9,LC"0;,;((J.P"C'$4'=XSU.3R
M8"/",,1)IF-+L?MKRL./<%>+;O/VG_48-B"GD\PL*$RD,N,6=*3C?\&6Z[?)
MG *&'MEPW8 (<KFJ.B.B*H;Z%"\I^R[RP28V5"?C<6KA&S_Z41=CXZ^K94P'
MFC+97APO+?&F^#]O<?^WWM[FH((2+\&LN8SOSQIT@-&\A[<ETV!0.M6]>E&P
M!=68NE9%5RY YO(P4N BSET.*)5SQA03,E5)F!,KB<1^X>>:!5;2DRF0(WOJ
M8^CT/=:JBQ;CUMERY X'.H>O_4U'[!)-W0LI=PTV)A44><9*%[ZXJWEK05+'
M0UG%RTI0J'5!TJGY$Z\>F]BMQG&FG"BFZ((,H?W,&8W00YN;J*!+YL9K3&[T
M!-K\_WZC;&1S*Y5>[^?#H(R%.SF%RKN-!,K&\S0SO))6YH_7?CEDJ*"]E5>
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M0<M6![Z9,ZOG95KKJ"URCJH'CKV1?+C@C,-=Y;.0I'OJ,"LHK-,%<7"_ES
M_$\4^,3PZ5^2<G 9YZCVF_J" [3F,JX[[]O!?5<:KNJ28<3J><)=]0R_O$U9
M#?KT\#'RN M]^L^^,E?GPS&@8=K4K3&NXR[4'Z2W&]4[5".KL(5R3:81LQ.
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M<,242KNXKS3MXQ_8H'!I)='\S?."*P*$'5P,U]#(';VO6>U'Q>9A+^F7[ZG
M60VG3@#RE8:F&-NG;3Q"M&QG^3=8JE;<M4*@51M'Y<O[DB(#)K8L\*/NP=!5
MM9VLA=7S>SU,*YJ/.&5/@#.?&R0+)24X@WUH\L9&&]G+:O:NT"S8VU9M&"<O
MC5/VYIG3/WO-SSJ/L@=!*E_*O>CZX;_6<+DNRV_(*AMX#RR2P3]/ZK<S$ IX
M^].0"(:;#E/M>4#/ZO^'Z+-6[Y#]-KKTA.TO&@?X16@HYG@%*]CK:^,DW15_
M$3V7&0:R>I11!9@PD]_3:=HI.#R\2? >A</24U?Y)^])";2A*CV-9<0J+N38
MY)+ZV<FM#]-EH#=0BZK\H9&E<N//DK<$?O3P;Z\:?ZW^%<F'7 >N94LORN"4
M?#J,!XMNT2R4XTLO#1F,B$O#+=+QEE-A$Q>M14SMB<S+W[6QF83%]I2OET(C
M$[E@C"0[A9WKF"/( QE6WZD)"47L^FN[?IY>R,%@P&(?53"J@'HI1:#/E?NC
M]/6+^Q_>^BVQ<'==2'(8]NN!@B0OT,V(9IT *![^QI6@=1E6O2R\I2&6\JL5
MDV)I8>3YPY8R=8$&H4$07BE>B O*91$H=*8/@J6<'%!TL(,<5M["M?.-V)$9
M=#W&";YC-83C+?5,::MK')_1)MM2*_@XG@ ,>5&OA#?%^EU%-#\OS^%F71GR
MQ]9R9^7U/BK?K2.K$A@WEAZF"1U61$3 7CJJ$3F?U4C*=U@-(-RM7H(C^/X6
MCO\B0O^)](&57R/C,!@!_IDZIWK@F@Z>F;JWDQ9H-=^GWG*[FJX0?C&)JYV:
MR.0G:4D<Z[O,IX4H*S..<0&W2$>M,4<[#E_N6*QE&.<&)NG.99D8WW*=-Z6@
M<BDKXLP#DD]B!Y*P>-*VK@]''ZFFC(Y.@$;0!6MG=%5_!K/S+?*EP!>^6*."
M<+_K4C5OMJN8E*L4/Y?)WHBEX;RVW01X*1:A.(^E9EIZ/N*8('N[49OY3/7C
MXE<5?/;G?CC>T&-5A40RI7#GV<%4C>506RYA+M%[>0R3+W?@%*E#N-2M=="<
M LXWX_"@94^7)23R4"K+AJ-^0%VWC&$X[1+3HC=&P$=^(U?/UF8XU\\1QF=%
M-N=PWXH8<4!R>LGI80'?P(%CWYG#',K=%C_6WH*>YG4-Q86W_OY9>V]VTZJP
MNR&"8[+/[0L:G3?$M"*]G&68:AZC5W >)\!ZDL83V_%Q\,%\6JCV>UK%CKDG
M;QL^T0@!NL>=!.13?[& BPE9=!S<EMLM0U/S1SOJY\&OA>80-FH.?[01!]*]
MIVID$TQ@^$<[\V]R;A?+_9W4VW\GE&$@03C'WO&,*TNV>2%ZL&:14'I_]#V&
MG_Z,[N@71V3ZDY"GUU+C)?Z4_VWIOQ-%T"_OMWY?H*ZG%C6 =Y&8?B%$:B4L
MGG,P3]PW!=R685$[75G:>"R)U0O>D; -&^/%6(O0L9V]/?NU=244V"[X,DS<
M>#E\I[X;1Z&Z\!-[K!,]S>-^P%?O+IZ=I;=9%'3TF1O 5Z\T3%#F[DCL',@C
M7R0C0BIB>S?2R.R?VWF/M.QIJ47 %[Y%@907*HFGO5-I/>Q<F2I<2M\5ZLJ)
M-3WQF&E*N;.!Z3$U7$K(0]QO0XY]<^MDX2*NH:6MV5IGI0*[Q>E#?ZG\0@M?
MO<9W:9'N85ROJR#YMP82HX%/X;/$,I=] W_C^]L)]G3>2EG5II/ _KTI7'X1
ME568-*Z> (@,B')D1QMFA&_M:HU-E<A^XKXV+0R[C )J'J/ FW_GF#H!*O^O
MUM<^(,D$8]=!1UL*@SRG<@[F\Z:3%@#U4PL1I19_.N02%O;H'"(X<H</!'M5
MK["_X/GV=\,G-*&OWH[RZ\8.V1;UH!M@4Z([65-W[5^V8;\LR3 &MF',:+$G
MP(2@[ZL!0A1[@G\.I"XFK8>Y@BF5LI9>&(XI"?YD5TJVTNEDQAP38]._$HRI
MW>MJ2.$AYS^\6=\8,1Y'-'KT"B-RZ/T[F$*[0#OG3\\V,4S#Z&WOVBX\W#A"
M5I;R-RTH]U9W1U;J\A!RUPY#)3]BI>MV0\GNS]V-H.BEMU;$O?W-O:!?"U3!
M4?P")>N):\S9:+^5S,=^Z&O4_@5'J82[DC3V6!MF^=LG#3Z_^U^CFB7=8$-%
M2W!+FU @\[G="UAW;P92UO*9[>P)D/F@=55OXA/!BN!ER$&S/]$3PBU/>FE/
M\P2P'&8M6=K32>(Z4_J'337^5$?'(A3(^Q>Z^=\^"NP]-=D<P6+\)P K@=4\
MO%>IML4+*, Q$6[NO 1^WU>]Z$JSC7R5%E9NS/;Y7#N7"GV.\G*[;$[?;##C
M\$9?_U?WC+VDU:I*.HDR0_?Q-%]KHK0[=K*=0].'N@'/K)R/HPB0&5%7\]0X
M7+:5'\TJ[F5KO>]5^C6KDFD:0FN[JV%D.J@OEZ&,?/GVAT%(NMQ=B0 S*Z(3
M0"$J%6<MW60%FQLG*$>4NW[%5FLQ27(@ :=IW!86'R'N)_1C2?IVGR1D8_]
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MCTJ9W4A[=7KUO.5;K@4,Q]>N5\8Q'+1@"7C .HI\N/-.@'K9J0HU%7:74)&
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M<6?UI1&C$:O=>G,74B<= \?H%+C>Y\B4;3:V"VS947+T<#Y!8%EL!V&]2_C
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M7K(H;=^5.C') 0=N&"/'C<\OK3FLL7D.#<8X*<R95)&]VDZVNO&*19I:B70
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M6[3*_X-I>]1)C/ZX-//T5::X/9MQB9U]W0=XA'R4493\P7.[3)48-A/%)NX
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MO[#^5P;Z"^K?\CH=PY_!;BOFW:"SE8BNGZ%!R $B2W+BH<#)T/\'4$L#!!0
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M[,TN ATVJ/EI+8([/T&GC0Y* 2E6-ASN+Q<I3M[]Y\$0GB$@<"A5*1AP1C2
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ML2?#<GP<Z0Z!8/>*^4) #Z$_=7PA?3K^X]KGR<^"&;M]HID4LKFZH_G#$M5
MFW T68!-X0[-FCV>ER,B)8">9G,MF6I0ISU!,]Z<PXY,B\;1)N)Y2,&R53#T
MZ1W4(:*!@B.<W/&;CG?#I>XYK)?C9TNLC,K(%T[9O;"4(2<HVRF7^M&^F?FN
MTC?&3:B<!2_)?L#N^#%?U(Z&W-"VP3(FV_;G3^V.AM:HZTIE%-$X#*8@XY,;
M (X1CWK1VFS5=T1<G*SEKA,">TWX9^).+JZ^B]!1<>:) .?-'EN.3>PAMZX
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MB_*+'KM.C=LX'I7>PS3UU;O+=:G?51;M?B[N[?Q(_SZJ4G^>ZUD*&WIU2.B
MG&3-!*V6#X!LNX?&GE!"2!#F$^5;A5> _9*;TB&B"L)OLSUY?%H8IYNFH2L
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MFH2F\498MHWPLJN< IW&YB_!*@'5\N9A!K@ZU1;X0\06M0O>30/A!]3>)GN
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MOG>TZ)_11V\7CJ$3$YT_LN:8-\:0Z&7&-ED4(K*!ARV( 2>F>EF[W_F>ASG
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M""E=*HY4T*KLMTW*X3L>((R(JT^V:C#,F]^'=8M< ;:(>)XZ2$BG+<T5$$.
M3!(>XWA68+M$JV+AG<0P>QIZ(@.\<-7EUX ;7S8;I+8(DF'=Y[>-;6N0./=^
M.]\5 P6UK_,J!3[Q]T0W)I&V@C\S7Y>]1-[_5I'9[ENY[DCPTI>.8-&438G;
MVSN>&=5VJK0Z%RQ/+\\K?6#L0);^PEB!W5H>JD"_9!'LQLP)OT]+_VJ KHM?
MH2!W[%=.DZ(&&R(@)&3\P.O[#E$PKU6N]][@BV)_1H-@2;:<7SE]V1A:F[\O
MG@R.N:@">WWNK7#WO)=PIDW!D=FTK&G["?U&A%,Q^$'F[**?\-W=HIG *V"E
M\4.H%36)DY= ?(77Y3$7!=M9C7NNTFX_2)5$5 -(&O>0<\^F=6V*_X0$;69:
M=[U>)ZK[ZS%&*5 QH<[K:=K%2$\2 G^7W4WTH63(LML,*O>"_+$%T*KZ>$.H
M*/>W%\Q/3C%KK_-F_+>6T;L:; ._>[D*$U)/Y9LW^,<S"P1>#G=PP'_1?HI>
M"8QT24)RELZG>0Q^^E'L8J%.D;U\5YS^)\7+G(6P9%FZC]PH;#P]ET/FU#'+
MI,C[IHR?Z>H&1O/BM#NGK$(C<6'TGW/Y[ZXY>3$8ZJC:6TW6IY5/3A\U+H^/
M_#"**)?U.H(Z")QN!^4D+E*OKLK;[81/U0Q:ER"*NR62/JN4&/NRL$?SG;!3
MAPU(P<\OPC\1]] F^CRO.:":F\_]='JRF[)JY)@XN?.N_@I(#R_,78_PUG87
M#^]+D24W;$C3GKB5<NKOYC7;9/<=/$J)).<W P9Y[^V>>8)SRH9^$LB*G7-_
MG.#LOYK-Y.3L>^S]^/%W*;VC<7GH8/$EQX71N@N5I#,G^H%N&M3$/?<).QO%
M3!2.;8 ZF%+1/QL[R!LV&(!Y$*A!8S]+1[]@G<"V$C'1M5&-NG![4*M134/+
MZ<FC?AK45+$CVZU(8#FKW)XZJ!:^+&IM/'"<7VP2Y_;+10]O$)#2ZI:6$IXD
MW)8;Q>;25$.*/J^WAXX5:J0ETU+7J7<%Y4 /1I2$Y*[AA6&YOD\P/K'$/ZOB
M#B%\L.F0]2P/A_J*"9[%!78]R#];8 SC)6XBBQ(*/V8GW6A4$.V*9<0V/?P(
M=QWE>T$O&(D)2_;]FUEA]/?1X,T"^$:E[N850%3&:.EFV=)\:7D%W+Y!V6CC
M%G)(2R<!OYE](.^>4$1O=EMU^=/W8!<-D0& S"#LD(Y"IS6>CIZY8']$38[:
M=;\.NZ<C[^;G610EN=4_:EW ]H?G\GV7"T<%2S/WL@==G+S#O'EW[@"U]CV!
M@OU[9?/&@HX\@0$71QQ_U3BA"BE/F*_Y0'_?Y/,D95(&YG2[HO2GU8/,ZC_V
M!> E453OB#/7%7BPQBNP/A%^?2Q],%C AWZ0FQMS/+V4MPIA\-'J1]YJ_^KC
M=JH=JM5ZH>W_>G+_6_V$Z,-=$E/HC>T^S#S?YRFU"$@Z#\94#%D$G9,E4"5=
M//4I@$Z;JV!G^V_(*^/H41Q9CWSW+;"L_5RJHT^F]W_LYJNUM1)Z,=,SI24M
M<_V"<PP2C7%%U/2'TU< Z2AV<*?XXC%A.J\A8P=TP8,[@$;S$$$<S'&">TE8
MO3'92;QCH<%U8.OUN_,B.L3'@^[AO&;$N&UOBUSN?5D5IFE%,&PY%B 7D%'U
M(@]^0D5.\CS).M/,M'5&=3V_Y:6U<Y\K+F76N. T?6+^Q-MIWA@>EB^LJW'0
M]?9T0)ZT7YA?V&>M=O;,.Q/_P6NWX%)0QLX1?H4N'3E81G2_T4,P98?6?%I=
MK;\YDR)JHMBXM=C8_WV,EV'1XFVNWI@E(5P[)J]+#ZE]!200A/ *.)A-!7B1
M&L;E,]G;<?/VO*]#2D&<_\N:Q]FV)GT'A@^':E1D# I550G2;4Y+/%.=J''(
M7*56*%IE:J-S&DRV*?Y'S=?:YS2(+^LD^8XVZ_"%QF=/V^I'C8_]OIL*W)?Y
M$U"^%AARH4@8R:NIQ#-3$*ASKGF*E?G\<A?X-JYW%3J7]1+'BG% 0;KS8OU^
M;?M8KLAV">*$5SC06)[N#H:.*<8;MR8'W.>+XT3;-*S9&I,=G4[U+.TS8GF'
MW]C9EGN='JQO-R+/C!$ZC>FO]2^WTQK7[;?U.BZ$Y^R/H:970.F0- ='7?S?
MF2WD'G+O7D6YJ*.HH]/N7KDH0WO]>MV).Y3YQ)M2^8DGQR.I<$MFN&[P\H(+
M&[&RFR14>9+?F8*BN(KS7:<P!)53?,*/8[W@\M'OYJDYW34LQ.M=YH"Y?#8&
M"308<W@07X!J0U/DDYF=^C!P,29/'4L10_X9-($7] 75_JZ[;*R:,]"$B_:W
M)2GD?9V]UMTTQ=M^D/!]A;<H?PC#MHLQ].N_VY'P $7K2ON969>SAE=V?F].
MOVZ_TNI_+9@]HR'R;;&9<=X43#T34VQ<%@1Q)]1O?AE\*.+GYEK,;2L6L;5O
M[EM6E.+M_.W<P5%^VK&O1*"&V  -/$AJ9>>7(UG(YO[<;]A-X;I3GA?0L(Z7
M0;WO8+BLA*&^YM52[ C)?N2]_-JFL5I^9WL :1Z%5[&S1'62^,0.(B,C\?0K
M5#LH;''?,ON<C]?,EC,M'H3IM?>SG0K0"(QZ4[\2 [*L>V^>3Q CC,,HP41X
MP5FP(MX$NQ^!Y\*X]^9R0YFV8 R58C/H9UEJS9-CWRQ%HT_$ZA9P,8%F-Y(W
M;QD]]V;5QYCV/GQ@_BM.7U)[<3]0?MM1?MY1&C\S=4_O1>J/Y-J_IA4I]5EM
M'M# BMSVP*_H* '@*(&"<!%?<5>F$M+3?,)V!1QGXNNP@_A;)"="&)Z>O& 8
MZW$.;#7B"VH?"5UY ^%LH^RXA=-:O0*8'#+INV4,!#IP95BAYQ/E=\U)?"!J
M#I]4RP)+%QXU) UY&Z7'O^49AY!"G,WG(D\B<2G8C!76'D34N5<I&A9BQH>1
M#5?0MRZ7[HRTF*DWC^I@;,86AYMWTY<N*;NNC@I?4L_OBH#SG*PBM#%L;7]&
MJ%H"83=XOM7)K-MOEDG[%TW/9NE/_MXN+P^DKW535*'X@M YU@--=P]H42G4
M\A _&[Z8*(6(\3>#!%7=\FGHO,IDB) _?,]M>)3C8=2D2MC:G]\ QRP:JV!5
MMI19SB.V(P3GNW+RNQX?F#X*T*WY2N1VT1[FRHWY8Y]'Y6Q=/N\1F1/8I>"O
M#( 9-53M)H)W=LA<E\.I\O#NQR7N=G7)D^T7]G>/8) N5XXI\E?,<7-R0N%H
MDJFDX>[]7-^2VVQ9[ L PD('6L63#MK.E8C5 >LKGC0>%*6D"^\4@_:3SBQ+
MMH>/>=\<#A>SUOYKN#17]A-_%9O2/C&I6]R6=A+(O53 ?Y^1U/0/6<*BHF$T
MH1.ZKAG)=*N[VXV("_NW\I4XR()<[<DR\],!BP6R!X-L:PP<1,U="+-.&3_7
M[ YP#&S^"D"FB53$+,L3HK:^Z<BFG.8F:2Q/G\R>'PK=: X&-BIYX2442;GM
M?O0_IR15#],\7JCV2!K0%8>%#0%E_M,IV6N ^M!&/.4&!84B3&)7)\2KZ.?:
M758A7$N'YA&G'*G58:(?-:12V2-5-VW7?VN_O2WCG5(74,@)I[4X[D(7D=-S
MHDF]^J7C45M- A9)DT*\P5+9^.]=5T"=!'R-2FF0^&LL 2QP7KS),2M[UODK
MZYX(=SO/VK!%7%)V33CI7?$GG*P(:$D9\\LG;U687Q#][V;B5'P%\'%1$'K,
M+VR/Y_0Y2@]+;?EG7UT!\VKY=+E;!TO#+RO8OC=;%),U7\NG,5\B)=+<8*;G
MC9VA:&()L,\58.BH8%%F8TGN0;D2//8RZS*_,,00.;SH3(OV>9:4&+4P*$QE
MH!K0".RFD-QO#5T0[V8YBY;M=L8]8(T*T$(OFFM?UG0P!$ PZ05HQ7?.$4$W
M)PA$RJN0'1AQ?EP Q''UAO>KYEK_."<4E=#T>W4C"8%0N<Q7^0ST4Y^EA97,
M[M]6_T-,Y?/^6;<\R=F %#4?+,UT417E3SN[<@7L:J_R)'32M_E?!&9<%CEY
ME-,87J8'4/S \Y@SV&4LT>-,+Q2*HPAW^E&M9?._G+N1D"B\AO</$\&+Y5]H
M&H<;3[>6)I8<LMH%178& E\3J,[0"<C9U=DH C_N"EBU&:PDQYO@V+_Y%*R*
M=>]*3@4(7 'A^E@A3=P@)F/P<498FY:WMYV%\Z-+Y>Y&F^?-CH\=<IY4A,2P
M7C!^#C:?YOA%YOREU5#E8]')C+%\<4MM8QMK0W(2(:Y4S9/CVV5GHMFM^L]!
MB,^TL8SB2"5(6HX#>B/F1Q#[X+=NK,VJ6N\N!ZJR%Q%KU-GES(531@O!@_AQ
MYB>?+BL4.,IL]0@L$W@(&L+LXR?&$/ <XU1OZ5ILYXI_//7AZ$)C3TS:.E[9
M[8[/14)<'A=8Q':9H>.Q?2XU;@[[ !(%YIV]EL:6)ZD8ELXH:1'CYY>?.V[X
MT*\B>LWI<22#03<Q4X^U%[AIX#[R!M/)4)9-AY*E+>RR]-&K.B_&#X34MSC?
M?#7G(H.[D2NNQ?_T7R[A_$;$;MCV+/=FN'[M:_0CJZZ]N!OKEE1B4#R9W^CA
MY<LYLI_60:">,#I\-4V>\*6BK%SE1D5S21RK#FO+9?@/*66[XNW94"+?'X;(
M'V/C\_:RK P1ZP46/RDIKB5K)5+X9!4#ZW%F-2(,\]0J7 &8%\Z1'>R7)6!!
M/!BGA49$\=3II& JC5)0 Y^+[9 9D6U0?S2,==,HNY.!-Z'O/+>Z$.:H;'<S
M<X#98X1RIF/I"@@U)\QWB%ZV$V[B3E=M$CJHYH,0W&"<-G9^U;N+G@/_*')@
M'/\L?K!OF<[)\='N.W6\AF.1;:)65L.]RALI:H\')LA=NA'_O%)6C+DX+L"S
MS^LF/7:%M>'*;POM3FYYZ=WV>*)N>S2OI?ZU<;(@::ZP*6)";N7S\,/L:DA$
M'D:)L0R3<++3<'.@S.Z:JRA=5B9IWM.>;WMI[YT8XK:NKO=>K,DUGHB7I_/-
M2Q6 ^7_8$QF\\!W?>#C;/8MO&2YT1._(=S\F)3-7$<64,4*D.RW$<$)+"1?T
M>*Z\+E96;CK<9[0&X5' >UPC?9]Q KEMR]UJ:]9^!/=6AT1L[[!/@U_\=VB$
MH[/%1/*)<)/JU_01]495&I[-<&8B_&4G_J9W_[GYKNEWO":&?J S(NCV94:;
M]876==7486$]CNXG@9B-F Z(G3FC1[F[,M8[MHT)E8"\>V'*9!@@@HM>O;SI
M:6H,G6H3\RRW;7@</I-68"_Q0.51T'D>1BM0'>>]LASI"8V507;DH3KGLU9A
MN]$_D+(10;\<5DV95L5G+)MP>IKV3[6@-?,.3$\[[O!64Y>?> K67M"K # P
M#VTG"K[,XK@7Q(IGQEU>O#$*,+T,AUC/0SG^+=? NN+H5\HSPCKN^7@_P8J&
ME_O(]CR&_><7CZ7A%"]V&R^" =>+QJV4>@32]):5FMBU!"Z5,]W/76KEF8LD
M4!E>:.,%+\O!9(3Q3F[8!V?Z '>,[$XYQGNU<N?L HQ_- &^88QC-9@DW I0
M!O,8:P1XK^[C-(_O!6BL+HK.]IZ;97F6(FV1 :PRMSWS8Q:M_..66Z=>4/R<
MA=5"NEN7X2?+=<^6*16 9:Z'1Z5UQI"8@:%?:,I'HU^KH!;2VC-B7+5S@[=]
M'9S%1KX7O;%P[PN:6:[9/=U51L$^=M!%]E?C[IA'0.HB=ZX [(X]B4ZLOJDF
M3R@/0YTS)P_M(&?RPW3'5<LB#JK*[J1R/9@XN7#8R75.7[$5:G#]N6=(]<'%
MT)MX[%N(?$AJ;:4U[1OON\MG/!M7P+0*,Y'VJMO/I_?)HDF3DJ6>TQRJX@:@
MJ][\EL5!:4&E":VLUR?N5V0H)TO6;-GR=+20[KGLH5&4FX'7&+CS'N*0#>^.
M_);R_9+CK%S/QM.-^3Z;WEK2+'\59+$LLO\ ]B5Q,0F5U/KS0[:CO'(5B!UE
MZ6Z3\H?S?$:B)3N1/*"ZE]C-(%&'(N#"8\RUNRVAZ?Z 9#Y!P(I 4N2?JVA_
M/Q*"N9= N-[\A,J)AMU-@I4N@8/0XBU<8N:=3DL)>IE=(N >/^<4Z";'M6#
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MY[>W^FQ((L]V+QW.@R*?VVOW"U?H.XK4=E9:SUQ\J(?<Z7S/@Q-4#;^0#K#
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M?V<5,=H+EIOIN(WK[4G!C3YMJ/>>G)DT3WE]TR[+X\*7KS:>K>"2Q3]PSTJ
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MG+I6V\H&ZLNU5HVP\EF5NC+8&T;J3K2_, L0DI+=#Y :WP_D*G+=3/_3.3T
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MC:/]K=*LB#?ACX"!T#/JB'%+ D097'D$2'(JSSAL_SUB-I]Y<,I665NP+^.
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M6/=4%SC/Q\YW;Q*]F8IOLN[-WKTO_=*7PVK(ZX1^S7P"9XC3T&I8IW,?5.^
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M."0]U-DZM'+U[TLR%Q'G.S_1B=\:0*&VES='+Y9^:.RF<*-+S1/JUU3I$N-
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MP:Z4!!P7,/ZSVUDLK'7E@H6BL%+%,27K'"#:EDMS]ST6T-RVY?#DVI9H8K8
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MU;/19U@?*%G?F1=1OOIY-*V*S;XO6^3R?E;(! W,B[LO\SY-[3<25OL"XR/
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MW*:?:"-X7DXVEM%&J_R=_8P&07XS_%#QA$3@*!0+ O-;F!5B:D,WOK,5-J*
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M9I7ZM6#7VC$IQZ8QWD:G\0&6%'_YBHJ)<?I?>F\WSSJA_KZL9O2);*>=QUF
M-,%TN>A#;14541GH7$KX\'P&$:9%8*D+JB+> S/LR@?&W3B;,1[EJXVP84&X
M2-ZW=&%Y#I%=VR@,7XD!_?B5HY=<W5$(43J?EO$D;Y.+.] ALTN0SBQNZ]LR
ME$5NYU<RW;OO$9MF[<^^]'(Q26/PYH;5;YZAM&0MW']9R<B2?MB1?I-\);K)
M95U >F(#Y]0WG)0BJ/1B=2U!P@4]D.^=[!<PH.H#$;=D[%3@V(D(R[< \DS'
MD!"<DW<3IQL]#.N:+!16L,61J3#RU"^PZ)^AC0L\#_OJ#P^B=FU<RF3:[HYD
M5VE30ESP,(9BKU65J#P5S*&Y?!'8IJP=Q1^J:F2,G_]:X(+-+GCC(#E7WC=1
MPYQ[KE_:\-7XU_/J;0$W-<#B+<I7[=6RH-G!^R+!#+4PRERV35D]W]OQ!_1>
M7V:4GG^\?N-.:0K5)YUW*]FGBQ3D)4V=6C/P:?5 ;9_ BLD9\UKTS:D2K8IG
MAU4&^1=YR/F#5R>-+DCL^>!.\,<E%8HB%PN;<&].55B77[9XZ]B.?>B!S01<
M4D+^X4DDY?9)HT^ZA ) _R2C^507/E>G(:9R"5J6^J "QUV"(M54 3C^P @?
M&5D'YD0$OAS=EH=R3F\I1X3;PW"6[!5'<KJJ0G<%DKL.:K39?[[_X<@IF[B%
M[SU6?;LYD/6TXI25('W+N&B.X=VLTMTD$T%6_M65\8!#HYY$:PNR=6=3JH=+
M+V)3EZ(:8L7%P1)":YPZM^YK<#NY&XN))5GO&]9$0^[!]YB=FIS[O;?K=[V:
M7Y7@1'";SPX*#&D@:MI_L"_<TG 0[":D:(('A??J"%;$)W0F4 ,P'&WN8HMI
M5S;/J-S.K<"]:].;6%1DU:$;S89">G"*7&K ,*N)\GM$UKS(JK?8HOAWJ\[1
M>X?%;F_2YY?N_D2G/!N@Z:+R(,>G:@I &:M-#YC-[*>NA68RU+T=??I%(I%9
MNK&<\,#A;>BC/[XWO-B\3E[]8/"GY!;[![['^7-;AQ>^KDI'>1>RXI'M_U [
M76'U<[)I36RF6Q!<D-71-:VEKC["[.LS1&G=> &KH?4HWI4NV]FJU5+)2EQ\
M3JK&;@XO=Z&,'=>3*-_>4>DC3\K0U86QY5-2@3,HRCV>]) _C;Y>EO(!_E9'
MP"FR/59K]+7N 821S<J6^D#+X%7<0&UJ;-4?.F&Q[N@F[N,5^/ZOTYB [WNA
MU_I>Q'H/ZA08^K4^.O_)]IR2PCVXR&/6*SGVH-;$:](T)7^'V]Y9E3FU<K?/
M*17K#*>]K0^9*"TP?+4?FB"1GR8S(N_O)E#[(W62/['0D\%?Z.<=M^E6Y^N-
MWX/"QZ4E8^FRH?<3FKLRP_JW3A@+:A7J\_M\2E]=I YH\&:%J/09^#]G=%>E
M]?0*ZX6(#S))Z)4(T<LJ7V=0\5QA4+K%_O?*N["W),BZ<!J.[QWI) Y4Q$I/
M.\,RD\7VSE\2%NEU;),6W6DI'\/L[>T+LI)''@K#FWSU86L>DQ4O%)DE!?.3
M:QH#6JRP&.^QC4!SCA?83D<7_JAC35A=S)WP^'G%N+5&I3>)$HFUCR47[NW,
M9+K+RCEU=V'CJSSU<F#-*>\8!)WSH[OMQ;FD*/M^-D?OLS" "(V5P]K26U.T
M(S/.])2L'/F)C[M?HE.<7K*'##[^]A8QQ*["&#T71=',QY:";$)*N&R-=Y0V
MY;Q?>.BZF,G=%O_-- _LF9UF (%AFEJ.,#:2M7]?%MS4S?;U-7W55UM06/K0
MJ6GA2/*K\&O-(97<)!4M4D 7NX%[B< 0EX<V6EJL\D6(X H;Y<-^NY!]T.KG
ME!4[+8C*M=!'_.2$S%"/Z&;RP=+E/\]M7[_]7.SI9_=*J/?-*N_FSQXS1\J0
MIV2)?,\6[AG(@'A3Q'I;Z>:Y#GIN_JY[NU#36/A?E:.PW9&%<U#2=@L\<.;9
MQ!Q$(3O!7""UHKYNKLIW1GYB5^1Q0/835JX+$]GLUKCXK*@]Z]S7TO3<'DQD
MPA>_#^06$Z?N&%P[.N5=(?ELU*MO7H)V,M6O')B4 GS8T[<I.D"@=:+>.K(F
MD>BYOW&"F;@$Z1U4/)=U&:.GNF[/==QKK2H;MM=>+-!O=]U2@EI*3.#B[_F^
MCU41&__>ZU#_ <MQU(JH^H6?^AF%48I?+ONJSNM\_AL/[R/<^T_\V3CC P("
MOA@[*8ZEFK8TFKLL5%R"RK+E[=\9PQXZLV1/NB6B;-365_>(+,(OIVH7_H)[
MZTD\.=UHQ59^( ,OW$'_OP?=I!J!(!3!4(J1^!*_EE",%!P/YIW1B6Q3 Q-6
ML[JP0C7+=JFBWAG.TQ]R'KP8#.Y"59^$D*XA3295WBRI_[6QO,B0G\0_)<7Y
M+&=I'S<0A'N;+/N=>>Y(158@Y<LW%6]&;*Z?I)Z=UD4LV7[4,U'\U-,Z<^Z+
M9"8H]@R!Y@%8]PFFQK?E_#XFDC1&2%L"[_ B-1<Q=+"I1I8J6!E"MZL>Q884
M+C6?1=!OI/_FSV_,I*'>I#?[<H_W[HI-.F8QJR9X$(\TGO"&DA/OX/<Z]Z(;
M41^.QH1CU'A(DUC3G8?X/2O\0,7YS&G]%%8]7N5IR3\,]B/+_N18-Y8G!4?]
MP#%^X7G4/=TI"IARY0!2O]+R5! M-E9YW)HA._HA[3O*94-+<KH5]MMZZ[/=
MV)333T6X=>-%S#DB^&\CY;;HN0)B^3B,0->I'H5BQ2PQ5;=&#+794,M]]>'V
M,_R)KB%-G1M4%_?\Z%Y"T6X<>SR3KV*<TR(X?[S]0ZL[-"=.!7ZE;</P4Q]:
MA8AR>)JJ-C#+UAG-26?"=!@.NB-*N#75B_6IS#E7GB']Y6@IBFREWC Y$\"^
M0^?<L<^Q^AGG,UV[(<$[YMT\CWO98&(SEH!E7=RVJ:7\WUF8O8M/IZ+<B))P
M0MD2:QR)Y160]'MTDK3^&,KAY(=E.IM+2>EY\[.A&MTJ],!>DKDWA<V'C/DT
M$;<'\"^$-AL1=!>K$B1)RL!6IS4+OK<S9WIKJ6A'$M\)&?:F0JJ?F_Y;^%$W
M"D-==T7JE\P].4L+*<2C/WZ>G]->0C\=EQP5]W/_5,GW#+*97YELN5F'#I(J
MO 0)ELAQ\=\HQ.6O*^X)HQN3]4N$TO4W'+(F*ZS.%+=[K\"0Q^]=?<5GJP)6
M.&@XQUX'^)KS_"V@A2"U:-HSQ CL/<7@UWMM(A>NJ:!*B*) PS+G#NWH/&?"
M=6<2.Z$UPU_U<T#X;,^>YG>.\BKNNC;F >"J@_>VT\6A\$95@/ [%"5)BJ@
M%&/!G0G8UBM?""4',+H$FIZO\!+G;,KXT<U]5;ZU?X^2FF4$[LQNFWH'9:1H
M5,X<V_WOD%Q _1@%3!&T<<$5!)LK.\*N<@TG18/4 5!XJ<6$>#G)6POM-C5#
MG=!X-;56((,PU&[Q,O5^W5#<CAHO,/2B,=L<J2,8J'H#R\U^+4(; :AS(T'
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M[JD.7:[O$U8/A)9%QEPEZY-,6]%PY_["LCE?Y3>?U^3=&7M[PI]]YEW,+.G
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M*5I<;FM*U$J<\4+Q[]XI/(KZC7T;I2029!&,9U8ET&OC>"AZ7UJ;-=Y+RQD
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M(83D8$F]Z=%*2IGOX5+ZP@?#XB79@^H_"[>C16?5/#"9V7$^CKY:^O!/\MR
M!&G@BW9-]\Q :*2H6Q[7G:!"0V^E"H\?8L,='WLSQV(9OGFF&/YQN'+OSH+J
MS*/D&Z\Y/E]E2ND)5:1:_KN<U+'L?71'Y[EU0QVP]>=8H?]N;C1@L;JQ(>[C
MG)9--1T 7NL!,.I]4F&FOB_94KSJ#NX\ 1L=0UPUQ7*4AQ5O^"C>B%90WOL]
MU+3CSC>J7,6JWE7F?PW=^[.0M2<LIU+C[^1A;.43L3?%&V]DWE,)<39[;/E[
M[CN6.: Z-.AD#*0+*FV&(*^Q^Z33RFF.S6NTJZTW"\O,.C@&A+@[5X/?I+Y\
M[_9R<?H:O<VOWC4ZT_M9SIQLK/>%%7[2Y=BGZ#])MM9_8JSGCK;"[Q_[^R@B
MX&Y<$ GU06.W[\8[N^2@E=ZDX<;TVVE^?!QVOXZ7;UX)"&6\J_L.Y:+WMC!Y
MX/;DWSRJ]ZDH_XVMG''K4@G+"(NF@5&1D)"\H!%U$MZ8^FBGZ;9J6)V):OYG
M5I!MB09=2 Z.O?4MKBI]"V&;7[:A(7K?66P[/:N-#505"TYA%5_D[^>Z_>#K
M7S&;EL-CWWI-QB" BA7NS!YF=_35!W=F=]#'[SVSQZXMZ!&28^\WXC%NGX/3
MZ/BG2,]'E16Z_/9QWYF*X(G"%OC8#YBQ*K^UKWVZR Z6E]\5;4M%BIBU+6@>
M^(ZQ(LQPYS8[0%+&,45Z0H;*ON,"D.=Q> 'P:OT#ISL+G(?C-0\6M'8N !@)
M^,%UHC=-T7WQ0!U!>()!>1+%] +0@*03'CD4/*8?O0#8C)Y_A*-^J(OG\$F:
M/N;NVSG)?S/SC\FJH?0"T&\*/]FYG%#Q5^HQUS)_V$X*?(K@G03@'AA]-M[V
MGQH!7X=3V:MVC(V^ $![_%' ''.P\#H$G8]%A ;+G8\NL;>RX!!7R<)]S:*C
MX=E6D=U@YE8#OV4$O5P#-GOV,)%Q*Z O\<,<ODZ>JONKRS1QDP7: &H,W7J0
M+H_7\E3^Q36*;=C&$=8[D;>0SBV)X?EU.GW; RNYTJ@EJFV*N;,G=A0#00%K
M@3U!/L'\L">$Q;(BL@F$8_-<K";R$?FY)\+(S;\,:ISUF&)/RGJEA@"2'A&9
M9B\ B;;<9U4^2YQH9"=OXEPV"GC-!TFS*2! ;.A*1/,^(3Z:;@@6Y02I%+>\
MD0MG[VTO*G9191OZNMFL6L!2+[7A@1T, 0N2$TD/SRH.%\3<E+J -:,4UC!L
M1M3.[H?,[=; KS#AR4,&OVZ&-ROQXC;-T\JYJJ#KSMU/&P-=>6=^Q00]$8E]
M.:EWN"92:X&)>#+EMHG F%4M:)9+;_S0^KD7)ZD\X5;:ME#;6ED<@\=D+A21
MK-J0KRNYHI;UXQZ=OU*H4.CZ:7 M1F2.]WNB_&^??5A$?-R[P2E^B_)OKG,=
M_-X-PMSXN!S&-@.ZJKN:TPZ?Q*8EWC@FO+R>OBNC4%<KZ!QQ;7'[_M7CS.0=
MXYXRF80(+@$M:.>CSC_>OU*I/:6ZPVH/XUC5A9BO!GC&'-2].$Z9DO?58<7;
M8PRUBEM\'^E@=A'@C4KE"T"D"$V:>)+N&-.S./Z"8UP)I"]Q&(Q6 A+V062Q
MT;.H_+IV.+]TAQU%^J#(Y%^W'7=3(K4&:BGUN PQ#$*KIUT6TJS+.J:"4FKI
MR*]#FG2?2G<83 8&')W,Y%J9%!@75BUU?Q]7LU[Z(2=O",?DGWA)'P*-WZAO
M@W96-D:/SC;<&>W<KQU;G-,*"B;R)4PF.5XWT'^,8K)]J4]'0"GLXO7Z(5+Z
M3T=\E_5_6,XG;7Y7X6MAO0!XW"2V"+%$Q67[^JKPNTZUQUXNC]795:T3G]'I
MBB=#C4VH$2^<UCT%&@"S@5;C1EQBD>*T.$"5FO[NK3)3JIMX,?WEI28ZV;T(
M7/B(<X,H);?R5EFCPL K/,M K19?XL+@/85VU7IS;AF &,G(9N?5G::FNF;,
M>E6^<JPGI7ZXU>Z#:7XV<C LSCON3 ,E5;<O.?%.>N)4]^_!<IBSW\&(YXA'
MD&?O?Q.2T?>ZDZ\:\C$MWD38XH8TJ+630P.FC#KC5?\*E)?,EQU).P<H'>C4
MH#]7;)C@"]$'&-!0</K\9N+N7?* FJ/1G%<1J2*C-[#AJ("R= %XVP$*:U=E
M1!+3@;4*-&>[QSSO2?N;UT:"SII.UE0@<O]%H#2OW+V"*X']$LH+=$PPAL6?
M<OZ,[43R6BQ? %"6P7]&'JNK7P ^%?]A5>KCVIB0,0&Q'VZJ[W&%==L#//L
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M7'Q%MEH?,>#A2Q\;%"4N*"W3]5P !#> ;+42N@#8@\EV5G+Y^0V%"P#-'O&
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M0<(/)$1[CXERZY34# )_@6;]229[&")F$N?629$$.KPD 6-(+EEFPF,8>"X
MIE,'QD;WB'DIBQS$_#"*'O:T/-;8M3M8CK#PM]+S^U;6^Z1O3=7ODM-OE/M[
MUS_HWN,\OR9$F(6)G;4*! X#UR_1]VOP3 (S&$W/*2!5&U41,\&0^?H_4"I_
M5[GVS<W*6NJC7>H_P0]/+@ F+DK7%43"4D=I0CJHO^)^5EP \+%"SQZ1CMTZ
M&VSGPMAH!V7"1L45?\6S.=DUZXE0#3]&Y_Y0,,^;LO 8G$G_T=^]*RS]I% Q
M[YK.EAKCNR4E\T!+9S>MI9/#*^ [VD3W0OO]OM],7D$GZ]KK63370(-QD:=]
MZAUX# )4 K**/#6=D#S=\A!4%]O[<T71-_SL>/'W1\-:#^:X>FC!Z<L>JNQL
M/>""6GVF;2.=$E6>4J>VW\B]VLJ]B9TK=NZW_GX?RLNNQGAB9$!T53J)=C&_
M>$KOJ8:CO%KY6(V"FT9Q+Q@K'5"8V'?S(*,AI8]?TX6/R&XQU(H)'G-]5O?+
M+5]#FNH,.N0B2$,2'5?MQ4=13U>M^6"%H?KT,A__^ S^M&TSH$ZXK_XO,.#4
MD:OG*H<P[=./7E3K=">)=LGX@1_=+ZME:^>M)#"-2F#+99SH9]K,!#/5_C[>
M!YJY"\Y+Z/1PL][>*I2V&D96M9Y.2"WGQ7YR$NCA>&I,0$OD834\4SXIMON!
MX>&KY,29/&1(63K7(&*P Z!K^KB#/VIW<ETG(,\E<ZHBM"8[]ND/>G%\_1<J
M#YLOQQ@S9L6,M\%/!Y_LT4I,O8_JSUNB2S[/=$S1^M HG#>/6RR:L.$%BUP
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MO6-KS0C1Z7I<&ZR*%!V,3%&$ #5%"S@ADS/397P= Y/LH#[N&;9RTY40B+B
MR=G0N5;[AJAU#=G/F<[+X;<#!Y/RK[0>TO$V5CWU?K+1N/CS9L2_)IO<,R4_
M)NA'H-Z:+G57R1]52GR-EZ?JL&6P_;N@ -S8358<,,ZL8P4 FLQ(.',7U(D=
M^[$]U44'QVQ0A%$_KT(5"%$7JAMS^MB6-"QXWE6*R<E.*KL45NB[A>$?KOE6
M;=59:VWY)O>>?('PCL45C___=['0Z5_=4WLY9>^][X0_./7:DB$C1[\K\O#
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MP-;EC%T08J@"<3Y:B6G^3.FU7*-34T=!)&*ID!7)R0E&QD#U@$*FTFT>L*=
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M*2$G<AW?D3MD.V8L!)SKP[!3L"3> +UMQ#CI$:.3%6&EJ#8$DS_I&./DL[>
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M*P2\1R:K&: _5&XJ&-CP#M7_L@MJ]?_3J]I8'?E=U$+^6M]%17>Q#'U.+*#
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MI_SL/*EZPVNZ 4:3;5CI08P4-=NP;<)V<Z>6#?DZN/E/.]3O5MT(QN+SY%*
MH$=Z)CYQ:UP^;L_FETIUO)2C9;:-C8>2J&BQR*]"TS-$"8("M@-AMHYD)K<3
M:^K6EN< [>1(HI@Z!JX;_V>K$,X-1/'_9YP]JR[BE9XA28S"416 %(8+B< _
M4 ,YOG( XJE9O]G51MZIDT3&:!5^?>/ZB]]G?&B8YI.$U5O%";/YRR@G5?QS
MDYU5"(=-="]9/%'^T"CYFW1+QCWBY^CCR.TZX#;>*S )XS^+LG/\#.6D$7D\
M7GE()D=FMNV>G7^I_2.W@"+&-D0?/MPP[276:1PUT8N&S9KEQW4:'P5L@T)0
MZG':R0)HF]M?AVH.974,+6^*UE871.NVV#6DKN1H((^.=P\L;^<\-6M.<]7*
MQJ-@]A3G!8.>;ROSU9ZC#1;-6A9+:1:&FXB\4=;Q67Y-JD][(XP3_=^*9#,^
M&J/O5XA&WF(:[:(CG)JK!]?_4!GLE%#:!<!X.LCK4Z]6 ,)S1;<N/F_IUM7"
M+L/R6B_FLP/0K'H7+CY7LLD#T@&/-N9A+*ZKSQ&C"%RC&!.:@_"=7"H[6_W%
M5M_UX5:B&,S-)XYIYOL9'7AWZ'FSG_405@<C/6(:E44;4Z]^5[WJN,JK^A]Y
MDG+,6!5CLO^I6H_%0Z.(>6 YF+D1?YJ.,Z\C8Y%5;X: /*I8UP$H2G>CKVRY
M"E!'-B<MT-M\5ZPGK*C]XA[!4Q6>.KK'_17$ I_VR@R%GF:&T)I@ BR1TM6,
MB:XH>()_,ZSC)$L#>.(O8S") %[0P&#WB:*8(D91M(K/%WD"4[3&M6#B:NE*
M)C::BUQG-V PT:EX7G(DE6A:/KVY.:A;0D1:28IJ?'_?G.4S\;GX;+%2?9#=
MNI-Z@!/" QDPK(L58JDR MM\!)8))QC&D2[4 Q X/V-W?28M?[S,&9+L1-1I
MR(A[-/A\]4VF%=CLUY9KCF4HYW7W)T\X'>-Y+>]6B;-:@0PJ/-E9D6D[#Q$F
MNA$Y5G U^9)^EGMJZ#R3;U&K5*>=L"9>IBY;Z)O69+_(BJ3M_DX;.%[2^=UG
M2YW&DKM0ETX#59(=QQ=)B;*/V_@P',18"3N"Y6D  LL!>INLS*'EX3D\B"?9
M$NP!6%4E/[R5K<3P]-R&3#:8EN<0%2;(X6QEM/'=PL.>TZ1!,T<M5GUS_+0L
MW6;HN<^;?.W7J!3Z#/G+E_592Y@2[>^,;D.F%UK>C$!X-RKQJ*$YN["^45 Q
M'_NDXU.4_LG\T \U3<Z]..3@.*6YKL%-U6#+_:=F\8^\$*0]WO31_.3J_.]0
M[Z",EOZ7%1AUQON!>Q[LD\,8^SE^G#V3GJ3".OY *7OV6Y,7+2AUU;F!49L5
MH(:T# _Z&'6AJUKG%A!N&A*_)Q5@F%RII1'3MA;19SO6>?>^<Z#0G<>"]9UK
MLZ^>'5.6*/OVO-Q:4\CLRX_/8@]@#Q,6E?7YABH_]]^(R#FN'&%+OC[*$9JY
MU8Z97EN/X?1^=EPZ%2Z^(O#GI9OK<5AX726RU\.0E>?_J3I4:!W/'_2SV?.-
M;#'1?\N7TC/=6!?JO2=U[=B[6V]57<=<6O^KX1#7;UV0LVCE_+W:?X4_&)L#
M'I?G"G_Z3O[$\3&.V:.W?Z)O\:PZ7VH(J$X(]-(T/R$*FG#DW*N,Y@$Q?YIT
MFO3/S,EV%9B>1[2E?4M%GN-+NLQ%&%'!VDWX-0*7;R>]CZ/^0*J*]*EYWU58
M=*-[;I&1@,M4MXLB8GN\AV)6=,$164#Q<68)%*3@T":="CRP[9X2+8D[/K0'
M_7K*/)]E#%STZ!'6%)>]FZMZ7>_?]=\(\B%K6_Q4+;IEGI)]PR6;A+KQ6J;K
MWAQ%>^E!V?+W_51"EJ&A9^;6#-LLP_Z&DX_IO_\JF?GO+_+(Z-__?IDMRB.O
MW\UUGT]Z]M7)AX]?=;= P^HRM,*T!KN^O2H^W6/J#[F44'QT/&P)*1I@EF,1
MI3:5:AD&+E[/_1GSS*G3HC^KTUQ"R'<3.F=T>3FN[GJ6KZ?.[\ E>D'C!:R\
MTK'X;W(/'=,BIF/^P'E.:+9.MLJ_XB5_4/[\$[08T6EV(UW/,(;/+Z+U8YBX
M?)1J:RM,0U_.7\XO;<TWQR,.:\NCG/..QT?APSS5X+[ I<M\ J;NOR%GUPO+
MET-]O+QV94Z)&#^?O#?MXZK>;QKR=R?86^[?PKW9!!</F<K9G96G-RVD+'B4
MB0OX=<D?N-DB",/*VN(?019+EMN1D+0/>_T*-RNW(^>_VK7\ **"[L892>S)
MY#R8<APQ^P$V#$Z;(&KBW"LA[!/_6P(ZZM)Z 'K)N5W_8/)9HFY+^XL>>2G'
M82[92Y_J-4X(^U9;UQE-!A)5E#:'2RVVM@S/&7B0FZ0 ,BD-*/CR?=NW876Q
M/'DX]J*=$@S-Q[?5\DYC:E.<C;'_Z_)1'\) X %5\=FHX<.&SP4-. !%HDI=
M** T(#Q(7&3?+5SFS(EGWZ=F-UY<6M1KT9O3GT\%(]B66G(XZA:.@7 V1GYE
M=UY(2]F 1 5_.55W(R%<;*^HJ _I0)WZ+:#64W!J<J&D'*)K8@A3=%GTF]8S
MBU'YL@[_;VTFS7&UD#Z?LLUZ,O,\+U!Z5X O00^Z"7(IO&:R)==3;_+^I74I
MFY[NR.S\ YXW0GP(JO(VQ#[^W2#THS>G2UX?XHR6B[2=?OI60GSR%7I*6%Q/
MF2N,0YHO";VZ_S'^M5O&G87,A=V^1Y]&ZWZGQTZC"IJRG)(7;QCZG+S)]#T
MN>:_V9K(1[IZK1-# ^L2<*W\#FGL$ZH'H*,#S_5<@8X]@YS@(\:0E?F UMG
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M4 _&5=O<.?LV^ 1BH_/1](0V)=:8 W,.*&>J'XJ%T)]-_H<=^/RO@W^>JUY
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ML7K3"N7?UP/H(:4!"!3@GADFW I;<9N';#_HQ^,V6O"W*I#39C]ASXGHW9)
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M[NN\SNL\G^=^[@O$;O1=17MC\L,^2>F8TW/^7B4/FG(7[*[M'WP]F7=5E<V
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M7P87U336)V(F?@.'.C^.-^EJB5F?NKKO;NGC^"CNC4#&A;M7F%L(F&A\O=(
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M8 +T^X D 9R@2V><H7954BMP]GLSXX A";=TN2GJK(\*WG>^O.9QBRR\W&5
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M[VKPN_RS-7E)R]%6=023^F<+N.#0G_:/WAH[3RG-30ZB60T5Z:: .]5O8,D
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M&=N,HE0Q>/B^HA\5FME3'S3.0^/C*ZCWI:>/0 ]3L'Q^F :7!I?OOK8^LQ0
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M;$ ;L$@J#TS\HQP*[6O'_B%--9Z[X)%K//;BYUN0SK%/*BRDH5.Y ^T@@D$
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M/H^C^$]/T#0(;.5M-L)+>Z5_M,L3?HI)''Y9^4<V\I.><X@DD')[!T5@.FX
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M?7F.,\_GDXX)))YKRBW12TP(!'V=.O;<5SCT')P!P <# KUW3^(T   $,8
MQ@>7$?Z_TZ5Y&,DZM%0?NW5N9/7XN;;3H[;]SZ?)*?(U=W?*[K[*NI/3K\WK
M^!__V5!+ 0(4 Q0    ( +* @EHZM[*XISH  !S/ 0 *              "
M 0    !E>#$Q+3(N:'1M4$L! A0#%     @ LH""6M:=1*X(!P  IQX   H
M             ( !SSH  &5X,3(M,2YH=&U02P$"% ,4    " "R@():E)WO
M^UH'  "#+@  "@              @ '_00  97@Q,BTR+FAT;5!+ 0(4 Q0
M   ( +* @EI "C;H& 4  ,TG   *              "  8%)  !E>#$S+3$N
M:'1M4$L! A0#%     @ LH""6K[J$QFP P  .!@   H              ( !
MP4X  &5X,34M,2YH=&U02P$"% ,4    " "R@():=WVZ:&$S  #/7P$ "0
M            @ &94@  97@R+3$N:'1M4$L! A0#%     @ LH""6B9(O.%.
M P  :B8   D              ( !(88  &5X."TQ+FAT;5!+ 0(4 Q0    (
M +* @EK;^>V\K @  #@)   .              "  9:)  !F:6YL;V=?,# Q
M+FIP9U!+ 0(4 Q0    ( +* @EK^.(Q7')$$  :B)P ,              "
M 6Z2  !F;W)M,C M9BYH=&U02P$"% ,4    " "R@():>NF0>,K[ 0 =%P(
M$               @ &T(P4 9F]R;3(P+69?,# U+FIP9U!+ 0(4 Q0    (
M +* @EIL!ZBVN@\  #>R   1              "  :P?!P!G;&UD+3(P,C0Q
M,C,Q+GAS9%!+ 0(4 Q0    ( +* @EK OBU3QQ,  .SV   5
M  "  94O!P!G;&UD+3(P,C0Q,C,Q7V-A;"YX;6Q02P$"% ,4    " "R@():
MTAS*:APS  # (@, %0              @ &/0P< 9VQM9"TR,#(T,3(S,5]D
M968N>&UL4$L! A0#%     @ LH""6L&7I]5;<   @5<& !4
M ( !WG8' &=L;60M,C R-#$R,S%?;&%B+GAM;%!+ 0(4 Q0    ( +* @EJ-
MO=:XL5   $0A!0 5              "  6SG!P!G;&UD+3(P,C0Q,C,Q7W!R
M92YX;6Q02P$"% ,4    " "R@():(%"_V3+E  "V]0  "@
M@ %0. @ =FE?,# Q+FIP9U!+ 0(4 Q0    ( +* @EKAH:!$4W@  !.    *
M              "  :H="0!V:5\P,#(N:G!G4$L! A0#%     @ LH""6NGX
MN+*8@P  Q)0   H              ( !)98) '9I7S P,RYJ<&=02P$"% ,4
M    " "R@():'O58!"3: 0!0W@$ "@              @ 'E&0H =FE?,# T
:+FIP9U!+!08     $P 3 &4$   Q] L    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>form20-f_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:GLMD="http://galmedpharma.com/20241231"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="glmd-20241231.xsd" xlink:type="simple"/>
    <context id="From2024-01-01to2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_dei_BusinessContactMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_srt_MinimumMember_custom_OfficeFurnitureAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">GLMD:OfficeFurnitureAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_srt_MaximumMember_custom_OfficeFurnitureAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">GLMD:OfficeFurnitureAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_srt_MinimumMember_custom_ComputerSoftwareElectronicEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">GLMD:ComputerSoftwareElectronicEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_srt_MaximumMember_custom_ComputerSoftwareElectronicEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">GLMD:ComputerSoftwareElectronicEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member_us-gaap_MutualFundMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member_us-gaap_MutualFundMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member_us-gaap_MutualFundMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_MutualFundMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member_custom_InvestmentInAssociateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">GLMD:InvestmentInAssociateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member_custom_InvestmentInAssociateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">GLMD:InvestmentInAssociateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member_custom_InvestmentInAssociateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">GLMD:InvestmentInAssociateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_custom_InvestmentInAssociateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">GLMD:InvestmentInAssociateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member_us-gaap_MutualFundMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member_us-gaap_MutualFundMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member_us-gaap_MutualFundMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_MutualFundMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member_custom_InvestmentInAssociateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">GLMD:InvestmentInAssociateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member_custom_InvestmentInAssociateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">GLMD:InvestmentInAssociateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member_custom_InvestmentInAssociateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">GLMD:InvestmentInAssociateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_custom_InvestmentInAssociateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">GLMD:InvestmentInAssociateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_MutualFundMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_MutualFundMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MutualFundMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_MutualFundMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-05-042023-05-04_custom_OnkaiIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GLMD:OnkaiIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-04</startDate>
            <endDate>2023-05-04</endDate>
        </period>
    </context>
    <context id="From2022-11-302022-11-30_custom_OnkaiIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GLMD:OnkaiIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-30</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_OnkaiIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GLMD:OnkaiIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_OnkaiIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GLMD:OnkaiIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-19_custom_OnkaiIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GLMD:OnkaiIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-19</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_AdministrativeServiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:AdministrativeServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_AdministrativeServiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:AdministrativeServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-10-15_custom_BridgeLoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GLMD:BridgeLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-15</instant>
        </period>
    </context>
    <context id="From2024-10-152024-10-15_custom_ServicesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GLMD:ServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-15</startDate>
            <endDate>2024-10-15</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_OnkaiIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GLMD:OnkaiIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_OfficersAndDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GLMD:OfficersAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_OfficersAndDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GLMD:OfficersAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_ServiceAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GLMD:ServiceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ServiceAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GLMD:ServiceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2021-06-272021-06-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
        </entity>
        <period>
            <startDate>2021-06-27</startDate>
            <endDate>2021-06-28</endDate>
        </period>
    </context>
    <context id="From2021-06-272021-06-28_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-27</startDate>
            <endDate>2021-06-28</endDate>
        </period>
    </context>
    <context id="AsOf2021-03-26_custom_NewSalesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GLMD:NewSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-26</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_NewSalesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GLMD:NewSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-05-152023-05-15_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-15</startDate>
            <endDate>2023-05-15</endDate>
        </period>
    </context>
    <context id="AsOf2023-05-15_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-15</instant>
        </period>
    </context>
    <context id="From2024-08-292024-08-29_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-29</startDate>
            <endDate>2024-08-29</endDate>
        </period>
    </context>
    <context id="AsOf2024-08-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
        </entity>
        <period>
            <instant>2024-08-29</instant>
        </period>
    </context>
    <context id="AsOf2024-08-29_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-29</instant>
        </period>
    </context>
    <context id="From2023-07-182023-07-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
        </entity>
        <period>
            <startDate>2023-07-18</startDate>
            <endDate>2023-07-18</endDate>
        </period>
    </context>
    <context id="AsOf2023-07-18_custom_PrefundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">GLMD:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-18</instant>
        </period>
    </context>
    <context id="From2023-07-182023-07-18_custom_PrefundedWarrantsMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">GLMD:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-18</startDate>
            <endDate>2023-07-18</endDate>
        </period>
    </context>
    <context id="AsOf2023-07-18_custom_InvestorWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">GLMD:InvestorWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-18</instant>
        </period>
    </context>
    <context id="From2023-07-182023-07-18_custom_InvestorWarrantsMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">GLMD:InvestorWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-18</startDate>
            <endDate>2023-07-18</endDate>
        </period>
    </context>
    <context id="AsOf2023-07-18_custom_InvestorWarrantsMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">GLMD:InvestorWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-18</instant>
        </period>
    </context>
    <context id="From2023-07-182023-07-18_custom_InvestorWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">GLMD:InvestorWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-18</startDate>
            <endDate>2023-07-18</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_PrefundedWarrantsMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">GLMD:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-07-18_custom_PrefundedWarrantsMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">GLMD:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-18</instant>
        </period>
    </context>
    <context id="AsOf2023-07-18_custom_PrefundedWarrantsMember_us-gaap_CommonStockMember_us-gaap_InvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">GLMD:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-18</instant>
        </period>
    </context>
    <context id="AsOf2024-08-30_custom_StandbyEquityPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GLMD:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-30</instant>
        </period>
    </context>
    <context id="AsOf2024-10-21_custom_StandbyEquityPurchaseAgreementMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GLMD:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-21</instant>
        </period>
    </context>
    <context id="From2024-08-302024-08-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
        </entity>
        <period>
            <startDate>2024-08-30</startDate>
            <endDate>2024-08-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-08-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
        </entity>
        <period>
            <instant>2024-08-30</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_StandbyEquityPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GLMD:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_StandbyEquityPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GLMD:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_CommonStockMember_custom_CaymanIslandsExemptLimitedPartnershipMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GLMD:CaymanIslandsExemptLimitedPartnershipMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_CaymanIslandsExemptLimitedPartnershipMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GLMD:CaymanIslandsExemptLimitedPartnershipMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-11-14_custom_DemandSalesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GLMD:DemandSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-14</instant>
        </period>
    </context>
    <context id="From2025-03-202025-03-21_custom_TwoThousandAndTwentySalesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GLMD:TwoThousandAndTwentySalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-20</startDate>
            <endDate>2025-03-21</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_IncentiveShareOptionPlan2013Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">GLMD:IncentiveShareOptionPlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2022-02-012022-02-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="AsOf2022-02-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="From2023-08-012023-08-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-31</endDate>
        </period>
    </context>
    <context id="From2023-08-012023-08-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-08-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
        </entity>
        <period>
            <instant>2023-08-31</instant>
        </period>
    </context>
    <context id="From2023-09-012023-09-30_srt_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_srt_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2024-11-122024-11-12_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-12</startDate>
            <endDate>2024-11-12</endDate>
        </period>
    </context>
    <context id="From2024-11-122024-11-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
        </entity>
        <period>
            <startDate>2024-11-12</startDate>
            <endDate>2024-11-12</endDate>
        </period>
    </context>
    <context id="From2024-11-122024-11-12_us-gaap_OptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-12</startDate>
            <endDate>2024-11-12</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_srt_MinimumMember_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_srt_MinimumMember_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_srt_MinimumMember_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_srt_MaximumMember_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_srt_MaximumMember_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_srt_MaximumMember_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-08-072023-08-07_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-07</startDate>
            <endDate>2023-08-07</endDate>
        </period>
    </context>
    <context id="AsOf2024-11-12_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-12</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember94762828">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_EmployeeStockOptionMember94762828">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember94762828">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember94762843">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember94762843">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_ChemistryAndFormulationStudiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">GLMD:ChemistryAndFormulationStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_ChemistryAndFormulationStudiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">GLMD:ChemistryAndFormulationStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_ChemistryAndFormulationStudiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">GLMD:ChemistryAndFormulationStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_SalariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">GLMD:SalariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_SalariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">GLMD:SalariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_SalariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">GLMD:SalariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_StockBasedCompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">GLMD:StockBasedCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_StockBasedCompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">GLMD:StockBasedCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_StockBasedCompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">GLMD:StockBasedCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_ResearchAndPreclinicalStudiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">GLMD:ResearchAndPreclinicalStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_ResearchAndPreclinicalStudiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">GLMD:ResearchAndPreclinicalStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_ResearchAndPreclinicalStudiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">GLMD:ResearchAndPreclinicalStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_ClinicalStudiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">GLMD:ClinicalStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_ClinicalStudiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">GLMD:ClinicalStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_ClinicalStudiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">GLMD:ClinicalStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_RegulatoryAndOtherExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">GLMD:RegulatoryAndOtherExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_RegulatoryAndOtherExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">GLMD:RegulatoryAndOtherExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_RegulatoryAndOtherExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">GLMD:RegulatoryAndOtherExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_ProfessionalFeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">GLMD:ProfessionalFeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_ProfessionalFeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">GLMD:ProfessionalFeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_ProfessionalFeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">GLMD:ProfessionalFeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_SalariesAndBenefitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">GLMD:SalariesAndBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_SalariesAndBenefitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">GLMD:SalariesAndBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_SalariesAndBenefitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">GLMD:SalariesAndBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_RentAndOfficeMaintenanceFeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">GLMD:RentAndOfficeMaintenanceFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_RentAndOfficeMaintenanceFeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">GLMD:RentAndOfficeMaintenanceFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_RentAndOfficeMaintenanceFeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">GLMD:RentAndOfficeMaintenanceFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_InsuranceAndOtherExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">GLMD:InsuranceAndOtherExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_InsuranceAndOtherExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">GLMD:InsuranceAndOtherExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_InsuranceAndOtherExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">GLMD:InsuranceAndOtherExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_IsraelTaxAuthorityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_IsraelTaxAuthorityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_IsraelTaxAuthorityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_MalteseSubsidiaryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">GLMD:MalteseSubsidiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_MalteseSubsidiaryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">GLMD:MalteseSubsidiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_MalteseSubsidiaryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">GLMD:MalteseSubsidiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_MalteseSubsidiaryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GLMD:MalteseSubsidiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_IsraeliSubsidiaryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GLMD:IsraeliSubsidiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_DeferredIncomeTaxChargesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RegulatoryAssetAxis">us-gaap:DeferredIncomeTaxChargesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-03-202025-03-21_custom_TwoThousandAndTwentySalesAgreementMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GLMD:TwoThousandAndTwentySalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-20</startDate>
            <endDate>2025-03-21</endDate>
        </period>
    </context>
    <context id="From2025-03-202025-03-21_us-gaap_SubsequentEventMember_custom_CaymanIslandsExemptLimitedPartnershipMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GLMD:CaymanIslandsExemptLimitedPartnershipMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-20</startDate>
            <endDate>2025-03-21</endDate>
        </period>
    </context>
    <context id="From2025-03-202025-03-21_custom_TwoThousandAndTwentySalesAgreementMember_us-gaap_SubsequentEventMember_custom_CaymanIslandsExemptLimitedPartnershipMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GLMD:TwoThousandAndTwentySalesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">GLMD:CaymanIslandsExemptLimitedPartnershipMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-20</startDate>
            <endDate>2025-03-21</endDate>
        </period>
    </context>
    <context id="From2025-03-212025-03-21_custom_TwoThousandAndTwentySalesAgreementMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595353</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GLMD:TwoThousandAndTwentySalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-21</startDate>
            <endDate>2025-03-21</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="Integer">
        <measure>GLMD:Integer</measure>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="ILSPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:ILS</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="ILS">
        <measure>iso4217:ILS</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2024-01-01to2024-12-31" id="Fact000003">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2024-01-01to2024-12-31" id="Fact000004">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="From2024-01-01to2024-12-31" id="Fact000005">0001595353</dei:EntityCentralIndexKey>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0089"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0092"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0099"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0122"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0123"
      unitRef="USD"
      xsi:nil="true"/>
    <GLMD:FinancialExpenses
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0182"
      unitRef="USD"
      xsi:nil="true"/>
    <GLMD:FinancialExpenses
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0183"
      unitRef="USD"
      xsi:nil="true"/>
    <GLMD:ImpairmentOnAssociate
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0186"
      unitRef="USD"
      xsi:nil="true"/>
    <GLMD:ImpairmentOnAssociate
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0187"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0244"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0246"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0247"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0250"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0252"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0253"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0260"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0261"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0263"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0266"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0267"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0268"
      unitRef="USD"
      xsi:nil="true"/>
    <GLMD:StockIssuedDuringPeriodValueOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0282"
      unitRef="USD"
      xsi:nil="true"/>
    <GLMD:StockIssuedDuringPeriodValueOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0283"
      unitRef="USD"
      xsi:nil="true"/>
    <GLMD:ExerciseOfPrefundedWarrants
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0292"
      unitRef="USD"
      xsi:nil="true"/>
    <GLMD:ExerciseOfPrefundedWarrants
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0293"
      unitRef="USD"
      xsi:nil="true"/>
    <GLMD:ExerciseOfPrefundedWarrants
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0294"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0298"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0300"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0301"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0304"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0305"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0307"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0310"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0311"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0312"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0334"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0335"
      unitRef="USD"
      xsi:nil="true"/>
    <GLMD:ExerciseOfPrefundedWarrants
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0352"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0360"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0372"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0374"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0375"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0378"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0379"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0381"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0384"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0385"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0386"
      unitRef="USD"
      xsi:nil="true"/>
    <GLMD:FinancialExpenses
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0437"
      unitRef="USD"
      xsi:nil="true"/>
    <GLMD:FinancialExpenses
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0438"
      unitRef="USD"
      xsi:nil="true"/>
    <GLMD:DecreaseInShorttermDeposits
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0446"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0449"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0450"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherAssetImpairmentCharges
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0457"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherAssetImpairmentCharges
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0458"
      unitRef="USD"
      xsi:nil="true"/>
    <GLMD:ChangeInFairValueConvertibleNote
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0462"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0488"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0489"
      unitRef="USD"
      xsi:nil="true"/>
    <GLMD:PaymentsForProceedsFromInvestmentInConvertibleNote
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0496"
      unitRef="USD"
      xsi:nil="true"/>
    <GLMD:PaymentsForProceedsFromInvestmentInConvertibleNote
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0497"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0501"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0502"
      unitRef="USD"
      xsi:nil="true"/>
    <GLMD:PaymentsForProceedsFromInvestmentInAssociate
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0504"
      unitRef="USD"
      xsi:nil="true"/>
    <GLMD:PaymentsForProceedsFromInvestmentInAssociate
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0506"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsForProceedsFromOtherDeposits
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0514"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0524"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0525"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0529"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0530"
      unitRef="USD"
      xsi:nil="true"/>
    <GLMD:ConversionOfConvertibleNoteIntoInvestmentInAssociate
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0564"
      unitRef="USD"
      xsi:nil="true"/>
    <GLMD:ConversionOfConvertibleNoteIntoInvestmentInAssociate
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0566"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentDepreciationMethodExtensibleEnumeration
      contextRef="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember"
      id="xdx2ixbrl0628">http://fasb.org/us-gaap/2024#UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember</us-gaap:PropertyPlantAndEquipmentDepreciationMethodExtensibleEnumeration>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member_us-gaap_CorporateDebtSecuritiesMember"
      id="xdx2ixbrl0644"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member_us-gaap_CorporateDebtSecuritiesMember"
      id="xdx2ixbrl0646"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member_us-gaap_USTreasurySecuritiesMember"
      id="xdx2ixbrl0649"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member_us-gaap_USTreasurySecuritiesMember"
      id="xdx2ixbrl0651"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member_us-gaap_MutualFundMember"
      id="xdx2ixbrl0655"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member_us-gaap_MutualFundMember"
      id="xdx2ixbrl0656"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member_custom_InvestmentInAssociateMember"
      id="xdx2ixbrl0659"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member_custom_InvestmentInAssociateMember"
      id="xdx2ixbrl0660"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member_us-gaap_CorporateDebtSecuritiesMember"
      id="xdx2ixbrl0669"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member_us-gaap_CorporateDebtSecuritiesMember"
      id="xdx2ixbrl0671"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member_us-gaap_USTreasurySecuritiesMember"
      id="xdx2ixbrl0674"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member_us-gaap_USTreasurySecuritiesMember"
      id="xdx2ixbrl0676"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member_us-gaap_MutualFundMember"
      id="xdx2ixbrl0680"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member_us-gaap_MutualFundMember"
      id="xdx2ixbrl0681"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member_custom_InvestmentInAssociateMember"
      id="xdx2ixbrl0684"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member_custom_InvestmentInAssociateMember"
      id="xdx2ixbrl0685"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="From2024-01-012024-12-31_us-gaap_USTreasurySecuritiesMember"
      id="xdx2ixbrl0728"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="From2023-01-012023-12-31_us-gaap_USTreasurySecuritiesMember"
      id="xdx2ixbrl0760"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0808"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList contextRef="AsOf2023-12-31" id="xdx2ixbrl0811">http://fasb.org/us-gaap/2024#OperatingLeaseRightOfUseAsset</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList contextRef="AsOf2023-12-31" id="xdx2ixbrl0812">http://fasb.org/us-gaap/2024#OperatingLeaseLiability</us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0836"
      unitRef="USD"
      xsi:nil="true"/>
    <GLMD:ShorttermLeaseObligation
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0902"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherNotesPayable
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0906"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember94762828"
      id="xdx2ixbrl1060"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember94762828"
      id="xdx2ixbrl1062"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <GLMD:ChangeInFairValueOfConvertibleNote
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl1290"
      unitRef="USD"
      xsi:nil="true"/>
    <GLMD:ChangeInFairValueOfConvertibleNote
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1292"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl1346"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1347"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1348"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2024-01-01to2024-12-31" id="Fact000015">20-F</dei:DocumentType>
    <dei:DocumentRegistrationStatement contextRef="From2024-01-01to2024-12-31" id="Fact000016">false</dei:DocumentRegistrationStatement>
    <dei:DocumentAnnualReport contextRef="From2024-01-01to2024-12-31" id="Fact000017">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2024-01-01to2024-12-31" id="Fact000018">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="From2024-01-01to2024-12-31" id="Fact000019">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2024-01-01to2024-12-31" id="Fact000020">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2024-01-01to2024-12-31" id="Fact000021">false</dei:DocumentTransitionReport>
    <dei:DocumentShellCompanyReport contextRef="From2024-01-01to2024-12-31" id="Fact000022">false</dei:DocumentShellCompanyReport>
    <dei:EntityFileNumber contextRef="From2024-01-01to2024-12-31" id="Fact000023">001-36345</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2024-01-01to2024-12-31" id="Fact000024">GALMED PHARMACEUTICALS LTD.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2024-01-01to2024-12-31" id="Fact000025">L3</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1 contextRef="From2024-01-01to2024-12-31" id="Fact000026">16 Abba Hillel Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2024-01-01to2024-12-31" id="Fact000027">Ramat Gan</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="From2024-01-01to2024-12-31" id="Fact000028">IL</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode contextRef="From2024-01-01to2024-12-31" id="Fact000029">5250608</dei:EntityAddressPostalZipCode>
    <dei:ContactPersonnelName
      contextRef="From2024-01-012024-12-31_dei_BusinessContactMember"
      id="Fact000030">Allen Baharaff</dei:ContactPersonnelName>
    <dei:EntityAddressAddressLine1
      contextRef="From2024-01-012024-12-31_dei_BusinessContactMember"
      id="Fact000031">16 Abba Hillel Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="From2024-01-012024-12-31_dei_BusinessContactMember"
      id="Fact000032">Ramat Gan</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry
      contextRef="From2024-01-012024-12-31_dei_BusinessContactMember"
      id="Fact000033">IL</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode
      contextRef="From2024-01-012024-12-31_dei_BusinessContactMember"
      id="Fact000034">5250608</dei:EntityAddressPostalZipCode>
    <dei:ContactPersonnelEmailAddress
      contextRef="From2024-01-012024-12-31_dei_BusinessContactMember"
      id="Fact000035">ab@galmedpharma.com</dei:ContactPersonnelEmailAddress>
    <dei:CityAreaCode
      contextRef="From2024-01-012024-12-31_dei_BusinessContactMember"
      id="Fact000036">+972.3</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="From2024-01-012024-12-31_dei_BusinessContactMember"
      id="Fact000037">693.8448</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2024-01-01to2024-12-31" id="Fact000038">Ordinary shares, par     value NIS 0.15 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2024-01-01to2024-12-31" id="Fact000039">GLMD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2024-01-01to2024-12-31" id="Fact000040">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000041"
      unitRef="Shares">1654428</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2024-01-01to2024-12-31" id="Fact000042">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2024-01-01to2024-12-31" id="Fact000043">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2024-01-01to2024-12-31" id="Fact000044">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2024-01-01to2024-12-31" id="Fact000045">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2024-01-01to2024-12-31" id="Fact000046">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityEmergingGrowthCompany contextRef="From2024-01-01to2024-12-31" id="Fact000047">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="From2024-01-01to2024-12-31" id="Fact000048">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="From2024-01-01to2024-12-31" id="Fact000049">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:DocumentAccountingStandard contextRef="From2024-01-01to2024-12-31" id="Fact000050">U.S. GAAP</dei:DocumentAccountingStandard>
    <dei:EntityShellCompany contextRef="From2024-01-01to2024-12-31" id="Fact000051">false</dei:EntityShellCompany>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="From2024-01-01to2024-12-31" id="Fact000052">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000056">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
have developed and maintain a cybersecurity risk management program, consisting of cybersecurity policies, procedures, compliance and
awareness programs to mitigate risk and to ensure compliance with security, availability and confidentiality trust principles. &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_903_ecyd--CybersecurityRiskManagementProcessesIntegratedTextBlock_c20240101__20241231_zgk7LVvGPvGd"&gt;The cybersecurity
process has been integrated into our overall risk management system and process, and is solely internally managed. Management is responsible
for identifying risks that threaten achievement of the control activities stated in the management&#x2019;s description of the services
organizations systems. Management has implemented a process for identifying relevant risks that could affect the organization&#x2019;s
ability to provide secure and reliable service to its users. In addition, we maintain cybersecurity insurance.&lt;/span&gt; The risk assessment occurs
as business needs change, and covers identification of risks that could act against the company&#x2019;s objectives as well as specific
risks related to a compromise to the security of data. See &#x201c;Item 3.D Risk Factors&#x2014; Risks Related to Information Technology,
Intellectual Property and Data Security and Privacy&#x2014;If we or our third-party service providers experience a security breach, data
loss or other compromise, including if unauthorized parties obtain access to our customers&#x2019; data, our reputation may be harmed,
demand for our products and services may be reduced, and we may incur significant liabilities.&#x201d;&lt;/span&gt;&#160;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90A_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_dbT_c20240101__20241231_zvVjYnBRuX9j"&gt;The
oversight of cybersecurity threats is undertaken by our IT external provider, who holds over 25 years of experience, and is supported
by management. Our audit committee is responsible for cybersecurity oversight and monitoring risk. Management informs the audit and remuneration
committee of such risk at committee meetings.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90C_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbT_c20240101__20241231_zviIkgx3w7Ve"&gt;As
of the date of this report, we are not aware of any material risks from cybersecurity threats that have materially affected or are reasonably
likely to materially affect us, including our business strategy, results of operations or financial condition.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&#160;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000057">The cybersecurity
process has been integrated into our overall risk management system and process, and is solely internally managed. Management is responsible
for identifying risks that threaten achievement of the control activities stated in the management&#x2019;s description of the services
organizations systems. Management has implemented a process for identifying relevant risks that could affect the organization&#x2019;s
ability to provide secure and reliable service to its users. In addition, we maintain cybersecurity insurance.</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag contextRef="From2024-01-01to2024-12-31" id="Fact000058">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef="From2024-01-01to2024-12-31" id="Fact000059">true</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <dei:AuditorFirmId contextRef="From2024-01-01to2024-12-31" id="Fact000060">1197</dei:AuditorFirmId>
    <dei:AuditorOpinionTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000061">We
have audited the accompanying consolidated balance sheets of Galmed Pharmaceuticals Ltd. and subsidiaries (the &#x201c;Company&#x201d;)
as of December 31, 2024 and 2023, the related consolidated statements of operations, comprehensive loss, changes in stockholders&#x2019;
equity and cash flows, for each of the three years in the period ended December 31, 2024, and the related notes (collectively referred
to as the &#x201c;consolidated financial statements&#x201d;). In our opinion, the consolidated financial statements present fairly, in
all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and
its cash flows for each of the three years in the period ended December 31, 2024, in conformity with accounting principles generally
accepted in the United States of America.</dei:AuditorOpinionTextBlock>
    <dei:AuditorName contextRef="From2024-01-01to2024-12-31" id="Fact000062">Brightman Almagor Zohar &amp; Co.</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2024-01-01to2024-12-31" id="Fact000063">Tel Aviv, Israel</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000071"
      unitRef="USD">4652000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000072"
      unitRef="USD">2861000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000074"
      unitRef="USD">121000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000075"
      unitRef="USD">117000</us-gaap:RestrictedCashCurrent>
    <us-gaap:DepositsAssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000077"
      unitRef="USD">3496000</us-gaap:DepositsAssetsCurrent>
    <us-gaap:DepositsAssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000078"
      unitRef="USD">2253000</us-gaap:DepositsAssetsCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000080"
      unitRef="USD">7183000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000081"
      unitRef="USD">7528000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000083"
      unitRef="USD">672000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000084"
      unitRef="USD">480000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000086"
      unitRef="USD">16124000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000087"
      unitRef="USD">13239000</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000090"
      unitRef="USD">42000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000093"
      unitRef="USD">83000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000095"
      unitRef="USD">2119000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000096"
      unitRef="USD">3265000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000098"
      unitRef="USD">257000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000101"
      unitRef="USD">2376000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000102"
      unitRef="USD">3390000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000104"
      unitRef="USD">18500000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000105"
      unitRef="USD">16629000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000113"
      unitRef="USD">1308000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000114"
      unitRef="USD">1879000</us-gaap:AccountsPayableCurrent>
    <us-gaap:OtherLoansPayableCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000116"
      unitRef="USD">865000</us-gaap:OtherLoansPayableCurrent>
    <us-gaap:OtherLoansPayableCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000117"
      unitRef="USD">871000</us-gaap:OtherLoansPayableCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000119"
      unitRef="USD">2173000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000120"
      unitRef="USD">2750000</us-gaap:LiabilitiesCurrent>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000131"
      unitRef="ILSPShares">1.80</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000133"
      unitRef="ILSPShares">1.80</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000135"
      unitRef="Shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000137"
      unitRef="Shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000139"
      unitRef="Shares">1664884</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000141"
      unitRef="Shares">1664884</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000143"
      unitRef="Shares">573741</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000145"
      unitRef="Shares">573741</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000128"
      unitRef="USD">742000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000129"
      unitRef="USD">209000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000147"
      unitRef="USD">216470000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000148"
      unitRef="USD">207076000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000150"
      unitRef="USD">-416000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000151"
      unitRef="USD">-454000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000153"
      unitRef="USD">-200469000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000154"
      unitRef="USD">-192952000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000156"
      unitRef="USD">16327000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000157"
      unitRef="USD">13879000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000159"
      unitRef="USD">18500000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000160"
      unitRef="USD">16629000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2024-01-01to2024-12-31" id="Fact000163">12-1 reverse split</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000165"
      unitRef="USD">2979000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000166"
      unitRef="USD">3569000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000167"
      unitRef="USD">12995000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000169"
      unitRef="USD">3299000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000170"
      unitRef="USD">3923000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000171"
      unitRef="USD">4656000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000173"
      unitRef="USD">6278000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000174"
      unitRef="USD">7492000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000175"
      unitRef="USD">17651000</us-gaap:OperatingExpenses>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000177"
      unitRef="USD">516000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000178"
      unitRef="USD">580000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000179"
      unitRef="USD">-215000</us-gaap:OtherNonoperatingIncomeExpense>
    <GLMD:FinancialExpenses
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000181"
      unitRef="USD">610000</GLMD:FinancialExpenses>
    <GLMD:ImpairmentOnAssociate
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000185"
      unitRef="USD">1145000</GLMD:ImpairmentOnAssociate>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000189"
      unitRef="USD">-7517000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000190"
      unitRef="USD">-6912000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000191"
      unitRef="USD">-17866000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000193"
      unitRef="USDPShares">8.08</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000195"
      unitRef="USDPShares">8.08</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000197"
      unitRef="USDPShares">30.00</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000199"
      unitRef="USDPShares">30.00</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact000201"
      unitRef="USDPShares">127.80</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact000203"
      unitRef="USDPShares">127.80</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000205"
      unitRef="Shares">930822</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000207"
      unitRef="Shares">930822</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000209"
      unitRef="Shares">230795</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000211"
      unitRef="Shares">230795</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact000213"
      unitRef="Shares">139682</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact000215"
      unitRef="Shares">139682</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2024-01-01to2024-12-31" id="Fact000218">12-1 reverse split</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000220"
      unitRef="USD">-7517000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000221"
      unitRef="USD">-6912000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000222"
      unitRef="USD">-17866000</us-gaap:NetIncomeLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000228"
      unitRef="USD">38000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000229"
      unitRef="USD">291000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000230"
      unitRef="USD">-574000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000232"
      unitRef="USD">-7479000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000233"
      unitRef="USD">-6621000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000234"
      unitRef="USD">-18440000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000242"
      unitRef="Shares">293682</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000236"
      unitRef="USD">70000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000237"
      unitRef="USD">198772000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000238"
      unitRef="USD">-171000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000239"
      unitRef="USD">-168174000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="Fact000240"
      unitRef="USD">30497000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000245"
      unitRef="USD">1296000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000248"
      unitRef="USD">1296000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000256"
      unitRef="USD">2000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000258"
      unitRef="Shares">643</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000251"
      unitRef="USD">70000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000254"
      unitRef="USD">70000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000262"
      unitRef="USD">-574000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000264"
      unitRef="USD">-574000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000269"
      unitRef="USD">-17866000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000270"
      unitRef="USD">-17866000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000278"
      unitRef="Shares">294325</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000272"
      unitRef="USD">70000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000273"
      unitRef="USD">200138000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000274"
      unitRef="USD">-745000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000275"
      unitRef="USD">-186040000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000276"
      unitRef="USD">13423000</us-gaap:StockholdersEquity>
    <GLMD:WarrantsNetOfIssuanceCosts
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000286"
      unitRef="USD">756000</GLMD:WarrantsNetOfIssuanceCosts>
    <GLMD:StockIssuedDuringPeriodSharesOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000288"
      unitRef="Shares">31667</GLMD:StockIssuedDuringPeriodSharesOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts>
    <GLMD:StockIssuedDuringPeriodValueOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000280"
      unitRef="USD">16000</GLMD:StockIssuedDuringPeriodValueOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts>
    <GLMD:StockIssuedDuringPeriodValueOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000281"
      unitRef="USD">6169000</GLMD:StockIssuedDuringPeriodValueOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts>
    <GLMD:StockIssuedDuringPeriodValueOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000284"
      unitRef="USD">6185000</GLMD:StockIssuedDuringPeriodValueOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts>
    <GLMD:ExerciseOfPrefundedWarrantsShares
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000296"
      unitRef="Shares">247749</GLMD:ExerciseOfPrefundedWarrantsShares>
    <GLMD:ExerciseOfPrefundedWarrants
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000290"
      unitRef="USD">123000</GLMD:ExerciseOfPrefundedWarrants>
    <GLMD:ExerciseOfPrefundedWarrants
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000291"
      unitRef="USD">-123000</GLMD:ExerciseOfPrefundedWarrants>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000299"
      unitRef="USD">892000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000302"
      unitRef="USD">892000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000306"
      unitRef="USD">291000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000308"
      unitRef="USD">291000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000313"
      unitRef="USD">-6912000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000314"
      unitRef="USD">-6912000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000322"
      unitRef="Shares">573741</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000316"
      unitRef="USD">209000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000317"
      unitRef="USD">207076000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000318"
      unitRef="USD">-454000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000319"
      unitRef="USD">-192952000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000320"
      unitRef="USD">13879000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000330"
      unitRef="Shares">573741</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000324"
      unitRef="USD">209000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000325"
      unitRef="USD">207076000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000326"
      unitRef="USD">-454000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000327"
      unitRef="USD">-192952000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000328"
      unitRef="USD">13879000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000338"
      unitRef="Shares">558775</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000332"
      unitRef="USD">272000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000333"
      unitRef="USD">4654000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000336"
      unitRef="USD">4926000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000346"
      unitRef="Shares">15784</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000340"
      unitRef="USD">8000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000341"
      unitRef="USD">62000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000344"
      unitRef="USD">70000</us-gaap:StockIssuedDuringPeriodValueOther>
    <GLMD:ExerciseOfPrefundedWarrantsShares
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000354"
      unitRef="Shares">186723</GLMD:ExerciseOfPrefundedWarrantsShares>
    <GLMD:ExerciseOfPrefundedWarrants
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000348"
      unitRef="USD">92000</GLMD:ExerciseOfPrefundedWarrants>
    <GLMD:ExerciseOfPrefundedWarrants
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000349"
      unitRef="USD">-92000</GLMD:ExerciseOfPrefundedWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000362"
      unitRef="Shares">36528</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000356"
      unitRef="USD">18000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000357"
      unitRef="USD">-18000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <GLMD:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000370"
      unitRef="Shares">293333</GLMD:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <GLMD:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000364"
      unitRef="USD">143000</GLMD:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <GLMD:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000365"
      unitRef="USD">4257000</GLMD:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <GLMD:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000368"
      unitRef="USD">4400000</GLMD:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000373"
      unitRef="USD">531000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000376"
      unitRef="USD">531000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000380"
      unitRef="USD">38000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000382"
      unitRef="USD">38000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000387"
      unitRef="USD">-7517000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000388"
      unitRef="USD">-7517000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000396"
      unitRef="Shares">1664884</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000390"
      unitRef="USD">742000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000391"
      unitRef="USD">216470000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000392"
      unitRef="USD">-416000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000393"
      unitRef="USD">-200469000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000394"
      unitRef="USD">16327000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000404"
      unitRef="Shares">1664884</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000398"
      unitRef="USD">742000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000399"
      unitRef="USD">216470000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000400"
      unitRef="USD">-416000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000401"
      unitRef="USD">-200469000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000402"
      unitRef="USD">16327000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2024-01-01to2024-12-31" id="Fact000408">12-1 reverse split</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000416"
      unitRef="USD">-7517000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000417"
      unitRef="USD">-6912000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000418"
      unitRef="USD">-17866000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000424"
      unitRef="USD">83000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000425"
      unitRef="USD">31000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000426"
      unitRef="USD">35000</us-gaap:DepreciationAndAmortization>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000428"
      unitRef="USD">-17000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000429"
      unitRef="USD">19000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000430"
      unitRef="USD">-2000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000432"
      unitRef="USD">-12000</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000433"
      unitRef="USD">-13000</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000434"
      unitRef="USD">-523000</us-gaap:GainLossOnSaleOfInvestments>
    <GLMD:FinancialExpenses
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000436"
      unitRef="USD">610000</GLMD:FinancialExpenses>
    <GLMD:ProceedsFinanceLeaseInterestExpenseIncome
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000440"
      unitRef="USD">1000</GLMD:ProceedsFinanceLeaseInterestExpenseIncome>
    <GLMD:ProceedsFinanceLeaseInterestExpenseIncome
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000441"
      unitRef="USD">6000</GLMD:ProceedsFinanceLeaseInterestExpenseIncome>
    <GLMD:ProceedsFinanceLeaseInterestExpenseIncome
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000442"
      unitRef="USD">-36000</GLMD:ProceedsFinanceLeaseInterestExpenseIncome>
    <GLMD:DecreaseInShorttermDeposits
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000444"
      unitRef="USD">-7000</GLMD:DecreaseInShorttermDeposits>
    <GLMD:DecreaseInShorttermDeposits
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000445"
      unitRef="USD">53000</GLMD:DecreaseInShorttermDeposits>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000448"
      unitRef="USD">7000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000452"
      unitRef="USD">531000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000453"
      unitRef="USD">892000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000454"
      unitRef="USD">1296000</us-gaap:ShareBasedCompensation>
    <us-gaap:OtherAssetImpairmentCharges
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000456"
      unitRef="USD">1145000</us-gaap:OtherAssetImpairmentCharges>
    <GLMD:ChangeInFairValueConvertibleNote
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000461"
      unitRef="USD">265000</GLMD:ChangeInFairValueConvertibleNote>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000468"
      unitRef="USD">192000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000469"
      unitRef="USD">-345000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000470"
      unitRef="USD">-300000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000472"
      unitRef="USD">-571000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000473"
      unitRef="USD">-681000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000474"
      unitRef="USD">-2311000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000476"
      unitRef="USD">35000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000477"
      unitRef="USD">468000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000478"
      unitRef="USD">-440000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000480"
      unitRef="USD">-5880000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000481"
      unitRef="USD">-6137000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000482"
      unitRef="USD">-18501000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000490"
      unitRef="USD">4000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <GLMD:PaymentsForInvestmentInAvailableForSaleSecurities
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000492"
      unitRef="USD">5115000</GLMD:PaymentsForInvestmentInAvailableForSaleSecurities>
    <GLMD:PaymentsForInvestmentInAvailableForSaleSecurities
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000493"
      unitRef="USD">4133000</GLMD:PaymentsForInvestmentInAvailableForSaleSecurities>
    <GLMD:PaymentsForInvestmentInAvailableForSaleSecurities
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000494"
      unitRef="USD">2373000</GLMD:PaymentsForInvestmentInAvailableForSaleSecurities>
    <GLMD:PaymentsForProceedsFromInvestmentInConvertibleNote
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000498"
      unitRef="USD">1500000</GLMD:PaymentsForProceedsFromInvestmentInConvertibleNote>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000500"
      unitRef="USD">250000</us-gaap:PaymentsToAcquireBusinessesGross>
    <GLMD:PaymentsForProceedsFromInvestmentInAssociate
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000505"
      unitRef="USD">1500000</GLMD:PaymentsForProceedsFromInvestmentInAssociate>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000508"
      unitRef="USD">5504000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000509"
      unitRef="USD">8633000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000510"
      unitRef="USD">21440000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsForProceedsFromOtherDeposits
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000512"
      unitRef="USD">1250000</us-gaap:PaymentsForProceedsFromOtherDeposits>
    <us-gaap:PaymentsForProceedsFromOtherDeposits
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000513"
      unitRef="USD">2200000</us-gaap:PaymentsForProceedsFromOtherDeposits>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000516"
      unitRef="USD">-1111000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000517"
      unitRef="USD">800000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000518"
      unitRef="USD">17563000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000526"
      unitRef="USD">70000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000528"
      unitRef="USD">4386000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <GLMD:IssuanceOfOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000532"
      unitRef="USD">-4400000</GLMD:IssuanceOfOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts>
    <GLMD:IssuanceOfOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000533"
      unitRef="USD">-6185000</GLMD:IssuanceOfOrdinarySharesPrefundedWarrantsAndWarrantsNetOfIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000536"
      unitRef="USD">8786000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000537"
      unitRef="USD">6185000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000538"
      unitRef="USD">70000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000540"
      unitRef="USD">1795000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000541"
      unitRef="USD">848000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000542"
      unitRef="USD">-868000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000544"
      unitRef="USD">2978000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000545"
      unitRef="USD">2130000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="Fact000546"
      unitRef="USD">2998000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000548"
      unitRef="USD">4773000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000549"
      unitRef="USD">2978000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000550"
      unitRef="USD">2130000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:InterestPaidNet
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000556"
      unitRef="USD">503000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000557"
      unitRef="USD">376000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000558"
      unitRef="USD">297000</us-gaap:InterestPaidNet>
    <GLMD:ConversionOfConvertibleNoteIntoInvestmentInAssociate
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000565"
      unitRef="USD">1765000</GLMD:ConversionOfConvertibleNoteIntoInvestmentInAssociate>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000571">&lt;p id="xdx_809_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zbP61AUVdI0f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
1 &#x2013; &lt;span id="xdx_825_zP36nn1Cx8rc"&gt;General&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Galmed
Pharmaceuticals Ltd. (the &#x201c;Company&#x201d;) was incorporated in Israel on &lt;span id="xdx_903_edei--EntityIncorporationDateOfIncorporation_c20240101__20241231_zNXhuVNnOKOk" title="Date of incorporation"&gt;July 31, 2013&lt;/span&gt; and commenced operations on &lt;span id="xdx_903_eus-gaap--OperationsCommencedDate1_c20240101__20241231_zAhbMXbA6BI3" title="Date of commenced operations"&gt;February 2,
2014&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company holds three wholly-owned subsidiaries, Galmed International Ltd., which is incorporated in Malta, and Galmed Research and Development
Ltd. (&#x201c;GRD&#x201d;) and Galtopa Therapeutics Ltd., both of which are incorporated in Israel. In July 2023, GRD established a new
wholly-owned subsidiary incorporated under the laws of England and Wales called Galmed Therapeutics UK Limited.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is a biopharmaceutical company focused on the development of Aramchol. The Company has focused almost exclusively on developing
Aramchol for the treatment of liver disease and previously was developing Aramchol for Primary Sclerosing Cholangitis,
or PSC. The Company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.
&lt;span style="background-color: white"&gt;In addition, as part of the Company&#x2019;s growth strategy, the Company is actively pursuing opportunities
to expand and diversify its product pipeline specifically targeting cardiometabolic indications and other innovative product candidates
that align with the Company&#x2019;s core expertise in drug development.&lt;/span&gt;. The Company has an operating history limited to pre-clinical
and clinical drug development.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company funded its research and development programs and operations to date primarily through proceeds from private placements and public
offerings. The Company currently has no products approved for marketing and has not generated any revenue from product sales to date.
As of December 31, 2024, the Company had cash and cash equivalents of $&lt;span id="xdx_901_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20241231_zXqkWGsftd87" title="Cash and cash equivalents"&gt;4.7&lt;/span&gt; million, restricted cash of $&lt;span id="xdx_907_eus-gaap--RestrictedCashCurrent_iI_pn5n6_c20241231_zXmnhDowRwce" title="Restricted cash"&gt;0.1&lt;/span&gt; million, short-term deposits
of $&lt;span id="xdx_902_eus-gaap--DepositsAssetsCurrent_iI_pn5n6_c20241231_zm4jTcWIOW8" title="Short-term deposits"&gt;3.5&lt;/span&gt; million and marketable debt securities of $&lt;span id="xdx_909_eus-gaap--ShortTermInvestments_iI_pn5n6_c20241231_zsVKsQGfeYYk" title="Marketable securities debt"&gt;7.2&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has incurred operating losses in each year since inception. The Company&#x2019;s loss attributable to holders of its ordinary
shares for the years ended December 31, 2022, 2023, and 2024 was approximately $&lt;span id="xdx_905_eus-gaap--ProfitLoss_pn5n6_c20220101__20221231_zUahAWqL4XP8" title="Profit loss"&gt;17.9&lt;/span&gt; million, $&lt;span id="xdx_905_eus-gaap--ProfitLoss_pn5n6_c20230101__20231231_zk1X3rszzmHl" title="Profit loss"&gt;6.9&lt;/span&gt; million, and $&lt;span id="xdx_905_eus-gaap--ProfitLoss_pn5n6_c20240101__20241231_zYN8a5pCEaDi" title="Profit loss"&gt;8.0&lt;/span&gt; million, respectively.
As of December 31, 2024, the Company had an accumulated deficit of $&lt;span id="xdx_900_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20241231_zJvmeL5xUFU9" title="Retained earnings accumulated deficit"&gt;200.5&lt;/span&gt; million. Substantially all of its operating losses resulted
from costs incurred in connection with the Company&#x2019;s development program and from general and administrative costs associated with
its operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company will need to raise substantial, additional capital to fund its operations and to develop Aramchol for, and beyond
its current development stage and any future commercialization, as well as any additional indications.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Based
on the Company&#x2019;s current operating plan, the Company&#x2019;s management currently estimates that its cash position will support
its current operations as currently conducted for more than 12 months from the date of issuance of these financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <dei:EntityIncorporationDateOfIncorporation contextRef="From2024-01-01to2024-12-31" id="Fact000573">2013-07-31</dei:EntityIncorporationDateOfIncorporation>
    <us-gaap:OperationsCommencedDate1 contextRef="From2024-01-01to2024-12-31" id="Fact000575">2014-02-02</us-gaap:OperationsCommencedDate1>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact000577"
      unitRef="USD">4700000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact000579"
      unitRef="USD">100000</us-gaap:RestrictedCashCurrent>
    <us-gaap:DepositsAssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact000581"
      unitRef="USD">3500000</us-gaap:DepositsAssetsCurrent>
    <us-gaap:ShortTermInvestments
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact000583"
      unitRef="USD">7200000</us-gaap:ShortTermInvestments>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-012022-12-31"
      decimals="-5"
      id="Fact000585"
      unitRef="USD">17900000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2023-01-012023-12-31"
      decimals="-5"
      id="Fact000587"
      unitRef="USD">6900000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="-5"
      id="Fact000589"
      unitRef="USD">8000000.0</us-gaap:ProfitLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact000591"
      unitRef="USD">-200500000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000593">&lt;p id="xdx_806_eus-gaap--SignificantAccountingPoliciesTextBlock_zFO5Oe2Wqqrc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
2 &#x2013; &lt;span id="xdx_822_zYZLUn7eiPMi"&gt;Significant Accounting Policies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zgAG2X9Y5v77" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;A.&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86E_z8rvBjjyI7xb"&gt;Basis of presentation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated financial statements have been prepared in accordance with United States Generally Accepted Accounting Principles (&#x201c;U.S.
GAAP&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--UseOfEstimates_z0kO2pZpw4p8" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;B.&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_866_znJjOyCAGxob"&gt;Use of estimates&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities as of the date of the financial statements, and the reported amounts of expenses
during the reporting period. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;GALMED
PHARMACEUTICALS LTD.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to Consolidated Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;div style="margin: 0pt auto; width: 100%"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
2 &#x2013; Significant Accounting Policies (Cont.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zMTom8fPyiR" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;C.&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_867_zvAm7mmhDgL8"&gt;Financial statement in U.S. dollars&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
functional currency of the Company and its subsidiaries is the U.S dollar (the &#x201c;dollar&#x201d;), because the dollar is the currency
of the primary economic environment in which the Company and its subsidiaries operate and expect to continue operating in the foreseeable
future. Transactions and balances denominated in dollars are presented in their original amounts. Non-dollar denominated transactions
and balances have been re-measured to dollars in accordance with the provisions of ASC 830, &#x201c;Foreign Currency Matters.&#x201d; All
transaction gains and losses from re-measurement of monetary balance sheet items denominated in non-dollar currencies are reflected in
the statement of operations as financial income or expenses, as appropriate.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--ConsolidationPolicyTextBlock_zhleHKi1imec" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;D.&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_860_zamApzJTutkh"&gt;Principles of consolidation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries: Galmed Research and Development
Ltd., Galmed International Ltd., Galtopa Therapeutics Ltd and Galmed Therapeutics UK Limited. All intercompany balances and transactions
have been eliminated upon consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zqH5FRoAuZ1e" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;E.&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_868_zLhKQzbTkWh8"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
equivalents are short-term, highly liquid investments that are readily convertible into cash with maturities of three months or less
as of the date acquired.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zyW1iWSTYwhb" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;F.&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_868_zRHhT8coz6O8"&gt;Restricted Cash&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
that is held for a specific purpose and is not available for immediate or general business use due to external restrictions is classified
in the Company&#x2019;s consolidated balance sheets as restricted cash.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_ecustom--ShortTermDepositsPolicyTextBlock_z6Lb1A38Pww7" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;G.&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86A_zKQgtsmvZrR1"&gt;Short-term deposits&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Bank
deposits with maturities of more than three months but less than one year are included in short-term bank deposits. Such short-term deposits
are stated at cost which approximates fair market value. Interest rates on the Company&#x2019;s short-term deposits were between &lt;span id="xdx_90A_eus-gaap--InvestmentInterestRate_iI_dp_c20241231__srt--RangeAxis__srt--MinimumMember_zrnKAFKsFb8b" title="Short-Term deposits interest rate"&gt;5.06&lt;/span&gt;%-&lt;span id="xdx_90A_eus-gaap--InvestmentInterestRate_iI_dp_c20241231__srt--RangeAxis__srt--MaximumMember_zvKFU0wY1879" title="Short-Term deposits interest rate"&gt;6.63&lt;/span&gt;%
during the year ended December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--MarketableSecuritiesPolicy_zZuUPur3p6sf" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;H.&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_865_zeDj7pNOxf15"&gt;Marketable debt securities&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company invests most of its excess cash primarily in debt securities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for its investments in investment grade debt securities in accordance with ASC 320 &#x201c;Investments - Debt and Equity
Securities&#x201d;. Management determines the appropriate classification of its investments in debt securities at the time of purchase
and re-evaluates such determinations at each balance sheet date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Marketable
debt securities are considered to be available for sale and are carried at fair value on the consolidated balance sheet. Unrealized gains
and losses net of tax, if any, are reported in a separate component of stockholders&#x2019; equity in accumulated other comprehensive
income (&#x201c;OCI&#x201d;). Gains and losses are recognized when realized, on a specific identification basis, in the Company&#x2019;s
consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Following
the adoption of ASC 326, current expected credit losses on the Company&#x2019;s marketable grade debt securities are recorded, if expected,
through an allowance for current expected credit losses. The amount of allowance for current expected credit losses is limited to the
amount that the fair value is less than the amortized cost basis. Any remaining unrealized losses are included in accumulated other comprehensive
loss in stockholders&#x2019; equity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If
the Company intends to sell the debt security (that is, it has decided to sell the security), or more likely than not will be required
to sell the security before recovery of its amortized cost basis, any allowance for current expected credit losses is written off and
the amortized cost basis shall be written down to the debt security&#x2019;s fair value at the reporting date with any incremental impairment
reported in earnings. Based on management&#x2019;s assessment, the Company does not intend to sell its securities for less than amortized
cost; therefore, an allowance for current expected credit losses has not been recorded as of December 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;GALMED
PHARMACEUTICALS LTD.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to Consolidated Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;div style="margin: 0pt auto; width: 100%"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
2 &#x2013; Significant Accounting Policies (Cont.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_zR0yP4KaGEUj" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;I.&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86C_z6MELlxtEgSl"&gt;Concentrations of credit risk&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments which potentially subject the Company to credit risk consist primarily of cash, cash equivalents, marketable debt securities
and short-term deposits. The Company hold these investments in highly-rated financial institutions, and, by policy, limit the amounts
of credit exposure to any one financial institution. These amounts at times may exceed federally insured limits. The Company has not
experienced any credit losses in such accounts and does not believe we are exposed to any significant credit risk on these funds. The
Company has no off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts, or other
hedging arrangements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zT95vhA3yXBd" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;J.&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_865_zZqdSXymQ8A"&gt;Property and equipment&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_ecustom--ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentTableTextBlock_zwrlmrQPQTvl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated
useful lives of the assets. The annual depreciation rates are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BC_zu3C94eWLw65"&gt;Schedule of Depreciation Rates for Property, Plant and Equipment&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 93%; border-collapse: collapse; margin-left: 0.5in"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;%&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 50%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Office
    furniture and equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentSalvageValuePercentage_iI_pid_dp_uPure_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndEquipmentMember_zdsLcXWNG2oj" title="Property and equipment, depreciation, percentage"&gt;7&lt;/span&gt;&#x2013;&lt;span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentSalvageValuePercentage_iI_pid_dp_uPure_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndEquipmentMember_z0H6Yi6QX3He" title="Property and equipment, depreciation, percentage"&gt;16&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Computer
    software and electronic equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentSalvageValuePercentage_iI_pid_dp_uPure_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerSoftwareElectronicEquipmentMember_zonOslvEYeMl" title="Property and equipment, depreciation, percentage"&gt;15&lt;/span&gt;&#x2013;&lt;span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentSalvageValuePercentage_iI_pid_dp_uPure_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerSoftwareElectronicEquipmentMember_zN9gwrrdvISk" title="Property and equipment, depreciation, percentage"&gt;33&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leasehold
    improvements&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentDepreciationMethodExtensibleEnumeration_iI_dxL_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zpQO8BQbJZv3" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2024%23UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0628"&gt;Shorter
    of the remaining lease term or useful life&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AE_zgIUUXRcts4j" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recorded depreciation expenses in a total of approximately $&lt;span id="xdx_903_eus-gaap--Depreciation_pn4n6_c20240101__20241231_zK6bs281Zfbi" title="Depreciation expenses"&gt;0.08&lt;/span&gt; million, $&lt;span id="xdx_907_eus-gaap--Depreciation_pn4n6_c20230101__20231231_z8IKX3h04Tt1" title="Depreciation expenses"&gt;0.03&lt;/span&gt; million and $&lt;span id="xdx_90A_eus-gaap--Depreciation_pn4n6_c20220101__20221231_zf8relcGANAi" title="Depreciation expenses"&gt;0.06&lt;/span&gt; million for the years ended
December 31, 2024, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zrrGTnJytw75" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;K.&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_866_zeP9cVpNefX2"&gt;Severance pay&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company employees are included under section 14 of the Severance Compensation Act, 1963 (&#x201c;Section 14&#x201d;) in Israel for a portion
of their salaries. According to Section 14, these employees are entitled to monthly deposits at a rate of &lt;span id="xdx_90B_ecustom--MonthlyDepositsOfEmployeesPercentageOnMonthlySalary_pid_dp_uPure_c20240101__20241231_zggLAPYGX5qe" title="Monthly deposits percentage"&gt;8.33&lt;/span&gt;% of their monthly salary,
contributed on their behalf with insurance companies. Under the Severance Compensation Act, 1963, payments in accordance with Section
14 release the Company from any future severance payments to those employees. Therefore, the Company does not recognize a liability for
severance pay due to these employees and the deposits under Section 14 are not recorded as an asset in the Company&#x2019;s consolidated
balance sheets. The Company&#x2019;s contributions to the defined contribution plans are charged to the consolidated statements of operations
as and when the services are received from the Company&#x2019;s employees.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;GALMED
PHARMACEUTICALS LTD.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to Consolidated Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;div style="margin: 0pt auto; width: 100%"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
2 &#x2013; Significant Accounting Policies (Cont.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z3XvbzKcrp1c" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;L.&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86B_z7Ci3ZnFql9k"&gt;Fair value of financial instruments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
estimated fair value of financial instruments was determined by the Company using available market information and valuation methodologies.
Considerable judgment is required in estimating fair values. Accordingly, the estimates may not be indicative of the amounts the Company
could realize in a current market exchange.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following methods and assumptions were used by the Company in estimating its fair value disclosures for financial instruments:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying amounts of cash and cash equivalents, short-term deposits, other accounts receivables, trade payables and other trade payables
approximate their fair value due to the short-term maturity of such instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair
value is an exit price representing the amount that would be received upon selling an asset or that would be paid to transfer a liability
in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based
on assumptions used by market participants in pricing an asset or a liability.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
three-tier fair-value hierarchy was established as a basis for considering such assumptions and for inputs used in the valuation methodologies
in measuring fair value:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    2 - Other inputs that are directly or indirectly observable in the marketplace; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    3 - Unobservable inputs that are supported by little or no market activity&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when
measuring fair value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zOB5ODJGcNJ8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of the Company&#x2019;s assets measured at fair value on a recurring basis by level within the fair value hierarchy are as
follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B3_zO8puHwV0nw7" style="display: none"&gt;Schedule of Assets Measured at Fair Value on Recurring Basis&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_ztWBlCt5Mr04" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_ze1DC6ihqWdf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zeNz5iE4EnBj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zlPtLLioYWOe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zwGbeKQwQqJh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Corporate bonds&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0644"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;2,367&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0646"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;2,367&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zCUvvjcAExU8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Treasury bills&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0649"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;533&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0651"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;533&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember_zPv2QFGWJita" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Mutual funds&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,283&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0655"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0656"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,283&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__custom--InvestmentInAssociateMember_zGGIL9wP0cQe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Investment in associate&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0659"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0660"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,119&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,119&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_zbmirx9aLf74" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;4,283&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;2,900&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;2,119&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;9,302&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zLK9o7TRzH3f" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zcyjbxTQ8IF7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zpg9gx3TYEvh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_znCRBj3zweN7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;b&gt;Fair&lt;/b&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Value&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zvg8XcErWjm" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Corporate bonds&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0669"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;1,969&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0671"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;1,969&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zYCkcRLGM1fe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Treasury bills&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0674"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;409&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0676"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;409&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember_z6XGAWOuzlRk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Mutual funds&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,150&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0680"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0681"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,150&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__custom--InvestmentInAssociateMember_zFeOz1hUX6Ce" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Investment in associate&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0684"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0685"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,265&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,265&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_z6FQkSJwzSW1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;5,150&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;2,378&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;3,265&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;10,793&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zIXA0OEOeNXl" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;b&gt;Derivative instrument&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Under ASC 815-40,
contracts that are not indexed to the Company&#x2019;s own equity are classified as liabilities recorded at fair value, as such, the Company
classifies the SEPA Agreement entered into (see Note 11A(5)) as a derivative instrument measured at fair value at each reporting period,
as settlement provisions under this agreement are not indexed to the Company&#x2019;s own equity.&lt;/span&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 18pt"&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zE5ODiPqkVT5" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;M.&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span&gt;&lt;span id="xdx_86D_zTToCDHGG1ga"&gt;Accounting for stock-based compensation&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for share-based compensation under ASC 718, Compensation - Stock Compensation (&#x201c;ASC 718&#x201d;), which requires
the measurement and recognition of compensation expense based on estimated fair values for all share-based payment awards made to employees,
non-employee consultants and directors, including options and restricted share units (&#x201c;RSUs&#x201d;) based on the fair value of
the awards on the date of grant. ASC 718 requires companies to estimate the fair value of equity-based payment awards on the date of
grant using an option-pricing model. The expense for share-based compensation cost is recognized over the requisite service period of
each individual grant using the straight-line method for service-based awards. Forfeitures are accounted for as they occur.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;GALMED
PHARMACEUTICALS LTD.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to Consolidated Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;div style="margin: 0pt auto; width: 100%"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
2 &#x2013; Significant Accounting Policies (Cont.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;M.&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Accounting for stock-based compensation (Cont.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company calculates the fair value of RSUs based on the fair value on the closing trading price of the underlying shares at the date of
grant and estimates the fair value of stock options granted using a &lt;span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDescription_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zr03dAoCGCpk" title="Black scholes option pricing model"&gt;Black-Scholes option-pricing model&lt;/span&gt;. The option-pricing model requires
a number of assumptions, the most significant of which are the expected stock-price volatility and the expected option term (the time
from the grant date until the options are exercised or expire).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s calculations of the expected volatility were based upon actual historical stock-price movements over the period, which
was equal to the expected option term. The expected option term was calculated for options granted to employees and directors in accordance
with ASC-718-10-S99, using the &#x201c;simplified&#x201d; method, and grants to non-employees were based on the contractual term. Historically,
the Company has not paid dividends, and has no foreseeable plans to do so. The risk-free interest rate is based on the yield from U.S.
Treasury zero-coupon bonds with an equivalent term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--ResearchAndDevelopmentExpensePolicy_zsmgn5zbkeyk" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;N.&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_864_zmrDVWBlDJG2"&gt;Research and development expenses&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development expenses are charged to the statements of operations as incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_zWvuoFjtfIN7" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;O.&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86E_zibACiF6s8o1"&gt;Income taxes&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for income taxes in accordance with ASC 740, Income Taxes (&#x201c;ASC 740&#x201d;), using the liability method whereby
deferred tax assets and liability account balances are determined based on the differences between financial reporting and the tax basis
for assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected
to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to the amounts that are more likely-than-not
to be realized. As of December 31, 2024 and 2023, the Company recorded a full valuation allowance against its deferred tax assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company applies a more-likely-than-not recognition threshold to uncertain tax positions based on the technical merits of the income tax
positions taken. The Company does not recognize a tax benefit unless it is more likely than not that the tax position will be sustained
upon examination, including resolution of any related appeals or litigation processes, based on the technical merits of the position.
The tax benefit that is recorded for these positions is measured at the largest amount of benefit that is greater than 50% likely of
being realized upon ultimate settlement. As of December 31, 2024 and 2023, no liability for unrecognized tax benefits was recorded due
to immateriality.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--EarningsPerSharePolicyTextBlock_zn8UeKVGd4ol" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;P.&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_863_zFxI6g2aD1Z1"&gt;Basic and diluted net loss per share&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
net loss per share is computed based on the weighted-average number of shares outstanding during each year. Diluted net loss per share
is computed based on the weighted-average number of shares outstanding during each year, plus the dilutive potential of the ordinary
shares considered outstanding during the year, in accordance with ASC 260-10, &#x201c;Earnings Per Share.&#x201d;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
outstanding stock options, RSUs, prefunded-warrants and warrants were excluded from the calculation of the diluted loss per share
for the years ended December 31, 2024, 2023 and 2022, because all such securities have an anti-dilutive effect.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;GALMED
PHARMACEUTICALS LTD.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to Consolidated Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;div style="margin: 0pt auto; width: 100%"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
2 &#x2013; Significant Accounting Policies (Cont.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--LesseeLeasesPolicyTextBlock_ztJF6bSmuRqc" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Q.&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86D_z81fguYtUhG4"&gt;Leases&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for leases in accordance with ASC 842 &#x201c;Leases.&#x201d; Arrangements that are determined to be operating leases
at inception are recognized as right-of-use operating lease assets and lease liabilities in the balance sheets at lease commencement.
The Company recognizes a lease liability at the present value of the lease payments to be made over the lease term, and concurrently
recognizes a right-of-use asset at the same amount of the liability, adjusted for any prepaid or accrued lease payments, plus initial
direct costs incurred in respect of the lease. The Company uses its incremental borrowing rate based on the information available at
the commencement date to determine the present value of the lease payments. The subsequent measurement depends on whether the lease is
classified as a finance lease or an operating lease. During the reporting periods, the Company has only operating leases. Lease terms
include options to extend the lease when it is reasonably certain that the Company will exercise that option. Lease expenses for operating
leases are recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has made a policy election not to capitalize leases with a term of 12 months or less. The Company made has also made a policy
election to include lease and non-lease components as a single lease component.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Payments
for variable lease costs are expensed as incurred and are not included in the operating lease right-of-use assets and lease liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
accordance with ASC 360-10, management reviews operating lease assets for impairment whenever events or changes in circumstances indicate
that the carrying amount of an asset may not be recoverable based on estimated future undiscounted cash flows. If so indicated, an impairment
loss would be recognized for the difference between the carrying amount of the asset and its fair value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--InvestmentPolicyTextBlock_z0Yq6MBcXBu1" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;R.&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_862_zWIp43wKc5ib"&gt;Investment in Associate at Fair Value&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company holds an equity investment of a privately-owned company, Onkai Inc. (&#x201c;Onkai&#x201d;), over which it has the ability to exercise
significant influence, but not control. The investment was included as a non-current asset in the balance sheet as of December 31, 2024.
The Company has elected the fair value option allowed by ASC 825, Financial Instruments, with respect to this investment because management
believes this approach will better reflect the economics of its equity interest. Under the fair value option, the investment is remeasured
at fair value (level 3) at each reporting period with changes in fair value, if any, recorded in the statement of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024, management, based on fair value estimation, assessed the qualitative aspects of the equity investment and macroeconomic
factors and determined that an impairment should be recognized in amount of $1.1 million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z7VU98c1aeO3" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;S.&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86C_zrB96f2tbo9"&gt;Recently adopted accounting pronouncements&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;From
time to time, new accounting pronouncements are issued by FASB, or other standard setting bodies and adopted by the Company as of the
specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have
a material impact on our financial position or results of operations upon adoption.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The ASU expands
public entities&#x2019; segment disclosures by requiring disclosure of significant segment expenses that are regularly reviewed by the
chief operating decision maker (&#x201c;CODM&#x201d;) and included within each reported measure of segment profit or loss, an amount and
description of its composition for other segment items, and interim disclosures of a reportable segment&#x2019;s profit or loss and assets.
The ASU also allows, in addition to the measure that is most consistent with U.S. GAAP, the disclosure of additional measures of segment
profit or loss that are used by the CODM in assessing segment performance and deciding how to allocate resources. The ASU is effective
for the Company&#x2019;s Annual Report on Form 20-F for the fiscal year ended December 31, 2024, and subsequent interim periods, with
early adoption permitted. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_ecustom--NewAccountingPronouncementsNotYetEffectivePolicyTextBlock_zXeQR5BViNok" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;T.&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86E_zsQbYWN4vhzh"&gt;Accounting pronouncements not yet effective&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2024, the FASB issued ASU 2024-03, &#x201c;Income Statement&#x2013;Reporting Comprehensive Income&#x2013;Expense Disaggregation
Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses&#x201d; (&#x201c;ASU 2024-03&#x201d;), which requires the disaggregation
of certain expenses in the financial statements notes, to provide enhanced transparency into the expense captions presented on the face
of the consolidated statement of operations. ASU 2024-03 is effective for annual reporting periods beginning January 1, 2027 and interim
periods beginning January 1, 2028 and may be applied either prospectively or retrospectively. The Company is currently evaluating the
impact that ASU 2024-03 will have on its related disclosures, and the transition method.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_851_z2X5hTML8xEi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;GALMED
PHARMACEUTICALS LTD.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to Consolidated Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;div style="margin: 0pt auto; width: 100%"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000595">&lt;p id="xdx_848_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zgAG2X9Y5v77" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;A.&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86E_z8rvBjjyI7xb"&gt;Basis of presentation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated financial statements have been prepared in accordance with United States Generally Accepted Accounting Principles (&#x201c;U.S.
GAAP&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2024-01-01to2024-12-31" id="Fact000597">&lt;p id="xdx_84A_eus-gaap--UseOfEstimates_z0kO2pZpw4p8" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;B.&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_866_znJjOyCAGxob"&gt;Use of estimates&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities as of the date of the financial statements, and the reported amounts of expenses
during the reporting period. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;GALMED
PHARMACEUTICALS LTD.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to Consolidated Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;div style="margin: 0pt auto; width: 100%"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
2 &#x2013; Significant Accounting Policies (Cont.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000599">&lt;p id="xdx_844_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zMTom8fPyiR" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;C.&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_867_zvAm7mmhDgL8"&gt;Financial statement in U.S. dollars&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
functional currency of the Company and its subsidiaries is the U.S dollar (the &#x201c;dollar&#x201d;), because the dollar is the currency
of the primary economic environment in which the Company and its subsidiaries operate and expect to continue operating in the foreseeable
future. Transactions and balances denominated in dollars are presented in their original amounts. Non-dollar denominated transactions
and balances have been re-measured to dollars in accordance with the provisions of ASC 830, &#x201c;Foreign Currency Matters.&#x201d; All
transaction gains and losses from re-measurement of monetary balance sheet items denominated in non-dollar currencies are reflected in
the statement of operations as financial income or expenses, as appropriate.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000601">&lt;p id="xdx_842_eus-gaap--ConsolidationPolicyTextBlock_zhleHKi1imec" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;D.&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_860_zamApzJTutkh"&gt;Principles of consolidation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries: Galmed Research and Development
Ltd., Galmed International Ltd., Galtopa Therapeutics Ltd and Galmed Therapeutics UK Limited. All intercompany balances and transactions
have been eliminated upon consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000603">&lt;p id="xdx_840_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zqH5FRoAuZ1e" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;E.&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_868_zLhKQzbTkWh8"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
equivalents are short-term, highly liquid investments that are readily convertible into cash with maturities of three months or less
as of the date acquired.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="From2024-01-01to2024-12-31" id="Fact000605">&lt;p id="xdx_841_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zyW1iWSTYwhb" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;F.&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_868_zRHhT8coz6O8"&gt;Restricted Cash&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
that is held for a specific purpose and is not available for immediate or general business use due to external restrictions is classified
in the Company&#x2019;s consolidated balance sheets as restricted cash.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <GLMD:ShortTermDepositsPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000607">&lt;p id="xdx_84B_ecustom--ShortTermDepositsPolicyTextBlock_z6Lb1A38Pww7" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;G.&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86A_zKQgtsmvZrR1"&gt;Short-term deposits&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Bank
deposits with maturities of more than three months but less than one year are included in short-term bank deposits. Such short-term deposits
are stated at cost which approximates fair market value. Interest rates on the Company&#x2019;s short-term deposits were between &lt;span id="xdx_90A_eus-gaap--InvestmentInterestRate_iI_dp_c20241231__srt--RangeAxis__srt--MinimumMember_zrnKAFKsFb8b" title="Short-Term deposits interest rate"&gt;5.06&lt;/span&gt;%-&lt;span id="xdx_90A_eus-gaap--InvestmentInterestRate_iI_dp_c20241231__srt--RangeAxis__srt--MaximumMember_zvKFU0wY1879" title="Short-Term deposits interest rate"&gt;6.63&lt;/span&gt;%
during the year ended December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</GLMD:ShortTermDepositsPolicyTextBlock>
    <us-gaap:InvestmentInterestRate
      contextRef="AsOf2024-12-31_srt_MinimumMember"
      decimals="INF"
      id="Fact000609"
      unitRef="Pure">0.0506</us-gaap:InvestmentInterestRate>
    <us-gaap:InvestmentInterestRate
      contextRef="AsOf2024-12-31_srt_MaximumMember"
      decimals="INF"
      id="Fact000611"
      unitRef="Pure">0.0663</us-gaap:InvestmentInterestRate>
    <us-gaap:MarketableSecuritiesPolicy contextRef="From2024-01-01to2024-12-31" id="Fact000613">&lt;p id="xdx_84E_eus-gaap--MarketableSecuritiesPolicy_zZuUPur3p6sf" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;H.&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_865_zeDj7pNOxf15"&gt;Marketable debt securities&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company invests most of its excess cash primarily in debt securities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for its investments in investment grade debt securities in accordance with ASC 320 &#x201c;Investments - Debt and Equity
Securities&#x201d;. Management determines the appropriate classification of its investments in debt securities at the time of purchase
and re-evaluates such determinations at each balance sheet date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Marketable
debt securities are considered to be available for sale and are carried at fair value on the consolidated balance sheet. Unrealized gains
and losses net of tax, if any, are reported in a separate component of stockholders&#x2019; equity in accumulated other comprehensive
income (&#x201c;OCI&#x201d;). Gains and losses are recognized when realized, on a specific identification basis, in the Company&#x2019;s
consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Following
the adoption of ASC 326, current expected credit losses on the Company&#x2019;s marketable grade debt securities are recorded, if expected,
through an allowance for current expected credit losses. The amount of allowance for current expected credit losses is limited to the
amount that the fair value is less than the amortized cost basis. Any remaining unrealized losses are included in accumulated other comprehensive
loss in stockholders&#x2019; equity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If
the Company intends to sell the debt security (that is, it has decided to sell the security), or more likely than not will be required
to sell the security before recovery of its amortized cost basis, any allowance for current expected credit losses is written off and
the amortized cost basis shall be written down to the debt security&#x2019;s fair value at the reporting date with any incremental impairment
reported in earnings. Based on management&#x2019;s assessment, the Company does not intend to sell its securities for less than amortized
cost; therefore, an allowance for current expected credit losses has not been recorded as of December 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;GALMED
PHARMACEUTICALS LTD.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to Consolidated Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;div style="margin: 0pt auto; width: 100%"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
2 &#x2013; Significant Accounting Policies (Cont.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2024-01-01to2024-12-31" id="Fact000615">&lt;p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_zR0yP4KaGEUj" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;I.&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86C_z6MELlxtEgSl"&gt;Concentrations of credit risk&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments which potentially subject the Company to credit risk consist primarily of cash, cash equivalents, marketable debt securities
and short-term deposits. The Company hold these investments in highly-rated financial institutions, and, by policy, limit the amounts
of credit exposure to any one financial institution. These amounts at times may exceed federally insured limits. The Company has not
experienced any credit losses in such accounts and does not believe we are exposed to any significant credit risk on these funds. The
Company has no off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts, or other
hedging arrangements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000617">&lt;p id="xdx_848_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zT95vhA3yXBd" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;J.&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_865_zZqdSXymQ8A"&gt;Property and equipment&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_ecustom--ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentTableTextBlock_zwrlmrQPQTvl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated
useful lives of the assets. The annual depreciation rates are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BC_zu3C94eWLw65"&gt;Schedule of Depreciation Rates for Property, Plant and Equipment&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 93%; border-collapse: collapse; margin-left: 0.5in"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;%&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 50%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Office
    furniture and equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentSalvageValuePercentage_iI_pid_dp_uPure_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndEquipmentMember_zdsLcXWNG2oj" title="Property and equipment, depreciation, percentage"&gt;7&lt;/span&gt;&#x2013;&lt;span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentSalvageValuePercentage_iI_pid_dp_uPure_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndEquipmentMember_z0H6Yi6QX3He" title="Property and equipment, depreciation, percentage"&gt;16&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Computer
    software and electronic equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentSalvageValuePercentage_iI_pid_dp_uPure_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerSoftwareElectronicEquipmentMember_zonOslvEYeMl" title="Property and equipment, depreciation, percentage"&gt;15&lt;/span&gt;&#x2013;&lt;span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentSalvageValuePercentage_iI_pid_dp_uPure_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerSoftwareElectronicEquipmentMember_zN9gwrrdvISk" title="Property and equipment, depreciation, percentage"&gt;33&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leasehold
    improvements&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentDepreciationMethodExtensibleEnumeration_iI_dxL_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zpQO8BQbJZv3" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2024%23UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0628"&gt;Shorter
    of the remaining lease term or useful life&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AE_zgIUUXRcts4j" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recorded depreciation expenses in a total of approximately $&lt;span id="xdx_903_eus-gaap--Depreciation_pn4n6_c20240101__20241231_zK6bs281Zfbi" title="Depreciation expenses"&gt;0.08&lt;/span&gt; million, $&lt;span id="xdx_907_eus-gaap--Depreciation_pn4n6_c20230101__20231231_z8IKX3h04Tt1" title="Depreciation expenses"&gt;0.03&lt;/span&gt; million and $&lt;span id="xdx_90A_eus-gaap--Depreciation_pn4n6_c20220101__20221231_zf8relcGANAi" title="Depreciation expenses"&gt;0.06&lt;/span&gt; million for the years ended
December 31, 2024, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <GLMD:ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000619">&lt;p id="xdx_899_ecustom--ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentTableTextBlock_zwrlmrQPQTvl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated
useful lives of the assets. The annual depreciation rates are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BC_zu3C94eWLw65"&gt;Schedule of Depreciation Rates for Property, Plant and Equipment&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 93%; border-collapse: collapse; margin-left: 0.5in"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;%&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 50%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Office
    furniture and equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentSalvageValuePercentage_iI_pid_dp_uPure_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndEquipmentMember_zdsLcXWNG2oj" title="Property and equipment, depreciation, percentage"&gt;7&lt;/span&gt;&#x2013;&lt;span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentSalvageValuePercentage_iI_pid_dp_uPure_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndEquipmentMember_z0H6Yi6QX3He" title="Property and equipment, depreciation, percentage"&gt;16&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Computer
    software and electronic equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentSalvageValuePercentage_iI_pid_dp_uPure_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerSoftwareElectronicEquipmentMember_zonOslvEYeMl" title="Property and equipment, depreciation, percentage"&gt;15&lt;/span&gt;&#x2013;&lt;span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentSalvageValuePercentage_iI_pid_dp_uPure_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerSoftwareElectronicEquipmentMember_zN9gwrrdvISk" title="Property and equipment, depreciation, percentage"&gt;33&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leasehold
    improvements&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentDepreciationMethodExtensibleEnumeration_iI_dxL_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zpQO8BQbJZv3" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2024%23UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0628"&gt;Shorter
    of the remaining lease term or useful life&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</GLMD:ScheduleOfDepreciationRatesForPropertyPlantAndEquipmentTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage
      contextRef="AsOf2024-12-31_srt_MinimumMember_custom_OfficeFurnitureAndEquipmentMember"
      decimals="INF"
      id="Fact000621"
      unitRef="Pure">0.07</us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage>
    <us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage
      contextRef="AsOf2024-12-31_srt_MaximumMember_custom_OfficeFurnitureAndEquipmentMember"
      decimals="INF"
      id="Fact000623"
      unitRef="Pure">0.16</us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage>
    <us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage
      contextRef="AsOf2024-12-31_srt_MinimumMember_custom_ComputerSoftwareElectronicEquipmentMember"
      decimals="INF"
      id="Fact000625"
      unitRef="Pure">0.15</us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage>
    <us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage
      contextRef="AsOf2024-12-31_srt_MaximumMember_custom_ComputerSoftwareElectronicEquipmentMember"
      decimals="INF"
      id="Fact000627"
      unitRef="Pure">0.33</us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage>
    <us-gaap:Depreciation
      contextRef="From2024-01-01to2024-12-31"
      decimals="-4"
      id="Fact000630"
      unitRef="USD">80000.00</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2023-01-012023-12-31"
      decimals="-4"
      id="Fact000632"
      unitRef="USD">30000.00</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2022-01-012022-12-31"
      decimals="-4"
      id="Fact000634"
      unitRef="USD">60000.00</us-gaap:Depreciation>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000636">&lt;p id="xdx_84C_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zrrGTnJytw75" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;K.&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_866_zeP9cVpNefX2"&gt;Severance pay&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company employees are included under section 14 of the Severance Compensation Act, 1963 (&#x201c;Section 14&#x201d;) in Israel for a portion
of their salaries. According to Section 14, these employees are entitled to monthly deposits at a rate of &lt;span id="xdx_90B_ecustom--MonthlyDepositsOfEmployeesPercentageOnMonthlySalary_pid_dp_uPure_c20240101__20241231_zggLAPYGX5qe" title="Monthly deposits percentage"&gt;8.33&lt;/span&gt;% of their monthly salary,
contributed on their behalf with insurance companies. Under the Severance Compensation Act, 1963, payments in accordance with Section
14 release the Company from any future severance payments to those employees. Therefore, the Company does not recognize a liability for
severance pay due to these employees and the deposits under Section 14 are not recorded as an asset in the Company&#x2019;s consolidated
balance sheets. The Company&#x2019;s contributions to the defined contribution plans are charged to the consolidated statements of operations
as and when the services are received from the Company&#x2019;s employees.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;GALMED
PHARMACEUTICALS LTD.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to Consolidated Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;div style="margin: 0pt auto; width: 100%"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
2 &#x2013; Significant Accounting Policies (Cont.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <GLMD:MonthlyDepositsOfEmployeesPercentageOnMonthlySalary
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000638"
      unitRef="Pure">0.0833</GLMD:MonthlyDepositsOfEmployeesPercentageOnMonthlySalary>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2024-01-01to2024-12-31" id="Fact000640">&lt;p id="xdx_842_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z3XvbzKcrp1c" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;L.&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86B_z7Ci3ZnFql9k"&gt;Fair value of financial instruments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
estimated fair value of financial instruments was determined by the Company using available market information and valuation methodologies.
Considerable judgment is required in estimating fair values. Accordingly, the estimates may not be indicative of the amounts the Company
could realize in a current market exchange.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following methods and assumptions were used by the Company in estimating its fair value disclosures for financial instruments:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying amounts of cash and cash equivalents, short-term deposits, other accounts receivables, trade payables and other trade payables
approximate their fair value due to the short-term maturity of such instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair
value is an exit price representing the amount that would be received upon selling an asset or that would be paid to transfer a liability
in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based
on assumptions used by market participants in pricing an asset or a liability.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
three-tier fair-value hierarchy was established as a basis for considering such assumptions and for inputs used in the valuation methodologies
in measuring fair value:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    2 - Other inputs that are directly or indirectly observable in the marketplace; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    3 - Unobservable inputs that are supported by little or no market activity&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when
measuring fair value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zOB5ODJGcNJ8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of the Company&#x2019;s assets measured at fair value on a recurring basis by level within the fair value hierarchy are as
follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B3_zO8puHwV0nw7" style="display: none"&gt;Schedule of Assets Measured at Fair Value on Recurring Basis&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_ztWBlCt5Mr04" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_ze1DC6ihqWdf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zeNz5iE4EnBj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zlPtLLioYWOe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zwGbeKQwQqJh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Corporate bonds&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0644"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;2,367&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0646"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;2,367&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zCUvvjcAExU8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Treasury bills&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0649"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;533&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0651"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;533&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember_zPv2QFGWJita" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Mutual funds&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,283&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0655"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0656"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,283&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__custom--InvestmentInAssociateMember_zGGIL9wP0cQe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Investment in associate&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0659"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0660"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,119&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,119&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_zbmirx9aLf74" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;4,283&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;2,900&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;2,119&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;9,302&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zLK9o7TRzH3f" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zcyjbxTQ8IF7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zpg9gx3TYEvh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_znCRBj3zweN7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;b&gt;Fair&lt;/b&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Value&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zvg8XcErWjm" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Corporate bonds&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0669"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;1,969&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0671"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;1,969&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zYCkcRLGM1fe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Treasury bills&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0674"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;409&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0676"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;409&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember_z6XGAWOuzlRk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Mutual funds&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,150&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0680"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0681"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,150&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__custom--InvestmentInAssociateMember_zFeOz1hUX6Ce" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Investment in associate&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0684"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0685"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,265&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,265&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_z6FQkSJwzSW1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;5,150&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;2,378&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;3,265&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;10,793&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zIXA0OEOeNXl" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;b&gt;Derivative instrument&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Under ASC 815-40,
contracts that are not indexed to the Company&#x2019;s own equity are classified as liabilities recorded at fair value, as such, the Company
classifies the SEPA Agreement entered into (see Note 11A(5)) as a derivative instrument measured at fair value at each reporting period,
as settlement provisions under this agreement are not indexed to the Company&#x2019;s own equity.&lt;/span&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 18pt"&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000642">&lt;p id="xdx_898_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zOB5ODJGcNJ8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of the Company&#x2019;s assets measured at fair value on a recurring basis by level within the fair value hierarchy are as
follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B3_zO8puHwV0nw7" style="display: none"&gt;Schedule of Assets Measured at Fair Value on Recurring Basis&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_ztWBlCt5Mr04" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_ze1DC6ihqWdf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zeNz5iE4EnBj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zlPtLLioYWOe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zwGbeKQwQqJh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Corporate bonds&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0644"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;2,367&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0646"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;2,367&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zCUvvjcAExU8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Treasury bills&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0649"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;533&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0651"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;533&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember_zPv2QFGWJita" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Mutual funds&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,283&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0655"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0656"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,283&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__custom--InvestmentInAssociateMember_zGGIL9wP0cQe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Investment in associate&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0659"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0660"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,119&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,119&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_zbmirx9aLf74" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;4,283&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;2,900&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;2,119&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;9,302&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zLK9o7TRzH3f" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zcyjbxTQ8IF7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zpg9gx3TYEvh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_znCRBj3zweN7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;b&gt;Fair&lt;/b&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Value&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zvg8XcErWjm" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Corporate bonds&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0669"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;1,969&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0671"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;1,969&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zYCkcRLGM1fe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Treasury bills&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0674"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;409&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0676"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;409&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember_z6XGAWOuzlRk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Mutual funds&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,150&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0680"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0681"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,150&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FinancialInstrumentAxis__custom--InvestmentInAssociateMember_zFeOz1hUX6Ce" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Investment in associate&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0684"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0685"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,265&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,265&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_z6FQkSJwzSW1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;5,150&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;2,378&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;3,265&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;10,793&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="Fact000645"
      unitRef="USD">2367000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="Fact000647"
      unitRef="USD">2367000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="Fact000650"
      unitRef="USD">533000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="Fact000652"
      unitRef="USD">533000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member_us-gaap_MutualFundMember"
      decimals="-3"
      id="Fact000654"
      unitRef="USD">4283000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_MutualFundMember"
      decimals="-3"
      id="Fact000657"
      unitRef="USD">4283000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member_custom_InvestmentInAssociateMember"
      decimals="-3"
      id="Fact000661"
      unitRef="USD">2119000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_custom_InvestmentInAssociateMember"
      decimals="-3"
      id="Fact000662"
      unitRef="USD">2119000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member"
      decimals="-3"
      id="Fact000664"
      unitRef="USD">4283000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member"
      decimals="-3"
      id="Fact000665"
      unitRef="USD">2900000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member"
      decimals="-3"
      id="Fact000666"
      unitRef="USD">2119000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact000667"
      unitRef="USD">9302000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="Fact000670"
      unitRef="USD">1969000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="Fact000672"
      unitRef="USD">1969000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="Fact000675"
      unitRef="USD">409000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="Fact000677"
      unitRef="USD">409000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member_us-gaap_MutualFundMember"
      decimals="-3"
      id="Fact000679"
      unitRef="USD">5150000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_MutualFundMember"
      decimals="-3"
      id="Fact000682"
      unitRef="USD">5150000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member_custom_InvestmentInAssociateMember"
      decimals="-3"
      id="Fact000686"
      unitRef="USD">3265000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_custom_InvestmentInAssociateMember"
      decimals="-3"
      id="Fact000687"
      unitRef="USD">3265000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member"
      decimals="-3"
      id="Fact000689"
      unitRef="USD">5150000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member"
      decimals="-3"
      id="Fact000690"
      unitRef="USD">2378000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member"
      decimals="-3"
      id="Fact000691"
      unitRef="USD">3265000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact000692"
      unitRef="USD">10793000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2024-01-01to2024-12-31" id="Fact000694">&lt;p id="xdx_848_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zE5ODiPqkVT5" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;M.&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span&gt;&lt;span id="xdx_86D_zTToCDHGG1ga"&gt;Accounting for stock-based compensation&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for share-based compensation under ASC 718, Compensation - Stock Compensation (&#x201c;ASC 718&#x201d;), which requires
the measurement and recognition of compensation expense based on estimated fair values for all share-based payment awards made to employees,
non-employee consultants and directors, including options and restricted share units (&#x201c;RSUs&#x201d;) based on the fair value of
the awards on the date of grant. ASC 718 requires companies to estimate the fair value of equity-based payment awards on the date of
grant using an option-pricing model. The expense for share-based compensation cost is recognized over the requisite service period of
each individual grant using the straight-line method for service-based awards. Forfeitures are accounted for as they occur.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;GALMED
PHARMACEUTICALS LTD.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to Consolidated Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;div style="margin: 0pt auto; width: 100%"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
2 &#x2013; Significant Accounting Policies (Cont.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;M.&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Accounting for stock-based compensation (Cont.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company calculates the fair value of RSUs based on the fair value on the closing trading price of the underlying shares at the date of
grant and estimates the fair value of stock options granted using a &lt;span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDescription_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zr03dAoCGCpk" title="Black scholes option pricing model"&gt;Black-Scholes option-pricing model&lt;/span&gt;. The option-pricing model requires
a number of assumptions, the most significant of which are the expected stock-price volatility and the expected option term (the time
from the grant date until the options are exercised or expire).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s calculations of the expected volatility were based upon actual historical stock-price movements over the period, which
was equal to the expected option term. The expected option term was calculated for options granted to employees and directors in accordance
with ASC-718-10-S99, using the &#x201c;simplified&#x201d; method, and grants to non-employees were based on the contractual term. Historically,
the Company has not paid dividends, and has no foreseeable plans to do so. The risk-free interest rate is based on the yield from U.S.
Treasury zero-coupon bonds with an equivalent term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <GLMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDescription
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockMember"
      id="Fact000696">Black-Scholes option-pricing model</GLMD:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDescription>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2024-01-01to2024-12-31" id="Fact000698">&lt;p id="xdx_843_eus-gaap--ResearchAndDevelopmentExpensePolicy_zsmgn5zbkeyk" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;N.&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_864_zmrDVWBlDJG2"&gt;Research and development expenses&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development expenses are charged to the statements of operations as incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000700">&lt;p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_zWvuoFjtfIN7" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;O.&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86E_zibACiF6s8o1"&gt;Income taxes&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for income taxes in accordance with ASC 740, Income Taxes (&#x201c;ASC 740&#x201d;), using the liability method whereby
deferred tax assets and liability account balances are determined based on the differences between financial reporting and the tax basis
for assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected
to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to the amounts that are more likely-than-not
to be realized. As of December 31, 2024 and 2023, the Company recorded a full valuation allowance against its deferred tax assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company applies a more-likely-than-not recognition threshold to uncertain tax positions based on the technical merits of the income tax
positions taken. The Company does not recognize a tax benefit unless it is more likely than not that the tax position will be sustained
upon examination, including resolution of any related appeals or litigation processes, based on the technical merits of the position.
The tax benefit that is recorded for these positions is measured at the largest amount of benefit that is greater than 50% likely of
being realized upon ultimate settlement. As of December 31, 2024 and 2023, no liability for unrecognized tax benefits was recorded due
to immateriality.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000702">&lt;p id="xdx_84C_eus-gaap--EarningsPerSharePolicyTextBlock_zn8UeKVGd4ol" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;P.&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_863_zFxI6g2aD1Z1"&gt;Basic and diluted net loss per share&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
net loss per share is computed based on the weighted-average number of shares outstanding during each year. Diluted net loss per share
is computed based on the weighted-average number of shares outstanding during each year, plus the dilutive potential of the ordinary
shares considered outstanding during the year, in accordance with ASC 260-10, &#x201c;Earnings Per Share.&#x201d;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
outstanding stock options, RSUs, prefunded-warrants and warrants were excluded from the calculation of the diluted loss per share
for the years ended December 31, 2024, 2023 and 2022, because all such securities have an anti-dilutive effect.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;GALMED
PHARMACEUTICALS LTD.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to Consolidated Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;div style="margin: 0pt auto; width: 100%"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
2 &#x2013; Significant Accounting Policies (Cont.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000704">&lt;p id="xdx_84C_eus-gaap--LesseeLeasesPolicyTextBlock_ztJF6bSmuRqc" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Q.&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86D_z81fguYtUhG4"&gt;Leases&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for leases in accordance with ASC 842 &#x201c;Leases.&#x201d; Arrangements that are determined to be operating leases
at inception are recognized as right-of-use operating lease assets and lease liabilities in the balance sheets at lease commencement.
The Company recognizes a lease liability at the present value of the lease payments to be made over the lease term, and concurrently
recognizes a right-of-use asset at the same amount of the liability, adjusted for any prepaid or accrued lease payments, plus initial
direct costs incurred in respect of the lease. The Company uses its incremental borrowing rate based on the information available at
the commencement date to determine the present value of the lease payments. The subsequent measurement depends on whether the lease is
classified as a finance lease or an operating lease. During the reporting periods, the Company has only operating leases. Lease terms
include options to extend the lease when it is reasonably certain that the Company will exercise that option. Lease expenses for operating
leases are recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has made a policy election not to capitalize leases with a term of 12 months or less. The Company made has also made a policy
election to include lease and non-lease components as a single lease component.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Payments
for variable lease costs are expensed as incurred and are not included in the operating lease right-of-use assets and lease liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
accordance with ASC 360-10, management reviews operating lease assets for impairment whenever events or changes in circumstances indicate
that the carrying amount of an asset may not be recoverable based on estimated future undiscounted cash flows. If so indicated, an impairment
loss would be recognized for the difference between the carrying amount of the asset and its fair value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:InvestmentPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000706">&lt;p id="xdx_849_eus-gaap--InvestmentPolicyTextBlock_z0Yq6MBcXBu1" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;R.&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_862_zWIp43wKc5ib"&gt;Investment in Associate at Fair Value&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company holds an equity investment of a privately-owned company, Onkai Inc. (&#x201c;Onkai&#x201d;), over which it has the ability to exercise
significant influence, but not control. The investment was included as a non-current asset in the balance sheet as of December 31, 2024.
The Company has elected the fair value option allowed by ASC 825, Financial Instruments, with respect to this investment because management
believes this approach will better reflect the economics of its equity interest. Under the fair value option, the investment is remeasured
at fair value (level 3) at each reporting period with changes in fair value, if any, recorded in the statement of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024, management, based on fair value estimation, assessed the qualitative aspects of the equity investment and macroeconomic
factors and determined that an impairment should be recognized in amount of $1.1 million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000708">&lt;p id="xdx_845_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z7VU98c1aeO3" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;S.&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86C_zrB96f2tbo9"&gt;Recently adopted accounting pronouncements&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;From
time to time, new accounting pronouncements are issued by FASB, or other standard setting bodies and adopted by the Company as of the
specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have
a material impact on our financial position or results of operations upon adoption.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The ASU expands
public entities&#x2019; segment disclosures by requiring disclosure of significant segment expenses that are regularly reviewed by the
chief operating decision maker (&#x201c;CODM&#x201d;) and included within each reported measure of segment profit or loss, an amount and
description of its composition for other segment items, and interim disclosures of a reportable segment&#x2019;s profit or loss and assets.
The ASU also allows, in addition to the measure that is most consistent with U.S. GAAP, the disclosure of additional measures of segment
profit or loss that are used by the CODM in assessing segment performance and deciding how to allocate resources. The ASU is effective
for the Company&#x2019;s Annual Report on Form 20-F for the fiscal year ended December 31, 2024, and subsequent interim periods, with
early adoption permitted. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <GLMD:NewAccountingPronouncementsNotYetEffectivePolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000710">&lt;p id="xdx_84A_ecustom--NewAccountingPronouncementsNotYetEffectivePolicyTextBlock_zXeQR5BViNok" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;T.&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86E_zsQbYWN4vhzh"&gt;Accounting pronouncements not yet effective&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2024, the FASB issued ASU 2024-03, &#x201c;Income Statement&#x2013;Reporting Comprehensive Income&#x2013;Expense Disaggregation
Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses&#x201d; (&#x201c;ASU 2024-03&#x201d;), which requires the disaggregation
of certain expenses in the financial statements notes, to provide enhanced transparency into the expense captions presented on the face
of the consolidated statement of operations. ASU 2024-03 is effective for annual reporting periods beginning January 1, 2027 and interim
periods beginning January 1, 2028 and may be applied either prospectively or retrospectively. The Company is currently evaluating the
impact that ASU 2024-03 will have on its related disclosures, and the transition method.&lt;/span&gt;&lt;/p&gt;

</GLMD:NewAccountingPronouncementsNotYetEffectivePolicyTextBlock>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000712">&lt;p id="xdx_807_eus-gaap--CashCashEquivalentsAndMarketableSecuritiesTextBlock_z5ElUcWHzoDj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
3 &#x2013; &lt;span id="xdx_828_zM8Eu57ykDzl"&gt;Marketable debt securities&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--MarketableSecuritiesTextBlock_ziorsCGksSsk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the Company&#x2019;s marketable debt securities as of December 31, 2024 and 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B7_zLSGCQ7oRRSc"&gt;Schedule of Marketable Debt Securities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Gross&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Gross&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Amortized&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Unrealized&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Unrealized&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Estimated&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Cost&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Gains&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Losses&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Corporate bonds&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20241231__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_z5pGNXVo15m1" style="width: 11%; text-align: right" title="Amortized Cost"&gt;2,529&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20240101__20241231__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zxu3sadovbg1" style="width: 11%; text-align: right" title="Gross Unrealized Gains"&gt;9&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20240101__20241231__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zZhrqtyHu77i" style="width: 11%; text-align: right" title="Gross Unrealized Losses"&gt;(171&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20241231__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zMkO1mcWkvQh" style="width: 11%; text-align: right" title="Estimated Fair Value"&gt;2,367&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Treasury bills&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20241231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zlnpOESAfzBe" style="text-align: right" title="Amortized Cost"&gt;530&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20240101__20241231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zW8dGQ697sa1" style="text-align: right" title="Gross Unrealized Gains"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20240101__20241231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zgJ5wvhkh6g1" style="text-align: right" title="Gross Unrealized Losses"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0728"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20241231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zHdxs25KFZ0c" style="text-align: right" title="Estimated Fair Value"&gt;533&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Mutual funds&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20241231__us-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember_z3opYpITlijf" style="border-bottom: Black 1pt solid; text-align: right" title="Amortized Cost"&gt;4,540&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20240101__20241231__us-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember_zMKHIuurUWhi" style="border-bottom: Black 1pt solid; text-align: right" title="Gross Unrealized Gains"&gt;23&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20240101__20241231__us-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember_zA5nio4FBf8a" style="border-bottom: Black 1pt solid; text-align: right" title="Gross Unrealized Losses"&gt;(280&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20241231__us-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember_zn5Ey2cwU955" style="border-bottom: Black 1pt solid; text-align: right" title="Estimated Fair Value"&gt;4,283&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total short-term investments&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20241231_zbZiAMju3MH2" style="border-bottom: Black 2.5pt double; text-align: right" title="Amortized Cost"&gt;7,599&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20240101__20241231_zbEGM5h03LV" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross Unrealized Gains"&gt;35&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20240101__20241231_zgkIQrNH6ZUa" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross Unrealized Losses"&gt;(451&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20241231_zyoIMognowkb" style="border-bottom: Black 2.5pt double; text-align: right" title="Estimated Fair Value"&gt;7,183&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Gross&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Gross&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Amortized&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Unrealized&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Unrealized&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Estimated&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Cost&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Gains&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Losses&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Corporate bonds&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zwMu8yQc0E5j" style="width: 11%; text-align: right" title="Amortized Cost"&gt;2,123&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zpHunG4JoUD1" style="width: 11%; text-align: right" title="Gross Unrealized Gains"&gt;6&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_z6syK3HtY8V7" style="width: 11%; text-align: right" title="Gross Unrealized Losses"&gt;(160&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zbs0K82Z1RP8" style="width: 11%; text-align: right" title="Estimated Fair Value"&gt;1,969&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Treasury bills&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zwBHrXpb881a" style="text-align: right" title="Amortized Cost"&gt;400&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_z54lJKA8hhQ4" style="text-align: right" title="Gross Unrealized Gains"&gt;9&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zfUhQ8ISTWRl" style="text-align: right" title="Gross Unrealized Losses"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0760"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zlWOlNyvzLQ8" style="text-align: right" title="Estimated Fair Value"&gt;409&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Mutual funds&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember_zIge1392z3Ce" style="border-bottom: Black 1pt solid; text-align: right" title="Amortized Cost"&gt;5,459&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember_zqFwdqgwBlVd" style="border-bottom: Black 1pt solid; text-align: right" title="Gross Unrealized Gains"&gt;1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember_zYSUBOil9V18" style="border-bottom: Black 1pt solid; text-align: right" title="Gross Unrealized Losses"&gt;(310&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember_zRKOzt5MpGBl" style="border-bottom: Black 1pt solid; text-align: right" title="Estimated Fair Value"&gt;5,150&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total short-term investments&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20231231_zV8pgetGHb0b" style="border-bottom: Black 2.5pt double; text-align: right" title="Amortized Cost"&gt;7,982&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20230101__20231231_zUN73WatyXV3" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross Unrealized Gains"&gt;16&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20230101__20231231_zqKOliB3p1o7" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross Unrealized Losses"&gt;(470&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20231231_zjdC2HKyqqfi" style="border-bottom: Black 2.5pt double; text-align: right" title="Estimated Fair Value"&gt;7,528&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_8AA_zGAD9W5tvry3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
contractual maturities of the aforementioned corporate bonds and treasury bills are less than one year for the year ended December 31,
2024 and one year and a half of the aforementioned corporate bonds for the year ended December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:MarketableSecuritiesTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000714">&lt;p id="xdx_891_eus-gaap--MarketableSecuritiesTextBlock_ziorsCGksSsk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the Company&#x2019;s marketable debt securities as of December 31, 2024 and 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B7_zLSGCQ7oRRSc"&gt;Schedule of Marketable Debt Securities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Gross&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Gross&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Amortized&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Unrealized&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Unrealized&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Estimated&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Cost&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Gains&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Losses&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Corporate bonds&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20241231__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_z5pGNXVo15m1" style="width: 11%; text-align: right" title="Amortized Cost"&gt;2,529&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20240101__20241231__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zxu3sadovbg1" style="width: 11%; text-align: right" title="Gross Unrealized Gains"&gt;9&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20240101__20241231__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zZhrqtyHu77i" style="width: 11%; text-align: right" title="Gross Unrealized Losses"&gt;(171&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20241231__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zMkO1mcWkvQh" style="width: 11%; text-align: right" title="Estimated Fair Value"&gt;2,367&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Treasury bills&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20241231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zlnpOESAfzBe" style="text-align: right" title="Amortized Cost"&gt;530&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20240101__20241231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zW8dGQ697sa1" style="text-align: right" title="Gross Unrealized Gains"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20240101__20241231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zgJ5wvhkh6g1" style="text-align: right" title="Gross Unrealized Losses"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0728"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20241231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zHdxs25KFZ0c" style="text-align: right" title="Estimated Fair Value"&gt;533&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Mutual funds&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20241231__us-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember_z3opYpITlijf" style="border-bottom: Black 1pt solid; text-align: right" title="Amortized Cost"&gt;4,540&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20240101__20241231__us-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember_zMKHIuurUWhi" style="border-bottom: Black 1pt solid; text-align: right" title="Gross Unrealized Gains"&gt;23&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20240101__20241231__us-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember_zA5nio4FBf8a" style="border-bottom: Black 1pt solid; text-align: right" title="Gross Unrealized Losses"&gt;(280&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20241231__us-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember_zn5Ey2cwU955" style="border-bottom: Black 1pt solid; text-align: right" title="Estimated Fair Value"&gt;4,283&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total short-term investments&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20241231_zbZiAMju3MH2" style="border-bottom: Black 2.5pt double; text-align: right" title="Amortized Cost"&gt;7,599&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20240101__20241231_zbEGM5h03LV" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross Unrealized Gains"&gt;35&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20240101__20241231_zgkIQrNH6ZUa" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross Unrealized Losses"&gt;(451&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20241231_zyoIMognowkb" style="border-bottom: Black 2.5pt double; text-align: right" title="Estimated Fair Value"&gt;7,183&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Gross&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Gross&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Amortized&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Unrealized&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Unrealized&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Estimated&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Cost&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Gains&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Losses&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Corporate bonds&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zwMu8yQc0E5j" style="width: 11%; text-align: right" title="Amortized Cost"&gt;2,123&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zpHunG4JoUD1" style="width: 11%; text-align: right" title="Gross Unrealized Gains"&gt;6&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_z6syK3HtY8V7" style="width: 11%; text-align: right" title="Gross Unrealized Losses"&gt;(160&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zbs0K82Z1RP8" style="width: 11%; text-align: right" title="Estimated Fair Value"&gt;1,969&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Treasury bills&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zwBHrXpb881a" style="text-align: right" title="Amortized Cost"&gt;400&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_z54lJKA8hhQ4" style="text-align: right" title="Gross Unrealized Gains"&gt;9&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zfUhQ8ISTWRl" style="text-align: right" title="Gross Unrealized Losses"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0760"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__us-gaap--USTreasurySecuritiesMember_zlWOlNyvzLQ8" style="text-align: right" title="Estimated Fair Value"&gt;409&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Mutual funds&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember_zIge1392z3Ce" style="border-bottom: Black 1pt solid; text-align: right" title="Amortized Cost"&gt;5,459&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember_zqFwdqgwBlVd" style="border-bottom: Black 1pt solid; text-align: right" title="Gross Unrealized Gains"&gt;1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember_zYSUBOil9V18" style="border-bottom: Black 1pt solid; text-align: right" title="Gross Unrealized Losses"&gt;(310&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__us-gaap--MutualFundMember_zRKOzt5MpGBl" style="border-bottom: Black 1pt solid; text-align: right" title="Estimated Fair Value"&gt;5,150&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total short-term investments&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pn3n3_c20231231_zV8pgetGHb0b" style="border-bottom: Black 2.5pt double; text-align: right" title="Amortized Cost"&gt;7,982&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedGain_pn3n3_c20230101__20231231_zUN73WatyXV3" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross Unrealized Gains"&gt;16&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_pn3n3_di_c20230101__20231231_zqKOliB3p1o7" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross Unrealized Losses"&gt;(470&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pn3n3_c20231231_zjdC2HKyqqfi" style="border-bottom: Black 2.5pt double; text-align: right" title="Estimated Fair Value"&gt;7,528&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="AsOf2024-12-31_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="Fact000716"
      unitRef="USD">2529000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="From2024-01-012024-12-31_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="Fact000718"
      unitRef="USD">9000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="From2024-01-012024-12-31_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="Fact000720"
      unitRef="USD">171000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="AsOf2024-12-31_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="Fact000722"
      unitRef="USD">2367000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="AsOf2024-12-31_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="Fact000724"
      unitRef="USD">530000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="From2024-01-012024-12-31_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="Fact000726"
      unitRef="USD">3000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="AsOf2024-12-31_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="Fact000730"
      unitRef="USD">533000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="AsOf2024-12-31_us-gaap_MutualFundMember"
      decimals="-3"
      id="Fact000732"
      unitRef="USD">4540000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="From2024-01-012024-12-31_us-gaap_MutualFundMember"
      decimals="-3"
      id="Fact000734"
      unitRef="USD">23000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="From2024-01-012024-12-31_us-gaap_MutualFundMember"
      decimals="-3"
      id="Fact000736"
      unitRef="USD">280000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="AsOf2024-12-31_us-gaap_MutualFundMember"
      decimals="-3"
      id="Fact000738"
      unitRef="USD">4283000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000740"
      unitRef="USD">7599000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000742"
      unitRef="USD">35000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000744"
      unitRef="USD">451000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000746"
      unitRef="USD">7183000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="AsOf2023-12-31_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="Fact000748"
      unitRef="USD">2123000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="From2023-01-012023-12-31_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="Fact000750"
      unitRef="USD">6000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="From2023-01-012023-12-31_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="Fact000752"
      unitRef="USD">160000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="AsOf2023-12-31_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="Fact000754"
      unitRef="USD">1969000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="AsOf2023-12-31_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="Fact000756"
      unitRef="USD">400000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="From2023-01-012023-12-31_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="Fact000758"
      unitRef="USD">9000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="AsOf2023-12-31_us-gaap_USTreasurySecuritiesMember"
      decimals="-3"
      id="Fact000762"
      unitRef="USD">409000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="AsOf2023-12-31_us-gaap_MutualFundMember"
      decimals="-3"
      id="Fact000764"
      unitRef="USD">5459000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="From2023-01-012023-12-31_us-gaap_MutualFundMember"
      decimals="-3"
      id="Fact000766"
      unitRef="USD">1000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="From2023-01-012023-12-31_us-gaap_MutualFundMember"
      decimals="-3"
      id="Fact000768"
      unitRef="USD">310000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="AsOf2023-12-31_us-gaap_MutualFundMember"
      decimals="-3"
      id="Fact000770"
      unitRef="USD">5150000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000772"
      unitRef="USD">7982000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000774"
      unitRef="USD">16000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000776"
      unitRef="USD">470000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000778"
      unitRef="USD">7528000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000780">&lt;p id="xdx_802_eus-gaap--LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_zPYLXOV76QC6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
4&#x2013; &lt;span id="xdx_822_zEg71KFV39pc"&gt;Other Receivables&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_zU0YQQcu491b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B8_zcVwmyobPA67"&gt;Schedule
of Other  Receivables&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20241231_z2qPXrmPFB2e" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20231231_zROnT5sZLdv6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--PrepaidExpenseCurrent_iI_pn3n3_maRNCz4tF_zH9Wg5qgz80b" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Prepaid expenses&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;463&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;315&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--GrantsReceivable_iI_pn3n3_maRNCz4tF_zAx1QN4A0UNb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Government institutions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;76&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;47&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--OtherReceivables_iI_pn3n3_maRNCz4tF_zoSnRg0fmu44" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Other receivables&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;133&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;118&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--ReceivablesNetCurrent_iTI_pn3n3_mtRNCz4tF_zZtiDosvOvsg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;672&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;480&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zipfSQigaL46" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000782">&lt;p id="xdx_894_eus-gaap--ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_zU0YQQcu491b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B8_zcVwmyobPA67"&gt;Schedule
of Other  Receivables&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20241231_z2qPXrmPFB2e" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20231231_zROnT5sZLdv6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--PrepaidExpenseCurrent_iI_pn3n3_maRNCz4tF_zH9Wg5qgz80b" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Prepaid expenses&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;463&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;315&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--GrantsReceivable_iI_pn3n3_maRNCz4tF_zAx1QN4A0UNb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Government institutions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;76&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;47&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--OtherReceivables_iI_pn3n3_maRNCz4tF_zoSnRg0fmu44" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Other receivables&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;133&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;118&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--ReceivablesNetCurrent_iTI_pn3n3_mtRNCz4tF_zZtiDosvOvsg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;672&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;480&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000784"
      unitRef="USD">463000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000785"
      unitRef="USD">315000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:GrantsReceivable
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000787"
      unitRef="USD">76000</us-gaap:GrantsReceivable>
    <us-gaap:GrantsReceivable
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000788"
      unitRef="USD">47000</us-gaap:GrantsReceivable>
    <us-gaap:OtherReceivables
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000790"
      unitRef="USD">133000</us-gaap:OtherReceivables>
    <us-gaap:OtherReceivables
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000791"
      unitRef="USD">118000</us-gaap:OtherReceivables>
    <us-gaap:ReceivablesNetCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000793"
      unitRef="USD">672000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000794"
      unitRef="USD">480000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000796">&lt;p id="xdx_80E_eus-gaap--LesseeOperatingLeasesTextBlock_zPcnNDdcyjS4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
5&#x2013; &lt;span id="xdx_820_ztU7bvZE5ZOk"&gt;Leases&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company leased, approximately &lt;span id="xdx_907_eus-gaap--AreaOfLand_iI_uSqft_c20241231_zycON41sONN3" title="Area of land under operating lease agreement"&gt;590&lt;/span&gt;
square meters at a facility located in Tel-Aviv, Israel. The lease expired on &lt;span id="xdx_905_eus-gaap--LeaseExpirationDate1_dd_c20240101__20241231_zCEVOnSUJprb" title="Lease expiry date"&gt;March
21, 2024&lt;/span&gt;. The Company did not extend the lease and the Company&#x2019;s employees are currently working remotely while
management is in the process of searching for a new permanent location for its principal executive offices.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 33pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
2024, 2023 and 2022, the Company recorded lease expenses in its statement of operations in the amount of $&lt;span id="xdx_908_eus-gaap--OperatingLeaseExpense_pn4n6_c20240101__20241231_zS30WNBUgOdh" title="Lease expense"&gt;0.04&lt;/span&gt; million, $&lt;span id="xdx_909_eus-gaap--OperatingLeaseExpense_pn5n6_c20230101__20231231_zZ06hxuMApCi" title="Lease expense"&gt;0.2&lt;/span&gt; million,
and $&lt;span id="xdx_906_eus-gaap--OperatingLeaseExpense_pn5n6_c20220101__20221231_z52qwBH9wZyk" title="Lease expense"&gt;0.2&lt;/span&gt; million respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 33pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
December 31, 2024, the Company&#x2019;s operating lease right-of-use assets and current lease liabilities for operating leases totaled
$&lt;span id="xdx_906_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_dxL_c20241231_ziUqPvO1Q6s" title="Operating lease right of use assets::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0808"&gt;0&lt;/span&gt;&lt;/span&gt; thousand and $&lt;span id="xdx_906_eus-gaap--OperatingLeaseLiability_iI_pn3n3_c20241231_ztFVQuUMbKji" title="Operating lease liability"&gt;0&lt;/span&gt; thousand, respectively, while at December 31, 2023, the Company&#x2019;s operating lease assets and lease liabilities
(both the current and non-current portion) for operating leases totaled $&lt;span id="xdx_909_eus-gaap--OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_iI_dxL_c20231231_z3SsKMWRQrI4" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2024%23OperatingLeaseRightOfUseAsset"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0811"&gt;42&lt;/span&gt;&lt;/span&gt; thousand and $&lt;span id="xdx_90A_eus-gaap--OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_iI_dxL_c20231231_zLNPd3S9HBFk" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2024%23OperatingLeaseLiability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0812"&gt;41&lt;/span&gt;&lt;/span&gt; thousand, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:AreaOfLand
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000798"
      unitRef="Sqft">590</us-gaap:AreaOfLand>
    <us-gaap:LeaseExpirationDate1 contextRef="From2024-01-01to2024-12-31" id="Fact000800">2024-03-21</us-gaap:LeaseExpirationDate1>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="-4"
      id="Fact000802"
      unitRef="USD">40000.00</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2023-01-012023-12-31"
      decimals="-5"
      id="Fact000804"
      unitRef="USD">200000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2022-01-012022-12-31"
      decimals="-5"
      id="Fact000806"
      unitRef="USD">200000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000810"
      unitRef="USD">0</us-gaap:OperatingLeaseLiability>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000814">&lt;p id="xdx_809_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zXUoc069fT8b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
6 &#x2013; &lt;span id="xdx_828_zDOgqzCMV6Wa"&gt;Property and equipment, net&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--PropertyPlantAndEquipmentTextBlock_zk2Ns6bbY8W3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BF_z81lMRSFFPlc"&gt;Schedule of Property and Equipment&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20241231_zNetz5pICHLb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20231231_zIY10BIZmWNl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--MachineryAndEquipmentGross_iI_pn3n3_maPPAEGzWKA_zZY4PcHfFz3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Medical equipment&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;737&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;737&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--FurnitureAndFixturesGross_iI_pn3n3_maPPAEGzWKA_zWkuntSH1YE2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Office furniture and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;55&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;55&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--CapitalizedComputerSoftwareGross_iI_pn3n3_maPPAEGzWKA_zDn4IKV7adRc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Computer software and electronic equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;75&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;75&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LeaseholdImprovementsGross_iI_pn3n3_maPPAEGzWKA_zroB6QTOVs47" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;236&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;235&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iTI_pn3n3_mtPPAEGzWKA_maPPAENzlLK_z45bbBTi5Ove" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,103&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,102&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENzlLK_z52HQWbqdROc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Less - Accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,103&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,019&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzlLK_zIAZEi5e5nvk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;Net book value&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0836"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;83&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zHWWNp4z3VEj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;GALMED
PHARMACEUTICALS LTD.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to Consolidated Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;div style="margin: 0pt auto; width: 100%"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000816">&lt;p id="xdx_897_eus-gaap--PropertyPlantAndEquipmentTextBlock_zk2Ns6bbY8W3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BF_z81lMRSFFPlc"&gt;Schedule of Property and Equipment&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20241231_zNetz5pICHLb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20231231_zIY10BIZmWNl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--MachineryAndEquipmentGross_iI_pn3n3_maPPAEGzWKA_zZY4PcHfFz3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Medical equipment&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;737&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;737&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--FurnitureAndFixturesGross_iI_pn3n3_maPPAEGzWKA_zWkuntSH1YE2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Office furniture and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;55&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;55&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--CapitalizedComputerSoftwareGross_iI_pn3n3_maPPAEGzWKA_zDn4IKV7adRc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Computer software and electronic equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;75&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;75&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LeaseholdImprovementsGross_iI_pn3n3_maPPAEGzWKA_zroB6QTOVs47" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;236&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;235&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iTI_pn3n3_mtPPAEGzWKA_maPPAENzlLK_z45bbBTi5Ove" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,103&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,102&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENzlLK_z52HQWbqdROc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Less - Accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,103&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,019&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzlLK_zIAZEi5e5nvk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;Net book value&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0836"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;83&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:MachineryAndEquipmentGross
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000818"
      unitRef="USD">737000</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:MachineryAndEquipmentGross
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000819"
      unitRef="USD">737000</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:FurnitureAndFixturesGross
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000821"
      unitRef="USD">55000</us-gaap:FurnitureAndFixturesGross>
    <us-gaap:FurnitureAndFixturesGross
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000822"
      unitRef="USD">55000</us-gaap:FurnitureAndFixturesGross>
    <us-gaap:CapitalizedComputerSoftwareGross
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000824"
      unitRef="USD">75000</us-gaap:CapitalizedComputerSoftwareGross>
    <us-gaap:CapitalizedComputerSoftwareGross
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000825"
      unitRef="USD">75000</us-gaap:CapitalizedComputerSoftwareGross>
    <us-gaap:LeaseholdImprovementsGross
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000827"
      unitRef="USD">236000</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:LeaseholdImprovementsGross
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000828"
      unitRef="USD">235000</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000830"
      unitRef="USD">1103000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000831"
      unitRef="USD">1102000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000833"
      unitRef="USD">1103000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000834"
      unitRef="USD">1019000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000837"
      unitRef="USD">83000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:InvestmentTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000839">&lt;p id="xdx_80B_eus-gaap--InvestmentTextBlock_zhyu9jLzwbQi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
&lt;/b&gt;7 &#x2013; &lt;b&gt;&lt;span id="xdx_82A_zvpI9q6cojjk"&gt;Investment in an Associate&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 4, 2023, the Company entered into a definitive agreement (the &#x201c;Agreement&#x201d;) for a $&lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_pn5n6_c20230504__20230504__srt--TitleOfIndividualAxis__custom--OnkaiIncMember_zE9FyBZ1mqsd" title="Additional investment on convertible safe notes"&gt;1.5&lt;/span&gt; million equity investment in OnKai,
a US-based technology company developing an AI-based platform to advance healthcare for underserved populations across the United States
by facilitating alignment between healthcare stakeholders.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Previously,
in November, 2022 the Company invested $&lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_pn5n6_c20221130__20221130__srt--TitleOfIndividualAxis__custom--OnkaiIncMember_zZnppgv1Ugb9"&gt;1.5&lt;/span&gt; million in OnKai through a Simple Agreement for Future Equity (&#x201c;SAFE&#x201d;) which
converted at a &lt;span id="xdx_902_ecustom--CapitalStockDiscountRate_pid_dp_uPure_c20221130__20221130__srt--TitleOfIndividualAxis__custom--OnkaiIncMember_zKvOliJu4sU2" title="Capital discount rate"&gt;15&lt;/span&gt;% discount into series seed preferred shares upon closing of the Investment Round (as defined below). The Company recorded
in its statement of operations a change in the fair value of the convertible note (the SAFE) which totaled $&lt;span id="xdx_903_eus-gaap--GainLossOnInvestments_pn5n6_c20230101__20231231__srt--TitleOfIndividualAxis__custom--OnkaiIncMember_zm3wFEXeZ8V3" title="Investments"&gt;0.3&lt;/span&gt; million for the year
ended December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s investment in OnKai was part of an approximately $&lt;span id="xdx_903_eus-gaap--PaymentsToAcquireInvestments_pn5n6_c20240101__20241231_zidFFboeH9a2" title="Investment"&gt;6.0&lt;/span&gt;
million investment round (the &#x201c;Investment Round&#x201d;) with other investors that was led by the Company of which SAFEs of
approximately $&lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_pn5n6_c20240101__20241231__srt--TitleOfIndividualAxis__custom--OnkaiIncMember_zMHZm85sS704" title="Value conversion"&gt;3.8&lt;/span&gt;
were converted into preferred shares of Onkai upon the consummation of the Investment Round. On June 19, 2023, the Investment Round
closed. Following the closing of the Investment Round, the Company holds &lt;span id="xdx_90F_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20230619__srt--TitleOfIndividualAxis__custom--OnkaiIncMember_zNwP2aCoSVq6" title="Shares owned"&gt;1,223,535&lt;/span&gt;
preferred shares which comprised approximately &lt;span id="xdx_906_eus-gaap--InvestmentOwnedPercentOfNetAssets_iI_pid_dp_uPure_c20230619__srt--TitleOfIndividualAxis__custom--OnkaiIncMember_zKReVlMpSMhh" title="Shares owned percentage"&gt;24&lt;/span&gt;%
of the outstanding share capital of OnKai on an as-converted basis as of December 31, 2023 and December 31, 2024. The Company&#x2019;s Chief Executive
Officer and director, Allen Baharaff, serves as one of three board members of OnKai.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 3pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under
the terms of the Agreement, during the three-year period following the closing of the Investment Round the Company will have the right
to merge with OnKai subject to the approval of the boards of directors of each of the Company and OnKai. The Company was granted certain
customary pre-emptive rights as well as registration rights, first refusal rights, co-sale, a board seat, and certain customary protective
provisions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the Agreement, the Company&#x2019;s wholly-owned subsidiary, GRD, entered into a services agreement (the &#x201c;Services
Agreement&#x201d;) with OnKai. The Services Agreement provides that GRD will on a non-exclusive basis (i) provide support services to
OnKai relating to finance, business development, strategic planning, execution and others; and (ii) lend its experience to OnKai in building
a strategy and for the development of treatments for the underserved and that OnKai shall on a non-exclusive basis (i) take part in plan
preparation to serve GRD&#x2019;s vision of developing drugs for the underserved population and (ii) when relevant, design a process on
the clinical trial dashboard that could potentially serve GDR&#x2019;s future trial.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the above mentioned Services Agreement, the Company recorded reimbursement of expenses of $&lt;span id="xdx_901_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20240101__20241231__srt--ProductOrServiceAxis__us-gaap--AdministrativeServiceMember_zGLhk4NLGCW1" title="Management fee income"&gt;48&lt;/span&gt; thousand and $&lt;span id="xdx_90D_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20230101__20231231__srt--ProductOrServiceAxis__us-gaap--AdministrativeServiceMember_zX20bJ6t8rIf" title="Management fee income"&gt;12&lt;/span&gt; thousand
in general and administrative expenses in its statement of operations for the years ended December 31, 2024 and December 31, 2023, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 15, 2024, the Company entered into a bridge loan agreement with OnKai pursuant to which the Company made a loan in an aggregate
amount of $&lt;span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_c20241015__us-gaap--TypeOfArrangementAxis__custom--BridgeLoanAgreementMember_zHFvVvvt3Inl" title="Loan amount"&gt;250,000&lt;/span&gt; to OnKai payable by January 1, 2028. The loan bears interest at an annual rate of &lt;span id="xdx_908_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20241015__us-gaap--TypeOfArrangementAxis__custom--BridgeLoanAgreementMember_zBZnWTlmFfz7" title="Interest rate"&gt;15&lt;/span&gt;%. In addition, in connection with the
Services Agreement, the Company paid OnKai $&lt;span id="xdx_900_eus-gaap--ProceedsFromOtherDebt_c20241015__20241015__us-gaap--TypeOfArrangementAxis__custom--ServicesAgreementMember_zW7OMRMGGNvi" title="Proceeds from debt"&gt;150,000&lt;/span&gt; for OnKai to assist the Company in (i) identifying and preparing eligible sites for
the Company&#x2019;s future clinical trials and (ii) preparing and submitting applications for clinical and research grants in respect
of such future clinical trials, including preparing reimbursement strategies. In the event that Onkai is awarded a clinical or research
grant, OnKai agreed to repay the Company the $&lt;span id="xdx_90F_eus-gaap--RepaymentsOfDebt_c20241015__20241015__us-gaap--TypeOfArrangementAxis__custom--ServicesAgreementMember_zszqb1F8osV3" title="Repayments of debt"&gt;150,000&lt;/span&gt; that it initially paid to OnKai.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024, management, based on fair value estimation, assessed the qualitative aspects of the equity investment and macroeconomic
factors and determined that an impairment should be recognized in amount of $&lt;span id="xdx_90F_eus-gaap--AssetImpairmentCharges_pn5n6_c20240101__20241231_zbmoMGPcwJ1e" title="Impairment charges"&gt;1.1&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Attached
is a summarized un-audited financial information of Onkai:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_ecustom--ScheduleOfBalanceSheetsTableTextBlock_zupYrJFyreB" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;span id="xdx_8B7_zLCxDACqeusf" style="display: none"&gt;Schedule
of Balance Sheets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Balance
sheet as of December 31, 2024&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 0.75in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20241231__srt--TitleOfIndividualAxis__custom--OnkaiIncMember_zXUwPwrBovBb" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AssetsCurrent_iI_pn3n3_msSEzDrf_zOzTqQ0pVvV9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: left"&gt;Current assets&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;105&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AssetsNoncurrent_iI_pn3n3_msSEzDrf_zt5GQthFEbv5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Non-current assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--LiabilitiesCurrent_iI_pn3n3_maSEzDrf_zobY668MRGo8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Current liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;324&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--LiabilitiesNoncurrent_iI_pn3n3_maSEzDrf_zMXlZzwTppjg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Non-current liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,665&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--StockholdersEquity_iNTI_pn3n3_di_mtSEzDrf_zkyvyScp2BRj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Equity&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,881&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zI1eLcJpUXbl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Statement
of operations for the year ended December 31, 2024:&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_ecustom--ScheduleOfStatementOfOperationsTableTextBlock_z2gmHRwAhNka" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B6_zPHAEsrbXx7d" style="display: none"&gt;Schedule of Statement of Operations&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20240101__20241231__srt--TitleOfIndividualAxis__custom--OnkaiIncMember_zkDMtB6dour2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--OperatingExpenses_pn3n3_msNILzGpU_z2RKoKHX4gFj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 82%; text-align: left"&gt;Total operating loss&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;2,485&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--NonoperatingIncomeExpense_pn3n3_maNILzGpU_zEeHcD4uNTQd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Financial expenses, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--IncomeTaxExpenseBenefit_pn3n3_msNILzGpU_zt7bQ6wUrWck" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Income tax&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;22&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--NetIncomeLoss_iNT_pn3n3_di_mtNILzGpU_zZzVj1WqR7h9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Net Loss&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,537&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_z44tMFV77x" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;GALMED
PHARMACEUTICALS LTD.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to Consolidated Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;div style="margin: 0pt auto; width: 100%"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:InvestmentTextBlock>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-05-042023-05-04_custom_OnkaiIncMember"
      decimals="-5"
      id="Fact000841"
      unitRef="USD">1500000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-11-302022-11-30_custom_OnkaiIncMember"
      decimals="-5"
      id="Fact000842"
      unitRef="USD">1500000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <GLMD:CapitalStockDiscountRate
      contextRef="From2022-11-302022-11-30_custom_OnkaiIncMember"
      decimals="INF"
      id="Fact000844"
      unitRef="Pure">0.15</GLMD:CapitalStockDiscountRate>
    <us-gaap:GainLossOnInvestments
      contextRef="From2023-01-012023-12-31_custom_OnkaiIncMember"
      decimals="-5"
      id="Fact000846"
      unitRef="USD">300000</us-gaap:GainLossOnInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="From2024-01-01to2024-12-31"
      decimals="-5"
      id="Fact000848"
      unitRef="USD">6000000.0</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-12-31_custom_OnkaiIncMember"
      decimals="-5"
      id="Fact000850"
      unitRef="USD">3800000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="AsOf2023-06-19_custom_OnkaiIncMember"
      decimals="INF"
      id="Fact000852"
      unitRef="Shares">1223535</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:InvestmentOwnedPercentOfNetAssets
      contextRef="AsOf2023-06-19_custom_OnkaiIncMember"
      decimals="INF"
      id="Fact000854"
      unitRef="Pure">0.24</us-gaap:InvestmentOwnedPercentOfNetAssets>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-012024-12-31_us-gaap_AdministrativeServiceMember"
      decimals="-3"
      id="Fact000856"
      unitRef="USD">48000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-12-31_us-gaap_AdministrativeServiceMember"
      decimals="-3"
      id="Fact000858"
      unitRef="USD">12000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-10-15_custom_BridgeLoanAgreementMember"
      decimals="0"
      id="Fact000860"
      unitRef="USD">250000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="AsOf2024-10-15_custom_BridgeLoanAgreementMember"
      decimals="INF"
      id="Fact000862"
      unitRef="Pure">0.15</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:ProceedsFromOtherDebt
      contextRef="From2024-10-152024-10-15_custom_ServicesAgreementMember"
      decimals="0"
      id="Fact000864"
      unitRef="USD">150000</us-gaap:ProceedsFromOtherDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="From2024-10-152024-10-15_custom_ServicesAgreementMember"
      decimals="0"
      id="Fact000866"
      unitRef="USD">150000</us-gaap:RepaymentsOfDebt>
    <us-gaap:AssetImpairmentCharges
      contextRef="From2024-01-01to2024-12-31"
      decimals="-5"
      id="Fact000868"
      unitRef="USD">1100000</us-gaap:AssetImpairmentCharges>
    <GLMD:ScheduleOfBalanceSheetsTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000870">&lt;p id="xdx_89D_ecustom--ScheduleOfBalanceSheetsTableTextBlock_zupYrJFyreB" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;span id="xdx_8B7_zLCxDACqeusf" style="display: none"&gt;Schedule
of Balance Sheets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Balance
sheet as of December 31, 2024&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 0.75in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20241231__srt--TitleOfIndividualAxis__custom--OnkaiIncMember_zXUwPwrBovBb" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AssetsCurrent_iI_pn3n3_msSEzDrf_zOzTqQ0pVvV9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: left"&gt;Current assets&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;105&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AssetsNoncurrent_iI_pn3n3_msSEzDrf_zt5GQthFEbv5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Non-current assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--LiabilitiesCurrent_iI_pn3n3_maSEzDrf_zobY668MRGo8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Current liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;324&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--LiabilitiesNoncurrent_iI_pn3n3_maSEzDrf_zMXlZzwTppjg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Non-current liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,665&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--StockholdersEquity_iNTI_pn3n3_di_mtSEzDrf_zkyvyScp2BRj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Equity&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,881&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</GLMD:ScheduleOfBalanceSheetsTableTextBlock>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-12-31_custom_OnkaiIncMember"
      decimals="-3"
      id="Fact000872"
      unitRef="USD">105000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="AsOf2024-12-31_custom_OnkaiIncMember"
      decimals="-3"
      id="Fact000874"
      unitRef="USD">3000</us-gaap:AssetsNoncurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2024-12-31_custom_OnkaiIncMember"
      decimals="-3"
      id="Fact000876"
      unitRef="USD">324000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="AsOf2024-12-31_custom_OnkaiIncMember"
      decimals="-3"
      id="Fact000878"
      unitRef="USD">1665000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_custom_OnkaiIncMember"
      decimals="-3"
      id="Fact000880"
      unitRef="USD">1881000</us-gaap:StockholdersEquity>
    <GLMD:ScheduleOfStatementOfOperationsTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000882">&lt;p id="xdx_894_ecustom--ScheduleOfStatementOfOperationsTableTextBlock_z2gmHRwAhNka" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B6_zPHAEsrbXx7d" style="display: none"&gt;Schedule of Statement of Operations&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20240101__20241231__srt--TitleOfIndividualAxis__custom--OnkaiIncMember_zkDMtB6dour2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--OperatingExpenses_pn3n3_msNILzGpU_z2RKoKHX4gFj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 82%; text-align: left"&gt;Total operating loss&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;2,485&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--NonoperatingIncomeExpense_pn3n3_maNILzGpU_zEeHcD4uNTQd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Financial expenses, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--IncomeTaxExpenseBenefit_pn3n3_msNILzGpU_zt7bQ6wUrWck" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Income tax&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;22&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--NetIncomeLoss_iNT_pn3n3_di_mtNILzGpU_zZzVj1WqR7h9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Net Loss&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,537&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</GLMD:ScheduleOfStatementOfOperationsTableTextBlock>
    <us-gaap:OperatingExpenses
      contextRef="From2024-01-012024-12-31_custom_OnkaiIncMember"
      decimals="-3"
      id="Fact000884"
      unitRef="USD">2485000</us-gaap:OperatingExpenses>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2024-01-012024-12-31_custom_OnkaiIncMember"
      decimals="-3"
      id="Fact000886"
      unitRef="USD">30000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-01-012024-12-31_custom_OnkaiIncMember"
      decimals="-3"
      id="Fact000888"
      unitRef="USD">22000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_custom_OnkaiIncMember"
      decimals="-3"
      id="Fact000890"
      unitRef="USD">-2537000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherLiabilitiesDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000892">&lt;p id="xdx_80B_eus-gaap--OtherLiabilitiesDisclosureTextBlock_zBeFeMlSalod" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
8 &#x2013; &lt;span id="xdx_820_zKXRHV6iQQz7"&gt;Other Payables&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--OtherLiabilitiesTableTextBlock_zaNda3wGO549" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BF_zMZzMlssmlv1"&gt;Schedule
of Other Payables&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%; margin-left: 0.75in"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20241231_zYN49w91ZZ6c" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20231231_z6YGup8Lcp3a" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--EmployeeRelatedLiabilitiesCurrentAndNoncurrent_iI_pn3n3_maOLzBhJ_zRyT3YMRNj1k" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Employees and related&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;603&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;571&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--CompensatedAbsencesLiability_iI_pn3n3_maOLzBhJ_zxo0qSQeVIYi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accrued Vacation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;256&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;259&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--ShorttermLeaseObligation_iI_pn3n3_maOLzBhJ_z2yrk2VWa5g7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Short-term lease obligation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0902"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;41&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--OtherNotesPayable_iI_pn3n3_maOLzBhJ_zymGl44N1hgb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;6&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0906"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--OtherLiabilities_iTI_pn3n3_mtOLzBhJ_zCDUx68QUafg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other Payables&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;865&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;871&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zCSbzujzOc39" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OtherLiabilitiesDisclosureTextBlock>
    <us-gaap:OtherLiabilitiesTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000894">&lt;p id="xdx_89D_eus-gaap--OtherLiabilitiesTableTextBlock_zaNda3wGO549" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BF_zMZzMlssmlv1"&gt;Schedule
of Other Payables&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%; margin-left: 0.75in"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20241231_zYN49w91ZZ6c" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20231231_z6YGup8Lcp3a" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--EmployeeRelatedLiabilitiesCurrentAndNoncurrent_iI_pn3n3_maOLzBhJ_zRyT3YMRNj1k" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Employees and related&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;603&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;571&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--CompensatedAbsencesLiability_iI_pn3n3_maOLzBhJ_zxo0qSQeVIYi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accrued Vacation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;256&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;259&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--ShorttermLeaseObligation_iI_pn3n3_maOLzBhJ_z2yrk2VWa5g7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Short-term lease obligation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0902"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;41&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--OtherNotesPayable_iI_pn3n3_maOLzBhJ_zymGl44N1hgb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;6&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0906"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--OtherLiabilities_iTI_pn3n3_mtOLzBhJ_zCDUx68QUafg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other Payables&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;865&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;871&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:OtherLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000896"
      unitRef="USD">603000</us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000897"
      unitRef="USD">571000</us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:CompensatedAbsencesLiability
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000899"
      unitRef="USD">256000</us-gaap:CompensatedAbsencesLiability>
    <us-gaap:CompensatedAbsencesLiability
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000900"
      unitRef="USD">259000</us-gaap:CompensatedAbsencesLiability>
    <GLMD:ShorttermLeaseObligation
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000903"
      unitRef="USD">41000</GLMD:ShorttermLeaseObligation>
    <us-gaap:OtherNotesPayable
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000905"
      unitRef="USD">6000</us-gaap:OtherNotesPayable>
    <us-gaap:OtherLiabilities
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000908"
      unitRef="USD">865000</us-gaap:OtherLiabilities>
    <us-gaap:OtherLiabilities
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000909"
      unitRef="USD">871000</us-gaap:OtherLiabilities>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000911">&lt;p id="xdx_809_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zWtBRc2Sjgnb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 3pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
9 &#x2013; &lt;span id="xdx_824_za6jximPdAh6"&gt;Related Parties&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
    of December 31, 2024, and 2023, the Company had an accrual in the amount of approximately $&lt;span id="xdx_906_eus-gaap--OtherLiabilitiesCurrent_iI_pn5n6_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersAndDirectorsMember_zeNcBHrV6v97" title="Due to related parties"&gt;0.5&lt;/span&gt; million and $&lt;span id="xdx_906_eus-gaap--OtherLiabilitiesCurrent_iI_pn5n6_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersAndDirectorsMember_zBLnwBX6TO6a" title="Due to related parties"&gt;0.6&lt;/span&gt; million, respectively,
    pursuant to an employment agreements with its officers and directors&#x2019; fee. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
    of December 31, 2024, the Company had a receivable balance of $&lt;span id="xdx_909_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember_zdNvTrPxdjI5" title="Related party services, balance amount"&gt;25&lt;/span&gt; thousand, pursuant to a service agreement with OnKai and a long
    term loan balance of $&lt;span id="xdx_90A_eus-gaap--LongTermDebt_iI_pn3n3_c20241231__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember_zpHttbkQw4D8" title="Long term loan"&gt;257&lt;/span&gt; thousand (see note 7).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
    2024, 2023 and 2022, the Company recorded salary expenses, stock-based compensation expenses and directors&#x2019; fees to its related
    parties in the amount of $&lt;span id="xdx_908_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn5n6_c20240101__20241231_z9ryINkykqE5" title="Related party transaction, expenses"&gt;3.1&lt;/span&gt; million, $&lt;span id="xdx_904_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn5n6_c20230101__20231231_z5NRUIqp1o0a" title="Related party transaction, expenses"&gt;2.8&lt;/span&gt; million and $&lt;span id="xdx_90F_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn5n6_c20220101__20221231_zRkDcOZDvtlj" title="Related party transaction, expenses"&gt;2.8&lt;/span&gt; million respectively. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
    2024, the Company recorded reimbursement of expenses pursuant to the service agreement with OnKai. And as well recorded research
    and development expenses in connection with the service agreement with Onkai (see note 7)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2024-12-31_custom_OfficersAndDirectorsMember"
      decimals="-5"
      id="Fact000913"
      unitRef="USD">500000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2023-12-31_custom_OfficersAndDirectorsMember"
      decimals="-5"
      id="Fact000915"
      unitRef="USD">600000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2024-01-012024-12-31_custom_ServiceAgreementMember"
      decimals="-3"
      id="Fact000917"
      unitRef="USD">25000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:LongTermDebt
      contextRef="AsOf2024-12-31_custom_ServiceAgreementMember"
      decimals="-3"
      id="Fact000919"
      unitRef="USD">257000</us-gaap:LongTermDebt>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2024-01-01to2024-12-31"
      decimals="-5"
      id="Fact000921"
      unitRef="USD">3100000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2023-01-012023-12-31"
      decimals="-5"
      id="Fact000923"
      unitRef="USD">2800000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2022-01-012022-12-31"
      decimals="-5"
      id="Fact000925"
      unitRef="USD">2800000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000927">&lt;p id="xdx_802_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zmpvnPBgCCW6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
10 &lt;/b&gt;&#x2013; &lt;b&gt;&lt;span id="xdx_82B_zIc8BnQjewvf"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
    of December 31, 2024, the Company recorded a pledge on its short-term deposit in favor of its bank in the amount of approximately
    $&lt;span id="xdx_902_ecustom--BankLienOnMarketableSecurities_pn3n3_c20240101__20241231_zy8yr6jZNaNb" title="Bank lien on marketable securities"&gt;121&lt;/span&gt; thousand to secure the Company&#x2019;s commitments to the bank&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Company enters into contracts in the ordinary course of business with contract research organizations for clinical trials and clinical
    supply manufacturing and with vendors for non-clinical research studies and other services and products for operating purposes, which
    generally provide for termination upon 30 to 90 days&#x2019; notice or less, and therefore are cancelable contracts and not considered
    as commitment or purchase obligations.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
    June 28, 2021, the Company entered into a license agreement with Yissum Research Development Company of the Hebrew University of
    Jerusalem (&#x201c;Yissum&#x201d;) pursuant to which Yissum granted to the Company a worldwide, exclusive and irrevocable license to
    develop and commercialize Amilo-5Mer. Under the license agreement, the Company is responsible for carrying out the development and
    commercialization of Amilo-5Mer and the prosecution and maintenance of the licensed patents under the license agreement. In consideration
    for the grant of the license, the Company paid Yissum an upfront license fee of $&lt;span id="xdx_907_ecustom--UpfrontLicenseFee_pn3n3_c20210627__20210628_zymwOabmFZc2" title="Upfront license fee"&gt;100&lt;/span&gt; thousand which was included in research and
    development expenses for the period ended December 31, 2021. In addition, the Company may be required to make payments of up to $&lt;span id="xdx_902_ecustom--PaymentsToRegulatoryMilestones_pn3n3_c20210627__20210628__srt--RangeAxis__srt--MaximumMember_zGjq0FD7O9g3" title="Payments to regulatory milestones"&gt;950&lt;/span&gt;
    thousand upon meeting certain regulatory milestones and may be entitled to pay single digit royalties on any future net sales and
    a share of any sublicense fees. The Company is not currently pursuing the development of Amilo-5MER.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;GALMED
PHARMACEUTICALS LTD.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to Consolidated Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;div style="margin: 0pt auto; width: 100%"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <GLMD:BankLienOnMarketableSecurities
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000929"
      unitRef="USD">121000</GLMD:BankLienOnMarketableSecurities>
    <GLMD:UpfrontLicenseFee
      contextRef="From2021-06-272021-06-28"
      decimals="-3"
      id="Fact000931"
      unitRef="USD">100000</GLMD:UpfrontLicenseFee>
    <GLMD:PaymentsToRegulatoryMilestones
      contextRef="From2021-06-272021-06-28_srt_MaximumMember"
      decimals="-3"
      id="Fact000933"
      unitRef="USD">950000</GLMD:PaymentsToRegulatoryMilestones>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000935">&lt;p id="xdx_80A_eus-gaap--ShareholdersEquityAndShareBasedPaymentsTextBlock_z3FCK3TRwFLk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
11 &#x2013; &lt;span id="xdx_826_zOM8itOHtfd8"&gt;Stockholders&#x2019; equity&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;A.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Ordinary
    shares&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Ordinary
    shares confer upon the holders the right to receive notice to participate and vote in general meetings of the Company and the right
    to receive dividends, if declared.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
    March 26, 2021, the Company entered into a Sales Agreement (the &#x201c;2021 Sales Agreement&#x201d;) with Cantor Fitzgerald &amp;amp; Co. and Canaccord
    Genuity LLC, as sales agents, pursuant to which the Company may offer and sell ordinary shares &#x201c;at the market&#x201d; having an
    aggregate offering price of up to $&lt;span id="xdx_90A_ecustom--MaximumAmountOfSharesToBeIssued_iI_pn5n6_c20210326__us-gaap--TypeOfArrangementAxis__custom--NewSalesAgreementMember_zuIBLx74F6pd" title="Aggregate offering price"&gt;50.0&lt;/span&gt;
    million from time to time through the sales agents. During 2022, the Company sold &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--NewSalesAgreementMember_zyAcvZIKVssi" title="Additional ordinary shares"&gt;643&lt;/span&gt;
    ordinary shares under its ATM program for total net proceeds of approximately $&lt;span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--NewSalesAgreementMember_zDjOISA2j37g" title="Proceeds from sale of ordinary shares"&gt;0.1&lt;/span&gt;
    million. The Company did not sell any ordinary shares the 2021 Sales Agreement in 2023 and 2024 and in August 2024, the Company
    terminated the 2021 Sales Agreement in connection with its entry into the 2024 Sales Agreement (as defined below). See Note
    11(A)(6).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
    May 15, 2023, the Company effected a reverse share split of the Company&#x2019;s ordinary shares at the ratio of &lt;span id="xdx_905_eus-gaap--StockholdersEquityReverseStockSplit_c20230515__20230515__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z4YdwSTmVXGg" title="Reverse stock split"&gt;1-for-15&lt;/span&gt;, such that
    each fifteen (15) ordinary shares, par value NIS &lt;span id="xdx_902_eus-gaap--CommonStockNoParValue_iI_pid_uILSPShares_c20230515__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5yOgznQn6l8" title="Common stock, par value"&gt;0.01&lt;/span&gt; per share, were consolidated into one (1) ordinary share, par value NIS &lt;span id="xdx_90D_eus-gaap--SaleOfStockPricePerShare_iI_pid_uILSPShares_c20230515__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_znbayBOH7ZW1" title="Share price"&gt;0.15&lt;/span&gt;.
    On August 29, 2024 the Company effected an additional reverse share split of the Company&#x2019;s ordinary shares at the ratio of
    &lt;span id="xdx_90A_eus-gaap--StockholdersEquityReverseStockSplit_c20240829__20240829__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ziNUIBHTH2Ol" title="Reverse stock split"&gt;1-for-12&lt;/span&gt;, such that each twelve (12) ordinary shares, par value NIS &lt;span id="xdx_908_eus-gaap--CommonStockNoParValue_iI_pid_uILSPShares_c20240829_zefy5ShkOKu8" title="Common stock, par value"&gt;0.15&lt;/span&gt; per share, were consolidated into one (1) ordinary share,
    par value NIS &lt;span id="xdx_903_eus-gaap--CommonStockNoParValue_iI_pid_uILSPShares_c20240829__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zbpGZoM4psik" title="Common stock, par value"&gt;1.80&lt;/span&gt; per share. As a result, all share and per share amounts prior to the reverse share split were adjusted retroactively
    for all periods presented in these consolidated financial statements.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
                                            July 18, 2023, the Company sold to investors in a public offering (i) &lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230718__20230718_z5dLrsBqjnlh"&gt;31,666&lt;/span&gt; ordinary shares,
                                            (ii) &lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20230718__us-gaap--SubsidiarySaleOfStockAxis__custom--PrefundedWarrantsMember_zhrJw6vAsFHb" title="Stock and warrants issued during period shares"&gt;435,000&lt;/span&gt; pre-funded warrants to purchase &lt;span id="xdx_904_eus-gaap--ConversionOfStockSharesIssued1_pid_c20230718__20230718__us-gaap--SubsidiarySaleOfStockAxis__custom--PrefundedWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zG0emCgmWM7d" title="Class of Warrant or Right, Number of Securities Called by Warrants or Rights"&gt;435,000&lt;/span&gt; ordinary shares (the &#x201c;Pre-Funded
                                            Warrants&#x201d;), and (iii) &lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20230718__us-gaap--SubsidiarySaleOfStockAxis__custom--InvestorWarrantsMember_zGNZfI0MzSI8" title="Stock and warrants issued during period shares"&gt;466,666&lt;/span&gt; warrants to purchase &lt;span id="xdx_900_eus-gaap--ConversionOfStockSharesIssued1_pid_c20230718__20230718__us-gaap--SubsidiarySaleOfStockAxis__custom--InvestorWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkRP9ftiEyd3" title="Class of Warrant or Right, Number of Securities Called by Warrants or Rights"&gt;466,666&lt;/span&gt; ordinary shares (the &#x201c;Investor
                                            Warrants&#x201d;), at a purchase price of $&lt;span id="xdx_90A_eus-gaap--SharePrice_iI_pid_c20230718__us-gaap--SubsidiarySaleOfStockAxis__custom--InvestorWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zifjnMTEABl8" title="Share price"&gt;15.0&lt;/span&gt; per share and accompanying Investor Warrant
                                            and $&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230718__us-gaap--SubsidiarySaleOfStockAxis__custom--InvestorWarrantsMember_zYB6Q8b5T7bd" title="Exercise price of warrants"&gt;14.99&lt;/span&gt; per Pre-Funded Warrant and accompanying Investor Warrant. The aggregate gross
                                            proceeds were $&lt;span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20230718__20230718__us-gaap--SubsidiarySaleOfStockAxis__custom--InvestorWarrantsMember_zaueRm6PB0Yf" title="Gross proceeds stock"&gt;7.0&lt;/span&gt; million ($&lt;span id="xdx_903_eus-gaap--PaymentsOfDebtIssuanceCosts_pn5n6_c20230718__20230718__us-gaap--SubsidiarySaleOfStockAxis__custom--InvestorWarrantsMember_zjAFNxgUx9F3" title="Issuance costs"&gt;6.2&lt;/span&gt; million net of issuance costs).&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Pre-Funded Warrants are immediately exercisable at an exercise price of $&lt;span id="xdx_900_eus-gaap--WarrantExercisePriceIncrease_pid_c20240101__20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--PrefundedWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHFQmA7DV567" title="Exercise price of warrants"&gt;0.001&lt;/span&gt; per ordinary share. As of December 31, 2024, all of
    the Pre-Funded Warrants have been exercised.&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Investor Warrants have an exercise price of $&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230718__us-gaap--SubsidiarySaleOfStockAxis__custom--PrefundedWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zIJtkgQmK9Kk" title="Exercise price of warrants"&gt;15&lt;/span&gt; per ordinary share, are immediately exercisable, and may be exercised until July
    18, 2028. During September 2024, a total of &lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230718__us-gaap--SubsidiarySaleOfStockAxis__custom--PrefundedWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zNxvBFQ1XSqb" title="Investor warrants, shares"&gt;293,333&lt;/span&gt; Investor Warrants have been exercised into &lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230718__us-gaap--SubsidiarySaleOfStockAxis__custom--PrefundedWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zzwyImVjepic" title="Warrant exercised, shares"&gt;293,333&lt;/span&gt; ordinary shares for a total
    net proceeds of $&lt;span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20230718__20230718_z2m0qxYSYGs3" title="Proceeds from sale of ordinary shares"&gt;4.4&lt;/span&gt; million. As of December 31, 2024 a total of &lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231_zXcJV7Ee1euk" title="Warrants are outstanding"&gt;173,333&lt;/span&gt; warrants are outstanding.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.
    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
                                            August 30, 2024, the Company entered into a Standby Equity Purchase Agreement (the &#x201c;SEPA&#x201d;)
                                            with YA II PN, LTD., a Cayman Islands exempt limited partnership (&#x201c;YA&#x201d;). Pursuant
                                            to the SEPA, the Company have the right, but not the obligation, to sell to YA from time
                                            to time, each such occurrence, an Advance, up to $&lt;span id="xdx_906_eus-gaap--OtherCommitment_iI_pn5n6_c20240830__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember_zpF3iro49RRd" title="Commitment amount"&gt;10.0&lt;/span&gt; million (the &#x201c;Commitment Amount&#x201d;),
                                            of the Company ordinary shares, during the 36 months following the execution of the SEPA,
                                            subject to the restrictions and satisfaction of the conditions in the SEPA. On October 21,
                                            2024, the Company and YA entered into an amendment to the SEPA to increase the Amount of
                                            the commitment to $&lt;span id="xdx_90A_eus-gaap--OtherCommitment_iI_pn5n6_c20241021__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember__srt--RangeAxis__srt--MaximumMember_zgrykBHimNQ4" title="Commitment amount"&gt;20.0&lt;/span&gt; million of the Company&#x2019;s ordinary shares.&lt;/span&gt;&lt;/p&gt;
                                                         &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
    consideration for YA&#x2019;s irrevocable commitment to purchase the Company&#x2019;s ordinary shares up to the Commitment Amount, the
    Company agreed to issue &lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240830__20240830_zxVC6KB6S9Z8" title="Issuance of ordinary shares"&gt;31,566&lt;/span&gt;
    ordinary shares (the &#x201c;Commitment Shares&#x201d;) to YA and also paid a $&lt;span id="xdx_906_eus-gaap--DebtInstrumentFeeAmount_iI_pn3n3_c20240830_zvYDdhcYQmfk" title="Structuring fee"&gt;15,000&lt;/span&gt;
    structuring fee to an affiliate of YA. The Commitment Shares shall be issued in four equal installments every 90 calendar days. As
    of December 31, 2024, the Company issued a total of &lt;span id="xdx_909_ecustom--CommitmentShare_iI_pid_c20241231_zWCvhxvb1D4c" title="Commitment share"&gt;15,784&lt;/span&gt;
    Commitment Share. The Commitment Shares and structuring fee were recorded as expense in &#x201c;Finance expenses related to
    SEPA&#x201d;, in amounts of $&lt;span id="xdx_906_ecustom--ProceedsFinanceLeaseInterestExpenseIncome_pn3n3_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember_zV8tH734tCI4" title="Finance expenses"&gt;70&lt;/span&gt;
    thousand and $&lt;span id="xdx_907_ecustom--ProceedsFinanceLeaseInterestExpenseIncome_pn3n3_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember_zjKxAUajMR21" title="Finance expenses"&gt;15&lt;/span&gt;
    thousand, respectively.&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Company evaluated the contract that includes the right to require YA to purchase shares of common stock in the future (&#x201c;put
    right&#x201d;) considering the guidance in ASC 815-40, &#x201c;Derivatives and Hedging &#x2014; Contracts on an Entity&#x2019;s Own Equity&#x201d;
    and concluded that it is an equity-linked contract that does not qualify for equity classification, and therefore requires fair value
    accounting and thus meet the definition of a derivative liability. Accordingly, the put right will be measured at fair value at each
    reporting period, and changes in its fair value will be recognized in the consolidated statement of operations. The Put right is
    measured under level 2 of the Fair Value hierarchy. The Company analyzed the terms of the freestanding put right and concluded that
    it has an immaterial value as of December 31, 2024.&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
    of December 31, 2024, the Company has issued an aggregate of &lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--CaymanIslandsExemptLimitedPartnershipMember_zObevxSNdBxd" title="Issuance of shares"&gt;574,559&lt;/span&gt;
    ordinary shares to YA for aggregate gross proceeds of approximately $&lt;span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--CaymanIslandsExemptLimitedPartnershipMember_zXLAHct5ROG4" title="Gross proceeds stock"&gt;5.0&lt;/span&gt;
    million (&lt;span id="xdx_90E_eus-gaap--PaymentsOfDebtIssuanceCosts_pn5n6_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--CaymanIslandsExemptLimitedPartnershipMember_zmCl3Bc9fVf8" title="Issuance costs"&gt;4.4&lt;/span&gt;
    million net of issuance costs). The Company recorded expenses in the amount of $&lt;span id="xdx_904_eus-gaap--OtherExpenses_pn5n6_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--CaymanIslandsExemptLimitedPartnershipMember_zFXAoviBi0U" title="Other expenses"&gt;0.6&lt;/span&gt; million in &#x201c;finance
expenses related to SEPA&#x201d; (including the commitment shares and structuring fee, as detailed above)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
    November 14, 2024, the Company entered into a Capital on Demand Sales Agreement (the &#x201c;2024 Sales Agreement&#x201d;) with JonesTrading
    Institutional Serviecs LLC, (&#x201c;JonesTrading). Pursuent to the 2024 Sales Agreement, the Company may offer and sell ordinary
    shares having an aggregate offering price of up to $&lt;span id="xdx_909_ecustom--MaximumAmountOfSharesToBeIssued_iI_pn5n6_c20241114__us-gaap--TypeOfArrangementAxis__custom--DemandSalesAgreementMember_zSabuyPzzcj7" title="Aggregate offering price"&gt;8.1&lt;/span&gt;
    million, from time to time through JonesTrading. Subsequent to the balance sheet date, As of March 21 2025, the Company sold &lt;span id="xdx_903_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20250320__20250321__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentySalesAgreementMember_zoAyVA0fTTbj" title="Sale of stock"&gt;541,996&lt;/span&gt;
    ordinary shares pursuant to the 2024 Sales Agreement, for a total consideration of approximately $&lt;span id="xdx_90E_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn5n6_c20250320__20250321__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentySalesAgreementMember_zThrcRtSe0c6" title="Total consideration"&gt;1.5&lt;/span&gt;
    million&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;GALMED
PHARMACEUTICALS LTD.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to Consolidated Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;div style="margin: 0pt auto; width: 100%"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
11 &#x2013; Stockholders&#x2019; equity (Cont.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;B.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Stock-based
    compensation&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Company has an equity-based incentive plan, the 2013 Incentive Share Option Plan (the &#x201c;2013 Plan&#x201d;). As of December 31,
    2023, based on the latest amendment to the plan from August 7, 2023, a total of &lt;span id="xdx_90D_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20231231__us-gaap--PlanNameAxis__custom--IncentiveShareOptionPlan2013Member_z31sbmaJg3n7" title="Shares reserved for future issuance"&gt;500,000&lt;/span&gt; ordinary shares were reserved for issuance
    under the 2013 Plan, of which a total of &lt;span id="xdx_900_ecustom--CommonStockCapitalSharesReservedForFutureIssuanceUnallocated_iI_pid_c20231231__us-gaap--PlanNameAxis__custom--IncentiveShareOptionPlan2013Member_zSR43I9Tutrk" title="Shares reserved for future issuance"&gt;63,253&lt;/span&gt; ordinary shares remain reserved, but unallocated for future equity awards. The 2013
    Plan, which was adopted by the Board on September 2, 2013, and approved by the Company&#x2019;s shareholders on December 30, 2013
    (as was amended by the Board and the Company&#x2019;s shareholders on March 30, 2015, May 11, 2015, August 30, 2018, August 7, 2023
    and November 12, 2024 respectively), provides for the grant of options to purchase the ordinary shares and the issuance of RSUs to
    the Company&#x2019;s officers, directors, employees, service providers and consultants. The 2013 Plan provides for such equity-based
    compensation under various and different tax regimes.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
    February 2022, the Company granted options to purchase &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220201__20220228_z9iMdpyD6jv4" title="Options granted"&gt;222&lt;/span&gt; ordinary shares of the Company to one of its officers. The options are
    exercisable at $&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20220228_zGuXqR4gjd12" title="Options exercisable per share"&gt;288&lt;/span&gt; per share, have a &lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220201__20220228_zV0xDydsDAoe" title="Contractual term"&gt;10&lt;/span&gt;-year term and vest over a period of &lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dt_c20220201__20220228_zSyNs9DbPHLk" title="Vest period"&gt;four years&lt;/span&gt;.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
    March 23, 2023, the Company received a ruling from the Israel Tax Authority (&#x201c;ITA&#x201d;) confirming the repricing of certain
    stock options. This repricing was accounted for as a modification of a share-based payment award. The incremental compensation expense
    recognized as a result of the modification during the year ended December 31, 2023 was approximately $&lt;span id="xdx_908_eus-gaap--OtherExpenses_pn5n6_c20230101__20231231_zPVzMPSSUXq1" title="Compensation expense"&gt;0.1&lt;/span&gt; million.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
    August 2023, the Company granted &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230801__20230831__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zqYmJKhfUsS1" title="Options granted"&gt;109,583&lt;/span&gt; RSUs and &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230801__20230831_ztF5u6aejao1" title="Options granted"&gt;6,250&lt;/span&gt; options to purchase &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230801__20230831_zRP4q85JGoGc" title="Options granted"&gt;6,250&lt;/span&gt; ordinary shares of the Company to its officers
    and directors. The options are exercisable at $&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20230831_zFukQF5Jfxob" title="Options exercisable per share"&gt;1.05&lt;/span&gt; per share and have a 10-year term. The options and RSUs vest over a period of
    three years. The aggregate grant date fair value of such RSUs and options was approximately $&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_pn5n6_c20230801__20230831_zr6uZ6slH8af" title="Aggregate grant fair value"&gt;0.9&lt;/span&gt; million.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
    September 2023, the Company extended the exercise period of &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230901__20230930__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zxgTuRsRp0eh" title="Options granted"&gt;1,805&lt;/span&gt; options with an exercise price of &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_uILSPShares_c20230930__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zLMNLRGisRid" title="Options granted"&gt;0.15&lt;/span&gt; NIS previously granted to
    the Company&#x2019;s Chief Executive Officer (and director), by approximately five years to December 31, 2028. the exercise period
    represented a modification in accordance with ASC 718. The Incremental compensation expense on the modification date was less than
    $&lt;span id="xdx_903_eus-gaap--OtherExpenses_pn3n3_c20230901__20230930__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zDdQdiOt2FHa" title="Compensation expense"&gt;1&lt;/span&gt; thousand.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6.
    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
    November 12, 2024, the Company&#x2019;s board of directors approved the grant of &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20241112__20241112__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_znlp37Xlhtei" title="Options granted"&gt;302,500&lt;/span&gt; RSUs and &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20241112__20241112_zS6adLTyhUqj" title="Options granted"&gt;17,500&lt;/span&gt; options to purchase &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20241112__20241112_zLUFvm1v4Kzh" title="Options granted"&gt;17,500&lt;/span&gt;
    ordinary shares of the Company to its officers and directors. The options and &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_pid_c20241112__20241112__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember_zD33oZrvMhLl" title="Restricted stock unit options"&gt;197,500&lt;/span&gt; of the RSUs are subject to the approval
    of the Company&#x2019;s shareholders. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 65pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;GALMED
PHARMACEUTICALS LTD.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to Consolidated Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;div style="margin: 0pt auto; width: 100%"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
11 &#x2013; Stockholders&#x2019; equity (Cont.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;B.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Stock-based
    compensation (Cont.)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
    summary of the status of the Company&#x2019;s outstanding options as of December 31, 2024 and 2023 and changes during the years then
    ended are presented below:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zguewmEJvuXf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none"&gt;&lt;span id="xdx_8B4_zZ6l0CFM7hFc"&gt;Summary
of Status of Company's Option Plans and Changes&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 96%; border-collapse: collapse; margin-left: 0.25in"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2023
    (*)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number
    of&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;average&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number
    of&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;average&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;share&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;exercise&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;share&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;exercise&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;options&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;price&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;options&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;price&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 40%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Options
    outstanding at beginning of year&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zWLAnmky41Ye" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Number of share options, Beginning"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;20,277&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zPy4aA2aXj48" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted average exercise price, Beginning"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;460&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zCnRDwTCWP91" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Number of share options, Beginning"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;14,973&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_z2SpChuqlEQ7" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted average exercise price, Beginning"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;654&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Granted&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zu7PmuIAJeM6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of share options, Granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1060"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zClQp5lDQYJa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, Granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1062"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zkw6Zng0TR4i" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of share options, Granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6,250&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zxH0vhVFriKe" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, Granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;12.6&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Forfeited&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240101__20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zIdJ4i6OqQAb" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of share options, Forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1,041&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zdvWLtcaz6of" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, Forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;94&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20230101__20231231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zFEWnAg1SZzk" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of share options, Forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(11,351&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zMVt6qpJBCxb" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, Forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;441.6&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Outstanding
    at end of year&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zW2ejCxeWnMg" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of share options, Ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;19,236&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zWBsxNgW3OE7" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, Ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;321&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zjjWoaIFNMvc" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of share options, Ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;20,277&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_z4GB1kLPmpXb" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, Ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;460&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Options
    exercisable at year end&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20240101__20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zIm8Sf8sRbn2" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of share options exercisable, Ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;14,966&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zXZBLkzawzW" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, Options exercisable, Ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;413&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zwGHpJuCoFfi" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of share options exercisable, Ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;13,269&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zxUQD2xG0Rr5" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, Options exercisable, Ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;670.56&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AC_z2dNKr9MSFmj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following assumptions were used for the fiscal year 2023 grants:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;dividend
    yield of &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zHzPfW3WoVGg" title="Dividend yield"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zBpYfMwPjME2" title="Dividend yield"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zWKVpxKXNBW3" title="Dividend yield"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;% for all periods.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;risk-free
    interest rate between &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zt3cgo0Wcrc5" title="Risk-free interest rate, minimum"&gt;0.80&lt;/span&gt;% and &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zMcDuzUootQ1" title="Risk-free interest rate, maximum"&gt;1.34&lt;/span&gt;% for the fiscal year 2021, &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zBgWm4RUQehb" title="Risk-free interest rate, maximum"&gt;1.94&lt;/span&gt;% for the fiscal year 2022 and &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgnGUuUnDK67" title="Risk-free interest rate"&gt;4.16&lt;/span&gt;% for the fiscal year 2023.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;an
    expected life between &lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zAvlkqxYP6Qk" title="Expected life, term"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zGQYzpbpfF37" title="Expected life, term"&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zDpef0XgM2Ag" title="Expected life, term"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; and &lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zsp8CSencube" title="Expected life, term"&gt;&lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zprI5R4wrxd" title="Expected life, term"&gt;&lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zAa9rslQSijc" title="Expected life, term"&gt;6.25&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; years for all periods.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and
    a volatility rate ranging between &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgYQTc14SXkb" title="Volatility rate, minimum"&gt;64&lt;/span&gt;% and &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zcRexkOB0Tg8" title="Volatility rate, maximum"&gt;81&lt;/span&gt;% for the fiscal year 2021, &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z6MXtW14SqDj" title="Volatility rate"&gt;65&lt;/span&gt;% for the fiscal year 2022 and &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zbSiVoN1E86a" title="Volatility rate"&gt;108&lt;/span&gt;% for the fiscal year
    2023.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024, and 2023, the weighted-average remaining contractual term of the outstanding options, excluding the &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zaBOz755R9vh" title="Options, granted"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z9mUVh2GntT9" title="Options, granted"&gt;270&lt;/span&gt;&lt;/span&gt; options
granted in 2002 that have no expiration date, is &lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zyLnTWWW9lP9" title="Contractual term"&gt;3.82&lt;/span&gt; and &lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zOwH39SJhGbc" title="Contractual term"&gt;6.24&lt;/span&gt; years, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
weighted average grant date fair value of the options granted during the years ended December 31, 2023 and 2022 is $&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z11vaQxD2b14" title="Weighted average grant date fair value"&gt;0.63&lt;/span&gt;, and $&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zJp1Ym5fk6D6" title="Weighted average grant date fair value"&gt;0.68&lt;/span&gt; respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024, a total of &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231_zCqS9JBKENj9" title="Options, exercisable"&gt;1,805&lt;/span&gt; outstanding and exercisable options are &#x201c;in the money&#x201d; with aggregate intrinsic value
of $&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231_zWCgm6i9TNIa" title="Options, intrinsic value"&gt;5&lt;/span&gt; thousand; while as of December 31, 2023 a total of &lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20231231_z0xfbf8T2Veb" title="Options, exercisable"&gt;21,654&lt;/span&gt; outstanding and exercisable options were &#x201c;in the money&#x201d; with
aggregate intrinsic value of $&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20231231_zA1tCaWBSXK7" title="Options, intrinsic value"&gt;1&lt;/span&gt; thousand.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
unrecognized compensation expense calculated under the fair-value method for stock options expected to vest as of December 31, 2024,
2023 and 2022 is approximately $&lt;span id="xdx_90D_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn4n6_c20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zFD26POnPyJj" title="Unrecognized share based compensation"&gt;0.03&lt;/span&gt; million, $&lt;span id="xdx_901_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn5n6_c20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zXcWvYIyAxl1" title="Unrecognized share based compensation"&gt;0.3&lt;/span&gt; million, and $&lt;span id="xdx_900_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn5n6_c20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zlF8WAAWeDJe" title="Unrecognized share based compensation"&gt;0.9&lt;/span&gt; million, respectively, and is expected to be recognized over a weighted-average
period of &lt;span id="xdx_905_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z5UPKpAmrl8l" title="Unrecognized compensation, term"&gt;1.0&lt;/span&gt; years, &lt;span id="xdx_902_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zAXDUWAP1LH5" title="Unrecognized compensation, term"&gt;0.3&lt;/span&gt; years and &lt;span id="xdx_904_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z25Gmt71VKYk" title="Unrecognized compensation, term"&gt;1.41&lt;/span&gt; years, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the years ended 2024, 2023 and 2022, the Company recorded a total of $&lt;span id="xdx_904_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zErVATd19F99" title="Allocated stock based compensation"&gt;0.5&lt;/span&gt; million, $&lt;span id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zZeCj8Charwk" title="Allocated stock based compensation"&gt;0.8&lt;/span&gt; million, and $&lt;span id="xdx_906_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zdomHhxA0e71" title="Allocated stock based compensation"&gt;1.3&lt;/span&gt; million of stock-based compensation
expenses, in connection with the above-mentioned options.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;GALMED
PHARMACEUTICALS LTD.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to Consolidated Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;div style="margin: 0pt auto; width: 100%"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
11 &#x2013; Stockholders&#x2019; equity (Cont.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;B.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Stock-based
    compensation (Cont.)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 7, 2023, the Company issued a total of &lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230807__20230807__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zTbmiCwd4id1"&gt;109,583&lt;/span&gt; RSUs. Upon vesting, each RSU will settle for the issuance of one ordinary
share. The RSUs vest over &lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dt_c20230807__20230807__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zuZx4nS6qzA8"&gt;three years&lt;/span&gt;. On November 12, 2024, the Company&#x2019;s board of directors approved the grant of &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20241112__20241112__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zaFJOQy2HjXa" title="Share based compensation granted"&gt;302,500&lt;/span&gt; of
which &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther_pid_c20241112__20241112__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zGV9l8VREFHg" title="Share based compensation subject to company shareholders"&gt;197,500&lt;/span&gt; are subject to the approval of the Company&#x2019;s shareholders. As of December 31, 2024, &lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pid_c20241112__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zSykou31asH" title="Share based compensation vested"&gt;36,528&lt;/span&gt; of the RSUs were
vested. With respect to the above-mentioned RSUs, the Company recorded stock-based compensation expenses in the amount of $&lt;span id="xdx_90C_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn5n6_c20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zC3yIoqCf9Gb" title="Unrecognized compensation expense"&gt;0.3&lt;/span&gt;
million and $&lt;span id="xdx_902_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn5n6_c20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zUnzjyPnxm21" title="Unrecognized compensation expense"&gt;0.1&lt;/span&gt; million for the years ended December 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
weighted average grant date fair value of the RSUs granted during the year ended December 31, 2024 and 2023 was $&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJfBjosh3Wkb" title="Weighted average grant date fair value"&gt;3.02&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z4dpZgmi1oZ7" title="Weighted average grant date fair value"&gt;0.63&lt;/span&gt;,
respectively&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
unrecognized compensation expense calculated for RSUs expected to vest as of December 31, 2024 and 2023 is approximately $&lt;span id="xdx_909_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn5n6_c20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zdlVElp3wGO3" title="Unrecognized share based compensation"&gt;0.7&lt;/span&gt;
million and $&lt;span id="xdx_909_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn5n6_c20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z9zM8efXAc11" title="Unrecognized share based compensation"&gt;0.7&lt;/span&gt; million, respectively and is expected to be recognized over a weighted-average period of &lt;span id="xdx_905_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zRQfdQO5GAY6" title="Unrecognized compensation, term"&gt;2.11&lt;/span&gt; years and &lt;span id="xdx_907_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zTrA9d7Yk4s1" title="Unrecognized compensation, term"&gt;2.5&lt;/span&gt; years, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <GLMD:MaximumAmountOfSharesToBeIssued
      contextRef="AsOf2021-03-26_custom_NewSalesAgreementMember"
      decimals="-5"
      id="Fact000937"
      unitRef="USD">50000000.0</GLMD:MaximumAmountOfSharesToBeIssued>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-01-012022-12-31_custom_NewSalesAgreementMember"
      decimals="INF"
      id="Fact000939"
      unitRef="Shares">643</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-01-012022-12-31_custom_NewSalesAgreementMember"
      decimals="-5"
      id="Fact000941"
      unitRef="USD">100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="From2023-05-152023-05-15_us-gaap_CommonStockMember"
      id="Fact000943">1-for-15</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:CommonStockNoParValue
      contextRef="AsOf2023-05-15_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000945"
      unitRef="ILSPShares">0.01</us-gaap:CommonStockNoParValue>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2023-05-15_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000947"
      unitRef="ILSPShares">0.15</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="From2024-08-292024-08-29_us-gaap_CommonStockMember"
      id="Fact000949">1-for-12</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:CommonStockNoParValue
      contextRef="AsOf2024-08-29"
      decimals="INF"
      id="Fact000951"
      unitRef="ILSPShares">0.15</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockNoParValue
      contextRef="AsOf2024-08-29_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000953"
      unitRef="ILSPShares">1.80</us-gaap:CommonStockNoParValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-07-182023-07-18"
      decimals="INF"
      id="Fact000954"
      unitRef="Shares">31666</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2023-07-18_custom_PrefundedWarrantsMember"
      decimals="INF"
      id="Fact000956"
      unitRef="Shares">435000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="From2023-07-182023-07-18_custom_PrefundedWarrantsMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000958"
      unitRef="Shares">435000</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2023-07-18_custom_InvestorWarrantsMember"
      decimals="INF"
      id="Fact000960"
      unitRef="Shares">466666</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="From2023-07-182023-07-18_custom_InvestorWarrantsMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000962"
      unitRef="Shares">466666</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:SharePrice
      contextRef="AsOf2023-07-18_custom_InvestorWarrantsMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000964"
      unitRef="USDPShares">15.0</us-gaap:SharePrice>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-07-18_custom_InvestorWarrantsMember"
      decimals="INF"
      id="Fact000966"
      unitRef="USDPShares">14.99</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-07-182023-07-18_custom_InvestorWarrantsMember"
      decimals="-5"
      id="Fact000968"
      unitRef="USD">7000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="From2023-07-182023-07-18_custom_InvestorWarrantsMember"
      decimals="-5"
      id="Fact000970"
      unitRef="USD">6200000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:WarrantExercisePriceIncrease
      contextRef="From2024-01-012024-12-31_custom_PrefundedWarrantsMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000972"
      unitRef="USDPShares">0.001</us-gaap:WarrantExercisePriceIncrease>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-07-18_custom_PrefundedWarrantsMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000974"
      unitRef="USDPShares">15</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2023-07-18_custom_PrefundedWarrantsMember_us-gaap_CommonStockMember_us-gaap_InvestorMember"
      decimals="INF"
      id="Fact000976"
      unitRef="Shares">293333</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-07-18_custom_PrefundedWarrantsMember_us-gaap_CommonStockMember_us-gaap_InvestorMember"
      decimals="INF"
      id="Fact000978"
      unitRef="Shares">293333</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-07-182023-07-18"
      decimals="-5"
      id="Fact000980"
      unitRef="USD">4400000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000982"
      unitRef="Shares">173333</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:OtherCommitment
      contextRef="AsOf2024-08-30_custom_StandbyEquityPurchaseAgreementMember"
      decimals="-5"
      id="Fact000984"
      unitRef="USD">10000000.0</us-gaap:OtherCommitment>
    <us-gaap:OtherCommitment
      contextRef="AsOf2024-10-21_custom_StandbyEquityPurchaseAgreementMember_srt_MaximumMember"
      decimals="-5"
      id="Fact000986"
      unitRef="USD">20000000.0</us-gaap:OtherCommitment>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-08-302024-08-30"
      decimals="INF"
      id="Fact000988"
      unitRef="Shares">31566</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="AsOf2024-08-30"
      decimals="-3"
      id="Fact000990"
      unitRef="USD">15000000</us-gaap:DebtInstrumentFeeAmount>
    <GLMD:CommitmentShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000992"
      unitRef="Shares">15784</GLMD:CommitmentShare>
    <GLMD:ProceedsFinanceLeaseInterestExpenseIncome
      contextRef="From2024-01-012024-12-31_custom_StandbyEquityPurchaseAgreementMember"
      decimals="-3"
      id="Fact000994"
      unitRef="USD">70000</GLMD:ProceedsFinanceLeaseInterestExpenseIncome>
    <GLMD:ProceedsFinanceLeaseInterestExpenseIncome
      contextRef="From2023-01-012023-12-31_custom_StandbyEquityPurchaseAgreementMember"
      decimals="-3"
      id="Fact000996"
      unitRef="USD">15000</GLMD:ProceedsFinanceLeaseInterestExpenseIncome>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember_custom_CaymanIslandsExemptLimitedPartnershipMember"
      decimals="INF"
      id="Fact000998"
      unitRef="Shares">574559</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember_custom_CaymanIslandsExemptLimitedPartnershipMember"
      decimals="-5"
      id="Fact001000"
      unitRef="USD">5000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember_custom_CaymanIslandsExemptLimitedPartnershipMember"
      decimals="-5"
      id="Fact001002"
      unitRef="USD">4400000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:OtherExpenses
      contextRef="From2024-01-012024-12-31_custom_CaymanIslandsExemptLimitedPartnershipMember"
      decimals="-5"
      id="Fact001004"
      unitRef="USD">600000</us-gaap:OtherExpenses>
    <GLMD:MaximumAmountOfSharesToBeIssued
      contextRef="AsOf2024-11-14_custom_DemandSalesAgreementMember"
      decimals="-5"
      id="Fact001006"
      unitRef="USD">8100000</GLMD:MaximumAmountOfSharesToBeIssued>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-03-202025-03-21_custom_TwoThousandAndTwentySalesAgreementMember"
      decimals="INF"
      id="Fact001008"
      unitRef="Shares">541996</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2025-03-202025-03-21_custom_TwoThousandAndTwentySalesAgreementMember"
      decimals="-5"
      id="Fact001010"
      unitRef="USD">1500000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2023-12-31_custom_IncentiveShareOptionPlan2013Member"
      decimals="INF"
      id="Fact001012"
      unitRef="Shares">500000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <GLMD:CommonStockCapitalSharesReservedForFutureIssuanceUnallocated
      contextRef="AsOf2023-12-31_custom_IncentiveShareOptionPlan2013Member"
      decimals="INF"
      id="Fact001014"
      unitRef="Shares">63253</GLMD:CommonStockCapitalSharesReservedForFutureIssuanceUnallocated>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-02-012022-02-28"
      decimals="INF"
      id="Fact001016"
      unitRef="Shares">222</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-02-28"
      decimals="INF"
      id="Fact001018"
      unitRef="USDPShares">288</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2022-02-012022-02-28" id="Fact001020">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2022-02-012022-02-28" id="Fact001022">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:OtherExpenses
      contextRef="From2023-01-012023-12-31"
      decimals="-5"
      id="Fact001024"
      unitRef="USD">100000</us-gaap:OtherExpenses>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-08-012023-08-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001026"
      unitRef="Shares">109583</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-08-012023-08-31"
      decimals="INF"
      id="Fact001028"
      unitRef="Shares">6250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-08-012023-08-31"
      decimals="INF"
      id="Fact001030"
      unitRef="Shares">6250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-08-31"
      decimals="INF"
      id="Fact001032"
      unitRef="USDPShares">1.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="From2023-08-012023-08-31"
      decimals="-5"
      id="Fact001034"
      unitRef="USD">900000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-09-012023-09-30_srt_ChiefExecutiveOfficerMember"
      decimals="INF"
      id="Fact001036"
      unitRef="Shares">1805</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-09-30_srt_ChiefExecutiveOfficerMember"
      decimals="INF"
      id="Fact001038"
      unitRef="ILSPShares">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:OtherExpenses
      contextRef="From2023-09-012023-09-30_srt_ChiefExecutiveOfficerMember"
      decimals="-3"
      id="Fact001040"
      unitRef="USD">1000</us-gaap:OtherExpenses>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-11-122024-11-12_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001042"
      unitRef="Shares">302500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-11-122024-11-12"
      decimals="INF"
      id="Fact001044"
      unitRef="Shares">17500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-11-122024-11-12"
      decimals="INF"
      id="Fact001046"
      unitRef="Shares">17500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2024-11-122024-11-12_us-gaap_OptionMember"
      decimals="INF"
      id="Fact001048"
      unitRef="Shares">197500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001050">&lt;p id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zguewmEJvuXf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none"&gt;&lt;span id="xdx_8B4_zZ6l0CFM7hFc"&gt;Summary
of Status of Company's Option Plans and Changes&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 96%; border-collapse: collapse; margin-left: 0.25in"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2023
    (*)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number
    of&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;average&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number
    of&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;average&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;share&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;exercise&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;share&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;exercise&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;options&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;price&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;options&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;price&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 40%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Options
    outstanding at beginning of year&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zWLAnmky41Ye" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Number of share options, Beginning"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;20,277&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zPy4aA2aXj48" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted average exercise price, Beginning"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;460&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zCnRDwTCWP91" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Number of share options, Beginning"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;14,973&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_z2SpChuqlEQ7" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted average exercise price, Beginning"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;654&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Granted&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zu7PmuIAJeM6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of share options, Granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1060"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zClQp5lDQYJa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, Granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1062"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zkw6Zng0TR4i" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of share options, Granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6,250&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zxH0vhVFriKe" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, Granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;12.6&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Forfeited&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240101__20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zIdJ4i6OqQAb" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of share options, Forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1,041&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zdvWLtcaz6of" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, Forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;94&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20230101__20231231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zFEWnAg1SZzk" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of share options, Forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(11,351&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zMVt6qpJBCxb" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, Forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;441.6&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Outstanding
    at end of year&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zW2ejCxeWnMg" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of share options, Ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;19,236&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zWBsxNgW3OE7" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, Ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;321&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zjjWoaIFNMvc" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of share options, Ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;20,277&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_z4GB1kLPmpXb" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, Ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;460&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Options
    exercisable at year end&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20240101__20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zIm8Sf8sRbn2" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of share options exercisable, Ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;14,966&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zXZBLkzawzW" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, Options exercisable, Ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;413&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zwGHpJuCoFfi" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of share options exercisable, Ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;13,269&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zxUQD2xG0Rr5" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, Options exercisable, Ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;670.56&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember94762828"
      decimals="INF"
      id="Fact001052"
      unitRef="Shares">20277</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember94762828"
      decimals="INF"
      id="Fact001054"
      unitRef="USDPShares">460</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-12-31_us-gaap_EmployeeStockOptionMember94762828"
      decimals="INF"
      id="Fact001056"
      unitRef="Shares">14973</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_us-gaap_EmployeeStockOptionMember94762828"
      decimals="INF"
      id="Fact001058"
      unitRef="USDPShares">654</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember94762843"
      decimals="INF"
      id="Fact001064"
      unitRef="Shares">6250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember94762843"
      decimals="INF"
      id="Fact001066"
      unitRef="USDPShares">12.6</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember94762828"
      decimals="INF"
      id="Fact001068"
      unitRef="Shares">1041</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember94762828"
      decimals="INF"
      id="Fact001070"
      unitRef="USDPShares">94</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember94762843"
      decimals="INF"
      id="Fact001072"
      unitRef="Shares">11351</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember94762843"
      decimals="INF"
      id="Fact001074"
      unitRef="USDPShares">441.6</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember94762843"
      decimals="INF"
      id="Fact001076"
      unitRef="Shares">19236</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember94762843"
      decimals="INF"
      id="Fact001078"
      unitRef="USDPShares">321</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember94762828"
      decimals="INF"
      id="Fact001080"
      unitRef="Shares">20277</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember94762828"
      decimals="INF"
      id="Fact001082"
      unitRef="USDPShares">460</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember94762843"
      decimals="INF"
      id="Fact001084"
      unitRef="Shares">14966</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember94762843"
      decimals="INF"
      id="Fact001086"
      unitRef="USDPShares">413</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember94762828"
      decimals="INF"
      id="Fact001088"
      unitRef="Shares">13269</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember94762828"
      decimals="INF"
      id="Fact001090"
      unitRef="USDPShares">670.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001092"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001094"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001096"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001098"
      unitRef="Pure">0.0080</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001100"
      unitRef="Pure">0.0134</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001102"
      unitRef="Pure">0.0194</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001104"
      unitRef="Pure">0.0416</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2024-01-012024-12-31_srt_MinimumMember_us-gaap_EmployeeStockOptionMember"
      id="Fact001106">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2023-01-012023-12-31_srt_MinimumMember_us-gaap_EmployeeStockOptionMember"
      id="Fact001108">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2022-01-012022-12-31_srt_MinimumMember_us-gaap_EmployeeStockOptionMember"
      id="Fact001110">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2021-01-012021-12-31_srt_MaximumMember_us-gaap_EmployeeStockOptionMember"
      id="Fact001112">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2022-01-012022-12-31_srt_MaximumMember_us-gaap_EmployeeStockOptionMember"
      id="Fact001114">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2023-01-012023-12-31_srt_MaximumMember_us-gaap_EmployeeStockOptionMember"
      id="Fact001116">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001118"
      unitRef="Pure">0.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001120"
      unitRef="Pure">0.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001122"
      unitRef="Pure">0.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001124"
      unitRef="Pure">1.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001126"
      unitRef="Shares">270</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001128"
      unitRef="Shares">270</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember"
      id="Fact001130">P3Y9M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember"
      id="Fact001132">P6Y2M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001134"
      unitRef="USDPShares">0.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001136"
      unitRef="USDPShares">0.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001138"
      unitRef="Shares">1805</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001140"
      unitRef="USD">5000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001142"
      unitRef="Shares">21654</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001144"
      unitRef="USD">1000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="-4"
      id="Fact001146"
      unitRef="USD">30000.00</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="-5"
      id="Fact001148"
      unitRef="USD">300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2022-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="-5"
      id="Fact001150"
      unitRef="USD">900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember"
      id="Fact001152">P1Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember"
      id="Fact001154">P0Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember"
      id="Fact001156">P1Y4M28D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="-5"
      id="Fact001158"
      unitRef="USD">500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="-5"
      id="Fact001160"
      unitRef="USD">800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="-5"
      id="Fact001162"
      unitRef="USD">1300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-08-072023-08-07_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001163"
      unitRef="Shares">109583</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="From2023-08-072023-08-07_us-gaap_RestrictedStockUnitsRSUMember"
      id="Fact001164">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2024-11-122024-11-12_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001166"
      unitRef="Shares">302500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther
      contextRef="From2024-11-122024-11-12_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001168"
      unitRef="Shares">197500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="AsOf2024-11-12_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001170"
      unitRef="Shares">36528</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-5"
      id="Fact001172"
      unitRef="USD">300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-5"
      id="Fact001174"
      unitRef="USD">100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001176"
      unitRef="USDPShares">3.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001178"
      unitRef="USDPShares">0.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-5"
      id="Fact001180"
      unitRef="USD">700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-5"
      id="Fact001182"
      unitRef="USD">700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      id="Fact001184">P2Y1M9D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      id="Fact001186">P2Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001188">&lt;p id="xdx_809_eus-gaap--ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_zZk84PJrZwaa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
12 &#x2013; &lt;span id="xdx_825_zS06Ih1Y0sv7"&gt;Research and Development Expenses&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock_ziuRnOx0P0rf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none"&gt;&lt;span id="xdx_8B8_zv2MOaxIgHVk"&gt;Schedule of Research and Development Expenses&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;Chemistry and formulation studies&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__custom--ChemistryAndFormulationStudiesMember_zDsfi0ig8y67" style="width: 14%; text-align: right" title="Research and development expense"&gt;696&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--ChemistryAndFormulationStudiesMember_zyE8JQIQubG9" style="width: 14%; text-align: right" title="Research and development expense"&gt;573&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__custom--ChemistryAndFormulationStudiesMember_zOlTd1YZTYmc" style="width: 14%; text-align: right" title="Research and development expense"&gt;2,448&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Salaries&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__custom--SalariesMember_zpI82J099YY5" style="text-align: right" title="Research and development expense"&gt;982&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--SalariesMember_zeDn0J9ezjF6" style="text-align: right" title="Research and development expense"&gt;676&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__custom--SalariesMember_ztdz1oqsyw1l" style="text-align: right" title="Research and development expense"&gt;1,692&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Stock-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__custom--StockBasedCompensationMember_z8wj4qyB3dd6" style="text-align: right" title="Research and development expense"&gt;112&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--StockBasedCompensationMember_z8goXa8TdSV7" style="text-align: right" title="Research and development expense"&gt;243&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__custom--StockBasedCompensationMember_zl26bsC9nsoj" style="text-align: right" title="Research and development expense"&gt;383&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Research and preclinical studies&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__custom--ResearchAndPreclinicalStudiesMember_zm8txvyA7r6h" style="text-align: right" title="Research and development expense"&gt;255&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--ResearchAndPreclinicalStudiesMember_z4n5cQkWnNFe" style="text-align: right" title="Research and development expense"&gt;460&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__custom--ResearchAndPreclinicalStudiesMember_zkCJ2CZk1hNl" style="text-align: right" title="Research and development expense"&gt;1,346&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Clinical studies&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__custom--ClinicalStudiesMember_z28YOLCpUlZ6" style="text-align: right" title="Research and development expense"&gt;291&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--ClinicalStudiesMember_zX0SYvubDGq9" style="text-align: right" title="Research and development expense"&gt;616&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__custom--ClinicalStudiesMember_zDn6uGm2gOYg" style="text-align: right" title="Research and development expense"&gt;6,532&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Regulatory and other expenses&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__custom--RegulatoryAndOtherExpensesMember_zsuWlwnT3cOf" style="border-bottom: Black 1pt solid; text-align: right" title="Research and development expense"&gt;643&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--RegulatoryAndOtherExpensesMember_zRXUnXXn2lg9" style="border-bottom: Black 1pt solid; text-align: right" title="Research and development expense"&gt;1,001&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__custom--RegulatoryAndOtherExpensesMember_zrwxLZ03siza" style="border-bottom: Black 1pt solid; text-align: right" title="Research and development expense"&gt;594&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20240101__20241231_zha7UvacKc6e" style="border-bottom: Black 2.5pt double; text-align: right" title="Research and development expense"&gt;2,979&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20230101__20231231_zdKICeaB44Gf" style="border-bottom: Black 2.5pt double; text-align: right" title="Research and development expense"&gt;3,569&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20220101__20221231_zIs0giyR4hz5" style="border-bottom: Black 2.5pt double; text-align: right" title="Research and development expense"&gt;12,995&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zxp9NFzOR6xk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001190">&lt;p id="xdx_890_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock_ziuRnOx0P0rf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none"&gt;&lt;span id="xdx_8B8_zv2MOaxIgHVk"&gt;Schedule of Research and Development Expenses&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;Chemistry and formulation studies&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__custom--ChemistryAndFormulationStudiesMember_zDsfi0ig8y67" style="width: 14%; text-align: right" title="Research and development expense"&gt;696&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--ChemistryAndFormulationStudiesMember_zyE8JQIQubG9" style="width: 14%; text-align: right" title="Research and development expense"&gt;573&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__custom--ChemistryAndFormulationStudiesMember_zOlTd1YZTYmc" style="width: 14%; text-align: right" title="Research and development expense"&gt;2,448&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Salaries&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__custom--SalariesMember_zpI82J099YY5" style="text-align: right" title="Research and development expense"&gt;982&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--SalariesMember_zeDn0J9ezjF6" style="text-align: right" title="Research and development expense"&gt;676&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__custom--SalariesMember_ztdz1oqsyw1l" style="text-align: right" title="Research and development expense"&gt;1,692&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Stock-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__custom--StockBasedCompensationMember_z8wj4qyB3dd6" style="text-align: right" title="Research and development expense"&gt;112&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--StockBasedCompensationMember_z8goXa8TdSV7" style="text-align: right" title="Research and development expense"&gt;243&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__custom--StockBasedCompensationMember_zl26bsC9nsoj" style="text-align: right" title="Research and development expense"&gt;383&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Research and preclinical studies&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__custom--ResearchAndPreclinicalStudiesMember_zm8txvyA7r6h" style="text-align: right" title="Research and development expense"&gt;255&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--ResearchAndPreclinicalStudiesMember_z4n5cQkWnNFe" style="text-align: right" title="Research and development expense"&gt;460&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__custom--ResearchAndPreclinicalStudiesMember_zkCJ2CZk1hNl" style="text-align: right" title="Research and development expense"&gt;1,346&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Clinical studies&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__custom--ClinicalStudiesMember_z28YOLCpUlZ6" style="text-align: right" title="Research and development expense"&gt;291&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--ClinicalStudiesMember_zX0SYvubDGq9" style="text-align: right" title="Research and development expense"&gt;616&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__custom--ClinicalStudiesMember_zDn6uGm2gOYg" style="text-align: right" title="Research and development expense"&gt;6,532&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Regulatory and other expenses&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__custom--RegulatoryAndOtherExpensesMember_zsuWlwnT3cOf" style="border-bottom: Black 1pt solid; text-align: right" title="Research and development expense"&gt;643&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--RegulatoryAndOtherExpensesMember_zRXUnXXn2lg9" style="border-bottom: Black 1pt solid; text-align: right" title="Research and development expense"&gt;1,001&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__custom--RegulatoryAndOtherExpensesMember_zrwxLZ03siza" style="border-bottom: Black 1pt solid; text-align: right" title="Research and development expense"&gt;594&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20240101__20241231_zha7UvacKc6e" style="border-bottom: Black 2.5pt double; text-align: right" title="Research and development expense"&gt;2,979&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20230101__20231231_zdKICeaB44Gf" style="border-bottom: Black 2.5pt double; text-align: right" title="Research and development expense"&gt;3,569&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20220101__20221231_zIs0giyR4hz5" style="border-bottom: Black 2.5pt double; text-align: right" title="Research and development expense"&gt;12,995&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-12-31_custom_ChemistryAndFormulationStudiesMember"
      decimals="-3"
      id="Fact001192"
      unitRef="USD">696000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31_custom_ChemistryAndFormulationStudiesMember"
      decimals="-3"
      id="Fact001194"
      unitRef="USD">573000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31_custom_ChemistryAndFormulationStudiesMember"
      decimals="-3"
      id="Fact001196"
      unitRef="USD">2448000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-12-31_custom_SalariesMember"
      decimals="-3"
      id="Fact001198"
      unitRef="USD">982000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31_custom_SalariesMember"
      decimals="-3"
      id="Fact001200"
      unitRef="USD">676000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31_custom_SalariesMember"
      decimals="-3"
      id="Fact001202"
      unitRef="USD">1692000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-12-31_custom_StockBasedCompensationMember"
      decimals="-3"
      id="Fact001204"
      unitRef="USD">112000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31_custom_StockBasedCompensationMember"
      decimals="-3"
      id="Fact001206"
      unitRef="USD">243000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31_custom_StockBasedCompensationMember"
      decimals="-3"
      id="Fact001208"
      unitRef="USD">383000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-12-31_custom_ResearchAndPreclinicalStudiesMember"
      decimals="-3"
      id="Fact001210"
      unitRef="USD">255000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31_custom_ResearchAndPreclinicalStudiesMember"
      decimals="-3"
      id="Fact001212"
      unitRef="USD">460000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31_custom_ResearchAndPreclinicalStudiesMember"
      decimals="-3"
      id="Fact001214"
      unitRef="USD">1346000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-12-31_custom_ClinicalStudiesMember"
      decimals="-3"
      id="Fact001216"
      unitRef="USD">291000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31_custom_ClinicalStudiesMember"
      decimals="-3"
      id="Fact001218"
      unitRef="USD">616000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31_custom_ClinicalStudiesMember"
      decimals="-3"
      id="Fact001220"
      unitRef="USD">6532000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-12-31_custom_RegulatoryAndOtherExpensesMember"
      decimals="-3"
      id="Fact001222"
      unitRef="USD">643000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31_custom_RegulatoryAndOtherExpensesMember"
      decimals="-3"
      id="Fact001224"
      unitRef="USD">1001000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31_custom_RegulatoryAndOtherExpensesMember"
      decimals="-3"
      id="Fact001226"
      unitRef="USD">594000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001228"
      unitRef="USD">2979000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001230"
      unitRef="USD">3569000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact001232"
      unitRef="USD">12995000</us-gaap:ResearchAndDevelopmentExpense>
    <GLMD:GeneralAndAdministrativeExpensesDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001234">&lt;p id="xdx_801_ecustom--GeneralAndAdministrativeExpensesDisclosureTextBlock_zinLv9zPo5l2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
13 &#x2013; &lt;span id="xdx_82E_z9pCqip28Azk"&gt;General and Administrative Expenses&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_ecustom--GeneralAndAdministrativeExpensesTableTextBlock_zc3DZSOklY" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none"&gt;&lt;span id="xdx_8B8_z6s0KlLNaH92"&gt;Schedule of General and Administrative Expenses&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;Stock-based compensation&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__custom--StockBasedCompensationMember_z1dA2h3OIgi4" style="width: 14%; text-align: right" title="General and administrative expenses"&gt;419&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--StockBasedCompensationMember_z6Pr0SVLyUP2" style="width: 14%; text-align: right" title="General and administrative expenses"&gt;649&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__custom--StockBasedCompensationMember_zA3NEe6Nuc8c" style="width: 14%; text-align: right" title="General and administrative expenses"&gt;913&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Professional fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__custom--ProfessionalFeeMember_zEQ1jAH6MHrh" style="text-align: right" title="General and administrative expenses"&gt;896&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--ProfessionalFeeMember_zUUUZQfcKdk4" style="text-align: right" title="General and administrative expenses"&gt;908&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__custom--ProfessionalFeeMember_z2WpLiFfOKPa" style="text-align: right" title="General and administrative expenses"&gt;1,084&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Salaries and benefits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__custom--SalariesAndBenefitsMember_zoS20LYjqApa" style="text-align: right" title="General and administrative expenses"&gt;1,478&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--SalariesAndBenefitsMember_zkv5dJOEydng" style="text-align: right" title="General and administrative expenses"&gt;1,428&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__custom--SalariesAndBenefitsMember_zL5geAw4doO3" style="text-align: right" title="General and administrative expenses"&gt;1,164&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Rent and office-maintenance fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__custom--RentAndOfficeMaintenanceFeesMember_zNl2NqVBOnQ7" style="text-align: right" title="General and administrative expenses"&gt;117&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--RentAndOfficeMaintenanceFeesMember_z6kOQICm3hGg" style="text-align: right" title="General and administrative expenses"&gt;261&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__custom--RentAndOfficeMaintenanceFeesMember_z7jXRxaxz2L8" style="text-align: right" title="General and administrative expenses"&gt;401&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Insurance and other expenses&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__custom--InsuranceAndOtherExpensesMember_zVjfrOB9y13a" style="border-bottom: Black 1pt solid; text-align: right" title="General and administrative expenses"&gt;389&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--InsuranceAndOtherExpensesMember_zgfeDWFmEPG" style="border-bottom: Black 1pt solid; text-align: right" title="General and administrative expenses"&gt;677&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__custom--InsuranceAndOtherExpensesMember_zIGcJJGXstW1" style="border-bottom: Black 1pt solid; text-align: right" title="General and administrative expenses"&gt;1,094&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20240101__20241231_z0U5gSchMxMf" style="border-bottom: Black 2.5pt double; text-align: right" title="General and administrative expenses"&gt;3,299&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20230101__20231231_z9uSjw6MrGWb" style="border-bottom: Black 2.5pt double; text-align: right" title="General and administrative expenses"&gt;3,923&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20220101__20221231_zzhwtv32kYGl" style="border-bottom: Black 2.5pt double; text-align: right" title="General and administrative expenses"&gt;4,656&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zqt2b8ey4TF2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;GALMED
PHARMACEUTICALS LTD.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to Consolidated Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;div style="margin: 0pt auto; width: 100%"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</GLMD:GeneralAndAdministrativeExpensesDisclosureTextBlock>
    <GLMD:GeneralAndAdministrativeExpensesTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001236">&lt;p id="xdx_896_ecustom--GeneralAndAdministrativeExpensesTableTextBlock_zc3DZSOklY" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none"&gt;&lt;span id="xdx_8B8_z6s0KlLNaH92"&gt;Schedule of General and Administrative Expenses&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;Stock-based compensation&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__custom--StockBasedCompensationMember_z1dA2h3OIgi4" style="width: 14%; text-align: right" title="General and administrative expenses"&gt;419&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--StockBasedCompensationMember_z6Pr0SVLyUP2" style="width: 14%; text-align: right" title="General and administrative expenses"&gt;649&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__custom--StockBasedCompensationMember_zA3NEe6Nuc8c" style="width: 14%; text-align: right" title="General and administrative expenses"&gt;913&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Professional fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__custom--ProfessionalFeeMember_zEQ1jAH6MHrh" style="text-align: right" title="General and administrative expenses"&gt;896&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--ProfessionalFeeMember_zUUUZQfcKdk4" style="text-align: right" title="General and administrative expenses"&gt;908&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__custom--ProfessionalFeeMember_z2WpLiFfOKPa" style="text-align: right" title="General and administrative expenses"&gt;1,084&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Salaries and benefits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__custom--SalariesAndBenefitsMember_zoS20LYjqApa" style="text-align: right" title="General and administrative expenses"&gt;1,478&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--SalariesAndBenefitsMember_zkv5dJOEydng" style="text-align: right" title="General and administrative expenses"&gt;1,428&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__custom--SalariesAndBenefitsMember_zL5geAw4doO3" style="text-align: right" title="General and administrative expenses"&gt;1,164&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Rent and office-maintenance fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__custom--RentAndOfficeMaintenanceFeesMember_zNl2NqVBOnQ7" style="text-align: right" title="General and administrative expenses"&gt;117&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--RentAndOfficeMaintenanceFeesMember_z6kOQICm3hGg" style="text-align: right" title="General and administrative expenses"&gt;261&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__custom--RentAndOfficeMaintenanceFeesMember_z7jXRxaxz2L8" style="text-align: right" title="General and administrative expenses"&gt;401&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Insurance and other expenses&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__custom--InsuranceAndOtherExpensesMember_zVjfrOB9y13a" style="border-bottom: Black 1pt solid; text-align: right" title="General and administrative expenses"&gt;389&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--InsuranceAndOtherExpensesMember_zgfeDWFmEPG" style="border-bottom: Black 1pt solid; text-align: right" title="General and administrative expenses"&gt;677&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__custom--InsuranceAndOtherExpensesMember_zIGcJJGXstW1" style="border-bottom: Black 1pt solid; text-align: right" title="General and administrative expenses"&gt;1,094&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20240101__20241231_z0U5gSchMxMf" style="border-bottom: Black 2.5pt double; text-align: right" title="General and administrative expenses"&gt;3,299&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20230101__20231231_z9uSjw6MrGWb" style="border-bottom: Black 2.5pt double; text-align: right" title="General and administrative expenses"&gt;3,923&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_c20220101__20221231_zzhwtv32kYGl" style="border-bottom: Black 2.5pt double; text-align: right" title="General and administrative expenses"&gt;4,656&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</GLMD:GeneralAndAdministrativeExpensesTableTextBlock>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-012024-12-31_custom_StockBasedCompensationMember"
      decimals="-3"
      id="Fact001238"
      unitRef="USD">419000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-12-31_custom_StockBasedCompensationMember"
      decimals="-3"
      id="Fact001240"
      unitRef="USD">649000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-01-012022-12-31_custom_StockBasedCompensationMember"
      decimals="-3"
      id="Fact001242"
      unitRef="USD">913000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-012024-12-31_custom_ProfessionalFeeMember"
      decimals="-3"
      id="Fact001244"
      unitRef="USD">896000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-12-31_custom_ProfessionalFeeMember"
      decimals="-3"
      id="Fact001246"
      unitRef="USD">908000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-01-012022-12-31_custom_ProfessionalFeeMember"
      decimals="-3"
      id="Fact001248"
      unitRef="USD">1084000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-012024-12-31_custom_SalariesAndBenefitsMember"
      decimals="-3"
      id="Fact001250"
      unitRef="USD">1478000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-12-31_custom_SalariesAndBenefitsMember"
      decimals="-3"
      id="Fact001252"
      unitRef="USD">1428000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-01-012022-12-31_custom_SalariesAndBenefitsMember"
      decimals="-3"
      id="Fact001254"
      unitRef="USD">1164000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-012024-12-31_custom_RentAndOfficeMaintenanceFeesMember"
      decimals="-3"
      id="Fact001256"
      unitRef="USD">117000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-12-31_custom_RentAndOfficeMaintenanceFeesMember"
      decimals="-3"
      id="Fact001258"
      unitRef="USD">261000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-01-012022-12-31_custom_RentAndOfficeMaintenanceFeesMember"
      decimals="-3"
      id="Fact001260"
      unitRef="USD">401000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-012024-12-31_custom_InsuranceAndOtherExpensesMember"
      decimals="-3"
      id="Fact001262"
      unitRef="USD">389000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-12-31_custom_InsuranceAndOtherExpensesMember"
      decimals="-3"
      id="Fact001264"
      unitRef="USD">677000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-01-012022-12-31_custom_InsuranceAndOtherExpensesMember"
      decimals="-3"
      id="Fact001266"
      unitRef="USD">1094000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001268"
      unitRef="USD">3299000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001270"
      unitRef="USD">3923000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact001272"
      unitRef="USD">4656000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001274">&lt;p id="xdx_805_eus-gaap--RevenueFromContractWithCustomerTextBlock_zvXR9B4dAAMi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
14 &#x2013; &lt;span id="xdx_82B_zBBfoUfcBbai"&gt;Financial income, net&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--ScheduleOfOtherNonoperatingIncomeByComponentTextBlock_zFdcfS2Q25A4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none"&gt;&lt;span id="xdx_8BE_ziOFMcPvD306"&gt;Schedule of Financial Income, Net&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20240101__20241231_zzb1ucyZ33Ie" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20230101__20231231_zDfH2kZowrVd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20220101__20221231_zcqyslIm7Gfh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--BankFees_iN_pn3n3_di_msONIEz4mj_zKZr1V4vqB77" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;Bank fees&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;15&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;11&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;22&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--InterestIncome_pn3n3_maONIEz4mj_zwhCBrfac05h" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Interest income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(503&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(375&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(297&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DebtSecuritiesAvailableForSaleGainLoss_pn3n3_maONIEz4mj_zKDn9fGmekm4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Loss from sale of marketable debt securities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;526&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--ChangeInFairValueOfConvertibleNote_pn3n3_maONIEz4mj_z5zWTc7hC6qb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Change in fair value of convertible note&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1290"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(265&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1292"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--ForeignCurrencyTransactionGainLossBeforeTax_pn3n3_maONIEz4mj_zY7KEqP1G7p9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Foreign currency (gains) losses&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(40&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;36&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(36&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--OtherNonoperatingIncomeExpense_iNT_pn3n3_di_mtONIEz4mj_zy0VsQvvfJy4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
    income net&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(516&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(580&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;215&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zqoB0Hagb4Oa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeByComponentTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001276">&lt;p id="xdx_89A_eus-gaap--ScheduleOfOtherNonoperatingIncomeByComponentTextBlock_zFdcfS2Q25A4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none"&gt;&lt;span id="xdx_8BE_ziOFMcPvD306"&gt;Schedule of Financial Income, Net&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20240101__20241231_zzb1ucyZ33Ie" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20230101__20231231_zDfH2kZowrVd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20220101__20221231_zcqyslIm7Gfh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--BankFees_iN_pn3n3_di_msONIEz4mj_zKZr1V4vqB77" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;Bank fees&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;15&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;11&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;22&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--InterestIncome_pn3n3_maONIEz4mj_zwhCBrfac05h" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Interest income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(503&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(375&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(297&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DebtSecuritiesAvailableForSaleGainLoss_pn3n3_maONIEz4mj_zKDn9fGmekm4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Loss from sale of marketable debt securities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;526&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--ChangeInFairValueOfConvertibleNote_pn3n3_maONIEz4mj_z5zWTc7hC6qb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Change in fair value of convertible note&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1290"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(265&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1292"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--ForeignCurrencyTransactionGainLossBeforeTax_pn3n3_maONIEz4mj_zY7KEqP1G7p9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Foreign currency (gains) losses&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(40&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;36&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(36&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--OtherNonoperatingIncomeExpense_iNT_pn3n3_di_mtONIEz4mj_zy0VsQvvfJy4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
    income net&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(516&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(580&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;215&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfOtherNonoperatingIncomeByComponentTextBlock>
    <GLMD:BankFees
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001278"
      unitRef="USD">-15000</GLMD:BankFees>
    <GLMD:BankFees
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001279"
      unitRef="USD">-11000</GLMD:BankFees>
    <GLMD:BankFees
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact001280"
      unitRef="USD">-22000</GLMD:BankFees>
    <GLMD:InterestIncome
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001282"
      unitRef="USD">-503000</GLMD:InterestIncome>
    <GLMD:InterestIncome
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001283"
      unitRef="USD">-375000</GLMD:InterestIncome>
    <GLMD:InterestIncome
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact001284"
      unitRef="USD">-297000</GLMD:InterestIncome>
    <us-gaap:DebtSecuritiesAvailableForSaleGainLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001286"
      unitRef="USD">12000</us-gaap:DebtSecuritiesAvailableForSaleGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleGainLoss
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001287"
      unitRef="USD">13000</us-gaap:DebtSecuritiesAvailableForSaleGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleGainLoss
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact001288"
      unitRef="USD">526000</us-gaap:DebtSecuritiesAvailableForSaleGainLoss>
    <GLMD:ChangeInFairValueOfConvertibleNote
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001291"
      unitRef="USD">-265000</GLMD:ChangeInFairValueOfConvertibleNote>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001294"
      unitRef="USD">-40000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001295"
      unitRef="USD">36000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact001296"
      unitRef="USD">-36000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001298"
      unitRef="USD">516000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001299"
      unitRef="USD">580000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact001300"
      unitRef="USD">-215000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001302">&lt;p id="xdx_80E_eus-gaap--IncomeTaxDisclosureTextBlock_ziq34bF35CA5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
15 &#x2013; &lt;span id="xdx_82A_zd8W2oqR6btg"&gt;Income Taxes&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;A.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;General&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is assessed for tax purposes on an unconsolidated basis. Each of the Company&#x2019;s subsidiaries is subject to the tax rules
prevailing in its country of incorporation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;B.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Corporate
    Taxation&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Israeli
Companies:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Israeli corporate income tax rate is &lt;span id="xdx_900_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_c20210101__20211231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--IsraelTaxAuthorityMember_zacWVWJ0Kuvh" title="Effective income tax rate reconciliation, at federal statutory income tax rate, percent"&gt;&lt;span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_c20230101__20231231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--IsraelTaxAuthorityMember_zpR4dLOqKd95" title="Effective income tax rate reconciliation, at federal statutory income tax rate, percent"&gt;&lt;span id="xdx_905_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_c20240101__20241231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--IsraelTaxAuthorityMember_zXR7aP9oeTj8" title="Effective income tax rate reconciliation, at federal statutory income tax rate, percent"&gt;23&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;% for the years 2022, 2023 and 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 7, 2018, the Israeli Tax Authority issued a ruling granting the Company&#x2019;s Israeli subsidiary, Galmed Research and Development
Ltd, a &#x201c;Preferred Technological Enterprise&#x201d; status as defined under the Encouragement of Capital Investment Law -1959 (the
&#x201c;Approval&#x201d;). The grant of the status means that the Company&#x2019;s Israeli subsidiary will be subject to a reduced Israeli
corporate tax rate that will range between 6%-12% on any future taxable &#x201c;technological income&#x201d; which includes sales, licenses
and royalties from its IP protected products. The tax ruling applies for five years until the end of 2022 and may be extended for further
periods subject to meeting certain requirements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Maltese
subsidiary:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Taxable
income of Maltese companies was subject to tax at the rate of &lt;span id="xdx_909_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_c20220101__20221231__us-gaap--IncomeTaxAuthorityNameAxis__custom--MalteseSubsidiaryMember_zB4ZoEgTIg2l" title="Effective income tax rate reconciliation, at federal statutory income tax rate, percent"&gt;&lt;span id="xdx_909_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_c20230101__20231231__us-gaap--IncomeTaxAuthorityNameAxis__custom--MalteseSubsidiaryMember_z85g1bxroSua" title="Effective income tax rate reconciliation, at federal statutory income tax rate, percent"&gt;&lt;span id="xdx_901_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_c20240101__20241231__us-gaap--IncomeTaxAuthorityNameAxis__custom--MalteseSubsidiaryMember_z1GdRFr0UtX9" title="Effective income tax rate reconciliation, at federal statutory income tax rate, percent"&gt;35&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;% for the years 2022, 2023, and 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;C.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Net
    Operating Loss Carry forward&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024, the Company had approximately $&lt;span id="xdx_905_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20241231_zmFPUDl5IPGj" title="Operating loss carry forwards"&gt;175.4&lt;/span&gt; million net-operating-loss carry forwards, consisting of approximately $&lt;span id="xdx_905_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MalteseSubsidiaryMember_zZJsUzBwRXfj" title="Operating loss carry forwards"&gt;11.7&lt;/span&gt;
million of Maltese net-operating-loss carry forwards and approximately $&lt;span id="xdx_90E_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--IsraeliSubsidiaryMember_zk55bgRB31m4" title="Operating loss carry forwards"&gt;163.7&lt;/span&gt; million Israeli net-operating-loss carry forward. Additionally,
the Company had approximately $&lt;span id="xdx_908_eus-gaap--DeferredTaxAssetsCapitalLossCarryforwards_iI_pn5n6_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--IsraeliSubsidiaryMember_zg2XFBzTJUk3" title="Deferred tax assets, capital loss carry forwards"&gt;3.1&lt;/span&gt; million of capital loss carry forward from the sale of marketable debt securities in Israel. The Maltese
and the Israeli loss carry forwards have no expiration date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;GALMED
PHARMACEUTICALS LTD.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to Consolidated Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;div style="margin: 0pt auto; width: 100%"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
15 &#x2013; Income Taxes (Cont.)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;D.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Deferred
    income taxes&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024, the significant components of the Company&#x2019;s deferred tax assets are net operating loss carryforward in the
amount of $&lt;span id="xdx_90B_eus-gaap--DeferredTaxAssetsCapitalLossCarryforwards_iI_pn5n6_c20241231_zUwB0TMHz5Ui" title="Deferred tax assets, capital loss carry forwards"&gt;175.4&lt;/span&gt; million. and research and development expenses in the amount of $&lt;span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_pn5n6_c20240101__20241231__us-gaap--RegulatoryAssetAxis__us-gaap--DeferredIncomeTaxChargesMember_zxXlc8rOZYpa" title="Research and development expenses"&gt;3.3&lt;/span&gt; million. The Company has evaluated the positive
and negative evidence bearing upon its ability to realize the deferred tax assets. Management has considered the Company&#x2019;s history
of cumulative net losses incurred since inception and its lack of commercialization of any products or generation of any revenue from
product sales since inception and has concluded that it is more likely than not that the Company will not realize the benefits of the
deferred tax assets. Accordingly, a full valuation allowance has been established against the deferred tax assets as of December 31,
2024. Management reevaluates the positive and negative evidence at each reporting period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;E.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Tax
    assessment&lt;/b&gt;s&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Israeli subsidiaries received final tax assessments through the year ended December 31, 2019.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;F.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Effective
    tax expense&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_z8W8nOrww3Vd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
reconciliation of the Company&#x2019;s effective tax expense to the Company&#x2019;s theoretical statutory tax benefit is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BC_zpOBbrXmcaTk" style="display: none"&gt;Schedule of Effective Income Tax Rate Reconciliation&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20240101__20241231_zI43QpEYMOXb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20230101__20231231_ziaulpg56Iz9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20220101__20221231_zj3jy4F0oDhi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn3n3_ztAHqONZnqb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: left; padding-bottom: 2.5pt"&gt;Loss before taxes on income, as reported in the consolidated statements of operations&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"&gt;7,517&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"&gt;6,912&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"&gt;17,866&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_zbKWAnV5rC57" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Statutory tax rate&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;23&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;23&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;12&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_maITEBzSAa_zQqEaK4ogOW2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Theoretical tax benefit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,729&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,590&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,144&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_maITEBzSAa_zd1KL1KEkRdk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Losses and other items for which a valuation allowance was provided or benefit from loss carry forwards&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,729&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,590&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(2,144&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3n3_mtITEBzSAa_ztV1u2QHBqcg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Actual tax expense&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1346"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1347"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1348"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zwk492MKDilb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2021-01-012021-12-31_us-gaap_IsraelTaxAuthorityMember"
      decimals="INF"
      id="Fact001304"
      unitRef="Pure">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2023-01-012023-12-31_us-gaap_IsraelTaxAuthorityMember"
      decimals="INF"
      id="Fact001306"
      unitRef="Pure">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2024-01-012024-12-31_us-gaap_IsraelTaxAuthorityMember"
      decimals="INF"
      id="Fact001308"
      unitRef="Pure">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2022-01-012022-12-31_custom_MalteseSubsidiaryMember"
      decimals="INF"
      id="Fact001310"
      unitRef="Pure">0.35</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2023-01-012023-12-31_custom_MalteseSubsidiaryMember"
      decimals="INF"
      id="Fact001312"
      unitRef="Pure">0.35</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2024-01-012024-12-31_custom_MalteseSubsidiaryMember"
      decimals="INF"
      id="Fact001314"
      unitRef="Pure">0.35</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact001316"
      unitRef="USD">175400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2024-12-31_custom_MalteseSubsidiaryMember"
      decimals="-5"
      id="Fact001318"
      unitRef="USD">11700000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2024-12-31_custom_IsraeliSubsidiaryMember"
      decimals="-5"
      id="Fact001320"
      unitRef="USD">163700000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards
      contextRef="AsOf2024-12-31_custom_IsraeliSubsidiaryMember"
      decimals="-5"
      id="Fact001322"
      unitRef="USD">3100000</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact001324"
      unitRef="USD">175400000</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-12-31_us-gaap_DeferredIncomeTaxChargesMember"
      decimals="-5"
      id="Fact001326"
      unitRef="USD">3300000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001328">&lt;p id="xdx_893_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_z8W8nOrww3Vd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
reconciliation of the Company&#x2019;s effective tax expense to the Company&#x2019;s theoretical statutory tax benefit is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BC_zpOBbrXmcaTk" style="display: none"&gt;Schedule of Effective Income Tax Rate Reconciliation&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20240101__20241231_zI43QpEYMOXb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20230101__20231231_ziaulpg56Iz9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20220101__20221231_zj3jy4F0oDhi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn3n3_ztAHqONZnqb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: left; padding-bottom: 2.5pt"&gt;Loss before taxes on income, as reported in the consolidated statements of operations&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"&gt;7,517&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"&gt;6,912&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"&gt;17,866&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_zbKWAnV5rC57" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Statutory tax rate&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;23&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;23&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;12&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_maITEBzSAa_zQqEaK4ogOW2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Theoretical tax benefit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,729&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,590&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,144&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_maITEBzSAa_zd1KL1KEkRdk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Losses and other items for which a valuation allowance was provided or benefit from loss carry forwards&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,729&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,590&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(2,144&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3n3_mtITEBzSAa_ztV1u2QHBqcg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Actual tax expense&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1346"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1347"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1348"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001330"
      unitRef="USD">7517000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001331"
      unitRef="USD">6912000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact001332"
      unitRef="USD">17866000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001334"
      unitRef="Pure">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001335"
      unitRef="Pure">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact001336"
      unitRef="Pure">0.12</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001338"
      unitRef="USD">1729000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001339"
      unitRef="USD">1590000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact001340"
      unitRef="USD">2144000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001342"
      unitRef="USD">-1729000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001343"
      unitRef="USD">-1590000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact001344"
      unitRef="USD">-2144000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001350">&lt;p id="xdx_80A_eus-gaap--SubsequentEventsTextBlock_ztFYymnC2Hq6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
16 &#x2013; &lt;span id="xdx_821_zXWHEo3Q1xt8"&gt;Subsequent events&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Subsequent
                                            to the balance sheet date, as of March 21 2025, the Company sold &lt;span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20250320__20250321__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentySalesAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zaZXSo3sUEd4" title="Sale of stock"&gt;541,996&lt;/span&gt; ordinary shares
                                            pursuant to the 2024 Sales Agreement with JonesTrading, for a total consideration of approximately
                                            $&lt;span id="xdx_908_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn5n6_c20250320__20250321__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentySalesAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zxjZbnqiJy1f" title="Total consideration"&gt;1.5&lt;/span&gt; million. See note 11(A)(6).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Subsequent
                                                                                                                                                                                                       to the balance sheet date, as of March 21, 2025 the Company has issued an aggregate of &lt;span id="xdx_907_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20250320__20250321__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--CaymanIslandsExemptLimitedPartnershipMember_z5ltgpUVk3gg" title="Sale of stock"&gt;7,891&lt;/span&gt;
                                                                                                                                                                                                       ordinary shares to YA as part of the Commitment Shares and an aggregate of &lt;span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20250320__20250321__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentySalesAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--CaymanIslandsExemptLimitedPartnershipMember_zNMbZ3TyF7Aj" title="Sale of stock"&gt;25,000&lt;/span&gt;
                                                                                                                                                                                                       ordinary shares that we sold to YA as Advance Shares for aggregate gross proceeds of approximately $&lt;span id="xdx_904_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn3n3_c20250321__20250321__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentySalesAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z9GrfEhogdBi" title="Commitment share,value"&gt;75&lt;/span&gt;
                                                                                                                                                                                                       thousand. See note 11(A)(5).&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-03-202025-03-21_custom_TwoThousandAndTwentySalesAgreementMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001352"
      unitRef="Shares">541996</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2025-03-202025-03-21_custom_TwoThousandAndTwentySalesAgreementMember_us-gaap_SubsequentEventMember"
      decimals="-5"
      id="Fact001354"
      unitRef="USD">1500000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-03-202025-03-21_us-gaap_SubsequentEventMember_custom_CaymanIslandsExemptLimitedPartnershipMember"
      decimals="INF"
      id="Fact001356"
      unitRef="Shares">7891</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-03-202025-03-21_custom_TwoThousandAndTwentySalesAgreementMember_us-gaap_SubsequentEventMember_custom_CaymanIslandsExemptLimitedPartnershipMember"
      decimals="INF"
      id="Fact001358"
      unitRef="Shares">25000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2025-03-212025-03-21_custom_TwoThousandAndTwentySalesAgreementMember_us-gaap_SubsequentEventMember"
      decimals="-3"
      id="Fact001360"
      unitRef="USD">75000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001362">&lt;p id="xdx_80B_eus-gaap--SegmentReportingDisclosureTextBlock_zEySMl5bj5ye" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
17 &#x2013; &lt;span id="xdx_82F_znQxEJ8yPQw8"&gt;Segment Reporting&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ASC
280, &#x201c;Segment Reporting&#x201d;, establishes standards for reporting information about operating segments. Operating segments are
defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief
operating decision maker (&#x201c;CODM&#x201d;) in deciding how to allocate resources and in assessing performance. The Company manages
its business on the basis of &lt;span id="xdx_905_eus-gaap--NumberOfReportableSegments_dc_uInteger_c20240101__20241231_zT41MWE2qx35" title="Number of reportable segments"&gt;one&lt;/span&gt; reportable segment and unit. The Company&#x2019;s chief operating decision maker is the chief executive
officer of the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
CODM assesses the performance of the Company and decides how to allocate resources based on the operating results available that is also
reported within the Consolidated Statements of Operations. The measure of segment assets that is reviewed by the CODM is reported within
the Balance Sheet as Total assets.&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001364"
      unitRef="Integer">1</us-gaap:NumberOfReportableSegments>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact000128"
          xlink:label="Fact000128"
          xlink:type="locator"/>
        <link:footnote id="Footnote000161" xlink:label="Footnote000161" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Retroactively
    adjusted to reflect the <xhtml:span
  id="xdx_903_eus-gaap--StockholdersEquityReverseStockSplit_c20240101__20241231_ztGOQ4rE0CZ9"
  title="Reverse stock split">12-1 reverse split</xhtml:span> that was effected in August 2024 (see Note 11(A)(3))</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000128"
          xlink:to="Footnote000161"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000129"
          xlink:label="Fact000129"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000129"
          xlink:to="Footnote000161"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000193"
          xlink:label="Fact000193"
          xlink:type="locator"/>
        <link:footnote id="Footnote000216" xlink:label="Footnote000216" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Retroactively
    adjusted to reflect the <xhtml:span
  id="xdx_908_eus-gaap--StockholdersEquityReverseStockSplit_c20240101__20241231_zsT0zUcMI9de"
  title="Reverse stock split">12-1 reverse split</xhtml:span> that was affected in August 2024 (see Note 11(A)(3))</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000193"
          xlink:to="Footnote000216"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000195"
          xlink:label="Fact000195"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000195"
          xlink:to="Footnote000216"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000197"
          xlink:label="Fact000197"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000197"
          xlink:to="Footnote000216"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000199"
          xlink:label="Fact000199"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000199"
          xlink:to="Footnote000216"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000201"
          xlink:label="Fact000201"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000201"
          xlink:to="Footnote000216"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000203"
          xlink:label="Fact000203"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000203"
          xlink:to="Footnote000216"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000205"
          xlink:label="Fact000205"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000205"
          xlink:to="Footnote000216"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000207"
          xlink:label="Fact000207"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000207"
          xlink:to="Footnote000216"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000209"
          xlink:label="Fact000209"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000209"
          xlink:to="Footnote000216"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000211"
          xlink:label="Fact000211"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000211"
          xlink:to="Footnote000216"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000213"
          xlink:label="Fact000213"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000213"
          xlink:to="Footnote000216"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000215"
          xlink:label="Fact000215"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000215"
          xlink:to="Footnote000216"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0250"
          xlink:label="xdx2ixbrl0250"
          xlink:type="locator"/>
        <link:footnote id="Footnote000405" xlink:label="Footnote000405" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Represents
    amounts less than $1</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0250"
          xlink:to="Footnote000405"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000242"
          xlink:label="Fact000242"
          xlink:type="locator"/>
        <link:footnote id="Footnote000406" xlink:label="Footnote000406" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Retroactively
    adjusted to reflect the <xhtml:span
  id="xdx_90E_eus-gaap--StockholdersEquityReverseStockSplit_c20240101__20241231_zflb9DMjyxOc"
  title="Reverse stock split">12-1 reverse split</xhtml:span> that was effected in August 2024 (see Note 11(A)(3))</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000242"
          xlink:to="Footnote000406"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000258"
          xlink:label="Fact000258"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000258"
          xlink:to="Footnote000406"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000278"
          xlink:label="Fact000278"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000278"
          xlink:to="Footnote000406"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000288"
          xlink:label="Fact000288"
          xlink:type="locator"/>
        <link:footnote id="Footnote000409" xlink:label="Footnote000409" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">See
    also Note 11(A)(4)</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000288"
          xlink:to="Footnote000406"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000288"
          xlink:to="Footnote000409"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000296"
          xlink:label="Fact000296"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000296"
          xlink:to="Footnote000406"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000296"
          xlink:to="Footnote000409"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000322"
          xlink:label="Fact000322"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000322"
          xlink:to="Footnote000406"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000330"
          xlink:label="Fact000330"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000330"
          xlink:to="Footnote000406"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000338"
          xlink:label="Fact000338"
          xlink:type="locator"/>
        <link:footnote id="Footnote000410" xlink:label="Footnote000410" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">See
    also Note 11(A)(5)</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000338"
          xlink:to="Footnote000410"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000338"
          xlink:to="Footnote000406"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000346"
          xlink:label="Fact000346"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000346"
          xlink:to="Footnote000410"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000346"
          xlink:to="Footnote000406"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000354"
          xlink:label="Fact000354"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000354"
          xlink:to="Footnote000406"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000354"
          xlink:to="Footnote000409"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000362"
          xlink:label="Fact000362"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000362"
          xlink:to="Footnote000406"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000370"
          xlink:label="Fact000370"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000370"
          xlink:to="Footnote000406"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000370"
          xlink:to="Footnote000409"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000396"
          xlink:label="Fact000396"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000396"
          xlink:to="Footnote000406"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000404"
          xlink:label="Fact000404"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000404"
          xlink:to="Footnote000406"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000280"
          xlink:label="Fact000280"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000280"
          xlink:to="Footnote000409"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000281"
          xlink:label="Fact000281"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000281"
          xlink:to="Footnote000409"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0282"
          xlink:label="xdx2ixbrl0282"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0282"
          xlink:to="Footnote000409"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0283"
          xlink:label="xdx2ixbrl0283"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0283"
          xlink:to="Footnote000409"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000284"
          xlink:label="Fact000284"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000284"
          xlink:to="Footnote000409"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000290"
          xlink:label="Fact000290"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000290"
          xlink:to="Footnote000409"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000291"
          xlink:label="Fact000291"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000291"
          xlink:to="Footnote000409"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0292"
          xlink:label="xdx2ixbrl0292"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0292"
          xlink:to="Footnote000409"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0293"
          xlink:label="xdx2ixbrl0293"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0293"
          xlink:to="Footnote000409"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0294"
          xlink:label="xdx2ixbrl0294"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0294"
          xlink:to="Footnote000409"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000348"
          xlink:label="Fact000348"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000348"
          xlink:to="Footnote000409"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000349"
          xlink:label="Fact000349"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000349"
          xlink:to="Footnote000409"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0352"
          xlink:label="xdx2ixbrl0352"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0352"
          xlink:to="Footnote000409"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000364"
          xlink:label="Fact000364"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000364"
          xlink:to="Footnote000409"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000365"
          xlink:label="Fact000365"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000365"
          xlink:to="Footnote000409"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000368"
          xlink:label="Fact000368"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000368"
          xlink:to="Footnote000409"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000332"
          xlink:label="Fact000332"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000332"
          xlink:to="Footnote000410"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000333"
          xlink:label="Fact000333"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000333"
          xlink:to="Footnote000410"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0334"
          xlink:label="xdx2ixbrl0334"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0334"
          xlink:to="Footnote000410"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0335"
          xlink:label="xdx2ixbrl0335"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0335"
          xlink:to="Footnote000410"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000336"
          xlink:label="Fact000336"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000336"
          xlink:to="Footnote000410"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000340"
          xlink:label="Fact000340"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000340"
          xlink:to="Footnote000410"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000341"
          xlink:label="Fact000341"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000341"
          xlink:to="Footnote000410"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000344"
          xlink:label="Fact000344"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000344"
          xlink:to="Footnote000410"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000448"
          xlink:label="Fact000448"
          xlink:type="locator"/>
        <link:footnote id="Footnote000567" xlink:label="Footnote000567" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">See
    also Note 7</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000448"
          xlink:to="Footnote000567"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0449"
          xlink:label="xdx2ixbrl0449"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0449"
          xlink:to="Footnote000567"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0450"
          xlink:label="xdx2ixbrl0450"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0450"
          xlink:to="Footnote000567"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000456"
          xlink:label="Fact000456"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000456"
          xlink:to="Footnote000567"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0457"
          xlink:label="xdx2ixbrl0457"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0457"
          xlink:to="Footnote000567"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0458"
          xlink:label="xdx2ixbrl0458"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0458"
          xlink:to="Footnote000567"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0496"
          xlink:label="xdx2ixbrl0496"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0496"
          xlink:to="Footnote000567"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0497"
          xlink:label="xdx2ixbrl0497"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0497"
          xlink:to="Footnote000567"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000498"
          xlink:label="Fact000498"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000498"
          xlink:to="Footnote000567"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000500"
          xlink:label="Fact000500"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000500"
          xlink:to="Footnote000567"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0501"
          xlink:label="xdx2ixbrl0501"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0501"
          xlink:to="Footnote000567"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0502"
          xlink:label="xdx2ixbrl0502"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0502"
          xlink:to="Footnote000567"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0504"
          xlink:label="xdx2ixbrl0504"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0504"
          xlink:to="Footnote000567"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000505"
          xlink:label="Fact000505"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000505"
          xlink:to="Footnote000567"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0506"
          xlink:label="xdx2ixbrl0506"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0506"
          xlink:to="Footnote000567"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000436"
          xlink:label="Fact000436"
          xlink:type="locator"/>
        <link:footnote id="Footnote000568" xlink:label="Footnote000568" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">See
    also Note 11(A)(5)</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000436"
          xlink:to="Footnote000568"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0437"
          xlink:label="xdx2ixbrl0437"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0437"
          xlink:to="Footnote000568"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0438"
          xlink:label="xdx2ixbrl0438"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0438"
          xlink:to="Footnote000568"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000528"
          xlink:label="Fact000528"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000528"
          xlink:to="Footnote000568"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0529"
          xlink:label="xdx2ixbrl0529"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0529"
          xlink:to="Footnote000568"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0530"
          xlink:label="xdx2ixbrl0530"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0530"
          xlink:to="Footnote000568"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000532"
          xlink:label="Fact000532"
          xlink:type="locator"/>
        <link:footnote id="Footnote000569" xlink:label="Footnote000569" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">See
    also Note 11(A)(4)</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000532"
          xlink:to="Footnote000569"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000533"
          xlink:label="Fact000533"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000533"
          xlink:to="Footnote000569"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
